Cancer diagnostics using biomarkers

ABSTRACT

Disclosed herein, in certain instances, are methods, systems and kits for the diagnosis, prognosis and determination of cancer progression of a cancer in a subject. Further disclosed herein, in certain instances, are methods, systems and kits for determining the treatment modality of a cancer in a subject. The methods, systems and kits comprise expression-based analysis of biomarkers. Further disclosed herein, in certain instances, are probe sets for use in assessing a cancer status in a subject.

CROSS REFERENCE TO RELATED APPLICATION

This application claims the benefit of priority under § 119(e) of U.S. Ser. No. 61/684,066 filed Aug. 16, 2012, U.S. Ser. No. 61/764,365 filed Feb. 13, 2013 and U.S. Ser. No. 61/783,124, filed Mar. 14, 2013, the entire contents of each are herein incorporated by reference.

BACKGROUND OF THE INVENTION

Cancer is the uncontrolled growth of abnormal cells anywhere in a body. The abnormal cells are termed cancer cells, malignant cells, or tumor cells. Many cancers and the abnormal cells that compose the cancer tissue are further identified by the name of the tissue that the abnormal cells originated from (for example, breast cancer, lung cancer, colon cancer, prostate cancer, pancreatic cancer, thyroid cancer). Cancer is not confined to humans; animals and other living organisms can get cancer. Cancer cells can proliferate uncontrollably and form a mass of cancer cells. Cancer cells can break away from this original mass of cells, travel through the blood and lymph systems, and lodge in other organs where they can again repeat the uncontrolled growth cycle. This process of cancer cells leaving an area and growing in another body area is often termed metastatic spread or metastatic disease. For example, if breast cancer cells spread to a bone (or anywhere else), it can mean that the individual has metastatic breast cancer.

Standard clinical parameters such as tumor size, grade, lymph node involvement and tumor-node-metastasis (TNM) staging (American Joint Committee on Cancer www.cancerstaging.org) may correlate with outcome and serve to stratify patients with respect to (neo)adjuvant chemotherapy, immunotherapy, antibody therapy and/or radiotherapy regimens. Incorporation of molecular markers in clinical practice may define tumor subtypes that are more likely to respond to targeted therapy. However, stage-matched tumors grouped by histological or molecular subtypes may respond differently to the same treatment regimen. Additional key genetic and epigenetic alterations may exist with important etiological contributions. A more detailed understanding of the molecular mechanisms and regulatory pathways at work in cancer cells and the tumor microenvironment (TME) could dramatically improve the design of novel anti-tumor drugs and inform the selection of optimal therapeutic strategies. The development and implementation of diagnostic, prognostic and therapeutic biomarkers to characterize the biology of each tumor may assist clinicians in making important decisions with regard to individual patient care and treatment. Thus, disclosed herein are methods, compositions and systems for the analysis of coding and non-coding targets for the diagnosis, prognosis, and monitoring of a cancer.

This background information is provided for the purpose of making known information believed by the applicant to be of possible relevance to the present invention. No admission is necessarily intended, nor should be construed, that any of the preceding information constitutes prior art against the present invention.

SUMMARY OF THE INVENTION

Disclosed herein in some embodiments is a method of diagnosing, prognosing, determining progression the cancer, or predicting benefit from therapy in a subject, comprising (a) assaying an expression level in a sample from the subject for a plurality of targets, wherein the plurality of targets comprises one or more targets selected from Tables 2, 4, 11 or 55; and (b) diagnosing, prognosing, determining progression the cancer, or predicting benefit from therapy in a subject based on the expression levels of the plurality of targets. In some embodiments, the cancer is selected from the group consisting of a carcinoma, sarcoma, leukemia, lymphoma, myeloma, and a CNS tumor. In some embodiments, cancer is selected from the group consisting of skin cancer, lung cancer, colon cancer, pancreatic cancer, prostate cancer, liver cancer, thyroid cancer, ovarian cancer, uterine cancer, breast cancer, cervical cancer, kidney cancer, epithelial carcinoma, squamous carcinoma, basal cell carcinoma, melanoma, papilloma, and adenomas. In some embodiments, the cancer is a prostate cancer. In some embodiments, the cancer is a pancreatic cancer. In some embodiments, the cancer is a thyroid cancer. In some embodiments, the plurality of targets comprises a coding target. In some embodiments, the coding target is an exonic sequence. In some embodiments, the plurality of targets comprises a non-coding target. In some embodiments, the non-coding target comprises an intronic sequence or partially overlaps an intronic sequence. In some embodiments, the non-coding target comprises a sequence within the UTR or partially overlaps with a UTR sequence. In some embodiments, the non-coding target comprises an antisense sequence or partially overlaps with an antisense sequence. In some embodiments, the non-coding target comprises an intergenic sequence or partially overlaps with an intergenic sequence. In some embodiments, the target comprises a nucleic acid sequence. In some embodiments, the nucleic acid sequence is a DNA sequence. In some embodiments, the nucleic acid sequence is an RNA sequence. In some embodiments, the plurality of targets comprises at least 5 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 10 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 15 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 20 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 30 targets selected from Tables 2, 11 or 55. In some embodiments, the plurality of targets comprises at least 35 targets selected from Tables 2, 11 or 55. In some embodiments, the plurality of targets comprises at least 40 targets selected from Tables 2, 11 or 55. In some embodiments, the diagnosing, prognosing, determining progression the cancer, or predicting benefit from therapy includes determining the malignancy of the cancer. In some embodiments, the diagnosing, prognosing, determining progression the cancer, or predicting benefit from therapy includes determining the stage of the cancer. In some embodiments, the diagnosing, prognosing, determining progression the cancer, or predicting benefit from therapy includes assessing the risk of cancer recurrence. In some embodiments, determining the treatment for the cancer includes determining the efficacy of treatment. In some embodiments, the method further comprises sequencing the plurality of targets. In some embodiments, the method further comprises hybridizing the plurality of targets to a solid support. In some embodiments, the solid support is a bead or array. In some embodiments, assaying the expression level of a plurality of targets may comprise the use of a probe set. In some embodiments, assaying the expression level may comprise the use of a classifier. The classifier may comprise a probe selection region (PSR). In some embodiments, the classifier may comprise the use of an algorithm. The algorithm may comprise a machine learning algorithm. In some embodiments, assaying the expression level may also comprise sequencing the plurality of targets.

Disclosed herein in some embodiments is a method of determining a treatment for a cancer in a subject, comprising (a) assaying an expression level in a sample from the subject for a plurality of targets, wherein the plurality of targets comprises one or more targets selected from Tables 2, 4, 11 or 55; and (b) determining the treatment for the cancer based on the expression level of the plurality of targets. In some embodiments, the cancer is selected from the group consisting of a carcinoma, sarcoma, leukemia, lymphoma, myeloma, and a CNS tumor. In some embodiments, cancer is selected from the group consisting of skin cancer, lung cancer, colon cancer, pancreatic cancer, prostate cancer, liver cancer, thyroid cancer, ovarian cancer, uterine cancer, breast cancer, cervical cancer, kidney cancer, epithelial carcinoma, squamous carcinoma, basal cell carcinoma, melanoma, papilloma, and adenomas. In some embodiments, the cancer is a prostate cancer. In some embodiments, the cancer is a pancreatic cancer. In some embodiments, the cancer is a thyroid cancer. In some embodiments, the plurality of targets comprises a coding target. In some embodiments, the coding target is an exonic sequence. In some embodiments, the plurality of targets comprises a non-coding target. In some embodiments, the non-coding target comprises an intronic sequence or partially overlaps an intronic sequence. In some embodiments, the non-coding target comprises a sequence within the UTR or partially overlaps with a UTR sequence. In some embodiments, the target comprises a nucleic acid sequence. In some embodiments, the nucleic acid sequence is a DNA sequence. In some embodiments, the nucleic acid sequence is an RNA sequence. In some embodiments, the plurality of targets comprises at least 5 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 10 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 15 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 20 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 30 targets selected from Tables 2, 11 or 55. In some embodiments, the plurality of targets comprises at least 35 targets selected from Tables 2, 11 or 55. In some embodiments, the plurality of targets comprises at least 40 targets selected from Tables 2, 11 or 55. In some embodiments, the diagnosing, prognosing, determining progression the cancer, or predicting benefit from therapy includes determining the malignancy of the cancer. In some embodiments, the diagnosing, prognosing, determining progression the cancer, or predicting benefit from therapy includes determining the stage of the cancer. In some embodiments, the diagnosing, prognosing, determining progression the cancer, or predicting benefit from therapy includes assessing the risk of cancer recurrence. In some embodiments, determining the treatment for the cancer includes determining the efficacy of treatment. In some embodiments, the method further comprises sequencing the plurality of targets. In some embodiments, the method further comprises hybridizing the plurality of targets to a solid support. In some embodiments, the solid support is a bead or array. In some embodiments, assaying the expression level of a plurality of targets may comprise the use of a probe set. In some embodiments, assaying the expression level may comprise the use of a classifier. The classifier may comprise a probe selection region (PSR). In some embodiments, the classifier may comprise the use of an algorithm. The algorithm may comprise a machine learning algorithm. In some embodiments, assaying the expression level may also comprise amplifying the plurality of targets. In some embodiments, assaying the expression level may also comprise quantifying the plurality of targets.

Further disclosed herein in some embodiments is a probe set for assessing a cancer status of a subject comprising a plurality of probes, wherein the probes in the set are capable of detecting an expression level of one or more targets selected from Tables 2, 4, 11 or 55, wherein the expression level determines the cancer status of the subject with at least 40% specificity. In some embodiments, the plurality of targets comprises at least 5 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 10 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 15 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 20 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 30 targets selected from Tables 2, 11 or 55. In some embodiments, the plurality of targets comprises at least 35 targets selected from Tables 2, 11 or 55. In some embodiments, the plurality of targets comprises at least 40 targets selected from Tables 2, 11 or 55. In some embodiments, the cancer is selected from the group consisting of a carcinoma, sarcoma, leukemia, lymphoma, myeloma, and a CNS tumor. In some embodiments, the cancer is selected from the group consisting of skin cancer, lung cancer, colon cancer, pancreatic cancer, prostate cancer, liver cancer, thyroid cancer, ovarian cancer, uterine cancer, breast cancer, cervical cancer, kidney cancer, epithelial carcinoma, squamous carcinoma, basal cell carcinoma, melanoma, papilloma, and adenomas. In some embodiments, the cancer is a prostate cancer. In some embodiments, the cancer is a pancreatic cancer. In some embodiments, the cancer is a thyroid cancer. In some embodiments, the probe set further comprises a probe capable of detecting an expression level of at least one coding target. In some embodiments, the coding target is an exonic sequence. In some embodiments, the probe set further comprises a probe capable of detecting an expression level of at least one non-coding target. In some embodiments, the non-coding target is an intronic sequence or partially overlaps with an intronic sequence. In some embodiments, the non-coding target is a UTR sequence or partially overlaps with a UTR sequence. In some embodiments, assessing the cancer status includes assessing cancer recurrence risk. In some embodiments, assessing the cancer status includes determining a treatment modality. In some embodiments, assessing the cancer status includes determining the efficacy of treatment. In some embodiments, the target is a nucleic acid sequence. In some embodiments, the nucleic acid sequence is a DNA sequence. In some embodiments, the nucleic acid sequence is an RNA sequence. In some embodiments, the probes are between about 15 nucleotides and about 500 nucleotides in length. In some embodiments, the probes are between about 15 nucleotides and about 450 nucleotides in length. In some embodiments, the probes are between about 15 nucleotides and about 400 nucleotides in length. In some embodiments, the probes are between about 15 nucleotides and about 350 nucleotides in length. In some embodiments, the probes are between about 15 nucleotides and about 300 nucleotides in length. In some embodiments, the probes are between about 15 nucleotides and about 250 nucleotides in length. In some embodiments, the probes are between about 15 nucleotides and about 200 nucleotides in length. In some embodiments, the probes are at least 15 nucleotides in length. In some embodiments, the probes are at least 25 nucleotides in length. In some embodiments, the expression level determines the cancer status of the subject with at least 50% specificity. In some embodiments, the expression level determines the cancer status of the subject with at least 60% specificity. In some embodiments, the expression level determines the cancer status of the subject with at least 65% specificity. In some embodiments, the expression level determines the cancer status of the subject with at least 70% specificity. In some embodiments, the expression level determines the cancer status of the subject with at least 75% specificity. In some embodiments, the expression level determines the cancer status of the subject with at least 80% specificity. In some embodiments, the expression level determines the cancer status of the subject with at least 85% specificity. In some embodiments, the non-coding target is a non-coding RNA transcript and the non-coding RNA transcript is non-polyadenylated.

Further disclosed herein in some embodiments is a system for analyzing a cancer, comprising: (a) a probe set comprising a plurality of target sequences, wherein (i) the plurality of target sequences hybridizes to one or more targets selected from Tables 2 or 4; or (ii) the plurality of target sequences comprises one or more target sequences selected from Table 11; and (b) a computer model or algorithm for analyzing an expression level and/or expression profile of the target hybridized to the probe in a sample from a subject suffering from a cancer. In some embodiments, the system further comprises an electronic memory for capturing and storing an expression profile. In some embodiments, the system further comprises a computer-processing device, optionally connected to a computer network. In some embodiments, the system further comprises a software module executed by the computer-processing device to analyze an expression profile. In some embodiments, the system further comprises a software module executed by the computer-processing device to compare the expression profile to a standard or control. In some embodiments, the system further comprises a software module executed by the computer-processing device to determine the expression level of the target. In some embodiments, the system further comprises a machine to isolate the target or the probe from the sample. In some embodiments, the system further comprises a machine to sequence the target or the probe. In some embodiments, the system further comprises a machine to amplify the target or the probe. In some embodiments, the system further comprises a label that specifically binds to the target, the probe, or a combination thereof. In some embodiments, the system further comprises a software module executed by the computer-processing device to transmit an analysis of the expression profile to the individual or a medical professional treating the individual. In some embodiments, the system further comprises a software module executed by the computer-processing device to transmit a diagnosis or prognosis to the individual or a medical professional treating the individual. In some embodiments, the plurality of targets comprises at least 5 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 10 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 15 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 20 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 30 targets selected from Tables 2, 11 or 55. In some embodiments, the plurality of targets comprises at least 35 targets selected from Tables 2, 11 or 55. In some embodiments, the plurality of targets comprises at least 40 targets selected from Tables 2, 11 or 55. In some embodiments, the cancer is selected from the group consisting of a carcinoma, sarcoma, leukemia, lymphoma, myeloma, and a CNS tumor. In some embodiments, the cancer is selected from the group consisting of skin cancer, lung cancer, colon cancer, pancreatic cancer, prostate cancer, liver cancer, thyroid cancer, ovarian cancer, uterine cancer, breast cancer, cervical cancer, kidney cancer, epithelial carcinoma, squamous carcinoma, basal cell carcinoma, melanoma, papilloma, and adenomas. In some embodiments, the system further comprises a sequence for sequencing the plurality of targets. In some embodiments, the system further comprises an instrument for amplifying the plurality of targets. In some embodiments, the system further comprises a label for labeling the plurality of targets.

Further disclosed herein in some embodiments is a method of analyzing a cancer in an individual in need thereof, comprising: (a) obtaining an expression profile from a sample obtained from the individual, wherein the expression profile comprises one or more targets selected from Tables 2, 4, 11 or 55; and (b) comparing the expression profile from the sample to an expression profile of a control or standard. In some embodiments, the plurality of targets comprises at least 5 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 10 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 15 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 20 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 30 targets selected from Tables 2, 11 or 55. In some embodiments, the plurality of targets comprises at least 35 targets selected from Tables 2, 11 or 55. In some embodiments, the plurality of targets comprises at least 40 targets selected from Tables 2, 11 or 55. In some embodiments, the cancer is selected from the group consisting of a carcinoma, sarcoma, leukemia, lymphoma, myeloma, and a CNS tumor. In some embodiments, the cancer is selected from the group consisting of skin cancer, lung cancer, colon cancer, pancreatic cancer, prostate cancer, liver cancer, thyroid cancer, ovarian cancer, uterine cancer, breast cancer, cervical cancer, kidney cancer, epithelial carcinoma, squamous carcinoma, basal cell carcinoma, melanoma, papilloma, and adenomas. In some embodiments, the cancer is a prostate cancer. In some embodiments, the cancer is a pancreatic cancer. In some embodiments, the cancer is a breast cancer. In some embodiments, the cancer is a thyroid cancer. In some embodiments, the cancer is a lung cancer. In some embodiments, the method further comprises a software module executed by a computer-processing device to compare the expression profiles. In some embodiments, the method further comprises providing diagnostic or prognostic information to the individual about the cardiovascular disorder based on the comparison. In some embodiments, the method further comprises diagnosing the individual with a cancer if the expression profile of the sample (a) deviates from the control or standard from a healthy individual or population of healthy individuals, or (b) matches the control or standard from an individual or population of individuals who have or have had the cancer. In some embodiments, the method further comprises predicting the susceptibility of the individual for developing a cancer based on (a) the deviation of the expression profile of the sample from a control or standard derived from a healthy individual or population of healthy individuals, or (b) the similarity of the expression profiles of the sample and a control or standard derived from an individual or population of individuals who have or have had the cancer. In some embodiments, the method further comprises prescribing a treatment regimen based on (a) the deviation of the expression profile of the sample from a control or standard derived from a healthy individual or population of healthy individuals, or (b) the similarity of the expression profiles of the sample and a control or standard derived from an individual or population of individuals who have or have had the cancer. In some embodiments, the method further comprises altering a treatment regimen prescribed or administered to the individual based on (a) the deviation of the expression profile of the sample from a control or standard derived from a healthy individual or population of healthy individuals, or (b) the similarity of the expression profiles of the sample and a control or standard derived from an individual or population of individuals who have or have had the cancer. In some embodiments, the method further comprises predicting the individual's response to a treatment regimen based on (a) the deviation of the expression profile of the sample from a control or standard derived from a healthy individual or population of healthy individuals, or (b) the similarity of the expression profiles of the sample and a control or standard derived from an individual or population of individuals who have or have had the cancer. In some embodiments, the deviation is the expression level of one or more targets from the sample is greater than the expression level of one or more targets from a control or standard derived from a healthy individual or population of healthy individuals. In some embodiments, the deviation is the expression level of one or more targets from the sample is at least about 30% greater than the expression level of one or more targets from a control or standard derived from a healthy individual or population of healthy individuals. In some embodiments, the deviation is the expression level of one or more targets from the sample is less than the expression level of one or more targets from a control or standard derived from a healthy individual or population of healthy individuals. In some embodiments, the deviation is the expression level of one or more targets from the sample is at least about 30% less than the expression level of one or more targets from a control or standard derived from a healthy individual or population of healthy individuals. In some embodiments, the method further comprises using a machine to isolate the target or the probe from the sample. In some embodiments, the method further comprises contacting the sample with a label that specifically binds to the target, the probe, or a combination thereof. In some embodiments, the method further comprises contacting the sample with a label that specifically binds to a target selected from Tables 2, 4, 11 or 55, or a combination thereof. In some embodiments, the method further comprises amplifying the target, the probe, or any combination thereof. In some embodiments, the method further comprises sequencing the target, the probe, or any combination thereof. In some embodiments, the method further comprises quantifying the expression level of the plurality of targets. In some embodiments, the method further comprises labeling the plurality of targets. In some embodiments, assaying the expression level of a plurality of targets may comprise the use of a probe set. In some embodiments, obtaining the expression level may comprise the use of a classifier. The classifier may comprise a probe selection region (PSR). In some embodiments, the classifier may comprise the use of an algorithm. The algorithm may comprise a machine learning algorithm. In some embodiments, obtaining the expression level may also comprise sequencing the plurality of targets.

Disclosed herein in some embodiments is a method of diagnosing cancer in an individual in need thereof, comprising (a) obtaining an expression profile from a sample obtained from the individual, wherein the expression profile comprises one or more targets selected from Tables 2, 4, 11 or 55; (b) comparing the expression profile from the sample to an expression profile of a control or standard; and (c) diagnosing a cancer in the individual if the expression profile of the sample (i) deviates from the control or standard from a healthy individual or population of healthy individuals, or (ii) matches the control or standard from an individual or population of individuals who have or have had the cancer. In some embodiments, the plurality of targets comprises at least 5 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 10 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 15 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 20 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 30 targets selected from Tables 2, 11 or 55. In some embodiments, the plurality of targets comprises at least 35 targets selected from Tables 2, 11 or 55. In some embodiments, the plurality of targets comprises at least 40 targets selected from Tables 2, 11 or 55. In some embodiments, the cancer is selected from the group consisting of a carcinoma, sarcoma, leukemia, lymphoma, myeloma, and a CNS tumor. In some embodiments, the cancer is selected from the group consisting of skin cancer, lung cancer, colon cancer, pancreatic cancer, prostate cancer, liver cancer, thyroid cancer, ovarian cancer, uterine cancer, breast cancer, cervical cancer, kidney cancer, epithelial carcinoma, squamous carcinoma, basal cell carcinoma, melanoma, papilloma, and adenomas. In some embodiments, the cancer is a prostate cancer. In some embodiments, the cancer is a pancreatic cancer. In some embodiments, the cancer is a breast cancer. In some embodiments, the cancer is a thyroid cancer. In some embodiments, the cancer is a lung cancer. In some embodiments, the method further comprises a software module executed by a computer-processing device to compare the expression profiles. In some embodiments, the deviation is the expression level of one or more targets from the sample is greater than the expression level of one or more targets from a control or standard derived from a healthy individual or population of healthy individuals. In some embodiments, the deviation is the expression level of one or more targets from the sample is at least about 30% greater than the expression level of one or more targets from a control or standard derived from a healthy individual or population of healthy individuals. In some embodiments, the deviation is the expression level of one or more targets from the sample is less than the expression level of one or more targets from a control or standard derived from a healthy individual or population of healthy individuals. In some embodiments, the deviation is the expression level of one or more targets from the sample is at least about 30% less than the expression level of one or more targets from a control or standard derived from a healthy individual or population of healthy individuals. In some embodiments, the method further comprises using a machine to isolate the target or the probe from the sample. In some embodiments, the method further comprises contacting the sample with a label that specifically binds to the target, the probe, or a combination thereof. In some embodiments, the method further comprises contacting the sample with a label that specifically binds to a target selected from Tables 2, 4, 11 or 55, or a combination thereof. In some embodiments, the method further comprises amplifying the target, the probe, or any combination thereof. In some embodiments, the method further comprises sequencing the target, the probe, or any combination thereof. In some embodiments, the method further comprises quantifying the expression level of the plurality of targets. In some embodiments, the method further comprises labeling the plurality of targets. In some embodiments, obtaining the expression level may comprise the use of a classifier. The classifier may comprise a probe selection region (PSR). In some embodiments, the classifier may comprise the use of an algorithm. The algorithm may comprise a machine learning algorithm. In some embodiments, obtaining the expression level may also comprise sequencing the plurality of targets.

Further disclosed herein in some embodiments is a method of predicting whether an individual is susceptible to developing a cancer, comprising (a) obtaining an expression profile from a sample obtained from the individual, wherein the expression profile comprises one or more targets selected from Tables 2, 4, 11 or 55; (b) comparing the expression profile from the sample to an expression profile of a control or standard; and (c) predicting the susceptibility of the individual for developing a cancer based on (i) the deviation of the expression profile of the sample from a control or standard derived from a healthy individual or population of healthy individuals, or (ii) the similarity of the expression profiles of the sample and a control or standard derived from an individual or population of individuals who have or have had the cancer. In some embodiments, the plurality of targets comprises at least 5 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 10 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 15 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 20 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 30 targets selected from Tables 2, 11 or 55. In some embodiments, the plurality of targets comprises at least 35 targets selected from Tables 2, 11 or 55. In some embodiments, the plurality of targets comprises at least 40 targets selected from Tables 2, 11 or 55. In some embodiments, the cancer is selected from the group consisting of a carcinoma, sarcoma, leukemia, lymphoma, myeloma, and a CNS tumor. In some embodiments, the cancer is selected from the group consisting of skin cancer, lung cancer, colon cancer, pancreatic cancer, prostate cancer, liver cancer, thyroid cancer, ovarian cancer, uterine cancer, breast cancer, cervical cancer, kidney cancer, epithelial carcinoma, squamous carcinoma, basal cell carcinoma, melanoma, papilloma, and adenomas. In some embodiments, the cancer is a prostate cancer. In some embodiments, the cancer is a pancreatic cancer. In some embodiments, the cancer is a breast cancer. In some embodiments, the cancer is a thyroid cancer. In some embodiments, the cancer is a lung cancer. In some embodiments, the method further comprises a software module executed by a computer-processing device to compare the expression profiles. In some embodiments, the deviation is the expression level of one or more targets from the sample is greater than the expression level of one or more targets from a control or standard derived from a healthy individual or population of healthy individuals. In some embodiments, the deviation is the expression level of one or more targets from the sample is at least about 30% greater than the expression level of one or more targets from a control or standard derived from a healthy individual or population of healthy individuals. In some embodiments, the deviation is the expression level of one or more targets from the sample is less than the expression level of one or more targets from a control or standard derived from a healthy individual or population of healthy individuals. In some embodiments, the deviation is the expression level of one or more targets from the sample is at least about 30% less than the expression level of one or more targets from a control or standard derived from a healthy individual or population of healthy individuals. In some embodiments, the method further comprises using a machine to isolate the target or the probe from the sample. In some embodiments, the method further comprises contacting the sample with a label that specifically binds to the target, the probe, or a combination thereof. In some embodiments, the method further comprises contacting the sample with a label that specifically binds to a target selected from Tables 2, 4, 11 or 55, or a combination thereof. In some embodiments, the method further comprises amplifying the target, the probe, or any combination thereof. In some embodiments, the method further comprises sequencing the target, the probe, or any combination thereof. In some embodiments, obtaining the expression level may comprise the use of a classifier. The classifier may comprise a probe selection region (PSR). In some embodiments, the classifier may comprise the use of an algorithm. The algorithm may comprise a machine learning algorithm. In some embodiments, obtaining the expression level may also comprise sequencing the plurality of targets. In some embodiments, obtaining the expression level may also comprise amplifying the plurality of targets. In some embodiments, obtaining the expression level may also comprise quantifying the plurality of targets.

Further disclosed herein in some embodiments is a method of predicting an individual's response to a treatment regimen for a cancer, comprising (a) obtaining an expression profile from a sample obtained from the individual, wherein the expression profile comprises one or more targets selected from Tables 2, 4, 11 or 55; (b) comparing the expression profile from the sample to an expression profile of a control or standard; and (c) predicting the individual's response to a treatment regimen based on (a) the deviation of the expression profile of the sample from a control or standard derived from a healthy individual or population of healthy individuals, or (b) the similarity of the expression profiles of the sample and a control or standard derived from an individual or population of individuals who have or have had the cancer. In some embodiments, the plurality of targets comprises at least 5 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 10 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 15 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 20 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 30 targets selected from Tables 2, 11 or 55. In some embodiments, the plurality of targets comprises at least 35 targets selected from Tables 2, 11 or 55. In some embodiments, the plurality of targets comprises at least 40 targets selected from Tables 2, 11 or 55. In some embodiments, the cancer is selected from the group consisting of a carcinoma, sarcoma, leukemia, lymphoma, myeloma, and a CNS tumor. In some embodiments, the cancer is selected from the group consisting of skin cancer, lung cancer, colon cancer, pancreatic cancer, prostate cancer, liver cancer, thyroid cancer, ovarian cancer, uterine cancer, breast cancer, cervical cancer, kidney cancer, epithelial carcinoma, squamous carcinoma, basal cell carcinoma, melanoma, papilloma, and adenomas. In some embodiments, the cancer is a prostate cancer. In some embodiments, the cancer is a pancreatic cancer. In some embodiments, the cancer is a breast cancer. In some embodiments, the cancer is a thyroid cancer. In some embodiments, the cancer is a lung cancer. In some embodiments, the method further comprises a software module executed by a computer-processing device to compare the expression profiles. In some embodiments, the deviation is the expression level of one or more targets from the sample is greater than the expression level of one or more targets from a control or standard derived from a healthy individual or population of healthy individuals. In some embodiments, the deviation is the expression level of one or more targets from the sample is at least about 30% greater than the expression level of one or more targets from a control or standard derived from a healthy individual or population of healthy individuals. In some embodiments, the deviation is the expression level of one or more targets from the sample is less than the expression level of one or more targets from a control or standard derived from a healthy individual or population of healthy individuals. In some embodiments, the deviation is the expression level of one or more targets from the sample is at least about 30% less than the expression level of one or more targets from a control or standard derived from a healthy individual or population of healthy individuals. In some embodiments, the method further comprises using a machine to isolate the target or the probe from the sample. In some embodiments, the method further comprises contacting the sample with a label that specifically binds to the target, the probe, or a combination thereof. In some embodiments, the method further comprises contacting the sample with a label that specifically binds to a target selected from Tables 2, 4, 11 or 55, or a combination thereof. In some embodiments, the method further comprises amplifying the target, the probe, or any combination thereof. In some embodiments, the method further comprises sequencing the target, the probe, or any combination thereof. In some embodiments, the method further comprises quantifying the target, the probe, or any combination thereof. In some embodiments, the method further comprises labeling the target, the probe, or any combination thereof. In some embodiments, obtaining the expression level may comprise the use of a classifier. The classifier may comprise a probe selection region (PSR). In some embodiments, the classifier may comprise the use of an algorithm. The algorithm may comprise a machine learning algorithm. In some embodiments, obtaining the expression level may also comprise sequencing the plurality of targets. In some embodiments, obtaining the expression level may also comprise amplifying the plurality of targets. In some embodiments, obtaining the expression level may also comprise quantifying the plurality of targets.

Disclosed herein in some embodiments is a method of prescribing a treatment regimen for a cancer to an individual in need thereof, comprising (a) obtaining an expression profile from a sample obtained from the individual, wherein the expression profile comprises one or more targets selected from Tables 2, 4, 11 or 55; (b) comparing the expression profile from the sample to an expression profile of a control or standard; and (c) prescribing a treatment regimen based on (i) the deviation of the expression profile of the sample from a control or standard derived from a healthy individual or population of healthy individuals, or (ii) the similarity of the expression profiles of the sample and a control or standard derived from an individual or population of individuals who have or have had the cancer. In some embodiments, the plurality of targets comprises at least 5 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 10 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 15 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 20 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 30 targets selected from Tables 2, 11 or 55. In some embodiments, the plurality of targets comprises at least 35 targets selected from Tables 2, 11 or 55. In some embodiments, the plurality of targets comprises at least 40 targets selected from Tables 2, 11 or 55. In some embodiments, the cancer is selected from the group consisting of a carcinoma, sarcoma, leukemia, lymphoma, myeloma, and a CNS tumor. In some embodiments, the cancer is selected from the group consisting of skin cancer, lung cancer, colon cancer, pancreatic cancer, prostate cancer, liver cancer, thyroid cancer, ovarian cancer, uterine cancer, breast cancer, cervical cancer, kidney cancer, epithelial carcinoma, squamous carcinoma, basal cell carcinoma, melanoma, papilloma, and adenomas. In some embodiments, the cancer is a prostate cancer. In some embodiments, the cancer is a pancreatic cancer. In some embodiments, the cancer is a breast cancer. In some embodiments, the cancer is a thyroid cancer. In some embodiments, the cancer is a lung cancer. In some embodiments, the method further comprises a software module executed by a computer-processing device to compare the expression profiles. In some embodiments, the deviation is the expression level of one or more targets from the sample is greater than the expression level of one or more targets from a control or standard derived from a healthy individual or population of healthy individuals. In some embodiments, the deviation is the expression level of one or more targets from the sample is at least about 30% greater than the expression level of one or more targets from a control or standard derived from a healthy individual or population of healthy individuals. In some embodiments, the deviation is the expression level of one or more targets from the sample is less than the expression level of one or more targets from a control or standard derived from a healthy individual or population of healthy individuals. In some embodiments, the deviation is the expression level of one or more targets from the sample is at least about 30% less than the expression level of one or more targets from a control or standard derived from a healthy individual or population of healthy individuals. In some embodiments, the method further comprises using a machine to isolate the target or the probe from the sample. In some embodiments, the method further comprises contacting the sample with a label that specifically binds to the target, the probe, or a combination thereof. In some embodiments, the method further comprises contacting the sample with a label that specifically binds to a target selected from Tables 2, 4, 11 or 55, or a combination thereof. In some embodiments, the method further comprises amplifying the target, the probe, or any combination thereof. In some embodiments, the method further comprises sequencing the target, the probe, or any combination thereof. In some embodiments, the method further comprises converting the expression levels of the target sequences into a likelihood score that indicates the probability that a biological sample is from a patient who will exhibit no evidence of disease, who will exhibit systemic cancer, or who will exhibit biochemical recurrence. In some embodiments, the method further comprises quantifying the expression level of the plurality of targets. In some embodiments, the method further comprises labeling the plurality of targets. In some embodiments, the target sequences are differentially expressed the cancer. In some embodiments, the differential expression is dependent on aggressiveness. In some embodiments, the expression profile is determined by a method selected from the group consisting of RT-PCR, Northern blotting, ligase chain reaction, array hybridization, and a combination thereof. In some embodiments, obtaining the expression level may comprise the use of a classifier. The classifier may comprise a probe selection region (PSR). In some embodiments, the classifier may comprise the use of an algorithm. The algorithm may comprise a machine learning algorithm. In some embodiments, obtaining the expression level may also comprise sequencing the plurality of targets. In some embodiments, obtaining the expression level may also comprise amplifying the plurality of targets. In some embodiments, obtaining the expression level may also comprise quantifying the plurality of targets.

Further disclosed herein is a classifier for analyzing a cancer, wherein the classifier has an AUC value of at least about 0.60. The AUC of the classifier may be at least about 0.60, 0.61, 0.62, 0.63, 0.64, 0.65, 0.66, 0.67, 0.68, 0.69, 0.70 or more. The AUC of the classifier may be at least about 0.71, 0.72, 0.73, 0.74, 0.75, 0.76, 0.77, 0.78, 0.79, 0.80 or more. The AUC of the classifier may be at least about 0.81, 0.82, 0.83, 0.84, 0.85, 0.86, 0.87, 0.88, 0.89, 0.90 or more. The AUC of the classifier may be at least about 0.91, 0.92, 0.93, 0.94, 0.95, 0.96, 0.97, 0.98, 0.99 or more. The 95% CI of a classifier or biomarker may be between about 1.10 to 1.70. In some instances, the difference in the range of the 95% CI for a biomarker or classifier is between about 0.25 to about 0.50, between about 0.27 to about 0.47, or between about 0.30 to about 0.45.

Further disclosed herein is a method for analyzing a cancer, comprising use of one or more classifiers, wherein the significance of the one or more classifiers is based on one or more metrics selected from the group comprising AUC, AUC P-value (Auc.pvalue), Wilcoxon Test P-value, Median Fold Difference (MFD), Kaplan Meier (KM) curves, survival AUC (survAUC), Kaplan Meier P-value (KM P-value), Univariable Analysis Odds Ratio P-value (uvaORPval), multivariable analysis Odds Ratio P-value (mvaORPval), Univariable Analysis Hazard Ratio P-value (uvaHRPval) and Multivariable Analysis Hazard Ratio P-value (mvaHRPval). The significance of the one or more classifiers may be based on two or more metrics selected from the group comprising AUC, AUC P-value (Auc.pvalue), Wilcoxon Test P-value, Median Fold Difference (MFD), Kaplan Meier (KM) curves, survival AUC (survAUC), Univariable Analysis Odds Ratio P-value (uvaORPval), multivariable analysis Odds Ratio P-value (mvaORPval), Kaplan Meier P-value (KM P-value), Univariable Analysis Hazard Ratio P-value (uvaHRPval) and Multivariable Analysis Hazard Ratio P-value (mvaHRPval). The significance of the one or more classifiers may be based on three or more metrics selected from the group comprising AUC, AUC P-value (Auc.pvalue), Wilcoxon Test P-value, Median Fold Difference (MFD), Kaplan Meier (KM) curves, survival AUC (survAUC), Kaplan Meier P-value (KM P-value), Univariable Analysis Odds Ratio P-value (uvaORPval), multivariable analysis Odds Ratio P-value (mvaORPval), Univariable Analysis Hazard Ratio P-value (uvaHRPval) and Multivariable Analysis Hazard Ratio P-value (mvaHRPval).

The one or more metrics may comprise AUC. The one or more metrics may comprise AUC and AUC P-value. The one or more metrics may comprise AUC P-value and Wilcoxon Test P-value. The one or more metrics may comprise Wilcoxon Test P-value. The one or more metrics may comprise AUC and Univariable Analysis Odds Ratio P-value (uvaORPval). The one or more metrics may comprise multivariable analysis Odds Ratio P-value (mvaORPval) and Multivariable Analysis Hazard Ratio P-value (mvaHRPval). The one or more metrics may comprise AUC and Multivariable Analysis Hazard Ratio P-value (mvaHRPval). The one or more metrics may comprise Wilcoxon Test P-value and Multivariable Analysis Hazard Ratio P-value (mvaHRPval).

The clinical significance of the classifier may be based on the AUC value. The AUC of the classifier may be at least about about 0.60, 0.61, 0.62, 0.63, 0.64, 0.65, 0.66, 0.67, 0.68, 0.69, 0.70 or more. The AUC of the classifier may be at least about 0.71, 0.72, 0.73, 0.74, 0.75, 0.76, 0.77, 0.78, 0.79, 0.80 or more. The AUC of the classifier may be at least about 0.81, 0.82, 0.83, 0.84, 0.85, 0.86, 0.87, 0.88, 0.89, 0.90 or more. The AUC of the classifier may be at least about 0.91, 0.92, 0.93, 0.94, 0.95, 0.96, 0.97, 0.98, 0.99 or more. The 95% CI of a classifier or biomarker may be between about 1.10 to 1.70. In some instances, the difference in the range of the 95% CI for a biomarker or classifier is between about 0.25 to about 0.50, between about 0.27 to about 0.47, or between about 0.30 to about 0.45.

The clinical significance of the classifier may be based on Univariable Analysis Odds Ratio P-value (uvaORPval). The Univariable Analysis Odds Ratio P-value (uvaORPval) of the classifier may be between about 0-0.4. The Univariable Analysis Odds Ratio P-value (uvaORPval) of the classifier may be between about 0-0.3. The Univariable Analysis Odds Ratio P-value (uvaORPval) of the classifier may be between about 0-0.2. The Univariable Analysis Odds Ratio P-value (uvaORPval) of the classifier may be less than or equal to 0.25, 0.22, 0.21, 0.20, 0.19, 0.18, 0.17, 0.16, 0.15, 0.14, 0.13, 0.12, 0.11. The Univariable Analysis Odds Ratio P-value (uvaORPval) of the classifier may be less than or equal to 0.10, 0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, 0.02, 0.01. The Univariable Analysis Odds Ratio P-value (uvaORPval) of the classifier may be less than or equal to 0.009, 0.008, 0.007, 0.006, 0.005, 0.004, 0.003, 0.002, 0.001.

The clinical significance of the classifier may be based on multivariable analysis Odds Ratio P-value (mvaORPval). The multivariable analysis Odds Ratio P-value (mvaORPval) of the classifier may be between about 0-1. The multivariable analysis Odds Ratio P-value (mvaORPval) of the classifier may be between about 0-0.9. The multivariable analysis Odds Ratio P-value (mvaORPval) of the classifier may be between about 0-0.8. The multivariable analysis Odds Ratio P-value (mvaORPval) of the classifier may be less than or equal to 0.90, 0.88, 0.86, 0.84, 0.82, 0.80. The multivariable analysis Odds Ratio P-value (mvaORPval) of the classifier may be less than or equal to 0.78, 0.76, 0.74, 0.72, 0.70, 0.68, 0.66, 0.64, 0.62, 0.60, 0.58, 0.56, 0.54, 0.52, 0.50. The multivariable analysis Odds Ratio P-value (mvaORPval) of the classifier may be less than or equal to 0.48, 0.46, 0.44, 0.42, 0.40, 0.38, 0.36, 0.34, 0.32, 0.30, 0.28, 0.26, 0.25, 0.22, 0.21, 0.20, 0.19, 0.18, 0.17, 0.16, 0.15, 0.14, 0.13, 0.12, 0.11. The multivariable analysis Odds Ratio P-value (mvaORPval) of the classifier may be less than or equal to 0.10, 0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, 0.02, 0.01. The multivariable analysis Odds Ratio P-value (mvaORPval) of the classifier may be less than or equal to 0.009, 0.008, 0.007, 0.006, 0.005, 0.004, 0.003, 0.002, 0.001.

The clinical significance of the classifier may be based on the Kaplan Meier P-value (KM P-value). The Kaplan Meier P-value (KM P-value) of the classifier may be between about 0-0.8. The Kaplan Meier P-value (KM P-value) of the classifier may be between about 0-0.7. The Kaplan Meier P-value (KM P-value) of the classifier may be less than or equal to 0.80, 0.78, 0.76, 0.74, 0.72, 0.70, 0.68, 0.66, 0.64, 0.62, 0.60, 0.58, 0.56, 0.54, 0.52, 0.50. The Kaplan Meier P-value (KM P-value) of the classifier may be less than or equal to 0.48, 0.46, 0.44, 0.42, 0.40, 0.38, 0.36, 0.34, 0.32, 0.30, 0.28, 0.26, 0.25, 0.22, 0.21, 0.20, 0.19, 0.18, 0.17, 0.16, 0.15, 0.14, 0.13, 0.12, 0.11. The Kaplan Meier P-value (KM P-value) of the classifier may be less than or equal to 0.10, 0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, 0.02, 0.01. The Kaplan Meier P-value (KM P-value) of the classifier may be less than or equal to 0.009, 0.008, 0.007, 0.006, 0.005, 0.004, 0.003, 0.002, 0.001.

The clinical significance of the classifier may be based on the survival AUC value (survAUC). The survival AUC value (survAUC) of the classifier may be between about 0-1. The survival AUC value (survAUC) of the classifier may be between about 0-0.9. The survival AUC value (survAUC) of the classifier may be less than or equal to 1, 0.98, 0.96, 0.94, 0.92, 0.90, 0.88, 0.86, 0.84, 0.82, 0.80. The survival AUC value (survAUC) of the classifier may be less than or equal to 0.80, 0.78, 0.76, 0.74, 0.72, 0.70, 0.68, 0.66, 0.64, 0.62, 0.60, 0.58, 0.56, 0.54, 0.52, 0.50. The survival AUC value (survAUC) of the classifier may be less than or equal to 0.48, 0.46, 0.44, 0.42, 0.40, 0.38, 0.36, 0.34, 0.32, 0.30, 0.28, 0.26, 0.25, 0.22, 0.21, 0.20, 0.19, 0.18, 0.17, 0.16, 0.15, 0.14, 0.13, 0.12, 0.11. The survival AUC value (survAUC) of the classifier may be less than or equal to 0.10, 0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, 0.02, 0.01. The survival AUC value (survAUC) of the classifier may be less than or equal to 0.009, 0.008, 0.007, 0.006, 0.005, 0.004, 0.003, 0.002, 0.001.

The clinical significance of the classifier may be based on the Univariable Analysis Hazard Ratio P-value (uvaHRPval). The Univariable Analysis Hazard Ratio P-value (uvaHRPval) of the classifier may be between about 0-0.4. The Univariable Analysis Hazard Ratio P-value (uvaHRPval) of the classifier may be between about 0-0.3. The Univariable Analysis Hazard Ratio P-value (uvaHRPval) of the classifier may be less than or equal to 0.40, 0.38, 0.36, 0.34, 0.32. The Univariable Analysis Hazard Ratio P-value (uvaHRPval) of the classifier may be less than or equal to 0.30, 0.29, 0.28, 0.27, 0.26, 0.25, 0.24, 0.23, 0.22, 0.21, 0.20. The Univariable Analysis Hazard Ratio P-value (uvaHRPval) of the classifier may be less than or equal to 0.19, 0.18, 0.17, 0.16, 0.15, 0.14, 0.13, 0.12, 0.11. The Univariable Analysis Hazard Ratio P-value (uvaHRPval) of the classifier may be less than or equal to 0.10, 0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, 0.02, 0.01. The Univariable Analysis Hazard Ratio P-value (uvaHRPval) of the classifier may be less than or equal to 0.009, 0.008, 0.007, 0.006, 0.005, 0.004, 0.003, 0.002, 0.001.

The clinical significance of the classifier may be based on the Multivariable Analysis Hazard Ratio P-value (mvaHRPval)mva HRPval. The Multivariable Analysis Hazard Ratio P-value (mvaHRPval)mva HRPval of the classifier may be between about 0-1. The Multivariable Analysis Hazard Ratio P-value (mvaHRPval)mva HRPval of the classifier may be between about 0-0.9. The Multivariable Analysis Hazard Ratio P-value (mvaHRPval)mva HRPval of the classifier may be less than or equal to 1, 0.98, 0.96, 0.94, 0.92, 0.90, 0.88, 0.86, 0.84, 0.82, 0.80. The Multivariable Analysis Hazard Ratio P-value (mvaHRPval)mva HRPval of the classifier may be less than or equal to 0.80, 0.78, 0.76, 0.74, 0.72, 0.70, 0.68, 0.66, 0.64, 0.62, 0.60, 0.58, 0.56, 0.54, 0.52, 0.50. The Multivariable Analysis Hazard Ratio P-value (mvaHRPval)mva HRPval of the classifier may be less than or equal to 0.48, 0.46, 0.44, 0.42, 0.40, 0.38, 0.36, 0.34, 0.32, 0.30, 0.28, 0.26, 0.25, 0.22, 0.21, 0.20, 0.19, 0.18, 0.17, 0.16, 0.15, 0.14, 0.13, 0.12, 0.11. The Multivariable Analysis Hazard Ratio P-value (mvaHRPval)mva HRPval of the classifier may be less than or equal to 0.10, 0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, 0.02, 0.01. The Multivariable Analysis Hazard Ratio P-value (mvaHRPval)mva HRPval of the classifier may be less than or equal to 0.009, 0.008, 0.007, 0.006, 0.005, 0.004, 0.003, 0.002, 0.001.

The clinical significance of the classifier may be based on the Multivariable Analysis Hazard Ratio P-value (mvaHRPval). The Multivariable Analysis Hazard Ratio P-value (mvaHRPval) of the classifier may be between about 0 to about 0.60. significance of the classifier may be based on the Multivariable Analysis Hazard Ratio P-value (mvaHRPval). The Multivariable Analysis Hazard Ratio P-value (mvaHRPval) of the classifier may be between about 0 to about 0.50. significance of the classifier may be based on the Multivariable Analysis Hazard Ratio P-value (mvaHRPval). The Multivariable Analysis Hazard Ratio P-value (mvaHRPval) of the classifier may be less than or equal to 0.50, 0.47, 0.45, 0.43, 0.40, 0.38, 0.35, 0.33, 0.30, 0.28, 0.25, 0.22, 0.20, 0.18, 0.16, 0.15, 0.14, 0.13, 0.12, 0.11, 0.10. The Multivariable Analysis Hazard Ratio P-value (mvaHRPval) of the classifier may be less than or equal to 0.10, 0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, 0.02, 0.01. The Multivariable Analysis Hazard Ratio P-value (mvaHRPval) of the classifier may be less than or equal to 0.01, 0.009, 0.008, 0.007, 0.006, 0.005, 0.004, 0.003, 0.002, 0.001.

The method may further comprise determining an expression profile based on the one or more classifiers. The method may further comprise providing a sample from a subject. The subject may be a healthy subject. The subject may be suffering from a cancer or suspected of suffering from a cancer. The method may further comprise diagnosing a cancer in a subject based on the expression profile or classifier. The method may further comprise treating a cancer in a subject in need thereof based on the expression profile or classifier. The method may further comprise determining a treatment regimen for a cancer in a subject in need thereof based on the expression profile or classifier. The method may further comprise prognosing a cancer in a subject based on the expression profile or classifier.

Further disclosed herein is a kit for analyzing a cancer, comprising (a) a probe set comprising a plurality of target sequences, wherein the plurality of target sequences comprises at least one target sequence listed in Table 11; and (b) a computer model or algorithm for analyzing an expression level and/or expression profile of the target sequences in a sample. In some embodiments, the kit further comprises a computer model or algorithm for correlating the expression level or expression profile with disease state or outcome. In some embodiments, the kit further comprises a computer model or algorithm for designating a treatment modality for the individual. In some embodiments, the kit further comprises a computer model or algorithm for normalizing expression level or expression profile of the target sequences. In some embodiments, the kit further comprises a computer model or algorithm comprising a robust multichip average (RMA), probe logarithmic intensity error estimation (PLIER), non-linear fit (NLFIT) quantile-based, nonlinear normalization, or a combination thereof. In some embodiments, the plurality of target sequences comprises at least 5 target sequences selected from Table 11. In some embodiments, the plurality of target sequences comprises at least 10 target sequences selected from Table 11. In some embodiments, the plurality of target sequences comprises at least 15 target sequences selected from Table 11. In some embodiments, the plurality of target sequences comprises at least 20 target sequences selected from Table 11. In some embodiments, the plurality of target sequences comprises at least 30 target sequences selected from Table 11. In some embodiments, the plurality of target sequences comprises at least 35 target sequences selected from Table 11. In some embodiments, the plurality of targets comprises at least 40 target sequences selected from Table 11. In some embodiments, the cancer is selected from the group consisting of a carcinoma, sarcoma, leukemia, lymphoma, myeloma, and a CNS tumor. In some embodiments, the cancer is selected from the group consisting of skin cancer, lung cancer, colon cancer, pancreatic cancer, prostate cancer, liver cancer, thyroid cancer, ovarian cancer, uterine cancer, breast cancer, cervical cancer, kidney cancer, epithelial carcinoma, squamous carcinoma, basal cell carcinoma, melanoma, papilloma, and adenomas. In some embodiments, the cancer is a prostate cancer. In some embodiments, the cancer is a pancreatic cancer. In some embodiments, the cancer is a breast cancer. In some embodiments, the cancer is a thyroid cancer. In some embodiments, the cancer is a lung cancer.

Further disclosed herein is a kit for analyzing a cancer, comprising (a) a probe set comprising a plurality of target sequences, wherein the plurality of target sequences hybridizes to one or more targets selected from Tables 2, 4, 11 or 55; and (b) a computer model or algorithm for analyzing an expression level and/or expression profile of the target sequences in a sample. In some embodiments, the kit further comprises a computer model or algorithm for correlating the expression level or expression profile with disease state or outcome. In some embodiments, the kit further comprises a computer model or algorithm for designating a treatment modality for the individual. In some embodiments, the kit further comprises a computer model or algorithm for normalizing expression level or expression profile of the target sequences. In some embodiments, the kit further comprises a computer model or algorithm comprising a robust multichip average (RMA), probe logarithmic intensity error estimation (PLIER), non-linear fit (NLFIT) quantile-based, nonlinear normalization, or a combination thereof. In some embodiments, the targets comprise at least 5 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the targets comprise at least 10 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the targets comprise at least 15 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the targets comprise at least 20 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the targets comprise at least 30 targets selected from Tables 2, 11 or 55. In some embodiments, the targets comprise at least 35 targets selected from Tables 2, 11 or 55. In some embodiments, the targets comprise comprises at least 40 targets selected from Tables 2, 11 or 55. In some embodiments, the targets are selected from Table 2. In some embodiments, the targets are selected from Table 4. In some embodiments, the targets are selected from Table 11. In some embodiments, the cancer is selected from the group consisting of a carcinoma, sarcoma, leukemia, lymphoma, myeloma, and a CNS tumor. In some embodiments, the cancer is selected from the group consisting of skin cancer, lung cancer, colon cancer, pancreatic cancer, prostate cancer, liver cancer, thyroid cancer, ovarian cancer, uterine cancer, breast cancer, cervical cancer, kidney cancer, epithelial carcinoma, squamous carcinoma, basal cell carcinoma, melanoma, papilloma, and adenomas. In some embodiments, the cancer is a prostate cancer. In some embodiments, the cancer is a pancreatic cancer. In some embodiments, the cancer is a breast cancer. In some embodiments, the cancer is a thyroid cancer. In some embodiments, the cancer is a lung cancer.

INCORPORATION BY REFERENCE

All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference in their entireties to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1. Overview of the studies. CONSORT diagram illustrating the design for the training and independent validation studies.

FIG. 2. KM curves for BCR, METS, PCSM and Overall Survival events for NED, PSA and METs patients in the Discovery cohort. For each plot, probability of the event (BCR, METS, PCSM or OS) is shown in the Y-Axis. METS are also named SYS (for systemic event) or CR (for Clinical Recurrence).

FIG. 3. 43-Biomarker Set Methods

FIG. 4. PSR Annotation of the 43-Biomarker Set

FIG. 5. Biomarker variable mean squared error for selection of 22-biomarker signature

FIGS. 6A-B. Biomarker signature variable importance plot

FIG. 7. Development of Genomic Classifier (GC).

FIG. 8. Survival ROC to compare the accuracy of predicting metastatic disease (METS) at 5 years in different models. Survival ROC evaluates the ability of a marker measured at baseline (in this case RP) to discriminate between patients who develop CP from those who do not over a follow-up interval of 5 years. C discrimination index with 95% confidence intervals are shown for each prognostic classifier.

FIGS. 9A-B. Standard ROC and Discrimination plot for GC, CC and GCC.

FIG. 10. Calibration plots for probability of METS

FIG. 11. Discrimination plots for CC, GC, and GCC models (for METS)

FIG. 12. Survival decision curve analysis for the prognostic models at 5 years following radical prostatectomy. Performance of models is compared to extremes of classifying all patients as CP (thus potentially treating all patients, light gray line), against classifying no patients as CP (this treating none, horizontal dark gray line). A decision-to-treat threshold is a cutoff used to classify a patient as having CP or not. In decision curve analysis, this threshold varies from 0 to 1, and the sensitivity and specificity are calculated at each threshold, to determine the net-benefit. A model with a high net-benefit that does not overlap the “Treat All” line is optimal. The x-axis is the threshold probabilities while the y-axis is the net-benefit.

FIG. 13. Comparison of CC, GC and GCC cumulative Incidence (for METS)

FIG. 14. Cumulative incidence removing patients with adjuvant hormones: GPSM and GCC

FIG. 15. Cumulative incidence removing patients with adjuvant hormones: GPSM and GC.

FIG. 16. 5-year metastasis-free survival ROC in sampled validation study

FIG. 17. Cumulative Incidence: D'Amico and GC

FIGS. 18A-B. Cumulative incidence of GPSM and GC groups. A) Patients are segregated into low (<5), intermediate (5-9) and high risk (≥10) GPSM groups as suggested in Thompson et al. B) GC scores were segregated into low (<0.5) and high (>=0.5) for tentative risk groups. Irrespective of the method used, red lines indicated higher risk, orange intermediate risk and green lower risk. Number of patients (weighting controls by a factor of 5) at risk is shown below the x-axis, and the total number of events in each risk group is shown in boxes beside the lines.

FIGS. 19A-B. Discrimination plots showing segregation of Gleason 7 patients by CC (or CM, for Clinical Model) and GCC (n=382)

FIGS. 20A-B. CM and GCC Risk Groups of Gleason 7, 4+3 and 3+4 patients with CR endpoint (n=150)

FIGS. 21A-B. GCC stratification of Gleason 7, 4+3 and 3+4 patients with PCSM endpoint (n=150)

FIGS. 22A-B. Gleason 4+3 (n=50) and 3+4 (n=100) sub-stratification by GCC with METS (or CR, for Clinical Recurrence) endpoint

FIGS. 23A-B. Gleason 4+3 (n=50) and 3+4 (n=100) sub-stratification by GCC with PCSM endpoint

FIGS. 24A-B. Stratification of uniformly treated N+ patient by GCC and CC (or CM, for Clinical Model) (n=97 and n=96) with METS (or CR, for Clinical Recurrence) endpoint

FIGS. 25A-B. Stratification of uniformly treated N+ patient by GCC and CC (or CM, for Clinical Model) (n=97 and n=96) with PCSM endpoint

FIG. 26. Multidimensional scaling plot of (A) the training and (B) the testing sets. Controls are indicated as ‘+’ and cases are indicated as circles. In both the training and validation sets the controls tend to cluster on the left of the plot and the cases on the right of the plot. In this manner, most of the biological differences are expressed in the first dimension of the scaling. Random forest proximity [http://www.stat.berkeley.edu/˜breiman/] was used to measure the 22 marker distance between samples.

FIG. 27. Performance of external signatures in training and testing sets. For each signature, the institution associated to it, year of publication, lead author, the AUC obtained in the training and testing sets, as well as the 95% Confidence Interval for this metric is shown.

FIG. 28. Performance of single genes in training and testing sets. For each gene, the AUC obtained in the training and testing sets, as well as the 95% Confidence Interval for this metric is shown.

FIG. 29. ROC curve and AUC with 95% confidence interval for classifiers and individual clinicopathologic variables in training and testing sets. CC: clinical-only classifier. GC: genomic classifier. GCC: combined genomic-clinical classifier.

FIGS. 30A-B. ROC curve of multivariable models and individual clinicopathologic variables. A) ROC curves in Training B) ROC curves in testing.

FIG. 31. Metastasis-Free 5-year Survival ROC of GC an individual clinicopathologic variables in the independent validation set.

FIG. 32. Metastasis-Free 5-year Decision Curve of GC an individual clinicopathologic variables in the independent validation set.

FIG. 33. Distribution of GC scores among pathologic GS categories in testing. GC scores are plotted with a jitter so as to more easily differentiate the patients among each Pathologic GS (x-axis) groups. Cases (black) and controls patients (gray) are shown for each category. The dashed black line indicates the GC cutoff of 0.5. Trends show the patients with high GC scores tend to have high Gleason Scores as well.

FIG. 34. Distribution of GC scores among pathologic GS categories in the independent validation set. METS=triangle, METS-free=circle

FIGS. 35A-C. Prostate Cancer Specific Mortality Kaplan-Meier Plots on Training and Testing Sets. FIG. 35A—Gleason Score=7; FIG. 35B—Gleason Score=8; FIG. 35C—Gleason Score>=9.

FIG. 36. Kaplan Meier estimates for all PSA Controls with metastasis endpoint. PSA controls were separated into two groups based on high (>0.5) or low risk according to GC. Log-rank p-values are shown in the upper right corner.

FIG. 37. Survival decision curve analysis of GC and CAPRA-S.

FIG. 38. Distribution of GC scores among CAPRA-S score categories.

FIGS. 39A-B. The cumulative incidence plot for the CAPRA-S high risk group (A) and stratified by GC score (B).

FIGS. 40A-C. Prediction Curve for GC, CAPRA-S and an integrated genomic-clinical model. (A) CAPRA-S; (B) GC; (C) Integrated Genomic-Clinical model.

FIGS. 41A-B. Breakdown of treatment recommendations pre and post-GC for Low and High GC Risk groups in the Adjuvant setting. (A) pre-GC; (B) post-GC.

FIG. 42. Proportion of recommendations for treatment for the indicated values of clinical variables (eg: Presence/Absence) Pre-GC and the resulting proportion recommended for treatment post-GC in High and Low GC Risk groups in the Adjuvant setting.

FIGS. 43A-B. Breakdown of treatment recommendations pre and post-GC for Low and High GC Risk groups in the Salvage setting. (A) pre-GC; (B) post-GC.

FIGS. 44A-B. Proportion of recommendations for treatment for the indicated values of clinical variables (eg: Presence/Absence) Pre-GC and the resulting proportion recommended for treatment post-GC in High and Low GC Risk groups in the Salvage setting.

FIG. 45. Urologists confidence in treatment recommendations made post GC test results.

FIG. 46. GC Score distribution among METS (right—light grey circles) and No-METS patients (left—dark grey circles).

FIG. 47. 3-year Survival ROC comparing GC and clinicopathologic features. Values within legend indicate AUC and its corresponding 95% Confidence Interval.

FIG. 48. 3-year Survival ROC of clinical-only and genomic-based models. Values within legend indicate AUC and its corresponding 95% Confidence.

FIG. 49. 3-year Survival ROC of clinical-only and genomic-based models after excluding patients with Adjuvant therapy. Values within legend indicate AUC and its corresponding 95% Confidence Interval.

FIG. 50. Distribution of GC scores among pathological Gleason Score categories for patients with and without metastasis after Biochemical Recurrence. METS (triangle); No-METS (circle).

FIG. 51. Cumulative Incidence of metastasis after BCR with a GC cut-off of 0.4

FIG. 52. Cumulative Incidence of metastasis after BCR with a GC cut-off of 0.5

FIG. 53. Cumulative Incidence of metastasis after BCR after excluding patients with Adjuvant Treatment

FIG. 54. Reclassification of BCR patients by GC

FIG. 55. 3-year Decision Curve Analysis

Table 1. Clinical characteristics of Discovery and Validation data set

Table 2. 43-Biomarker Set. Chromosomal coordinates correspond to the hg19 version of the human genome.

Table 3. Gene Ontology Terms Enriched in the 43-Biomarker Signature

Table 4. 22-Biomarker Set. Chromosomal coordinates correspond to the hg19 version of the human genome.

Table 5. Comparison of Discrimination ability of classifiers in different datasets

Table 6. Reclassification of GPSM categories by GC.

Table 7. Univariable Analysis for panel of prognostic classifiers and clinicopathologic variables (for METS)

Table 8. Multivariable Cox regression analysis.

Table 9. Multivariable Analysis for panel of prognostic classifiers and clinicopathologic variables Adjusted for Hormone Therapy (for METS)

Table 10. Multivariable Analysis of GC compared to GPSM and CC (for METS)

Table 11. List of Target Sequences

Table 12. Univariable and Multivariable Logistic Regression Analysis in Testing Set

Table 13. Multivariable Cox proportional hazards modeling comparing genomic classifier (GC) to clinicopathologic variables using different Gleason Score parameterization in the independent validation set.

Table 14. Multivariable Cox proportional hazard models of GC with Stephenson Nomogram

Table 15. Multivariable Cox proportional hazards modeling of decile risk groups of the genomic classifier (GC) after adjusting for treatment.

Table 16. Survival analysis of GC score risk groups (<0.4, 0.4-0.6, >0.6).

Table 17. Reclassification by GC of Gleason Risk categories among cases and controls in the testing set.

Table 18. Number of metastasis and PCSM events for different GC score risk groups among pathologic GS categories in the independent validation set.

Table 19. Number of patients at risk of developing PCSM at various time points after BCR

Table 20. Number of patients at risk of metastasis at various time points after BCR

Table 21. Clinical characteristics of the cohort in Example 9.

Table 22. Survival ROC AUCs and associated 95% confidence intervals for GC, CAPRA-S and other individual clinical variables.

Table 23. Reclassification of GC low risk (GC Score<0.4) and GC high risk (GC Score≥0.4) for CAPRA-S low, intermediate and high risk scores.

Table 24. Univariable and Multivariable Analysis for GC, CAPRA-S and individual clinical variables.

Table 25. Characteristics of urologists participating in study.

Table 26. Characteristics of patient cases.

Table 27. Probability of Changing Treatment Recommendation from Pre to Post GC test

Table 28. Change in treatment intensity by initial Perceived and GC risks.

Table 29. Detailed Overview of Probability of Changing Treatment Recommendation from Pre to Post GC test.

Table 30. Proportions of patients with treatment recommended.

Table 31. Urologist reported confidence in and influence on treatment recommendations.

Table 32. Breakdown of treatment recommendations pre and post-GC for Low and High GC Risk groups in the Adjuvant setting

Table 33. Clinical and pathologic characteristics of patient cohort.

Table 34. Number of patients at risk of developing metastasis at various time points after BCR.

Table 35. Number of patients at risk of developing metastasis at various time points after BCR.

Table 36. Number of patients at risk of developing metastasis at various time points after BCR.

Table 37. Survival Analysis for GC and clinicopathologic factors. Multivariable analysis is adjusted for adjuvant treatment, GC reported for 10% unit increase.

Table 38. Survival Analysis for GC, Stephenson and CAPRA-S. Multivariable analyses are adjusted for adjuvant treatment, GC and Stephenson reported for 10% unit increase.

Table 39: biomarkers from the 43 biomarker panel with significance for Wilcoxon P-value (auc.pvalue) and other metrics for the BCR event endpoint.

Table 40: biomarkers from the 43 biomarker panel with significance for Wilcoxon P-value (auc.pvalue) and other metrics for the ECE endpoint.

Table 41: biomarkers from the 43 biomarker panel with significance for Wilcoxon P-value (auc.pvalue) and other metrics for the LCR event endpoint.

Table 42: biomarkers from the 43 biomarker panel with significance for Wilcoxon P-value (auc.pvalue) and other metrics for the LNI endpoint.

Table 43: biomarkers from the 43 biomarker panel with significance for Wilcoxon P-value (auc.pvalue) and other metrics for the MET event endpoint.

Table 44: biomarkers from the 43 biomarker panel with significance for Wilcoxon P-value (auc.pvalue) and other metrics for the OS event endpoint.

Table 45: biomarkers from the 43 biomarker panel with significance for Wilcoxon P-value (auc.pvalue) and other metrics for the pathological Gleason endpoint.

Table 46: biomarkers from the 43 biomarker panel with significance for Wilcoxon P-value (auc.pvalue) and other metrics for the PCSM event endpoint.

Table 47: biomarkers from the 43 biomarker panel with significance for Wilcoxon P-value (auc.pvalue) and other metrics for the psaDT endpoint.

Table 48: biomarkers from the 43 biomarker panel with significance for Wilcoxon P-value (auc.pvalue) and other metrics for the SVI endpoint.

Table 49: pairwise biomarkers from the 43 biomarker panel with significance for Wilcoxon P-value (auc.pvalue<=0.05) and other metrics for the BCR event endpoint.

Table 50: pairwise biomarkers from the 43 biomarker panel with significance for Wilcoxon P-value (auc.pvalue<=0.001) and other metrics for the MET event endpoint.

Table 51: pairwise biomarkers from the 43 biomarker panel with significance for Wilcoxon P-value (auc.pvalue<=0.05) and other metrics for the PCSM event endpoint.

Table 52: pairwise biomarkers from the 43 biomarker panel with significance for Wilcoxon P-value (auc.pvalue<=0.05) and other metrics for the psaDT endpoint.

Table 53: biomarkers from the 2,040 biomarker library with significance for Wilcoxon P-value (auc.pvalue<=0.05) and other metrics for the BCR event endpoint.

Table 54: biomarkers from the 2,040 biomarker library with significance for Wilcoxon P-value (auc.pvalue<=0.05) and other metrics for the MET event endpoint.

Table 55: 2,040 biomarker library. For each feature, genomic category, associated Affymetrix probeset ID, Associated Gene, Kolmogorov Smirnov Test P-value demonstrating statistical significance at 0.05 level is shown, together with Mean Decrease in Gini and Mean Decrease in Accuracy.

DETAILED DESCRIPTION OF THE INVENTION

The present invention discloses systems and methods for diagnosing, predicting, and/or monitoring the status or outcome of a cancer in a subject using expression-based analysis of a plurality of targets. Generally, the method comprises (a) optionally providing a sample from a subject suffering from a cancer; (b) assaying the expression level for a plurality of targets in the sample; and (c) diagnosing, predicting and/or monitoring the status or outcome of the cancer based on the expression level of the plurality of targets.

Assaying the expression level for a plurality of targets in the sample may comprise applying the sample to a microarray. In some instances, assaying the expression level may comprise the use of an algorithm. The algorithm may be used to produce a classifier. Alternatively, the classifier may comprise a probe selection region. In some instances, assaying the expression level for a plurality of targets comprises detecting and/or quantifying the plurality of targets. In some embodiments, assaying the expression level for a plurality of targets comprises sequencing the plurality of targets. In some embodiments, assaying the expression level for a plurality of targets comprises amplifying the plurality of targets. In some embodiments, assaying the expression level for a plurality of targets comprises quantifying the plurality of targets. In some embodiments, assaying the expression level for a plurality of targets comprises conducting a multiplexed reaction on the plurality of targets.

In some instances, the plurality of targets comprises one or more targets selected from Tables 2, 4, 11 or 55. In some instances, the plurality of targets comprises at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, or at least about 10 targets selected from Table 2, 4, and 11. In other instances, the plurality of targets comprises at least about 12, at least about 15, at least about 17, at least about 20, at least about 22, at least about 25, at least about 27, at least about 30, at least about 32, at least about 35, at least about 37, or at least about 40 targets selected from Tables 2, 4, 11 or 55. In some instances, the targets are selected from Table 2. In some instances, the targets are selected from Table 4. In some instances, the targets are selected from Table 11. In some instances, the plurality of targets comprises a coding target, non-coding target, or any combination thereof. In some instances, the coding target comprises an exonic sequence. In other instances, the non-coding target comprises a non-exonic sequence. In some instances, the non-exonic sequence comprises an untranslated region (e.g., UTR), intronic region, intergenic region, or any combination thereof. Alternatively, the plurality of targets comprises an anti-sense sequence. In other instances, the plurality of targets comprises a non-coding RNA transcript.

Further disclosed herein, is a probe set for diagnosing, predicting, and/or monitoring a cancer in a subject. In some instances, the probe set comprises a plurality of probes capable of detecting an expression level of one or more targets selected from Tables 2, 4, 11 or 55, wherein the expression level determines the cancer status of the subject with at least about 45% specificity. In some instances, detecting an expression level comprise detecting gene expression, protein expression, or any combination thereof. In some instances, the plurality of targets comprises one or more targets selected from Tables 2, 4, 11 or 55. In some instances, the plurality of targets comprises at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, or at least about 10 targets selected from Table 2, 4, and 11. In other instances, the plurality of targets comprises at least about 12, at least about 15, at least about 17, at least about 20, at least about 22, at least about 25, at least about 27, at least about 30, at least about 32, at least about 35, at least about 37, or at least about 40 targets selected from Tables 2, 4, 11 or 55. In some instances, the targets are selected from Table 2. In some instances, the targets are selected from Table 4. In some instances, the targets are selected from Table 11. In some instances, the plurality of targets comprises a coding target, non-coding target, or any combination thereof. In some instances, the coding target comprises an exonic sequence. In other instances, the non-coding target comprises a non-exonic sequence. In some instances, the non-exonic sequence comprises an untranslated region (e.g., UTR), intronic region, intergenic region, or any combination thereof. Alternatively, the plurality of targets comprises an anti-sense sequence. In other instances, the plurality of targets comprises a non-coding RNA transcript.

Further disclosed herein are methods for characterizing a patient population. Generally, the method comprises: (a) providing a sample from a subject; (b) assaying the expression level for a plurality of targets in the sample; and (c) characterizing the subject based on the expression level of the plurality of targets. In some instances, the plurality of targets comprises one or more targets selected from Tables 2, 4, 11 or 55. In some instances, the plurality of targets comprises at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, or at least about 10 targets selected from Tables 2, 4, 11 or 55. In other instances, the plurality of targets comprises at least about 12, at least about 15, at least about 17, at least about 20, at least about 22, at least about 25, at least about 27, at least about 30, at least about 32, at least about 35, at least about 37, or at least about 40 targets selected from Tables 2, 4, 11 or 55. In some instances, the targets are selected from Table 2. In some instances, the targets are selected from Table 4. In some instances, the targets are selected from Table 11. In some instances, the plurality of targets comprises a coding target, non-coding target, or any combination thereof. In some instances, the coding target comprises an exonic sequence. In other instances, the non-coding target comprises a non-exonic sequence. In some instances, the non-exonic sequence comprises an untranslated region (e.g., UTR), intronic region, intergenic region, or any combination thereof. Alternatively, the plurality of targets comprises an anti-sense sequence. In other instances, the plurality of targets comprises a non-coding RNA transcript.

In some instances, characterizing the subject comprises determining whether the subject would respond to an anti-cancer therapy. Alternatively, characterizing the subject comprises identifying the subject as a non-responder to an anti-cancer therapy. Optionally, characterizing the subject comprises identifying the subject as a responder to an anti-cancer therapy.

Before the present invention is described in further detail, it is to be understood that this invention is not limited to the particular methodology, compositions, articles or machines described, as such methods, compositions, articles or machines can, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention.

Definitions

Unless defined otherwise or the context clearly dictates otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In describing the present invention, the following terms may be employed, and are intended to be defined as indicated below.

The term “polynucleotide” as used herein refers to a polymer of greater than one nucleotide in length of ribonucleic acid (RNA), deoxyribonucleic acid (DNA), hybrid RNA/DNA, modified RNA or DNA, or RNA or DNA mimetics, including peptide nucleic acids (PNAs). The polynucleotides may be single- or double-stranded. The term includes polynucleotides composed of naturally-occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as polynucleotides having non-naturally-occurring portions which function similarly. Such modified or substituted polynucleotides are well known in the art and for the purposes of the present invention, are referred to as “analogues.”

“Complementary” or “substantially complementary” refers to the ability to hybridize or base pair between nucleotides or nucleic acids, such as, for instance, between a sensor peptide nucleic acid or polynucleotide and a target polynucleotide. Complementary nucleotides are, generally, A and T (or A and U), or C and G. Two single-stranded polynucleotides or PNAs are said to be substantially complementary when the bases of one strand, optimally aligned and compared and with appropriate insertions or deletions, pair with at least about 80% of the bases of the other strand, usually at least about 90% to 95%, and more preferably from about 98 to 100%.

Alternatively, substantial complementarity exists when a polynucleotide may hybridize under selective hybridization conditions to its complement. Typically, selective hybridization may occur when there is at least about 65% complementarity over a stretch of at least 14 to 25 bases, for example at least about 75%, or at least about 90% complementarity.

“Preferential binding” or “preferential hybridization” refers to the increased propensity of one polynucleotide to bind to its complement in a sample as compared to a noncomplementary polymer in the sample.

Hybridization conditions may typically include salt concentrations of less than about 1M, more usually less than about 500 mM, for example less than about 200 mM. In the case of hybridization between a peptide nucleic acid and a polynucleotide, the hybridization can be done in solutions containing little or no salt. Hybridization temperatures can be as low as 5° C., but are typically greater than 22° C., and more typically greater than about 30° C., for example in excess of about 37° C. Longer fragments may require higher hybridization temperatures for specific hybridization as is known in the art. Other factors may affect the stringency of hybridization, including base composition and length of the complementary strands, presence of organic solvents and extent of base mismatching, and the combination of parameters used is more important than the absolute measure of any one alone. Other hybridization conditions which may be controlled include buffer type and concentration, solution pH, presence and concentration of blocking reagents to decrease background binding such as repeat sequences or blocking protein solutions, detergent type(s) and concentrations, molecules such as polymers which increase the relative concentration of the polynucleotides, metal ion(s) and their concentration(s), chelator(s) and their concentrations, and other conditions known in the art.

“Multiplexing” herein refers to an assay or other analytical method in which multiple analytes are assayed. In some instances, the multiple analytes are from the same sample. In some instances, the multiple analytes are assayed simultaneously. Alternatively, the multiple analytes are assayed sequentially. In some instances, assaying the multiple analytes occurs in the same reaction volume. Alternatively, assaying the multiple analytes occurs in separate or multiple reaction volumes.

A “target sequence” as used herein (also occasionally referred to as a “PSR” or “probe selection region”) refers to a region of the genome against which one or more probes can be designed. A “target sequence” may be a coding target or a non-coding target. A “target sequence” may comprise exonic and/or non-exonic sequences. Alternatively, a “target sequence” may comprise an ultraconserved region. An ultraconserved region is generally a sequence that is at least 200 base pairs and is conserved across multiple species. An ultraconserved region may be exonic or non-exonic. Exonic sequences may comprise regions on a protein-coding gene, such as an exon, UTR, or a portion thereof. Non-exonic sequences may comprise regions on a protein-coding, non protein-coding gene, or a portion thereof. For example, non-exonic sequences may comprise intronic regions, promoter regions, intergenic regions, a non-coding transcript, an exon anti-sense region, an intronic anti-sense region, UTR anti-sense region, non-coding transcript anti-sense region, or a portion thereof.

As used herein, a probe is any polynucleotide capable of selectively hybridizing to a target sequence or its complement, or to an RNA version of either. A probe may comprise ribonucleotides, deoxyribonucleotides, peptide nucleic acids, and combinations thereof. A probe may optionally comprise one or more labels. In some embodiments, a probe may be used to amplify one or both strands of a target sequence or an RNA form thereof, acting as a sole primer in an amplification reaction or as a member of a set of primers.

As used herein, a non-coding target may comprise a nucleotide sequence. The nucleotide sequence is a DNA or RNA sequence. A non-coding target may include a UTR sequence, an intronic sequence, or a non-coding RNA transcript. A non-coding target also includes sequences which partially overlap with a UTR sequence or an intronic sequence. A non-coding target also includes non-exonic transcripts.

As used herein, a coding target includes nucleotide sequences that encode for a protein and peptide sequences. The nucleotide sequence is a DNA or RNA sequence. The coding target includes protein-coding sequence. Protein-coding sequences include exon-coding sequences (e.g., exonic sequences).

As used herein, diagnosis of cancer may include the identification of cancer in a subject, determining the malignancy of the cancer, or determining the stage of the cancer.

As used herein, prognosis of cancer may include predicting the clinical outcome of the patient, assessing the risk of cancer recurrence, determining treatment modality, or determining treatment efficacy.

“Having” is an open-ended phrase like “comprising” and “including,” and includes circumstances where additional elements are included and circumstances where they are not

“Optional” or “optionally” means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not.

As used herein ‘NED’ describes a clinically distinct disease state in which patients show no evidence of disease (NED’) at least 5 years after surgery, ‘PSA’ describes a clinically distinct disease state in which patients show biochemical relapse only (two successive increases in prostate-specific antigen levels but no other symptoms of disease with at least 5 years follow up after surgery; TSA′) and ‘SYS’ describes a clinically distinct disease state in which patients develop biochemical relapse and present with systemic cancer disease or metastases (‘SYS’) within five years after the initial treatment with radical prostatectomy.

The terms “METS”, “SYS”, “systemic event”, “Systemic progression”, “CR” or “Clinical Recurrence” may be used interchangeably and generally refer to patients that experience BCR (biochemical reccurrence) and that develop metastases (confirmed by bone or CT scan). The patients may experience BCR within 5 years of RP (radial prostectomy). The patients may develop metastases within 5 years of BCR. In some cases, patients regarded as METS may experience BCR after 5 years of RP.

As used herein, the term “about” refers to approximately a +/−10% variation from a given value. It is to be understood that such a variation is always included in any given value provided herein, whether or not it is specifically referred to.

Use of the singular forms “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise. Thus, for example, reference to “a polynucleotide” includes a plurality of polynucleotides, reference to “a target” includes a plurality of such targets, reference to “a normalization method” includes a plurality of such methods, and the like. Additionally, use of specific plural references, such as “two,” “three,” etc., read on larger numbers of the same subject, unless the context clearly dictates otherwise.

Terms such as “connected,” “attached,” “linked” and “conjugated” are used interchangeably herein and encompass direct as well as indirect connection, attachment, linkage or conjugation unless the context clearly dictates otherwise.

Where a range of values is recited, it is to be understood that each intervening integer value, and each fraction thereof, between the recited upper and lower limits of that range is also specifically disclosed, along with each subrange between such values. The upper and lower limits of any range can independently be included in or excluded from the range, and each range where either, neither or both limits are included is also encompassed within the invention. Where a value being discussed has inherent limits, for example where a component can be present at a concentration of from 0 to 100%, or where the pH of an aqueous solution can range from 1 to 14, those inherent limits are specifically disclosed. Where a value is explicitly recited, it is to be understood that values, which are about the same quantity or amount as the recited value, are also within the scope of the invention, as are ranges based thereon. Where a combination is disclosed, each sub-combination of the elements of that combination is also specifically disclosed and is within the scope of the invention. Conversely, where different elements or groups of elements are disclosed, combinations thereof are also disclosed. Where any element of an invention is disclosed as having a plurality of alternatives, examples of that invention in which each alternative is excluded singly or in any combination with the other alternatives are also hereby disclosed; more than one element of an invention can have such exclusions, and all combinations of elements having such exclusions are hereby disclosed.

Coding and Non-Coding Targets

The methods disclosed herein often comprise assaying the expression level of a plurality of targets. The plurality of targets may comprise coding targets and/or non-coding targets of a protein-coding gene or a non protein-coding gene. A protein-coding gene structure may comprise an exon and an intron. The exon may further comprise a coding sequence (CDS) and an untranslated region (UTR). The protein-coding gene may be transcribed to produce a pre-mRNA and the pre-mRNA may be processed to produce a mature mRNA. The mature mRNA may be translated to produce a protein.

A non protein-coding gene structure may comprise an exon and intron. Usually, the exon region of a non protein-coding gene primarily contains a UTR. The non protein-coding gene may be transcribed to produce a pre-mRNA and the pre-mRNA may be processed to produce a non-coding RNA (ncRNA).

A coding target may comprise a coding sequence of an exon. A non-coding target may comprise a UTR sequence of an exon, intron sequence, intergenic sequence, promoter sequence, non-coding transcript, CDS antisense, intronic antisense, UTR antisense, or non-coding transcript antisense. A non-coding transcript may comprise a non-coding RNA (ncRNA).

In some instances, the plurality of targets may be differentially expressed. In some instances, a plurality of probe selection regions (PSRs) is differentially expressed.

In some instances, the plurality of targets comprises one or more targets selected from Tables 2, 4, 11 or 55. In some instances, the plurality of targets comprises at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, or at least about 10 targets selected from Tables 2, 4, 11 or 55. In other instances, the plurality of targets comprises at least about 12, at least about 15, at least about 17, at least about 20, at least about 22, at least about 25, at least about 27, at least about 30, at least about 32, at least about 35, at least about 37, or at least about 40 targets selected from Tables 2, 4, 11 or 55. In some instances, the targets are selected from Table 2. In some instances, the targets are selected from Table 4. In some instances, the targets are selected from Table 11. In some instances, the plurality of targets comprises a coding target, non-coding target, or any combination thereof. In some instances, the coding target comprises an exonic sequence. In other instances, the non-coding target comprises a non-exonic sequence. Alternatively, a non-coding target comprises a UTR sequence, an intronic sequence, or a non-coding RNA transcript. In some instances, a non-coding target comprises sequences which partially overlap with a UTR sequence or an intronic sequence. A non-coding target also includes non-exonic transcripts. Exonic sequences may comprise regions on a protein-coding gene, such as an exon, UTR, or a portion thereof. Non-exonic sequences may comprise regions on a protein-coding, non protein-coding gene, or a portion thereof. For example, non-exonic sequences may comprise intronic regions, promoter regions, intergenic regions, a non-coding transcript, an exon anti-sense region, an intronic anti-sense region, UTR anti-sense region, non-coding transcript anti-sense region, or a portion thereof. In other instances, the plurality of targets comprises a non-coding RNA transcript.

In some instances, the plurality of targets is at least about 70% identical to a sequence selected from SEQ ID NOs 1-43. Alternatively, the plurality of targets is at least about 80% identical to a sequence selected from SEQ ID NOs 1-43. In some instances, the plurality of targets is at least about 85% identical to a sequence selected from SEQ ID NOs 1-43. In some instances, the plurality of targets is at least about 90% identical to a sequence selected from SEQ ID NOs 1-43. Alternatively, the plurality of targets is at least about 95% identical to a sequence selected from SEQ ID NOs 1-43.

Probes/Primers

The present invention provides for a probe set for diagnosing, monitoring and/or predicting a status or outcome of a cancer in a subject comprising a plurality of probes, wherein (i) the probes in the set are capable of detecting an expression level of at least one non-coding target; and (ii) the expression level determines the cancer status of the subject with at least about 40% specificity.

The probe set may comprise one or more polynucleotide probes. Individual polynucleotide probes comprise a nucleotide sequence derived from the nucleotide sequence of the target sequences or complementary sequences thereof. The nucleotide sequence of the polynucleotide probe is designed such that it corresponds to, or is complementary to the target sequences. The polynucleotide probe can specifically hybridize under either stringent or lowered stringency hybridization conditions to a region of the target sequences, to the complement thereof, or to a nucleic acid sequence (such as a cDNA) derived therefrom.

The selection of the polynucleotide probe sequences and determination of their uniqueness may be carried out in silico using techniques known in the art, for example, based on a BLASTN search of the polynucleotide sequence in question against gene sequence databases, such as the Human Genome Sequence, UniGene, dbEST or the non-redundant database at NCBI. In one embodiment of the invention, the polynucleotide probe is complementary to a region of a target mRNA derived from a target sequence in the probe set. Computer programs can also be employed to select probe sequences that may not cross hybridize or may not hybridize non-specifically.

In some instances, microarray hybridization of RNA, extracted from prostate cancer tissue samples and amplified, may yield a dataset that is then summarized and normalized by the fRMA technique. The 5,362,207 raw expression probes are summarized and normalized into 1,411,399 probe selection regions (“PSRs”). After removal (or filtration) of cross-hybridizing PSRs, highly variable PSRs (variance above the 90th percentile), and PSRs containing more than 4 probes, approximately 1.1 million PSRs remain. Following fRMA and filtration, the data can be decomposed into its principal components and an analysis of variance model is used to determine the extent to which a batch effect remains present in the first 10 principal components.

These remaining 1.1 million PSRs can then be subjected to filtration by a T-test between CR (clinical recurrence) and non-CR samples. Using a p-value cut-off of 0.01, 18,902 features remained in analysis for further selection. Feature selection was performed by regularized logistic regression using the elastic-net penalty. The regularized regression was bootstrapped over 1000 times using all training data; with each iteration of bootstrapping features that have non-zero co-efficient following 3-fold cross validation were tabulated. In some instances, features that were selected in at least 25% of the total runs were used for model building.

One skilled in the art understands that the nucleotide sequence of the polynucleotide probe need not be identical to its target sequence in order to specifically hybridize thereto. The polynucleotide probes of the present invention, therefore, comprise a nucleotide sequence that is at least about 65% identical to a region of the coding target or non-coding target selected from Tables 2, 4, 11 or 55. In another embodiment, the nucleotide sequence of the polynucleotide probe is at least about 70% identical a region of the coding target or non-coding target from Tables 2, 4, 11 and 55. In another embodiment, the nucleotide sequence of the polynucleotide probe is at least about 75% identical a region of the coding target or non-coding target from Tables 2, 4, 11 and 55. In another embodiment, the nucleotide sequence of the polynucleotide probe is at least about 80% identical a region of the coding target or non-coding target from Tables 2, 4, 11 and 55. In another embodiment, the nucleotide sequence of the polynucleotide probe is at least about 85% identical a region of the coding target or non-coding target from Tables 2, 4, 11 and 55. In another embodiment, the nucleotide sequence of the polynucleotide probe is at least about 90% identical a region of the coding target or non-coding target from Tables 2, 4, 11 and 55. In a further embodiment, the nucleotide sequence of the polynucleotide probe is at least about 95% identical to a region of the coding target or non-coding target from Tables 2, 4, 11 and 55. In some instances, the targets are selected from Table 2. In some instances, the targets are selected from Table 4. In some instances, the targets are selected from Table 11.

Methods of determining sequence identity are known in the art and can be determined, for example, by using the BLASTN program of the University of Wisconsin Computer Group (GCG) software or provided on the NCBI website. The nucleotide sequence of the polynucleotide probes of the present invention may exhibit variability by differing (e.g. by nucleotide substitution, including transition or transversion) at one, two, three, four or more nucleotides from the sequence of the coding target or non-coding target.

Other criteria known in the art may be employed in the design of the polynucleotide probes of the present invention. For example, the probes can be designed to have <50% G content and/or between about 25% and about 70% G+C content. Strategies to optimize probe hybridization to the target nucleic acid sequence can also be included in the process of probe selection.

Hybridization under particular pH, salt, and temperature conditions can be optimized by taking into account melting temperatures and by using empirical rules that correlate with desired hybridization behaviors. Computer models may be used for predicting the intensity and concentration-dependence of probe hybridization.

The polynucleotide probes of the present invention may range in length from about 15 nucleotides to the full length of the coding target or non-coding target. In one embodiment of the invention, the polynucleotide probes are at least about 15 nucleotides in length. In another embodiment, the polynucleotide probes are at least about 20 nucleotides in length. In a further embodiment, the polynucleotide probes are at least about 25 nucleotides in length. In another embodiment, the polynucleotide probes are between about 15 nucleotides and about 500 nucleotides in length. In other embodiments, the polynucleotide probes are between about 15 nucleotides and about 450 nucleotides, about 15 nucleotides and about 400 nucleotides, about 15 nucleotides and about 350 nucleotides, about 15 nucleotides and about 300 nucleotides, about 15 nucleotides and about 250 nucleotides, about 15 nucleotides and about 200 nucleotides in length. In some embodiments, the probes are at least 15 nucleotides in length. In some embodiments, the probes are at least 15 nucleotides in length. In some embodiments, the probes are at least 20 nucleotides, at least 25 nucleotides, at least 50 nucleotides, at least 75 nucleotides, at least 100 nucleotides, at least 125 nucleotides, at least 150 nucleotides, at least 200 nucleotides, at least 225 nucleotides, at least 250 nucleotides, at least 275 nucleotides, at least 300 nucleotides, at least 325 nucleotides, at least 350 nucleotides, at least 375 nucleotides in length.

The polynucleotide probes of a probe set can comprise RNA, DNA, RNA or DNA mimetics, or combinations thereof, and can be single-stranded or double-stranded. Thus the polynucleotide probes can be composed of naturally-occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as polynucleotide probes having non-naturally-occurring portions which function similarly. Such modified or substituted polynucleotide probes may provide desirable properties such as, for example, enhanced affinity for a target gene and increased stability. The probe set may comprise a coding target and/or a non-coding target. Preferably, the probe set comprises a combination of a coding target and non-coding target.

In some embodiments, the probe set comprise a plurality of target sequences that hybridize to at least about 5 coding targets and/or non-coding targets selected from Tables 2, 4, 11 or 55. Alternatively, the probe set comprise a plurality of target sequences that hybridize to at least about 10 coding targets and/or non-coding targets selected from Tables 2, 4, 11 or 55. In some embodiments, the probe set comprise a plurality of target sequences that hybridize to at least about 15 coding targets and/or non-coding targets selected from Tables 2, 4, 11 or 55. In some embodiments, the probe set comprise a plurality of target sequences that hybridize to at least about 20 coding targets and/or non-coding targets selected from Tables 2, 4, 11 or 55. In some embodiments, the probe set comprise a plurality of target sequences that hybridize to at least about 30 coding targets and/or non-coding targets selected from Tables 2, 4, 11 or 55. In some instances, the targets are selected from Table 2. In some instances, the targets are selected from Table 4. In some instances, the targets are selected from Table 11.

In some embodiments, the probe set comprises a plurality of target sequences that hybridize to a plurality of targets, wherein the at least about 20% of the plurality of targets are targets selected from Tables 2, 4, 11 or 55. In some embodiments, the probe set comprises a plurality of target sequences that hybridize to a plurality of targets, wherein the at least about 25% of the plurality of targets are targets selected from Tables 2, 4, 11 or 55. In some embodiments, the probe set comprise a plurality of target sequences that hybridize to a plurality of targets, wherein the at least about 30% of the plurality of targets are targets selected from Tables 2, 4, 11 or 55. In some embodiments, the probe set comprise a plurality of target sequences that hybridize to a plurality of targets, wherein the at least about 35% of the plurality of targets are targets selected from Tables 2, 4, 11 or 55. In some embodiments, the probe set comprise a plurality of target sequences that hybridize to a plurality of targets, wherein the at least about 40% of the plurality of targets are targets selected from Tables 2, 4, 11 or 55. In some embodiments, the probe set comprise a plurality of target sequences that hybridize to a plurality of targets, wherein the at least about 45% of the plurality of targets are targets selected from Tables 2, 4, 11 or 55. In some embodiments, the probe set comprise a plurality of target sequences that hybridize to a plurality of targets, wherein the at least about 50% of the plurality of targets are targets selected from Tables 2, 4, 11 or 55. In some embodiments, the probe set comprise a plurality of target sequences that hybridize to a plurality of targets, wherein the at least about 60% of the plurality of targets are targets selected from Tables 2, 4, 11 or 55. In some embodiments, the probe set comprise a plurality of target sequences that hybridize to a plurality of targets, wherein the at least about 70% of the plurality of targets are targets selected from Tables 2, 4, 11 or 55. In some instances, the targets are selected from Table 2. In some instances, the targets are selected from Table 4. In some instances, the targets are selected from Table 11.

The system of the present invention further provides for primers and primer pairs capable of amplifying target sequences defined by the probe set, or fragments or subsequences or complements thereof. The nucleotide sequences of the probe set may be provided in computer-readable media for in silico applications and as a basis for the design of appropriate primers for amplification of one or more target sequences of the probe set.

Primers based on the nucleotide sequences of target sequences can be designed for use in amplification of the target sequences. For use in amplification reactions such as PCR, a pair of primers can be used. The exact composition of the primer sequences is not critical to the invention, but for most applications the primers may hybridize to specific sequences of the probe set under stringent conditions, particularly under conditions of high stringency, as known in the art. The pairs of primers are usually chosen so as to generate an amplification product of at least about 50 nucleotides, more usually at least about 100 nucleotides. Algorithms for the selection of primer sequences are generally known, and are available in commercial software packages. These primers may be used in standard quantitative or qualitative PCR-based assays to assess transcript expression levels of RNAs defined by the probe set. Alternatively, these primers may be used in combination with probes, such as molecular beacons in amplifications using real-time PCR.

In one embodiment, the primers or primer pairs, when used in an amplification reaction, specifically amplify at least a portion of a nucleic acid sequence of a target selected from any of Tables 2, 4, 11 and 55 (or subgroups thereof as set forth herein), an RNA form thereof, or a complement to either thereof. In some instances, the targets are selected from Table 2. In some instances, the targets are selected from Table 4. In some instances, the targets are selected from Table 11.

As is known in the art, a nucleoside is a base-sugar combination and a nucleotide is a nucleoside that further includes a phosphate group covalently linked to the sugar portion of the nucleoside. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound, with the normal linkage or backbone of RNA and DNA being a 3′ to 5′ phosphodiester linkage. Specific examples of polynucleotide probes or primers useful in this invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. As defined in this specification, oligonucleotides having modified backbones include both those that retain a phosphorus atom in the backbone and those that lack a phosphorus atom in the backbone. For the purposes of the present invention, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleotides.

Exemplary polynucleotide probes or primers having modified oligonucleotide backbones include, for example, those with one or more modified internucleotide linkages that are phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3′-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3′amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkyl-phosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3′-5′ linkages, 2′-5′ linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3′-5′ to 5′-3′ or 2′-5′ to 5′-2′. Various salts, mixed salts and free acid forms are also included.

Exemplary modified oligonucleotide backbones that do not include a phosphorus atom are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. Such backbones include morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulphone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulphamate backbones; methyleneimino and methylenehydrazino backbones; sulphonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂ component parts.

The present invention also contemplates oligonucleotide mimetics in which both the sugar and the internucleoside linkage of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. An example of such an oligonucleotide mimetic, which has been shown to have excellent hybridization properties, is a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza-nitrogen atoms of the amide portion of the backbone.

The present invention also contemplates polynucleotide probes or primers comprising “locked nucleic acids” (LNAs), which may be novel conformationally restricted oligonucleotide analogues containing a methylene bridge that connects the 2′-O of ribose with the 4′-C. LNA and LNA analogues may display very high duplex thermal stabilities with complementary DNA and RNA, stability towards 3′-exonuclease degradation, and good solubility properties. Synthesis of the LNA analogues of adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil, their oligomerization, and nucleic acid recognition properties have been described. Studies of mismatched sequences show that LNA obey the Watson-Crick base pairing rules with generally improved selectivity compared to the corresponding unmodified reference strands.

LNAs may form duplexes with complementary DNA or RNA or with complementary LNA, with high thermal affinities. The universality of LNA-mediated hybridization has been emphasized by the formation of exceedingly stable LNA:LNA duplexes. LNA:LNA hybridization was shown to be the most thermally stable nucleic acid type duplex system, and the RNA-mimicking character of LNA was established at the duplex level. Introduction of three LNA monomers (T or A) resulted in significantly increased melting points toward DNA complements.

Synthesis of 2′-amino-LNA and 2′-methylamino-LNA has been described and thermal stability of their duplexes with complementary RNA and DNA strands reported. Preparation of phosphorothioate-LNA and 2′-thio-LNA have also been described.

Modified polynucleotide probes or primers may also contain one or more substituted sugar moieties. For example, oligonucleotides may comprise sugars with one of the following substituents at the 2′ position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C₁ to C₁₀ alkyl or C₂ to C₁₀ alkenyl and alkynyl. Examples of such groups are: O[(CH₂)_(n)O]_(m)CH₃, O(CH₂)_(n)OCH₃, O(CH₂)_(n)NH₂, O(CH₂)_(n)CH₃ONH₂, and O(CH₂)_(n) ON[(CH₂)_(n)CH₃)]₂, where n and m are from 1 to about 10. Alternatively, the oligonucleotides may comprise one of the following substituents at the 2′ position: C₁ to C₁₀ lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH₃, OCN, Cl, Br, CN, CF₃, OCF₃, SOCH₃, SO₂CH₃, ONO₂, NO₂, N₃, NH₂, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. Specific examples include 2′-methoxyethoxy (2′-O—CH₂CH₂OCH₃, also known as 2′-O-(2-methoxyethyl) or 2′-MOE), 2′-dimethylaminooxyethoxy (O(CH₂)2 ON(CH₃)₂ group, also known as 2′-DMA0E), 2′-methoxy (2′-O—CH₃), 2′-aminopropoxy (2′-OCH₂CH₂CH₂NH₂) and 2′-fluoro (2′-F).

Similar modifications may also be made at other positions on the polynucleotide probes or primers, particularly the 3′ position of the sugar on the 3′ terminal nucleotide or in 2′-5′ linked oligonucleotides and the 5′ position of 5′ terminal nucleotide. Polynucleotide probes or primers may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar.

Polynucleotide probes or primers may also include modifications or substitutions to the nucleobase. As used herein, “unmodified” or “natural” nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U).

Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further nucleobases include those disclosed in U.S. Pat. No. 3,687,808; The Concise Encyclopedia Of Polymer Science And Engineering, (1990) pp 858-859, Kroschwitz, J. I., ed. John Wiley & Sons; Englisch et al., Angewandte Chemie, Int. Ed., 30:613 (1991); and Sanghvi, Y. S., (1993) Antisense Research and Applications, pp 289-302, Crooke, S. T. and Lebleu, B., ed., CRC Press. Certain of these nucleobases are particularly useful for increasing the binding affinity of the polynucleotide probes of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2° C.

One skilled in the art recognizes that it is not necessary for all positions in a given polynucleotide probe or primer to be uniformly modified. The present invention, therefore, contemplates the incorporation of more than one of the aforementioned modifications into a single polynucleotide probe or even at a single nucleoside within the probe or primer.

One skilled in the art also appreciates that the nucleotide sequence of the entire length of the polynucleotide probe or primer does not need to be derived from the target sequence. Thus, for example, the polynucleotide probe may comprise nucleotide sequences at the 5′ and/or 3′ termini that are not derived from the target sequences. Nucleotide sequences which are not derived from the nucleotide sequence of the target sequence may provide additional functionality to the polynucleotide probe. For example, they may provide a restriction enzyme recognition sequence or a “tag” that facilitates detection, isolation, purification or immobilization onto a solid support. Alternatively, the additional nucleotides may provide a self-complementary sequence that allows the primer/probe to adopt a hairpin configuration. Such configurations are necessary for certain probes, for example, molecular beacon and Scorpion probes, which can be used in solution hybridization techniques.

The polynucleotide probes or primers can incorporate moieties useful in detection, isolation, purification, or immobilization, if desired. Such moieties are well-known in the art (see, for example, Ausubel et al., (1997 & updates) Current Protocols in Molecular Biology, Wiley & Sons, New York) and are chosen such that the ability of the probe to hybridize with its target sequence is not affected.

Examples of suitable moieties are detectable labels, such as radioisotopes, fluorophores, chemiluminophores, enzymes, colloidal particles, and fluorescent microparticles, as well as antigens, antibodies, haptens, avidin/streptavidin, biotin, haptens, enzyme cofactors/substrates, enzymes, and the like.

A label can optionally be attached to or incorporated into a probe or primer polynucleotide to allow detection and/or quantitation of a target polynucleotide representing the target sequence of interest. The target polynucleotide may be the expressed target sequence RNA itself, a cDNA copy thereof, or an amplification product derived therefrom, and may be the positive or negative strand, so long as it can be specifically detected in the assay being used. Similarly, an antibody may be labeled.

In certain multiplex formats, labels used for detecting different targets may be distinguishable. The label can be attached directly (e.g., via covalent linkage) or indirectly, e.g., via a bridging molecule or series of molecules (e.g., a molecule or complex that can bind to an assay component, or via members of a binding pair that can be incorporated into assay components, e.g. biotin-avidin or streptavidin). Many labels are commercially available in activated forms which can readily be used for such conjugation (for example through amine acylation), or labels may be attached through known or determinable conjugation schemes, many of which are known in the art.

Labels useful in the invention described herein include any substance which can be detected when bound to or incorporated into the biomolecule of interest. Any effective detection method can be used, including optical, spectroscopic, electrical, piezoelectrical, magnetic, Raman scattering, surface plasmon resonance, colorimetric, calorimetric, etc. A label is typically selected from a chromophore, a lumiphore, a fluorophore, one member of a quenching system, a chromogen, a hapten, an antigen, a magnetic particle, a material exhibiting nonlinear optics, a semiconductor nanocrystal, a metal nanoparticle, an enzyme, an antibody or binding portion or equivalent thereof, an aptamer, and one member of a binding pair, and combinations thereof. Quenching schemes may be used, wherein a quencher and a fluorophore as members of a quenching pair may be used on a probe, such that a change in optical parameters occurs upon binding to the target introduce or quench the signal from the fluorophore. One example of such a system is a molecular beacon. Suitable quencher/fluorophore systems are known in the art. The label may be bound through a variety of intermediate linkages. For example, a polynucleotide may comprise a biotin-binding species, and an optically detectable label may be conjugated to biotin and then bound to the labeled polynucleotide. Similarly, a polynucleotide sensor may comprise an immunological species such as an antibody or fragment, and a secondary antibody containing an optically detectable label may be added.

Chromophores useful in the methods described herein include any substance which can absorb energy and emit light. For multiplexed assays, a plurality of different signaling chromophores can be used with detectably different emission spectra. The chromophore can be a lumophore or a fluorophore. Typical fluorophores include fluorescent dyes, semiconductor nanocrystals, lanthanide chelates, polynucleotide-specific dyes and green fluorescent protein.

Coding schemes may optionally be used, comprising encoded particles and/or encoded tags associated with different polynucleotides of the invention. A variety of different coding schemes are known in the art, including fluorophores, including SCNCs, deposited metals, and RF tags.

Polynucleotides from the described target sequences may be employed as probes for detecting target sequences expression, for ligation amplification schemes, or may be used as primers for amplification schemes of all or a portion of a target sequences. When amplified, either strand produced by amplification may be provided in purified and/or isolated form.

In one embodiment, polynucleotides of the invention include (a) a nucleic acid depicted in Tables 2, 4, 11 and 55; (b) an RNA form of any one of the nucleic acids depicted in Tables 2, 4, 11 and 55; (c) a peptide nucleic acid form of any of the nucleic acids depicted in Tables 2, 4, 11 and 55; (d) a nucleic acid comprising at least 20 consecutive bases of any of (a-c); (e) a nucleic acid comprising at least 25 bases having at least 90% sequenced identity to any of (a-c); and (f) a complement to any of (a-e).

Complements may take any polymeric form capable of base pairing to the species recited in (a)-(e), including nucleic acid such as RNA or DNA, or may be a neutral polymer such as a peptide nucleic acid. Polynucleotides of the invention can be selected from the subsets of the recited nucleic acids described herein, as well as their complements.

In some embodiments, polynucleotides of the invention comprise at least 20 consecutive bases of the nucleic acid sequence of a target selected from any of Tables 2, 4, 11 and 55 or a complement thereto. The polynucleotides may comprise at least 21, 22, 23, 24, 25, 27, 30, 32, 35 or more consecutive bases of the nucleic acids sequence of a target selected from any of Tables 2, 4, 11 and 55, as applicable. In some instances, the targets are selected from Table 2. In some instances, the targets are selected from Table 4. In some instances, the targets are selected from Table 11.

The polynucleotides may be provided in a variety of formats, including as solids, in solution, or in an array. The polynucleotides may optionally comprise one or more labels, which may be chemically and/or enzymatically incorporated into the polynucleotide.

In one embodiment, solutions comprising polynucleotide and a solvent are also provided. In some embodiments, the solvent may be water or may be predominantly aqueous. In some embodiments, the solution may comprise at least two, three, four, five, six, seven, eight, nine, ten, twelve, fifteen, seventeen, twenty or more different polynucleotides, including primers and primer pairs, of the invention. Additional substances may be included in the solution, alone or in combination, including one or more labels, additional solvents, buffers, biomolecules, polynucleotides, and one or more enzymes useful for performing methods described herein, including polymerases and ligases. The solution may further comprise a primer or primer pair capable of amplifying a polynucleotide of the invention present in the solution.

In some embodiments, one or more polynucleotides provided herein can be provided on a substrate. The substrate can comprise a wide range of material, either biological, nonbiological, organic, inorganic, or a combination of any of these. For example, the substrate may be a polymerized Langmuir Blodgett film, functionalized glass, Si, Ge, GaAs, GaP, SiO₂, SiN₄, modified silicon, or any one of a wide variety of gels or polymers such as (poly)tetrafluoroethylene, (poly)vinylidenedifluoride, polystyrene, cross-linked polystyrene, polyacrylic, polylactic acid, polyglycolic acid, poly(lactide coglycolide), polyanhydrides, poly(methyl methacrylate), poly(ethylene-co-vinyl acetate), polysiloxanes, polymeric silica, latexes, dextran polymers, epoxies, polycarbonates, or combinations thereof. Conducting polymers and photoconductive materials can be used.

Substrates can be planar crystalline substrates such as silica based substrates (e.g. glass, quartz, or the like), or crystalline substrates used in, e.g., the semiconductor and microprocessor industries, such as silicon, gallium arsenide, indium doped GaN and the like, and include semiconductor nanocrystals.

The substrate can take the form of an array, a photodiode, an optoelectronic sensor such as an optoelectronic semiconductor chip or optoelectronic thin-film semiconductor, or a biochip. The location(s) of probe(s) on the substrate can be addressable; this can be done in highly dense formats, and the location(s) can be microaddressable or nanoaddressable.

Silica aerogels can also be used as substrates, and can be prepared by methods known in the art. Aerogel substrates may be used as free standing substrates or as a surface coating for another substrate material.

The substrate can take any form and typically is a plate, slide, bead, pellet, disk, particle, microparticle, nanoparticle, strand, precipitate, optionally porous gel, sheets, tube, sphere, container, capillary, pad, slice, film, chip, multiwell plate or dish, optical fiber, etc. The substrate can be any form that is rigid or semi-rigid. The substrate may contain raised or depressed regions on which an assay component is located. The surface of the substrate can be etched using known techniques to provide for desired surface features, for example trenches, v-grooves, mesa structures, or the like.

Surfaces on the substrate can be composed of the same material as the substrate or can be made from a different material, and can be coupled to the substrate by chemical or physical means. Such coupled surfaces may be composed of any of a wide variety of materials, for example, polymers, plastics, resins, polysaccharides, silica or silica-based materials, carbon, metals, inorganic glasses, membranes, or any of the above-listed substrate materials. The surface can be optically transparent and can have surface Si—OH functionalities, such as those found on silica surfaces.

The substrate and/or its optional surface can be chosen to provide appropriate characteristics for the synthetic and/or detection methods used. The substrate and/or surface can be transparent to allow the exposure of the substrate by light applied from multiple directions. The substrate and/or surface may be provided with reflective “mirror” structures to increase the recovery of light.

The substrate and/or its surface is generally resistant to, or is treated to resist, the conditions to which it is to be exposed in use, and can be optionally treated to remove any resistant material after exposure to such conditions.

The substrate or a region thereof may be encoded so that the identity of the sensor located in the substrate or region being queried may be determined. Any suitable coding scheme can be used, for example optical codes, RFID tags, magnetic codes, physical codes, fluorescent codes, and combinations of codes.

Preparation of Probes and Primers

The polynucleotide probes or primers of the present invention can be prepared by conventional techniques well-known to those skilled in the art. For example, the polynucleotide probes can be prepared using solid-phase synthesis using commercially available equipment. As is well-known in the art, modified oligonucleotides can also be readily prepared by similar methods. The polynucleotide probes can also be synthesized directly on a solid support according to methods standard in the art. This method of synthesizing polynucleotides is particularly useful when the polynucleotide probes are part of a nucleic acid array.

Polynucleotide probes or primers can be fabricated on or attached to the substrate by any suitable method, for example the methods described in U.S. Pat. No. 5,143,854, PCT Publ. No. WO 92/10092, U.S. patent application Ser. No. 07/624,120, filed Dec. 6, 1990 (now abandoned), Fodor et al., Science, 251: 767-777 (1991), and PCT Publ. No. WO 90/15070). Techniques for the synthesis of these arrays using mechanical synthesis strategies are described in, e.g., PCT Publication No. WO 93/09668 and U.S. Pat. No. 5,384,261. Still further techniques include bead based techniques such as those described in PCT Appl. No. PCT/US93/04145 and pin based methods such as those described in U.S. Pat. No. 5,288,514. Additional flow channel or spotting methods applicable to attachment of sensor polynucleotides to a substrate are described in U.S. patent application Ser. No. 07/980,523, filed Nov. 20, 1992, and U.S. Pat. No. 5,384,261.

Alternatively, the polynucleotide probes of the present invention can be prepared by enzymatic digestion of the naturally occurring target gene, or mRNA or cDNA derived therefrom, by methods known in the art.

Diagnostic Samples

Diagnostic samples for use with the systems and in the methods of the present invention comprise nucleic acids suitable for providing RNAs expression information. In principle, the biological sample from which the expressed RNA is obtained and analyzed for target sequence expression can be any material suspected of comprising cancer tissue or cells. The diagnostic sample can be a biological sample used directly in a method of the invention. Alternatively, the diagnostic sample can be a sample prepared from a biological sample.

In one embodiment, the sample or portion of the sample comprising or suspected of comprising cancer tissue or cells can be any source of biological material, including cells, tissue or fluid, including bodily fluids. Non-limiting examples of the source of the sample include an aspirate, a needle biopsy, a cytology pellet, a bulk tissue preparation or a section thereof obtained for example by surgery or autopsy, lymph fluid, blood, plasma, serum, tumors, and organs. In some embodiments, the sample is from urine. Alternatively, the sample is from blood, plasma or serum. In some embodiments, the sample is from saliva.

The samples may be archival samples, having a known and documented medical outcome, or may be samples from current patients whose ultimate medical outcome is not yet known.

In some embodiments, the sample may be dissected prior to molecular analysis. The sample may be prepared via macrodissection of a bulk tumor specimen or portion thereof, or may be treated via microdissection, for example via Laser Capture Microdissection (LCM).

The sample may initially be provided in a variety of states, as fresh tissue, fresh frozen tissue, fine needle aspirates, and may be fixed or unfixed. Frequently, medical laboratories routinely prepare medical samples in a fixed state, which facilitates tissue storage. A variety of fixatives can be used to fix tissue to stabilize the morphology of cells, and may be used alone or in combination with other agents. Exemplary fixatives include crosslinking agents, alcohols, acetone, Bouin's solution, Zenker solution, Helv solution, osmic acid solution and Carnoy solution.

Crosslinking fixatives can comprise any agent suitable for forming two or more covalent bonds, for example an aldehyde. Sources of aldehydes typically used for fixation include formaldehyde, paraformaldehyde, glutaraldehyde or formalin. Preferably, the crosslinking agent comprises formaldehyde, which may be included in its native form or in the form of paraformaldehyde or formalin. One of skill in the art would appreciate that for samples in which crosslinking fixatives have been used special preparatory steps may be necessary including for example heating steps and proteinase-k digestion; see methods.

One or more alcohols may be used to fix tissue, alone or in combination with other fixatives. Exemplary alcohols used for fixation include methanol, ethanol and isopropanol.

Formalin fixation is frequently used in medical laboratories. Formalin comprises both an alcohol, typically methanol, and formaldehyde, both of which can act to fix a biological sample.

Whether fixed or unfixed, the biological sample may optionally be embedded in an embedding medium. Exemplary embedding media used in histology including paraffin, Tissue-Tek® V.I.P.™, Paramat, Paramat Extra, Paraplast, Paraplast X-tra, Paraplast Plus, Peel Away Paraffin Embedding Wax, Polyester Wax, Carbowax Polyethylene Glycol, Polyfin™, Tissue Freezing Medium TFMFM, Cryo-Get™, and OCT Compound (Electron Microscopy Sciences, Hatfield, Pa.). Prior to molecular analysis, the embedding material may be removed via any suitable techniques, as known in the art. For example, where the sample is embedded in wax, the embedding material may be removed by extraction with organic solvent(s), for example xylenes. Kits are commercially available for removing embedding media from tissues. Samples or sections thereof may be subjected to further processing steps as needed, for example serial hydration or dehydration steps.

In some embodiments, the sample is a fixed, wax-embedded biological sample. Frequently, samples from medical laboratories are provided as fixed, wax-embedded samples, most commonly as formalin-fixed, paraffin embedded (FFPE) tissues.

Whatever the source of the biological sample, the target polynucleotide that is ultimately assayed can be prepared synthetically (in the case of control sequences), but typically is purified from the biological source and subjected to one or more preparative steps. The RNA may be purified to remove or diminish one or more undesired components from the biological sample or to concentrate it. Conversely, where the RNA is too concentrated for the particular assay, it may be diluted.

RNA Extraction

RNA can be extracted and purified from biological samples using any suitable technique. A number of techniques are known in the art, and several are commercially available (e.g., FormaPure nucleic acid extraction kit, Agencourt Biosciences, Beverly Mass., High Pure FFPE RNA Micro Kit, Roche Applied Science, Indianapolis, Ind.). RNA can be extracted from frozen tissue sections using TRIzol (Invitrogen, Carlsbad, Calif.) and purified using RNeasy Protect kit (Qiagen, Valencia, Calif.). RNA can be further purified using DNAse I treatment (Ambion, Austin, Tex.) to eliminate any contaminating DNA. RNA concentrations can be made using a Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies, Rockland, Del.). RNA can be further purified to eliminate contaminants that interfere with cDNA synthesis by cold sodium acetate precipitation. RNA integrity can be evaluated by running electropherograms, and RNA integrity number (RIN, a correlative measure that indicates intactness of mRNA) can be determined using the RNA 6000 PicoAssay for the Bioanalyzer 2100 (Agilent Technologies, Santa Clara, Calif.).

Kits

Kits for performing the desired method(s) are also provided, and comprise a container or housing for holding the components of the kit, one or more vessels containing one or more nucleic acid(s), and optionally one or more vessels containing one or more reagents. The reagents include those described in the composition of matter section above, and those reagents useful for performing the methods described, including amplification reagents, and may include one or more probes, primers or primer pairs, enzymes (including polymerases and ligases), intercalating dyes, labeled probes, and labels that can be incorporated into amplification products.

In some embodiments, the kit comprises primers or primer pairs specific for those subsets and combinations of target sequences described herein. At least two, three, four or five primers or pairs of primers suitable for selectively amplifying the same number of target sequence-specific polynucleotides can be provided in kit form. In some embodiments, the kit comprises from five to fifty primers or pairs of primers suitable for amplifying the same number of target sequence-representative polynucleotides of interest.

In some embodiments, the primers or primer pairs of the kit, when used in an amplification reaction, specifically amplify a non-coding target, coding target, or non-exonic target described herein, at least a portion of a nucleic acid sequence depicted in one of SEQ ID NOs: 1-43, a nucleic acid sequence corresponding to a target selected from Tables 2, 4, 11 or 55, an RNA form thereof, or a complement to either thereof. The kit may include a plurality of such primers or primer pairs which can specifically amplify a corresponding plurality of different amplify a non-coding target, coding target, or non-exonic transcript described herein, nucleic acids depicted in one of SEQ ID NOs: 1-43, a nucleic acid sequence corresponding to a target selected from Tables 2, 4, 11 or 55, RNA forms thereof, or complements thereto. At least two, three, four or five primers or pairs of primers suitable for selectively amplifying the same number of target sequence-specific polynucleotides can be provided in kit form. In some embodiments, the kit comprises from five to fifty primers or pairs of primers suitable for amplifying the same number of target sequence-representative polynucleotides of interest. In some instances, the targets are selected from Table 2. In some instances, the targets are selected from Table 4. In some instances, the targets are selected from Table 11.

The reagents may independently be in liquid or solid form. The reagents may be provided in mixtures. Control samples and/or nucleic acids may optionally be provided in the kit. Control samples may include tissue and/or nucleic acids obtained from or representative of tumor samples from patients showing no evidence of disease, as well as tissue and/or nucleic acids obtained from or representative of tumor samples from patients that develop systemic cancer.

The nucleic acids may be provided in an array format, and thus an array or microarray may be included in the kit. The kit optionally may be certified by a government agency for use in prognosing the disease outcome of cancer patients and/or for designating a treatment modality.

Instructions for using the kit to perform one or more methods of the invention can be provided with the container, and can be provided in any fixed medium. The instructions may be located inside or outside the container or housing, and/or may be printed on the interior or exterior of any surface thereof. A kit may be in multiplex form for concurrently detecting and/or quantitating one or more different target polynucleotides representing the expressed target sequences.

Devices

Devices useful for performing methods of the invention are also provided. The devices can comprise means for characterizing the expression level of a target sequence of the invention, for example components for performing one or more methods of nucleic acid extraction, amplification, and/or detection. Such components may include one or more of an amplification chamber (for example a thermal cycler), a plate reader, a spectrophotometer, capillary electrophoresis apparatus, a chip reader, and or robotic sample handling components. These components ultimately can obtain data that reflects the expression level of the target sequences used in the assay being employed.

The devices may include an excitation and/or a detection means. Any instrument that provides a wavelength that can excite a species of interest and is shorter than the emission wavelength(s) to be detected can be used for excitation. Commercially available devices can provide suitable excitation wavelengths as well as suitable detection component.

Exemplary excitation sources include a broadband UV light source such as a deuterium lamp with an appropriate filter, the output of a white light source such as a xenon lamp or a deuterium lamp after passing through a monochromator to extract out the desired wavelength(s), a continuous wave (cw) gas laser, a solid state diode laser, or any of the pulsed lasers. Emitted light can be detected through any suitable device or technique; many suitable approaches are known in the art. For example, a fluorimeter or spectrophotometer may be used to detect whether the test sample emits light of a wavelength characteristic of a label used in an assay.

The devices typically comprise a means for identifying a given sample, and of linking the results obtained to that sample. Such means can include manual labels, barcodes, and other indicators which can be linked to a sample vessel, and/or may optionally be included in the sample itself, for example where an encoded particle is added to the sample. The results may be linked to the sample, for example in a computer memory that contains a sample designation and a record of expression levels obtained from the sample. Linkage of the results to the sample can also include a linkage to a particular sample receptacle in the device, which is also linked to the sample identity.

In some instances, the devices also comprise a means for correlating the expression levels of the target sequences being studied with a prognosis of disease outcome. In some instances, such means comprises one or more of a variety of correlative techniques, including lookup tables, algorithms, multivariate models, and linear or nonlinear combinations of expression models or algorithms. The expression levels may be converted to one or more likelihood scores, reflecting likelihood that the patient providing the sample may exhibit a particular disease outcome. The models and/or algorithms can be provided in machine readable format and can optionally further designate a treatment modality for a patient or class of patients.

The device also comprises output means for outputting the disease status, prognosis and/or a treatment modality. Such output means can take any form which transmits the results to a patient and/or a healthcare provider, and may include a monitor, a printed format, or both. The device may use a computer system for performing one or more of the steps provided.

In some embodiments, the method, systems, and kits disclosed herein further comprise the transmission of data/information. For example, data/information derived from the detection and/or quantification of the target may be transmitted to another device and/or instrument. In some instances, the information obtained from an algorithm is transmitted to another device and/or instrument. Transmission of the data/information may comprise the transfer of data/information from a first source to a second source. The first and second sources may be in the same approximate location (e.g., within the same room, building, block, campus). Alternatively, first and second sources may be in multiple locations (e.g., multiple cities, states, countries, continents, etc).

In some instances, transmission of the data/information comprises digital transmission or analog transmission. Digital transmission may comprise the physical transfer of data (a digital bit stream) over a point-to-point or point-to-multipoint communication channel. Examples of such channels are copper wires, optical fibers, wireless communication channels, and storage media. In some embodiments, the data is represented as an electromagnetic signal, such as an electrical voltage, radiowave, microwave, or infrared signal.

Analog transmission may comprise the transfer of a continuously varying analog signal. The messages can either be represented by a sequence of pulses by means of a line code (baseband transmission), or by a limited set of continuously varying wave forms (passband transmission), using a digital modulation method. The passband modulation and corresponding demodulation (also known as detection) can be carried out by modem equipment. According to the most common definition of digital signal, both baseband and passband signals representing bit-streams are considered as digital transmission, while an alternative definition only considers the baseband signal as digital, and passband transmission of digital data as a form of digital-to-analog conversion.

Amplification and Hybridization

Following sample collection and nucleic acid extraction, the nucleic acid portion of the sample comprising RNA that is or can be used to prepare the target polynucleotide(s) of interest can be subjected to one or more preparative reactions. These preparative reactions can include in vitro transcription (IVT), labeling, fragmentation, amplification and other reactions. mRNA can first be treated with reverse transcriptase and a primer to create cDNA prior to detection, quantitation and/or amplification; this can be done in vitro with purified mRNA or in situ, e.g., in cells or tissues affixed to a slide.

By “amplification” is meant any process of producing at least one copy of a nucleic acid, in this case an expressed RNA, and in many cases produces multiple copies. An amplification product can be RNA or DNA, and may include a complementary strand to the expressed target sequence. DNA amplification products can be produced initially through reverse translation and then optionally from further amplification reactions. The amplification product may include all or a portion of a target sequence, and may optionally be labeled. A variety of amplification methods are suitable for use, including polymerase-based methods and ligation-based methods. Exemplary amplification techniques include the polymerase chain reaction method (PCR), the lipase chain reaction (LCR), ribozyme-based methods, self sustained sequence replication (3SR), nucleic acid sequence-based amplification (NASBA), the use of Q Beta replicase, reverse transcription, nick translation, and the like.

Asymmetric amplification reactions may be used to preferentially amplify one strand representing the target sequence that is used for detection as the target polynucleotide. In some cases, the presence and/or amount of the amplification product itself may be used to determine the expression level of a given target sequence. In other instances, the amplification product may be used to hybridize to an array or other substrate comprising sensor polynucleotides which are used to detect and/or quantitate target sequence expression.

The first cycle of amplification in polymerase-based methods typically forms a primer extension product complementary to the template strand. If the template is single-stranded RNA, a polymerase with reverse transcriptase activity is used in the first amplification to reverse transcribe the RNA to DNA, and additional amplification cycles can be performed to copy the primer extension products. The primers for a PCR must, of course, be designed to hybridize to regions in their corresponding template that can produce an amplifiable segment; thus, each primer must hybridize so that its 3′ nucleotide is paired to a nucleotide in its complementary template strand that is located 3′ from the 3′ nucleotide of the primer used to replicate that complementary template strand in the PCR.

The target polynucleotide can be amplified by contacting one or more strands of the target polynucleotide with a primer and a polymerase having suitable activity to extend the primer and copy the target polynucleotide to produce a full-length complementary polynucleotide or a smaller portion thereof. Any enzyme having a polymerase activity that can copy the target polynucleotide can be used, including DNA polymerases, RNA polymerases, reverse transcriptases, enzymes having more than one type of polymerase or enzyme activity. The enzyme can be thermolabile or thermostable. Mixtures of enzymes can also be used. Exemplary enzymes include: DNA polymerases such as DNA Polymerase I (“Pol I”), the Klenow fragment of Pol I, T4, T7, Sequenase® T7, Sequenase® Version 2.0 T7, Tub, Taq, Tth, Pfic, Pfu, Tsp, Tfl, Tli and Pyrococcus sp GB-D DNA polymerases; RNA polymerases such as E. coil, SP6, T3 and T7 RNA polymerases; and reverse transcriptases such as AMV, M-MuLV, MMLV, RNAse H MMLV (SuperScript®), SuperScript® II, ThermoScript®, HIV-1, and RAV2 reverse transcriptases. All of these enzymes are commercially available. Exemplary polymerases with multiple specificities include RAV2 and Tli (exo-) polymerases. Exemplary thermostable polymerases include Tub, Taq, Tth, Pfic, Pfu, Tsp, Tfl, Tli and Pyrococcus sp. GB-D DNA polymerases.

Suitable reaction conditions are chosen to permit amplification of the target polynucleotide, including pH, buffer, ionic strength, presence and concentration of one or more salts, presence and concentration of reactants and cofactors such as nucleotides and magnesium and/or other metal ions (e.g., manganese), optional cosolvents, temperature, thermal cycling profile for amplification schemes comprising a polymerase chain reaction, and may depend in part on the polymerase being used as well as the nature of the sample. Cosolvents include formamide (typically at from about 2 to about 10%), glycerol (typically at from about 5 to about 10%), and DMSO (typically at from about 0.9 to about 10%). Techniques may be used in the amplification scheme in order to minimize the production of false positives or artifacts produced during amplification. These include “touchdown” PCR, hot-start techniques, use of nested primers, or designing PCR primers so that they form stem-loop structures in the event of primer-dimer formation and thus are not amplified. Techniques to accelerate PCR can be used, for example centrifugal PCR, which allows for greater convection within the sample, and comprising infrared heating steps for rapid heating and cooling of the sample. One or more cycles of amplification can be performed. An excess of one primer can be used to produce an excess of one primer extension product during PCR; preferably, the primer extension product produced in excess is the amplification product to be detected. A plurality of different primers may be used to amplify different target polynucleotides or different regions of a particular target polynucleotide within the sample.

An amplification reaction can be performed under conditions which allow an optionally labeled sensor polynucleotide to hybridize to the amplification product during at least part of an amplification cycle. When the assay is performed in this manner, real-time detection of this hybridization event can take place by monitoring for light emission or fluorescence during amplification, as known in the art.

Where the amplification product is to be used for hybridization to an array or microarray, a number of suitable commercially available amplification products are available. These include amplification kits available from NuGEN, Inc. (San Carlos, Calif.), including the WT-Ovation™ System, WT-Ovation™ System v2, WT-Ovation™ Pico System, WT-Ovation™ FFPE Exon Module, WT-Ovation™ FFPE Exon Module RiboAmp and RiboAmp Plus RNA Amplification Kits (MDS Analytical Technologies (formerly Arcturus) (Mountain View, Calif.), Genisphere, Inc. (Hatfield, Pa.), including the RampUp Plus™ and SenseAmp™ RNA Amplification kits, alone or in combination. Amplified nucleic acids may be subjected to one or more purification reactions after amplification and labeling, for example using magnetic beads (e.g., RNAClean magnetic beads, Agencourt Biosciences).

Multiple RNA biomarkers can be analyzed using real-time quantitative multiplex RT-PCR platforms and other multiplexing technologies such as GenomeLab GeXP Genetic Analysis System (Beckman Coulter, Foster City, Calif.), SmartCycler® 9600 or GeneXpert® Systems (Cepheid, Sunnyvale, Calif.), ABI 7900 HT Fast Real Time PCR system (Applied Biosystems, Foster City, Calif.), LightCycler® 480 System (Roche Molecular Systems, Pleasanton, Calif.), xMAP 100 System (Luminex, Austin, Tex.) Solexa Genome Analysis System (Illumina, Hayward, Calif.), OpenArray Real Time qPCR (BioTrove, Woburn, Mass.) and BeadXpress System (Illumina, Hayward, Calif.).

Detection and/or Quantification of Target Sequences

Any method of detecting and/or quantitating the expression of the encoded target sequences can in principle be used in the invention. The expressed target sequences can be directly detected and/or quantitated, or may be copied and/or amplified to allow detection of amplified copies of the expressed target sequences or its complement.

Methods for detecting and/or quantifying a target can include Northern blotting, sequencing, array or microarray hybridization, by enzymatic cleavage of specific structures (e.g., an Invader® assay, Third Wave Technologies, e.g. as described in U.S. Pat. Nos. 5,846,717, 6,090,543; 6,001,567; 5,985,557; and 5,994,069) and amplification methods, e.g. RT-PCR, including in a TaqMan® assay (PE Biosystems, Foster City, Calif., e.g. as described in U.S. Pat. Nos. 5,962,233 and 5,538,848), and may be quantitative or semi-quantitative, and may vary depending on the origin, amount and condition of the available biological sample. Combinations of these methods may also be used. For example, nucleic acids may be amplified, labeled and subjected to microarray analysis.

In some instances, target sequences may be detected by sequencing. Sequencing methods may comprise whole genome sequencing or exome sequencing. Sequencing methods such as Maxim-Gilbert, chain-termination, or high-throughput systems may also be used. Additional, suitable sequencing techniques include classic dideoxy sequencing reactions (Sanger method) using labeled terminators or primers and gel separation in slab or capillary, sequencing by synthesis using reversibly terminated labeled nucleotides, pyrosequencing, 454 sequencing, allele specific hybridization to a library of labeled oligonucleotide probes, sequencing by synthesis using allele specific hybridization to a library of labeled clones that is followed by ligation, real time monitoring of the incorporation of labeled nucleotides during a polymerization step, and SOLiD sequencing.

Additional methods for detecting and/or quantifying a target include single-molecule sequencing (e.g., Helicos, PacBio), sequencing by synthesis (e.g., Illumina, Ion Torrent), sequencing by ligation (e.g., ABI SOLID), sequencing by hybridization (e.g., Complete Genomics), in situ hybridization, bead-array technologies (e.g., Luminex xMAP, Illumina BeadChips), branched DNA technology (e.g., Panomics, Genisphere). Sequencing methods may use fluorescent (e.g., Illumina) or electronic (e.g., Ion Torrent, Oxford Nanopore) methods of detecting nucleotides.

Reverse Transcription for ORT-PCR Analysis

Reverse transcription can be performed by any method known in the art. For example, reverse transcription may be performed using the Omniscript kit (Qiagen, Valencia, Calif.), Superscript III kit (Invitrogen, Carlsbad, Calif.), for RT-PCR. Target-specific priming can be performed in order to increase the sensitivity of detection of target sequences and generate target-specific cDNA.

TaqMan® Gene Expression Analysis

TaqMan®RT-PCR can be performed using Applied Biosystems Prism (ABI) 7900 HT instruments in a 5 1.11 volume with target sequence-specific cDNA equivalent to 1 ng total RNA.

Primers and probes concentrations for TaqMan analysis are added to amplify fluorescent amplicons using PCR cycling conditions such as 95° C. for 10 minutes for one cycle, 95° C. for 20 seconds, and 60° C. for 45 seconds for 40 cycles. A reference sample can be assayed to ensure reagent and process stability. Negative controls (e.g., no template) should be assayed to monitor any exogenous nucleic acid contamination.

Classification Arrays

The present invention contemplates that a probe set or probes derived therefrom may be provided in an array format. In the context of the present invention, an “array” is a spatially or logically organized collection of polynucleotide probes. An array comprising probes specific for a coding target, non-coding target, or a combination thereof may be used. Alternatively, an array comprising probes specific for two or more of transcripts of a target selected from any of Tables 2, 4, 11 and 55 or a product derived thereof can be used. Desirably, an array may be specific for 5, 10, 15, 20, 25, 30, 50, 75, 100, 150, 200 or more of transcripts of a target selected from any of Tables 2, 4, 11 and 55. In some instances, the target is selected from Table 2. In other instances, the target is selected from Table 4. In some embodiments, the target is selected from Table 11. Expression of these sequences may be detected alone or in combination with other transcripts. In some embodiments, an array is used which comprises a wide range of sensor probes for prostate-specific expression products, along with appropriate control sequences. In some instances, the array may comprise the Human Exon 1.0 ST Array (HuEx 1.0 ST, Affymetrix, Inc., Santa Clara, Calif.).

Typically the polynucleotide probes are attached to a solid substrate and are ordered so that the location (on the substrate) and the identity of each are known. The polynucleotide probes can be attached to one of a variety of solid substrates capable of withstanding the reagents and conditions necessary for use of the array. Examples include, but are not limited to, polymers, such as (poly)tetrafluoroethylene, (poly)vinylidenedifluoride, polystyrene, polycarbonate, polypropylene and polystyrene; ceramic; silicon; silicon dioxide; modified silicon; (fused) silica, quartz or glass; functionalized glass; paper, such as filter paper; diazotized cellulose; nitrocellulose filter; nylon membrane; and polyacrylamide gel pad. Substrates that are transparent to light are useful for arrays that may be used in an assay that involves optical detection.

Examples of array formats include membrane or filter arrays (for example, nitrocellulose, nylon arrays), plate arrays (for example, multiwell, such as a 24-, 96-, 256-, 384-, 864- or 1536-well, microtitre plate arrays), pin arrays, and bead arrays (for example, in a liquid “slurry”). Arrays on substrates such as glass or ceramic slides are often referred to as chip arrays or “chips.” Such arrays are well known in the art. In one embodiment of the present invention, the Cancer Prognosticarray is a chip.

Data Analysis

In some embodiments, one or more pattern recognition methods can be used in analyzing the expression level of target sequences. The pattern recognition method can comprise a linear combination of expression levels, or a nonlinear combination of expression levels. In some embodiments, expression measurements for RNA transcripts or combinations of RNA transcript levels are formulated into linear or non-linear models or algorithms (e.g., an ‘expression signature’) and converted into a likelihood score. This likelihood score indicates the probability that a biological sample is from a patient who may exhibit no evidence of disease, who may exhibit systemic cancer, or who may exhibit biochemical recurrence. The likelihood score can be used to distinguish these disease states. The models and/or algorithms can be provided in machine readable format, and may be used to correlate expression levels or an expression profile with a disease state, and/or to designate a treatment modality for a patient or class of patients.

Assaying the expression level for a plurality of targets may comprise the use of an algorithm or classifier. Array data can be managed, classified, and analyzed using techniques known in the art. Assaying the expression level for a plurality of targets may comprise probe set modeling and data pre-processing. Probe set modeling and data pre-processing can be derived using the Robust Multi-Array (RMA) algorithm or variants GC-RMA, fRMA, Probe Logarithmic Intensity Error (PLIER) algorithm or variant iterPLIER. Variance or intensity filters can be applied to pre-process data using the RMA algorithm, for example by removing target sequences with a standard deviation of <10 or a mean intensity of <100 intensity units of a normalized data range, respectively.

Alternatively, assaying the expression level for a plurality of targets may comprise the use of a machine learning algorithm. The machine learning algorithm may comprise a supervised learning algorithm. Examples of supervised learning algorithms may include Average One-Dependence Estimators (AODE), Artificial neural network (e.g., Backpropagation), Bayesian statistics (e.g., Naive Bayes classifier, Bayesian network, Bayesian knowledge base), Case-based reasoning, Decision trees, Inductive logic programming, Gaussian process regression, Group method of data handling (GMDH), Learning Automata, Learning Vector Quantization, Minimum message length (decision trees, decision graphs, etc.), Lazy learning, Instance-based learning Nearest Neighbor Algorithm, Analogical modeling, Probably approximately correct learning (PAC) learning, Ripple down rules, a knowledge acquisition methodology, Symbolic machine learning algorithms, Subsymbolic machine learning algorithms, Support vector machines, Random Forests, Ensembles of classifiers, Bootstrap aggregating (bagging), and Boosting. Supervised learning may comprise ordinal classification such as regression analysis and Information fuzzy networks (IFN). Alternatively, supervised learning methods may comprise statistical classification, such as AODE, Linear classifiers (e.g., Fisher's linear discriminant, Logistic regression, Naive Bayes classifier, Perceptron, and Support vector machine), quadratic classifiers, k-nearest neighbor, Boosting, Decision trees (e.g., C4.5, Random forests), Bayesian networks, and Hidden Markov models.

The machine learning algorithms may also comprise an unsupervised learning algorithm. Examples of unsupervised learning algorithms may include artificial neural network, Data clustering, Expectation-maximization algorithm, Self-organizing map, Radial basis function network, Vector Quantization, Generative topographic map, Information bottleneck method, and IBSEAD. Unsupervised learning may also comprise association rule learning algorithms such as Apriori algorithm, Eclat algorithm and FP-growth algorithm. Hierarchical clustering, such as Single-linkage clustering and Conceptual clustering, may also be used. Alternatively, unsupervised learning may comprise partitional clustering such as K-means algorithm and Fuzzy clustering.

In some instances, the machine learning algorithms comprise a reinforcement learning algorithm. Examples of reinforcement learning algorithms include, but are not limited to, temporal difference learning, Q-learning and Learning Automata. Alternatively, the machine learning algorithm may comprise Data Pre-processing.

Preferably, the machine learning algorithms may include, but are not limited to, Average One-Dependence Estimators (AODE), Fisher's linear discriminant, Logistic regression, Perceptron, Multilayer Perceptron, Artificial Neural Networks, Support vector machines, Quadratic classifiers, Boosting, Decision trees, C4.5, Bayesian networks, Hidden Markov models, High-Dimensional Discriminant Analysis, and Gaussian Mixture Models. The machine learning algorithm may comprise support vector machines, Naïve Bayes classifier, k-nearest neighbor, high-dimensional discriminant analysis, or Gaussian mixture models. In some instances, the machine learning algorithm comprises Random Forests.

Additional Techniques and Tests

Factors known in the art for diagnosing and/or suggesting, selecting, designating, recommending or otherwise determining a course of treatment for a patient or class of patients suspected of having cancer can be employed in combination with measurements of the target sequence expression. The methods disclosed herein may include additional techniques such as cytology, histology, ultrasound analysis, MRI results, CT scan results, and measurements of PSA levels.

Certified tests for classifying disease status and/or designating treatment modalities may also be used in diagnosing, predicting, and/or monitoring the status or outcome of a cancer in a subject. A certified test may comprise a means for characterizing the expression levels of one or more of the target sequences of interest, and a certification from a government regulatory agency endorsing use of the test for classifying the disease status of a biological sample.

In some embodiments, the certified test may comprise reagents for amplification reactions used to detect and/or quantitate expression of the target sequences to be characterized in the test. An array of probe nucleic acids can be used, with or without prior target amplification, for use in measuring target sequence expression.

The test is submitted to an agency having authority to certify the test for use in distinguishing disease status and/or outcome. Results of detection of expression levels of the target sequences used in the test and correlation with disease status and/or outcome are submitted to the agency. A certification authorizing the diagnostic and/or prognostic use of the test is obtained.

Also provided are portfolios of expression levels comprising a plurality of normalized expression levels of the target selected from any of Tables 2, 4, 11 and 55. In some instances, the target is selected from Table 2. In other instances, the target is selected from Table 4. In some embodiments, the target is selected from Table 11. Such portfolios may be provided by performing the methods described herein to obtain expression levels from an individual patient or from a group of patients. The expression levels can be normalized by any method known in the art; exemplary normalization methods that can be used in various embodiments include Robust Multichip Average (RMA), probe logarithmic intensity error estimation (PLIER), non-linear fit (NLFIT) quantile-based and nonlinear normalization, and combinations thereof. Background correction can also be performed on the expression data; exemplary techniques useful for background correction include mode of intensities, normalized using median polish probe modeling and sketch-normalization.

In some embodiments, portfolios are established such that the combination of genes in the portfolio exhibit improved sensitivity and specificity relative to known methods. In considering a group of genes for inclusion in a portfolio, a small standard deviation in expression measurements correlates with greater specificity. Other measurements of variation such as correlation coefficients can also be used in this capacity. The invention also encompasses the above methods where the expression level determines the status or outcome of a cancer in the subject with at least about 45% specificity. In some embodiments, the expression level determines the status or outcome of a cancer in the subject with at least about 50% specificity. In some embodiments, the expression level determines the status or outcome of a cancer in the subject with at least about 55% specificity. In some embodiments, the expression level determines the status or outcome of a cancer in the subject with at least about 60% specificity. In some embodiments, the expression level determines the status or outcome of a cancer in the subject with at least about 65% specificity. In some embodiments, the expression level determines the status or outcome of a cancer in the subject with at least about 70% specificity. In some embodiments, the expression level determines the status or outcome of a cancer in the subject with at least about 75% specificity. In some embodiments, the expression level determines the status or outcome of a cancer in the subject with at least about 80% specificity. In some embodiments, t the expression level determines the status or outcome of a cancer in the subject with at least about 85% specificity. In some embodiments, the expression level determines the status or outcome of a cancer in the subject with at least about 90% specificity. In some embodiments, the expression level determines the status or outcome of a cancer in the subject with at least about 95% specificity.

The invention also encompasses the any of the methods disclosed herein where the accuracy of diagnosing, monitoring, and/or predicting a status or outcome of a cancer is at least about 45%. In some embodiments, the accuracy of diagnosing, monitoring, and/or predicting a status or outcome of a cancer is at least about 50%. In some embodiments, the accuracy of diagnosing, monitoring, and/or predicting a status or outcome of a cancer is at least about 55%. In some embodiments, the accuracy of diagnosing, monitoring, and/or predicting a status or outcome of a cancer is at least about 60%. In some embodiments, the accuracy of diagnosing, monitoring, and/or predicting a status or outcome of a cancer is at least about 65%. In some embodiments, the accuracy of diagnosing, monitoring, and/or predicting a status or outcome of a cancer is at least about 70%. In some embodiments, the accuracy of diagnosing, monitoring, and/or predicting a status or outcome of a cancer is at least about 75%. In some embodiments, the accuracy of diagnosing, monitoring, and/or predicting a status or outcome of a cancer is at least about 80%. In some embodiments, the accuracy of diagnosing, monitoring, and/or predicting a status or outcome of a cancer is at least about 85%. In some embodiments, the accuracy of diagnosing, monitoring, and/or predicting a status or outcome of a cancer is at least about 90%. In some embodiments, the accuracy of diagnosing, monitoring, and/or predicting a status or outcome of a cancer is at least about 95%.

The accuracy of a classifier or biomarker may be determined by the 95% confidence interval (CI). Generally, a classifier or biomarker is considered to have good accuracy if the 95% CI does not overlap 1. In some instances, the 95% CI of a classifier or biomarker is at least about 1.08, 1.10, 1.12, 1.14, 1.15, 1.16, 1.17, 1.18, 1.19, 1.20, 1.21, 1.22, 1.23, 1.24, 1.25, 1.26, 1.27, 1.28, 1.29, 1.30, 1.31, 1.32, 1.33, 1.34, or 1.35 or more. The 95% CI of a classifier or biomarker may be at least about 1.14, 1.15, 1.16, 1.20, 1.21, 1.26, or 1.28. The 95% CI of a classifier or biomarker may be less than about 1.75, 1.74, 1.73, 1.72, 1.71, 1.70, 1.69, 1.68, 1.67, 1.66, 1.65, 1.64, 1.63, 1.62, 1.61, 1.60, 1.59, 1.58, 1.57, 1.56, 1.55, 1.54, 1.53, 1.52, 1.51, 1.50 or less. The 95% CI of a classifier or biomarker may be less than about 1.61, 1.60, 1.59, 1.58, 1.56, 1.55, or 1.53. The 95% CI of a classifier or biomarker may be between about 1.10 to 1.70, between about 1.12 to about 1.68, between about 1.14 to about 1.62, between about 1.15 to about 1.61, between about 1.15 to about 1.59, between about 1.16 to about 1.160, between about 1.19 to about 1.55, between about 1.20 to about 1.54, between about 1.21 to about 1.53, between about 1.26 to about 1.63, between about 1.27 to about 1.61, or between about 1.28 to about 1.60.

In some instances, the accuracy of a biomarker or classifier is dependent on the difference in range of the 95% CI (e.g., difference in the high value and low value of the 95% CI interval). Generally, biomarkers or classifiers with large differences in the range of the 95% CI interval have greater variability and are considered less accurate than biomarkers or classifiers with small differences in the range of the 95% CI intervals. In some instances, a biomarker or classifier is considered more accurate if the difference in the range of the 95% CI is less than about 0.60, 0.55, 0.50, 0.49, 0.48, 0.47, 0.46, 0.45, 0.44, 0.43, 0.42, 0.41, 0.40, 0.39, 0.38, 0.37, 0.36, 0.35, 0.34, 0.33, 0.32, 0.31, 0.30, 0.29, 0.28, 0.27, 0.26, 0.25 or less. The difference in the range of the 95% CI of a biomarker or classifier may be less than about 0.48, 0.45, 0.44, 0.42, 0.40, 0.37, 0.35, 0.33, or 0.32. In some instances, the difference in the range of the 95% CI for a biomarker or classifier is between about 0.25 to about 0.50, between about 0.27 to about 0.47, or between about 0.30 to about 0.45.

The invention also encompasses the any of the methods disclosed herein where the sensitivity is at least about 45%. In some embodiments, the sensitivity is at least about 50%. In some embodiments, the sensitivity is at least about 55%. In some embodiments, the sensitivity is at least about 60%. In some embodiments, the sensitivity is at least about 65%. In some embodiments, the sensitivity is at least about 70%. In some embodiments, the sensitivity is at least about 75%. In some embodiments, the sensitivity is at least about 80%. In some embodiments, the sensitivity is at least about 85%. In some embodiments, the sensitivity is at least about 90%. In some embodiments, the sensitivity is at least about 95%.

In some instances, the classifiers or biomarkers disclosed herein are clinically significant. In some instances, the clinical significance of the classifiers or biomarkers is determined by the AUC value. In order to be clinically significant, the AUC value is at least about 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, or 0.95. The clinical significance of the classifiers or biomarkers can be determined by the percent accuracy. For example, a classifier or biomarker is determined to be clinically significant if the accuracy of the classifier or biomarker is at least about 50%, 55%, 60%, 65%, 70%, 72%, 75%, 77%, 80%, 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, or 98%.

In other instances, the clinical significance of the classifiers or biomarkers is determined by the median fold difference (MDF) value. In order to be clinically significant, the MDF value is at least about 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.9, or 2.0. In some instances, the MDF value is greater than or equal to 1.1. In other instances, the MDF value is greater than or equal to 1.2. Alternatively, or additionally, the clinical significance of the classifiers or biomarkers is determined by the t-test P-value. In some instances, in order to be clinically significant, the t-test P-value is less than about 0.070, 0.065, 0.060, 0.055, 0.050, 0.045, 0.040, 0.035, 0.030, 0.025, 0.020, 0.015, 0.010, 0.005, 0.004, or 0.003. The t-test P-value can be less than about 0.050. Alternatively, the t-test P-value is less than about 0.010.

In some instances, the clinical significance of the classifiers or biomarkers is determined by the clinical outcome. For example, different clinical outcomes can have different minimum or maximum thresholds for AUC values, MDF values, t-test P-values, and accuracy values that would determine whether the classifier or biomarker is clinically significant. In another example, a classifier or biomarker is considered clinically significant if the P-value of the t-test was less than about 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, 0.02, 0.01, 0.005, 0.004, 0.003, 0.002, or 0.001. In some instances, the P-value may be based on any of the following comparisons: BCR vs non-BCR, CP vs non-CP, PCSM vs non-PCSM. For example, a classifier or biomarker is determined to be clinically significant if the P-values of the differences between the KM curves for BCR vs non-BCR, CP vs non-CP, PCSM vs non-PCSM is lower than about 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, 0.02, 0.01, 0.005, 0.004, 0.003, 0.002, or 0.001.

In some instances, the performance of the classifier or biomarker is based on the odds ratio. A classifier or biomarker may be considered to have good performance if the odds ratio is at least about 1.30, 1.31, 1.32, 1.33, 1.34, 1.35, 1.36, 1.37, 1.38, 1.39, 1.40, 1.41, 1.42, 1.43, 1.44, 1.45, 1.46, 1.47, 1.48, 1.49, 1.50, 1.52, 1.55, 1.57, 1.60, 1.62, 1.65, 1.67, 1.70 or more. In some instances, the odds ratio of a classifier or biomarker is at least about 1.33.

The clinical significance of the classifiers and/or biomarkers may be based on Univariable Analysis Odds Ratio P-value (uvaORPval). The Univariable Analysis Odds Ratio P-value (uvaORPval) of the classifier and/or biomarker may be between about 0-0.4. The Univariable Analysis Odds Ratio P-value (uvaORPval) of the classifier and/or biomarker may be between about 0-0.3. The Univariable Analysis Odds Ratio P-value (uvaORPval) of the classifier and/or biomarker may be between about 0-0.2. The Univariable Analysis Odds Ratio P-value (uvaORPval) of the classifier and/or biomarker may be less than or equal to 0.25, 0.22, 0.21, 0.20, 0.19, 0.18, 0.17, 0.16, 0.15, 0.14, 0.13, 0.12, 0.11. The Univariable Analysis Odds Ratio P-value (uvaORPval) of the classifier and/or biomarker may be less than or equal to 0.10, 0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, 0.02, 0.01. The Univariable Analysis Odds Ratio P-value (uvaORPval) of the classifier and/or biomarker may be less than or equal to 0.009, 0.008, 0.007, 0.006, 0.005, 0.004, 0.003, 0.002, 0.001.

The clinical significance of the classifiers and/or biomarkers may be based on multivariable analysis Odds Ratio P-value (mvaORPval). The multivariable analysis Odds Ratio P-value (mvaORPval) of the classifier and/or biomarker may be between about 0-1. The multivariable analysis Odds Ratio P-value (mvaORPval) of the classifier and/or biomarker may be between about 0-0.9. The multivariable analysis Odds Ratio P-value (mvaORPval) of the classifier and/or biomarker may be between about 0-0.8. The multivariable analysis Odds Ratio P-value (mvaORPval) of the classifier and/or biomarker may be less than or equal to 0.90, 0.88, 0.86, 0.84, 0.82, 0.80. The multivariable analysis Odds Ratio P-value (mvaORPval) of the classifier and/or biomarker may be less than or equal to 0.78, 0.76, 0.74, 0.72, 0.70, 0.68, 0.66, 0.64, 0.62, 0.60, 0.58, 0.56, 0.54, 0.52, 0.50. The multivariable analysis Odds Ratio P-value (mvaORPval) of the classifier and/or biomarker may be less than or equal to 0.48, 0.46, 0.44, 0.42, 0.40, 0.38, 0.36, 0.34, 0.32, 0.30, 0.28, 0.26, 0.25, 0.22, 0.21, 0.20, 0.19, 0.18, 0.17, 0.16, 0.15, 0.14, 0.13, 0.12, 0.11. The multivariable analysis Odds Ratio P-value (mvaORPval) of the classifier and/or biomarker may be less than or equal to 0.10, 0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, 0.02, 0.01. The multivariable analysis Odds Ratio P-value (mvaORPval) of the classifier and/or biomarker may be less than or equal to 0.009, 0.008, 0.007, 0.006, 0.005, 0.004, 0.003, 0.002, 0.001.

The clinical significance of the classifiers and/or biomarkers may be based on the Kaplan Meier P-value (KM P-value). The Kaplan Meier P-value (KM P-value) of the classifier and/or biomarker may be between about 0-0.8. The Kaplan Meier P-value (KM P-value) of the classifier and/or biomarker may be between about 0-0.7. The Kaplan Meier P-value (KM P-value) of the classifier and/or biomarker may be less than or equal to 0.80, 0.78, 0.76, 0.74, 0.72, 0.70, 0.68, 0.66, 0.64, 0.62, 0.60, 0.58, 0.56, 0.54, 0.52, 0.50. The Kaplan Meier P-value (KM P-value) of the classifier and/or biomarker may be less than or equal to 0.48, 0.46, 0.44, 0.42, 0.40, 0.38, 0.36, 0.34, 0.32, 0.30, 0.28, 0.26, 0.25, 0.22, 0.21, 0.20, 0.19, 0.18, 0.17, 0.16, 0.15, 0.14, 0.13, 0.12, 0.11. The Kaplan Meier P-value (KM P-value) of the classifier and/or biomarker may be less than or equal to 0.10, 0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, 0.02, 0.01. The Kaplan Meier P-value (KM P-value) of the classifier and/or biomarker may be less than or equal to 0.009, 0.008, 0.007, 0.006, 0.005, 0.004, 0.003, 0.002, 0.001.

The clinical significance of the classifiers and/or biomarkers may be based on the survival AUC value (survAUC). The survival AUC value (survAUC) of the classifier and/or biomarker may be between about 0-1. The survival AUC value (survAUC) of the classifier and/or biomarker may be between about 0-0.9. The survival AUC value (survAUC) of the classifier and/or biomarker may be less than or equal to 1, 0.98, 0.96, 0.94, 0.92, 0.90, 0.88, 0.86, 0.84, 0.82, 0.80. The survival AUC value (survAUC) of the classifier and/or biomarker may be less than or equal to 0.80, 0.78, 0.76, 0.74, 0.72, 0.70, 0.68, 0.66, 0.64, 0.62, 0.60, 0.58, 0.56, 0.54, 0.52, 0.50. The survival AUC value (survAUC) of the classifier and/or biomarker may be less than or equal to 0.48, 0.46, 0.44, 0.42, 0.40, 0.38, 0.36, 0.34, 0.32, 0.30, 0.28, 0.26, 0.25, 0.22, 0.21, 0.20, 0.19, 0.18, 0.17, 0.16, 0.15, 0.14, 0.13, 0.12, 0.11. The survival AUC value (survAUC) of the classifier and/or biomarker may be less than or equal to 0.10, 0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, 0.02, 0.01. The survival AUC value (survAUC) of the classifier and/or biomarker may be less than or equal to 0.009, 0.008, 0.007, 0.006, 0.005, 0.004, 0.003, 0.002, 0.001.

The clinical significance of the classifiers and/or biomarkers may be based on the Univariable Analysis Hazard Ratio P-value (uvaHRPval). The Univariable Analysis Hazard Ratio P-value (uvaHRPval) of the classifier and/or biomarker may be between about 0-0.4. The Univariable Analysis Hazard Ratio P-value (uvaHRPval) of the classifier and/or biomarker may be between about 0-0.3. The Univariable Analysis Hazard Ratio P-value (uvaHRPval) of the classifier and/or biomarker may be less than or equal to 0.40, 0.38, 0.36, 0.34, 0.32. The Univariable Analysis Hazard Ratio P-value (uvaHRPval) of the classifier and/or biomarker may be less than or equal to 0.30, 0.29, 0.28, 0.27, 0.26, 0.25, 0.24, 0.23, 0.22, 0.21, 0.20. The Univariable Analysis Hazard Ratio P-value (uvaHRPval) of the classifier and/or biomarker may be less than or equal to 0.19, 0.18, 0.17, 0.16, 0.15, 0.14, 0.13, 0.12, 0.11. The Univariable Analysis Hazard Ratio P-value (uvaHRPval) of the classifier and/or biomarker may be less than or equal to 0.10, 0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, 0.02, 0.01. The Univariable Analysis Hazard Ratio P-value (uvaHRPval) of the classifier and/or biomarker may be less than or equal to 0.009, 0.008, 0.007, 0.006, 0.005, 0.004, 0.003, 0.002, 0.001.

The clinical significance of the classifiers and/or biomarkers may be based on the Multivariable Analysis Hazard Ratio P-value (mvaHRPval)mva HRPval. The Multivariable Analysis Hazard Ratio P-value (mvaHRPval)mva HRPval of the classifier and/or biomarker may be between about 0-1. The Multivariable Analysis Hazard Ratio P-value (mvaHRPval)mva HRPval of the classifier and/or biomarker may be between about 0-0.9. The Multivariable Analysis Hazard Ratio P-value (mvaHRPval)mva HRPval of the classifier and/or biomarker may be less than or equal to 1, 0.98, 0.96, 0.94, 0.92, 0.90, 0.88, 0.86, 0.84, 0.82, 0.80. The Multivariable Analysis Hazard Ratio P-value (mvaHRPval)mva HRPval of the classifier and/or biomarker may be less than or equal to 0.80, 0.78, 0.76, 0.74, 0.72, 0.70, 0.68, 0.66, 0.64, 0.62, 0.60, 0.58, 0.56, 0.54, 0.52, 0.50. The Multivariable Analysis Hazard Ratio P-value (mvaHRPval)mva HRPval of the classifier and/or biomarker may be less than or equal to 0.48, 0.46, 0.44, 0.42, 0.40, 0.38, 0.36, 0.34, 0.32, 0.30, 0.28, 0.26, 0.25, 0.22, 0.21, 0.20, 0.19, 0.18, 0.17, 0.16, 0.15, 0.14, 0.13, 0.12, 0.11. The Multivariable Analysis Hazard Ratio P-value (mvaHRPval)mva HRPval of the classifier and/or biomarker may be less than or equal to 0.10, 0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, 0.02, 0.01. The Multivariable Analysis Hazard Ratio P-value (mvaHRPval)mva HRPval of the classifier and/or biomarker may be less than or equal to 0.009, 0.008, 0.007, 0.006, 0.005, 0.004, 0.003, 0.002, 0.001.

The clinical significance of the classifiers and/or biomarkers may be based on the Multivariable Analysis Hazard Ratio P-value (mvaHRPval). The Multivariable Analysis Hazard Ratio P-value (mvaHRPval) of the classifier and/or biomarker may be between about 0 to about 0.60. significance of the classifier and/or biomarker may be based on the Multivariable Analysis Hazard Ratio P-value (mvaHRPval). The Multivariable Analysis Hazard Ratio P-value (mvaHRPval) of the classifier and/or biomarker may be between about 0 to about 0.50. significance of the classifier and/or biomarker may be based on the Multivariable Analysis Hazard Ratio P-value (mvaHRPval). The Multivariable Analysis Hazard Ratio P-value (mvaHRPval) of the classifier and/or biomarker may be less than or equal to 0.50, 0.47, 0.45, 0.43, 0.40, 0.38, 0.35, 0.33, 0.30, 0.28, 0.25, 0.22, 0.20, 0.18, 0.16, 0.15, 0.14, 0.13, 0.12, 0.11, 0.10. The Multivariable Analysis Hazard Ratio P-value (mvaHRPval) of the classifier and/or biomarker may be less than or equal to 0.10, 0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, 0.02, 0.01. The Multivariable Analysis Hazard Ratio P-value (mvaHRPval) of the classifier and/or biomarker may be less than or equal to 0.01, 0.009, 0.008, 0.007, 0.006, 0.005, 0.004, 0.003, 0.002, 0.001.

The classifiers and/or biomarkers disclosed herein may outperform current classifiers or clinical variables in providing clinically relevant analysis of a sample from a subject. In some instances, the classifiers or biomarkers may more accurately predict a clinical outcome or status as compared to current classifiers or clinical variables. For example, a classifier or biomarker may more accurately predict metastatic disease. Alternatively, a classifier or biomarker may more accurately predict no evidence of disease. In some instances, the classifier or biomarker may more accurately predict death from a disease. The performance of a classifier or biomarker disclosed herein may be based on the AUC value, odds ratio, 95% CI, difference in range of the 95% CI, p-value or any combination thereof.

The performance of the classifiers and/or biomarkers disclosed herein may be determined by AUC values and an improvement in performance may be determined by the difference in the AUC value of the classifier or biomarker disclosed herein and the AUC value of current classifiers or clinical variables. In some instances, a classifier and/or biomarker disclosed herein outperforms current classifiers or clinical variables when the AUC value of the classifier and/or or biomarker disclosed herein is greater than the AUC value of the current classifiers or clinical variables by at least about 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20, 0.022, 0.25, 0.27, 0.30, 0.32, 0.35, 0.37, 0.40, 0.42, 0.45, 0.47, 0.50 or more. In some instances, the AUC value of the classifier and/or or biomarker disclosed herein is greater than the AUC value of the current classifiers or clinical variables by at least about 0.10. In some instances, the AUC value of the classifier and/or or biomarker disclosed herein is greater than the AUC value of the current classifiers or clinical variables by at least about 0.13. In some instances, the AUC value of the classifier and/or or biomarker disclosed herein is greater than the AUC value of the current classifiers or clinical variables by at least about 0.18.

The performance of the classifiers and/or biomarkers disclosed herein may be determined by the odds ratios and an improvement in performance may be determined by comparing the odds ratio of the classifier or biomarker disclosed herein and the odds ratio of current classifiers or clinical variables. Comparison of the performance of two or more classifiers, biomarkers, and/or clinical variables can be generally be based on the comparison of the absolute value of (1-odds ratio) of a first classifier, biomarker or clinical variable to the absolute value of (1-odds ratio) of a second classifier, biomarker or clinical variable. Generally, the classifier, biomarker or clinical variable with the greater absolute value of (1-odds ratio) can be considered to have better performance as compared to the classifier, biomarker or clinical variable with a smaller absolute value of (1-odds ratio).

In some instances, the performance of a classifier, biomarker or clinical variable is based on the comparison of the odds ratio and the 95% confidence interval (CI). For example, a first classifier, biomarker or clinical variable may have a greater absolute value of (1-odds ratio) than a second classifier, biomarker or clinical variable, however, the 95% CI of the first classifier, biomarker or clinical variable may overlap 1 (e.g., poor accuracy), whereas the 95% CI of the second classifier, biomarker or clinical variable does not overlap 1. In this instance, the second classifier, biomarker or clinical variable is considered to outperform the first classifier, biomarker or clinical variable because the accuracy of the first classifier, biomarker or clinical variable is less than the accuracy of the second classifier, biomarker or clinical variable. In another example, a first classifier, biomarker or clinical variable may outperform a second classifier, biomarker or clinical variable based on a comparison of the odds ratio; however, the difference in the 95% CI of the first classifier, biomarker or clinical variable is at least about 2 times greater than the 95% CI of the second classifier, biomarker or clinical variable. In this instance, the second classifier, biomarker or clinical variable is considered to outperform the first classifier.

In some instances, a classifier or biomarker disclosed herein more accurate than a current classifier or clinical variable. The classifier or biomarker disclosed herein is more accurate than a current classifier or clinical variable if the range of 95% CI of the classifier or biomarker disclosed herein does not span or overlap 1 and the range of the 95% CI of the current classifier or clinical variable spans or overlaps 1.

In some instances, a classifier or biomarker disclosed herein more accurate than a current classifier or clinical variable. The classifier or biomarker disclosed herein is more accurate than a current classifier or clinical variable when difference in range of the 95% CI of the classifier or biomarker disclosed herein is about 0.70, 0.60, 0.50, 0.40, 0.30, 0.20, 0.15, 0.14, 0.13, 0.12, 0.10, 0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, 0.02 times less than the difference in range of the 95% CI of the current classifier or clinical variable. The classifier or biomarker disclosed herein is more accurate than a current classifier or clinical variable when difference in range of the 95% CI of the classifier or biomarker disclosed herein between about 0.20 to about 0.04 times less than the difference in range of the 95% CI of the current classifier or clinical variable.

In some instances, the methods disclosed herein may comprise the use of a genomic classifier (GC) model. A general method for developing a GC model may comprise (a) providing a sample from a subject suffering from a cancer; (b) assaying the expression level for a plurality of targets; (c) generating a model by using a machine learning algorithm. In some instances, the machine learning algorithm comprises Random Forests. In another example, a GC model may developed by using a machine learning algorithm to analyze and rank genomic features. Analyzing the genomic features may comprise classifying one or more genomic features. The method may further comprise validating the classifier and/or refining the classifier by using a machine learning algorithm.

The methods disclosed herein may comprise generating one or more clinical classifiers (CC). The clinical classifier can be developed using one or more clinicopathologic variables. The clinicopathologic variables may be selected from the group comprising Lymph node invasion status (LNI); Surgical Margin Status (SMS); Seminal Vesicle Invasion (SVI); Extra Capsular Extension (ECE); Pathological Gleason Score; and the pre-operative PSA. The method may comprise using one or more of the clinicopathologic variables as binary variables. Alternatively, or additionally, the one or more clinicopathologic variables may be converted to a logarithmic value (e.g., log 10). The method may further comprise assembling the variables in a logistic regression. In some instances, the CC is combined with the GC to produce a genomic clinical classifier (GCC).

In some instances, the methods disclosed herein may comprise the use of a genomic-clinical classifier (GCC) model. A general method for developing a GCC model may comprise (a) providing a sample from a subject suffering from a cancer; (b) assaying the expression level for a plurality of targets; (c) generating a model by using a machine learning algorithm. In some instances, the machine learning algorithm comprises Random Forests.

Cancer

The systems, compositions and methods disclosed herein may be used to diagnosis, monitor and/or predict the status or outcome of a cancer. Generally, a cancer is characterized by the uncontrolled growth of abnormal cells anywhere in a body. The abnormal cells may be termed cancer cells, malignant cells, or tumor cells. Many cancers and the abnormal cells that compose the cancer tissue are further identified by the name of the tissue that the abnormal cells originated from (for example, breast cancer, lung cancer, colon cancer, prostate cancer, pancreatic cancer, thyroid cancer). Cancer is not confined to humans; animals and other living organisms can get cancer.

In some instances, the cancer may be malignant. Alternatively, the cancer may be benign. The cancer may be a recurrent and/or refractory cancer. Most cancers can be classified as a carcinoma, sarcoma, leukemia, lymphoma, myeloma, or a central nervous system cancer.

The cancer may be a sarcoma. Sarcomas are cancers of the bone, cartilage, fat, muscle, blood vessels, or other connective or supportive tissue. Sarcomas include, but are not limited to, bone cancer, fibrosarcoma, chondrosarcoma, Ewing's sarcoma, malignant hemangioendothelioma, malignant schwannoma, bilateral vestibular schwannoma, osteosarcoma, soft tissue sarcomas (e.g. alveolar soft part. sarcoma, angiosarcoma, cystosarcoma phylloides, dermatofibrosarcoma, desmoid tumor, epithelioid sarcoma, extraskeletal osteosarcoma, fibrosarcoma, hemangiopericytoma, hemangiosarcoma, Kaposi's sarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, lymphosarcoma, malignant fibrous histiocytoma, neurofibrosarcoma, rhabdomyosarcoma, and synovial sarcoma).

Alternatively, the cancer may be a carcinoma. Carcinomas are cancers that begin in the epithelial cells, which are cells that cover the surface of the body, produce hormones, and make up glands. By way of non-limiting example, carcinomas include breast cancer, pancreatic cancer, lung cancer, colon cancer, colorectal cancer, rectal cancer, kidney cancer, bladder cancer, stomach cancer, prostate cancer, liver cancer, ovarian cancer, brain cancer, vaginal cancer, vulvar cancer, uterine cancer, oral cancer, penic cancer, testicular cancer, esophageal cancer, skin cancer, cancer of the fallopian tubes, head and neck cancer, gastrointestinal stromal cancer, adenocarcinoma, cutaneous or intraocular melanoma, cancer of the anal region, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, cancer of the urethra, cancer of the renal pelvis, cancer of the ureter, cancer of the endometrium, cancer of the cervix, cancer of the pituitary gland, neoplasms of the central nervous system (CNS), primary CNS lymphoma, brain stem glioma, and spinal axis tumors. In some instances, the cancer is a skin cancer, such as a basal cell carcinoma, squamous, melanoma, nonmelanoma, or actinic (solar) keratosis. Preferably, the cancer is a prostate cancer. Alternatively, the cancer may be a thyroid cancer, bladder cancer, or pancreatic cancer.

In some instances, the cancer is a lung cancer. Lung cancer can start in the airways that branch off the trachea to supply the lungs (bronchi) or the small air sacs of the lung (the alveoli). Lung cancers include non-small cell lung carcinoma (NSCLC), small cell lung carcinoma, and mesotheliomia. Examples of NSCLC include squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. The mesothelioma may be a cancerous tumor of the lining of the lung and chest cavitity (pleura) or lining of the abdomen (peritoneum). The mesothelioma may be due to asbestos exposure. The cancer may be a brain cancer, such as a glioblastoma.

Alternatively, the cancer may be a central nervous system (CNS) tumor. CNS tumors may be classified as gliomas or nongliomas. The glioma may be malignant glioma, high grade glioma, diffuse intrinsic pontine glioma. Examples of gliomas include astrocytomas, oligodendrogliomas (or mixtures of oligodendroglioma and astocytoma elements), and ependymomas. Astrocytomas include, but are not limited to, low-grade astrocytomas, anaplastic astrocytomas, glioblastoma multiforme, pilocytic astrocytoma, pleomorphic xanthoastrocytoma, and subependymal giant cell astrocytoma. Oligodendrogliomas include low-grade oligodendrogliomas (or oligoastrocytomas) and anaplastic oligodendriogliomas. Nongliomas include meningiomas, pituitary adenomas, primary CNS lymphomas, and medulloblastomas. In some instances, the cancer is a meningioma.

The cancer may be a leukemia. The leukemia may be an acute lymphocytic leukemia, acute myelocytic leukemia, chronic lymphocytic leukemia, or chronic myelocytic leukemia. Additional types of leukemias include hairy cell leukemia, chronic myelomonocytic leukemia, and juvenile myelomonocytic-leukemia.

In some instances, the cancer is a lymphoma. Lymphomas are cancers of the lymphocytes and may develop from either B or T lymphocytes. The two major types of lymphoma are Hodgkin's lymphoma, previously known as Hodgkin's disease, and non-Hodgkin's lymphoma. Hodgkin's lymphoma is marked by the presence of the Reed-Sternberg cell. Non-Hodgkin's lymphomas are all lymphomas which are not Hodgkin's lymphoma. Non-Hodgkin lymphomas may be indolent lymphomas and aggressive lymphomas. Non-Hodgkin's lymphomas include, but are not limited to, diffuse large B cell lymphoma, follicular lymphoma, mucosa-associated lymphatic tissue lymphoma (MALT), small cell lymphocytic lymphoma, mantle cell lymphoma, Burkitt's lymphoma, mediastinal large B cell lymphoma, Waldenström macroglobulinemia, nodal marginal zone B cell lymphoma (NMZL), splenic marginal zone lymphoma (SMZL), extranodal marginal zone B cell lymphoma, intravascular large B cell lymphoma, primary effusion lymphoma, and lymphomatoid granulomatosis.

Cancer Staging

Diagnosing, predicting, or monitoring a status or outcome of a cancer may comprise determining the stage of the cancer. Generally, the stage of a cancer is a description (usually numbers I to IV with IV having more progression) of the extent the cancer has spread. The stage often takes into account the size of a tumor, how deeply it has penetrated, whether it has invaded adjacent organs, how many lymph nodes it has metastasized to (if any), and whether it has spread to distant organs. Staging of cancer can be used as a predictor of survival, and cancer treatment may be determined by staging. Determining the stage of the cancer may occur before, during, or after treatment. The stage of the cancer may also be determined at the time of diagnosis.

Cancer staging can be divided into a clinical stage and a pathologic stage. Cancer staging may comprise the TNM classification. Generally, the TNM Classification of Malignant Tumours (TNM) is a cancer staging system that describes the extent of cancer in a patient's body. T may describe the size of the tumor and whether it has invaded nearby tissue, N may describe regional lymph nodes that are involved, and M may describe distant metastasis (spread of cancer from one body part to another). In the TNM (Tumor, Node, Metastasis) system, clinical stage and pathologic stage are denoted by a small “c” or “p” before the stage (e.g., cT3N1M0 or pT2N0).

Often, clinical stage and pathologic stage may differ. Clinical stage may be based on all of the available information obtained before a surgery to remove the tumor. Thus, it may include information about the tumor obtained by physical examination, radiologic examination, and endoscopy. Pathologic stage can add additional information gained by examination of the tumor microscopically by a pathologist. Pathologic staging can allow direct examination of the tumor and its spread, contrasted with clinical staging which may be limited by the fact that the information is obtained by making indirect observations at a tumor which is still in the body. The TNM staging system can be used for most forms of cancer.

Alternatively, staging may comprise Ann Arbor staging. Generally, Ann Arbor staging is the staging system for lymphomas, both in Hodgkin's lymphoma (previously called Hodgkin's disease) and Non-Hodgkin lymphoma (abbreviated NHL). The stage may depend on both the place where the malignant tissue is located (as located with biopsy, CT scanning and increasingly positron emission tomography) and on systemic symptoms due to the lymphoma (“B symptoms”: night sweats, weight loss of >10% or fevers). The principal stage may be determined by location of the tumor. Stage I may indicate that the cancer is located in a single region, usually one lymph node and the surrounding area. Stage I often may not have outward symptoms. Stage II can indicate that the cancer is located in two separate regions, an affected lymph node or organ and a second affected area, and that both affected areas are confined to one side of the diaphragm—that is, both are above the diaphragm, or both are below the diaphragm. Stage III often indicates that the cancer has spread to both sides of the diaphragm, including one organ or area near the lymph nodes or the spleen. Stage IV may indicate diffuse or disseminated involvement of one or more extralymphatic organs, including any involvement of the liver, bone marrow, or nodular involvement of the lungs.

Modifiers may also be appended to some stages. For example, the letters A, B, E, X, or S can be appended to some stages. Generally, A or B may indicate the absence of constitutional (B-type) symptoms is denoted by adding an “A” to the stage; the presence is denoted by adding a “B” to the stage. E can be used if the disease is “extranodal” (not in the lymph nodes) or has spread from lymph nodes to adjacent tissue. X is often used if the largest deposit is >10 cm large (“bulky disease”), or whether the mediastinum is wider than ⅓ of the chest on a chest X-ray. S may be used if the disease has spread to the spleen.

The nature of the staging may be expressed with CS or PS. CS may denote that the clinical stage as obtained by doctor's examinations and tests. PS may denote that the pathological stage as obtained by exploratory laparotomy (surgery performed through an abdominal incision) with splenectomy (surgical removal of the spleen).

Therapeutic Regimens

Diagnosing, predicting, or monitoring a status or outcome of a cancer may comprise treating a cancer or preventing a cancer progression. In addition, diagnosing, predicting, or monitoring a status or outcome of a cancer may comprise identifying or predicting responders to an anti-cancer therapy. In some instances, diagnosing, predicting, or monitoring may comprise determining a therapeutic regimen. Determining a therapeutic regimen may comprise administering an anti-cancer therapy. Alternatively, determining a therapeutic regimen may comprise modifying, recommending, continuing or discontinuing an anti-cancer regimen. In some instances, if the sample expression patterns are consistent with the expression pattern for a known disease or disease outcome, the expression patterns can be used to designate one or more treatment modalities (e.g., therapeutic regimens, anti-cancer regimen). An anti-cancer regimen may comprise one or more anti-cancer therapies. Examples of anti-cancer therapies include surgery, chemotherapy, radiation therapy, immunotherapy/biological therapy, photodynamic therapy.

Surgical oncology uses surgical methods to diagnose, stage, and treat cancer, and to relieve certain cancer-related symptoms. Surgery may be used to remove the tumor (e.g., excisions, resections, debulking surgery), reconstruct a part of the body (e.g., restorative surgery), and/or to relieve symptoms such as pain (e.g., palliative surgery). Surgery may also include cryosurgery. Cryosurgery (also called cryotherapy) may use extreme cold produced by liquid nitrogen (or argon gas) to destroy abnormal tissue. Cryosurgery can be used to treat external tumors, such as those on the skin. For external tumors, liquid nitrogen can be applied directly to the cancer cells with a cotton swab or spraying device. Cryosurgery may also be used to treat tumors inside the body (internal tumors and tumors in the bone). For internal tumors, liquid nitrogen or argon gas may be circulated through a hollow instrument called a cryoprobe, which is placed in contact with the tumor. An ultrasound or MRI may be used to guide the cryoprobe and monitor the freezing of the cells, thus limiting damage to nearby healthy tissue. A ball of ice crystals may form around the probe, freezing nearby cells. Sometimes more than one probe is used to deliver the liquid nitrogen to various parts of the tumor. The probes may be put into the tumor during surgery or through the skin (percutaneously). After cryosurgery, the frozen tissue thaws and may be naturally absorbed by the body (for internal tumors), or may dissolve and form a scab (for external tumors).

Chemotherapeutic agents may also be used for the treatment of cancer. Examples of chemotherapeutic agents include alkylating agents, anti-metabolites, plant alkaloids and terpenoids, vinca alkaloids, podophyllotoxin, taxanes, topoisomerase inhibitors, and cytotoxic antibiotics. Cisplatin, carboplatin, and oxaliplatin are examples of alkylating agents. Other alkylating agents include mechlorethamine, cyclophosphamide, chlorambucil, ifosfamide. Alkylating agents may impair cell function by forming covalent bonds with the amino, carboxyl, sulfhydryl, and phosphate groups in biologically important molecules. Alternatively, alkylating agents may chemically modify a cell's DNA.

Anti-metabolites are another example of chemotherapeutic agents. Anti-metabolites may masquerade as purines or pyrimidines and may prevent purines and pyrimidines from becoming incorporated in to DNA during the “S” phase (of the cell cycle), thereby stopping normal development and division. Antimetabolites may also affect RNA synthesis. Examples of metabolites include azathioprine and mercaptopurine.

Alkaloids may be derived from plants and block cell division may also be used for the treatment of cancer. Alkyloids may prevent microtubule function. Examples of alkaloids are vinca alkaloids and taxanes. Vinca alkaloids may bind to specific sites on tubulin and inhibit the assembly of tubulin into microtubules (M phase of the cell cycle). The vinca alkaloids may be derived from the Madagascar periwinkle, Catharanthus roseus (formerly known as Vinca rosea). Examples of vinca alkaloids include, but are not limited to, vincristine, vinblastine, vinorelbine, or vindesine. Taxanes are diterpenes produced by the plants of the genus Taxus (yews). Taxanes may be derived from natural sources or synthesized artificially. Taxanes include paclitaxel (Taxol) and docetaxel (Taxotere). Taxanes may disrupt microtubule function. Microtubules are essential to cell division, and taxanes may stabilize GDP-bound tubulin in the microtubule, thereby inhibiting the process of cell division. Thus, in essence, taxanes may be mitotic inhibitors. Taxanes may also be radiosensitizing and often contain numerous chiral centers.

Alternative chemotherapeutic agents include podophyllotoxin. Podophyllotoxin is a plant-derived compound that may help with digestion and may be used to produce cytostatic drugs such as etoposide and teniposide. They may prevent the cell from entering the G1 phase (the start of DNA replication) and the replication of DNA (the S phase).

Topoisomerases are essential enzymes that maintain the topology of DNA. Inhibition of type I or type II topoisomerases may interfere with both transcription and replication of DNA by upsetting proper DNA supercoiling. Some chemotherapeutic agents may inhibit topoisomerases. For example, some type I topoisomerase inhibitors include camptothecins: irinotecan and topotecan. Examples of type II inhibitors include amsacrine, etoposide, etoposide phosphate, and teniposide.

Another example of chemotherapeutic agents is cytotoxic antibiotics. Cytotoxic antibiotics are a group of antibiotics that are used for the treatment of cancer because they may interfere with DNA replication and/or protein synthesis. Cytotoxic antibiotics include, but are not limited to, actinomycin, anthracyclines, doxorubicin, daunorubicin, valrubicin, idarubicin, epirubicin, bleomycin, plicamycin, and mitomycin.

In some instances, the anti-cancer treatment may comprise radiation therapy. Radiation can come from a machine outside the body (external-beam radiation therapy) or from radioactive material placed in the body near cancer cells (internal radiation therapy, more commonly called brachytherapy). Systemic radiation therapy uses a radioactive substance, given by mouth or into a vein that travels in the blood to tissues throughout the body.

External-beam radiation therapy may be delivered in the form of photon beams (either x-rays or gamma rays). A photon is the basic unit of light and other forms of electromagnetic radiation. An example of external-beam radiation therapy is called 3-dimensional conformal radiation therapy (3D-CRT). 3D-CRT may use computer software and advanced treatment machines to deliver radiation to very precisely shaped target areas. Many other methods of external-beam radiation therapy are currently being tested and used in cancer treatment. These methods include, but are not limited to, intensity-modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), Stereotactic radiosurgery (SRS), Stereotactic body radiation therapy (SBRT), and proton therapy.

Intensity-modulated radiation therapy (IMRT) is an example of external-beam radiation and may use hundreds of tiny radiation beam-shaping devices, called collimators, to deliver a single dose of radiation. The collimators can be stationary or can move during treatment, allowing the intensity of the radiation beams to change during treatment sessions. This kind of dose modulation allows different areas of a tumor or nearby tissues to receive different doses of radiation. IMRT is planned in reverse (called inverse treatment planning). In inverse treatment planning, the radiation doses to different areas of the tumor and surrounding tissue are planned in advance, and then a high-powered computer program calculates the required number of beams and angles of the radiation treatment. In contrast, during traditional (forward) treatment planning, the number and angles of the radiation beams are chosen in advance and computers calculate how much dose may be delivered from each of the planned beams. The goal of IMRT is to increase the radiation dose to the areas that need it and reduce radiation exposure to specific sensitive areas of surrounding normal tissue.

Another example of external-beam radiation is image-guided radiation therapy (IGRT). In IGRT, repeated imaging scans (CT, MRI, or PET) may be performed during treatment. These imaging scans may be processed by computers to identify changes in a tumor's size and location due to treatment and to allow the position of the patient or the planned radiation dose to be adjusted during treatment as needed. Repeated imaging can increase the accuracy of radiation treatment and may allow reductions in the planned volume of tissue to be treated, thereby decreasing the total radiation dose to normal tissue.

Tomotherapy is a type of image-guided IMRT. A tomotherapy machine is a hybrid between a CT imaging scanner and an external-beam radiation therapy machine. The part of the tomotherapy machine that delivers radiation for both imaging and treatment can rotate completely around the patient in the same manner as a normal CT scanner. Tomotherapy machines can capture CT images of the patient's tumor immediately before treatment sessions, to allow for very precise tumor targeting and sparing of normal tissue.

Stereotactic radiosurgery (SRS) can deliver one or more high doses of radiation to a small tumor. SRS uses extremely accurate image-guided tumor targeting and patient positioning. Therefore, a high dose of radiation can be given without excess damage to normal tissue. SRS can be used to treat small tumors with well-defined edges. It is most commonly used in the treatment of brain or spinal tumors and brain metastases from other cancer types. For the treatment of some brain metastases, patients may receive radiation therapy to the entire brain (called whole-brain radiation therapy) in addition to SRS. SRS requires the use of a head frame or other device to immobilize the patient during treatment to ensure that the high dose of radiation is delivered accurately.

Stereotactic body radiation therapy (SBRT) delivers radiation therapy in fewer sessions, using smaller radiation fields and higher doses than 3D-CRT in most cases. SBRT may treat tumors that lie outside the brain and spinal cord. Because these tumors are more likely to move with the normal motion of the body, and therefore cannot be targeted as accurately as tumors within the brain or spine, SBRT is usually given in more than one dose. SBRT can be used to treat small, isolated tumors, including cancers in the lung and liver. SBRT systems may be known by their brand names, such as the CyberKnife®.

In proton therapy, external-beam radiation therapy may be delivered by proton. Protons are a type of charged particle. Proton beams differ from photon beams mainly in the way they deposit energy in living tissue. Whereas photons deposit energy in small packets all along their path through tissue, protons deposit much of their energy at the end of their path (called the Bragg peak) and deposit less energy along the way. Use of protons may reduce the exposure of normal tissue to radiation, possibly allowing the delivery of higher doses of radiation to a tumor.

Other charged particle beams such as electron beams may be used to irradiate superficial tumors, such as skin cancer or tumors near the surface of the body, but they cannot travel very far through tissue.

Internal radiation therapy (brachytherapy) is radiation delivered from radiation sources (radioactive materials) placed inside or on the body. Several brachytherapy techniques are used in cancer treatment. Interstitial brachytherapy may use a radiation source placed within tumor tissue, such as within a prostate tumor. Intracavitary brachytherapy may use a source placed within a surgical cavity or a body cavity, such as the chest cavity, near a tumor. Episcleral brachytherapy, which may be used to treat melanoma inside the eye, may use a source that is attached to the eye. In brachytherapy, radioactive isotopes can be sealed in tiny pellets or “seeds.” These seeds may be placed in patients using delivery devices, such as needles, catheters, or some other type of carrier. As the isotopes decay naturally, they give off radiation that may damage nearby cancer cells. Brachytherapy may be able to deliver higher doses of radiation to some cancers than external-beam radiation therapy while causing less damage to normal tissue.

Brachytherapy can be given as a low-dose-rate or a high-dose-rate treatment. In low-dose-rate treatment, cancer cells receive continuous low-dose radiation from the source over a period of several days. In high-dose-rate treatment, a robotic machine attached to delivery tubes placed inside the body may guide one or more radioactive sources into or near a tumor, and then removes the sources at the end of each treatment session. High-dose-rate treatment can be given in one or more treatment sessions. An example of a high-dose-rate treatment is the MammoSite® system. Bracytherapy may be used to treat patients with breast cancer who have undergone breast-conserving surgery.

The placement of brachytherapy sources can be temporary or permanent. For permanent brachytherapy, the sources may be surgically sealed within the body and left there, even after all of the radiation has been given off. In some instances, the remaining material (in which the radioactive isotopes were sealed) does not cause any discomfort or harm to the patient. Permanent brachytherapy is a type of low-dose-rate brachytherapy. For temporary brachytherapy, tubes (catheters) or other carriers are used to deliver the radiation sources, and both the carriers and the radiation sources are removed after treatment. Temporary brachytherapy can be either low-dose-rate or high-dose-rate treatment. Brachytherapy may be used alone or in addition to external-beam radiation therapy to provide a “boost” of radiation to a tumor while sparing surrounding normal tissue.

In systemic radiation therapy, a patient may swallow or receive an injection of a radioactive substance, such as radioactive iodine or a radioactive substance bound to a monoclonal antibody. Radioactive iodine (131I) is a type of systemic radiation therapy commonly used to help treat cancer, such as thyroid cancer. Thyroid cells naturally take up radioactive iodine. For systemic radiation therapy for some other types of cancer, a monoclonal antibody may help target the radioactive substance to the right place. The antibody joined to the radioactive substance travels through the blood, locating and killing tumor cells. For example, the drug ibritumomab tiuxetan (Zevalin®) may be used for the treatment of certain types of B-cell non-Hodgkin lymphoma (NHL). The antibody part of this drug recognizes and binds to a protein found on the surface of B lymphocytes. The combination drug regimen of tositumomab and iodine I 131 tositumomab (Bexxar®) may be used for the treatment of certain types of cancer, such as NHL. In this regimen, nonradioactive tositumomab antibodies may be given to patients first, followed by treatment with tositumomab antibodies that have 131I attached. Tositumomab may recognize and bind to the same protein on B lymphocytes as ibritumomab. The nonradioactive form of the antibody may help protect normal B lymphocytes from being damaged by radiation from 131I.

Some systemic radiation therapy drugs relieve pain from cancer that has spread to the bone (bone metastases). This is a type of palliative radiation therapy. The radioactive drugs samarium-153-lexidronam (Quadramet®) and strontium-89 chloride (Metastron®) are examples of radiopharmaceuticals may be used to treat pain from bone metastases.

Biological therapy (sometimes called immunotherapy, biotherapy, or biological response modifier (BRM) therapy) uses the body's immune system, either directly or indirectly, to fight cancer or to lessen the side effects that may be caused by some cancer treatments. Biological therapies include interferons, interleukins, colony-stimulating factors, monoclonal antibodies, vaccines, gene therapy, and nonspecific immunomodulating agents.

Interferons (IFNs) are types of cytokines that occur naturally in the body. Interferon alpha, interferon beta, and interferon gamma are examples of interferons that may be used in cancer treatment.

Like interferons, interleukins (ILs) are cytokines that occur naturally in the body and can be made in the laboratory. Many interleukins have been identified for the treatment of cancer. For example, interleukin-2 (IL-2 or aldesleukin), interleukin 7, and interleukin 12 have may be used as an anti-cancer treatment. IL-2 may stimulate the growth and activity of many immune cells, such as lymphocytes, that can destroy cancer cells. Interleukins may be used to treat a number of cancers, including leukemia, lymphoma, and brain, colorectal, ovarian, breast, kidney and prostate cancers.

Colony-stimulating factors (CSFs) (sometimes called hematopoietic growth factors) may also be used for the treatment of cancer. Some examples of CSFs include, but are not limited to, G-CSF (filgrastim) and GM-CSF (sargramostim). CSFs may promote the division of bone marrow stem cells and their development into white blood cells, platelets, and red blood cells. Bone marrow is critical to the body's immune system because it is the source of all blood cells. Because anticancer drugs can damage the body's ability to make white blood cells, red blood cells, and platelets, stimulation of the immune system by CSFs may benefit patients undergoing other anti-cancer treatment, thus CSFs may be combined with other anti-cancer therapies, such as chemotherapy. CSFs may be used to treat a large variety of cancers, including lymphoma, leukemia, multiple myeloma, melanoma, and cancers of the brain, lung, esophagus, breast, uterus, ovary, prostate, kidney, colon, and rectum.

Another type of biological therapy includes monoclonal antibodies (MOABs or MoABs). These antibodies may be produced by a single type of cell and may be specific for a particular antigen. To create MOABs, a human cancer cells may be injected into mice. In response, the mouse immune system can make antibodies against these cancer cells. The mouse plasma cells that produce antibodies may be isolated and fused with laboratory-grown cells to create “hybrid” cells called hybridomas. Hybridomas can indefinitely produce large quantities of these pure antibodies, or MOABs. MOABs may be used in cancer treatment in a number of ways. For instance, MOABs that react with specific types of cancer may enhance a patient's immune response to the cancer. MOABs can be programmed to act against cell growth factors, thus interfering with the growth of cancer cells.

MOABs may be linked to other anti-cancer therapies such as chemotherapeutics, radioisotopes (radioactive substances), other biological therapies, or other toxins. When the antibodies latch onto cancer cells, they deliver these anti-cancer therapies directly to the tumor, helping to destroy it. MOABs carrying radioisotopes may also prove useful in diagnosing certain cancers, such as colorectal, ovarian, and prostate.

Rituxan® (rituximab) and Herceptin® (trastuzumab) are examples of MOABs that may be used as a biological therapy. Rituxan may be used for the treatment of non-Hodgkin lymphoma. Herceptin can be used to treat metastatic breast cancer in patients with tumors that produce excess amounts of a protein called HER2. Alternatively, MOABs may be used to treat lymphoma, leukemia, melanoma, and cancers of the brain, breast, lung, kidney, colon, rectum, ovary, prostate, and other areas.

Cancer vaccines are another form of biological therapy. Cancer vaccines may be designed to encourage the patient's immune system to recognize cancer cells. Cancer vaccines may be designed to treat existing cancers (therapeutic vaccines) or to prevent the development of cancer (prophylactic vaccines). Therapeutic vaccines may be injected in a person after cancer is diagnosed. These vaccines may stop the growth of existing tumors, prevent cancer from recurring, or eliminate cancer cells not killed by prior treatments. Cancer vaccines given when the tumor is small may be able to eradicate the cancer. On the other hand, prophylactic vaccines are given to healthy individuals before cancer develops. These vaccines are designed to stimulate the immune system to attack viruses that can cause cancer. By targeting these cancer-causing viruses, development of certain cancers may be prevented. For example, cervarix and gardasil are vaccines to treat human papilloma virus and may prevent cervical cancer. Therapeutic vaccines may be used to treat melanoma, lymphoma, leukemia, and cancers of the brain, breast, lung, kidney, ovary, prostate, pancreas, colon, and rectum. Cancer vaccines can be used in combination with other anti-cancer therapies.

Gene therapy is another example of a biological therapy. Gene therapy may involve introducing genetic material into a person's cells to fight disease. Gene therapy methods may improve a patient's immune response to cancer. For example, a gene may be inserted into an immune cell to enhance its ability to recognize and attack cancer cells. In another approach, cancer cells may be injected with genes that cause the cancer cells to produce cytokines and stimulate the immune system.

In some instances, biological therapy includes nonspecific immunomodulating agents. Nonspecific immunomodulating agents are substances that stimulate or indirectly augment the immune system. Often, these agents target key immune system cells and may cause secondary responses such as increased production of cytokines and immunoglobulins. Two nonspecific immunomodulating agents used in cancer treatment are bacillus Calmette-Guerin (BCG) and levamisole. BCG may be used in the treatment of superficial bladder cancer following surgery. BCG may work by stimulating an inflammatory, and possibly an immune, response. A solution of BCG may be instilled in the bladder. Levamisole is sometimes used along with fluorouracil (5-FU) chemotherapy in the treatment of stage III (Dukes' C) colon cancer following surgery. Levamisole may act to restore depressed immune function.

Photodynamic therapy (PDT) is an anti-cancer treatment that may use a drug, called a photosensitizer or photosensitizing agent, and a particular type of light. When photosensitizers are exposed to a specific wavelength of light, they may produce a form of oxygen that kills nearby cells. A photosensitizer may be activated by light of a specific wavelength. This wavelength determines how far the light can travel into the body. Thus, photosensitizers and wavelengths of light may be used to treat different areas of the body with PDT.

In the first step of PDT for cancer treatment, a photosensitizing agent may be injected into the bloodstream. The agent may be absorbed by cells all over the body but may stay in cancer cells longer than it does in normal cells. Approximately 24 to 72 hours after injection, when most of the agent has left normal cells but remains in cancer cells, the tumor can be exposed to light. The photosensitizer in the tumor can absorb the light and produces an active form of oxygen that destroys nearby cancer cells. In addition to directly killing cancer cells, PDT may shrink or destroy tumors in two other ways. The photosensitizer can damage blood vessels in the tumor, thereby preventing the cancer from receiving necessary nutrients. PDT may also activate the immune system to attack the tumor cells.

The light used for PDT can come from a laser or other sources. Laser light can be directed through fiber optic cables (thin fibers that transmit light) to deliver light to areas inside the body. For example, a fiber optic cable can be inserted through an endoscope (a thin, lighted tube used to look at tissues inside the body) into the lungs or esophagus to treat cancer in these organs. Other light sources include light-emitting diodes (LEDs), which may be used for surface tumors, such as skin cancer. PDT is usually performed as an outpatient procedure. PDT may also be repeated and may be used with other therapies, such as surgery, radiation, or chemotherapy.

Extracorporeal photopheresis (ECP) is a type of PDT in which a machine may be used to collect the patient's blood cells. The patient's blood cells may be treated outside the body with a photosensitizing agent, exposed to light, and then returned to the patient. ECP may be used to help lessen the severity of skin symptoms of cutaneous T-cell lymphoma that has not responded to other therapies. ECP may be used to treat other blood cancers, and may also help reduce rejection after transplants.

Additionally, photosensitizing agent, such as porfimer sodium or Photofrin®, may be used in PDT to treat or relieve the symptoms of esophageal cancer and non-small cell lung cancer. Porfimer sodium may relieve symptoms of esophageal cancer when the cancer obstructs the esophagus or when the cancer cannot be satisfactorily treated with laser therapy alone. Porfimer sodium may be used to treat non-small cell lung cancer in patients for whom the usual treatments are not appropriate, and to relieve symptoms in patients with non-small cell lung cancer that obstructs the airways. Porfimer sodium may also be used for the treatment of precancerous lesions in patients with Barrett esophagus, a condition that can lead to esophageal cancer.

Laser therapy may use high-intensity light to treat cancer and other illnesses. Lasers can be used to shrink or destroy tumors or precancerous growths. Lasers are most commonly used to treat superficial cancers (cancers on the surface of the body or the lining of internal organs) such as basal cell skin cancer and the very early stages of some cancers, such as cervical, penile, vaginal, vulvar, and non-small cell lung cancer.

Lasers may also be used to relieve certain symptoms of cancer, such as bleeding or obstruction. For example, lasers can be used to shrink or destroy a tumor that is blocking a patient's trachea (windpipe) or esophagus. Lasers also can be used to remove colon polyps or tumors that are blocking the colon or stomach.

Laser therapy is often given through a flexible endoscope (a thin, lighted tube used to look at tissues inside the body). The endoscope is fitted with optical fibers (thin fibers that transmit light). It is inserted through an opening in the body, such as the mouth, nose, anus, or vagina. Laser light is then precisely aimed to cut or destroy a tumor.

Laser-induced interstitial thermotherapy (LITT), or interstitial laser photocoagulation, also uses lasers to treat some cancers. LITT is similar to a cancer treatment called hyperthermia, which uses heat to shrink tumors by damaging or killing cancer cells. During LITT, an optical fiber is inserted into a tumor. Laser light at the tip of the fiber raises the temperature of the tumor cells and damages or destroys them. LITT is sometimes used to shrink tumors in the liver.

Laser therapy can be used alone, but most often it is combined with other treatments, such as surgery, chemotherapy, or radiation therapy. In addition, lasers can seal nerve endings to reduce pain after surgery and seal lymph vessels to reduce swelling and limit the spread of tumor cells.

Lasers used to treat cancer may include carbon dioxide (CO2) lasers, argon lasers, and neodymium:yttrium-aluminum-garnet (Nd:YAG) lasers. Each of these can shrink or destroy tumors and can be used with endoscopes. CO2 and argon lasers can cut the skin's surface without going into deeper layers. Thus, they can be used to remove superficial cancers, such as skin cancer. In contrast, the Nd:YAG laser is more commonly applied through an endoscope to treat internal organs, such as the uterus, esophagus, and colon. Nd:YAG laser light can also travel through optical fibers into specific areas of the body during LITT. Argon lasers are often used to activate the drugs used in PDT.

For patients with high test scores consistent with systemic disease outcome after prostatectomy, additional treatment modalities such as adjuvant chemotherapy (e.g., docetaxel, mitoxantrone and prednisone), systemic radiation therapy (e.g., samarium or strontium) and/or anti-androgen therapy (e.g., surgical castration, finasteride, dutasteride) can be designated. Such patients would likely be treated immediately with anti-androgen therapy alone or in combination with radiation therapy in order to eliminate presumed micro-metastatic disease, which cannot be detected clinically but can be revealed by the target sequence expression signature.

Such patients can also be more closely monitored for signs of disease progression. For patients with intermediate test scores consistent with biochemical recurrence only (BCR-only or elevated PSA that does not rapidly become manifested as systemic disease only localized adjuvant therapy (e.g., radiation therapy of the prostate bed) or short course of anti-androgen therapy would likely be administered. For patients with low scores or scores consistent with no evidence of disease (NED) adjuvant therapy would not likely be recommended by their physicians in order to avoid treatment-related side effects such as metabolic syndrome (e.g., hypertension, diabetes and/or weight gain), osteoporosis, proctitis, incontinence or impotence. Patients with samples consistent with NED could be designated for watchful waiting, or for no treatment. Patients with test scores that do not correlate with systemic disease but who have successive PSA increases could be designated for watchful waiting, increased monitoring, or lower dose or shorter duration anti-androgen therapy.

Target sequences can be grouped so that information obtained about the set of target sequences in the group can be used to make or assist in making a clinically relevant judgment such as a diagnosis, prognosis, or treatment choice.

A patient report is also provided comprising a representation of measured expression levels of a plurality of target sequences in a biological sample from the patient, wherein the representation comprises expression levels of target sequences corresponding to any one, two, three, four, five, six, eight, ten, twenty, thirty, fifty or more of the target sequences corresponding to a target selected from any of Tables 2, 4, 11 and 55, or of the subsets described herein, or of a combination thereof. In some instances, the target is selected from Table 2. In other instances, the target is selected from Table 4. In some embodiments, the target is selected from Table 11. In some embodiments, the representation of the measured expression level(s) may take the form of a linear or nonlinear combination of expression levels of the target sequences of interest. The patient report may be provided in a machine (e.g., a computer) readable format and/or in a hard (paper) copy. The report can also include standard measurements of expression levels of said plurality of target sequences from one or more sets of patients with known disease status and/or outcome. The report can be used to inform the patient and/or treating physician of the expression levels of the expressed target sequences, the likely medical diagnosis and/or implications, and optionally may recommend a treatment modality for the patient.

Also provided are representations of the gene expression profiles useful for treating, diagnosing, prognosticating, and otherwise assessing disease. In some embodiments, these profile representations are reduced to a medium that can be automatically read by a machine such as computer readable media (magnetic, optical, and the like). The articles can also include instructions for assessing the gene expression profiles in such media. For example, the articles may comprise a readable storage form having computer instructions for comparing gene expression profiles of the portfolios of genes described above. The articles may also have gene expression profiles digitally recorded therein so that they may be compared with gene expression data from patient samples. Alternatively, the profiles can be recorded in different representational format. A graphical recordation is one such format. Clustering algorithms can assist in the visualization of such data.

EXEMPLARY EMBODIMENTS

Disclosed herein, in some embodiments, is a method for diagnosing, predicting, and/or monitoring a status or outcome of a cancer a subject, comprising: (a) assaying an expression level of a plurality of targets in a sample from the subject, wherein at least one target of the plurality of targets is selected from the group consisting of targets identified in Tables 2, 4, 11 and 55; and (b) for diagnosing, predicting, and/or monitoring a status or outcome of a cancer based on the expression levels of the plurality of targets. In some embodiments, the cancer is selected from the group consisting of a carcinoma, sarcoma, leukemia, lymphoma, myeloma, and a CNS tumor. In some embodiments, the cancer is selected from the group consisting of skin cancer, lung cancer, colon cancer, pancreatic cancer, prostate cancer, liver cancer, thyroid cancer, ovarian cancer, uterine cancer, breast cancer, cervical cancer, kidney cancer, epithelial carcinoma, squamous carcinoma, basal cell carcinoma, melanoma, papilloma, and adenomas. In some embodiments, the cancer is a prostate cancer. In some embodiments, the cancer is a pancreatic cancer. In some embodiments, the cancer is a thyroid cancer. In some embodiments, the cancer is a bladder cancer. In some embodiments, the cancer is a lung cancer. In some embodiments, the method further comprises assaying an expression level of a coding target. In some instances, the coding target is selected from the group consisting of targets identified in Tables 2, 4, 11 and 55. In some embodiments, the coding target is an exon-coding transcript. In some embodiments, the exon-coding transcript is an exonic sequence. In some embodiments, the method further comprises assaying an expression level of a non-coding target. In some instances, the non-coding target is selected from the group consisting of targets identified in Tables 2, 4, 11 and 55. In some instances, the non-coding target is a non-coding transcript. In other instances, the non-coding target is an intronic sequence. In other instances, the non-coding target is an intergenic sequence. In some instances, the non-coding target is a UTR sequence. In other instances, the non-coding target is a non-coding RNA transcript. In some embodiments, the target comprises a nucleic acid sequence. In some embodiments, the nucleic acid sequence is a DNA sequence. In some embodiments, the nucleic acid sequence is an RNA sequence. In other instances, the target comprises a polypeptide sequence. In some instances, the plurality of targets comprises 2 or more targets selected from the group of targets identified in Tables 2, 4, 11 and 55. In some instances, the plurality of targets comprises 5 or more targets selected from the group of targets identified in Tables 2, 4, 11 and 55. In some instances, the plurality of targets comprises 10 or more targets selected from the group of targets identified in Tables 2, 4, 11 and 55. In some instances, the plurality of targets comprises 15 or more targets selected from the group of targets identified in Tables 2, 4, 11 and 55. In some instances, the plurality of targets comprises 20 or more targets selected from the group of targets identified in Tables 2, 4, 11 and 55. In some instances, the plurality of targets comprises 25 or more targets selected from the group of targets identified in Tables 2, 4, 11 and 55. In some instances, the plurality of targets comprises 30 or more targets selected from the group of targets identified in Tables 2, 4, 11 and 55. In some instances, the plurality of targets comprises 35 or more targets selected from the group of targets identified in Tables 2, 4, 11 and 55. In some instances, the plurality of targets comprises 40 or more targets selected from the group of targets identified in Tables 2, 4, 11 and 55. In some instances, the target is selected from Table 2. In other instances, the target is selected from Table 4. In some embodiments, the target is selected from Table 11. In some embodiments, assaying the expression level comprises detecting and/or quantifying a nucleotide sequence of the plurality of targets. Alternatively, assaying the expression level comprises detecting and/or quantifying a polypeptide sequence of the plurality of targets. In some embodiments, assaying the expression level comprises detecting and/or quantifying the DNA levels of the plurality of targets. In some embodiments, assaying the expression level comprises detecting and/or quantifying the RNA or mRNA levels of the plurality of targets. In some embodiments, assaying the expression level comprises detecting and/or quantifying the protein level of the plurality of targets. In some embodiments, the diagnosing, predicting, and/or monitoring the status or outcome of a cancer comprises determining the malignancy of the cancer. In some embodiments, the diagnosing, predicting, and/or monitoring the status or outcome of a cancer includes determining the stage of the cancer. In some embodiments, the diagnosing, predicting, and/or monitoring the status or outcome of a cancer includes assessing the risk of cancer recurrence. In some embodiments, diagnosing, predicting, and/or monitoring the status or outcome of a cancer may comprise determining the efficacy of treatment. In some embodiments, diagnosing, predicting, and/or monitoring the status or outcome of a cancer may comprise determining a therapeutic regimen. Determining a therapeutic regimen may comprise administering an anti-cancer therapeutic. Alternatively, determining the treatment for the cancer may comprise modifying a therapeutic regimen. Modifying a therapeutic regimen may comprise increasing, decreasing, or terminating a therapeutic regimen.

Further disclosed, in some embodiments, is method for determining a treatment for a cancer in a subject, comprising: a) assaying an expression level of a plurality of targets in a sample from the subject, wherein at least one target of the plurality of targets is selected from the group consisting of targets identified in Tables 2, 4, 11 and 55; and b) determining the treatment for a cancer based on the expression levels of the plurality of targets. In some embodiments, the cancer is selected from the group consisting of a carcinoma, sarcoma, leukemia, lymphoma, myeloma, and a CNS tumor. In some embodiments, the cancer is selected from the group consisting of skin cancer, lung cancer, colon cancer, pancreatic cancer, prostate cancer, liver cancer, thyroid cancer, ovarian cancer, uterine cancer, breast cancer, cervical cancer, kidney cancer, epithelial carcinoma, squamous carcinoma, basal cell carcinoma, melanoma, papilloma, and adenomas. In some embodiments, the cancer is a prostate cancer. In some embodiments, the cancer is a pancreatic cancer. In some embodiments, the cancer is a bladder cancer. In some embodiments, the cancer is a thyroid cancer. In some embodiments, the cancer is a lung cancer. In some embodiments, the coding target is selected from a sequence listed in Tables 2, 4, 11 and 55. In some embodiments, the method further comprises assaying an expression level of a coding target. In some instances, the coding target is selected from the group consisting of targets identified in Tables 2, 4, 11 and 55. In some embodiments, the coding target is an exon-coding transcript. In some embodiments, the exon-coding transcript is an exonic sequence. In some embodiments, the method further comprises assaying an expression level of a non-coding target. In some instances, the non-coding target is selected from the group consisting of targets identified in Tables 2, 4, 11 and 55. In some instances, the non-coding target is a non-coding transcript. In other instances, the non-coding target is an intronic sequence. In other instances, the non-coding target is an intergenic sequence. In some instances, the non-coding target is a UTR sequence. In other instances, the non-coding target is a non-coding RNA transcript. In some embodiments, the target comprises a nucleic acid sequence. In some embodiments, the nucleic acid sequence is a DNA sequence. In some embodiments, the nucleic acid sequence is an RNA sequence. In other instances, the target comprises a polypeptide sequence. In some instances, the plurality of targets comprises 2 or more targets selected from the group of targets identified in Tables 2, 4, 11 and 55. In some instances, the plurality of targets comprises 5 or more targets selected from the group of targets identified in Tables 2, 4, 11 and 55. In some instances, the plurality of targets comprises 10 or more targets selected from the group of targets identified in Tables 2, 4, 11 and 55. In some instances, the plurality of targets comprises 15 or more targets selected from the group of targets identified in Tables 2, 4, 11 and 55. In some instances, the plurality of targets comprises 20 or more targets selected from the group of targets identified in Tables 2, 4, 11 and 55. In some instances, the plurality of targets comprises 25 or more targets selected from the group of targets identified in Tables 2, 4, 11 and 55. In some instances, the plurality of targets comprises 30 or more targets selected from the group of targets identified in Tables 2, 4, 11 and 55. In some instances, the plurality of targets comprises 35 or more targets selected from the group of targets identified in Tables 2, 4, 11 and 55. In some instances, the plurality of targets comprises 40 or more targets selected from the group of targets identified in Tables 2, 4, 11 and 55. In some instances, the target is selected from Table 2. In other instances, the target is selected from Table 4. In some embodiments, the target is selected from Table 11. In some embodiments, assaying the expression level comprises detecting and/or quantifying a nucleotide sequence of the plurality of targets. In some embodiments, determining the treatment for the cancer includes determining the efficacy of treatment. Determining the treatment for the cancer may comprise administering an anti-cancer therapeutic. Alternatively, determining the treatment for the cancer may comprise modifying a therapeutic regimen. Modifying a therapeutic regimen may comprise increasing, decreasing, or terminating a therapeutic regimen.

The methods use the probe sets, probes and primers described herein to provide expression signatures or profiles from a test sample derived from a subject having or suspected of having cancer. In some embodiments, such methods involve contacting a test sample with a probe set comprising a plurality of probes under conditions that permit hybridization of the probe(s) to any target nucleic acid(s) present in the test sample and then detecting any probe:target duplexes formed as an indication of the presence of the target nucleic acid in the sample. Expression patterns thus determined are then compared to one or more reference profiles or signatures. Optionally, the expression pattern can be normalized. The methods use the probe sets, probes and primers described herein to provide expression signatures or profiles from a test sample derived from a subject to classify the cancer as recurrent or non-recurrent.

In some embodiments, such methods involve the specific amplification of target sequences nucleic acid(s) present in the test sample using methods known in the art to generate an expression profile or signature which is then compared to a reference profile or signature.

In some embodiments, the invention further provides for prognosing patient outcome, predicting likelihood of recurrence after prostatectomy and/or for designating treatment modalities.

In one embodiment, the methods generate expression profiles or signatures detailing the expression of the target sequences having altered relative expression with different cancer outcomes.

In some embodiments, the methods detect combinations of expression levels of sequences exhibiting positive and negative correlation with a disease status. In one embodiment, the methods detect a minimal expression signature.

The gene expression profiles of each of the target sequences comprising the portfolio can fixed in a medium such as a computer readable medium. This can take a number of forms. For example, a table can be established into which the range of signals (e.g., intensity measurements) indicative of disease or outcome is input. Actual patient data can then be compared to the values in the table to determine the patient samples diagnosis or prognosis. In a more sophisticated embodiment, patterns of the expression signals (e.g., fluorescent intensity) are recorded digitally or graphically.

The expression profiles of the samples can be compared to a control portfolio. The expression profiles can be used to diagnose, predict, or monitor a status or outcome of a cancer. For example, diagnosing, predicting, or monitoring a status or outcome of a cancer may comprise diagnosing or detecting a cancer, cancer metastasis, or stage of a cancer. In other instances, diagnosing, predicting, or monitoring a status or outcome of a cancer may comprise predicting the risk of cancer recurrence. Alternatively, diagnosing, predicting, or monitoring a status or outcome of a cancer may comprise predicting mortality or morbidity.

Further disclosed herein are methods for characterizing a patient population. Generally, the method comprises: (a) providing a sample from a subject; (b) assaying the expression level for a plurality of targets in the sample; and (c) characterizing the subject based on the expression level of the plurality of targets. In some embodiments, the method further comprises assaying an expression level of a coding target. In some instances, the coding target is selected from the group consisting of targets identified in Tables 2, 4, 11 and 55. In some embodiments, the coding target is an exon-coding transcript. In some embodiments, the exon-coding transcript is an exonic sequence. In some embodiments, the method further comprises assaying an expression level of a non-coding target. In some instances, the non-coding target is selected from the group consisting of targets identified in Tables 2, 4, 11 and 55. In some instances, the non-coding target is a non-coding transcript. In other instances, the non-coding target is an intronic sequence. In other instances, the non-coding target is an intergenic sequence. In some instances, the non-coding target is a UTR sequence. In other instances, the non-coding target is a non-coding RNA transcript. In some embodiments, the target comprises a nucleic acid sequence. In some embodiments, the nucleic acid sequence is a DNA sequence. In some embodiments, the nucleic acid sequence is an RNA sequence. In other instances, the target comprises a polypeptide sequence. In some instances, the plurality of targets comprises 2 or more targets selected from the group of targets identified in Tables 2, 4, 11 and 55. In some instances, the plurality of targets comprises 5 or more targets selected from the group of targets identified in Tables 2, 4, 11 and 55. In some instances, the plurality of targets comprises 10 or more targets selected from the group of targets identified in Tables 2, 4, 11 and 55. In some instances, the plurality of targets comprises 15 or more targets selected from the group of targets identified in Tables 2, 4, 11 and 55. In some instances, the plurality of targets comprises 20 or more targets selected from the group of targets identified in Tables 2, 4, 11 and 55. In some instances, the plurality of targets comprises 25 or more targets selected from the group of targets identified in Tables 2, 4, 11 and 55. In some instances, the plurality of targets comprises 30 or more targets selected from the group of targets identified in Tables 2, 4, 11 and 55. In some instances, the plurality of targets comprises 35 or more targets selected from the group of targets identified in Tables 2, 4, 11 and 55. In some instances, the plurality of targets comprises 40 or more targets selected from the group of targets identified in Tables 2, 4, 11 and 55. In some instances, the target is selected from Table 2. In other instances, the target is selected from Table 4. In some embodiments, the target is selected from Table 11. In some embodiments, assaying the expression level comprises detecting and/or quantifying a nucleotide sequence of the plurality of targets. In some instances, the method may further comprise diagnosing a cancer in the subject. In some embodiments, the cancer is selected from the group consisting of a carcinoma, sarcoma, leukemia, lymphoma, myeloma, and a CNS tumor. In some embodiments, the cancer is selected from the group consisting of skin cancer, lung cancer, colon cancer, pancreatic cancer, prostate cancer, liver cancer, thyroid cancer, ovarian cancer, uterine cancer, breast cancer, cervical cancer, kidney cancer, epithelial carcinoma, squamous carcinoma, basal cell carcinoma, melanoma, papilloma, and adenomas. In some embodiments, the cancer is a prostate cancer. In some embodiments, the cancer is a pancreatic cancer. In some embodiments, the cancer is a bladder cancer. In some embodiments, the cancer is a thyroid cancer. In some embodiments, the cancer is a lung cancer. In some instances, characterizing the subject comprises determining whether the subject would respond to an anti-cancer therapy. Alternatively, characterizing the subject comprises identifying the subject as a non-responder to an anti-cancer therapy. Optionally, characterizing the subject comprises identifying the subject as a responder to an anti-cancer therapy.

Further disclosed herein are methods for selecting a subject suffering from a cancer for enrollment into a clinical trial. Generally, the method comprises: (a) providing a sample from a subject; (b) assaying the expression level for a plurality of targets in the sample; and (c) characterizing the subject based on the expression level of the plurality of targets. In some embodiments, the method further comprises assaying an expression level of a coding target. In some instances, the coding target is selected from the group consisting of targets identified in Tables 2, 4, 11 and 55. In some embodiments, the coding target is an exon-coding transcript. In some embodiments, the exon-coding transcript is an exonic sequence. In some embodiments, the method further comprises assaying an expression level of a non-coding target. In some instances, the non-coding target is selected from the group consisting of targets identified in Tables 2, 4, 11 and 55. In some instances, the non-coding target is a non-coding transcript. In other instances, the non-coding target is an intronic sequence. In other instances, the non-coding target is an intergenic sequence. In some instances, the non-coding target is a UTR sequence. In other instances, the non-coding target is a non-coding RNA transcript. In some embodiments, the target comprises a nucleic acid sequence. In some embodiments, the nucleic acid sequence is a DNA sequence. In some embodiments, the nucleic acid sequence is an RNA sequence. In other instances, the target comprises a polypeptide sequence. In some instances, the plurality of targets comprises 2 or more targets selected from the group of targets identified in Tables 2, 4, 11 and 55. In some instances, the plurality of targets comprises 5 or more targets selected from the group of targets identified in Tables 2, 4, 11 and 55. In some instances, the plurality of targets comprises 10 or more targets selected from the group of targets identified in Tables 2, 4, 11 and 55. In some instances, the plurality of targets comprises 15 or more targets selected from the group of targets identified in Tables 2, 4, 11 and 55. In some instances, the plurality of targets comprises 20 or more targets selected from the group of targets identified in Tables 2, 4, 11 and 55. In some instances, the plurality of targets comprises 25 or more targets selected from the group of targets identified in Tables 2, 4, 11 and 55. In some instances, the plurality of targets comprises 30 or more targets selected from the group of targets identified in Tables 2, 4, 11 and 55. In some instances, the plurality of targets comprises 35 or more targets selected from the group of targets identified in Tables 2, 4, 11 and 55. In some instances, the plurality of targets comprises 40 or more targets selected from the group of targets identified in Tables 2, 4, 11 and 55. In some instances, the target is selected from Table 2. In other instances, the target is selected from Table 4. In some embodiments, the target is selected from Table 11. In some embodiments, assaying the expression level comprises detecting and/or quantifying a nucleotide sequence of the plurality of targets. In some instances, the method may further comprise diagnosing a cancer in the subject. In some embodiments, the cancer is selected from the group consisting of a carcinoma, sarcoma, leukemia, lymphoma, myeloma, and a CNS tumor. In some embodiments, the cancer is selected from the group consisting of skin cancer, lung cancer, colon cancer, pancreatic cancer, prostate cancer, liver cancer, thyroid cancer, ovarian cancer, uterine cancer, breast cancer, cervical cancer, kidney cancer, epithelial carcinoma, squamous carcinoma, basal cell carcinoma, melanoma, papilloma, and adenomas. In some embodiments, the cancer is a prostate cancer. In some embodiments, the cancer is a pancreatic cancer. In some embodiments, the cancer is a bladder cancer. In some embodiments, the cancer is a thyroid cancer. In some embodiments, the cancer is a lung cancer. In some instances, characterizing the subject comprises determining whether the subject would respond to an anti-cancer therapy. Alternatively, characterizing the subject comprises identifying the subject as a non-responder to an anti-cancer therapy. Optionally, characterizing the subject comprises identifying the subject as a responder to an anti-cancer therapy.

Further disclosed herein is a method of analyzing a cancer in an individual in need thereof, comprising (a) obtaining an expression profile from a sample obtained from the individual, wherein the expression profile comprises one or more targets selected from Tables 2, 4, 11 or 55; and (b) comparing the expression profile from the sample to an expression profile of a control or standard. In some embodiments, the plurality of targets comprises at least 5 targets selected from Tables 2, 4, 11 or 55. In some embodiments, wherein the plurality of targets comprises at least 10 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 15 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 20 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the cancer is selected from the group consisting of a carcinoma, sarcoma, leukemia, lymphoma, myeloma, and a CNS tumor. In some embodiments, the cancer is selected from the group consisting of skin cancer, lung cancer, colon cancer, pancreatic cancer, prostate cancer, liver cancer, thyroid cancer, ovarian cancer, uterine cancer, breast cancer, cervical cancer, kidney cancer, epithelial carcinoma, squamous carcinoma, basal cell carcinoma, melanoma, papilloma, and adenomas. In some embodiments, the method further comprises a software module executed by a computer-processing device to compare the expression profiles. In some embodiments, the method further comprises providing diagnostic or prognostic information to the individual about the cardiovascular disorder based on the comparison. In some embodiments, the method further comprises diagnosing the individual with a cancer if the expression profile of the sample (a) deviates from the control or standard from a healthy individual or population of healthy individuals, or (b) matches the control or standard from an individual or population of individuals who have or have had the cancer. In some embodiments, the method further comprises predicting the susceptibility of the individual for developing a cancer based on (a) the deviation of the expression profile of the sample from a control or standard derived from a healthy individual or population of healthy individuals, or (b) the similarity of the expression profiles of the sample and a control or standard derived from an individual or population of individuals who have or have had the cancer. In some embodiments, the method further comprises prescribing a treatment regimen based on (a) the deviation of the expression profile of the sample from a control or standard derived from a healthy individual or population of healthy individuals, or (b) the similarity of the expression profiles of the sample and a control or standard derived from an individual or population of individuals who have or have had the cancer. In some embodiments, the method further comprises altering a treatment regimen prescribed or administered to the individual based on (a) the deviation of the expression profile of the sample from a control or standard derived from a healthy individual or population of healthy individuals, or (b) the similarity of the expression profiles of the sample and a control or standard derived from an individual or population of individuals who have or have had the cancer. In some embodiments, the method further comprises predicting the individual's response to a treatment regimen based on (a) the deviation of the expression profile of the sample from a control or standard derived from a healthy individual or population of healthy individuals, or (b) the similarity of the expression profiles of the sample and a control or standard derived from an individual or population of individuals who have or have had the cancer. In some embodiments, the deviation is the expression level of one or more targets from the sample is greater than the expression level of one or more targets from a control or standard derived from a healthy individual or population of healthy individuals. In some embodiments, the deviation is the expression level of one or more targets from the sample is at least about 30% greater than the expression level of one or more targets from a control or standard derived from a healthy individual or population of healthy individuals. In some embodiments, the deviation is the expression level of one or more targets from the sample is less than the expression level of one or more targets from a control or standard derived from a healthy individual or population of healthy individuals. In some embodiments, the deviation is the expression level of one or more targets from the sample is at least about 30% less than the expression level of one or more targets from a control or standard derived from a healthy individual or population of healthy individuals. In some embodiments, the method further comprises using a machine to isolate the target or the probe from the sample. In some embodiments, the method further comprises contacting the sample with a label that specifically binds to the target, the probe, or a combination thereof. In some embodiments, the method further comprises contacting the sample with a label that specifically binds to a target selected from Tables 2, 4, 11 or 55 or a combination thereof. In some instances, the target is selected from Table 2. In other instances, the target is selected from Table 4. In some embodiments, the target is selected from Table 11. In some embodiments, the method further comprises amplifying the target, the probe, or any combination thereof. In some embodiments, the method further comprises sequencing the target, the probe, or any combination thereof. In some embodiments, the method further comprises converting the expression levels of the target sequences into a likelihood score that indicates the probability that a biological sample is from a patient who will exhibit no evidence of disease, who will exhibit systemic cancer, or who will exhibit biochemical recurrence. In some embodiments, the target sequences are differentially expressed the cancer. In some embodiments, the differential expression is dependent on aggressiveness. In some embodiments, the expression profile is determined by a method selected from the group consisting of RT-PCR, Northern blotting, ligase chain reaction, array hybridization, and a combination thereof.

Also disclosed herein is a method of diagnosing cancer in an individual in need thereof, comprising (a) obtaining an expression profile from a sample obtained from the individual, wherein the expression profile comprises one or more targets selected from Tables 2, 4, 11 or 55; (b) comparing the expression profile from the sample to an expression profile of a control or standard; and (c) diagnosing a cancer in the individual if the expression profile of the sample (i) deviates from the control or standard from a healthy individual or population of healthy individuals, or (ii) matches the control or standard from an individual or population of individuals who have or have had the cancer. In some embodiments, the plurality of targets comprises at least 5 targets selected from Tables 2, 4, 11 or 55. In some embodiments, wherein the plurality of targets comprises at least 10 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 15 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 20 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the cancer is selected from the group consisting of a carcinoma, sarcoma, leukemia, lymphoma, myeloma, and a CNS tumor. In some embodiments, the cancer is selected from the group consisting of skin cancer, lung cancer, colon cancer, pancreatic cancer, prostate cancer, liver cancer, thyroid cancer, ovarian cancer, uterine cancer, breast cancer, cervical cancer, kidney cancer, epithelial carcinoma, squamous carcinoma, basal cell carcinoma, melanoma, papilloma, and adenomas. In some embodiments, the method further comprises a software module executed by a computer-processing device to compare the expression profiles. In some embodiments, the deviation is the expression level of one or more targets from the sample is at least about 30% greater than the expression level of one or more targets from a control or standard derived from a healthy individual or population of healthy individuals. In some embodiments, the deviation is the expression level of one or more targets from the sample is less than the expression level of one or more targets from a control or standard derived from a healthy individual or population of healthy individuals. In some embodiments, the deviation is the expression level of one or more targets from the sample is at least about 30% less than the expression level of one or more targets from a control or standard derived from a healthy individual or population of healthy individuals. In some embodiments, the method further comprises using a machine to isolate the target or the probe from the sample. In some embodiments, the method further comprises contacting the sample with a label that specifically binds to the target, the probe, or a combination thereof. In some embodiments, the method further comprises contacting the sample with a label that specifically binds to a target selected from Tables 2, 4, 11 or 55, or a combination thereof. In some embodiments, the method further comprises amplifying the target, the probe, or any combination thereof. In some embodiments, the method further comprises sequencing the target, the probe, or any combination thereof. In some embodiments, the method further comprises converting the expression levels of the target sequences into a likelihood score that indicates the probability that a biological sample is from a patient who will exhibit no evidence of disease, who will exhibit systemic cancer, or who will exhibit biochemical recurrence. In some embodiments, the target sequences are differentially expressed the cancer. In some embodiments, the differential expression is dependent on aggressiveness. In some embodiments, the expression profile is determined by a method selected from the group consisting of RT-PCR, Northern blotting, ligase chain reaction, array hybridization, and a combination thereof.

In some embodiments is a method of predicting whether an individual is susceptible to developing a cancer, comprising (a) obtaining an expression profile from a sample obtained from the individual, wherein the expression profile comprises one or more targets selected from Tables 2, 4, 11 or 55; (b) comparing the expression profile from the sample to an expression profile of a control or standard; and (c) predicting the susceptibility of the individual for developing a cancer based on (i) the deviation of the expression profile of the sample from a control or standard derived from a healthy individual or population of healthy individuals, or (ii) the similarity of the expression profiles of the sample and a control or standard derived from an individual or population of individuals who have or have had the cancer. In some embodiments, the plurality of targets comprises at least 5 targets selected from Tables 2, 4, 11 or 55. In some embodiments, wherein the plurality of targets comprises at least 10 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 15 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 20 targets selected from Tables 2, 4, 11 or 55. In some instances, the target is selected from Table 2. In other instances, the target is selected from Table 4. In some embodiments, the target is selected from Table 11. In some embodiments, the cancer is selected from the group consisting of a carcinoma, sarcoma, leukemia, lymphoma, myeloma, and a CNS tumor. In some embodiments, the cancer is selected from the group consisting of skin cancer, lung cancer, colon cancer, pancreatic cancer, prostate cancer, liver cancer, thyroid cancer, ovarian cancer, uterine cancer, breast cancer, cervical cancer, kidney cancer, epithelial carcinoma, squamous carcinoma, basal cell carcinoma, melanoma, papilloma, and adenomas. In some embodiments, the method further comprises a software module executed by a computer-processing device to compare the expression profiles. In some embodiments, the deviation is the expression level of one or more targets from the sample is at least about 30% greater than the expression level of one or more targets from a control or standard derived from a healthy individual or population of healthy individuals. In some embodiments, the deviation is the expression level of one or more targets from the sample is less than the expression level of one or more targets from a control or standard derived from a healthy individual or population of healthy individuals. In some embodiments, the deviation is the expression level of one or more targets from the sample is at least about 30% less than the expression level of one or more targets from a control or standard derived from a healthy individual or population of healthy individuals. In some embodiments, the method further comprises using a machine to isolate the target or the probe from the sample. In some embodiments, the method further comprises contacting the sample with a label that specifically binds to the target, the probe, or a combination thereof. In some embodiments, the method further comprises contacting the sample with a label that specifically binds to a target selected from Tables 2, 4, 11 or 55, or a combination thereof. In some embodiments, the method further comprises amplifying the target, the probe, or any combination thereof. In some embodiments, the method further comprises sequencing the target, the probe, or any combination thereof. In some embodiments, the method further comprises converting the expression levels of the target sequences into a likelihood score that indicates the probability that a biological sample is from a patient who will exhibit no evidence of disease, who will exhibit systemic cancer, or who will exhibit biochemical recurrence. In some embodiments, the target sequences are differentially expressed the cancer. In some embodiments, the differential expression is dependent on aggressiveness. In some embodiments, the expression profile is determined by a method selected from the group consisting of RT-PCR, Northern blotting, ligase chain reaction, array hybridization, and a combination thereof.

In some embodiments is a method of predicting an individual's response to a treatment regimen for a cancer, comprising: (a) obtaining an expression profile from a sample obtained from the individual, wherein the expression profile comprises one or more targets selected from Tables 2, 4, 11 or 55; (b) comparing the expression profile from the sample to an expression profile of a control or standard; and (c) predicting the individual's response to a treatment regimen based on (i) the deviation of the expression profile of the sample from a control or standard derived from a healthy individual or population of healthy individuals, or (ii) the similarity of the expression profiles of the sample and a control or standard derived from an individual or population of individuals who have or have had the cancer. In some embodiments, the plurality of targets comprises at least 5 targets selected from Tables 2, 4, 11 or 55. In some embodiments, wherein the plurality of targets comprises at least 10 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 15 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 20 targets selected from Tables 2, 4, 11 or 55. In some instances, the target is selected from Table 2. In other instances, the target is selected from Table 4. In some embodiments, the target is selected from Table 11. In some embodiments, the cancer is selected from the group consisting of a carcinoma, sarcoma, leukemia, lymphoma, myeloma, and a CNS tumor. In some embodiments, the cancer is selected from the group consisting of skin cancer, lung cancer, colon cancer, pancreatic cancer, prostate cancer, liver cancer, thyroid cancer, ovarian cancer, uterine cancer, breast cancer, cervical cancer, kidney cancer, epithelial carcinoma, squamous carcinoma, basal cell carcinoma, melanoma, papilloma, and adenomas. In some embodiments, the method further comprises a software module executed by a computer-processing device to compare the expression profiles. In some embodiments, the deviation is the expression level of one or more targets from the sample is at least about 30% greater than the expression level of one or more targets from a control or standard derived from a healthy individual or population of healthy individuals. In some embodiments, the deviation is the expression level of one or more targets from the sample is less than the expression level of one or more targets from a control or standard derived from a healthy individual or population of healthy individuals. In some embodiments, the deviation is the expression level of one or more targets from the sample is at least about 30% less than the expression level of one or more targets from a control or standard derived from a healthy individual or population of healthy individuals. In some embodiments, the method further comprises using a machine to isolate the target or the probe from the sample. In some embodiments, the method further comprises contacting the sample with a label that specifically binds to the target, the probe, or a combination thereof. In some embodiments, the method further comprises contacting the sample with a label that specifically binds to a target selected from Tables 2, 4, 11 or 55, or a combination thereof. In some embodiments, the method further comprises amplifying the target, the probe, or any combination thereof. In some embodiments, the method further comprises sequencing the target, the probe, or any combination thereof. In some embodiments, the method further comprises converting the expression levels of the target sequences into a likelihood score that indicates the probability that a biological sample is from a patient who will exhibit no evidence of disease, who will exhibit systemic cancer, or who will exhibit biochemical recurrence. In some embodiments, the target sequences are differentially expressed the cancer. In some embodiments, the differential expression is dependent on aggressiveness. In some embodiments, the expression profile is determined by a method selected from the group consisting of RT-PCR, Northern blotting, ligase chain reaction, array hybridization, and a combination thereof.

A method of prescribing a treatment regimen for a cancer to an individual in need thereof, comprising (a) obtaining an expression profile from a sample obtained from the individual, wherein the expression profile comprises one or more targets selected from Tables 2, 4, 11 or 55; (b) comparing the expression profile from the sample to an expression profile of a control or standard; and (c) prescribing a treatment regimen based on (i) the deviation of the expression profile of the sample from a control or standard derived from a healthy individual or population of healthy individuals, or (ii) the similarity of the expression profiles of the sample and a control or standard derived from an individual or population of individuals who have or have had the cancer. In some embodiments, the plurality of targets comprises at least 5 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 10 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 15 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 20 targets selected from Tables 2, 4, 11 or 55. In some instances, the target is selected from Table 2. In other instances, the target is selected from Table 4. In some embodiments, the target is selected from Table 11. In some embodiments, the cancer is selected from the group consisting of a carcinoma, sarcoma, leukemia, lymphoma, myeloma, and a CNS tumor. In some embodiments, the cancer is selected from the group consisting of skin cancer, lung cancer, colon cancer, pancreatic cancer, prostate cancer, liver cancer, thyroid cancer, ovarian cancer, uterine cancer, breast cancer, cervical cancer, kidney cancer, epithelial carcinoma, squamous carcinoma, basal cell carcinoma, melanoma, papilloma, and adenomas. In some embodiments, the method further comprises a software module executed by a computer-processing device to compare the expression profiles. In some embodiments, the deviation is the expression level of one or more targets from the sample is at least about 30% greater than the expression level of one or more targets from a control or standard derived from a healthy individual or population of healthy individuals. In some embodiments, the deviation is the expression level of one or more targets from the sample is less than the expression level of one or more targets from a control or standard derived from a healthy individual or population of healthy individuals. In some embodiments, the deviation is the expression level of one or more targets from the sample is at least about 30% less than the expression level of one or more targets from a control or standard derived from a healthy individual or population of healthy individuals. In some embodiments, the method further comprises using a machine to isolate the target or the probe from the sample. In some embodiments, the method further comprises contacting the sample with a label that specifically binds to the target, the probe, or a combination thereof. In some embodiments, the method further comprises contacting the sample with a label that specifically binds to a target selected from Tables 2, 4, 11 or 55, or a combination thereof. In some embodiments, the method further comprises amplifying the target, the probe, or any combination thereof. In some embodiments, the method further comprises sequencing the target, the probe, or any combination thereof. In some embodiments, the method further comprises converting the expression levels of the target sequences into a likelihood score that indicates the probability that a biological sample is from a patient who will exhibit no evidence of disease, who will exhibit systemic cancer, or who will exhibit biochemical recurrence. In some embodiments, the target sequences are differentially expressed the cancer. In some embodiments, the differential expression is dependent on aggressiveness. In some embodiments, the expression profile is determined by a method selected from the group consisting of RT-PCR, Northern blotting, ligase chain reaction, array hybridization, and a combination thereof.

Further disclosed herein is a kit for analyzing a cancer, comprising (a) a probe set comprising a plurality of target sequences, wherein the plurality of target sequences comprises at least one target sequence listed in Table 11; and (b) a computer model or algorithm for analyzing an expression level and/or expression profile of the target sequences in a sample. In some embodiments, the kit further comprises a computer model or algorithm for correlating the expression level or expression profile with disease state or outcome. In some embodiments, the kit further comprises a computer model or algorithm for designating a treatment modality for the individual. In some embodiments, the kit further comprises a computer model or algorithm for normalizing expression level or expression profile of the target sequences. In some embodiments, the kit further comprises a computer model or algorithm comprising a robust multichip average (RMA), probe logarithmic intensity error estimation (PLIER), non-linear fit (NLFIT) quantile-based, nonlinear normalization, or a combination thereof. In some embodiments, the plurality of targets comprises at least 10 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 15 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 20 targets selected from Tables 2, 4, 11 or 55. In some instances, the target is selected from Table 2. In other instances, the target is selected from Table 4. In some embodiments, the target is selected from Table 11. In some embodiments, the cancer is selected from the group consisting of a carcinoma, sarcoma, leukemia, lymphoma, myeloma, and a CNS tumor. In some embodiments, the cancer is selected from the group consisting of skin cancer, lung cancer, colon cancer, pancreatic cancer, prostate cancer, liver cancer, thyroid cancer, ovarian cancer, uterine cancer, breast cancer, cervical cancer, kidney cancer, epithelial carcinoma, squamous carcinoma, basal cell carcinoma, melanoma, papilloma, and adenomas.

Further disclosed herein is a system for analyzing a cancer, comprising (a) a probe set comprising a plurality of target sequences, wherein (i) the plurality of target sequences hybridizes to one or more targets selected from Tables 2 or 4; or (ii) the plurality of target sequences comprises one or more target sequences selected from Table 11; and (b) a computer model or algorithm for analyzing an expression level and/or expression profile of the target hybridized to the probe in a sample from a subject suffering from a cancer. In some embodiments, the system further comprises electronic memory for capturing and storing an expression profile. In some embodiments, the system further comprises a computer-processing device, optionally connected to a computer network. In some embodiments, the system further comprises a software module executed by the computer-processing device to analyze an expression profile. In some embodiments, the system further comprises a software module executed by the computer-processing device to compare the expression profile to a standard or control. In some embodiments, the system further comprises a software module executed by the computer-processing device to determine the expression level of the target. In some embodiments, the system further comprises a machine to isolate the target or the probe from the sample. In some embodiments, the system further comprises a machine to sequence the target or the probe. In some embodiments, the system further comprises a machine to amplify the target or the probe. In some embodiments, the system further comprises a label that specifically binds to the target, the probe, or a combination thereof. In some embodiments, the system further comprises a software module executed by the computer-processing device to transmit an analysis of the expression profile to the individual or a medical professional treating the individual. In some embodiments, the system further comprises a software module executed by the computer-processing device to transmit a diagnosis or prognosis to the individual or a medical professional treating the individual. In some embodiments, the plurality of targets comprises at least 5 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 10 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 15 targets selected from Tables 2, 4, 11 or 55. In some embodiments, the plurality of targets comprises at least 20 targets selected from Tables 2, 4, 11 or 55. In some instances, the target is selected from Table 2. In other instances, the target is selected from Table 4. In some embodiments, the target is selected from Table 11. In some embodiments, the cancer is selected from the group consisting of a carcinoma, sarcoma, leukemia, lymphoma, myeloma, and a CNS tumor. In some embodiments, the cancer is selected from the group consisting of skin cancer, lung cancer, colon cancer, pancreatic cancer, prostate cancer, liver cancer, thyroid cancer, ovarian cancer, uterine cancer, breast cancer, cervical cancer, kidney cancer, epithelial carcinoma, squamous carcinoma, basal cell carcinoma, melanoma, papilloma, and adenomas.

Examples Example 1. Validation Studies in Subjects with Prostate Cancer

Study Design

This study used a previously described case-control study for biomarker discovery and a case-cohort for independent validation. A STROBE flow diagram providing an overview of the case-control study is available in (FIG. 1).

The discovery study was a nested case-control described in detail in Nakagawa et al 2008. Archived formalin-fixed paraffin embedded (FFPE) blocks of tumors were selected from 621 patients that had undergone a radical prostatectomy (RP) at the Mayo Clinic Comprehensive Cancer Centre between the years 1987-2001 providing a median of 18.16 years of follow-up. The patients were randomly split into a training and test sets; the training set was used for biomarker discovery and classifier development and the testing set was used to measure performance and with model selection.

Patients were retrospectively classified into one of three outcomes: NED: No evidence of disease for those patients with no biochemical or other clinical signs of disease progression (at least 10 years follow-up); PSA: prostate-specific antigen biochemical recurrence for those patients with two successive increases in PSA measurements above an established cut-point of >0.2 ng/(with the subsequent measure 0.05 ng/mL above the first measurement) within 5 years of RP and no detectable metases up to 10 years after RP; METS: for those patients experience BCR within 5 years of RP and that developed metastases (confirmed by bone or CT scan) within 5 years of BCR. Patient selection for nested case-control design is outlined in Nakagawa.

On average, METS patients were diagnosed within 3.22 years following BCR and 5.79 years following RP, implying that this METS group experienced rapid onset of metastatic disease. Some PSA patients do experience metastatic disease (n=18, or 9.9% of all PSA patients in the discovery study), however, these patients have the event 10 years beyond RP and thus are outside the MET definition. Due to the condition that both PSA and MET groups had to experience BCR event within 5 years of RP, there is no statistically significant difference for the time to BCR between PSA (median: 1.70 years [IQR:0.65-3.44]) and MET (median: 2.26 years [IQR:0.78-3.94]) groups. Patients in this study did not receive a consistent treatment regimen, and may be highly treated with adjuvant interventions compared to other cohorts. Where possible we account for adjuvant interventions in analysis to mitigate its impact as a confounding factor (See Statistical Analysis).

We conducted a study that investigated the differences between NED, PSA and METS outcome groups and found there to be no statistically significant differences between the NED and PSA groups, with the largest difference in genomic and clinicopathologic variables to be found when comparing METS against NED or PSA groups. We have evidence to believe that NED and PSA groups may represent a less aggressive type of prostate cancer, and that these patients will likely not experience metastatic progression in their life-time, conversely METS patients represent rapid disease onset and more aggressive prostate cancer. To maximize discovery of biomarkers that identified oncogenic drivers of aggressive disease, we combined the NED and PSA groups into a unified Non-METS group to compare against the METS.

The discovery study included 621 patients who underwent RP at the Mayo Clinic between 1987-2001. Patients who received neo-adjuvant interventions were excluded. After chip quality control (www.affymetrix.com), 545 unique patients (209 with mets after RP and 336 with BCR only or NED) were available for the biomarker discovery study (median follow-up, 18.2 years). The study patients were further subdivided by random draw into training (n=359) and testing (n=186) subsets, balancing for the distribution of clinicopathologic variables (Table 1) as previously described.

TABLE 1 Clinical characteristics of Discovery and Validation data set Discovery Independent Clinical Training Testing Validation variable Values No mets mets No mets mets No mets mets # patients — 218 141 118 68 150 69 Pathological Tumour Stage T2 105 40 56 18 71 14 T3/4 101 67 18 37 62 40 TxN+ 12 34 14 13 17 15 Pre-Op PSA <10 ng/ml 124 66 58 34 86 33 ≥10≤20 53 31 22 11 39 20 >20 ng/ml 38 43 33 17 25 16 NA 3 1 5 6 0 0 Pathological Gleason score ≤6 41 4 16 2 15 0 7 125 49 70 27 82 29 ≥8 52 88 32 39 53 40 Path features SM+ 98 81 54 33 84 39 ECE+ 96 86 50 41 54 44 SVI+ 47 63 34 32 45 36 Biochemical recurrence (BCR) Censored 99 0 58 0 109 0 Event 119 141 60 68 41 69 Prostate-specific mortality Censored 216 47 117 33 150 41 (PCSM) Event 2 94 1 35 0 28 Adjuvant Radiation No 203 120 112 56 135 60 Yes 15 21 6 12 15 9 Adjuvant ADT No 187 95 89 50 108 37 Yes 31 46 29 18 42 32

The initial Clinical characteristics of these samples related to biochemical recurrence (BCR), METS (or clinical recurrence (CR)), prostate cancer specific mortality (PCSM) and overall survival are shown in FIG. 2.

Subjects for independent validation were identified from a population of 1,010 men prospectively enrolled in the Mayo Clinic tumor registry who underwent RP for prostatic adenocarcinoma from 2000-2006 and were at high risk for disease recurrence. High-risk for recurrence was defined by pre-operative PSA >20 ng/mL, or pathological Gleason score≥8, or seminal vesicle invasion (SVI) or GPSM (Gleason, PSA, seminal vesicle and margin status) score≥10. Data was collected using a case-cohort design over the follow-up period (median, 8.06 years), 71 patients developed metastatic disease (mets) as evidenced by positive bone and/or CT scans. Data was collected using a case-cohort design, which involved selection of all 73 cases combined with a random sample of 202 patients (˜20%) from the entire cohort. After exclusion for tissue unavailability and samples that failed microarray quality control, the independent validation cohort consisted of 219 (69 cases) unique patients.

RNA Extraction and Microarray Hybridization

Following pathological review of FFPE primary prostatic adenocarcinoma specimens from patients in the discovery and validation cohorts, tumor was macrodissected from surrounding stroma from 3-4 10 μm tissue sections. Total RNA was extracted, amplified using the Ovation FFPE kit (NuGEN, San Carlos, Calif.), and hybridized to Human Exon 1.0 ST GeneChips (Affymetrix, Santa Clara, Calif.) that profiles coding and non-coding regions of the transcriptome using approximately 1.4 million probe selection regions, hereinafter referred to as features.

For the discovery study, total RNA was prepared as described herein. For the independent validation study, total RNA was extracted and purified using a modified protocol for the commercially available RNeasy FFPE nucleic acid extraction kit (Qiagen Inc., Valencia, Calif.). RNA concentrations were determined using a Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies, Rockland, Del.). Purified total RNA was subjected to whole-transcriptome amplification using the WT-Ovation FFPE system according to the manufacturer's recommendation with minor modifications (NuGen, San Carlos, Calif.). For the discovery study the WT-Ovation FFPE V2 kit was used together with the Exon Module while for the validation only the Ovation® FFPE WTA System was used. Amplified products were fragmented and labeled using the Encore™ Biotin Module (NuGen, San Carlos, Calif.) and hybridized to Affymetrix Human Exon (HuEx) 1.0 ST GeneChips following manufacturer's recommendations (Affymetrix, Santa Clara, Calif.). Only 604 out of a total 621 patients had specimens available for hybridization.

Microarray Processing

Microarray Quality Control

The Affymetrix Power Tools packages provide an index characterizing the quality of each chip, independently, named “pos_vs_neg_AUC”. This index compares signal values for positive and negative control probesets defined by the manufacturer. Values for the AUC are in [0, 1], arrays that fall under 0.6 were removed from analysis.

Only 545 unique samples, out of the total 604 with available specimens (inter- and intra-batch duplicates were run), were of sufficient quality for further analysis; 359 and 187 samples were available from the training and testing sets respectively. We re-evaluated the variable balance between the training and testing sets and found there to be no statistically significant difference for any of the variables.

Microarray Normalization, Probeset Filtering, and Batch Effect Correction

Probeset summarization and normalization was performed by fRMA, which is available through Bioconductor. The fRMA algorithm relates to RMA with the exception that it specifically attempts to consider batch effect during probeset summarization and is capable of storing the model parameters in so called ‘frozen vectors’. We generated a custom set of frozen vectors by randomly selecting 15 arrays from each of the 19 batches in the discovery study. The frozen vectors can be applied to novel data without having to renormalize the entire dataset. We furthermore filtered out unreliable PSRs by removing cross-hybridizing probes as well as high PSRs variability of expression values in a prostate cancer cell line and those with fewer than 4 probes. Following fRMA and filtration the data was decomposed into its principal components and an analysis of variance model was used to determine the extent to which a batch effect remains present in the first 10 principal components. We chose to remove the first two principal components, as they were highly correlated with the batch processing date.

Non-Coding RNA Analysis

Sequence information from each probe in a PSR can be aligned and annotated against the human reference genome by xmapcore (Yates, et al., X:Map: Annotation and visualization of genome structure for Affymetrix exon array analysis, Nucleic Acids Res. (2008), Epub.) Using annotation data from the human genome version hg19/GRCh37 (Ensembl annotation release 62), we categorize the PSRs into coding, non-coding (UTR) and non-coding (intronic) as defined by xmapcore.

The PSRs that cannot be categorized in the groups above are further categorized as follows:

Non-coding (Non-unique): one or more probes don't align perfectly to the genome, or one or more probes align perfectly to multiple regions of the genome.

Non-coding (ncTranscript): PSR correspond to the exon of a non-coding transcript.

Non-coding (CDS_Antisense): PSR corresponds to a segment in the opposite strand of the coding sequence of a protein-coding transcript.

Non-coding (UTR_Antisense): PSR corresponds to a segment in the opposite strand of the UTR sequence (5′ or 3′) of a transcript.

Non-coding (Intronic_Antisense): PSR correspond to a segment in the opposite strand of the intronic sequence of a protein-coding transcript.

Non-coding (ncTranscript_Antisense): PSR correspond to the exon of a non-coding transcript in the opposite strand.

Non-coding (Intergenic): if the probes were not categorized under any of the groups above and it is annotated as ‘intergenic’ by xmapcore.

We additionally used xmapcore to annotate the gene symbol, gene synonym, Ensembl gene ID and biological description for any PSRs that overlapped with a transcript when necessary; this excludes alignments to non-coding (non-unique) and non-coding (intergenic) sequences.

Example 2: A 43-Biomarker Set for Prostate Cancer

Overview of the entire microarray analysis pipeline is provided in FIG. 3.

Feature Selection

The remaining features following the analysis in Example 1 were subjected to filtration by a t-test between the METS and non-METS samples in the training set (n=359). Using a p-value cut-off of 0.01, 18,902 features remain in analysis for further selection. Feature selection was performed by regularized logistic regression using the elastic-net penalty through the glmnet v1.7 package available in R with an alpha-value of 0.5 with three-fold cross validation. The regularized regression, with cross validation, was bootstrapped over 1000 times using all training data (n=359); with each iteration of bootstrapping we tabulated features that had a non-zero co-efficient. Features that were selected in at least 25% of the total runs were used for model building.

Non-Coding RNA Analysis

We annotated the 43-biomarker set with labels described in Example 1 to identify the extent of non-coding features. We show the various labels within the 43-biomarker set in FIG. 4. Table 2 shows that most of the PSRs are found within the boundaries of a gene, with only one probe set (3802328) being intergenic. Assessment of the ontology term enrichment for the genes in Table 3 using DAVID tools shows that the set of genes is enriched, as expected in the case of cancer, for the biological processes of sister chromatid segregation, cell division and chromosome segregation (after Bonferroni correction, significance level of 0.08, Table 3).

TABLE 2 43-Biomarker Set. Chromosomal coordinates correspond to the hg19 version of the human genome. (Markers in the 43-biomarker set are annotated as RF43. Markers in the 22- biomarker set are annotated as RF22.) SEQ ID Biomarker ENSEMBL NO: Panel Chromosome Start End Category Strand Symbol ID 1. RF22, 1 164790778 164790861 CODING 1 PBX1 ENSG00000185630 RF43 2. RF22, 12 102043061 102043198 CODING 1 MYBPC1 ENSG00000196091 RF43 3. RF22, 17 37054699 37054747 CODING 1 LASP1 ENSG00000002834 RF43 4. RF22, 1 20809088 20810189 NON_CODING 1 CAMK2N1 ENSG00000162545 RF43 (CDS_ANTISENSE) 5. RF22, 9 125827478 125827705 NON_CODING −1 RABGAP1 ENSG00000011454 RF43 (CDS_ANTISENSE) 6. RF22, 20 44445347 44445562 NON_CODING −1 UBE2C ENSG00000175063 RF43 (CDS_ANTISENSE) 7. RF22, 5 14001862 14002003 NON_CODING 1 PCAT- RF43 (ncTRANSCRIPT) 32 8. RF22, 9 14089154 14089187 NON_CODING −1 NFIB ENSG00000147862 RF43 (INTRONIC) 9. RF22, 12 102021374 102021490 NON_CODING 1 MYBPC1 ENSG00000196091 RF43 (INTRONIC) 10. RF22, 13 24157611 24158003 NON_CODING 1 TNFRSF19 ENSG00000127863 RF43 (INTRONIC) 11. RF22, 4 30975279 30975441 NON_CODING 1 PCDH7 ENSG00000169851 RF43 (INTRONIC) 12. RF22, 2 242138538 242138661 NON_CODING 1 ANO7 ENSG00000146205 RF43 (ncTRANSCRIPT) 13. RF22, 11 58811043 58811070 NON_CODING 1 GLYATL1P4 ENSG00000254399 RF43 (ncTRANSCRIPT) 14. RF22, 6 32330751 32331082 NON_CODING −1 C6orf10 ENSG000000206310 RF43 (INTRONIC) 15. RF22, 1 156495410 156496002 NON_CODING −1 IQGAP3 ENSG00000183856 RF43 (UTR) 16. RF22, 2 242163962 242164581 NON_CODING 1 ANO7 ENSG00000146205 RF43 (UTR) 17. RF22, 6 169616207 169616770 NON_CODING −1 THBS2 ENSG00000186340 RF43 (UTR) 18. RF22, 8 144939574 144939986 NON_CODING −1 EPPK1 ENSG00000227184 RF43 (UTR) 19. RF22, 15 41672463 41672932 NON_CODING 1 NUSAP1 ENSG00000137804 RF43 (UTR) 20. RF22, 15 66841241 66841800 NON_CODING 1 ZWILCH ENSG00000174442 RF43 (UTR) 21. RF22, 19 3180095 3180328 NON_CODING 1 S1PR4 ENSG00000125910 RF43 (UTR) 22. RF22, 20 44445472 44445507 NON_CODING 1 UBE2C ENSG00000175063 RF43 (UTR) 23. RF43 3 101212717 101212786 CODING −1 SENP7 ENSG00000138468 24. RF43 7 36450679 36450750 CODING 1 ANLN ENSG00000011426 25. RF43 10 88730250 88730288 CODING 1 C10orf116 ENSG00000148671 26. RF43 11 68382513 68382688 CODING 1 PPP6R3 ENSG00000110075 27. RF43 13 33327527 33327656 CODING 1 PDS5B ENSG00000083642 28. RF43 17 38552572 38552698 CODING −1 TOP2A ENSG00000131747 29. RF43 3 190366433 190366480 CODING 1 IL1RAP ENSG00000196083 30. RF43 4 104057451 104057507 CODING −1 CENPE ENSG00000138778 31. RF43 12 4854600 4854755 CODING 1 GALNT8 ENSG00000130035 32. RF43 17 38555314 38555364 CODING −1 TOP2A ENSG00000131747 33. RF43 11 2772266 2772592 NON_CODING −1 KCNQ1 ENSG00000053918 (CDS_ANTISENSE) 34. RF43 18 24237326 24237436 NON_CODING −1 (INTERGENIC) 35. RF43 6 72119721 72119751 NON_CODING −1 C6orf155 ENSG00000233237 (INTRONIC) 36. RF43 11 24997429 24997706 NON_CODING 1 LUZP2 ENSG00000187398 (INTRONIC) 37. RF43 12 102030525 102030872 NON_CODING 1 MYBPC1 ENSG00000196091 (INTRONIC) 38. RF43 16 50104059 50104087 NON_CODING 1 HEATR3 ENSG00000155393 (INTRONIC) 39. RF43 3 132829328 132829491 NON_CODING −1 TMEM108 ENSG00000144868 (INTRONIC_ANTISENSE) 40. RF43 6 31914455 31914576 NON_CODING 1 CFB ENSG00000243649 (ncTRANSCRIPT) XXbac- ENSG00000244255 BPG116M5.17 41. RF43 7 5967689 5967716 NON_CODING 1 (NON_UNIQUE) 42. RF43 1 53379570 53379755 NON_CODING −1 ECHDC2 ENSG00000121310 (UTR) 43. RF43 11 13376793 13376832 NON_CODING 1 ARNTL ENSG00000133794 (UTR)

TABLE 3 Gene Ontology Terms Enriched in the 43-Biomarker Signature Biological Adjusted GO Term Process Genes Involved P-value P-value GO: Sister CENPE, NUSAP1, 6.99E−05 0.0736 0000819 Chromatid PDS5B, TOP2A Segregation GO: Cell Division ANLN, CENPE, 7.04E−05 0.074 0051301 NUSAP1, PDS5B, UBE2C, ZWILCH GO: Chromosome CENPE, NUSAP1, 7.27E−05 0.0765 0007059 Segregation PDS5B, TOP2A

The set of probe sets reported here is rich in novel information for prostate cancer prognosis, as most of the probe sets fall in non-coding regions suggesting that non-coding RNAs may constitute a set of highly informative markers for prostate cancer.

Example 3: A 22-Biomarker Signature for Prostate Cancer and Comparison to Clinical and Integrated Models

To further ensure robustness of the features in the signature, we applied a final filtration method that would establish the minimal number of features required to minimize the mean squared error (MSE) of the model. To do this we used the rfcv function from the randomForest package, using 10-fold cross validation and a step value of 0.9. This method will order the features in accordance to their variable importance and iteratively remove 10% of lowest ranking features and measure the MSE at each step. We selected the number of features that were at the knee of the curve, shown in FIG. 5. At all features to the left of this knee have a highly variable MSE, which becomes more stable to the right of the knee of the curve. The knee of the curve occurs at approximately 22 features. FIG. 6 calculated the variable importance by ranking the features according to their mean decrease in accuracy (MDA) and mean decrease in gini (MDG). Some features have low MDA and MDG, which may warrant their removal from the marker set, however FIG. 5 shows that the inclusion of even some of the less differentiating features still contributed to a lower MSE. An overview of the feature selection and microarray methods is shown in FIG. 7.

Classifier Development

We developed three classifiers using the aforementioned 22 features, clinicopathologic variables, and a combination of both. We referred to the classifiers as the genomic classifier (GC), clinical classifier (CC) and integrated genomic clinical classifier (GCC); they are described in detail below. The primary endpoint for classifier development was the METS event. Although it is typical to report probabilities of progression at 2, 5, 7 or 10 years after METS, the design of the discovery study prevents us from reporting probabilities that are meaningful outside of study. For this reason, the scores for all of the aforementioned models prognosticate whether a given individual will experience metastatic disease progression, as this endpoint is not subject to modeling disease prevalence or time to an event but rather the presence or absence of features that indicate disease aggression.

Genomic Classifier (GC)

A total of 22 features were used for model building. As a further method of standardization, the expression values for the 22 features were percentile ranked for each patient. We used a random forest from the randomForest package available in R for model building and used the tune function, from the e1071 package, to identify the optimal model parameters; the optimal parameters were established to be: nodesize=80, ntree=700, mtry=15. The tuning parameters were selected to optimize classification accuracy in the training set. The model built from the training data is frozen and stored for future application to novel data. The model for classification built from the 22-biomarker feature set is henceforth referred to as the genomic classifier (GC) when applied to novel data. Notable, the final feature set (Table 4) is such that most of the 22 features in GC were ncRNA and only three were from protein-encoding mRNA (Table 4).

The GC outputs a score between [0,1], where 1 indicates higher metastatic potential. The score is derived as an output of the random forest, and rather than representing a probability it represents the total percentage of the trees in the forest that classified a new case as METS. Alternatively, it may also be said that each decision tree within the random forest decides whether the expression levels of the 22 features in a given tumor sample is more representative of MET disease or not. We used a 0.5 cutoff to classify patients as having METS or not because it is objective and used the simple Majority rule logic.

Clinical Classifier (CC)

A clinical classifier (CC) for predicting the METS end point was developed using the following clinicopathologic variables: Lymph node invasion status (LNI); Surgical Margin Status (SMS); Seminal Vesicle Invasion (SVI); Extra Capsular Extension (ECE); Pathological Gleason Score; and the pre-operative PSA. The first four clinical variables (LNI, SMS, SVI and ECE) are used as binary variables, indicating present or not; the pre-operative PSA values are taken to log 10. The clinical variables were assembled in a logistic regression and the trained model was used to predict METS in the testing set and validation study. CC produces a probability between 0 and 1, where 0 indicates low metastatic potential and 1 indicates a high metastatic potential.

TABLE 4 22-Biomarker Set. Chromosomal coordinates correspond to the hg19 version of the human genome. Differential Expression Gene Cyt. Band # Markers Annotation of Markers Biology mets vs Non-mets CAMK2N1 1p36.12 1 CODING AS Cell Cycle Upregulated Progression/ Control Of Signaling Pathway IQGAP3 1q23.1 1 3′ UTR Cell Proliferation/ Upregulated Control Of Signaling Pathway PBX1 1q23.3 1 CODING Proto-Oncogene/ Downregulated Transcription Factor/ Immune Response ANO7 2q37.3 2 3′ Cell Adhesion Downregulated UTR/ncTRANSCRIPT** PCDH7 4p15.1 1 INTRONIC Cell Adhesion Downregulated PCAT-32 5p15.2 1 ncTRANSCRIPT ncRNA Downregulated DIFFERENTIALLY EXPRESSED IN PROSTATE CANCER TSBP 6p21.32 1 INTRONIC Testis-Specific Downregulated Basic Protein/ Immune Response THBS2 6q27 1 3′ UTR Cell-Cell, Cell- Upregulated Matrix Interaction/ Modulator Of Angiogenesis EPPK1 8q24.3 1 3′ UTR Cytoskeleton Upregulated Maintenance In Epithelial Cells NFIB 9p23 1 INTRONIC Cell Proliferation/ Downregulated Transcription Factor RABGAP1 9q33.2 1 CODING AS Cell Cycle Upregulated Progression/ Microtubule Nucleation GLYATL1P4 11q12.1 1 ncTRANSCRIPT Pseudogene Downregulated MYBPC1 12q23.2 2 CODING/INTRONIC Epithelial Cell Downregulatec Protein TNFRSF19 13q12.12 1 INTRONIC Type I Cell Surface Downregulated Receptor/Control Of Signaling Pathway NUSAP1 15q15.1 1 3′ UTR Cell Cycle Upregulated Progression/ Microtubule Stabilization ZWILCH 15q22.31 1 3′ UTR Cell Cycle Upregulated Progression/ Chromosome Segregation LASP1 17q12 1 CODING Cell Proliferation/ Upregulated Cytoskeletal- Associated Protein S1PR4 19p13.3 1 3′ UTR Cell Differentiation Upregulated UBE2C 20q13.12 2 3′UTR/CODING AS Cell Cycle Upregulated Progression

The motivation for developing the CC was to compare the GC and GCC (described below) against a prognostic model that was developed for a similar endpoint. As the majority of post-operative nomograms prognosticate BCR in an “all-comers” population, we felt it was necessary to compare GC and GCC against a nomogram based on a high-risk population with the METS endpoint. The CC served as an intermediate benchmark between the GC and GCC and made it possible to quantify the difference additional genomic information provided in risk prediction.

Genomic Clinical Classifier (GCC)

The GC scores were assembled along with clinicopathologic variables used for CC using a logistic linear regression model fitted to the training data. The combined GC and CC model is referred to as Genomic Clinical Classifier (GCC).

Comparison to Nakagawa 17-Gene Signature

This discovery cohort was previously profiled using the Illumina DASL expression microarray (Cancer Panel v1) containing 502 oncogenes, tumor suppressors genes and genes in their associate pathways. Nakagawa (2008) describes the development of a 17 gene signature to predict METS (referred to as systemic progression in that text). We translated the 17 gene signature from the DASL platform to the HuEx platform and re-modeled those genes in the training set using logistic regression. We compare the performance of the 17-gene signature against GC, CC and GCC.

We found that in both training and testing, GC, CC and GCC outperformed the 17-gene signature (and also the GPSM nomogram); the AUC results are summarized in Table 5.

TABLE 5 Comparison of Discrimination ability of classifiers in different datasets Model Training Testing Validation* GC 0.90 0.76 0.79 GCC 0.90 0.75 0.82 CC 0.76 0.70 0.70 GPSM 0.71 0.62 0.59 DASL17 0.73 0.60 0.64 *Survival ROC analysis was used for case-cohort validation study

Statistical Analysis

The CC, GC and GCC prediction models were evaluated in the independent validation cohort and compared to the GPSM scores for predicting the primary endpoint of mets. Researchers at GenomeDx were blinded to the outcomes and the initial analysis was conducted by Mayo Clinic statisticians (RC and EJB). C discrimination index (c-index), an extension of the area under the ROC curve for the case of censored survival data was used to initially compare the performance of each model to predict mets. The 95% confidence intervals for the c-index were approximated through bootstrapping.

Following de-blinding, several additional analyses were performed. Calibration plots, survival ROC, and decision curves were used to assess overall discrimination. Decision curve analysis was used to compare the net benefit (e.g., the gain in sensitivity weighted by a loss in specificity) over a range of ‘decision-to-treat’ threshold probabilities using the clinical-only vs. genomic models. Survival ROC and decision curves were evaluated for prediction of mets within 5 years after RP. Graphical diagnostic, ROC-based, and Censored data methods were used to determine a tentative cut-off for GC on the discovery set.

Cox proportional hazards regression analysis was used to test for associations between models and the mets endpoint. Proportional hazards assumptions of the Cox model were confirmed by evaluating the scaled Schoenfeld residuals. Due to the case-cohort design of the validation study, survival analysis utilized the Lin-Ying method, weighting the controls to reflect mets incidence in the cohort at large. Cumulative incidence curves were constructed using competing risks analysis to accommodate censoring due to death, and other events, which bias Kaplan-Meier estimates of incidence. CC, GC and GCC models were subdivided into tertiles as an objective demarcation of low, intermediate and high risk groups. The GPSM score risk groups were defined previously.

Analyses were performed using R v 2.14.1 (www.R-project.org). All tests were two-sided and a Type I error probability of 5%. The study was approved by the Mayo Clinic Institutional Review Board.

Biomarker Evaluation

Independent Validation of Prognostic Classifiers

In a blinded-independent validation study, 5-year survival ROC curves for metastasis-free end point showed a c-index of 0.70 and 0.59 for CC and GPSM, respectively (FIG. 8). GC outperformed these clinicopathologic prediction models with a c-index of 0.79, which increased to 0.82 in the integrated GCC model. In addition, the 95% confidence intervals (CIs) of the genomic models overlapped extensively, indicating comparable predictive performances (FIG. 8).

Moreover, discrimination box-plots and calibration curves show the improved performance for classifiers that used the genomic variables over clinicopathologic models (CC and GPSM) (FIGS. 9-11).

A decision curve comparing the models is shown in FIG. 12. At ‘decision-to-treat’ threshold probabilities (e.g., probability of metastatic disease at 5 years after RP), ranging from 5-25%, the net benefit of the genomic-based models exceeded that of both clinical-only models. Collectively, these data imply that the genomic panel significantly improves predictive ability.

Cumulative incidence plots compared the incidence of mets events in the risk groups for each model (FIG. 3). Difference in cumulative incidence between risk groups defined by GC tentative cut-off was highly significant for GC (p<0.001), with the group below the 0.5 potential cut-off having an incidence of <2.5% at 5-years post RP, and the group equal or above the cut-off had 5-year post RP cumulative incidence of ˜18%. However, after using a prior cut-off for GPSM, the risk groups were not significantly different (p=0.35). We also compared cumulative incidence plots of mets events between tertiles for each model (FIG. 13, 14, 15). In order to assess the performance of the models in a different categorization of risk groups, we used the D'Amico definition of low, intermediate and high risk patients (FIGS. 16, 17). Based on this, ˜60% of our high-risk cohort falls under the definitions of low and intermediate risk patients as defined by D'Amico as low or intermediate.

Difference in cumulative incidence between tertiles was highly significant for GCC (p<0.001), with the 1st tertile group having an incidence of <1% at 5-years post RP and only three cases of mets (which all occurred >5 years post RP). The 2nd tertile had 5-year post RP cumulative incidence of 5% (less than the 7.5% rate in the full cohort) and the 3rd tertile GCC group had 44 mets events, with 5-year incidence of ˜15%. In addition, the majority of patients in the 3rd GCC tertile experienced mets within 3 years of RP. The cumulative incidence differences between tertiles were also significant for both GC and CC models (FIG. 13). The GPSM, and GC groups defined by their pre-determined cut-offs, and GPSM and GCC groups defined by tertiles were also compared when patients who received adjuvant androgen deprivation therapy were excluded from the analysis, and GC and GCC groups were significantly different (FIGS. 14-15).

Table 6 shows the comparison of GPSM and GC categorization of subjects to risk groups. The study consists of mainly high-risk patients; as such there are no GPSM low risk patients. Here we show that GC can adequately identify those patients that are truly high-risk from those that are not, we confirm this using a McNemar's test. Considering this is a high-risk cohort of adverse pathology, most patients were GPSM high-risk (n=196) with a smaller number of GPSM intermediate-risk (n=23). GPSM and GC gave consistent results in 88 (40%) of subjects, but GC reclassified 124 out of 196 (63%) GPSM high-risk (GPSM>10) patients into lower risk groups. With additional genomic information, the GC systematically downgraded GPSM high-risk subjects to lower risk categories (p<0.0001 McNemar's test). Given, the low cumulative incidences of metastatic disease (FIG. 18), even patients with ‘high-risk’ adverse pathology or GPSM scores who have low GC scores, have a very low probability of mets.

Univariable analysis is detailed in Table 7 and shows that in this high-risk cohort, the majority of the clinicopathologic variables, with the exception of margin status and pre-operative PSA, were significant prognostic factors. GC has a high precision in estimating increasing risk of 56% of developing mets for every 0.1 unit increment in GC score (HR=1.56, CI: 1.35-1.80, p<0.001). However, with multivariable Cox regression modeling of the individual clinical and genomic components of the GCC model, while GC remained a significant variable with an HR of 1.48 (CI: 1.27-1.73, p<0.001) for every 0.1 unit increment in GC score, no clinical variables remained significant for predicting mets (Tables 8-9). In Table 8, GC is adjusted for clinicopathologic components of GCC (seminal vesicle invasion, pathological Gleason sum, pre-operative PSA, extra-capsular extension, lymph node involvement and positive margin as well as administration of adjuvant hormones. The Lin-Ying method was used to account for the case-cohort design when determining the hazard ratios. The GC hazard ratio is for a 0.1 unit change in the GC risk score.

GC was also adjusted for CC and GPSM in separate multivariable regression analyses and yet remained the only significant risk factor (Table 10).

TABLE 6 Reclassification of GPSM categories by GC. #patients (% mets by 5 years) GC <0.5 GC >=0.5 GPSM Totals GPSM Intermediate 16(4%) 7(4%) 23(8%) GPSM High 124(29%) 72(63%) 196(92%) GC Totals 140(33%) 79(67%)

TABLE 7 Univariable Analysis for panel of prognostic classifiers and clinicopathologic variables (for mets) Hazard ratio (95% CI) p-value GC 1.56 (1.35-1.80) <0.001 GCC 1.40 (1.24-1.58) <0.001 CC 1.31 (1.15-1.49) <0.001 Pathologic Gleason Sum 2.45 (1.38-4.36) =0.002 GPSM 1.32 (1.12-1.56) <0.001 Extra Capsular Extension 2.68 (1.49-4.83) =0.001 Seminal Vesicle Invasion 2.18 (1.22-3.87) =0.007 Lymph Node Invasion 2.18 (1.04-4.56) 0.04 Pre-operative PSA 1.21 (0.94-1.57) 0.15 Positive Margins 0.96 (0.54-1.69) 0.88

TABLE 8 Multivariable Cox regression analysis. Hazard ratio (95% CI) p-value GC 1.48 (1.27-1.75) <0.001 Gleason Sum 1.83 (0.83-4.09) 0.14 Seminal Vesicle Invasion 1.47 (0.70-3.08) 0.30 Extra Capsular Extension 1.37 (0.63-3.01) 0.43 Pre-operative PSA 1.13 (0.79-1.63) 0.51 Positive Margins 1.10 (0.53-2.25) 0.80 Lymph Node Invasion 0.94 (0.28-3.15) 0.92 *adjusted for adjuvant hormone therapy

TABLE 9 Multivariable Analysis for panel of prognostic classifiers and clinicopathologic variables Adjusted for Hormone Therapy (for mets) Hazard ratio (95% CI) p-value GC 1.49 (1.27-1.75) <0.001 Seminal Vesicle Invasion 1.75 (0.80-3.85) 0.16 Gleason Sum 1.43 (0.70-2.90) 0.33 Extra Capsular Extension 1.32 (0.61-2.86) 0.49 Pre-operative PSA 1.15 (0.81-1.62) 0.44 Positive Margins 1.09 (0.53-2.25) 0.81 Lymph Node Invasion 0.85 (0.30-2.45) 0.77 Hormone Therapy* 0.92 (0.44-1.93) 0.84 *adjusted for salvage or adjuvant hormone therapy

TABLE 10 Multivariable Analysis of GC compared to GPSM and CC (for mets) Hazard ratio (95% CI) p-value MVA with GC and GPSM GC 1.51 (1.31-1.75) <0.001 GPSM 1.16 (0.96-1.39) 0.17 MVA with GC and CC GC 1.51 (1.29-1.75) <0.001 GPSM 1.12 (0.96-1.30) 0.16

DISCUSSION

This study describes the development and independent validation of a novel prognostic biomarker signature, a genomic classifier (GC) identified by analyzing 764 high-risk radical prostatectomy patients (545 in discovery set and 219 in an independent validation set) with long-term follow-up. The GC was designed to predict rapid metastatic disease progression, an endpoint based on radiographic imaging that is clinically much more relevant for aggressive prostate cancer than most previous biomarker reports using the BCR endpoint. All tumor specimens were profiled using high-density microarray analysis of RNA from archived patient FFPE specimens. The transcriptome-wide approach allowed interrogation of a much richer genomic dataset, including many thousands of ncRNAs, compared to previous efforts which were primarily protein-coding ‘gene-centric’. The GC model was validated in an independent blinded study of a contemporary cohort (2000-2006) of prostatectomy patients with adverse pathology, reflecting the population where clinical variables and nomogram models fail to decipher the small percentage of men who will develop lethal prostate cancer.

In the high-risk validation cohort of 1,010 men treated at the Mayo Clinic, only 7.5% developed metastatic disease. Even after accounting for use of adjuvant therapy, risk stratification based on pathology alone failed to accurately predict metastatic disease and supporting the notion that even high risk prostate cancer is a molecularly heterogeneous disease. The improved calibration of genomic models over clinical-only models may be due to incorporation of true molecular drivers of aggressive disease in the GC models, so that even in a clinicopathologic homogeneous ‘high-risk’ patient population, GC can better segregate ‘true high-risk’ patients from the majority who will not progress. Decision curve analysis also showed that the prognostic classifiers using genomic information had a broader range of clinical benefit, based on “decision-to-treat” thresholds, compared to clinical-only models. Again, the limited range of benefit shown by the CC and GPSM models may be a further reflection of their limited discriminative ability in high risk men. Lastly, even after adjusting for adjuvant therapy multivariable analysis showed GC remained the only significant predictor, suggesting that the genomic signature captures most of the prognostic information as it relates to metastatic disease development in the high-risk cohort.

To our knowledge, this is the first study to extensively validate a biomarker signature based primarily on ncRNA. This may be an important reason why the GC model (only 3 features selected from protein-encoding mRNA; see Table 4) showed significantly improved performance over previous gene-based models. Supporting this notion, we recently reported our reanalysis of the MSKCC Prostate Oncogenome Project expression data and demonstrated that ncRNA expression was more prognostic than protein-coding genes and in multivariable analysis provided predictive information independent of the Kattan nomogram. The importance of ncRNA in aggressive prostate cancer is further highlighted by several recent studies that have demonstrated their involvement in tumor cell invasion and metastasis.

The vast majority of patients with aggressive disease have adverse pathology. However, the fact remains that most patients with adverse pathology will not die from prostate cancer. The question remains for most urologists and their patients, of when, and how, to intervene for patients with adverse pathology. Up to 20% of RP patients with adverse pathology in contemporary practice will inevitably require additional intervention with radiation, hormones or chemotherapy as durable cancer control will not be achieved using radical surgery alone. Three large, randomized clinical trials (SWOG 8794, EORTC 22911 and ARO 96-02) have shown improved biochemical recurrence-free and/or metastasis-free survival for men with adverse pathology when treated with immediate adjuvant radiation therapy versus initial observation. Initial reports from the RTOG 96-01 trial, which randomized early salvage radiation patients to anti-androgen therapy or observation, indicated that intensification with multimodal therapy post RP reduces the incidence of metastatic disease. Despite this evidence, urologists have not widely adopted adjuvant intervention after RP and favor instead treatment upon PSA relapse or biochemical recurrence (BCR).

This practice, however, may lead to under-treatment of some patients in the adjuvant setting, where radiation has a proven benefit and over-treatment of many patients in the salvage setting, since BCR is a poor surrogate for metastatic disease.

As management strategies evolve, a ‘reverse stage-shift’ has occurred in the last decade, whereby more low-risk patients opt for active surveillance and more high-risk patients undergo RP. As a result, urologists are seeing a higher proportion of patients with adverse pathology after RP. In a contemporary cohort of men with adverse pathology we show that adding genomic variables to established clinical risk factors significantly improves prediction models for metastatic disease. Furthermore, we found that most of the prognostic information for predicting metastatic disease is captured by the genomic variables, which are measured in the primary tumor. This data supports the notion that genomic alterations in lethal prostate cancer manifest early on, many years before metastatic disease can be radiographically imaged. Improved identification of patients most at risk for developing disease may better serve those most in need for adjuvant therapy. It is in these patients that we are further testing the performance of this classifier, its usefulness in guiding risk stratification and decision-making after RP in additional validation studies. More accurate prediction of lethal prostate cancer within this high risk population of surgical prostate cancer patients may lead ultimately to improved outcomes.

Gleason 7 Sub Cohort Analysis

Patients with pathological Gleason stage 7 represent a difficult to classify intermediate category in prostate-cancer clinical decision making. It has been suggested that patients with a primary Gleason 4 and secondary Gleason 3 (4+3) have a worse outcome than 3+4 patients. We demonstrated that GCC was better able to segregate Gleason 7 patients with improved outcome compared to the current 4+3 vs. 3+4 method. First, we compared the capacity of the CC (also referred to as the Clinical Model, or CM) and GCC to segregate Gleason 7 patients (FIG. 19), the discrimination plots in this analysis showed that CC does not segregate these patients at all. Departing from CC model, we compared the survival outcome for the Gleason 7 patients based on the aforementioned clinical practice and GCC. FIG. 20 clearly shows the superiority of the GCC in segregating these patients with a mets endpoint (also referred to as Clinical Recurrence, or CR). Importantly, the GCC is also able to segregate patients when the endpoint was changed to PCSM; the conventional 4+3 vs. 3+4 methods has a limited capacity to separate patients as shown in FIG. 21. We further separate samples into their respective 4+3 and 3+4 categories and assessed the performance of the GCC within these groups and found that for both mets and PCSM end points the GCC was capable of significantly segregating patients into high (GCC>=0.5) and low risk (GCC<0.5) groups (FIGS. 22-23).

Application to Adjuvant Hormones Lymph Node Positive Patients

We assessed the capacity of GCC to segregate a set of Lymph Node positive (N+) patients uniformly treated with adjuvant hormone therapy. We compared its performance against CC and used both the mets and PCSM endpoint (FIGS. 24-25). Since GCC and CC contain LNI status as a variable in model training and prediction, the LNI status might augment the results when the analysis is focused solely on N+ patients. Overall however either model is intended to be applied to broad range of patients with varying pathological characteristics and so it is practical to consider CC and GCC with LNI status even when focusing on the N+ group. Furthermore, N+ patients are uniformly treated in clinical settings with Adjuvant Hormones (ADTHx+) as standard of care; the ability of the GCC to further segregate the N+ patients into good and poor outcomes even after ADT might indicate an important clinical utility that could warrant the treatment of high risk (GCC>0.5) patients with additional therapies. Currently, there are no existing clinical instruments that further differentiate N+ patients.

Example 4: Method of Diagnosing a Leukemia in a Subject

A subject arrives at a doctor's office and complains of symptoms including bone and joint pain, easy bruising, and fatigue. The doctor examines the subject and also notices that the subject's lymph nodes are also swollen. Bone marrow and blood samples are obtained from the subject. Microarray analysis of the samples obtained from the subject reveal aberrant expression of one or more transcripts selected from Tables 2, 4, 11 or 55 and the subject is diagnosed with acute lymphoblastic leukemia.

Example 5: Method of Determining a Treatment for Breast Cancer in a Subject

A subject is diagnosed with breast cancer. A tissue sample is obtained from the subject. Nucleic acids are isolated from the tissue sample and a probe set comprising at least ten probes capable of detecting the expression of at least one non-coding RNA transcript and at least one protein-coding transcript. Analysis of the expression level of one or more transcripts selected from Tables 2, 4, 11 or 55 reveals the subject has a tamoxifen-resistant breast cancer and gefitinib is recommended as an alternative therapy.

Example 6: Method of Determining the Prognosis a Pancreatic Cancer in a Subject

A subject is diagnosed with pancreatic cancer. A tissue sample is obtained from the subject. The tissue sample is assayed for the expression level of biomarkers comprising one or more transcripts selected from Tables 2, 4, 11 or 55. Based on the expression level of the one or more transcripts selected from Tables 2, 4, 11 or 55, it is determined that the pancreatic cancer has a high risk of recurrence.

Example 7: A 22-Marker Genomic Classifier (GC) Outperformed Previously Reported Genomic Signatures and Individual Gene Biomarkers

As described in Example 3, a final set of 22 markers was selected for building a random forest classifier. The high-density array used in this study permits measurement of the expression patterns of RNAs associated with multiple biological processes in prostate cancer progression. Also, this transcriptome-wide approach allowed interrogation of a much richer genomic dataset, including thousands of ncRNA. Furthermore, the genomic markers measure the biological potential of the tumor to metastasize. The biological processes represented in the 22 markers include cell cycle progression, cell adhesion, tumor cell motility, migration and immune system modulation Multidimensional scaling analysis depicts clustering of cases and controls based on the expression of these 22 markers (FIG. 26). Controls correspond to pooled NED and PSA patients since, at a fold-change threshold of 1.5 (after correcting for false-discovery), only 2 (out of ˜1.4 million) features were found to be differentially expressed between these two groups groups, compared to 1187 and 887 in metastasis outcomes compared to NED and PSA groups. A random forest machine-learning algorithm was used to generate GC scores on the training and testing set after assembling the 22 markers with forest parameters to optimize for highest accuracy in the training set. The performance of GC was compared to that of previously published gene signatures: Agell et al 2012, Bibikova et al 2007, Bismar et al 2006, Cuzick et al 2011, Glinsky et al 2005, LaPointe et al 2004, Larkin et al 2012, Nakagawa et al 2008, Olmos et al 2012, Penney et al 2011, Ramaswamy et al 2003, Ross et al 2012, Talantov et al 2010, Varambally et al 2005 and Yu et al 2007 and individual genomic markers associated with prostate cancer progression including CHGA, DAB2IP, GOLPH2, PAP, ETV1 and ERG, KI-67, PSA, PSCA, PSMA, AMACR, GSTP1, PCA3, B7-H3, TOP2A and CAV1. Each genomic marker and gene in the signatures were mapped to its associated Affymetrix core transcript Cluster (www.affymetrix.com/analysis/index.aff) where available, otherwise the extended transcript cluster was used. Based on the fRMA summarized expression values for the individual genes, the signatures were modeled in the training set using a random forest and tuned with the tune.randomForest function from the e1071 R package. Tuning involved performing a 20 by 20 grid search to find the optimal “mtry” and “nodesize” model parameters evaluated via 5-fold cross validation in order to maximize accuracy.

The performance of the classifiers and the individual genes was subsequently assessed in both training and testing sets (FIG. 27 and FIG. 28). As expected, we observed high AUCs in training for nearly all the external signatures, similar to what was observed with GC. When applied to testing, the AUC for each model decreased. Among the 17 external signatures that were modeled, 12 were statistically significant predictors of metastasis (e.g., their 95% confidence intervals did not drop below a threshold random chance AUC of 0.5) (FIG. 27). The AUC of GC was 0.08 points higher than the top performing external signature, the 16-gene signature reported by Bibikova et al, which had an AUC of 0.68 (95% CI: 0.60-0.76). In contrast to the expression signature models, the performance of the 16 single genes tested were expected to be similar in the training and testing sets. These genomic markers showed an overall agreement in performance, with differences in significance possibly explained by the smaller sample size of the testing set compared to the training set (FIG. 28). Of the 16 genomic markers, only B7-H3 (CD276), GSTP1 and PCA3 were statistically significant in both the training and testing sets (FIG. 28). Again, none of the individual genomic markers outperformed GC or the top performing clinical predictor, GS (AUCs≤0.64).

Example 8: A 22-Marker Genomic Classifier (GC) Outperformed Individual Clinicopathologic Variables and was Prognostic within Different Gleason Scores Groups

Clinical variables were calculated, categorized or transformed as follows. Pathological Gleason Score (GS, or pathGS) was dichotomized into groups with the threshold of ≥8; although convention is to segregate GS into three groups (<6, 7, ≥8) the relative lack of patients with GS≤6 prompted the dichotomization of GS. The pre-operative PSA (pPSA), measured immediately prior to RP, was loge-transformed. The following variables were binary: Extra-capsular Extension (ECE); Seminal Vesicle Invasion (SVI); Surgical Margins (SM+, or SMS) and Lymph Node Involvement (N+, or LNI). Hormone and radiation therapy were included as separate binary covariates if administered in an adjuvant (<90 days post RP) or salvage (following PSA rise) setting. Treatments administered subsequent to clinical metastasis were not included.

In the training set (see Example 1), ROC area-under the curve (AUC) values for GC, CC and GCC were 0.90, 0.76 and 0.91 respectively, outperforming all individual clinical variables: GSm N+, ECE, SVI, SM+, N+, pPSA and Tumor Volume (FIG. 29). In the testing set, GC and GCC had the highest AUC of 0.75, and 0.74, respectively for predicting cases. The clinical-only CC had an AUC of 0.69, which was only marginally better than pathological Gleason score alone (0.65). The shape of the ROC curves for GC and GCC showed that these models had the highest specificity and sensitivity compared to clinical models above a threshold of ˜50% specificity (FIG. 30).

A blinded study independently validated GC for prediction of clinical metastasis (metastasis) following radical prostatectomy. The results showed that the GC model had improved performance over any individual clinicopathologic variable or multivariable prediction model. In this independent validation set, the AUC of 5-year survival ROC curves demonstrated that GC had higher discriminatory ability than individual clinicopathologic variables (FIG. 31). The GC model had an AUC of 0.79 for predicting clinical metastasis at 5 years post RP with median follow up of 6.7 years. Furthermore, 5-year survival decision curve analysis on the independent validation set showed that GC had a higher net benefit over a wider range of ‘decision-to-treat’ probabilities than clinicopathologic factors (FIG. 32).

In order to test for the effect size of individual variables as well as dependencies among these variables, we performed univariable and multivariable analyses using logistic regression on the testing set (Table 12). In univariable analysis, we found GC, CC, GCC, GS, SVI and ECE to be statistically significant predictors of cases (p<0.05). The odds ratio for GC was 1.42 for every 10% increase in GC score. When dichotomized into low and high GC risk groups, as described above, the odds ratio was 6.79 (95% CI: 3.46-13.29), more than twice the odds ratio of Gleason score (OR: 3.02 (95% CI: 1.61-5.68)) for predicting cases. In multivariable analysis, after adjustment for post RP treatment, GC remained the only significant prognostic variable (p<0.001) with an OR of 1.36 for every 10% increase in GC score. The independent significance of GC suggested that a more direct measure of tumor biology (e.g., 22-marker expression signature) added significant prognostic information for prediction of early metastasis after rising PSA, which was not captured by the clinical variables available from pathological analysis.

In univariable analysis (UVA) on the independent validation set, GC had the highest significant hazard ratio (HR) among classifiers (Table 7). In multivariable analysis (MVA) on the independent validation set, only GC retained a significant HR when adjusted for clinical variables and postoperative adjuvant therapy (Table 8; P<0.001). Gleason score was alternatively parameterized (e.g., 3+4, 4+3, 8, 9-10) but this did not change the significance of GC (Table 13). Three additional MVA models were performed to model GC with CC, GPSM and the Stephenson nomogram. Only the Stephenson nomogram retained a significant HR (p<0.04) with GC as the dominant variable in the model (Table 10, Table 14).

TABLE 12 Univariable Multivariable Odds Ratio Odds Ratio (95% CI) P (95% CI) P GC 1.42 (1.28-1.60) p < 0.001 1.36 (1.16-1.60) p < 0.001 GCC 1.36 (1.21-1.53) p < 0.001 n.a n.a CC 1.35 (1.15-1.59) p < 0.001 n.a n.a pPSA 0.99 (0.77-1.26) 0.92 0.75 (0.52-1.07) 0.11 Pathologic 3.02 (1.61-5.68) p < 0.001 1.91 (0.85-4.33) 0.12 GS ≥ 8 SVI 2.44 (1.30-4.58) 0.01 1.93 (0.79-4.73) 0.15 Tumor 1.02 (0.97-1.06) 0.44 0.97 (0.92-1.04) 0.42 Volume N+ 1.69 (0.74-3.88) 0.21 1.42 (0.41-4.96) 0.58 SM+ 1.05 (0.57-1.93) 0.87 0.93 (0.40-2.17) 0.87 ECE 2.01 (1.18-3.73) 0.03 1.00 (0.45-2.20) 0.99 * MVA adjusted for adjuvant and salvage treatment interventions

TABLE 13 Hazard Ratio (95% CI) P GC ¹ 1.47 (1.26-1.73) <0.001 Pathological Gleason Score* 6 + 7(3 + 4) ref 7(4 + 3) 3.30 (1.21-9.04) 0.02 8  3.99 (1.48-10.77) 0.01 9-10 2.21 (0.78-6.25) 0.14 Pre-operative Prostate-specific Antigen ² 1.23 (0.81-1.85) 0.34 Seminal Vesicle Invasion 2.05 (0.85-4.98) 0.11 Positive Surgical Margin 1.21 (0.55-2.67) 0.64 Extra-capsular Extension 1.29 (0.55-3.01) 0.56 Lymph Node Involvement 0.75 (0.21-2.70) 0.66 Adjuvant Radiation 0.87 (0.23-3.32) 0.83 Adjuvant Hormone 0.88 (0.35-2.24) 0.79 *Reference Gleason score combined 6 and 3 + 4 as model did not converge with using Gleason 6 only as reference ¹ Hazard ratio reported for 10% increase of GC score. ² Hazard ratio reported for 1.0 unit increments of log-transformed level. Abbreviations - CI: confidence interval; GC: genomic classifier.

TABLE 14 Hazard Ratio (95% CI) P Model GC ¹ 1.49 (1.27-1.73) <0.001 Stephenson ¹ 1.15 (1.01-1.31) 0.04 ¹ Hazard ratio reported for 10% increase of GC score. Abbreviations - CI: confidence interval; GC: genomic classifier

To investigate the magnitude of the hazards ratio for incremental increases in GC score we evaluated the effect size of each 10% increase in GC score for predicting clinical metastasis after adjusting for postoperative treatment (Table 15). We observed a general trend of increasing HR, and decreasing probability of metastasis-free survival with increasing deciles. However, this was not statistically significant because of the small number of patients, in the higher GC deciles. GC score deciles were then incrementally collapsed to create three GC risk groups (GC scores<0.4, 0.4-0.6, ≥0.6) and these showed significant differences in HR (and survival) in comparison to the reference group as well as to the prior level (Table 16).

TABLE 15 ref = first ref = prior Clinical Metastasis-free GC decile GC decile Probability GC % of HR (95% HR (95% 3- 5- 8- Deciles Patients CI) P CI) P year year year 0.00000- 10 NA NA 100%  98% 98% 0.1 0.10001- 17%  0.60 (0.04-10.20) 0.72 0.60 (0.04-10.20) 0.72 100%  100%  99% 0.2 0.20001- 19%  5.56 (0.66-47.14) 0.12 9.28 (1.13-76.08) 0.04 100%  97% 92% 0.3 0.30001- 13%  5.86 (0.64-53.68) 0.12 1.05 (0.33-3.32) 0.93 96% 95% 92% 0.4 0.40001- 12%  6.06 (0.68-53.89) 0.11 1.04 (0.29-3.74) 0.96 96% 95% 90% 0.5 0.50001- 9%  11.12 (1.25-99.33) 0.03 1.83 (0.52-6.49) 0.35 96% 92% 80% 0.6 0.60001- 12%  17.35 (2.06-146.25) 0.009 1.56 (0.52-4.71) 0.43 89% 86% 77% 0.7 0.70001- 4%  16.68 (1.62-171.63) 0.02 0.96 (0.24-3.84) 0.96 87% 78% NA* 0.8 0.80001- 2%  95.51 (8.82-1034.17) <0.001 5.73 (0.97-33.63) 0.05 65% NA* NA* 0.9 0.90001- 1% 106.63 (11.20-1014.70) <0.001 1.12 (0.21-5.83) 0.9 80% NA* NA* 1.0 *Model adjusted for adjuvant treatment **No patients left due to censoring or experiencing clinical metastasis events

TABLE 16 reference = reference prior GC GC < 0.4 group Hazard Hazard Clinical Metastasis-free GC risk % of Ratio Ratio (95% Probability categories Patients (95% CI) P CI) P 3-year 5-year 8-year <0.4 60% NA NA 99% 98% 95% 0.4-0.6 21% 2.39 (1.10-5.17) 0.03 2.39 (1.10-5.17) 0.03 96% 94% 87% >0.6 19% 7.30 (3.51-15.14) <0.001 3.06 (1.40-6.72) 0.005 86% 78% 73% Model adjusted for adjuvant treatments

The distribution of cases and controls in the testing set by both GC and Gleason score risk groups was illustrated in FIG. 33 and summarized in Table 17. Among GS≤6 tumors (n=18) none had high GC scores, while among GS 7 tumors (n=97), nearly a third (29%) had high GC scores and half of these were cases that developed early metastasis after rising PSA. While most patients with high Gleason scores (≥8) had high GC scores, among the 29 (40%) with low GC scores there were only 7 cases with 3 deaths from prostate cancer. Overall, 116 out of 186 (62%) testing set patients had low GC scores of which only 21 were cases resulting in 7 deaths from prostate cancer. Among the 70 (38%) patients with high GC scores, there were 42 cases and 25 of these men died of prostate cancer. In the independent validation set, GC distribution in Gleason score groups showed high concordance (FIG. 34, Table 18); still GC identified significant number of clinically high risk patients who did not experience adverse outcomes in this set. Among patients with low Gleason score (GS 5 to 6), none had high GC scores (≥0.6) or had clinical metastasis on study follow up. As expected, 40% of patients with GS≥8 had high GC scores (≥0.6), of whom 62% experienced metastasis and 41% died of their disease. However, more than a third of patients with GS≥8 (36%) had low GC scores (<0.4), and the majority of these men did not have metastasis (77%) or die of prostate cancer (85%) at follow up. Among patients with GS 7 tumors, 41% had high GC scores (≥0.4) and 44% of these men had clinical metastasis but for GS 7 with low GC scores (<0.4), 86% of them did not metastasize and only 3% died of their disease. This reclassification demonstrated that while GC scores trend higher with higher Gleason score, GC may be used to further identify a considerable number of men with ‘high risk’ Gleason≥8 tumors that may never develop clinical metastasis and conversely from among ‘intermediate risk’ Gleason 7 tumors a subset enriched for clinical metastasis events.

TABLE 17 GC ≤ 0.5 GC > 0.5 Gleason n METs n METs Category n (%*) n PCSM (%) n (%) n PCSM (%) GS ≤ 6 18 2 (11) 0 0 0 0 GS 7 69 12 (17)  4 (5.7) 28 14 (50) 4 (14) GS 8 12 4 (33) 1 (8.3) 11  6 (54) 5 (45) GS ≥ 9 17 3 (17) 2 (12) 31 22 (70) 16 (51) 

TABLE 18 GC Score < 0.4 0.4 ≤ GC Score ≤ 0.6 GC Score > 0.6 Path GS Total N Total N Total N Categories (%) Mets PCSM (%) Mets PCSM (%) Mets PCSM TOTAL 5-6 13 (87) 0 0  2 (13) 0 0 0 (0) 0 0 15 7 66 (59) 9 2 24 (22) 10 1 21 (19) 10 3 111 8 16 (42) 6 2  9 (24) 3 1 13 (34) 7 6 38 9-10 17 (31) 4 3 14 (25) 4 1 24 (44) 16 9 55 TOTAL N 112 (51)  19 7 49 (22) 17 3 58 (27) 33 18 219

The clinical significance of GC was further evidenced by the statistically significant differences of low and high-risk GC groups for the Prostate Cancer Specific Mortality Endpoint (PCSM) found within different Gleason Score Risk Groups (FIGS. 35A-C and Table 19). Also, GC was able to significantly (p<0.05) separate those PSA patients that would go on to experience later clinical metastasis (FIG. 36). As the KM method not only takes into consideration the number of patients at risk but also censored data (e.g., patients for which there was a loss of follow up at some point in time) to compute the proportions, the number of patients at risk for each time point in FIG. 35-36 are shown in Tables 19-20, respectively. These results suggested that GC can accurately predict metastasis long before it can be detected radiographically, may better guide post-surgical treatment decisions, and may help prevent over-treatment, toxicity, and morbidity.

TABLE 19 Time to PCSM after BCR (years) 0 5 10 15 20 on GC ≤ 0.5 217 118 85 24 1 # Patients Score = 7 GC > 0.5 54 39 14 2 — at risk Gleason GC ≤ 0.5 38 22 16 4 — Score = 8 GC > 0.5 30 26 14 4 1 Gleason GC ≤ 0.5 55 37 20 1 — Score = 9 GC > 0.5 88 40 16 4 1

TABLE 20 Time to PCSM after BCR (years) 0 5 10 15 20 GC ≤ 0.5 158 158 118 38 4 # Patients GC > 0.5 26 26 16 5 — at risk

Example 9: Combined Value of Genomic Biomarkers and CAPRA-S in Predicting Prostate Cancer Death in a High-Risk Surgical Cohort

Most men with lethal prostate cancer present initially with localized disease, and develop biochemical recurrence (BCR) following local treatment. Biomarkers potentially improve prediction of progression risk after radical prostatectomy (RP). We compared two validated post-RP classifiers: a genomic classifier (GC) and CAPRA-S(based on standard clinicopathologic parameters), to predict cancer-specific mortality (CSM) in a contemporary cohort of RP patients.

Materials and Methods

Patient Population

Subjects were identified from a population of 1,010 men prospectively enrolled in the Mayo Clinic tumor registry who underwent RP for prostatic adenocarcinoma from 2000-2006 (see Example 1). This population was clinically high-risk for metastasis, as defined by pre-operative prostate-specific antigen (PSA) levels>20 ng/mL, pathological Gleason score≥8, Seminal Vesicle Invasion (SVI), or GPSM (Gleason score; pre-operative PSA; SVI; surgical margin status, SMS) score≥10. Data was collected using a case-cohort design; of the 1,010 men, 73 (7.2%) patients developed metastatic disease as evidenced by bone and/or CT scans. These 73 men were defined as cases. A 20% random sample of the entire cohort was selected for analysis (202 patients), which included 19 cases. The remaining 54 cases not selected by random sampling were also included for analysis, resulting in a total of 256 patients. After exclusion for tissue unavailability and quality control, the independent validation cohort consisted of 219 patients (69 cases and 150 controls; median follow-up, 6.69 years).

Tissue Processing

Following histopathological review, total RNA was extracted and amplified from macrodissected FFPE primary prostatic adenocarcinoma specimens, and hybridized to Human Exon 1.0 ST GeneChips (Affymetrix, Santa Clara, Calif.) that profile coding and non-coding regions of the transcriptome using approximately 1.4 million probe selection regions, hereafter referred to as features.

Classifier Development

We compared and integrated two validated post-RP classifiers: GC and CAPRA-S. The GC was developed using a nested-case control study and contains the 22 biomarker set as disclosed in Example 3. The primary endpoint of GC was metastatic disease progression, defined as a positive bone or CT scan. Patients with GC scores≥0.4 were considered at high risk of progression to metastases. GC was independently validated in follow-up blinded study, of the patient population presented here. CAPRA-S is a nomogram that is based on standard clinical parameters, developed using the CAPSURE registry and biochemical recurrence (BCR) as the primary endpoint (Cooperberg, M. R., et al, The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer, 117(22), 5039-46). CAPRA-S scores≥6 were considered at higher risk of BCR. Out of the 219 patients, 212 had sufficient data with which to calculate the CAPRA-S score. Of these, 28 had CSM events.

GC and CAPRA-S were integrated using a cox-proportional hazard model with prostate cancer specific mortality (CSM) as the primary endpoint. Although GC and CAPRA-S classifiers were developed for different endpoints (metastases and BCR, respectively), high scores in these models could translate to greater risk of CSM. Neither GC nor CAPRA-S were trained or further refined on this patient population and the raw classifier scores were used for an integrated genomic and clinical classifier. This integrated genomic-clinical classifier, characterized by the equation 0.20*CAPRA-S+5.68*GC, was validated using the optimism estimate of the c-index (calculated by bootstrapped validation), and its performance was further evaluated in an independent low risk patient population.

Statistical Analysis

The area under the receiver operating characteristic (ROC) curve was used to initially compare classifier performance to predict metastasis. Calibration plots, ROC curves and decision curves were used to assess overall discrimination. Survival decision curve analysis was used to compare the net benefit (e.g., gain in sensitivity weighted by loss in specificity) over a range of “decision-to-treat” threshold probabilities using the GC and CAPRA-S classifiers. The decision curve was evaluated for prediction of CSM within 5 years post-RP.

Cox proportional hazards analysis was used to test for associations between classifiers and adverse pathologic features (APFs) for the CSM endpoint. The proportional hazard analysis used a Barlow weighting scheme to account for the case-cohort design of the study, the Lin-Ying method was used to refine estimates of the variance. Cumulative incidence curves were constructed using Fine-Gray competing risks analysis to accommodate censoring due to death. Analyses were performed using R v2.14.1.

Results

Table 21 shows the clinical characteristics of the cohort used for this study. The high number of metastasis and CSM events demonstrated the high risk of this cohort. CAPRA-S and GC were the most prognostic indicators of CSM by survival ROC analysis (Table 22). GC had a survival AUC of 0.78 (0.65-0.89 95% CI) whereas CAPRA-S had a survival AUC of 0.76 (0.65-0.88 95% CI). Survival decision curve analysis (FIG. 37) showed that GC had a higher Net Benefit over a range of “decision-to-treat” threshold probabilities.

TABLE 21 Total n (%) Pre-operative Prostate-specific Antigen <10 ng/mL 119 (54)  10-20 ng/mL 59 (27) >20 ng/mL 41 (19) Pathological Gleason Score ≤6 15 (7)  7 111 (51)  ≥8 93 (42) Pathological Stage pT2N0M0 85 (39) pT3/4N0M0 102 (47)  pTanyN + M0 32 (15) Adverse Pathologic Features Positive surgical margins 123 (56)  Extra-capsular extension 95 (43) Seminal vesicle invasion 81 (37) Post-Operative Treatment Adjuvant radiation 24 (11) Adjuvant androgen deprivation therapy 74 (34) Salvage radiation 68 (31) Salvage androgen deprivation therapy 86 (39) Clinical Outcomes Biochemical recurrence 110 (50)  Clinical metastasis 69 (31) Prostate cancer-specific mortality 28 (13)

TABLE 22 Survival AUC (95% CI) GC 0.78 (0.65-0.89) CAPRA-S 0.76 (0.65-0.88) Pathologic Gleason Score 0.73 (0.63-0.84) Pre-operative PSA 0.48 (0.33-0.56) Positive Margins 0.51 (0.35-0.65) Lymph Nodes 0.62 (0.46-0.72) Seminal Vesicle Invasion 0.60 (0.42-0.70) Extra Capsular Extension 0.48 (0.33-0.56)

When GC and CAPRA-S scores were compared, while trends suggest that both GC and CAPRA-S had high agreement with respect to patients that are truly at risk of lethal prostate cancer (FIG. 38), there was also substantial reclassification of CAPRA-S risk categories by GC. Namely GC was more specific as it reclassified 108 patients to lower risk without significantly impacting sensitivity (Table 23).

TABLE 23 GC Score <0.4 GC Score ≥0.4 Total Total CAPRA-S Patients Total CSM Patients Total CSM risk n n (csm total %) n n (csm total %) Total ≤2 1 n.a n.a n.a 1 3 to 5 68 6 (8.8) 40  2 (5.0) 108 ≥6 39 1 (2.5) 64 19 (30) 103 Total 108 7 104 21 212

The cumulative incidence plot (accounting for other causes of death as a competing risk) for the CAPRA-S high risk group was shown (CAPRA-S≥6; FIG. 39A). When this group was stratified by GC (FIG. 39B), patients with both high CAPRA-S scores and GC scores were at considerably higher risk than those with low GC scores.

Univariable (UVA) and Multivariable analysis (MVA) was used to further assess the statistical significance of the classifiers and clinical variables individually (UVA) and in presence of other variables (MVA). As shown in Table 24, GC, CAPRA-S and pathological Gleason Score were highly statistically significant in UVA (p-value<0.001), whereas Lymph Node Involvement and Extra capsular Extension were significant (p-value=0.01). In MVA, while CAPRA-S was not included in multivariable analysis as the clinicopathologic factors in this analysis comprise CAPRA-S, only GC and pathological Gleason Score remained statistically significant (Table 24).

TABLE 24 Univariable Analysis Multivariable Analysis Hazard Ratio (95% CI) p-value Hazard Ratio (95% CI) p-value GC* 1.83 (1.42-2.36) p < 0.001 1.61 (1.24-2.10) p < 0.001 CAPRA-S** 1.42 (1.19-1.70) p < 0.001 n.a n.a Path Gleason Score  7.84 (2.80-21.97) p < 0.001  4.80 (1.38-16.71) 0.01 Pre-operative PSA 1.11 (0.79-1.56) 0.54 1.01 (0.60-1.70) 0.96 Positive Margins 0.66 (0.29-1.52) 0.33 0.50 (0.18-1.38) 0.18 Lymph Nodes 3.53 (1.36-9.16) 0.01 1.45 (0.43-4.91) 0.55 Seminal Vesicle Invasion 2.11 (0.92-4.86) 0.08 1.79 (0.60-5.29) 0.29 Extra Capsular Extension 3.52 (1.40-8.81) 0.01 2.11 (0.69-6.42) 0.19 *GC hazard ratio is adjusted for a step size of 0.1 **CAPRA-S is not included in multivariable analysis as the clinicopathologic factors in this analysis comprise CAPRA-S

A second MVA between GC and CAPRA-S suggested both GC (HR:1.62, p<0.001) and CAPRA-S(HR:1.22, p=0.01) offered independent and statistically significant prognostic information. An integrated model improved risk stratification over either model alone (FIG. 40).

In summary, among men treated with RP at high risk of recurrence based on clinicopathologic variables, both GC and CAPRA-S were significant predictors of CSM. GC was able to effectively ‘down-risk’ men stratified to high risk based on CAPRA-S alone. GC provided independent prognostic information, and a model integrating GC and CAPRA-S may further improve prediction of lethal prostate cancer.

Example 10: Clinical Utility of a Genomic-Based Prognostic Test for Metastasis in High-Risk Post-Prostatectomy Patients

Prostate cancer presents a significant population health burden in the United States. As the most frequently diagnosed cancer among men, almost 240,000 new cases are projected for 2013 (ACS, 2013). About half of these men will be treated with radical prostatectomy (RP) (Marciscano et al., 2012) and while many will achieve a durable cure, up to 50% will present with one or more adverse pathology features such as, seminal vesicle invasion (SVI), extracapsular extension (ECE) or positive surgical margins (Swanson et al., 2007, NCCN, 2013). Although these patients are considered by guidelines to be at an increased risk for disease progression, only a minority will develop metastatic disease and ultimately die of prostate cancer (Pound et al.). Further, while close monitoring with postoperative PSA testing can identify men at risk, the time to biochemical recurrence (BCR) after RP is not predictive for metastatic disease (Boorjian et al., 2011). And, while PSA doubling time (PSAdt) is a good surrogate, its accurate determination may not be possible in all patients as it requires precious time that the patient might not have (Freedland et al., 2007).

Treatment recommendations from National Comprehensive Cancer Network (NCCN) guidelines include radiation and/or hormone therapy or active surveillance (observation). These guidelines are based in part on results from three independent phase III randomized clinical trials that have demonstrated improvements in biochemical-free, metastasis-free and cancer-specific survival in high-risk post-RP men treated with radiation therapy (RT) (Bolla et al., 2005; Thompson et al., 2009; Wiegel et al., 2009). Despite this, deciding on appropriate use of radiation therapy post RP remains a challenging task. Knowledge that most clinically high-risk post-RP patients will never develop metastasis may be resulting in concern over inappropriate or over-utilization of secondary therapy in this population. Recognizing these factors, guidelines state that “predicting prognosis is essential for patient decision-making, treatment selection, and adjuvant therapy” (NCCN, 2013). Therefore, a need persists to more accurately characterize a patient's risk of metastasis following RP to guide treatment decisions.

Current assessment of risk used when considering postoperative secondary therapy is conducted based on individual clinicopathologic variables and/or through use of nomograms (Lughezzani et al, 2010). However, the ability to identify patients at substantially higher risk of metastasis and lethal prostate cancer on the basis of clinicopathologic features alone is limited. Therefore, the need is evident for novel risk prediction tools such as genomic information that reflect the true biological potential for tumor recurrence and spread. One such tool is a postoperative genomic classifier (GC) test as described in Example 3 that uses a whole-transcriptome microarray assay with formalin-fixed paraffin embedded prostate cancer specimens. Developed in collaboration with the Mayo Clinic, it was designed to predict early clinical metastasis following RP (Erho 2013). In a blinded clinical validation study of a contemporary high-risk population of post RP men with adverse pathology, the GC test was found to more accurately predict metastasis post-RP than clinical risk models (Davicioni, E. et al 2013).

In assessing a novel molecular test, experts have recommended that evidence be collected not only on the clinical validity of the test, but also on how use of the test influenced clinical practice management, a well-established measure of the test's clinical utility (Hornberger et al. Mole Gen, 2012, CDC, 2007). The primary objective of the study herein, was to determine how urologists' knowledge of results of the GC test influenced adjuvant and salvage treatment recommendations following RP.

Materials and Methods

This clinical utility study used a prospective, pre-post design, consisting of two independent sub-studies to assess patient cases at different points in patient management; both are collectively referred to herein as the DECIDE study (DECision-Impact DEcipher). In one study, urologist treatment recommendations were assessed in the adjuvant setting, following RP without any evidence of PSA rise or BCR. In the other, treatment recommendations were assessed for a different cohort of cases in the salvage setting, following RP with evidence of PSA rise or BCR. Urologists were invited to review a set of twelve cases and provide treatment recommendations for cases at each of the adjuvant and salvage time points. Urologists were presented de-identified clinical results from real patients involved in a previously conducted clinical validation study (Davicioni et al. 2013) and asked to provide treatment recommendations based solely on the clinical information provided (pre-GC). Then, results of the GC test were assessed for the same de-identified cases and urologists were asked again to provide treatment recommendations (post-GC). Twenty urologists participated in the adjuvant setting study and 15 in the salvage setting study.

The study was conducted in accordance with the Declaration of Helsinki and the Belmont report and was reviewed and approved by an independent IRB (Quorum Review Inc., Seattle, Wash.).

The primary objective of this study was to assess the effect of the GC test on urologists' adjuvant and salvage treatment recommendations for clinically and pathologically high-risk post-RP cases. Secondary objectives were to investigate specific changes in recommendation, proclivity of the GC result to result in more or less intensification of treatment, the relative importance of the GC to clinical variables and impact of the GC on urologist confidence with treatment recommendations. Protocol-defined eligibility criteria for participation in the study required US board certified urologists practicing for at least 3 years and performing a high volume of RPs annually (Table 25). All urologists participating in the study were fellowship trained, urologic oncologists. Potential participants were identified through conference delegate lists and through established networks of key opinion leaders and were assessed for eligibility using an available database. Email invites were sent to 50 urologists meeting the inclusion criteria. Enrollment packages were sent to eligible urologists interested in participating in the study and included a cover letter, an educational primer on the GC test, a confidentiality agreement and a web link to the study's informed consent form (ICF) and electronic case report questionnaires (eCRQ).

TABLE 25 Adjuvant Salvage Total Evaluation Evaluation n = 21 n = 20 n = 15 No. (%) No. (%) No. (%) Practice setting Tertiary Care 13 (62%)  12 (60%)  9 (60%) Community (hospital or private) 8 (38%) 8 (40%) 6 (40%) No. of years in practice Mean 8.1 8.3 7.8 Range 3-25 3-25 3-25 No. Radical Prostatectomy per year Mean 184    179    200    Range 30-300 30-300 30-300 Geographic region West/South Central 4 (20%) 4 (20%) 3 (20%) South East 4 (20%) 4 (20%) 3 (20%) Mid Atlantic 4 (20%) 3 (15%) 2 (13%) North East 5 (25%) 5 (25%) 5 (33%) North Central 4 (20%) 4 (20%) 2 (13%)

Twenty-four high-risk post-RP patient cases (12 adjuvant and 12 salvage) were selected for urologist review from the previously conducted clinical validation study. The number of patient cases was selected to provide enough cases to sufficiently evaluate urologist decision making across a range of high-risk patient types and was limited to twelve cases in each treatment setting so as to minimize study participant fatigue in reviewing patient cases. All cases were high-risk post-RP as defined by the presence of one or more adverse pathological features including (1) pathological Gleason score 8+ or Gleason score 7 with primary pattern 4; (2) pathological stage T3a (extracapsular extension) or T3b (seminal vesicle invasion); (3) positive surgical margins; or (4) Gleason grade upgrade from biopsy to surgery. Cases that did not experience a PSA nadir after RP were excluded from the study.

Cases were selected on the basis of their clinical risk factors and the GC predicted probability of developing metastatic disease at 5 and 3 years post-RP for the adjuvant and salvage treatment settings, respectively. In the adjuvant setting, six cases with concordant clinical risk features and GC risk and six cases with discordant predicted risk were selected. In the salvage setting, these numbers were 5 and 7, respectively. Clinical risk was determined based on the following clinicopathological variables: age at surgery, pre-operative PSA levels, pathologic stage, biopsy and pathologic Gleason score, presence or absence of SVI, presence or absence of ECE, surgical margin status and lymph node involvement (Table 26). Additionally, PSA doubling time (PSAdt) and time to BCR were provided for cases evaluated in the salvage setting. High (low) GC risk was defined as a 5- or 3-year predicted probability of metastasis greater (less) than 6% for the adjuvant setting and greater (less) than 18% for the salvage setting. The predicted probability was obtained from a prediction curve that uses Cox regression modeling to convert the oligonucleotide microarray 22-marker GC score into a patient probability of clinical metastasis at 5 years post RP. A function was created that translated GC scores into 5-year clinical metastasis event probabilities, and the resulting line of best fit was used for future predictions for novel patients. The curve allowed for the translation of a GC score (x-axis) into a patient's probability of clinical metastasis (y-axis) by visual inspection or by simple calculation. The threshold cut-off for the GC test of ≥6% was used to identify a patient at elevated risk for clinical metastasis above the average risk for other similar high-risk (e.g., patients with one or more adverse pathology features) or conversely at lower risk than the average risk of such patients for patients with Decipher test results<6%.

TABLE 26 Adjuvant Salvage No. (N = 12) (%) No. (N = 12) (%) Age (Years at RP or at BCR) Median (Min, Max) 60 (48, 70) 66 (57, 74) Pre-operative Prostate-specific Antigen <10 ng/mL 10 (83.3) 9 (75) 10-20 ng/mL 1 (8.3) 2 (16.7) >20 ng/mL 1 (8.3) 0 NA 0 1 (8.3) D'Amico risk groups Low 2 (16.7) 1 (8.3) Intermediate 4 (33.3) 7 (58.3) High 6 (50) 4 (33.3) Pathological Stage pT2N0M0 6 (50) 8 (66.7) pT3N0M0 6 (50) 4 (33.3) Extra-capsular Extension Present 5 (41.7) 3 (25) Seminal Vesicle Invasion Present 4 (33.3) 2 (16.7) Surgical Margin Status Positive 8 (66.7) 6 (50) Pathological Gleason Score 6 3 (25) 0 7 (3 + 4) 4 (33.3) 2 (16.7) 7 (4 + 3) 1 (8.3) 4 (33.3) 8 1 (8.3) 5 (41.7) 9 2 (16.7) 1 (8.3) 10 1 (8.3) 0 Time to BCR (months) Median (Min, Max) NA 16 (1, 112) ≤36 months NA 9 (75) >36 months NA 3 (25) PSAdT <6 months NA 5 (41.7) ≥6 months NA 6 (50) <9 months NA 9 (75) ≥9 months NA 2 (16.7) NA NA 1 (8.3)

All cases were de-identified and presented in a randomized fashion to eliminate bias toward the urologist's pre- and post-GC treatment recommendations. Cases were randomized both from urologist to urologist and from pre to post-GC. Clinical variables and GC test results information were provided to urologists through a secure online platform, and all treatment recommendations were collected using the eCRQ. Treatment recommendations included referral to a radiation oncologist for radiation and/or initiation of hormones, close observation, or any other recommendation not listed on the eCRQ.

Confidence intervals for probability of recommendation change from pre- to post-GC were constructed using a normal approximation, a significance level of 5%, and all recommendations were considered as independent. Chi-squared tests were used for univariate assessment of treatment predictors and multivariable analyses were performed using logistic regression. All statistical analyses were performed using SAS 9.2 (Cary, N.C.). All tests were 2-sided with a Type I error probability of 5%.

Results

Participating physicians were all practicing, ‘high-volume’ urologists performing an average of 184 RPs per year (Table 25). Twenty-one urologists from 18 different institutions across the US participated: 20 in the adjuvant, and 15 in the salvage settings. Fourteen of these urologists completed assessment of cases in both sub-studies. Of the 21 urologists, 38% (n=8) practiced in a community-based hospital or private practice setting and 62% (n=13) practiced in tertiary care centers, the majority (85%) of which are National Cancer Institute (NCI) designated comprehensive cancer centers. Urologists had been practicing and performing surgery for 3 to 25 years (mean 8.1 years) and all had extensive experience managing and treating patients with prostate cancer both before and after RP.

Twelve patient cases were retrospectively selected for urologist review in each of the adjuvant and salvage settings (Table 26). Half of the adjuvant patient cases were pre-operatively deemed low to intermediate risk according to D'Amico risk groups but were all subsequently up-graded/staged postoperatively. Furthermore, 75% of these cases presented with a pathologic Gleason score≥7, and 36% were ≥65 years of age at the time of surgery. For cases reviewed in the salvage setting, half had a time to BCR≤24 months, and 75% presented with a rapid PSAdt (<9 months). The majority (58%) of these cases were ≥65 years of age at the time of BCR.

In the adjuvant treatment setting, 43% (95% CI: 37-49%) of recommendations changed following review of the GC test results (Table 27). Specifically, among case evaluations with a pre-GC recommendation involving treatment, 27% (95% CI: 19-35%) of recommendations were changed to observation post-GC. Notably, for case evaluations with a pre-GC recommendation of radiation alone (n=100), 31% (95% CI: 22-41%) changed to observation post-GC (Table 27). Among the case evaluations where observation was initially chosen (n=114), treatment was recommended for 37% of case evaluations post-GC, primarily in favor of radiation therapy (37/42). This can be visualized in FIG. 41, which shows how in comparison to pre-GC, post-GC urologist recommendations for observation or treatment (radiation and/or hormones) aligned to a high degree with the risk assigned by the GC test.

TABLE 27 Adjuvant Salvage Treatment Treatment Recommendation Recommendation N Pre- Change N 95% N Pre- Change N 95% Pre-GC Post-GC GC (%) CI GC (%) CI Overall Any 240 103 (43%)  37-49% 180 95 (53%) 45-60% Change Observation Any 114 42 (37%) 28-46% 31 19 (61%) 42-78% Treatment Radiation 114 37 (32%) 24-42% 31 12 (39%) 22-58% Hormone 114 4 (4%) 1-9% 31 0 (0%) therapy Radiation + 114   1 (0.9%) 0-5% 31  7 (23%) 10-41% Hormone therapy Other* 114 1 (1%) 0-5% 31 2 (7%) 0.8-21% Any Observation 125 34 (27%) 19-35% 143 23 (16%) 11-23% Treatment Radiation Observation 100 31 (31%) 22-41% 82 11 (13%)  7-23% Hormone Observation 1  1 (100%)  3-100% 6  1 (17%) 0.4-64%  therapy Radiation + Observation 24 2 (8%)  1-27% 55 11 (20%) 10-33% Hormone therapy Other* Observation 1  1 (100%)  3-100% 6 0 (0%) *In the advjuant setting, ‘other’ treatment recommendations included: “recheck path” and “medical oncologist and radiation oncoogist consult” *In the salvage setting ‘other’ treatment recommendations included: “DRE, imaging” ×3, “DRE, imaging, possible referral to radiation oncologist” ×2, and “referral to medical oncologist”

In the salvage setting, treatment recommendations changed 53% (95% CI: 45-60%) of the time (Table 27). Among case evaluations with a pre-GC recommendation involving treatment (n=143), 16% (95% CI: 11-23%) changed to observation post-GC. Expectedly, there were fewer pre-GC recommendations of observation (n=31) for case evaluations with BCR, 61% were recommended to change from observation to any treatment post-GC with radiation alone (n=12) or in combination with hormonal therapy (n=7) (Table 27). Similar to the analysis of the adjuvant setting above, we observed a trend that showed alignment of observation versus treatment recommendations with the GC score, even though treatment recommendation rates were higher overall in the salvage setting (FIG. 43). When accounting for intra-observer correlation, urologists' probability of changing recommendation was approximately normally distributed, with estimated probabilities of recommendation change of 43% (95% CI 36-50%) in the adjuvant setting and 53% (95% CI 39-67%) in the salvage setting. This indicated that no urologist is always changing or failing to change their recommendation from pre- to post-GC in either setting.

To further examine the impact of the relationships between clinicopathologic variables and the GC test results in urologist treatment recommendations, we evaluated the proportion of urologists recommending treatment pre- and post-GC over the complete set of case evaluations as well as within individual clinicopathologic variables for high and low GC risk patients (Table 29A-B). GC risk was established based on whether the predicted probability of developing metastasis was above (high GC risk) or below (low GC risk) the average risk for the original study population (see methods). Overall, in the adjuvant setting, treatment was recommended 52% of the time pre-GC. Upon reviewing the GC test results, those with a low GC risk were recommended treatment only 21% of the time compared to those with a high GC risk who were recommended treatment 90% of the time (p<0.0001). Similarly, in the salvage setting, the overall proportion of treatment recommendation was 79% pre-GC, but post-GC fell to 75% in the low GC risk group and rose to 85% in the high-risk GC group (p=0.031).

TABLE 29A Table 29A. Adjuvant Setting Post-GC Recommendation N (row %) [95% CI] Radiation ± Any Radiation Hormone Hormone Observe Treatment therapy therapy therapy Other Totals Pre-GC Recommendation Observe 71 (62%)  42 (37%)  37 (32%) 1 (0.9%)  4 (4%) 1 (1%) 114 [52-71%] [28-46%] [24-42%]  [0-5%] [1-9%] [0-5%] Any 34 (27%)  91 (73%) NA NA 0 0 125 Treatment [19-35%] [64-806%] Radiation 31 (31%) NA 51 (51%) 18 (18%) 0 0 100 therapy [22-41%] [41-61%] [11-27%] Radiation +  2 (8%) NA  6 (25%) 16 (67%) 0 0 24 Hormone  [1-27%] [10-47%] [45-84%] Therapy Hormone 1 (100%) NA 0 0 0 0 1 Therapy [3-100%] Other* 1 (100%) 0 0 0 0 0 1 [3-100%] Totals 106 133 94 35 4 1 240 Italicized and underlined region breaks out ″Any Treatment″ into the three available treatment options and are not included in row and column totals *In the advjuant setting, ′other′ treatment recommendations included: ″recheck path″ and ″medical oncologist and radiation oncoogist consult″

TABLE 29b Table 29B. Salvage Setting Post-GC Recommendation N (row %) [95% Cl] Radiation Any Radiation ± Hormone Hormone Observe Treatment therapy therapy therapy Other Totals Pre-GC Observe 10 (32%) 19(61%) 12 (39%) 7 (23%) 0 2 (7%) 31 Recommendation [17-51%] [42-78%] [22-58%] [10-41%] [0.8-21%] Any 23 (16%) 118 (86%) 78 (55%) 37 (26%) 3 (2%) 2 (2%) 143 Treatment [11-23%] [79-91%] [46-63%] [19-34%] [0.4-6%] [0.3-9%] Radiation 11 (13) 69 (84%) 53 (65%) 16 (20%) 0 2 (2%) 82 [7-23%] [74-91%] [53-75%] [12-30%] [0.3-9%] Radiation + 11 (20%) 44 (80%) 23 (42%) 20 (36%) 1 (2%) 0 55 Hormone Therapy [10-33%] [67-90%] [29-56%] [24-50%] [0-10%] Hormone 1 (17%) 5 (83%) 2 (33%) 1 (17%) 2 (33%) 0 6 Therapy [0.4-64%] [36-100%] [4-78%] [0.4-64%] [4.3-78%] Other*  0 6 (100%) 1 (17%) 5 (83%) 0 0 6 [54-100%] [0.4-64%] [36-100%] Totals 33 143 91 49 3 4 180 Italicized and underlined region breaks out ″Any Treatment″ into the three available treatment options are not included in row and column totals *In the salvage setting ′other′ treatment recommendations included: ″DRE, imaging″ ×3, ″DRE, imaging, possible referral to radiation oncologist″ ×2, and ″referral to medical oncologist″

When evaluating individual clinical variables in the adjuvant setting (Table 30), patients with ECE represented the subgroup with the highest proportion of treatment recommendations pre-GC (77%); this fell to 28% for low GC risk case evaluations and rose to 97% for high GC risk case evaluations post-GC (p<0.0001) (FIG. 42). Similarly, in cases with positive surgical margins, 54% were recommended treatment pre-GC. Treatment recommendation dropped to 18% for cases with low GC risk and rose to 93% in high GC risk cases (p<0.0001). For cases with pathological Gleason score≥7 disease, 50% were recommended treatment pre-GC, among those with low GC risk only 25% were recommended treatment versus 88% of those cases with high GC risk (p<0.01). The largest magnitude in change was observed in cases with SVI. Pre-GC, 70% of SVI cases were recommended treatment, but this dropped to 42% of cases post-GC. Among those cases with low GC risk, only 23% were recommended treatment in the presence of SVI. Cases with high GC risk apparently were perceived by urologists to reinforce the high-risk SVI pathology and 95% were recommended for treatment (p<0.0001). These results reinforced the impact of the GC test and indicated that the proportion of treatment recommendation was more strongly associated with the GC risk (or probability of developing metastasis) than any of the clinical variables (Table 30). Evaluation of individual clinical variables in the salvage setting (Table 30), showed that differences in adverse pathology within ECE, SVI and margin status did not appear to influence treatment recommendations post-GC (FIG. 44). The main driver for treatment recommendations was PSAdt. As expected, cases with a rapid PSAdt of <6 months were recommended for treatment by 93% of urologists pre-GC. However, the proportion dropped to 73% within low GC risk patients post-GC. For cases with longer PSAdt (and hence a presumed better prognosis), only 14 recommendations for treatment were made pre-GC, but this increased to 25 post-GC and all of these cases had high GC risk. As observed for the adjuvant setting, within the salvage setting study, GC risk had a stronger impact on the recommendation to treat than most clinical variables (other than margin status).

TABLE 30 Treatment P-values Recommended P-Value for Post-GC Post-GC for Effect Treatment Treatment Low High of Clinical Effect Effect of Time Recommended GC GC Variable of GC clinical point Variable Pre-GC Risk Risk Pre-GC risk Variable Adjuvant Overall  125 (52.1%) 25 108  <0.0001 NA (20.8%)   (90%) ECE Absent   48 (34.3%) 14 50 <0.0001 <0.0001 0.16 (17.5%) (83.3%) Present 77 (77%) 11 58 (27.5%) (96.7%) SVI Absent   69 (43.1%) 11 89 <0.0001 <0.0001 0.36 (18.3%)   (89%) Present 56 (70%) 14 19 (23.3%)   (95%) Positive Absent   39 (48.8%) 14 15 0.49 <0.0001 0.24 Margins (23.3%) (75%) Present 86 (53.8%) 11 93 (18.3%)   (93%) Gleason Downgrade   40 (66.7%) 9 20 <0.0001 Upgrading (22.5%)  (100%) No   45 (37.5%) 13 49 <0.0001 0.97 Change (21.7%) (81.7%) Upgrade   40 (66.7%)  3 39   (15%) (97.5%) Pathological <7 36 (45%) 10 20 0.046 Gleason (16.7%) (100%)  7 50 (50%) 15 35 0.011 0.5   (25%) (87.5%) >7 39 (65%) 53 (88.3%) Salvage Overall  143 (79.4%) 79 64 0.031 NA (75.2%) (85.3%) ECE Absent   98 (72.6%) 42 64 0.0003 0.009 0.1   (70%) (85.3%) Present  45 (100%) 37 (82.2%) SVI Absent  113 (75.3%) 56 64 0.0051 0.03 0.62 (74.7%) (85.3%) Present  30 (100%) 23 (76.7%) Positive Absent   53 (58.9%)  7 64 <0.0001 0.0005 0.007 Margins (46.7%) (85.3%) Present  90 (100%) 72   (80%) Gleason No  101 (74.8%) 48 64 0.008 0.23 0.14 Upgrading Change   (80%) (85.3%) Upgrade   42 (93.3%) 31 (68.9%) Pathological  7   75 (83.3%) 48 26 0.29 0.03 0.37 Gleason   (80%) (86.7%) >7   68 (75.6%) 31 38 (68.9%) (84.4%) BCR Time <36  123 (91.1%) 79 27 <0.0001 0.8 0.11 months (79.2%) (90.0%) ≥36   20 (44.4%) 37 months (82.2%) PSAdt <6   70 (93.3%) 44 14 0.007 0.058 0.72 months (73.3%) (93.3%) ≥6   67 (74.4%) 35 38 months (77.8%) (84.4%) <9  123 (91.1%) 79 27 <0.0001 0.11 0.93 months (75.2%)   (90%) ≥9   14 (46.7%) 25 months (83.3%) Low (High) GC Risk at Advjuvant timepoint = 5 year predicted probability <6% (>6%) Low (High) GC Risk at Salvage timepoint = 3 year predicted probability <18% (>18%)

To measure recommended changes in treatment intensity, we established a baseline clinical perception of risk (hereafter referred to as perceived risk). Cases were considered low perceived risk if less than half of urologists recommended treatment and high perceived risk if more than half recommended treatment in the absence of the GC test results. In the adjuvant and salvage settings we observed that if perceived risk was high but GC risk was low, then, respectively, 50% and 46% of recommendations reduced treatment intensity post-GC (e.g., radiation to observation or radiation/hormone combination to radiation only) (Table 28). Very few recommendations were made that increased treatment intensity, (only 5% and 3.8%, respectively for adjuvant and salvage treatment recommendations). Conversely, for cases with an initial low perceived risk but high GC risk, we observed a 55% and 58% increase in treatment intensity in both the adjuvant and salvage settings, respectively. Influence of GC risk on change in intensity for all clinical risk categories and treatment settings were highly statistically significant (<0.0001). Furthermore, a multivariable model adjusting for the pre-GC clinical risk showed that GC risk influenced change in treatment recommendation intensity (p<0.0001). To understand the extent to which the GC test result impacts confidence in making a treatment recommendation, urologists were asked to report on the degree to which they felt confident in the treatment recommendation made for case evaluations both pre- and post-GC, as well as the extent to which they felt the GC test result influenced those treatment recommendations. Results showed that for case evaluations where a treatment recommendation was made, urologist confidence in treatment recommendations increased by 25% and 23% in the adjuvant and salvage settings, respectively. Additionally, urologists reported that the GC test result influenced their treatment recommendation in 83.5% (adjuvant) and 87.4% (salvage) of case evaluations (Table 31). As shown in FIG. 45, urologists report increased confidence in treatment recommendations made post GC test results. Table 32 shows five de-identified patients from the cohort used in this study, their clinical characteristics, the predicted probability at five years based on GC test and the actual clinical outcome observed. As seen there, Low predicted probabilities by GC test correspond with no evidence of disease, whereas high predicted probability corresponds with metastatic disease.

TABLE 28 Perceived GC No Timepoint Risk Risk Decrease Change Increase Adjuvant high low 20 (50%)  18 (45%)  2 (5%)  high 3 (5%)  35 (58.3%) 22 (36.7%) low low 15 (18.8%) 60 (75%)  5 (6.3%) high 3 (5%)  24 (40%)  33 (55%)  Salvage high low 48 (45.7%) 53 (50.5%) 4 (3.8%) high 1 (3.3%) 17 (56.7%) 12 (40%)  low high 4 (8.9%) 15 (33.3%) 26 (57.8%) Low (High) Perceived Risk = <half (>half) of clinicians initially recommend treatment Low (High) GC Risk at Advjuvant timepoint = 5 year predicted probability <6% (>6%) Low (High) GC Risk at Salvage timepoint = 3 year predicted probability <18% (>18%)

TABLE 31 All Recommendation Changed Pre-GC Post-GC Pre-GC Post-GC Test Test Test Test Adjuvant Confidence in treatment recommendation Agree 72.9% 81.7% 70.9% 88.3% Disagree  3.8%  5.8%  4.9%  2.9% Neutral 23.3.%  12.5% 24.3%  8.7% GC test influenced treatment recommendation Agree NA 62.5% NA 83.5% Disagree NA  8.3% NA  2.9% Neutral NA 29.2% NA 13.6% Salvage Confidence in treatment recommendation Agree 72.8% 82.2% 68.4% 84.2% Disagree  4.4%  2.8%  5.3%  2.1% Neutral 22.8% 15.0% 26.3% 13.7% GC test influenced treatment recommendation Agree NA 68.3% NA 87.4% Disagree NA 11.1% NA  4.2% Neutral NA 20.6% NA  8.4% Agreement with confidence in treatment recommendation was assessed on a 5 point Likert scale where 3 was considered neutral

TABLE 32 Predicted prob of mets at 5 Actual Age pPSA ECE SVI SM Gleason Nomogram* years outcome** A 58 194 + + + 3 + 4 High Low NED (5%) B 60 22 + − + 4 + 3 High Low NED (4%) C 46 11 − − + 3 + 4 Int Low NED (2%) D 54 10 + − + 3 + 4 Int High MET (44%) E 61 5 − − − 4 + 4 Low High MET (55%) Note: All of these patients were conservatively managed and did not receive any treatment post-RP *UCSF CAPRA-S **NED = No evidence of disease; MET = metastatic disease

DISCUSSION

This clinical utility study was designed to prospectively assess the effect of a genomic classifier (GC) test that predicts metastasis following RP on urologists' adjuvant and salvage treatment recommendations. The performance of the GC test was previously reported in a blinded, independent validation study of a population of 1,010 men at high risk of recurrence (based on adverse pathology) post RP. That study revealed that 60% of clinically high-risk patients would be reclassified as low risk with a cumulative incidence of metastasis of only 2.4% at 5 years post RP. Conversely, patients with the highest GC scores (19% of the population) had nearly 10 times higher cumulative incidence of metastasis by 5 years. Findings from this current study demonstrated that knowledge of the GC test result frequently impacted urologists' treatment recommendations in both the adjuvant (43%) and salvage settings (53%). Furthermore, we were able to show that for patients with low GC risk, while pre-GC urologists recommended treatment 43% of the time, post-GC they were recommended to observation 79% of the time. Taken together, the clinical validation and utility results implied that among the population of prostate cancer patients at high-risk of recurrence following RP, the majority of patients tested post GC will be recommended to close observation.

Guidelines on evidence development for molecular tests drafted in the past 3-5 years have urged going beyond obtaining evidence on assay analytical and clinical validity, encouraging additional research on how a test influences clinical practice management. To date in this nascent field, the number of published studies is fairly limited, but growing. In a clinical study of a molecular assay for stage II colon cancer, Srivastava et al. found that physicians changed chemotherapy decisions in 45% of patients, which fully validated predictions from a simulation of changes in NCCN guideline-directed treatment. One of the most studied areas of practice management change in molecular medicine has been risk prediction in breast cancer. In a comprehensive and systematic review of clinical validity and changes in clinical practice patterns, Hornberger et al. found 15 studies reporting on 5 different tests. They found chemotherapy recommendation changed between <1%-13% as reported in 4 studies of an online clinical decision support tool, compared with a median change across all studies of less than 35% in recommendations for a multi-gene assay. In comparison with these examples of accepted oncology tests, the finding in our study of a 43-53% change in recommendation upon receipt of the test results is supportive evidence that the GC test provides additional useful clinical information to guide therapy selection.

This study revealed relevant findings relating to current practice patterns for high-risk patients post-RP and confirmed urologist proclivity for not only increased salvage treatment at the point of BCR but also increased intensification of treatment when compared to the adjuvant setting. Overall, urologists' recommended treatment over 1.5 times as often in the salvage versus the adjuvant setting; treatment recommendations were made for 79% of case evaluations pre-GC in the salvage setting, 39% of which involved a recommendation for multi-modal (e.g., radiation and hormone) therapy. This compares to a recommendation for multi-modal therapy in only 19% of case evaluations pre-GC in the adjuvant setting. In addition, the findings imply a potential to over-treat in the salvage setting as evidence suggested that even in patients presenting with BCR, less than one-third will go on to develop metastasis. This is not without consequences for the patient as both postoperative radiation and hormone therapy incur with considerable morbidities including urinary incontinence and impotence, which can affect long-term patient quality of life.

Results from this study also confirmed that urologist decision-making in the adjuvant setting was mainly focused on whether or not to recommend postoperative radiation therapy. Prior to presentation of the GC test results, urologists recommended treatment in 52% of case evaluations with 99% of those recommendations including radiation therapy and only 20% of recommendations including hormone therapy. Accurate direction of radiation therapy to patients who are at highest biological risk for developing metastasis is critical as the morbidities and costs associated with treating patients with radiation modalities such as IMRT run high. Furthermore, we observed that the GC risk significantly influenced the treatment recommendations irrespective of the presence or absence of specific clinicopathogic features. Additionally, these findings suggested that in the salvage setting, the sensitivity of PSA rise may motivate urologists to recommend treatment despite its poor specificity. This hinted towards a role for the GC test to improve urologist decision-making in this setting. Similar results were found relating to the intensification of treatment, where changes in intensity were driven primarily by GC risk rather than the perceived risk. This suggested that given the information from the GC test, presumably measuring the true biological potential of a patient's tumor, urologists are more willing to commit to the intensification of therapy than if this recommendation were solely based on rising PSA and clinicopathologic variables (e.g., pre-GC).

Treatment recommendations changed in 43% of adjuvant setting case evaluations and 53% of salvage setting case evaluations. These findings demonstrated that knowledge of the genomic biomarker information in this GC test frequently influences these urologists' judgments about appropriate treatment in both the adjuvant and salvage settings.

Conclusion:

The DECIDE study assessed the effect of the GC test on urologist treatment recommendations for high-risk case evaluations in the adjuvant and salvage treatment settings. Findings demonstrated that knowledge of the GC test result frequently impacted urologists' treatment recommendations in both the adjuvant and salvage settings. Furthermore, the GC test appeared to better direct urologist treatment recommendations irrespective of the presence or absence of conventional pathology and clinical variables that are currently used to assess risk in these patients.

In conclusion, this study suggested that when implemented into routine clinical practice, the GC test had the potential to change treatment recommendations after radical prostatectomy and better identify patients that may benefit from intensive multimodal therapy, while sparing those who can be closely observed without initiating aggressive secondary therapy.

Example 11: Validation of a Genomic Classifier that Predicts Metastatic Disease Progression in Men with Biochemical Recurrence Post Radical Prostatectomy

Roughly 50,000 men per year will present with biochemical recurrence (BCR) following local treatment for prostate cancer. These men, with rising PSAs as the lone indicator of recurrence, present a management dilemma due to their varied outcomes. While the post-radical prostatectomy (RP) recurrence group of patients is highly enriched for those who will develop lethal disease, many of these patients will experience BCR without developing subsequent metastases. Thus, there is a clear need to improve patient risk stratification in this context. Here, we evaluated a genomic classifier (GC, see Example 3) in men with BCR for its ability to predict clinical metastasis (e.g. positive bone or CT scans).

Methods

Patient Cohort

The aim of this study was to determine whether molecular features of primary prostate tumor specimens could aid in the prediction of outcomes at the time of BCR. Accordingly, we selected 110 Caucasian patients from a high risk cohort of over 1,000 men who experienced BCR following radical prostatectomy and for whom tissue was available (see Example 1). Only men with adenocarcinoma at the time of radical prostatectomy were included. Following prostatectomy, men were typically followed by a PSA measurement every 3 months for the first year, every 6 months for the second year and then annually thereafter. Biochemical recurrence was defined as a PSA>0.2 ng/ml with a subsequent confirmatory value. At the time of biochemical recurrence, men were restaged with a CT or MRI as well as a bone scan which were then performed on a yearly basis. Time to biochemical recurrence was defined as the time from radical prostatectomy to first detectable PSA>0.2 ng/ml. Metastasis was defined as a positive bone scan or visceral or extra-pelvic nodal metastasis seen on CT scan. Men who experienced BCR less than 6 months or had missing clinicopathologic variables were excluded from the analyses (n=85). Men who experienced metastasis following biochemical recurrence were designated as “Mets” and men without metastasis after biochemical recurrence were designated as “No-Mets”. Adjuvant setting was defined as any treatment within 90 days after surgery. Salvage therapy was defined as any treatment after 90 days. Patient tumor and treatment characteristics are detailed in Table 33.

TABLE 33 Total Mets Mets-Free Patients n Characteristics n (row %) n (row %) n (row %) P-value* Study Cohort 85 51(60) 34(40) Age 0.822 46-60 35 21(60) 14(40) 61-74 50 30(60) 20(40) Pathological Stage 0.026 pT2N0M0 22  8(36) 14(64) pT3/4N0M0 46 30(65) 16(35) pTanyN + M0 17 13(76)  4(24) Pathological Gleason 0.034 Score (path GS) ≤6 4  0 (0.0)    4(100.0) 7 44 23(52) 21(48) ≥8 27 18(67)  9(33) Pre-operative Prostate- 0.362 specific Antigen (pre-op PSA) <10 ng/mL 38 22(58) 16(42) 10-20 ng/mL 28 15(54) 13(46) >20 ng/mL 19 14(74)  5(26) Seminal Vesicle 38 29(76)  9(24) 0.011 Invasion (SVI) Positive Surgical 50 29(58) 21(42) 0.822 Margin (SM+) Extra-capsular 50 36(72) 14(28) 0.013 Extension (ECE) Prostate Cancer- 22  22(100) 0(0) — specific Mortality Adjuvant Radiation 11  8(72)  3(27) 0.552 Therapy Adjuvant Androgen 37 29(78)  8(22) 0.005 Deprivation Therapy Salvage Radiation 41 25(61) 16(39) 0.965 Therapy Salvage Androgen 57 44(77) 13(23) <0.001 Deprivation Therapy Time to BCR 0.19 ≤2 years 51 34(67) 17(33) >2 years 34 17(50) 17(50) PSAdT (NA = 12) 0.006 ≤9 months 48 33(68) 15(31) >9 months 25  8(32) 17(68) *Pearson's chi-squared or Fisher Exact Test

Specimen Selection and Processing

Following histopathological review, formalin-fixed paraffin embedded (FFPE) prostatic adenocarcinoma tissues from the primary tumor at the time of prostatectomy were macrodissected. Total RNA was then extracted and purified using RNeasy FFPE nucleic acid extraction kit (Qiagen Inc., Valencia, Calif.), and subjected to whole-transcriptome amplification using the WT-Ovation FFPE system (NuGen, San Carlos, Calif.). Amplified products were fragmented, labeled, and hybridized to Human Exon 1.0 ST GeneChips (Affymetrix, Santa Clara, Calif.) that profile coding and non-coding regions of the transcriptome using approximately 1.4 million probe selection regions, each representing a genomic biomarker or feature. Following microarray quality control using the Affymetrix Power Tools packages, probeset summarization and normalization was performed by frozen robust multi-array analysis, which is available through Bioconductor. Human Exon GeneChip files corresponding to these cases are available from the National Center for Biotechnology Information's Gene Expression Omnibus database.

Calculation of GC Scores, PSADT and Nomogram Scores

Previously we described a validated 22-marker genomic classifier (GC) (see Example 3). Here we employed the same GC, with GC scores outputted as a value between 0 and 1. Depending on the analysis, GC score were treated as a categorical or continuous variable. Graphical diagnostic, receiver operating characteristic (ROC)-based methods on the training dataset was used to estimate an optimal cut-off for GC score. PSADT a measure of how fast the PSA levels doubles was calculated by natural log of 2 divided by slope of linear regression line of log 2 of PSA measures over time. CAPRA-S scores were calculated as described in Cooperberg et al. (Cooperberg Cancer 2011), and Stephenson 5 year probability of survival were calculated using nomogram described in Stephenson et al.

Statistical Analyses

All statistical analyses were performed in R v2.14.1. All tests were two-sided with a type I error probability of 5%. GC was compared to standard clinicopathologic variables, PSADT, time to BCR, clinical-only classifiers (CC, CAPRA-S scores and Stephenson's nomogram) and the integrated clinical and genomic classifier (GCC) for predicting metastatic disease. The concordance summary index (extension of c-index), an extension of area under the ROC curve (AUC) for censored data was used to compare classifier performance to predict metastasis. For the survival ROC function, the nearest-neighbour estimator was used with λ=0.002 to approximate survival function density. Calibration plots were used to assess the agreement between observed and predicted outcomes. Decision curve analysis was used to assess the net increase/decrease in the proportion of necessary/unnecessary treated patients. Survival ROC and decision curves were evaluated for prediction of metastasis within 3 years post-BCR.

Cox Proportional Hazard Regression model for case-cohort design was used to evaluate the prognostic value and significance of GC and clinicopathologic risk factors in predicting the development of metastasis after BCR. Proportional hazards assumptions of the Cox model were confirmed by evaluating the scaled Schoenfeld residuals. GC was used as a continuous variable (step size=0.1); pathological Gleason score was dichotomized into <8 and ≥8 considering the small number of patients who had the score of 6 and below; pre-operative PSA values were log transformed due to their skewed distribution; SVI, SM, extra-capsular extension (ECE) were used as binary variables. In the Cox model, the estimated risks were adjusted for the administration of adjuvant hormone therapy. Cumulative incidence curves were constructed using Fine-Gray competing risks analysis to estimate the risk of failure due to prostate cancer only, after removing other type of failures (e.g. other reason for death). Time-dependent analyses were performed by weighting patients without the event as suggested by Barlow.

Results

Characteristics of men in our cohort who experienced BCR following RP are detailed in Table 33. Median time to BCR was 14.60 months (range 1.1-85.33). Men experiencing metastasis following BCR (“mets”) did so with a median time of 37.16 months (range 3.15-111.54). These men had higher pathological grade and stage at prostatectomy, higher pre-operative PSAs, a more rapid time to BCR and more rapid PSAdTs (Table 33). They were also more likely to receive adjuvant and salvage therapies (Table 33).

Discrimination plots of the GC scores for mets (right—light grey circles) and no-mets (left—dark grey circles) patients is shown in FIG. 46. Non-overlap of the notches demonstrates that the difference in GC score distribution between mets and no-mets is statistically significant. Based on the AUC of 3-year survival ROC analysis, GC shows better performance (sens/spec) than clinical measures as it outperforms clinicopathologic factors (FIG. 47) and clinical-only classifiers (FIG. 48). GC was not improved when integrating it with clinicopathologic features (GCC, FIG. 48). As this represented a high risk population, a sizable fraction of men in the study received adjuvant therapy and this could potentially confound the results. When excluding patients with adjuvant therapy, the AUC of 3-year survival ROC remained statistically significant (FIG. 49). GC score distribution among pathological Gleason Score groups showed that, while there is an overall direct correlation between both scores, GC was able to reassess the risk of many patients based on the biology of the primary tumor (FIG. 50—Mets=triangle, No-Mets=circle).

The cumulative incidence of GC high risk patients were statistically higher than GC low risk patients at any point in time following BCR using an optimal ROC-based cut-off of ≥0.4, encompassing 73% of men who would develop metastasis (FIG. 51). As shown in FIG. 51, at 3 years from BCR, the GC low group has a 0.08 incidence rate and the GC high group has a 0.4 incidence rate. At 5 years from BCR, the GC low group has an incidence rate of 0.1 and the GC high group has an incidence rate of 0.54 (FIG. 51). Statistical significance was also achieved when partitioning the set of patients into low and high risk when using a cut off of 0.5 (majority-based criteria) (FIG. 52). As the KM method not only takes into consideration the number of patients at risk but also censored data (e.g., patients for which there was a loss of follow up at some point in time) to compute the proportions, the number of patients at risk for each time point in FIG. 51-52 are shown in Tables 34-35, respectively.

TABLE 34 Time to PCSM after BCR (years) 0 2 4 6 8 GC Low 139 106 76 41 10 # Patients GC High 82 39 19 10 5 at risk

TABLE 35 Time to PCSM after BCR (years) 0 2 4 6 8 10 GC ≤0.5 183 177 139 92 61 15 # Patients GC >0.5 91 72 51 20 11 — at risk

As shown in FIG. 53, at 3 years, the GC low group has a 0.08 incidence rate and the GC high group has a 0.17 incidence rate; and at 5 years, the GC low group has a 0.11 incidence rate and the GC high group has a 0.26 incidence rate. Since treatment was confounded with the patient's diagnosis or disease status, we observed that by excluding treated patients we lost a group of cases, thus having a lower incidence rate for GC>=0.4 patients (FIG. 53). Still, the difference in cumulative incidence between GC high risk and GC low risk patients remained statistically significant. As the KM method not only takes into consideration the number of patients at risk but also censored data (e.g., patients for which there was a loss of follow up at some point in time) to compute the proportions, the number of patients at risk for each time point in FIG. 53 is shown in Table 36.

TABLE 36 Time to PCSM after BCR (years) 0 2 4 6 8 GC Low 104 79 50 25 10 # Patients GC High 30 27 18 10 5 at risk

Majority of patients with GC<0.4 (64%) did not develop metastatic disease by the end of study follow-up time (FIG. 54).

Hypothetically, if a decision to treat is made when a classifier implies a risk of 25% or higher, using the estimated net benefit, it can be shown that the reduction in unnecessary treatments among 100 patients using the GC model was 31 patients in comparison to maximum 10 patients for clinical-only models (FIG. 55).

Univariable (UVA) and Multivariable analysis (MVA) based on Cox Proportional Hazard was used to further assess the statistical significance of the classifiers and clinical variables individually (UVA) and in presence of other variables (MVA). These analyses show that GC accurately predicts metastasis following BCR. In univariable analysis, GC score predicted metastasis following BCR, as did clinicopathologic variables and clinical-only models (Table 37 and Table 38). GC score and pathological Gleason Score remained the only significant predictors of metastatic disease in a multivariable model after adjusting for clinicopathologic information (Table 37). In multivariable models involving GC and clinical-only classifiers, GC remained significant while the clinical-only classifiers were not significant (Table 38).

In summary, when compared to clinicopathologic variables, GC better predicted metastatic progression among our cohort of men with BCR following RP. These results suggested that use of GC allowed for better selection of men requiring additional treatment at the time of BCR.

TABLE 37 Univariable Multivariable Cox Proportional Cox Proportional Hazard Hazard Hazard Hazard Ratio 95% CI P Ratio 95% CI P GC 1.62 1.33-1.96 <0.001 1.36 1.09-1.68 0.01 Path 2.55 1.14-5.70 0.02 2.7 1.02-7.16 0.05 GS ≥8 Pre-op 1.15 0.74-1.77 0.53 1.06 0.75-1.51 0.73 PSA (log2) SVI 3.05 1.36-6.85 0.01 1.61 0.62-4.21 0.33 SM 0.55 0.25-1.25 0.16 0.63 0.27-1.52 0.31 ECE 3.02 1.31-6.96 0.01 1.47 0.62-3.48 0.38 LNI 5.22  1.93-14.13 0 0.62 0.18-2.15 0.46

TABLE 38 Univariable Cox Multivariable Cox Proportional Proportional Hazard Hazard Hazard Hazard Ratio 95% CI P Ratio 95% CI P GC 1.62 1.33-1.96 <0.001 1.4 1.12-1.75 0 Stephen- 1.51 1.33-1.72 <0.001 1.13 0.92-1.37 0.25 son GC 1.62 1.33-1.96 <0.001 1.44 1.16-1.78 <0.001 CAPRA-S 1.58 1.35-1.85 <0.001 1.11 0.89-1.39 0.34

Example 12: Prognostic Value of Univariable and Pairwise Combination of Prognostic Features from a 43 Biomarker Panel for Prostate Cancer Progression Across Different Endpoints

The 43 biomarkers discovered in Example 2 (Table 2) were assessed for their performance across a range of different metrics and endpoints.

In tables 39 to 48, those biomarkers that were found as univariable classifiers to be statistically significant in the training and testing sets (see Example 1) based on a Wilcoxon test (p-value<=0.05) for the Area under the ROC curve (AUC) metric, are shown for a number of relevant clinical endpoints: Extra Capsular Extension (ECE), Seminal Vesicle Invasion (SVI), Surgical Margin Status (SMS), Lymph Node Involvement (LNI), Biochemical Recurrence Event (BCR), Local Recurrence Event (LCR), Metastasis Event (Mets Event), Prostate Cancer Specific Mortality Event (PCSM), Overall Survival (OS), pathological Gleason (pathGS) and Prostate Specific Antigen Doubling Time (PSADT). Endpoints associated to a time-to-event present also metrics that allow to consider this component in the performance assessment. Whereas results are shown for the testing set (as defined in Example 1), these biomarkers were significant also in the training set of the discovery study.

Further significance of the selected features was evidenced by multiple metrics and are also listed in tables 39 to 48 (either in their raw values or as their associated P-value for assessment of statistical significance) including:

-   -   Sensitivity: proportion of the actual number of patients with         the event that are correctly identified as such. Higher values         indicate better performance.     -   Specificity: proportion of the actual number of patients without         the event that are correctly identified as such. Higher values         indicate better performance.     -   Area under the ROC curve (AUC). Corresponds to the area under         the receiver operating characteristic curve, which plots the         performance of a feature or classifier for all thresholds of         sensitivity and specificity. Higher values indicate better         performance.     -   Accuracy: Proportion of patients correctly predicted. Higher         values indicate better performance.     -   Positive Predictive Value: proportion of predicted events that         are true events. Higher values indicate better performance.     -   Negative Predictive Value: proportion of predicted non-events         that are true non-events. Higher values indicate better         performance.     -   Detection Rate: The portion of true positives from the whole         population. Higher values indicate better performance.     -   Detection Prevalence: The portion of predicted events from the         whole population. Higher values indicate better performance.     -   Median Fold Difference: the ratio of the median expression value         for each group. Values away from 1 indicate better performance.     -   Survival AUC: assesses the discriminatory power of the         classifier across all thresholds of sensitivity and specificity         taking into account the time to event. Higher values indicate         better performance.     -   KM P-value: Kaplan Meier curves are obtained by partitioning the         expression values into low and high risk groups using the PAM         clustering method. A Kaplan Meier curve for one of these groups         shows the probability over time of being free of the event,         given the number of patients at risk and the censored data. The         p-value is computed and measures the significance of the         differences between both groups over time. P-values<=0.05 are         considered significant. Lower values indicate better         performance.     -   Univariable Analysis (UVA) odds ratio: measures the effect size         of the feature or classifier when partitioning the scores into         low and high risk groups. For this metric, these groups are         obtained by partitioning the set of samples into low and high         risk values using the PAM clustering method. Values away from 1         indicate better performance.     -   Multivariable Analysis (MVA) odds ratio: measures the         independent prognostic ability of the feature or classifier when         partitioning the values into low and high risk groups. For this         metric, these groups are obtained by partitioning the set of         samples into low and high risk using the PAM clustering method.         Values away from 1 indicate better performance.     -   UVA hazard ratio: measures the ratio of the hazard rates when         partitioning the values into low and high risk groups and         incorporates the time to event through Cox proportionate hazard         modeling. For this metric, these groups are obtained by         partitioning the scores into low and high risk using the PAM         clustering method. Values away from 1 indicate better         performance.     -   MVA hazard ratio: measures the independent prognostic ability         relative to other variables when partitioning the values into         low and high risk groups and incorporates the time to event         through Cox proportionate hazard modeling. For this metric,         these groups are obtained by partitioning the scores into low         and high risk using the PAM clustering method. Values away from         1 indicate better performance.

The associated p-value provided for the metrics gives a measure of the statistical significance of the corresponding metric. The threshold of P-value<=0.05 is used as a way of defining those features that are statistically significant for the given metric and endpoint. The AUC lower and AUC upper, as well as the Accuracy lower and Accuracy upper, represent the lower and upper bound of the 95% Confidence Interval for those metrics.

TABLE 39 biomarkers from the 43 biomarker panel with significance for Wilcoxon P-value (auc.pvalue) and other metrics for the BCR event endpoint. SEQ auc. Pos.Pred. Neg.Pred. ID NO. auc pvalue Accuracy Sensitivity Specificity Value Value SEQ ID 0.62 0.01 0.61 0.62 0.59 0.77 0.41 NO. 6 SEQ ID 0.60 0.03 0.59 0.63 0.52 0.74 0.38 NO. 22 SEQ ID 0.59 0.04 0.60 0.63 0.53 0.75 0.39 NO. 19 SEQ ID 0.59 0.04 0.59 0.64 0.48 0.73 0.38 NO. 28 SEQ ID 0.61 0.02 0.42 0.45 0.34 0.60 0.22 NO. 16 SEQ ID 0.60 0.03 0.61 0.66 0.50 0.75 0.40 NO. 5 SEQ ID 0.60 0.02 0.48 0.30 0.86 0.83 0.36 NO. 4 SEQ uvaOR KM uvaHRP mvaHRP ID NO. mfd Pval mvaORPval P-value survAUC val val SEQ ID 1.09 0.02 0.06 0.00 0.64 0.00 0.08 NO. 6 SEQ ID 1.15 0.03 0.09 0.03 0.64 0.00 0.01 NO. 22 SEQ ID 1.06 0.13 0.02 0.00 0.65 0.02 0.01 NO. 19 SEQ ID 1.09 0.06 0.02 0.08 0.63 0.01 0.01 NO. 28 SEQ ID 0.97 0.12 0.58 0.01 0.39 0.11 0.86 NO. 16 SEQ ID 1.08 0.05 0.05 0.16 0.54 0.19 0.52 NO. 5 SEQ ID 1.03 0.02 0.06 0.00 0.65 0.00 0.00 NO. 4 Auc. pvalue: Wilcoxon Test P-value. MFD: Median Fold Difference. KM: Kaplan Meier curves. survAUC: survival AUC. uvaORP val: Univariable Analysis Odds Ratio P-value. mvaORP val: multivariable analysis Odds Ratio P-value. uvaHRP val: Univariable Analysis Hazard Ratio P-value. mvaHRP val: Multivariable Analysis Hazard Ratio P-value.

TABLE 40 biomarkers from the 43 biomarker panel with significance for Wilcoxon P-value (auc.pvalue) and other metrics for the ECE endpoint. SEQ ID NO. auc auc.pvalue Accuracy Sensitivity Specificity SEQ ID 0.62 0.01 0.57 0.63 0.52 NO. 6 SEQ ID 0.65 0.00 0.59 0.67 0.51 NO. 22 SEQ ID 0.59 0.04 0.53 0.68 0.39 NO. 15 SEQ ID 0.60 0.02 0.55 0.63 0.47 NO. 19 SEQ ID 0.59 0.03 0.58 0.68 0.47 NO. 28 SEQ ID 0.59 0.03 0.45 0.46 0.43 NO. 16 SEQ ID 0.62 0.00 0.61 0.74 0.49 NO. 17 SEQ ID 0.59 0.04 0.41 0.32 0.49 NO. 10 SEQ ID 0.60 0.02 0.45 0.31 0.58 NO. 37 Pos. Pred. Neg. Pred. SEQ ID NO. Value Value mfd uvaORPval mvaORPval SEQ ID 0.55 0.59 1.08 0.01 0.12 NO. 6 SEQ ID 0.56 0.62 1.20 0.00 0.06 NO. 22 SEQ ID 0.52 0.56 1.04 0.04 0.10 NO. 15 SEQ ID 0.53 0.57 1.07 0.03 0.64 NO. 19 SEQ ID 0.55 0.61 1.10 0.02 0.66 NO. 28 SEQ ID 0.44 0.46 0.97 0.02 0.49 NO. 16 SEQ ID 0.58 0.66 1.06 0.01 0.28 NO. 17 SEQ ID 0.38 0.43 0.90 0.10 0.66 NO. 10 SEQ ID 0.41 0.47 0.94 0.02 0.11 NO. 37 auc.pvalue: Wilcoxon Test P-value. MFD: Median Fold Difference. KM: Kaplan Meier curves. uvaORPval: Univariable Analysis Odds Ratio P-value. mvaORPval: multivariable analysis Odds Ratio P-value.

TABLE 41 biomarkers from the 43 biomarker panel with significance for Wilcoxon P-value (auc.pvalue) and other metrics for the LCR event endpoint. SEQ auc. ID NO. auc pvalue Accuracy Sensitivity Specificity Pos.Pred.Value Neg.Pred.Value SEQ ID 0.76 0.00 0.78 0.67 0.80 0.30 0.95 NO. 4 SEQ ID 0.65 0.02 0.42 0.86 0.37 0.15 0.95 NO. 36 SEQ ID 0.64 0.03 0.54 0.71 0.52 0.16 0.93 NO. 26 SEQ KM P- ID NO. mfd uvaPval mvaPval value survAUC uvaHRPval mvaHRPval SEQ ID 1.19 0.00 0.02 0.00 0.93 0.00 0.00 NO. 4 SEQ ID 1.03 0.14 0.09 0.04 0.77 0.12 0.05 NO. 36 SEQ ID 1.06 0.04 0.03 0.02 0.78 0.02 0.01 NO. 26 auc.pvalue: Wilcoxon Test P-value. mfd: Median Fold Difference. KM: Kaplan Meier curves. survAUC: survival AUC. uvaORPval: Univariable Analysis Odds Ratio P-value. mvaORPval: multivariable analysis Odds Ratio P-value. uvaHRPval: Univariable Analysis Hazard Ratio P-value. mvaHRPval: Multivariable Analysis Hazard Ratio P-value.

TABLE 42 biomarkers from the 43 biomarker panel with significance for Wilcoxon P-value (auc.pvalue) and other metrics for the LNI endpoint. SEQ ID NO. auc auc.pvalue Accuracy Sensitivity Specificity SEQ ID 0.66 0.01 0.49 0.81 0.43 NO. 28 SEQ ID 0.72 0.00 0.59 0.81 0.55 NO. 32 SEQ ID 0.65 0.01 0.47 0.81 0.42 NO. 17 SEQ ID 0.63 0.04 0.54 0.19 0.60 NO. 37 SEQ ID 0.62 0.04 0.31 0.56 0.27 NO. 42 Pos. Pred. Neg. Pred. SEQ ID NO. Value Value mfd uvaORPval mvaORPval SEQ ID 0.20 0.93 1.15 0.01 0.72 NO. 28 SEQ ID 0.23 0.95 1.18 0.00 0.21 NO. 32 SEQ ID 0.19 0.93 1.05 0.02 0.70 NO. 17 SEQ ID 0.07 0.81 0.92 0.07 0.97 NO. 37 SEQ ID 0.11 0.78 0.96 0.03 0.12 NO. 42 auc.pvalue: Wilcoxon Test P-value. MFD: Median Fold Difference. KM: Kaplan Meier curves. uvaORPval: Univariable Analysis Odds Ratio P-value. mvaORPval: multivariable analysis Odds Ratio P-value.

TABLE 43 biomarkers from the 43 biomarker panel with significance for Wilcoxon P-value (auc.pvalue) and other metrics for the MET event endpoint. SEQ ID auc. Pos. Pred. Neg. Pred. NO. auc pvalue Accuracy Sensitivity Specificity Value Value SEQ ID 0.67 0.00 0.61 0.72 0.54 0.48 0.77 NO. 6 SEQ ID 0.66 0.00 0.59 0.74 0.51 0.46 0.77 NO. 22 SEQ ID 0.65 0.00 0.60 0.72 0.53 0.47 0.77 NO. 20 SEQ ID 0.70 0.00 0.59 0.82 0.46 0.47 0.82 NO. 15 SEQ ID 0.67 0.00 0.60 0.74 0.52 0.47 0.77 NO. 19 SEQ ID 0.60 0.03 0.44 0.41 0.45 0.30 0.57 NO. 12 SEQ ID 0.66 0.00 0.58 0.75 0.48 0.46 0.77 NO. 28 SEQ ID 0.61 0.01 0.59 0.63 0.57 0.46 0.73 NO. 32 SEQ ID 0.66 0.00 0.37 0.34 0.38 0.24 0.50 NO. 16 SEQ ID 0.61 0.02 0.55 0.74 0.45 0.43 0.75 NO. 17 SEQ ID 0.61 0.01 0.58 0.47 0.64 0.43 0.68 NO. 18 SEQ ID 0.67 0.00 0.73 0.47 0.87 0.68 0.74 NO. 4 SEQ ID 0.59 0.04 0.40 0.46 0.37 0.30 0.54 NO. 2 SEQ ID 0.64 0.00 0.63 0.56 0.67 0.49 0.72 NO. 24 SEQ ID 0.59 0.03 0.56 0.99 0.59 0.54 0.43 NO. 26 SEQ ID uva mva KM P- surv uva mva NO. mfd ORPval ORPval value AUC HRPval HRPval SEQ ID 1.10 0.00 0.02 0.00 0.75 0.00 0.01 NO. 6 SEQ ID 1.24 0.00 0.04 0.00 0.69 0.00 0.00 NO. 22 SEQ ID 1.07 0.00 0.01 0.00 0.73 0.00 0.00 NO. 20 SEQ ID 1.10 0.00 0.05 0.00 0.74 0.00 0.03 NO. 15 SEQ ID 1.14 0.00 0.01 0.00 0.75 0.00 0.00 NO. 19 SEQ ID 0.96 0.03 0.20 0.03 0.31 0.01 0.01 NO. 12 SEQ ID 1.18 0.00 0.05 0.00 0.67 0.00 0.01 NO. 28 SEQ ID 1.14 0.01 0.15 0.01 0.64 0.00 0.02 NO. 32 SEQ ID 0.95 0.00 0.21 0.00 0.34 0.00 0.06 NO. 16 SEQ ID 1.04 0.01 0.23 0.01 0.67 0.01 0.09 NO. 17 SEQ ID 1.05 0.00 0.06 0.08 0.62 0.00 0.07 NO. 18 SEQ ID 1.09 0.00 0.01 0.00 0.71 0.00 0.00 NO. 4 SEQ ID 0.92 0.04 0.55 0.03 0.39 0.05 0.76 NO. 2 SEQ ID 1.12 0.00 0.00 0.00 0.72 0.00 0.00 NO. 24 SEQ ID 1.02 0.03 0.02 0.04 0.64 0.02 0.02 NO. 26 auc.pvalue: Wilcoxon Test P-value. mfd: Median Fold Difference. KM: Kaplan Meier curves. survAUC: survival AUC. uvaORPval: Univariable Analysis Odds Ratio P-value. mvaORPval: multivariable analysis Odds Ratio P-value. uvaHRPval: Univariable Analysis Hazard Ratio P-value. mvaHRPval: Multivariable Analysis Hazard Ratio P-value.

TABLE 44 biomarkers from the 43 biomarker panel with significance for Wilcoxon P-value (auc.pvalue) and other metrics for the OS event endpoint. SEQ ID auc. Pos.Pred. Neg.Pred. NO. auc pvalue Accuracy Sensitivity Specificity Value Value SEQ ID 0.60 0.02 0.58 0.65 0.50 0.59 0.56 NO. 22 SEQ ID 0.60 0.02 0.54 0.61 0.47 0.56 0.52 NO. 19 SEQ ID 0.59 0.04 0.46 0.59 0.32 0.49 0.41 NO. 9 SEQ ID 0.62 0.00 0.58 0.68 0.45 0.58 0.56 NO. 17 SEQ ID 0.59 0.04 0.54 0.44 0.65 0.58 0.51 NO. 18 SEQ ID 0.65 0.00 0.63 0.39 0.90 0.81 0.57 NO. 4 SEQ ID 0.61 0.01 0.42 0.49 0.35 0.46 0.38 NO. 2 SEQ ID uva mva KM P- surv uva mva NO. mfd ORPval ORPval value AUC HRPval HRPval SEQ ID 1.18 0.02 0.12 0.00 0.61 0.00 0.03 NO. 22 SEQ ID 1.06 0.06 0.40 0.00 0.82 0.00 0.03 NO. 19 SEQ ID 0.96 0.03 0.34 0.66 0.46 0.20 0.32 NO. 9 SEQ ID 1.04 0.01 0.45 0.01 0.63 0.00 0.18 NO. 17 SEQ ID 1.03 0.02 0.23 0.06 0.62 0.01 0.44 NO. 18 SEQ ID 1.04 0.00 0.03 0.00 0.64 0.00 0.05 NO. 4 SEQ ID 0.92 0.01 0.81 0.13 0.47 0.20 0.93 NO. 2 auc.pvalue: Wilcoxon Test P-value. mfd: Median Fold Difference. KM: Kaplan Meier curves. survAUC: survival AUC. uvaORPval: Univariable Analysis Odds Ratio P-value. mvaORPval: multivariable analysis Odds Ratio P-value. uvaHRPval: Univariable Analysis Hazard Ratio P-value. mvaHRPval: Multivariable Analysis Hazard Ratio P-value.

TABLE 45 biomarkers from the 43 biomarker panel with significance for Wilcoxon P-value (auc.pvalue) and other metrics for the pathological Gleason endpoint. SEQ ID NO. auc auc.pvalue Accuracy Sensitivity SEQ ID 0.74 0.00 0.52 0.41 NO. 6 SEQ ID 0.67 0.02 0.62 0.63 NO. 22 SEQ ID 0.81 0.00 0.71 0.66 NO. 20 SEQ ID 0.79 0.00 0.70 0.65 NO. 15 SEQ ID 0.80 0.00 0.70 0.63 NO. 19 SEQ ID 0.69 0.01 0.34 0.34 NO. 12 SEQ ID 0.83 0.00 0.70 0.66 NO. 28 SEQ ID 0.77 0.00 0.39 0.46 NO. 16 SEQ ID 0.65 0.05 0.58 0.66 NO. 9 SEQ ID 0.74 0.00 0.73 0.73 NO. 17 SEQ ID 0.72 0.00 0.60 0.54 NO. 18 SEQ ID 0.69 0.01 0.44 0.30 NO. 4 SEQ ID 0.68 0.02 0.53 0.45 NO. 24 SEQ ID 0.69 0.01 0.55 0.68 NO. 40 SEQ ID 0.69 0.01 0.66 0.66 NO. 26 SEQ ID Pos.Pred. Neg.Pred. NO. Specificity Value Value mfd uvaORPval SEQ ID 0.94 0.97 0.29 1.21 0.00 NO. 6 SEQ ID 0.56 0.85 0.28 1.29 0.03 NO. 22 SEQ ID 0.89 0.96 0.40 1.13 0.00 NO. 20 SEQ ID 0.89 0.96 0.39 1.18 0.00 NO. 15 SEQ ID 0.94 0.98 0.40 1.25 0.00 NO. 19 SEQ ID 0.33 0.67 0.11 0.89 0.01 NO. 12 SEQ ID 0.83 0.94 0.38 1.62 0.00 NO. 28 SEQ ID 0.11 0.67 0.05 0.91 0.00 NO. 16 SEQ ID 0.28 0.78 0.17 0.92 0.05 NO. 9 SEQ ID 0.72 0.91 0.41 1.17 0.00 NO. 17 SEQ ID 0.83 0.93 0.31 1.17 0.02 NO. 18 SEQ ID 1.00 1.00 0.26 1.05 0.01 NO. 4 SEQ ID 0.83 0.91 0.28 1.20 0.04 NO. 24 SEQ ID 0.06 0.74 0.04 0.97 0.02 NO. 40 SEQ ID 0.67 0.89 0.33 1.08 0.03 NO. 26 auc.pvalue: Wilcoxon Test P-value. mfd: Median Fold Difference. uvaORPval: Univariable Analysis Odds Ratio P-value.

TABLE 46 biomarkers from the 43 biomarker panel with significance for Wilcoxon P-value (auc.pvalue) and other metrics for the PCSM event endpoint. SEQ ID auc. Pos.Pred. Neg.Pred. NO. auc pvalue Accuracy Sensitivity Specificity Value Value SEQ ID 0.72 0.00 0.56 0.81 0.51 0.28 0.92 NO. 6 SEQ ID 0.71 0.00 0.55 0.83 0.48 0.28 0.92 NO. 22 SEQ ID 0.71 0.00 0.54 0.78 0.49 0.27 0.90 NO. 20 SEQ ID 0.67 0.00 0.49 0.86 0.41 0.26 0.92 NO. 15 SEQ ID 0.73 0.00 0.54 0.81 0.48 0.27 0.91 NO. 19 SEQ ID 0.68 0 00 0.40 0.25 0.44 0.10 0.71 NO. 12 SEQ ID 0.74 0.00 0.57 0.94 0.48 0.30 0.97 NO. 28 SEQ ID 0.61 0.03 0.52 0.69 0.47 0.24 0.87 NO. 43 SEQ ID 0.66 0.00 0.58 0.72 0.55 0.28 0.89 NO. 32 SEQ ID 0.70 0.00 0.39 0.25 0.42 0.09 0.70 NO. 16 SEQ ID 0.61 0.05 0.48 0.75 0.41 0.23 0.87 NO. 17 SEQ ID 0.66 0.00 0.65 0.61 0.65 0.30 0.88 NO. 18 SEQ ID 0.72 0.00 0.78 0.58 0.83 0.45 0.89 NO. 4 SEQ ID 0.70 0.00 0.63 0.61 0.63 0.29 0.87 NO. 24 SEQ ID 0.61 0.03 0.35 0.53 0.31 0.16 0.73 NO. 40 SEQ ID 0.66 0.00 0.59 0.75 0.55 0.29 0.90 NO. 26 uva mva OR OR KM P- surv uva mva SEQ ID NO. mfd Pval Pval value AUC HRPval HRPval SEQ ID 1.16 0.00 0.04 0.00 0.79 0.00 0.02 NO. 6 SEQ ID 1.26 0.00 0.05 0.00 0.73 0.00 0.05 NO. 22 SEQ ID 1.12 0.00 0.01 0.00 0.82 0.00 0.00 NO. 20 SEQ ID 1.07 0.00 0.23 0.00 0.63 0.00 0.33 NO. 15 SEQ ID 1.18 0.00 0.03 0.00 0.87 0.00 0.01 NO. 19 SEQ ID 0.92 0.00 0.19 0.00 0.29 0.00 0.01 NO. 12 SEQ ID 1.21 0.00 0.01 0.00 0.76 0.00 0.00 NO. 28 SEQ ID 1.01 0.02 0.01 0.11 0.44 0.03 0.07 NO. 43 SEQ ID 1.14 0.00 0.29 0.00 0.75 0.00 0.21 NO. 32 SEQ ID 0.93 0.00 0.24 0.00 0.40 0.00 0.04 NO. 16 SEQ ID 1.05 0.06 0.80 0.04 0.58 0.03 0.46 NO. 17 SEQ ID 1.11 0.00 0.05 0.00 0.73 0.00 0.18 NO. 18 SEQ ID 1.17 0.00 0.02 0.00 0.77 0.00 0.03 NO. 4 SEQ ID 1.20 0.00 0.01 0.00 0.87 0.00 0.00 NO. 24 SEQ ID 0.98 0.03 0.71 0.11 0.47 0.04 0.89 NO. 40 SEQ ID 1.05 0.01 0.06 0.00 0.71 0.00 0.12 NO. 26 auc.pvalue: Wilcoxon Test P-value. mfd: Median Fold Difference. KM: Kaplan Meier curves. survAUC: survival AUC. uvaORPval: Univariable Analysis Odds Ratio P-value. mvaORPval: multivariable analysis Odds Ratio P-value. uvaHRPval: Univariable Analysis Hazard Ratio P-value. mvaHRPval: Multivariable Analysis Hazard Ratio P-value.

TABLE 47 biomarkers from the 43 biomarker panel with significance for Wilcoxon P-value (auc.pvalue) and other metrics for the psaDT endpoint. Pos. Neg. uva mva SEQ ID auc. Pred. Pred. OR OR NO. auc pvalue Accuracy Sensitivity Specificity Value Value mfd Pval Pval SEQ ID 0.62 0.02 0.43 0.52 0.38 0.32 0.58 0.97 0.01 0.07 NO. 6 SEQ ID 0.62 0.03 0.40 0.43 0.38 0.28 0.54 0.83 0.01 0.30 NO. 28 SEQ ID 0.62 0.02 0.56 0.57 0.56 0.42 0.70 1.04 0.04 0.02 NO. 16 auc.pvalue: Wilcoxon Test P-value. mfd: Median Fold Difference. uvaORPval: Univariable Analysis Odds Ratio P-value. mvaORPval: multivariable analysis Odds Ratio P-value.

TABLE 48 biomarkers from the 43 biomarker panel with significance for Wilcoxon P-value (auc.pvalue) and other metrics for the SVI endpoint. uva SEQ ID auc. Pos.Pred. Neg.Pred. ORP mvaOR NO. auc pvalue Accuracy Sensitivity Specificity Value Value mfd val Pval SEQ ID 0.63 0.00 0.56 0.67 0.51 0.43 0.73 1.08 0.00 0.08 NO. 6 SEQ ID 0.60 0.03 0.53 0.65 0.46 0.40 0.71 1.08 0.02 0.15 NO. 22 SEQ ID 0.64 0.00 0.56 0.70 0.49 0.43 0.75 1.09 0.00 0.04 NO. 19 SEQ ID 0.67 0.00 0.58 0.77 0.47 0.44 0.79 1.06 0.00 0.02 NO. 17 SEQ ID 0.61 0.01 0.63 0.55 0.68 0.49 0.73 1.10 0.04 0.08 NO. 18 SEQ ID 0.69 0.00 0.68 0.41 0.83 0.57 0.72 1.09 0.00 0.02 NO. 4 SEQ ID 0.61 0.01 0.59 0.64 0.57 0.45 0.74 1.04 0.07 0.09 NO. 26 auc.pvalue: Wilcoxon Test P-value. mfd: Median Fold Difference. uvaORPval: Univariable Analysis Odds Ratio P-value. mvaORPval: multivariable analysis Odds Ratio P-value.

In addition to the good performance of these variables as univariable predictors, the combination of them in pairs (pairwise classifiers) through a machine learning algorithm results in enhanced performance. As shown in Tables 49 to 52, pairwise classifiers can result in an improved performance for a given endpoint compared to their univariable counterparts, with all the classifiers listed presenting statistical significance based on, at least, Wilcoxon P-value. In those tables, each classifier name is described by the machine learning algorithm that combines the biomarkers as well as the SEQ ID NO of the corresponding biomarkers (Table 2, Table 11). The machine learning algorithms included in this analysis are Naïve Bayes (NB), recursive Partitioning (Rpart), Support Vector Machines (SVMs), Random Forest (RF) and K Nearest Neighbors (KNN). These machine learning algorithms were executed with default parameters using packages rpart 4.1-0, HDclassif 1.2.2, randomForest 4.6-7, caret 5.15-61, cluster 1.14.3, e1071 1.6-1, class 7.3-5 in R. Tables 49 to 52 contain metrics and endpoints described above for tables 39 to 48.

TABLE 49 pairwise biomarkers from the 43 biomarker panel with significance for Wilcoxon P-value (auc.pvalue <= 0.05) and other metrics for the BCR event endpoint. Pos. Neg. auc. Pred. Pred. KM P- Mva Classifier auc pvalue Sensitivity Specificity Value Value value HRPval svm~5 + 6 0.68 0.00 0.42 0.78 0.81 0.38 0.01 0.03 knn~5 + 19 0.67 0.00 0.59 0.69 0.81 0.43 0.00 0.00 rpart~4 + 39 0.66 0.00 0.42 0.81 0.83 0.39 0.00 0.00 nb~13 + 6 0.67 0.00 0.50 0.84 0.88 0.43 0.00 0.03 rpart~40 + 19 0.66 0.00 0.76 0.38 0.73 0.42 0.03 0.12 svm~16 + 5 0.65 0.00 0.58 0.71 0.81 0.43 0.00 0.50 rf~4 + 39 0.65 0.00 0.57 0.67 0.79 0.41 0.00 0.00 rpart~4 + 1 0.64 0.00 0.60 0.62 0.78 0.41 0.00 0.03 rpart~13 + 6 0.64 0.00 0.50 0.79 0.84 0.42 0.00 0.07 svm~16 + 6 0.65 0.00 0.48 0.72 0.79 0.39 0.00 0.05 nb~4 + 16 0.65 0.00 0.30 0.88 0.84 0.36 0.00 0.01 nb~4 + 13 0.65 0.00 0.26 0.91 0.87 0.36 0.00 0.00 svm~4 + 39 0.65 0.00 0.45 0.81 0.84 0.40 0.00 0.00 knn~18 + 28 0.64 0.00 0.68 0.50 0.75 0.41 0.01 0.11 nb~9 + 6 0.65 0.00 0.54 0.66 0.78 0.39 0.00 0.15 nb~4 + 1 0.64 0.00 0.35 0.86 0.85 0.38 0.00 0.00 rpart~18 + 13 0.64 0.00 0.52 0.67 0.78 0.39 0.01 0.89 svm~4 + 16 0.64 0.00 0.40 0.76 0.78 0.36 0.01 0.02 nb~18 + 13 0.64 0.00 0.57 0.64 0.78 0.40 0.01 0.21 rf~13 + 6 0.64 0.00 0.56 0.66 0.78 0.40 0.00 0.25 svm~4 + 24 0.64 0.00 0.29 0.86 0.82 0.35 0.00 0.00 svm~4 + 6 0.64 0.00 0.40 0.79 0.81 0.37 0.00 0.05 rpart~13 + 26 0.64 0.00 0.38 0.83 0.83 0.38 0.00 0.01 nb~1 + 6 0.64 0.00 0.37 0.78 0.78 0.36 0.04 0.03 knn~18 + 10 0.64 0.00 0.69 0.45 0.73 0.39 0.05 0.52 nb~4 + 32 0.64 0.00 0.32 0.86 0.84 0.36 0.00 0.00 rf~19 + 3 0.64 0.00 0.54 0.71 0.80 0.41 0.00 0.00 knn~13 + 22 0.64 0.00 0.73 0.43 0.74 0.42 0.01 0.10 nb~13 + 19 0.64 0.00 0.63 0.62 0.79 0.43 0.00 0.00 rpart~5 + 28 0.63 0.00 0.57 0.62 0.77 0.40 0.01 0.23 rpart~24 + 22 0.63 0.00 0.41 0.81 0.83 0.38 0.00 0.00 svm~5 + 28 0.64 0.00 0.49 0.72 0.80 0.39 0.01 0.29 svm~15 + 5 0.64 0.00 0.31 0.84 0.82 0.36 0.03 0.22 nb~5 + 6 0.64 0.00 0.36 0.81 0.81 0.36 0.01 0.05 rpart~13 + 20 0.64 0.00 0.54 0.62 0.76 0.38 0.06 0.01 svm~5 + 19 0.64 0.00 0.57 0.64 0.78 0.40 0.01 0.04 knn~5 + 22 0.63 0.00 0.54 0.71 0.80 0.41 0.00 0.03 knn~18 + 13 0.63 0.00 0.71 0.43 0.73 0.40 0.06 0.27 svm~13 + 6 0.64 0.00 0.47 0.79 0.83 0.40 0.00 0.10 rf~4 + 19 0.64 0.00 0.50 0.74 0.81 0.40 0.00 0.00 nb~16 + 5 0.64 0.00 0.61 0.62 0.78 0.42 0.02 0.33 knn~4 + 19 0.63 0.00 0.51 0.76 0.82 0.41 0.00 0.02 nb~16 + 6 0.64 0.00 0.44 0.78 0.81 0.38 0.00 0.07 nb~4 + 6 0.64 0.00 0.36 0.83 0.82 0.37 0.00 0.01 svm~4 + 5 0.64 0.00 0.55 0.67 0.79 0.40 0.01 0.27 rf~13 + 22 0.63 0.00 0.60 0.66 0.79 0.43 0.00 0.08 rpart~4 + 32 0.63 0.00 0.41 0.76 0.79 0.37 0.01 0.00 knn~4 + 39 0.63 0.00 0.70 0.47 0.74 0.42 0.01 0.00 rf~18 + 8 0.63 0.00 0.55 0.67 0.79 0.41 0.01 0.36 knn~4 + 22 0.63 0.00 0.67 0.55 0.77 0.43 0.00 0.02 rpart~11 + 5 0.63 0.00 0.41 0.78 0.80 0.37 0.07 0.09 rpart~9 + 6 0.63 0.00 0.50 0.74 0.81 0.40 0.00 0.27 knn~17 + 5 0.63 0.00 0.53 0.69 0.79 0.40 0.01 0.06 rpart~29 + 22 0.63 0.00 0.54 0.64 0.77 0.39 0.01 0.02 svm~16 + 18 0.63 0.00 0.41 0.72 0.76 0.36 0.06 0.22 knn~8 + 22 0.63 0.00 0.48 0.72 0.79 0.39 0.00 0.07 nb~4 + 28 0.63 0.00 0.34 0.83 0.81 0.36 0.00 0.00 svm~15 + 19 0.63 0.00 0.30 0.86 0.83 0.36 0.01 0.08 nb~13 + 22 0.63 0.00 0.48 0.72 0.79 0.39 0.01 0.01 rf~7 + 19 0.63 0.00 0.63 0.62 0.79 0.43 0.00 0.98 knn~4 + 9 0.63 0.00 0.44 0.76 0.80 0.38 0.00 0.01 rf~4 + 38 0.63 0.00 0.44 0.76 0.80 0.38 0.00 0.33 svm~9 + 6 0.63 0.00 0.44 0.72 0.78 0.37 0.01 0.40 rf~16 + 18 0.63 0.00 0.51 0.72 0.80 0.40 0.01 0.12 rf~42 + 19 0.63 0.00 0.57 0.66 0.78 0.41 0.00 0.00 rpart~18 + 32 0.63 0.00 0.49 0.67 0.77 0.38 0.02 0.07 knn~29 + 18 0.63 0.00 0.45 0.76 0.81 0.39 0.01 0.57 rf~12 + 38 0.63 0.01 0.45 0.74 0.79 0.38 0.02 0.36 rf~4 + 8 0.63 0.01 0.65 0.55 0.76 0.42 0.00 0.02 knn~11 + 5 0.62 0.01 0.72 0.45 0.74 0.42 0.05 0.42 rf~4 + 1 0.63 0.01 0.52 0.67 0.78 0.39 0.01 0.07 rf~16 + 39 0.63 0.01 0.49 0.69 0.78 0.38 0.01 0.74 nb~33 + 6 0.63 0.01 0.41 0.79 0.82 0.38 0.01 0.21 nb~32 + 6 0.63 0.01 0.31 0.90 0.87 0.37 0.00 0.04 svm~13 + 28 0.63 0.01 0.47 0.72 0.79 0.38 0.01 0.00 svm~1 + 6 0.63 0.01 0.41 0.72 0.76 0.36 0.03 0.07 svm~9 + 19 0.63 0.01 0.54 0.64 0.77 0.39 0.01 0.05 knn~5 + 6 0.62 0.01 0.51 0.76 0.82 0.41 0.00 0.20 nb~28 + 6 0.63 0.01 0.46 0.76 0.81 0.39 0.00 0.01 rpart~4 + 31 0.62 0.01 0.49 0.74 0.81 0.40 0.00 0.00 knn~16 + 39 0.62 0.01 0.71 0.38 0.72 0.37 0.23 0.62 svm~5 + 32 0.63 0.01 0.42 0.78 0.81 0.38 0.05 0.29 rpart~4 + 18 0.62 0.01 0.44 0.71 0.77 0.36 0.01 0.33 rpart~16 + 20 0.62 0.01 0.60 0.60 0.77 0.41 0.00 0.04 knn~32 + 6 0.62 0.01 0.46 0.72 0.79 0.38 0.01 0.02 svm~4 + 15 0.63 0.01 0.26 0.84 0.79 0.34 0.01 0.01 nb~7 + 6 0.62 0.01 0.45 0.78 0.82 0.39 0.00 0.54 knn~18 + 6 0.62 0.01 0.41 0.79 0.82 0.38 0.01 0.58 knn~39 + 22 0.62 0.01 0.53 0.67 0.78 0.39 0.00 0.06 rf~18 + 13 0.62 0.01 0.55 0.64 0.77 0.39 0.02 0.30 rpart~20 + 6 0.62 0.01 0.49 0.66 0.76 0.37 0.02 0.04 svm~19 + 28 0.62 0.01 0.43 0.76 0.80 0.38 0.01 0.01 svm~19 + 6 0.62 0.01 0.44 0.74 0.79 0.37 0.00 0.01 knn~12 + 22 0.62 0.01 0.45 0.76 0.81 0.39 0.00 0.00 knn~20 + 6 0.62 0.01 0.59 0.55 0.75 0.38 0.03 0.03 nb~1 + 22 0.62 0.01 0.49 0.59 0.72 0.34 0.31 0.01 nb~15 + 13 0.62 0.01 0.45 0.72 0.78 0.37 0.03 0.42 nb~16 + 18 0.62 0.01 0.50 0.67 0.77 0.38 0.02 0.27 nb~4 + 9 0.62 0.01 0.37 0.86 0.85 0.38 0.00 0.04 nb~9 + 22 0.62 0.01 0.41 0.74 0.78 0.36 0.03 0.12 svm~18 + 6 0.62 0.01 0.38 0.78 0.79 0.36 0.01 0.09 knn~4 + 16 0.62 0.01 0.54 0.66 0.78 0.39 0.01 0.01 rf~18 + 9 0.62 0.01 0.48 0.69 0.77 0.37 0.05 0.27 nb~5 + 19 0.62 0.01 0.61 0.53 0.74 0.38 0.09 0.05 svm~4 + 41 0.62 0.01 0.27 0.88 0.83 0.35 0.00 0.03 nb~4 + 36 0.62 0.01 0.22 0.88 0.80 0.34 0.01 0.01 nb~4 + 5 0.62 0.01 0.36 0.84 0.84 0.37 0.00 0.02 svm~24 + 6 0.62 0.01 0.34 0.83 0.81 0.36 0.00 0.09 nb~36 + 6 0.62 0.01 0.40 0.81 0.82 0.38 0.00 0.05 rpart~4 + 28 0.62 0.01 0.39 0.79 0.81 0.37 0.00 0.04 svm~5 + 22 0.62 0.01 0.48 0.71 0.78 0.38 0.03 0.01 rpart~39 + 18 0.61 0.01 0.45 0.71 0.77 0.37 0.02 0.52 rf~4 + 31 0.62 0.01 0.47 0.72 0.79 0.38 0.01 0.02 svm~28 + 6 0.62 0.01 0.41 0.74 0.78 0.36 0.01 0.01 rpart~18 + 22 0.61 0.01 0.37 0.84 0.84 0.38 0.00 0.32 nb~4 + 22 0.62 0.01 0.38 0.84 0.84 0.38 0.00 0.00 nb~4 + 24 0.62 0.01 0.26 0.90 0.85 0.35 0.00 0.00 nb~8 + 6 0.62 0.01 0.41 0.81 0.83 0.38 0.01 0.24 nb~13 + 32 0.62 0.01 0.50 0.67 0.77 0.38 0.06 0.02 rpart~13 + 22 0.62 0.01 0.59 0.59 0.76 0.40 0.01 0.11 rpart~16 + 28 0.62 0.01 0.45 0.71 0.77 0.37 0.05 0.06 rf~29 + 22 0.62 0.01 0.56 0.67 0.79 0.41 0.00 0.06 rpart~4 + 16 0.62 0.01 0.46 0.74 0.80 0.38 0.00 0.00 rf~1 + 22 0.62 0.01 0.54 0.66 0.78 0.39 0.01 0.16 svm~4 + 19 0.62 0.01 0.49 0.76 0.82 0.40 0.00 0.00 nb~18 + 6 0.62 0.01 0.44 0.74 0.79 0.37 0.00 0.04 nb~5 + 22 0.62 0.01 0.52 0.66 0.77 0.38 0.02 0.02 knn~10 + 22 0.62 0.01 0.73 0.45 0.75 0.43 0.01 0.61 rpart~4 + 8 0.62 0.01 0.50 0.69 0.78 0.38 0.01 0.14 nb~16 + 13 0.62 0.01 0.42 0.69 0.75 0.35 0.21 0.64 nb~4 + 33 0.62 0.01 0.29 0.91 0.88 0.37 0.00 0.05 rf~13 + 26 0.62 0.01 0.45 0.67 0.75 0.36 0.03 0.46 svm~18 + 8 0.62 0.01 0.48 0.69 0.78 0.38 0.03 0.44 rf~7 + 18 0.62 0.01 0.55 0.55 0.73 0.36 0.20 0.52 svm~38 + 6 0.62 0.01 0.46 0.76 0.81 0.39 0.00 0.18 nb~25 + 6 0.62 0.01 0.41 0.84 0.85 0.39 0.00 0.03 svm~32 + 6 0.62 0.01 0.36 0.81 0.81 0.36 0.00 0.02 svm~16 + 13 0.62 0.01 0.40 0.69 0.74 0.34 0.36 0.81 svm~4 + 9 0.62 0.01 0.39 0.79 0.81 0.37 0.00 0.15 svm~7 + 6 0.62 0.01 0.52 0.71 0.80 0.40 0.00 0.42 knn~15 + 41 0.61 0.01 0.56 0.64 0.77 0.40 0.02 0.46 rf~18 + 28 0.62 0.01 0.56 0.64 0.77 0.40 0.00 0.06 rpart~18 + 19 0.61 0.01 0.59 0.60 0.77 0.40 0.00 0.03 nb~4 + 7 0.62 0.01 0.36 0.79 0.79 0.36 0.02 0.25 svm~18 + 13 0.62 0.01 0.47 0.69 0.77 0.37 0.01 0.08 rpart~21 + 22 0.61 0.01 0.46 0.66 0.75 0.36 0.08 0.52 nb~37 + 6 0.62 0.01 0.48 0.72 0.79 0.39 0.00 0.21 rf~18 + 38 0.62 0.01 0.45 0.79 0.83 0.39 0.00 0.72 rf~8 + 22 0.62 0.01 0.54 0.64 0.77 0.39 0.01 0.21 nb~4 + 2 0.62 0.01 0.40 0.74 0.77 0.36 0.04 0.53 svm~39 + 32 0.62 0.01 0.32 0.86 0.84 0.36 0.02 0.01 knn~16 + 38 0.61 0.01 0.77 0.45 0.75 0.46 0.00 0.97 nb~2 + 6 0.62 0.01 0.46 0.74 0.80 0.38 0.01 0.99 rf~4 + 12 0.62 0.01 0.52 0.60 0.74 0.36 0.07 0.03 svm~4 + 13 0.62 0.01 0.33 0.90 0.88 0.38 0.00 0.00 nb~5 + 32 0.62 0.01 0.58 0.62 0.77 0.40 0.07 0.08 knn~12 + 16 0.61 0.01 0.43 0.78 0.81 0.38 0.00 0.04 knn~4 + 6 0.61 0.01 0.42 0.76 0.79 0.37 0.01 0.01 rf~9 + 19 0.62 0.01 0.58 0.64 0.78 0.41 0.00 0.00 rf~18 + 6 0.62 0.01 0.49 0.64 0.75 0.36 0.09 0.48 nb~4 + 8 0.62 0.01 0.25 0.90 0.84 0.35 0.00 0.02 svm~12 + 6 0.62 0.01 0.45 0.76 0.81 0.39 0.00 0.02 rpart~1 + 18 0.61 0.01 0.31 0.84 0.82 0.36 0.05 0.62 rpart~18 + 28 0.61 0.01 0.41 0.79 0.82 0.38 0.00 0.25 nb~19 + 6 0.62 0.01 0.38 0.79 0.80 0.37 0.01 0.01 nb~13 + 28 0.62 0.01 0.43 0.74 0.79 0.37 0.02 0.00 rpart~41 + 18 0.61 0.01 0.45 0.74 0.79 0.38 0.00 0.55 rpart~18 + 21 0.61 0.01 0.55 0.60 0.76 0.38 0.03 0.89 rf~4 + 34 0.61 0.01 0.68 0.47 0.74 0.40 0.04 0.03 nb~22 + 6 0.61 0.01 0.46 0.74 0.80 0.38 0.00 0.02 rf~12 + 31 0.61 0.01 0.53 0.57 0.73 0.35 0.03 0.05 knn~4 + 12 0.61 0.01 0.27 0.79 0.74 0.33 0.12 0.06 knn~4 + 5 0.61 0.01 0.72 0.43 0.74 0.41 0.07 0.34 rpart~4 + 42 0.61 0.01 0.55 0.66 0.78 0.40 0.01 0.62 svm~13 + 19 0.61 0.01 0.62 0.55 0.75 0.40 0.02 0.06 nb~16 + 38 0.61 0.01 0.36 0.69 0.72 0.33 0.58 0.41 nb~24 + 6 0.61 0.01 0.27 0.84 0.79 0.34 0.04 0.02 knn~16 + 6 0.61 0.01 0.45 0.71 0.77 0.37 0.04 0.49 nb~15 + 6 0.61 0.01 0.30 0.86 0.83 0.36 0.00 0.07 nb~15 + 5 0.61 0.01 0.55 0.71 0.81 0.42 0.00 0.43 svm~31 + 6 0.61 0.01 0.46 0.69 0.77 0.37 0.05 0.07 nb~5 + 28 0.61 0.01 0.49 0.72 0.80 0.39 0.01 0.05 rpart~39 + 22 0.61 0.01 0.53 0.62 0.76 0.38 0.03 0.01 nb~4 + 19 0.61 0.01 0.36 0.84 0.84 0.37 0.00 0.00 rf~4 + 16 0.61 0.01 0.55 0.60 0.76 0.38 0.05 0.00 nb~7 + 22 0.61 0.01 0.51 0.67 0.77 0.38 0.02 0.57 rpart~1 + 28 0.61 0.01 0.45 0.69 0.76 0.36 0.03 0.22 rpart~15 + 33 0.61 0.01 0.27 0.93 0.89 0.36 0.00 0.03 rf~35 + 5 0.61 0.01 0.58 0.59 0.76 0.39 0.09 0.83 rpart~8 + 6 0.61 0.01 0.45 0.78 0.82 0.39 0.00 0.25 rpart~18 + 26 0.61 0.01 0.26 0.83 0.77 0.34 0.08 0.38 svm~8 + 6 0.61 0.01 0.46 0.76 0.81 0.39 0.00 0.54 knn~9 + 22 0.61 0.01 0.45 0.71 0.77 0.37 0.02 0.15 rf~5 + 19 0.61 0.01 0.55 0.62 0.76 0.38 0.03 0.03 rpart~2 + 19 0.61 0.01 0.71 0.36 0.71 0.36 0.30 0.34 nb~16 + 22 0.61 0.01 0.45 0.69 0.76 0.36 0.05 0.02 nb~35 + 6 0.61 0.01 0.38 0.78 0.79 0.36 0.02 0.17 svm~4 + 7 0.61 0.01 0.44 0.78 0.81 0.38 0.00 0.38 svm~15 + 6 0.61 0.01 0.37 0.81 0.81 0.37 0.00 0.08 knn~9 + 19 0.61 0.01 0.59 0.62 0.77 0.40 0.01 0.06 rf~18 + 22 0.61 0.01 0.50 0.64 0.75 0.37 0.06 0.03 nb~1 + 28 0.61 0.01 0.41 0.74 0.78 0.36 0.03 0.00 nb~18 + 9 0.61 0.01 0.52 0.64 0.76 0.37 0.02 0.81 knn~16 + 28 0.61 0.01 0.77 0.41 0.74 0.44 0.00 0.03 nb~11 + 6 0.61 0.01 0.31 0.90 0.87 0.37 0.00 0.07 svm~21 + 6 0.61 0.01 0.45 0.71 0.77 0.37 0.02 0.58 nb~4 + 18 0.61 0.02 0.37 0.78 0.78 0.36 0.01 0.01 rf~4 + 7 0.61 0.02 0.51 0.64 0.76 0.37 0.05 0.45 svm~13 + 22 0.61 0.02 0.49 0.71 0.79 0.39 0.00 0.16 nb~4 + 38 0.61 0.02 0.38 0.74 0.76 0.35 0.07 0.67 rf~26 + 22 0.61 0.02 0.49 0.69 0.78 0.38 0.00 0.04 svm~41 + 6 0.61 0.02 0.49 0.71 0.79 0.39 0.01 0.07 rf~39 + 32 0.61 0.02 0.59 0.60 0.77 0.40 0.01 0.00 knn~29 + 6 0.61 0.02 0.44 0.72 0.78 0.37 0.02 0.04 rpart~33 + 9 0.59 0.02 0.45 0.74 0.79 0.38 0.00 0.01 svm~19 + 38 0.61 0.02 0.49 0.69 0.78 0.38 0.01 0.09 rf~7 + 6 0.61 0.02 0.58 0.62 0.77 0.40 0.02 0.92 svm~4 + 1 0.61 0.02 0.31 0.84 0.82 0.36 0.02 0.01 svm~26 + 19 0.61 0.02 0.37 0.79 0.80 0.36 0.01 0.03 nb~13 + 20 0.61 0.02 0.52 0.62 0.75 0.37 0.03 0.03 nb~41 + 6 0.61 0.02 0.33 0.83 0.81 0.36 0.01 0.11 rf~1 + 18 0.61 0.02 0.64 0.53 0.75 0.40 0.09 0.72 rpart~15 + 3 0.61 0.02 0.34 0.76 0.75 0.34 0.27 0.10 svm~4 + 28 0.61 0.02 0.38 0.78 0.79 0.36 0.01 0.00 nb~34 + 6 0.61 0.02 0.43 0.76 0.80 0.38 0.01 0.19 nb~32 + 22 0.61 0.02 0.48 0.64 0.74 0.36 0.09 0.01 nb~4 + 41 0.61 0.02 0.31 0.83 0.80 0.35 0.01 0.03 rf~5 + 22 0.61 0.02 0.59 0.59 0.76 0.39 0.07 0.05 nb~10 + 6 0.61 0.02 0.30 0.86 0.83 0.36 0.01 0.23 svm~3 + 28 0.61 0.02 0.26 0.84 0.79 0.34 0.04 0.01 knn~40 + 28 0.61 0.02 0.37 0.86 0.85 0.38 0.00 0.25 nb~1 + 18 0.61 0.02 0.34 0.74 0.75 0.34 0.25 0.17 nb~18 + 22 0.61 0.02 0.55 0.66 0.78 0.40 0.00 0.01 knn~37 + 6 0.61 0.02 0.65 0.43 0.72 0.36 0.22 0.63 svm~9 + 22 0.61 0.02 0.38 0.78 0.79 0.36 0.01 0.29 svm~16 + 38 0.61 0.02 0.36 0.74 0.75 0.34 0.18 0.40 nb~13 + 26 0.61 0.02 0.61 0.52 0.74 0.38 0.12 0.10 knn~13 + 6 0.61 0.02 0.67 0.50 0.75 0.41 0.02 0.31 svm~7 + 22 0.61 0.02 0.52 0.67 0.78 0.39 0.01 0.66 nb~4 + 20 0.61 0.02 0.41 0.76 0.79 0.37 0.00 0.01 svm~34 + 6 0.61 0.02 0.51 0.64 0.76 0.37 0.02 0.16 nb~1 + 16 0.61 0.02 0.37 0.72 0.75 0.34 0.44 0.51 rf~4 + 9 0.61 0.02 0.48 0.66 0.75 0.36 0.02 0.03 rpart~12 + 5 0.60 0.02 0.49 0.71 0.79 0.39 0.02 0.50 rpart~18 + 8 0.60 0.02 0.48 0.74 0.81 0.39 0.00 0.86 svm~2 + 6 0.61 0.02 0.52 0.64 0.76 0.38 0.02 0.98 rpart~9 + 19 0.60 0.02 0.59 0.59 0.76 0.39 0.01 0.02 svm~4 + 8 0.61 0.02 0.31 0.81 0.78 0.35 0.03 0.04 rpart~31 + 22 0.60 0.02 0.45 0.72 0.78 0.38 0.01 0.03 nb~4 + 15 0.61 0.02 0.32 0.83 0.80 0.36 0.00 0.01 svm~10 + 6 0.61 0.02 0.36 0.81 0.81 0.36 0.00 0.18 nb~18 + 32 0.61 0.02 0.41 0.72 0.77 0.36 0.02 0.02 svm~4 + 38 0.61 0.02 0.35 0.78 0.78 0.35 0.02 0.16 nb~4 + 25 0.61 0.02 0.38 0.83 0.83 0.38 0.00 0.00 knn~30 + 6 0.60 0.02 0.50 0.62 0.74 0.36 0.12 0.14 nb~15 + 16 0.61 0.02 0.33 0.71 0.71 0.32 0.56 0.59 svm~2 + 28 0.61 0.02 0.52 0.59 0.74 0.36 0.07 0.21 rpart~4 + 5 0.60 0.02 0.48 0.66 0.76 0.37 0.13 0.91 nb~16 + 28 0.61 0.02 0.52 0.66 0.77 0.38 0.02 0.02 svm~26 + 6 0.61 0.02 0.38 0.76 0.77 0.35 0.02 0.09 svm~16 + 34 0.61 0.02 0.37 0.74 0.76 0.35 0.16 0.43 rf~15 + 28 0.61 0.02 0.52 0.59 0.74 0.36 0.17 0.52 nb~18 + 5 0.61 0.02 0.63 0.48 0.73 0.37 0.48 0.39 rf~26 + 19 0.61 0.02 0.56 0.69 0.80 0.42 0.00 0.01 rpart~28 + 22 0.60 0.02 0.48 0.67 0.77 0.37 0.01 0.00 knn~12 + 6 0.60 0.02 0.46 0.76 0.81 0.39 0.00 0.02 knn~28 + 21 0.60 0.02 0.70 0.41 0.73 0.39 0.11 0.11 knn~36 + 6 0.60 0.02 0.48 0.67 0.76 0.37 0.04 0.01 rf~19 + 22 0.60 0.02 0.35 0.72 0.74 0.34 0.19 0.00 knn~13 + 21 0.60 0.02 0.73 0.45 0.75 0.43 0.05 0.21 rpart~1 + 29 0.60 0.02 0.30 0.83 0.80 0.35 0.23 0.68 rpart~26 + 22 0.60 0.02 0.38 0.79 0.80 0.37 0.00 0.01 nb~1 + 15 0.60 0.02 0.37 0.71 0.73 0.34 0.54 0.37 rpart~5 + 32 0.60 0.02 0.42 0.71 0.76 0.36 0.24 0.16 rf~9 + 28 0.60 0.02 0.48 0.69 0.77 0.37 0.01 0.02 svm~18 + 19 0.60 0.02 0.50 0.72 0.80 0.40 0.00 0.01 nb~14 + 6 0.60 0.02 0.40 0.81 0.82 0.38 0.00 0.03 knn~17 + 37 0.60 0.02 0.71 0.50 0.76 0.44 0.00 0.22 nb~9 + 19 0.60 0.02 0.56 0.60 0.76 0.38 0.00 0.07 rpart~20 + 28 0.60 0.02 0.63 0.50 0.73 0.38 0.03 0.00 svm~15 + 13 0.60 0.02 0.40 0.76 0.78 0.36 0.01 0.15 nb~17 + 6 0.60 0.02 0.48 0.67 0.76 0.37 0.02 0.01 rf~38 + 28 0.60 0.02 0.52 0.62 0.75 0.37 0.07 0.05 nb~16 + 32 0.60 0.02 0.39 0.71 0.75 0.34 0.19 0.12 rf~4 + 22 0.60 0.02 0.59 0.60 0.77 0.40 0.00 0.00 svm~16 + 22 0.60 0.02 0.47 0.60 0.72 0.34 0.23 0.09 nb~28 + 22 0.60 0.02 0.46 0.67 0.76 0.36 0.02 0.00 svm~41 + 38 0.60 0.02 0.34 0.76 0.75 0.34 0.33 0.78 knn~19 + 22 0.60 0.02 0.70 0.38 0.71 0.37 0.31 0.01 rpart~4 + 9 0.60 0.02 0.43 0.69 0.75 0.35 0.05 0.23 nb~28 + 32 0.60 0.02 0.45 0.64 0.73 0.35 0.10 0.00 svm~16 + 31 0.60 0.02 0.32 0.71 0.71 0.32 0.84 0.82 knn~15 + 24 0.60 0.02 0.57 0.59 0.75 0.38 0.05 0.13 rpart~4 + 34 0.60 0.02 0.53 0.64 0.76 0.38 0.01 0.10 svm~7 + 19 0.60 0.02 0.59 0.59 0.76 0.40 0.01 0.47 nb~1 + 19 0.60 0.02 0.70 0.45 0.74 0.41 0.05 0.00 rpart~26 + 19 0.60 0.02 0.62 0.53 0.75 0.39 0.04 0.01 rf~4 + 13 0.60 0.02 0.38 0.81 0.81 0.37 0.00 0.02 rpart~16 + 18 0.58 0.02 0.30 0.90 0.86 0.37 0.00 0.37 nb~18 + 28 0.60 0.02 0.42 0.64 0.72 0.33 0.21 0.01 svm~4 + 29 0.60 0.03 0.28 0.84 0.80 0.35 0.00 0.03 svm~1 + 18 0.60 0.03 0.35 0.81 0.80 0.36 0.02 0.90 rf~25 + 28 0.60 0.03 0.45 0.59 0.70 0.32 0.85 0.01 nb~24 + 22 0.60 0.03 0.51 0.62 0.75 0.36 0.05 0.00 svm~1 + 19 0.60 0.03 0.49 0.64 0.75 0.36 0.04 0.05 rf~8 + 19 0.60 0.03 0.35 0.72 0.74 0.34 0.25 0.04 nb~2 + 22 0.60 0.03 0.46 0.64 0.74 0.35 0.16 0.73 nb~12 + 6 0.60 0.03 0.51 0.67 0.77 0.38 0.01 0.02 svm~39 + 6 0.60 0.03 0.40 0.81 0.82 0.38 0.00 0.11 rpart~4 + 13 0.60 0.03 0.44 0.72 0.78 0.37 0.01 0.00 rpart~5 + 20 0.60 0.03 0.57 0.55 0.74 0.37 0.05 0.16 svm~4 + 22 0.60 0.03 0.42 0.83 0.84 0.39 0.00 0.00 svm~25 + 6 0.60 0.03 0.54 0.62 0.76 0.38 0.02 0.11 rpart~22 + 6 0.60 0.03 0.41 0.74 0.78 0.36 0.04 0.02 knn~4 + 1 0.60 0.03 0.70 0.41 0.73 0.39 0.19 0.04 rpart~7 + 20 0.60 0.03 0.65 0.50 0.74 0.39 0.03 0.88 nb~18 + 2 0.60 0.03 0.41 0.69 0.74 0.34 0.19 0.23 knn~17 + 22 0.60 0.03 0.45 0.66 0.74 0.35 0.03 0.01 knn~19 + 28 0.60 0.03 0.52 0.59 0.74 0.36 0.07 0.03 rpart~20 + 22 0.60 0.03 0.42 0.72 0.77 0.36 0.02 0.01 svm~39 + 22 0.60 0.03 0.52 0.62 0.75 0.37 0.04 0.02 knn~22 + 6 0.60 0.03 0.66 0.50 0.75 0.40 0.03 0.06 rpart~14 + 22 0.60 0.03 0.38 0.83 0.83 0.38 0.00 0.02 rpart~24 + 5 0.60 0.03 0.38 0.76 0.78 0.36 0.08 0.02 rf~16 + 38 0.60 0.03 0.52 0.66 0.77 0.38 0.01 0.69 svm~8 + 28 0.60 0.03 0.45 0.66 0.74 0.35 0.07 0.01 svm~4 + 32 0.60 0.03 0.38 0.76 0.78 0.36 0.01 0.00 nb~20 + 6 0.60 0.03 0.44 0.67 0.75 0.35 0.05 0.03 rpart~1 + 20 0.60 0.03 0.66 0.50 0.75 0.40 0.03 0.01 knn~24 + 13 0.60 0.03 0.58 0.53 0.73 0.36 0.07 0.03 rpart~41 + 28 0.60 0.03 0.38 0.78 0.79 0.36 0.00 0.00 svm~8 + 22 0.60 0.03 0.41 0.76 0.79 0.37 0.01 0.14 rf~16 + 28 0.60 0.03 0.47 0.67 0.76 0.36 0.08 0.12 nb~4 + 37 0.60 0.03 0.34 0.83 0.81 0.36 0.00 0.05 svm~28 + 21 0.60 0.03 0.40 0.76 0.78 0.36 0.00 0.06 nb~1 + 32 0.60 0.03 0.40 0.66 0.72 0.33 0.58 0.01 rpart~32 + 22 0.60 0.03 0.39 0.78 0.79 0.37 0.00 0.02 knn~42 + 19 0.60 0.03 0.61 0.59 0.76 0.40 0.01 0.02 knn~15 + 13 0.60 0.03 0.61 0.50 0.73 0.37 0.16 0.20 svm~13 + 26 0.60 0.03 0.27 0.90 0.85 0.36 0.00 0.05 rf~16 + 3 0.60 0.03 0.32 0.81 0.79 0.35 0.07 0.00 svm~16 + 28 0.60 0.03 0.43 0.84 0.86 0.40 0.00 0.01 nb~36 + 22 0.60 0.03 0.53 0.57 0.73 0.35 0.08 0.02 svm~24 + 5 0.60 0.03 0.30 0.84 0.81 0.36 0.04 0.02 nb~15 + 22 0.60 0.03 0.36 0.81 0.81 0.36 0.00 0.03 svm~4 + 18 0.60 0.03 0.32 0.78 0.76 0.34 0.05 0.03 svm~19 + 22 0.60 0.03 0.40 0.74 0.77 0.36 0.03 0.01 nb~15 + 28 0.60 0.03 0.34 0.81 0.80 0.36 0.00 0.01 nb~37 + 22 0.60 0.03 0.48 0.60 0.73 0.35 0.10 0.10 svm~33 + 6 0.60 0.03 0.41 0.69 0.75 0.35 0.20 0.27 svm~16 + 41 0.60 0.03 0.30 0.72 0.71 0.32 0.77 0.87 nb~21 + 6 0.60 0.03 0.42 0.76 0.79 0.37 0.01 0.34 nb~24 + 5 0.60 0.03 0.59 0.60 0.77 0.40 0.06 0.06 knn~1 + 18 0.60 0.03 0.70 0.43 0.73 0.40 0.09 0.61 nb~4 + 29 0.60 0.03 0.36 0.74 0.75 0.34 0.06 0.13 svm~16 + 10 0.60 0.03 0.53 0.62 0.76 0.38 0.08 0.67 nb~23 + 6 0.60 0.03 0.39 0.78 0.79 0.37 0.03 0.82 svm~16 + 19 0.60 0.03 0.47 0.62 0.73 0.35 0.26 0.18 rpart~4 + 41 0.60 0.03 0.33 0.84 0.82 0.36 0.00 0.20 rf~12 + 22 0.60 0.03 0.45 0.71 0.77 0.37 0.00 0.00 rf~20 + 6 0.60 0.03 0.51 0.62 0.75 0.36 0.11 0.25 nb~4 + 17 0.60 0.03 0.33 0.83 0.81 0.36 0.00 0.00 svm~4 + 27 0.60 0.03 0.38 0.74 0.77 0.35 0.00 0.01 knn~26 + 22 0.59 0.03 0.64 0.52 0.75 0.39 0.03 0.02 nb~16 + 2 0.60 0.03 0.49 0.69 0.78 0.38 0.03 0.14 svm~1 + 22 0.60 0.03 0.38 0.79 0.80 0.37 0.01 0.05 rf~9 + 6 0.60 0.03 0.45 0.66 0.74 0.35 0.07 0.20 rpart~24 + 19 0.59 0.03 0.52 0.62 0.75 0.37 0.04 0.00 nb~16 + 20 0.60 0.03 0.57 0.53 0.73 0.36 0.05 0.06 rpart~1 + 21 0.60 0.03 0.36 0.76 0.77 0.35 0.20 0.27 nb~38 + 6 0.60 0.03 0.39 0.76 0.78 0.36 0.04 0.99 nb~16 + 41 0.60 0.03 0.32 0.72 0.72 0.33 0.56 0.74 nb~4 + 14 0.60 0.03 0.26 0.88 0.83 0.35 0.00 0.01 rpart~42 + 22 0.59 0.03 0.49 0.60 0.73 0.35 0.07 0.09 nb~2 + 28 0.60 0.03 0.44 0.67 0.75 0.35 0.05 0.51 nb~4 + 11 0.60 0.03 0.23 0.93 0.88 0.35 0.00 0.01 nb~4 + 35 0.60 0.03 0.30 0.88 0.84 0.36 0.00 0.05 rpart~19 + 3 0.59 0.04 0.47 0.72 0.79 0.38 0.00 0.01 nb~5 + 2 0.60 0.04 0.38 0.86 0.86 0.38 0.00 0.31 svm~12 + 5 0.60 0.04 0.52 0.62 0.75 0.37 0.07 0.28 nb~35 + 5 0.60 0.04 0.64 0.53 0.75 0.40 0.09 0.77 rpart~20 + 34 0.59 0.04 0.59 0.53 0.74 0.37 0.10 0.03 knn~1 + 28 0.59 0.04 0.73 0.40 0.73 0.40 0.08 0.23 rf~41 + 20 0.60 0.04 0.52 0.66 0.77 0.38 0.02 0.03 nb~19 + 22 0.60 0.04 0.59 0.59 0.76 0.39 0.01 0.00 rpart~18 + 9 0.58 0.04 0.38 0.81 0.82 0.37 0.00 0.86 rpart~15 + 3 0.59 0.04 0.20 0.88 0.78 0.33 0.13 0.18 nb~8 + 22 0.60 0.04 0.55 0.60 0.75 0.38 0.06 0.10 nb~19 + 32 0.60 0.04 0.41 0.72 0.76 0.36 0.04 0.00 svm~17 + 6 0.60 0.04 0.39 0.72 0.76 0.35 0.05 0.04 rpart~16 + 22 0.59 0.04 0.49 0.67 0.77 0.38 0.02 0.18 svm~31 + 19 0.60 0.04 0.52 0.66 0.77 0.38 0.01 0.00 rpart~5 + 19 0.59 0.04 0.66 0.53 0.76 0.42 0.00 0.01 knn~41 + 19 0.59 0.04 0.73 0.40 0.73 0.40 0.02 0.00 nb~41 + 28 0.60 0.04 0.48 0.60 0.73 0.35 0.13 0.01 svm~15 + 22 0.60 0.04 0.34 0.84 0.83 0.37 0.00 0.05 rf~35 + 6 0.60 0.04 0.52 0.57 0.73 0.35 0.28 0.89 rpart~1 + 6 0.59 0.04 0.47 0.66 0.75 0.36 0.07 0.79 rf~17 + 9 0.60 0.04 0.49 0.67 0.77 0.38 0.04 0.17 nb~15 + 9 0.60 0.04 0.46 0.67 0.76 0.36 0.03 0.90 nb~26 + 6 0.60 0.04 0.45 0.72 0.78 0.37 0.01 0.05 rpart~15 + 20 0.59 0.04 0.52 0.66 0.77 0.38 0.00 0.13 rpart~1 + 19 0.59 0.04 0.54 0.64 0.77 0.39 0.03 0.00 knn~35 + 6 0.59 0.04 0.58 0.57 0.75 0.38 0.10 0.36 knn~35 + 5 0.59 0.04 0.45 0.72 0.78 0.37 0.09 0.81 rf~9 + 22 0.60 0.04 0.42 0.71 0.76 0.36 0.05 0.08 rpart~39 + 28 0.59 0.04 0.50 0.69 0.78 0.38 0.00 0.00 knn~24 + 8 0.59 0.04 0.52 0.62 0.75 0.37 0.06 0.13 rf~38 + 22 0.59 0.04 0.48 0.69 0.78 0.38 0.00 0.14 nb~16 + 11 0.59 0.04 0.42 0.64 0.72 0.33 0.44 0.80 svm~29 + 28 0.59 0.04 0.32 0.76 0.75 0.34 0.12 0.02 knn~39 + 32 0.59 0.04 0.67 0.48 0.74 0.40 0.10 0.00 knn~24 + 22 0.59 0.04 0.37 0.78 0.78 0.36 0.02 0.06 knn~4 + 36 0.59 0.04 0.69 0.40 0.72 0.37 0.09 0.07 knn~16 + 22 0.59 0.04 0.51 0.69 0.78 0.39 0.00 0.18 knn~16 + 3 0.59 0.04 0.62 0.57 0.76 0.40 0.04 0.02 rpart~18 + 38 0.59 0.04 0.55 0.60 0.75 0.38 0.05 0.22 nb~36 + 19 0.59 0.04 0.63 0.62 0.78 0.43 0.00 0.01 svm~16 + 32 0.59 0.04 0.30 0.79 0.76 0.34 0.10 0.13 knn~24 + 6 0.59 0.04 0.63 0.48 0.73 0.37 0.17 0.07 rpart~4 + 7 0.59 0.04 0.48 0.67 0.77 0.37 0.05 0.92 nb~25 + 22 0.59 0.04 0.48 0.72 0.79 0.39 0.00 0.01 knn~40 + 13 0.59 0.04 0.62 0.55 0.75 0.40 0.03 0.23 svm~39 + 19 0.59 0.04 0.54 0.64 0.77 0.39 0.00 0.00 nb~3 + 6 0.59 0.04 0.27 0.86 0.81 0.35 0.02 0.05 rpart~4 + 14 0.59 0.04 0.37 0.76 0.77 0.35 0.02 0.19 nb~18 + 8 0.59 0.04 0.41 0.72 0.77 0.36 0.06 0.86 svm~33 + 28 0.59 0.04 0.52 0.57 0.73 0.35 0.27 0.02 rf~20 + 22 0.59 0.04 0.43 0.69 0.75 0.35 0.07 0.04 nb~41 + 22 0.59 0.04 0.49 0.64 0.75 0.36 0.04 0.06 knn~37 + 20 0.59 0.04 0.36 0.81 0.81 0.36 0.00 0.15 knn~15 + 39 0.59 0.04 0.55 0.60 0.75 0.38 0.07 0.85 svm~2 + 22 0.59 0.04 0.57 0.52 0.72 0.35 0.16 0.41 nb~29 + 6 0.59 0.04 0.38 0.78 0.79 0.36 0.01 0.27 rf~31 + 19 0.59 0.04 0.56 0.52 0.72 0.35 0.20 0.02 nb~9 + 28 0.59 0.04 0.41 0.74 0.78 0.36 0.01 0.05 rf~29 + 19 0.59 0.04 0.54 0.59 0.74 0.37 0.02 0.00 svm~41 + 22 0.59 0.04 0.45 0.67 0.75 0.35 0.07 0.12 knn~15 + 3 0.59 0.04 0.46 0.64 0.74 0.35 0.25 0.11 nb~18 + 36 0.59 0.04 0.48 0.59 0.72 0.34 0.23 0.43 knn~4 + 42 0.59 0.04 0.76 0.29 0.70 0.35 0.27 0.04 svm~29 + 19 0.59 0.04 0.45 0.74 0.79 0.38 0.01 0.02 knn~39 + 19 0.59 0.04 0.54 0.66 0.78 0.39 0.01 0.00 nb~15 + 18 0.59 0.04 0.39 0.74 0.77 0.36 0.01 0.28 nb~7 + 28 0.59 0.04 0.45 0.71 0.77 0.37 0.01 0.41 rpart~1 + 22 0.59 0.04 0.30 0.86 0.83 0.36 0.01 0.09 rpart~25 + 22 0.59 0.04 0.56 0.50 0.71 0.34 0.34 0.13 rf~24 + 6 0.59 0.04 0.56 0.55 0.73 0.36 0.15 0.10 svm~4 + 34 0.59 0.04 0.36 0.74 0.75 0.34 0.05 0.01 rf~38 + 6 0.59 0.04 0.52 0.66 0.77 0.38 0.02 0.08 knn~5 + 32 0.59 0.05 0.70 0.45 0.74 0.40 0.04 0.08 svm~28 + 22 0.59 0.05 0.39 0.78 0.79 0.37 0.01 0.00 rpart~16 + 6 0.59 0.05 0.40 0.71 0.75 0.35 0.06 0.44 knn~4 + 20 0.59 0.05 0.56 0.57 0.74 0.37 0.01 0.03 nb~4 + 12 0.59 0.05 0.34 0.79 0.78 0.35 0.02 0.00 svm~4 + 42 0.59 0.05 0.49 0.72 0.80 0.39 0.00 0.01 rf~12 + 18 0.59 0.05 0.42 0.72 0.77 0.36 0.04 0.26 rpart~10 + 22 0.59 0.05 0.44 0.72 0.78 0.37 0.01 0.03 svm~35 + 19 0.59 0.05 0.42 0.74 0.78 0.37 0.03 0.05 knn~18 + 32 0.59 0.05 0.72 0.45 0.74 0.42 0.02 0.07 rpart~17 + 22 0.59 0.05 0.44 0.69 0.76 0.36 0.04 0.27 rpart~15 + 9 0.58 0.05 0.31 0.79 0.77 0.34 0.05 0.74 knn~4 + 34 0.59 0.05 0.67 0.40 0.71 0.35 0.22 0.01 knn~14 + 32 0.59 0.05 0.63 0.52 0.74 0.39 0.01 0.01 rpart~35 + 31 0.58 0.05 0.32 0.83 0.80 0.36 0.05 0.72 rf~1 + 28 0.59 0.05 0.52 0.62 0.75 0.37 0.09 0.39 svm~36 + 19 0.59 0.05 0.45 0.67 0.75 0.36 0.03 0.02 rpart~9 + 20 0.59 0.05 0.62 0.50 0.73 0.37 0.06 0.18 rf~26 + 28 0.59 0.05 0.54 0.57 0.73 0.36 0.02 0.01 knn~16 + 10 0.59 0.05 0.70 0.43 0.73 0.40 0.07 0.49 knn~42 + 18 0.59 0.05 0.52 0.59 0.73 0.35 0.24 0.68 rpart~9 + 22 0.58 0.05 0.39 0.79 0.81 0.37 0.00 0.17 rpart~4 + 6 0.59 0.05 0.43 0.67 0.74 0.35 0.14 0.13 rf~41 + 18 0.59 0.05 0.41 0.74 0.78 0.36 0.04 0.53 rf~18 + 37 0.59 0.05 0.38 0.78 0.79 0.36 0.03 0.91 svm~4 + 31 0.59 0.05 0.41 0.66 0.73 0.34 0.19 0.00 rpart~39 + 6 0.59 0.05 0.45 0.76 0.80 0.38 0.00 0.10 knn~18 + 8 0.59 0.05 0.46 0.69 0.77 0.37 0.02 0.84 svm~39 + 28 0.59 0.05 0.45 0.71 0.77 0.37 0.01 0.00 nb~11 + 22 0.59 0.05 0.59 0.55 0.75 0.38 0.03 0.03 rf~3 + 28 0.59 0.05 0.44 0.71 0.77 0.36 0.02 0.00 nb~39 + 6 0.59 0.05 0.39 0.71 0.75 0.34 0.10 0.10 nb~5 + 20 0.59 0.05 0.60 0.55 0.75 0.39 0.07 0.23 auc.pvalue: Wilcoxon Test P-value. mfd: Median Fold Difference. KM: Kaplan Meier curves. MvaHRPval: Multivariable Analysis Hazard Ratio P-value.

TABLE 50 pairwise biomarkers from the 43 biomarker panel with significance for Wilcoxon P-value (auc.pvalue <= 0.001*) and other metrics for the MET event endpoint. Pos. Neg. KM auc. Pred. Pred. P- Mva Classifier auc pvalue Sensitivity Specificity Value Value value HRPval nb~4 + 16 0.747 0.000 0.471 0.890 0.711 0.745 0.000 0.000 svm~4 + 16 0.741 0.000 0.544 0.763 0.569 0.744 0.000 0.001 nb~4 + 35 0.726 0.000 0.471 0.890 0.711 0.745 0.000 0.002 nb~16 + 6 0.725 0.000 0.574 0.746 0.565 0.752 0.000 0.001 nb~4 + 15 0.725 0.000 0.471 0.839 0.627 0.733 0.000 0.000 rpart~4 + 16 0.719 0.000 0.588 0.712 0.541 0.750 0.000 0.002 nb~15 + 16 0.724 0.000 0.471 0.771 0.542 0.717 0.000 0.005 nb~4 + 8 0.721 0.000 0.397 0.907 0.711 0.723 0.000 0.000 svm~4 + 8 0.718 0.000 0.441 0.822 0.588 0.719 0.000 0.000 nb~4 + 13 0.718 0.000 0.397 0.907 0.711 0.723 0.000 0.000 svm~35 + 19 0.717 0.000 0.544 0.729 0.536 0.735 0.000 0.001 nb~35 + 6 0.716 0.000 0.515 0.780 0.574 0.736 0.000 0.006 knn~4 + 16 0.711 0.000 0.735 0.669 0.562 0.814 0.000 0.000 nb~16 + 22 0.714 0.000 0.588 0.695 0.526 0.745 0.000 0.000 nb~15 + 24 0.714 0.000 0.500 0.763 0.548 0.726 0.000 0.001 svm~16 + 18 0.714 0.000 0.574 0.754 0.574 0.754 0.000 0.001 nb~16 + 19 0.713 0.000 0.662 0.678 0.542 0.777 0.000 0.000 nb~4 + 24 0.713 0.000 0.412 0.907 0.718 0.728 0.000 0.000 nb~16 + 18 0.712 0.000 0.647 0.669 0.530 0.767 0.000 0.001 svm~15 + 13 0.711 0.000 0.529 0.754 0.554 0.736 0.000 0.021 svm~16 + 19 0.711 0.000 0.618 0.661 0.512 0.750 0.000 0.001 nb~16 + 20 0.710 0.000 0.706 0.559 0.480 0.767 0.000 0.000 nb~15 + 28 0.710 0.000 0.471 0.805 0.582 0.725 0.000 0.002 svm~16 + 22 0.710 0.000 0.574 0.627 0.470 0.718 0.003 0.003 nb~35 + 19 0.710 0.000 0.765 0.602 0.525 0.816 0.000 0.001 nb~15 + 8 0.709 0.000 0.441 0.822 0.588 0.719 0.000 0.046 svm~19 + 28 0.708 0.000 0.559 0.737 0.551 0.744 0.000 0.001 svm~4 + 29 0.707 0.000 0.426 0.864 0.644 0.723 0.000 0.000 svm~13 + 22 0.706 0.000 0.618 0.678 0.525 0.755 0.000 0.003 rpart~15 + 33 0.697 0.000 0.338 0.873 0.605 0.696 0.000 0.121 nb~15 + 13 0.705 0.000 0.574 0.712 0.534 0.743 0.000 0.034 svm~31 + 19 0.705 0.000 0.662 0.653 0.523 0.770 0.000 0.000 svm~15 + 8 0.704 0.000 0.397 0.831 0.574 0.705 0.000 0.065 nb~35 + 22 0.704 0.000 0.750 0.525 0.477 0.785 0.000 0.007 svm~16 + 6 0.703 0.000 0.603 0.695 0.532 0.752 0.000 0.001 nb~4 + 1 0.703 0.000 0.500 0.839 0.642 0.744 0.000 0.000 svm~4 + 41 0.703 0.000 0.353 0.847 0.571 0.694 0.001 0.001 rpart~4 + 1 0.697 0.000 0.691 0.559 0.475 0.759 0.001 0.004 svm~4 + 31 0.702 0.000 0.574 0.712 0.534 0.743 0.000 0.000 nb~13 + 6 0.702 0.000 0.603 0.729 0.562 0.761 0.000 0.001 nb~4 + 12 0.702 0.000 0.500 0.822 0.618 0.740 0.000 0.000 nb~15 + 35 0.702 0.000 0.574 0.746 0.565 0.752 0.000 0.183 nb~4 + 2 0.701 0.000 0.559 0.763 0.576 0.750 0.000 0.056 svm~15 + 16 0.701 0.000 0.426 0.805 0.558 0.709 0.000 0.039 rpart~4 + 31 0.698 0.000 0.632 0.703 0.551 0.769 0.000 0.005 nb~4 + 28 0.700 0.000 0.471 0.822 0.604 0.729 0.000 0.000 nb~4 + 9 0.699 0.000 0.529 0.839 0.655 0.756 0.000 0.002 nb~35 + 20 0.699 0.000 0.824 0.449 0.463 0.815 0.000 0.001 nb~4 + 33 0.698 0.000 0.441 0.898 0.714 0.736 0.000 0.005 rpart~4 + 42 0.694 0.000 0.676 0.627 0.511 0.771 0.000 0.028 nb~4 + 19 0.697 0.000 0.500 0.822 0.618 0.740 0.000 0.000 nb~4 + 20 0.697 0.000 0.559 0.754 0.567 0.748 0.000 0.000 svm~4 + 19 0.696 0.000 0.691 0.746 0.610 0.807 0.000 0.000 svm~4 + 28 0.696 0.000 0.485 0.763 0.541 0.720 0.000 0.001 svm~8 + 22 0.695 0.000 0.529 0.737 0.537 0.731 0.000 0.004 rpart~4 + 13 0.692 0.000 0.544 0.703 0.514 0.728 0.000 0.000 nb~15 + 19 0.695 0.000 0.441 0.805 0.566 0.714 0.000 0.002 nb~15 + 6 0.695 0.000 0.397 0.839 0.587 0.707 0.000 0.006 nb~13 + 22 0.695 0.000 0.603 0.695 0.532 0.752 0.000 0.002 svm~29 + 19 0.695 0.000 0.603 0.729 0.562 0.761 0.000 0.000 rpart~4 + 18 0.690 0.000 0.559 0.703 0.521 0.735 0.000 0.005 svm~4 + 1 0.694 0.000 0.471 0.856 0.653 0.737 0.000 0.001 nb~16 + 28 0.694 0.000 0.632 0.627 0.494 0.747 0.000 0.001 svm~8 + 19 0.693 0.000 0.603 0.644 0.494 0.738 0.000 0.000 nb~8 + 22 0.692 0.000 0.706 0.619 0.516 0.785 0.000 0.003 nb~4 + 40 0.692 0.000 0.441 0.915 0.750 0.740 0.000 0.007 svm~13 + 28 0.692 0.000 0.588 0.695 0.526 0.745 0.000 0.000 rpart~15 + 13 0.688 0.000 0.456 0.780 0.544 0.713 0.000 0.151 nb~16 + 17 0.691 0.000 0.485 0.780 0.559 0.724 0.000 0.001 svm~19 + 38 0.691 0.000 0.632 0.678 0.531 0.762 0.000 0.003 rpart~15 + 20 0.674 0.000 0.691 0.661 0.540 0.788 0.000 0.000 svm~15 + 2 0.690 0.000 0.559 0.754 0.567 0.748 0.000 0.472 svm~15 + 28 0.690 0.000 0.441 0.805 0.566 0.714 0.000 0.002 nb~4 + 37 0.690 0.000 0.456 0.814 0.585 0.722 0.000 0.004 svm~40 + 6 0.690 0.000 0.691 0.576 0.485 0.764 0.000 0.050 nb~8 + 19 0.690 0.000 0.618 0.686 0.532 0.757 0.000 0.000 svm~8 + 6 0.690 0.000 0.588 0.720 0.548 0.752 0.000 0.005 nb~4 + 6 0.689 0.000 0.500 0.814 0.607 0.738 0.000 0.002 nb~15 + 22 0.689 0.000 0.471 0.788 0.561 0.721 0.000 0.004 svm~4 + 40 0.689 0.000 0.632 0.610 0.483 0.742 0.001 0.139 rpart~4 + 8 0.685 0.000 0.647 0.678 0.537 0.769 0.000 0.000 svm~15 + 19 0.689 0.000 0.412 0.847 0.609 0.714 0.000 0.010 svm~40 + 19 0.689 0.000 0.618 0.585 0.462 0.726 0.005 0.017 nb~15 + 9 0.688 0.000 0.574 0.669 0.500 0.731 0.001 0.069 nb~9 + 22 0.688 0.000 0.529 0.737 0.537 0.731 0.000 0.007 nb~4 + 32 0.688 0.000 0.500 0.873 0.694 0.752 0.000 0.000 nb~9 + 19 0.688 0.000 0.691 0.593 0.495 0.769 0.000 0.000 nb~40 + 6 0.687 0.000 0.515 0.780 0.574 0.736 0.000 0.033 rf~9 + 19 0.687 0.000 0.721 0.610 0.516 0.791 0.000 0.000 knn~4 + 12 0.684 0.000 0.382 0.831 0.565 0.700 0.000 0.002 nb~16 + 26 0.687 0.000 0.500 0.771 0.557 0.728 0.000 0.000 nb~4 + 31 0.687 0.000 0.485 0.839 0.635 0.739 0.000 0.001 nb~4 + 22 0.687 0.000 0.515 0.814 0.614 0.744 0.000 0.001 knn~4 + 19 0.683 0.000 0.647 0.703 0.557 0.776 0.000 0.000 nb~15 + 18 0.687 0.000 0.515 0.746 0.538 0.727 0.000 0.032 rpart~18 + 32 0.684 0.000 0.632 0.669 0.524 0.760 0.000 0.004 nb~4 + 42 0.686 0.000 0.397 0.856 0.614 0.711 0.000 0.005 nb~40 + 22 0.686 0.000 0.662 0.602 0.489 0.755 0.001 0.025 knn~4 + 42 0.681 0.000 0.838 0.314 0.413 0.771 0.021 0.001 nb~4 + 17 0.686 0.000 0.471 0.831 0.615 0.731 0.000 0.001 nb~13 + 19 0.685 0.000 0.779 0.576 0.515 0.819 0.000 0.000 nb~16 + 24 0.685 0.000 0.515 0.712 0.507 0.718 0.001 0.000 svm~24 + 2 0.685 0.000 0.456 0.771 0.534 0.711 0.000 0.008 rpart~16 + 20 0.678 0.000 0.721 0.568 0.490 0.779 0.000 0.001 rpart~35 + 6 0.681 0.000 0.529 0.737 0.537 0.731 0.000 0.007 rpart~13 + 6 0.680 0.000 0.647 0.729 0.579 0.782 0.000 0.001 nb~8 + 6 0.685 0.000 0.515 0.763 0.556 0.732 0.000 0.005 rf~4 + 12 0.684 0.000 0.647 0.610 0.489 0.750 0.000 0.002 svm~8 + 28 0.684 0.000 0.588 0.678 0.513 0.741 0.000 0.008 rpart~20 + 28 0.671 0.000 0.750 0.508 0.468 0.779 0.000 0.000 svm~4 + 13 0.684 0.000 0.456 0.856 0.646 0.732 0.000 0.000 svm~29 + 22 0.684 0.000 0.618 0.610 0.477 0.735 0.001 0.004 svm~4 + 27 0.684 0.000 0.515 0.754 0.547 0.730 0.000 0.006 nb~4 + 41 0.683 0.000 0.441 0.831 0.600 0.721 0.000 0.003 rpart~13 + 22 0.680 0.000 0.706 0.559 0.480 0.767 0.000 0.009 nb~28 + 6 0.683 0.000 0.588 0.720 0.548 0.752 0.000 0.002 rpart~2 + 19 0.674 0.000 0.809 0.381 0.430 0.776 0.005 0.060 svm~4 + 15 0.682 0.000 0.397 0.873 0.643 0.715 0.000 0.000 svm~4 + 38 0.682 0.000 0.515 0.805 0.603 0.742 0.000 0.001 rpart~4 + 32 0.679 0.000 0.500 0.729 0.515 0.717 0.001 0.001 svm~13 + 19 0.681 0.000 0.735 0.534 0.476 0.778 0.000 0.000 nb~8 + 28 0.681 0.000 0.647 0.686 0.543 0.771 0.000 0.002 knn~40 + 28 0.677 0.000 0.485 0.814 0.600 0.733 0.000 0.005 nb~15 + 20 0.680 0.000 0.662 0.610 0.495 0.758 0.000 0.003 rpart~35 + 19 0.677 0.000 0.618 0.686 0.532 0.757 0.000 0.008 nb~4 + 27 0.680 0.000 0.574 0.695 0.520 0.739 0.000 0.001 nb~15 + 17 0.680 0.000 0.471 0.729 0.500 0.705 0.001 0.011 nb~24 + 28 0.680 0.000 0.485 0.754 0.532 0.718 0.000 0.000 nb~9 + 6 0.680 0.000 0.632 0.610 0.483 0.742 0.001 0.011 svm~4 + 12 0.680 0.000 0.485 0.814 0.600 0.733 0.000 0.003 nb~37 + 22 0.679 0.000 0.603 0.627 0.482 0.733 0.001 0.010 svm~26 + 19 0.679 0.000 0.529 0.805 0.610 0.748 0.000 0.001 svm~4 + 9 0.679 0.000 0.529 0.780 0.581 0.742 0.000 0.006 nb~15 + 32 0.679 0.000 0.309 0.873 0.583 0.687 0.000 0.008 rf~4 + 31 0.679 0.000 0.559 0.678 0.500 0.727 0.001 0.003 svm~9 + 19 0.679 0.000 0.676 0.627 0.511 0.771 0.000 0.000 svm~15 + 35 0.679 0.000 0.426 0.847 0.617 0.719 0.000 0.229 nb~28 + 22 0.679 0.000 0.559 0.661 0.487 0.722 0.001 0.001 nb~35 + 28 0.678 0.000 0.603 0.712 0.547 0.757 0.000 0.025 svm~35 + 6 0.678 0.000 0.485 0.771 0.550 0.722 0.000 0.007 knn~4 + 43 0.674 0.000 0.515 0.720 0.515 0.720 0.001 0.018 nb~2 + 22 0.678 0.000 0.559 0.644 0.475 0.717 0.005 0.129 rpart~15 + 2 0.671 0.000 0.647 0.627 0.500 0.755 0.000 0.587 svm~9 + 22 0.678 0.000 0.500 0.763 0.548 0.726 0.000 0.014 svm~16 + 28 0.677 0.000 0.544 0.771 0.578 0.746 0.000 0.002 svm~19 + 22 0.677 0.000 0.500 0.729 0.515 0.717 0.000 0.001 nb~24 + 6 0.677 0.000 0.353 0.839 0.558 0.692 0.000 0.001 rpart~15 + 26 0.670 0.000 0.338 0.864 0.590 0.694 0.000 0.061 svm~16 + 38 0.677 0.000 0.471 0.754 0.525 0.712 0.001 0.054 rpart~4 + 28 0.673 0.000 0.515 0.771 0.565 0.734 0.000 0.002 svm~15 + 31 0.677 0.000 0.353 0.814 0.522 0.686 0.003 0.170 nb~40 + 19 0.677 0.000 0.706 0.534 0.466 0.759 0.001 0.008 nb~15 + 2 0.676 0.000 0.529 0.763 0.563 0.738 0.000 0.474 nb~40 + 20 0.676 0.000 0.691 0.559 0.475 0.759 0.001 0.007 svm~41 + 6 0.676 0.000 0.588 0.661 0.500 0.736 0.000 0.005 nb~4 + 23 0.676 0.000 0.500 0.805 0.596 0.736 0.000 0.052 svm~4 + 6 0.676 0.000 0.544 0.780 0.587 0.748 0.000 0.016 nb~4 + 29 0.676 0.000 0.485 0.763 0.541 0.720 0.000 0.010 knn~4 + 39 0.672 0.000 0.794 0.432 0.446 0.785 0.001 0.000 rf~13 + 26 0.675 0.000 0.588 0.686 0.519 0.743 0.000 0.001 rpart~9 + 19 0.662 0.000 0.706 0.568 0.485 0.770 0.000 0.001 nb~4 + 38 0.675 0.000 0.544 0.780 0.587 0.748 0.000 0.013 rf~4 + 19 0.675 0.000 0.574 0.661 0.494 0.729 0.000 0.000 nb~4 + 34 0.675 0.000 0.441 0.839 0.612 0.723 0.000 0.002 rf~4 + 1 0.675 0.000 0.632 0.644 0.506 0.752 0.000 0.023 nb~13 + 28 0.675 0.000 0.544 0.720 0.529 0.733 0.000 0.001 rpart~4 + 11 0.644 0.000 0.441 0.797 0.556 0.712 0.000 0.008 svm~37 + 19 0.675 0.000 0.647 0.585 0.473 0.742 0.001 0.000 nb~20 + 28 0.675 0.000 0.618 0.602 0.472 0.732 0.001 0.000 nb~42 + 6 0.674 0.000 0.500 0.788 0.576 0.732 0.000 0.018 rpart~33 + 19 0.647 0.000 0.574 0.720 0.542 0.746 0.000 0.001 rf~4 + 16 0.674 0.000 0.691 0.602 0.500 0.772 0.000 0.002 rpart~4 + 39 0.663 0.000 0.529 0.754 0.554 0.736 0.000 0.000 nb~4 + 36 0.674 0.000 0.368 0.915 0.714 0.715 0.000 0.001 nb~8 + 20 0.674 0.000 0.691 0.500 0.443 0.738 0.009 0.000 nb~24 + 22 0.674 0.000 0.618 0.619 0.483 0.737 0.001 0.000 svm~4 + 32 0.673 0.000 0.500 0.754 0.540 0.724 0.000 0.003 svm~13 + 6 0.673 0.000 0.559 0.712 0.528 0.737 0.000 0.001 rpart~4 + 29 0.669 0.000 0.559 0.678 0.500 0.727 0.001 0.000 svm~39 + 19 0.673 0.000 0.632 0.602 0.478 0.740 0.000 0.000 nb~15 + 40 0.672 0.000 0.382 0.856 0.605 0.706 0.000 0.258 nb~15 + 26 0.672 0.000 0.471 0.771 0.542 0.717 0.000 0.012 nb~17 + 28 0.672 0.000 0.529 0.686 0.493 0.717 0.001 0.001 nb~9 + 20 0.672 0.000 0.544 0.610 0.446 0.699 0.021 0.001 nb~13 + 20 0.672 0.000 0.603 0.593 0.461 0.722 0.004 0.000 nb~2 + 6 0.672 0.000 0.588 0.712 0.541 0.750 0.000 0.175 rpart~16 + 18 0.634 0.000 0.412 0.864 0.636 0.718 0.000 0.001 svm~4 + 35 0.672 0.000 0.471 0.797 0.571 0.723 0.000 0.007 svm~15 + 10 0.672 0.000 0.441 0.856 0.638 0.727 0.000 0.099 knn~15 + 8 0.668 0.000 0.735 0.542 0.481 0.780 0.000 0.113 knn~4 + 20 0.669 0.000 0.691 0.576 0.485 0.764 0.000 0.003 nb~15 + 37 0.671 0.000 0.426 0.771 0.518 0.700 0.001 0.150 svm~18 + 8 0.671 0.000 0.588 0.661 0.500 0.736 0.001 0.014 nb~2 + 19 0.671 0.000 0.544 0.695 0.507 0.726 0.001 0.033 nb~19 + 28 0.671 0.000 0.647 0.653 0.518 0.762 0.000 0.000 rpart~19 + 20 0.666 0.000 0.735 0.500 0.459 0.766 0.001 0.003 svm~4 + 42 0.671 0.000 0.588 0.669 0.506 0.738 0.000 0.012 svm~16 + 26 0.670 0.000 0.412 0.788 0.528 0.699 0.001 0.000 knn~15 + 16 0.666 0.000 0.750 0.466 0.447 0.764 0.003 0.002 svm~16 + 10 0.670 0.000 0.676 0.627 0.511 0.771 0.000 0.033 svm~17 + 19 0.670 0.000 0.485 0.754 0.532 0.718 0.000 0.001 nb~41 + 6 0.670 0.000 0.441 0.814 0.577 0.716 0.000 0.016 nb~40 + 28 0.670 0.000 0.662 0.661 0.529 0.772 0.000 0.028 svm~15 + 40 0.670 0.000 0.485 0.661 0.452 0.690 0.040 0.565 rf~4 + 8 0.670 0.000 0.721 0.492 0.450 0.753 0.003 0.001 knn~10 + 19 0.665 0.000 0.382 0.881 0.650 0.712 0.000 0.000 nb~37 + 19 0.669 0.000 0.544 0.678 0.493 0.721 0.000 0.000 knn~4 + 31 0.665 0.000 0.544 0.712 0.521 0.730 0.000 0.002 nb~33 + 6 0.669 0.000 0.544 0.763 0.569 0.744 0.000 0.029 nb~20 + 22 0.669 0.000 0.603 0.619 0.477 0.730 0.001 0.001 rf~8 + 26 0.669 0.000 0.574 0.695 0.520 0.739 0.000 0.002 svm~33 + 19 0.669 0.000 0.574 0.627 0.470 0.718 0.003 0.000 nb~19 + 6 0.669 0.000 0.515 0.780 0.574 0.736 0.000 0.001 nb~4 + 18 0.669 0.000 0.485 0.771 0.550 0.722 0.000 0.004 svm~4 + 18 0.668 0.000 0.441 0.797 0.556 0.712 0.000 0.016 knn~15 + 13 0.665 0.000 0.735 0.517 0.467 0.772 0.001 0.235 svm~4 + 39 0.668 0.000 0.544 0.729 0.536 0.735 0.000 0.000 svm~42 + 15 0.668 0.000 0.471 0.720 0.492 0.702 0.006 0.638 svm~10 + 6 0.668 0.000 0.485 0.797 0.579 0.729 0.000 0.004 rf~4 + 24 0.668 0.000 0.574 0.678 0.506 0.734 0.000 0.000 svm~19 + 6 0.668 0.000 0.559 0.720 0.535 0.739 0.000 0.001 nb~1 + 6 0.667 0.000 0.485 0.771 0.550 0.722 0.000 0.007 nb~15 + 33 0.667 0.000 0.471 0.737 0.508 0.707 0.003 0.452 svm~12 + 6 0.667 0.000 0.544 0.703 0.514 0.728 0.000 0.002 nb~15 + 31 0.667 0.000 0.412 0.788 0.528 0.699 0.002 0.155 rpart~15 + 31 0.662 0.000 0.324 0.890 0.629 0.695 0.000 0.155 knn~4 + 22 0.664 0.000 0.735 0.475 0.446 0.757 0.002 0.005 svm~40 + 24 0.667 0.000 0.632 0.653 0.512 0.755 0.000 0.006 nb~12 + 6 0.667 0.000 0.618 0.644 0.500 0.745 0.000 0.002 nb~18 + 28 0.667 0.000 0.515 0.661 0.467 0.703 0.012 0.005 knn~15 + 31 0.663 0.000 0.706 0.585 0.495 0.775 0.000 0.060 svm~4 + 24 0.667 0.000 0.426 0.864 0.644 0.723 0.000 0.000 nb~42 + 22 0.667 0.000 0.647 0.525 0.440 0.721 0.021 0.032 rpart~4 + 34 0.666 0.000 0.618 0.602 0.472 0.732 0.002 0.063 svm~4 + 37 0.667 0.000 0.574 0.686 0.513 0.736 0.000 0.003 svm~4 + 2 0.667 0.000 0.662 0.678 0.542 0.777 0.000 0.077 nb~22 + 6 0.667 0.000 0.559 0.695 0.514 0.732 0.000 0.004 nb~42 + 15 0.666 0.000 0.485 0.712 0.493 0.706 0.005 0.521 svm~40 + 22 0.666 0.000 0.721 0.475 0.441 0.747 0.013 0.086 knn~29 + 18 0.662 0.000 0.529 0.695 0.500 0.719 0.002 0.029 nb~12 + 22 0.666 0.000 0.559 0.669 0.494 0.725 0.000 0.001 svm~10 + 22 0.666 0.000 0.544 0.678 0.493 0.721 0.002 0.015 svm~35 + 22 0.666 0.000 0.456 0.771 0.534 0.711 0.000 0.024 svm~8 + 26 0.666 0.000 0.441 0.780 0.536 0.708 0.001 0.006 nb~4 + 25 0.666 0.000 0.515 0.805 0.603 0.742 0.000 0.002 nb~17 + 6 0.666 0.000 0.588 0.661 0.500 0.736 0.000 0.002 svm~26 + 22 0.666 0.000 0.500 0.720 0.507 0.714 0.001 0.005 nb~38 + 28 0.666 0.000 0.559 0.703 0.521 0.735 0.000 0.023 nb~18 + 13 0.666 0.000 0.618 0.559 0.447 0.717 0.024 0.011 nb~37 + 6 0.666 0.000 0.588 0.678 0.513 0.741 0.000 0.016 rf~4 + 13 0.666 0.000 0.471 0.771 0.542 0.717 0.000 0.002 nb~4 + 7 0.666 0.000 0.456 0.771 0.534 0.711 0.001 0.028 nb~4 + 10 0.666 0.000 0.353 0.924 0.727 0.712 0.000 0.003 svm~24 + 6 0.666 0.000 0.426 0.788 0.537 0.705 0.000 0.018 rf~4 + 39 0.665 0.000 0.662 0.602 0.489 0.755 0.000 0.002 nb~19 + 22 0.665 0.000 0.706 0.568 0.485 0.770 0.000 0.000 svm~26 + 28 0.665 0.000 0.426 0.797 0.547 0.707 0.000 0.004 nb~33 + 19 0.665 0.000 0.721 0.568 0.490 0.779 0.000 0.016 rf~4 + 42 0.665 0.000 0.588 0.644 0.488 0.731 0.002 0.015 svm~24 + 19 0.665 0.000 0.456 0.814 0.585 0.722 0.000 0.002 nb~4 + 26 0.665 0.000 0.426 0.856 0.630 0.721 0.000 0.001 nb~15 + 10 0.665 0.000 0.706 0.483 0.440 0.740 0.018 0.404 knn~15 + 19 0.661 0.000 0.794 0.398 0.432 0.770 0.006 0.003 nb~19 + 20 0.665 0.000 0.706 0.517 0.457 0.753 0.001 0.000 rf~15 + 2 0.665 0.000 0.647 0.619 0.494 0.753 0.000 0.846 svm~40 + 28 0.665 0.000 0.676 0.602 0.495 0.763 0.000 0.039 nb~1 + 22 0.664 0.000 0.603 0.610 0.471 0.727 0.003 0.008 svm~15 + 24 0.664 0.000 0.338 0.890 0.639 0.700 0.000 0.135 rpart~4 + 20 0.640 0.000 0.765 0.508 0.473 0.789 0.000 0.001 svm~18 + 2 0.664 0.000 0.632 0.610 0.483 0.742 0.002 0.252 svm~37 + 22 0.664 0.000 0.632 0.636 0.500 0.750 0.000 0.042 nb~34 + 6 0.664 0.000 0.500 0.703 0.493 0.709 0.002 0.012 rpart~1 + 20 0.659 0.000 0.779 0.483 0.465 0.792 0.000 0.000 nb~4 + 39 0.664 0.000 0.515 0.814 0.614 0.744 0.000 0.004 nb~31 + 6 0.664 0.000 0.515 0.729 0.522 0.723 0.000 0.007 svm~2 + 28 0.664 0.000 0.647 0.602 0.484 0.747 0.001 0.039 knn~24 + 22 0.659 0.000 0.485 0.771 0.550 0.722 0.000 0.014 nb~18 + 6 0.664 0.000 0.544 0.712 0.521 0.730 0.000 0.009 rf~26 + 22 0.663 0.000 0.618 0.669 0.519 0.752 0.000 0.015 svm~31 + 6 0.663 0.000 0.544 0.661 0.481 0.716 0.004 0.044 nb~20 + 6 0.663 0.000 0.544 0.678 0.493 0.721 0.001 0.001 nb~4 + 43 0.663 0.000 0.397 0.873 0.643 0.715 0.000 0.006 svm~1 + 22 0.663 0.000 0.500 0.771 0.557 0.728 0.000 0.006 nb~40 + 17 0.663 0.000 0.632 0.610 0.483 0.742 0.001 0.140 nb~37 + 28 0.663 0.000 0.603 0.653 0.500 0.740 0.000 0.019 nb~17 + 8 0.663 0.000 0.559 0.686 0.507 0.730 0.001 0.017 svm~12 + 19 0.663 0.000 0.588 0.678 0.513 0.741 0.000 0.004 nb~27 + 6 0.663 0.000 0.588 0.636 0.482 0.728 0.001 0.012 nb~32 + 22 0.663 0.000 0.559 0.627 0.463 0.712 0.006 0.002 rf~42 + 19 0.663 0.000 0.662 0.593 0.484 0.753 0.000 0.000 nb~2 + 28 0.663 0.000 0.529 0.669 0.480 0.712 0.005 0.101 rpart~4 + 24 0.655 0.000 0.412 0.805 0.549 0.704 0.000 0.001 svm~18 + 19 0.663 0.000 0.603 0.669 0.513 0.745 0.000 0.002 knn~9 + 19 0.659 0.000 0.691 0.576 0.485 0.764 0.000 0.005 svm~38 + 22 0.663 0.000 0.632 0.712 0.558 0.771 0.000 0.035 rf~4 + 38 0.662 0.000 0.515 0.703 0.500 0.716 0.001 0.024 nb~17 + 22 0.662 0.000 0.662 0.568 0.469 0.744 0.001 0.002 nb~10 + 6 0.662 0.000 0.412 0.847 0.609 0.714 0.000 0.012 rpart~4 + 6 0.658 0.000 0.574 0.703 0.527 0.741 0.000 0.012 knn~35 + 19 0.658 0.000 0.824 0.424 0.452 0.806 0.001 0.011 rpart~20 + 6 0.660 0.000 0.574 0.627 0.470 0.718 0.003 0.000 nb~2 + 20 0.662 0.000 0.603 0.678 0.519 0.748 0.000 0.078 knn~16 + 10 0.655 0.000 0.824 0.432 0.455 0.810 0.001 0.031 svm~10 + 28 0.662 0.000 0.559 0.686 0.507 0.730 0.000 0.022 svm~2 + 22 0.662 0.000 0.691 0.542 0.465 0.753 0.001 0.179 svm~10 + 19 0.662 0.000 0.559 0.712 0.528 0.737 0.000 0.000 knn~4 + 38 0.658 0.000 0.750 0.475 0.451 0.767 0.002 0.002 svm~19 + 32 0.661 0.000 0.485 0.771 0.550 0.722 0.000 0.001 nb~15 + 12 0.661 0.000 0.485 0.720 0.500 0.708 0.002 0.013 nb~17 + 13 0.661 0.000 0.618 0.619 0.483 0.737 0.001 0.014 nb~18 + 22 0.661 0.000 0.662 0.610 0.495 0.758 0.000 0.005 rf~4 + 41 0.660 0.000 0.588 0.636 0.482 0.728 0.002 0.007 rpart~4 + 35 0.652 0.000 0.544 0.737 0.544 0.737 0.000 0.016 rpart~24 + 19 0.654 0.000 0.603 0.593 0.461 0.722 0.003 0.002 knn~16 + 19 0.658 0.000 0.647 0.610 0.489 0.750 0.000 0.000 nb~33 + 22 0.660 0.000 0.706 0.492 0.444 0.744 0.007 0.031 svm~24 + 28 0.659 0.000 0.250 0.890 0.567 0.673 0.001 0.012 nb~19 + 32 0.659 0.000 0.515 0.720 0.515 0.720 0.000 0.000 rf~39 + 32 0.659 0.000 0.676 0.559 0.469 0.750 0.001 0.000 svm~42 + 6 0.659 0.000 0.574 0.661 0.494 0.729 0.001 0.012 nb~24 + 19 0.659 0.000 0.574 0.712 0.534 0.743 0.000 0.000 rf~15 + 28 0.659 0.000 0.618 0.585 0.462 0.726 0.004 0.204 rpart~4 + 38 0.658 0.000 0.603 0.661 0.506 0.743 0.000 0.045 knn~4 + 34 0.655 0.000 0.765 0.415 0.430 0.754 0.008 0.009 nb~41 + 22 0.659 0.000 0.603 0.636 0.488 0.735 0.001 0.027 rpart~35 + 20 0.657 0.000 0.603 0.644 0.494 0.738 0.001 0.050 rf~31 + 19 0.659 0.000 0.676 0.542 0.460 0.744 0.002 0.000 rpart~5 + 28 0.651 0.000 0.706 0.602 0.505 0.780 0.000 0.029 rf~35 + 6 0.658 0.000 0.618 0.585 0.462 0.726 0.009 0.007 nb~24 + 20 0.658 0.000 0.662 0.517 0.441 0.726 0.007 0.000 rpart~24 + 10 0.638 0.000 0.382 0.839 0.578 0.702 0.000 0.005 nb~12 + 28 0.658 0.000 0.632 0.669 0.524 0.760 0.000 0.001 svm~4 + 22 0.658 0.000 0.544 0.771 0.578 0.746 0.000 0.002 nb~36 + 6 0.658 0.000 0.485 0.754 0.532 0.718 0.000 0.010 nb~34 + 22 0.658 0.000 0.618 0.576 0.457 0.723 0.009 0.012 knn~16 + 38 0.653 0.000 0.824 0.373 0.431 0.786 0.007 0.206 svm~29 + 6 0.658 0.000 0.529 0.746 0.545 0.733 0.000 0.009 nb~38 + 6 0.658 0.000 0.500 0.746 0.531 0.721 0.000 0.061 svm~1 + 19 0.658 0.000 0.603 0.636 0.488 0.735 0.000 0.003 nb~16 + 32 0.658 0.000 0.515 0.729 0.522 0.723 0.000 0.005 svm~38 + 28 0.658 0.000 0.632 0.695 0.544 0.766 0.000 0.008 rpart~20 + 22 0.654 0.000 0.515 0.703 0.500 0.716 0.001 0.005 svm~15 + 39 0.658 0.000 0.500 0.780 0.567 0.730 0.000 0.153 nb~41 + 28 0.658 0.000 0.559 0.602 0.447 0.703 0.024 0.008 rpart~8 + 19 0.655 0.000 0.618 0.644 0.500 0.745 0.000 0.001 nb~31 + 19 0.657 0.000 0.603 0.695 0.532 0.752 0.000 0.002 rpart~15 + 8 0.656 0.000 0.426 0.763 0.509 0.698 0.003 0.243 rf~15 + 8 0.657 0.000 0.529 0.686 0.493 0.717 0.002 0.788 rf~7 + 19 0.657 0.000 0.735 0.551 0.485 0.783 0.000 0.016 rf~29 + 19 0.657 0.000 0.676 0.602 0.495 0.763 0.000 0.000 nb~35 + 17 0.657 0.000 0.618 0.610 0.477 0.735 0.002 0.135 svm~16 + 17 0.657 0.000 0.515 0.737 0.530 0.725 0.000 0.004 knn~18 + 28 0.653 0.000 0.735 0.441 0.431 0.743 0.010 0.002 nb~16 + 2 0.657 0.000 0.632 0.678 0.531 0.762 0.000 0.422 nb~26 + 28 0.656 0.000 0.544 0.678 0.493 0.721 0.001 0.002 rf~16 + 18 0.656 0.000 0.632 0.678 0.531 0.762 0.000 0.008 svm~4 + 25 0.656 0.000 0.588 0.653 0.494 0.733 0.000 0.031 nb~15 + 41 0.656 0.000 0.574 0.602 0.453 0.710 0.019 0.212 rpart~40 + 24 0.650 0.000 0.471 0.771 0.542 0.717 0.000 0.005 nb~17 + 19 0.656 0.000 0.706 0.610 0.511 0.783 0.000 0.000 svm~27 + 6 0.656 0.000 0.588 0.619 0.471 0.723 0.002 0.034 svm~19 + 34 0.656 0.000 0.588 0.610 0.465 0.720 0.002 0.001 rpart~16 + 28 0.655 0.000 0.515 0.669 0.473 0.705 0.011 0.009 rf~7 + 6 0.656 0.000 0.691 0.585 0.490 0.767 0.000 0.022 knn~29 + 6 0.652 0.000 0.529 0.695 0.500 0.719 0.001 0.022 knn~4 + 1 0.652 0.000 0.750 0.381 0.411 0.726 0.072 0.004 rpart~24 + 5 0.654 0.000 0.485 0.746 0.524 0.715 0.001 0.007 nb~32 + 6 0.656 0.000 0.412 0.847 0.609 0.714 0.000 0.004 nb~10 + 22 0.656 0.000 0.632 0.534 0.439 0.716 0.030 0.024 rpart~23 + 19 0.648 0.000 0.721 0.466 0.438 0.743 0.008 0.021 rpart~4 + 12 0.652 0.000 0.603 0.653 0.500 0.740 0.000 0.004 rf~4 + 14 0.656 0.000 0.544 0.678 0.493 0.721 0.001 0.007 nb~33 + 20 0.656 0.000 0.824 0.398 0.441 0.797 0.003 0.013 knn~4 + 35 0.652 0.000 0.471 0.746 0.516 0.710 0.001 0.050 rf~4 + 20 0.655 0.000 0.618 0.551 0.442 0.714 0.018 0.005 nb~18 + 8 0.655 0.000 0.485 0.695 0.478 0.701 0.018 0.023 svm~5 + 28 0.655 0.000 0.603 0.678 0.519 0.748 0.000 0.024 rf~10 + 19 0.655 0.000 0.574 0.686 0.513 0.736 0.000 0.000 svm~28 + 22 0.655 0.000 0.515 0.763 0.556 0.732 0.000 0.001 rpart~10 + 22 0.652 0.000 0.500 0.678 0.472 0.702 0.020 0.048 rf~4 + 18 0.655 0.000 0.603 0.661 0.506 0.743 0.000 0.006 nb~16 + 37 0.655 0.000 0.647 0.593 0.478 0.745 0.001 0.085 nb~19 + 34 0.655 0.000 0.574 0.686 0.513 0.736 0.000 0.001 rpart~4 + 25 0.652 0.000 0.706 0.534 0.466 0.759 0.001 0.024 knn~26 + 22 0.650 0.000 0.735 0.492 0.455 0.763 0.002 0.002 rf~35 + 19 0.654 0.000 0.618 0.636 0.494 0.743 0.000 0.010 rpart~15 + 3 0.647 0.000 0.279 0.890 0.594 0.682 0.000 0.294 svm~15 + 22 0.654 0.000 0.426 0.805 0.558 0.709 0.000 0.004 nb~28 + 32 0.654 0.000 0.544 0.644 0.468 0.710 0.003 0.004 svm~22 + 6 0.654 0.000 0.426 0.746 0.492 0.693 0.008 0.006 knn~42 + 19 0.649 0.000 0.721 0.551 0.480 0.774 0.000 0.005 nb~24 + 32 0.654 0.000 0.235 0.873 0.516 0.665 0.009 0.000 nb~16 + 35 0.654 0.000 0.515 0.737 0.530 0.725 0.001 0.205 nb~37 + 20 0.654 0.000 0.559 0.602 0.447 0.703 0.013 0.002 rpart~40 + 19 0.648 0.000 0.853 0.364 0.436 0.811 0.002 0.056 rpart~4 + 9 0.651 0.001 0.588 0.720 0.548 0.752 0.000 0.006 rf~15 + 39 0.653 0.001 0.544 0.720 0.529 0.733 0.000 0.221 svm~4 + 33 0.653 0.001 0.544 0.729 0.536 0.735 0.000 0.016 nb~13 + 26 0.653 0.001 0.662 0.483 0.425 0.713 0.051 0.002 svm~27 + 19 0.653 0.001 0.588 0.610 0.465 0.720 0.004 0.005 svm~15 + 37 0.653 0.001 0.412 0.805 0.549 0.704 0.000 0.070 nb~16 + 38 0.653 0.001 0.471 0.729 0.500 0.705 0.005 0.079 rpart~16 + 6 0.645 0.001 0.471 0.695 0.471 0.695 0.009 0.098 rpart~4 + 5 0.647 0.001 0.603 0.653 0.500 0.740 0.001 0.023 svm~2 + 19 0.653 0.001 0.676 0.500 0.438 0.728 0.011 0.019 rpart~24 + 20 0.644 0.001 0.529 0.712 0.514 0.724 0.000 0.001 svm~14 + 22 0.653 0.001 0.515 0.729 0.522 0.723 0.000 0.009 nb~36 + 22 0.653 0.001 0.632 0.576 0.462 0.731 0.003 0.013 rpart~26 + 28 0.649 0.001 0.456 0.746 0.508 0.704 0.001 0.001 rf~15 + 9 0.652 0.001 0.544 0.695 0.507 0.726 0.001 0.451 knn~24 + 19 0.648 0.001 0.824 0.373 0.431 0.786 0.004 0.002 nb~23 + 6 0.652 0.001 0.500 0.754 0.540 0.724 0.000 0.158 svm~34 + 22 0.652 0.001 0.632 0.576 0.462 0.731 0.003 0.007 nb~18 + 37 0.652 0.001 0.500 0.695 0.486 0.707 0.006 0.144 svm~31 + 22 0.652 0.001 0.574 0.619 0.464 0.716 0.009 0.011 rpart~18 + 13 0.651 0.001 0.559 0.602 0.447 0.703 0.037 0.050 knn~16 + 20 0.649 0.001 0.779 0.483 0.465 0.792 0.000 0.032 nb~40 + 24 0.652 0.001 0.529 0.636 0.456 0.701 0.023 0.005 nb~15 + 34 0.652 0.001 0.397 0.797 0.529 0.696 0.001 0.129 svm~16 + 24 0.652 0.001 0.265 0.890 0.581 0.677 0.000 0.005 svm~35 + 28 0.652 0.001 0.412 0.814 0.560 0.706 0.000 0.271 nb~26 + 6 0.652 0.001 0.559 0.703 0.521 0.735 0.000 0.003 nb~20 + 32 0.652 0.001 0.618 0.525 0.429 0.705 0.029 0.001 rpart~4 + 27 0.641 0.001 0.559 0.712 0.528 0.737 0.000 0.001 nb~26 + 22 0.652 0.001 0.676 0.602 0.495 0.763 0.000 0.002 rpart~13 + 26 0.647 0.001 0.500 0.788 0.576 0.732 0.000 0.000 rpart~7 + 20 0.644 0.001 0.735 0.475 0.446 0.757 0.005 0.052 svm~15 + 17 0.652 0.001 0.397 0.754 0.482 0.685 0.005 0.033 nb~16 + 9 0.652 0.001 0.471 0.703 0.478 0.697 0.022 0.058 rpart~39 + 19 0.644 0.001 0.735 0.458 0.439 0.750 0.004 0.010 svm~18 + 28 0.652 0.001 0.485 0.686 0.471 0.698 0.009 0.010 nb~26 + 19 0.652 0.001 0.691 0.542 0.465 0.753 0.001 0.001 knn~16 + 18 0.648 0.001 0.779 0.373 0.417 0.746 0.038 0.004 nb~17 + 32 0.651 0.001 0.515 0.678 0.479 0.708 0.002 0.002 svm~28 + 6 0.651 0.001 0.500 0.720 0.507 0.714 0.001 0.002 rf~16 + 19 0.651 0.001 0.603 0.585 0.456 0.719 0.007 0.001 nb~4 + 5 0.651 0.001 0.456 0.797 0.564 0.718 0.000 0.006 svm~42 + 19 0.651 0.001 0.500 0.712 0.500 0.712 0.001 0.002 svm~35 + 17 0.651 0.001 0.515 0.712 0.507 0.718 0.001 0.217 nb~1 + 28 0.651 0.001 0.529 0.729 0.529 0.729 0.000 0.007 nb~12 + 18 0.651 0.001 0.500 0.686 0.479 0.704 0.005 0.004 nb~9 + 28 0.651 0.001 0.500 0.720 0.507 0.714 0.001 0.021 nb~18 + 19 0.651 0.001 0.647 0.602 0.484 0.747 0.000 0.002 knn~16 + 28 0.648 0.001 0.838 0.364 0.432 0.796 0.003 0.001 knn~16 + 6 0.648 0.001 0.515 0.661 0.467 0.703 0.016 0.038 nb~33 + 28 0.651 0.001 0.603 0.585 0.456 0.719 0.014 0.036 svm~35 + 20 0.651 0.001 0.618 0.585 0.462 0.726 0.005 0.030 svm~24 + 8 0.651 0.001 0.338 0.831 0.535 0.685 0.003 0.002 knn~4 + 8 0.647 0.001 0.794 0.381 0.425 0.763 0.010 0.004 rpart~4 + 21 0.648 0.001 0.426 0.771 0.518 0.700 0.003 0.044 rf~16 + 38 0.651 0.001 0.632 0.627 0.494 0.747 0.000 0.244 knn~2 + 20 0.648 0.001 0.779 0.432 0.442 0.773 0.003 0.013 svm~24 + 13 0.650 0.001 0.353 0.864 0.600 0.699 0.000 0.000 rf~8 + 22 0.650 0.001 0.647 0.610 0.489 0.750 0.000 0.029 knn~35 + 6 0.646 0.001 0.647 0.534 0.444 0.724 0.017 0.012 rpart~8 + 28 0.646 0.001 0.574 0.678 0.506 0.734 0.000 0.079 knn~37 + 6 0.647 0.001 0.721 0.432 0.422 0.729 0.032 0.006 nb~43 + 6 0.650 0.001 0.382 0.797 0.520 0.691 0.002 0.052 rpart~15 + 14 0.646 0.001 0.338 0.814 0.511 0.681 0.004 0.614 nb~1 + 15 0.650 0.001 0.412 0.695 0.438 0.672 0.106 0.161 nb~12 + 19 0.650 0.001 0.632 0.602 0.478 0.740 0.001 0.000 svm~32 + 6 0.650 0.001 0.456 0.780 0.544 0.713 0.000 0.003 rpart~18 + 8 0.644 0.001 0.588 0.686 0.519 0.743 0.000 0.047 knn~38 + 22 0.648 0.001 0.559 0.644 0.475 0.717 0.002 0.007 rpart~4 + 40 0.649 0.001 0.603 0.593 0.461 0.722 0.006 0.159 nb~16 + 13 0.650 0.001 0.485 0.669 0.458 0.693 0.029 0.032 nb~18 + 20 0.650 0.001 0.632 0.525 0.434 0.713 0.019 0.003 svm~4 + 26 0.650 0.001 0.397 0.907 0.711 0.723 0.000 0.002 svm~17 + 8 0.650 0.001 0.471 0.805 0.582 0.725 0.000 0.019 nb~18 + 2 0.650 0.001 0.485 0.686 0.471 0.698 0.030 0.390 rf~4 + 34 0.650 0.001 0.765 0.441 0.441 0.765 0.005 0.022 rpart~9 + 20 0.643 0.001 0.721 0.500 0.454 0.756 0.003 0.055 svm~17 + 13 0.650 0.001 0.441 0.729 0.484 0.694 0.008 0.020 nb~15 + 14 0.650 0.001 0.324 0.831 0.524 0.681 0.003 0.310 rpart~26 + 22 0.642 0.001 0.485 0.763 0.541 0.720 0.000 0.004 knn~4 + 2 0.646 0.001 0.779 0.424 0.438 0.769 0.003 0.083 nb~42 + 19 0.649 0.001 0.574 0.644 0.481 0.724 0.001 0.003 svm~29 + 28 0.649 0.001 0.397 0.763 0.491 0.687 0.010 0.009 nb~42 + 28 0.649 0.001 0.529 0.686 0.493 0.717 0.001 0.025 knn~39 + 19 0.646 0.001 0.647 0.619 0.494 0.753 0.000 0.000 rf~4 + 32 0.649 0.001 0.544 0.653 0.474 0.713 0.004 0.004 svm~16 + 8 0.649 0.001 0.485 0.703 0.485 0.703 0.006 0.309 svm~17 + 28 0.649 0.001 0.485 0.695 0.478 0.701 0.002 0.003 svm~41 + 22 0.649 0.001 0.544 0.669 0.487 0.718 0.003 0.019 rpart~14 + 20 0.634 0.001 0.735 0.551 0.485 0.783 0.000 0.001 svm~16 + 13 0.649 0.001 0.471 0.686 0.464 0.692 0.027 0.069 svm~28 + 32 0.649 0.001 0.441 0.771 0.526 0.705 0.000 0.006 svm~19 + 21 0.648 0.001 0.500 0.763 0.548 0.726 0.000 0.004 knn~42 + 18 0.643 0.001 0.632 0.602 0.478 0.740 0.004 0.016 nb~38 + 22 0.648 0.001 0.529 0.695 0.500 0.719 0.001 0.060 knn~4 + 41 0.645 0.001 0.456 0.746 0.508 0.704 0.002 0.007 rpart~15 + 24 0.638 0.001 0.721 0.517 0.462 0.763 0.001 0.064 rpart~10 + 28 0.640 0.001 0.441 0.746 0.500 0.698 0.011 0.086 rf~15 + 41 0.648 0.001 0.603 0.703 0.539 0.755 0.000 0.701 svm~33 + 22 0.648 0.001 0.544 0.610 0.446 0.699 0.024 0.061 rpart~33 + 28 0.645 0.001 0.603 0.593 0.461 0.722 0.006 0.211 rpart~2 + 22 0.640 0.001 0.706 0.508 0.453 0.750 0.003 0.125 nb~17 + 9 0.648 0.001 0.559 0.703 0.521 0.735 0.000 0.044 svm~16 + 29 0.648 0.001 0.368 0.873 0.625 0.705 0.000 0.005 svm~37 + 28 0.648 0.001 0.603 0.627 0.482 0.733 0.001 0.035 knn~32 + 6 0.645 0.001 0.500 0.653 0.453 0.694 0.024 0.008 nb~16 + 8 0.648 0.001 0.500 0.686 0.479 0.704 0.012 0.042 rpart~4 + 14 0.644 0.001 0.515 0.780 0.574 0.736 0.000 0.001 knn~5 + 19 0.644 0.001 0.647 0.585 0.473 0.742 0.001 0.003 nb~27 + 22 0.647 0.001 0.706 0.534 0.466 0.759 0.001 0.016 svm~4 + 14 0.647 0.001 0.456 0.822 0.596 0.724 0.000 0.002 nb~12 + 20 0.647 0.001 0.662 0.500 0.433 0.720 0.015 0.001 svm~16 + 31 0.647 0.001 0.426 0.754 0.500 0.695 0.007 0.267 nb~24 + 8 0.647 0.001 0.618 0.568 0.452 0.720 0.008 0.000 nb~35 + 26 0.647 0.001 0.603 0.602 0.466 0.724 0.012 0.007 rpart~18 + 22 0.638 0.001 0.426 0.771 0.518 0.700 0.002 0.049 nb~16 + 40 0.647 0.001 0.500 0.720 0.507 0.714 0.003 0.173 svm~18 + 6 0.647 0.001 0.456 0.737 0.500 0.702 0.003 0.046 svm~7 + 6 0.647 0.001 0.618 0.653 0.506 0.748 0.000 0.025 svm~40 + 17 0.647 0.001 0.603 0.644 0.494 0.738 0.000 0.059 rpart~16 + 22 0.644 0.001 0.574 0.636 0.476 0.721 0.003 0.042 rf~8 + 19 0.647 0.001 0.441 0.737 0.492 0.696 0.002 0.004 nb~4 + 11 0.647 0.001 0.382 0.941 0.788 0.725 0.000 0.009 nb~40 + 18 0.647 0.001 0.618 0.534 0.433 0.708 0.051 0.230 nb~17 + 24 0.647 0.001 0.515 0.678 0.479 0.708 0.002 0.000 svm~18 + 37 0.647 0.001 0.441 0.754 0.508 0.701 0.004 0.011 nb~20 + 34 0.647 0.001 0.691 0.542 0.465 0.753 0.001 0.004 svm~4 + 34 0.646 0.001 0.471 0.754 0.525 0.712 0.000 0.014 nb~29 + 6 0.646 0.001 0.500 0.763 0.548 0.726 0.000 0.032 rpart~25 + 19 0.640 0.001 0.647 0.542 0.449 0.727 0.005 0.014 rpart~29 + 20 0.632 0.001 0.706 0.534 0.466 0.759 0.001 0.004 rf~13 + 22 0.646 0.001 0.676 0.568 0.474 0.753 0.001 0.080 nb~18 + 9 0.646 0.001 0.588 0.602 0.460 0.717 0.023 0.068 svm~38 + 6 0.646 0.001 0.574 0.712 0.534 0.743 0.000 0.021 rpart~4 + 26 0.644 0.001 0.485 0.678 0.465 0.696 0.016 0.005 knn~17 + 22 0.643 0.001 0.559 0.661 0.487 0.722 0.001 0.036 knn~37 + 22 0.643 0.001 0.750 0.432 0.432 0.750 0.014 0.001 svm~18 + 13 0.646 0.001 0.559 0.661 0.487 0.722 0.002 0.006 nb~43 + 22 0.646 0.001 0.691 0.559 0.475 0.759 0.001 0.054 rpart~41 + 20 0.635 0.001 0.794 0.398 0.432 0.770 0.008 0.054 knn~4 + 27 0.643 0.001 0.529 0.619 0.444 0.695 0.038 0.061 svm~12 + 18 0.646 0.001 0.485 0.669 0.458 0.693 0.018 0.018 svm~1 + 6 0.645 0.001 0.515 0.720 0.515 0.720 0.000 0.008 svm~12 + 22 0.645 0.001 0.559 0.644 0.475 0.717 0.002 0.006 svm~39 + 22 0.645 0.001 0.588 0.593 0.455 0.714 0.008 0.024 nb~31 + 28 0.645 0.001 0.574 0.661 0.494 0.729 0.001 0.009 svm~34 + 6 0.645 0.001 0.603 0.619 0.477 0.730 0.001 0.005 knn~15 + 9 0.642 0.001 0.382 0.805 0.531 0.693 0.001 0.050 nb~16 + 5 0.645 0.001 0.662 0.534 0.450 0.733 0.011 0.023 rpart~17 + 22 0.640 0.001 0.515 0.669 0.473 0.705 0.007 0.390 svm~4 + 11 0.645 0.001 0.441 0.873 0.667 0.730 0.000 0.004 svm~32 + 22 0.645 0.001 0.456 0.737 0.500 0.702 0.002 0.002 rf~4 + 7 0.645 0.001 0.588 0.610 0.465 0.720 0.009 0.016 svm~35 + 24 0.645 0.001 0.279 0.873 0.559 0.678 0.005 0.031 svm~7 + 19 0.645 0.001 0.691 0.551 0.470 0.756 0.001 0.017 nb~35 + 18 0.645 0.001 0.559 0.602 0.447 0.703 0.036 0.086 nb~17 + 37 0.645 0.001 0.618 0.661 0.512 0.750 0.000 0.111 knn~20 + 6 0.642 0.001 0.676 0.525 0.451 0.738 0.005 0.001 knn~4 + 6 0.641 0.001 0.544 0.737 0.544 0.737 0.000 0.003 rf~24 + 19 0.644 0.001 0.515 0.703 0.500 0.716 0.000 0.000 knn~4 + 32 0.642 0.001 0.618 0.653 0.506 0.748 0.000 0.077 nb~26 + 2 0.644 0.001 0.397 0.771 0.500 0.689 0.018 0.213 rpart~4 + 37 0.626 0.001 0.412 0.763 0.500 0.692 0.005 0.002 nb~29 + 22 0.644 0.001 0.515 0.720 0.515 0.720 0.001 0.035 nb~39 + 6 0.644 0.001 0.485 0.712 0.493 0.706 0.002 0.030 rf~33 + 19 0.644 0.001 0.647 0.483 0.419 0.704 0.051 0.009 nb~35 + 24 0.644 0.001 0.471 0.763 0.533 0.714 0.000 0.010 rpart~1 + 19 0.639 0.001 0.632 0.602 0.478 0.740 0.000 0.003 knn~4 + 14 0.642 0.001 0.529 0.712 0.514 0.724 0.000 0.005 rf~12 + 31 0.644 0.001 0.588 0.551 0.430 0.699 0.045 0.144 nb~15 + 36 0.644 0.001 0.500 0.754 0.540 0.724 0.000 0.267 nb~36 + 19 0.644 0.001 0.706 0.542 0.471 0.762 0.000 0.003 svm~27 + 22 0.644 0.001 0.588 0.636 0.482 0.728 0.002 0.023 svm~1 + 28 0.644 0.001 0.515 0.780 0.574 0.736 0.000 0.003 knn~4 + 9 0.641 0.001 0.529 0.712 0.514 0.724 0.000 0.007 knn~4 + 36 0.641 0.001 0.721 0.373 0.398 0.698 0.099 0.002 knn~39 + 22 0.641 0.001 0.632 0.627 0.494 0.747 0.000 0.161 rpart~24 + 32 0.641 0.001 0.353 0.831 0.545 0.690 0.001 0.000 rpart~12 + 18 0.642 0.001 0.618 0.551 0.442 0.714 0.022 0.039 svm~16 + 21 0.643 0.001 0.559 0.669 0.494 0.725 0.001 0.442 svm~17 + 6 0.643 0.001 0.471 0.712 0.485 0.700 0.004 0.012 nb~24 + 18 0.643 0.001 0.456 0.678 0.449 0.684 0.042 0.001 nb~15 + 43 0.643 0.001 0.485 0.703 0.485 0.703 0.005 0.444 svm~5 + 6 0.643 0.001 0.471 0.703 0.478 0.697 0.011 0.015 knn~26 + 19 0.640 0.001 0.794 0.364 0.419 0.754 0.018 0.048 nb~16 + 41 0.643 0.001 0.368 0.729 0.439 0.667 0.149 0.188 rf~20 + 22 0.643 0.001 0.485 0.661 0.452 0.690 0.032 0.021 knn~9 + 22 0.640 0.001 0.574 0.695 0.520 0.739 0.000 0.022 nb~4 + 14 0.643 0.001 0.397 0.890 0.675 0.719 0.000 0.004 nb~10 + 28 0.643 0.001 0.397 0.797 0.529 0.696 0.001 0.035 rf~15 + 19 0.643 0.001 0.574 0.636 0.476 0.721 0.005 0.021 nb~15 + 27 0.643 0.001 0.471 0.669 0.451 0.687 0.025 0.181 nb~16 + 31 0.643 0.001 0.471 0.720 0.492 0.702 0.007 0.059 knn~24 + 2 0.639 0.001 0.735 0.475 0.446 0.757 0.005 0.202 knn~13 + 26 0.638 0.001 0.662 0.483 0.425 0.713 0.045 0.002 knn~18 + 13 0.639 0.001 0.779 0.398 0.427 0.758 0.016 0.042 svm~15 + 29 0.642 0.001 0.397 0.822 0.563 0.703 0.000 0.371 svm~17 + 2 0.642 0.001 0.544 0.661 0.481 0.716 0.005 0.196 knn~37 + 19 0.639 0.001 0.853 0.314 0.417 0.787 0.008 0.011 rpart~18 + 28 0.641 0.001 0.485 0.729 0.508 0.711 0.001 0.016 svm~42 + 22 0.642 0.001 0.559 0.636 0.469 0.714 0.004 0.027 svm~33 + 28 0.642 0.001 0.588 0.568 0.440 0.705 0.040 0.015 rpart~24 + 8 0.637 0.001 0.324 0.814 0.500 0.676 0.009 0.003 svm~43 + 19 0.642 0.001 0.515 0.720 0.515 0.720 0.000 0.064 nb~23 + 20 0.642 0.001 0.765 0.466 0.452 0.775 0.002 0.095 nb~35 + 32 0.642 0.001 0.500 0.695 0.486 0.707 0.003 0.050 svm~4 + 21 0.642 0.001 0.441 0.839 0.612 0.723 0.000 0.026 rpart~24 + 2 0.637 0.001 0.382 0.856 0.605 0.706 0.000 0.005 nb~15 + 38 0.642 0.001 0.412 0.746 0.483 0.688 0.018 0.369 nb~7 + 6 0.642 0.001 0.515 0.695 0.493 0.713 0.002 0.077 nb~8 + 26 0.642 0.001 0.750 0.381 0.411 0.726 0.068 0.003 knn~4 + 37 0.639 0.001 0.779 0.390 0.424 0.754 0.011 0.006 svm~15 + 7 0.642 0.001 0.456 0.712 0.477 0.694 0.010 0.662 knn~15 + 24 0.637 0.001 0.632 0.542 0.443 0.719 0.019 0.072 rf~1 + 22 0.641 0.001 0.632 0.610 0.483 0.742 0.001 0.010 rpart~24 + 33 0.635 0.001 0.368 0.788 0.500 0.684 0.005 0.002 rpart~8 + 6 0.639 0.001 0.529 0.703 0.507 0.722 0.001 0.016 rpart~2 + 28 0.639 0.001 0.574 0.686 0.513 0.736 0.000 0.336 svm~41 + 19 0.641 0.001 0.441 0.746 0.500 0.698 0.004 0.034 rpart~1 + 2 0.640 0.001 0.529 0.712 0.514 0.724 0.002 0.188 rpart~31 + 22 0.634 0.001 0.544 0.686 0.500 0.723 0.001 0.002 svm~4 + 17 0.641 0.001 0.426 0.780 0.527 0.702 0.001 0.003 rpart~16 + 10 0.628 0.001 0.515 0.763 0.556 0.732 0.000 0.033 rpart~32 + 6 0.637 0.001 0.485 0.678 0.465 0.696 0.020 0.021 rpart~16 + 33 0.640 0.001 0.603 0.636 0.488 0.735 0.001 0.732 knn~4 + 11 0.637 0.001 0.441 0.771 0.526 0.705 0.001 0.014 svm~14 + 19 0.641 0.001 0.471 0.712 0.485 0.700 0.002 0.006 svm~35 + 18 0.641 0.001 0.382 0.754 0.473 0.679 0.053 0.027 rpart~15 + 12 0.637 0.001 0.324 0.746 0.423 0.657 0.179 0.348 rpart~4 + 33 0.639 0.001 0.618 0.568 0.452 0.720 0.009 0.007 nb~28 + 34 0.641 0.001 0.574 0.653 0.488 0.726 0.001 0.009 knn~28 + 21 0.636 0.001 0.779 0.398 0.427 0.758 0.015 0.017 nb~17 + 2 0.640 0.001 0.529 0.686 0.493 0.717 0.004 0.465 rpart~20 + 38 0.632 0.001 0.706 0.508 0.453 0.750 0.003 0.194 rf~18 + 8 0.640 0.001 0.632 0.602 0.478 0.740 0.002 0.011 svm~15 + 20 0.640 0.001 0.559 0.644 0.475 0.717 0.002 0.058 nb~18 + 32 0.640 0.001 0.500 0.703 0.493 0.709 0.002 0.005 rpart~14 + 22 0.633 0.001 0.441 0.754 0.508 0.701 0.001 0.013 rf~15 + 20 0.640 0.001 0.647 0.559 0.458 0.733 0.009 0.512 svm~41 + 28 0.640 0.001 0.471 0.669 0.451 0.687 0.043 0.013 rf~19 + 3 0.640 0.001 0.603 0.619 0.477 0.730 0.001 0.001 auc.pvalue: Wilcoxon Test P-value. mfd: Median Fold Difference. KM: Kaplan Meier curves. MvaHRPval: Multivariable Analysis Hazard Ratio P-value. *Multiple classifiers with p-values between 0.001 and 0.05 not included.

TABLE 51 pairwise biomarkers from the 43 biomarker panel with significance for Wilcoxon P-value (auc.pvalue <= 0.05) and other metrics for the PCSM event endpoint. Pos. Neg. KM auc. Pred. Pred. P- Mva Classifier auc pvalue Sensitivity Specificity Value Value value HRPval svm~31 + 19 0.80 0.00 0.78 0.61 0.33 0.92 0.00 0.00 nb~16 + 19 0.79 0.00 0.83 0.65 0.36 0.94 0.00 0.00 svm~4 + 16 0.78 0.00 0.64 0.72 0.35 0.89 0.00 0.02 nb~4 + 16 0.78 0.00 0.61 0.85 0.49 0.90 0.00 0.01 svm~16 + 19 0.78 0.00 0.75 0.63 0.33 0.91 0.00 0.00 nb~16 + 22 0.77 0.00 0.78 0.68 0.37 0.93 0.00 0.01 nb~16 + 18 0.77 0.00 0.78 0.63 0.34 0.92 0.00 0.01 svm~40 + 19 0.77 0.00 0.83 0.59 0.33 0.94 0.00 0.01 nb~4 + 28 0.77 0.00 0.58 0.79 0.40 0.89 0.00 0.01 svm~35 + 19 0.77 0.00 0.69 0.71 0.36 0.91 0.00 0.01 nb~16 + 28 0.77 0.00 0.81 0.61 0.33 0.93 0.00 0.00 nb~16 + 20 0.77 0.00 0.81 0.53 0.29 0.92 0.00 0.00 nb~16 + 6 0.77 0.00 0.72 0.71 0.38 0.91 0.00 0.00 rpart~4 + 16 0.76 0.00 0.72 0.68 0.35 0.91 0.00 0.04 svm~39 + 19 0.77 0.00 0.81 0.59 0.32 0.93 0.00 0.00 svm~16 + 28 0.77 0.00 0.67 0.73 0.38 0.90 0.00 0.04 svm~16 + 18 0.77 0.00 0.75 0.73 0.40 0.92 0.00 0.01 nb~40 + 28 0.76 0.00 0.83 0.63 0.35 0.94 0.00 0.01 nb~28 + 6 0.76 0.00 0.75 0.69 0.37 0.92 0.00 0.00 nb~40 + 19 0.76 0.00 0.86 0.52 0.30 0.94 0.00 0.01 nb~12 + 28 0.76 0.00 0.81 0.65 0.35 0.93 0.00 0.00 svm~43 + 19 0.76 0.00 0.69 0.71 0.37 0.91 0.00 0.00 nb~43 + 19 0.76 0.00 0.94 0.51 0.32 0.97 0.00 0.00 nb~4 + 24 0.76 0.00 0.53 0.87 0.49 0.88 0.00 0.00 nb~24 + 28 0.76 0.00 0.58 0.73 0.34 0.88 0.00 0.00 nb~15 + 28 0.76 0.00 0.58 0.77 0.38 0.89 0.00 0.01 svm~13 + 22 0.76 0.00 0.81 0.66 0.36 0.93 0.00 0.04 knn~16 + 18 0.75 0.00 0.92 0.37 0.26 0.95 0.00 0.02 svm~4 + 24 0.76 0.00 0.56 0.83 0.44 0.89 0.00 0.00 nb~19 + 28 0.76 0.00 0.81 0.63 0.34 0.93 0.00 0.00 nb~4 + 12 0.75 0.00 0.64 0.79 0.42 0.90 0.00 0.01 nb~28 + 22 0.75 0.00 0.75 0.66 0.35 0.92 0.00 0.01 svm~16 + 22 0.75 0.00 0.75 0.63 0.33 0.91 0.00 0.02 nb~12 + 22 0.75 0.00 0.75 0.67 0.35 0.92 0.00 0.01 nb~4 + 35 0.75 0.00 0.61 0.85 0.49 0.90 0.00 0.03 svm~29 + 19 0.75 0.00 0.69 0.68 0.34 0.90 0.00 0.00 nb~35 + 19 0.75 0.00 0.81 0.53 0.29 0.92 0.00 0.01 nb~4 + 19 0.75 0.00 0.61 0.78 0.40 0.89 0.00 0.01 nb~16 + 24 0.75 0.00 0.67 0.70 0.35 0.90 0.00 0.00 nb~20 + 28 0.75 0.00 0.75 0.59 0.30 0.91 0.00 0.00 nb~18 + 28 0.75 0.00 0.64 0.65 0.31 0.88 0.00 0.01 nb~43 + 6 0.75 0.00 0.47 0.78 0.34 0.86 0.00 0.01 nb~35 + 6 0.75 0.00 0.61 0.74 0.36 0.89 0.00 0.01 nb~35 + 20 0.75 0.00 0.89 0.41 0.26 0.94 0.00 0.00 svm~8 + 22 0.75 0.00 0.67 0.71 0.36 0.90 0.00 0.01 nb~16 + 26 0.75 0.00 0.58 0.73 0.34 0.88 0.00 0.00 nb~12 + 6 0.75 0.00 0.78 0.63 0.33 0.92 0.00 0.01 nb~40 + 24 0.74 0.00 0.64 0.63 0.29 0.88 0.00 0.00 rpart~20 + 22 0.74 0.00 0.61 0.68 0.31 0.88 0.00 0.01 nb~4 + 43 0.74 0.00 0.53 0.85 0.45 0.88 0.00 0.01 nb~12 + 18 0.74 0.00 0.69 0.69 0.35 0.90 0.00 0.02 svm~16 + 6 0.74 0.00 0.75 0.67 0.35 0.92 0.00 0.00 svm~4 + 12 0.74 0.00 0.64 0.79 0.42 0.90 0.00 0.04 rpart~8 + 28 0.74 0.00 0.75 0.67 0.35 0.92 0.00 0.01 nb~40 + 22 0.74 0.00 0.72 0.56 0.28 0.89 0.00 0.07 svm~13 + 28 0.74 0.00 0.64 0.65 0.30 0.88 0.00 0.02 nb~26 + 28 0.74 0.00 0.67 0.66 0.32 0.89 0.00 0.00 nb~40 + 6 0.74 0.00 0.61 0.74 0.36 0.89 0.00 0.03 svm~12 + 6 0.74 0.00 0.67 0.68 0.33 0.89 0.00 0.00 knn~24 + 22 0.73 0.00 0.67 0.76 0.40 0.90 0.00 0.04 rpart~4 + 38 0.74 0.00 0.75 0.64 0.33 0.91 0.00 0.05 svm~19 + 22 0.74 0.00 0.58 0.70 0.32 0.88 0.00 0.01 svm~40 + 28 0.74 0.00 0.83 0.58 0.32 0.94 0.00 0.02 rpart~4 + 24 0.73 0.00 0.56 0.79 0.39 0.88 0.00 0.01 svm~19 + 28 0.74 0.00 0.69 0.71 0.36 0.91 0.00 0.00 svm~4 + 31 0.74 0.00 0.69 0.68 0.34 0.90 0.00 0.04 nb~4 + 20 0.74 0.00 0.69 0.72 0.37 0.91 0.00 0.01 nb~4 + 15 0.74 0.00 0.56 0.79 0.39 0.88 0.00 0.03 svm~33 + 19 0.74 0.00 0.64 0.60 0.28 0.87 0.00 0.00 nb~24 + 22 0.74 0.00 0.72 0.59 0.30 0.90 0.00 0.00 nb~12 + 19 0.74 0.00 0.75 0.58 0.30 0.91 0.00 0.00 nb~4 + 23 0.74 0.00 0.61 0.77 0.39 0.89 0.00 0.06 nb~4 + 31 0.74 0.00 0.56 0.79 0.38 0.88 0.00 0.03 svm~13 + 19 0.74 0.00 0.83 0.50 0.29 0.93 0.00 0.03 nb~4 + 6 0.74 0.00 0.58 0.77 0.38 0.88 0.00 0.04 nb~43 + 28 0.74 0.00 0.69 0.68 0.34 0.90 0.00 0.00 nb~28 + 32 0.74 0.00 0.67 0.63 0.30 0.89 0.00 0.02 nb~19 + 6 0.74 0.00 0.61 0.74 0.36 0.89 0.00 0.00 knn~4 + 16 0.73 0.00 0.78 0.59 0.31 0.92 0.00 0.02 nb~13 + 22 0.74 0.00 0.75 0.67 0.35 0.92 0.00 0.07 rf~31 + 19 0.74 0.00 0.81 0.53 0.29 0.92 0.00 0.00 nb~43 + 22 0.74 0.00 0.83 0.54 0.30 0.93 0.00 0.02 nb~4 + 8 0.73 0.00 0.53 0.87 0.50 0.89 0.00 0.03 nb~4 + 32 0.73 0.00 0.61 0.82 0.45 0.90 0.00 0.05 nb~4 + 40 0.73 0.00 0.58 0.87 0.53 0.90 0.00 0.04 svm~4 + 13 0.73 0.00 0.61 0.83 0.46 0.90 0.00 0.01 rpart~4 + 39 0.72 0.00 0.67 0.73 0.37 0.90 0.00 0.00 svm~29 + 22 0.73 0.00 0.69 0.58 0.28 0.89 0.00 0.04 nb~40 + 20 0.73 0.00 0.78 0.53 0.28 0.91 0.00 0.01 nb~35 + 22 0.73 0.00 0.81 0.48 0.27 0.91 0.00 0.03 rf~13 + 26 0.73 0.00 0.72 0.66 0.34 0.91 0.00 0.02 svm~8 + 19 0.73 0.00 0.72 0.62 0.31 0.90 0.00 0.00 nb~24 + 20 0.73 0.00 0.78 0.51 0.27 0.90 0.00 0.00 nb~15 + 6 0.73 0.00 0.42 0.79 0.33 0.85 0.00 0.03 svm~35 + 22 0.73 0.00 0.58 0.75 0.36 0.88 0.00 0.09 nb~8 + 19 0.73 0.00 0.72 0.65 0.33 0.91 0.00 0.01 nb~4 + 22 0.73 0.00 0.61 0.77 0.39 0.89 0.00 0.05 svm~4 + 40 0.73 0.00 0.72 0.58 0.29 0.90 0.00 0.18 svm~4 + 8 0.73 0.00 0.64 0.81 0.45 0.90 0.00 0.00 nb~13 + 19 0.73 0.00 0.83 0.51 0.29 0.93 0.00 0.02 svm~4 + 29 0.73 0.00 0.56 0.83 0.44 0.89 0.00 0.01 svm~4 + 38 0.73 0.00 0.64 0.77 0.40 0.90 0.00 0.01 nb~19 + 32 0.73 0.00 0.67 0.71 0.35 0.90 0.00 0.01 nb~13 + 28 0.73 0.00 0.61 0.68 0.31 0.88 0.00 0.01 nb~26 + 19 0.73 0.00 0.83 0.53 0.30 0.93 0.00 0.01 nb~35 + 28 0.73 0.00 0.64 0.65 0.31 0.88 0.00 0.01 nb~24 + 6 0.73 0.00 0.44 0.82 0.37 0.86 0.00 0.00 svm~19 + 6 0.73 0.00 0.67 0.69 0.34 0.90 0.00 0.01 nb~19 + 22 0.73 0.00 0.81 0.53 0.29 0.92 0.00 0.01 nb~24 + 19 0.73 0.00 0.67 0.67 0.33 0.89 0.00 0.00 nb~4 + 13 0.73 0.00 0.56 0.88 0.53 0.89 0.00 0.03 svm~4 + 15 0.73 0.00 0.44 0.83 0.38 0.86 0.00 0.04 nb~8 + 28 0.73 0.00 0.72 0.63 0.32 0.90 0.00 0.01 svm~37 + 19 0.73 0.00 0.72 0.55 0.28 0.89 0.00 0.01 nb~12 + 24 0.73 0.00 0.64 0.77 0.40 0.90 0.00 0.00 nb~13 + 6 0.73 0.00 0.69 0.68 0.34 0.90 0.00 0.02 nb~20 + 6 0.73 0.00 0.67 0.66 0.32 0.89 0.00 0.00 svm~4 + 14 0.73 0.00 0.58 0.79 0.40 0.89 0.00 0.02 knn~40 + 6 0.72 0.00 0.94 0.29 0.24 0.96 0.00 0.02 nb~4 + 26 0.73 0.00 0.56 0.83 0.43 0.89 0.00 0.02 nb~32 + 6 0.73 0.00 0.50 0.81 0.39 0.87 0.00 0.03 svm~38 + 28 0.73 0.00 0.69 0.64 0.32 0.90 0.00 0.01 rpart~13 + 6 0.72 0.00 0.72 0.67 0.34 0.91 0.00 0.05 svm~4 + 35 0.73 0.00 0.61 0.77 0.39 0.89 0.00 0.05 nb~4 + 18 0.73 0.00 0.58 0.74 0.35 0.88 0.00 0.05 nb~12 + 26 0.73 0.00 0.58 0.77 0.38 0.89 0.00 0.01 rf~24 + 22 0.73 0.00 0.69 0.67 0.34 0.90 0.00 0.02 svm~19 + 38 0.73 0.00 0.72 0.63 0.32 0.90 0.00 0.02 nb~19 + 20 0.73 0.00 0.78 0.49 0.27 0.90 0.00 0.01 nb~31 + 28 0.73 0.00 0.78 0.66 0.35 0.93 0.00 0.00 svm~40 + 24 0.73 0.00 0.78 0.63 0.33 0.92 0.00 0.02 svm~12 + 28 0.73 0.00 0.64 0.68 0.32 0.89 0.00 0.08 knn~18 + 32 0.72 0.00 0.89 0.39 0.26 0.94 0.00 0.03 nb~4 + 33 0.72 0.00 0.56 0.85 0.48 0.89 0.00 0.07 nb~31 + 19 0.72 0.00 0.75 0.67 0.35 0.92 0.00 0.01 nb~8 + 22 0.72 0.00 0.78 0.57 0.30 0.91 0.00 0.06 svm~14 + 19 0.72 0.00 0.58 0.70 0.32 0.88 0.00 0.01 nb~32 + 22 0.72 0.00 0.67 0.61 0.29 0.88 0.00 0.05 nb~4 + 36 0.72 0.00 0.50 0.89 0.51 0.88 0.00 0.03 svm~40 + 6 0.72 0.00 0.81 0.55 0.30 0.92 0.00 0.08 svm~39 + 22 0.72 0.00 0.75 0.59 0.31 0.91 0.00 0.03 rpart~16 + 6 0.71 0.00 0.61 0.69 0.32 0.88 0.00 0.04 knn~13 + 19 0.72 0.00 0.50 0.75 0.32 0.86 0.00 0.07 rpart~4 + 31 0.72 0.00 0.75 0.66 0.35 0.92 0.00 0.04 svm~13 + 6 0.72 0.00 0.69 0.69 0.35 0.90 0.00 0.04 svm~4 + 42 0.72 0.00 0.69 0.64 0.32 0.90 0.00 0.09 nb~12 + 20 0.72 0.00 0.75 0.49 0.26 0.89 0.00 0.00 nb~22 + 6 0.72 0.00 0.64 0.66 0.31 0.88 0.00 0.02 rpart~4 + 43 0.72 0.00 0.56 0.71 0.32 0.87 0.00 0.01 rf~13 + 22 0.72 0.00 0.78 0.54 0.29 0.91 0.00 0.45 nb~26 + 6 0.72 0.00 0.69 0.68 0.34 0.90 0.00 0.01 svm~35 + 6 0.72 0.00 0.58 0.74 0.35 0.88 0.00 0.05 nb~20 + 22 0.72 0.00 0.69 0.59 0.29 0.89 0.00 0.01 rf~4 + 12 0.72 0.00 0.69 0.57 0.28 0.89 0.00 0.02 nb~14 + 28 0.72 0.00 0.61 0.75 0.37 0.89 0.00 0.01 rpart~24 + 38 0.71 0.00 0.61 0.77 0.39 0.89 0.00 0.00 svm~4 + 28 0.72 0.00 0.61 0.74 0.36 0.89 0.00 0.04 svm~24 + 13 0.72 0.00 0.42 0.83 0.38 0.86 0.00 0.02 svm~19 + 21 0.72 0.00 0.64 0.74 0.37 0.90 0.00 0.01 nb~18 + 6 0.72 0.00 0.64 0.68 0.32 0.89 0.00 0.02 svm~13 + 26 0.72 0.00 0.53 0.86 0.48 0.88 0.00 0.18 nb~17 + 28 0.72 0.00 0.64 0.67 0.32 0.88 0.00 0.00 rpart~39 + 28 0.71 0.00 0.78 0.64 0.34 0.92 0.00 0.01 nb~37 + 28 0.72 0.00 0.69 0.62 0.30 0.89 0.00 0.02 nb~24 + 43 0.72 0.00 0.61 0.67 0.31 0.88 0.00 0.00 rf~16 + 19 0.72 0.00 0.72 0.57 0.29 0.90 0.00 0.01 svm~15 + 28 0.72 0.00 0.56 0.78 0.38 0.88 0.00 0.02 svm~31 + 22 0.72 0.00 0.69 0.61 0.30 0.89 0.00 0.05 rpart~31 + 19 0.71 0.00 0.86 0.54 0.31 0.94 0.00 0.01 nb~16 + 17 0.72 0.00 0.61 0.75 0.37 0.89 0.00 0.02 rpart~26 + 22 0.71 0.00 0.61 0.74 0.36 0.89 0.00 0.03 svm~16 + 24 0.72 0.00 0.39 0.89 0.45 0.86 0.00 0.02 svm~40 + 26 0.72 0.00 0.75 0.59 0.30 0.91 0.00 0.05 nb~43 + 20 0.72 0.00 0.78 0.50 0.27 0.90 0.00 0.00 svm~12 + 19 0.72 0.00 0.72 0.65 0.33 0.91 0.00 0.03 rpart~24 + 32 0.71 0.00 0.50 0.83 0.41 0.87 0.00 0.02 svm~31 + 28 0.72 0.00 0.81 0.63 0.34 0.93 0.00 0.01 nb~20 + 32 0.72 0.00 0.75 0.53 0.28 0.90 0.00 0.02 rpart~16 + 20 0.71 0.00 0.78 0.52 0.28 0.91 0.00 0.04 rpart~4 + 13 0.71 0.00 0.64 0.67 0.32 0.89 0.00 0.04 nb~24 + 26 0.72 0.00 0.72 0.67 0.34 0.91 0.00 0.00 rpart~24 + 22 0.71 0.00 0.64 0.73 0.37 0.89 0.00 0.02 rpart~8 + 19 0.71 0.00 0.75 0.62 0.32 0.91 0.00 0.00 nb~15 + 22 0.72 0.00 0.50 0.74 0.32 0.86 0.00 0.06 svm~28 + 32 0.72 0.00 0.53 0.75 0.33 0.87 0.00 0.09 svm~4 + 41 0.72 0.00 0.42 0.82 0.36 0.85 0.00 0.01 svm~4 + 19 0.72 0.00 0.81 0.68 0.38 0.94 0.00 0.02 knn~12 + 22 0.71 0.00 0.67 0.68 0.33 0.89 0.00 0.05 nb~16 + 32 0.72 0.00 0.64 0.71 0.34 0.89 0.00 0.06 nb~26 + 22 0.72 0.00 0.78 0.57 0.30 0.91 0.00 0.03 svm~12 + 18 0.72 0.00 0.67 0.68 0.33 0.89 0.00 0.05 nb~8 + 6 0.72 0.00 0.58 0.72 0.33 0.88 0.00 0.03 svm~18 + 19 0.72 0.00 0.72 0.64 0.33 0.91 0.00 0.01 rf~33 + 19 0.72 0.00 0.75 0.48 0.26 0.89 0.01 0.00 svm~26 + 19 0.72 0.00 0.64 0.76 0.39 0.90 0.00 0.01 nb~15 + 16 0.72 0.00 0.53 0.73 0.32 0.87 0.00 0.05 nb~42 + 6 0.71 0.00 0.61 0.75 0.37 0.89 0.00 0.04 nb~18 + 22 0.71 0.00 0.81 0.59 0.32 0.93 0.00 0.05 nb~14 + 19 0.71 0.00 0.81 0.45 0.26 0.91 0.00 0.01 rpart~33 + 28 0.71 0.00 0.72 0.58 0.29 0.90 0.00 0.15 svm~4 + 1 0.71 0.00 0.56 0.81 0.41 0.88 0.00 0.03 svm~24 + 19 0.71 0.00 0.58 0.79 0.40 0.89 0.00 0.01 nb~33 + 6 0.71 0.00 0.64 0.72 0.35 0.89 0.00 0.07 nb~42 + 28 0.71 0.00 0.61 0.66 0.30 0.88 0.00 0.02 knn~15 + 16 0.71 0.00 0.81 0.43 0.25 0.90 0.00 0.07 svm~16 + 26 0.71 0.00 0.56 0.78 0.38 0.88 0.00 0.03 rpart~24 + 28 0.71 0.00 0.44 0.77 0.31 0.85 0.00 0.02 nb~31 + 6 0.71 0.00 0.64 0.71 0.34 0.89 0.00 0.01 svm~12 + 22 0.71 0.00 0.67 0.63 0.30 0.89 0.00 0.08 nb~15 + 19 0.71 0.00 0.53 0.77 0.36 0.87 0.00 0.03 nb~18 + 19 0.71 0.00 0.72 0.57 0.29 0.89 0.00 0.02 nb~23 + 20 0.71 0.00 0.89 0.45 0.28 0.94 0.00 0.01 knn~4 + 32 0.71 0.00 0.78 0.63 0.34 0.92 0.00 0.37 knn~40 + 19 0.71 0.00 0.83 0.48 0.28 0.92 0.00 0.02 svm~15 + 19 0.71 0.00 0.47 0.81 0.37 0.86 0.00 0.07 nb~4 + 41 0.71 0.00 0.53 0.79 0.38 0.88 0.00 0.05 rpart~18 + 22 0.70 0.00 0.53 0.75 0.34 0.87 0.00 0.12 rf~13 + 19 0.71 0.00 0.89 0.35 0.25 0.93 0.01 0.05 nb~15 + 24 0.71 0.00 0.58 0.73 0.34 0.88 0.00 0.01 rpart~20 + 28 0.70 0.00 0.81 0.47 0.27 0.91 0.00 0.01 knn~31 + 19 0.71 0.00 0.78 0.53 0.28 0.91 0.00 0.01 svm~7 + 19 0.71 0.00 0.78 0.52 0.28 0.91 0.00 0.05 rf~40 + 28 0.71 0.00 0.86 0.49 0.29 0.94 0.00 0.10 knn~40 + 28 0.71 0.00 0.58 0.77 0.38 0.89 0.00 0.01 rpart~4 + 32 0.71 0.00 0.61 0.71 0.33 0.88 0.00 0.19 nb~4 + 42 0.71 0.00 0.53 0.83 0.43 0.88 0.00 0.07 svm~8 + 28 0.71 0.00 0.69 0.65 0.32 0.90 0.00 0.02 rf~12 + 19 0.71 0.00 0.64 0.66 0.31 0.88 0.00 0.01 nb~42 + 22 0.71 0.00 0.72 0.51 0.26 0.88 0.01 0.16 nb~4 + 11 0.71 0.00 0.47 0.89 0.52 0.88 0.00 0.09 nb~40 + 18 0.71 0.00 0.75 0.53 0.28 0.90 0.00 0.16 nb~15 + 32 0.71 0.00 0.33 0.84 0.33 0.84 0.00 0.15 svm~4 + 32 0.71 0.00 0.61 0.73 0.35 0.89 0.00 0.13 svm~29 + 28 0.71 0.00 0.47 0.75 0.31 0.85 0.00 0.02 knn~16 + 19 0.71 0.00 0.81 0.59 0.32 0.93 0.00 0.00 nb~4 + 29 0.71 0.00 0.58 0.73 0.34 0.88 0.00 0.10 svm~4 + 39 0.71 0.00 0.64 0.69 0.33 0.89 0.00 0.00 knn~18 + 13 0.71 0.00 0.89 0.39 0.26 0.94 0.00 0.43 svm~19 + 32 0.71 0.00 0.61 0.75 0.37 0.89 0.00 0.01 svm~28 + 22 0.71 0.00 0.64 0.73 0.37 0.89 0.00 0.01 svm~8 + 6 0.71 0.00 0.67 0.67 0.33 0.89 0.00 0.02 nb~4 + 14 0.71 0.00 0.50 0.85 0.45 0.88 0.00 0.03 rf~24 + 13 0.71 0.00 0.64 0.57 0.26 0.87 0.01 0.01 rf~9 + 19 0.71 0.00 0.83 0.57 0.32 0.93 0.00 0.00 nb~41 + 28 0.71 0.00 0.67 0.59 0.28 0.88 0.00 0.02 nb~42 + 19 0.71 0.00 0.69 0.63 0.31 0.90 0.00 0.04 nb~4 + 1 0.71 0.00 0.58 0.79 0.40 0.89 0.00 0.05 svm~1 + 19 0.71 0.00 0.69 0.61 0.30 0.89 0.00 0.00 knn~35 + 19 0.70 0.00 0.89 0.39 0.26 0.94 0.00 0.00 svm~4 + 11 0.71 0.00 0.53 0.83 0.42 0.88 0.00 0.04 nb~18 + 32 0.71 0.00 0.61 0.69 0.32 0.88 0.00 0.12 nb~24 + 32 0.71 0.00 0.42 0.89 0.48 0.86 0.00 0.01 nb~33 + 28 0.71 0.00 0.72 0.57 0.29 0.90 0.00 0.02 rpart~4 + 18 0.70 0.00 0.67 0.67 0.33 0.89 0.00 0.03 svm~4 + 18 0.71 0.00 0.53 0.77 0.35 0.87 0.00 0.16 svm~2 + 28 0.71 0.00 0.75 0.57 0.30 0.91 0.00 0.03 svm~16 + 29 0.71 0.00 0.44 0.84 0.40 0.86 0.00 0.01 nb~4 + 39 0.71 0.00 0.58 0.76 0.37 0.88 0.00 0.04 svm~24 + 31 0.71 0.00 0.44 0.84 0.40 0.86 0.00 0.00 svm~39 + 28 0.71 0.00 0.69 0.67 0.34 0.90 0.00 0.01 nb~14 + 22 0.71 0.00 0.75 0.56 0.29 0.90 0.00 0.05 knn~4 + 42 0.70 0.00 0.89 0.29 0.23 0.92 0.02 0.02 knn~16 + 17 0.70 0.00 0.64 0.69 0.33 0.89 0.00 0.03 svm~32 + 22 0.71 0.00 0.58 0.73 0.34 0.88 0.00 0.04 rpart~14 + 28 0.68 0.00 0.53 0.80 0.39 0.88 0.00 0.07 rpart~15 + 33 0.70 0.00 0.42 0.85 0.39 0.86 0.00 0.78 rpart~14 + 24 0.70 0.00 0.47 0.79 0.35 0.86 0.00 0.02 svm~42 + 19 0.71 0.00 0.58 0.69 0.31 0.87 0.00 0.11 nb~18 + 20 0.71 0.00 0.72 0.51 0.26 0.89 0.00 0.02 rpart~4 + 42 0.70 0.00 0.75 0.58 0.30 0.91 0.00 0.12 svm~12 + 24 0.71 0.00 0.39 0.87 0.41 0.86 0.00 0.04 rpart~32 + 22 0.70 0.00 0.61 0.73 0.35 0.89 0.00 0.17 nb~4 + 25 0.71 0.00 0.64 0.77 0.40 0.90 0.00 0.14 nb~24 + 18 0.71 0.00 0.56 0.67 0.29 0.86 0.00 0.01 svm~43 + 6 0.71 0.00 0.47 0.77 0.33 0.86 0.00 0.03 rpart~4 + 11 0.67 0.00 0.53 0.77 0.35 0.87 0.00 0.04 nb~4 + 37 0.71 0.00 0.58 0.79 0.40 0.89 0.00 0.06 svm~19 + 3 0.71 0.00 0.56 0.77 0.37 0.88 0.00 0.13 rpart~33 + 19 0.67 0.00 0.67 0.68 0.33 0.89 0.00 0.01 nb~37 + 22 0.71 0.00 0.67 0.59 0.28 0.88 0.00 0.11 nb~8 + 20 0.71 0.00 0.75 0.47 0.25 0.89 0.01 0.01 rpart~12 + 24 0.70 0.00 0.47 0.83 0.40 0.87 0.00 0.00 rpart~9 + 19 0.69 0.00 0.78 0.53 0.28 0.91 0.00 0.01 nb~4 + 38 0.70 0.00 0.67 0.74 0.38 0.90 0.00 0.02 svm~17 + 19 0.70 0.00 0.56 0.72 0.32 0.87 0.00 0.01 nb~4 + 9 0.70 0.00 0.61 0.78 0.40 0.89 0.00 0.06 nb~23 + 6 0.70 0.00 0.58 0.72 0.33 0.88 0.00 0.03 rpart~25 + 19 0.69 0.00 0.78 0.53 0.29 0.91 0.00 0.02 knn~4 + 12 0.70 0.00 0.53 0.82 0.41 0.88 0.00 0.07 nb~17 + 6 0.70 0.00 0.67 0.63 0.30 0.89 0.00 0.01 svm~31 + 6 0.70 0.00 0.67 0.65 0.31 0.89 0.00 0.03 svm~21 + 22 0.70 0.00 0.58 0.69 0.31 0.87 0.00 0.07 rpart~14 + 22 0.69 0.00 0.53 0.73 0.32 0.87 0.00 0.05 nb~37 + 19 0.70 0.00 0.61 0.65 0.29 0.87 0.00 0.01 nb~26 + 20 0.70 0.00 0.75 0.52 0.27 0.90 0.00 0.01 rpart~40 + 26 0.69 0.00 0.64 0.63 0.29 0.88 0.01 0.03 svm~26 + 22 0.70 0.00 0.61 0.70 0.33 0.88 0.00 0.04 svm~24 + 26 0.70 0.00 0.31 0.92 0.48 0.85 0.00 0.00 svm~28 + 6 0.70 0.00 0.64 0.71 0.34 0.89 0.00 0.00 nb~40 + 26 0.70 0.00 0.78 0.47 0.26 0.90 0.01 0.08 rpart~42 + 22 0.69 0.00 0.67 0.59 0.28 0.88 0.00 0.36 nb~36 + 6 0.70 0.00 0.58 0.73 0.34 0.88 0.00 0.02 nb~36 + 22 0.70 0.00 0.72 0.55 0.28 0.89 0.00 0.08 nb~16 + 40 0.70 0.00 0.58 0.69 0.31 0.87 0.00 0.09 svm~18 + 6 0.70 0.00 0.56 0.72 0.32 0.87 0.00 0.08 nb~41 + 6 0.70 0.00 0.53 0.78 0.37 0.87 0.00 0.05 svm~16 + 31 0.70 0.00 0.53 0.74 0.33 0.87 0.00 0.15 nb~12 + 17 0.70 0.00 0.53 0.77 0.36 0.87 0.00 0.02 nb~36 + 28 0.70 0.00 0.72 0.59 0.30 0.90 0.00 0.01 rpart~16 + 19 0.69 0.00 0.83 0.56 0.31 0.93 0.00 0.00 knn~40 + 24 0.70 0.00 0.86 0.41 0.26 0.93 0.00 0.01 svm~37 + 22 0.70 0.00 0.69 0.59 0.29 0.89 0.00 0.51 rpart~24 + 5 0.70 0.00 0.58 0.72 0.33 0.88 0.00 0.01 rf~4 + 39 0.70 0.00 0.75 0.57 0.29 0.90 0.00 0.00 nb~4 + 34 0.70 0.00 0.53 0.80 0.39 0.88 0.00 0.05 nb~17 + 19 0.70 0.00 0.78 0.56 0.30 0.91 0.00 0.01 rf~16 + 18 0.70 0.00 0.67 0.62 0.30 0.89 0.00 0.19 svm~14 + 22 0.70 0.00 0.53 0.68 0.28 0.86 0.01 0.06 svm~18 + 28 0.70 0.00 0.64 0.69 0.33 0.89 0.00 0.01 rpart~7 + 20 0.69 0.00 0.81 0.45 0.26 0.91 0.00 0.03 svm~42 + 6 0.70 0.00 0.67 0.63 0.30 0.89 0.00 0.03 nb~4 + 27 0.70 0.00 0.67 0.66 0.32 0.89 0.00 0.07 nb~11 + 6 0.70 0.00 0.50 0.81 0.39 0.87 0.00 0.06 rf~35 + 19 0.70 0.00 0.72 0.61 0.31 0.90 0.00 0.01 svm~26 + 28 0.70 0.00 0.53 0.77 0.36 0.87 0.00 0.02 nb~1 + 28 0.70 0.00 0.61 0.69 0.32 0.88 0.00 0.01 nb~11 + 28 0.70 0.00 0.56 0.71 0.31 0.87 0.00 0.05 rf~4 + 32 0.70 0.00 0.64 0.63 0.29 0.88 0.00 0.23 rpart~4 + 26 0.70 0.00 0.58 0.67 0.30 0.87 0.00 0.02 nb~13 + 20 0.70 0.00 0.69 0.57 0.28 0.89 0.00 0.02 nb~37 + 6 0.70 0.00 0.69 0.65 0.32 0.90 0.00 0.08 svm~25 + 28 0.70 0.00 0.72 0.59 0.30 0.90 0.00 0.09 svm~40 + 18 0.70 0.00 0.72 0.55 0.28 0.89 0.00 0.10 nb~14 + 20 0.70 0.00 0.78 0.51 0.28 0.91 0.00 0.01 knn~32 + 22 0.70 0.00 0.64 0.69 0.33 0.89 0.00 0.06 rpart~19 + 20 0.69 0.00 0.81 0.47 0.27 0.91 0.00 0.02 rf~4 + 31 0.70 0.00 0.61 0.64 0.29 0.87 0.00 0.05 rpart~4 + 28 0.70 0.00 0.58 0.73 0.34 0.88 0.00 0.03 svm~24 + 22 0.70 0.00 0.42 0.83 0.38 0.86 0.00 0.05 knn~4 + 19 0.70 0.00 0.72 0.65 0.33 0.91 0.00 0.07 nb~4 + 17 0.70 0.00 0.58 0.79 0.40 0.89 0.00 0.05 svm~12 + 16 0.70 0.00 0.39 0.87 0.42 0.86 0.00 0.08 rpart~4 + 1 0.69 0.00 0.69 0.51 0.25 0.87 0.01 0.09 svm~24 + 6 0.70 0.00 0.56 0.77 0.37 0.88 0.00 0.03 knn~39 + 22 0.70 0.00 0.78 0.61 0.32 0.92 0.00 0.38 rpart~4 + 23 0.69 0.00 0.67 0.67 0.33 0.89 0.00 0.03 svm~29 + 6 0.70 0.00 0.64 0.71 0.35 0.89 0.00 0.01 knn~4 + 31 0.69 0.00 0.61 0.67 0.31 0.88 0.00 0.01 knn~35 + 28 0.69 0.00 0.89 0.43 0.27 0.94 0.00 0.12 nb~4 + 2 0.70 0.00 0.64 0.71 0.35 0.89 0.00 0.15 nb~17 + 22 0.70 0.00 0.69 0.53 0.26 0.88 0.01 0.04 nb~26 + 32 0.70 0.00 0.67 0.59 0.28 0.88 0.00 0.05 knn~29 + 6 0.69 0.00 0.61 0.67 0.31 0.88 0.00 0.03 svm~38 + 22 0.70 0.00 0.67 0.65 0.31 0.89 0.00 0.11 svm~34 + 22 0.70 0.00 0.64 0.53 0.25 0.86 0.03 0.01 nb~33 + 19 0.70 0.00 0.81 0.53 0.29 0.92 0.00 0.05 rpart~31 + 22 0.69 0.00 0.64 0.66 0.31 0.88 0.00 0.01 svm~12 + 32 0.70 0.00 0.44 0.83 0.38 0.86 0.00 0.10 rpart~28 + 34 0.69 0.00 0.56 0.66 0.28 0.86 0.00 0.06 knn~4 + 34 0.69 0.00 0.81 0.39 0.24 0.89 0.02 0.15 svm~21 + 6 0.70 0.00 0.61 0.65 0.30 0.88 0.00 0.02 nb~15 + 20 0.70 0.00 0.75 0.57 0.30 0.91 0.00 0.02 svm~4 + 43 0.70 0.00 0.50 0.83 0.42 0.87 0.00 0.01 knn~12 + 19 0.69 0.00 0.67 0.59 0.28 0.88 0.00 0.01 rpart~24 + 31 0.69 0.00 0.47 0.83 0.40 0.87 0.00 0.00 svm~4 + 6 0.70 0.00 0.64 0.73 0.37 0.89 0.00 0.14 nb~14 + 6 0.70 0.00 0.64 0.74 0.37 0.90 0.00 0.02 rpart~40 + 18 0.69 0.00 0.81 0.45 0.26 0.91 0.01 0.07 rf~4 + 38 0.70 0.00 0.58 0.67 0.30 0.87 0.00 0.07 rpart~23 + 19 0.69 0.00 0.81 0.45 0.26 0.91 0.00 0.01 rpart~18 + 32 0.69 0.00 0.69 0.62 0.30 0.89 0.00 0.11 svm~1 + 22 0.70 0.00 0.58 0.73 0.34 0.88 0.00 0.02 svm~4 + 22 0.70 0.00 0.64 0.73 0.36 0.89 0.00 0.16 rpart~4 + 6 0.69 0.00 0.61 0.65 0.30 0.88 0.00 0.11 svm~4 + 25 0.70 0.00 0.67 0.62 0.30 0.89 0.00 0.33 svm~42 + 22 0.70 0.00 0.64 0.61 0.28 0.88 0.00 0.07 nb~16 + 43 0.70 0.00 0.58 0.67 0.30 0.87 0.01 0.01 knn~4 + 20 0.69 0.00 0.72 0.53 0.27 0.89 0.00 0.02 svm~19 + 34 0.70 0.00 0.75 0.61 0.31 0.91 0.00 0.00 svm~4 + 21 0.70 0.00 0.58 0.81 0.43 0.89 0.00 0.11 rf~12 + 22 0.70 0.00 0.64 0.66 0.31 0.88 0.00 0.04 rpart~4 + 17 0.69 0.00 0.58 0.67 0.30 0.87 0.00 0.02 knn~17 + 22 0.69 0.00 0.67 0.64 0.31 0.89 0.00 0.11 rf~24 + 19 0.70 0.00 0.58 0.67 0.30 0.87 0.00 0.00 nb~9 + 6 0.70 0.00 0.69 0.57 0.28 0.89 0.00 0.07 svm~9 + 19 0.70 0.00 0.78 0.59 0.31 0.92 0.00 0.01 rpart~4 + 29 0.69 0.00 0.64 0.65 0.30 0.88 0.00 0.01 svm~27 + 19 0.69 0.00 0.67 0.59 0.28 0.88 0.00 0.03 svm~13 + 32 0.69 0.00 0.47 0.79 0.35 0.86 0.00 0.31 svm~36 + 28 0.69 0.00 0.61 0.64 0.29 0.87 0.00 0.02 svm~11 + 28 0.69 0.00 0.61 0.69 0.32 0.88 0.00 0.46 nb~28 + 34 0.69 0.00 0.61 0.61 0.28 0.87 0.00 0.01 nb~18 + 43 0.69 0.00 0.61 0.67 0.31 0.88 0.00 0.09 rf~4 + 16 0.69 0.00 0.75 0.55 0.29 0.90 0.00 0.21 svm~15 + 22 0.69 0.00 0.50 0.77 0.35 0.87 0.00 0.05 nb~28 + 21 0.69 0.00 0.53 0.71 0.30 0.86 0.00 0.00 rf~38 + 28 0.69 0.00 0.69 0.58 0.28 0.89 0.00 0.47 svm~4 + 33 0.69 0.00 0.64 0.69 0.33 0.89 0.00 0.04 nb~4 + 3 0.69 0.00 0.50 0.81 0.39 0.87 0.00 0.10 rpart~28 + 22 0.68 0.00 0.67 0.62 0.30 0.89 0.00 0.12 svm~1 + 28 0.69 0.00 0.61 0.74 0.36 0.89 0.00 0.00 knn~13 + 26 0.69 0.00 0.75 0.47 0.25 0.89 0.01 0.08 nb~40 + 32 0.69 0.00 0.64 0.65 0.31 0.88 0.00 0.31 rf~26 + 22 0.69 0.00 0.67 0.62 0.30 0.89 0.00 0.12 svm~15 + 40 0.69 0.00 0.58 0.65 0.29 0.87 0.01 0.85 knn~4 + 43 0.69 0.00 0.58 0.69 0.31 0.87 0.00 0.08 rf~40 + 24 0.69 0.00 0.67 0.62 0.30 0.89 0.00 0.03 nb~12 + 16 0.69 0.00 0.58 0.73 0.34 0.88 0.00 0.05 rf~4 + 13 0.69 0.00 0.56 0.74 0.34 0.87 0.00 0.09 knn~24 + 13 0.69 0.00 0.81 0.52 0.29 0.92 0.00 0.06 knn~4 + 37 0.69 0.00 0.86 0.37 0.25 0.92 0.01 0.02 rf~4 + 14 0.69 0.00 0.64 0.65 0.31 0.88 0.00 0.01 rpart~16 + 18 0.65 0.00 0.47 0.82 0.39 0.87 0.00 0.03 nb~34 + 6 0.69 0.00 0.56 0.67 0.29 0.86 0.00 0.03 svm~12 + 13 0.69 0.00 0.31 0.83 0.31 0.83 0.03 0.07 nb~16 + 13 0.69 0.00 0.58 0.66 0.29 0.87 0.01 0.20 svm~39 + 6 0.69 0.00 0.61 0.73 0.35 0.89 0.00 0.07 knn~24 + 43 0.69 0.00 0.67 0.57 0.27 0.88 0.02 0.00 nb~42 + 20 0.69 0.00 0.72 0.52 0.27 0.89 0.00 0.04 svm~28 + 21 0.69 0.00 0.64 0.72 0.35 0.89 0.00 0.02 svm~14 + 28 0.69 0.00 0.53 0.76 0.35 0.87 0.00 0.05 rpart~17 + 22 0.68 0.00 0.58 0.65 0.28 0.87 0.00 0.41 nb~9 + 19 0.69 0.00 0.78 0.55 0.29 0.91 0.00 0.02 rpart~25 + 22 0.69 0.00 0.72 0.50 0.26 0.88 0.01 0.22 nb~9 + 22 0.69 0.00 0.58 0.69 0.31 0.87 0.00 0.12 svm~43 + 22 0.69 0.00 0.53 0.73 0.32 0.87 0.00 0.04 svm~18 + 32 0.69 0.00 0.58 0.68 0.30 0.87 0.00 0.23 rpart~39 + 19 0.68 0.00 0.83 0.44 0.26 0.92 0.00 0.01 nb~39 + 6 0.69 0.00 0.56 0.69 0.30 0.87 0.00 0.04 rpart~24 + 20 0.68 0.00 0.67 0.69 0.34 0.90 0.00 0.01 nb~38 + 28 0.69 0.00 0.61 0.66 0.30 0.88 0.00 0.02 nb~16 + 31 0.69 0.00 0.56 0.70 0.31 0.87 0.00 0.11 rpart~20 + 38 0.68 0.00 0.78 0.48 0.26 0.90 0.00 0.07 rpart~4 + 40 0.69 0.00 0.67 0.57 0.27 0.88 0.01 0.25 rpart~24 + 19 0.68 0.00 0.69 0.57 0.28 0.89 0.00 0.01 nb~11 + 22 0.69 0.00 0.83 0.52 0.29 0.93 0.00 0.13 knn~37 + 6 0.69 0.00 0.81 0.42 0.25 0.90 0.01 0.01 knn~13 + 22 0.69 0.00 0.89 0.37 0.25 0.93 0.00 0.33 nb~4 + 7 0.69 0.00 0.56 0.75 0.34 0.88 0.00 0.08 nb~25 + 6 0.69 0.00 0.56 0.73 0.33 0.87 0.00 0.16 knn~28 + 21 0.68 0.00 0.92 0.39 0.27 0.95 0.00 0.05 nb~15 + 12 0.69 0.00 0.56 0.69 0.30 0.87 0.00 0.06 nb~33 + 22 0.69 0.00 0.78 0.47 0.26 0.90 0.01 0.17 svm~3 + 28 0.69 0.00 0.39 0.81 0.33 0.85 0.00 0.17 nb~12 + 32 0.69 0.00 0.64 0.69 0.33 0.89 0.00 0.05 nb~27 + 28 0.69 0.00 0.78 0.54 0.29 0.91 0.00 0.03 nb~39 + 28 0.69 0.00 0.44 0.71 0.27 0.84 0.03 0.01 nb~3 + 6 0.69 0.00 0.42 0.81 0.35 0.85 0.00 0.05 knn~12 + 6 0.69 0.00 0.64 0.67 0.32 0.88 0.00 0.02 nb~15 + 26 0.69 0.00 0.53 0.73 0.32 0.87 0.00 0.11 nb~16 + 14 0.69 0.00 0.61 0.71 0.33 0.88 0.00 0.05 rf~19 + 3 0.69 0.00 0.69 0.59 0.29 0.89 0.00 0.00 svm~33 + 28 0.69 0.00 0.69 0.56 0.27 0.88 0.00 0.04 nb~23 + 19 0.69 0.00 0.67 0.64 0.31 0.89 0.00 0.04 svm~30 + 19 0.69 0.00 0.64 0.63 0.29 0.88 0.00 0.00 rpart~13 + 26 0.68 0.00 0.61 0.75 0.37 0.89 0.00 0.07 svm~23 + 6 0.69 0.00 0.58 0.70 0.32 0.88 0.00 0.01 svm~12 + 26 0.69 0.00 0.47 0.83 0.40 0.87 0.00 0.10 svm~24 + 38 0.69 0.00 0.42 0.83 0.37 0.86 0.00 0.00 rpart~4 + 25 0.69 0.00 0.78 0.50 0.27 0.90 0.00 0.03 svm~33 + 22 0.69 0.00 0.67 0.61 0.29 0.88 0.00 0.08 rpart~43 + 19 0.69 0.00 0.72 0.59 0.30 0.90 0.00 0.01 nb~17 + 24 0.69 0.00 0.67 0.67 0.33 0.89 0.00 0.00 nb~36 + 19 0.69 0.00 0.81 0.51 0.28 0.92 0.00 0.02 rpart~37 + 28 0.68 0.00 0.69 0.61 0.30 0.89 0.00 0.16 knn~37 + 22 0.68 0.00 0.86 0.42 0.26 0.93 0.00 0.01 knn~33 + 19 0.68 0.00 0.44 0.78 0.33 0.85 0.00 0.07 nb~9 + 28 0.69 0.00 0.53 0.68 0.28 0.86 0.01 0.03 svm~34 + 6 0.69 0.00 0.72 0.60 0.30 0.90 0.00 0.00 rf~4 + 43 0.69 0.00 0.69 0.62 0.30 0.89 0.00 0.08 nb~25 + 28 0.69 0.00 0.58 0.67 0.30 0.87 0.00 0.04 knn~24 + 19 0.68 0.00 0.89 0.35 0.25 0.93 0.00 0.02 svm~2 + 19 0.69 0.00 0.72 0.47 0.25 0.88 0.02 0.06 nb~21 + 6 0.69 0.00 0.61 0.69 0.32 0.88 0.00 0.02 rpart~1 + 19 0.68 0.00 0.75 0.58 0.30 0.91 0.00 0.01 nb~1 + 6 0.69 0.00 0.56 0.73 0.33 0.87 0.00 0.03 svm~16 + 21 0.69 0.00 0.58 0.63 0.27 0.86 0.01 0.05 svm~33 + 6 0.69 0.00 0.58 0.67 0.30 0.87 0.00 0.09 rpart~16 + 22 0.68 0.00 0.64 0.61 0.28 0.88 0.00 0.28 svm~4 + 26 0.69 0.00 0.50 0.87 0.47 0.88 0.00 0.04 rpart~8 + 26 0.68 0.00 0.42 0.83 0.38 0.86 0.00 0.00 knn~29 + 32 0.68 0.00 0.83 0.38 0.24 0.90 0.01 0.02 rpart~26 + 28 0.68 0.00 0.56 0.73 0.33 0.87 0.00 0.01 nb~15 + 18 0.69 0.00 0.58 0.71 0.32 0.88 0.00 0.15 rf~39 + 24 0.69 0.00 0.72 0.54 0.27 0.89 0.00 0.01 nb~33 + 20 0.69 0.00 0.89 0.37 0.25 0.93 0.00 0.02 svm~29 + 18 0.69 0.00 0.36 0.81 0.31 0.84 0.02 0.10 knn~39 + 24 0.68 0.00 0.75 0.59 0.30 0.91 0.00 0.00 nb~11 + 20 0.69 0.00 0.78 0.45 0.25 0.89 0.01 0.03 svm~40 + 22 0.69 0.00 0.78 0.45 0.25 0.89 0.02 0.27 svm~16 + 32 0.69 0.00 0.50 0.78 0.35 0.87 0.00 0.26 nb~25 + 19 0.69 0.00 0.67 0.65 0.32 0.89 0.00 0.12 rf~4 + 24 0.69 0.00 0.64 0.64 0.30 0.88 0.00 0.02 nb~27 + 6 0.69 0.00 0.64 0.60 0.28 0.87 0.00 0.05 svm~12 + 40 0.69 0.00 0.61 0.60 0.27 0.87 0.05 0.12 knn~17 + 19 0.68 0.00 0.44 0.79 0.34 0.86 0.00 0.04 nb~13 + 26 0.69 0.00 0.78 0.48 0.26 0.90 0.01 0.24 rpart~41 + 20 0.67 0.00 0.83 0.37 0.24 0.90 0.01 0.04 knn~35 + 22 0.68 0.00 0.75 0.50 0.26 0.89 0.01 0.22 rpart~24 + 33 0.68 0.00 0.44 0.77 0.32 0.85 0.00 0.01 nb~16 + 8 0.69 0.00 0.58 0.67 0.30 0.87 0.01 0.13 nb~17 + 43 0.69 0.00 0.56 0.69 0.30 0.87 0.00 0.05 nb~12 + 40 0.69 0.00 0.53 0.71 0.30 0.86 0.01 0.07 rf~4 + 19 0.68 0.00 0.64 0.63 0.29 0.88 0.00 0.05 nb~18 + 13 0.68 0.00 0.69 0.54 0.27 0.88 0.01 0.48 nb~23 + 22 0.68 0.00 0.67 0.65 0.31 0.89 0.00 0.07 rpart~1 + 22 0.67 0.00 0.42 0.79 0.33 0.85 0.00 0.09 svm~17 + 6 0.68 0.00 0.56 0.69 0.30 0.87 0.00 0.04 nb~7 + 6 0.68 0.00 0.56 0.66 0.28 0.86 0.01 0.05 nb~4 + 30 0.68 0.00 0.56 0.78 0.38 0.88 0.00 0.02 rpart~12 + 32 0.68 0.00 0.69 0.69 0.35 0.90 0.00 0.53 rpart~35 + 6 0.68 0.00 0.56 0.69 0.30 0.87 0.00 0.26 svm~24 + 28 0.68 0.00 0.36 0.89 0.43 0.85 0.00 0.02 knn~43 + 22 0.68 0.00 0.81 0.45 0.26 0.91 0.00 0.01 nb~34 + 22 0.68 0.00 0.67 0.55 0.26 0.87 0.01 0.07 nb~29 + 6 0.68 0.00 0.61 0.73 0.35 0.89 0.00 0.07 nb~21 + 22 0.68 0.00 0.69 0.61 0.30 0.89 0.00 0.03 nb~29 + 28 0.68 0.00 0.61 0.67 0.31 0.88 0.00 0.05 rpart~14 + 20 0.67 0.00 0.78 0.50 0.27 0.90 0.00 0.01 rpart~29 + 20 0.67 0.00 0.78 0.50 0.27 0.90 0.00 0.01 nb~10 + 6 0.68 0.00 0.50 0.81 0.39 0.87 0.00 0.05 nb~41 + 22 0.68 0.00 0.64 0.59 0.27 0.87 0.01 0.14 nb~23 + 28 0.68 0.00 0.47 0.75 0.31 0.85 0.01 0.02 svm~43 + 28 0.68 0.00 0.58 0.72 0.33 0.88 0.00 0.01 knn~4 + 13 0.68 0.00 0.67 0.69 0.34 0.90 0.00 0.59 nb~17 + 32 0.68 0.00 0.67 0.67 0.33 0.89 0.00 0.10 svm~37 + 6 0.68 0.00 0.69 0.62 0.30 0.89 0.00 0.14 svm~7 + 28 0.68 0.00 0.58 0.60 0.26 0.86 0.03 0.26 svm~32 + 6 0.68 0.00 0.58 0.76 0.37 0.88 0.00 0.01 nb~31 + 22 0.68 0.00 0.72 0.55 0.28 0.89 0.00 0.06 svm~38 + 6 0.68 0.00 0.64 0.67 0.32 0.88 0.00 0.03 nb~11 + 19 0.68 0.00 0.69 0.62 0.30 0.89 0.00 0.07 nb~19 + 21 0.68 0.00 0.72 0.61 0.31 0.90 0.00 0.01 rpart~4 + 8 0.68 0.00 0.69 0.62 0.30 0.89 0.00 0.02 nb~15 + 43 0.68 0.00 0.56 0.68 0.29 0.86 0.01 0.08 svm~22 + 6 0.68 0.00 0.53 0.73 0.32 0.87 0.00 0.03 nb~24 + 31 0.68 0.00 0.53 0.76 0.35 0.87 0.00 0.00 svm~28 + 34 0.68 0.00 0.58 0.65 0.29 0.87 0.00 0.16 rpart~4 + 37 0.66 0.00 0.53 0.75 0.34 0.87 0.00 0.01 rf~4 + 40 0.68 0.00 0.69 0.49 0.25 0.87 0.04 0.07 svm~25 + 6 0.68 0.00 0.67 0.55 0.26 0.87 0.01 0.22 svm~42 + 16 0.68 0.00 0.47 0.73 0.29 0.85 0.02 0.12 nb~2 + 28 0.68 0.00 0.56 0.63 0.27 0.86 0.02 0.04 svm~35 + 28 0.68 0.00 0.50 0.79 0.36 0.87 0.00 0.39 nb~3 + 28 0.68 0.00 0.47 0.71 0.28 0.85 0.01 0.04 svm~12 + 39 0.68 0.00 0.36 0.81 0.31 0.84 0.02 0.12 rf~4 + 42 0.68 0.00 0.64 0.61 0.28 0.88 0.01 0.20 nb~29 + 22 0.68 0.00 0.58 0.69 0.31 0.87 0.00 0.18 nb~10 + 28 0.68 0.00 0.47 0.77 0.33 0.86 0.00 0.06 svm~11 + 22 0.68 0.00 0.61 0.69 0.32 0.88 0.00 0.40 rpart~24 + 34 0.67 0.00 0.36 0.89 0.43 0.85 0.00 0.00 rf~32 + 22 0.68 0.00 0.61 0.65 0.29 0.87 0.00 0.25 rf~24 + 28 0.68 0.00 0.61 0.61 0.27 0.87 0.01 0.02 nb~1 + 22 0.68 0.00 0.64 0.57 0.26 0.87 0.01 0.08 nb~36 + 20 0.68 0.00 0.78 0.55 0.29 0.91 0.00 0.01 knn~15 + 22 0.68 0.00 0.81 0.46 0.26 0.91 0.00 0.32 svm~10 + 6 0.68 0.00 0.56 0.75 0.35 0.88 0.00 0.06 nb~10 + 22 0.68 0.00 0.69 0.51 0.26 0.88 0.02 0.23 nb~19 + 34 0.68 0.00 0.69 0.66 0.33 0.90 0.00 0.01 svm~17 + 28 0.68 0.00 0.56 0.67 0.29 0.86 0.00 0.02 svm~37 + 28 0.68 0.00 0.67 0.59 0.28 0.88 0.00 0.08 nb~4 + 21 0.68 0.00 0.58 0.81 0.43 0.89 0.00 0.03 nb~37 + 20 0.68 0.00 0.64 0.59 0.27 0.87 0.00 0.01 svm~42 + 28 0.68 0.00 0.81 0.59 0.32 0.93 0.00 0.26 knn~4 + 40 0.67 0.00 0.75 0.51 0.27 0.90 0.01 0.23 knn~12 + 40 0.67 0.00 0.75 0.57 0.30 0.91 0.00 0.22 nb~18 + 26 0.68 0.00 0.69 0.63 0.31 0.90 0.00 0.12 rpart~15 + 24 0.67 0.00 0.78 0.48 0.26 0.90 0.00 0.08 nb~15 + 40 0.68 0.00 0.42 0.81 0.35 0.85 0.00 0.30 svm~10 + 19 0.68 0.00 0.64 0.67 0.32 0.89 0.00 0.01 svm~12 + 29 0.68 0.00 0.44 0.79 0.34 0.86 0.00 0.01 rpart~4 + 33 0.68 0.00 0.67 0.54 0.26 0.87 0.02 0.00 rpart~24 + 25 0.67 0.00 0.50 0.75 0.33 0.86 0.00 0.00 knn~15 + 19 0.67 0.00 0.89 0.38 0.26 0.93 0.00 0.06 knn~8 + 6 0.67 0.00 0.75 0.49 0.26 0.89 0.01 0.01 nb~39 + 22 0.68 0.00 0.72 0.47 0.25 0.88 0.02 0.08 nb~31 + 20 0.68 0.00 0.72 0.49 0.25 0.88 0.01 0.01 rpart~13 + 22 0.68 0.00 0.78 0.52 0.28 0.91 0.00 0.36 knn~4 + 38 0.67 0.00 0.75 0.43 0.24 0.88 0.03 0.04 rf~15 + 28 0.68 0.00 0.69 0.56 0.27 0.88 0.00 0.17 svm~9 + 22 0.68 0.00 0.56 0.72 0.32 0.87 0.00 0.16 knn~37 + 19 0.67 0.00 0.94 0.30 0.24 0.96 0.00 0.01 svm~15 + 16 0.68 0.00 0.50 0.77 0.35 0.87 0.00 0.23 nb~16 + 21 0.68 0.00 0.61 0.62 0.28 0.87 0.01 0.01 rf~19 + 6 0.68 0.00 0.67 0.66 0.32 0.89 0.00 0.01 nb~41 + 19 0.68 0.00 0.69 0.59 0.29 0.89 0.00 0.05 svm~7 + 22 0.68 0.00 0.67 0.59 0.28 0.88 0.00 0.28 nb~31 + 32 0.68 0.00 0.39 0.75 0.27 0.84 0.05 0.28 rf~7 + 22 0.68 0.00 0.75 0.49 0.26 0.89 0.01 0.14 rpart~1 + 24 0.67 0.00 0.58 0.77 0.38 0.88 0.00 0.00 rf~16 + 24 0.68 0.00 0.64 0.59 0.27 0.87 0.01 0.02 svm~16 + 13 0.68 0.00 0.53 0.67 0.28 0.85 0.03 0.33 rf~18 + 22 0.68 0.00 0.69 0.60 0.29 0.89 0.00 0.22 rf~31 + 22 0.68 0.00 0.75 0.56 0.29 0.90 0.00 0.10 knn~19 + 21 0.67 0.00 0.78 0.57 0.30 0.91 0.00 0.00 auc.pvalue: Wilcoxon Test P-value. MFD: Median Fold Difference. KM: Kaplan Meier curves. MvaHRPval: Multivariable Analysis Hazard Ratio P-value.

TABLE 52 pairwise biomarkers from the 43 biomarker panel with significance for Wilcoxon P-value (auc.pvalue <= 0.05) and other metrics for the psaDT endpoint. auc. Pos.Pred. Neg.Pred. Classifier auc pvalue Sensitivity Specificity Value Value mvaPval svm~4 + 12 0.71 0.00 0.15 0.56 0.16 0.54 0.00 rpart~24 + 32 0.70 0.00 0.07 0.65 0.09 0.55 0.00 rpart~15 + 14 0.69 0.00 0.09 0.63 0.12 0.55 0.03 svm~12 + 24 0.70 0.00 0.04 0.71 0.08 0.57 0.01 knn~12 + 26 0.31 0.00 0.02 0.73 0.04 0.57 0.00 svm~15 + 24 0.69 0.00 0.00 0.83 0.00 0.60 0.01 nb~12 + 19 0.69 0.00 0.28 0.50 0.24 0.55 0.00 rf~4 + 12 0.69 0.00 0.24 0.41 0.19 0.49 0.01 knn~12 + 18 0.68 0.00 0.33 0.45 0.25 0.54 0.00 svm~12 + 26 0.69 0.00 0.11 0.70 0.17 0.58 0.01 nb~15 + 24 0.69 0.00 0.15 0.59 0.17 0.55 0.00 nb~16 + 19 0.69 0.00 0.20 0.52 0.19 0.54 0.01 nb~12 + 24 0.68 0.00 0.04 0.68 0.07 0.56 0.00 rpart~12 + 24 0.68 0.00 0.09 0.65 0.12 0.56 0.00 rf~12 + 22 0.68 0.00 0.22 0.44 0.18 0.50 0.00 nb~12 + 6 0.68 0.00 0.37 0.44 0.27 0.55 0.00 nb~12 + 26 0.68 0.00 0.15 0.60 0.18 0.56 0.00 rf~12 + 26 0.68 0.00 0.20 0.65 0.24 0.59 0.00 nb~12 + 18 0.68 0.00 0.15 0.57 0.17 0.55 0.00 svm~16 + 24 0.68 0.00 0.07 0.71 0.11 0.57 0.01 nb~37 + 19 0.68 0.00 0.33 0.49 0.26 0.56 0.08 knn~12 + 22 0.68 0.00 0.28 0.45 0.22 0.53 0.01 svm~15 + 12 0.68 0.00 0.04 0.70 0.07 0.56 0.01 svm~16 + 19 0.68 0.00 0.35 0.48 0.27 0.57 0.02 rpart~12 + 6 0.67 0.00 0.37 0.43 0.27 0.55 0.03 rpart~1 + 24 0.67 0.00 0.17 0.57 0.19 0.55 0.01 rpart~4 + 16 0.67 0.00 0.35 0.48 0.27 0.57 0.03 knn~4 + 12 0.67 0.00 0.07 0.62 0.09 0.54 0.01 nb~15 + 12 0.67 0.00 0.20 0.59 0.21 0.56 0.00 svm~16 + 21 0.67 0.00 0.20 0.56 0.20 0.55 0.01 rf~42 + 19 0.67 0.00 0.41 0.34 0.26 0.51 0.16 rpart~15 + 24 0.66 0.00 0.46 0.34 0.28 0.53 0.04 rpart~1 + 6 0.67 0.00 0.35 0.46 0.27 0.56 0.14 svm~24 + 10 0.67 0.00 0.09 0.71 0.14 0.58 0.01 knn~24 + 13 0.66 0.00 0.37 0.30 0.23 0.46 0.11 rf~12 + 31 0.67 0.00 0.33 0.54 0.28 0.59 0.03 svm~24 + 8 0.66 0.00 0.13 0.72 0.21 0.60 0.30 svm~12 + 28 0.66 0.00 0.30 0.56 0.28 0.59 0.08 svm~12 + 18 0.66 0.00 0.17 0.54 0.17 0.54 0.01 svm~12 + 37 0.66 0.00 0.33 0.49 0.26 0.56 0.14 svm~15 + 38 0.66 0.00 0.15 0.61 0.18 0.56 0.01 rpart~4 + 32 0.66 0.00 0.24 0.50 0.21 0.54 0.05 rf~4 + 24 0.66 0.00 0.28 0.45 0.22 0.53 0.03 rf~12 + 18 0.66 0.00 0.30 0.51 0.26 0.57 0.01 nb~4 + 12 0.66 0.00 0.15 0.57 0.17 0.55 0.01 nb~16 + 24 0.66 0.00 0.13 0.65 0.17 0.57 0.00 nb~15 + 28 0.66 0.00 0.26 0.55 0.24 0.57 0.08 nb~24 + 28 0.66 0.00 0.26 0.56 0.25 0.58 0.08 nb~12 + 22 0.66 0.00 0.30 0.51 0.26 0.57 0.01 svm~1 + 12 0.66 0.00 0.26 0.55 0.24 0.57 0.01 svm~15 + 10 0.66 0.00 0.17 0.63 0.21 0.58 0.01 nb~24 + 37 0.66 0.00 0.28 0.49 0.24 0.55 0.09 nb~12 + 28 0.66 0.00 0.39 0.48 0.30 0.58 0.02 knn~15 + 35 0.65 0.00 0.15 0.68 0.21 0.59 0.12 nb~10 + 19 0.65 0.00 0.41 0.40 0.28 0.55 0.04 svm~8 + 19 0.65 0.00 0.33 0.43 0.24 0.53 0.03 svm~26 + 19 0.65 0.00 0.22 0.55 0.21 0.56 0.03 knn~1 + 24 0.65 0.00 0.39 0.35 0.25 0.51 0.01 rpart~15 + 12 0.65 0.00 0.15 0.60 0.18 0.56 0.02 svm~13 + 26 0.65 0.00 0.13 0.67 0.18 0.58 0.05 knn~15 + 17 0.65 0.00 0.22 0.59 0.23 0.57 0.02 nb~15 + 14 0.65 0.00 0.09 0.71 0.14 0.58 0.04 nb~12 + 20 0.65 0.00 0.48 0.37 0.30 0.56 0.01 knn~4 + 32 0.65 0.00 0.35 0.44 0.26 0.55 0.40 rf~12 + 20 0.65 0.00 0.46 0.41 0.30 0.58 0.16 rf~12 + 19 0.65 0.00 0.33 0.50 0.27 0.57 0.01 knn~17 + 24 0.64 0.00 0.30 0.48 0.25 0.55 0.01 nb~16 + 6 0.65 0.00 0.30 0.50 0.25 0.56 0.02 nb~15 + 16 0.65 0.00 0.17 0.65 0.22 0.58 0.01 svm~13 + 19 0.65 0.00 0.48 0.30 0.28 0.51 0.31 svm~1 + 19 0.65 0.00 0.26 0.49 0.22 0.54 0.01 svm~24 + 13 0.65 0.01 0.07 0.65 0.09 0.55 0.01 knn~16 + 28 0.65 0.01 0.39 0.40 0.27 0.54 0.06 nb~13 + 19 0.65 0.01 0.52 0.32 0.30 0.54 0.11 nb~24 + 6 0.65 0.01 0.13 0.67 0.18 0.58 0.03 rf~4 + 43 0.65 0.01 0.35 0.44 0.26 0.55 0.26 knn~18 + 13 0.64 0.01 0.57 0.21 0.29 0.46 0.38 knn~24 + 43 0.64 0.01 0.35 0.45 0.26 0.55 0.04 rpart~4 + 15 0.64 0.01 0.15 0.59 0.17 0.55 0.04 rf~9 + 19 0.65 0.01 0.41 0.37 0.27 0.53 0.03 nb~16 + 26 0.65 0.01 0.20 0.60 0.21 0.57 0.01 knn~4 + 16 0.64 0.01 0.43 0.40 0.29 0.56 0.06 knn~1 + 28 0.64 0.01 0.57 0.17 0.28 0.41 0.15 knn~40 + 24 0.64 0.01 0.50 0.30 0.29 0.52 0.01 rpart~28 + 34 0.64 0.01 0.33 0.55 0.29 0.59 0.38 nb~16 + 18 0.65 0.01 0.28 0.50 0.24 0.55 0.01 nb~15 + 10 0.65 0.01 0.52 0.35 0.31 0.57 0.01 svm~42 + 16 0.65 0.01 0.17 0.61 0.20 0.57 0.01 rf~4 + 32 0.65 0.01 0.26 0.50 0.23 0.55 0.05 nb~35 + 19 0.65 0.01 0.24 0.54 0.22 0.56 0.15 nb~28 + 6 0.65 0.01 0.35 0.50 0.28 0.58 0.23 nb~4 + 24 0.65 0.01 0.13 0.67 0.18 0.58 0.04 nb~16 + 21 0.65 0.01 0.26 0.52 0.24 0.56 0.03 rpart~43 + 22 0.64 0.01 0.28 0.49 0.24 0.55 0.09 svm~37 + 22 0.64 0.01 0.37 0.48 0.28 0.57 0.67 svm~15 + 13 0.64 0.01 0.26 0.52 0.24 0.56 0.10 rpart~24 + 8 0.64 0.01 0.20 0.73 0.29 0.62 0.21 svm~42 + 24 0.64 0.01 0.04 0.73 0.08 0.58 0.09 rpart~12 + 5 0.64 0.01 0.33 0.41 0.24 0.52 0.00 knn~4 + 17 0.64 0.01 0.24 0.49 0.21 0.53 0.04 svm~4 + 16 0.64 0.01 0.22 0.51 0.20 0.54 0.05 rf~39 + 19 0.64 0.01 0.50 0.33 0.29 0.54 0.03 nb~12 + 17 0.64 0.01 0.11 0.59 0.13 0.54 0.01 svm~12 + 13 0.64 0.01 0.07 0.73 0.12 0.58 0.01 nb~36 + 19 0.64 0.01 0.67 0.22 0.33 0.55 0.05 rf~7 + 19 0.64 0.01 0.52 0.29 0.29 0.52 0.18 nb~19 + 6 0.64 0.01 0.24 0.61 0.26 0.59 0.07 knn~4 + 34 0.64 0.01 0.35 0.44 0.26 0.55 0.70 nb~11 + 6 0.64 0.01 0.20 0.62 0.23 0.58 0.15 rpart~4 + 10 0.64 0.01 0.24 0.57 0.24 0.57 0.01 knn~15 + 37 0.64 0.01 0.48 0.29 0.28 0.50 0.11 nb~15 + 13 0.64 0.01 0.33 0.50 0.27 0.57 0.04 svm~12 + 22 0.64 0.01 0.39 0.48 0.30 0.58 0.06 rf~15 + 17 0.64 0.01 0.30 0.52 0.26 0.57 0.06 nb~37 + 6 0.64 0.01 0.24 0.59 0.24 0.58 0.14 rf~15 + 26 0.64 0.01 0.33 0.55 0.29 0.59 0.01 knn~15 + 24 0.64 0.01 0.43 0.35 0.27 0.53 0.04 nb~4 + 19 0.64 0.01 0.26 0.59 0.26 0.59 0.15 rpart~12 + 26 0.39 0.01 0.09 0.68 0.13 0.57 0.01 rpart~24 + 31 0.63 0.01 0.11 0.71 0.17 0.59 0.01 svm~15 + 16 0.64 0.01 0.15 0.65 0.19 0.58 0.01 nb~21 + 6 0.64 0.01 0.26 0.52 0.24 0.56 0.12 rf~4 + 15 0.64 0.01 0.22 0.57 0.22 0.57 0.08 nb~16 + 20 0.64 0.01 0.46 0.38 0.29 0.55 0.03 rf~4 + 16 0.64 0.01 0.41 0.41 0.28 0.56 0.23 knn~13 + 19 0.63 0.01 0.24 0.63 0.27 0.60 0.14 knn~4 + 24 0.63 0.01 0.20 0.60 0.21 0.57 0.21 knn~38 + 22 0.63 0.01 0.33 0.44 0.25 0.54 0.25 knn~32 + 22 0.63 0.01 0.26 0.48 0.22 0.53 0.11 nb~11 + 28 0.64 0.01 0.24 0.63 0.27 0.60 0.71 nb~12 + 16 0.64 0.01 0.17 0.57 0.19 0.55 0.01 rpart~24 + 34 0.63 0.01 0.07 0.79 0.15 0.60 0.05 nb~13 + 6 0.64 0.01 0.43 0.44 0.30 0.58 0.12 rf~19 + 21 0.63 0.01 0.33 0.37 0.22 0.49 0.01 knn~15 + 8 0.63 0.01 0.48 0.32 0.28 0.52 0.19 nb~15 + 37 0.63 0.01 0.20 0.61 0.22 0.57 0.06 nb~12 + 37 0.63 0.01 0.37 0.46 0.28 0.57 0.08 knn~16 + 19 0.63 0.01 0.41 0.40 0.28 0.55 0.01 rf~39 + 22 0.63 0.01 0.35 0.50 0.28 0.58 0.08 rf~15 + 35 0.63 0.01 0.26 0.55 0.24 0.57 0.12 rf~4 + 42 0.63 0.01 0.37 0.49 0.29 0.58 0.23 nb~4 + 28 0.63 0.01 0.22 0.60 0.23 0.58 0.39 rpart~15 + 9 0.62 0.01 0.15 0.60 0.18 0.56 0.08 knn~12 + 19 0.63 0.01 0.37 0.46 0.28 0.57 0.01 rf~4 + 39 0.63 0.01 0.33 0.49 0.26 0.56 0.04 rpart~17 + 13 0.39 0.01 0.13 0.68 0.19 0.58 0.05 rpart~15 + 16 0.40 0.01 0.07 0.74 0.13 0.59 0.06 rpart~12 + 17 0.62 0.01 0.24 0.50 0.21 0.54 0.02 nb~16 + 17 0.63 0.01 0.17 0.65 0.22 0.58 0.01 svm~37 + 6 0.63 0.01 0.37 0.45 0.27 0.56 0.37 knn~12 + 31 0.63 0.01 0.63 0.30 0.34 0.60 0.03 rpart~4 + 13 0.63 0.01 0.35 0.51 0.29 0.58 0.10 rf~42 + 26 0.63 0.01 0.57 0.30 0.31 0.56 0.32 rf~32 + 22 0.63 0.01 0.30 0.46 0.24 0.54 0.06 rf~16 + 10 0.63 0.01 0.22 0.60 0.23 0.58 0.02 nb~37 + 28 0.63 0.01 0.28 0.55 0.26 0.58 0.69 nb~12 + 32 0.63 0.01 0.17 0.55 0.18 0.54 0.01 rf~37 + 19 0.63 0.01 0.41 0.37 0.27 0.53 0.20 rpart~16 + 41 0.63 0.01 0.24 0.55 0.23 0.56 0.01 svm~35 + 19 0.63 0.01 0.30 0.54 0.27 0.58 0.28 nb~4 + 17 0.63 0.01 0.22 0.62 0.24 0.59 0.11 knn~12 + 6 0.63 0.01 0.28 0.44 0.22 0.52 0.03 svm~10 + 19 0.63 0.01 0.28 0.51 0.25 0.56 0.00 rf~24 + 28 0.63 0.01 0.35 0.50 0.28 0.58 0.04 rf~24 + 13 0.63 0.01 0.37 0.48 0.28 0.57 0.14 rpart~4 + 24 0.62 0.02 0.20 0.62 0.23 0.58 0.08 knn~24 + 28 0.63 0.02 0.17 0.65 0.22 0.58 0.04 rpart~15 + 8 0.63 0.02 0.20 0.59 0.21 0.56 0.42 nb~25 + 6 0.63 0.02 0.33 0.52 0.28 0.58 0.09 svm~12 + 10 0.63 0.02 0.20 0.61 0.22 0.57 0.01 rpart~15 + 13 0.63 0.02 0.26 0.62 0.28 0.60 0.10 svm~19 + 28 0.63 0.02 0.37 0.54 0.31 0.60 0.26 svm~24 + 37 0.63 0.02 0.22 0.63 0.25 0.59 0.71 rpart~16 + 6 0.62 0.02 0.26 0.52 0.24 0.56 0.06 rpart~16 + 22 0.63 0.02 0.37 0.44 0.27 0.55 0.02 svm~40 + 19 0.63 0.02 0.37 0.44 0.27 0.55 0.16 svm~4 + 24 0.63 0.02 0.15 0.63 0.19 0.57 0.02 rpart~11 + 22 0.38 0.02 0.22 0.57 0.22 0.57 0.49 rf~12 + 6 0.63 0.02 0.33 0.39 0.23 0.51 0.01 nb~4 + 16 0.63 0.02 0.17 0.63 0.21 0.58 0.06 nb~16 + 28 0.63 0.02 0.39 0.48 0.30 0.58 0.11 svm~11 + 28 0.63 0.02 0.24 0.59 0.24 0.58 0.85 knn~9 + 6 0.63 0.02 0.48 0.30 0.28 0.51 0.26 svm~13 + 6 0.63 0.02 0.39 0.50 0.31 0.59 0.63 svm~28 + 32 0.63 0.02 0.33 0.66 0.35 0.64 0.40 svm~40 + 24 0.63 0.02 0.35 0.46 0.27 0.56 0.08 rpart~14 + 24 0.62 0.02 0.07 0.74 0.13 0.59 0.05 rpart~16 + 26 0.63 0.02 0.22 0.62 0.24 0.59 0.05 knn~16 + 29 0.38 0.02 0.26 0.56 0.25 0.58 0.02 nb~15 + 6 0.63 0.02 0.15 0.66 0.20 0.58 0.03 rf~29 + 19 0.63 0.02 0.37 0.41 0.26 0.54 0.00 rf~4 + 21 0.63 0.02 0.33 0.54 0.28 0.59 0.51 nb~4 + 15 0.63 0.02 0.11 0.61 0.14 0.55 0.07 rf~24 + 19 0.63 0.02 0.26 0.56 0.25 0.58 0.02 nb~9 + 19 0.63 0.02 0.35 0.48 0.27 0.57 0.70 svm~21 + 6 0.63 0.02 0.33 0.49 0.26 0.56 0.16 rf~15 + 10 0.63 0.02 0.30 0.52 0.26 0.57 0.01 knn~17 + 37 0.62 0.02 0.65 0.26 0.33 0.57 0.28 rpart~17 + 18 0.39 0.02 0.22 0.56 0.22 0.56 0.14 nb~1 + 19 0.63 0.02 0.57 0.30 0.31 0.56 0.04 svm~1 + 16 0.63 0.02 0.09 0.74 0.16 0.59 0.03 rpart~42 + 15 0.62 0.02 0.22 0.56 0.22 0.56 0.33 rpart~4 + 12 0.62 0.02 0.35 0.44 0.26 0.55 0.00 rf~15 + 19 0.63 0.02 0.30 0.56 0.28 0.59 0.00 rf~15 + 24 0.63 0.02 0.30 0.50 0.25 0.56 0.06 nb~26 + 6 0.63 0.02 0.26 0.59 0.26 0.59 0.08 svm~16 + 18 0.62 0.02 0.22 0.55 0.21 0.56 0.03 nb~16 + 22 0.62 0.02 0.35 0.52 0.29 0.59 0.06 nb~17 + 6 0.62 0.02 0.28 0.63 0.30 0.61 0.10 nb~24 + 13 0.62 0.02 0.17 0.66 0.22 0.59 0.05 knn~12 + 10 0.62 0.02 0.50 0.29 0.28 0.51 0.02 knn~9 + 19 0.62 0.02 0.48 0.35 0.29 0.55 0.79 svm~16 + 26 0.62 0.02 0.20 0.60 0.21 0.57 0.02 rf~4 + 8 0.62 0.02 0.59 0.29 0.32 0.56 0.14 rf~10 + 22 0.62 0.02 0.37 0.43 0.27 0.55 0.03 nb~37 + 22 0.62 0.02 0.37 0.48 0.28 0.57 0.45 svm~13 + 28 0.62 0.02 0.35 0.46 0.27 0.56 0.42 rf~1 + 19 0.62 0.02 0.41 0.46 0.30 0.58 0.18 nb~15 + 35 0.62 0.02 0.30 0.56 0.28 0.59 0.07 svm~4 + 25 0.62 0.02 0.37 0.45 0.27 0.56 0.28 nb~12 + 13 0.62 0.02 0.26 0.59 0.26 0.59 0.04 nb~24 + 10 0.62 0.02 0.39 0.43 0.28 0.56 0.02 rf~10 + 19 0.62 0.02 0.37 0.44 0.27 0.55 0.02 rpart~16 + 10 0.61 0.02 0.24 0.55 0.23 0.56 0.00 svm~12 + 5 0.62 0.02 0.39 0.41 0.27 0.55 0.06 svm~9 + 19 0.62 0.02 0.35 0.40 0.25 0.52 0.24 svm~32 + 22 0.62 0.02 0.26 0.57 0.26 0.58 0.03 knn~15 + 28 0.62 0.02 0.17 0.65 0.22 0.58 0.19 nb~16 + 32 0.62 0.02 0.26 0.55 0.24 0.57 0.03 rpart~42 + 24 0.62 0.02 0.17 0.68 0.24 0.60 0.07 nb~14 + 6 0.62 0.02 0.24 0.61 0.26 0.59 0.16 nb~12 + 38 0.62 0.02 0.20 0.59 0.21 0.56 0.00 rf~13 + 19 0.62 0.02 0.57 0.33 0.32 0.57 0.13 nb~16 + 37 0 62 0.02 0.33 0.44 0.25 0.54 0.21 svm~4 + 42 0.62 0.02 0.39 0.44 0.28 0.56 0.22 rpart~37 + 22 0.61 0.03 0.33 0.48 0.26 0.56 0.72 knn~18 + 10 0.38 0.03 0.54 0.23 0.28 0.48 0.13 rf~4 + 10 0.62 0.03 0.17 0.66 0.22 0.59 0.34 svm~4 + 28 0.62 0.03 0.30 0.59 0.29 0.60 0.58 nb~18 + 6 0.62 0.03 0.33 0.56 0.29 0.60 0.13 nb~12 + 41 0.62 0.03 0.15 0.63 0.19 0.57 0.06 nb~12 + 10 0.62 0.03 0.35 0.56 0.31 0.61 0.02 svm~11 + 22 0.62 0.03 0.33 0.54 0.28 0.59 0.71 svm~8 + 28 0.62 0.03 0.30 0.46 0.24 0.54 0.10 nb~10 + 6 0.62 0.03 0.17 0.63 0.21 0.58 0.05 rf~31 + 19 0.62 0.03 0.41 0.39 0.28 0.54 0.05 rf~12 + 2 0.62 0.03 0.33 0.49 0.26 0.56 0.04 svm~16 + 38 0.62 0.03 0.22 0.56 0.22 0.56 0.01 nb~39 + 6 0.62 0.03 0.24 0.59 0.24 0.58 0.06 rf~16 + 19 0.62 0.03 0.41 0.44 0.29 0.57 0.01 svm~12 + 6 0.62 0.03 0.30 0.49 0.25 0.56 0.01 svm~16 + 34 0.62 0.03 0.28 0.60 0.28 0.60 0.05 rf~15 + 8 0.62 0.03 0.28 0.51 0.25 0.56 0.15 nb~10 + 28 0.62 0.03 0.22 0.65 0.26 0.60 0.31 nb~10 + 20 0.62 0.03 0.37 0.45 0.27 0.56 0.10 rpart~4 + 18 0.61 0.03 0.35 0.51 0.29 0.58 0.89 knn~35 + 19 0.39 0.03 0.57 0.24 0.30 0.50 0.14 rpart~18 + 32 0.62 0.03 0.39 0.45 0.29 0.57 0.09 svm~7 + 28 0.62 0.03 0.39 0.52 0.32 0.61 0.76 knn~1 + 22 0.39 0.03 0.37 0.51 0.30 0.59 0.02 rpart~4 + 41 0.61 0.03 0.22 0.61 0.24 0.58 0.08 svm~43 + 22 0.62 0.03 0.22 0.62 0.24 0.59 0.25 rpart~1 + 28 0.62 0.03 0.33 0.48 0.26 0.56 0.60 rpart~12 + 31 0.62 0.03 0.28 0.59 0.28 0.59 0.05 rpart~10 + 22 0.61 0.03 0.33 0.50 0.27 0.57 0.01 nb~40 + 24 0.62 0.03 0.28 0.54 0.25 0.57 0.07 svm~4 + 10 0.62 0.03 0.15 0.61 0.18 0.56 0.05 svm~13 + 32 0.62 0.03 0.24 0.71 0.31 0.62 0.52 rpart~4 + 1 0.39 0.03 0.52 0.35 0.31 0.57 0.35 rf~16 + 24 0.62 0.03 0.30 0.55 0.27 0.58 0.16 rf~4 + 19 0.62 0.03 0.37 0.45 0.27 0.56 0.05 rpart~24 + 10 0.40 0.03 0.20 0.67 0.25 0.60 0.00 svm~19 + 6 0.62 0.03 0.37 0.52 0.30 0.60 0.14 nb~15 + 36 0.62 0.03 0.26 0.55 0.24 0.57 0.01 knn~43 + 22 0.61 0.03 0.43 0.24 0.24 0.43 0.13 knn~4 + 7 0.61 0.03 0.22 0.67 0.27 0.60 0.22 nb~20 + 6 0.62 0.03 0.28 0.55 0.26 0.58 0.19 rpart~24 + 38 0.61 0.03 0.24 0.62 0.26 0.59 0.15 svm~24 + 25 0.61 0.03 0.20 0.66 0.24 0.59 0.07 knn~11 + 28 0.61 0.03 0.59 0.23 0.30 0.50 0.78 rf~24 + 43 0.61 0.03 0.17 0.67 0.23 0.59 0.05 rf~9 + 22 0.61 0.03 0.28 0.51 0.25 0.56 0.10 knn~26 + 2 0.61 0.03 0.59 0.21 0.29 0.47 0.22 knn~24 + 20 0.39 0.03 0.17 0.78 0.31 0.63 0.07 rf~24 + 10 0.61 0.03 0.30 0.55 0.27 0.58 0.02 svm~29 + 22 0.61 0.03 0.46 0.46 0.32 0.60 0.24 nb~43 + 6 0.61 0.03 0.20 0.62 0.23 0.58 0.11 rpart~1 + 15 0.61 0.03 0.22 0.63 0.25 0.59 0.05 rpart~38 + 22 0.61 0.03 0.39 0.40 0.27 0.54 0.87 rpart~18 + 13 0.61 0.03 0.43 0.44 0.30 0.58 0.95 nb~16 + 38 0.61 0.03 0.28 0.61 0.29 0.60 0.01 nb~18 + 13 0.61 0.03 0.37 0.48 0.28 0.57 0.26 nb~24 + 31 0.61 0.03 0.26 0.56 0.25 0.58 0.01 svm~26 + 37 0.61 0.03 0.15 0.68 0.21 0.59 0.95 knn~4 + 42 0.39 0.03 0.70 0.21 0.33 0.55 0.08 svm~16 + 8 0.61 0.03 0.26 0.55 0.24 0.57 0.02 rf~18 + 13 0.61 0.03 0.48 0.43 0.32 0.59 0.95 nb~13 + 28 0.61 0.04 0.33 0.54 0.28 0.59 0.61 rf~19 + 28 0.61 0.04 0.41 0.39 0.28 0.54 0.03 svm~36 + 19 0.61 0.04 0.30 0.50 0.25 0.56 0.02 svm~12 + 9 0.61 0.04 0.26 0.60 0.27 0.59 0.14 svm~12 + 27 0.61 0.04 0.30 0.52 0.26 0.57 0.01 rpart~16 + 3 0.41 0.04 0.11 0.82 0.25 0.62 0.67 rf~10 + 28 0.61 0.04 0.50 0.44 0.33 0.61 0.41 nb~35 + 6 0.61 0.04 0.24 0.56 0.23 0.57 0.12 knn~4 + 10 0.39 0.04 0.22 0.60 0.23 0.58 0.14 svm~4 + 11 0.61 0.04 0.13 0.63 0.17 0.57 0.20 nb~16 + 11 0.61 0.04 0.35 0.57 0.31 0.61 0.17 knn~37 + 22 0.61 0.04 0.54 0.27 0.29 0.51 0.26 rpart~16 + 25 0.60 0.04 0.41 0.45 0.30 0.58 0.26 nb~15 + 31 0.61 0.04 0.26 0.60 0.27 0.59 0.02 knn~12 + 28 0.61 0.04 0.15 0.63 0.19 0.57 0.19 knn~4 + 43 0.39 0.04 0.33 0.52 0.28 0.58 0.41 svm~16 + 22 0.61 0.04 0.37 0.50 0.29 0.59 0.15 svm~16 + 28 0.61 0.04 0.33 0.51 0.27 0.58 0.19 nb~4 + 10 0.61 0.04 0.11 0.71 0.17 0.59 0.13 knn~16 + 18 0.61 0.04 0.28 0.45 0.22 0.53 0.14 knn~8 + 19 0.61 0.04 0.37 0.44 0.27 0.55 0.23 nb~18 + 37 0.61 0.04 0.35 0.49 0.28 0.57 0.41 svm~24 + 2 0.61 0.04 0.22 0.60 0.23 0.58 0.74 knn~18 + 20 0.61 0.04 0.17 0.70 0.24 0.60 0.24 knn~26 + 20 0.61 0.04 0.48 0.43 0.32 0.59 0.10 nb~16 + 13 0.61 0.04 0.26 0.54 0.24 0.56 0.14 nb~14 + 28 0.61 0.04 0.28 0.61 0.29 0.60 0.66 svm~42 + 15 0.61 0.04 0.26 0.61 0.27 0.60 0.13 svm~4 + 21 0.61 0.04 0.22 0.63 0.25 0.59 0.64 rpart~24 + 33 0.60 0.04 0.17 0.67 0.23 0.59 0.23 rpart~13 + 22 0.61 0.04 0.48 0.34 0.29 0.54 0.50 rf~1 + 28 0.61 0.04 0.37 0.39 0.25 0.52 0.21 knn~24 + 10 0.61 0.04 0.37 0.41 0.26 0.54 0.01 rf~40 + 24 0.61 0.04 0.33 0.54 0.28 0.59 0.03 knn~4 + 20 0.61 0.04 0.46 0.38 0.29 0.55 0.20 rpart~20 + 28 0.60 0.04 0.54 0.33 0.31 0.56 0.30 rf~15 + 16 0.61 0.04 0.17 0.61 0.20 0.57 0.01 svm~31 + 28 0.61 0.04 0.43 0.49 0.32 0.61 0.26 nb~10 + 22 0.61 0.04 0.33 0.56 0.29 0.60 0.19 knn~4 + 8 0.61 0.04 0.13 0.71 0.20 0.59 0.11 svm~4 + 19 0.61 0.04 0.35 0.43 0.25 0.54 0.19 knn~29 + 19 0.61 0.04 0.17 0.65 0.22 0.58 0.03 nb~38 + 28 0.61 0.04 0.30 0.49 0.25 0.56 0.04 svm~16 + 31 0.61 0.04 0.20 0.61 0.22 0.57 0.03 nb~16 + 29 0.61 0.04 0.26 0.63 0.29 0.60 0.09 knn~26 + 19 0.61 0.05 0.41 0.43 0.29 0.56 0.03 nb~22 + 6 0.61 0.05 0.35 0.52 0.29 0.59 0.19 svm~2 + 28 0.61 0.05 0.35 0.43 0.25 0.54 0.65 svm~37 + 28 0.61 0.05 0.37 0.46 0.28 0.57 0.99 rf~19 + 34 0.61 0.05 0.33 0.44 0.25 0.54 0.02 svm~4 + 14 0.61 0.05 0.15 0.60 0.18 0.56 0.27 svm~28 + 21 0.61 0.05 0.33 0.56 0.29 0.60 0.67 rpart~29 + 6 0.60 0.05 0.33 0.54 0.28 0.59 0.09 svm~16 + 13 0.61 0.05 0.24 0.57 0.24 0.57 0.09 rpart~15 + 6 0.60 0.05 0.33 0.52 0.28 0.58 0.31 rpart~31 + 6 0.60 0.05 0.39 0.50 0.31 0.59 0.40 nb~4 + 6 0.61 0.05 0.24 0.57 0.24 0.57 0.33 svm~15 + 22 0.61 0.05 0.22 0.60 0.23 0.58 0.16 svm~15 + 37 0.61 0.05 0.17 0.66 0.22 0.59 0.21 svm~16 + 32 0.61 0.05 0.13 0.67 0.18 0.58 0.02 knn~4 + 15 0.40 0.05 0.24 0.56 0.23 0.57 0.06 knn~12 + 2 0.60 0.05 0.39 0.49 0.30 0.59 0.24 nb~15 + 34 0.61 0.05 0.20 0.68 0.26 0.60 0.07 svm~8 + 32 0.61 0.05 0.22 0.66 0.26 0.60 0.03 nb~1 + 6 0.61 0.05 0.26 0.60 0.27 0.59 0.09 nb~12 + 5 0.61 0.05 0.59 0.28 0.31 0.55 0.04 svm~35 + 6 0.61 0.05 0.24 0.59 0.24 0.58 0.48 nb~16 + 31 0.61 0.05 0.24 0.59 0.24 0.58 0.05 svm~4 + 37 0.61 0.05 0.30 0.50 0.25 0.56 0.51 nb~12 + 35 0.61 0.05 0.20 0.61 0.22 0.57 0.08 rpart~10 + 32 0.60 0.05 0.24 0.68 0.30 0.62 0.02 svm~15 + 35 0.60 0.05 0.20 0.67 0.25 0.60 0.62 svm~14 + 6 0.60 0.05 0.37 0.59 0.33 0.62 0.25 rf~24 + 22 0.60 0.05 0.30 0.48 0.25 0.55 0.14 auc.pvalue: Wilcoxon Test P-value. MFD: Median Fold Difference. KM: Kaplan Meier curves. mvaHRPval: Multivariable Analysis Hazard Ratio P-value.

Example 13: A 2,040 Biomarker Library for Prostate Cancer Progression

In order to define, from the entire set of 1.4 million features, a comprehensive library of biomarkers that presents prognostic ability, the Discovery Set (Training and Testing) presented in Example 1 was processed as follows. First, all features with a probe count lower than 4 or with cross-hybridizing probes as defined by affymetrix (www.affymetrix.com) were removed. Second, a background filter was applied in order to ensure signal in the expression capture for each feature. To achieve this, features that had a median expression value in the group of mets patients and in the group of non-mets patients (separately) lower than 1.2 times the background signal (captured by the control antigenomic probes defined by affymetrix (www.affymetrix.com)) were removed. Third, the statistical significance of the differential expression observed between the mets and non-mets groups was assessed using the Kolmogorov-Smimov test for each feature. Those features with a p-value greater than 0.05 were removed. Last, a Random forest variable importance was calculated by building a random forest with 450,000 trees. Features with Mean Decrease Gini (or MDG)<=0 were discarded and features with MDG>6.5e-3 and Mean Decrease in Accuracy (or MDA)>0 were selected, reducing the feature set to 2,040 features. MDA is defined as the average difference in accuracy of the true variable vs the variable randomized for trees in the forest. MDG is defined as the mean of the change in gini between a parent node and a child node when splitting on a variable across the whole forest.

These represent the most important features (based on MDG and MDA) that are statistically significant (based on Kolmogorov-Smirnov Test) for the differential expression between mets and non-mets patients (Table 55) and provides a biomarker library for prostate cancer progression.

In tables 53 and 54, those biomarkers from the 2,040 in the library that were found statistically significant in the training and testing sets based on a Wilcoxon test (p-value<=0.05) for the Area under the ROC curve (AUC) metric, are shown for Biochemical Recurrence Event (BCR) and Metastasis Event (Mets Event). Whereas results are shown for the testing set (as defined in Example 1), these biomarkers were significant also in the training set of the discovery study.

Further significance of the selected features was evidenced by multiple metrics and are also listed in tables 53 and 54. Metrics are defined in Example 12.

These results demonstrate, based on the multiple metrics shown, that the library of biomarkers built has the ability to capture the biology underlying the progression of prostate cancer, as defined by diverse clinical variables.

TABLE 53 biomarkers from the 2,040 biomarker library with significance for Wilcoxon P-value (auc.pvalue <= 0.05) and other metrics for the BCR event endpoint. SEQ Pos. Neg. ID auc. Sensi- Speci- Pred. Pred. KM P- Mva NO. auc pvalue tivity ficity Value Value value HRPval 55 0.60 0.03 0.62 0.52 0.74 0.38 0.10 0.02 58 0.59 0.04 0.55 0.48 0.70 0.33 0.22 0.00 90 0.59 0.05 0.66 0.31 0.68 0.29 0.80 0.04 97 0.62 0.01 0.51 0.67 0.77 0.38 0.02 0.00 107 0.62 0.01 0.53 0.62 0.76 0.38 0.07 0.35 109 0.60 0.02 0.42 0.43 0.62 0.25 0.11 0.73 117 0.60 0.04 0.66 0.45 0.73 0.38 0.06 0.38 125 0.61 0.02 0.65 0.17 0.63 0.18 0.02 0.47 165 0.59 0.04 0.45 0.64 0.73 0.35 0.06 0.55 170 0.61 0.02 0.42 0.71 0.76 0.36 0.01 0.92 176 0.61 0.02 0.63 0.55 0.76 0.41 0.01 0.00 178 0.61 0.01 0.35 0.79 0.79 0.36 0.03 0.74 179 0.61 0.02 0.45 0.69 0.76 0.36 0.01 0.73 183 0.59 0.05 0.73 0.28 0.69 0.31 0.68 0.29 208 0.61 0.02 0.67 0.47 0.74 0.39 0.03 0.01 228 0.60 0.02 0.48 0.66 0.75 0.36 0.01 0.55 246 0.65 0.00 0.70 0.53 0.77 0.45 0.00 0.00 251 0.59 0.04 0.45 0.43 0.63 0.26 0.05 0.22 311 0.61 0.02 0.39 0.71 0.75 0.34 0.13 0.33 315 0.59 0.05 0.59 0.53 0.74 0.37 0.09 0.40 316 0.61 0.02 0.65 0.50 0.74 0.39 0.03 0.06 317 0.61 0.02 0.33 0.78 0.76 0.34 0.03 0.38 339 0.60 0.03 0.55 0.33 0.64 0.25 0.26 0.87 357 0.63 0.00 0.51 0.71 0.79 0.39 0.00 0.41 437 0.65 0.00 0.42 0.78 0.81 0.38 0.00 0.36 465 0.60 0.03 0.48 0.71 0.78 0.38 0.00 0.98 473 0.60 0.03 0.70 0.48 0.75 0.42 0.01 0.29 522 0.59 0.05 0.63 0.52 0.74 0.38 0.02 0.01 582 0.60 0.03 0.40 0.79 0.81 0.37 0.00 0.07 615 0.59 0.04 0.40 0.47 0.62 0.26 0.02 0.00 643 0.62 0.01 0.54 0.67 0.78 0.40 0.00 0.00 693 0.63 0.00 0.62 0.59 0.77 0.41 0.01 0.01 696 0.59 0.04 0.63 0.45 0.72 0.36 0.17 0.15 791 0.61 0.02 0.73 0.41 0.73 0.41 0.02 0.12 836 0.59 0.04 0.52 0.38 0.65 0.27 0.14 0.49 981 0.63 0.00 0.52 0.31 0.63 0.23 0.02 0.03 1024 0.59 0.04 0.58 0.48 0.71 0.34 0.12 0.00 1062 0.60 0.02 0.63 0.52 0.74 0.39 0.06 0.42 1094 0.60 0.02 0.48 0.34 0.62 0.23 0.03 0.52 1247 0.62 0.01 0.69 0.40 0.72 0.37 0.22 0.01 1249 0.61 0.02 0.48 0.41 0.64 0.26 0.03 0.17 1251 0.59 0.04 0.59 0.57 0.75 0.39 0.01 0.53 1270 0.59 0.04 0.47 0.67 0.76 0.36 0.05 0.16 1285 0.60 0.03 0.54 0.66 0.78 0.39 0.01 0.68 1378 0.61 0.02 0.36 0.53 0.63 0.27 0.06 0.02 1485 0.59 0.05 0.73 0.16 0.66 0.21 0.19 0.75 1509 0.60 0.01 0.43 0.36 0.60 0.22 0.02 0.02 1517 0.59 0.04 0.37 0.55 0.64 0.28 0.22 0.07 1537 0.60 0.02 0.57 0.59 0.75 0.38 0.00 0.45 1540 0.61 0.02 0.36 0.50 0.61 0.26 0.06 0.00 1541 0.62 0.01 0.69 0.50 0.75 0.42 0.01 0.01 1576 0.62 0.01 0.49 0.69 0.78 0.38 0.01 0.29 1581 0.59 0.05 0.52 0.60 0.74 0.36 0.18 0.24 1634 0.64 0.00 0.54 0.66 0.78 0.39 0.03 0.00 1656 0.60 0.03 0.36 0.76 0.77 0.35 0.02 0.54 1706 0.60 0.02 0.41 0.43 0.62 0.25 0.06 0.64 1719 0.60 0.02 0.50 0.64 0.75 0.37 0.00 0.17 1721 0.61 0.02 0.57 0.59 0.75 0.38 0.01 0.05 1783 0.61 0.02 0.63 0.53 0.75 0.39 0.02 0.83 1801 0.61 0.02 0.60 0.53 0.74 0.38 0.24 0.18 1823 0.61 0.02 0.37 0.48 0.61 0.26 0.05 0.21 1902 0.64 0.00 0.53 0.71 0.80 0.41 0.00 0.02 1958 0.60 0.03 0.67 0.50 0.75 0.41 0.00 0.00 1964 0.60 0.03 0.70 0.36 0.71 0.35 0.14 0.01 1965 0.62 0.01 0.47 0.71 0.78 0.38 0.00 0.84 2014 0.61 0.02 0.59 0.53 0.74 0.37 0.09 0.01 Auc.pvalue: Wilcoxon Test P-value. KM: Kaplan Meier curves. mvaHRPval: Multivariable Analysis Hazard Ratio P-value.

TABLE 54 biomarkers from the 2,040 biomarker library with significance for Wilcoxon P-value (auc.pvalue <= 0.05) and other metrics for the MET event endpoint. SEQ Pos. Neg. ID auc. Sensi- Speci- Pred. Pred. KM P-Mva NO. auc pvalue tivity ficity Value Value value HRPval 50 0.65 0.00 0.32 0.42 0.24 0.52 0.00 0.14 51 0.64 0.00 0.59 0.58 0.45 0.71 0.01 0.02 53 0.69 0.00 0.78 0.47 0.46 0.79 0.00 0.00 55 0.60 0.02 0.65 0.47 0.41 0.70 0.11 0.10 58 0.65 0.00 0.63 0.51 0.43 0.71 0.03 0.00 59 0.63 0.00 0.76 0.44 0.44 0.76 0.00 0.39 60 0.63 0.00 0.71 0.50 0.45 0.75 0.01 0.05 63 0.60 0.03 0.59 0.55 0.43 0.70 0.04 0.15 68 0.59 0.04 0.81 0.40 0.44 0.78 0.00 0.46 71 0.60 0.02 0.46 0.42 0.31 0.57 0.06 0.09 76 0.60 0.03 0.81 0.37 0.43 0.77 0.01 0.25 82 0.63 0.00 0.68 0.55 0.46 0.75 0.00 0.03 87 0.59 0.05 0.82 0.31 0.41 0.75 0.03 0.04 90 0.63 0.00 0.74 0.37 0.40 0.71 0.08 0.07 96 0.62 0.01 0.78 0.38 0.42 0.75 0.01 0.02 97 0.67 0.00 0.60 0.64 0.49 0.74 0.00 0.00 100 0.63 0.00 0.32 0.42 0.24 0.52 0.00 0.07 102 0.60 0.02 0.66 0.45 0.41 0.70 0.09 0.00 107 0.61 0.01 0.57 0.57 0.43 0.70 0.09 0.10 108 0.60 0.02 0.50 0.66 0.46 0.70 0.01 0.13 117 0.61 0.01 0.71 0.42 0.41 0.71 0.06 0.02 119 0.61 0.01 0.75 0.41 0.42 0.74 0.02 0.04 120 0.59 0.05 0.76 0.36 0.41 0.73 0.04 0.19 126 0.59 0.04 0.46 0.37 0.30 0.54 0.02 0.28 130 0.63 0.00 0.65 0.56 0.46 0.73 0.00 0.12 131 0.59 0.05 0.60 0.53 0.42 0.70 0.04 0.02 137 0.60 0.02 0.43 0.69 0.45 0.68 0.09 0.13 144 0.59 0.05 0.63 0.54 0.44 0.72 0.02 0.73 151 0.63 0.00 0.56 0.70 0.52 0.73 0.00 0.23 152 0.69 0.00 0.60 0.63 0.48 0.73 0.00 0.00 155 0.61 0.01 0.56 0.49 0.39 0.66 0.68 0.24 163 0.61 0.02 0.63 0.54 0.44 0.72 0.03 0.14 165 0.65 0.00 0.53 0.64 0.46 0.70 0.02 0.04 169 0.59 0.04 0.68 0.52 0.45 0.73 0.01 0.08 170 0.63 0.00 0.51 0.69 0.49 0.71 0.00 0.13 175 0.59 0.04 0.74 0.40 0.41 0.72 0.05 0.02 176 0.60 0.02 0.69 0.49 0.44 0.73 0.01 0.01 179 0.66 0.00 0.57 0.69 0.51 0.74 0.00 0.36 183 0.60 0.02 0.79 0.31 0.40 0.73 0.08 0.07 187 0.62 0.01 0.76 0.40 0.42 0.75 0.02 0.01 188 0.61 0.01 0.43 0.40 0.29 0.55 0.03 0.88 192 0.64 0.00 0.35 0.40 0.25 0.52 0.00 0.12 197 0.60 0.02 0.53 0.61 0.44 0.69 0.02 0.01 204 0.59 0.05 0.79 0.30 0.39 0.71 0.22 0.94 213 0.59 0.04 0.68 0.48 0.43 0.72 0.02 0.01 225 0.64 0.00 0.74 0.47 0.44 0.75 0.01 0.02 228 0.64 0.00 0.59 0.65 0.49 0.73 0.00 0.06 230 0.61 0.01 0.40 0.45 0.29 0.56 0.06 0.39 239 0.61 0.02 0.69 0.47 0.43 0.73 0.01 0.02 241 0.59 0.03 0.50 0.37 0.31 0.56 0.10 0.93 246 0.65 0.00 0.82 0.48 0.48 0.83 0.00 0.01 251 0.59 0.05 0.37 0.45 0.28 0.55 0.02 0.30 255 0.60 0.02 0.62 0.60 0.47 0.73 0.00 0.34 268 0.59 0.05 0.65 0.51 0.43 0.71 0.02 0.10 269 0.59 0.04 0.72 0.42 0.42 0.72 0.03 0.02 271 0.63 0.00 0.41 0.41 0.29 0.55 0.01 0.51 273 0.59 0.04 0.40 0.44 0.29 0.56 0.03 0.20 275 0.59 0.05 0.38 0.51 0.31 0.59 0.11 0.05 277 0.60 0.02 0.47 0.45 0.33 0.60 0.25 0.02 285 0.65 0.00 0.38 0.36 0.25 0.50 0.00 0.47 288 0.62 0.01 0.53 0.57 0.41 0.68 0.13 0.05 291 0.61 0.02 0.59 0.53 0.42 0.69 0.08 0.19 292 0.63 0.00 0.54 0.28 0.30 0.52 0.01 0.02 293 0.59 0.04 0.54 0.38 0.34 0.59 0.35 0.62 299 0.59 0.05 0.62 0.53 0.43 0.71 0.04 0.08 314 0.60 0.03 0.34 0.53 0.29 0.58 0.06 0.01 317 0.66 0.00 0.41 0.77 0.51 0.69 0.00 0.07 333 0.60 0.02 0.75 0.27 0.37 0.65 0.61 0.05 336 0.60 0.02 0.56 0.35 0.33 0.58 0.28 0.42 344 0.60 0.03 0.78 0.37 0.42 0.75 0.02 0.00 350 0.60 0.03 0.59 0.57 0.44 0.71 0.02 0.18 352 0.61 0.01 0.43 0.41 0.29 0.55 0.02 0.00 356 0.60 0.02 0.71 0.42 0.41 0.71 0.09 0.11 357 0.64 0.00 0.54 0.62 0.45 0.70 0.02 0.03 360 0.60 0.02 0.50 0.36 0.31 0.55 0.05 0.92 362 0.65 0.00 0.62 0.59 0.47 0.73 0.00 0.04 367 0.60 0.02 0.59 0.51 0.41 0.68 0.14 0.09 371 0.60 0.02 0.50 0.33 0.30 0.53 0.01 0.04 373 0.60 0.03 0.75 0.31 0.38 0.68 0.39 0.08 383 0.62 0.01 0.50 0.62 0.43 0.68 0.13 0.15 394 0.60 0.03 6.54 0.31 0.31 0.54 0.06 0.43 397 0.61 0.01 0.59 0.57 0.44 0.71 0.04 0.14 400 0.60 0.03 0.69 0.45 0.42 0.72 0.05 0.24 409 0.60 0.02 0.54 0.58 0.43 0.69 0.03 0.10 418 0.62 0.01 0.68 0.47 0.42 0.71 0.02 0.01 419 0.64 0.00 0.69 0.57 0.48 0.76 0.00 0.01 425 0.59 0.04 0.60 0.47 0.40 0.67 0.25 0.08 441 0.61 0.02 0.81 0.34 0.41 0.75 0.03 0.10 445 0.60 0.02 0.59 0.53 0.42 0.69 0.06 0.22 447 0.62 0.01 0.60 0.58 0.45 0.72 0.01 0.08 459 0.59 0.05 0.44 0.46 0.32 0.59 0.27 0.22 466 0.59 0.04 0.28 0.58 0.28 0.58 0.05 0.03 473 0.59 0.04 0.76 0.42 0.43 0.76 0.01 0.48 477 0.61 0.01 0.46 0.75 0.52 0.71 0.00 0.12 478 0.60 0.02 0.66 0.47 0.42 0.71 0.04 0.04 484 0.62 0.01 0.75 0.44 0.44 0.75 0.01 0.10 485 0.61 0.02 0.29 0.53 0.26 0.56 0.02 0.19 493 0.61 0.01 0.59 0.55 0.43 0.70 0.03 0.40 494 0.61 0.01 0.74 0.36 0.40 0.70 0.13 0.23 500 0.59 0.05 0.71 0.39 0.40 0.70 0.17 0.08 509 0.60 0.03 0.32 0.50 0.27 0.56 0.02 0.58 516 0.65 0.00 0.28 0.53 0.25 0.56 0.01 0.03 517 0.59 0.04 0.62 0.52 0.42 0.70 0.04 0.05 522 0.62 0.01 0.69 0.48 0.44 0.73 0.01 0.14 539 0.66 0.00 0.75 0.45 0.44 0.76 0.00 0.00 548 0.61 0.01 0.71 0.42 0.41 0.71 0.08 0.07 552 0.61 0.01 0.68 0.47 0.42 0.71 0.03 0.03 559 0.62 0.01 0.37 0.40 0.26 0.52 0.00 0.00 563 0.59 0.04 0.35 0.46 0.27 0.55 0.01 0.68 568 0.61 0.01 0.75 0.37 0.41 0.72 0.06 0.07 571 0.60 0.02 0.72 0.41 0.41 0.72 0.04 0.07 572 0.65 0.00 0.65 0.56 0.46 0.73 0.00 0.01 579 0.60 0.02 0.72 0.42 0.42 0.72 0.03 0.03 582 0.68 0.00 0.54 0.78 0.59 0.75 0.00 0.00 586 0.61 0.02 0.44 0.38 0.29 0.54 0.02 0.04 589 0.60 0.02 0.49 0.39 0.31 0.57 0.14 0.91 614 0.64 0.00 0.75 0.44 0.44 0.75 0.01 0.11 616 0.61 0.01 0.63 0.54 0.44 0.72 0.01 0.87 618 0.62 0.01 0.60 0.54 0.43 0.70 0.04 0.01 639 0.63 0.00 0.66 0.56 0.46 0.74 0.00 0.03 643 0.60 0.03 0.57 0.58 0.44 0.70 0.02 0.00 645 0.64 0.00 0.53 0.61 0.44 0.69 0.04 0.04 650 0.63 0.00 0.35 0.43 0.26 0.54 0.01 0.37 671 0.62 0.01 0.43 0.37 0.28 0.53 0.01 0.08 688 0.59 0.05 0.72 0.41 0.41 0.72 0.05 0.00 693 0.64 0.00 0.68 0.52 0.45 0.73 0.01 0.00 695 0.60 0.03 0.63 0.50 0.42 0.70 0.03 0.11 696 0.64 0.00 0.71 0.45 0.42 0.73 0.04 0.02 698 0.59 0.04 0.68 0.48 0.43 0.72 0.02 0.02 704 0.59 0.03 0.76 0.36 0.41 0.72 0.05 0.02 707 0.59 0.03 0.50 0.32 0.30 0.53 0.01 0.99 717 0.59 0.04 0.54 0.34 0.32 0.56 0.07 0.33 721 0.63 0.00 0.82 0.34 0.42 0.77 0.02 0.00 724 0.60 0.03 0.38 0.51 0.31 0.59 0.11 0.51 729 0.60 0.02 0.43 0.41 0.29 0.55 0.02 0.11 733 0.59 0.04 0.60 0.56 0.44 0.71 0.01 0.16 737 0.60 0.02 0.26 0.60 0.28 0.59 0.05 0.07 752 0.60 0.03 0.56 0.31 0.32 0.55 0.09 0.09 760 0.60 0.03 0.66 0.52 0.44 0.73 0.02 0.91 761 0.62 0.01 0.68 0.49 0.43 0.73 0.02 0.24 772 0.66 0.00 0.71 0.55 0.48 0.76 0.00 0.00 799 0.60 0.02 0.68 0.47 0.43 0.72 0.05 0.75 802 0.59 0.04 0.72 0.41 0.41 0.72 0.09 0.02 804 0.60 0.02 0.29 0.58 0.29 0.59 0.08 0.01 816 0.59 0.05 0.62 0.56 0.45 0.72 0.03 0.41 821 0.59 0.04 0.71 0.34 0.38 0.67 0.42 0.11 825 0.59 0.03 0.62 0.50 0.42 0.69 0.06 0.29 826 0.61 0.01 0.65 0.58 0.47 0.74 0.00 0.12 830 0.59 0.03 0.29 0.58 0.29 0.59 0.04 0.11 836 0.61 0.01 0.47 0.40 0.31 0.57 0.09 0.13 840 0.62 0.00 0.75 0.37 0.41 0.72 0.05 0.03 845 0.64 0.00 0.59 0.62 0.47 0.72 0.01 0.04 863 0.60 0.03 0.79 0.29 0.39 0.71 0.20 0.21 864 0.64 0.00 0.68 0.55 0.46 0.75 0.00 0.01 884 0.59 0.04 0.65 0.49 0.42 0.71 0.08 0.08 887 0.61 0.01 0.53 0.57 0.41 0.68 0.15 0.00 889 0.61 0.01 0.38 0.49 0.30 0.58 0.11 0.59 892 0.59 0.03 0.56 0.57 0.43 0.69 0.11 0.11 901 0.59 0.04 0.49 0.60 0.41 0.67 0.18 0.06 913 0.62 0.01 0.72 0.41 0.41 0.72 0.04 0.01 920 0.61 0.01 0.84 0.21 0.38 0.69 0.34 0.08 921 0.60 0.02 0.25 0.53 0.23 0.55 0.00 0.82 924 0.61 0.02 0.75 0.42 0.43 0.75 0.01 0.28 950 0.59 0.03 0.69 0.44 0.42 0.71 0.07 0.09 959 0.66 0.00 0.54 0.30 0.31 0.53 0.03 0.21 967 0.59 0.04 0.65 0.47 0.41 0.70 0.13 0.05 971 0.62 0.00 0.24 0.53 0.23 0.55 0.00 0.34 977 0.59 0.04 0.41 0.42 0.29 0.55 0.02 0.10 979 0.59 0.04 0.57 0.31 0.32 0.55 0.10 0.55 981 0.62 0.01 0.46 0.36 0.29 0.53 0.01 0.44 988 0.64 0.00 0.56 0.62 0.46 0.71 0.01 0.01 993 0.61 0.01 0.66 0.54 0.45 0.74 0.00 0.00 997 0.59 0.04 0.51 0.31 0.30 0.53 0.01 0.07 1001 0.63 0.00 0.66 0.58 0.47 0.75 0.00 0.08 1005 0.63 0.00 0.68 0.45 0.41 0.71 0.13 0.62 1008 0.61 0.01 0.62 0.53 0.43 0.71 0.04 0.09 1024 0.59 0.04 0.59 0.46 0.38 0.66 0.29 0.02 1032 0.60 0.02 0.38 0.43 0.28 0.55 0.01 0.14 1036 0.61 0.01 0.65 0.48 0.42 0.70 0.04 0.01 1047 0.59 0.04 0.50 0.35 0.31 0.55 0.03 0.00 1051 0.63 0.00 0.43 0.39 0.29 0.54 0.01 0.12 1055 0.64 0.00 0.68 0.52 0.45 0.73 0.01 0.08 1066 0.59 0.04 0.72 0.42 0.42 0.72 0.04 0.05 1070 0.60 0.03 0.68 0.37 0.38 0.67 0.28 0.14 1078 0.61 0.01 0.49 0.65 0.45 0.69 0.10 0.00 1079 0.64 0.00 0.79 0.42 0.44 0.78 0.00 0.02 1084 0.60 0.02 0.75 0.41 0.42 0.74 0.02 0.27 1094 0.63 0.00 0.40 0.38 0.27 0.52 0.00 0.91 1104 0.60 0.02 0.34 0.50 0.28 0.57 0.04 0.18 1116 0.59 0.04 0.62 0.47 0.40 0.68 0.22 0.50 1122 0.63 0.00 0.69 0.37 0.39 0.68 0.26 0.02 1130 0.61 0.01 0.41 0.46 0.30 0.57 0.09 0.61 1145 0.61 0.01 0.75 0.39 0.41 0.73 0.04 0.06 1161 0.62 0.01 0.57 0.60 0.45 0.71 0.02 0.00 1164 0.65 0.00 0.71 0.53 0.46 0.76 0.00 0.00 1166 0.61 0.01 0.56 0.61 0.45 0.71 0.02 0.01 1169 0.60 0.03 0.82 0.27 0.39 0.73 0.08 0.03 1171 0.60 0.03 0.28 0.52 0.25 0.55 0.01 0.78 1194 0.59 0.04 0.75 0.41 0.42 0.74 0.04 0.64 1200 0.59 0.04 0.62 0.51 0.42 0.70 0.07 0.02 1203 0.62 0.00 0.34 0.47 0.27 0.55 0.01 0.77 1206 0.61 0.01 0.74 0.40 0.41 0.72 0.09 0.09 1215 0.63 0.00 0.65 0.53 0.44 0.72 0.01 0.13 1227 0.60 0.02 0.66 0.47 0.42 0.71 0.03 0.13 1241 0.59 0.04 0.46 0.41 0.31 0.56 0.11 0.78 1249 0.60 0.02 0.40 0.42 0.28 0.55 0.01 0.16 1251 0.64 0.00 0.68 0.53 0.46 0.74 0.01 0.17 1257 0.61 0.02 0.51 0.34 0.31 0.55 0.05 0.91 1259 0.60 0.03 0.65 0.53 0.44 0.72 0.01 0.02 1270 0.60 0.02 0.50 0.62 0.43 0.68 0.05 0.02 1277 0.60 0.02 0.76 0.38 0.42 0.74 0.05 0.24 1290 0.60 0.03 0.68 0.53 0.45 0.74 0.01 0.05 1291 0.60 0.02 0.46 0.42 0.31 0.57 0.09 0.38 1294 0.61 0.02 0.75 0.27 0.37 0.65 0.52 0.06 1299 0.60 0.02 0.53 0.29 0.30 0.52 0.01 0.07 1307 0.59 0.04 0.75 0.35 0.40 0.71 0.09 0.11 1311 0.60 0.02 0.71 0.39 0.40 0.70 0.10 0.02 1319 0.59 0.05 0.87 0.19 0.38 0.72 0.19 0.11 1323 0.62 0.01 0.57 0.57 0.43 0.70 0.09 0.32 1324 0.66 0.00 0.59 0.60 0.46 0.72 0.02 0.15 1332 0.59 0.04 0.44 0.40 0.30 0.55 0.01 0.01 1336 0.59 0.04 0.69 0.43 0.41 0.71 0.08 0.09 1337 0.59 0.05 0.65 0.48 0.42 0.70 0.06 0.29 1339 0.64 0.00 0.82 0.34 0.42 0.77 0.01 0.04 1343 0.60 0.02 0.84 0.31 0.41 0.77 0.02 0.15 1348 0.61 0.01 0.21 0.56 0.21 0.55 0.00 0.87 1355 0.62 0.01 0.59 0.31 0.33 0.56 0.13 0.36 1366 0.61 0.01 0.78 0.41 0.43 0.76 0.01 0.09 1369 0.66 0.00 0.62 0.56 0.45 0.72 0.02 0.26 1378 0.64 0.00 0.25 0.53 0.23 0.55 0.00 0.01 1379 0.61 0.02 0.60 0.52 0.42 0.69 0.06 0.18 1380 0.60 0.02 0.63 0.48 0.41 0.70 0.11 0.13 1383 0.60 0.02 0.38 0.72 0.44 0.67 0.11 0.08 1388 0.61 0.02 0.68 0.42 0.40 0.69 0.17 0.12 1403 0.62 0.01 0.22 0.66 0.27 0.60 0.09 0.23 1405 0.60 0.02 0.78 0.34 0.40 0.73 0.07 0.24 1408 0.60 0.03 0.69 0.41 0.40 0.70 0.10 0.06 1413 0.61 0.02 0.65 0.55 0.45 0.73 0.00 0.11 1417 0.61 0.01 0.38 0.37 0.26 0.51 0.00 0.41 1421 0.60 0.02 0.68 0.47 0.42 0.71 0.02 0.01 1428 0.59 0.04 0.43 0.42 0.30 0.56 0.03 0.01 1439 0.60 0.02 0.47 0.42 0.32 0.58 0.19 0.97 1447 0.59 0.04 0.59 0.31 0.33 0.56 0.07 0.43 1451 0.63 0.00 0.74 0.43 0.43 0.74 0.01 0.19 1458 0.59 0.05 0.50 0.42 0.33 0.60 0.30 0.61 1465 0.61 0.01 0.40 0.47 0.30 0.58 0.06 0.00 1477 0.61 0.01 0.41 0.43 0.29 0.56 0.06 0.12 1480 0.59 0.04 0.62 0.50 0.42 0.69 0.09 0.21 1491 0.63 0.00 0.46 0.37 0.30 0.54 0.03 0.01 1500 0.60 0.03 0.63 0.53 0.44 0.72 0.01 0.21 1502 0.60 0.02 0.68 0.46 0.42 0.71 0.04 0.02 1509 0.65 0.00 0.34 0.42 0.25 0.52 0.00 0.03 1514 0.59 0.04 0.57 0.58 0.44 0.70 0.04 0.30 1517 0.63 0.00 0.28 0.54 0.26 0.57 0.02 0.04 1523 0.59 0.05 0.43 0.45 0.31 0.58 0.04 0.06 1524 0.66 0.00 0.49 0.71 0.49 0.71 0.00 0.03 1528 0.60 0.02 0.57 0.51 0.40 0.67 0.25 0.02 1535 0.61 0.01 0.60 0.64 0.49 0.74 0.00 0.27 1537 0.63 0.00 0.65 0.55 0.45 0.73 0.01 0.10 1540 0.62 0.01 0.31 0.54 0.28 0.58 0.05 0.00 1541 0.62 0.00 0.75 0.44 0.44 0.75 0.00 0.01 1543 0.59 0.04 0.57 0.52 0.41 0.68 0.20 0.15 1547 0.67 0.00 0.60 0.67 0.51 0.75 0.00 0.00 1549 0.63 0.00 0.59 0.58 0.45 0.71 0.02 0.14 1554 0.59 0.05 0.59 0.47 0.39 0.67 0.34 0.22 1558 0.60 0.02 0.66 0.46 0.41 0.70 0.09 0.12 1559 0.64 0.00 0.66 0.57 0.47 0.74 0.00 0.00 1563 0.61 0.02 0.68 0.44 0.41 0.70 0.09 0.06 1566 0.62 0.00 0.38 0.47 0.29 0.57 0.04 0.04 1576 0.59 0.04 0.49 0.59 0.41 0.67 0.18 0.13 1578 0.64 0.00 0.44 0.72 0.48 0.69 0.02 0.10 1580 0.60 0.02 0.66 0.47 0.42 0.71 0.13 0.14 1583 0.61 0.01 0.81 0.34 0.41 0.75 0.03 0.04 1586 0.59 0.04 0.63 0.47 0.41 0.69 0.20 0.02 1588 0.60 0.02 0.62 0.47 0.40 0.68 0.15 0.00 1593 0.64 0.00 0.59 0.69 0.52 0.74 0.00 0.16 1595 0.61 0.01 0.65 0.47 0.42 0.70 0.07 0.01 1600 0.61 0.02 0.66 0.51 0.44 0.72 0.02 0.03 1606 0.61 0.01 0.38 0.42 0.27 0.54 0.01 0.49 1615 0.61 0.01 0.60 0.49 0.41 0.68 0.15 0.03 1623 0.59 0.05 0.41 0.48 0.31 0.59 0.16 0.79 1628 0.61 0.01 0.29 0.51 0.26 0.56 0.01 0.85 1634 0.64 0.00 0.59 0.58 0.45 0.71 0.02 0.00 1642 0.63 0.00 0.75 0.43 0.43 0.75 0.01 0.24 1646 0.60 0.02 0.78 0.42 0.43 0.77 0.00 0.06 1651 0.60 0.03 0.50 0.42 0.33 0.59 0.17 0.84 1656 0.61 0.01 0.47 0.76 0.53 0.71 0.00 0.12 1660 0.59 0.04 0.78 0.39 0.42 0.75 0.01 0.09 1663 0.60 0.02 0.57 0.61 0.46 0.71 0.01 0.11 1671 0.61 0.01 0.68 0.52 0.45 0.73 0.00 0.04 1681 0.61 0.01 0.65 0.57 0.46 0.74 0.00 0.31 1683 0.60 0.03 0.72 0.45 0.43 0.74 0.01 0.07 1691 0.63 0.00 0.87 0.24 0.40 0.76 0.08 0.00 1694 0.59 0.04 0.71 0.45 0.42 0.73 0.03 0.38 1704 0.62 0.01 0.41 0.80 0.54 0.70 0.00 0.69 1705 0.61 0.01 0.43 0.42 0.30 0.56 0.05 0.79 1712 0.62 0.00 0.74 0.51 0.46 0.77 0.00 0.06 1718 0.63 0.00 0.50 0.64 0.44 0.69 0.04 0.00 1719 0.64 0.00 0.57 0.61 0.46 0.71 0.01 0.09 1720 0.62 0.01 0.54 0.23 0.29 0.47 0.00 0.17 1721 0.64 0.00 0.65 0.55 0.45 0.73 0.00 0.02 1722 0.59 0.04 0.57 0.51 0.40 0.67 0.31 0.05 1734 0.60 0.02 0.49 0.63 0.43 0.68 0.08 0.06 1738 0.61 0.01 0.79 0.35 0.41 0.75 0.02 0.05 1742 0.64 0.00 0.63 0.57 0.46 0.73 0.00 0.03 1756 0.60 0.03 0.56 0.63 0.46 0.71 0.01 0.00 1757 0.61 0.02 0.57 0.56 0.43 0.69 0.04 0.02 1764 0.59 0.05 0.85 0.26 0.40 0.76 0.07 0.02 1778 0.60 0.03 0.76 0.32 0.39 0.70 0.19 0.03 1782 0.62 0.01 0.69 0.49 0.44 0.73 0.01 0.01 1783 0.66 0.00 0.74 0.52 0.47 0.77 0.00 0.00 1784 0.59 0.03 0.76 0.36 0.41 0.72 0.04 0.02 1790 0.63 0.00 0.72 0.52 0.46 0.76 0.00 0.03 1798 0.59 0.04 0.56 0.64 0.48 0.72 0.00 0.04 1806 0.61 0.01 0.28 0.50 0.24 0.55 0.00 0.31 1814 0.63 0.00 0.43 0.35 0.27 0.51 0.00 0.20 1816 0.63 0.00 0.62 0.58 0.46 0.73 0.00 0.04 1819 0.61 0.01 0.71 0.48 0.44 0.74 0.00 0.12 1820 0.62 0.01 0.49 0.66 0.45 0.69 0.02 0.07 1821 0.59 0.05 0.57 0.59 0.45 0.71 0.03 0.44 1823 0.64 0.00 0.28 0.51 0.25 0.55 0.00 0.16 1824 0.61 0.01 0.49 0.67 0.46 0.69 0.01 0.08 1833 0.63 0.00 0.76 0.43 0.44 0.76 0.00 0.00 1836 0.60 0.03 0.68 0.43 0.41 0.70 0.09 0.02 1837 0.61 0.01 0.54 0.59 0.44 0.69 0.07 0.06 1838 0.59 0.04 0.50 0.64 0.44 0.69 0.05 0.46 1843 0.64 0.00 0.68 0.50 0.44 0.73 0.01 0.00 1844 0.61 0.02 0.63 0.58 0.46 0.73 0.01 0.60 1845 0.64 0.00 0.60 0.61 0.47 0.73 0.00 0.04 1852 0.62 0.01 0.51 0.63 0.44 0.69 0.05 0.10 1853 0.63 0.00 0.68 0.47 0.42 0.71 0.03 0.01 1858 0.61 0.01 0.65 0.58 0.47 0.74 0.00 0.06 1859 0.60 0.02 0.75 0.44 0.44 0.75 0.00 0.00 1864 0.59 0.05 0.53 0.60 0.43 0.69 0.08 0.34 1866 0.62 0.01 0.54 0.68 0.49 0.72 0.00 0.06 1872 0.63 0.00 0.65 0.51 0.43 0.71 0.02 0.04 1874 0.59 0.03 0.54 0.54 0.41 0.67 0.14 0.03 1877 0.59 0.04 0.51 0.67 0.47 0.71 0.01 0.08 1879 0.59 0.04 0.66 0.44 0.41 0.69 0.09 0.02 1880 0.64 0.00 0.84 0.41 0.45 0.81 0.00 0.00 1882 0.60 0.03 0.62 0.53 0.43 0.71 0.03 0.29 1902 0.62 0.01 0.60 0.63 0.48 0.73 0.00 0.38 1904 0.60 0.02 0.65 0.53 0.44 0.72 0.02 0.23 1907 0.59 0.04 0.71 0.45 0.42 0.73 0.03 0.22 1908 0.61 0.02 0.56 0.61 0.45 0.71 0.02 0.01 1912 0.61 0.01 0.79 0.36 0.42 0.75 0.01 0.06 1915 0.63 0.00 0.63 0.52 0.43 0.71 0.03 0.00 1916 0.62 0.01 0.59 0.61 0.47 0.72 0.00 0.04 1921 0.64 0.00 0.59 0.53 0.42 0.69 0.05 0.09 1922 0.60 0.02 0.65 0.54 0.45 0.73 0.00 0.13 1926 0.61 0.01 0.69 0.46 0.42 0.72 0.04 0.02 1927 0.59 0.05 0.76 0.38 0.42 0.74 0.03 0.01 1930 0.59 0.04 0.29 0.55 0.27 0.58 0.02 0.90 1932 0.59 0.03 0.50 0.61 0.43 0.68 0.06 0.00 1934 0.61 0.01 0.60 0.59 0.46 0.72 0.01 0.22 1936 0.63 0.00 0.66 0.53 0.45 0.73 0.01 0.02 1938 0.60 0.02 0.79 0.36 0.42 0.75 0.02 0.18 1939 0.59 0.05 0.47 0.48 0.34 0.61 0.51 0.04 1941 0.61 0.02 0.69 0.44 0.42 0.71 0.04 0.04 1945 0.61 0.02 0.50 0.58 0.41 0.67 0.35 0.00 1946 0.60 0.02 0.74 0.42 0.42 0.73 0.02 0.05 1948 0.60 0.02 0.65 0.50 0.43 0.71 0.02 0.03 1949 0.60 0.03 0.56 0.60 0.45 0.70 0.02 0.10 1950 0.63 0.00 0.66 0.59 0.48 0.75 0.00 0.02 1953 0.62 0.01 0.72 0.42 0.42 0.72 0.03 0.01 1957 0.59 0.04 0.75 0.44 0.44 0.75 0.01 0.31 1958 0.61 0.01 0.71 0.43 0.42 0.72 0.03 0.03 1959 0.61 0.02 0.72 0.46 0.43 0.74 0.01 0.02 1963 0.70 0.00 0.29 0.42 0.22 0.51 0.00 0.00 1964 0.64 0.00 0.76 0.37 0.41 0.73 0.04 0.01 1965 0.67 0.00 0.54 0.66 0.48 0.72 0.00 0.02 1967 0.62 0.01 0.56 0.59 0.44 0.70 0.03 0.01 1970 0.59 0.05 0.69 0.52 0.45 0.74 0.00 0.12 1971 0.60 0.02 0.59 0.56 0.43 0.70 0.03 0.01 1972 0.66 0.00 0.62 0.62 0.48 0.74 0.00 0.00 1976 0.59 0.05 0.66 0.48 0.42 0.71 0.05 0.09 1977 0.59 0.05 0.54 0.57 0.42 0.68 0.11 0.11 1978 0.60 0.02 0.65 0.47 0.42 0.70 0.04 0.09 1980 0.61 0.01 0.63 0.53 0.43 0.71 0.04 0.31 1981 0.59 0.04 0.60 0.55 0.44 0.71 0.03 0.58 1984 0.63 0.00 0.41 0.85 0.61 0.71 0.00 0.10 1986 0.63 0.00 0.69 0.49 0.44 0.73 0.01 0.06 1988 0.60 0.03 0.72 0.46 0.43 0.74 0.01 0.00 1990 0.62 0.01 0.56 0.62 0.46 0.71 0.01 0.01 1991 0.59 0.05 0.59 0.54 0.43 0.70 0.06 0.64 1992 0.64 0.00 0.74 0.45 0.43 0.75 0.01 0.01 1994 0.59 0.03 0.56 0.55 0.42 0.68 0.12 0.31 1998 0.66 0.00 0.60 0.60 0.47 0.72 0.00 0.00 1999 0.60 0.02 0.66 0.46 0.41 0.70 0.05 0.00 2004 0.60 0.02 0.71 0.43 0.42 0.72 0.05 0.02 2005 0.67 0.00 0.63 0.65 0.51 0.75 0.00 0.01 2007 0.62 0.01 0.54 0.62 0.45 0.70 0.01 0.02 2009 0.60 0.02 0.60 0.53 0.42 0.70 0.04 0.00 2012 0.61 0.02 0.71 0.45 0.42 0.73 0.02 0.01 2013 0.59 0.04 0.53 0.61 0.44 0.69 0.03 0.09 2014 0.59 0.04 0.59 0.47 0.39 0.67 0.36 0.21 2016 0.60 0.02 0.68 0.42 0.40 0.69 0.13 0.28 2018 0.59 0.04 0.63 0.50 0.42 0.70 0.05 0.44 2019 0.65 0.00 0.71 0.52 0.46 0.75 0.00 0.01 2023 0.61 0.02 0.57 0.59 0.45 0.71 0.01 0.00 2024 0.59 0.04 0.65 0.50 0.43 0.71 0.06 0.07 2025 0.59 0.03 0.69 0.48 0.44 0.73 0.01 0.03 2027 0.61 0.01 0.68 0.53 0.45 0.74 0.00 0.00 2030 0.61 0.01 0.66 0.47 0.42 0.71 0.04 0.01 2032 0.59 0.05 0.59 0.57 0.44 0.71 0.02 0.05 2033 0.63 0.00 0.66 0.55 0.46 0.74 0.00 0.68 2034 0.60 0.03 0.41 0.70 0.44 0.67 0.11 0.10 2036 0.62 0.01 0.68 0.47 0.42 0.71 0.04 0.17 2037 0.59 0.03 0.59 0.48 0.40 0.67 0.30 0.38 2039 0.64 0.00 0.69 0.57 0.48 0.76 0.00 0.00 2042 0.59 0.05 0.78 0.35 0.41 0.73 0.04 0.59 2043 0.63 0.00 0.56 0.65 0.48 0.72 0.01 0.01 2044 0.63 0.00 0.63 0.49 0.42 0.70 0.08 0.01 2046 0.61 0.01 0.66 0.53 0.45 0.73 0.01 0.06 2048 0.62 0.01 0.69 0.51 0.45 0.74 0.01 0.96 2050 0.59 0.05 0.57 0.61 0.46 0.71 0.01 0.01 2052 0.64 0.00 0.76 0.46 0.45 0.77 0.00 0.01 2054 0.61 0.01 0.74 0.47 0.45 0.76 0.00 0.05 2056 0.62 0.01 0.71 0.48 0.44 0.74 0.00 0.01 2058 0.63 0.00 0.72 0.46 0.43 0.74 0.01 0.02 2060 0.62 0.01 0.74 0.47 0.44 0.75 0.00 0.00 2061 0.62 0.01 0.72 0.48 0.45 0.75 0.00 0.06 2062 0.59 0.04 0.82 0.31 0.41 0.76 0.04 0.42 2063 0.61 0.01 0.63 0.50 0.42 0.70 0.06 0.09 2064 0.62 0.00 0.63 0.57 0.46 0.73 0.00 0.01 2067 0.62 0.01 0.62 0.55 0.44 0.71 0.02 0.09 2068 0.60 0.02 0.53 0.58 0.42 0.68 0.07 0.11 2069 0.62 0.01 0.85 0.28 0.41 0.77 0.02 0.08 2070 0.66 0.00 0.54 0.64 0.46 0.71 0.02 0.10 2071 0.65 0.00 0.69 0.54 0.47 0.75 0.00 0.01 2072 0.59 0.04 0.74 0.38 0.41 0.71 0.07 0.06 2073 0.63 0.00 0.50 0.61 0.43 0.68 0.12 0.01 2074 0.60 0.02 0.66 0.47 0.42 0.71 0.06 0.29 2076 0.62 0.01 0.75 0.46 0.44 0.76 0.00 0.12 2080 0.60 0.03 0.75 0.42 0.43 0.75 0.01 0.01 2081 0.60 0.02 0.72 0.43 0.42 0.73 0.02 0.01 2082 0.61 0.01 0.72 0.38 0.40 0.70 0.12 0.24 Auc.pvalue: Wilcoxon Test P-value. KM: Kaplan Meier curves. mvaHRPval: Multivariable Analysis Hazard Ratio P-value.

TABLE 11 List of Target Sequences SEQ ID NO: SEQUENCE SEQ ID  ATACCCTTCGCCATGTTATCAGCCAGACAGGAGGATAC NO: 1 AGTGATGGACTCGCAGCCAGTCAGATGTACAGTCCGCA SEQ ID  GGGCATCATCCCTGGTCCAAAATCAAGATACCGAATTA NO: 2 GAGTTGAGGGTAAAAAACACATCTTGATCATAGAGGGA GCAACAAAGGCTGATGCTGCAGAATATTCAGTAATGAC AACAGGAGGACAATCATCTGCTAAACTTAGTG SEQ ID  GCAAAGGTTTCAGCGTAGTGGCAGACACGCCCGAGCTC NO: 3 CAGAGAATCAA SEQ ID  CAGCTGGTGTGCCTTAAGAGAATCCCTATAAATAACAG NO: 4 AAAAGACACTCCAAGCATTCCTGTACGTGGACTCAGAG CACAGAGAAAAGAAACTAAAATGCCTTTTGGCATTTCA AGATATTTGGCACTCTTGTGATTACATTTTTTTACAGT CCATTAAAGAGAATAAACTGACATAATATTAGAGAAAT AAACAGGCTGCTCACACAACAGACTGCAAGGGGAAGTT AGAAAAAGCTCAAGCATTTTTTTCTTTGTTTTTCGTGT GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTTTTTCT GACATAAAAAATGTGTCCATTTGCATTAACTTGGGCAG ATAGCTTGCAGCAACAAAGAAACACAAGCTTTACAACT CATTTTAAAATAAAATCTTTTCTATGTATCATTCCTTA GAAAAGTTCTCTTCTTGTTTTAAACACATTCCTGATAA CTTCTAAAGATGACCAAAATAAAACAGAATATCTACAG AGATCATTTTCTGAATTTTTTGTACATCCAAGGATAAC AACATAAAAAAAATAAAACTGGACAGCATTTCACATCC AAGTGCACAGAACCATTTTTGCAAGATTAAATAATGTA AACATTGGGAACAGCCAAATCAGCGAAGAATGCCAACA CCTCAAAACACCTGGTGTTGCCGCTTCATTAAGTGGTT CAAAATCCAGATCTATAATTGCGCAATATTCACCGTAT ATAAAAAGAAATGGATATTAATTTTGACAAATAGCTGC AACTGAGACTTCTTTTTATTTCTTTATATGTGTATATA GTGAATTTTTATTATTTTTAAAATTTTATTTATTTTTT TATTTTTATTTTTGCAGAGGAGCCCAGAGCCTTCTCCT CCTCCTCCTCCTCCTCTCGCCTCATCTGTCTCCCGGCC TGATACCAGATACAGGTTGTTGATTTCATCGTGGGTAG CAAGCTAGTAATAAATTTCAAAGTGCTTTCTCTTTTCA TGCTTTTTGCCAATAACTGTTACCGCCGTTCTTATTCT CTCCCTTAACTCATTGTCTTTGGGGGAGTTAGACACCA GGAGGTGCCTTGTCGGTCATATTTTTCAGCACGTCATC SEQ ID CTCCTGTGTCCTTAAAGTAGTCATGGGCTGGGAATGTT NO: 5 CGGTTAATATCCCGGGTGATAGCACTGTCCTGGGGAGA CTCCTGTGGAAACATAAGGAAAGAGAGGGTTTAGTTAG GTTAATCATGTAAACTCTTATTCAGGTTTAGGCAAGGT CTTCTCATTTACACACTTTAAATGTTGCAGGGACATAC ATACACATATGTATGCCCATAGTTACTGCCTCTTCAGG SEQ ID TATACAAGGGCTCAACCGAGGCTTAATTTAAAAGACAA NO: 6 AAACAAAACAAAAATACCACAGCTCAAGATAAAGAGTC CTATACAGAAATCACAAAAAGGACAGACCATCTAAGGA AAAATTAAAAAGACGACACAAGGACAGGCTGGGCAGCC TGGGTCAGGGCTCCTGGCTGGTGACCTGCTTTGAGTAG GTTTCTTGCAGGTACTTCTTAAAAGC SEQ ID GCTGAGGCACCAATCATACCCTATACAGACAGCTAAGC NO: 7 ACATTGTGTAAGGCAGATGTTGCCCACCACTCAGCCCA TTAGAGAGCTCATGCACCATCAAACCCAGAATAAAGCA ATAAGCCCAATGGTGATCCAACCCTTTG SEQ ID TCAGGCTTCTGTTGCAAGCCAATGTAGGGAACCA NO: 8 SEQ ID GCTTTCATACTTGGAGCTCTACTGATTTTCCATCCAAG NO: 9 CCAACTTGTAGGGTTTTTTCCTTCCTATCACCAGAGGA GACAGGGTTTAGGGGAATCCAAGAAGGTTGAAGTCAGC ACT SEQ ID GGGTTATCTTCTAGTCCACATGTCACATAATATGTACC NO: 10 TTTATTTACCTTTTAAACTGAAGTTTTAAAACCTGGGT TTTAAAAAGAGAACAACTACCCATCAGCAATTACAGAA GACAAAGGAACTTGTGTGTCTGAAGACTGAGTGTTATT TAGCAGCTCTTTGGTCAGCTTGGATTGGTCACATATGT GGAAACTGGGAAATAATAGGGGCTACTTACACTGGAGA AGAACACTACAAATGGTGTAAAGAGTGGTTTTGGAATG TATCCAGACTTCCTTCTAAAATAAAAATTTAAACAGCT GTGTTTGAGAGATGGGTATGCACAATTCTTGTAAGAAA GACTGTGTAGATGTTTGAGGTCCCCTTAGTCCCTGATG CTACCATTGTTCC SEQ ID GGGCAAAATATTCCTGGAGTGCTGAGCAATACATGTCA NO: 11 CAGTCTCCAATTTTTTTTTTATTCTTACGTTAGTTCAG ATTCCACTGTATCCAATATGTGCTTGAGAGTGAAAATT GTATTAGTTTCTATTGTAATCTATCTCCATTTCGCCTC GAGAAAAATTA SEQ ID TGTCGAGGCCCGGTTGGCTTTCAGAGGCGTATCCATGG NO: 12 GAGTAGGTGTCATGTATCAAATAGGAGATTCAAAGTCA GCTGTTACCACGGCTACAGAAATGCCAGTCTTTTCCTA AGAGTGCGAA SEQ ID CCGGGTATCAGATGGTTATTATCCGACC NO: 13 SEQ ID GTTGCAACTATCTATGCTGCCTGTAGCAGACACACTCC NO: 14 AGCTCTAAGGATACATATAGAATGAAAGTAAAGGGATG AAAAGAAGATGCTCCATGCAAATGGAAAACAAAAGACG GTAGGGGTGGCTATACTTACATCAGGCAAAATAGACTT TTAGTCAAAAATTATAACAAGAGACAAAGGAGCTCACT ATATAATTATAAAGGGCTAATTCATCAAGAGGATATAA AAATTATAAGTACATATGCACATAATGTCAGAGCACCT AAATATATAATATTTACATAACTGAAGGGAGAAACAGC AATATAATAATCGTAGCGGACTTCAGTA SEQ ID CCTTGACCTGGGAAAGCCATTACTCTTGTGTCTGCTAC NO: 15 TGCCCTCCCACAGTCACCCCAATATTACAAGCACTGCC CCAGCGGCTTGATTTCCCCTCTGCCTTCCTTCTCTCTG CACTCCCACAAAGCCAGGGCCAGGCTCCCCATCCCTAC CTCCCACTGCATCAGCAGTGGGTGTTCCTGCCCTTCCT GAGTCTAGGCAGCTCTGCTGCTGTGATCTGCACACCCT CCAACCTGGGCAGGGACTGGGGGGATGCAGTGTGTGTT AGTGCCCATGTGGCATTGTGGCACTGTTGCCCCCCATG GCGGCATGGGCAAGATGACCTTCCATTAGCTTCAAGTC TTGTTCTCTTGTCTGTGGTCTGTTTAATATGTGGGTCA CTAGGGTATTTATTCTTTCTCCCATCCTTACACTCTGG ATCATTGTGCAGACTTAATCAGGGTTTTAACGCTTTCA TTTTTTTTTTTTTTTTTTTTTTTTTGAGCTCAAAGAGA GTTCTCATTTTCCCTATTCAAACTAATACCCATGCCGT GTTTTTTACCTTGGATTTAAAGTCACCTTAGGTTGGGG CAACAGATTCTCACTCATGTTTA SEQ ID TTCGAATGTTTCAGAGCGCAGGGCCGTTCTCCCTCGTG NO: 15 TCCTCTGGACCCACCCGCCCCTTCCTGCCCTGTTTGCG CAGGGACATCACCCACATGCCCCAGCTCTCGGACCCTG CAGCTCTGTGTCCCAGGCCACAGCAAAGGTCTGTTGAA CCCCTCCCTCCATTCCCAGTTATCTGGGTCCTCTGGAT TCTTCTGTTTCTTGAATCAGGCTCTGCTTTCCCCCTAG CCACTACAGGCAGCCTCTGACAGTGCCGCTTTACTTGC ATTCTGCAGCAATTACATGTGTCCTTTTGATCCTTGCC CAACTTCCCTCCCTCTCCCAGCTCCTGGCCCCTGGCCC AGGGCCCCTCTTGCTGTTTTTACCTCTGTTCCTTGGGG CCTAGTACCCAGCAAGCACCCAAATGGGGGAGGTTTTG GGATGAGAGGAGGAAACGTGTATACCTGTAACATCTGG TGGCTCTTCCCCCAGAAGTTTGTGTTCATACATAATTG TTTTCCACGCTGGATCATAATGTGACGTGCAGTTCTGC CCTGTGCTGGGGAGCCACATGAAGCTTCCCCTGGCTAA CTTGCTACCCCGCAGCAATCCCAGTGTGGCCGTCTGCT TGCTAAAAAATG SEQ ID TCACGATGAAGCATGCTAGAAGCTGTAACAGAATACAT NO: 17 AGAGAATAATGAGGAGTTTATGATGGAACCTTAAATAT ATAATGTTGCCAGCGATTTTAGTTCAATATTTGTTACT GTTATCTATCTGCTGTATATGGAATTCTTTTAATTCAA ACGCTGAAAAGAATCAGCATTTAGTCTTGCCAGGCACA CCCAATAATCAGTCATGTGTAATATGCACAAGTTTGTT TTTGTTTTTGTTTTTTTTGTTGGTTGGTTTGTTTTTTT GCTTTAAGTTGCATGATCTTTCTGCAGGAAATAGTCAC TCATCCCACTCCACATAAGGGGTTTAGTAAGAGAAGTC TGTCTGTCTGATGATGGATAGGGGGCAAATCTTTTTCC CCTTTCTGTTAATAGTCATCACATTTCTATGCCAAACA GGAACAATCCATAACTTTAGTCTTAATGTACACATTGC ATTTTGATAAAATTAATTTTGTTGTTTCCTTTGAGGTT GATCGTTGTGTTGTTGTTTTGCTGCACTTTTTACTTTT TTGCGTGTGGAGCTGTATTCCCGAGACCAACG SEQ ID GTCCATCGAGGTGTTTCATAAGTTTTTTGGTGTGTTTT NO: 18 CTGGGTCGTCTATGTGTCATATGGTTTTACTTTTCTCT CCTTTTTCGTTTTCAGAACATTTTTCTGTCTGTTTTGG ATTCACTGCTTCCATTTTACAGAATGTCACTCTTTAGA CTCTCAGTCCATCATGCCATCGGGTACTCTTGTTGCAG TGTAATTTTTATTACATGCGGTTATTTCCCTAACGATG TGCTATTCACGTTCATCTTCAAACTCATTTTCCATCAG CCAGTGTCTACTATTTAGTGCCCTGGCTCTATTTCGGT CCTCCTCCCCGGGCTTTCCCTGGCTGCTGTGCTGGCCA AAAGCATGGGCTTTATTCTCTCCATTGGCTGCTGCTCC ACCTTAGAGGTGTGACCTCACTAGCGTTGACTG SEQ ID CCCACTTTAGTCACGAGATCTTTTTCTGCTAACTGTTC NO: 19 ATAGTCTGTGTAGTGTCCATGGGTTCTTCATGTGCTAT GATCTCTGAAAAGACGTTATCACCTTAAAGCTCAAATT CTTTGGGATGGTTTTTACTTAAGTCCATTAACAATTCA GGTTTCTAACGAGACCCATCCTAAAATTCTGTTTCTAG ATTTTTAATGTCAAGTTCCCAAGTTCCCCCTGCTGGTT CTAATATTAACAGAACTGCAGTCTTCTGCTAGCCAATA GCATTTACCTGATGGCAGCTAGTTATGCAAGCTTCAGG AGAATTTGAACAATAACAAGAATAGGGTAAGCTGGGAT AGAAAGGCCACCTCTTCACTCTCTATAGAATATAGTAA CCTTTATGAAACGGGGCCATATAGTTTGGTTATGACAT CAATATTTTACCTAGGTGAAATTGTTTAGGCTTATGTA CCTTCGTTCAAATA SEQ ID ATTAGCAGCCATATTCCACAGTTCCTATAATTTTTACT NO: 20 GGGGGGGATTTGTGATAGGAAAGTCCTTGGGAAACATT TCCAATCTTTCAAAATATTATTGTGTATCTTAAGAAGT ATAGGAACTTGTATGTTGAAATGTTGTATGGTAGTTCT TGTATAGTTAAATAATAATCTTTTTAAGAGTTAATGAT AAGCATATGTTATGTGCATTATTAATAAAATAGTGGCC ACTTAGGTAATACCCACTTTTATCTTGTGTGCTGGGTA CTCTGGTTACTGAGATAAATAAGGCACTGGACATCCTC ACGTGGAGTTCACAGGCTCATCAGTGAATTCTGTACCA CATTTCAACCTTGTTTATTTTAGTTTAATGGAATATAC ATTCTTAGTATTGCCTGATTATTTAAATTTGTTGAGGG GGATTGCATGTTGCTTTATTGGCCTGTAAAAATAGCTA GTTTGGTAAGATTTGGTCTCGCACCTTCCATCTTTGCT ACCACATTAAAGATGAGCTTGTTAAAAAGGAAAGCATA TTTCTCTGATTGCCCTTATGGAGAAATA SEQ ID GGCTTCTGACGCCAAATGGGCTTCCCATGGTCACCCTG NO: 21 GACAAGGAGGCAACCACCCCACCTCCCCGTAGGAGCAG AGAGCACCCTGGTGTGGGGGCGAGTGGGTTCCCCACAA CCCCGCTTCTGTGTGATTCTGGGGAAGTCCCGGCCCCT CTCTGGGCCTCAGTAGGGCTCCCAGGCTGCAAGGGGTG GACTGTGGGATGCATGCCCTGGCAACATTGAAGTTCGA TCATGG SEQ ID GTGATTTCTGTATAGGACTCTTTATCTTGAGCTGTG NO: 22 SEQ ID AGAGGATGTCCATGTTCAATCACCACTGTCCAAATTCA NO: 23 GAAGCTCAGAACGCTGGACTCTCCCTTTGCAG SEQ ID AGAACTAGCATGTCTTCGTGGCCGATTTGACAAGGGCA NO: 24 ATATATGGAGTGCAGAAAAAGGCGGAAACTCAAA SEQ ID AAGACCACCCAGGAAACCATCGACAAGACTGCTAACCA NO: 25 G SEQ ID GTGTCTTGCTTCATCCCACTGACTGCTGGGAGAGAGCC NO: 26 TCTGGGACTTTTCTTTGGGGCATCATTTTGTTTTGTCT TTCGTAGCAGGGAAAGGATATGACAATGGGGAGGACAG TTCTTTTGGAGGTTGGAGGGGCCAAGCCAAGGACAGGA GCAAGTGTGCCCTCATTTTGTTTC SEQ ID CGTTTACGGCTTCCACTTGAGTATATGGCAATCTGTGC NO: 27 CCTTTGTGCAAAAGATCCTGTAAAGGAGAGAAGAGCTC ATGCTAGGCAATGTTTGGTGAAAAATATAAATGTAAGG CGGGAGTATCTGAAGC SEQ ID AACAAGATGAACAAGTCGGACTTCCTGGGAAAGGGGGG NO: 28 AAGGCCAAGGGGAAAAAAACACAAATGGCTGAAGTTTT GCCTTCTCCGCGTGGTCAAAGAGTCATTCCACGAATAA CCATAGAAATGAA SEQ ID GTCCCAGGCGGTCTAGCAGTGATGAGCAGGGCCTCTCG NO: 29 TATTCATCTT SEQ ID AAGAGATACTCAGAGATGGATGATCATTATGAGTGCTT NO: 30 GAATAGATTGTCTCTTGAC SEQ ID AGCCAATCTTGGCTCGGATTCAGGAGGACCGCACTGTG NO: 31 ATTGTGTCTCCTGTGTTTGACAACATTCGTTTTGACAC CTTCAAACTGGATAAGTATGAACTGGCAGTTGATGGGT TTAACTGGGAACTCTGGTGCCGCTACGATGCACTGCCA CAAG SEQ ID ATTAATTAAAGTTCTGATTCAGAGGGGATATGATTCGG NO: 32 ATCCTGTGAAGGC SEQ ID AAACGCTGGCGTCCGTTTCTGCTGAGAGCGTGGGGCTT NO: 33 TCTCTGCAAGTGGGGGGTGGGAGATGAGGGTTTGGATG AGGGTGTGGGAGGACCCTAAACTGATTCCCATGCTAGT TGGAGAAAGAAAGGTGTGGATGAGGATAAAGTTTTCAT GGTGACCAGGGTGACCCTCCGCTCAGAGGGACGAGCGG AGCCCGGCAAAACCAGTCACTGCCTTGTAGTTCCAAGC TTTGGGGATGATCAGCTCCCAAGAAATTGCTGTGGGGT GCGGGGGCTGTGGGTGACCCAAATTGGGCAGAGGGCCT ACAGGTCTGAGGCTGCCTGCACA SEQ ID CATTTCTCTCTGGTGTGGCGAGCCGAGCAGATCGCTGG NO: 34 GAGAGAAATCGGAAAAGGGGGGAGAGGAAAAGGAAAAG GGGACTTGGAGAGAGACTTTGTGCTTCAATGTTTC SEQ ID TTTGAGTCAGGTTATCTCTGTCGCTCAAGCT NO: 35 SEQ ID ACATTTGTCTGCTTGGGCTGTCATAACAAAATACCATC NO: 36 GACTAGTGTAAAAATAAAAATCTATTATCTCTCAGTTC TGGATGCTAGAAGTCCCAGAGTAAGGTGTCCATATATT TAGTTTCTGGCGAAGGCTCTTCCTGGCTTGTAGTCAGT GCCTTCTCTGTCTGCCCTCACTTGGCCTATCCACCTGT GAACACAAATAAATATCTCTGTTGTTTTTTTCCTCTCC TTATGTGAACATGTGTCCTATGGAATTAGGGCCTCACT CTTGTGACTTCA SEQ ID AGTGAGACATTGTGGCCTGGAAGTCTTTCAGACACCCA NO: 37 CTCAGAGAAGTCAAGTTTAAAGTGGATGTTCTTCAGAG AATTTTTCATTTCTGAAAATGTGTTTTGCTTATAGAAT ATAACAGAGTTGACTAGAAAGAGAGAAACAACTGCATA CTAATCTTTTAAAGCCTTTAACAGTTGCTTTTAAACTT TCTTTTTAAATGTTTCATGACTCTTCACCTATTTTTTT TTAAATGGGGACGAAGAGATATGAAAACTGAGACATAA GACAAATACCTAGAAACCTCTAAGACTGCACATATGAT TTGGTAGAAGTCTGAAGGTATACACATTGTAAGAGGCA GACCTA SEQ ID CAGGGTGCTAATCATGATATTTGGTTACA NO: 38 SEQ ID CTGGCCCTGTGATATAACACAGATCAGCAATGGATTCA NO: 39 CAATACTCTCTGGCTATGTGACAACAAGATGCAGGTCA CCCAGCAACTCGACACTTCCTCAGACCACTACAGGTCA AAGTCAATTCCTGATCCAACTAGAAATGTCACGAACAT GCCTTTCAGATG SEQ ID GATGAGACTAGGCAGGGTGACAAGGTGGGCTGACCGGG NO: 40 AGTAGGAGCAGTTTTAGGGTGGCAGGCGGAAAGGGGGC AAGAAAAAGCGGAGTTAACCCTTACTAAGCATTTACCC TGGGCTTC SEQ ID TTCCTTTTTATGTCAACGACGCCCATAG NO: 41 SEQ ID ATGAGGACAGGCCTTGAGTCTGTCCTGGTCTCTGGAAT NO: 42 CACGGTGTCTAGTAGAGGCCAGCACACAGCAAATATAT AAATGTACAAATGAGTGAATGAAGAGAATCTGATTGGC CTTAAGGAACTTACGCACTTAAAATAATTGGGCAGAAG AGAAGCAGTGAAGGAGTGCAGAGGCATCACCTGA SEQ ID AGCACAATGGCTGGAGGTCAGATGCCCACTAGGAGATG NO: 43 CT

TABLE 55 Affymetrix Probeset ID = Aff P-ID A = Category: 1 = Non_Coding (Intergenic); 2 = Non_Coding (Utr); 3 = NON_CODING (Nctranscript); 4 = Non_Coding (Intronic); 5 = Non_Coding (Cds_Antisense); 6 = Non_Coding (Non_Unique); 7 = Non_Coding (Utr_antisense); 8 = Non_Coding (Intronic_Antisense); 9 = Coding B = Associated Gene; C = Kolmogorov Smirnov p-value; D = Mean Decrease Gini; E = Mean Decrease Accuracy SEQ Aff ID NO P-ID A B Sequence C D E  313 2315652 1 AATGGCAAAGGACCACGGTGCCCTGCCC 0.013881148 0.009628618 4.57E−06 AGCCGCCTGCTGCAGGGAGAGCAGCTCC CTCAGACCCGGAGTGCTCTGCTGT 1865 2318066 1 ATCAGAAGATTTCCGGGAATGGCCCTGG 0.000124059 0.007038957 3.54E−06 CCAAAACCAATGTTGACCAAACCA  851 2318095 2 KCNAB2 TGAGTGAGCAGCCTGCGGCAGCCCTGAC 0.017721275 0.008633649 5.18E−06 TCACTGCGGGTCGTGCCGTCTGTGCAGC ACTGGGGTACCCACCACCC  375 2320530 3 NPPA-AS1 GTGAAGACCCGTGGCCAGCTTCTGTTGT 0.017194217 0.009820199 7.40E−06 TGCCATCGGCCATTGCTTTTTGTTCGCTT GCTTTTGGTTTTGCAAGAAGAGCGGCCT CTGTCTCTGATCTGCTTCAAATCATCATT CCATCAGTGACAGAAGTGGCTGTTCCAT CAGTGGTCGCAGCCAGTTC 1289 2321544 4 KAZN ATTCCTTCCTCCAGTGTGACCATCACACA 0.015428709 0.007819131 3.23E−06 TTGTCCATATGGCTGGATGTGAG 1326 2324753 9 ZBTB40 GTAAGGGATGTCTCTGCGCCATCCTCAG 0.0060277 0.007357121 4.99E−06 2077 2324895 2 C1QB GCTGCTTCACATCCACCCCGGCTCCCCCT 0.001253978 0.006841561 3.40E−06 GCCAGCAACGCTCACTCTACCCCCAACA CCACCCCTTGCCCAACCAATGCACACAG TAGGGCTTGGTGAATGCTGCTGAGT  418 2326211 5 STMN1 CCACCTGTAACGTAGAGCAAGCAAACCA 7.48E−05 0.021492165 1.52E−05 CCAAGTAGAATCTTGAGATTCTCTCTCA ACTGTTCTCTAGAAACACGCTTGTGCTTT TAATCTGCCTTTTAAAAGGGACACAGAA CAAAAAATGGTTGTTTGCAAATAAACAT CTGAAAGAAAGTAACAGCTGACCTGGGC TGAGGCATCCAAACAAAGCAGTCATTGT GGAAGGAGACAATGCAAACCACACTGG GGCAAGAAACGGGGCAGAGAACGTGCG GTCATTTGTGCGTTGGGTATTTCTACCAG CCCCAAAGGCCCCATCTGGAACAAGTAT CAACCAGGAGGGGCTCTATGGCTTGATT TATTAACCTAACTCAAAAGAAGTCACTG CCACCAACAGCACTGTGCAGTTTTATTA ACCATTCAAGTCCAGTAGCATCTGGTAA GATTGGGACAGAATTGGGATTGAAAAGT GAACAGATATTCAGCATCTAACAGTTCA AAAGAAGCCACTACATACTCTTTTCACA AATATGTTTTCACAGAGCCAATACAGTA CTAGCCATTAACCCAGTACACCAAGTGT ACTGAAGTAGAAAAGATGCAACAAGAA AAATAGCTACATTAGAAAGACCAACACT TTAGAAAAAGAGTAAAACACTTTCAGTT TCTCCCCTTTAGCCCCTAAAACAACATCT TACAGTCTGGATCTGGATCTACCTATAC AGTCCTACATTAGCTTCTAAAATATTTGT CAGGAGGGAAAAAATAAAATGACACTG GCCAGTACAGTCTTTGGATATTTAGGAA GGGGATGGGGAGAAAGTCAGTTCTCAGA ACAAATTAGTCAGCTTCAGTCTCGTCAG CAGGGTCTTT 1954 2326780 2 SFN TGCGCGCGCGCCAGTGCAAGACCGAGAT 0.000243178 0.00786279 3.51E−06 TGAGGGAAAGCATGTCTGCTG 1304 2327444 4 PHACTR4 ACCGGGAAGGCATCGAATTTGCTGCGAT 0.002984774 0.006653744 2.06E−06 GTCTGTGCAGCTCACATCTGTGATCGGT GGACCAAAGAACCAGT 1385 2329291 4 ZNF362 ACCTCTGCCAGATTGTGCCTATACAACG 0.012844897 0.007545796 4.23E−06 TGTAATGTGGCGGTTACCCTTTTTTTGGA GAATCTTCGTTTGTCAGTGTTTCTGAACA AGCAGAGATTGATGTCTTTTTATAACCTT AAAGGCTGAAATTCCACAAGCCATAAGC AGGTCCAGTCCGGTTTCCTGGAGGCCCG GGGAGGCCTCATTCCCACTTTTGAAGTG CAGTCCTTGTTTCTTACTCTCAGGCTTGT CATGCCTAATTAAATGAAATTTGTCTTTA ACTGTGACATTTCTGGCACAGCCATGGT TACAAATTTGATTTACCCAATTATATCCT GTTAGGAAGGAGGACAGATTCTTACAGA TCCTGTTTACAGAACTAATGATCGTAAA AGAAAAGGGTCTCAGCAAAGGTACTTTG AAGAGTTTTTAGCTATTATTCCTAGTAGT TTTGTAGATAAGGCCAATTACATTTGTTG TTTTCAATAGAATGATTATTTGAACATTT CCTTGATGATTTATTATTTCATATCTATG TTAGGTTTTTATAGTCCCCCTCCCACCCT CACCCCCAGAATTCTGAAGAGTTAGTTG GAAGAAGGAAGAAGGCACCATTTTAGG AATATTTTATTCCAGTTTATTGAATACAG CCTCCTAAATTGAGGATTAGCGACAGTA ATAAAGAAAAAAAAAGACCTTTAGAAA ATTAGAACATTAAGGGTGAAATCAGTTT CATCCAGTCCTGGGGAAAAATTCCTGTT CCTCTGATCCTGGGTTAGTTAGCCTGC  135 2329991 5 CLSPN CCCATCTGTTGGTTCCTAGGTCCTCCATC 0.001302035 0.022069922 1.50E−05 TAAGAAATCGTTCTTTTGGCTGGGCACA GTGGCTCACGCCTGTAATCTCAGCACTTT GGGAGGCTGAGGCAGCTGGATCACTTGA GGTCAGGAGATCGAGACCAGCCTGGCCA ACATGGTGACTCCCTGTCTCCACTAAAA ATACAAAAATTAGCCAGGTGTGGTGGCA TGCACCTGTAGTCCCAGCTACTTGGGAG GCTGAGACAGGAGAATCACTTGAACCCG GGAGGCAGAGGTTGCCGTGAGCCGAGAT TGCGCCACTGCACTCCAGACTGGGCAAC AAAGTGAGACTATCTCAAAAAAAAAAA AAGAAATCTTTCTTTCACCGAGCCCTGGT CATCATGGTACGTATCTCATGGGTGTAA AGGAGTCATTA  143 2329993 3 RP11- TACTTCATCAATTACGTCCTCTTCATATT 9.91E−07 0.026064562 2.95E−05 435D7.3 CATCAATTTCTTCCCCATCATACTCATCT TCGCTTCCCACATCACTTC   56 2329994 3 RP11- CCAGTGCCAGATCATTACCAGAGTCACT 4.78E−07 0.046754573 5.18E−05 435D7.3 GTGTTCATCCTACAAAATCAGCATCATA TCCAAATTAAGCAGAATAAAATGCGTCC TCAATGAAAAAAGGATTTATAAACATCT GCCCAAATACCTCATTCTAGGAAATTGT TTCTGATAAGATGCCAAACTTAGAATTC TCAAGAACTGAGGGGAAAAAAACACTT GAGGGCAGCAATACATGGAGCTCAGTTA TGATTACTTTGTTCCCTTCATACTCACCT CATCACTATCAAACTCATTATCATTTGAA ACAAGCCGAAAGTCTC 1342 2330255 4 ADPRHL2 CCAGTGCGATCTCCGGCCTTATAGACGT 0.000235082 0.00711415 4.83E−06 CTCGCCCCGAACATCCCGTGCTCGGGGC GTGGCAGCACCGGGGCCTCAACCGTGCA GGGTGTGGATAAACCCATCGTAAGTTGA AAATACCTGAAGTGGAAAGTGCGCTTTC AGCTTAGACGACCGTTTTATCTGGACGC AGCCCCATCGGACGTCGAGGAGCCTATG AATGCGTATCAGCGTTATCAGAAAGCCG AAAAAAACTTAAGTTGAACCATCCTAAG TCGGGGACTGTCTGTCCACCCTTGCCGA CTTGACCTCTTTTTCCCGGTTCTCTAGAG TCAGTATACCACCAGCCCGTTC 1861 2330579 5 GRIK3 GTTTCTGAAATATGAGCCAGCCTTGACA 0.003259761 0.007150962 7.11E−06 GTCACGATGCCCCATCCACCCGACTGGG CACCTCCTGTCCTGACACCATCCTG 1747 2330744 2 DNALI1 TTCCACATGATTAATTTCCAACAAGACA 0.001040005 0.007171718 4.91E−06 CTTGGGAGTTATTTACTGTGTTCCTCTGG CAGCCAATAAAATCA  403 2332283 2 FOXO6 TCAGTTTCATTTGCGGAGGCCTAGCCGT 0.000604099 0.012992693 6.72E−06 GACCCCGCGCCCACCCCAAACACGGATC TGATTCCCACTTGACACACTTTCCCACTG GTCTTAGTCTCACCCACCCGAAGCCAGC AACCCTCTGCGGAAAACTCACA 1225 2332781 4 C1orf50 GTCTGCATTGAATAGTGGGGATCCCCTC 0.021592904 0.006558798 3.37E−06 AACAAAATTTTCAGGAGGAGGAGGATAT CCCTGTTATTTTCCAGAATAATCAGTGAT ACTCTGTGATATTGATAATCTACCTTGTT GGCCCTTACCAAATTACTGGGTGTGAGT AACAGCTGACTGTAGCTCCCTTTCTCTAC CCTAGTGCTCTGGAAGGAGGAAAGGAG AGCTGGCTTGTATCTTACTTTCTCAAGTT ATCAGTCCACAAACATGAAGAGTATTAG TGTTACAGATACAAAGATGATAACTACT GTCTTATGAGCCTTTATTCTGCTAAGTGT ATCCATTATCTCTTTTAATCTTCACACAA CCCACCATCAATGAGGTATATAGTATTC TTATGTTACACAGCAGGAACATCTCAGA GATTCTGAAACTGGCCCGTGGTTATACA GATGGGAAGTGGTAGAGGTCAGATTCAG ACACAGTCCTGTTTGAGTCTGACCATAA CCTTAATCCTG  976 2334624 2 TSPAN1 CCCAGTGCTCTACTGGGGGATGAGAGAA 0.018262733 0.006574417 5.96E−06 AGGCATTTTATAGCCTGGGCATAAGTGA AATCAGCAGAGCCT 1628 2337238 9 HEATR8 ACTGGATTCTCTCTCAAGCTCCGTCCGCA 0.000113163 0.008182282 4.36E−06 AGCAGGCCATGGA  104 2337538 3 RP11- CCTACATGTCTATGTTCAGAAGCTGCCTT 0.000731459 0.018213477 1.45E−05 90C4.1 GATGCCACATGCGGGAGGCTGGAAACGC TGAAGGATGACCACTGCTCAGCAGCAGT CTACCAGTGATGGATGAGAGTTGGTGCA CAAATACCCCAGCTCCCTTGCCTCTCAGT TTGGATAATC  832 2337700 5 PPAP2B ACCCAGCCGCCTTTAGATATTTCTAAAAT 0.00035324 0.006977438 4.81E−06 GGTGCAGCCACTATGAAAAACAGTTTGG CAGTTCCTCAAAAAGGTAAATGTGGAGT TACCATAGGACCCAGCAATTTCACTCCT AGGTAGTAGGTTTCTCTATGAAATCTTCC AAGATAAAAATAAAAAGAAAAACAAAA AGAAAACTTCATTTGCTCTCCTCGTTCAC CAAAATAAAACTCAAATTCCTTAGCTGC CTGCCATACCCAGTCCCCTTTCATAATCT AGCTCTAACCTATCTCTCCAGCCTCATCT CCAATGTCCTCCTTTCTTCCCCCGCACAG TGCAAACACACAATATTGACATTCCAGC CTCCAGCTACTCACTCTTCCCAAATAGGT CCCTGCTTCCAAGTCTCAGCACCTGTGCT TCACTCTGCTGCAATACCTTCTCCCCCTT CCTGGCTTGTGAGCTATTATTTATCTTGC AAGACCCAGCTCCACACCCTCAGGCAAG CTTCATCACTCTTCACTGTGCTGCTAGAG TAGGCCCTCCCTTAAGGCTCCAAAGTCA TCACTTATATAGTGTTTGTCATTAGGCAA AAGCCTGTTCCACTTTCACCAGCCTGGG AATTCCTTAAGGCCATGGAAACCCTGGG GCCTGGCATATAGTAGGTGCTCAAGAAT CATCTGCAGAAGACAAGGCTTATACCTG AAAGACAGGTACAAACATAGGCTTAATA GGCTCTCTAGAAATTATACTGATTGATA CCACAAACTAATTTGGGGGCCAGATATA AAGAAACCATCAATGAGAATGGTTTCCT TCGTGTCAATGTAATAGTGTATTATGTGT TTTAGGGATACATAAACAGGAACCAAAG CACACTACTTATTATGACAAGGCGCTTA TAATGATTTGCATTTCTCTGCAAAACTCT TTAGGCATATAATTTTGTTAATTTGTGAC AAACCTCAAAAACACACTTACCACCAAT ACCTTGATTGCAATATATACTTTCAAATC ACACAGAAATCAAGTTCCTTTCAAAGGT TTCCAAAAGAGTCTGAAGTGCGTTGTTTT GTTTGGTTTGTTTTAAATTTGGGAATTTA AATGCAGATCATAATTTATAATTTAACC CAGACTTAAGGGAAGAATAATTTCACAA GGATGTTCAAGAACCTGACCTAGCCTTC TTTTGAATGTTGGCACTGACAATGCGTG ACCTTG  451 2338845 4 NFIA GTGATCATCTTTAACTCTGCTTTTCCCAG 0.002123679 0.009137592 7.92E−06 GGCTCTTTGAACTCTTGTTTTATTAGGTA ATATGCTATGCTGTTATTTTATTGCTGTT TAAAAAACCTTCTCTTTTGGGAAAGAAA ACATGTGAATTCTTTGGTTTCTAGATAGA AATTAGCAATCTTTTGCTCGGAATGTAA AAGTATGCTGTATTATCACAAACTGACC CTCCTCCTCCCCAAGAATTCTAGGGAGT AAAATGCGTGCACA  414 2343884 4 LPHN2 GTCAATTTAAGCCACCTTTCCTGTGTCAG 6.92E−05 0.01266909 6.27E−06 GGATCAATGTAA 1141 2344229 6 GCTGTTTCTGTTGATCCCAACCCTACATC 0.000731459 0.006584977 4.40E−06 AGAAGGGATATCGTCGTGGCTATGATAA CTAG 1197 2345198 9 HS2ST1 TGGCCTTCGCGGTGGCGATGCTCTTCTTG 0.005416181 0.007195699 2.34E−06 GAAAACCAGATCCAGAAACTGGAGGAG TCCCGCTCGA 2026 2345779 7 GBP4 CCCTCAATTCTAGCTGCAAGTTTTGAGCA 0.000276837 0.007850394 6.56E−06 CTAGACAGCAGAAATAAATTCCTAAAAT GTTGAGTTGAGCAAATAGTTCAATGCTA TCCCT  668 2348920 4 CDC14A ACATGCCTTTCTAGCGGCAGCCTCAGCT 0.023196567 0.007069116 4.57E−06 CCACCTGGAAACTTGTTAGAAATGCAAA TTCTCAGGCCCTGCCTTTGGCCTACTGAA TTAGAAACTTGAGGTGGGGCCCAGCAGC CTGTGTCTGTGGAACTATCCGGGTGATG CCAATACACACTAAAGTTTTAGAGGCCC TGGTCTAGAGAGAGAGAGTATGGAGTGA GAAGAATTTTGGTCTAGAGTTGAACCTT GAGAAGGTTTGACTTTTAAAGACTGGGA AGTGAAGGATGACTTTGCAAAGGAGGTT GGAAGTAGTGTTTAGAGGGTAGAAGGA AAATCCAGGAACCAAGAGAAGAGAGCA AAGTAGGGAGTTACTTGTTGCTGACATA TTAGGCTAAGATGATGCATGCACAATGT TCTCTGGGTTTA  761 2348926 4 CDC14A CTGAGGATCTCTTAGCGTGTTTAGACTA 0.015428709 0.007499352 5.74E−06 GAGGCTGATAACTGGTGCTCAAAGTCAG CCAATGGGCATGTTTTATTTGGTTTCACA GGAGTTAAAAACCTAATTTAAAAAGTCA ACATTTTAAAAAGAGAGTTTTCACATGA AAATTCAGTTGGAAGATCAGCTGTGTTC AGTTGGCTTTCCTACAAGGTGTCTCATTA GCTGGAGTGGAGGAGCACCTGACTCTAT GTATG 1586 2349294 8 RP5- CAAAACAACAGCGAGTGCAAGAGGACA 0.0015655 0.006876156 5.64E−06 936J12.1 CAGCAAATTAGAGAATGCATGCCCCTAT CTAACAGATGCG 1770 2350297 3 PRPF38B GTGGTTTAATGTCTTCAAGAACTTCCTGT 0.000683093 0.006540911 5.89E−06 AGTTAAATTTATTTCAGTGAGATACTTTT GGAATTAATGTCCTTTTACTGAGACCTG ATGGCTTTTATGTATTTTAGGGTAAATTT CTGAAGTTTTATTTTCTTGTTTTAAAATT GTTTAAATGTGTTTGGTAACTATTGGAA AATTTTCTCTTCTTAATTATGTTCTGTGT ATTGTATTGATCCTGAATTGTATAGTTAA TAGTGACTTTTCAAGATGGGGCATGCTC AAGATCGAACAGATA  734 2351311 4 KCNC4 TGGCAACAGTAATACAAGACGGATCATG 0.000115017 0.008419847 6.31E−06 AGAGGTGCCACAGGAGTCGTAAGAAAA TAAAGTTCAATAGGAAGTGAGAGG  583 2351412 6 ACTGGTTGAACAGCGGATGAAGATATGG 0.000118813 0.013583363 8.53E−06 AAT  593 2351598 3 RP11- TTGGGAGGCCTCAACCATTCCTGAGGTA 0.010913939 0.012701614 1.35E−05 96K19.2 CTGGTGGTGGCAGTTGCAAGTATCTTTTG CTGCACTGAAGGAGGCAATGATGACGCT GGTACAGATTTCACTTCAGCATGGGCTG GAATCTGTAAATGATGCCCAGAAGGCAA AACTGGAGACTTCACAGTCACTGGAAGA CTCTGGGTATTAACTACAATAAAAGATG AGTCTTTTTGTGTTGAGGGAGGAACAGC AAATGTTTGCATGGTGAGTCCATCAATTT TCACACCATGACTCTGAACTTTAGAAAC TGATGAAGAAAAATTTCCAGTTCCCACA GAAGTAACTCTACCTTTTTCTGATGTATC TACTGTTCTTGTAAGAAAATAGTTTGAA GAACTGGCTGGCTGAAAAATGGGCAATT GAACTGATGCACTTGTGGAAGAGCTGGA AATCTGAGTCTGAAAAGTAACTTGAACT GGTTTTCCTGTATTCCCTTTCAAAGCATC AGACATGACTGAAGATTGAACTAGTGGT ATAAGATTTCCAGAAGACTTAGGAATTG GAAGTAATTGCAGAAGATTTTTTCCATC CGAGCCAATCGTCTGAACTACTTG  932 2352425 6 GGAAAAGTCAGCCTCTTACACAAGGTTT 6.62E−06 0.01526752 1.41E−05 TGTATCTATACTTTTACTCTGTCAATTAC AGTGGTATTTTAAATGCATTGAATATAA TTCATTGAATGTCTGTATCTTTCTGCCTC GATTTAAGTGATATTAGGTTAAAAAAAT ATTTACAGTTTTCATTCTGGTCCACCTTC CCTCCTTATCCTTATACTGAATCCATTTC TCTACTTTTCAGGTAAGTGAAAGGGGTC ACAAAATTTTTAGGTTTGTGTGGAGGGT AAAAATGCATCCAGCAATTCTAAGCACA ACAATTTTCTGTAAGGCCTTCTCTGAAAA AAGAGAAGGAATTACTTATTAAAACTAA GCACACTTAGCAACTTCTTTCCCAATCCT ATCTTTATTCGTTTGCCTGGTGCCAAATT TTTCTGGCC  474 2352537 9 LRIG2 GTACCCGGGTGATTTGCTCAGATTGTTAT 0.000177948 0.011098091 8.26E−06 GACAATGCCAACATCTACTCCAGGACCC GAGAATACTGTCCATACACCTATATTGC TGAGGAGGACGTTCTTGATCAGACACTG TCCAGCCTCATGGTCCAAATGCCTAAAG AGACATATTTAGTACATCCTCCCCAGGA TACTACTGCCCTAGAGAGCCTGATACCG TCAGCCAACAGAGAGCCATCTGCCTTTC CCACCAACCATGAGAGGATAAGTGAGA AGAAACTTCCCTCCACACAGATGAGCGG TG  796 2353802 4 TTF2 GCCAGGGAAGTGGAGTTGGAGCCACAG 0.005280805 0.007398234 4.66E−06 ATGGTTTAATGGGAGTCTTTCTCAGCCTC CACGATAGCAAGAGGACCTCCCTGGAG 1426 2354664 4 PHGDH GTCCTTTAGCTCTCTGGTGAGTGAATAGC 0.00022254 0.008825131 7.03E−06 CCTGAGTCCCAGTGAACCAGGTGTTGAT GGCTCTTTTGAGACTTTGGTTCCTGTCTT CTTAGTTTAAAAGAATTTAAACAAGAGA CACGGTGCAGCATTGAGGAGTTTATTGC AAAGGAAAAAGAATATTTTAGAAAGTTAA GTGCAGAGTAGACAGTACACCTCGGGAG AGA  859 2354667 3 PHGDH GAAACATGGCTTGGATCATTCCGTCTCC 0.001151831 0.007373918 4.66E−06 CACCTCAGCCCCTCCGGAGCTGCCTGGA CCTCATCATTCCGGAGAGTCTAAGTGGC   61 2355118 6 GTCCCTAACGTACTGGACAGAGCTAGGA 0.033605237 0.024962916 4.91E−05 AAGCAAACCCATTTGCTTCTTCCTGCAG GAAACCCCTTGAGG  717 2356711 5 FMO5 TCCGATGTCATCAGTCCTTTCAAAGCAG 0.00032469 0.011169866 8.71E−06 ACAGGTTCCAAGCCTTCTTCTACGCAGC ACTTGATGGAAGAGAGCCCGCTCACTCC TCCCCCAATCACAGCAATTCTTTTCTTAG TCATGGTCTCCCGAGATCTTCACCTGTTA GTGTC 1815 2358768 4 PIP5K1A GCAGACTTCTTGGAGTGGTAGTTCATGG 0.001426456 0.006739963 5.31E−06 TCTTCTTCTAAGAAGGCTGTGGATGCCTT AAAAGCATTATTTGACGCTGGCTCCCAT ATCTCACTGCCCTCTCCAAAAAATGTGTT ACCCTAACATAGAAGTATCTTTTCTCAG AATTCTTCAGTATATTATGAATCAGTGAC TACCTTTTCTCTCCCTTGAAATTTTCCTGT AACTTAATGTTCATTTCCTTTTGTTTCAG TAAACCAGTCTCAACTCTTTTCCTTTTCT CTTTCTGTTGTACCTCTCATTTCCCCGAC CCTTCCTGTCCTGTAGATGGCATTTCATA ATTCACATTGATAATAATTGCTAGAATTT ATAGGCATTTATTGTAGATTAAGTAGAG CATTTATTATAGATTAAGCCTATACGTAA CTTGTTGAATTCTCATAACAACCTTAGGA AGTACATGTTGTTACTTCCACATTTTATA GATAAGGTAGCCAGTCTGCTCTAGAGAA ATTTTA 1906 2358817 4 PIP5K1A TACAGGGCCAGCCTTCTAGCCTTTAACA 0.00011347 0.008659372 2.79E−06 ATTCAGGAAATCATAAACCATCACTTGT TCCTGCCAACTTCCTAATTCCTCTGGTAC CATGCAGACAAAGAAACACTCTCTTCCA ATCGCAAATAAAATCTTTTTTCTCTTTTT TTAGGTGGACTCTTGCTCTTGTCACCCAG GCTGGAGTGCAGTGGGGTGATCTTGGCT CATTGCAGCCTCAGCCTCCCGGGTTCAA GCGAGTTGCCTGCTCAGCCTCCCAAGTA ACAGATTACAGGCACCTGCCACCACATC TGACTAATTTTTGTATTTTAGTAGAGACA GGGTTTCACCATGTTGGCCAGGCTGGTC TCAAACTCCTGACCTCAGGTGATCCACC CATCTCGGGCTCCCATAGTGCTGGGATT ACAGGCGTGAGCCACCATGCCCTGCCAG TAAAGTCTTTTT 1344 2358866 9 ZNF687 TGCCCGTCTGTCAGCCCTTGAAGGAAGA 0.047189944 0.007896143 2.93E−06 AGATGATGATGAGGGGCCAGTGGACAA GTCTTCCCCAGGAAGTCCCCAGAGTCCC TCTAGTGGGGCCGAGGCTGCAGATGAGG ACAGCAATGACTCCCCTGCCTCCAGCTC CTCTAGGCCTCTTAAGGTGCGGATCAAG ACCATTAAAACATCCTGCGGGAATATCA CAAGGACTGTAACTCAGGTCCCCTCAGA TCCTGATCCACCTGCCCCCTTGGCTGAGG GGGCCTTCTTGGCTGAGGCTAGCCTCTTG AAGCTGTCCCCTGCAACACCTACTTCTG AGGGTCCAAAGGTGGTGAGCGTACAGTT GGGTGATGGTACAAGGCTGAAAGGCACT GTGCTGCCTGTGGCCACCATCCAGAACG CCAGTACTGCCATGCTGATGGCAGCCAG TGTGGCTCGCAAGGCTGTGGTGCTGCCT GGGGGGACTGCCACCAGCCCTAAGATGA TTGCTAAGAACGTGCTAGGCCTGGTGCC CCAAGCCCTGCCTAAGGCTGACGGGCGG GCAGGGCTGGGGACTGGGGGACAGAAG GTGAATGGTGCCTCGGTGGTGATGGTGC AACCTTCAAAGACAGCTACTGGGCCAAG TACAGGGGGCGGCACAGTGATATCACGG ACCCAGTCCAGCCTGGTGGAGGCCTTCA ACAAGATCCTCAACAGCAAGAACCTGCT CCCTGCCTATAGGCCAAACCTGAGCCCA CCAGCTGAGGCTGGGCTGGCCCTGCCTC CCACCGGCTACCGCTGCCTGGAGTGTGG GGATGCCTTCTCATTGGAGAAGAGCCTG GCACGGCACTATGACCGTCGGAGCATGC GCATCGAGGTCACCTGCAACCACTGCGC CCGCCGCCTGGTCTTCTTCAACAAGT  318 2359022 4 TUFT1 CCCACCTGAGCTTGAGGGTAGCATACTT 0.008412239 0.019281699 2.24E−05 AGGATTTGTCTATTTGCAGAATTGTTTTG AGAGCCTAAGGCCCCATAACTGGGAGGC TGTATGTGCTTCATGTCAGCTCCATTAGT GTCTGTTTTATTTAGTGCTGTTTTCCATT ATCTCGAACAGAGTCAGTCATATAGTA 1991 2359172 7 S100A10 GCTAAGTGTCCTGATCTGCTCATGAAAT 2.46E−05 0.008579579 1.13E−05 CCTTCTATGGGGGAAGCTGTGGGGCAGA TTCCTTAAGCGACCCTTTGGGACAACTCT TATCAGGGAGGAGCGAACTGCTC 1973 2360177 9 HAX1 AGAGACTACAGTAACCCGACACGAAGC 0.000475873 0.007177691 5.19E−06 AG  619 2361306 4 LMNA GTGGTGTGTGTACTTGTTATATTTAGCCA 9.15E−05 0.010680811 5.62E−06 CCTCCCTCTGTTCTCCCCCACTGATCCTG GCTGGAAAGGCTGGGCTTCCGGAAAAGA GAGGTGGATTTGCACACCTGGATCCCAA GCTGATAGAAAGTGGGGTGAAGACAAA GGGGACTCAGACTGGGGTGTCTGTCCTC TTCTATGCCCACAGTAGGAGGAGCCAGG ATTGGTTACTCCCTGC   60 2361561 7 IQGAP3 GCAGGACTGCAGATCTATGGAAATTGCC 6.53E−05 0.052285286 7.62E−05 TGGAAGAGTCAGCTGTAAGGGATGAGA ATCCTGAGGGTAAAAGAGAAAAGGGAA AGACTCCTCTTTGATCTTATGAAGCTGAA ATAACAAGATCTTAAACATGAGTGAGAA TCTGTTGCCCCAACCTAAGGTGACTTTAA ATCCAAGGTAAAAAACACGGCATGGGTA TTAGTTTGAATA  591 2361774 9 NTRK1 CTGCAGTGTCATGGGCAAGGGCCCCTGG 0.001689593 0.009588501 9.17E−06 CCCACATGCCCAATGCCAG 1397 2361937 1 GGTCTCAAGCTGGACGAAGGGGAGCCCC 0.008429307 0.011369338 9.16E−06 AGGTCACCCTGAGCGCTGGGGCCGCAGT GGGAACTTGCGGCGATGTCACCCCTGCC CTGC 1609 2362760 2 SLAMF8 TGGGCACCGTTTTGCAGGAAACACCATA 0.000293755 0.008851971 3.93E−06 TTAATAGACATCCTCACCATCTCCATCCG CTCTCACGCCTCCTGCAGGATCTGGGAG TGAGGGTGGAGAGTCTTTCCTCACGCTC CAGCACAGTGGCCAGGAAAAGAAATAC TGAATTTGCCCCAGCCAACAGGACGTTC TTGCACAACTTCAAGAAAAGCAGCTCAG CTCAGGATGAGTCTTCCTGCCTGAAACT GAGAGAGTGAAGAACCATAAAACGCTA TGCAGAAGGAACATTATGGAGAGAAAG GGTACTGAGGCACTCTAGAATCTGCCAC ATTCATTTTCAAATGCAAATGCAGAAGA CTTACCTTAGTTCAAGGGGAGGGGACAA AGACCCCACAGCCCAACAGCAGGACTGT AGAGGTCACTCTGACTCCATCAAACTTTT TATTGTGGCCATCTTAGGAAAATACATT CTGCCCCTGAATGATTCTGTCTAGAAAA GCTCTGGAGTATTGATCACTACTGGAAA AACACTTAAGGAGCTAAACTTACCTTCG GGGATTATTAGCTGATAAGGTTCACAGT TTCTCTCACCCAGGTGTAACTGGATTTTT TCTGGGGCCTCAATCCAGTCTTGATAAC AGCGAGGAAAGAGGTATTGAAGAAACA GGGGTGGGTTTGAAGTACTATTTTCCCA GGGTGGCTTCAATCTCC  415 2362943 2 ATP1A2 TCAGCAGGCTAAGTTGCGGGGTATATAA 0.000931652 0.010267038 8.99E−06 ATTGGGGTGATGACCCCATAGACCTAAC TGTGAACAATCAGATTAGACACTATGTG TTAGAGTCCCCCCGACCAGATCCTTTTCC ATCCCACTCCACTATGTTGTCTATTTTTT CTGAGGAATTAAGGGTTACCCCACCCTG CCCACTCCCATCCCTTCAACCCCACTTCC TACTGTAATAGATCAGCATCCAAAAGCA GGAACCCATCTAAACCAGAAGG 1121 2363443 7 RP11- GCACATGAACAGCTACGCCGGGTTGGGT 0.000105163 0.008348104 5.02E−06 297K8.2 TGGGAAAGAGTCGGAAATAGGGGATGC TCTGGTCAGGAGTGGGAATGAAATGTTG ACTGTTCCCCCTGCTGCTCAGATCTACCT TTGTCCTTTAGTGGTGAGCCATGCTTTGC CCTACCGTGTTAGCCTGCAAGAAGTGGT TTTGCCGGACCAGCACTTCCCGCCCTCCA GGGATCTTCCCAGCCCTCTGTGAAGTGC TAGATGCTTCTCCACTGGTCTGCGGGCTG GACCCAGGCCTGCAGTTTGCCATACTTG CGCCCCTGCTGTTTGGGAAGGATCTGTG CTGTAAGCCTCGCGGCCATACTACGACT GTCAGATCTCCATCCCTATGGGCTATAG GATGGGGCGACGGCACCCTATACCTCAG GGACTTGCTTTGGA 1478 2363596 2 TOMM40L TCCTGCATGGGATTAGCTGACCATCCTGT 0.001351803 0.006766808 2.02E−06 TTTCCATCCCAGAGCCTCCCAAGGCTGG GAAAGTAGGGCTGAAGGGCTAGATGTTT GGTCTCAGGAAGTGGGGCCCACCCATTC CCAGAAGGAGCTTCTTTACCTCTTAGCCC TGAGGTTTCCTCCTTCCCATCTTCTGTGC TTCCAGAGAACAACTTTGTTCCTATGGTC ACCCCCACTATCCCCATGACCGCATGAA GAGGCAGTTATTGCTTTAGTCTTTCATTG CAACCACTGGGCTCCCTTTGAACCCGGC CCAATCTTTGGTCCCAGCATTTTCCCACT CCAGTGTATCCAGGGTGTTCCAGGTGAG CTGGGGAAGGAAGTGAGCATGGCCTCAG CTGCAGATCTCCTGGAGCAGCGGCATCA TGGCAGACAGGCCCTGGATGTGCTGGAT TTGGTACCCGTAGGCCTCATTAATGCTCC GGAGCTCAGCCAGCAGGCCTAGCAACTT CGCATACAGAAACCTTTGGAGGAAGTAG TGGGGTTGCCAGGAAAACAGGAGGGAA ATAAGGCAGTTGGGAGTCTTGTCTCTAG GCCCTGATCCCCTGAACTATTCCTCAGTG AAGCCAGGTCTGAACATTAGAGAAAATC ATGCTCTGGTATGACAGACTATCAGAGG TTCCAAAGGTCCTCCAGGGGGCCTCGGT CTGACACTGTCTTCTCTCACCATGCTCAG TTTTTTCTGAACCCAGAGCTCTGAGAGCC GAGTGTGAAGAAAGCTCCAGACTTGGCC AGAACTCCAACCATGTGGA 1807 2363918 2 DUSP12 GTGCTGCCTTTGCTTCTTATCATTCATGG 6.39E−06 0.008024841 5.36E−06 CAGATTGTTTGTGCTTTCAACATTTCATT TGAAATGGGAGAAGATAAAATCACTTGA TGTAACCTGGAAACTATGCTTTACATGG CAATCAAAGCCTTTTG 1775 2364168 9 UHMK1 GTGTTTACAATCCACTTTTCTCCAAATGT 9.30E−05 0.006583588 3.54E−06 GCCATCACGCTGTCTGTTGCTTGAACTCC TGGATGTCAGTGTTTCGGAATTGCT 1636 2365136 4 MGST3 AAGAAGCAACACCATTCAGTTCAGAACA 0.001286836 0.006751106 3.74E−06 CCCATACTGACTTTGAGCTGATGGCCTTT GTAGGTTTCTAACTGGAAGTGAAATTTTT TCTATTTTTAAAACTTTCTTTTTATTTCAT AGTTACTTTTTAAGCTTTTTTTGTTAAAA ATTAAGACACAAACACACACCTTATCCT AGGCCTATACAGGGTCAGGATCATCAGT ATCCGTCTTCTGC 1433 2367711 8 AL645568.1 ATTCCTGGGGCACCCCTGACAAAGGGAG 1.65E−05 0.009625929 4.05E−06 TCAGTGGGCCACCAGATGGAGGAAGACT CGGTGCAATCCCACTG 1255 2368310 8 KIAA0040 CTGAGAAAGCCTTGAGCGTTCGGAGAAA 0.000252191 0.006744191 4.61E−06 GTCATCTGGAAGTCAACATATGATATG 1258 2369335 4 C1orf49; GTGCCTGTATCATGTAGACAAAATCCAA 0.004267545 0.007220492 2.75E−06 C1orf220; AGCAGCTTGTTTCAGACAAAACATTTTG AL513013.1 CTTTGGAAACTTTTGAAACTTCCATGGCC GTTGAATATAGCAGAGATGATCTAAAAA TTTTAGAAGCGGTTGAGGTACCCGTGGT AGGGGCAAGGCATGGGAGTGGTGATCCT TAAGGGGCTTGTCTTTAGTTTGAGGGCC ACACA 1571 2370215 9 KIAA1614 CTCGTACCCAAAACCTGCCTGATGGGCA 0.004407176 0.006575102 1.91E−06 GCTGGACGGCAGCATCAATGAGGAGCA ACCCGCCAGGGATG 1835 2371053 2 DHX9 AGGCATGCTATGTGTTACGTGTTTTTTCC 0.001027681 0.009724721 7.95E−06 AGTATGTTTATTTGCCACCAAAAAGTAA ATGCATTTTCACCCATTCTGTGGTTCATT GTAGTTTAAGGAAACCAAGCATATAGAT GCATTAGTGATTTTGTTTATATTATGTAA AATATAACGATCTCTTAAAAATACCACA GTTTGTATTTTTTCTTTAAGGAGTAAAGA TTTGCCTTTAAATAACTTGGTATTTTCCT GGCTTTCGTTTAATACAATAGA 1246 2371206 7 NMNAT2 GACTCGTGTCCCAGGTTTCAGAACCCGA 0.000742232 0.007072308 5.66E−06 AAATCTCACTCCTGATCAAAGGTTGCTG CTGCTGCTGCTGCTGCTGCTACTGCTATA TGTGTGTGTGTATGTGCGTGCGCGGGTG CACACGCATGTGTGCGTGTGTGTGTGTG TGCGTGTGTGTGGTGCTGAAGAAGTGGA GGTTGCTTGGCCTTCTCTACTGGGTGTGG CCCTGATGAACTCACTGAGTGCTGAGGC TGGCTACAATGTCCTATCAGAGGGGAAG TAATACCACAGGAGCACATCAAGACTAC AAACATAAAGAACCATGGACACTGATTT CATCCAAGTTCTACAGGGAGTGA 1968 2373881 4 PTPRC TGTGTCGTGGTATAGCAGAAGTGCTTGA 0.003830941 0.008142194 4.66E−06 AGATTTGTTTCTCTGCCTTATCTTTAGTA ATTGTGTTTATGTTGGCTATCTGGCTATT GCCCTTGCGTGAC 1910 2374274 1 GTGAGACCCTCCCGACAGGACAAACCAC 1.92E−05 0.007591419 3.48E−06 TCTGCCGTTATATGTGA  251 2375421 3 RP11- CGGTCTCTGCCTTGCTCGTGCTTCTACCA 2.80E−05 0.014753778 1.93E−05 480I12.3 CCACCCTTCCCCTCCCAACCCGGTGGATC CTCTCGTCTCC 1405 2376434 5 KLHDC8A CAAGGAGATTCCAGCGGCTGCCCATACT 3.24E−05 0.008440933 7.36E−06 GTTTGTGCCAGGCAG  276 2376513 1 CTCTGCAAGAATTGCTGCAGACCTCGAA 0.000310846 0.011470781 7.56E−06 TACACCTCCTGCTGCTG 1891 2376804 4 IKBKE CTTCTGTGTAATGTCCGCTCCTACCTGAT 4.25E−05 0.006524562 4.11E−06 1161 2377129 2 PFKFB2 ACTTGCATTGTGCTAGGGATCTGCCCTAT 2.67E−05 0.01046144 7.14E−06 ATCTTTGCCTCTGGTGTTTCGTTGTTGTT GTTATTGTTTGTTTGTTTCCAAAGAAGTT GGAGTTAAGGACACAATATATTTGTACC CCTAGACTGAATGGGTGAGTATTCCATA TGAGGATCTGGGTAATCCTCTTTGCAAC CCACATTTGGTCTTCAGAGACACTGGCA TTTTGAAGAAACATATGATATAGCTGTTT GGAAATAAATTCATCTATGTTACTTTTTT TTTCTTTTTTTTTTTTTTTTATGAGCAGGA GATCTTAATTGACAGAAACTCATTGGTG GTTGGAGTGGCCAATGGGCACGGGAAA AAGTATCCAGTAATCAGAAGAATTGTAT CTGGGTTATGTAATCTTATGCACATTCCA TTGTCTTTGCCAAGCCCAGAAGCCATGTT GTGTTCATTGTTAAGAAATTTGATAGATT TACCCAGCTTTTCTATGTATTTTGACTTA TTGAAAATATGTAACAACTGAGTCGGGT TGCAGCACTGGTGGGGTAGAATCGACTT TCCCTGAAGGTGACACAGATGTCAGAAT TGTGTCCAGGGATTTAATTTAGACCCAT ACTGTCCAGGAGACTGTCTCTAGTTGGA TCTCTGTGCTGACTGACTGACAGACAGA CTTTAGTGTCTGTGTGCTGACTGACAGAC TCTAGTAGTGTCTATATGTTGACCAACTG GTAGACCAGGAGGATCTGTGTGCTGATT GACTCTAGTAGGATCTGTTTGTCACTGAC AGACTGTAGTAGTGTCTGTGTGCTGACT GATAGATAGACTATAGTAAAATTTGGGT GTTGCCTGACTAACGGTCTA  261 2378098 9 HSD11B1 GAGGAATGTGCCCTGGAGATCATCAAAG 0.012161553 0.014861289 1.03E−05 GGGGA  358 2379173 9 FAM71A TTCGCCACTGGCAGATCTTGCTATCTGCA 6.53E−05 0.012088903 5.38E−06 ATTGTGTCCCGCTCTTGACACACGGGAT GACCTCTTTGCCTATTGGGAAAAACTAA TTTACCTCTTGCGGCCACCCATG  467 2379454 9 RPS6KC1 GACACATTCAGCTAACGTATTTTAGCAG 0.015937432 0.011695155 1.18E−05 GTGGAGTGAGGTTGAAGATTCCTGTGAC AGCGATGCCATAGAGAGAATGTACTGTG CCC  811 2379471 4 RPS6KC1 TTCTGGTCCGTATGACTTTTGCTTTAAGA 6.60E−05 0.011990906 1.17E−05 CTATTGCTCAAGCTATTTTGTAAGTTTGG GGTTCTCCCACACAAGTACATTGACTAA GCATTGGTTAAAAGGCTAGGCACCTGAG TACCACTTACATGTTTTACTTTCCAAGTT CCAACCTAACTACTTATAAACTTGAAAG TAGTTATGAATTGTGGGTTACCTATAGTC AAATAGTAGGGTTTTTTTTTTTTTCAGTC AATTGGAAATGAAAGGGCAGGTATTGGC AAGGCTTCGGGACTAATTTA  572 2379903 9 CENPF ATTGAGCATGAAGCCCTCTACCTGGAGG 2.09E−05 0.019043146 1.94E−05 CTGACTTAGAGGTAGTTCAAACAGAGAA GCTATGTTTAGAAAAAGACAATGAAAAT AAGCAGAAGGTTATTGTCTGCCTTGAAG AAGAACTCTCAGTGGTCACAAGTGAGAG AAACCAGCTTCGTGGAGAATTAGATACT ATGTCAAAAAAAACCACGGCACTGGATC AGTTGTCTGAAAAAATGAAGGAGAAAA CACAAGAGCTTGAGTCTCATCAAAGTGA GTGTCTCCATTGCATTCAGGTGGCAGAG GCAGAGGTGAAGGAAAAGACGGAACTC CTTCAGACTTTGTCCTCTGATGTGAGTGA GCTGTTAAAAGACAAAACTCATCTCCAG GAAAAGCTGCAGAGTTTGGAAAAGGACT CACAGGCACTGTCTTTGACAAAATGTGA GCTGGAAAACCAAATTGCACAACTGAAT AAAGAGAAAGAATTGCTTGTCAAGGAAT CTGAAAGCCTGCAGGCCAGACTGAGTGA ATCAGATTATGAAAAGCTGAATGTCTCC AAGGCCTTGGAGGCCGCACTGGTGGAGA AAGGTGAGTTCGCATTGAGGCTGAGCTC AACACAGGAGGAAGTGCATCAGCTGAG AAGAGGCATCGAGAAACTGAGAGTTCGC ATTGAGGCCGATGAAAAGAAGCAGCTGC ACATCGCAGAGAAACTGAAAGAACGCG AGCGGGAGAATGATTCACTTAAGGATAA AGTTGAGAACCTTGAAAGGGAATTGCAG ATGTCAGAAGAAAACCAGGAGCTAGTG ATTCTTGATGCC  845 2379907 9 CENPF AGAGAAAAATAGGCTAGCTGGAGAGTT 4.92E−05 0.016468854 9.51E−06 GC  525 2381284 4 MOSC2 ACTGTCTGTGGCCTAAAGTACTTTGTACT 0.000881522 0.01234807 6.65E−06 TTGTCCGTGTAGCTCAGAATATTAAACG ATTTTTAAAAGGCTGCTTCCTTGGGTCAG TGTGGTGTGCTTGAGTTCCGGGAATGCA GCAAAATGAAGTTTAGAAATAATGAAAT TGACCAATGCTTCCTATCTCTGTAGTTGG CCATTGTGGGGTCAGTGTTTACTGATCTT TGCTCACTGTCCTGATGAGATAAACTTG  539 2382372 9 DEGS1 TCTGGAAGTTATCAATACCGTGGCACAG 3.86E−06 0.020088544 1.45E−05 GTCACTTTTGACATTTTAATTTATTACTT TTTGGGAATTAAATCCTTAGTCTACATGT TGGCAGCATCTTTACTTGGCCTGGGTTTG  316 2382373 4 DEGS1 TGGCCAGGCTAGTATTTTGTCAGTCCAA 6.13E−05 0.019451886 1.79E−05 GCAGTTCATTAAAAAAAAAAAAAACAA AAAGAGCAAGAATATAAATACTGCATCT TCCAGCCTACTTTTACAAAGGGTTCACTC TTGGGTCCTTAAGCTTAGTGGT 1948 2382443 2 CNIH4 CCGTGGTTGAAGTCAGCCTACACTACAG 0.000243178 0.008587751 4.58E−06 TGCACAGTTGAGGAGCCAGAGACTTCTT AAATCATCCTTAGAACCGTGACCATAGC AGTATATATTTTCCTCTTGGAACAAAAA ACTATTTTTGCTGTATTTTTACCATATAA AGTATTTAAAAAACATGAATTGAGTTTC TGTAGATTTCTAGTTCTCAACTTTAGCCT GAACGCCAACACTTGAAGGTGTTTTTCA TCCTCTGTATGTTGAAGGTGGTTATTTGT ATGTAGGAACAGGACTGCCATCCCAGCT TTGCATGCCAAAGAAATAAAGAACACAC TTTAAAGGGCAAACTGAAGAGATGAGCG AGCAAAGGTGCCCTTCAGGTCTACTGAA AAGTTAGAGTACAAAACAACACTGTTGA TCTGGACAAAAGAAGAAAAATTACCCTT TTTGCTTGTGTTGTGACAACTTCATTTAA TATGGTTTAAAGATTTATGAGACTGTCA GCTAAAAGTCTTTTCACAAGAATGTCAA CAGAGAATGGCATCTCAAAATATATATA TTTCTTTGCACAATTTGTGAAACCTTATA AGCCATTTTCCCCAGGTACAATGTAGTTC CTGCTGATAGAAAGGAAATATTTTGTCA AGAGCTTTCATTTAAAAGCTACTACCTCC ACAATCACCCCCAAACCCAGAAAATCCC CACTGGCTCTTGCCAGTCTGGTTTTCGTA TTGCAGTTATTCCAATTGTATTTGATCTC CCTGATAACGTATTTTCATGGGTTTGGGT AGAAGATGCTAATCAGATTAGAAGCAGG AATAGTTATTTGCTGTCTGTGAAATTGAG CCTTTTGGTGCGCCACGTGGTGCCAGAT CAACACTTCTATCCCTCTGCACTGACCAC GTTGTGAACTGGGAGACCAAA 1652 2382480 4 CNIH3 AATCTCAGTTGCCAAACCTGTGTCGGCC 0.002187152 0.006827297 3.25E−06 ACATTAAAGCAACAGTTACTATATCAGT CATGG 1435 2383093 5 PARP1 CCCGGTGGCATACATTGAATGCCTAGGG 0.017390197 0.00692499 4.35E−06 CAGAAAGGAAGTGGGAATGGCGAAGAT GTGACGTGCCTCGGTGTTAGATACTGT  743 2384613 5 C1orf96 AGGCACCATCCATATCACAACGCTGCCT 0.00026838 0.007981474 5.05E−06 AAAAATTGTATTTATATTGCATGCAAAT ATTTGACAACTCCATCACAAACAATAAA AGATCGGGGAGAGAAAAGCCATTTAGCC TGATAAAGTACATCTCAATTTAGCTAGC AGATCAGTACCCACAGGAATAATCTGGA AGGCATGTTCCCTACCCCCTCCACCTTCT GTTATTTGCATTTCTAGCAGTGATCACTG AAGCATCAGGATTTGTGGGGATTCACAA GTAACATCATGATGGGAGGAGGCAGCCC TGCCTCCGATGATGAGCTGAAAATAGCT GAAGATGGTAAAACCAAGAGCAAAGCA ACCCGGCTCATAGCCGAAATTTCATCTC CTCCTCAGCCTCTCACAGAGAAGCCAGG AAGAGTCTGATTGGCTTGCA 1238 2386188 5 IRF2BP2 AGGTGGGGCCTGTCTATTATATAAAACC 0.000108061 0.008100112 2.38E−06 CTTAATTTCTTTAATTTCCACTAGTTTAT CATTTTTTTCCAGAACAGTATTATTCACT TGGTATTTCAAACACATGTTAAGAAGGA AATTACAGGTTTCCTCCACCCACATTTGG GCTGTCACTGATATGCCCAAGGGCAGTC CTGGCAGCACCACGCGGCTGTTACTGTC ATTGTACCATACTGTATTCAGCACTCACT AGAAACAGGGTATAGGTGATAGTATCAA CAGCAATAGCACTACAGGTAAATGATAA ACAAAACAAAACAGAAACAAAACCAAT CCCACAATCTCCAAGTTCACCTGGACTG TAACTTCTCTTGCAACTCTTTCAAAATAA AGGACAACAGCAACAACAAACAGACCT CTAGGGTGTTTAAAAAGATGAAGTGGCG CTGCAGAGCTGGGCTCTGCTCAAAGATG GCAGTGCCATCTTGTACACACCACCATC CATTATAACCGCCTTCCATCACTGGAATT GTATCTTATGTAACCAACTAGCATGCAG CATTGTAATCTTACAACTGATCACGTGG ACAGTGAACAGCGGTCAACTTTGTCTTA AAAAAAAAAAAACAAAAAACCCCAAAA GACCACACAATCCTGAAAATTTCCCAGC AGCACTCTCAGTCATCAGTATCTCAGGA ACTGAACTTTTGAGCAAAATAGAGATTC AAAATCCACTTTCCTACTCCTCTGAGGAC AATGTTTCAGGGTAAACTGGTGGTATTT CCCAGTGGCATGCCCACTTGACAACATG CCCGTTCGATCATTTCCTTTCCTTCTCCA CCACTTGGCCTCCGGCCTGAGAAAGGGG CCAGCAATAAGGAATGACAGACAGTAA GGCAATCTTACAATGTCAGAAAATGTAT TTGGCTTTTTTTTTCTTTTTAAAATAAGT GCATACAAATACAGCTAGAAGCATTTCT GATTTGCCAAGTGCTCTAAAAAAGCAGC GCAAGTCACAGCCTACATAGAACGGTAA CTGTCACCAGGATAATAAAGCACAAAGA TATGCTAATAACGTTAACAAAAGAAAAA AATGTCTTTATAAGTACATACCTTTTGTC GTCAAAAAAAATATAGAAACACAATGTA TTCAAAAAAAATCAAAATTATACAGCCA TGTTTATGAAGTCTACATTTCCCTTGTCT TGGATATATATATATATGGAGATATATA TACAATTCAAGCAGTTTTAATTAAGGGT AATCATTGGGTTTTTCTGAAACCGGAAA AGTCACGAGTCTCTCTCTTTTTTCACTTT CACATCTCCAGCAAGGATGGTTGCAATT TCCCCTTGCATAAAGGCCCAGGGGACAT TGGAGCCCACAAGAGGGCATTTTTCCCC ACTGGGACAATAGACCTCTCCACTAGCT CCCTGCTGTTTGATGCTTTGTCTGGAGCA AGGGAAGCAGAACTTGTGCGAAGGGAC GGACGGGCACTGCACAAAATGGGTGTCC TCCAGCCGCTCGTGGCAGAGGGTGCAGC ACAGCGGGGCACTGGTTGCCAGAGAGG AGTCCGGGAGGCTGGCAGGGTGCACTGG CTCCAGTCCTCCTGTGTTGCCTGCTCCCT GGCCCCCCACCTCTCTGGGGCCCAGCCT TCTTTGGTTCATA 1678 2386782 4 GPR137B GTCACCAGGCTCACACAATCATTTAAGA 0.001757031 0.007939934 4.07E−06 AATAAAAACACATACACAAAAATGTAG GCTGCCCCTACAATCTAATTTATGATAA AATAAGATGAATTTCAGCCTAAGAATAC TTCATTTATTTTCTTAGTTGTGAAAAAAT TAGTTAAGAACCTTAAAAAGAACTTTTT ACTCTAACCAGATCTTTTAATTTCCTAGA ACATACTCTAATATACTAGTTTTCCTAAG CTTGAAACAAATCACAGTACAGAAAAAA ACAATAAATGGACATGAGCGAGGATTTT CTCCAGTAAACAGTTTAAATAATAGCCT TTAACTGAGGGAGTGGTGAAATAACACT ATCAAAAAGTTCTTTACATTTAGAGTGA TAAACAAAGTGCAGATTTTTCACATCTT AAACTCTGAGTGAATACTAAGAATAATT CTTACTAATTTACTAGTTAAATTAATTGG ATAGTCACTTTTTAGACAGTTTGCCTTAA GGCCCCCCTCCCCCACCATACAATACTT GCAACCCTCAAGAAAAAGTAGAGGAGG CTCCAATCAAGTCA 1381 2389967 1 GAGGTGATACCAGAGCCTTCGCAACACC 2.60E−06 0.008282347 6.16E−06 AG  908 2391060 4 C1orf159 ATGGTGCTGCTAATGTGTCTAGAATTGG 9.88E−05 0.011500656 5.14E−06  825 2391846 2 GNB1 CACTTATTGCTGAAACCAAGAGCACAAT 0.000128482 0.014644576 1.14E−05 TCCCATTGAGAGAAAGATCTCTGTGCTG TAAACTAAAACAAATTGTGCATTCCTTC CGGGGCCATCGTCTTTG  529 2393322 1 AGCGCTCTGGCCGAGCACCAGTGTGCCA 0.010386073 0.008019303 4.22E−06 GCCAGAAAGCACACCTCTATCTGCGGGA GCAGAGCTCCTTTCCTGC  606 2395510 9 ENO1 TAAGTTTGGTGCGAACGCCATTCTGGGG 0.000156233 0.019298761 2.09E−05 GTGTCCCTTGCCGTCTGCAAAGCTGGTG CCGTTGAGAAGGGGGTCCCCCTGTACCG CCACATCGCTGACTTGGCTGGCAACTCT GAAGTCATCCTG  333 2396027 9 LZIC TGACACTCGGAACGTCAAGAACTGGAGG 1.95E−06 0.020081931 2.37E−05 TTTGTGCAATTTGAGACCGGTCGGCACT GTGCAGAGATCAGA  348 2397591 5 KAZN GAGCTTGGAGATGATGTGCCCCCTGGTT 1.81E−06 0.015572111 1.63E−05 TTCTCACATACTGCCTCTCAGCTGCAGAG ATGCTGCAGACCCGTCATTCACACCTATT TCAACAAGCCGAATACACTGGAGTTTAG  695 2398901 6 CTCCCTGAGGTTCCGTTTTACACATGATC 7.23E−06 0.016623913 1.75E−05 CAACGTTAACTACCTTTTTTTCTGTATGC TTTCCAAAGTCCTTTTTTTTCCCTTAATGT TGAATTAAAATACTTGCTCATAGTTGATT TACCATTCCTACAAAAGAGGCAGAAACT TTGAGCAATCTAGGTTTTTTTTTTTTTTA AGTTTTTTCTTTCTTCCTCTCCTGAATAC ACTCCCCAAAACACCCCTTTCCAGTTAC AATTAGCATCGTGATCCAAGCAGATGCC ACATGGAAGAGGAATCGCCATTTACTCA GAAAAAATGTCCCTTACAGGAACCGGCA GCAGCTAGGCAGTCACCGGCCCGCCTCC ATCCAAAATCACGCTCGCGTGCTTCGGA AGCATC 1507 2399450 9 UBR4 AAAATCATTAGTTTGGACCTTCCTGTGGC 3.56E−05 0.008422828 4.92E−06 TGAAGTTTACAAGAAAGTCTGGTG 1181 2400148 3 RP4- CAGAGAGGGTCCGTGGCATGTCCAAGGT 0.001221904 0.010206572 5.86E−06 749H3.1 TACTCTG  152 2400178 2 CAMK2N1 TGTTGGCATTCTTCGCTGATTTGGCTGTT 9.01E−06 0.026063706 2.59E−05 CCCAATGTTTACATTATTTAATCTTGCAA AAATGGTTCTGTGCACTTGGATGTGAAA TGCTGTCCAGTTTTATTTTTTTTATGTTGT TATCCTTGGATGTACAAAAAATTCAGAA AATGATCTCTGTAGATATTCTGTTTTATT TTGGTCATCTTTAGAAGTTATCAGGAAT GTGTTTAAAACAAGAAGAGAACTTTTCT AAGGAATGATACATAGAAAAGATTTTAT TTTAAAATGAGTTGTAAAGCTTGTGTTTC TTTGTTGCTGCAAGCTATCTGCCCAAGTT AATGCAAATGGACACATTTTTTATGTCA GAAAAACACACACACACACACACACAC ACACACACACACACGAAAAACAAAGAA AAAAATGCTTGAGCTTTTTCTAACTTCCC CTTGCAGTCTGTTGTGTGAGCAGCCTGTT TATTTCTCTAATATTATGTCAGTTTATTC TCTTTAATGGACTGTAAAAAAATGTAAT CACAAGAGTGCCAAATATCTTGAAATGC CAAAAGGCATTTTAGTTTCTTTTCTCTGT GCTCTGAGTCCACGTACAGGAATGCTTG GAGTGTCTTTTCTGTTATTTATAGGGATT CTCTTAAGGCACACCAGCTGCCTGTTTTG CATGGTATTTGCAAAAATGCCTCTTGCGT GAGGAAATCTTTTACC  582 2400179 2 CAMK2N1 GAAATTTATTACTAGCTTGCTACCCACG 4.47E−05 0.01559515 9.45E−06 ATGAAATCAACAACCTGTATCTGGTATC AGGCCGGGAGACA   97 2400180 2 CAMK2N1 GGAGAGAATAAGAACGGCGGTAACAGT 3.66E−06 0.031824392 3.10E−05 TATTGGCAAAAAGC   58 2400181 9 CAMK2N1 TTGTTATTGAAGATGATAGGATTGATGA 0.000198282 0.038963268 4.21E−05 CGTGCTGAAAAATATGACCGACAAGGCA CCTCCTG  575 2400707 9 RAP1GAP GACAAGTCCTTCACTTCTCGCCGGAGTG 0.003098917 0.010613844 6.50E−06 TGT 1813 2401703 4 MYOM3; CTGCTGGGGTGAAGTTCAAAATCCCTGG 7.38E−05 0.006696158 3.40E−06 RP11- CCACTGGTTCGTGCTAGAGATGCTGGAC 293P20.3 TGCGGATTAATGGGAACCC 1753 2402420 2 C1orf135 GTGGGAAGGTGGCATGGGATGAAGTTGT 0.00010346 0.009232187 3.30E−06 CATTACTGAGCATCTTCTCTGTGTAAATA AAGGGCAGTACCA  643 2402463 2 STMN1 GACTGTATAGGTAGATCCAGATCCAGAC 2.42E−06 0.018080299 1.07E−05 TGTAAGATGTTGTTTTAGGGGCTAAAGG GGAGAAACTGAAAGTGTTTTACTCTTTTT CTAAAGTGTTGGTCTTTCTAATGTAGCTA TTTTTCTTGTTGCATCTTTTCTACTTCAGT ACACTTGGTGTACTGGGTTAATGGCTAG TACTGTATT  484 2402464 9 STMN1 GCACATTGAAGAAGTGCGGAAGAACAA 0.000363271 0.023971946 2.62E−05 AGAATCCAAAGACCCTGCTGACGAGACT GAAGCTGA 1879 2402466 9 STMN1 ATGGCTGCCAAACTGGAACGTTTGCGAG 4.53E−05 0.010009361 5.91E−06 AGAAG 1581 2406442 9 CLSPN TGACTCTGGTAATGATCTGGCACTGGAA 0.000150908 0.010372461 7.04E−06 GACCATGAAGATGATGATGAAGAAGAA CTCCTGAAGCGATCTGAGAAGTTGAA 1799 2406443 9 CLSPN ATTTGGAGACTTTCGGCTTGTTTCAAATG 0.000126082 0.008736274 4.61E−06 ATA 1562 2406607 3 TRAPPC3 GGGCCACCTGTCCATGCTGAAGAATTGC 0.002919457 0.007068394 3.93E−06 TGCTGAGAGGCACTGCTTACCACTCTTTC TATCTCCCTTAGAGAGGCCTTTAATCTCC CAAAAGACTGGCTAGGCAGCTCTTTGGG TCAAAAAAACATTCCAGGTCGTTAGGGA ATAGCATAGATTATTTAATCCCTGTGGAT TAAAGCCCCACTGAAATCAAAGCCTGAG CTTTTCCACTGTGAAGGTG  450 2409634 4 ERI3 TCAGAGCTGAATCTGTGGGCAGAGCTGG 0.00060261 0.008504212 4.47E−06 CTTGTCTCTAGGAGAGACATGGCACTAG CTGAG  139 2410530 2 POMGNT1 TGAGACTTAATTACTAACTCCAAGGGGA 0.004360173 0.017748354 1.83E−05 GGGTTCCCCTGCTCCAACACCCCGTTCCT GAGTTAAAAGTCTATTTATTTACTTCCTT GTTGGAGAAGGGCAGGAGAGTACCTGG GAATCATTACGATCCCTAGCAGCTCATC CTGCCCTTTGAATACCCTCACTTTCCA 1411 2413541 4 HSPB11 TGGAAGCGCCACTACCAGCCCACGAAAC 0.011398396 0.006601892 4.14E−06 TCTTTGAGGCCAGAAATAGCGTCTTGAC CCCC 1011 2414409 4 PPAP2B AGGCTAGGTCAGGTTCTTGAACATCCTT 0.003064934 0.007911982 5.54E−06 GTGAAATTATTCTTCCCTTAAGTCTGGGT TAAATTATAAATTATGATCTGCATTTAAA TTCCCAAATTTAAAACAAACCAAACAAA ACAACGCACTTCAGACTCTTTTGGAAAC CTTTGAAAGGAACTTGATTTCTGTGTGAT TTGAAAGTATATATTGCAATCAAGGTAT TGGTGGTAAGTGTGTTTTTGAGGTTTGTC ACAAATTAACAAAATTATATGCCTAAAG AGTTTTGCAGAGAAATGCAAATCATTAT AAGCGCCTTGTCATAATAAGTAGTGTGC TTTGGTTCCTGTTTATGTATCCCTAAAAC ACATAATACACTATTACATTGACACGAA GGAAACCATTCTCATTGATGGTTTCTTTA TATCTGGCCCCCAAATTAGTTTGTGGTAT CAATCAGTATAATTTCTAGAGAGCCTAT TAAGCCTATGTTTGTACCTGTCTTTCAGG TATAAGCCTTGTCTTCTGCAGATGATTCT TGAGCACCTACTATATGCCAGGCCCCAG GGTTTCCATGGCCTTAAGGAATTCCCAG GCTGGTGAAAGTGGAACAGGCTTTTGCC TAATGACAAACACTATATAAGTGATGAC TTTGGAGCCTTAAGGGAGGGCCTACTCT AGCAGCACAGTGAAGA  754 2414437 5 PRKAA2 CTGCATTCCAGCGTTAAACAACACCCCA 4.32E−05 0.011624453 7.82E−06 GGAAGAAAGACTCACAACCTCTGGCCCC TGGAGCATCCCCCAAACAGTCACCCCCA ACAACCGAGAGTCCTGGAACGTGA 1378 2415125 1 CCACACTTTGATTAGCAAGGATTTAGAG 1.22E−05 0.00685264 1.64E−06 CCAAGGGGCTTCCATAGCACAGACAATA TTGGATCCACCACCAAAAGGTTACAAAT CA  222 2415666 5 NFIA GAAACCAGACTTCTCCGACTTCTTCAGT 0.013961818 0.010182727 9.23E−06 GTGGTTGGAGATGGCATTCCTGGCAA  234 2420021 1 GATATAAGCCAAGCTAAGAAGAACAAG 0.022075503 0.011356751 8.96E−06 GACTCTGTGAAAGGAAAGTCACCTGTTT CTCTGGCCCAAGTGTTCGCCTGTCAATCT GCTGTTCCAGATCCAGACTATAA 1362 2423947 3 RP11- GAACAGAATTTACACTCAGCCCTGGTAA 0.000333103 0.006732521 4.49E−06 86H7.6 CCAGTCTATCCGTCAGTACCAG  544 2423977 1 TCTGCTTATATTACAGAGGGGAGCTGGG 0.002202047 0.009340892 1.02E−05 GTGAAGGCTGGGGGGAGCCAGCAGGAC GAGTTCTGAAGCCTCTTATT  203 2425002 5 PALMD TGGGCCTTTTCGTTGTTCTTCAGTGTGGG 0.001460097 0.011648419 1.24E−05 CCACGTTCACTTTCAGACAGTAACTCTGT AGGGATAACTCTGTCAGTGGTACGTTCA GTCCTTCATCTCACGCTTCTTCATCTCAC TCTTCTCGAGAATGCTGGAGTCATTGGT ATCCTCAGTTCCA  708 2425301 5 CDC14A GGGCATCTCTGAACTTCCAATCTGAAGT 0.028404922 0.006591512 4.33E−06 AGCCAGCCAGTCACCAGCACATCACCAA CTTGCCATTATCACTGACCTCTTATTTGT TTGTTTCTCCCAGCAAAATCTAAGCTCTG TCAGGACAGGGATTTTCTCTCTCTTGTCC ATTACCATATCCTTAGAGCTCAGAAGGG GTGTCTGGCCCAGGTGCTCAATGACTGT TTGTTCAATGAAAGAATGAACAAATGAA TCACACAAAAGGAGAGAGGAAAATACT ATTTCCCATTAAAATGAAGAAAGAGTTT TTATTAGAAGGGAAGGCCACAGCAGCCC TCTACTACCCTCTTTTGACTAAACTTCCA GGAAATTCATTACTAAGTTTTGGGCTTCA GTAAGTCAGAGTCAATTT 1886 2425955 7 AMY2B; TGTGGCAGTGGCCATCTACTGCTCAAAG 0.000731459 0.007223839 4.52E−06 ACTG1P4 TCCAGGGCAACATAGCACAGTTTCTCCT TGACGTAGTGTCTGATCTCCCGCTCGGC AG 1256 2428116 2 KCND3 TGTTATGACCCATGACCCTCGGAGCCCA 0.003923309 0.00762346 5.07E−06 AACAGCACCATGAAGAGCATCATTAAAA CTAAGAGAAAGTGGCTATCAGAAAATGA AACAGCTTTAAAGGGGTTCCTTTTAGT CTTGTTTTCTATTCAGAATGTTCTGTGTT TTTTCTCAAGTGTGGGAATGACATTTATC TTAGCAGGTTACTCAACTACACTGGATG ATGTCACTCTAACCAGTGTACGGCACTG ACCCAAGTCCTGGGGGGCTCCTTGGACC AATGGACTATTTTACAAACCTGGGAGGT GGGAGGGATGGTATATTTTTGATAATCA GACATTCCAATGTAATGTTTTCCTTAGAG GTCACACCCTTCCCCCCATTAATGTCATC GTGAGATACATCAAGTGTGTTCTTTTCTA TTTTCGTATAATAAATGGGCTTTGCTTAT CAACATCACAATGGCAAAGAAGAAATAT ACTGTACAAAACTGCAGGAAGATAAAAC ATGAAAACTTTCTATGAAAAAAAAAAAA CACCCTTGAGTTTCCTGTCGTCTTC  866 2428148 4 KCND3 CCAGAAACTTCTTACCCGTATTGAGCTG 0.000333956 0.00838534 4.70E−06 CCAGAAGCTGCAAGTGCTGTTGCAAGAT G 1653 2428490 6 AATGCTTTGTCTGCCTTATTTGTCAATGA 1.05E−05 0.006690888 3.07E−06 GCTCCACCCTGAACTCAATAATCTGGTT AAAAGCAAAAGCTAAATTGGAAAGTTCC TAACTAAATTAGTAAACTCAACACTTCA GGATCTTTGTTA 1030 2428505 2 SLC16A1 TCCATGGGGCTGAAGGGTAAATTGAGCA 8.27E−06 0.012777404 7.84E−06 GTTCATGACCCAGGATATCTGAAAATAT TCTACTGGCCTGTAATCTACCAGTGGTGC TCAATGCAAATAGTAGACATTTGTGTGG AAATCATACCAGTTGTTCATTGATGGGA TTTTTGTTTGACTCCTTACCAATAGCCTG AATTTGAGGAGGGAATGATTGGTAGCAA AGGATGGGGGAAAGAAGTAGGTTCTGTT TTGTTTTGTTTTAATCTTAGCTTTTAATA GTGTCATAAAGATTATAATATGTGCCTT AAGTTTTAGTCTTTAGAACTCTAGAGAG CCTTAACTTCTTAAACCATTTTTGCTGAA TTCATCTATTTCGAGTGTTGTGTTAAAAG GAAAAATAACAACTAACTTGTTTGAGGC AAATCTAAAATTTAAAATTAATCTTGCTT CATTGTTACATGTAATATATTTCAGACAT TTTCACTGGAAGATTTATGAACAGAAAT ATTGGTTGAAAGTTAGAGATTTTACAAA ATGCTGACAAAAATATTTTCCTAGCATC AGTAGATTTCTGGCATATGTTTCTGCTAG CTATA 1824 2428507 9 SLC16A1 GTATCTATCTCTTCATTGGCATGGGCATC 0.000131632 0.007514531 2.97E−06 AATTATCGACTTTTGGCAAAAGAACAGA AAGCAAACGAGCAGAA  536 2431143 9 NOTCH2 AGCGGTGTACCATTGACATTGACGAGTG 3.08E−05 0.012700774 8.14E−06 TATCTCCAAGCCCTGCATGAACCATGGT CTCTGCCATAACACCCAGGGCAGCTACA TGTGTGAATGTCCACCAGGCTTCAGTG 1737 2432473 6 TCCGCGCGGAGGGATCTACTACGAGTCA 5.28E−06 0.007929227 4.32E−06 CTGGCCCCGTCCGCATCCTTCTCCAGCGG CCCCGGGGGCCGCCGCGCCTTAACTCGA TCAGG 1109 2432882 6 GCCATAGGCCCTGATGACCCAAAACCCC 0.002356255 0.006664499 3.11E−06 AGGCTTATGAGAGGCTCCAGACCTCCAT ACTTTCACAATGACAGTTGTATCAATGG TGTTTTTTTCCACTAAGCTTATGTGGCCA TGACATGACCAGGACTTCCTGGGTAAGA ACGGAGATGGGAAACCCATG  699 2433254 2 FMO5 GCGACACTAACAGGTGAAGATCTCGGGA 0.00580501 0.009377878 2.79E−06 GACC 1560 2433880 4 RP11- TCCCAATGGAACACCCATGACGACTCAT 0.000454879 0.006744412 3.44E−06 744H18.2 GAGG  964 2434001 6 CCCGGCTGCTCTTTTTTATAGACGAAGA 3.58E−06 0.013245904 1.02E−05 AATTGAGGTACAGAAAATCCAGTAACGT TTTAAAAGTCACGTCATGAATGAACCAA GATTTCAACCCAGAAATTGAGGCTTCAC TACAAGTGAAGACTGGGGTTTTCTTGTTT TCAATTATTGGGAGTTTTGGATTTCCAGG AATGTGCAATTGTAAAAACCCAGCTTCA GGAGGTGATGAAATAGGTGCAGTGGCTC TGGCGTAAGCTCTGAAGCCCCAGGCTCA GGCTCTATTGAAAAATTACTTTTGCTGAA ATATTCCTGTTTTTAGGAACTTCCATGGA ACTTGAGCCTTCACGCAGCATATTTTGGC ATCTGATTCAAAGCTAATAGAGGTCCGG AGGATTCCCAGGATTAAAGTCTTTAAAC AGAAACTGTGAATCTTGCCTAAGCAAAA GGTGCCATCCCTGGATGGGCTTGCACCA CCAACCTTTCAGT 1858 2434095 1 TCGTTGGGACACTGAAGGGAGATCCAGA 0.001705241 0.006866301 4.85E−06 GTTCCGACTGAAATTTGAGAAGCTCTTT GCTATTCAAGTGGATATGTGCAGTTGAC AGTTTGAGAGATGCATCTAGGGTTCAGT AAAGACAACACAAGCCTGTCTTTAGGGT CTACCTGTGAACTGTGAACACAGCAATG AGAATGATGGACATCACCTTTAAGTATT TTTCTAGACTTTATTACTCATGTGTTTGT CATGAGGTGTAACTTAGTAGTTCATAGT CCTATAATGTATGTTATTGACTAGGTAGC ATTTATTTTTCTAATTGTTTCTGTTATAGT GCTGCCACATGTGTTTCCCAGAAACGCA TTTTACCCACAGTTCTTAGGGTTGGCCTG ATTAGTTTAATTGCTGTCTGAACCTGCTT CTTACTG 1432 2434340 5 CA14; TGTCCCTCAGAGATTGGCCTTATCCCCCC 0.008706715 0.006743011 5.10E−06 snoU13.115; AGCATGACTTTTCCTAAGGTCCAGATCCT CA14 TTCCCCAGGACCACCCATCCCTGTTACTT TGTCTGAGTCCCAGCTCTTTGTTCCCTGG TACCTCTGCAAATGTGGCTTCACTGTTGA TCTGGTGTTCTGACCCCCCTGGGGATCCT TTCTGACCCCAGTGCAGGTGGAGCTGGG CAGCTACATATTTTCGGGGAAGTCCACC CAGATACAGGGTAGAGGGCAGAGAGAG TTGCACTGTGAGGAAAAGAGCAAACTCG GATTGGTGGAGGCATGTGGATACATTCC CACTCCTGGGTTGCCACCACTTCTTGGGA GACTTGGCCCTCTTCCAGTTTTCTCCCCC AGTAGCACCCAGTTCCTCCCATAGGCCA GTGCTTTTCTAGCATATCTTCCTTTTTCTT GGTGAAGACCAAGTCAGTGCAATGATAC CTACCTACTGAGCTTGGTTATAAACATTT CGATTCCCGCTTTGGCTACAGGATCCTG ATCCCCATTCTCATATCTCCAAATTCATG GACAAAGGTTTTTGAGAATTCGTAGGTT AGGAAAATGCTGCTTTCCTCTGACTCCTG AGGTTATTTGTTTGTTTATTTATGTCAGA TGGGTAATGTGCCAACATCTTGACAAGA TTTGAGGGCGGCACATC 1647 2435365 4 THEM4 GTTGGTCTCGCTTCCTATCTCACTAAGAG 6.81E−05 0.006800674 2.64E−06 AAAATAAAAGCAGTCAGAAGAGAACTC CCAGTCTCCCATTGCCTCACATATCCTCC CCCCTGCATCTGTGCCTGATGTTCTGCTT CTTCCTGCTGTGAGTGAACCATCCACACT CTTAGGGAGACCAAGCCTTCCATTTGTG CGCTGCATTCCATTTTCTTTGGCCTACTG AAGGACATCCATCTCTGCTAGATGTTTC GTATCAGCATATAAACATGCCACAACTG CATTTCTCTCTTCCCAGTCTCTCTCTCTCT CTCTCTTTTGTTTTGGGTTTTTTTGTTTTG TTGTTTTTTTGTTTTTTTTGTTTTTGGTTTT GAGAATGAGTCTCACTGAGTCACTCAGG CTGGAATGCAGTGGCGTGACCTCGGCTC ACTGCAACCTCCTCCTCCCGGGTTCAAGT GATTCTCCCACCTCAACCTCTCAAGTAGC TGGGATTACAGGTGCATGCCACCACACC CAGCTTATTTTTATATTTTTAATAGAGAC AGGGTTTCACAATGTTGGCCGGGCTGGT CTCGAACTCCTAAATTCAAGTGATCTGC CCCACCTTGGCCTCCCAAAGTGCGGGGA TTACAGGCATGAGCCACTGTGCCCAGCC TATCTTGAACCCACTCCCTCAAAACAGC TCTTGCCAAAGGTACCAGTGACCTTCAT GTTGCTGAGTCCGCTAACCTCTCAGCTTT TGGCACAGCTGTTGACTCCTTTC 2045 2435391 2 S100A10 GCAGAAATGAGCAGTTCGCTCCTCCCTG 2.12E−05 0.007179441 6.15E−06 ATAAGAGTTGTCCCAAAGGGTCGCTTAA GGAATCTGCCCCACAGCTTCCCCCATAG AAGGATTTCATGAGCAGATCAGGACACT TAGCAAATGTA  138 2435392 9 S100A10 TCTTTTCCCTAATTGCGGGCCTCACCATT 1.64E−06 0.029375761 3.58E−05 GCATGCA  420 2436400 5 CREB3L4 CCAGCCACGCGTCCAGCAGGTCAGGGAT 0.010140998 0.009145342 7.79E−06 T 2046 2436718 2 UBE2Q1 TGCTGTATTTGGATCTCACGCTGCCTCTG 1.24E−05 0.008826572 5.71E−06 TGGTTCCCTCCCTCATTTTTCCTGGACGT GATAGCTCTGCCTATTGCAGGACAATGA TGGCTATTCTAAACGCTAAGGAAAAAAA ACAAACACAGAACTGTTTCAAGTACTCA AGACTGACTTACAGACCAACCAACCACC TTGCTGGAACCCTTGCTAGCAGGCATTCT TATAAAAGAAACTTTCGAGCCTCCTTAT ATTGCTGGAAACTCAGCTGTGCTCCAGA CTAGAGCCTCCTTACCTATGCTATGGA 1559 2436760 9 ADAR TCCAAAAGGCAATCCGGGAAGACTAAG 0.000333103 0.007188607 4.31E−06 GAGACAAGCGTCAACTGGTGTCTGGCTG ATGGCTATGACCTGGAGATCCTGGACGG TACCAGAGGCACTGTG 2081 2436777 9 ADAR TTTTCTGGGAAGAGCCCCGTCACCACAC 0.00055537 0.006511312 3.94E−06 TGCTTGAGTGTATGCACAAATTGGGGAA CTCCTGCGA 1816 2438283 2 IQGAP3 GACTCTTCCAGGCAATTTCCATAGATCTG 0.019281916 0.007219209 5.36E−06 CAGTCCTGCCTCTGCCACAGTCTCTCTGT TGTCCCCACATCTACCCAACTTCCTGTAC TGTTGCCCTTCTGATGTTAA 1403 2438403 4 RP11- GATGCGCGCCGTACATCCGGCACTGGGT 0.009861702 0.007020494 4.83E−06 284F21.7 CTCTGCCTCCTCCCAGCTCCTTCGTGTGG AAAAGTGCTTGTAGCAGGCGCCCT  702 2439112 9 FCRL1 ATCATCTTACCTCAGGAGTCATTGAGGG 0.00180613 0.010454141 6.09E−06 GCTGCTCAGCACCCTTGGTCCAGCCACC GTGGCCTTATTATTTTGCTACGGCCTCAA AAGA  697 2439713 1 ATCCATGGATCTGCTGCCAGGTTCAGTG 0.018818925 0.009054474 6.05E−06 ACTGGAATGCACTTGCCCCAGCGGGTTC AAGTTCTTTGTAGAAACAGACCCCTCAA AGATGACAGCAGCTGGCTTCCTCCAGAA GTGTCCTTCAACACTGTCTTTCAGTACTA AGTGACCAGTAGAAGTTACTCCATAAAG ACCATAGCCAGGAATGAATTATGGGGCT TCCTGCATATCAAATGGTTACCTAGGGA AGGCATATGGTAAACTAGTTAAGCACAG AGGTTCTGGAATCAGACTGCCTAGGTCC AAATCCTGGCTTTACAACTTACTAGCTAT GTGACCTTAGGTGATATAACCTCTTTACG CCTCAGTTTTCTTACCTACAAAGCAGGA GAAATAATAGTAATTAGCTCAAAGGGTT GCTATAAGAATCAAAGAAAATCATGCAA GCAAAGCACTTACTACAGTGCCTGGCAC ATAGTAAGCTCTTATAACAGTTTTCTGGT ATTATTCTTATTAAGCCATTTTGTATTAT ATCCATAAATGTAGATTCATAAAATACA TAAAAATACAACTTGGTAGAATTTGTCT TGGTTGGCAGCAGTTGAAGCTTCTC  713 2440486 9 F11R ATTCAAACAGACCTCGTCATTCCTGGTGT 0.002951948 0.009184105 4.04E−06 G 1854 2440934 6 CTGGTAATTGGGCTCTTTGTTCTTCTGGA 0.000329714 0.009574997 9.06E−06 GCTTCCGACTGCATAAGCAGTGAATAGG TGATTTTGTTCTCAGCATGGAGAAGGCA GAAACCAGCAGTAGGGATCCACAGAGA GGGCATAGGAAAGAAGATGTTAAAGAG GCTGGACATTGGGGCTGATGCTGGTCAT CC 1880 2441254 7 UHMK1 CATGATGTGATTCCAATGTACCCGAATC 0.000674778 0.007808112 7.85E−06 TGAATAAAGCCACCTAGCATGTACCCCT GCATAAGTGTCTAGGTAAATAGATGGTT ACTGAGTGTCTCCC  479 2441293 1 TGGAAAGAGATCATGGAGGAACGTTCCC 0.04486637 0.007065833 3.64E−06 ATA   52 2442609 9 CD247 CACCAAGGACACCTACGACGCCCTTCAC 1.32E−08 0.058186499 7.57E−05 ATGCAGGCCCTGCCC  146 2442711 4 CREG1 GTACTTACACATCTTTCACCTAAGATTGC 0.044564191 0.016459758 1.51E−05 CGCCCTTACAGCCATCCTCAGCCTTCTAA GGCAAGGGGGGTTTAACCGTTTCATGTG CCCTGGACACCCTGGGCAGTCTGGTAAA GCCGCTGAC 1139 2443145 2 DPT GGAGGCAGAGCTGAAAACAGGGTTGGA 0.001689593 0.008816218 5.73E−06 AGGA 1553 2445386 9 ASTN1 CCCAAGGTGCTGACATTCCCAGAATACA 0.00081399 0.007829511 7.28E−06 TCACCAGCTTGTCAGACTCCGGCACCAA GCACATGGCGGCTGGAGTCCGCATGGAG TGCCACAGCAAGGGACGATGCCCCTCGT CCTGCCCCCTGTGTCATGTGACATCCAGC CCTGACACCCCTGCTGAGCCGGTTCTGCT GGAGGTGACCAAAGCAGCCCCCATCTAT GAACTAGTGACCAACA  201 2445439 4 ASTN1 TGCAGGGCACACTCTGTCTGGCTGGGCT 0.000986793 0.015663776 1.28E−05 CTCCTCCGTACCATGACACGTCTCTCCGT TGGAGTCCTATGTACACCACCATGGAGT CGGCGCCTCATG 1306 2445596 1 AGGCACGCATGCAAGGCCTGCCTGCCGT 2.37E−05 0.008143377 5.57E−06 GCCTCCCTCTGCCAAAGGCATTTTTAGCA ATTTCCTAAAAATGTGGCTACAATGGAA AATGAAGCTGTTCAGGGGGAGAAGTGAT GGCCCCGAAATGCATCCAACAGCC 1045 2445659 4 AL359075.1; TTCAGTACAATATGATCCTGAGACAACA 2.89E−05 0.008115986 5.64E−06 SEC16B GTCCCACTGCCTT 2059 2446213 2 TOR1AIP2 CTTATTTCCTGGGTCCATGGGAAGCATG 0.000701725 0.006905728 3.97E−06 AGTCTGTTGGGACTTGGGACAAGAAGAA AACAAGACATCTTCACAAGGAAAACCAA GTACTAAAAAAAGTATCCTCCCAACTCT GAAGAGATAGAACACAAA 1017 2449595 9 ASPM TGGCTTTTTCACGAGATTTCCTAAGTGGT 0.00028481 0.011214528 1.13E−05 GAAGGTGACCTTTCCCGTCACCTTGGCTT ATTGGGATTACCTGTTAACCATGTTCAG ACACCATTTGATGAATTTGATTTTGCCGT TACAAATCTTGCCGTAGACTTGCAATGT GGAGTGCGCCTTG 1479 2450707 7 IGFN1 ACACACACGACCTTGATGCCCTAGTCCT 0.008126841 0.006840666 3.17E−06 CACCCAGGTCCTCTGACCTCCTCTCCTCT TCCCTCCCAGTGGTCACAGCAGGCCCAG CTGTGCCCACCCTCCCTCCAAACGGCTC AGCCCAGGAAAATAAGGAGCCGGCCCA TC 1990 2452640 2 NUCKS1 GCCAGGTTAAGCAACAGCCAAGTTCTCA 6.19E−05 0.006513548 4.46E−06 GTAATTGTTTGCCTTGATTTATCTTTTAG ACTTCATTTTGCCAGCTCTAAAACTCCCA GTCTTCCTTGATTTTAGTCCTTAATCTTTT ATGTTCTGAGCAGGAAGGGTAAAAGACA GGAACCTGCTTCACTGTATTAACTAGTCC ATGGGCTGAGACCGGGGCATCTCTTTTC TT 1907 2452665 9 NUCKS1 AAAGAGCAGCGGAGTTTGAGAAGCCAG 1.22E−05 0.00700385 2.12E−06 CAGCTCGGGGTTCGGCAGCAGCGGTCCC ATCGGCTGAAGTTCGGGGGGGGTGGGGC GCCGAGCGCGCGGGGTGGGGGGGGTCCT GGTCTTTGGCTTCTCGACTCGGTCCTGTT TCGACAGCGAA  226 2453257 3 C1orf132 CGGGGAATCCTCAGACGTCTCCATTCAG 0.003864295 0.015604689 1.46E−05 AATCTCCCAAACGATTGTTCTCTTTTTTG CATTCTTCTCCTTCTGGCTTTTCTGTGTG GGGTTAGTAACCAGCACAGGGTTGGGGG CAGAATGGGCAGCTGAAGTGGTCGGGCT GTGCGGACGTGTGGGAGATAGCTGGGTA GTGTTGCTGGGTGTGGCAGTTGGCAGAG CATTTGGGCCTCCCACAGTAATAGAAAC TCTCTTTGGCTCCAGCATCCAGCAGGAG GTTCTGGGTTTAACCCCTCGGTAATCCTG GGAGCCTTCCTGGTGCCTGGGGATTCTCT CCCCTGTGTAGTCTCAGTGGATGGCCTGT CTTAACTCTAGATACATTTTGCCTTGAGG GGGCTTAGTCTAGGTTGGTGGTCTGGAG TTTGGACTGGGCTGAGCAGTGAGCTTTG GGACTCTCCCTAATTTTGGGGTTTCTTTG AATGAGCCACTTTCTTCCTCTAGGCCTTC ATTACCTTTGCCTTAAAAAACAAAATCC CTGGTCCAGTAAGCCATTGCAAAGCATC TCTAGGAAGTTGACAAAGAAATGCTTTT CTTCTGCCTCACTTGCTGCCGATCACAGT AATAGCAATGGTGATTAAAAATGAAAAA TGATGACGGCCTGCAGAATCAGGGAGGT CAGTGGCATCATTGATACAATTCACAAA GCAGACTCTCGGTGCCCACACATCACTA GGAAGTCTCTCTCCTATCGAGTAGATGA CTACAGCATTCTTGGCCAGTAAAGCCAG TTGGAATTAGCCAACAGCAGATTGGTCT GGGCTCTAAAGATAAAAGGAATTATGTT GGGTAATTTTCGGAGGTACCTATGGGAT CCTACCTCTGGCCACACAGTGGTCGCCT CTCTCTGCTCATATGTTTCGGTGGGGGTG GGGGGTTCCTCTTCCCCATGCTGCTCCCG TTGCTATCCAGGGAAGATTGGCCAATTC TGCTTCCTGTTATTTCTTCTTCTCCTCTGT CCATTTGAGGTGAGTCTCTAGGTTGGCT GTGAACAGCCTGAGGAACCCAGGGCTGT TTGGAAGAATCTGATGTCTCTTCCTTCAA GGACCCTGACAGGTCTCAGCCCTCCAGC AGTACTGCAGTGAGGGATGGCAGGGGGT GTTGGAGTGGAGAGATATCGACTTGGGT GCAGCTGGGGAGACTAAAAGGAGTGAG CCAAGTCCCTCAAGAAGTGTTGGCTAGA GTCTGGCCAGCCCTGGCTGTAGGGCTGG AGCCAGACGTAGCTGCTGGCTGTGCTTG GGAGTCTCAGCCCTCATATGTGCAGTGT GTCCCTGGGCATGGCTCTTCGTGATCCCC ACTCCCACGAATAGCCCTGTCCTTGGTTA GATTGGGAAAACCAGGGTGGGAAGTAA AGGGGAGGTTGGTTTTGCTCGTGGTCAT GCAGTTATCTCTCTGGCCTCTGATGTTTC CAGAATTGGGATTGGTGCTTCCCTGCTG ATTTTCCTATTTTTGTCCCTCATCTGGTTC TTTTCCTCCTTGCTCACCAGCCTGGGTTC TACACACATGACATGGGGCATTGTGTGT TCCCAATGAGGATAGCAGAACAGTTGGT ATCTCCTGAGAGAGGGGCCAGCATATCT GGCACTTTTTTCTTGACCTTTGAATTTCT GAGGTCTGGGAGTCAGGAGGCAGCATG GGGCCTCTCCATCCGGGATCCAGCAGAG GTTAACAGAGTTGGTGGCTCTGGAGCTG AGGTGGTGTGGCTTGGCTGGGAGTTGTG GGGGAGAGGCCCTGCCAGGGGCCCTGAT TGGTCAGTACCTTCTCTATTCCATTGAAT CCTGGTCCGGTCAGCTCTGTGAATTGTTT AATGCATATCTTGGCTCTGTCCCCTGGCT CGAGTGTCCCTAAGGCTGCAGCCACAGC TTTAGAGAGGATCTGTACCTTGTGCTGGT CACTTTTTTTGGGCGTGTTACCTCCCTCT GAGATATGTAAGAGATACCACCCTTTCC CACCAGCCGGCTGTCTGTGGGAGGCCCT CATTTTGCTTTGCTTTTCTGAGACTTGGA GTGACTGTGAGGAAAGCATGGACTGAGT TTGCTTTCTTGCTGGTTCCTTCCACAAGA GCTGCTCATGGGCTGATAAAGCCAGAGA ACACCTCCAGGGCCCCATGGCCTGTGCG GAGCCTGGTACCATAGTGTCAAGCCTA  856 2454934 7 VASH2 AGTCCTCCCTTAGTTTGATTCTTGGCATC 9.17E−05 0.01002888 5.93E−06 CTTCAGAAGAATCAAAGCCTGCCTCAGT TTAAAAATCAGATGAAATGTGAACAGAA AGGTTTTTTGGTTCTGAAGACCTGCTGAT CACTCCTGGTCTCTGCCTGAGTGTGTTAA TGTCAGAGGTAAATCCAGTACCGCTAAA TTTGTATAATAGTACGTGACCTCTTGTGC 1742 2455571 5 CENPF GGCATCAAGAATCACTAGCTCCTGGTTT 0.000909538 0.012399382 9.59E−06 TCTTCTGACATCTGCAATTCCCTTTCAAG GTTCTCAACTTTATCCTTAAGTGAATCAT TCTCCCGCTCGCGTTCTTTCAGTTTCTCT GCGATGTGCAGCTGCTTCTTTTCATCGGC CTCAATGCGAACTCTCAGTTTCTCGATGC CTCTTCTCAGCTGATGCACTTCCTCCTGT GTTGAGCTCAGCCTC 1382 2455740 9 USH2A TGAGGACATTGCAAGCACCTCCAGAAGG 6.92E−05 0.008670255 3.56E−06 TCTCTCTCCACCTGTGATATCCTATGTTT CTATGAATCCC  367 2458002 4 PARP1 CTTCATTCTTGAGTAGGGACTTATTGTAT 8.76E−05 0.022724911 2.24E−05 CATCCATCACAAAATCATACAGTACTTTT ATCCAGGAATTGTAGTGAGGGAGGTTGT CATAGTATTCAGCTGCTATTTTCCTCACC TAGAAGGGAAAAAATACAGCAAGATGA AAAATGAGTGTTACTAGGTTCTTTCAAA GATGACTGATGAATGGTTGACACAAACA CTGAGAAGGGAAACCATGAGACCTGCCT CC  494 2458051 9 PARP1; GAGAGTGATATGAAACGGAAAGGCAAG 0.000839994 0.018192256 2.19E−05 NVL CTAA  614 2458059 9 PARP1; TTTAGCATAATTAGTAGTGAGAAGGAAC 0.001013073 0.018177128 2.33E−05 NVL TTAAGAATTTAACAGAATTAGAAGATGA ACATTTGGCAAAAAGGGCAAGACAAGG TGA  772 2458061 9 PARP1; ATATGTGGACATTGGAGTCTTAGCGTCT 0.000120755 0.016719436 1.39E−05 NVL GATTTACAAAGAGTG  371 2460770 7 RP5- GGAAATGCAGGGCATCTCCGCCACTGGG 0.030881616 0.013148273 1.70E−05 865N13.2 AGTGACC  240 2461554 1 CTTGCTTCAGGCTTGTGAATTCCTAGAC A 1.71E−05 0.015540624 6.99E−06 CAACCCTACCCAAAGACTTCCTTCACCA ACATATTTTTCTTTCTAGATAATAGGCAC AAAAACCATTTAGAAGTTTGAGATGGAA ATCATGCAATGCACTCTGCTCTTTATATA TGTTACTGAGGAATCTGGAAGCTTTTCC GGGTTGAAATGCAATTCCTAGGAAATTA TTCTTGCTCTTTTCCTGTGGCTGTTTTTAA CACAGCAGCAATGCAATTTCAGTGGCTC TGCTCCTTCACAAAGACCTTTGAGAGGG AACTATGCTGAGAGATGCAAATTCAAGG TTTTCTGAAAACACCTCAGAATTGTCCA GTTCTGCCCCCAGATAAAACCACTAGAA TAAAGGTCAGGAAATCTCCAGATGTTCT TGGGACTTGCGCAGTCATCTCAGGTA  647 2461808 3 ARID4B TATGTAGGGGTTTGGAGCAACCAACTGT 1.85E−05 0.009733544 4.19E−06 CCAGGCACTGCTTTCCTCAGACAACCGT GTCAAACTGATTTTCAAGCCTGACTAAC TTGT 1888 2461983 2 GNG4 ACAGGGGGCCGAGCAGAAGCCCCCAGC 2.45E−05 0.006679482 3.66E−06 GTCCAGGGCCGGGGGAGGGTCCGCCTGC GCCCCCAGGCCCGCGTGGTCGGGCCCTG CAGGGCGGGAGGCGCGGCGCGGGGCGG GGCCGGTGACGGGACGCGGAGACCCCG CGGGCGGCGGGAGGGGCACGAGGCGCG CGTTTGCACCCGAG  987 2462132 4 LYST ACCTTCATTCCAGAGGCATCCTGCCCTGT 0.005853836 0.008761152 3.61E−06 ATCCGGGAAGAAGGAATGCTGCACACA GATGCCAAGAAGAATCGGAACAGACAG GCATTGCTGGATCCCCCCTCGGTCTATTA CCACGAGATCAAACTCTTTTGTCCAATC ACATGTCTACAGTGCTGTCCATTCTTCA  646 2462390 5 EDARADD TACTCAACTGCTCTCTCGGCACAGAGCC 0.009608615 0.008062889 5.07E−06 CCTGGCGAGCGCACCCAGCTGTGCTTAG CGCTGCTGCTTCCAACACGCCAAAGAGC TCATCTTGCCATAGTGGGTTTAATGTCC  391 2462402 6 CACCGGGACTGGCAAGATGACTTTGGAG 0.024995647 0.013921384 1.34E−05 TTGCCAGACAAGTCGGCGATGTGGTGGT ACAGGGGAACCCCCTTCTCAACAGCACT AGCTTTGCAGGCAGCGAGGGACACTCCC AGAATGGCATTTGCACCAAATTTAGATT TATTTTCTGTTCCATCCATCTCTATCATA AGTTTGTCAATCTTCTCTTGTTCTGTGAC GTTCAGTTTCTTGCTAACCAGGACAGGT GCAATAGTTTTATTGATGGGCTCAACAG GCTTTGAGACACCCTTCCCCATATAGCG AGTCTTATCATTGTCCTGGAGCTCTAGGA CCTCATAGATACCAGTTGAAGCACCACT GGGCACAGCAGCTCTGAAGAGACCTTCT GAGGTGAAGAGATCAACCTCAACAGTGG GATTCCCACGAGAGTCAAAGAGCTCCCT GGCATGGATCTTGAGAATA  148 2463199 4 GREM2 TTAGCTTTACCAGTTGAAATCCATCACAC 5.31E−05 0.020014135 1.68E−05 TTCAAAGCCCAAATGCTACGCCTTCAAG CTCTGA 1688 2463907 6 GTCCCAGTTTCCATGGTCAGCCTTACGTC 3.87E−05 0.009135293 5.78E−06 CCATTACCAGTTGTTTGAGTGGTCTCTCC CAATGCATCCCCCATAAATTATGCTAATT CCTGCCTGCTCTTT  480 2464645 5 KIF26B GAGAAACATCGAAAGCGCAGCCTGCAG 0.000394997 0.01015051 6.15E−06 CCG 1745 2464725 5 KIF26B GCTGCACAATTAGAGCCAGCCCACAGGC 0.02996467 0.007436111 2.41E−06 TGTGACTGGCTATGAACTTCTCTGTCATT TTTGGGCTGCCAAACTTAAACACCCTTTC GACAAAGCTCTTCAGTCTGCTTTCCCTCT TCAGTGCACCCTAAGTCCTGCTGACATG GAAGTCATGAGATCTTCCCTGGAGAGTG ACCTGGCCCCACAGGGGACTTTGCATAA ACCA  961 2465112 4 SMYD3 CGGTTTTCCTGCCACATGATGCTGACGG 0.000740426 0.00859054 3.68E−06 ACCTCAGCCTCTCCCGGCCTTGGTGCAC ATACAACAGCCTGTAAAAGCTCCACTTT CTATTCCAGATTGCTGTTATGCGTCTGCT TCTCATTCAAAGGAAATAAGAGGAGATG TAAATCGTCGCTGTGCAGTTACGTGTTTA ATGAAAATGATCTTGCATGCTAGATTCA CGTCCAGGAGCGAGTCGCCCTTACTGCT GGTATTGAACTCACTCTCCTTGGAGCGC CCCAAGGCTGTGGGCTGTGGGGGGGCAT TAGTGTGTGTGGGCGCAGCTATTATTTGT ACCAGGA 1228 2468077 1 AGGTGAAGTTCACAAGGCCAGTGCCTGC 0.001320494 0.008632826 6.05E−06 TTCCATGGTGCCTACTGCCAGGCCTGCTA TTGCCTTTGAGATCTGACTCAGAACACA ATGCCAAGAGCTTTCTATTAGATACAAA CACCCGACTTTGGACACTCTGTTACTCAG GTTTTTTTAATCCCTCACATAGAAAAGCA CCAGAGTTGTCACCATACAGA 1438 2468096 1 TATTGGCTGCTGAGAGCCCTCCAGAATG 0.00199727 0.006948306 3.18E−06 TAGACGTCTGGTCTGGGGAAACTCAATG GATTTCTGTTCTTGGTACACGCACCCACT TATGTGTTCATGTCCCACCCCCCATCCTC ACAGCCATTACATGAAAGCATCTGAGTG TTGTACAAGGTTAAAGCTTTTTGTGTTAA TCTATCCCATATGGAGCAGGTATTA 1499 2468976 2 IAH1 TTTCCTCAGGCTTAAACCTTTGCCACTGA 6.79E−05 0.009755437 5.56E−06 1773 2469870 9 GREB1 ACTTCGGGCTGTCGGAGTTTATTGAATCC 0.005601625 0.007192075 3.14E−06 ACCCTTTCAGGACACAGCCTCCCCTTGCT CAGATACGATAGCTCCTTTGAGGCCATG GTCACTGCATTAGGAAAA  369 2469885 4 GREB1 GTGCCTAGGCACTTTTTATATATCAGTCT 0.004872298 0.010268236 8.27E−06 CTCCCAACCTTTTATGCAATAGAAAATA TTTATCCTGGACACATAGAAATGGATAA GGCTCCTGACCCAGGGCTCTGGCTGCCT CAGGCCCTGGTGGGTCACCTGAAGCCAC GCCTGCAAGCCACCCAAGGTGTGCTGGA TGGGAGCTGTCCTATCTAGTGTCCTATTT A  660 2470495 2 FAM84A TCACTGATGGTGACACTACTTGTAATTAC 0.028813689 0.01106141 8.18E−06 TGTATTTTTTGGCAGAACACTCAGATGA ACAGATTCCTATGCTGTGGACTTTTATCA TTCTTTTTGATGGCTGATAGTAGAAAGC ACACAGTAGGTACTCCATAAATGTAAGA CTATGGCAGCTGTCTAGTACAAGTGCTT CTCACTGATTCTTGGTTACCAGGAAAAC CAGAAAGCCCGTCACTTGCCTTGCCTGC AAAGGCGAGCCTAAAG 1270 2470675 9 DDX1 AGCTTCTGATAATTGGAGGTGTTGCAGC 0.000126422 0.011859396 8.45E−06 CCGGGATCAGCTCTCTGTTTTGGAA  807 2471816 1 ATGGATCGGATTCTGGTGCAGAGAGGAA 0.003031295 0.011034735 1.03E−05 GGTTGAGAGAAATGGAGGAAGGTGAAA CCAACAAGAAGTGTCCGGACACGCTAGC AGGATTTCAGCATACAGAGCTAACAAGA TGCGGGG 1190 2472863 4 KLHL29 ACCTGAAAGAACCAAGTCGCCACGACTC 0.00028481 0.008335196 6.23E−06 CCAAGTGCCACCTCAGTAAGGGACCTCA ACGGGACGACCAAGGCCCAGTGGAAGC CTCGACGGCCCTTGACCATGGAAGCTGC CCAGAGCATCTCAAATAAGTCAGCAGCC TTTCCACTGGGCCTATTC 1359 2472904 5 ATAD2B AATTACAGTGATGCGCCCCACCATATCC 7.63E−05 0.010695906 5.99E−06 CAATTAAATACCTCTTTCATAACCAGCAT CCATCAACAGAATACAGTGCCCAATAAG AAAAGCAAAACCAGGATATCTTCTACCT TAATATA  822 2473804 4 EPT1 ATGCTCAGGTGGAGTTTCATTTCTCTGAT 0.00515944 0.009520516 5.10E−06 CTATGTGCTTCTCCACTTTTGCTCAGCCA CACTGAATTTGCCTATTGTGTCCTGAATA TATTTT  604 2473817 2 EPT1 AGGAGCCTGTTATAATTCTGCAAGATCT 0.000162598 0.009646651 3.60E−06 GTGAATAGCATTATAAATCTGGGGCAGG TGCCTGTAATCCCAGCACTTTGGGAAGC CAAGGCAGGTGGATTGCTTGAGCCCAGG AGTTCGACACCAACCTGAGCAACATGGC GAAACCCCGTCTGTAATAAAAATACAAA AAAATTAGCTGGGCATGGTGGCATGTGC CTGTAATCCCAGTTACTGGGGAGGCTGA GGCAGGAGAATCACTTGAACCTGGGAGA TGGAGATTGCAGTGAGCAGAGATTGTGC CACTGCACTCCAGCCAGAGTGACAGAGC AAGACTCCATCTCAAAAAATAATAATAA AAATAAACAAATCTGTTTAAATTACTGT TGCCTTTCAGCATTAGACTTTGAGTTTAA TAACTACAAATTGAGACTGCTCACAATA TTAACTTTTTTTGTAGGTTATTTTGTTGTT TAGATAACTTGCCTCCCTAGAGGAGCAT TCAGGAGATAAAGACCTAGCTACATGTA ATGATATGATCATTTCAAAAATGTGCCA AGAAAGCAAAATTCATTATTGAACTCTA AATTTCTGGGTGTTTTTTTTTTTAAAGTA GCATTTTCTCTGGGTAAAGGGAAAGGCA ATGAATGATTGCCAACATGTAAACTCCC TGCTGCCCGCCTTCCCCCAGTCCCCTCCA TCTAACATAATACAGTAAATTTGTAGCC AGTTGTAGAAAAAGAAATTGATATCTTT CTGAGTAAGGTTTCATGCCCTGTGACTA AGAATAGGTGGAGGAATCATGGCCAAAT CAAATATGAATTGTTTAGCTTGGTCCTGT TGCAGTTGGCTTTCTGTAGTGTTCTGAAA CAAGAGGACGATTCCATTCCTTCTCAGG AACCTAGAAACAACACCGCTTGAGCAAC TGGAATATGTTTGCTGCAAGCAGAATAT TTTGGGGAGAGGAAGAGTAGTTTAATTC AAGTAGTTTAATTGAACATATTAGTCATT GGTCTGTCTGGGACGTGCAGTGTTCATA GTAGCAATGTATGTACCATTTATTTTATC TGGTTGTGTGTGATGTGTGTGTATGCCTA TTTAATATGTACACATATATTCACTACAT ATGTATGTATGATATATTCATATATACAT GCAGTCTGCTTGATTATCAGCAAAATGG TCAGCCTTTATCAGATAGTTTCTTCATGT GGAGTTCATCTGCATGTGGCCCTTACTCT GAAGC  740 2473976 2 C2orf18; GTGCATAACACACCTGGGTAACTTTTAT 0.000228432 0.008345388 4.46E−06 CENPA AGAGATGGGGTTTCACCATGTTGGCCAG GCTGGTCTCAAACTCCTGACCTCAGGTG ATCTGCCTGCCTCGGCCTCCCAAAGTGCT GGGATTACAGGCGTGAGACACCACACCC AGCCATAACTAAGCATTATGTTTTCTAA AACTTCTAAGATCCTCCCTAAACCCGTCT GGAGACATGGGTTTTAGCCCAGACTCTG CCTCAAACTCATTGTAGCTCCCAGCACA TTACCCAGTTGCTCTGGGCCTTGGTGTTA TGCTCTGGGAAGTAGATGTTGATGCTGT GGCCTTAGTGCCTTCTGGCCCCAGCATTC CATGGGCCTGTGATCTTGACCAACCTGA GAAAACAGTAACAGCCCATCCACTGGAA ATA 1033 2473979 2 C2orf18; CTGGGCGTTGCGTTAAGTTGCTTAACTTT 0.001106343 0.006681413 3.51E−06 CENPA CATTCTGTCTTACGATAGTCTTCAGAGGT GGGAACAGATGAAGAAACCATGCCCCA GAGAAGGTTAAGTGACTTCCTCTTTATG GAGCCAGTGTTCCAACCTAGGTTTGCCT GATACCAGACCTGTGGCCCCACCTCCCA TGCAGGTCTCTGTGGGGTCTTTGGGATG GATCTCCTAGGGCTGGGCTGGAAGCCTC ATGTACTGTTGTCTTCTAGGTAACCACCC TGAAGAGAAGGGGTGGCATCAGGAACC GCAGGGAACCAAGCAGCCTTTGGTCCAG TGCTGCTCCTTGGAACAGTTGAGTGTGG CCTCAAACCATTCTCCTGGGTAGCTCAGT CATAAAACACCGAATGCCTGCCTCAAAA TAGCCTCTGAGGGAAGGGAGCTGTTGAC AAGTGAAGCCCTCAGGTTGTGTGGGATT CCAGCAGGTTATTACAGCTTGTGGGGGG AGGGAGGGTCCATTCCACCAGCTTT 1926 2474461 4 TRIM54 GGGCCATTTGTTCTTGACCGACTTCACTC 2.15E−05 0.006718124 3.84E−06 CAAGGATCTGGTGTGGGCCAAGGCTAGG GAGTGGGCAGAAGGCGATGGCTGGTTGG AGAGAAGCCAGGCCGTCTAGTGGGGGA GGATGGTTGGAACATAGCATTGAAGTGG GCTCGGCTTTCAAGCTGCATACGGTGGC CCAGTG 1650 2475693 2 LBH; AGCAGTGGAGCCCTCTGACAATTTGCAA 2.46E−05 0.010241028 5.98E−06 AC104698.1 GGCCCTCTGAGAAAGGAAGCTGCTTAGA GCCAGGGGGTTAGTGGGTGAGGGGAGC GAGTGCTGTTTTTGAGATCATTATCTGAA CTCAGGCAGCCTAGTAGAGGCAGTGGTG GGATTCCAATGGGTCTTGGTGGGTGGGA GGTGGGGCATGTGCAAAGCAAGCAAGG AACATTTGGGGTAAGAAAACAAACATGA GGCAAAAGAAAAAATACATGTTTTTAAG AAAACATTGAGCAGAGAACTGCAGCCA GGATGCGCTCAGCAGACATTCACTCTGG CTGCTGGGACATCAGAAAACAAAGTCTT CATCTCTCTCTCCAGTTTCACCCACCCCA CCCTTTGCTTTCATTTCAGGTGTGTTGGT CTATATGACAGGGAGGAGAGTAAAGGA GAGCAGGAGCAATTGGCTGCCTGCAAAG CCAGCTGGAGGTGAAGTGCAGGAAAGG AAAGGTCACCCCATTCTACTCCATGGCC TCTCTGCTCCCAGCTGTGGTAGGCTCACA TAGCCAGTGTGATCGGTTTTTAAGAGGC AGTGCTTTTCAGCTTTTCTCCCTGATATA TCCATTTTGCTTCCCAGCACTTTTTAGGA GTAGTGAGAGCACTTCCTGCCCTTGTTG GAAGCCCCAGGGTGGACACTCAGCACGA AGGTCTCTCCCTTAACTGCTGCCCTTCCA AGACTTGCTCCCGAGATGGAGTGGGCGT GGTCTTCCAGGCTGGCCCTTCCTTCTCCT CACCGCCACCTTCCCTGCCCCAGCCCCA GCAGCCATGGGTACATGGGTCCCCAGCT CACCTATGGATTCCCGCCAGTCTGCCCA GCTGCAGTACTCACGCCCCATGGGGGAT CTTGGTCTGTTTTTCTTGTGGGAGCCTAG TGGAGAGCAGACGTGGCTTTTTATGTGT CTTGTTGGGGAGGTGACTTGCATGGTGG GGACAAGGCTGTCGTGGCAACCTTGGGA TCGAGTTTGAGACTAAAGGATGTCATGA GATCCCTGGCTTCTCCCCATGTTGTTCCC GGACAAGGGCAGAAGGGAGGCATGGCA AGGGACCTCTGCTGTCCTTACTCAACAG TGGTCCTCATCCCTCCCCACCTCCCACTG CTTCCTGCAAGGGCACCAGTTGTATGAG AAAGTTGGCCTTTGGACTTAGGATTTCTT ATTGTAGCTAAGAGCCATCTGAAGCAGC AGGTTGCAGGACAAATGCTTCAGTCCGC CGAGAGCAGTACCGTGTGGCCAAGAGGT GGACTCAGAGCCTTCCTTGAGCTAAACT CGGCCAACCAAGGCACGCAGCATGTCCC CTCAGGTCTCCAGTCAGTCCAGGTTG  291 2475695 2 LBH; CCCTAGACCACTTTGTATGACCGTTTGCA 9.56E−07 0.016675474 1.27E−05 AC104698.1 GTCTGAGCAGGCCAGGGGCTGACAGCTA ATGTCAGGACCCTCAGCGGTGGAGCCTG CTGGGGGGACCCAGCTGCTCTTGGACAA GTGGCTGAGCTCCTATCTGGCCTCCTCTT TTTTTTTTTTTCAAGTAATTTGTGTGTATT TCTAACTGATTGTATTGAAAAAATTCCTA GTATTTCAGTAAAAATGCCTGTTGTGAG ATGAACCTCCTGTAACTTCT 1191 2477478 1 TCTCATGGCTGAAATCCGATGAGGCATT 0.000269075 0.00759234 2.13E−06 GGACCTCCTCACGCAGAGTCTTTGGATG CTTCTGTCTGAGCCTGAGCAGTGGGCCA GATGGACTATCGGTCTGCCTCA  857 2480873 5 CALM2; CAGTCAGTCCAGAGCACATGAGATCAGC 2.34E−05 0.007532819 2.91E−06 C2orf61 T 1481 2483422 1 AGGAGTGTCAGGCTCGACGATCACCTCA 0.000297559 0.008805039 2.45E−06 ATGCAGGGCAGATCCTGGGGATGCACTC TCCAGCGACACCGCACAGAGCTTCTTCC CG  641 2484202 5 BCL11A CTCAGAAGACAACCTGGATGTGACCGAC 0.015223504 0.008222288 7.55E−06 AACTTCTTTGTGATGGATCTGAACAGCCT CCCTTGGTTCTAGCAGAAGGACTTACC  732 2485722 2 CEP68 GCTGAGCTCTTAGCCACTACCCTTGGCTG 0.000146537 0.008285681 2.36E−06 CTTCCTAACTCAGAGGTATTCTGAACAA AAAAGGTTTTGTGCACAGATGCCTTTAG GAAACACTGGGCTAAACAAAGGTAAGT GGCTTTCTTGACTGCAGGACTTCTAGAG CTTCATTTGCCACAGTGGTTTAAGTGCAA AGTTAGGGGCATTGGATGTACTGTTGCC TAGACTTTGTGGCCACCGGACCATCTTGT GAACCAAATGA 1594 2487212 2 ANTXR1 CTGGGCTCTCTCAGAAACTTCAGGAGAT 0.006898401 0.008932501 1.10E−05 GTTAGAACAAGTCTTTCCAGTTAGAGAA GAGGAGTGGTGATAAAGCCCACTGACCT TCACACATTCTAAAAATTGGTTGGCAAT GCCAGTATACCAACAATCATGATCAGCT GAAAGAAACAGATATTTTAAATTGCCAG AAAACAAATGATGAGGCAACTACAGTCA GATTTATAGCCAGCCATCTATCACCTCTA GAAGGTTCCAGAGACAGTGAAACTGCAA GATGCTCTCAACAGGATTATGTCTCATG GAGACCAGTAAGAAAATCATTTATCTGA AGGTGAAATGCAGAGTTGGATAAGAAAT ACATTGCTGGGTTTCTAAAATGCTGCCTT CCTGCCTCTACTCCACCTCCATCCCTGGA CTTTGGACCCTTGGCCTAGGAGCCTAAG GACCTTCACCCCTGTGCACCACCCAAGA AAGAGGAAAACTTTGCCTACAACTTTGG AAATGCTGGGGTCCCTGGTGTGGTAAGA AACTCAACATCAGACGGGTATGCAGAAG GATGTTCTTCTGGGATTTGCAGGTACATA AAAAATGTATGGCATCTTTTCCTTGCAA ATTCTTCCAGTTTCCAAGTGAGAAGGGG AGCAGGTGTTTACTGATGGAAAAGGTAT GTTGCTATGTTGATGTGTAAGTGAAATC AGTTGTGTGCAATAGACAGGGGCGTATT CATGGGAGCATCAGCCAGTTTCTAAAAC CCACAGGCCATCAGCAGCTAGAGGTGGC TGGCTTTGGCCAGACATGGACCCTAAAT CAACAGACAATGGCATTGTCGAAGAGCA ACCTGTTAATGAATCATGTTAAAAATCA AGGTTTGGCTTCAGTTTAAATCACTTGAG GTATGAAGTTTATCCTGTTTTCCAGAGAT AAACATAAGTTGATCTTCCCAAAATACC ATCATTAGGACCTATCACACAATATCAC TAGTTTTTTTTTGTTTGTTTGTTTTTTGTTT TTTTTCTTGGTAAAGCCATGCACCACAG ACTTCTGGGCAGAGCTGAGAGACAATGG TCCTGACATAATAAGGATCTTTGATTAA CCCCCATAAGGCATGTGTGTGTATACAA ATATACTTCTCTTTGGCTTTTCGACATAG AACCTCAGCTGTTAACCAAGGGGAAATA CATCAGATCTGCAACACAGAAATGCTCT GCCTGAAATTTCCACCATGCCTAGGACT CACCCCATTTATCCAGGTCTTTCTGGATC TGTTTAATCAATAAGCCCTATAATCACTT GCTAAACACTGGGCTTCATCACCCAGGG ATAAAAACAGAGATCATTGTCTTGGACC TCCTGCATCAGCCTATTCAAAATTATCTC TCTCTCTAGCTTTCCACAAATCCTAAAAT TCCTGTCCCAAGCCACCCAAATTCTCAG ATCTTTTCTGGAACAAGGCAGAATATAA AATAAATATACATTTAGTGGCTTGGGCT ATGGTCTCCAAAGATCCTTCAAAAATAC ATCAAGCCAGCTTCATTCACTCACTTTAC TTAGAACAGAGATATAAGGGCCTGGGAT GCATTTATTTTATCAATACCAATTTTTGT GGCCATGGCAGACATTGCTAATCAATCA CAGCACTATTTCCTATTAAGCCCACTGAT TTCTTCACAATCCTTCTCAAATTACAATT CCAAAGAGCCGCCACTCAACAGTCAGAT GAACCCAACAGTCAGATGAGAGAAATG AACCCTACTTGCTATCTCTATCTTAGAAA GCAAAAACAAACAGGAGTTTCCAGGGA GAATGGGAAAGCCAGGGGGCATAAAAG GTACAGTCAGGGGAAAATAGATCTAGGC AGAGTGCCTTAGTCAGGGACCACGGGCG CTGAATCTGCAGTGCCAACACCAAACTG ACACATCTCCAGGTGTACCTCCAACCCT AGCCTTCTCCCACAGCTGCCTACAACAG AGTCTCCCAGCCTTCTCAGAGAGCTAAA ACCAGAAATTTCCAGACTCATGAAAGCA ACCCCCCAGCCTCTCCCCAACCCTGCCG CATTGTCTAATTTTTAGAACACTAGGCTT CTTCTTTCATGTAGTTCCTCATAAGCAGG GGCCAGAATA 1005 2487217 2 ANTXR1 ATGACGAGACCCTTGTTTGCACAGCATT 0.000374519 0.013610335 2.20E−05 AATAAGAACCTTGATAAGAACCATATTC TGTTGACAGCCAGCTCACAGTTTCTTGCC TGAAGCTTGGTGCACCCTCCAGTGAGAC ACAAGATCTCTCTTTTACCAAAGTTGAG AACAGAGCTGGTGGATTAATTAATAGTC TTCGATATCTGGCCATGGGTAACCTCATT GTAACTATCATC 1684 2487383 4 AC092431.1 GCAACAGTATGTTCAATCCCATGTGCTCT 0.000701725 0.007954263 5.49E−06 TCCAAAAACCCTACCCCCTACCTCAATC AAGAGATGGCATCTATGTCCTTTCCCCTT GAACCCAGGTAGGCTTCTCGGACGGGTT TCTGTGACTGCACCTCTAAAGTAATGCT ATGTTGG  432 2488699 4 SMYD5 TTGCCCAAGACGTAAGACCTCTAGTTGT 7.87E−05 0.015768425 1.14E−05 CTGTTGTCTGCTCTCAGCGTCATCATATT GATCTAGTTTTCCAGCTCA 1395 2489016 4 ACTG2 CCTGGCTGATTTCTTGGTCTCTTGCCCTC 0.022775596 0.007854953 6.38E−06 ATTCACCGAATTAATTCTCTACACTGCTG CAAAACTGATCTTTCTAAACACAGGTCA GCTCATGTCACTCACCTCCTCAGAAATCT TCAGTAGCTCTTCATTAACCAACAGGGG GTTCCTAACTCCCCGTCTTGGCATTGGAG GACCTTTCCCTGCCTGATCCCCGCGATCA TCTTTTCCTGCAATATTTACTCAGGCCAG TGCTCACCCCTTCTTTAAAATGCTGGTGC TGGCTCAAGAGAGGCAAACAGCCATCTC TCTCATTCTTATCTTCCCTGTCAAGACTT CACATAGGTGGACTGATGCTAGACTATG ATGATGAGTCTCCAGTGAAAGTTTCTAA GTAGAACTCTCTCAGGGTTTCTAGAAGC ATTTTTGTTTAAGAAAATATTGTGGGGG GAGCGGGATTTTTAAATGGTGGAGCTCA TGGTAAACAAAATTATGTGTGCAAAATG TTAATAGAGCCTTTCTAATATTCTTGTGA TTAACTCTGGTGACAGTTGGCTGAGTGTT CTTGTTTCTGCAACGCCTGTCTTTG  982 2489925 1 ATCTGTGTGACCCTGTTCAGACATGCAT 0.004689092 0.006770824 1.87E−06 GCCT  169 2491288 2 TMSB10 TGGGAGCACCAGGATCTCGGGCTCGGAA 1.18E−07 0.02981693 4.03E−05 C 1034 2492588 6 GTCAGGGGAGGGACTTATATGATTTGGA 1.82E−05 0.009689749 6.82E−06 TCTGTGTCCCCACTCAAATCTCACACCAA ATTATAATCCCCAATGCTGGAGGTGGGG CCTGGTGGGAGGTGATTGGATCATGGGG GCAGTTTCTTATGCTTTAACAACATCCCC CTTGGTGTTGTCACAGTGACAGTAAGTT ATCACAAGATCTGGTTGTTTAAAAGTGT GTAGCATGTCCCTCTGTC 1538 2492639 6 AGGGAAGCCAGGTTGTTCATGGACATTC 0.00115456 0.007687908 5.59E−06 AGTGGAAGAATTAAGGCAATTAAATGTT AAGTTTTGCAGGGCTGGTCGACAAGAGA A 1697 2496842 9 MAP4K4 GACCGCACTGGCCAAAGAGCTTCGAGCA 0.000896506 0.006816041 2.44E−06 GTGGAAGATGTACGGCCACCTCACAAAG TAACGGACTACTCCTCATCCAGTGAGGA GTCGGGGACGACGGATGAGGAGGACGA CGATGTGGAGCAGGAAGGGGCTGACGA GTCCACCTCAGGA  719 2500274 4 BCL2L11 CCACGGCCTCTGTCTCTTAGGGCGACTG 0.000106893 0.013001365 7.72E−06 GGCGCGGAAGAAAAGCTGGAGAGCCCC TGCGGGGTGGCAGGAGGAGGGTGCCTG AGTCCCGCGAGAGGCCCGGGCGAGGAA GATGCGCAGCCTGCTGATCCGCGTCCCG CCCGGCGCCAGGGACCCTCAGAGGGAG GAGAGCTCAAAGACCTCGCCCCGCGCCT TCGCGAGGACCAACCCAGTCCCCGCGCC TGCCCCAGAGCGGCTTAGAAACTCAGGG CACAGTGAGAGCGCAGGGCGCCTCCC  129 2500383 6 GGAAACCGACCAGACCAGCCCATGACCA 0.000862602 0.031191838 3.41E−05 AAATATCACAGGCAGACCACCCGCAAAT GCAGAGGCCTCAGAGTCCACAGTGGGCA GTTGGAACCAGGCCCCAGGGAATCTTTC AGCTGCATTCCGGCTGTGATCGGCGGGC AACAGGTAGAGGTGCTGGAGGGGGATG AGTCGTGATTTTCAGTGTCTGTCATATTC GATCAAGTGTG 1098 2500950 4 SLC20A1 TCTGCCCTTTTCATCGATGTGAAGGCTGG 0.016212799 0.007999574 6.76E−06 GTTAGCAAGTTGAAGTTTATCGTTTCGA AGCTGAGGGATGCATAGACTGCAGTGGT GTTAGGAAGAACGCTGCGTCACCGCAGC TGAACCGAAGAGCCTCCGAGAGGTTCTG TGCTAGTCTGGCTGTGCCGAGTGCACGG TGGGAACCAGGCTTTCAGGACTCTCTGG CCTCATTTTCCCTCTCTGGGAGGAGTTGA GACAAGTCTTGCTTTATGTTAGTCAGTCT GTAGTTTGACTGAGGTGCCTGGATGGAT AGGTCAGCATACTG 1080 2502419 1 AGGCTGAGAATGTGGATCGTCCTCCGAA 0.009101689 0.00713435 5.92E−06 GACGCTGTCCAGGGAAGACCTGGAGTGA ATCATGGGCCAAGGGTGGAGGCCAAGTT ACGGGGACAGAGAGGCGAAGACAAGGG CAGCAGTGCCCACAACAGGAATTCCTAC CCTTCAACTTTGTTCATAGTGGTCCCTAC TTTTA  942 2503248 1 CTGGAACTTTGAGCCCCAAACCTGGTGA 0.032905271 0.009185376 8.32E−06 CCCCACGAGCACCTCGCACTTCTTCACTT TTCCTCGGTTTTACATCACAT 1587 2504114 4 CNTNAP5 CTGCGCAGTCCAGCCTTTCTCCTGTTGGG 0.020351547 0.006559961 4.15E−06 TGATGCTGCTAAGCATGCTCCCAGGATA GAGGAAGCATCTGCCATGCTTGTGGGTA GACATGGGTTACTAAGTAACA 1404 2504466 1 TGGAGACCACCACTGTCCACGTGCGCAA 0.001732949 0.007924953 6.78E−06 AGCGACGTCCCAGTTTCCTCACGCGTGG GCTGCAGCTT 1730 2505547 3 PTPN18 TATAGGTTATAAGTATAGCTGCCTGTGCT 0.033429032 0.007152644 5.39E−06 TCCACCACGAGCACCTGGGGTGTCTTGT GGCATGATTGAGCTAGCTCTGAAGCTGA CTCCCTCTTC  736 2508938 5 ZEB2; GCCATTTTCATAGCGGGAGTGGACAGGT 0.000595218 0.008601963 6.26E−06 ZEB2; TTTCAAAAAATTCAAAGTAAGTGCTATA AC009951.1 GTTATTTTCTTTTCTTTTTCTTTTTTTTTTT TATCACACTCCTAAAACCAAGTAGAAGG GGAATGCTGGGCTTTGTACTGGATAATG TGAGTCCCCATGTAAATTGTGAGCGATT GCAAAGTACGGAAAGGTTTATTACCTAA GGTGAGCCCTCCCAGAGCTCCCGGAGTA TAAAAGCATTAAGCGCATGTTCTAACAA AC  302 2510012 4 LYPD6B TGCTCAGATGCATAAGGAATACCAGTAA 0.001713115 0.010465528 8.12E−06 AGAACATATCACCTACTTTTTCTTTGCTT TTGAGAGACTGCTCTATTTTTTATCTTGC CTAGTGTTCTGATCCCCTTGGTTGTAACC ATAAGAAAATCTGATGAGAATTATGTAG GCCATCTGCCCTAACTTCACAAATGAGA GAAAAGGAGACTTTACCTGGGGAACCTC ATCTCTTTTCTGATGAAAAATGATGAGT AACCCGTGATTGCTTGAAATACAATGTT GAATGGGTGAATAACAAAGGGCATGTG AGATTTGTGGGGTTGCTTGCATGCTTCCT AAAACTCAGCATATATGGCACATCCTTT AAACAGAAAAAGGTCCTCTGCTGGTTAT C 1633 2511767 4 UPP2 GGTAGCTGATTTCCGCCTGCAAATAGCT 0.000134132 0.009381362 4.93E−06 CTCCCCCAGGCCACTGCTGCAGCCTTTCA TGGAGTAGACCCCTTCTA 1883 2512731 9 PSMD14 ATTGATGCCTTCAGATTGATCAATGCTA 2.46E−05 0.008283694 5.51E−06 ATATGATGGTCTTAGGACATGAACCAAG ACAAACAACTTCGAATCTGGGTCACTTA AACAAGC 1140 2514422 9 BBS5; CTGGCTGGATCTCTGTATGCAATTGGTG 0.000293755 0.012231572 7.96E−06 RP11- GTTTTGCTATGATTCAACTGGAGTCTAAA 724O16.1; GAATTTGCACCCACTGAAGTCAATGACA KBTBD10 TA  241 2514660 9 UBR3 GAAATCCCTGGCCTCCATATAAGAAAAG 0.043299568 0.009434778 9.95E−06 GACATCACTCCATCCTAGCTATAAAGGT CTTATGAGACTTTTGCACTGTAAAACTTT ACACATTGTGCTATTCACTCTGC  303 2515814 2 RAPGEF4 TGTGTCTTCAAGCTTTTCCATGGAGTGGC 5.13E−05 0.012849118 1.19E−05 AAAATGATTCAAATCCAGAAAGGAAGG GAGTGAAGTTATTAGGAGCTAACTA  849 2516546 8 ATF2 AAACATCTGTTATCATGGGCTGGGCACA 0.049782645 0.008503428 5.55E−06 GTGGCTCATGCCTGTAATCCCAGCACTTT GGGAGGCCAAGGTGGGTGGATCACGAG ATCAGGAGTTTAAGACCAGCCTGGCCAA GATGGTGAAACCCTTTCTCTACTAAAAA TACAAAAATTAGCTGAGCGTAGTGGCAG GTGCCTGTAATCCCAGCTACTCAGAAGG CTAACGCAGAGAACTGCTTGAACCCGGG AGGCAGAGGTTGCAGTGAGCCGAGATCG CGCTACTGCACTCCAGGCTGGGTGACAG AGTGAGACTCTGTCTCAAAAAAAAAAAA ACACCAATATCTGTCATCATGTAGGCAC AGCCAAGGTGAACTGAAGCAGGATACG AACACTCAGTACATTCATGACTATCTTCA TACATTCCTGAAATGATCCTAGAGATCA CCTTGGGAATAGCAAAGTGGTCATA  170 2518113 8 AC009478.1 AATAAATCTGTGAGGTCTCCCATCAACC 3.25E−07 0.026250826 2.61E−05 TGAAAG 1251 2518123 1 TGCACCTGTTTAGTTTGTGACAATCTGAG 6.28E−06 0.013391344 1.23E−05 CCCAGTACATGGTTCTCTGATTCCTAAGC CAGGAGTCTCTCTGTAACCAAACTGCTA TTATGTGAGCATAGAACAGCTCTCAAAG TAAATGTCCCACTTCTATTTCTGGCAGGT TATGTTTAGCTACCTTTCCAAAAGAGTCC CAATCCTAGTATGCCTTTCAACAGTGTC  317 2518126 1 CTTAGTGGGGTTTGGAACTGCCTGAGAA 2.05E−05 0.020141631 1.48E−05 TATTCCTATAGAAACTGGGTCATCTTGCC TTCTGTGCCACTAGAACCTCCTGTCTCTC CAATAGCTGCTTCTCTCTAATTCTTCACC ATAGTTTTCTTTCTGTGGTCTTTTGAGGT TCTCTCCT 1537 2518128 1 CATAGCTAGGCAGTGTTGGAGATCAGCA 0.000144203 0.008894878 3.10E−06 GGAACTAGACACAATGAATGGATATGGC ATCAATACTCATGAACATGCCATTCTTCC AGCAGTGCTTGGCAACTCAGGTTGAGGA ACAGAGAAGGTGGATGGCTTAGGTAATG GAATTGGATGCTTTTTAAATGTCAGTGG CTGTCAAAACTGTATA 1719 2518146 1 TGGCATGACATAGCTAAAGCACTGAAGG 3.51E−05 0.00934739 5.22E−06 AAAAAGTATTTTATCCTAGAATAGTATA TCCAGTGAAAATATCCTTTAAAAATGTG GGAGAAATAAAGACTTCTCCAGACAAAC TAAAATAAGGGATTTCATCAATACCAGA TCTGTCCTATAAGAAATGCTGAAAGAAG TTCTTCAGTCTGAAATAAAAGGATGTTA ATGAATTAGAAATCATTTGAAGGTGAAA AACTCACTAATAATAGGAAGTACACAGA AAGAGAACAAAAAAACACTGCAATTTTG GTGTGTTAACTACTCATATCTTGAGTAGA AAGATAAAAAAGATGAACCAATCAGAA ATAACCACAACTTCTTAAGACATAGACA GTACAATAAAATTTAAATGCAAACAACA AAAAGTTTAAAAGCTGGGGGATGAAGTC AAAGTGTACAGTTTTTATTAGTTTTCTTT CTGAGTGTTTGTTTATGCAGTTAGTGATA AGTTATCATC 1852 2518152 1 TAATTCAGTATGCTGTCCAGGGGCCTGG 0.009120022 0.007551326 5.14E−06 AAATCACTCAGCACAGTCTACCACCATT GGCACATGAACACTTCTCCCAGGGTCTA AGGACAGGCTGACATAACATGCTAATAC CACCAGAGCTGGCACTCACCCAGATGTA CCACATCAGGCCAGGAAGCAGAAACTAC CAACATCCCAGCAAACCATGTGGAGGCC CCCAAATCAGACTGCTTGGGCCTAACA 1965 2518159 1 AATGGTTGTTCAAGCCAGGCCTGCCTCA 9.59E−05 0.006815639 4.29E−06 TTGAAAGGGTGAAATCTTCCTTCACTGG AAGGAAGTGAGAGAATTAGTCAAGCAG CTATCTGAGGAAAGAACATTCCAAGTAA AGAATATACAGCCCATACATTGTTGGAT GTGTGTACATTGAAATTTTTGTGCAGTAA AATGAATATTTCATTTACCTATATAATTT TACATAAAATAAAATATATTTTGAATGT GAGTTTGTTCCAAACAAATCATTTTCTTG CCTTCAAAACCACTGAGCTTAAAGAACT CTTTCAAGTGTCATTAGAGATAGATTCC AACTACAATCAACATTGTGGAATCCAGA GGAGGCAAAATGAAGGAAGCAGCACTC ATTACAAAATGCTGCTTTGTAAAGAATT AATTCTGTCCTGGTATGTTTCACATTAGG TAATATGAAGGAAATGAATATGTCATGA ACCCTCCTTGAGGATGTGGGGGAATTAA AAGTAATTTCGCTTAATATCCAACTCTCA CTTTTGGCTTTGTAGTCAGAGGGAAACA ATGCTTTCCCAGGTTCTAAGGTAAACGTT AAAAGGTTACAAGGAGACTTGGAAGAG TCAAGGAACGCTTCCACCAACTATTCCT GCCATTCCAGTTGGGAGGGTT  357 2518161 1 TGTCCAACAGGTGACACACATGTTAAGT 2.94E−05 0.018291423 1.92E−05 GGCAGAAATGGAGTTTGAACCATGTGTT ATGGCTCTAGGGCTCAAGCTCTTAACAC TATCCCAAGTAGGGTGGGAAAGGACAAT TTGCCTCACTC 1470 2519298 4 FAM171B GCCCAGCCTTTGGTCCCTTGATCTGGTGT 0.000281159 0.008194504 4.50E−06 CGGGAATCTGCCCTCCGGGTAATGAGCT TTCTGA 2016 2519657 2 COL3A1 CTCTTGTTCTAATCTTGTCAACCAGTGCA 4.06E−05 0.008943244 6.69E−06 AGTGACCGACAAAATTCCAGTTATTTAT TTCCAAAATGTTTGGAAACAGTATAATT TGACAAAGAAAAATGATACTTCTCTTTTT TTGCTGTTCCACCAAATACAATTCAAAT GCTTTTTGTTTTATTTTTTTACCAATTCCA ATTTCAAAATGTCTCAATGGTGCTATAAT AAA 2051 2519667 5 COL5A2 TGTCGATGTGTCTTGGCTTACTTTACACA 0.000620704 0.007056377 5.54E−06 AAACAAACTGGCCCAATTTCAACGCCGA ATTCCTGGTCTGTGCCGCCAACATCCAC AGGAGCAAGATCTATGATGGGCAAGCGT GCCACATTCTGTGTTC 1620 2521265 2 CCDC150 TCTGCCTCAGAGACTCCCTGATTGGCCCC 0.01434388 0.007186124 3.87E−06 TTTTCTGAGAGGATGTGCTATCTCTGCAG T 1321 2522030 4 C2orf47 GTACTGCCATATTCCACATGCCCGTTCCC 0.000509079 0.007679796 4.01E−06 TCACGTGGTGTGTAGGTCCTGGGGATGT TAAACACTTATGGA   84 2522842 7 ALS2CR4 TGTCCAGCAGCTCACTCTGTTCTTAGGGT 0.003428273 0.021356529 1.53E−05 TCATGTTATGCAACATAAAGTACACAGC ATCACAGATGAAGTCATATTTTTTTAAA AAATCTAATCAAACCACCAGACCTAACC TCCAGTCTATAGGAAATTCAGGAGATTG AGGAACAAATTAAGTGATGTCATTAGGA AAAAGTCAGACAATTAAAAAATGTAGGT GAGGCACTCTAAAGCAACTAGCTTGGAC TCTTCAAAAAATTGTCATGGGAAATTAG AATGGTACCGCCAACTCTGGAAAACA  492 2523250 9 BMPR2 GGCCAAGCATGTTTGATTCCTGATGTTCT 3.28E−05 0.012246342 1.00E−05 GCCTACTCAGATCTATCCTCTCCCCAAGC AGCAGAACCTTCCCAAGAGACCTACTAG TTTGCCTTTGAACACCAAAAATTCAACA AAAGAGCCCCGGCTAAAATTTGGCAGCA AGCACAAATCAAACTTGAAACAAGTCGA AACTGGAGTTGCCAAGATGAATACAATC AATGCAGCAGAACCTCATGTGGTGACAG TCACCATGAATGGTGTGGCAGGTAGAAA CCACAGTGTTAACTCCCATGCTGCCACA ACCCAATATGCCAATGGGACAGTACTAT CTGGCCAAACAACCAACATAGTGACACA TAGGGCCCAAGAAATGTTGCAGAATCAG TTTATTGGTGAGGACACCCGGCTGAATA TTAATTCCAGTCCTGATGAGCATGAGCC TTTACTGAGACGAGAGCAACAAGCTGGC CATGATGAAGGTGTTCTGGATCGTCTTGT GGACAGGAGGGAACGGCCACTAGAAGG TGGCCGAACTAATTCCAATAACAACAAC AGCAATCCATGTTCAGAACAAGATGTTC TTGCACAGGGTGTTCCA 1635 2524751 4 FASTKD2 GACAGATATTTGCATCGGGATGACATCT 0.000873066 0.00892817 5.63E−06 GTG  915 2527797 3 CTDSP1 CGCACTCCCTATGTGGGCGCCTTAATAC 0.00051035 0.00707731 4.80E−06 CTGCTAGACCTATTTGTCTGGGAGCTGC AGGAGCCTTGCAGTTGATTGTGGAGCCC TGACAGGGGCGTTTCAGAGAAAGTCAGG AGCTGCCTTCGTGTGTCTGGATGAAGGG GCCACGGCAAGATCCTCCTGGCTCAGGG GTTCACACCTGGGCACACATGCAGGATT CTGCAGGCCAGTGTGCACCGAGCCTCCA ACTTGT  198 2528111 9 CYP27A1 AGCTGATTGATGAGAAGCTCGAAGATAT 0.006771364 0.012183336 1.06E−05 GGAGGCCCAACTGCAGGCAGCAGGGCC AGATGGCATCCAGGTGTCTGGCTAC 1455 2529187 5 EPHA4 ACCACCCTCGCTGGACTCATCATCAAAG 0.001895132 0.006902755 5.45E−06 TAAAAAGTCAGCTCCACCCCCAACAGCT TTTAGTTGCTACATCATGCATCCACAC  850 2533263 3 TRPM8 GTTGATATTTCCAAGCTGCTGATGTCCC 0.006310467 0.008441188 3.54E−06 1064 2533688 4 AGAP1 TTGTCTGTGCACCACTGCGGAACTGTGA 0.005613406 0.008401337 5.08E−06 GCTCCCAGAGTGCACAGATATGTGCCAG ACACCAAGATCAGAATGGGTGCTTCGCA GTGCTCAATACATTATTTATTGAATGACT TAATGTAGAATGACTAGTTACACAGTTC AGGTGCTAGGAGGCAGTATAAAAGTCAG AGAGCAAATGCTTTAAGAAACTGTAGTA TACACCAGGAAATGCAATTCTTTAGTTA GATACCTTCTCCTTTCAGTAAAATTATGT TCAGTGCTGTAAATAGGCAACTTTCAGT GATTTGTTTTCAAACAAGTGGCTTTTTA TCTTTTCCTCTTGACAGTGAGTGTCTCTC CATGTGTGAAGTATTTTCTCCTCTCATAT CTGTGAAGTCCTGCTTGTAAGTGTTTCGG TTATGCAACATTTCATGGGGAATTTGAG CACTGGAATTCTTGGTCGCTAGTTAGGT GGGTCTTACCGCA  682 2534019 2 CXCR7 AGCAAAGTAGCTTCGGGTCTTGATGCTT 0.007173756 0.01141102 7.05E−06 GAGTAGAGTGAAGAGGGGAGCACGTGC CCCCTGCATCCATTCTCTCTTTCTCTTGA TGACGCAGCTGTCATTTGGCTGTGCGTG CTGACAGTTTTGCAACAGGCAGAGCTGT GTCGCACAGCAGTGCTGTGCGTCAGAGC CAGCTGAGGACAGGCTTGCCTGGACTTC TGTAAGATAGGATTTTCTGTGTTTCCTGA ATTTTTTATATGGTGATTTGTATTTAAAT TTTAAGACTTTATTTTCTCACTATTGGTG TACCTTATAAATGTATTTGAAAGTTAAAT ATATTTTAAATATTGTTTGGGAGGCATA GTGCTGACATATATTCAGAGTGTTGTAG TTTTAAGGTTAGCGTGACTTCAGTTTTGA CTAAGGA 1657 2534732 9 FAM132B GCGCGGAGCCCGAACCCTGTACGTGTGG 1.12E−05 0.009726611 8.21E−06 CCCCGCCGGGCCGGTCGCTGCGAGCCTC GCCCCGGTCTCGGCCACCG  728 2535587 1 CCAGCGGTTCCTCCAGTGACGCTGAACT 6.50E−05 0.008364795 5.93E−06 TGACCAGAT  862 2535780 4 GPC1 TCCGGCTGCGCGGTTTGCCGTCTTCGTCC 0.04726916 0.007338948 3.68E−06 CTGGCCGCGGCGGCTGGCGACTGGCATC GGGGCGCCCGGGACCCCCAGGGCGGCG ACGCTGCCGCCGGTGCCGCCGAGCCTTT GTTCCGCCGCCGGGGCCGGTTTCACGCC TGTCGCCCTCGCAAGCAGCC  354 2536222 9 ANO7 CTGAAGCTAGACAGGCAGCAGGACAGT 2.05E−05 0.014644119 1.34E−05 GCCGCCCGGGACAGAACAGACATGCAC AGGACCTGGCGGGAGACTTTTCTGGATA ATCTTCGTGCGGCTGG   71 2536223 9 ANO7 TGACCCATGACCTTGCCGCATGAGGCCT 0.000206799 0.028782637 2.44E−05 GAGGGCATGGTGTCCAGAGTCCCAGAGC AGATCAGGCCCCAAAGTCCTGCTGGACC CCCCAGCCACCGTGAGCTCCTCCGTGTG GCTAGGGAGCTGCTGTCCAGAGGCGGAG GTAAACATTGATCCCTCCTGCACACTCA GCTCTCTCATGGAAGTCGGAGCCCTCAG GGTCACCTGAAAACTCT  485 2536224 2 ANO7 TTGCCATTCACCTGTCCCGTCTCCAACAT 0.000570716 0.011820556 1.20E−05 TAAAGCTT  277 2536236 9 ANO7 CGAACCCCATCACGGGTGAGGACGAGCC 2.42E−05 0.016689851 1.24E−05 CTACTTCCCTGAGAGGAGCCGCGCGCGC CGCATGCTGGCCGGCTCTGTGGTGATCG TGGT  140 2536237 9 ANO7 TGTGCCTCGTGTCTATCATCCTGTACCGT 0.017291959 0.017903985 1.67E−05 GCCATCATGGCCATCGTGGTGTCCAGGT CGGGCAACACCCTTCTCGCAG  109 2536238 9 ANO7 CATCGCCAGCCTCACGGGGTCTGTAGTG 0.000173296 0.024766753 2.94E−05 AACCTCGTCTTCATCCTCATCCTCTCCAA GATCTATGTATCCCTGGCCCACG 1491 2536242 3 ANO7 TCTTCCATTCGAGCTTTGATTTGCAGCAA 0.012572419 0.006741049 3.26E−06 TTCCTCCCACCACCGGCTATTTCCATCGC CCAGCCAGGG  321 2536250 4 ANO7 AGAGTATCCTGTTTGGGAAGAATTCCCA 0.000142667 0.018967199 1.42E−05 TTTCAGGCACCCTCGATGAAGAGCCAGG CCAGGAACATGGGATGAGAGAGCGAAA TGGTGGAAAAAGGGGAGATAGGCTAATT CCAGA 1449 2536358 2 SEPT2 AGATGCATGATCCAGCTGTGTGTTTTCA 9.99E−06 0.009644912 8.09E−06 ATCCTTGGGAGGGTGCCATCCACATTTT AACAGTACCTGTGCCTGA 1198 2537304 1 TCAGTGAGCTGAGCATCTGCATCTCGGG 0.002329878 0.00823596 5.31E−06 GTTCTGTTGTACATGGGGTTAATACTCCA TCCGAGTGAGCTGGGCATCCGCATCTCT GGGTTTTGTGTGCGTGGGGTTAACACTC CATCTGAGTGAGCTGGGTGACTGCCTCC ATGAGTCCTGTTGTG  768 2537460 5 SNTG2 TCAGAACCTACAGCCGTGCGTGGGAACC 0.000192114 0.010858597 5.00E−06 CTCAGAGCTCACCGTGCTCCCATGAGCA GGCAGTAGGAGCACCCCCTTCAGAACCT AGGAACCCTCAGAGCTCACCATGCTCCC ATGAGCAGGCAGTAGGAGCACCCCCTTC AGAACCTACAGCCATGCCCGGGAACCCT CAGAGCTCACCGTGCTCCCATGAGCAGG CAGTAGGAGCACCCCCTTCAGAACCTAT AGCCGTGCCCCGGAACCCTCAGAGCTCA CCGTGCTCCCAGCTCCTCCACGAGGGCA GAGTCCTCTGTCTGCATCCAGCTGAACC CTGA  803 2537866 8 MYT1L TCTTGCCCTGGGTAGCAATCAGGTGGTT 0.021197932 0.006898528 6.62E−06 CATGAGTGGTGCCAACCAGTTACATTTC CTGATATGCAATACAGCTGGCAGCA  502 2538478 1 GTTTGGGCGTCATCAACAGTACTTCTATT 0.000173296 0.013636136 1.07E−05 TGTAAAATGC 1472 2539249 5 RNF144A GCAACCCAGCGTAGGGAAGAACTGCTTC 4.58E−05 0.00662945 5.00E−06 TGGACTGCACCTGAGGCAGCACCACCGG CAACGGAGCCCCGCCACCTGCTGTACCC GTCCACCTTCTCTGGTTGACCTCCCTGGG GCCAGACAGCCCACTCAGAGTCCGTGCT CCCTCCTATGG  162 2539540 4 KIDINS220 GCTGTCTCTGCTTCCTAATTAATTCACTT 2.33E−06 0.018153181 1.91E−05 TTTTCAATTATTTAGTTATATTACTATGG ACTCATGGAAATTTATTTTATCTATGAGG CATAATCCAGTAAGATCATTAGTTATTTT GTTGATTAAACTATTTTTTTGTGATTTTTT TGAACAACAAAAAATGTAAACAATTGTA ACTGTATCCAGAGCAAGGAGACTGGTTG AGGAATAAAAGCATTTGAAAGATAGAA AAGATAAATATGACTCAGCAATAAGAAG AAATGAAGGACTGGCATGTTATGACATG GTGGACCTTGAAAACATTATGTTAAGTG AAAGAAGTTGGAAAAAGGAAAATAGGA AGTTATAAGACCTGATAAGTTACAGTTC TGGTTCAGGTTTACTACTAACTAGTTATT TGTTCTGTGACTTTAAAGTCCTGATTTTG ACCAGGCTGATGCACCCTCTAAACCACA ATGAGCACATCTGTGCTGGGAAGATGCA TTTATC  258 2540638 5 GREB1 CTCCTTCTATCCCAATCGGACAGTGATAT 0.004267545 0.016181776 1.93E−05 GACCCTGGGGATGTTCCATGAATCATTT GTTCCTCTTTGGCCCCATCTGATTGTGTA CTTATCTCCTTACACAGTCCTTCTGACCT TGAAATGATCCAGAAAAGATGTAAAAG AGTAAATTCTATAGTCAGTTTAAAAGGC AGCAGGAAAGGATTGGGAAGCATTTTGG ACAAGGGGTCTAGGAGACAGGCCCAGCT CTGCACTTTTCCGTGGGACAAAGGCCTTT GCATTCTCTCCTGTA  278 2542638 8 AC013400.2 GAGGACTGGCTGACCCTTTCTTATACAT 0.00877735 0.010171152 9.08E−06 GAGGAAGTATGAGTAGGACTGGGGCGG GGGCTTGAGGCTGTTAGAAGTCAGGGGA AGTTCCTAACTGAGAAGCTGCACAGAAG TGATGGAAGTCTCATTTGGTAGACTCAG ATCTATTGGGAGATTTGGTCCTGTATTAG TCCCTTC  182 2543788 8 KLHL29 TCACGGAGGACACAAACTCACCACTGTT 1.26E−06 0.021121055 2.52E−05 CCT  722 2544499 4 ADCY3 TGGCCAAGCAACATCTCGAGACCTCTCT 0.000333956 0.012620568 6.33E−06 GTCCTGGGACTGTCTCCTCAAATTCAGA GCCGGTCAGCATTGACTGGGTGACCTGT ATACCAGGGAGAATGCTTTTACACACGC GCGGAGCCCCCCTAGGAGACTGCCGATT TTATGT  911 2545313 1 AGATATTGTTGCCACCTTCTCCACACTGC 0.001054975 0.009808729 6.93E−06 TGTGGGAGTCCATGGCATCCCGTTTGAC CCTAGGAAATGTACCTG  721 2545500 4 CGREF1 GCCAGATGGGGATGTTCCTGATCTCTGC 0.008310486 0.008345871 6.14E−06 TAGACCATCAAGCATCTGACGGTTTTTCT TTCTAGAGATGGGCTTGGGGTCTCATGC CTTGGCTTTGGTGGGCTTCTGCTTCCTCA GGAACTCACACTACCTGTACATACCCTG GGACTCACCAGAAAGCTTTAGGCTCTGT TTGATTGGTCCATTCTATCCTTGACTGTT TTCATATACTCAAGTGGTTGATTTTGCCA ATGGGCCTAAGCCATGTCAGTCTTAGGG GAAGTTTTTGTTTTTTCCTTTATAGTGGG TCTAATTTTCCTAACTGCATTTAGCAAAT AGCAATTCCTGGGGCCACTGTTGGTCTG ACCCTGATTTA 1808 2546680 5 LBH CTGAGCGCATCCTGGCTGCAGTTCTCTGC 0.000150908 0.00755128 3.85E−06 TCAATGTTTTCTTAAAAACATGTATTTTT TCTTTTGCCTCATGTTTGTTTTCTTACCCC AAATGTTCCTTGCTTGCTTTGCACATGCC CCACCTCCCACCCACCAAGACCCATTGG AATCCCACCACTGCCTCTACTAGGCTGC CTGAGTTCAGATAATGATCTCAAAAACA GCACTCGCTCCCCTCACCCACTAACCCCC TGGCTCTAAGCAGCTTCCTTTCTCAGAGG GCCTTGCAAATTGTCAGA  694 2548823 4 ATL2 GAATTCAAGGATGTTCCAGTCCCTGGAA 0.002912998 0.009530356 6.26E−06 CATGGTATAGTATTTGCATATAACCTATG TGCATCCTCCCGTACACTTGAATCTCTAC ACTATAATACCTAATACAATGTAAATCA TTGTTATACTGTATGCTTGGGGAATAATG ACAAGAAAAAATTGTACATGTTCAGTAC AGATGCAGTTAAATAATTTTTCTATTCCT GGTTGGTTGAATTCATGGATGTAGAACC CATAGATATGGAGGGCTGACTTGACTGT ATAGTGCATTGGCTTTTCAAACAGTAAA TCTGCAAAATCTAACTTGGGTCTGTTATG C 1266 2552574 1 TGATTAACATTAGAGATGGTTCTGGAAG 0.016649629 0.007187407 7.40E−06 GGTGAGTAATATGCCAATAATTAGAATA AGGCAATGGAGGGATGGAGGAATTGAT CATTCAGAGAAAGATATTCCCAATGGAG AGATACACGAAGGCAAAGGTAAGAATA AG 2053 2555538 3 XPO1 CAGGCACCTCTGACACCAAGTTGTGTGG 0.001173835 0.007493161 3.61E−06 ACAGCTTAAAACCCTACTCCATGGCATT GGGCTTCTAATGGGACAGCACTCAGTTT TTATTTACAATGGAAAATGTTATAATTCT GGTCCTTTTTTAAGTTTGAACAGAAGGG TTGATCAAAATGTGTTTTGTCTGTTTTAG GCTTGATGATTCACGCTTCTCTTTAAACT GCCTTAAAGTAATAAATACTATGGCATT CTGTTTAATACACGAAAGGTTTCCACTTG ATATAC 1439 2556553 1 TCGAACTCACCGTCCTGTACTCGAGTGA 0.001280802 0.006668129 4.29E−06 CGCACAGACACCCCCCGCCCACAGCCCA GACGCCCCCTCCCTCGCTGCCACCCCGA CCCGTCTCGGAGCTGGACTGGGTGCCGA CTTCTTCGCAGAAGG  293 2556767 4 SPRED2 TGGCTCTTGGTCTGGCCACTCACTATTTG 0.000188103 0.013452402 9.14E−06 TGAGATCCTGGCAGGAGTGAAACTTCAG TTTCCGGAGCCTTCACTCTATCCTTCTCC TGTCCGCATCTC  897 2558656 4 TGFA GGGAGAAGACAAGTAGCTCTGGTTCAGA 0.02996467 0.007536374 5.60E−06 CTGGGCCACAGCCCAGGCTCTGTCACTC AGAAGGGCCCTCCTCGAGGAGCAGGAG CAAGCTAGTGGGCTGCCA 1414 2559989 9 DCTN1 TGCCCTTCGTGCAGAGATCACAGATGCT 0.037954575 0.006518274 3.07E−06 GAAGGCCTGGGTTTGAAGCTCGAAGATC GAGAGACAGTTATTAAGGAGTTGAA 1229 2567271 4 CHST10 ATGTCCCTGGCTGTGTCAAGGACTGCCC 0.001429788 0.007566499 4.27E−06 GATGTCCTACACCTCCTG 1634 2570887 4 AC068491.1 CAGATCTCAGCTGCCGAGTGGAAACCCC 0.001219026 0.008462262 3.38E−06 ATTCTCACACCATAGCTATGGGACTGGG GGAAAGGGGAGGAAATAACTAAAGAGT AAGGAATTGGGGGAGGCTTTGAGGTTTG GATGTGACAGGTAGTTTGCATGTAGTTG GAATGCAGTAACATTGGTCCACAAGGTT 1058 2571158 6 GTGTCAGAAAATGAATCCCTCCTGCCTT 0.00022254 0.008954674 6.74E−06 ATTCCATTGTCATATCCCTTTGGGATACT AAAATCTCGGGGAGGGAAAGCCTATGTA GTTACAAATGGAAACTTCTCTTTCTTCCA TTCATTTTGGTGGGTGGGACAAAGGAAA AGAAGGTGAATATATATGTGATTGCGAA GCAGGAAGTCTGCATTTGTGTGTGAACT CCCCAAGTGATTCCCACGTGCACCTCAC TGTCCTTTCCCTACCCTACCTCATATACT TAATATGTCCTTTTAGTCTCCCAAG 1477 2571255 7 ZC3H6 CGGCCGCCGCCGACAGGTGACGAAGTGG 2.01E−05 0.007653159 2.75E−06 TAAAAACTCA  114 2572052 1 GATGTGAATTGCCACACCCTTCTGGAAA 0.000364196 0.019834692 2.14E−05 GTTATGTAGCAGTATCTGCTAAAACTTA ATATTCACATATATTAGACTTAGGAATTT CATTTTGTTGAATTCTAAAGACATAAAA ATACTGATGTCGGAGAAATCGTGATTCT GAAAGATTTTAAAATCAGAAGATTTAGA AATACATTGTTTGTTCCCAGTGCCACTAT GGCCAGGTAAATCTCAGGGGCTTTCTTA GCCCAGAAGG  776 2573159 5 AC069154.2 GCCACGCTGTGTGCAACCACTGCCACCC 0.000205715 0.0076573 4.39E−06 ATCAAGGGTATATTGAGCAC  903 2573284 1 GCGCCACCTGTAGCGAGTTATTTAAGGA 9.46E−05 0.009345976 3.05E−06 GAAGAGCTGGGCTTATGGAGGAACCGTG GAAAGATCACAGGCTATCTTCAGAGAAG CTGCTGGTGGAATTCCCAAGTCCTTACTG GGTTTGGGGCTTGATTACCCACTCAGTG CCCAGCTGGTCATCATCATGTTGGCCAA CCACCAGAGGGGA  812 2574817 9 MAP3K2 AGAGAGCTATCCAAAATCACGAATGCCT 0.000425014 0.013698999 8.31E−06 AGGGCTCAGAGCTACCCAGATAATCATC AGGAATTTTCAG 1592 2576618 6 AGTCCCGCTGGGCCCTAGACCAAGACAC 3.46E−05 0.008938034 4.32E−06 GGGAGAACCTGTGACCCACCGCCCCCTG GTTAGGGCACAGAGGATCCACACCTTGC CGTGCCCTGGACTACAGCACGGAGGGAC CCCGATCTGCCGGGCACTGGGCTCCTGC ACAGAGGAGCCCCTGCCATGGAGGTCTG GACTGTCCTTGCCCCACCGCACCCTGGA CTACTGCACGCCAAGACCCTCGCCTGAA CGCGCCCTACACTCTGGCATGGGAGAAC CCTGCCCCGCAGAGCCCTGGACTCCGCC ACTGGAGGACTCG 1985 2576850 6 TCATCATTTTGTTGCAACCCTCCTGACCC 3.58E−06 0.006932694 7.40E−06 GGCGTCTCAA  830 2577477 5 MGAT5 AGCTTCTTTGGTTACAGGGATTTTGTGGA 0.002388272 0.007909049 6.65E−06 CTTTTGTGAGCTGGCAGAGCAGGACAGG GTAACCCACCTGGACATGAGATCAAGCT CGCTGGTCCCTCTCAATGCTGTCTGATGT TGCTG 1839 2577916 9 MCM6 GACGTGCGGGATCAAGTTGCTATTCATG 3.19E−05 0.009421871 2.84E−06 AAGCTATGGAACAGCAGACCATATCCAT CACTAAAGCA  795 2577927 9 MCM6 ACTGATTCGTCCTGAGAGAAACACATTG 1.29E−05 0.013004413 6.45E−06 GTTGTGAGTTTTGTGGACCTGGAACAAT TTAACCAGCAACTTTC  675 2579064 4 LRP1B GAGATCTTCACACATGTTAAAGAAGCTT 0.016903952 0.007936997 7.43E−06 GAAAACAATGAAGAAAAACCCAGGGGA GACCGTTAGAGAGAGGGAAAGACAGAG ATGAGAGTGGTAGGGAAAAACAGTGAG GGATCAGAGCAGCACCCTGAGAGCGCAC CTGGACATCAGCCATTACACGTGAGGGG GAGGAACTTTTCTGAGTTTCCCTAAAAG GCTTAAAGTAAGGGGTTGTTGGGTGGAC CACACATGACATATTA 1368 2580293 5 ACVR2A TTTACTGAAATAAGCCATTCAATCAATG 0.001709174 0.007527767 3.54E−06 GGCAATAATCCTTGGATATAAATGCCCA GGCTTTGCCACCCACTAGGGTGACTCTA AGCCAAGTCACTTCATCTATGAATGCC 1127 2581981 1 GCCCAAGTGCCCCTACACCAGAGCACCT 0.001070147 0.011265964 9.12E−06 CTTGCTTTCAGCA 1097 2582242 3 AC021849.1 GTGCCATTGCTCCACCTGAAGTCACTGT 0.010636495 0.006584575 2.40E−06 ACCAGCCCAGAACACTAGTCTGGGTCCC AAGAAGTCATTT  677 2582451 2 CYTIP GGAACATTCCTTTCCACATCGCCTGAGTC 0.0015655 0.011798932 1.18E−05 TGACAGCCCGGATCAAAAACAAGCAGG CTTTGTGTCAAGACGTGGCACGTGTCAG AGAATTTGA 1739 2587120 1 CTGCCCTGTGAGGAGCGACCATTCTGCT 0.000260166 0.006806629 3.86E−06 CCATCTGACTCAAGACTCGGGATTATTTC AGCAGCTTGGATGTCTCAGGGCCTATCA CCCAAGAGG  194 2587539 4 SP3 CATGTATCAAGGGGAGCCTGGACTCCTG 0.009861702 0.012931293 1.26E−05 AGGCACTGTCATGATCACATCTCCCTTAC CAACCTGAATTGGACATT 1176 2589145 3 PDE11A; AGGAAGCTCTGTGATAAAGTTGCCCTTC 0.019718284 0.011752117 1.04E−05 AC011998.1 TTTCTAATGTGCTTCAGCATCATTCTTGG AATTTTTATTTGTTTGTTTGTTTCTGATGG AGATTATAGTTTTGTGACAGCTAGGCCC TTGTCTGTTGTTTCA 1794 2590293 1 CCTCTATCATGGCAGGGACTTCCCAATA 0.004699102 0.007499753 4.42E−06 AATTCTATACTCATTGTGGCCAGCTGAA CGCCTGACATTTAGTAGACTCCTCAAAA ATGATTTTTGAATGAATGATGACTGACC AACTGAATGAATGACCAATCTTAAAGCA CCAGTGAATGTTTTTACTGTCTTCACAGA GCTCAGAATAGATCCTTGGAAGCCATTC TGGAAAAGGGCAACTTTCCAAGGATGTT TTCAAAAAGACCAACATATAAGCACGTG TATTTGGTTGACCCTC 1734 2590313 4 AC009478.1 TGGCCTCTTTTCTCACTACAGCTTGTCTT 3.34E−05 0.008654695 7.53E−06 TCAGTTCCACAATCTAAGGAGGATAATA GATAGCCAGATTTTATTGGTCCCAACCA CATCGTCTTCCCCACAAACCAGCAGCTC ACTCACTTTTCTATTTTTTACGTTGGCCA GATTAGAAACTTGTGTCATCATCATCATT TTCCCCTACCGTGTCTCAAAGATCTAGG 1642 2590317 4 AC009478.1 CGCGGGTTTGTAAATAGAGTCCCTGTAT 4.52E−05 0.008749677 5.73E−06 CTGCAGGTTTAACTGGTCAGTCTTTGACA GGCTTTTAAGCAAGGACATTTCAATGAT GTGAGGAAAAAAAAAAGTGCCACAAAG CTTTGAGAATC  179 2590322 4 AC009478.1 CTAGAATTAAGATATGCTGATGAGTTGC 1.05E−07 0.023171685 2.54E−05 TTCTGCAGTTCAT 1578 2590330 1 AGCTCTCAGGTTCGTGGGAAAGCTAACA 0.007866301 0.00767295 6.39E−06 TACAA 1656 2590333 1 ATGACTGGAGTAAGAAGAGTGAAGATTC 0.000194662 0.008938714 7.05E−06 CCTCGATGCCACACC  228 2590342 4 AC009478.1 TTAGCATTTCTGTGCAGACAGCTTTTTTG 5.66E−07 0.021717658 1.52E−05 CTGTTCTTGGTCCTCAGCAATGACAATG GCTCCGAGGAGAT 1524 2590346 1 CTGATATCGGAAGTGGAATCCTGCAGGA 3.04E−05 0.009745903 8.95E−06 AGAGAAAGTGGGGCAAGGCCGAGGGCA TAAATGTGTGTTTCGAATGAGAAAAAAC AAATTGCTTATTCGGACCTCTAGCAACT GCCAATA  477 2590349 1 ATGGAATATGGAGCAAAAGGGGTCCTGT 1.31E−05 0.015351436 1.07E−05 GCT 1108 2590723 9 FRZB CGCTGGGATATGAAGCTTCGTCATCTTG 4.39E−05 0.00810083 4.99E−06 GACTCAGTAAAAGTGATTCTAGCAATAG TGATTCCACTCAGAGTCAGAAGTCTGGC AGGAACTCGAACCCCCGGCAA  836 2591456 4 TFPI GGTGACTGCCTGTATCAAATCTTTACTGC 0.009724683 0.007478175 2.86E−06 CTTTTTCAAATTCTTACCATTTTTATAAA AAGGAGTCACACTACTCAATCTATACAT CAGTGTTAAATATGATTTTTACTAATTTT TTTTTTTTTTTACCAACACTATCTTAAAA AATCTGACAGCATAGAGCAGTGATTAAA GGCATTTGCTTCAGGGTCAAATATAGTT ACACTGCTGTTTTTTGGACAATTTGTTAT TTTGAACCATTGTTTCTTACCTTTATAAA ATGAGCATAAGATAATGTTCTTTTAAGG TGAGTATGAGATACAAATGAGAAAAGC AATAATAATAAAGATTCAACAATGGAAA CTGCTATTTACATTATGATTGTTATAATT AGAAGGACAAACTGTAATTTAACGTTCC TATAGTAATAAAATGGCATCTACAGAGC AAATCTAAACAGACTTAATCTTCATATA ACAATTCATCCCAGATAATTTGAATTGA CCATAATAACATGTTTGAAAGGAGGCTG AAATAAAACAGGGTTTGCTCTTTTCAAC TCTTTAGCCAAGACTTTTTTTAAAAAAAA CTGGTATATAAATGCTTTGTATTTCCTTT CAAGTTTGAAGGGAAAATAAATATAATA CTTAATAGATTTTCAAGTATCTCTTTAGA CATTCTCTTGTTTAGGCTTGTACTAATCC ATTCATTCAGGGTTTGACTGTTGGGTGA ACTTCTTTGCCCTATTCCCAGCTGTGAGA GGCAATTCTCCAGGTTTCTAAGCTTTAGA CCTACGCCCTTCTCTGATGAGGTTAATTA GGGTTTGGGCTGAAACCCAGATTCCTAT ATATGTGGATAGAGTGATGTAGAAGTAC TTTATGATAATAAATATAAATGAAATTT AGATTTTAATTTAGAAATAGAAAACATT TAGGCAACTCACTGAATCAAAAATAAAT ATAGACAAATTTAATTAATATATTTATTT ATTATATTTTCCTGGGTTGGGCTTTGGCC TCTATTTCATATATTTTGTTTATTTTTCAG GATGTTCTGGGATAATGTAGTCCAGGTT CTAGTTCTGCC 2062 2591636 5 COL3A1 GGCACTTATGCATGTTTCCCCAGTTTCCA 0.00028925 0.007114892 8.20E−06 TATTACAGAATACCTTGATAGCATCCAA TTTGCATCCTTGGTTAGGGTCAACCCAGT  345 2591688 9 COL5A2 AAAAGATGGTGAAGTTGGTCCTTCTGGT 0.000442481 0.007495535 6.23E−06 C 1066 2592274 4 STAT1 GCTGAGGTTTAGCTGTCAGTTCTTTTTGC 0.000449203 0.00766067 5.93E−06 CCTTTGGGAATTCGGCATGGTTTCATTTT ACTGCACTAGCCAAGAGACTTTACTTTT AAGAAGTATTAAAATTCTAAAATTCTAT TAATCTCTCATTAATAGTATTTAATATAA AGATTCTTAAAATTACTGACGTTATGAA TTGGTTTGATGC 1338 2592645 4 TMEFF2 AGAAGAATAATGGAACCACTTTGGAAAT 0.014482591 0.009295027 5.86E−06 AGG  118 2592648 9 TMEFF2 GGAGACATCCACCTGTGATATTTGCCAG 0.013588933 0.024063565 2.28E−05 TTTGGTGCAGAATGTGACGAAGATGCCG AG  535 2595779 1 AGGAAGCCTGGCCGAAATGTGCTTTTGG 6.19E−05 0.010523583 4.82E−06 ATAAAATGTCCCGATTAACCAAGAGCAC ACAAAATGTGCAGAC 1974 2597276 2 C2orf67 GGAGGAAATAAAGCCCTGTTCTGGATCC 0.035105592 0.006946012 7.83E−06 CCCATCCCCTCCAGAATAAGAGCATGTT CTGCATGTATTAATCTTTTATGCTGTTTA TGAAACAGGCAAGATAAGTCTGTTTTTC CTTCTGGAACCATAAGGGTAACCAGATT TTCATCTACAGACAAGTGGTAGTCATTT GTGTTTATCATGCAACTTACTTACAAACA CCAAGATATTAATTGCTGCAACTTGATG TCAAATCACATTACTGGGTAATTTTTAAG ACTATGTACCCACACCATACATACATAC ATATATATATACACATACATACAAACCT GTGTGCCAAGTGACAGCTATTTTTTTATA TACATGGTAATTCATTAAAATTGCCTTAG TAATATATTAGAATATACAAATATGTGT GTATAAAATAAACATACACACACACACA CACCCCTATGTAGTTTTTAAAACACTGGC AATGACCCACTCCCCTTGGAAATGCATG TATGAACTACCCTATGAAATGTAAGCTG CAGAATAGATAAAACACAGGTTTCCACT AATAAAAGACATCTGAACGTCCTGAATA TAGAGACAGAAGTTTTTTGTTGTTGTTGT TGTTGTTTTAACATGTTTAACCAACAGAA GTTATTTACAGAAATTCATATATCCAGG CAACACAAAACTCCTTTATTCAAAATCA CTGCTATCTTTGGGACTAAACACAGGCT ACTTTC  781 2599275 4 TNS1 TGGGACAAACAGCAGTACCTCCCTCATC 9.17E−05 0.008975208 8.42E−06 AGGTACTGTGGGATTAAATGAGATTATA TATATATATGCTGGGCTCCAAACAGAGC CTGATATATAGCAAGCATTCAGTGAATC TTAACCAGCATCATTGTGATTCCACACA GGAGCCCATCTGCTTGAGGAATTTAGCT GTAAAAATAAAAGTTTGAACACTACTGG ATGGGATGATC 1632 2599476 2 USP37 TTATTTGCCATACAGTAACCAGAGACCT 0.029541528 0.006562388 4.64E−06 CCAACTAGGGGC  910 2599863 1 GGCTTCCTATATCTCCCTTCCTGGTCAGC 4.52E−05 0.008829888 5.90E−06 AATATAGCCCATTCTCTGGAGCTTCCCGT GGGGATTTTTCTTCCCAGTGAATTCTTCC TATTAGTTATCTAAGTGGTTTAACTGTTG AAATGTTTTCCGTCATCTTTAGATCCTTT TGAAACCACTTTCTCTACCTGCTTCAGTT CCATTTGATGACCGCCATCATCTTTGAGA TTCCCATCCAGAACCATGCATACCTCTTA GGTTCTCACAGCCAGGAGCTATTTCCTA AGTTGTCTTTCTGGTGGAAAGCTCAGCTC CTACTAAGCAGTCCTTGCTTCAAAATGG CTTTGATGAATGACCCAAAGGAGCCAGG CCAGTCCCTGAGTCATCACAGAGCACCC TAGGTGAGAAACCCTGAAGTGTTCTCTG CTGTTG  965 2599915 9 C2orf24 CCCATGTGCTATGATGCTGGCTCTGGTGT 0.000742232 0.007348425 2.98E−06 ACATTGAACGGCTCCGGCACCGAAACCC AGACTACTTGCAGCATGTGTCATCCTCTG ACTTGTTCCTGA  335 2600704 9 EPHA4 CATTGAGGAAGGCTATCGGTTACCCCCT 1.55E−05 0.018536235 1.63E−05 CCAATGGACTGCCCCATTGCGCTCCACC AGCTGATGCTAGACTGCTGGCAGAAGGA GAGGAGCGACAGGCCTAAATTTGGGCAG ATTGTCAACATGTTGG  378 2600943 1 TTTTTGAGCCACGATCACCGGAAGGGAG 0.014566395 0.008784565 3.86E−06 GAGGCTCATACCTCTGGCACGTCAACAG TGACAGC 1809 2601389 4 WDFY1 ACCCTGTGCATGTTCCGATGAAAGAGGG 0.000306094 0.007084701 3.35E−06 CCCCAGAGATGTGGTGTGGAATGATTTC CTCTGGGGAGCAGAAGGCAGAATTGCCA TGCCCAAGCCCGAGC  154 2601681 9 DOCK10 TGAAGGCCATAAGCAGCACAGATCACAA 7.88E−06 0.02628921 2.68E−05 ACTTTACCTATAATTCGAGGCAAAAATG CACTTTCTAACCCCAAACTCTTACAGATG TTAGACA 1081 2602465 3 5S_rRNA.424 CATAGTACTCTGAACATGCCCGATTTCAT 0.000144203 0.007318832 2.05E−06 CTGT 1234 2602539 4 SPHKAP CGCTCTAGTCAAGGGCCAAGCCCTTTGC 9.28E−05 0.008361255 2.05E−06 CATCCCCTCCTCCAGGGAGAACTGACCA GTCCATCCTTGGTGATAGCTGACCTGGA TTGTCTTGGATCAAAGCA 1157 2602918 9 TRIP12 TCCAGGGCCTGTTTGCGCTTCCCTTTGGT 1.47E−05 0.008997078 6.95E−06 AGGACAGCAAAGCCAGCTCATATCGCAA AGGTTAAGATGAAGTTTCGCTTCTTAGG AAAATTAATGGCCAAGGCTATCATGGAT TTCA 2061 2602948 9 TRIP12 GGATGATGCTCGAGCACAGCTTATGAAA 0.000753154 0.007525896 5.35E−06 GAGGATCCGGAACTGGCTAAGTCTTTTA TTAAGACATTATTTGGTGTTCTTTATGAA GTGTATAGTTCCTCAGCAGGACCTGCGG TCAGACATAAGTGCCTTAGAGCAATTCT TAGGATAATTTATTTTGCGGATGCTGAA CTTCTGAAGGA  396 2603204 1 CATCAGAGGCGGGATAGGCCCTCCCCCT 0.012720391 0.008693728 8.76E−06 GGCTTGGACCTTGGGCAGTTCCCCACCA GAGGCTGTGGAGGTCTCCAACATCCGGC AACATCCTTCCCAAGTGCCTGGCTCAAC CCTTCTGTGCCTGGGAGTTTTCTCAGATG CCATGGGGGCTTGCAGGACTGCAAGCTG GAGAAAGAGAAACTCCCAACAGTTATGG CCC  723 2603264 5 CAB39 CTCTTTGACACATGGTGCTGCTACACCGC 0.011153791 0.00928397 4.96E−06 CCTTCATGGCAGGTCTGCTACTTCTGAAT GGGACATACCCTTCCACCGATGCATTAT A  286 2605670 5 FAM132B; CAACAGGTTTCTCAGCTGCAGGGCTTCT 0.003288508 0.011313889 6.50E−06 AC016757.1 CAGAGCCTGCAAGGGCTCCAAGTCAGGT GGGAGGGTGGCCCTTCCCCACAGGCAGT CATTTGGCAGAGCCTTCCGTGAAACCAG CACTCTAGCCTGGCTGCTCCAAACGTGG TCATGCACCAGCAGCGTGGTCATGCACC AGCAGTGTCACATTCCCTGGGAACTCCC AGAAATGCAGAATCTGGGATCCACCCAG ACCTGCCTCAGGATCTGCATCTTAAGAT CCAGGTGGGGCAGAGACCATCTGAGTTC ACCAAGCATGCTGTGTGGCACCCAGAAG GGACCTCTAAATGCCTTTCAGCAAGCAC AGACTCTGGGCCAGACAGCCTGGCCTCC ATTTCTGGCTCTGCTGTGTGAACTTGGGC TAACTCGGGGAGTAGCTCTACCTTC  788 2605785 9 PER2 CCAATGAAGAGTATTACCAGCTGCTGAT 0.000524526 0.009752043 4.77E−06 GTCCAGCGAGGGTCACCCCTGTGGAGCA GACGTGCCCTCCTACACCGTGGAGGAGA TGGAGAGCGTTACCTCTGAGCACATTGT GA 1004 2606698 1 GAGTAAGGTTGGAGCGTTCTCCCTACCC 5.32E−05 0.011144864 8.01E−06 CCCTCCTGTGCGGCTAAGAGGGTGCTGA CCGTCTCCCCTGGGCCTGGTGACCAAGC CAGCCTTGTCCAC 1695 2606919 9 KIF1A TGACCAATGCCCTGGTGGGTATGAGCCC 0.042209752 0.006760359 3.63E−06 CTCATCCTCGCTCTCAGCCCTGTCCAGCC GCGCGGCCTCCGTGTCCAGCCTCCACGA GCGCATCTTGTTTGCCCCGGGCAGCGAG GAGGCCATTGAAAGACTG 2067 2608200 3 TRNT1 GTCCCATCAATGACATGCTACCAGACAT 5.06E−05 0.007942636 2.32E−06 ATCAGATTCCACAGGATAATGGCACCAA GCTACCCAAGTAGATGTTTCTGGTATTCT AGACTGCCGTTCATGCTTGTTTCCTAAAG TATACTTAAAAGTTTCAAATACAGTTTCA CTTAGAAACTGCAACCCTCCAAGTAATG TTATG 1430 2608310 8 SUMF1 CGGAGCAGCCAATCCGCGCGCGGCCCAT 0.000664925 0.010575278 7.69E−06 CAGCTGACCGCCTTTGCTTACA 1942 2608320 4 LRRN1 TCCCTTTAGCTCACCATTATAGATGCTAT 0.006310467 0.007137097 3.69E−06 TTTTATACTTATATTCAGAGGTTGCAAAC TGGCCATGGGCCATAAAGGGACTCTGAA AGCAGGTAGGTTCTGTTTGGCCTGCACA GCTAAAACATTTTGGGTTGCCTTTTGGAA TTCATGCACTCTCCAGCCTTCTACATGAC TACTGCTTCTTACTGTGTTAGAATCAACT CCCTACACCTACCTGGCCCTAGAAAGCA TTAAGT  155 2608321 2 LRRN1 TGAAATAATTCATGCCACGGACCTGTGC 0.000173296 0.019550721 1.90E−05 ACATGCCTGGAATTGAGAGACACAGTTA AAAGACTCCAAGTTGCTTTCTGCCTTTTG AAAACTCCTGAAAACCATCCCTTTGGAC TCTGGAATTCTACACAGCTCAACCAAGA CTTTGCTTGAATGTTTACATTTTCTGCTC GCTGTCCTACATATCACAATA 1549 2608324 9 LRRN1 GGTGCTGGGCCTACTAATGACTTCATTA 0.000363271 0.011008854 7.59E−06 ACCGAGTCTTCCATACAGAATAGTGAGT GTCCACAACTTTGCGTATGTGAAATTCGT CCCTGGTTTACCCCACAGTCAACTTACA GAGAAGCCACCACTGTTGATTGCAATGA CCTCCGCTTAACAAGGATTCCCAGTAAC CTCTCTAGTGACACACAAGTGCTTCTCTT ACAGAGCAATAACATCGCAAAGACTGTG GATGAGCTGCAGCAGCTTTTCAACTTGA CTGAACTAGATTTCTCCCAAAACAACTTT ACTAACATTAAGGAGGTCGGGCTGGCAA ACCTAACCCAGCTCACAACGCTGCATTT GGAGGAAAATCAGATTACCGAGATGACT GATTACTGTCTACAAGACCTCAGCAACC TTCAAGAACTCTACATCAACCACAACCA AATTAGCACTATTTCTGCTCATGCTTTTG CAGGCTTAAAAAATCTATTAAGGCTCCA CCTGAACTCCAACAAATTGAAAGTTATT GATAGTCGCTGGTTTGATTCTACACCCA ACCTGGAAATTCTCATGATCGGAGAAAA CCCTGTGATTGGAATTCTGGATATGAAC TTCAAACCCCTCGCAAATTTGAGAAGCT TAGTTTTGGCAGGAATGTATCTCACTGAT ATTCCTGGAAATGCTTTGGTGGGTCTGG ATAGCCTTGAGAGCCTGTCTTTTTATGAT AACAAACTGGTTAAAGTCCCTCAACTTG CCCTGCAAAAAGTTCCAAATTTGAAATT CTTAGACCTCAACAAAAACCCCATTCAC AAAATCCAAGAAGGGGACTTCAAAAAT ATGCTTCGGTTAAAAGAACTGGGAATCA ACAATATGGGCGAGCTCGTTTCTGTCGA CCGCTATGCCCTGGATAACTTGCCTGAA CTCACAAAGCTGGAAGCCACCAATAACC CTAAACTCTCTTACATCCACCGCTTGGCT TTCCGAAGTGTCCCTGCTCTGGAAAGCTT GATGCTGAACAACAATGCCTTGAATGCC ATTTACCAAAAGACAGTCGAATCCCTCC CCAATCTGCGTGAGATCAGTATCCATAG CAATCCCCTCAGGTGTGACTGTGTGATC CACTGGATTAACTCCAACAAAACCAACA TCCGCTTCATGGAGCCCCTGTCCATGTTC TGTGCCATGCCGCCCGAATATAAAGGGC ACCAGGTGAAGGAAGTTTTAATCCAGGA TTCGAGTGAACAGTGCCTCCCAATGATA TCTCACGACAGCTTCCCAAATCGTTTAA ACGTGGATATCGGCACGACGGTTTTCCT AGACTGTCGAGCCATGGCTGAGCCAGAA CCTGAAATTTACTGGGTCACTCCCATTGG AAATAAGATAACTGTGGAAACCCTTTCA GATAAATACAAGCTAAGTAGCGAAGGTA CCTTGGAAATATCTAACATACAAATTGA AGACTCAGGAAGATACACATGTGTTGCC CAGAATGTCCAAGGGGCAGACACTCGGG TGGCAACAATTAAGGTTAATGGGACCCT TCTGGATGGTACCCAGGTGCTAAAAATA TACGTCAAGCAGACAGAATCCCATTCCA TCTTAGTGTCCTGGAAAGTTAATTCCAAT GTCATGACGTCAAACTTAAAATGGTCGT CTGCCACCATGAAGATTGATAACCCTCA CATAACATATACTGCCAGGGTCCCAGTC GATGTCCATGAATA  645 2608325 2 LRRN1 TGGTAGTAAGGAGCACAAAGACGTTTTT 6.21E−05 0.019434045 1.39E−05 GCTTTATTCTGCAAAAGTGAACAAGTTG AAGACTTTTGTATTTTTGACTTTGCTAGT TTGTGGCAGAGTGGAGAGGACGGGTGG ATATTTCAAATTTTTTTAGTATAGCGTAT CGCAAGGGTTTGACACGGCTGCCAGCGA CTCTAGGCTTCCAGTCTGTGTTTGGTTTT TATTCTTATCATTATTATGATTGTTATTA TATTATTATTTTATTTTAGTTGTTGTGCTA AACTCAATAATGCTGTTCTAACTACAGT GCTCAATA 1008 2608339 5 SUMF1 TGAGCAAAACCACAGGCAGCAATCCTCA 2.54E−05 0.012507145 5.22E−06 AGCCCATTTCTATTCTTCTGGATAAAAAA GACATTTTTTTTTTTTTTCAAAATATAGG GGATGTCATCTTTTTCCCAGCCATCTTGT GAGGGAAGAAGATAGCAAGACAGAAAT AACTCCTTATAATCTTTTCAAATACCAAA GCATTCCACTTCCCATGCAATCATTTTGA ACCTCTAACACGAGCAAAAACTATAGCT GTTATGGAGAAAAGAACTCTTAGTTTGA AAAGATCGAGTACTAGCATATAGAATCC CCCAAACCACTTTAAATTAATGAGTCAT ACAATATATCTGACATGTTACCAAATCC TCCCCAGACCCAAGGCTCAACAGTTTTT GAAATCTCAACACACATTTTCTGAGGAA TTGCAGTTTGGAATGAAACTAGGGCTTC TGGTGGAGTGATCTGTACAGTAGTCACA GGATGGTCCTT 1746 2608671 9 ITPR1 GGAGTCCACCATGAAACTTGTCACGAAC 0.000933891 0.006561627 5.98E−06 CTTTCTGGCCAGCTGTCGGAATTAAAGG ATCAG 1597 2611429 1 AGCTGCTTCCTGTCAAGGCGCCCCAACT 0.000611594 0.007531947 4.72E−06 CGCTTTCCACCCCCCTTCTCAGAGCTGCT TTCTACAAGCATGTAGTTAAC 1532 2612685 5 RFTN1 GACCCAGCTCTGATAGGGCTTCTGAGGT 0.000197241 0.007072248 3.46E−06 GCCAGAAACCTCCAGCTGGAATATCCTG CCTTCAGGACACATCAGACATCTGGCTG TTCATTAGTCCAATGTTACAAGTCCTGCA GTCCACCTCCCATTCTATCTGGCTCCCTG CTCTACCAGAGACAAATCCACCAGAGCC ATAACAGATGCGCTGCCGGGTCCCCATC AGCATCTGCACTGAGACCTACCACGGGA CAAACCAATGATGAAAAACCCAAAGTCC AGAAAATGAAAATGGTCTCAGAGAGACT GGCCAATCCTATTTGGGGTCCTCTA 1419 2616182 4 CRTAP AGGAGGTGGCAAAACTAGGCGACTTTCC 0.001052466 0.006830214 3.37E−06 AAATC  916 2617484 9 DLEC1 TTCGGGAGCTCTATAAGCAGCGGCTGGA 0.013431886 0.008587469 5.38E−06 TGAGTTTGAAATGTTGGAGAGACATATC ACTCAGGCCCAAGCACGGGCTATTGCGG AAAATGAGCGGGTCATGAGCCAGGCTGG AGTACAGGACCTCGAGAGCCTT  816 2617540 9 DLEC1 GGGGCAGCAGTACCATCTACATCTCCTT 0.017888918 0.007446384 3.41E−06 CACCCCTATGGTGCTCAGCCCTGAGATC CTGCACAAGGTGGAGTGTACTGGCTACG CCCTGGGTTTCATGAGC 1694 2618614 2 EIF1B GGCTGCCTTGTGAAATGATTCCCTGCAG 6.41E−05 0.006862005 2.47E−06 TAAACGGACTTTTCATTTATTTAATCATT CAAACTTCCATTCACATCTGCATGATTAC AGAAAACATGGGGTATGTAGACTAGTAA CACATAAGAAAATTGCAGTAAGATGGTA ACAAAACCTCATATTGTCTTTACATGTTT CCAATGGAAAATGTTTTGAGTGTTTATTG TTCAGTTTATTACGTTTCACTTGATTAAA TTTTTTTGTTGTTGTATTAAACCATGTAC GTTGCAGCTTAACAATA   98 2619175 9 TRAK1 GCCAATGTCCAGATTGCTAGTATCTCAG 0.004114217 0.025408058 2.25E−05 AGGAACTGGCCAAGAAGACGGAAGATG CTGCCCGCCAGCAAGAGGAGATCACACA CCTGCTATCGCAAATAGTTGATTTG  269 2622081 7 RHOA GAGAGACTGAGTGCCACCCATGAGAACT 2.76E−05 0.023574859 3.36E−05 GGTGGCTCCTCTGGGAGGGAACCTGGAT ACAGTGAGGAGAAAAGAGCACTGTGAA TTAGAGCCAGATGCTTAAGTCCAGGTGA GACAGGTTATGCCATCTTCCAAAGTGTC TAATTGCCTCAGGCGTGAAACCAATTCC TATTTACTTAGCCCAGCTCCATGGGGTAC TGAGATACATGGGGCCGAAAAGGGGTA ATATGGCCATCTTTTATCAGAAAAAGTG ACAAAACGGGAATTTAAAAAATGAATTT TCCATCTGACTTTATTTCCAAATACACTT TCTTTTTTAAAAAACCAATACACTTTCTT TGAGGATGACAGTATTAGGAAATCCAAT TATACAAAAAATACTACATCTAGTCTGG GGTAGATATAATTTATTTTTGGTAACATAC ATTAAGTGGCACTAATTACACAGTAACT ATAAGGTAACTAACATGAAACCACAGAA CTGTAACTCTGCCACAGCTGCATGAACT TGGGCTTTTCTGGTTGAGCCCATTTTCAA AAAACTGCCCACCCCAGAGCTATGCCAA CAAAATCTGTTACGGAGTAAAGCCCTGA AGTGGTGACTCACCAGAGTACCTTGCAG CTGACAGATAATAGGCAGGACATGTTAG TTATAAAGTAGTTACAGCCTAATTCACA AAAGTTACCAACTGTTTCTCTTTCTAGAA AGAAGCAAGAAGTTAAGAAATTCCTTGA ATTAGCGCCTGGTGTGTCAGGTGGGAGT GCAGAGGAGGGCTGTTAGAGCAGTGTCA AAAGGACCCTGGTGGGCCAGACGGGTTG GACATCGTTAATA  545 2623385 5 IQCF1 CAATTGGAGTCTAGCAGGGAATACCAGA 0.00071035 0.008401967 6.10E−06 TCAATTTAAAGCCTAAAATCAAATAGCT GCAGGATTTGAGTCAATATTTTGTTGAG AGACAATTAATAAAAATATAGATTGAAT AAACTACATATGCTACAACCAACAGCGA TTTATTAACTACACTAGAGATGGTGTTA AAGGAATAGCTGAGCAATTAGGGGCTAC TAGCCGGATGGCTTGGGAAAATAGGATA GGCTTAGACATGATAATAGCAGAAAGAG GAGGAGTTTGCCTCATGATTAAAACTCA ATGTTGTACCTTCATCCCAAACAACACT GCCCCTGATGGAAGTATAACAAAGGCAT TGCAAGGTCTGACTGCCCTGTCCAATGA GTTAGCCAACAACTCAGGGTTAAATGAG CCCTTTACAGGATGGCTAGAAAAGTGGT TCAGTAAATGGAAAAGAATTATAGCCTC AATTCTCACTTCCCTGGCAGCCGCAATG GGTGTATTTATT  690 2626663 8 FHIT CTGGCAAGGCATACCGCCTGACCTGCAC 0.007866301 0.010201017 7.71E−06 AC 1156 2627422 9 ATXN7 CTACTGAAATCTGCGGTGGGGCCAACCT 8.27E−06 0.012122322 1.25E−05 GTCCTGCTACTGTGAGTTCCTTAGTCAAG CCTGGCCTTAACTGCCCCTCAATACCAA AGCCAACCTTGCCTTCACCTGGACAGAT TCTGAATGGCAAAGGGCTTCCTG  651 2629053 5 FOXP1 TGCTAACCCACGATCAAGGTCATGGGGT 0.000436951 0.011217143 6.81E−06 CAGATAGTTATTCAGTGTGGCAGAGACT CTTTCCTTGCCCATCAGAATGGAGGGAA AAGAATATTACACAGAAATCAAAGAAG AGCTTGGAAGGACACGTATTTCACAAAT GCATTGATGAGTAAGAGAGAAAACTTAT CCAAGGCAGTGACAAGAGACTCCTGAGA CAACTGGCACA  409 2629551 7 RYBP CGTGCACATGCCAGTAACAGGAATATAT 0.001173835 0.015072362 1.96E−05 TAACATCTTTTATTTGCTAGACAAAGAG CAGTGTCCAATATAAATTTCCCCCAAAA CATTTAAGACCTGTGAATTTTTGACCAGT TCACAAAACCACCAACTGACACTTTAGC ATGAAGAAAAAAACAAACCTAACAGAC TGTCAGCTCTAAAGACATTACAGAGCAG AAACTTCCAAAAGCGTTATACAAGCTGT CTTTCTGGGCAAATGAAAAATATAGCTC GTATAATACATTAACAAAAATTCACAAG ATAAGATTGTTTTGACATACTTAACAAG CATTCTCTATTTGTCTCCAACAAACAAAG CTAAGGAAATAATGTAACCATCTTTACA CAGTAAATTAAGGTTACAAGTCATACAC AAGAACAGAACTGCTTGCGCATTAAAAA CTGTTCAGCTCCATTGTCATACTCTAAAT GTTGGCTCTTAAACCATTTTCGGTTACAT ACAAGCAAAGGTTATTATATATTCAGCA ATTAATAAATTTTCAATAATTTAAGATAC GGTAGCTTAAAAAAGTAGACTGAGAATG GTCTTGATAAGGCAGGTGAAACATCTTA GTGGAACTAAACTCACAGAAGCTTCTGC CAATGTTTTTAAATATCCAGATTGAAACT GAAAGGTTTTGATTAGAATATTGTGTGG GTGTCAAGATGTCTTTTTTTTTGTAACTG CATGACTCAAGCAGAGCAAGTCAGGTAA GCTCTGTGTGCGCGCACACGCACGAGTG TGAAAGATTGCGTGGTATTAAAACAAAT GGAAACTTGCAAGCGTAACACTGTG  738 2629744 4 PPP4R2 TGTATTCCACAATGGCCGCGCCATTTTAC 0.04726916 0.008537673 9.19E−06 GTTCCCATCAGCAGTGCCCATTGGTCCC AGTTTCTC 1410 2630507 4 ROBO2 TATGGTACTGTTAAGAACCCTGAGTTTG 0.001302035 0.008310638 3.52E−06 CAGTCATGTTATTTTCATTTTTAACAATT TAATTTAGAATTCAAAAACTTTTTATATG TTTTTCCTGATAAATAGTGCTTAAATTAC TTGTCAATATTCTGTTCCAAAGAATGCAT ACAAATTGGATTTTGTTTTTCATTTGATG TGTGTTAAGAGTGGAAAAGATGCATAAC TGACGTGCATCTGGCATATCTGATGTGC CGCAACTGCCAACAGTTCAGATAACTTT ATGGTGGTCACAGGTCAGTCATAATGA 1748 2635824 9 PLCXD2 TCTTATTTTCTACCACTGTCCCTTCTACA 3.62E−05 0.008886785 7.53E−06 AGCAGTACCCCTTCCTGTGGCCAGGAAA GAAGATTCCAGCGCCCTGGGCAAACACC ACAAGTGTGCGCAAACTAATCCTCTTCTT GGAGACCACTCTGAGTGAGCGGGCCTCA 1166 2636575 6 CCACACCATGGTTTCCCAATAGTTCTCTT 0.002123679 0.009197633 9.18E−06 TTTGGAGGACTTTTCAATTGATGAGTAA ACTGCTTTAGATATTTCAGAACTTCATTC CCCAAATGAAAGCTAATCTGGACAAACT ATATATTGCATAGATTTCTCTACAGATTC TTTGCTTTAAAACCTAAATGCAACTAAC ATAGTGTAATTTTAACCTATTTGCCCCAC AGTAAAAACTATCTGTCCTGAAAAATAT GATGGATATATCCTGTGATTTTCCAGTTA ACAGAATTGTTCTACTTCAAAGATAATT ATTATCATATATCAAAATAACCAGCTCA ACATAGGACATTACTTCAGTCTTTACTGA CTCATAGGCATATGAACTTGTGCCCAGC TTT  423 2638147 9 C3orf15 GGCAAAAATTCAGCGCACGCATGTATCA 0.009193693 0.007970185 8.90E−06 A 1233 2638761 2 SLC15A2 TGACTCCCTAGATTCTGTCCTGACCCCAA 0.000352341 0.00718282 1.84E−06 TTCCTGGCCCTGTCTTGAAGCATTTTTTT TCTTCTACTGGATTAGACAAGAGAGATA GCAGCATATCAGAGCTGATCTCCTCCAC CTTTCTCCAATGACAGAAGTTCCAGGAC TGGTTTTCCAGTACATCTTTAAACAAGGC CCCAGAGACTCTATGTCTGCCCGTCCA 1834 2642793 4 DNAJC13 GGCAGCTTATTCACGTGGCCTTTCCTCCG 0.045938047 0.007033282 3.08E−06 CTGCTGTGATTTTATCTTTGAATGTGGCC TTTGGAGTGGGTAAAGTAGGACTTAGAC GCTCAGTGAAGTGGCT  184 2643246 4 TFP1; ACACATGTGCGTGTGGCCTTCTTGCCCCT 0.018126 0.010721006 8.87E−06 TF GTTTGCCTGGAGGGGTAATATTATAAAT ATTCCTTCTATGGTCTTCTCTCTCCCCTG CAACCCTAGGAAGGTTTTCCTG 1052 2643765 1 GGGCCCAACCACTCTCCACATGGCAGCC 0.000108061 0.008880817 1.02E−05 AGGAAGAACATGGGTGTTTATCAGACTG TGTCACTTACAATCAAGTCCAGACTCCA CACCACA  510 2644440 9 CLDN18 ACAAGAAGATATACGATGGAGGTGCCCG 0.003266926 0.017008691 1.45E−05 CAC 1523 2647113 4 CPA3 TATTTTACTGTCAATGCCCATGGGACTAC 6.21E−05 0.008005576 4.00E−06 AAAAGACTATTGAACATAAGGGGAAAG CAGGAGCTATCTGGATAATTCAGCCAAT GGCCAATACTTCACCTGTTCTG 1771 2647816 6 CCTCAGTGTATAAGATGTGCAAGACAAA 1.85E−05 0.010052151 7.45E−06 TATGCTTATTTCCTTTTCTAGAATATAAG TGATATTATTTGCTTATGACACTAACACT ATTAATGACAGGAGTCAATCAGCCTTTA CAGCTATCAAAATATAATGAGATCCCAA TGATGATTCTTTTTTACTTTGAATGTTAA TTAGTTTGGGACTTTGATTGGCTGGCAA ACATTTTATCATTGTCAGAATTTAATTTA GATTTCAAAAATAGCTTACAGGATTTTA AACATGGTGTGGTATTCTAAAGCCTTTTT TTTAAAAAAAGAGATCTTTTTGAGAGAA ACAAATGAGGATTGTAAAGTTTGGGGAC TTACCTCTGTAGCATTG  952 2647934 9 MED12L TGCTGCTCTTCTGCGAGTTCATCCGCCAT 0.004800285 0.007000581 2.37E−06 GATGTCTTCTCCCATGACGCATACATGTG TACCCTCATATCTCGAGGAGATTTGTCA GTCACTGCCTCAACTCGGCCGCGGTCAC CAGTAGGGGAAAATGC 1723 2648885 9 GMPS GAGACCTTAAGGATGGCCACCACCACTA 0.000172838 0.007554839 3.61E−06 TGAAGGAGCTGTTGTCATTCTGGATGCT GGTGCTCAGTACGGGAAAGTCATAGACC GAAGAGTGAGGGAACTGTTCGTGCAGTC TGAAATTTTCC 1035 2649525 1 AGCACTGCGAATGGGGCCAAGAAATTTT 8.59E−05 0.007182612 3.53E−06 GGCCTTTCTCGCCGGACCTGGCTGCCTCC GCGGGCCTCTCCGCCTACCGCGCTCCCG CCGCGGCCCGACTCCCGCGGGTCTCCGC GCCGAACCCACCTGGCTCCTATCGCACG GGACATTCCCGACCCACCCACGCCGCGT CACTGAGCCTCTGTACCGATA  934 2649935 2 IQCJ- GCCCGCCGGTGGATGCTCCGCGCCTGCC 6.02E−05 0.010720906 8.75E−06 SCHIP1; CTCCGCAGCCTCGCTCAGCAGTCCTGCG AC063955.1 TTGGGGTCTGCGCCCTAGGATGCACTGA G 1421 2650228 9 SMC4 AGATATAATTGGTTGTGGACGGCTAAAT 3.17E−06 0.016266742 1.10E−05 GAACCTATTAAAGTCTTGTGTCGGAGAG TT 2003 2650244 9 SMC4 GGGGACTTAGGAGCCATTGATGAAAAAT 1.68E−05 0.00695319 2.52E−06 ACGACGTGGCTATATCATCCTGTTGTCAT GCACTGGACTACATTGTTGTTGATTCTAT TGATATAGCCCAAGAATGTG  907 2651198 3 RP11- TGTGATGTCTTTCCCCATCCGTCATAAGG 5.24E−07 0.013460027 1.71E−05 298O21.6; GTCATGG RP11- 298O21.2 1508 2651858 4 GPR160 AATTTCCTGAAACTGGGCTAATTCTTTGT 1.95E−05 0.008579857 3.86E−06 AGAAATGTGAACGCTGAATTTATTAAAA AATAATAATAAAACACAGGAAACAACTT ACATGTACATAGGTCTTGAAGTGAGTGA AGCGGCTGTATTTTTTTGGGGGGGGCAT TGCTTTTGTTTTTGTAGAAGAGATTGAGA TGATACTCTATTCTAATCAAAATTAGAG ATTTGTAGTGGGACCA 1855 2652236 5 TNIK CCTGCAGGCGTTCATATGAGAGATGTGC 9.17E−05 0.007559912 2.17E−06 AATGCCTGTGCTAGGACAGTGGTGGCAG AGACAGAAAACAGAAGAGAGAAATCAG GAACCATTTAGGAAATAGGATCAGCTGG GCTTGGTGATGAAATTCAGGAGATGATG TCATGGGTGACTCCTAGTTGGTTCTTGGA GTTGTGATAATGCCCTTC 1823 2652297 1 TCTTGGCATCGCCACACCCAGGACTTGC 3.08E−05 0.006668549 3.20E−06 TCGTGCCGCAATTCCCCACGGAAACAA  526 2653422 8 TBL1XR1 AATTAAATTATCAACTGTGGTCATCTGC 0.003210012 0.010540491 6.82E−06 AATGAAGTGACTAA  445 2655291 5 ABCC5 GTCGAGTTATACAGGACTAGCCATCTAA 6.39E−06 0.015888528 1.09E−05 CAGGTCATCTGGTCTCCGACGGTTGTTTA ACGACACACAGTAGAAATAGAGAATAG AACCCATATCTGTTTCCAGAGTCCAAAG TAGTATATCAGGCTGACAGCACTCAATC AGTGAGGGCTCCTGAGGTTGCAATGATT CTGCAACGGAGTAGATTCTCTAGGAAAA AAGACCTTGCTGCTAAGGAAAGAGAATT AAAAACAAAACAAAACGAAAAGCTCCC CAAAGAGGTACTCTGCTCAAAATGGCTG GTGCTACTGGTGCACTAAGTTGTGAGGA ATTACCTCTGCTCGGGACAGA 1939 2658515 1 TTCCACTGGACTCAACATCCTTTTGCCCG 3.13E−05 0.007764126 4.87E−06 TATC 1213 2658524 1 AATATTGCAGGGTTGAGCAGGTGCAATG 0.002147887 0.007985716 5.27E−06 TTGTAATAGAGGTAGCAGGCCTGAGCGT GTGCAATGTTGTAATAGAGGTAGCAGGG CTGAGCGTGTGCAATGTTGTAATA   93 2658918 5 C3orf21 GGAAGGGACTCGGAGAAAGCTACAAGC 0.000102061 0.020156465 1.03E−05 TGGGGCCCT  616 2660844 4 SUMF1 TTCCAGGTTGGGTGTAGAATCAAACCAG 0.002052564 0.013982945 1.22E−05 CGACTATCAATAACTTTCAATTTGTTGGA GTTCAGGTGGAGCCTTAATAGATTTTTTA AGCCTGCAAAAGCATGAGCAGAAATAGT GCTAATTTGGTTGTGGTTGATGTAGAGTT CTTGAAGGTTGCTGAGGTCTTGTAGACA GTAATCAGTCATCTCGGTAATCTGATTTT CCTCCAAATGCAGCGTTGTGAGCTGGGT TAGGTTTGCCAGCCCGACCTCCTTAATGT TAGTAAAGTTGTTTTGGGAGAAATCTAG TTCAGTCAAGTTGAAAAGCTGCTGCAGC TCATCCACAGTCTTTGCGATGTTATTGCT CTGTAAGAGAAGCACTTGTGTGTCACTA GAGAGGTTACTGGGAATCCTTGTTAAGC GGAGGTCATTGCAATCAACAGTGGTGGC TTC 1801 2660916 4 SUMF1 GCTCTGTGAGGCTGAGTAAACACTATTC 0.006537209 0.006595054 4.89E−06 TCTAACATAGGGACGACATGGGCAACTG AAAGGATTCAATGTAAGTAATCTCTGTG AAGCTCCTAGCAGAGGGTTAGATGCACA AC  296 2661905 4 AC087859.1 TGGTTTTTAAGTACTGTGGACAGAATGA 7.38E−05 0.010850848 7.91E−06 CCTCTCTTTCTGTCCCAGGGGCCACTCTA GACCAAAACCCATCCACAGCGAAGTTGG TGC  757 2662405 3 RPUSD3 CCAGAGGTGTATGTGACCAGGCCCAGCT 0.011000613 0.009676955 5.52E−06 AGAGGAGGCAGCTTCAGGCTAGCACCCC AACAGGAAAGAACAGTCCTTAGGCCCGG TGGCTTCAGCAATTAAATCAGGGTTGCA TCTCATCATGAGTGGATCCCACAGCCAG GCAGATTGATAGCTGTGATCGTCCTGAC GTGTTATGTGTCCCTCTCTGGATGCAGGG GCCATAGTACTGACCTCACTGA 1357 2663942 3 GRIP2 CTACCCCGCAAGTCGGGCAGCCTCAGTG 0.003473534 0.00850067 5.57E−06 AGACCAGTGATGCTGATGAGGACCCAGC AGATGCCCTGAAAGGAGGCCTGCCAGCA GCCCGCTTCTCGCCGGCTGTGCCCAGTGT GGACAGTGCTGTGGAGTCTTGGGACAGC TCGGCCAC 1027 2664336 2 COLQ TGACCACCGAAACGTGCAGGCATTCTCA 0.000769819 0.007370036 1.10E−06 CTCACACTGGGCAGCCCGCTGTCGGGTC TCTCTAGGCCTATGAACCACAAAGCAGG GAAGTGGGCACGTTCTCTCGGGGTGGCT CACAGCTTTGAACCTGCCAAAGGACCCC TCGACTGGCCACAGCCCAGCCCAGCCTG ACGTGGATGTGGCTGCCCAGGAAAAGAC TTAACTGTGAAAAAGTACTGAGAACCCA CCTGACCCAGGCTTGCCCCAAGCAGAGG CTAGAGAAGAGGCTCCTCTTCTCAGTGT TTCC  963 2666262 3 THRB; ACTAAGTAAGACCTCTCAGGATCTCAAA 2.79E−05 0.009236679 6.52E−06 AC112217.2 GCCAAGTGTTTTACAGAGAAGAGAAGAT AGAAAAGGCATATTATCTAGGAGTGGAA AAGAATTTTATGCTGAAAATGTTGAAGA GAGAATTCAAAATCAAATTCAACATTCC ACCTAGGAGGCTTCCATCTCTGCTTAGG AGCTGAGTAATGGAGGTGATTGGTGTAA GTGTTCAGTACCTATGAAGACCTAACTC TTGAGGGAGAGACTCCA  696 2666522 9 TOP2B TCAAGATGGTTCTCACATAAAAGGCCTG 2.38E−06 0.013163028 1.15E−05 CTTATTAATTTCATCCATCACAATTGGCC ATCACTTTTGAAGCATGGTTTTCTTGAAG A 1149 2666743 1 CTCCATGGGATGGTATCCGAGTGGCTTG 0.005051331 0.008825818 3.83E−06 GAAAATAATATTTAGTTGTGTTCACCCA CCT  883 2667008 1 TTCCTTTACATGCTCCCTCGGGTGAAGCA 6.41E−05 0.007673324 2.51E−06 AGGCAGATGGAGAAGGCTTTAGCAGAC AGCGTGGGCATGTTTCCAAGCCCTCAGG CTGCTGAGCAACAATGCCGATGCCAGCA 1552 2670412 1 TTGGCTCCCCAGTACCTAGGCATGTTGG 0.004140901 0.008171632 8.16E−06 ATTCAGA 2022 2673028 9 MAP4 CACAGGAACGGGGAAAAAGTGCAGCTT 2.38E−06 0.007570706 7.03E−06 GCCGGCCGAGGAGGATTCTGTGTTAGAA AAACTAGGGGAAAGGAAACCATGCAAC AGTCAACCTTCTGAGCT  113 2673623 9 CELSR3 AGTTCCACTACCGACCGCGGGGCAGTGA 0.003413307 0.016791865 2.15E−05 CTCTTGCCTCCCATGTGACTGCTACCCTG TGGGCTCCACCTCGCGCTCATGTGCACC CCACAGCGGGCAGTGCCCCTGTCGCCCA GGAGCCCTTGGCCGCCAGTGCAACAGCT GTGACAG  704 2674247 2 RHOA CACAGCCCTTATGCGGTTAATTTTGAAGT 3.07E−06 0.018909578 2.10E−05 GCTGTTTATTAATCTTAGTGTATGATTAC TGGCCTTTTTCATTTATCTATAATTTACC TAAGATTACAAATCAGAAGTCATCTTGC TACCAGTATTTAGAAGCCAACTATGATT ATTAACGATGTCCAACCCGTCTGGCCCA CCAGGGTCCTTTTGACACTGCTCTAACA GCCCTCCTCTGCACTCCCACCTGACACAC CAGGCGCTAATTCAAGGAATTT 1602 2676932 2 RP11- TCTAAGAAGCAGACAACCGGACATGCGC 0.003181899 0.006579698 2.72E−06 884K10.5 ATTCATAGCAGAAGGAAACCATCAAGAA GTGGAAGGCTGACCATGATGAGCAGTAG ATGAATGTGTATGTCTAAACAAGGACTG CTCTGTGTCCTCACAGATGAATGAGGTC ATGCTGGGAATTCCCTCTGCAGGGAACT GGCCTGACTGACATGCAGTTCCATAAAT GCAGATGTTTGTCTCATTACCTTTT  512 2676993 5 CACNA2D3 GAACCAACCACACTGTACCAAAATGAGC 0.013302264 0.012413878 1.18E−05 TGTTCCCTAGGTCTTGTCCC 1547 2677357 2 WNT5A TATACCCGATTTAGCAGTGTCAGCGTATT 0.000483071 0.008107545 3.23E−06 TTTTCTTCTCATCCTGGAGCGTATTCAAG ATCTTCCCAATACAAGAAAATTAATAAA AAATTTATATATAGGCAGCAGCAAAAGA GCCATGTTCAAAATAGTCATTATGGGCT CAAATAGAAAGAAGACTTTTAAGTTTTA ATCCAGTTTATCTGTTGAGTTCTGTGAGC TACTGACCTCCTGAGACTGGCACTGTGT AAGTTTTAGTTGCCTACCCTAGCTCTTTT CTCGTACAATTTTGCCAATACCAAGTTTC AATTTGTTTTTACAAAACATTATTCAAGC CACTAGAATTATCAAATATGACGCTATA GCAGAGTAAATACTCTGAATAAGAGACC GGTACTAGCTAACTCCAAGA  774 2678668 1 AGGACGGGACTCCAGGTCCACATTACAC 0.000183201 0.013190267 1.35E−05 CAGACACCAGGACGAGCACCGACCCAG CCCCTGTGGTGCCCTGGAGCACTGAGAT CTTGTGCCAGCTCTAA 1371 2678742 2 FHIT TACCTAGACCTAAACGGCTCAGACAGGC 5.15E−05 0.008580237 6.43E−06 AGATTTGAGGTTTCCCCCTGTCTCCTTAT TCGGCAGCCTTATGATTAAACTTC 1189 2678879 4 FHIT TTTAGACATGAAGTATGAGGCCGGCATC 0.034438352 0.007911619 3.61E−06  829 2679967 9 PRICKLE2 ATCAGCAAACTCATGTTTGACTTTCAGA 0.000250234 0.010916403 6.29E−06 GGAACTCGACCTCAGATGATGACTCAGG CTGTGCTTTGGAAGAGTATGCCTGGGTC CCGCCGGGTCTGAAGCCTGAACA 1847 2680050 2 ADAMTS9 CATGAGCCTAACACCCTGCCGGTTTTCAT 6.62E−06 0.008282353 5.23E−06 GCCCGCTGCAG 1085 2680626 4 LRIG1 GGAGCCCGGCTGTGGTACAGAAATAGTG 0.001040005 0.00879174 3.90E−06 TCCTCCCA  264 2682971 9 CNTN3 AAGACGCACACAGCCACTGTAGTTGAGT 0.015576799 0.011505616 5.10E−06 TAAACCCATGGGTGGAATATGAATTTCG GGTTGTAGCCAGTAACA  770 2685234 3 RP11- CTCCACTGGGCAGGGGTTTCTTCTATTTT 0.008044591 0.00862745 5.44E−06 91A15.1 AGGGGCCATTAACTTTATTACCACAGTC ATTAACATAAAACCCCCAGCCATATCAA ACACCACTTTTCATCTGATCAGTC  470 2686545 9 ABI3BP TCTCAGCAAAAGGACCCCGGAAACATTG 0.000628393 0.011468681 7.23E−06 CAAACTATTCTAATACCTCAGTTTGAATT GCCACTGAGCACTCTAG  751 2687361 1 TGAAACATATTGTACGCACCAGGAACTA 0.002066608 0.007528671 2.37E−06 CTTGCTGG 2023 2688904 4 C3orf17 CCTGTGACTGGGAATTGCAGTAATAAAA 0.000438052 0.00735558 2.33E−06 AATTGTTGGTAGTAGTCATATTGCAACA GGCCGTTTAAAATGATGCTAATCCTGGG CTGGCTGTATCACTTGATTCTTTCTGTCA CTCGGTTTCTAATTTTTAATGGCAATGAT AAATGCAATTTTTGACCTTCTTATGTGCT AGACTATTTTCTTCCATCTCAAACACCAC TGCTTTTTTGAGCATATTTAGTTGATGTA TGCTGGTAATACTTGGAAACTAAAGAGA CATCTCTTTCATGTCTCTCAGTACATATT GTGAAACTGATCTGATGGATAATTAGAA TTTGCCCGTATCTGTAAGAAGGCCTGTTT TGGGCCATTTCAAACAATTAAGATTATT AGTTCTAATATGAATGTAAGAAAACATT GGATGGAGAAAAGAAAAAAAGTTTCTGT GTTTAGAGATTGAAAACCTTGCTTTGAT ATCTTAACCTGGATATCTCAAATAGTATT TCCTATTGTTTTATTTTTTATTCTACTTAT TCTTAATCAGAGGTAACAATGTTTGATT ACTAATCATATTATTTTAAAATGCTAAAC CTTTGATACTCTCTTCTGTAATGAAAATA GCTTTAATTTTTGCTGATTATAATACATG CCTGTTTTAAGAAATTTAAAAAGAGAAA TGTGAAGAACCTGAAATTTGCCTAAAAT CTCACCATCTACCACACTTAAAACTTTGA TATGCATCCTTTTGTACATTTCTCCATGT AGTACTTTTTGAATATATATATATCTTTC CTGGTAGACTGTCTTACA  975 2689033 5 BOC GCTGCAGTTGGTCTGTCAAACAGTCCCT 0.000143818 0.008308479 5.46E−06 GCCTTCTGCTGGAAGCCCCCAGCCCCAA CCCCTGCCAGCTCTCCCCAACTTGGGAA GCTCAGTGGCCTCGGTGCAAGGCTGGCA CATGCAGAGAAAACAAACACATGGAGC CTTGCCAGCTGGATCAGGCACCACTGTT TACAGCAGGAGCAAAGTGTGGGGAATTG GAGAGGCATGAAGAAGGGAAGGAGCAG AGGGGGTGGGGATAATTCTAGCCTCCTG CTCTTAGGCTCCACCAGTTGCAAAGAG 1755 2689214 6 GTAGGCTCCCTATCATTATATATAGAGTT 1.57E−05 0.007486134 3.62E−06 TCTTTTTCCACGGTAGTCAGTGACTTAAC CTGAATTGTAAATGTTTGTAAAGGGTTA ATTGTCCTACATCAAACTTAGTTAAATA ATTCCATCCACTTATGGAGGAGGAGGAG AATGTGGAAGAGGTAAAAAGCTGGGCA CAAGTTCATATGCCTATGAGTCAGTAAA GACTGAAGTAATGTCCTATGTTGAGCTG GTTATTTTGATATATGATAATAATTATCT TTGAAGTAGAACAATTCTGTTAACTGGA AAATCACAGGATATATCCATCATATTTTT CAGGACAGATAGTTTTTACTGTGGGGCA AA  106 2689313 9 KIAA1407 AAGGCAGAAGTGACTCCCGAAATTCTCT 0.015311147 0.019661807 1.60E−05 TTCTGGACTCAGAAGGAAACCAAAGCAA TTGATGACACCGCATCCCATACTAAA  382 2691686 9 HCLS1 TGGAGAAGGATAAATGGGACAAAGCAG 0.039015171 0.014788972 1.95E−05 CTCTGGGATATGACTACAAGGGAGAGAC GGAGAAACACGAGTCCCA 1669 2692363 4 ADCY5 GGAGGAAGCAACACCAGCCGCTTTGGGG 0.00180613 0.0065665 2.64E−06 AGGAGCTCCTAGCCTACCAAGAGAGATG GAAAGCATAGACTGGGACCCGAATGTCA CCACCATCATCTCATCTTCACCACCATCT GGCAGCTTCCATGCCTCCTAAGCCAGTG CGTCCCAGGCACTGGGCCAGGCTCTGCC CACCTTATCACCAGTCCTCCTGACAGCA CTGCAAGCCAGCTACCTTTATCAACACA CCCGGTTGATAGATGGCTCATG 1037 2693582 4 ZXDC GAGAATTTTGCCCAGCAGTCCCTCGTGG 0.047746878 0.008220293 6.80E−06 CTCCCTCCACACCACTGACCCTTACGCAT CCAAGGTTGGAGC 1354 2694294 1 GCGGGCCATCTGCATGACAAAGGCGCGC 0.000674778 0.00923119 7.11E−06 CCCGG  996 2696131 9 SLCO2A1 ATTCTATCTTCCACCCGGTCTGTGGAGAC 0.003217076 0.010887966 6.31E−06 AATGGAATCGAGTACCTCTCCCCTTGCC ATGCCGGCTGCAGCAACATCAACATGAG CTCTGCAACCTCCAAGCA 1099 2698045 5 CLSTN2 TAGAGCTAGTCGTCCTTGTAAATTCAGA 6.11E−05 0.007604148 1.93E−06 GTTGAAAAATGTAATTCAGGCATTAAAT GCTGGGGAGCCATAGTAGAGAAGACAG ATAATCACCAGCTCCAAAGCACAGTGCC TGGGCGGGCATATTGTGTGTGCTGAGCA TCCCACCGTGCAAGGCAGTGTTTAAAGC TGTGAACACACAGATGCAGGGACTGTGG TCTCCCTTTTCATGGTGTTCTCACCCTTC ATGGCATCCTTGGTCAAGGTAGGGAGGC CAGAGAGAGCTATAAAGATATA  372 2698593 9 TFDP2 AGCAGAGAATAAACCCTCACCAGGCACT 2.19E−05 0.010880081 5.99E−06 GAATCTGCCGGCACTTTCATTTTGGACCT CTCAGCAACCTC 1117 2699041 2 PCOLCE2 AGCTCCTCAGGGGAAACTAAGCGTCGAG 0.008011904 0.009640861 1.01E−05 TCAGACGGCACCATAATCGCCTTTAAAA GTGCCTCCGCCCTGCCGGCCGCGTATCC CCCGGCTACCTGGGCCGCCCCGCGGCGG TGCGCGCGTGAGAGGGAGCGCGCGGGC AGCCGAGCGCCGGTGTGAGCCAGCGCTG CTGCCAGTGTGAGCGGCGGTGTGAGCGC GGTGGGTGCGGAGGGGCGTGTGTGCCGG CGCGCGCGCCGTGGGGTGCAAACCCCGA GCGTCTACGCTG  581 2699705 9 PLSCR2 TGTCTACCCTAAGCACCAGGCTGGACAC 4.99E−05 0.013537973 1.13E−05 ACTGGGAAACAGGCTGACCACCTGGGCT CCCAGGCCTTCTACCCAGGACGTCAGCA TGACTACCTAGTCCCACCTGCTGGCACA GCTGGCATTCCTGTTCAAAATC 1699 2701408 1 TGGTAGACAAGGTAGACCCCCAACAGAA 8.76E−05 0.006644833 2.64E−06 TGTGGAGCCACCTGCCTCCCTGAAGCAT AGGTCACCAAGCCTAAAAGCAGAGAAG 1866 2701986 6 CCATATCGGGAACCAAGTAGTACTGTAA 0.000461778 0.009788617 6.40E−06 TGGGTTTGGCCAGATATCATCTTTGATGA CCTCTCCTAACTCATCAGCACCTGCATCA GAATGGTCAGTAAACCAGGTAAAGAAG CTCTCTGGTTCCTCATGCTGCCTCTTCCT GCTGGCTTTATTCTGTGTTTGACTTGAAC GTTTCGTCAAATCCTTTCCAGATTTCCAT TTGATTTCGGTGGACTTCGAAGATGGAT CAC  780 2703842 9 SLITRK3 ATCCAAATGCAATGCCACAGGCTGTTTG 0.002842819 0.00956677 5.48E−06 AGGATGGTGGAGGTGGTGGTGGCGGAA GTGGGGGTGGTGGTCGA 1928 2704213 9 PDCD10 TGATTGAACGACCAGAGCCAGAATTCCA 0.000203565 0.008620506 6.27E−06 AGACCTAAACGAAAAGGCACGAGCACTT AAACAAATTCTCAGTAAGATCCCAGATG AGATCAATGACAG  532 2705096 5 CLDN11 GGAATGCCTATTGGGAAGGTGCTCCAGC 0.000256815 0.01098403 7.29E−06 CAAAGAATTCAAGGGACCAGAGGTCAA GAAAGAGCAGAGAATCAAAGCTGGGCC CCTTGTGGGGAGGCCGAAGTCAGGCAAA ACAAGTGACA  809 2706654 6 AATGAGTAAGGTTGATAGTGTGGTAGAG 2.79E−05 0.009580406 3.21E−06 ATAGCTGGGGAGAGGTAGAGGGTGGCA TAAAAATGGGAATGAGAATAAGAGTGA GTATAAAAGTAAAGAGTAGAACTTCATC AGGGTGAAAGAATTGGAGGGTCCCCTGC CAGCAAAGATCATCTATGCACTCTAAGA GGGAGTT  547 2706734 3 RP11- GTTTGTCAGACTCTCGGGACCATGCTGTT 0.000413384 0.014860356 8.42E−06 385J1.2 GAAACCACTAAACCACGCTGCCTCTG  805 2708067 2 KLHL6 CTATTCTGGTCTCAATGGCTTCGGGAAA 0.009399078 0.008372295 5.09E−06 CACACATATACACATACACCATGCCCTT GAACTCAAAGCAAACTACGCTCTCAGGG AAATACAAATATCACGTTCTTATAGCTG TAAAGTATAGCTTAGCTATTTATAGAAG ACTATGAGGTACTGTTGTGAGTTATTTGC TTATCCTGTTTTATTCTGAAAAATGAAAG TGCTCAATAGAATTTTTAACGTTGGCAA CACCATAAGGATTTCTTATGTTAAGTCCC AACTTGGGGTTGCAAAATCATTTTTTCCC TTAATACCTGGGTGTTGTATTAGATCTCA TA  373 2708335 2 ABCC5 GTAGCTACCTCCAGACCGTGGTGTCTGG 7.23E−06 0.021678507 2.02E−05 CCTCCATTTTTGTCTGTCATTCAGCTCTG ACTTACAGCTGCAGTCACCTTTGCTATAA GGCACCTGGGTAGAAGGGTGGATGGGCT TCACATCAATTTTTTTCTTCCTTTAGGGT GGGGGATTGGTTTGGCTTTCTTTTGTTGT GGTTTTTTGTTTTATTTTTGTCAAGATTG ATTTTTAGATGCAAGGACTTGAAAAGAC CCAGAAGGATGCCACCAGTTTTTCCTTG AGGCCTAGGATTTTTTATTCTGTCCCGAG CAGAGGTAATTCCTCACAACTTAGTGCA CCAGTAGCACCAGCCATTTTGAGCAGAG TACCTCTTTGGGGAGCTTTTCGTTTTGTT TTGTTTTTAATTCTCTTTCCTTAGCAGCA AGGTCTTTTTTCCTAGAGAATCTACTCCG TTGCAGAATCATTGCAACCTCAGGAGCC CTCACTGATTGAGTGCTGTCAGCCTGAT ATACTACTTTGGACTCTGGAAACAGATA TGGGTTCTATTCTCTATTTCTACTGTGTG TCGTTAAACAACCGTCGGAGACCAGATG ACCTGTTA  939 2708654 1 AGTGGTCCTCAAGAATCGCTGGTCCAGC 0.029020011 0.007307342 7.26E−06 CACTCAC  624 2708847 3 TMEM41A GCTCTTGGGGAGGATACTTAATCTCTCA 0.001685702 0.010692634 7.69E−06 CCTGTAGAATGGGGCAAGGATGGCATGA CTCAGGGATGTAGTGAGGATTACACAGG ACATGTAGTCAAGCACTTAACACAGTGC TTAGCGGCTCCCCAGCTTCCCACTTCCAA GGCTTCCTTTTACTTTCTCTCTTGGATCC CATGTTTTGTCAGGATGATGTCTACCAAC CAAAATGCATTTAGGAAGTATTGGTTCA CTTTTCCCTTTTTCTTAAACCAAGACATC TTCAAATGTCTGCTAGAGCTCTGGTCAA CATGGAACCCCGGTATTAACATACTGCA TAGATGTAATTCCAGCAAAAAGCAAAGA AACAAGACATCTTACATAGCTTGTGTGG TCTTACCAAGGGAAAATTCATGGTTTGT GTTCATCTTTTGAAATAGTAAAAATAAC TCGTGAGTTTCATTTCTACTTTCTTGGAG CCCCAGTCATTGCAGAATCTACCACAGC CACAGATCCCATTTCATTCTCTCCTGCCC CCTGAGGCTTTTIATCCTTATCCTCATTTT CAAGGTGAAGAGACTGACGGCAGGTGT AGTTCCCAGCCTTTTCATAATTTTTCATT CACCTCTTTAAATGGCAATTGGGACCTG GGGCAGTGGCTCACGCCTGTAATCCTAG CACTTTGGGAGGCTGAGGTGGGAGGATC ACTTGAGTCCGGGAGTTTGAAACCAGCC TGGGCAACACAGTGAGACCCCATCTCCA CAAAAAATTTTAAAAAGTGGGTGAATGT GGTGGTGTGTGCCTACAGTCCTAGCTGC TTGGGAGGCTGAGGCAGGAGGATCGCTT GAGTCCAGGAGTTCGAGGATGCAGTGAG CTATGATCATGTCACTGTACTCCAGCCTG GGTGACAGAGCGAGATCCTGTTTCTTAA AAATAAATAAATAACGCAATTGGGTTTT AGCTGGAAAAAAGCAGTGAAGGAGGAG GGAACCTATGACTCTCAGGCTCCAAGAT GACGTGCCTGGTAGCTGCCA  671 2710829 1 GCACGCTGGAAGATAGATGTTGAACAGT 0.000480661 0.012195242 9.06E−06 TTGCCAGATTCATTTTGAGAAATCACGG ATTGGGAGATTA 1884 2711363 1 AGTTCTTCCAGCCATTGCGACTGTGGCCC 6.02E−05 0.006846258 7.64E−07 ACGCATGTGGGGGAAGAGGCCATTTTTC ACGCCCATCCCAGTTGAGTCTTTAGATG ATCCCTTCCTG  824 2711369 1 GAAGACAGTTATTCAAACGGACCTAAAG 0.00250353 0.008479945 8.04E−06 CATATGATGCTCTGTGCAACACTGGCCC CGTTCACAATGAATGCACTTACA   74 2712860 2 UBXN7 CTGTATTGATCCTGCTAGTCCAAGAATG 0.00020038 0.035827272 4.83E−05 GACATGAAGTGAACCTATCGTGGTGACT GGGATAGGAAGGTGCTTGCTATTTTTGC CAGCACAGCATATTAGTTCCTTTGGAGC CCTCCATTGTCTGAGTCTGCAGTGATCTG TAGGAAGGCAGCTGGTCAATAATCATGT AGTACAATGGCTTGGAATTGTAACCACT ATGGTTATTGATTGTCCTGTGTTGTTTCA GGCATACTTAGGTATGTCCCTGGGGAAA AAGAAAACCATTCAGCTGAGAGTTGCTA ACCATGTTCTTTTGGTTAGAAATAATGGT TCATTTTTTGCCCCTGGTTGGAATAGTCT CTAAAAGGCTCTGGTGACTGAATTGAAC ATGAGTCCGCATGCTGTTTTCTTTCAAAA GGTATCAAAACGGAAAGCCTCTCTAAGG GGAAGACCTTTCAACTCCATTCA 1006 2713195 2 DLG1 AACCGAATCCAAGAGCCGTTAGGCAGCA 0.005359393 0.008326261 5.45E−06 GAGTGTGTTACCACATTGAAATACACAG TGCTGCTGTTAGACTAAATGTCGTAGGTT GTTAACCACATAGAAACACACTAGTATG AAGAAAACTGTTGTAAAATCTCAAGAGC TTCAGAAACTGCCTTACAAGA 1146 2713748 6 ATCTTACGGGGAGGCTGTCTCCAGACAA 0.000151311 0.012719493 1.44E−05 CCAGCAGCCTGGGCTCCAGGACGACGCC AAACCCACAGGC 1806 2714218 3 MYL5 ATCTTCAGCTCCTGCTAGGCGCCGGGGA 0.005051331 0.007306045 2.72E−06 AAGTACCAGGCGCTGGCCTGTAACCTCC TTCCGGCTCTGTCCCCATCAGCGGCTCCC CCAGAAGTGATGGCC 1527 2714265 9 PCGF3 CTGTGGGACATCAACGCCCACATCACCT 0.00055537 0.006717865 2.23E−06 GCCGCCTGTGCAGCGGGTACCTCATCGA CGCCACCACGGTGACCGAGTGTCTGCAC A  810 2714497 2 FGFRL1 CCGTGAAGCCTGCAGTACGTGTGCCGTG 0.000131632 0.009136359 6.17E−06 AGGCTCATAGTTGATGAGGGACTTTCCC TGCTCCACCGTCACTCCCCCAACTCTGCC CGCCTCTGTCCCCGCCTCAGTCCCCGCCT CCATCCCCGCCTCTGTCCCCTGGCCTTGG CGGCTATTTTTGCCACCTGCCTTGGGTGC CCAGGAGTCCCCTACTGCTGTGGGCTGG GGTTGGGGGCACAGCAGCCCCAAGCCTG AGAGGCTGGAGCCCATGGCTAGTGGCTC ATCCCCACTGCATTCTCCCCCTGACACAG AGAAGGGGCCTTGGTATTTATATTTAAG AAATGAAGATAATATTAATAATGATGGA AGGAAGACTGGGTTGCAGGGACTGTGGT CTCTCCTGGGGCCCGGGACCCGCCTGGT CTTTCAGCCAT 1686 2715217 2 C4orf48 GGACCACGCTGCTCCGTGTGAATAAATG 5.66E−05 0.009995655 4.38E−06 CCCAGTGGCA  361 2715538 4 FAM193A CTAGAAAAATAGTTGATGGCAGTGGCTT 0.014622507 0.010400399 1.38E−05 CCCCCCCACCCTTCCCCGCCAACTGGCTG TTGCGCTTCTGAGGC 1143 2715773 4 GRK4 GCCCTGCATATATTATCTATGACTAACCC 1.60E−05 0.008298962 6.27E−06 CAAAACAGACAGCTT  947 2717272 4 SORCS2 TTGTCTGGCTGGAGGTCTTCGTCCATGTT 0.013148205 0.007377617 5.17E−06 GGCTGGCGGGTGAGGTGGTCTCCAGACC AGTGTAACTCTTTAAGAACAGC  312 2717882 9 GPR78; TGTCCAGAGCCTACGCTGACGTCCACCC 0.038548018 0.010132666 9.20E−06 CPZ CATGATGATGGACAGGTCGGAGAATAGG TGTGGAGGCAATTTCCTGAAGAGGGGGA GCATCATCAACGGGGCGGACTGGTACAG CTTCAC 1025 2718833 1 AGCTTAAGTGGACAGGTTCTGCCCCTGC 0.038548018 0.006597734 7.31E−06 1651 2719625 9 BST1 GACTCGATTACCAATCCTGCCCTACATC 0.000130223 0.008372717 2.39E−06 AGAAGACTGTGAAAATAATCCTGTGGAT TCCT 1639 2719826 1 GACCCGTGTCCTTGCAGAGCTCATTTCTG 0.000909538 0.007775232 3.00E−06 GAGAAGAAAGATCTGGTTGCATAGAGTG CCCTGTGATGAGGGCTGTAATGGAAGGG GCAGAGAGTTCCATGGAAAACTGGAGA GAGGAGGCAGAAACTGCTGCAATATCTG GGCTTGAGCTTCACAG   94 2720275 9 NCAPG AAGATAGGACATGTCTGAGAGCTTTGGA 2.38E−05 0.025732286 2.34E−05 GAAAATCAAGATTCAGTTAGAAAAAGG AAATAAAGAATTTGGTGACCAAGCTGAA GCAGCACAGGATGCCACCTTGACTACAA CTACT 1227 2720285 9 NCAPG TGAGACTACCAAGACGAGCCAAAACCGC 1.10E−05 0.010793838 5.59E−06 AGCACTAGAAAAAAGT  210 2720599 4 SLIT2 CCCTCCGACAGTTCCAATTGATTGAAAA 0.000279712 0.011956609 7.08E−06 AAGCCTAATTTAAAGTTCTGTTTGTTCTA TGTCTTAAACCATCAGAATTCTCTTTTGG GACCTGAGGAATGCTCTGGAGGAAAAA GAATCCAAGGATAAAAAGTCATTGCAAG CCAACAATTGTTCCTAATCCTCACAAAA TGCTGGAGAAATTAAATTTATTCTTTATT GCTCAAAGTGTTACCTAGGTCACTGGGC GATGGGAAAATTGGACTGGAAGTCGAGT AGGCGCAAGCTTTGTTTTGTGTCTAGATG CTTAACCTTAGACACGACAAGGCATCTT AGAGTGTTGTGGGAACTTGGTTCAGAGC ATTAACACCAAGACTTTTATTACCCCGG ATTTATAATAGGCTGTGCTG  838 2720737 2 PACRGL CGTGAACCGCGGGTACAGGTGTCCTGTC 0.000111639 0.008424719 2.21E−06 TGCGCTCTCTGCCAAGCCGGCTTGCTTCC TGA 1040 2721165 4 RP11- TACTCATGGGAAATTGGGTACTGCAGAG 0.011398396 0.009482342 5.16E−06 412P11.1 CAGAGGAGTGGAATGTAGTATAAAATAT TAGTAAAGAGCAAGCACTTTGAATTCAA ATAGGTCTGATTTGGTTACTGATGTTGCC ACTTCTTACCTGTGTGACCTTGAGCAACT TAACTTACCTCTTGTGTTAGTTATCTATT GTCACATAACAAATTAACGAATTTAGTG GCTTAAAAAAACATACATTTATTATCTC ACAGTTTCTGTGGGTCAAAGAGTTGGGG CATTTTTACTGGTCTTCCGCCTAGTGCCT CAGAAAGCTGCAACTCACGTTTAAATCA AGCCTGGGTTCTCATGAGAGGCTCAGCT GGGAAACACTCCATTTC  592 2724294 4 WDR19 CATTACATTATGACGAGACCCAGGTACC 4.25E−05 0.009963907 5.26E−06 TGAATCTTGGATCCAGACCTTAGCCCAG GGAGATGACTGGATTGGTAATGACAAAT GG 1193 2725201 4 LIMCH1 CCAAGTATGGATAAGGGCCAGTCTACCC 0.00081399 0.007780391 4.53E−06 ATTCATCACCTCCTTAGTTGCCAGTCAAT TTCCAGTCAAGTAGCAGTGGGAATGAAT TATCTAAAAGCTCTCTGCTAGCATACAC GTGAAATA 2034 2725364 2 TMEM33 CTGCGCTGTGTTGCTAATGGTTAAAGAA 0.000760518 0.007417092 5.94E−06 GTCTGTATCTAGTGATAAATATACCAGTT TTTTTAAAAAGATGCTGTTGTGCCTATAT CATGAAGTACATTAATTTCTCATGTAAA AAAAATAGCTCTAAAATTTGTTTCAACC TAATTGGTAACCTGAGTTTATATCTGGCA TGAATTCATTATGGTGATACACATATGT GAATTCAGTACATTTTGAGACAGTATTCT ACCATTCAGTAATTTTGGTTAATGATTTT AACACTTCTCAGTGTATTTAATTTCAAAT TGTTTTTTTAATTGGTTTTATGCTGCTTTG TTAGGACAGATGTGTTTTGAATGTACCA TTATAAGAAGAATTCTATGTATCTTAAA CTATGATCTTCTAAAATTTTATTTCCGTA AGTACTTCTGTGGCCTTGAGTATTTTTTA AAAGGCTCAACTGTAAGCCTCTTAGCCA GTTGGATAAATATTTGGGGTCACCTAGC CATTGAAAGCAGAAAGCAGTAGTGACAC AGCTTTCCCTTCAAAGAGCCATTGAGAA ACATTTCTCAAACAGGAAATCCTTCTTTT ACTAATGTGGACATATAGATTATTCGTA TTATAGTTTGTAGAACTACCTAGTTCAGA ATCTTGACTGCCAGTTTTCTTGGTTTCTT AGGCTTGAATTTTCATAGACAATTGCAA CAGTTTAGATGCCTTTTGAAAGGAATGT AATGAAGATTCAGCATCTGACTATATGT GTGTCTATCCTGAAATAATAATGGAGAG TATACTGTAGATTACATGTTTACCCATCA AATCTGACTTAAAAGGTTAAATGGAAGG TTTTATAGGTAAGGTAATTGATTGGGAA TGGGGTAGGGGGAGGAGTTGTGGGGGA ATAATGTGCATTTCAGTCTCAACGCATA GATAAATTTAGGGGAATTGGATGTATTA TTCAACTTTGATTTGGGTTGTAAAATGTG TTAAATCCTGTTCATTGAACTCCCATCAA CTCTTATAAAATTCATGCTGATCTTCATT ACCGTTGC 1848 2728354 7 HOPX TTCTGGCCCAACAGGCTTCTTTCCAAGTT 2.26E−05 0.009545719 6.32E−06 AATGCAGCTATATTCCAAGGAAGTGTTT TATGAAATCTGAATACTCAAACACCCCT TCTGTATTTTCACTCAACCATCATTGTAT TAGATGATACATAAGGAAAGTGACTTAG GGAAGTAAGTTCAGAAGGAAATGTGTTC CCTTCTCCCTCATATTATCTTTTCAACAG AGGCCTGGATTGCTAAATGGATTATGAA AGCAAATTGCTACTGGGAGGTGATGGTC AAAAGCAAACTTA  337 2728905 1 TTATTTAAGCCAACTATTCCAGATGTCCA 0.03372316 0.015384819 1.83E−05 CCCACGGGCACAGAGCCGCAGAATCAG ATGGTATGACCTGTGTGCCAAAGAAAAA C  622 2731160 4 RP11- CACTTCTCTTTGGTAGGAGGTTCTCTTCC 0.000158328 0.011497866 7.81E−06 692D12.1 AGCTCTGTGCCTTAAATTAACCGAACAT GGCCATGGTTCCAGAAATTTGCCTGCCC TGATCTGTTCACTATGATGATTATGTACA TGATTCCCTGGTTCCAGATCTGCACTCAC TCCATA 1018 2731449 4 MTHFD2L ACAGGCCACGTTAGGAATGCATATTTTA 0.000391017 0.00826973 4.23E−06 TAACTTGAATAATGTGTTAGCCTCTTACC TCTTCACTATATTGGTTACCTTTCAAACA TACAAGGGCTGAGTTCTTTCTCCCTTTAG ATCTTAGCGTAAATGTCACTGCTTTGGG GAAGCTTTTCCAGCCCATGCC  594 2732857 9 ANXA3 GATTATCCAGACTTTAGCCCATCAGTGG 0.000487927 0.008250723 5.40E−06 ATGCTG 1273 2733095 4 RP11- ACATTTCTTCTCACAGGTCTCTGTCCCTC 0.000314052 0.00752303 3.35E−06 438E5.1 AATACAAGTAATTAACCCAAATAGATGT CTGCAAACCTCTGCTAACTTTTTAGCAGA CACAGGAACTTCTCAATTTTATTGTAATT ACTACAGACTATGGTAAAAGTAACGGCA AAGTTTACTTACTAGGGTCTGGGGGGCA TACATGGAAAAAGCACTTAATTCAAGCT CAGGGAAGTGAGCATGGGGAGCTGGAA GGATTCCTGAAAGACAATACAACAAAAC TGAGAACCTAAGAAAAAGTGGCAATTAG CTAGGCTACATGGACCCTTA  426 2734127 8 RP11- CTGCCTTGATGTGCCCACCACAATACCA 0.002481187 0.014163778 1.48E−05 8L2.1 GGCGGGCAAGATGATAATCATCGAGCCA GCTATTATGAGCAGTATAAACAAATGAC AAATCTCTGGGTGCAGGAAA 1873 2735462 4 HERC3 CAAACCAGGGCAACCAGACCGAGAGGA 0.004105357 0.007182623 6.66E−06 GC  674 2736504 9 BMPR1B TCCTCATCAAAGAAGATCAATTGAATGC 0.000254163 0.013616013 1.23E−05 TGCACAGAAAGGAACGAATGTAATAAA GACCTACACCCTACACTGCCTCCATTGA AAAACA  933 2736527 4 BMPR1B AAACACAGTAGAGTCTGCAAATTTCATC 0.009101689 0.006962968 2.94E−06 AGTCAGACCAAGATAGTTACCGTCCTCG TAGAGGGGTATGCTGGATTTCCAAA 1950 2737930 5 CENPE AAGGTTTTCCTTGAGCTGGTCTCTCTCTA 0.000664925 0.007944468 5.90E−06 CTTTGAGAGTCTCCTCCACACTCCTAAGG TCATCTCTTTCTTTTGTTACAGATCTCATT TCTTCAAGGTTTTCATGTAGTATCTGAGT CAACCTTATATTCTCCGTTTCTATGTTTT CCAGGTTTAACTTCTGGGTCTCAAATTGC TCCTTCAAGTGTTCTATTTCACACATTTT CTCCTGAGTCTCATTGACAGCTGTC  176 2737932 5 CENPE TCTCTCTATCTGAAGGGCCTCCTGTACTC 2.22E−06 0.026656504 2.45E−05 TTTTCATTTCCTCTTTTTCCTTAATCATAA TTTGTATTTCTTCTTGACTTTCTTGAAGTC TGTTGGTCAACTCGAGCATCTTACTTTCT ATACTTTGTAGTGCTGAATCCTTGGCTTT GCGATGCTCCTTG  867 2737940 5 CENPE TGGTTATAGATTTCACTTCCTCATAATTT 4.53E−05 0.015521495 1.13E−05 TCATTAAGTTTCTGAGCCAACTCAAGCCT CTCTGTTTCCATATGTTCCAATGTCAATT CTTTGTTCTTTAATTCATTCTTTAAATTCT CTATTTCATTAATCTTTTTCTGCATCTCA CTCATCTCTTCTTGTACATTAAGAAGTTG TTGCTG 1447 2740920 4 NDST3 TGTAACATTCCCTCTATCTCAAATGTCTC 0.001339198 0.008462414 8.23E−06 TTCAAATTACTCCCATCCTTCAAGGCTCT ACCCAAATCCTACTCCACAGTACAGCCT CACCACCCCCTGGAGCATTCCACAGACT CCCCCACTTGCCATGGTCTCTTTCTTCTC TCATCCTGTTATAGTCATTGTCTCTAATC CACAACCCTCACATTATTATCATTCTTGT CACTATCTCTGCTTTATAATTTAGAACAT TTTAAATAAATTCAGTCTGCTGAACATTT ATATTTTAAATAGCATGAGAGCTACCCC ATAAATGTTTGAATGCATGACATATATA CC 1930 2746264 1 AAGAGGAACTTCCGCCCTGTCCCTGGAC 0.000292246 0.006691996 4.00E−06 CTCACATTTTCCTGGAAAAGAAAGCTTC TGGCACTGGTGCACACATTAGGCCAAGA GGAGCCTGCTTTCCTTGACTTTTCTG  280 2746800 9 ARHGAP10 TACAAACCTCCAGGGAACCTGGCTGGCT 0.000356857 0.010703669 8.03E−06 AGAAGGGACTCTGAACGGCAAGAGGGG GCTGATTCCACAGAACTACGTC  161 2746996 1 CACAAAGACAACAGGTGGAACTGGCAT 0.006154763 0.011745989 6.30E−06 AGCATTTACCCTTGGTCTGAGAGATGGC CTGGGCCACTTTGAGAAAGGAGTAGAGC TAGAAGC  238 2747807 1 AGCCGCCGCTTCACATCGGGGTCCCCGC 0.004167745 0.012491376 6.74E−06 CCCCCCGGCCGGGGGGTGGTTGCCGAGC TTGGTTGGGGCCCCGGTTCATACACTCC GGGGCAAGATGCTACGGCCCCGGGCGG GTGGCCGAGTCGGCGGCAAGGCGAGGG ACCCGGCCGGCTCCGCTCGGCGCCGCCC CCGCTCCCGGCTCCCGCATGTGTCGCTGC GGCTGG  700 2750636 4 CPE GCATGTATATCCATCATCGAAATACAGT 0.013148205 0.013210393 1.20E−05 ACTCATAAAAGAAACCTTTATTAACTTA TGTCTAAGTAATGGATTCTGTGTTCCCAG ACCACTCGACCCGGAGTTAAAT 1147 2750647 4 CPE TGAGTACAGCCCACTGATTGACATTCAA 0.00059375 0.011114732 9.38E−06 GACCCATTGGAAAAATCAGGAGACACA AGAGTGGGAAGAGTGCAGATTGGAGCA GCTATCCAAAAATACA 1003 2751964 4 GALNT7 TTATTCTGGCACACAACCTGGTTTACATT 0.000111337 0.006519285 3.50E−06 TTTTGAATTATTATTTCTAAACTATACAT TGGTGAAAGGAGATGGAAACATTATACA ACACACAACACAAAATTATGCTCTATTC CAGCTCTGTTGTCCCCTGTCCTCTGTAAG AACGCAAGGCCTGCAGATGTTCCCCAAA TGGAGGTCCCTAGGACAGCAAAGGTGCC CCTCACCACCTTCTGTCACCTTCACCCCA CCCTTTTCCTCCCTCCTTCAGCCCCTTGA TGTTTCTAATTCCGTCCTGTCTCCCATTC AAAGTTTCTATCTTGCCCTTTTCCCCAAG TTGCTATCTTCTGCCTTAGAAGCAAGTCC CAAATTTCCTTTCATGTTTTACGTATTTT CACCAATTCTGGTGTCCGTTGTAAATC 1259 2751997 5 HMGB2 CTAGGTCAACTGTGTCTAAGAACTACTA 0.000731459 0.014936895 1.55E−05 GGCAGAAATACCGAAAAAAATCAACAT AGCTCTGGTCTTCAAATGGCTTTTTTAAA GTGAAAATTAACTTAGCATATTAAGACA AAGACAATAGAAATAATATACATAATTT TATTACAAAATTTTTTTTAAAAAAACGA AATGCAACATCCTAAAAAACCCAAAATT TACTATTGATACTAATTCCTACAAGTTTG CTGTGCTACCATACACAAGAAATTAAAA AAACCATTAAATATTTAGGAACATTCAA CATCAGAAGCTGTAAAATCTAACTGTAT GAGTAGCCCATCAAAAAGCTACAACCTG CATTTTTTAAAAGTATTTTCTCTACAGAG AATCTTATCAGCTATACAAAAATCTGTA CAGTTTTTATACTGAAGCTAGTATTGAGC TGCACTTGAATTCACATTCTTAGCAAAAT AATTGCCTGAGCACACACACACATTCCA CACGCATCATTAAAGGATAGCCATTTAT TCTTCATCTTCATCCTCTTCCTCCTCATCT TCATCTTCTTCTTCCTCCTCCTCCTCCTCA TCTTCTGGTTCGTTCTTCTTCTTTGAGCC 1860 2754413 5 MLF1IP CCTGGGACCGATTAAGGTGTCAACATTT 0.000257482 0.008133228 5.30E−06 TAAAATTACTCAAGATATTAACCAGAAA AGATGATTATGGCCTTTAAAACTATTGG ACAAACTGATGCTATTTAACATTGTTCAC AGCCATTTAATTTGAATAACAAATTTTA GATTCTAAGTAGGCCATAACTTCTTTGCA AAACAATTGATTTATAAAGGTACAGTTT CAGAAGGTAACAGCATGAGACTAGTCTT CCTATAGGCACATTTTAGTAGACTGCTCT TCTCATCCCTGGTCAAGGAGCTTCTCTAA CTGATGGTTGATATTTCGCAGATGGCTTT CGGCTCCCAGAAGTGTTCTTGCTTTAAAT AACAGAGCTGGAAGGCTGGATGAATCAT ACTGTTGAAAGAAAATTATATAATTAGC AATATCAAAAACTCATAACCTTGTCCTT AGATAGCCCAATCTTATGACTAATGCAA ATTTTGATTGAGCTTTCCATTAACTACTC CTCCTCTCATTTTTAACTAGGACCATTAA GACAATTGGTTTTAATCCATTTCCCTTAG AATATAATTGATCACAAAGTTGCTAGGG AGCTGCTC 1274 2757410 1 AGGGAACCCTCCATCCAGGTGGTCAGGG 0.000310049 0.008014173 7.49E−06 1130 2757591 4 WHSC2 GGGCCGCCCTGAACATGTTGTAGTGGAG 0.012547908 0.007213149 4.68E−06 CTTCCGTCTGTCTTCAGCTTCCGTCAACA CTGAACCAGCTCATCTAAGCACCAGACA CAAGATTTTACTGCTTTTGTCAGGTGGAG TGGGAAGTCGCACCCACGTCTGGCCAGT TGGGTCGGCTGTAACTCAGACTTTGGAC TGACTTGTCACCCAGCTCATATAGCAAG GAGTTCCTGATGGCAGCTGGGGGAGCTG ACATCAGTGTCAGCTCAGACTCTTAGGC AGTTA   88 2758470 1 GCCAGGCACGCAAATATGGGGCCCTTGT 0.003071703 0.024935438 2.95E−05 GTGGTGTGC  385 2759511 5 SORCS2 TGGGTTAAATGGTGCTCCACACATGCAA 0.000790656 0.006915943 5.83E−06 ATTTATGCTCACCTCGAACCTCAGAATGT GACCTTATTTGGGAATAGAGACTTTGCA GATATAATTAGTGAAGACAAGGTCATCC TGGAATAGGCTAGACCCTAAATCCAATG GCTGTGTTCTTATAAGAAGCAGGAAACT TGGACAAACACACACAGAGAAGTCCATA CAAAAAGGCAGCTGCAGAGATGGAGTG GGGTGGCCAAGAAGAAGCCAAGGACTG CCAGTAACCATCAGAGGCTGGAAGAGGC AAGGAAGGAAACTGCCCTGGGCTTGGGG CCTGCCCACACCTTGATGTCAGACTCTG GTCCAGAGCAGTGTGAGAATACGTTTCT GTTACTTTAAGCCATCCAATCTGTGGTCC TTCATTATGGCAGCCATGGGACACAGAT GCAGGTTGTATATTAAAGCAATACCAAC CAAAATGAAACAAAACCAAGTAGAACA TGCAACAGAGACAGCGTATGCCCCTAAA GCTTAAAGTATGTACCATCTAGCCCTTTA CAGAAAACGTTTGCCAACCCCTGTTCTT GAGTAGAATCCAAACTCCCTATCACTAT CCCAGCGTTCACAGCCTACTGTCTCCCCA GCCTCATCCCAGGCCATCCCTCCTCCTTG TAGCCACCACTCTTGCCATGCTCAGTCTC ACTCACTGACCATCCACCTTTTTTTTGCC TCAGGGCCTTTGTGTACGCAGCTGATCA CAGCTCATGCACCACTTCCTCAGGGCAG CCTCTTTCCCATCTCCCCACAGCCTGGGT CGAGCACATTGTGACACTACTTCAGAGA ACCCTGACCTCCCTTTTCCCAACACAATC ATGGGGTAATTAAGTACAATTACTAGCT AGTGATAATGAATTATAATCAATCGAGA AGTTCAATTAACTGGGTGATCATTCACTT ACTGCCTGCCCCCATACTAAGTTGTCAA CTCCATGGGGTAGGGGCTAAGTCACCAG TAACCACCACAGTGCTTTGTACAGATCA AGTACGTCCTCTAGAAATATTTGTGGGA CGGATGGGTAGATGGATAAATGAATACA TGGATTAAGAGGTAGATGGATAGATGGA TGGATAGGTAGATGGATGCATGAGTAGA TTGATGGATAGGTAGATGGATGAATGGA TGAGTAGACTGATGGATGGGTAGATGGA TGGATGGAAGGATGGATGGGCAGATGA ATGGATGTATAGATGGGTAGACAGATGG GCAAATGGACAGATGGACAGATGGATTG AGGGAGAGATGGGTGGATGAGTAGGTG GATGGATGGATAGATGGATGGGTAGATG AATGGATGGTAGATAAATGGATGGGTAG GTGGATGGATAGATGGATGAATGGGTAG ACGGATGGATGGGTAGATGAATGGGTAG ATAGACGGATGGGTAGATAGATGGATAG ATGGATGAATGGATAGATGGATTGGTAG GTAGATGAATAGGTAGATGCATGAATGG ATACATGGATGGATGGGTAGATGGATGG ATAGATGGATGAATGGGTAGATGGATGG ACAGGTAGATGGATGAATGGATAGATGG ATTGGTAGGTGGATGAATAGGTAGATGG ATGAATGGATACATGGATGGATGGGTAG ATGGATGTATGGATGAACAAACATAATT TCAGGAGCTCCCCAGGCTAGTCTGGACT TCCAGCCGCTCCCCTCCATGTCTGTAGTT AGTCCTAGGTTCCTACCTGGCCTGGAGT CCCACCTAGACCTCAGATCCAATAGATA AAAGTGATTCTCTTGTTCCCATGTCTCAG TAGCCCTGTATGACAAATTAAAAACTGA GTGGGTTTGAATAAAGGGCCACGAAGCC CCCATTTGGGCCCAGATCTATACTGAGT AGGACTCTAGACACCCAGGGATG  504 2759598 2 AFAP1 GCCAGCCTGAAGTCACGGTCCTGGCCCA 0.021792834 0.006631939 1.53E−06 GCA 1327 2762889 5 SLIT2 TGCTGGCCCAAAGCCAGTCCAGCACTGC 0.025498894 0.007381634 3.06E−06 CTCCTCTGACTCTAAAATCAGAAGAGTC CTGA 1676 2763219 4 KCNIP4 GCTCAGGTCTCTTATTGGGAATTTACATG 9.72E−05 0.007286607 5.33E−06 ATGTTCTGGTGTAGGCAGAGGCATTTCA AATTGGTGTAGGAATTTTCAAATTAAAT AGGATGTTTCTCTAATTTTTAAACTTAAT TTTGGGAATCACTTATTTTAGGGATATTA TTATACATCATCTAATATTTCAAGCACTT GTGAAAGTCACATTCTGCTCAACTTTTCT CACATCCTTTCCAAGAATTTTAAATCACT TTTTCCATATCATCTACTTTCATAAACTC CCTTTAATTTGAAGATGAGTCTTTTCTAC TTTGATGCACAGTATTATTGCAGTGGTTA TCTGTTCCCTGTCCGCTCATGGTCCAGTT TCATCAGGATTTTCTGCTGAAGTCATGAT ATCTGAGAGAGTTGGCACATACTCTGAA ACGTAGGTGCACTGTGTTAATTTAAAAG TTGTGGGGAGGAAAATCTTGGGGACAAG TATAAAACAATGAGAGTGCAGAACCAG GCATTGAGAAACATGGAAAAAGGAAGC CAGAACCTGTAAAATACAATATCCAGGG ACATGGAGTGAGGGAATTCTCCTACTGT GGATTTATAGAATAAATCTCATCTTTTAA AATGGAGATGTTGTAAGATAGTTTTTAA GAAAGGGCACACATCTAAACTGGGAAG CTGGAAGGTAATAAATACTAACACTTCT GATGTAATTTAAGTACAGGAGTCTCCGC TACACCCTGTAAG  231 2763921 9 CCDC149 GACCCCACTCTTCCTAGTGGACAGAGGT 4.35E−07 0.020155155 2.18E−05 CGAGATCCCCACTGCTGAAGTTTGTCGA GCAGCCCACTGAGAAC  275 2767308 4 BEND4 GGTGCAGCAAATCCGTTTTCTCCTTTTAC 0.002052564 0.017199346 1.77E−05 ATTGGAGCCCTGGGGTTAGATGCAGACG AGTAGTGTTTTCCCACGCCAGGCAGGCA CCGACTGCAAGACAGACACTGGGTAGAA CCCAGAAGAATGTAATGGAACCAGATCA TTCCTGGTTTCCCCAAGTCCGAGACATG GTTGCAGCTAGCA  475 2769840 9 KDR TGTAAGTACCCTTGTTATCCAAGCGGCA 0.000199853 0.007321611 4.45E−06 AATGTGTCAGCTTTGTACAAATGTGAAG CGGTCAACAAAGTCGGGAGAGGAGAGA GGGTGATCTCCTTCCACGTGACCA  489 2771025 5 LPHN3 CTCTTGCAAATTTCACAAGCTTTGGCTGT 0.000172838 0.01109885 9.41E−06 GCTCCCTGAAAAATCAGCAGCAGCAATG TCCTTCAGGCAGCAGCT  574 2771634 4 RP11- TTTACTAGGTTGCATAATGACTCCCAAA 0.003428273 0.009027656 3.62E−06 584P21.2 ATTTACGTCCACTTGGAATGTCAGAATG TGACTTCATTTGCAAATAGGGACTTTGTA GATGTAAAGTAAGCATCAAGATGAGTTT ATGCTGTACTAGGGTCAGCCCTAAATTC ACTTCTAAGAGACAGAAGGACACCCAGG AATACATGGAAGGCCATGTGAAAATGGA GGCAGAGCTTGGAGTGATGCCCGCCACA AGTCAAGGGATGCTGGGAGCCACCAAA AACTGGAAGAGGCAAGGAAAGTTTCTCC CCGAGAGCCGTTAGTGGGAGTGTGGCTC TGCTGGCAACTTGATTTCAGACTTCTAGC CTCCAGAACTCTGAGGTAATAAGTTTCT CTTGTTTTAAGACCCCAGGTTTGAAGTA GTTTGTTACAGCAGCCCAAGAAACAATT AATATGTCTGAAAGTGCTACCAGATGAT TTGCATGTCTCTTTAGAGTGATTACCCTG ACAACATA 1248 2772766 5 SLC4A4 TTCTTCCCTCTCCTAACTCCGTCAGACTG 5.40E−05 0.009353946 6.89E−06 GCCCCAAGACTGTGGCTTCAAGGGCCAC CAGTCCCTTACTCTTCAAGCCCTGACTAT GGAGTTGGCAGATGA  573 2773378 1 AGCATCTCCCAGAGGGCTGCGTGCCTCA 0.000425014 0.008077849 2.20E−06 GAAAAGCCGGCATCCCTAGCCCGCTCTG GCACAGGCCATGAG  817 2775033 4 ANTXR2 GGAATAAGACACATTGTACCCACTAAGT 0.002641545 0.011265019 7.43E−06 AATTTTTCATCCTCCACTCCCCTCTCTCC CCCATGCTTGTGAACTCTTTTCTATTGTA TATTTTTAGCAGACTATCAGCACAAGTCT TACAGATAGTATTGTGTATACCAATAGC TATTTTGCCTAGACGGATTCCTCCTGGAA GTTCATACCTTTATTTCTGCCTATTCTGT GCCCTCTGAG  814 2775038 9 ANTXR2 GAAAGCAGGAGGCTTGAAAACCTCCAGT 0.045938047 0.010132648 2.35E−06 ATCATAATTGCTCTGACAGATGGCAAGT TGGACGGTCTGGTGCCATCATATGCAGA GAAAG  340 2775115 1 TGTCATAGCAGGATGATAGGTACCCCGC 0.000146929 0.015266238 9.71E−06 AAACAAGCACAAACAGGGAACGTGATG AGAGTGGAAGTGGTGGCCTGCAGCCCCA AATTGGCTTGGGAGGATCATACCATGAT GACAGGGAAGCCTGCAGTACTCCAGCAG ACATGAGAGTCACCCAGAGCTTATA  948 2776793 3 MAPK10 GCTCCTTGCAGCAATATAGCAACTTAGA 0.001522517 0.00974321 4.48E−06 AATGGCGGG 1164 2776796 2 MAPK10 CTGCAGTGTGGTGAACTCCAACTTTTAG 0.003534738 0.007120783 3.70E−06  555 2778529 4 UNC5C TGGGGCTACAACTCATGTTCCTTGGCTCC 0.005485054 0.009116757 6.23E−06 CGGTTCCAGCTGCTTTCTACCACACAGC ACTGCATCTTCAGCTGCCCCCATGCAGA TTTATATTGCATGCCTCTGAGTCTTATGC TTCCTTGGCAAACCAGGCAGTCGCAAGC TCCAGTGCCTACTGGGACCAATGAGGTT ACGTGAGTAAGTGGGCTGAATGTAGTAC AACAGATTCTGCTGGAAAGTGTGGTGAT CTGGAGAGCACATGTCCCGTCTAAAACA AAAGACTCCAGGTTCTCACTGCAGGA   45 2780211 9 CENPE ACAATTCAAGGAGCATCGCAAAGCCAAG 7.94E−08 0.085631944 0.000102736 GATTCAGCACTACAAAGTATAGAAAGTA AGATGCTCGAGTTGACCAACAGACTTCA AGAAAGTCAAGAAGAAATACAAATTAT GATTAAGGAAAAAGAGGAAATGAAAAG AGTACAGGAGGCCCTTCAGATAGAGAGA GACC  821 2780715 3 RP11- CAAACTTGTGGCTTGGTGATCCAGGGGT 0.004749446 0.009335921 7.74E−06 710F7.2 TGGAAAAGAGGCTGTTCACTGCCTTGGT CAAGAGGAGCTGGGATGTGCTCGTCTTC ACACCAGGAAGAAG  565 2781004 2 PAPSS1 CAGTCACTCCACCTTTGACACATTACTAG 0.002537394 0.011813474 8.67E−06 TAACAAGAGGGGACCACATAGTCTCTGT TGGCATTTCTTTGTGGTGTCTGTCTGGAC ATGCTTCCTAAAAACAGACCATTTTCCTT AACTTGCATCAGTTTTGGTCTGCCTTATG AGTTCTGTTTTGAACAAGTGTAACACAC TGATGGTTTTAATGTATCTTTTCCACTTA TTATAGTTATATTCCTACAATACAATTTT AAAATTGTCTTTTTATATTATATTTATGC TTCTGTGTCATGATTTTTTCAAGCTGTTA TATTAGTTGTAACCAGTAGTATTCACATT A 1966 2782139 1 AGCCTGCTTAGACAAATCCTGCTACCTG 0.000402054 0.006574721 2.46E−06 TCAGCCCTCCTGTGGGTGCCAAACCGGC TGCCAGGTTAACCTCTGGGGAAACAGGA AGACCTGCTGATTTAACCCCTACTTCCCT TCCTATAATCCACAGTAA 1129 2788582 1 CCCGCCCGTGCTCTGTTGCCGCCGCCCCT 0.014042909 0.007952057 7.05E−06 TCGCAGCGTCCCGCGGCTGCTACTCACA ATCGCGCCCCCACT 1902 2790298 5 KIAA0922 TGAATGGTTATGCAAAATGTGGCATATC 2.67E−05 0.008591867 4.35E−06 CTACAATGTGTATTATTTGCAATAAAAA GGAATGAAATACATGGATGAAACTGAA AACATGCTAAGGGAAAGATGCCAATCAC AAAAGACCATACATTTCATTTATATAAG ATGTTCAAAATAGACAAATCTTTAGAGA CAGAAAGTAAGAGACTGAGGCAATGAA AATGTTCTAAAATTAGACAGTGATCGTG AGGGCTGCACAA 1604 2792487 5 CPE CTCTGAGGGTTGAGAAACATTTCCCAAC 0.00241526 0.007846726 2.23E−06 TATCCTGTACAATTCTCTACATGTGAATT ATCATGTAATCCCTTTGAACTACATATCA TGCACAGAATTTATGATTTCAAGTTCTAT CCTGTGCTATTTAATTTCTAAGCTGAACA CATATTTAACAGAAGGCAAGAAAGAAG ATGAAATGTGGTTCACACATTTTTCATCA TAATCCATTTATATAAGATAACTTGGAA AAGAATCTGTAAGTCATTTTTATTAGTCT GTCAAAGAAATGGCTGCTAATAAAACTG CCGAATCAAATCATTACCAGTACTGTGC ATTGACCCTTGGCATA  840 2793953 2 HMGB2 GTGCAGCTCAATACTAGCTTCAGTATAA 1.54E−05 0.017289428 1.47E−05 AAACTGTACAGATTTTTGTATAGCTGAT AAGATTCTCTGTAGAGAAAATACTTTTA AAAAATGCAGGTTGTAGCTTTTTGATGG GCTACTCATACAGTTAGATTTTACAGCTT CTGATGTTGAATGTTCCTAAATATTTAAT GGTTTTTTTAATTTCTTGTGTATGGTAGC ACAGCAAACTTGTA  730 2794726 4 ASB5 CTTGGTTATGTTGGATCTGTTTCCCTTTTT 0.024147101 0.007418717 7.68E−06 TGTGTTGTTCCAAGTGAGATTGGAAGAA AAGATAATGTAAGAGTTGGATGGCA  861 2795876 1 GCCCTGCTGTAATTGTGAATGGACACAT 0.029646817 0.009793545 8.29E−06 GCAACAAGCCCAGCCTTAGGAGAGTGTG ATCATCAAGGGCTCACACCTCTCAGGAA TGAAGAGTTGGTTCACACCACC 1119 2796405 4 IRF2 AGAGGAAGCGAGACCACAGGAACTAAT 0.003781407 0.008632721 4.33E−06 GGGGGCCCAGGTGGAGAGGCGAAGTCC GGAAAGGCAGACAGCGGGTCGGAAGTT TGGTT 1330 2798289 1 CTTTGCCGCCGGCTTGGGCACGTTTCCTC 0.001108971 0.00695949 1.53E−06 AGCGTCTCTGGCTCCCCGTATTCTTGTCT TCAACACAATGGGTGGAAGTGTGGTTCA GTGTCTAAGAAAGTCTCCAGCACAGTGT G 1703 2798596 4 PDCD6 CAGTGGGCATTGCTGTCGGTGCTCCCTTT 0.003906364 0.006523124 7.17E−06 CCGGG  801 2799905 1 ATGCTATTAAATCCGGTCAACGGTGTGT 0.026532368 0.007637195 7.17E−06 GTGGAGCCTGCTCCATGGCCAGCACCCT ATTGGGTCATCACCCCGACCATGGAGGA CAGAGGGTGCCATCCCTAGAGATGC 1047 2800042 9 ADAMTS16 CCAGGACTGGTGATAAGTCACCACGCAG 0.049865614 0.007127301 7.62E−06 ACCACACCTTAAGTAGCTTCTGCCAGTG GCAGTCTGGATTGATGGGGAAAGATGGG ACTCGTCATGACCACGCCATCTTACTGA CTGGTCTGGATATATGTTCCTGGAAGAA TGAGCCC  909 2801585 1 GAAGCCAAGCATATTCGAACTCCGAATC 0.001054975 0.009377942 6.51E−06 CGCTCGATCGCCGGGGACCTGCCATCTG GGTTCGGTTCCCCAAGGTCGCTGCCGAC CTTAGACCGCG 1356 2803060 4 FBXL7 AGGTTTCATTGGACATATACTTCCATGTG 0.001602179 0.007148233 4.28E−06 GCTGGGGAGATCTCAGAATCATGACAGG GAGGTGAAAGGCACTTCTTACATGGTGG TGGCAAGAGAAAATGAAGAAGATGCAA AAGCGGAAACCCCTGATAAAACCATCAG ATCTTGTGAGACTTATTCACTATCACAAG AACAGTATCATGGGGAAACCGACCCCAT GATTCAAATTATTTCCCACCTGGTCCCTC CCACAACACGTAGGAATTATGGGAGCTA CAATTCAAGATGAGATTTGGGTGGGGAC ACAGAGCTAAACCAGGGGAAAAGCACA TTCTGGGGCCTATCAGA 1721 2803194 7 FAM134B TTCAGGTATATTCCTCCAAAACCCACAC 0.000412342 0.009777832 1.19E−05 AGTTCAGAGATTTTCAAACACCAGGTTT CCATTTGTATTAAAATGGGCAAGATAAT GAAGGCACAGGCTC 1961 2806221 4 TTC23L TGTTGTACAGGGCAGCATGTCCTGAAAG 0.003181899 0.007438554 4.93E−06 GGGCTGCAAGAAATGCTGATTCCAAGGG ATGTGTGCCAGTTCTCT 1031 2807753 9 C7 GCAAATGTGTCTGCCGAGAAGCATCGGA 0.001320494 0.009484133 6.00E−06 GTGCGAGGAAGAAGGGTTTAGCATTTGT GTGGAAGTGAACGGCAAGGAGCAGACG ATGTCTGAGTGTGAGGCGGGCGCTCTGA GATGCAGAGGGCAGAGCATCTCTGTCAC CAGCATAAGGCCTTGTGCTG 2057 2810394 2 MAP3K1 TGAACAGCTATGAACGAGGCCAGTGGGG 0.00010346 0.006765207 3.83E−06 AACCCTTACCTAAGTATGTGATTGACAA ATCATGATCTGTACCTAAGCTCAGTATG CAAAAGCCCAAACTAGTGCAGAAACTGT AAACTGTGCCTTTCAAAGAACTGGCCCT AGGTGAACAGGAAAACAATGAAGTTTGC ATGACTAAATTGCAGAAGCATAATTTTA TTTTTTTGGAGCACTTTTTCAGCAATATT AGCGGCTGAGGGGCTCAGGATCTATTTT AATATTTCAATTATTCTTCCATTTCATAT AGTGATCACAAGCAGGGGGTTCTGCAAT TCCGTTCAAATTTTTTGTCACTGGCTATA AAATCAGTATCTGCCTCTTTTAGGTCAGA GTATGCTATGAGTAGCAATACATACATA TATTTTTAAAAGTTGATACTTCTTTATGA CCCACAGTTGACCTTTATTTTCTTAAATA CCAGGGCAGTTGTGGCTCATTGTGCATTT TACTGTTGGCCCATTCATTTCGTTTTTGG AAATTATGGTTTTGTATTTTCATGTTTAT TTACATTCATTTTTGTTTATTCAGGGAAA GCTGATCTTTTTTTCAAACCAGAAAAAA AAAATGAACTAGATATGAAGTAGAGTTC ATTAAATATCTTGCTATTGTCAGAGTTTT TAAAATATAGACTTAATTTTGTTTTTTTA AATTGGAATACAATAAAGTACTACCTAC ATTTGAGTCAGTCACCACTCTTATTGTGC AGGTTAAGTACAAGTTAACTAAAAATAA ACTGTCCTCTCTGGTGCAACTCACAACC AAGATCAAGATTACCTTAAAATTTATTT GAATTTTTTAGATGTTTTGGTTGTCAAAC TGTAGGAAACTTCACAACATTTAAGTCT TACTCTGTATGTAACAATCCATCATTCAC CTTCACTACTGGTAGTAACATAGAGCTG CCATTTTCCTTTTACCATGCATCATCTCT TTACAGTAGGCCTGGCAGATCATTTTTTA AAAAGATTATTCAACTACCAATCAGTAA TGTTTTTAAACAGTACATTTGCTTTGAAC TTGGAAAATGTGTTCAGAAAGAAAAATG GAATTGAATTTCATTTATACACTAATTCC TTGGATTTTGCACAGTTACCTAACGGTTT TAGTCTGGAGTTAAATTCAGATGCATGG AATCCTGAAGGAAAATGGTAGCTTTTTA ATCTTTTTGTGTGTGTGTGAGTCTTTTAA ATCAAGTACTGATTAACTATTAAGTACA ACTTTGAGATTTTAGTTTTAACTCTTCAG AAGCCAGTGTGAAATAGAATTGGTTATT CTCAAAGACTCAGGATAAACTAAATAAG CTATATATAGAGTACATTTAAAATGTAC AACACAAATTGGAAATAAAATAAGTTAC AAGATAAGTTTACAGGGATATATTGCTT ACAATTTTTAAAAGGCAGTTTGTTTTTTA TGTGAATATGTTTCTTAGTGAAATTTTAC ATTCCTTTGTTTTGGAAGATTGGCGATAT TTGAAGAGTTAAAAATAGTACAGAAATG TGAAGTTTGGTATCTCTAAATGTGTTGTA CTTGACTTTCTTTTTTATTTTGTTTTTTTT TTTTTTTGACTACTTAGAATTTTCACAAT TCTAATAAGATTGTTTCCAAGTCTCTCAT GTGCAAGCTTTAAAGGATGCACTCTTGC CATTTTATGTACTGGAAGATCATTGGTCA GATGAATACTGTGTCTGACAAAAATGTA AACTGTATAAACTGAGGAACCTCAGCTA ATCAGTATTACTTTGTAGATCACCATGCC CACCACATTTCAAACTCAAACTATCTGT AGATTTCAAAATCCATTGTGTTTGAGTTT GTTTGCAGTTCCCTCAGCTTGCTGGTAAT TGTGGTGTTTTGTTTTTTGTTTTGTTTTCA ATGCAAATGTGATGTAATATTCTTATTTT CTTTGGATCAAAGCTGGACTGGAAATTG TATCGTGTAATTATTTTTGTGTTCTTAAT GTTATTTGGTACTCAAGTTGTAAATAAC GTCTACTACTGTTTATTCCAGTTTCTACT ACCTCAGGTGTCCTATAGATTTTTCTTCT ACCAAAGTTCACTTTCACAATGAAATTA TATTTGCTGTGTGACTATGATTCCTAAGA TTTCCAGGGCTTAAGGGCTAACTTCTA  199 2810960 5 PDE4D GAGAAGGGTAAAAGTCTTCATGCTCTCC 0.000625307 0.017332263 1.85E−05 CACTCTCCAATGATGCTCATGAAA  520 2811016 5 PDE4D TGCCCAAATTGAAACTTGAGCCCTGGCT 0.000249584 0.013631798 1.22E−05 TTCAGACTCTGGAGCCGGAGTTCTTCCTC TCACCCTTCAGCTAGCTGCATTAAGTCA ATCAATCAATAAATAACTTTTTATTGCCT GTTCTTTCTCTTCCTCCTCCTTATTCTAAT CAAGATATTTTAAGTTTTGAATTAAAAA TTTATCTCATTCTTATGGCAAAGTAGGTT TCAAGCCATTTCACGGAAATTTATACAA GTGCCTTTGTGCTACAATGGCTGAACCA GAGCACCCAGCTCTCAGGCAGTCCCCAC TGTGGAGACAGAGCCTGCTGTCCCACTG GACAGAGCCTCAACCCTGGCTGACTCAC AGCCCTGTGTATGTCACTTGGCAGCTTCT TCCAGTAGCATGTCCTTCCA  127 2811062 5 PDE4D TAACAGCATTGTTCCCATCCAGGTAGCA 1.71E−05 0.024255342 2.78E−05 AGGTCAGCCCTTTCCATTGCCTCACAGG CCCTTGGAGCCCTCACAAGTGAGGATCT CATCTGTTACCCCCACCTCTCAACTCAAT CTCTGGTTCGCTACTAG 1137 2811064 5 PDE4D AAATGACAGATACTGGCGAGGCTGAAA 0.009608615 0.007519077 2.39E−06 AGGGAATGCTTATACACCATTGGTGGGA ATGTAAATTAGTCCAGTTATTTTGGAAA GCAGTCTGGAGATTTCTCAAAGAACTTA AAACAGAATTACCATTTGACCCAGCAAT CCCATTACCAGGTATATACTTCCACAAA AATA 1158 2811075 3 CTD- TGAAGTTCTTGAGAGCATCCCAGCTCTCT 0.001065067 0.007478452 5.17E−06 2254N19.1 CTCTGTCTAAGATGTCACATCCCTCATTA CATCTCAATGTCCCTCTCAGCCTGCGCTC CCAGGCTCCAGATACAGCTGCGAAGCCT CTATTACAAACATATTCCTTTGCCGATGC TGACC 1896 2811116 8 PDE4D TGGATGTGTTCCGAGGCAACTCAGCATG 0.005601625 0.006976064 4.08E−06 TGCAGTTGGAAATGTGCCGCTTTTATTTG GCAG 1743 2811117 8 PDE4D AGTCAAATCTCCTCCAAACCAGACCCTT 0.00811033 0.007133926 2.86E−06 1644 2811124 8 PDE4D GTTGCACTACGCGAATGGCCTTTGCTGA 0.001463501 0.006801354 4.84E−06 CGTCTTCTGAAACAGGATTAGATATAGC CATGCAGCT  875 2811133 8 PDE4D ATCTATGATGCTATCAATCCTCTACTCAG 0.004194748 0.011585515 1.06E−05 AAAAAAAAAAAAAAAATCACCGAAATG GTGTCTACA 1374 2811137 8 PDE4D CTACAGGTGTTAGTTTCTCTCCAGAAAA 0.008310486 0.00749324 3.24E−06 GAAAAAGCAAAATACTTGGATATTGAAG TGCTAATTTTAAATGTCTGTAAAAATTTG TGAGGGAACAAAGTTATTTTCTATTATG AATTTACTAAACACTAGATGACATTTTA AGCCATCATATGTTATCAATAAAAATTA GCACAAGAGAAATTCCAGCACAGGGCA CAGGATATAGTAGGCAATAATATACCTT AGAGAGAGAGAAGAAGGAAAATGAGAG ACAGAGGAAGGCTCTATTTTAAAATGAC ATAAATCATTTTCCTGATCTTGAAGACTA ATGGAGATAGGGAGAAAGGATAAAATA AGCCCATGTAAAATTGCCTAGACTCTGA ACAAGCAACAAG  587 2814538 6 CTACAATTTTGTGAGTAATGGGGACCAC 0.003217076 0.009592647 6.55E−06 GGGCATGGGACAGTTTCACCCAGAGGAG CTGTGATCTCCCAAGAGACATCAGCAGT TGTGGTCTTGCC  679 2814695 9 CARTPT AGAGCTCCCGCGTGAGGCTGCTGCCCCT 0.001127536 0.009790303 8.15E−06 CCTGGGCGCCGCCCTGCTGCTGATGCTA CCTCTGTTGGGTACCCGTGCCCAGGAGG ACGCCGAGCTCCAGCCCCGAGCCCTGGA CATCTACTCTGCCGTGGATGATGCCTCCC 1334 2818565 9 VCAN GGTCCACAGACGGTAGTTTCCAAGACCG 4.84E−05 0.014054659 1.35E−05 TTTCAGGGAATTCGAGGATTCCACCTTA AAACCTAACAGAAAAAAACCCACTGAA AATATTATCATAGACCTGGACAAAGAGG ACAAGGATTTAATATTGACAATTACAGA GAGTACCATCCTTGAAATTCTACCTGAG CTGACATCGGATAAAAATACTATCATAG ATATTGATCATACTAAACCTGTGTATGA AGACATTCTTGGAATGCAAACAGATATA GATACAGAGGTACCATCAGAACCACATG ACAGTAATGATGAAAGTAATGATGACAG CACTCAAGTTCAAGAGATCTATGAGGCA GCTGTCAACCTTTCTTTAACTGAGGAAA CATTTGAGGGCTCTGCTGATGTTCTGGCT AGCTACACTCAGGCAACACATGATGAAT CAATGACTTATGAAGATAGAAGCCAACT AGATCACATGGGCTTTCACTTCACAACT GGGATCCCTGCTCCTAGCACAGAAACAG AATTAGACGTTTTACTTCCCACGGCAAC ATCCCTGCCAATTCCTCGTAAGTCTGCCA CAGTTATTCCAGAGATTGAAGGAATAAA AGCTGAAGCAAAAGCCCTGGATGACATG TTTGAATCAAGCACTTTGTCTGATGGTCA AGCTATTGCAGACCAAAGTGAAATAATA CCAACATTGGGCCAATTTGAAAGGACTC AGGAGGAGTATGAAGACAAAAAACATG CTGGTCCTTCTTTTCAGCCAGAATTCTCT TCAGGAGCTGAGGAGGCATTAGTAGACC ATACTCCCTATCTAAGTATTGCTACTACC CACCTTATGGATCAGAGTGTAACAGAGG TGCCTGATGTGATGGAAGGATCCAATCC CCCATATTACACTGATACAACATTAGCA GTTTCAACATTTGCGAAGTTGTCTTCTCA GACACCATCATCTCCCCTCACTATCTACT CAGGCAGTGAAGCCTCTGGACACACAGA GATCCCCCAGCCCAGTGCTCTGCCAGGA ATAGACGTCGGCTCATCTGTAATGTCCC CACAGGATTCTTTTAAGGAAATTCATGT AAATATTGAAGCGACTTTCAAACCATCA AGTGAGGAATACCTTCACATAACTGAGC CTCCCTCTTTATCTCCTGACACAAAATTA GAACCTTCAGAAGATGATGGTAAACCTG AGTTATTAGAAGAAATGGAAGCTTCTCC CACAGAACTTATTGCTGTGGAAGGAACT GAGATTCTCCAAGATTTCCAAAACAAAA CCGATGGTCAAGTTTCTGGAGAAGCAAT CAAGATGTTTCCCACCATTAAAACACCT GAGGCTGGAACTGTTATTACAACTGCCG ATGAAATTGAATTAGAAGGTGCTACACA GTGGCCACACTCTACTTCTGCTTCTGCCA CCTATGGGGTCGAGGCAGGTGTGGTGCC TTGGCTAAGTCCACAGACTTCTGAGAGG CCCACGCTTTCTTCTTCTCCAGAAATAAA CCCTGAAACTCAAGCAGCTTTAATCAGA GGGCAGGATTCCACGATAGCAGCATC  951 2818582 2 VCAN CCTATCACCTCGAGAAGTAATTATCAGT 2.99E−05 0.013285949 1.06E−05 TGGTTTGGATTTTTGGACCACCGTTCAGT CATTTTGGGTTGCCGTGCTCCCAAAACAT TTTAAATGAAAGTATTGGCATTCAAAAA GACAGCAGACAAAATGAAAGAAAATGA GAGCAGAAAGTAAGCATTTCCAGCCTAT CTAATTTCTTTAGTTTTCTATTTGCCTCCA GTGCAGTCCATTTCCTAATGTATACCAGC CTACTGTACTATTTAAAATGCTCAATTTC AGCACCGATGGCCATGTAAATA 1039 2819807 3 GPR98 TTCCCTTGCCATTCTAAGTTTCTCACAGT 0.000212853 0.010053274 4.60E−06 ATTAGTGAGATTTTAGCAAATGGTGCCC TGCCTCCTTTTTCCCCTTCCCACACTTCTT TCTGTGTTGACAG  711 2820736 5 MCTP1 TTGAGCCAATAGCTGATGACTACTCTGTT 0.000175608 0.010900573 6.10E−06 ATTGATCTCTCAGTGTTACCACTTGCTGA GTGTTGGACCTCTGTCATCACGGCAAAG TACAAGATGCACCAGAGTCATCA  215 2820823 3 FAM81B CAGGCCAACGCAGCCATCTGATTCAGGT 0.027553244 0.01114295 1.20E−05 TGGGTTGCCCAGGGAACAGACTCTGAGA TGGAGATTGGCGAATAGAAGGCTTATTA CAGAGCACACTGGGATC 1601 2820990 4 RHOBTB3 CTCCCTCCTTCAGTCATAGTAGTTCCACT 0.013562644 0.007317207 7.76E−06 TTATCTGTTTCATATCTTGAGTTCTACCT AAAATTTTACTTCGTAAAAAAGACTCTG CTGGTAAAAGATATAAAAATCATATGGT CAAGATGGTGATTCCACCTCGGTGTAAT CCCAGCCAACTTGGGAGGCTGAGGCTGA AGGATCACTTGAACCCAGGAGTTTGAGT CCAGCCTGAGCAACATAACGAGACTTCT GTCTCTAAAAGAAAAAAGAGTAAAAATC TCTTGTTTTTATTCAGCTACTTGTGCAGT TAAAGAAAACCCAGGAACACACAATCC GTTTTTGGGAGATGTATTCAGCC  831 2821794 2 RGMB GATGTTTGTCCTGGGACACCCACCAGAT 0.000373569 0.013055543 9.09E−06 TGTACATACTGTGTTTGGCTGTTTTCACA TATGTTGGATGTAGTGTTCTTTGATTGTA TCAATTTTGTTTTGCAGTTCTGTGAAATG TTTTATAATGTCCCTGCCCAGGGACCTGT TAGAAAGCACTTTA 1496 2822927 1 ATGTACTTTGACAAGGAGTGTGTTGGAA 0.000189098 0.008702002 3.67E−06 ACGACTGCCAGCCTGTGCCTGCTGCCAA CTCCACTCAGCTACAAATAGAA  164 2823841 9 WDR36 CTCGTGAAAGTGACTGGGATGGTATCAT 2.38E−06 0.01812122 1.20E−05 TGCTT  827 2824081 1 AGACCTTCCATCCTGATCTGACTGCACTA 0.000280435 0.009511252 5.20E−06 AGCAATTGCTGACCTGCATCATTCTGGT GTGGAGCCCCCAGGAGACAAGCAAAGA ATCCTTGGCCACAACTA 1781 2824971 1 TGCTTCTACCCATGCCCGAAGTGTAACTC 0.046795588 0.006732733 6.92E−06 CAACAAGTGTGGGCCCGAGTGCCGCTGC AACCGACGGTGGGTTTACGATGCCATCG TCACTGAGTCAGGAGAGGTCATCAGCAC GCTGCCGTTTAATGTTCCTGACTA 1124 2827090 4 GRAMD3 TGTAGCTGTATTAGACCTCACTTTTTAAC 0.008480701 0.006592995 5.52E−06 ATCTGGGACATGCTATGGGGTGGAGGTG GGAGGATGACATGAAATGTAATTAAACT AAATGGTCAAACTTCAAAGAGGTCAAAT GCTTACAGTAGCCTGCA  550 2827181 9 C5orf48 CCATGGGGAAGATCGTAAAGTTGTCTTC 0.000701725 0.010009205 4.36E−06 CAAAAAGGCCCACCAGAAATAAAAATT GCAGATATGCCTTTGCATTCGCCTCTCTC CAGATACCAAAGCACTGTGATTTCCCAT GGCTTCAGGAGGCGACTAGTCTA  309 2827382 2 MEGF10 TGAACTTGCAGAACTCCCTCGGAGACGC 0.00195225 0.012497339 9.89E−06 AGGTTGCAGTGGACATTGGGATTGTTGC TTGAAAAATTAAAATTTGAATATTTTCTC TCTCATTTGCATCATACAGCTCTACCTAG GATTGTACAGTTTACCATAAAATTTACTT CATGAAAGTGGGAATCACTGAACATGTA GAAGACAAGGAACATATTGTTAACTCCT GATTCTTAACTTTATTCAACTGGACTCAG AATTGTAGGGATAATATGAATGCAGGAG GAAACATTCTGTCAGGCGGTATGACTGG ACAGACTTTGAATATACTCTAAAAGTGG ACAGAAAATTTACGAAAATCTTAGATTT TGTTTAGAATGAGAAAATATACAATTAG AATTATTTTAGAAATAGTAGGAAGTATT GCAGAAGTCAATACACAAATGTGCCAGG CAGAGGTGGTTTTCTCTGTTTGACTCTCA ACCAACTTCAGATCTATGACATTATTCTG ATCACTGGCTCCATCATACATATTCACCA CTTGAGATTCATAACATATCAATAGTTAT TTCATAAATATAGAAATGAAATAATTTT ATTTTTGACAGACTGGATGGAATGAGTG TGTAATGATTGATAAAGGTTGTAAATTTT AAATGCAAGATGACGCTTACGTTCTGTA AACCATTAGTAATACATGCTGTAATATA GAATTAGTGGAACATTTTGATTAATCTTT CCCTAGAAGTGACTGAAATATTTTTGTG CATATTTGAGAAAGGGAACTTTCCTTTTA TTAATTGTCAATTTAGAGAAACTATGCTT AAGCTGGTCTTTTGCATTGCTAATGTGAC ATGTACCCAACTTTTCATTAATTTGTATT TCCATTTTTAAATTGCATATTCTATGTTT TGTAGTGTTTGGATTGTTAATGAAAAAA TATTATATGTTCGTTATTCCTTGTATTATT GCCACTTATCTTTTGCTTGATAAAAATGC GTTGTTCTTTTTTCTTTTGGAGGGACAAG ATGAAAATATATAATTTGAATTGATTAA AATTGGTCGTTACTAAAATAGTATAGTA ACCACAAGTGATTGGCTTATAAATGAAG TAGAAATGCTTTTTAATATTCCAAAATA GAGTTCCTTTTGATCTGTTGGTGCTGAGC CTTGGTTAAACCAGGGAGAAGGGGAGC AGAAAGGAAACGTTGTTACTGATGAGTA CCACAGACTCATCTTAAAAAAAACTCTC ATTATGGTGATCATAGAATTGACCATCC AAACTGGGACACTCTTGAGAGTAAATGG AGGGCATTATTAATAATTATCTTGTAATG AACTTAAATCTGGACTGTTCCAGGCAAA CCAGACTTATCTTGCAATATGAGAATGC TGACACAATGCAGGAAAGCCAGTTTCCC TTTTGTTGATCTACTTGACCAAGCAAAG GGGCTGAAAAACTGAATAAGGAAACAA CTTTATAAGAGAAACAGTGGTCTTCAAT CTTTTAAAGACATGAAATCCTATATGGC ATTCTGTCTCAGTGAGTCAGTTAACAAA TACGTATGTGCAACCCTTCTGCTAGTAGT GCACATAAGTGATTATCCCTGCCAGGTA TCGAGTTGGAATATCCAGTTATTTCATGT CACACATCGGCACGTATGATGGTGGTTT GGTCAGATGGATAATACAGCAGACACAC TTAGAACACTCACTGCACTGGTGGCTGT TCATTTTGAGGAACTCCAAAGTCAATTC AAGGAAATAAGGAATGACCTGGAACAG GCCTTAGAAACAATTGATTTATTCCAAT AGTTAACCACTGGCTGGCTCCCAACTCT AGGTGATAGGCATCTAATTGAGACATGT GTGAGTCAATAGCCATCGGGGTCCTT 1752 2827801 9 ADAMTS19 GATTATGGTGCAAGGTAGAAGGTGAGAA 3.34E−05 0.008103524 2.94E−06 AGAATGCAGAACCAAGCTAGACCC 1361 2828481 2 SLC22A4 GGCTTCGCGCCCCAATTTCTAACAGCCT 0.015786268 0.007598853 6.85E−06 GCCTGTCCCCCGGGAACGTTCTAACATC CTTGGGGAGCGCCCCAGCTACAAGACAC TGTCCTGAGAACGCTGTCATCACCCGTA  570 2828804 2 LEAP2 AAGGACAGCAGTCACCTCCGACAATGCT 0.021355142 0.006802107 3.41E−06 CCGTTCTATGGAATATTGA 1010 2829040 1 AGCTAATCTAGCCTGGGCTCGGTTGTAC 4.84E−06 0.011084794 9.79E−06 CAGACTCAACTCCAGACTTCTTGTCAGA TTCACATTTGCCCGCGGTCTTCATTCA 1841 2829806 4 CTC- GCGCATGGTCATCTTAGCTTTCGAAAGA 2.01E−05 0.007691385 6.15E−06 321K16.1 GGACTGCACTGTTTAACATTGAAGAATT ACATGGGGAATCACAAATATATTGCTTT AGTACTGCATGTTCTGTTGTGGTGAGGG AAAGAAACATGCTTTGAAGGTTTTCCCT TGTCAACAGAATGTGTGTCTGTAGCTGT GTATTGCGCATGTA 1053 2829898 5 IL9 TTGTTGATGAGGAAGTTGATGTCCAGGA 0.000185636 0.007264838 4.67E−06 TCCCCGCCAAGGTTGGACACCCCTGGCC TGCCACGGAGCACAGGAGCA 1184 2830875 9 EGR1 GGGCGAGCAGCCCTACGAGCACCTGACC 0.012281121 0.006583967 3.65E−06 GCAG  128 2832532 7 TAF7; CGCCTCGGGTACTTACAATCCAGTGACG 0.001173835 0.021583374 2.37E−05 AC005618.1 ATTATAAGTTCAGTTTCACCGGGCCGGA GCGAAGGGAAGAGGAGGCCGCAAGGAG CCAAGCGGGAGAGAGCCGAGCGTCTCCT TGTCGTTTCCTTAATTCTTCCTGCCGCTT GGCAGAGTGATCCACTACCGATTACTGA TGAAAGGGCCCGGGATGGGCAGCGCGA AATCTTGCCGAGAGGCGCAGCTCGCATC ACCAGACCCCGCACCTCGCCGGCCCTCC GTCCGGGTCGCCTACCCAGCAAAAACGG AAGTG  466 2834899 4 ABLIM3 TCCGGTTGGCTAGGCCTGAATTCCCAGC 4.52E−06 0.012756132 5.66E−06 AGTTTCCAAGTGCCTTGGACGTTGGCTCC ATTTCCGGACCCTCCTCAGACATTCATTG AGCAACAAGCTGATGCTAGGCTTGTCCC ACATTCTC  680 2835934 7 SPARC CCTGTGAGATCCGACCATCCCATTAACTT 1.72E−06 0.018740722 2.49E−05 TGAAGTTTCTCTTGATTAATAGAAGAAA AAAGGGGAGGGTGAAGAAAAGGAGGAA CATGCTAAAAACCTTATGACAATCATCC AAATGTGAGGAAAGAACAACCGATTCAC CAACTCCACTTTTTCTATTTTACAACTTT CTACATCTCACTCTTGATTTTGGCCTTCC TGGCTGAAACAGCCTGGCAGTCCCTAGA GCCCCTGAGAAGAGCCCTGGTTCTCCAA AAGACAGAGGAGGAGAAGCCCTGCAGG ATGCGCTGACCACTTCCCAGAGAACTGA CAGTCCGTGCTCCCAAAAGTTTGAACCA ACAGCCTAATGTGAAAAGAAACTGCACT GAAAGGTAAAGGAGGAAATGGTGATGA ACTGGGCTTATGTGAGAATGTCTATATTT TCATAACACAGCCCCAGAATCTTTCTCTC AGTTACAGCCTCAGGCA 1483 2836555 4 GALNT10 AAATGACCTTTTCTAGAGCCACCTACAC 0.001171064 0.007953627 3.86E−06 CAAACAAAGGAATTGGAGGGTTGATATG GTTCTGCCCTTGG 2012 2836811 9 LARP1 CAAGTTGTTTGGTGCTCCTGAGCCCTCCA 5.49E−05 0.008860871 6.50E−06 CCATCGCCCGCTCTCTACCAACCACTGTC CCAGAGTCACCAAACTACCGCAACACCA GGACCCCTCGCACTCCCCGGACACCACA GCTCAAAGACTCAAGCCAGACATCACGG TTTTACCCAGTGGTGAAAGAAGGACGGA CACTGGATGCCAAG  904 2840276 4 KCNIP1 ACAAAGTTTTGGACACTAGGCAGGCTGG 0.003724362 0.007065134 1.81E−06 AATTGAGGTGTTGCAGCTGTTTACTGGA ATTGTCTGGGAAAGCAGAAGCCTTCACA CTGGGGACTTTGAGACCTGTGAGATATC ATCATCCCTCTACCAAG 1911 2840930 7 FBXW11 TCCAGAGTATGGCTGGGAATTACTATTA 0.000269075 0.007625411 4.11E−06 TAATCCCAGAAAGTCAGAACTCCTTGGG TGCCAAAGTCCCCTGCTATAATTTAGTA GGCACAATTCAAAGGTTGTCTGCATATT CAAAGGCCATCATCTCCCAAGGAACGAG GGGAACTTCTATATTAAACATGCAAAAA CAACAAAAAATCCATTCATTCATTCAGA ATTGCCTCCTCCCCTGCCCCCTCCCTTCC CCCTGGGCTTTCCTAACCAGTTTGATATT GAAGCT  455 2842772 4 UNC5A GTGGTGGCCCAATTGTCACAGCCTCCTC 0.001157296 0.011866543 6.61E−06 AGCCCTGGGAGCTCACCACACTGTGCCA CAATGCCCCAGCTTGAAGTGACATGGGA CACTAAGTGTATCTGTTGCAAATATTAG AACCCAACTCACACTGGCTTAAGGAAAA AAAAGGAAAACGAAGAAGAAGGAGACC ATAATGGCACATGGAACTGAACTCAGGG GTGGCTGTGGCTTCAGGCATGGTTGTAT CCAGGGAGAACAGTATGGCCAAGATCCT TCCCTCA 1798 2844247 2 CANX ATGTCTGCAGGTTTCTCCTTGAAGCAAAT 9.77E−05 0.009485266 1.11E−05 GTGTGGGATCATTGCATTTCCAGAAATC TGCCTCCTTCACCCTCCGTTGACAGTATA TGTCATGCCTCACTTTC 1222 2844255 4 CANX TACCCGATGGATTTGTGAGGATTAAATT 0.000636171 0.00806974 3.62E−06 AAGATATGTATACAATAAGACAGGGAA GTCCGACATTTAGTAACTGCTCGATGAT CATTGCGGTACGTTA 1615 2844539 2 SQSTM1 GCCCAGCACATAGCTTGCCTAATGGCTT 0.002162534 0.008729973 9.01E−06 TCACTTTCTCTTTTGTTTTAAATGACTCA TAGGTCCCTGACATTTAGTTGATTATTTT CTGCTACAGACCTGGTACACTCTGATTTT AGATAAAGTAAGCCTAGGTGTTGTCAGC AGGCAGGCTGGGGAGGCCAGTGTTGTGG GCTTCCTGCTGGGACTGAGAAGGCTCAC GAAGGGCATCCGCAATGTTGGTTTCACT GAGAGC  211 2844540 2 SQSTM1 ACATAGTCGTGTGGGTCGAGGATTCTGT 0.036159066 0.011382357 7.36E−06 GCCTCCAGGACCAGGGGCCCACCCTCTG CCCAGGGAGTCCTTGCGTCCCATGAGGT CTTCCCGCAAGGCCTCTCAGACCCAGAT GTGACGGGGTGTGTGGCCCGAGGAAGCT GGACAGCGGCAGTGGGCCTGCTGAGGCC TTCTCTTGAGGCCTGTGCTCTGGGGGTCC CTTGCTTAGCCTGTGCTGGACCAGCTGG CCTGGGGTCCCTCTGAAGAGACCTTGG 1645 2844718 4 CNOT6 TCCAGCCTACTGTTGATGGCAGCTAGGT 6.32E−05 0.006891649 2.87E−06 TGATTCCATGTTTTTGCTATTGTGAATAG TGCTGCAGTGAATATACCAGTGCATGTA CCTTTTTTGTAGAAAGATTTATTTTTCTTT GGGTATAGAACCAGTAATGGAATTGCTG GGCCAAACGGGTAGTTCTGGTTTTTTATT TATTTATTTTTATCTGTCTGTCTATGTATC TATCTGTCTATTGAGACAGAGTTTCACTC TTATCACCGAGGCTGGAGTGCAGTGGTG TGATCTCAGCTCACTGCAAACTCCATGTC CTAGGCTCAGACGATCCTCCCAAGTAGC TGGGACCACAGGTACATGCCACCATGCT GGCTAATTTTTGTATTTTTTTTTTGTAGA GATGGGGTTTTGCCTTGTTGCCCAGGCTG GTCTTGAATTCTTGGCTCAGGTGATCCGC CCTCGTAGGCCCCCCAAAATGCTGGGAT TGTAAGTGTGAGCCACTGGGCCTGGCTT AGTTCTATTTTTA 1525 2845394 4 SLC9A3 TGTCCCACGGGTTCTGGCCTTTCCACCAG 0.000104877 0.007173792 4.58E−06 TGCTTCCGTCCCACACGAACACCTTAGA GCTCCGTGGCAGCGTACGGCCACGTTTC CTTTCCCACACAGCATCTGGCTTTGCCTG GAGGGAACGATGGTCTCTGTCGCTGCTC TTG  635 2845607 4 BRD9 TTTGACACTTTGCTGCACTTGGAGCTGTG 0.001877871 0.010609655 7.35E−06 GGCCATTGTGCACGTGCCTGGTGGACAG TCCTGACCCTCGCTGTCTGATAAAAAAG CACTGGCCACATGGCCGCTGGGAAATTT GAATGTGGCCAGTCTGAATTTAGATGTG ATGTGTGAGCTACAAACTAGATCTTAAA AAACTAATGCAAAAAACGTAAAAATATG AGTAACGATTTCTTATGGCCCACATG 1484 2845672 5 NKD2 GATCTTCTACAAGAAACTGCTCCCACTG 0.001354972 0.007318934 3.90E−06 ACCAAGAACTGGGCATCCCACTG 1221 2845675 5 NKD2 GGGTAGGCTCTGTTATCCAAAAACAGCT 0.009101689 0.009826739 8.25E−06 GCTGTAGCTCTTGTCACGTCCCCCTTAGC GGATGTGAGAGGCCTCGTCCTGGAAGTA CATCCACGCAGGACCACGGCCTTAAGGG CAGGTGGGAGCCCTGGAGGGTCCTGCCA GCTACCGACGTGAGTGCCTCACGGAGAA CCTCACTGGAGACAGCAAGGAGGGACCC CCGTTTCCATCGGCCTCTGGCAAGGCTCT CAGTCTAAATCCG 1536 2846862 1 TCTCCATGAAGCCAAACGTGGGTCCTGG 4.46E−05 0.007535106 1.50E−06 1185 2847247 1 CCATGCCAGTCTGAGCACTCCATTTAATT 0.033429032 0.007973611 7.35E−06 A 1897 2847334 6 CAGCCTGTGGCCTGTAAAGCATATATTT 0.001587412 0.006770776 3.66E−06 CTAATGACTGCAGACTGGTGGGATCATA GGAGCCTTCTGAATGACCAGGACTGCTT TCTTTGGAGCTGATGAAAATGTACTCTTT TAGCGTGTTAGAAATCACTTGTTTTATTT TGTTTCTTTGGCCAAGCTGGGTCTAGTGT TTCTTTTGCTGGGAATAGACTTTCAAAAG TTGTACTTCTATCAAGAAACAAAACTGC CCTTGCAGAAATTTCAGGTCTTTTGTTAA GCCTGTATTGGTCTTAAGGTGCAGTATTT TTTAAATTATTATTTATAGAAAGAATCTA TAAATTCTTGGGGAAGTGTGTTATAAGC TTTAATAATTACATTGAGCTGCACCTCAG TGGTGTGTCATTAACATGCAGTGGGGTT AATATCTGAGGCCTC  818 2848815 9 CTNND2 TCAGCCTCAGAGAAGACGAGTTCCCTGA 0.000155817 0.007745231 4.67E−06 GCCCCGGCTTAAACACCTCCAACGGGGA TGGCTCTGAAACAGAAACCACCTCTGCC ATCCTCGCCTCAGTCAAAGAA 1032 2849087 9 DNAH5 CCTGAGATAAGTGCCCGTACCTCCATCA 8.61E−05 0.00794934 5.03E−06 TTGACTTCACTGTCACCATGAAAGGTCT AGAAGATCAGTTACTGGGGAGGGTCATT CTCACAGA 1333 2849099 9 DNAH5 TTCCTATGATATTGACTGCAGTTTGGAAA 0.040101547 0.007167069 3.66E−06 TCAAGAAGGAGGTGGTCCAATGCATGGG CTCCTTCCAGGATGGGGTGGCTGAGAAG TGTGTTGATTATTTTCAGAGATTCCGACG TTCTACCCACGTGACGCCCAAATCATAC CTCTCCTTTATTCAGGGC 1285 2849102 9 DNAH5 GTGTCATTCGTACTCCTCAGGGAAATGC 0.002537394 0.006928127 3.69E−06 CCTCCTGGTCGGGGTGGGCGGATCAGGA AAGCAGAGCCTGACGAGGTTGGCTTCAT TCATTGCTGGCTACGTTTCCTTCCAGATC A  841 2849152 9 DNAH5 GAAGAAGCCCGCGAGTTACTCTCTCATT 0.013562644 0.007538097 6.90E−06 TCAACCATCAGAACATGGATGCTCTTCT GAAAGTTACAAGGAATACACTAGAGGCC A  145 2849177 3 DNAH5 GGCGACTGTCCTAGGAGTATGACCAACC 0.000297559 0.019731072 9.73E−06 CTCCTTCAATGCTAGGCTTCAGCCACCTC CTCCTGAAAGCTGTCCTGTCATCCCCACC CCTACCCCTTATCAACTCCAGGCTAGAG TGGGAGACCCTTCTTTTTGCTCCTTCTCT GTAGACCCATAAATGCCCCTGCATTTGG AGACCCATAAATC  460 2849511 4 ANKH AGTGAGTTGGGTTGTAAGGAGAGTAGCA 0.006926925 0.010661478 7.13E−06 CGGAGCCATCAACAACCACGCAAAATGT CAGCATCCCTGAAGGACGGAGTGGAGGC TTAG 1611 2849802 5 FBXL7 TCTGGTAAGGCTAGAAGGTCATGCGAGA 0.001124866 0.006581459 5.10E−06 AACTGTATGAAGAGACACAGAGTAAGG ATGGGCATGAGAGATGAACACGAACAA GTGTG  117 2849995 2 FAM134B TCTAGGAATCAGCTTGCAACAGAGCACA 0.00014459 0.026361181 3.38E−05 AA 1701 2850497 6 GCTACTCAAGGAGACTCAATACAGGGAC 0.008143382 0.007243822 3.72E−06 CTCAGACCCACTGATCAGT  503 2851189 1 AGTTGCATCTTCCAGGGAAGCAGGCTCC 0.000191608 0.011471627 7.40E−06 CAGTACTTTAGTCAGCCCCAGTGGC  944 2854889 2 HEATR7B2 CCATTTTGTTGGTTAGCAGGAGTTCAGA 0.030501101 0.007657939 3.05E−06 CGCAAGACAATGTCATAGTGGTAGAATA CAGTATCAACTTCAACAGCAAGCCCATC TCTGGAAGCTCCCAGACCATTGTGCCAA TCAAGTGGAGGAGGCACTTTCATTTAGA GAGGCTTATGTGAACCTTATATGAGAAA CTTGCCAACCTGCCTCTTTGATTTTTTAG CCTTACTATTTCTAATACTTAGGTGCTAT CTTTTAGAGACC 1012 2856493 4 MOCS2 GTCAGAAGAGGAATATTGCCCGGTTTGC 0.000310049 0.007523726 3.12E−06 CAG  739 2856671 4 ARL15 TTACTCGCCTTCAGGTGTCATGTTCTTGT 0.001095886 0.007898792 4.05E−06 TCC 1390 2857094 4 RP11- TGGTCGTGAAGGTGGTAAACCCAGCCAA 0.003174906 0.006645723 3.59E−06 528L24.3 CTGTCAACGACTCTCCAGCAACTCATCA AAGAGTCAGCCTTTTCCATATTTAGGAC ATTTCTCTCCCCCGTGGAGAAGTCGAAC CGCTGGATCTACATAGCGCTTTATCTGG GATCG 1101 2858235 4 PDE4D AACATAGCCCTACGTTCCATGAACACTC 0.001709174 0.007746921 6.08E−06 AGTAACATCATCAAAACGTGATGCAATT AAATTTTACCAGGTTTACTGCTGTCCTGA TGCTTTCCAATTTTTTTTGACAACAGTTT TGCCTTTTTCAAATTCAAATGGTATAATT GGGGCTTGGTAGTTGATGTTTATCTTAAT TGAAACAGATTCTCTTCATCCTTTTGCTC TGAGACTCCCACTTTGAGGCTGAAAGGT CATTTTAAATCTGCAGAGCACTCGAGAA GCCAC  476 2858299 4 PDE4D CCCTTGGACTGGGAGTTTAGCACTATCA 0.016744596 0.010941528 4.86E−06 CCTGCACACTAGACCTGCAGTCTATGAA GAGAGGCTGTCAGGGATTTGGGGCTATC ACAGTTGCTCCTCCCAGAGCAAAAAATA TTCAACCCTCCCACACACACAGGCAGCA GCCTCATCTCAAATGGACTG  368 2858312 4 PDE4D TGAGAGGAAGAACTCCGGCTCCAGAGTC 0.007144307 0.010799351 6.79E−06 TGAAAGCCAGGGCTCAAGTTTCAATTTG GGCATTTCCCAGCTTTGAACAACAGAAA AACACTGTTTACCTTTTCAGAACCTCAGT TTCCTTAGATCTGTAAATTAGCAATAAA AACTAATGTGCCTTCCAAGGTTATGGTA AAAATCAAATATCTTATGCCTGTGTAAA TCTTTTTCAAAAAACAATAGACACTGCA AATATTGGGCATTCTTATGATGATGTTTA TTCTTCACTGGGAGCATTGATGGATTGAT TGTTACTTTTCAATAACTTTTTCCATATTT GCTCTAGTTTTAAATTTGCAAATTTTAAT TCAGTATTGTTTATAATAAGACAAAAGC TCTTCTTTAAGGTTGGGGCATTA  436 2858317 4 PDE4D CTTTCAGTGTTCTCAGTGAGTGCTTCACA 0.000553994 0.012556713 8.30E−06 GATTAGGTTTCCAAGAGAAGAAGATTGC CTCTGAGGAAGAAGAGATGGGGTAGCA AGAGGC  469 2858354 4 PDE4D AAATGAGAAGTAACGTCAGCAGCTCCGT 0.000367918 0.014805117 1.60E−05 AGGTTCTGA 1605 2858355 4 PDE4D ATATTAGGCTCAATTAGAGAAACAATAA 0.01732465 0.007281016 1.82E−06 AG 1360 2858366 4 PDE4D AGCTACACAGGAAATAACACCACCAAA 0.006926925 0.009640878 7.22E−06 AATAACACATTCAAACTCAGAGGGCAAT CTTCCCTAA 1445 2858387 4 PDE4D GGGGAATGCAACTGAAATTGCTAGGAGT 0.001543869 0.009130611 7.79E−06 TGAGTCAGGCAGCTATGAGCAA 1392 2858392 4 PDE4D GGCCCAGCTTCATGGATATACAAACTAT 0.000931652 0.008377171 7.70E−06 ACATTCACATGGGTTCCACACCTAGATG GGCTCTTACATCATGTAGCTGGTCCTACC TGGGAGAGAGC 1867 2858399 4 PDE4D CAATCATTATGTTGCATGAGGTACAGCC 0.001283816 0.006649943 4.90E−06 ATATGAATAAATATGTACTAACACATAC CTAGACATACACAATCAGCCCT  507 2858418 4 PDE4D AACAGAACAGAAGTTAGGAATGGTGAA 0.000328031 0.013378586 4.08E−06 AT  835 2858532 4 PDE4D CTGGTGAAACGTCCAGCCTTATGGAGTA 0.000984436 0.01321077 1.06E−05 GGCCCCTGAGGTATAGAAATGGTTTTGA TGGCATAGGATGTAGCCTTGGGAATGTC CTGGAAGAGTAGGAGCGGCCAGTTAGGC ATTAACACTCAGGAGTAAGGAGACTGCA TT 1720 2858540 4 PDE4D ACCTGGTCATCTTCCCCTACATTGTAGCC 0.000720832 0.00689557 3.83E−06 TACCAGAACTACCTGGGCTGTAATCTAA TAT  398 2858550 4 PDE4D CTAGGAGAAATGGTAACACGCAAAGATT 0.000175143 0.015741974 1.65E−05 GGTATCAGTTTACACCAAAACAGAACAC A  563 2858551 4 PDE4D AAACGTATACCAGAGACGAAGAGGCAC 0.00160589 0.011660697 6.79E−06 TTTGAATTTGTCCGGGTAGGTGCTTCTTG GTTTGGGGATGTTATGACCTTAGATA 1566 2858567 4 PDE4D GAATCCCTAGATCCAACTTTCTTTGGTGA 0.001752996 0.008574915 4.99E−06 GTTTGCAGGGGTTTCTGATGGTTCTCTTG TTTCACGGGTT  360 2858575 4 PDE4D AATCTGAAAGGGCTTGAAAAGTTAGGAT 0.000142286 0.016665493 1.59E−05 GTAGACTG  973 2858577 4 PDE4D AAGTGTGTCTGAATGACTTCGCATGTTTA 4.53E−05 0.013041407 1.47E−05 GTGAAGCTCATTGCCAGAACTGCGACTT CCCCTGTTGCCTTGAATCTGCTGATCAGC CCTGGCAGCACACGTTTTTTAAATTATTT AAAAAGGGACAAGGGTTATAAAGATGA AAACCACATTTTTACCAGCCTCTGCAAA CTCCTAATTTGGTGGGTG 1466 2858619 9 DEPDC1B TGTGGTACAAGCGTCACAGTATTGCAAT 0.019828743 0.007090047 4.33E−06 TGGAGAGGTGCCAGCTTGCCGTCTTGTC CACCGCAGACAGCTGACAGAGGCCA  384 2860275 3 RP11- GGAGTCCATGTTGCCTCGCCTGGTCTTGG 0.038217335 0.014699721 1.45E−05 83M16.5 ACTATT 262 2860360 1 ACCAGCATCTCGAGCCCTGCCCTTTCCAC 0.004426107 0.013556498 1.14E−05 CCAGGACACCAAATGGGATGCTGGATCA GTTGCTGAGACAATGGCCAAAGGGTCAG CTGGA 1372 2863463 2 ZBED3 ACGTGTGAATGCAGCGCTGTGTCTTTAA 2.19E−05 0.008828438 5.87E−06 GGGGCACGCGCGGAGGTTTTCCGTCCGG GACAAAATGTCAGCGAGGCGCCTGGAG GGGGATCTACCATCTCGGACTCCCGA  253 2863936 4 LHFPL2 ACGTGTCACCGGACTGACTTCTAGGGCC 1.57E−06 0.015136691 1.37E−05 AGTCACAGAAAGCCATGCAGTTCCTGTC TTGTTGGAAGGAACACTGCTCTTCAAGC CCTGAGCTCCGCTTCGTAAGTCCAACTCC CCTAAGGCCATCATGGCAGGAGAGGCCA TATCTGGGCGCTTCAGTGGATGTTCTTAT CTGGACCCAGCCTTCCAGCTATCCCCACT GACATGCAAACCAAGCCTCTAGACCAGC CCGTCCACCGGCCGAATGCTGCCTGTGA CCGACCTCTGCCATTGCCACATGGAACA GAAGCACCTCCCAGCTGC  374 2864082 4 ARSB TTGGCCGCTATTTGCTTACACTTGCCATC 0.001480634 0.012463709 7.11E−06 TGTGCAACCGCTCTACCCGTGGCCTCCCC CGCTTTGTGGTTGTCTTCTAACAGGAGCA GTCCACGCAAAGCCTTCCTGA  336 2864402 1 CGAGTAAAGATCTGCACGCACAGTTGAT 0.004699102 0.012757132 1.00E−05 GGACAAACTCATACGGGGCAGTTTGCCT GCTGGGCTGGCACACACGTGGTCTACCT TGGGAATCCTAAAGGACAAAGAGTTACA ACCTCCACGACAGGCCTTTGCCGTGTAT CCC 1733 2869244 7 PAM CAGCCGCTACTTCATGGCCCGGGCACGG 0.042209752 0.008127007 4.53E−06 CGGGCGTCCTGCGGCGGCCACACACCAT CCGCCAGCGAGAGCAGCGAGCTGGCCGC GGCGAGGCGTCTCGGTCACGAGCGGCGG GCAAAAAGCCGTGGGCAGGCGGGACTTT TGTCCGGCCCGCAGGCGGAAGCTT 1424 2869909 4 EFNA5 AATTTAATGTTCTACCAGAAAGTGCTAT 0.000722593 0.010990528 7.75E−06 GCATATGTAAGTATATTTCTTCAGCTTTT ATGCCAGAAATTCATATTTAAACTAAAA CAGAAAAACAATAGGCACCTCCCACAG  756 2870559 1 GGGTGGTCCTCTAAAGAATTGCAACTTC 0.004851623 0.009976688 7.50E−06 TGGCCCTTGAAAAA 1979 2871561 5 KCNN2 AAGTCAAGTATGGTGAGAAACATCCAGA 0.017956371 0.007538282 3.77E−06 ACACACAGGACAGTCCCACATGAAAAA GAATTATTCAGCCAAAAAAGTCACGAGT GCCAAGGTTGAGAGGCCCTGGAATACAG CAACTACACTATAAAACCAACTTGGAAT GTCTCCCAAATGAAACTGGTTGACCTCG GTGAACTTCATAAA  304 2873260 7 CSNK1G3 GCTGCTCGGATTCGGTCCCTGCACTGCC 0.001286836 0.013895424 1.35E−05 GCTGGTGCCTCCTACCGCCGCCGCTGGC CGGAGAGTCGCCGCCCGAGCCTCTGCTG TCGCCACCGATGCAGCCCGGAATGAATG CACAGCAGCGCCTCGCTTATCCGGAGGT CAAACATCCTTCTG 1503 2873713 4 RP11- GAGAACAAGACTTTTGGTGGGACTGGAT 8.45E−05 0.006843065 4.69E−06 114J13.1 AAAGACA 2056 2873861 7 LMNB1 GGAATCCATCATCCAGAGTGCTTACATG 0.001797859 0.008557564 6.17E−06 GTGATTAGGTTAATATTGCCTTCTTACAA AATTTCTATTTTAAAAAAAATTATAACCT TGATTGCTTATTACAAAAAAATTCAGTA CAAAAGTTCAATATATTGAAAAATGCTT TTCCCCTCCCTCACAGCACCGTTTTATAT ATAGCAGAGAATAATGAAGAGATTGCTA GTCTAGATGGGGCAATCTTCAAATTACA CCAAGACGCACAGTGGTTTATTT  540 2874627 4 CTC- CCAGAGTGGGACTAACTGGACTTGAAGG 0.007850273 0.012194012 1.37E−05 575N7.1 ACTGATTGAGCCTGGATTGGATGCCAAG G 1019 2876122 5 SEC24A CCACTATTATAGCACTGTTTACATGTGTC 1.65E−05 0.008469393 7.83E−06 CAAAGAACCACCAAAAAACCACCACAA TGATACAGGTATCTACTGCAAATTTTCTG CTTCTTGTCTGCTACCTTGTAAAAGGTAC AGCCTCCCAATTA  891 2877487 4 ETF1 TCTTTGAACTTGAGATTGAGGATCGGCC 0.002849134 0.008531733 6.73E−06 CAGTACAGCACCAC 1558 2877961 2 DNAJC18 GCTGGATGGGGCAGCATCTCAATCATAT 0.003692121 0.007016632 2.32E−06 AGGGCACAGGAC  692 2878005 2 TMEM173 AGAAGCTGCCCTTGGCTGCTCGTAGCGC 8.12E−06 0.010978292 9.08E−06 CGGGCCTTCTCTCCTCGTCATC  775 2880995 4 CSNK1A1 AAGAACCCGGTGCATATAGGCGATCCGC 0.000385118 0.010477403 7.49E−06 TGAGGGAAGCACGGAATGGGGAAGTGG GTAGAGGCAGGTAATGAGACCAGCTGA ATCCGGGTCTTGGTGTTTTA  684 2881838 1 TTGGGGTTGCAGAGGCTATAGCCTCCAT 0.00021174 0.007683315 6.31E−06 GGGGGTCTTCATCTGCATGGGCTTCTGG CTCCCGTCTGCTTTGGGTTT 1997 2882121 2 SPARC TGGTGAATCGGTTGTTCTTTCCTCACATT 3.72E−05 0.008293392 7.47E−06 TGGATGATTGTCATAAGGTTTTTAGCATG TTCCTCCTTTTCTTCACCCTCCCCTTTTTT CTTCTATTAATCAAGAGAAACTTCAAAG TTAATGGGATGGTCGGATCTCACAGGCT GAGAACTCGTTCACCTCCAAGCATTTCA TGAAAAAGCTGCTTCTTATTAATCATAC AAACTCTCACCATGATGTG  115 2882122 2 SPARC GCTGTTGGTTCAAACTTTTGGGAGCACG 5.12E−06 0.032841204 3.86E−05 GACTGTCAGTTCTCTGGGAAGTGGTCAG CGCATCCTGCAGGGCTTCTCCTCCTCTGT CTTTTGGAGAACCAGGGC 2054 2882125 2 SPARC CCACAGTACCGGATTCTCTCTTTAACCCT 1.71E−05 0.007415852 3.23E−06 CCCCTTCGTGTTTCCCCCAATGTTTAAAA TGTTTGGATGGTTTGTTGTTCTGCCTGGA GACAAGGTGCTAACATAGATTTAAGTGA ATACATTAACGGTGCTAAAAATGAAAAT TCTAACCCAAGACATGACATTCTTAGCT GTAACTTAACTATTAAGGCCTTTTCCACA CGCATTAATAGTCCCATTTTTCTCTTGCC ATTTGTAGCTTTGCCCATTGTCTTATTGG CACATGG 2079 2882128 9 SPARC ATGGAGCATTGCACCACCCGCTTTTTCG 1.47E−05 0.00652917 2.77E−06 AGACCTGTGACCTGGACAATGACAAGTA CATCGCCCTGGATGAGTGGGCCGGCTGC TTCGGCATCAAGCAG 1643 2882142 9 SPARC ATCTGTGGGAGCTAATCCTGTCCAGGTG 3.85E−06 0.012687273 1.48E−05 GAAGTAGGAGAATTTGATGATGGTGCAG A  518 2884192 4 EBF1 ACTGAGCCGCTTCACTGGAGCACTAATC 0.000885779 0.011197582 6.32E−06 GATTTGCTGTCAAGGTGGCCTGCTGGGG TTTCAAGCCAGAGAGGAATTGAGAGGCG CTCTGGCCCAATTTCCATAATTGCTCACT GCCTTT  792 2885859 5 ODZ2 TTACGCCCTCCCAATTGCTACATAATCAT 0.002565937 0.007653162 8.95E−06 GACCTATTCCAAGTTTATTCAAGCAGCC AAGTCAGGATGTCTCCCCAGC 1554 2886153 9 PANK3 TGACAAGCTGGTCCGTGATATTTATGGA 1.62E−05 0.008848725 5.11E−06 GG 1353 2887118 9 STK10 CTGCGCCTGTCTACCTTCGAGAAGAGAA 0.000160023 0.008064688 4.64E−06 AGTCCCGCGAATATGAGCACGTCCGCCG CGACCTGGACCCCAACGAGGTGTGGGAG ATCGTGGGCGAGCTGGGCGACGGCGCCT TCGGCAAGGTTTACAAG  365 2887495 2 STC2 ACATCTGACTGCCTGACATGGACTCCTG 0.000619177 0.018246493 2.35E−05 CCCACTTGGGGGAAACCTTATACCCAGA GGAAAATACACACCTGGGGAGTACATTT GACAAATTTCCCTTAGGATTTCGTTATCT CACCTTGACCCTCAGCCAAGATTGGTAA AGCTGCGTCCTGGCGATTCCAGGAGACC CAGCTGGAAACCTGGCTTCTCCATGTGA GGGGATGGGAAAGGAAAGAAGAGAATG AAGACTACTTAGTAATTCCCATCAGGAA ATGCTGACCTTTTACATAAAATCAAGGA GACTGCTGAAAATCTCTAAGGGACAGGA TTTTCCAGATCCTAATTGGAAATTTAGCA ATAAGGAGAGGAGTCCAAGGGGACAAA TAAAGGCAGAGAGAAGAGACAGAACTA AAAATACGAGGAAAGGAGAGTGAGGAT TTTCATTAAAAGTCTCAGCAGTGGGTTTC TTGGGTTATTTAAAACATCACCTAAATA GGCCTTTTCTTCCTAATTGGCCATCAAAT TAAAGCCTATCCTTTCTCAAGCAGGAGC TGGTATTGTAGGGAGTGGCCGGGTATTC TGGGCTGGGCTCTTCTGGAGTAGGGGGT CAGCAAACATTGTCTGCAAAGGGCCAGA TACTGAATCCAGTACTTTCAGTTTGGCGA GCCGTGAGGTCTCTGTCGAAACTACTC 1188 2887512 4 STC2 TGACACGACCCGAACCGTGCGCCTCCTC 0.039351871 0.008021546 4.68E−06 TGCTCTACCGGCTCTTGGCTCACCGGCA AGCTGCAAAGCAGAGCCAGGCGTGCAG GGCACGGGGCTGGCCCTTTTCCCAGCTC GGAAAGAGAAAGAAAATCTGCCTACAG CTCCTTCGCTCCACGACCCCTCCCCCGAC TTTGGGGGGCCGTGTGAACGCGGCAGCG GCGGCGTGCGTGCGCTCACCGCACGAGC TGGAATGCACGAGTGCCCATTAGGGACG CC  546 2888080 1 ATGGTAACACGCTGGCTAGCCCTGCTGG 4.89E−05 0.010112214 5.90E−06 GTCCATGCCTGGAGCTGGGGTGGGGCTT ATTCCCTTCCGGACCTCATGGGCTCGGA GAGGCAAGTGATGGGTCTCTGAATGAAA TCAGTGCTGGGTTCATGGACACGGAAGG GAGGGTTGTTGTTACTTCTGTTTTACTGG TGAAGAAAACACCCGTGTTCACTACTGT CCTATTGGCAGCGAATTTGAACACC 1727 2888742 2 F12 TCCTTGGTGATTCCGCAGTGAGAGAGTG 0.000183201 0.007635791 5.72E−06 GCTGGGGCATGGAAGGCAAGATTGTGTC CCATTCCCCCAGTGCGGCCAGCTCCGCG CCAGGATGGCGCAGGA 1209 2889481 1 GCCTAATCGGATTGTAAGCTCGTCGAGG 0.000292999 0.0077346 3.92E−06 CCGCTGGTCTCTTGCTCTCGAGGACTCCA TCCCAGCATTGGCAGCCTCCGCCTCCCC ATGTCCCAAAAGAGGAAACTGGGCTGGA GAAAGTTTCGCAGCCCAAGGACGCGTGG CTGGAAGTGGCAGAACCCGGGCTTCCGA GGTTGGGCGAGTGGGGTCCTCCAAGGCC CTCAGCACGGGTCGGAGGGATTGGGACT GAACCCGCCATCCCCCTGGACCTTGGTG CCCTCCAAGCCCCGCGCTCGCGCCCTGT CCGTCGCCTCCCCCAGAGATGCTCTGCA GGGACGATGAGACCTTGGTGTTCCCCGG TTCTCTGTCCCCTGGCACCACCTGAACGA TTGACATC  227 2890130 5 RUFY1 GCCAGAGCTCAGTAACATCCACATCCCA 0.003458386 0.015862344 1.98E−05 GAGTACAGAGAGAAAGCCAGCCTGGGT CACAGTAGTCAGCGTCTCCAGGGCCAGG CTGCCAGGAGAGTGGGCTCCCTGCAGAC CAAGGTTTCAGGATGAGCAAGCAAGGTG AAAACACCAACTTGCCACACGCAAATGG CTCGACACAACCCTTA 1442 2890334 9 TBC1D9B TGCATGTTCCCACGCAGGGAGTATAGTG 0.01496327 0.007323032 1.43E−06 CGCGCCAGTTCCGGCAAATGTCCTCCCC GAAACGCTGCACCAAGCACAGGAGCTGT GCACAGACCACCCCTCAGTAACAGGCAC AGCAGGCGCGGGTGGAAGGGGTCATTA GGGTTCCCCTGAGTTCTAGCAGGAACAT TCCCCAGAGTTCTAGCAGGAACTATAGA ATTCGTTAGTCCTCAGACTGGTCTATAGC CCTCATCATTGTTCACGTCAAAACCAGC ATGTTGAGACTTGTATTCATTTGAAAAA AGGAATTGAGGGTTTGGCGGCCTTTATT TTAACCTGACCAAGTGAGGGAATGCTCA GGCCCTTTTGCTCTGGTGCCATAGGGCG GGGCTGGGCGGGCCAGGCAGGAGGTGT GGCATGGGAGACCTGCTCCCCAGGGCCT GGCCTGGGGCTGGCTGTACAGAAACACA GACTACATCTCAAGGACCCCAGGAGCTT GCAGTCCCAACAGCA  767 2891058 4 GNB2L1 CTGGGAGCTAAGCTTTCTCAGCCTCCAC 0.016586586 0.006763538 5.07E−06 GTAATGACATTTTGGTCTGAGTAACTCTG TTGTGGTGTGCAGTCCTGTACATTCCAGG ATGTTTAGCAGCATTTCCAGCTTCTACTA GATGTCAGTAGCAAACCATCCTTCC 1346 2891302 4 DUSP22 TGGCACCATCTCTGTGGTGAAGTCACAG 0.000958852 0.007004444 1.00E−06 GTGCAAGCCCACGTGGATGCAGACGTGC ACATGTGTGTGACGTTTCGGGTTT 1000 2893481 3 RP1- AGTAAATGACCATCGTGCGCCCATGGGA 0.049041286 0.007653208 3.62E−06 80N2.2 AGAGTGCTGCATCCACGGAGGACATGGG CCAACAGTGCTCTCAAATGGGTTTCATG AAAGCATCTGTGACTCATCCCTGTTCAA GAATGTTTTCATTACGATTCAGCAGAAG CGATGTGCCAGGTCAGCAAATACAACTG CAAAACCGGGGCCTG  957 2893660 4 RREB1 CTGCAGCCCGCAGTGAACACATGTGCCC 1.26E−05 0.010296887 6.32E−06 CGACCCAGCGCAGTCGGCTCTGCCCTGC GCTTGCCCGTGTGAAGGGCCAGGGTCCT TGGCTCTCAGAAGAGGGATATTCTT 1217 2894668 2 PAK1IP1 AGAACCTCCTCATGTGGCATCTTTACTTA 0.000323032 0.00766513 2.99E−06 TTCTCTTCTTGGAAAATCCATGTGACCTC CCCGCGCTTAAAGTGTTTCCACGTTACA GGCGACTTAAAGGCAGCCCTGGAGCCTG ACGTATAATTCGAGCGCCGATGCAGA  147 2896936 9 CAP2 GGTCCTGTAGCATCCACAGTATCAGCGT 0.032161453 0.02300686 3.11E−05 TTTCTGTCCTCTC 1783 2898612 3 GMNN TGTAGAAAGCATGGGGCTAAAAGTATTT 0.01160212 0.01009499 9.29E−06 TGACATAATTTATCCAAATTTAGCCTGGC TATAATTTCTGTAAGCCTTGAGTTAGTCA GAGGATGAGTAACAATAGAGAACATTTT TAAAAAACTAATTACGGTTGAATATTAA GTCTGACCCAA 1595 2898626 2 GMNN TGCCGAAGTTTACCTCCACTAGTTCTTTG 6.42E−05 0.009780056 3.60E−06 TAGCAGAGTACATAACTACATAATGCCA ACTCTGGAATCAAATTTCCTTGTTTGAAT CCTGGGACCCTATTGCATTAAAGTA 1239 2899122 4 HFE GGTGGAAACACACTTCTGCCCCTATACT 3.62E−05 0.007219004 2.43E−06 CTAGTGGCAGAGTGGAGGAGGTTGCAGG GCACGGAATCCCTGGTTGGAGTTTCA 2043 2901929 2 TUBB TCTGGTGCCCATTCCATTTGTCCAGTTAA 0.003390971 0.008049603 8.03E−06 TACTTCCTCTTAAAAATCTCCAAGAAGCT GGGTCTCCAGATCCCATTTAGAACCAAC CAGGTGCTGAAAACACATGTAGATAATG GCCATCATCCTAAGCCCAAAGTAGAAAA TGGTAGAAGGTAGTGGGTAGAAGTCACT ATATAAGGAAGGGGATGGGATTTTCCAT TCTAAAAGTTTTGGAGAGGGAAATCCAG GCTATTAAAGTCACTAAATTTCTAAGTAT GTCCATTTCCCATCTCAGCTTCAAGGGA GGTGTCAGCAGTATTATCTCCACTTTCAA TCTCCCTCCAAGCTCTACTCTGGAGGAGT CTGTCCCACTCTGTCAAGTGGAATCCTTC CCTTTCCAACTCTACCTCCCTCACTCAGC TCCTTTCCCCTGATCAGAGAAAGGGATC AAGGGGGTTGGGAGGGGGGAAAGAGAC CAGCCTTGGTCCCTAAGCCTCCAGAAAC GTCTTCTTAATCCCCACCTTTTCTTACTC CCAAAAAAGAATGAACACCCCTGACTCT GGAGT 1186 2902700 5 VARS CACCACCATGGGGTTGTCCTCAATGCCA 0.000252847 0.00748735 2.36E−06 CGGAACAGTCCCCGCTCCTTCAGCGCCA CCAGCACCGCTTTCCTGGCCTCAAACCT GGGCAGGCCCTGGGTAGGAATGAGGCCT CATCATGGCGATGCCCAGCCATCCCTCC ATCTCCCTGACCCGGGCACTCTTGCCTCA GGCAGCCTCACCAGGAAAGGCGGAGGC ACATTGATGAGGGCCCCCCGGGAGTCCA TGATGCTGATGGCCTCCAGCCCGTGCCG CTGCCCAACTTCATAGTCATTTTGGTCAT GTGCGGGGGTGATCTTCACAGCACCTGG GTGTA 1007 2902874 3 CFB; AGGGCTTAGGGGACATCTACTGAGTGAC 0.016243657 0.006650439 4.11E−06 XXbac- AAAGGCAATGGGGAGATGACAGTGGTG BPG116M5.17 GGAGCAGCTGAAGTGACGCAGTCTATTC GTCC  936 2903195 9 HLA- ATGTGATCATCCAGGCCGAGTTCTATCT 0.000384143 0.013596025 1.40E−05 DRA GAATCCTGACCAATCAGGCGAGTTTATG TTTGACTTTGATGGTGATGAGATTTTCCA TGTGGATATGGCAAAGAAGGAGACGGTC TGGCGGCTTGAAGAATTTGGACGATTTG CCAGCTTTGAGGCTCAAGGTGCATTGGC CAACATAGCTGTGGACAAAGCCAACCTG GAAATCATGACAAAGCGCTCCAACTATA CTCCGATCA  216 2903200 9 HLA- CCCAGAGACTACAGAGAACGTGGTGTGT 0.000226058 0.023137572 2.88E−05 DRA GCCCTGGGCCTGACTGTGGGTCTGGTGG GCATCATTATTGGGACCATCTTCATCATC AAGGGATTGCGCAAAAGCAATGCAGCA GAACGCAGGGGGCCT 1913 2903425 9 HLA- TGATTCTGCCCGGAGTAAGACATTGACG 0.019535405 0.007421118 6.20E−06 DPB1 GGAGCTGGGG 1810 2903456 3 HLA- CCAGGGGCTTCATGCTGGGGCTCATCAT 0.001140973 0.007189358 4.98E−06 DPB2 CTGTGGAGTGGACATCTTCACGCACAGA AGGAGGAA 1173 2903747 4 SYNGAP1 CCATTTCACCAGAGCGTCCTTAGGGGCT 0.006813471 0.006836913 3.73E−06 GGGGGTGGGTTTGTTAATGGGGTGGAGG CAATGATGGGTTGGAGGATCTTGGCTAT AGGGGCTGTGCTGACTGCAGCAGGTAGG TTGGGTTTCCCTCTTCCTTCCCTAATCTT GGTTCTCTACCCTCCTTTCCACTCCTCAC CTGATTCTCTCTCTTCCTCCTCCTTATATC TGTGAGGCAGAAGGCATCTGAAGCTCAT ATTAGCCCCCATTGGGTGGGAATTAGGA GTGGGTAGTTAACTCAGGGAGACTTGAG ATACCCTGGAAAAAATGCTATTGAGATG TCCTGACATTAGGCAGGGTGGATGGAAC AAGAAGGAGCAAGAAAGGAACCTCAGG CAGATGTTAGGACATGGACTTGATCATG TGGCCTGGGAGTTTAGAAATGGGGAGAG ACATCCTCCTAGATCAGATCGTGGGCTC AGTAGGCATGTTGATT  914 2904304 9 UHRF1BP1 GCAGTAGAGTCCCTACAGGCCAAGAAAC 0.009512851 0.008610073 5.37E−06 TGAGCAGAACCCAAGCCTCCAGCTCACC AGCTGCATTGAAGCCCCCAGCTGGCAGG GAGACTGCTGTGAATGGACAGGGTGAGC TCATCCCCTTGAAGAACATTGAGGGAGA ATTGTCAAGTGCTATTCACATGACCAAG GATGCCACCAAGGAGGCTCTACATGCCA CCATGGACCTCACCAAGGAAGCTGTGTC CCTGACTAAGGATGCCTTCAGTTTGGGC AGAGATCGAATGACCTCC 1311 2905788 2 ZFAND3 TGGCCACCACGTGACGCTGTTCTTAGTTC 0.000250234 0.009189307 1.18E−05 ACTAATGTTAGCCTTATTTAGGACAAAG TCAGCCAGACACCTTGTACTGGGCACGC GTCAGACTGCAGCCAGTCCGTTTCCTTTC TTTAGCCAGCCATCCTGGTACTGTAGTTT AGGGGTTGATGGTGGTTGAAATTGATTT CTGGCTGGTTACTAAGGTGCCTGCTAGC CATTGTATAAA 1522 2906151 1 ATGGGAACAGAGATCCAATATTGTGTGA 0.027602711 0.006514376 3.25E−06 CTACAAGGAAGGAGTCGAACTGAGTGTC CC  753 2907867 4 TTBK1 GCCCGGGTAGAAAAGCATGCACTGAGCC 2.23E−05 0.010219124 7.77E−06 CCCTGCCCCTAGACTGCGAGTACTGTAC AAATCCAACACTTGAAACCGACACGCAC ACGCGCGG 1617 2909086 5 RCAN2 AGCAGCCAACTTGGACCCGCAAGTGGGA 0.000200907 0.007185162 2.21E−06 CCAAGTATGGAGCATGGCAGGGCTTGCT TCCAGGATCCCTGAATGACACTGTGGGG CAAAGCTACCGACCCTCCATGGA  424 2909642 1 TGTGCAAGTCCGAATAGAGCTGGGTTTT 0.016461142 0.010554498 4.48E−06 GGACTGGTCCAGGGGGAAAAGGCTGTTG GCCAGGCTGTGCTGGATCTTGGCCAGGT TGTGGCTGGAGCGACCAGGCGCTCCCAG TCACCTTCGGACTGGAAGCGGTTTA  292 2909752 1 TGGGACTCACATGAGGCCTATTACCCCT 0.022567667 0.011174444 1.02E−05 TTCTTCTGGCCTATTCCTCCCTTTTGGAA TGGGAATGTCTGCACCACCACTGTATCTT GGAAGTAAATAACTTCTTTTTTTATTTTA CAGGTTCACAGTTGTAAGGAACTTGCCT TGAGTCTCAAATGAGACTTTAGACTTTTG AGTTGATGCTGGAACAAGTTAAGACTTT GGGGGATGGAATAATTGTATTTTGCAAT GCAAGAAAGACATGAGATTTGTTTTTCA TGCCACCAAATCTTATGTTGAAATTTGAT GCCCAATATTGGAGGTGGGGCCAGATGG GAGAAATTTGGGAACAGATCCCCCATGA ATGGCTTGGTGACATTCTCCCAGGAGTA AATAAGTTCTC  967 2910038 1 AGCTCCAGCAGGACTACCAAGGGCTGCC 0.000792576 0.007667081 3.42E−06 ACTGGCTGTCTGACAGTGCCTGG  720 2916447 6 ACAGCTCGGTTGTAGTGCACAATTAAAA 1.19E−06 0.013525256 1.66E−05 TCACACTAACTTCATCTGAAGTGTCATTC TACAGTTTTATTTACACAACCAGTGAAG GGCATGTTCTAGAATACCAGCTTTAATC CTTTTCAAACATTAATATAAGAAGCCAA ATTGTAATGATACAGCAAAATGAGGCCA CTGGTATTAATACAGGTAGCAAAGGTCC ACATCCAGGTGGTACTGACATCAGGGAA ATTTCCAAAACCAGTTGCTGCTGCCTAA GAGTGGTTGCCACTGACGAAAGCTTGAA 1842 2918773 3 RP11- TAAGGTCCCTCCAGTGTACAACAATTTG 3.52E−05 0.008939061 7.01E−06 1414.3 1845 2919791 4 AIM1 TCTGAATGCTGAAGTGACAGTTGGAGAT 0.000116584 0.007440145 4.92E−06 GG  650 2923986 2 CLVS2 ATGCCAGGGAGTGCCGCATTGCTTAGCG 2.50E−05 0.014201609 9.88E−06 ACCCCGCCTCTGGG 1180 2926824 9 MYB AGACAGTGCACCTGTTTCCTGTTTGGGA 0.000449203 0.006598249 3.58E−06 GAACACCACTCCACTCCATCTCTGCCAG CGGATCCTGGCTCCCTACCTGAAGAAAG CGCCTCGCCAGCAAGGTGCATGATCGTC CACCAGGGCACCA 1550 2927252 1 CTCTGTCTTGGGAGGCTATGAATTAAGT 3.56E−05 0.006844416 4.85E−06 CAATGGGCTCCCTTCCTTTCTGTTTATCA GTTGGATTTGGTCAGTGGGGAGTCCAGG CAGGGATCTGCAGGAGGAAGGACATTG GGAGCTGGGTATTTCTCTCCTGGACTCAC TCTGTATGAGTCACTACAGGCTGGCTGT GTTCTTCAACAGAAGGTTATTGCTCTTCC CAAGGTGACAGCTCCTATGGGACTCACT TTCTAACAGGG 1446 2929703 1 TGGGAAAAGGCTGTCCCTTTGCATCCCA 0.000272577 0.008755676 5.51E−06 AATAAGGCAATACGAAATTGTAACTGGA TGCTACCATGGACACCCAGATTCTATCC AGGAGAACATAAATAGAAGTGATGAGA ACACCCTCTCCCTGCTGGAAATACATGT GGGGTCC  229 2934526 4 SLC22A3 TTCCGGATTCGCTTATGGTCTCCAGGGTC 0.000205715 0.018234968 1.72E−05 AAAGGAAAGGGCGAACCAACGTTTGAA GGCAGCAGCAGCTTTTTTCCAGTTGCCC AAATGGTTACTCAAAATGCAAGGGGACA 1291 2934538 9 SLC22A3 TGACAGAAATAGTAGGTTCGAAACAAAG 0.00362841 0.009917021 1.07E−05 GAGGATTGTGGGAATCGTGATTCAAATG TTCTTTACCCTTGGAATCATAATTCTCCC TGGAATTGCCTACTTCATCCCCAACTGGC AAGGAATCCAGTTAGCCATCACGCTGC 1427 2934539 9 SLC22A3 CCCGTTGGCTGATTACTCGGAAGAAAGG 0.001777336 0.007323945 3.98E−06 AGATAAAGCATTACAGATCCTGAGACGC ATTGCTAAGTGCAATGGGAAATACCTCT CATCAAATTACTC  266 2934543 4 SLC22A3 AGGCTCTCTGAACATACAAACAGTATAA 6.72E−05 0.017329092 1.57E−05 CTGTTGTTCACTAAATGGAAAAATCCCA AAATCAAAAACCAATGCAAAACAGTGA AGTGGCTTGAGCTCCTAGGAGGTTAGGT AGAAATTAAAGAGAATCAGTGGATGGGT AGAATTTTAAGCAGTAGGTAGTTACCCA ATGTAGAACGAGGATTAGCTTAGACACC TAGTCTGG 1565 2934557 4 SLC22A3 AGAGTGTCGATACTAGGCAACAAGCCTC 0.000509079 0.00868456 8.95E−06 TGAACAGATAGTGTTACCCGGAACATCA CCCTTTTCTCCCTTTGCTTCAAATCAAAA CCAGCATCCCCCATTTAGACAGCATAAA AGGTATG  180 2934569 4 SLC22A3 AGGGGCAGGTAAGTGAGAGTGTCAGTG 4.44E−05 0.022037658 2.59E−05 AGCGGGCGCAGAGGGGACTCCC  513 2934571 4 SLC22A3 TATACAGGGGCCGTGGTGCTACTCAGGG 0.000771692 0.013671209 1.16E−05 TTTGAGGAAGGGAGAGAACCTTTGAAGC TGTGGTAAGGGAGAGCTGGGGCATTGAT CTGGGATGCAGAGGTTGCTGTGGTTGAG AGCTACTCCAGTGAGCAACATGATGGCT TCAGAGTGAGCAGGCCCCATGGGAGAG GGCCCAGCTGTGTCTTCCTGGAGCGGTA ACACCTT 1174 2934586 4 SLC22A3 TGCTGGCTACAATTTGGAACTGTGCAGT 0.02563769 0.010772341 8.50E−06 TTAAATATTTATTTATTTTGTTTTGTTTTT ACTCTTTCTAATTTGGATATTAGGTTTTG CTTCATCTGTGTTTTTTTTCTCTTACTCAG TCAATAACCATATCTCCAAACTAAATTA ACGTTACTAAAGTGGGGAATTTCCCCTT CCTATATTCTCATAAGTGATTGAGCATCT GTCCTCATATAGGACTTGCTGCCTTGGA GGGGAGGGGCCAGACCTGGGAAAAAGA GGAGCCATGAATAACTCTGCTTCCTACA TTTGGCTTCTTCTCTTCCTCCATATCCAT GATTTATATATGTGAAGGAAGAACAAGA AATAACTTAATAGGCCATTTGTCAATGA GAGTACAGTGTAGGAAGGGTGGAAAGT GAATATAAAATCTAGATTGGGGCTTCTG GTTTCCTGTTCAGCCTATAAGGAGCTTAG AATTTGCCACTCAGTCTTGACAACAAGT AAAATGCTGAACAAACTGAAAAATCAAT AATTCTTCTCAGATCCATAAGAGAAGTG AGATTACAGGGCAAACTACTACCTTCAG CATCACCCCGCACCCCCAACCCCACTAA ATAGAAAGACAGGAGAATACAGAGAAT CATAACACAGGCGCAGAAACCTCCTTGA GAGAGCCAGGGTAGATAAACATGAACT GTAATTGATGAATTCCTGGAGGATCACT GTGGATGACCTGAAGGATTAAAAACTCT AGAGGGACTCACTCAAAGGAGGGCCCA AGCTTTTGTGATTTTTTTTTTTTTTTTTTT TTTTTTTGCCACCTGAAGCTCTACAAGGT TCCAAAGGTGAATATTAAGGAAAATCCC TCATGCTCTGGCAGCCAGAGGGGAAAAG GAACAATTTTGAAATATGCCAGAATATC GTTCTTAACAATGTCTGCCCTCAGGAGA AGATGTTTAACCAGAGCCTAATCTTCTG GGGTTTTCTGAGAGCCTCATTGATCTGG GGGAAGGGAAATACCAACTCCAGCCCCT TCTAGCCTTCCAAGTGGAGAAAGAGAAA CACCAAATTCTAGCCTCCTCTAGCTTTCA ACTTGGAAGAAGGGAAATACCCAGCTCC AGCCCCCTCTAGCCTTTCTCCCCTAGTTC AGAGGAGAGGGATAGAGAAGCATTTGT GAAGTTCACCGTTTAGAGACATAGGTTC  990 2934942 8 AGPAT4 ATGGGTTTGCTTTGATCGGACCAACCGG 0.000540412 0.00716353 4.90E−06 ATTCCTGAGTGT  787 2935707 1 GGCAGCCGGAGGAAACCTCACTCCCCAG 5.15E−05 0.011241051 7.14E−06 ACTCTGCAGGAAACTTACGTGCAAGTCT TTT  584 2936726 3 RP11- TGAAGAAAAATAATGTGGGTAGCCGGGC 0.02244372 0.011771471 1.03E−05 568A7.2 TTCATCTTAGCAACACGAGCACCTCATTT TGGTTTTC 1366 2937410 4 XXyac- ACGCTTCGTTGGTCTCGGGAATACAGCT 1.83E−05 0.014910823 1.15E−05 YX65C7_A.2 CCACACGCAAAAAAGTAAAAAGTGCAG CAAAACAACAACACAACGATCAACCTCA AAGGAAACAACAAAATTAATTTTATCAA AATGCAATGTGTACATTAAGACTAAAGT TATGGATTGTTCCTGTTTGGCATAGAAAT GTGATGACTATTAACAGAAAGGGGAAA AAGATTTGCCCCCTATCCATCATCAGAC AGACAGACTTCTCTTACTAAACCCCTTAT GTGGAGTGGGATGAGTGACTATTTCCTG CAGAA  925 2937411 4 XXyac- TGGCTTATGCACAGTATTCCCTTCAACTC 3.03E−05 0.017161552 9.44E−06 YX65C7_A.2 CATATACACATAAATACAATAAGTAATT ACATTTTATATGTAAACGTCATTCTTTTT AAACAAACAAGAAAAAGCAATGTAATG GCATGCCCAATTTTCACTCCACATAAAG TCTCATATATCACCAAACTGGTTTCCTCT AGTGGGTTAGATGTTCATCTCTGAGTTCC ATTGATATTTATCCTCTGAAGGCACTTGG GTTTGGGGTTGCTGGCAGGAGGTGAAGA ACCATCAGAGTTAAGGTCAAGGGACAGG AGGTGCTGCTAGAGAGAGAAGCCACAA GGACCACAATGAACTGAGGTGTCTAGGG ACCATGGCATGCACAGGGCATTG  895 2937484 5 WDR27 GCAGGCCAACAACGATGTCTGCGTGCCC 0.039759255 0.008047812 5.15E−06 CAGAGTCTGATAGGCAGCAGCCCGAGCC AG  741 2938547 7 FOXF2 TCAGATTGGGGAACGCTACCTTGCCAGC 0.000412342 0.008173684 5.12E−06 GGTTGTCCTTCTTCCAGCAGTAGGCAAA TAACAGTGACCAACGCGATCCTGGGCAT TCTG  381 2938741 9 GMDS TTGACCTCGCTGAGTACACTGCGGACGT 0.014877417 0.008255843 7.22E−06 TGACGGAGTTGGCACTCTACGACTTCTA GATGCAGTTAAGACTTGTGGCCTTATCA ACTCTGTGAAGTTCTACCAAGCCTCAA  412 2941607 7 TMEM14C CAAGTAGCAGCATGCGCCCTGCATTCAG 0.000933891 0.019147592 1.94E−05 CGGGTGGAGAGTGGGGCGGGGCATCGC GGCGAGCTCCTGAGTCCAGGGAACGCGG CGGGGAATCTCTGTGCTTCCC  672 2941759 6 GGGAACGATGGCCTCCCAATAGATAGGA 0.000378341 0.00855831 5.95E−06 AACACCTGAAGCTGGTGATCAGCCACTT CCTGATAAGATCTCAGGAGTTGGGTGCG CAGGCTCAAGCATGCACCCTAAGAGGCA AAATAGTGGCATTTAACTCATATATGAC CTTCCTTTAGGAAGGCTTGACTGGTAAG GGAAAAACTCCTCCAGTGAACACGTGCA CAACTTCAGTAAAAACACTGCACATGCG TCCCCTCCCAAGTGCTGGCAGGCCACTG TGCATGCAGACAGCCCGCCCCAAAGAAA AATCAGAGGAGGAGAAATGGAAACCCC GGAACAATGCCAATGTATAAAACCCCAA GTCAAGGGCCTACCAAGGCAATTGGATC TCTCAAGTCACCCGCTTGGCTCTCTTCAA GTGCACTTTGCTTCCTTTTGTTCTTGCTCT AAAACTTTTACTCCTGCTATAAAACTTGC CTTGGACTATCATGCTACCTTACGCCTCC CCGGCCAAATTCCCTCCTCTCCTCCGGGG GGCAAGGATGGAGTCTGCTGCAGACCCA TTGGATTTGCTG  174 2941893 2 NEDD9 CCACTCACATCCGACGTGTGTGGTTGCTC 0.006757381 0.017550027 2.12E−05 AGTAGGGAAATGCTTACAGCTGCCTCTA GAAGCAAGTCCGCTCGCTGCATGGAG 1631 2943773 5 CAP2 ATGGCGCTTCTGGCCCTCAATCAGCCAG 0.023624431 0.006508257 4.92E−06 GG 1179 2944071 2 DEK CAGCGGCAGTGTGTCCATCATATTAAAA 1.41E−06 0.012319789 1.03E−05 ATATACAAGCTACAGTTGTCCAGATCAC TGAATTGGAACTTTTCTCCTGCATGTGTA TATATGTCAAATTGTCAGCATGACAAAA GTGACAGATGTTATTTTTGTATTTTTAAA AAACAATTGGTTGTATATAAAGTTTTTTT ATTTCTTTTGTGCAGATCACTTTTTAAAC TCACATAGGTAGGTATCTTTATAGTTGTA GACTATGGAATGTCAGTGTTCAGCCAAA CAGTATGATGGAACAGTGAAAGTCAATT CAGTGATGGCAACACTGAAGGAACAGTT ACCCTGCTTTGCCTCGAAAGTGTCATCA ATTTGTAATTTTAGTATTAACTCTGTAAA AGTGTCTGTAGGTACGTTTTATATTATAT AAGGACAGACCAAAAATCAACCTATCAA AGCTTCAAAAACTTTGGGAAAGGGTGGG ATTAAGTACAAGCACATTTGGCTTACAG TAAATGAACTGATTTTTATTAACTGCTTT TGCCCATATAAAATGCTGATATTTACTG GAAACCTAGCCAGCTTCACGATTATGAC TAAAGTACCAGATTATAATGCCAGAATA TAATGTGCAGGCAATCGTGGATGTCTCT GACAAA  246 2945999 5 LRRC16A AAATGGCAAAAGAATCACATAAGGCAG 2.93E−05 0.01735269 1.41E−05 AAAT 1712 2948594 7 TUBB GTATACACCACTCCAGAGTCAGGGGTGT 0.002029355 0.013237004 7.19E−06 TCATTCTTTTTTGGGAGTAAGAAAAGGT GGGGATTAAGAAGACGTTTCTGGAGGCT TAGGGACCAAGGCTGGTCTCTTTCCCCC CTCCCAACCCCCTTGATCCCTTTCTCTGA TCAGGGGAAAGGAGCTGAGTGAGGGAG GTAGAGTTGGAAAGGGAAGGATTCCACT TGACAGAGTGGGACAGACTCCTCCAGAG TAGAGCTTGGAGGGAGATTGAAAGTGGA GATAATACTGCTGACACCTCCCTTGAAG CTGAGATGGGAAATGGACATACTTAGAA ATTTAGTGACTTTAATAGCCTGGATTTCC CTCTCCAAAACTTTTAGAATGGAAAATC CCATCCCCTTCCTTATATAGTGACTTCTA CCCACTACCTTCTACCATTTTCTACTTTG GGCTTAGGATGATGGCCATTATCTACAT GTGTTTTCAGCACCTGGTTGGTTCTAAAT GGGATCTGGAGACCCAGCTTCTTGGAGA TTTTTAAGAGGAAGTATTAACTGGACAA ATGGAA  537 2949541 3 EHMT2 ATTGTTATTGGGTTGTCGCTGCTTCTAGG 0.033900726 0.007162816 5.30E−06 ACTTTTGAGTGGGCAGACTTAGGAAATT TTTGTTCGTTTTTTCTTTTAAGAGACAGG GTCTTGCTATGTCACCCAGGCTGAAGTA CAGTAGCAGTTCACAGACAGTCATAGCT CTCTGCAGCCTCGAAATCCTGGGCTCAA GCAACCCTCCCATCTCAGTCACATGAGT AGCTGGGACTACAGGCATGCACCTCCAT GACCAGCTCCTGGCTGTATTTTTTGGAAA GAGAACAATTACTTTATTTTCTCTCTGGC ATCAGATGGTAGACGCTACTAGTCCCAT TTTTG 1358 2949792 4 PRRT1 GGCTGATGCCAGCCCGGGCGTGCCCCTC 3.41E−05 0.010959106 4.97E−06 AACAC  954 2950359 3 HLA- CGAGGTAAGCGTCTTTCCCAAGGAGCCT 0.0264846 0.006794213 5.43E−06 DPA2 GTGGATCTGGGCCAGCCCAACACCCTCG TCTGCCATGTTGACAAGTTCTTCCCACCA GTGCTGAACATCACGTGGCTGCGCAATG GGGAGCCAGTCATTGAGGGTATTGCAGA GACCATCTTCCTGCCCAGCAAGAAACTC AGATTACACAGGTTCCACTATCTGACCC TCGTTC 1074 2950628 1 AGGGTACTCCACCAGCGAGGATACACCG 0.002531721 0.007373825 5.32E−06 AGCCGACGGGGATCTCGGTCTCGGCGCC GGAAGCCTCTGAGAGCCGAATCTGGAAC CGGATGTGGCTGCTTCCTGCCCCGCCCCC TGCCGAGGGGGCGGGAATCGAGGGCCCT TCGGAAAACCCGGCCGGGATTTCGGTCA GCTACATTC 1957 2951240 9 C6orf106 GAGATTGCAGATGTCAGCGTCCAGATGT 0.000742232 0.006740159 2.55E−06 GCAGCCCCAGCAGAGCAGGAATGTATCA GGGACAGTGGCGGATGTGCACTGCT 1705 2951657 2 FKBP5 GGCATGTCCTCTTAGACCTGCTCTATGGT 0.01612054 0.006552065 5.39E−06 TTTTCTCTTACTCAGACTCCTTGGGTGAG GGTTGGAGTATTTGTGGGGAGAGACAAC TCGGCAGTGAGATGTACGCGCTGCTTGG GCTGTGGTAAATCCTAGTAACATGGTCT TAACACTGTTGGTCAGGCATTGAATTTA 1150 2952044 4 CPNE5 ACTTTCTACAATGTGGAGGAGGCTGGTG 0.000292246 0.007034962 1.80E−06 TTGGGGGGCCATGGCCCCTGAGAGCCCC CAATGAAGCCCTTAAGTGGGACAGCAGT GC  270 2952341 9 MDGA1 TGTGGCTATACCCAGGACCTGACAGACA 0.029384212 0.01770572 1.92E−05 ACTTTGACTGGACGCGGCAGAATGCCCT CACCCA  437 2952713 5 DNAH8 TGTTTGTTGTTTGGTTATGATCTTGCTT 0.000896506 0.012004253 1.16E−05 1280 2954808 3 GTPBP2 GATTGGGTCTGTACAGTGTATGGTAACT 0.008619147 0.009128367 6.34E−06 GCTCACTGTTT 1607 2956143 5 GPR115 TACCATCATATATCACGCATTTCCCCCTC 0.004167745 0.007592338 4.65E−06 CTGGAATATGTGCAAAAACAAGCCTTTC TTCAACAGGAAAATGGTGCTGGTGTAGG ACATCTACTCACGGCATCCAGGAAGTAG ATCTAGCAGCCCAGA 1918 2965266 1 ATGGCACAGATCAACCCAGTGTCCATTC 7.04E−05 0.006704181 4.77E−06 CATGGAAGCATTCAGAGACTGAGGCTCC TCAGTCCTACCACAGAAACACTGAGAGT TACAGAATGGCAAATATCTGTAACTGGT TCCAAGCAAGAG   89 2965642 1 GGATTATGCCGGTTTCTACTGTGTCATGC 2.62E−05 0.025473063 1.96E−05 AGGTTGTCAGGGAAGTGAGGGAAAGCC AGGAGTCACAGATCTCACCCAGCTTCCA TGCAATCCAAAGGGCCGTTCTCACTCCC AATGTGCCCCCGGACCCAACAGCACTGA GTCTGTTTCCAGGCAGTGGGTAAGCAGG GCTGAGAACTTTCCCCAGGCAATCTGCT TCCCAGCTGTGAAAGCAAATATGGCTTT CCTTCTTCCCCCACCTGTGGAGACTGCAC ACCGGATTCACGCCCTTCCCTGAGTTCTG GCCAGGAGTGTTCTCAATCAGCTCAAAT TGTTACAAAGTTCAGCTGGAGGTTTTCTT CTCCTGTGGCTTTTCCCGGCATCTCTGGT CGCCCTCCTGAAG 1267 2968105 4 SEC63 GGGTCAGCAGCGTTTCCCTCGGCGCTTCT 0.002641545 0.00762644 6.71E−06 CC 1406 2969569 1 ATGTGCAAATATCACCACTAATTCCAGA 7.50E−05 0.009287234 7.32E−06 ATATTTAATCACCTCAAAAAGAACCCCC CTGACACACACACCCAGTAGCAGTCCAT GCCCCACTTCC 1046 2970405 1 CTCTCCAGTCTATTGAGCCCCTGCCCCCA 1.39E−06 0.012220589 9.68E−06 CACCCTATCGGGTTCAGAGCAGAGCT 1903 2974773 1 TTGCCTTAGAGGGAAATGATGCCTTGTA 0.000450333 0.006875027 2.38E−06 CATATCTCATCCCACAGTGCTGCTGAAT GCGTCCATTTCAGGCAATGCCCAATTTG GAGAAAAGAAGAAGTGCAAAAAAAGAT GTTTCTTTGACCTCACCGCAAATA  869 2976265 1 ATGTTCTGGTTCCTAGAGAGCAAGACAT 0.000148906 0.008014361 2.11E−06 GGTGCACAGACCTGTGGGTGAAACCCGA TGGAGACCCATGG 1216 2980527 9 CNKSR3 GTCAGCTGGTTTACGCGCCTCAAACTGTT 0.006618995 0.010696705 8.84E−06 GA  779 2980896 4 NOX3 GGTGGCAGTTCTGCCGCTGCCACTGCCT 0.044188955 0.0069985 8.86E−06 GTGCCTAAGACTTCTCCCGTGGTCCCTCA GCTGGTGGACAGAAACACATTCTCCACG GAAGAAGTGCC  763 2982371 4 SOD2 CTGAGCTGTTGGAGGACTTATTACCATTC 0.000562297 0.007631489 4.53E−06 CCTGGAGAAGAAGGAAAGTCATCTTCGG TTGTGTTGCCCTCCCTGTGAAATCCAGAC CCAGACGTCCTCTGGCGGGAGGAGCTAC CATTACTTGGTCCGTTTGTCAGACGACTG CAGTCTTTACTTGTGGCCTCTGACTGTTC TACAGGTTCAGAAGCTGTAGTCCTGCTG GTACTTG 1154 2982612 5 SLC22A3 CAGAAGATTAGGCTCTGGTTAAACATCT 0.00199727 0.007947392 5.12E−06 TCTCCTGAGGGCAGACATTGTTAAGAAC GATATTCTGGCATATTTCAAAATTGTTCC TTTTCCCCTCTGGCTGCCAGAGCATGAG GGATTTTCCTTAATATTCACCTTTGGAAC CTTGTAGAGCTT 1299 2982619 5 SLC22A3 GTGGTACGGACCCTTTCCATGATCCCCA 0.000394997 0.009799409 9.65E−06 AAAGTTTCCTTGTGTCTCAGTGAAGTCA GTCCCCTCCCCCCACTCTGGGCTCTGGAA ACCCAGATCTGCTTTCTGTCATGACAGTT TTGCTTTTTCTAGAATTTCATAGAAACAG AATCAACAGTGTCTCACTTGGCGTCCCG TTTTGTCATACCTTTTATGCTGTCTAAAT GGGGGATGCTGGTTTTGATTTGAAGCAA AGGGAGAAAAGGGTGATGTTCCGGGTA ACACTATCTGTTCAGAGGCTTGTTGCCTA GTATCGACACTCTCTATTCATGGGAAAA  598 2982626 5 SLC22A3 GAGGTCTATAAACAGTCGCACTGGGAGA 0.008884278 0.009911085 7.59E−06 GTCTGCCTTATGCGGTTGAGATAAGGAC TGAAATACACCCTGGCCTCCTGCAGTAC CCTCAGGCTTACTAGGATTGGGAAACCC CGCCCTGGTAAATTTGAGGTCAGACCAG TTCTCTGCTCTAGAACCCTGTTTTCTGTT GITTAAGATGTTTATCAAGACAATACAT GCACCGCTGAACATAGACCCTTTTCAGT CATTCTGCTTTTGCTCTTTGTCTTGTGAT GTTTGT 1038 2983744 1 CCTGCAGCTGCATAAGTAGTGTTTCATTG 0.025498894 0.008506019 9.12E−06 CACCCCAGCAGGAGCTGGTACCGGTTCT TCCCTTGCCTCATGCTGGGGTAGATTTTA TTTAGGATTGGGAGCAGGGAAAGGAGCT AGAGAAAGGAAGGGTTCCAGGAAGCTG GGAAGGGAGATGTCAGGTGGGGTGATG GGAAAGGAGGCCAAGGACCACCTTTGCC TGTATGGTGGGCTGAACTGTGTCCCCAC AAAAGATAGGGCGTCCTAACCCCAGATA CCTGTGAATGTGACCTTATTTGGGAATA GAGTTTTTGCAAATGGAATCAAGTCATG ATGACGTCATTAGCATGAGCCTTAATTT AATAGGATTGATGTCCTTCTAAGAAGAG AAGACAGGGACACACAGGAGAAAGCCA TGTGATGAAGCAGGCAGGAGCTGGAGC GACACTACCACAGGCCAAGGAACATTGG GACCAGAAGAGGCGAGGAGGGGCCGTT CCCTAGAGGCTTTGGAGAGAGCATGGCT CATCAACACCTTGACTTCAGACTGGTAG CCCCCAAACGGTGACAGAATAATTGTCT ATTGTTTTAAGCCCCCTGGCTTATAGTAC GTTGTAAAGGCAGCCCTAGGAAGCCCTA AGCCAGTTTCACTCATTATGATAAATATC ATAGATGATGACTGTCATATATTGGATG TGCTGGAGATCTTCACAGCCACAGAATA AACTGCAGGCCAAAAAAAGAACATTCAT ATGAGGTCCCCAGCAGGGGCTGGCTGTG CAAGTCAGAGACTGCAGAACCAGGTAG GCAGACAAAGCGAAATTGCCTGGAGCTG GACACATATGTGCACCACTGGGAAATAA ATAGACTTGCGGTGGAAATGACCAACGT GGATGGCCAGGGAAATGCCAGCAGCAA TAAAAGAAAAGAGTGCACAAGGCCTGT AAATCAGCAGATGCGAGAGCTCCCGAAA AGTAGCGAAGTCTGAAATAAAAGGCAG GCTCAGGCTGGTGGTCCAAGAAGTTAAA GCAGGAAATGAGAGCGTGGGCACTGTGT GTGCTGGGCTCCCAAAGACTGCAGGGAG TGGCCAGATGTCTCCAGAGGCAGCGTCA TGTGGAGCAAAGGGGACCTGAGGAGTGT CAGCATCCTCAGTCACCTCCTCCTTTGAA CCAGCTGTTCGGAATCTGGTCTCTTACTT AGGATAATTGTAGGAACTGACTTTTTTTT TTTTTCTTTTCTCACCTATTGGCTGACTG AAAGAACCGACTTTTAAATGAGCACCTC CCTCATTAGAATTGCTCAAATGACAACA GCTGCAGCGGTGGGAGCAGCAGCAAGTT TGAAAATCCAACAGTCTGCATTCCACAG TGACAGTATTCTTGGTCACCTCGGAGAC ATGGCAGCCGGGAGCCACGGCTCTCATT GCTCGGGGTTGGTTGGGTTACCAGCCCT AGGGCTACAGAATGTATCTAAAAGAGAG GCTTGGCTGGCAGTTTAAGAGGGGTGCA GGACAGCAGGATGGGGTTCATGAGGCA AGAGTGGATGGAGCCTGTGGCCCAGTTG GGATGAGATGGGACAGTTCCAATGGGCA GGACAAACCCCAGCCACCGTCTCAGGGT ATTTGACAGGAGGTAAACAGCAGACAA AATCCTGGAGCACAGGGGGGCAGGGCT GTCTCGTTCCCATGAATGGCA 1545 2985812 2 THBS2 CATCCTTGCAAATGGGTGTGACGCGGTT 9.90E−05 0.012219435 9.02E−06 CCAGATGTGGATTTGGCAAAACCTCATT TAAGTAAAAGGTTAGCAGAGCAAAGTGC GGTGCTTTAGCTGCTGCTTGTGCCGCTGT GGCGTCGGGGAGGCTCCTGCCTGAGCTT CCTTCCCCAGCTTTGCTGCCTGAGAGGA ACCAGAGCAGACGCACAGGCCGGAAAA GGCGCATCTAACGCGTATCTAGGCTTTG GTAACTGCGGACAAGTTGCTTTTACCTG  173 2985814 2 THBS2 TCCTGTCCCTTGACCTTAACTCTGATGGT 7.38E−07 0.023947968 2.18E−05 TCTTCAC 1365 2985815 2 THBS2 ATGCCATGGTCCCTAGACACCTCAGTTC 4.36E−06 0.0130199 8.34E−06 ATTGTGG  257 2985821 9 THBS2 ACCGACGTGGACAATGACCTTGTTGGGG 5.55E−05 0.019474651 1.88E−05 ACCAGTGTGACAACAACGAGGACATAG ATGACGACGGCCACCAGAACAACCAGG ACAACTGCCCCTACATCTCCAACGCCAA CCAGGCTGACCATGACAGAGACGGCCAG GGCGACGCCTGTGACCCTGATGATGACA ACGATGGCGTCCCCGATGACAGGGACAA CTGCCGGCTTGTGTTCAACC  912 2985825 9 THBS2 TTCAATCCCCGCCAGGCTGACTATGACA 0.000212296 0.009058079 5.43E−06 AGGATGAGGTTGGGGACCGCTGTGACAA CTGCCCTTACGTGCACAACCCTGCCCAG ATCGACACAGACAACAATGGAGAGGGT GACGCCTGCTCCGTGGACATTGATGG   55 2985827 9 THBS2 ACAAGGACGGGATTGGCGATGCCTGTGA 2.10E−08 0.04925015 6.11E−05 TGAT 1672 2985830 9 THBS2 TGAGCCCGAAAACCCATGCAAGGACAA 0.00060261 0.008283886 6.83E−06 GACACACAACTGCCACAAGCACGCGGA GTGCATCTACCTGGGCCACTTCAGCGAC CCCATGTACAAGTGCGAGTGCCAGACAG GCTACGCGGGCGACGGGCTCATCTGCGG GGAGGACTCGGACCTGGACGGCTGGCCC AACCTCAATCTG 1900 2985852 4 THBS2 GACCCTCACTGTGCCTGTTACCTGAGGG 1.07E−05 0.006706587 7.05E−07 GTGATTTGCAGCACAGGCAGAGTTATCT TGGCTCCAGCACTCTGCGTGCCAGGGCC TCAGCTTCATGAGGCAGTGCTCTTCTGG GGGTTCCTGGGGTGCAGTTGGCTGTGGG GCTTTTGGGTACTTTTTGTTGCAATAATG TTTTTTCAGTCTGATATATTTATATGTAT ACGTGTGTGTGTGTGTGTGTGCGTGCGT GTGTATTTTCACTAATATAGAAAAATATT GTTTTTATAAACAAAACATATATGCAAA TATTCTTTGTATGAAAGAAAATATACCCT TCGCGGTGTTCCTAATCACATGTTTGTAC TATAATTTCACGTGGGTTCAGTTAAACTA GAGCTAAGGTTGTCCATGGCATGTTGAG TCAGTTGTCATAATGGTCAGTGAGTAAA ACTAACCTACTATGACAAACGTGACTTA CACCTCTATGTGAGCAAACACCTTGTGT GTGTGTGTGTGTGTGTGTGTGTGTTACCA GCATACACCCTAGTAGG 1263 2986383 4 DLL1 GAGATTTCCGTATCCGGCCTCTGTGCCA 0.00076237 0.006667557 2.62E−06 GGTCTCCAGTCAGAGGCGCCCCTTCACG TGGGAAGGTTCTGGTTTCCCGACTCCTA GACGCGTTGGTGGCGCGATTACCCGCGC AGCGCGACCGCTACCACCCGGAGCGTGC CCATCCCCCAAGAAAAATGACAAGGGCC CTCGGGCCTCTTCCACCCCATCCTGCCTG CATTCTCTCTCTCTCTCTAATTAAAAAAA CAACGTAATATCCTGTAGTACAGGCTGA AAAAACACGTCAGGAAACCACTCTTTAA AAAGTTCTTCCATTTCCTTAGGGAAGGT GAGAGCAGGCAGGAGGTGCGTGGAGAC CCTCTCCAGACACGCTGCCCCAGACCTG CAGCCTTCAGGCCTCTGTTGCTGACCTGG CTGTTAGGAATGACTGCTTTTTGCCGTTT TCTTTTCGTTACCTTTCTGGGTTGTCTAA CGTCTTCTCC 1041 2986512 4 PSMB1 TACCAGTGGGTAATGTAGGGCTCGCAAA 0.012305161 0.007787863 2.74E−06 GGTATAGTAAAGCTAGGATTTGCAGTCA CTGTATTGTCATGCTAAGACCCTGTTTTG GATGCTTGTGTTCTCTACTGTAGATGTTT TAAGGATCACGACCACTGCTGTGTATTA AAATCATGCAGAGTAAGGGTGCTGCCCT GTGTCTTCTGTTCTCACAGAGATCTGCTC CACAAAGAGAGGGACTTACATCTAGGTT TGATCAGGGATTGCCGTAATTTTTCTGTA AAGGACCAGATAGTAAATATTTACAGCT TTATGGGCCTCATTTGATCTGCTTCTGTA GTGAAAAAGCAGCCACGGACAATATTCA TAGCAATAGGGAGTAGGCTGGATTTGGC CCCTGAGCCAAACTACAGGGGTAGTTTG TTGACCCCTGGTCTATATGCAGAGTGAG GGAGAGAGATGGATTTAAACCCATCTTC CTTAGGCCACTTCATGTGCCCTTTCATAC ACATTAGCTCTTGGATTAGCAGTACCTG AGATAAGGGTGGTATGGAAAATAGAGTC TAAACCAGAGAGCTGAGGGCAAACTTGG CATTCCTTCCCTTA 1517 2987970 6 AGTGAGCACACCCAGGCCGACGGCTACC 0.000701725 0.008122069 6.02E−06 CAGATGTATCCAGTGGGTACACCCACGC CCACGGCTACCCGGATGTATCCAGTGGG TACACCTTGGCCCACAG 1160 2988685 5 FBXL18 GATCCTCCTATAGTTCCTCAATGTGATGA 2.14E−06 0.013965334 9.39E−06 CTGGGTGTTCACACTCATTGGCGAGATG TGCCTCTCTCAAACCTTGTTCAGATGCTG CAGA  301 2988989 9 USP42 TCAGTTAATAGGTCCTCAGTGATCCCAG 5.20E−06 0.018386695 1.25E−05 AACATCCTAAGAAACAAAAAATTACAAT CAGTATTCACAACAAGTTGCCTGTTCGC CAGTGTCAGTCTCAACCTAACCTTCATA GTAATTCTTTGGAGAACCCTACCAAGCC CGTTCCCTCTTCTACCATTACCAATTCTG CAGTACAGTCTACCTCGAACG 1278 2989490 5 COL28A1 TGAATCATGGTGCTCCTACTAAATTCCA 0.003684101 0.006751514 1.06E−06 GGTGTCCC 1425 2989606 4 AC006465.3; AGAGAGTAATAGCATGCGCACCCTAAAG 0.024995647 0.00697113 4.25E−06 GLCCI1 TTCACATTCCTTTTTCAGCAATCACTGGA TAATCCCTGGCTCCTGACATTTTCTCCAT ACAGAGTAGAGGTTCATGATCACTTTTT CATAATACTTTTAGGTAATTTTAATATACT GAGGGATAGTGACTTAGGATTTGCTCAC TTCGTATAAGATAAAACCAATGATGGGC ACACATTTACCTGTGTAACAAACCTGCA CGTCCTGCACATCTATCCTGGAACTTTAA GTTAAAAAAAAACCAGTGAACACCCAAC TAGACATATTCCTGAATG  893 2990835 5 AGMO TAAGAAGAAACAGTAATACCAGCAGCA 0.000106893 0.008642024 4.81E−06 GCATATTGGTGGCTGGATACA 1859 2993333 7 CYCS TGCGGCCTCCGCGACCCGCTCTCACCTCT 1.63E−05 0.009327163 5.44E−06 TTTTAGTCGCTGGCACAACGAACACTCC CGCTCCGAAGCCGGA  558 2993375 1 TGTGTCCAAGAAAGTGTGGCTAGTAAAA 0.000920533 0.009480199 2.07E−06 TAGACTTTGGAGATGGGCCGAAGTATCC ACTGATTGAAGAAAACAGACAAGTCCAA GGAGGAAATGCATACAAGGCAGAGGTG GTAGGCAAAGAGGAGTATAAGATTGAC AAGGA  465 2993385 1 GATTTGGTTGTTAGGGATGGAATCAAAC 0.000496534 0.011230659 7.84E−06 AAGACACGGGATTTGAGCTGATCTT 1709 2994249 1 CTCACTCGGTAAAAGCCAGGTCCTGACA 0.000611594 0.008053291 5.10E−06 CGGGCATTCGTGGTCCCACACGAGAGCC TGCCTGCTGCTTCTTCAATCACACCTCTT ACCACCCATGGCCCCTTGCTCACTCCACT CGAAACCCGGAGGTCTCCTTTCTGTTTCT GCCTCAGGACCTTTGCACTGGCTGTCTTC CAACCTGAAAGGTTGCTTTTGCCCTTGGT TCCTCCAGGTCTTGACTCAAATGTCATCT TACCAGTAAAGTCTTTTCACCTTGGCAGT TTTTATCCCTCTTTCTTGCTCAGTTTTTGT TTTATATTACATTGCACTTAACACCATTC CATACTTAATACCAAACAACGTCTTCTTT GTTTATTATCTGTCTCCCCCTAAAATGTA AGTTCCATGAGATTTTTTTTTTTCATTGC TATATCCAAAATGCCTAGAGTTGTTACT GGAACATAGTAGGTGGTCTGTACACATG AACC 1065 2994656 4 CREB5 CTATGGCAGGTATACCAGGCCCAGAGCA 2.98E−05 0.00904156 8.03E−06 ATGAGCGAGAGAGGTGGTCA 1001 2995111 7 SCRN1 CATTTCGGGATGTTTGGAGTCAATCAGA 0.000242546 0.006895394 4.13E−06 TAAAGCACATTATGACAGAAACCATAAG AGGGGAGCTGGGACCTGGGACTGTGCAG AATGAAAAGCCACGGCTACGGGAAGCA TAAGCTTGTGCTGCAACGGCATGTGCAC ATGACCTGCTGCTCCTGGCCCTCTACGA AGCATGCCCAGCAAGGGAACCTCCTCCG TCCCTCCTCCACGTGCTTCCTTCCTAAGG CTGAGAGCTCAACTGAAGACCTTCCCCA ATAAATGACAGATGGCTCTTCAGTCAGG AATGCAGTTAGTGGTTTCATGACAGACA CACTGGTCCCACCCGGCTTCCCTGCTGA ACCACCCAGTACTGAATAACACCTGTAC CAATGTGGGATGACA 1026 2995377 1 CAGGCCCAAGTTCGCCCAGAGGTGACAC 4.39E−05 0.00926322 5.50E−06 ACTTGGGAATTTGTGGTGCCATCGTGCC AGGTCCCTCCTCGTAAAAGTGCCTACCC AGCGCCTGCAACCAGAGCCAAAGCCTGG ACATGATAGGGAAACTCTTGTTAAAACG CGACACGTGGTCCTG 1782 2995444 9 GARS ATCTTGCCATTTGTGATGAGTGCTACATT 5.76E−05 0.011995848 8.82E−06 ACAGAAATGGA  404 2997012 1 GGACTTGCTTCTCAAGGTGGGACTTTGCT 0.000118492 0.012317168 6.55E−06 GCACGCTGTACAAATTGGTTGCTTCTG  370 2997133 4 SEPT7 AAGTTGTCTTCTCTAGGTTTCTGCATTCT 7.71E−05 0.010482923 5.22E−06 CCTTATTAATTCTTGAGCTTCTTAATTTC TAGGATGTGTTTTCTCCCTGTGTCCTTCC CTAATCTTACACCTGTTGCTCCTCAATTT GTGTGTATGCACATGTACATGTAAGGAT TTTTCTGATGAATGTTCAGGGAGCAGTG CTGTACTTAGTTTTACCTTACTTTTGCCA GATTCTACTAAAAATTTTACGTGAGTTTA GCCCTGTTTATTCAACTAAATAAGATACT TGGGAATTTATATCTAAAGGAAGAATCT CAGTCATTGTAAATAAATGACCTAAAGT CATTATTGTGGAAATCAATCAGAGAAAT CCCTTTCTGGAGTTTTACATCCTTTTTGG AACTCTTTTGGTATGACAGCTA  444 2997175 6 GGATTCTTGGACCATCCAGAGGACAAGG 0.009101689 0.013517476 1.49E−05 GGCGGCCCCTCTTCAAAGATCTCTCA 1450 2997383 4 ANLN GCCACTGAGTTTGGGTGGTGTCTCCGGT 0.023754148 0.009205054 7.66E−06 ACCAGCAAGGCAATGGAAGGCACACTG CCCATGCTTGACATTTAATGAACCCTTTT CACTCTCTATTTGCTGAACCAACTCTCTA AAGTTTAGGTTGTTAATCTCCAGAAGTG GTGGAATTAAACACAAGCACACACACAC ATACACACAAACAAAAACTCACCTGTAG TCTTACTCTTTCCTCAATCCTAGGATTGA TTCCCAGCCAGCATCAGACAGCCTCCTT AGTCTTTTCCTGGAGTGTA   79 2997407 9 ANLN GCTATTACTCCAAAGCGACTCCTCACAT 1.29E−05 0.027389498 2.57E−05 CTATAACCACA  628 2997645 5 ELMO1 TACGGAGGGGCATTCCTGCTAATCCAGA 0.021002867 0.009159887 6.97E−06 ATCTGCATGTCAGGACATTCTGGAAGCC TTTTGCTTTGCACTAAAGTCAACCTCAAA AATTAATATCCCACAATCACATATAGCA GAAACGCAGAGCAAAGAGTT 1779 2998743 4 C7orf10 AATACTATGGGAGTTGGCAGCTAGAAAC 0.00011347 0.007120881 5.41E−06 ACAAGTTAGGAAAGG 2070 2998957 7 AC005027.3; GGCGTTGCTGAATACTGTCCACTAACTG 6.01E−05 0.006964308 2.98E−06 INHBA TACAAAATATTGACTGCATGCCTCGCAA ACACCAAAATATCCGCTGGAATGCCATA GAAATAAATAACTTCTGCTATAAACACA TGAA  718 2999112 5 GLI3 CCAGGGTGAACACTGTGGTGCACTCCGG 0.001466913 0.009358662 6.89E−06 GATGTTCGGCTGCAAATAGAGAAGACAG GGCAGCAGCTAGAGAAGACCCAAGGCC AGAAGTGCTGTGTGGATGTTTTGACTCT GTTTGTTTATGGGTGGAAGGCACTGGAG CCACCGAAGTGGAGGAAGAATGAAGTG AGAAAGGAGAGTACCGATGGAGTCAGG GTCCCTAGAATCCAGAAT 2058 3000529 7 IGFBP3 GGTGAATCTCTATGTGCTCCCAGTGTCCT 0.000391017 0.006979675 2.90E−06 GGATGGGCTCCCCAGCAAGCCATTCCTC CTTCCTGTTCTGATATTACTATTCTTTTTT ACATTGTGCTAAGGAGGACAAAAGATGA GAGATGAAAATAAAGCTTTGCCTTTAAA GAGCTTATCCTCAGAAATAAGCTTCGTC TTGAGTTGTTGAACTACAAAACACTATTT TCTGCAGTCATCCGAAGAATTGTGCCAT TACTTGTGATGCCTCTGAATGTGGAGGC TGACTCTCCCTGTCTCTCTGTCCCTCCTA CCCCACGGGGCCGCAGCAAAAGCCATCC TGGGCCTTCGACTGGGCCATGTCTTCAG GAAGATTCCTGAAGAGGAGGGCCCGAA ATACCTGCCTTTATAGGTTCCCAGAGTGC CCTAGAACATTCTTAGATACATATTTTTT AAACAAGTAGGACTCCACCTTATTTTCTC CAATAGTCCCCAAGCAGTACAGGTCACT TGAAGACATAAACATTCTTCTTGGTTGA GGGATCCACGCCCTTGTTTCAGAAATGA CACCACAGAAGGCTGTGAGCTCCAGGAG CATGCGTTGGGATGTCCGGATGACCGGG GTTTAAAGGTTTTCCTATTCTCGATAAAG CCTGTGCGCACTGTACGGGGAGTGGGGG TGAAGCGTGTTCTCTACATAGGCAACAC AGCCGCCTAAGTCACAAAGTCAGTGGTC GGCCGCTTCGACCAACATGTGGTGAGCA TTCCACGGGCGCATGAAGTCTGGGTGCT GTGCTCGAGTCTCTGAATA  823 3006506 1 TCTGACTGAGTGTATTGAATGGCCTTCTA 1.22E−05 0.009439851 9.16E−06 CGGTACTAGTCATGTGTCAGACCAGACA CCTGATCTCAGTGGATATGCCTCCTCAG GC 1980 3010073 5 TMEM60 ATATGAGGAACCAGTTCCAAGGTGCTTT 0.00041969 0.006577928 3.02E−06 CTCA  991 3010612 5 SEMA3C CCAGGTTTATTTCTAGAGGCCCATGGGT 0.001082945 0.009528208 6.30E−06 ATTTACACTTTTCCTTGTGTGTTGTTGAG TATACCAAAACAGAACTGCCAGCCATTA GCCCATGGCTTTTCTGCCTACGTGAAAA CAGCAGGATTATAGTACAAAGGGCAGA GACCTAAGCCAAGATTATGTGCTAAGAA GAACGGTAAGAGCATAAGCCCGCTGAAT TACTGGCACCTTATGATCCTGGAACTGA GAGCCCTGACAGGGTTTGATCCACTATT TTGGTTCTTTCTGCTCTACCTCTGCCCAT CCCTCCTAATGCAGATAAAATTCATTCAT TCTTTCACTTTCAAGTATTTGCAGTCACG CATCCCTTAACAATG  446 3011436 9 RUNDC3B GACAAGAGTTAACTGCCCATCTCACCAA 5.65E−05 0.009499059 7.55E−06 CCAGTGGCCTTCTCCAGGAGCTCTGGAT GTCAATGCTGTTGCCTTGGATACGTTGCT TTACCGAAAACACAATAAACAGTGGTAT G 1463 3012549 9 ANKIB1 TTCCGTAAAGCACTCATCAATGGTGATG 0.000586459 0.008029494 2.20E−06 AAAACCTGGCCTGCCAAATATATGAAAA CAATCCTCAGCTAAAAGAATCTCTTGAT CCAAATACATCTTATGGGGAGCCCTACC AGCACAATACTC  548 3013157 9 COL1A2 TTGCATACATGGATGAGGAGACTGGCAA 1.66E−06 0.017474811 1.42E−05 CCTG 1418 3013369 4 PPP1R9A CAATCCTAAACATATTTGGGAGCTGCAC 4.61E−05 0.009215595 3.64E−06 ACCTAAAAGAGGAGCTCCC 1622 3013678 4 DYNC1I1 ATTGGACTTCAAGGAGAAATTAAGGAGG 0.029646817 0.006940481 2.98E−06 GTGGTCGAATGTAGATCAAATTAA 1796 3014762 2 BUD31 TGGACTCTGGACTTCGCAGGTTCCTGCCT 0.000120755 0.007722082 4.42E−06 GTCACGCCACCCCCTTCCTGGGAGCAGC GAGCAGTGCCCCAGGCCCGAGTTGGAGC ACGGTCTCTATGG 1626 3015101 6 GGCATCCCAGTCTTCGGTCTCCAAATCC 0.002212029 0.00893252 8.09E−06 ACCTCCTGTCTGTCCCCCCACACTGCTCC TCAGGCCTTGTGGATCCATTGACTGTGAT TTCTGTGGTTCAGCTCCCACATCAGGCA GGAAGGGCAGCTACTGGGTCTGAGATCC CACATTGCCTCCAACCCTTGCTTCCTAGC TGGCCTCCCAGGGCACCACGAGGGGCTG GGCCAGGCTGCTGTGCTGCACGTGGCAG GAGTAGGGGGCTGTGTCCTGCGGGGGCA CTGCCACCACCACCCAGGACTGGTAAGT GCCATTTCCATTGTGAAGAACATCTCCCC GTAACTCAGGCTCCTGCACCTCGCCGGC CCGAGTCCAGTGCACATCAATTTTCCCTG GGTAGA 1793 3015540 2 PILRA GGGCCAGCTTTGATAATGGAGCGAGATG 3.04E−05 0.006597037 4.97E−06 CC  497 3017037 4 LRRC17 GAATGTAAGGGCCAGAAAGCTTGAATGC 0.000200907 0.013948871 7.99E−06 CCAGAA 1269 3017439 4 LHFPL3 GAAATGTAACATGGGCAACTCCGAGCCC 0.011739756 0.006799509 2.22E−06 ATGACATGTTACAAGGACAAAT 1890 3017590 9 MLL5 CGTTTGGCAACATATTGACTGCATGGGG 0.000333103 0.008691028 6.56E−06 ATTGATAGGCAGCATATTCCTGATACAT ATCTATGTGAACGTTGTCAGCCTA  585 3017615 9 MLL5 TTGGGAAGCCAGTAGTTTGGGCTTAGTG 0.004464194 0.007736726 6.92E−06 ACAGCTGCTCTGCATATGGTAATTGTTGC TGCCTTTACATGGGCT 1218 3018430 9 HBP1 GTGATCCTACCCAATCTGGCATGTACCA 0.005019305 0.006977198 6.61E−06 GCTGAGTTCAGATGTTTCACATCAAGAA TACCCAAGATCATCTTGGAACCAAAATA CCTCAGACATACCAGAAACTACTTACCG TGAAAATGAGGTGGACTGGCTAACAGAA TTGGCAAATATCGCGACCAGTCCA  900 3020009 4 MDFIC AGAGTCCTGTTATACCGCCACTGGGCAG 3.41E−05 0.013179927 1.10E−05 GTGATAGTCGTAGCAGCTAAAGAATGGG GAACAACTGGGGGTGCTCTGTGGCGTTG ATGTTAAAGCTACAGAGTCAGGTTTGAC CTCAAAGCAATTTCCTAAATTACTAAAT ACACATAACTCTTATTGTTCATGCTTTAA TCCATGGTCTTTGGCATATTATTGGCCTG TTAAATGCTAATAAACCTTTGTTTCTCAG CATGTAGTTTACATGATGGGGACTTGAT TAAGAAAGTACTTTCAAGCATCTTATTTC ATAGGAAACTTTATTAGAGATAAGATAA GACCCATTCAAATATGCATTCTCTTAAA AATGGGTTGTGAGTTATTCTCAGAATTCT CTGCTGTCTGTCCTTTCCTGTACTCCACT TTA  209 3022789 7 IMPDH1 GTGAAGCCTGGGAGACCTCCTGACATGG 0.037823788 0.01275585 1.46E−05 GGCCCACCTGCACCAGCACACCCCCACC CCACCCCCAGTACCTCAACACCCTCAAA CCTTCCTGGGGAGGCAGGGCCTGGTGCC ATACCCCCCAGCCCAACTCTGATGGGGC TCCAGCCACCCAATGGACAGGGCATACA GACAGGATAGTGGAGGCGTTGAGACCTG CTTGATTTATTCCAAGTATTTAATACACA ATGACGCAACTGTGATCCCAAGTGTGCA AAGTTAAAGCCTTCGACTGCAGCTGAGG AGAAGGGAGGAATGGTTCACCTGGGGA CGGTGGTGAGTCAGGAATGACAGGCAG GCGGCCATGACCAGGGCAGTCTCCTACC CATG 1057 3023361 9 SMO TGCCGTATACATGCCCAAGTGTGAGAAT 0.000729678 0.007489073 4.24E−06 GACCGGGTGGAGCTGCCCAGCCGTACCC TCTGCCAGGCCACCCGAGGCCCCTGTGC CATCGTGGAGAGGGAGCGGGGCTGGCCT GACTTCCTGCGCTGCACTCCTGACCGCTT CCCTGAAGGCTGCACG 1196 3023750 4 KLHDC10 GCAGTTCGTAACTCCTGACTTTATGAAAT 9.02E−05 0.009325147 9.03E−06 GTCTGAGAAGCCAGGTTCAATGTCCCAT ATTCCTCATTAATAATTTATAACACTATA ATGTGATTTCGCCCTGTGGGTGGATAGG CTTTTTACTAGGGTAATAACAGTATGGT GATTCCAAATTATTTGGGTCCTGAGTTTG AATTCAGCTTGTCAGGTGAGTTTTAGCTT TAATTTCCTAACTTGCAAAATGGGATTA ATAATATCTTAGAGGGTTCAATATAAAG TATCACGCAGTAGAAGGTCAACAAATGG GGCTTATGACGATGACAGTTA 1696 3024264 8 AC058791.2 TCAGTCTGCCATACAGCAATTTTTAAATG 0.000454879 0.006967013 4.72E−06 ACATAATCCTTTAGAAATCAAGCAGTGA TCAGTGCTCAACTTGAAAAGTGATGGGG GTGGGGGGAACAGGCAAAAAAAAAAAA AATCACAGAACTTTAGAAGATACTGTCT ATCCCAACGGCTCTCAAAGTTTGGCCCT CTGACCAGCAACGTCAGCATTACCTGGA AACTTGTAAGAAATATACATTAGTGGGC CCACCCTAGACCTT 1829 3024911 5 CHCHD3 TTAGAGTGCCTGTGAGATACTAGGCACT 0.01615124 0.006700971 3.74E−06 GTGGGACAAGACCAAGAGACTGAGTCA GGCAGACCTATCTAGCCCATTAAGAACT GCTTTAAAGGGACACATCTGGCAACAGT AAAA 1726 3027105 4 CLEC2L GAACAAGTGGATAAACGGTAACTGACTT 2.22E−05 0.007139137 3.31E−06 CACCCCATCTGAGAAAGTCCAGAGAGCA GAGGAGTTACCTGAGCCTCATGG 1885 3027444 1 TCCTGAGCTCACAGGTTTCTCCCACCTCA 0.008028233 0.006511512 4.30E−06 GCCTCCCAAAGTGCTGGGATTACAGGCA TGAGCCACCATGCCTGGCACAATTTCTTT CTAGAACCCAAATCATCTGCCAGATCAG AAGTCATTTT  487 3027586 5 BRAF CTCAAGGGTGAAGAATGAGTCTTACCTG 5.28E−06 0.01350394 8.95E−06 ACACACATTAGATAATGAACAAGCTCAA GTCTTAAAATCCTGATTTATTTTAAACTA GTGCTTAGACATGACTGTGGTTCAAGTTT GGCAGACAGGTTTAAATGTCAAATCCAA CACTAGAGACAATACCATTTATTTCAGTT AAGGAATATAGACTTTGCCACCAAATAA TTACATATTTTTCATTCCTGTATGACATG GATGCCTCTATTTGCATGACCTCTGAGTA TGAAGTAATAATATATTAATTTTCAACA ACTGATCTGTCTGAAAAATACAAAGAAA CAGCAAAATGGTGATATTAAAACTGACT CACCACTGTCCTCTGTTTGTTGGGCAGGA AGACTCTAACGATAGGTTTTTGTGGTGA CTTGGGGTTGCTCCGTGCCACATCTGTGG GA 1485 3028591 1 TGTTCCCCTATCACCGATGCACAGACCC 0.000945161 0.007818806 4.35E−06 AGAAG 1153 3029904 2 CNTNAP2 CCCGGCGTTGCACTGGCACACAGTGCAA 0.006827559 0.006900031 5.28E−06 GAGGCAATACCCGCACGGAGGGAGAAC GAAGGCTGAGACTCCCCTGCCGCTCCAA GCCCGGAAGAACTGGAGCCTGGAGGGG GGTGAGGGGAGAAGAGGAAGCGGGAGG GGCTTGGCTTCCTCGCGTATTTGAGGAC AGCCCATCT 1529 3030862 1 GCAGAAGCAGTTCCCTAGGTCTAGGTCT 4.47E−05 0.010863593 6.72E−06 CCAGGACCTGTCCACAGTCACTGAAACG CCTTCTAGAATTGATCTAGTGGAAAATC TAGATGCAGTTTAGGTCTTTGGCACTGTG CCCATCTCCTTTAAGAACTGTGCAGTGTG GCTTGGAAGAGGAAATGTGGTCCCTTTG ATGGGAGAAACTGAAGGACCTTTTTGAA CTCAAAGGAGCTCCAGGGTTTGGAATTG GGGGCAGAGAAGGCTCCAGGCTGCTCAT TCCATCCTGGGTGAGCCGAACGGGTCCT GGCTGATCTGAGTGCGACCTTCCCAGTC TG  747 3030882 3 SSPO GGCTTTGTGACAACCAGGACGACTGTGG 0.001705241 0.008747664 3.19E−06 CGATGGCTC  323 3031189 4 ATP6V0E2 AGGTGATTCTGACGTGCTGCCCGCCAGG 5.87E−06 0.015735604 8.36E−06 CCTGCCCTGTTCGCTCCCTGGTGCATGGA GCCGG 1310 3031580 3 GIMAP5 GTGATGAGTGTTGCGGGCATCAGCAGGT 0.003557945 0.007082989 2.22E−06 GCACAGCTGGTGGAGCACAGCCTGAAGA ATCTGTGCCTGCACTCACAGCCCAGTCC CAGGACAGCGGGCTTTGCTGCCCCATTG CCCATTACTTAGCCAAGTCGATCTCCATG AAA 1452 3031668 9 ABP1 AAGCCCGTGCCGTCATCTTCTTTGGTGAC 0.002849134 0.00784346 4.34E−06 CAGGAGCATCCCAATGTCACCGAGTTTG CTGTGGGGCCCCTGCCAGGGCCCTGCTA CATGCGAGCACTGTCCCCCAGGCCTGGG TACCAGTCCTCCTGGGCATCGAGGCCCA TCTCCACAGCAGAGTATGCCCTCCTCTAC CACACCCTGCAGGAAGCCACCAAGCCCC TGCATCAGTTCTTCCTCAATACCACAGGC TTCTCATTCCAAGACTGCCATGACAGAT GCCTGGCCTTCACCGATGTGGCCCCCCG GGGTGTGGCTTCTGGCCAGCGCCGCAGT TGGCTTATCATACAGCGCTATGTAGAAG GCTACTTTCTGCACCCCACTGGGCTGGA GCTCCTCGTGGATCATGGGAGCACAGAT GCTGGGCACTGGGCCGTGGAGCAGGTGT GGTACAACGGGAAGTTCTATGGGAGCCC AGAGGAACTGGCTCGGAAGTATGCAGAT GGAGAGGTGGACGTGGTGGTCCTGGAGG ACCCGCTGCCTGGGGGCAAGGGGCATGA CAGCACAGAGGAGCCGCCCCTCTTCTCC TCCCACAAGCCCCGCGGGGACTTCCCCA GCCCCATCCATGTGAGCGGCCCCCGCTT GGTCCAGCCCCACGGCCCTCGCTTCAGG CTGGAGGGCAACGCTGTGCTCTACGGCG GCTGGAGCTTTGCCTTCCGGCTGCGCTCC TCCTCCGGGCTGCAGGTCCTGAACGTGC ACTTCGGCGGAGAGCGCATTGCCTATGA GGTCAGCGTGCAAGAGGCAGTGGCGCTG TATGGAGGACACACACCTGCAGGCATGC AGACCAAGTACCTCGATGTCGGCTGGGG CCTGGGCAGCGTCACTCATGAGTTAGCC CCCGGCATCGACTGCCCGGAGACCGCCA CCTTCCTGGACACTTTCCACTACTATGAT GCCGATGACCCGGTCCATTATCCCCGAG CCCTCTGCCTCTTTGAAATGCCCACAGG GGTGCCCCTTCGGCGGCACTTTAATTCCA ACTTTAAAGGTGGCTTCAACTTCTATGCG GGGCTGA  764 3032568 1 TGCAGACACCAGATGCGAGACAATAGG 0.001797859 0.006590099 2.66E−06 AAGAGCTGACTGGGTGGTTCAGGACCTG CCACTGGGGACAGTTTCTTCGTCCACCTT TGGTCTTGGGTCCATGCTTCCATGTCCTT C  417 3033649 1 ATGCAGGAGCGACTGGACCCCACATCCT 3.28E−05 0.016185129 1.54E−05 G 1497 3034150 5 PTPRN2 CAATTCCCGCTCATACACAGCAGGCCAG 0.001268815 0.006942742 3.14E−06 AAAGACTTCCACGCTGCACACAACGCTC AGAGCAGAACGTCTGGGAATCAATCTAT CCAAATTTG 1400 3034165 5 PTPRN2 AGTCACTCTGGCATCGCCTGCAACAGCA 0.000142286 0.007604817 5.46E−06 AATAAATGAGTGGCAAACAAGCTCTCGC GGAGGGTATTTAAATATTTTATGTGACT AAGAAGAATGAGATACGTCCATTTGCTG TGATAAGAAAAGATATTCCACAGTTTCG TATTTGTTAAGTATTTTCAGCAAATCATG GAACACGATGCAACACCCGATTC   62 3034212 5 PTPRN2 CCAGAGCCACAGTATGCTGAGGGTCCAC 5.67E−06 0.041004965 4.35E−05 GCATTACATCCTTCCATCTATCCACCACT AAACCACAGCCACAGTACACTGAGGGTC CATGCGTCACGTCCCTCTGT 1509 3034226 5 PTPRN2 CCATGGGAACTCCACACCATGAGAACAG 4.26E−05 0.009473058 6.04E−06 GGCTTCAGAGACCGCAGAAACTCCACAC CACGAGAACAGGGCTTCAGAGACCGCA GAAACTCCACACCACGAGAACAGGGCTT CAGAGACCAGAGTAACTCCACACCGTGA GAACAGG  449 3034229 5 PTPRN2 AGCTCCTTTGTTCCTAAAATCAATGCCAC 7.50E−05 0.01521519 1.17E−05 GTCCCCAGCTTACAACTCCTTGTTCCTAA ATCAACGCTGCGTCCCCAGCTTACAACT CCTTGTTCCTAAATCAACGCCACGTCCCC AGCTTACAACTCCTTGTTCTAAAATCAAC GCTGTGTCCACAGCTTACAACTCCTTGTT CCTAAATCAACGCTGCATCCCCAGCTTA CAACTCCTTGTTCCTAAAATCAACGCCG CATCCCCAGCTTATAGCTC 1769 3034583 6 ACAGTTGCAGGCACGCAGCGGTCTCCCA 0.001374129 0.007171184 4.35E−06 GCGTCAGGGCGCACCGCGA 1792 3034982 5 SUN1; ATGGTTCTACCATGAAGACACACGCACT 0.003031295 0.008267621 3.22E−06 GET4 CAAATGCCCACTGCAGCACCACTCACAA CAGCACCGACATGGAATCAAGCTGGGGC CTGTCAGCGGCAGACGGATAAAGAGGAT GTGGTCCATATACACCGCGGAATACTAT GCAGCCATAAAAAGGAACAAGATCATG CCCTTTGCAGGAACTTGGATGGAGCTGG AGGCCATTATCCTTCGCAAACTAATGCG GGGACAGAATCCCGGGCACTACACTTCC CCACTTACAAGTGGAAGCTGAATGATGA GAACACAGGGACAGAAAGGGGCCAACA ACACACACTGGGGCCGGCCTGAGGGAA GAGGGAGAGGCTCAGAAAACCATTTTAA CAAAACTGTCAGGTACCCATGCTTGGTA CCCGGTGCTGAAATGATCTGTAGGACAA ACCCTAGTC 1925 3034996 4 ADAP1; CTGGATGTAGGGCCTGCCTCGGCGACCT 0.001925692 0.007392579 3.91E−06 COX19 GCCGGTCACGGGCCCTCTCTGAC 1260 3035770 3 GRIFIN CAGCTGGGACGCGGAGCACTTCCACGTC 0.000180795 0.007217638 2.93E−06 TACGCCCCGGAGCACAAGGTGCTACAGT TCCCATGCCGTCAGAGGCCGCTGGGCGC CACCACCAGGGTGCGCGTGCTGAGT 1115 3036697 5 WIPI2 ACTGCGTAAGGCAAGAACGTCTCTACTG 0.000167867 0.00903808 4.79E−06 TGACTTCACCTAGTCACTGTATCTCAGGG TGCAGCTACTGGCTGTCATCATGTCCACT CTACAGCCAGCAGCCTAATCAGCTTTCC CTGCAGGGAGTGCGGGCAGAATCAGATT GCCAGGGGTCTCCCGGGTGGTGCTGTTA CCCTGGGCGTGAGCACAAGCT 1516 3036972 6 GAAGCTACTATCATGGGCGTTTAGAGTT 9.88E−05 0.007741062 6.32E−06 ATACAAATGACACTTACAAAAAATAAAA GACCAAGACACCCAGAGTGAGATGCATG TTGGGGACGGGGGAGGCTGGCAGCAGG GGGGCCCCGGCGGCTCACCCCAGGGCTC CCGGAGGGGGCGACGCCTGGCTTCATCC ACCCGGGAGGCCCAGGGAGCACCAATC ACAGCAGGGGCTCTGGCCCAGGTGTCGG CAGCCCAGGCCCAGGGCTGGGGCTGGAC GGGAAGGACGGAAAGAGGGGGCTGAGA TGCACCCCCTGGGGAGGGTGCTGAGACG CCCCCCGCCAGATCACTCGCTACTACAG CCAGGCTTGCCTGGGACGCCTCCAGCAA TAATATTTC 1683 3037200 9 EIF2AK1 GCTCTTTCAGCCGTTTGGAACAGAAATG 2.49E−05 0.007813506 5.78E−06 GAGCGAGCAGAAGTTCTAACAGGTTTAA GAACTGGTCAGTTGCCGGAATCCCTCCG TAAAAGGTGTCCAGTGCAAGCCAAGTAT ATCCAGCACTTAACGAGAAGGAACTC 1958 3037328 6 CAAAGTTCAGTGCTCGGTGTTCTCGGCA 5.98E−06 0.008945527 7.37E−06 CAACAATGCAGTGTAGTTCAGAAGGTAT TTTGGCAACTCTTAATCTGAACAAGAAT GGGGGGGGCGCTTTTGAAAAATAAGGCT TTAAGAAGGCTTGTCATTTTAGGGCTAA ATTTTAATAGAATGTGAGTCTGAACTCTT ACATTTAGAACAAACAAAACCTTAAAAT TACTGATTGGTTCAAAAAATGGTTTTATG GAAAAATTAATCTGTAACAAAAAGTTGG CATTGAGTGCGAAGGCTCCACCGTTGTT TTTTTTTTTTGTTTTTTTTTTTTGTTTTTTT TTGAGCAAAGCGTACAAAGGTTCCAAGG GACAGGACCAAGAACGAGGGGCTGAGA CATTTACAACAGCAGGCATTTTCTCTTCC TCTTCTTCACGGGAGGCGGGCAGAGGAC TGCTCGGATCGCTTCGTCAAACACTG 1464 3037738 1 GATAGGAGGTTAAAATGATCAAGGATAG 0.006389661 0.007386167 4.59E−06 TCAGGGACATGACAAAGGTGGCACATGT GCCTTTACAGATTTGGCACGAGTTTAAC CCTGAGTCTTTATTTGGAAAATGGTTTCC AGCTATAGGAGGATTTAAACCCCTCATT GTAGGTGTATTGCTAGTGATAGGAGCTT GCTTGCTGCTCCCCCGTGTATTACCCTCG CTTTTTCAAATGACAAAAGGTTTTGTTGC TACTTTGATTCATCAGAAAACTTCAGCA CAGGTGTATTATATAAATCACTATCGTTC AATCTCACAGAGAGACTCAAAAAGTAAA GATGAGAGCGAGAACTCCCACTAAAAGT GAAAATTCTCAAAGGAGGGAAATATGGT GTGAGACCACCACGTCTCCTGCTG  784 3039035 5 SCIN TTTCTCCCTCCTCGACAGCATCATGATCC 7.97E−05 0.009191604 2.92E−06 TCCACCAGAGCATCATGATCCTCCACCG TATGTCCCTGCTCCGGCTCTACCCCTCTC CCCCACTCTCTCCAACCAACCCACTTCTG ACTCTGAGTCCTCTCTGCCTCCTCCCCTC ACCCGCTCTCGGGCCCAATGTGCTCAGC AACCAGCTCCCTTGCTTCCTCTCCGGGAA GTAGCGGGAGTTGAGGGGATCGTCCATG TCCACGTCCCTTTCTCCTTCTACGATCTC TTACAG 1383 3039818 2 AGR2 GCTGACCTATTGCTGAGGACTATGAGAA 0.000128137 0.011486351 1.09E−05 AAAAGTTATTACAGAATGAGTCATATGG AAAACACTTGCAAAC  629 3041213 4 AC099759.1 ATTGCTGGCAATTCCTGGTCATGCTGGTG 0.004590062 0.011694926 8.46E−06 CATTTCCTCTTGGAGTCAGACATGTGGGT TCTGTGATGATTCTCTGAGTCCAGGATTT ATCCAGCC  254 3042471 3 HNRNPA2B1 TCATTGCGGCGTGAACAATAATTTGACT 0.003098917 0.012381991 9.24E−06 AGAAGTTGATTCGGGTGTTTCCGGAAGG GGCCGAGTCAATCCGCCGAGTTGGGGCA CGGAAAACAAAAAGGGAAGGCTACTAA GATTTTTCTGGCGGGGGTTATCATTGGCG TAACTGCAGGGACCA 1118 3043075 7 RP5- AATCAGTGTTGCCTGGTGGATAGCAAAT 0.000701725 0.010817936 7.40E−06 1103I5.1; CAAGTTTCAAGGTTACAGA AC004009.3 1457 3043108 8 RP5- TGCTCAATCTTCGACTTCATACGCTTCAT 0.013431886 0.008758105 6.86E−06 1103I5.1; TTTTTCCTTACCTCCATCAACTAAATAAC AC004009.3 GCCCTCTTGCC  330 3044438 1 GTCAGGAGCCCTCTGTATAGACAAGGGT 0.000224879 0.011215692 7.96E−06 AGAGAGAAGCTCAGGAGGTCCTTAGCAG CACCCTGTGGGAGAGCAGGGAAGGCCA CAGGAAACCTGACCCCTAAGACCTGGGT CCGGGACTCAAGAGAATGGAAATGGAG AGGAACCAAGAGGAAGCACAGACTGGT AGTGGGCACCCTGTCATTGGAGCTATGT GAGGCGATAAGGTTTGGCTGTGTCCCCA CCCAAATCTCATCTTGAATTGTAGTTCCC ATAATCCCCACGTGTCATGGGAGGGACC CGATGGGAGGTAATTGAATCGTGGGAGC GGTTTCCCCCATGCTATTCCTGTGATACT GAGTCAGTTCTCACAAGATCTGATGGTT TTATAAGGGGCTTTTTCCTTTTTGCTGGG CACTTCTTGCTGCCGCCATGGAAGAAGG ATATGTTTGCTCCCCCTTCTGCCACGATT GTAAATTTCCTGAGGCCTTCCCGGCCCTG CCAAACTTGGTCAATT 1448 3044555 1 CCCATGAGTGGGGAGACTTAGTATTCAG 0.032104854 0.006681803 7.10E−06 CCCGTGCTTTCAGCATC  136 3044692 9 PDE1C CAGAACTGTCTGTGGAACTCCCTCATCG 3.19E−05 0.020143883 1.83E−05 ATGGGCTCACAGGGAATGTCAAGGAGA AGCCAAGGCCAACAATTGTCCATGACCC TCGACCCCCAGAGGAGATCCTAGCTGAT GAATTGCCACA  255 3046448 2 SFRP4 TGTTGTTGCAATGTTAGTGATGTTTTAA 1.66E−06 0.023764559 2.43E−05  350 3046449 2 SFRP4 AAATAATGCTTGTTACAATTCGACCTAA 6.33E−07 0.020534054 3.08E−05 TATGTGCATTGTAAAATA  868 3046453 9 SFRP4 CAGGAACAGCGGAGAACAGTTCAGGAC 8.12E−06 0.017228888 1.44E−05 AAGAAGAAAACAGCCGGGCGCACCAGT CGTAGTAATCCCCCCAAACCAAAGGGAA AGCCTCCTGCTCCCAAACCAGCCAGTCC CAAGAAGAACA  630 3046457 9 SFRP4 TTAGTTGAAAAATGGAGAGATCAGCTTA 4.28E−06 0.01509688 1.74E−05 GTAAAAGA   49 3046459 9 SFRP4 GTCACAACGGTGGTGGATGTAAAAGAGA 2.62E−09 0.069643156 0.000104049 TCTTCAAGTCCTCATCACCCATCCCTCGA ACTCAAGTCCCGCTCATTACAAATTCTTC TTGCCAGTGTCCACACATCCTGCCCCATC AAGATGTTCTCATCATGTGTTACGAGTG GCGCTCA 1318 3047600 2 AC005027.3; GTGCCAATACCATGAAGAGGAGCTCAGA 0.000729678 0.012639164 1.27E−05 INHBA CAGCTCTTACCACATGATACAAGAGCCG GCTGGTGGAAGAGT  943 3047613 4 AC005027.3; ATTAGGTGATGGTAGCGGACTAGCCGAC 0.000339114 0.011103507 3.96E−06 INHBA GGAGGGCAGGCAGGGGAGGGGGAGAGG ACTTTACAGAAAAGGAATTCTCGGTCGA GCTCTGCCTGGAGATGACTGGCTTACAC TTACTAAACCCAGCGGGTCA 1475 3049299 9 IGFBP3 GTGTGGATAAGTATGGGCAGCCTCTCCC 0.002537394 0.011328252 9.82E−06 AGGCTACACCACCAAGGGGAAGGAGGA CGTGCACTGCTACAGCATG  284 3050416 9 DDC TTGCAGATTCATTCAACTTTAATCCCCAC 0.02980537 0.010140623 1.36E−05 A 1163 3051219 1 CCTTCAAGCTGGAGGTCGTGGCTGCAGA 0.00102279 0.00821568 4.94E−06 GGCCTCTACCCGACAAAGCATTAG  559 3052483 6 CCTCCAGCTCTAGGCTGCGGGGATCCCC 0.005952617 0.012033356 1.36E−05 TCTGCCATTGAGGCCTGGCCCCTCTATAC TGGGCCCTGAGCATGTACCTGGCTCCCC CAGTGTACCCGAGGGCCTTGCTGTCACT GGATGGATTGAACAACTCAACCGAGTGT GCATGCTCATGCTAACCAACATTCAGTC  742 3052982 6 TTGGAAGCTCTACTTGTAGCACAACTTG 0.032963108 0.009953901 6.39E−06 GTTAACTTCTCTTGTGAATTTCATGTTTT CCCTGGAACTTGGGCTAGGTCCCATGGC CCCTGGTGTGTGTGTCTTTTTTTCTGTTA ATATTTTCTTATTTTTGTTCAACTTGCGGA GAGATTTTCTCTACTTTTATCTTCTAACC CCTTCTGTTTTCTTGAATTTTAAAATTTTC TGCTGTCATTTAAAAAAATTCTCCACCA GCGGCAGTGGCTTACATC 1444 3056252 4 STX1A GGAGGAAAGGCCCACTTCGCCCATCCCC 7.08E−06 0.007013993 4.56E−06 TCTAGGTTTTGCTTGGAGCTGTGGCTGGT TTGACCATGCCTCAGAGGTCAGGCCCTC AGCCCCCCGACTGGCTTTGGGGCCAATC TCAATGCCACCTCCAGGGTAGACTTGAC CTGCGTGCCCCCATCTACCCTGGCCCTGA TCTCCCTTTCCCCAGCCCTACCCTCATAG ACGGAGGGTCCAGAGGAGGATGCGGGC ATCTCTCCTCCCA 1204 3058806 4 SEMA3C TCGAGTCTAAGACACCATGTCATGGATT 0.01496327 0.007578283 3.96E−06 TGAACAATGTTGATGGTGGAGACTCAGA CAAATGGGGCTGGAGAAACCTAACCTGG CTCATGAACTGTCCAAACGATGAGACAA GTTGCCCTGACAGGGCAGTTGTTTGGAA 1125 3062164 5 DYNC1I1 GCCCAGACACAATGGGGCGTTAGTAGAA 0.000553994 0.007395291 5.33E−06 GTCCAGTCCCTATCCCTACCCGAAGAAA GACAAACCCCCTGGCGAACATCTCATGC AATAAAATGGAGGATAAACCCTTCAGCA TAATC  567 3062175 5 DYNC1I1 AGGGCTGTTTCCAGAGCAGTGAATGACG 0.000837966 0.007293075 6.55E−06 ACCGGAGAGCATGGGAACCCCTTTTCTT TGTAGCAGCCCATATTAATGAGATCTCT GTTTCTCTCAAGACAGTCAGGGCCGTCT GGTC 1257 3063591 2 AZGP1 CACAGTCAATGGATCCACAAGGCCTGAG 0.007770575 0.010789364 8.53E−06 GAGCAGTGTGGGGGGACAGACAGGAGG TGGATTTGGAGACCGAAGACTGGGATGC CTGTCTTGAGTAGACTTGGACCCAAAAA ATCATCTCACCTTGAGCCCA  889 3063598 9 AZGP1 TGAGATCGAGAATAACAGAAGCAGCGG 0.002481187 0.013545858 1.28E−05 AGCATTCTGGAAATATTACTAT 1094 3063601 9 AZGP1 GGAGACCCTGAAAGACATCGTGGAGTAT 0.001219026 0.010779914 8.76E−06 TACAACG  724 3063605 6 TCCAGGTAAGCCTTGGCCCGCTGCACGT 0.001184984 0.012200652 1.10E−05 AGACTGGTTCTGCCTCCTACTTCTGCTTG GTGTTCTGGGCTTCCGGGACCAAGGGGA CTCAGGCTGGGATTTCTTTGTTGAATTCA ATGTAGTCCTTTCCATCATAGGCATTCTT C  376 3064449 1 TGGGGCTGCCTAGCTACTCTAGAACCCA 0.004304377 0.007354949 4.54E−06 GACTTGGAG  979 3065014 9 ALKBH4 AAGTCCTTCGGGAATGCGGTTGCAAGGG 0.003217076 0.007568557 3.61E−06 CATCCGGACCTGTCTGATCTGCGAGCGG CAGCGCGGCAGTGACCCGCCCTGGGAGC TGCCC  625 3066949 4 CTB- ATTCTAGGGGCCAGTCGTTGGTATCCAG 0.012043037 0.006585706 3.61E−06 111H14.1 AGGCAG 1988 3067307 9 LAMB1 ATGCCAGAAGGAAAGCCGAAATGCTAC 1.96E−05 0.009872566 7.52E−06 AAAATGAAGCAAAAACTCTTTTAGCTCA AGCAAATAGCAAGCTGCAACTGCTCAAA G 1658 3067310 9 LAMB1 CGCATCAGCGAGTTAGAGAGGAATGTGG 5.38E−06 0.011224347 8.31E−06 AAGAACTTAAGCGGAAAGCTGCCCAAA ACTCCGGGGAGGCAGAATATATTGAAAA 1606 3067585 4 NRCAM AGCAAGCCCCTCTGTTCAGGGAAACCCA 0.000354141 0.009376832 8.46E−06 ATGTCCTTCAGGCTCTCCCTGCTTCTCCT TACCACGCCCACTGTTGTGGTTGTGCTGG CT 1443 3068373 6 GAGGCGGACGCATGCCCGGTGGCTCTAA 0.004416632 0.006818008 5.24E−06 GGCG  416 3070220 9 AASS TTTACATGGAATGGGTTTAAGGCTCCTTG 0.016398739 0.0070476 9.29E−06 CTTTGGGACATCACACACCTTTTA  440 3072337 4 UBE2H AGGAACAAACAGCTCAGATTACACGGGT 4.44E−05 0.011046023 6.90E−06 TTCCTTGTTGGTGGGGGTTACTCGTCTCA C 2064 3074661 6 TCTAAGCGGTAATGGAGGAAGACTAGTG 5.67E−06 0.007879089 7.19E−06 CTTTGTGCATTTTGATATATTTGAGTTCA TTTTTTCCACAATGTCATACTTTTGACGC AGTTGGGTTTCTCATAAGTATCCTAGTTC ATGTACATCCGAATGC  778 3075021 4 DGKI CCCAGCCACCTCATGGCCTCGCAGGAGG 0.002232119 0.007232854 4.83E−06 CTC 1949 3076101 9 SLC37A3 CTCTCGGGTATTGAGGCAGAAGAAAACT 0.001173835 0.008365773 5.62E−06 TTGAAGAAGACTCACACAGGCCATTAAT TAATGGTGGTGAAAATGAAGACGAATAT GAGCCGAATTATTCAATCCAAGATGATA GTTCTGTTGCCCAAGTCAAGGCGATAAG CTTC 1637 3077525 2 FAM115A CCGCTCCCAAATCCCGGCTCGGTCGCCC 0.006757381 0.006736752 1.22E−06 AGTCACTGGTACAGGGAAGCCTCTTCCC TGTGCATTCCTCTCTGCGCCAGGCTCTGC CCGCTCCCACCTGCCCCCGTGGAAATCG CAGGGTGACCTG  363 3077790 4 TPK1 AGTAAAAGAGGTATGCTCTTATTTAAAA 0.026532368 0.009554661 1.31E−05 ATTCATTTACTAAAAACTAGAGCTTCTGT ATGACAAATTGGAGAAATGACTCTCCTT AAGATATCTTAATGTCGGCTGGGCACCG TCGTTCATGC 1531 3081037 7 INSIG1 GACCAGCGCTCACAGGCAAGTTCCTCTA 2.94E−05 0.011796154 8.27E−06 AGCTTCCATTCTGCTGACTGGTGGCTTCC ATTTAAAAGGAGTCTTTTAATCAAGCCA CTTTCACAGAATTTAAAACAAACCAAAC ACATGTAAATTGCAAAATACAAAAAGGT AAATTTATAAGTAAAAATGACCAAACCC ACAAAACTGGAGTATTTCGAAGGTTGAG GGTTCAGTGGAGGGTGTAACACGAAAGG AACTTCACAACTGAAAGAAATCATTGCC GAGTTTCCTCCAGGCAGCACTGAAATGA ATGGAGAACCTTCTCTCGAACATCTCAC ACGTTAAAAAAAATAAATATTTAAGAGA TACAAGGCTCAGATTGGTTTTCATATAC ATTGCACTTGAAGTTTAAGACCCAATAC TTGCAAATTAGGTCTGGTATGGTCTATGC CATTAAATGAATACATTGTGCTCACCAA TATCATTGACTAGAAACACCACACGTTT AATGCAGTGCCATATGCACTCTCCTTTTT ACAAGGCAATCACAGATTGCAAATTCCA TAGGGCTGTGGCAAAAAACAGTCATCTC TATTCTGTAGTAACAAACAAACAATTTT GGCTCACTAAGATTGAAATACATGGCAG ACAGGTATTCATTCTTAGATGACTATGG ATTTCGAAATAAACTTCATAAACTGAGG TGAAAATTCCAATATATCGCAGTGTGGG AACCAAGACTTTTCATTGCCTTTTGCTCA GTAAGATTGTCTACACAAACTGCCACGG GAGGAATGACAAGCAGTTGACCCACTGG TGATACACACACGTGTGACCATGTAAAC ACGCCACTGCAGGACGGACGAGCGTGAC CGTGAAGCGTGGCCACGCCGCGACCCCA CTTAGAGTGTGACCTCTCTATAATCACTG CTGCTTTTCTTGTTTTGTTTTTTTTTTTAA ACACAGCCCTATTTTTAAAAATCTTTTGG ATAAATATTATTCCTATTACACCATACTT CATGTTTGTTAAGCACCATCAACCTACCT CCTTTGGGCACTGACACAAAACTGCGGG 2060 3082100 7 DNAJB6 TGTTTAGGGTTACATTGTCCACAGAAAG 0.011785961 0.007939522 6.41E−06 CATCAAATACCACTCCTCTCCCCGCCAA AACCAAATAAACAAAGCCAACTCTTTGG CAACAGTTGTGTTAAATAAAATCCCAGG TCACACTTGTTTCTGGCTCCCAAGCCTGG GTCACTGCTACATGGATTGCGCCAAAAA ATTCCCAGCTTCAACACTGCTAGATTAA AATTGCTGGCATTTTTAAATCACAGCAA AGCTTTTCACAATGCCCTCAAGTCCAAG AGGACAAAGGAGAAAGCAACATGAACG GCAGATCCTCATGTGAAAGGGA  813 3082532 1 CGTCGACAGGGCAGGATCTTAGGCCCCT 0.000206799 0.008814925 6.04E−06 ACTGCCACATATGGAACAAGCTCCAGTT CCAGTCTATCACCCAGCACCTGGCCAGC CTCTGTTAGCAATACTGCTGACTGAAGA AGAACAAGTTAGAACAGCTCAAAGACTA AGCCTTCTACAGTGTCTGCCTGAAGAAG TTTATGACCCTGGAAGAGATAAATCAGA AGAGGAGATGCCAGAGTGTGTGATCTGT TTACTGGAATTTGTTTGTGGGGACCCCAT TCGATGTCTGCCATGCAAACACTTCTTTC ACCTTGACTGCATAGACACATGGCTGCT GCGATCTTTCACATGTCCCTACTGCCGGG GGCCAGTGGATGCAGCGCTGTCTACATC CTTGGGA 1096 3082626 5 ERICH1 GGAAATGGCCACATGTGAACCACCATCC 4.91E−05 0.009444815 6.17E−06 CCTGCAAGGGCAGGGATTCTGTGCAACC CAGGAAAAGGCTACACATGACCCACCAC CCCTGCAATGGTGCATTCACTTGCAGGG GATGGAGA 1132 3083218 5 CSMD1 AGGTTATTTGAAGCCACGTCCTGCAGCT 0.003855932 0.008232629 5.74E−06 TCACCTTCTCTTTAGGGTTTTAGAAGTCA CTACTATTCTGGCAGGCACTGTCTTGTCT GACTATGAATAGCGTATTGGCTTCATGC TCACAAGGACAGGGGCATGAGCTCACTT TCTACAAGGACCAGTGAGCTGTCCTCGG TTCAGGGACAGCACCCTGTGCCGTCATT GCACTTGGACGCTGTTCAATGTGCATA 1384 3084878 1 GTCAGCATCACAAGACGCATGAAAGAG 0.003420783 0.008068285 1.37E−06 GACTCATCGCCAGGGCATGGAGC  448 3090530 4 DOCK5 GGGGTTTGTTAATCAGATCTCCTTAAGGT 0.02092529 0.006719573 4.33E−06 TGGAAGAGTAAATTCTCCCCTCTCCATCC AAAGGGGAAGATGCCTGTGTCTCCTGGG TTTTTTCCAGGTGGAGGTTTTGTTATAAG TAAGGTTTGGCTGTTAAATATCTTCCCTT TTTTAAGAGTTCTAGGAAGGAAGTGTGT TTGAGGAGGTTTGAGCCTGCAAAGTGGA AGTGACACTGTGGGTTGCACGGTTTGGC CACTGACTTCTCACGTGGTTTCAGTCCTT AGCACCGTGGTATTGACATGACATC 1077 3090561 4 DOCK5 TTCTTGGATGATGTGACAGTGGCGGATA 0.011465942 0.007494898 6.10E−06 ATGCAGAAAAGG  553 3090589 9 DOCK5 GCTTGTTAAATTGGCGTTCCAACTCCCAG 0.00084815 0.008174387 6.42E−06 AACA  955 3090592 4 DOCK5 ACACCAGTGACAGTGGCCGTTCCACCCA 0.042066262 0.007251473 6.58E−06 G 1060 3093827 9 KCNU1 TGGTCTGATACTAAATCCACCTCCACAA 2.12E−05 0.012045129 4.30E−06 GTGAGGATACGTAAGAACACATTAGGGT TCTTTATTGCTGAAACTCCAA 1249 3094697 5 FGFR1 TGGGCTGGCTGCAGACCGCCCTCTCTCA 0.000120755 0.006868788 3.88E−06 GCTCCCTGGTCAATGCACTTCAAATTC  578 3097271 1 CCTCTCTGGAAACAACGGCACCATGAGC 0.006687861 0.010902639 1.13E−05 CACGTGGAGCACCAAGTTCCTGTACAAG CGGGACCCACTGTGAGGTGTGCCACCCC ATCAGGCGGTGTGAGGACCTTTTGACGC CATTAGCAGAGTGGAGTAGAAAAGAGTT TAGTGTCTCCCCAAATCACTGGGTTCTTC AAAAAGTTGTTGGGCAAATGCTCAGAAC CCAAGTTAAGGTCTCAAGCAAGTC 1107 3099025 4 LYN TGAATATAATATACGGGGCTGTGGAGAA 0.000180795 0.007929824 4.64E−06 AATATTTGTAACATTAATTCTATATTGTT TATTCCAGCCTTTTAATTACAAATTAAAA CATGAACATTACCATACACACAGAACTA AATATAATGCAAAAAATCTACTTCTTTAT TTTCCCACATTCTGTATTATATATATGAA CCAAAAATGCACAGAGAGGCCTAAGTTC CCCAGCCTGTGGCACATTGTCAGGGGGC CAAGCATGGTCGGGACTGCAGGGCCTTT CTTGGGCTAGGATTGCCCACGTGGTTAT GACTGAGGATTCTTATGCTCTCACCCAC GA 1711 3100547 3 CLVS1 AGCCTCCGCTTGCACCGTCTAGAGACAG 0.031155964 0.008689629 4.81E−06 GCAGGCACCTTTCTGGGCAGCGTGTTCC CTGTGGTGTGGCCTTGTTAAAAAGCACT TGCTTATTCTGAGTAAGATGACATAGGT CTGCCCTCTGAA 2000 3101370 7 ARMC1 TAGGTGCCCTGAAAGTTATTGTTGCTTTT 0.001873579 0.008741283 4.65E−06 TTTGTTTTTTTTTTTTCAGTTTGTGCGTGT CACTTGAATCAGAAACCAAACACATGTA AAAAAATATCATCCTCAATGCCCCCCAT TAACTCTCTCTCCAGAAGGTGACAATGT TAGTGAACTCAAGACTCTCACTGATGAT GGTATTTTACAATGAAAACACAAGGAAA CCCTTTGAGGTCCAATTTTCACATCATAT TCTCCAAATAGTAAAATAGCAGCTCTAC ATGTTGATGAAAAGAAATTTCAATTTCTT CCTATTTGTTTTTACTCATATCAACATTA ATATGTATCTGGATTTATTAATTTCCAAA AAGAAAATTTTAGTTACCAAATATTTCA GAAATTTAATAAAGCATTACATATATGT AATTAGCACTTATCTACCAAAAAAACAT ATGTGTATGTATTTATTTATCTTACCTTC ACTGAAGTTCTTTTTTCTGGCTGGACATG AGAAACAGGATTAAGTGATCAATGCTGG CTTTATTTCTTCATAAGCAGTAATTTGGG TCTTTTTCATTCAACACAACGCAGCATTT TCATAATAAATTCACAAAAGACAATACA AAGAAACACCTACTGAATAGAACTCTGT CGAGCAATTCATGTTTTAAAGTTGGACT CTATACCAAACTGGCATTATGGTATTAT AGGCATTTGATTTTTGTTTTCTTATTTTCA GTTTGTCAGTTTCTTTACTACCATTATTTT TTTCTAGCCGGAGATAACGTATAATCA 1952 3102393 9 SULF1 GGGAAGCCTCTGTTCGACTGTCAGATCC 0.00035324 0.009114519 5.56E−06 CCGAGGTTCAGAGGACGGATACAGCAG GAACGAAAAAACATCCGACCCAACATTA TTCTTGTGCTTACCGATGATCAAGATG 1870 3102402 4 SULF1 CGGCATCAGATCTTTGGGTTAGTCACTAT 0.000740426 0.007834969 3.81E−06 TGCTGGCTTTAAAAGAAATTCCTTGGCTT CAGGTAGTTCCTGGAAATTTTTCTAAGC ATTATGGAACAGGTTGTCCTAGACAGAA GTAGCATGGCCTGAAGCCAACAATAATT ACAATCAGGTCTTCTGATCTTTCTCCCTG CCCCCCAACCCCCACCACCTTCTTAAAC AGCTGTGAAGGGAAGTGCTTAATGGTAT CCAAAACAAAGAGGATGGGTAAATGGC ACATTAGTGATGTATTCAGATAGTAGGA GTTGAATTGAATTGCCAATGCCGAAGGA TAGAAAAATATTGAACTATACGTAACCT ACATGTAGACATAATGGCAGTAAGGGCA AGAAAGCTAAATTCACCTTAGGAAGGGA AAAAGAGATTTAATACATCTGGAGGAAA ATAATTAGAGGGCCAGATAATCAATTGC AGAGCGCCGCCAGGAAACATCGTGTTGA AAGAGGCCGGGGTGATTACAAACGAGTC TCAATGTCATGAGGCAACAAAAAGGCCA GAGCAACTGGAGGCCAACAGTGCTGCAC CCTGACACCCAAGGCCCCCATCAGCCTT GGAATGAGTGTGATGGGTGAGCGCACAT CTGGAATACTGA 1343 3102414 9 SULF1 GTCCCACAGATCGTTCTCAACATTGACTT 0.000462937 0.012550374 8.12E−06 GGCCCCCACGATCCTGGATATTGCTGGG CTCGACACACCTCCTGATGTGGACGGCA AGTCTG  828 3102439 9 SULF1 GCTCAGGAAGTAGATAGCAAACTGCAAC 2.80E−06 0.015931026 1.68E−05 TTTTCAAGGAGAACAACCGTAGGAGGAA GAAGGAGAGGAAGGAGAAGAGACGGCA GAGGAAGGGGGAAGAGTGCAGCCTGCC TGGCCTCACTTGCTTCACGCATGACAAC AACCACTGGCAGACAGCC 2010 3102445 9 SULF1 CACACGGTAGAACGAGGCATTTTGAATC 0.000194662 0.008480409 5.98E−06 AGCTACACGTACAACTAATGGAGCTCAG AAGCTGTCAAGGATATAAGCAGTGCAAC CCAAGACCTAAGAATCTT 1759 3102461 2 SULF1 TTGCACTGCTGAAGAGTCACTATGAGCA 0.000177948 0.009249871 6.69E−06 AAATAAAACAAATAAGACTCAAACTGCT CAAAGTGACGGGTTCTTGGTTGTCTCTGC TGAGCACGCTGTGTCAATGGAGATGGCC TCTGCTGACTCAGATGAAGACCCAAGGC ATAAGGTTGGGAAAACACCTCATTTGAC CTTGCCAGCTGACCTTCAAACCCTGCATT TGAACCGACCAACATTAAGTCCAGAGAG TAAACTTGAATGGAATAACGACATTCCA GAAGTTAATCATTTGAATTCTGAACACT GGAGAAAAACCGAAAAATGGACGGGGC ATGAAGAGACTAATCATCTGGAAACCGA TTTCAGTGGCGATGGCATGACAGAGCTA GAGCTCGGGCCCAGCCCCAGGCTGCAGC CCATTCGCAGGCACCCGAAAGAACTTCC CCAGTATGGTGGTCCTGGAAAGGACATT TTTGAAGATCAACTATATCTTCCTGTGCA TTCCGATGGAATTTCAGTTCATCAGATGT TCACCATGGCCACCGCAGAACACCGAAG TA 2037 3102463 2 SULF1 CCCTGGGTACCTTTGTGCAGTAGAAGCT 0.000131986 0.008176341 7.53E−06 AGTGAGCATGTGAGCAAGCGGTGTGCAC ACGGAGACTCATCGTTATAATTTACTATC TGCCAAGAGTAGAAAGAAAGGCTGGGG ATATTTGGGTTGGCTTGGTTTTGATTTTT TGCTTGTTTGTTTGTTTTGTACTAAAACA GTATTATCTTTTGAATATCGTAGGGACAT AAGTATATACATGTTATCCAATCAAGAT GGCTAGAATGGTGCCTTTCTGAGTGTCT AAAACTTGACACCCCTGGTAAATCTTTC AACACACTTCCACTGCCTGCGTAATGAA GTTTTGATTCATTTTTAACCACTGGAATT TTTCAATGCCGTCATTTTCAGTTAGATGA TTTTGCACTTTGAGATTAAAATGCCATGT CTATTTGATTAGTCTTATTTTTTTATTTTT ACAGGCTTATCAGTCTCACTGTTGGCTGT CATTGTGACAAAGTCAAATAAACCCCCA AGGACGACACACAGTATGGATCACATAT TGTTTGACATTAAGCTTTTGCCAGAAAAT GTTGCATGTGTTTTACCTCGACTTGCTAA 1982 3102464 2 SULF1 GTGCCTAGCCTCAAAGCGTTCATCATAC 4.81E−05 0.008098921 4.23E−06 ATCATACCTTTAAGATTGCTATATTTTGG GTTATTTTCTTGACAGGAGAAAAAGATC TAAAGATCTTTTATTTTCATCTTTTTTGGT TTTCTTGGCATGACTAAGAAGCTTAAAT GTTGATAAAATATGACTAGTTTTGAATTT ACACCAAGAACTTCTCAATAAAAGAAAA TCATGAATGCTCCACAATTTCAACATAC CACAAGAGAAGTTAATTTCTTAACATTG TGTTCTATGATTATTTGTAAGACCTTCAC CAAGTTCTGATATCTTTTAAAGACATAGT TCAAAATTGCTTTTGAAAATCTGTATTCT TGAAAATATCCTTGTTGTGTATTAGGTTT TTAAATACCAGCTAAAGGATTACCTCAC TGAGTCATCAGTACCCTCCTATTCAGCTC CCCAAGATGATGTGTTTTTGCTTACCCTA AGAGAGGTTTTCTTCTTATTTTTAGATAA TTCAAGTGCTTAGATAAATTATGTTTTCT TTAAGTGTTTATGGTAAACTCTTTTAAAG AAAATTTAATATGTTATAGCTGAATCTTT TTGGTAACTTTAAATCTTTATCATAGACT CTGTACATATGTTCAAATTAGCTGCTTGC CTGATGTGTGTATCATCGGTGGGATGAC AGAACAAAC 1380 3103453 5 UBE2W CAAGCCCAAATTATGGACTGCAGCAATT 5.92E−05 0.010791524 6.97E−06 TAATCATCACTGCCATTTTTCTTACTTCC AAAATAAAGCCTTGATTAAACCATTCAT ACCCTATATTACTCATACCTTTACTTCAG AGATTGAGGAACTATATACAACAAATTA ATTTATTTTCACCATAGGGATAACATACT GTACCTCTCTGCCAATGTTACTTGAAAAT CTTCCATGTCAAAACAACTTGACAGTAG ATATAAACAATTCAATAAATATGCAATG ATCTTTCATTACAGTCCTTTAAAGACGCA TGTTAATTCATGCTGTTAACCTTAGGATC ACAGTGCATAGAATCCAAATATAAACAG TTGGGGTGACTTTTAAAGTAATGTTGGA TCCCTCACTTTATTTATATTCCCACTATA ACCAGTAAGTTCATTTCATAGGCCCTATC ATGCATTAATCATTGAATGGCAGGAGTT AATGAAAACTTTTCCTGTTACAACGCCC ATTGCCGGCAATGAACGTACCAAAACCG CCAAGGAAGTCATTGTTATTGCACAATA CATGAGGACCTGG 1576 3103632 2 GDAP1 TAGCTAGACCCTGTGATTGCCCGTGGCT 0.000629941 0.011534464 8.50E−06 CTCTGAGTCTGTCTTATTGAGTAGTTAGC AGTATTTTTTCCTAAAATTCAGAAGTCAT CTTTGTTACACAACACAGGGGTTCAGGT AGCAATAGGACACAAAATTGCTTTATTC TACAACTGCCAGCTCCAGGCAGAAATAG GAAGGCAAAGAGATAAGAGAAGGAAAA ATGAGAGAATGAAGTCTGTATAGGGTAG AGCAATAGAAAGTAAGCTTCGGGTGCCT CCAACGTTCATGGCTGCCTG  218 3103710 4 PI15 CAGAGAGGTGGTAACTCCCGAGTAAGCA 0.000674778 0.015711899 1.73E−05 ATGCCAATCCTTCAGGCAAAGATAAGGA AGAACCGCACAGCTGCTCCAACATAAAG TGG 1528 3104056 4 ZFHX4 GAGAACCCAGATAAGGTAGCTAATACAT 0.0001169 0.006655882 2.13E−06 AAATCTGAAACAAAATGCATGACTATAG AAAAAGAGAGTCTTGAAATACGGGCAG GTTTTCAACAAGGGGAGAGGGAAGTGAT TAGGTAGTGATACTCCAGATGAAGTAAA ACCTGGGAAGCAAAGGCTCTGAGTTTCA AAACCACAGGGTGTGTTGGAGGTCAGTA GCACAGTTTGGCTGAGATGCATGGTA 2071 3104305 2 PKIA CATGTCTTTTTTCAGCCCTCTCAGATCCA 0.001547455 0.007394509 6.93E−06 AATGTTATTATGCACTTTTTAATGTTTGT AAACTTTTACTAATAATTAGTGTGAATTG CATTCTGATACAATAATGATTATCATTAG AAGCTAACAAAATTCTCATTAATACTGT GTTTGATGGCCTCTGCTGTGTTTTAACAT CGTGCTTCTTATATGGAAAGTTTTTGTGA GCTGTGTAATCCCTCTGGTCAGTATTATG AAATCA 1986 3104626 5 TPD52 TAGGAGGTTCCACTCTCAAGTCACCTAG 1.85E−05 0.008255373 5.59E−06 AAGTTTGATTACATATTGTTACTTACAAA ACTATAATAAATTGGATGCACAGCTGTT TACTTCAGTCTGGTGTCTTCAACCAAAAT ATGTACCTTATACCAAAACAATGCTTATT CCAAAATATTTTTTGTAGCTAGTAGTTCT TTCCTTGGA 1893 3104778 7 ZNF704 GGAGGTACTTCCCTTCAGGTCATTCTCTC 0.037111478 0.006548322 6.22E−06 CTTGCTTCAGGCAGCTGCTCCCAGAGGA GAAAATGGCAGCTCCCTGGGAGGTACTT AGGGATGGTGACCACCAGCTGATCAGCA CCAAGAAGATGAGCAAGAGCCAGGTGT CCACAGCCCTCTTGTACCTCCCCCCTGAC TCCCTTGCTACCTGTGTGTTTTCTCCAGG CTGTCACACTGCCTCCCACCCACCAATG CAGCACACATCTGCTGGGAAGGCCCAAG GCTTAACACCACTGCCTGCTGGCCACTCT GCTTTGTCGCTCTCTGGAGAATGTCCTGT CAGTCACTATGAAATGACTTCTTTGGAG AGAGATGAAAAACCTTTTCTGAAGGCTG GGGTGTCAAAGGATAAAAAAAAAATCA AAAGGCTACATCATGCCTTACTTAGAAA TATTTTGGGACCAGAATCCATTGTTTTGC ATGCCTTTTGCGTAGATTGGCCTCTG 1577 3105433 9 LRRCC1 GAAGTGGAAAACGAAGACGGCGACAGC 0.000172838 0.007157123 2.51E−06 AGCTGCGGGGATGTATGCTTCATGGACA AA 1183 3105924 9 CPNE3 CTGGCTCCAATGGTGACCCAAGGTCTCC 0.009861702 0.007692419 7.28E−06 AGACTCCCTTCATTACATCAGCCCCAAT GGCGTTAATGAGTATTTGACTGCTCTCTG GTCTGTGGGACTGGTCATTCAA 1055 3106288 9 OSGIN2 TGCAATACTTTGGTGACAACTTGGGGCG 3.12E−06 0.012037745 1.11E−05 AA 1802 3106314 4 DECR1 GAGCACTGACCTTTGACGTCCTTTGTTGT 0.004800285 0.007172927 6.53E−06 GAGGAAAGTCCATCTATGTGTTAGTTAT GGAATTAAACACTAATACAAACAAATTA TCATAAAAATGAAACAAAAACAAAACC CCAGCTGTTTATAGACTCCCCTTCCCAGA TGTATAGCTGGGAGAGGTCCGTCTCACA CTGGCTTCCCCCTCTCTCTGGCCCACACT CCTGTCACCATCTCCATTGCACCCATAGT GGAAATAGCTAGGAAGTGAAAACAGCT AGGAAGAAGAAAGAGAAACAAAAACAA AAAGAAGCAATAATATCCAAGACAAGC CCTCCCCACATCTAAATTACAAAATTGTT ATAAGTAAACTAAAAAGCACATTTTCTT TAGCCAGGTAGAAAAATTAATATGTCAA CTGTGAAAAAACTTCTTTTGATTTGATAG AATAGACAGCCATGGTGTTGTTTTTCA  881 3107647 6 GATTAGTTTCAGTGGTTCTCATTTCACTT 2.38E−05 0.016569088 1.45E−05 TTATACGTAATTTCTTAACTATATTAAGA TAGTTGCAGGCAGTGTACCTCAGGTTGA CTCTGTACATCTGAATAGTGAGTCACTA GTATTTTGCTTCAAGCCTTCTGAAAATAT AACCATAGTTACCTAAGCACACAGTGAA TAGTCACATGGTAGTACTTG  612 3107695 3 INTS8 GATAGCACCATAAGCCAAACATTTATGC 0.004639335 0.010553457 9.22E−06 TAATTTTATGTAAATTATGTGCTATGGTC CACGCCCCGCCCCCACATGCGATTAAAA AGTTGATTTTTAGTGTGCTAAAGCACAT GCTAAAACAGATGCTACATTTTCAAAAG GCAAGGGTCTTTTAGAATGCTTGATGTCT GTGAGGTTGACAGGAGCAATATTAAATA AATATACATACACTGTTTAAGGATTCTGT G 1316 3107732 4 C8orf38 TGACCTTACCTAGGATATAGCCTGGCAT 5.22E−05 0.008155705 5.18E−06 CATGTAACATAAGAAAGTTGTTTTCATTT TGGTACAAGCAAAATGAAATATGTTTAG CCTCATAAAAAATCATCTACAATATTGA GACTTGAGAGTATGGCAAACTCTGGTAA AGTTAATAAATTAATGTGCTGCCTAGGG TTTGTTTATATCTGGAAAACAGGAAACG GTAGGTAGGTAGGTAGGTAGGTACATAG GTAGATAGATATAGATAGATAGATAGAT AGATAGATAGATAGATAGATAGATAGAT ATAATACAATACTTTTCTTAGAGTCAGA GCCTGGACATGACAACACTAACAATAGG GATATTCTGAACTGCTCCAAGGATCCAA ATCCACCTGGACCCTCAACCTAAGAGAG GGAATGCCAACATTC 1812 3107789 4 C8orf38 ATAGAGTAATTTCAGTAGATGGTTGGGG 0.000450333 0.007765135 5.80E−06 GTCAAACTGGAGTATAATGGGTTAAGAA GTAAGTCAGGAAGTAGAGGGCTTTTCCT GGTGTTAGGGACAATATAAATGAAGACA TGGAGACAGGAGTGGGCTTGGCGAACAC AGGATGATGGGCATCAGCCTGAGTGACC AGGTGTTCGTAGCTCAGA  499 3107876 4 KB- TCTGAGGCACATACACAGCTGGTTGGCA 0.033900726 0.007197605 3.82E−06 1047C11.2 GTTCTGCTTCTAAAGCTGTGGCACTCCCC ATCTTAAAGGTTTTGAATCTGCCTGCTGT TCCAGACATGGGGA 1670 3108459 9 MTDH GTCTGTAAAACTCTCCTCACAGATCAGT 0.006687861 0.00668549 3.67E−06 GCAGGTGAGGAGAAGTGGAACTCCGTTT CACCTGCTTCTGCAGGAAAGAGGAAAAC TGAGCCATCTGCCTGGAGTCAAGACACT GGAGATGCTAATACAAATGGAAAAGACT GGGGAAGGAGTTGGAGTGACCGTTCAAT A 2039 3108479 2 MTDH GCCTTAACCTGTAGTGCGTAGAATATGC 2.93E−05 0.006961325 4.37E−06 ATCAATTTCTTGAAGGAGATTCATGTTTT TATAAGAATTTTCATGTAATTATTGCAAT TGTGGTCAAATAAGGAACGTTTCCTGCT TGAAATTATATTGATTTAAATGATGTGTG AGATGTTTCACCATTTTCAGGCACTGTGT AATTCTATTGTAATAAACTGGCAGGTAT CTTTGTAACTATAAATAGTGCATGCTCA GCCATGTACACTGTAAATAGCCTTTACC AAACGTGTTTGACAAGGACCATAATTAA CATCACTTAGTGAATTGTGATAAAGAAA AAAAAGCCATGATTTATTCGATGTGATT GGCTTGTTTTTATGTGGCGCCAAGAACG AACCTGTTTAACAGCTGTAACCAATGGT ACTGATCTATCCATCCAATGTTGTCATTA TATTTGACTGTGGTTCAACAGTATTGCGT TGTCAGACTAGGAAAGCTAAACGAACAA AATGGTTTTAGTTTTGCTGAAGACTGGCC TTATTAATG 1345 3108839 5 STK3 ATGGCTATAAGAACACACCCAATGCCAG 1.98E−05 0.011035218 8.64E−06 TCTCTACCACACCGCAGCAGCATAACTT ACTACAG 1016 3108873 4 OSR2 ACATCTTCCTTGGTGACAGCCAGTCAAG 0.002531721 0.006675267 5.33E−06 TAAATTTTACAAAATTTCTCCACATGCCT GGAAATTCCTGTGAAGAAGACTGATGAA AGAAAAGTAGCCTCAGCTCCACCAACAT ATTTATGACTTTTCATTGGTTTAAGTTTC TTTCCTTGCAAGATTAAAAGTAACCAGT GGTCTGAAACGGGACGGTGGAGAAATG ACAGCAGATGATGATCGCTGTTATTTCCT GAAAGGGAGTGTGGGAACTACAAGGCT CAGCTCTA  533 3109199 2 POLR2K CTTATCTTCGGGAGATACATTCCAAGGC 5.32E−05 0.017958214 1.73E−05 CCCCAGTGAACTCCTGAAACCTCAAACA G 1500 3109252 3 SPAG1 TGTTGCTTCTTTGGACCACTTGGTGGCAC 0.000306094 0.010773506 7.30E−06 TAGATTTACCTTCAGGCAAGCCACTGGA TGAACCGCCAGCATGACTTCGGGTGGCA CTGCCATCATCCACACTACTGCTTCCACT GTTGTGCCTGAATTTGGATGGCTTTGACT CA 1916 3109448 6 GTGAACCGTTTCTGCCCTTATCCAGAGTA 9.77E−05 0.012137832 1.07E−05 AAATGGGTCACAACTTTGTCTAAAGGAA CACTTCTGCAGCTGTAGTCAAAGGTGTA CACATTGAGTATTCCACAGATATACATG GTTTAATATGTGGTATCCATGGGGTATG ATTCTACCACAGCCTTGTAAGTGCTCCA AACCTTAAAGTACCCACAATTACTACAC CTGTGACTGGAACCAATGATCCCTTTTAT TCCCCGCCAGGACAAACCAGTATGTAG  797 3109660 8 KB- CTCCTCTGAGCCAAGAACGACAGTGATG 0.009842021 0.007123883 3.92E−06 1930G5.4 CCAGTGTCTCCACTGCTGCAAAGGTTCTC ATTTTGTTC 1704 3109903 7 UBR5 GTAGTTAAGCTGCTCACGAACATTTAAA 0.000260842 0.007334514 3.82E−06 ATTTTCCAAAATGTATCTTCAATAATCAT GATCTTATAAAACATTTTACAGTTATCAG AAAGTGCCCAGGCTGAGTTTACATAACT GAAATACCTTAGTACAAATGTCTAGTTA GAACTGAAGTGCAGTAACCTCTTGAGAC TGACTGCTCATTGAAATAGGGATACAAA GAAAAAGTTGATTGTGATAAAAGTATTG TGCATTGGCCCCATCATATGTACAAAAA AAGTGCCCTCACTCAAATGAGCAAATTA CATGCAAAATATTAGTGATATCATTTAA TATCCTAGAGCTCAATGCAGTCAAACCG 1805 3109920 5 UBR5 TGCCTTCAAGTGTTCGTAAGCTAGCTTCT 0.000103742 0.009519129 5.07E−06 TCTCGCGCAGTCATCCTCTCTCTTCTCGC TGAATTCTGAGAAGCGTGAAGAGGATGA TTTGGATGTCCAGGATCACCAGCAGATG CTAATGCAGAACCATAACGTAATTGAGC TTCAGTAGAATCCATAATACTGACCATC CAGTTCCAAGTGGGAATAAGCTTTTCTTC 1049 3110126 4 KB- GAGATTGCCACGTGATTGCCCAGTGTGA 0.025777155 0.007009345 8.94E−06 1507C5.2; TTGAAAGTTTGAAGTCCGTATTTCTCTGA KB- AAACTTTGGTGTATCTAGATTCTGTATGT 1507C5.3 CTCTTGGACAGATGAAGAGCTGCTGTAC ACAGAAGGGAGATTTTTTTTTTTAATTGA GGAATCTAACTCAAGAATAAATTCAAGG CCAGGTGCAGTGGCTCACGCCTGTAATC CCAGCACTTTGGGAGGCCGGGGTGGAAG GATCACCTGAGGTCAGTAGTTCGAGACC AGCCTGACCAACGTGGTGAAACCCTGTC TCTACTAAAAATACAAAAATGAGCTGGG GGTGGTGGCGTGTGCCTGTAGTTCCAGC TACTCAGGAGACTGAGGCACAGGAATCA CTTGAACCTGGGAGGTGGAGATTGCAGT GAGTTGAGATCATACCACTGCACTCCAG CCTGGGTAACAGAGCAAGACTCCATCTC AAAAAAAAAGGAAAAGAAATTTGGATC CTTTAGAAATCTTCAGACACTTGGCATA ACATGAAGTTAAAACAACACCCCACTTA GTTCCATGATATTTCTGATGAATAAGAA ATATGACACCACAGAGTGAAACCAATAT TTTTAAAAACCTCCTGAAGAGACTTTTTT TCTTTGTTGATTACCATCCAGAGACAAC ATTTGTTTGAAACTTTGAACAGAATCAG TTTGTAGGGATGAAACCCTCATTCTTCCC CGCCTGGGCCCAGACTTTCCATATCTTGT ACTCTGAGAACCTTAAAGTCTTGAAATG ATTTGCAGTCCCAGCGAAGAAGCTAAAA TCAAAACTGATTTGGGGAAAAACCGTTT ACTTTCTGACCTCTTTGTACTCTTCAGAG AATTTTTGTATGCTTGTTTATTTTCTTAAT GTCTCTTGGTAATGTTTTTTCCTGTTTTG GTTTCATATATGAAATGTTCCATCTGTGT ATTCATTTTCTGGATTTATTCCCTAGAAT TTTAAGTAAGAGTGTTTCTCAAACTTTTT TTTTACTCCAACCCACAATAAGAAATAT ATTTTGCATGTTAACCTAAATACACATAT ATTTACATATATATCTAAAACAAGTTTCA TGAAATAATACTCTTGCAATGAGGTATG CACTATGGTTTTTTAAAATTCTATTCCAC TTTATATATACAAAAGTTGGGACAGAGG TTCAGGAGCAGGGAAGGGATGAATAGG CAGAACACAGGGCACTTTTAGGGCAGTG ATAGATGCATGACATTATACATTTATCA AACCCCACAGAACTGTACAACAAAAGA GTGAATCCTCATGTAAACTGTGGACTTTT TATTATTATTTTTTAAGACAGGGTCTCAC TCTGTCACCCAGGCTGGAGTATAGTGGC ACAATCTTGGCTCACTGCAACCTCCACCT CCTGGATTCAAGTGATTCTTGTGCCTCAG CCTCCTGAGTAGCTGGGATTACAGGTGC ACGCTACCATGCCAGGCTAATTTTTATAT TTTTAGTAGAGACAGGGTTTCACCATGTT ACCCAGGCTGATCTCAAACTCTTGGCTTC AACTGATCTGCCTGCCTCGGCCTCCCAA AGTGCTGGGATTATAGGTGTGAGCCACC CACCATGCACGGCCAAACTATGGACTTT GGTTAATGCTAGTGTATCAATATTAGTTC ATTAATTGTATCAAATATACTTTCTGTGC AATTTTTGTGTTAACCTAAAATTGTTCTA GAGCATATTATAAATATTTGTAAAAGTA AAACACGAAGTTGGATTTAGCCTACTAA AATTGACTTTACTATCCATTAATGACTTG CTTTCCATGGTTTGAAAACTTGTGGCCGT GGCCTGGTGGGGAGTACCCTGGGTTTCT CTTAGGTTGGTGCAAAAGTAATTGCGGT TTTGCCATTAAATGGCAATTACTTTTGCA CCAACCTAATAACTACATCCCAGCCTCT GTCACTCTATAGAGCCTGCCCTTCAACA AGCCACATAATAATGTCTCTCAGCTTTCT CATCTGAAAAATAGAGTGTTTGATCAGA TGAATGCCAAGGTCCTTTCCAGATCCAA AATATTATACCTGTAAGTATAAATTCTCA TTTTAAAATGTCTTAGAGTAAAAGAAAA GTCATGAAGCATGAATTGTAAATTATGT GCATGTTATTTAGGCATGTTTTATGTTTT ATAGGCATCAAATGGGTACTTTTCATCTT ATTTAAAATAAGTAAAATGAAAAGTAAT TGTTCTCCAGCAAAATATATAAATTACA TTTCTCTCTGAGTTCCTGATTCAAGATCT CTGTAGAAGAAGAATAACAAAGAACAC CTAGGAATGATACAAATGATACTTTCAA TTTTGGCACTTGTCTGCCCTACTGCCATG TCCTCATGAGAGTATCCCTGAACTCAGTT CTCGTTGGTCATTTGACGTTTGCTGGGAG CGTACTATGGGCGAGGTCTTATGCTGAG GGTGAGCCTAGTGGTGTCTCACTTCTTGT AGCTTGGGTCAGGAAATGGAGATCAGCT ACTGTATCCCAGAACCTTCTTGCCTTCCC AGTCCCAAGGCAGGTGCTGTGGGAAGAG TGTGTATAAGGTCTGATGGGGACAGACC TGGGGTGAATCTCAGTGGCACTT  439 3110185 9 ATP6V1C1 TTAAACCACAACGACTGGATTAAGCAGT 4.20E−06 0.017215388 9.26E−06 ATGAAACACTAGCCGAAATGGTAGTTCC AAGGTCTAGCAA  213 3110198 2 ATP6V1C1 CTCACTTGCTATGCTGCTTCCAGGATTTT 1.58E−05 0.023734636 1.63E−05 GTTATATGCTGAGGTGTAACCATTTGTGT TGTCTGACTTTCGTATGATTTAATTGAGC CAAATTTGGGTCAGAACACAAATTTGAA GATGACTTTTCAGTATATGATGGGTATTT A 1975 3110329 9 CTHRC1 GGCCAATGGCATTCCGGGTACACCTGGG 0.000134132 0.00898655 5.05E−06 ATCCCAGGTCGGGATGGATTCAAAGGAG AAAAGGGGGAATGTCTGAGGGAAAGCT TTGAGGAGTCCTGGACACCCAACTACAA GCAGTGTTCATGGAGTTCA 1548 3110790 4 RP11- TTTGCATCCGGACTGGATTTGGATGCAG 0.000101783 0.00824034 1.85E−06 127H5.1 CCAATCCTCCTTTGGCTGATGGAATAGTC TCCCCTCCCCACAGCCCCGGCGCGCCCC TCCCTCGCGCGCCTCGCCGCCTCCCGCCG CAGAACAGGAGCTG  441 3112570 4 UTP23 CCAGGTGCATAATTTCCCATCAGTCTGTC 9.04E−06 0.021427543 1.64E−05 CTTGTAGTAGGCAGGGCAATTTCTGTTTT CATGATCGGAATACTCAAATATATCCAA ACATCTTTTTAAAACTTTGATTTATAGCT CCTAGAAAGTTATGTTTTTTAATAGTCAC TCTACTCTAATCAGGCCTAGCTTTGCTCA TTTTGGAGCCTCACTAAAATAACAGATT TCAGTATAGCCAAGTTCATCAGAAAGAC TCAAATGGAATGATTTACAAAATAGAAC ACTTTAAACCAGGTCAGTCCTATCTTTTT GTAGCTGAAGGCTATCAGTCATAACACA ATTTCGCGTACACCTCTGCTCATTATGGA ATTACACTTAAAACGAATCTCAAGAGGG TGACCATTGTTGTTTCAGATACCATCCCT AAGGAGAGTGGTTAACAGGAAGATTGCC AGTGTTACTGATGGAAAGAAGTGTTTGT TTGTTTTTTTTTCTTGTCAAAGACTTACA CCATAGTTTTAAATTAAACTGTCAGGCA TTTTCTCAGACAGGTTTTC 1043 3112714 1 GGGAGTCCGTATCATGTCACAGAGAAGC 0.00160589 0.009852004 4.57E−06 GTACAAGCTTAGGAATCTTGTTTTCTGAA TTCGAATCGCAGGTTGCCAGTTACACCT GTATGCGACTCAACAAGTACTTTAACCT GTCTCTTAGCTGTTATACTACAAACCTCA GGCTTGTTAAGAGAAAATGCTCCGCAAG GAACTAAACACAGAAGGTTCTAACGCTG AGCCAAGACTGGGAAACGAACTCTGGG AACTCACCCCAGGCTCCCCAAGAACATC GCCCCTCTGGCTGGAGCGCAATTGGTGA TTGGCTACTTAACCCGTCCGTCCTTTCCC GCCCAGGGGTCCAATCCAATCCAGCCCG GCTCCGCTCGGAGACAGTTCGCCGAGTG GGCGGTGTCTATGACGTTTTCTGA 1363 3112879 5 EXT1 TAGGGTCTTGGGGTATCAATGTCTCCCA 0.027405312 0.009431374 7.50E−06 CTCCATTTCCTGCTCATCTTCCAGGACTG GGTCTAGTTTCCCATTCACACACCTCTGT GGCTCCTCCCTGGTTACCTAATTCTTGAC TCTGTCAATTTAAGGAGCAGCAGATAAG GCTTAGTAACTTACTATTGATGTTTTGGA TCCATGAGCATCAGCTAAGGCCTGCTGG AAAGCTTCAGGCAACGCACAGAGCACA GCAGCTCACCAGGACTGACCCTCACACT GGGCCCGGTGGTGTGCACTCCACCAGCA CTAACTCGTCATGTCTCTCATCAAAAAAT TTGGCATGTCCACTGTGCCAACAAAGTC CTG  858 3113688 3 HAS2- CCCGTTCATCGGCTGGGCGCTCGAGACG 0.000219649 0.012595807 9.78E−06 AS1 GCGCCCCCAGATCTCCCACCGGGCAGTG TCC 1062 3114046 3 RP11- GCCCAATTCTGCACTGAAGGACAAGGAC 1.20E−05 0.011270582 7.70E−06 557C18.3 TGCTGCAAAAGAAATGAGTGAGACCCTC AAAATAAATGAAAGGCACACAGCTCAG CCACTAAGGAGATGGACAAGCCATGTCA ACCTCTGATCTGCTACTTTTTGCATCTAT AAAATGGTAACACTGCTACTTATACCTC AGGATGTTGTGAGGATTAAAAATTGAGT AAGCTAAGTGCCTGGTGCAGTCCTGGCA CAGTCACTAAGCATTTACTATCTTTATGC AGTTTCTTTTTGTAATGCTAACTGCCCTC CAAATTCCTCCAAAGTAAACACATGGAT TAGTAAATGAGAAAGAAACAATGCTTAA AACAACTATGGGTAACATACCTGTTTCA AGTCGCGTAGAATA 1476 3114081 9 WDR67 GCAGACTTGTAAACTTCTCTTTGAGATTG 0.000280435 0.013530226 1.04E−05 GGAGCCTCGATGAAGGAATTAGCTCATC AGCAATTAGCCCACATGGACGGTACATT GCATCTA  633 3114092 9 WDR67 ATGGAGACCACGCCTACTGACATTCATC 8.88E−05 0.013744083 7.95E−06 C 1909 3114096 9 WDR67 TATATATGAGAGATCGAGAAATTGCTGC 0.000862602 0.008984675 8.61E−06 CACAGCCAGAGACCTAGAAATGAGACA GCTGGAACTCGAATCACAAAAGAGAC 1551 3114703 5 MTSS1 AGCACGCCATTAATTGCTGATGCTTGAG 0.002997998 0.0115069 6.12E−06 TACAGAAAGAAGAGAAAGAATAGGATT CCCTTTAGGCCCACGGTTTGAGTTACATT AAGCCTGTGGTCATTTCCTTTAAGACCTG GGAACATGGGCATTGCTCATTTTCATGT ACTATT 1708 3114847 9 SQLE GCAAAGTTTATTGAAGGTGTTGTGTTAC 0.001236387 0.009381479 7.07E−06 AGTTAT 1837 3115587 3 PVT1 GACTTCGCAGGTGAGCAGTAACGGAAAT 0.000212296 0.007279185 1.96E−06 CAGCCCCGTTTATTCCTCCCAGCACCTGC CTTATCCAACTCCCCACGCTGTGGCTGA GTCCCAGCCTGCTATGGAAGCATCACTG GACTCCCATTGAACTCTGTGCAGATTCG CTGTTCGTAGACATGGTACCTGATGGAC ACCAAGCTACGTACAGCTTC 1661 3115998 4 RP11- GCACACATCACAGCTTTTAACGTTAGTT 0.000553994 0.011864556 1.23E−05 473O4.5 AATAAAGGTTAAACACACAACATACATC CTTACAAAAAAAGTCAAAATGCAAACTT AAAACTTTAAACAAAAGTATTACTAATT TAAAAAAAGTTTGTGTTGGGTACCATTT GTACAACACAGTTAATTTAAACATTTTC ATTTTGGTTGCACATGAAAAAGGCGGCA GTAGAAAATAAAGTCATTGAGGGTTTTT AAATAGCAGAATAGGCAGTTTTGCCATG CAGGAGAAGCAATATTAAATATTAGTTT CAAAAAAAATCCACATTTAAAAATATTT AGTTCAAGTCACAGAATTTTTCTCAGTA GAGACCCCAATGCAATGCATAATTAGCT GCCTTAGATGGCCCGTTTGAAAGGATGA TATCCCTTCAGAGTGTAACTTTACTGATT TTGGCACAGAAAAGAAGTCTTAAGAACA TGATTAAAAAAGAGGGAAGAGGAACAG AGGAAAGAAATAAAAGCAAGAATAAAT GAGATAGTAATTGCAATCACTAAAAAAC TGCATTCTCAGTCATTGCAGAATACTGTC TTCTGTCTACAGCAGGTGCTTATT  411 3117908 6 CAGGAACAAATGCACCAGGAAAGGCAA 0.002991379 0.011194815 2.75E−06 TGTGACCAGGTGGGCAGCTGCATCCAGA ACCTGAGATTCAGAGTGGAGGATGCCAC CCTCATGTCCCCTGATGATGCTTTCGTGG AAGAGTGGGGGCCTGGCACTAGAATGTG TTCACTAATG  339 3118152 1 CCGCGCTGTGGGCTACGTCTGAGCCGTC 0.010386073 0.011188769 6.80E−06 AGGTCCTCGCTGGGTCTGCGGGCGCCCT GGGGCGAGGGAGCGGGGAGCCCTACCC CGAGCAGGCACTCTCCCCAGATTCATTTT GGAAACCAAGGCCCCCGCGCTCGGCAAG TGAGCCTGGCT 1168 3118707 3 DENND3 CCCGGGGCCCATAGCCCACACCGTGCCC 0.001965656 0.007321616 4.60E−06 TGCGTTTCA  185 3119251 2 C8orf55 AGAGTCCTGCCTGGCCCTACGATGAGGC 1.42E−05 0.015914535 1.24E−05 CACTCATGTGGGCCTAGGTAGGGGAGGA TGGTGCCTGGAGCAGAGGGACCCACAAG TGCCTCCCGAGCCTAGATCCTGGCTCGG ACCACTGCAAGGGCCGAGGCAGGGCCA GACCAGAGCATCCTGGGTACAGGCCTGG GCTCTCCAGGGCCTGGGCCTGATTCAGG TGCAGTGGGCACTCCTGAAGGGTCAGAG CGGCATCTGCCAGGCAGCCCCTCTGGCT TCCGCTGAGGTGGTTGCAGGCCTGGGGC AGAGCCTGGGTGGTCAGAGGCCGGGGCT AGAGGCAGATGGAAGGGAGGCATTTGCT GACAGAGGACGGGGCACCCGGGCTCCCC ACTGCAGTCGGCCTTGCCTCCTCCTCCTC CTCTACCTCCAGTCAGGCTGGACGGGAG GGTAGCCTTGTGGCTGAGAGGGGTCAGA CTAGGTGGCACAGGGGCTCCTGGAAAGA CAGCAGGCTTCCTGCTGGGCGTTCCCTTG TTGGAGGGAATAGAGTGGGGGTGGGACT CTGCAGGGGTGTCCTTGTCCACTCGCAC CCCTCGCCGCCCACCAGGGCCATGCTCT GTGACTTGGGCTGATCCCCACCCTTTCTG GGCCTACAGCACCACAGGCCGCTGTACC CCCTTAGAGCTGCCCCTCTCTGGCCTGGC CGGCAGGCGTCTTCTTAACTCCT  137 3119919 7 EPPK1 CACTGCAACAAGAGTACCCGATGGCATG 4.35E−06 0.028826853 2.57E−05 ATGGACTGAGAGTCTAAAGAGTGACATT CTGTAAAATGGAAGCAGTGAATCCAAAA CAGACAGAAAAATGTTCTGAAAACGAA AAAGGAGAGAAAAGTAAAACCATATGA CACATAGACGACCCAGAAAACACACCA AAAAACTTATGAAACACCTCGATGGACA AAGGAAAAGTTTCTGTCACATGACAACT TAAAACGTTTTCCACAGATAACGAATGG GTA  560 3119979 9 SPATC1 CCCAGAGCCTCTCAGCATGGCGTTTGCA 0.0060277 0.013334373 1.31E−05 GGAGCACCCCTCCAGACCTCCACCCCTA TCGGAGCCATGGGCACACCTGCTCCCAA GACGGCCTTCTCCTTCAACACTT 1300 3120764 5 ARHGAP39 CAGAGACACCCAAGACGAGCTCGGAGG 0.000122727 0.010438117 4.98E−06 CCTCCCACGACTCTGCCTCTGGTGTG  806 3124365 2 AF131216.2 AGCTCCTCCGTATTGTCCTGCCGGGAGG 1.77E−05 0.01362045 1.26E−05 ACAGGATCAAGTGGTGGCCCGTCAGGCA CAGGGTGCCCTCGACAGCCGGGTAGAAA GGCCGGTGCAGCACCACATTGTCCACCC GCGGGGTCTTAATCAGCTCCGCAAACTC CATGCT 1947 3124528 5 FDFT1 CTCTCGGCTTTTGGGTGATGCCACACAA 0.023281585 0.007309709 5.45E−06 CTTGCAGGCGGCATATGCCCGTAGATTT ACTGATATGCACCTAAAAATTCAGTGTA AATCAAGTTTACTAAACCCTGAAATTCT ATAGCCAAATGCTTCTGTGATAGAAATA ATCAGCCCTCAGTATCTGCTAAGCGTAA ATTTTTTCCCTAGTTTGCAGAGAGAAACT GGTTGGGTGCAGTGGCTCACACCTGTAA TCCCAGCACTTTGAAGGCTGAGGTGGGA AAATCGCTTGAGCTCAGGAGTTCAAGAC CAGCCTGGGCAATGCAGCGAGACATTGT GTCTACAAAAAAATTTAAAAATTAGCCA TGCATTGGTGACACGTGCCTGGAGTCCC AGCTACTCGGGATCAGGAAGCCGAGGTG GGAGGATGGCTTCAGCCAAGGAAGTCAA AACTGGAGTGAGTCATGTTCAGGCCACA  848 3125600 9 MSR1 GTCTTAAAGGTGATCGGGGAGCAATTGG 0.000181274 0.017085539 1.35E−05 CTTTCCTGGAAGTCGAGGACTCCCAG  929 3127573 1 GAGGGATACGGGGAGCCTCCATCTTTGG 0.048959505 0.007288313 3.51E−06 ATTCTTTTGGTACAGGAACAACATCCCTC CAGGTGACCTCCACCTACCATGGCTCTG TAGACGCCAGCTCCTCA  664 3129039 9 CHRNA2 GAACCAAATGATGACCACCAACGTCTGG 0.002388272 0.011092138 6.33E−06 CTAAAA 1458 3129619 4 KIF13B ACTTGGCGTCAACATAATGCTGGAAACA 0.001135581 0.00738277 4.70E−06 CTTACATCTCCAGGCTTCAGTGCAACTTC CTTCGCCTGACTTCCCTTCCCTCGGTCCG CGATCCACTCCTGGGACT  386 3132919 1 GGAGCCGTGGTGTTGGAAGCAGCATGGG 0.005684569 0.01383766 1.03E−05 GAGGCTGCTTCTCTTCCCAAGTCCAGCA GCCTGCAGCCTCCTTCCCTCCGCCAGCCC AGAAGGCATGTGTTCCAAAGCCCCTCAT TAGGCCTCTCTTAGCAAGCAAAC 2042 3134154 9 PRKDC AGAAGAGTCTCTGGTGGAACAGTTTGTG 7.26E−05 0.00675565 4.66E−06 TTTGAAGCCTTGGTGATATACATGGAGA GTCTGGCCTTAGCACAT 1629 3135385 1 ATAGGAGACCTCATTCCTACAAATAATA 0.002024742 0.008228586 4.97E−06 AAAAAAATTAGCCAGCTCTGGTGGCGTG TGCTTATTGGTCTCAGCTACTTGGGAGGC TGAGGTGGGAGGACTGCTTGAGCCCAGA AGATCGCAGCTGCATTGAGCCAT  902 3135419 1 CACACGTGTGGTAGGATGCAGAGTGCTC 0.002543079 0.009783809 9.62E−06 TGGGCAGGCCACTCAGAGGCCCAGGTCT GCTCCATGGTCCCAG 2052 3138424 2 ARMC1 TCTTTTCATCAACATGTAGAGCTGCTATT 3.35E−05 0.009405851 3.32E−06 TTACTATTTGGAGAATATGATGTGAAAA TTGGACCTCAAAGGGTTTCCTTGTGTTTT CATTGTAAAATACCATCATCAGTGAGAG TCTTGAGTTCACTAACATTGTCACCTTCT GGAGAGAGAGTTAATGGGGGGCATTGA GGATGATATTTTTTTACATGTGTTTGGTT TCTGATTCAAGTGACACGCACAAACTGA AAAAAAAAAAACAAAAAAAGCAACAAT AACTTTCAGGGCACCTATTGCTCTAAAT GCATAATATAACTTGCTGCCAGAACCAG ATGTGTTTAAAAAAGAAAATAAAACCAC CTTCTTTCTATAGCCATTAAAGCAAACTT TACTGTTCTAACAAATTTGTATTTTATTT TGCATTGCCACACATCTGCTTATTTAAAA ACTACATCCCTTTGGTAGTAATGTTTCAG GACAAGTAGGTATTACAGC 1488 3138480 9 PDE7A TGGGTGTGAGTCCACTTTGCGATCGTCA 0.01575619 0.011220854 1.37E−05 CACTGAATCTATTGCCAACATCCAG 1971 3138675 7 RRS1; ACTCCCGCTCTGATACACAAACTTGTTGT 0.006898401 0.006687195 5.87E−06 ADHFE1 AAAAATAATGCAGAAACATATACGTCAA TCTAAGTCTCTGAAATATGGCCAACTCT ACCTCGCCGTATATCCAACATTAAAAAG AAAAAAAAAGGCTGTTTAAGAATAGAA CTCATTCCCGGTTTCCACCAAATTATTTC CCTAATTCTTAAATCCTCAAATAAGTTCT TAATCTCCAAAGTCTCGGTTGTGGGAAA AACATTAATTTGTGCAGTCCAACACTTA CATACTTTCTTGACGGAAGGGCAATCCT GTCCCTTTAAACTCAATGAAGGCAGCGG CC 1983 3138814 9 VCPIP1 TCAGGTTCGAGCAGAGGCTACTACAAGA 5.66E−05 0.007953518 1.54E−06 AGTAGGGAATCAAGTCCCTCACATGGGC TATTAAAACTAGGTAGTGGTGGAGTAGT GAAAAAGAAATCTGAGCAACTTCATAAC GTAACTGCCTTTCAGGGAAAAGGGCATT CTTTAGGAACTGCATCTGGTAACCCACA CCTTGATCCAAGAGCTAGGGAAACTTCA GTTGTAAGAAAGCATAATACAGGGACAG ACTTTAGTAATAGTTCCACTAAAACAGA GCCTTCTGTATTCACAGCTTCTTCTAGTA ATAGTGAGCTTATTCGAATAGCTCCTGG AGTAGTAACAATGAGAGACGGCAGGCA GCTTGATCCTGATTTGGTTGAGGCCCAG CGAAAAAAATTGCAGGAAATGGTTTCTT CTATTCAGGCTTCAATGGACAGGCACCT TCGGGATCAAAGTA 2063 3139046 2 ARFGEF1 CTGAGATACTGGTAATCATCCTGTGAAA 0.000629941 0.007275746 6.32E−06 AATGTACAGAGATGCAGGTCTGTAATAT AAAAATCTTAAAACATTATATAGTTCTTC CTGCACTGTTTTCTTTATTTTCTTATTCAT TTGCTAAATACCCATAATATTTTGTCAAA TGCACTAAACATTTGGGTGGAACTTTCTT TTTTATTTTATAGGGATTTTTAGTTTTGC CCTTTTTGGTAGGTGGTGATTTTGAGGCT GTAACATGCCCAGAAGCTGTTGTGGCCG ACACTTCAACAATAGGGAAAAAAAGGT AGAAAATATCCCTACTGACAGTAACTAC CTGTCACATATTTCTCTTAGGACTTTTAA AGATGAGCCATTAAAATAGAATGATCCT TTATGGACCAAAACTTGAATCACTGC  984 3139077 4 ARFGEF1 ATGTTCAGATTATGGGTAGATTCCAGTT 0.001852254 0.008893133 6.29E−06 GTTAAAGAGGTTGTGTGTGTTCTAGTTA GTAAAGGAGAGAGAAAAGATCAGTAAA CTTTGTTCAGTGATGGCCTTTGATTTTCC TACCTCATCCCAGGATATGTATGGG  119 3139107 9 ARFGEF1 TTAGAATGCTTAGTGTCGATTTTGAAGTG 6.61E−08 0.033566027 3.81E−05 TATGGTTGAATGGAGTAAGGATCAGTAT GTGAATC 1079 3139108 9 ARFGEF1 CTATGACTGTGACTTAAATGCAGCCAAT 1.18E−05 0.015040305 6.57E−06 ATATTTGAAAGACTAGTAAATGATCTAT CAAAAATTGCTCAAGGAAGGGGCAGTCA AGAACTTGGTATGAGTA  265 3139551 5 SULF1 CGGATGTTTTTTCGTTCCTGCTGTATCCG 2.63E−05 0.021575493 2.25E−05 TCCTCTGAACCTCGGGGATCTGACAGTC GAACAGAGGCTTCCCAGCAATTCTGTGC CCAGG 1236 3139562 7 SULF1 TTAGCAAGTCGAGGTAAAACACATGCAA 2.88E−05 0.01622433 1.99E−05 CATTTTCTGGCAAAAGCTTAATGTCAAA CAATATGTGATCCATACTGTGTGTCGTCC TTGGGGGTTTATTTGACTTTGTCACAATG ACAGCCAACAGTGAGACTGATAAGCCTG TAAAAATAAAAAAATAAGACTAATCAA ATAGACATGGCATTTTAATCTCAAAGTG CAAAATCATCTAACTGAAAATGACGGCA TTGAAAAATTCCAGTGGTTAAAAATGAA TCAAAACTTCATTACGCAGGCAGTGGAA GTGTGTTGAAAGATTTACCAGGGGTGTC AAGTTTTAGACACTCAGAAAGGCACCAT TCTAGCCATCTTGATTG 1337 3139607 9 SLCO5A1 CTGAGAGTGCCATTGTAACTGCTTTCATT 0.01612054 0.00752669 5.63E−06 ACCTTCATTCCCAAGTTCATCGAGTCACA GTTTGGTATCCCAGCCTCCAATGCCAGC ATC  186 3139630 9 SLCO5A1 TCTGGGTACCTGAGCAGCGTAATTACCA 0.000367918 0.011111055 1.14E−05 CCATTGAAAGGCGCTACAGTCTGAAGAG TTCCGAGTCGGGGCTGCTGGTCAGCTGC TTTGACATCGGGAACCTGGTGGTGGTGG TGTTCGTCAGCTACTTCGGCGGCCGGGG TCGGCGGCCCCTGTGGCTGGCCGTGGGT GGACTCCTCATCGCCTTCGGGGCAGCCC TCTTCGCCTTACCTCACTTCATCTCGCCC CCCTACCAGATCCAAGAGTTGAACGCCT CGGCCCCCAACGACGGCCTGTGTCAGGG TGGCAACTCCACCGCCACTTTGGAGCCT CCGGCCTGTCCGAAGGACTCGGGAGGAA ATAATCACTGGGTCTACGTGGCTTTATTC ATTTGCGCGCAGATTCTCATTGGAATGG GCTCCACACCTATTTATACCCTGGGACC AACCTACTTAGATGA 1706 3139726 2 NCOA2 TTGCTTCTTCAGCTGACCGGGCTCACTTG 3.46E−05 0.009051694 5.98E−06 CTCAAAACACTTCCAGTCTGGAGAGCTG TGTCTATTTGTTTCAACCCAACTGACCTG CCAGCCGGTTCTGCTAGAGCAGACAGGC CTGGCCCTGGTTCCCAGGGTGGCGTCCA CTCGGCTGTGGCAGGAGGAGCTGCCTCT TCTCTTGACAGTCTGAAGCTCGCATCCA GACAGTCGCTCAGTCTGTTCACTGCATTC ACCTTAGTGCAACTTAGATCTCTCCTGCA AAAGTAAATGTTGACAGGCAAATTTCAT ACCCATGTCAGATTGAATGTATTTAAAT GTATGTATTTAAGGAGAACCATGCTCTT GTTCTGTTCCTGTTCGGTTCCAGACACTG GTTTCTTGCTTTGTTTTCCCTGGCTAACA GTCTAGTGCAAAAGATTAAGATTTTATC TGGGGGAAAGAAAAGAATTTTTTAAAAA ATTAAACTAAAGATGTTTTAAGCTAAAG CCTGAATTTGGGATGGAAGCAGGACAGA CACCGTGGACAGCGCTGTATTTACAGAC ACACCCAGTGCGTGAAGACCAACAAAGT 1822 3139788 9 NCOA2 AAGAAAGCGCAAGGAATGTCCTGACCA 1.08E−05 0.008651908 6.79E−06 ACTTGG  820 3139840 4 NCOA2 TCAGACTGTGGCTTAATATACAATAATTT 6.21E−05 0.016208818 1.23E−05 TCTCAGAAAAATGAAGCTCTTGCGAAGA ATGGTTGGGCATATTTCACCAAAATCAA GTATTTGTGTGTGTGTTTTTTTTTTTTGGA GTTTGAATATAATCCTGTAAGTAGATGC TTCAAAACCACTTGAATCACCATGGAAA GCAAATCTCTTTAGTTATTCTCCATCTAA GCAGCCTTTGCCGTACAGTTTAATT  256 3139841 4 NCOA2 CATCTCTTTTAAGGTGGACCAGTTCCCGT 1.77E−05 0.014482929 1.28E−05 GGTTTGTTTTGTTTGTTTAGACTTTTTAG AGTCTAAGCCAGTTGTCCTGAAGAGGAT GCAATTGTTCTATCAATTTTGGGGTGTCA GACTTCAGTTTCTCCAGAACTGTTAGGA AATTAAGTTGTTAATGTGTTACTGAGTTT GATCAGGGCTGAAGAAGCACAGCCAAC CTTTGAGAGCTTATTGCTTGAAATGATG GCATCCTTGGACCTTTTCATGGCATGTTC CTTCTGAAGTCTCTAGGTCTGGGCC 1585 3139843 3 NCOA2 TGGCATATGCTGTAGTGATCATGTCCTG 0.004639335 0.007233204 3.77E−06 GACCTC 1969 3139907 2 TRAM1 GTTCTTGAAAATACAGTCTGTGCTCTTTG 6.51E−05 0.008461955 5.00E−06 ATTTTTGCTATTGTACGGTTTCATGCATT TTTTTAAAGGGCATTTGAGGGGAGGATT ATTGCTATGAATGAAAAAAATATTTTAG CTTAGACTAAGCTACCTGCCTTCAAAAT AGTTTAGGGACCACCACCATATTTTATTT TGTTTTTATTTTTGAACATTTTTCTAATG ATTTGGAGAGAAAACTATTTACAAAAAT TCCACATATCAGTGATACAATTTCTTGCT GTCACCAATTTTTTATAATAGCAGAGTG GCCTGTTCTAAGAAGGCCATATTTTTTAA GTTATCTTTCAGGGTAACATGGAAATAC TATAAAGTTGGATGTCAAACTTTAATAT GTTTTCAGTGTTCTCTAATTTTTTGGAAT TTTTGTAGACTTTACACCTGGAAAAAAA GATTTGTAAAATCACCGGAACAATTGTG TGCTTTATTTTATAGGTAGTGGTTATTAG TATTACATCCCCATTTTAAAAACAAAAA CATAATAATCGTTACAACACGTGGAGTT TTACTAACATA 1944 3139925 9 TRAM1 GAAAACTACATCTCAGACCCAACTATCT 0.002671169 0.007740888 7.55E−06 TATGGAGGGCTTATCCCCATAACCTGAT GA 2001 3139926 9 TRAM1 AATTAACAGGCGAATGCACTTCTCCAAA 1.31E−05 0.008848099 5.28E−06 ACAAAACACAGCAAGTTTAATGAATCTG GTCAGCTTAGTGCGTTCTACCTTTTTGCC  447 3140775 2 UBE2W CCAGGTCCTCATGTATTGTGCAATAACA 0.001052466 0.017989974 1.81E−05 ATGACTTCCTTGGCGGTTTTGGTACGTTC ATTGCCGGCAATGGGCGTTGTAACAGGA AAAGTTTTCATTAACTCCTGCCATTCAAT GATTAATGCATGATAGGGCCTATGAAAT GAACTTACTGGTTATAGTGGGAATATAA ATAAAGTGAGGGATCCAACATTACTTTA AAAGTCACCCCAACTGTTTATATTTGGAT TCTATGCACTGTGATCCTAAGGTTAACA GCATGAATTAACATGCGTCTTTAAAGGA CTGTAATGAAAGATCATTGCATATTTATT GAATTGTTTATATCTACTGTCAAGTTGTT TTGACATGGAAGATTTTCAAGTAACATT GGCAGAGAGGTACAGTATGTTATCCCTA TGGTG 1526 3140795 4 UBE2W CTTCTCCAGTACATATGCCACATTGTTGT 0.005613406 0.009006123 6.57E−06 CAGCATGATCATATTTTTATTTAAAAATA CTTTACATATGTTTATTGCCAAATATTAG AAAATACAGATTCATGGAAAGAAAAATC ACTGTCCCAAGGAGATCACTGCATGGTG AGATTAAGGGGTGATTTTAATTTTTAAA AATGTATATTTTTTCCTGTGTAGAGTAGT AACACCCATTGAAAACACAATCCCTTGT AAAGTCTCTAATTCTGTACTCCGCATCTA GCTGATCTCTTCTTTCTCAGATATTTTAC AATTTCATTTATCACCACCTTTCTCTAGC CTTTACCCGTCTCTTCAATATTTACATAT GCAGAAGTTTCTCCTAACAAACACCTGC CTCTGCCTCAGTTCTGCTACCACCCTGTT GCTTTC 1830 3141853 4 MRPS28 GTCATCTATCCGAAGGCATTTTGTAATTG 0.003636318 0.00677358 3.50E−06 TGCTTGTGTGTGTGTGTATATGTGTGTGT TTGTGTTACAGTTTAAAATCTTACTGTAT TACCTACATCATTGAAAGAATCATCATG CAGCCTTTCTCAACAAAGGCTTATCTAG AGAATTATACCCTAATATCCTAAAGTAT ATTTAATGAATTAATAAATATTTAATGA ATTAACTTACTCATTCCTGGGAGAATTG AGAATAGAGTCATTCAAATCATTTTCTAT GGGGTTAAATTCTTTGGCTGAACCCGAG TTGAGAAAGGCTGCTAGAGAATGCATTG AAGACC 1663 3141865 2 TPD52 ATGATACTGTAGAACCTGTCTCCTACTTT 0.000637737 0.011384196 1.16E−05 GAAAACTGAATGTCAGGGCTGAGTGAAT CAAAGTGTCTAGACATATTTGCATAGAG GCCAAGGTATTCTATTCTAATAACTGCTT ACTCAACACTACCACCTTTTCCTTATACT GTATATGATTATGGCCTACAATGTTGTA 1959 3141883 9 TPD52 ATGTTGCTGCCACGATCAGTGCCACAGA 4.84E−05 0.007772796 7.02E−06 G 1920 3141894 4 TPD52 CATTTCAGGTAGAGCGTGTCACATGGAT 0.000961152 0.007445917 4.49E−06 GTAAATACCAAAGGTCAAGGACATGGGC TTGAGAGATGGTGAGAAGGATGGAGGT GACTGTGGCTTGCATTCTATCCGTATCAC TATTAATTACCTTCTAATGCCTTTGGCTC TAGGTGGTGGAACAAGTAAAGTAATGGA CAAATACTTTTTCTACCAATATTTAGTGA CCAAATGCAGAGTTATGGAGAGGGCCAG GGACCTCATGAACCATACTC  638 3142136 2 ZNF704 CCTCAGGGATATACAGCGGAGTTTCATG 0.025498894 0.012518258 1.63E−05 ATAAACTACCCATACTTTCCCAAAAAAG GTTGAGGAGCAATACATAACTTTGCAGA TTACAAACCCTTGTTTTACTTTTTAAACC TTTTTTCCATACTCTGCTTATTGGAAATC GATGGCTGTGATGTGACCAACACCTGTG ATGATAGCAAAGCCCCTCCTTTCACAGT CTCCTGACTGTTCGGGGAACCTCCTTGGT CATTGGTAGAAAGCTTTAGAAAAGACTT AGCTTTTTAGGGAAGAACTAAAAAATCT CCAAAACATACTAGTCCCATGACTTCGA TAACTGAAAATGTCCTGGGTGTAAACTA ACCCAGGAATGTGGATCATACATGTTTT TTTTAAAAAAAATCCCTGAATCAATATTT TCCTACAACACACCCTAAAATTCCTATTT TTGTAATTAATGGTTGGACAGTGATCAG CCATTTAAACATAGGCTTTCTGGAATAA CCAGACACTAGAATAGTTTCCAAAGTGT TTTGCGTATCAAAATCCTATATACTTAGA AGAAGAACTCAGGATAAGAAAAAATCG CTAGGTCCCAAAGGGTTCATGACTATCA TCAGATGCAACTGCGAGTGGCCTACGGT CATTTTTTCAAATGAGAAGACTGGAGAG AGAGAACAACAGTAATCACAAAACCTCT GTTGCCCTTAGTCCATGACAATGTTTAAG GAAACTTTAAAAAATTAAGCCATCTTCT GAATTGTTTTCTACACCAAATCTAAAAT ATTAAAATGAAATTATTAAATATTTAAA ATGGGGTATTTAGTGGAAATGCAATCAG TAGAAAACATTGCTTTTTAGTGCCTGCTA AACAAGTAAAGGAGAAAGAATGAAGAG AAAACAGCAGTCCTTCCTGTGTGACACT CGTGTGGAAATGACAGGCATTCACATGT CATTGAGTGCTAACTCAAAAGCTAGGTG GCAATGCTGTCCAATGTTTA 1838 3142146 2 ZNF704 AACAGGATGTAGAAAGACCCATGAAGA 6.13E−05 0.006851634 5.15E−06 AAGAAAGAAGAAAGCTATGGTTCCGAA AGCAG 1460 3142170 2 ZNF704 TTTCATAGTGACTGACAGGACATTCTCC 0.000357766 0.009437061 6.74E−06 AGAGAGCGACAAAGCAGAGTGGCCAGC AGGCAGTGGTGTTAAGCCTTGGGCCTTC  716 3142182 9 ZNF704 AAAGTGTCGGAAGGTGTACGGGATGGA 0.002612225 0.011108751 5.96E−06 GAACCGAGACATGTGGTGTACCGCCTGC CGCTGGAAGAAGGCCTGCCAGAGGTTCC TCGACTGA 1022 3143340 4 FAM82B TGCCTTCACATCTGATATGTGTTTGTCTT 5.59E−05 0.01435305 9.55E−06 TTTCTCCGAATTTTTTTCCTGATTTTAGCC AGTCATTCACATCTGCATTTTGTTTGTCC AGTTCTGAGTTTTTAAGTTGCTATTTCAG ATTTTTTAAATATCTAATAATTTAATTCA TATTAGCATATTGTGTTAAAGTTTACTCT CCTTTTTCTCATTTTCAATTTCTCTTTAGA GTGACTTTATTTTTTTTCCCTAGGGATGT AATTTTATGTTGAGTTACCAGCAATACTA GGTCATCAAATGGGAAGAAAGGGTCTGG GTTAGTTCAAGAATAT  325 3143470 4 CNGB3 AGTCCCAAGTTGAGTGCATGCTGTTTTGT 2.71E−05 0.017979346 2.25E−05 AAACCACAGTGTCTAAACTGTAGCAAAA ATCAGATGCATAGACAGGTTATTTTTAC CTTGCAGAAAAGCACTGTATACAGAGTT ACAGGAACAAATTTGATATCATATAATT TAAGAAGCTCTCATAATCAGGTATGGAC ATTGGCTTATACAACATACACTGTGAAT CAGGCACAGCAACCTGCAAACCACATCA TCCCAACAGTTTTCCATTCTTCCTATTGA CAAACACTTAAACACAGCATTTTCATCA TATGAAAGTAAACAAAAACAACAACAG AATAAGCTTTCCCCACACTAATTTCTAAT CCAAAGAGCTTTACTGCAATTAATGTAA ATTGCTATCAATCACTGAATTGACTGGG CAAAGATGGACTTGGCACTGTCCC 1584 3143922 4 RP11- ATAATGTTGGTGACTCTGTGAAGGATAT 3.87E−05 0.007023854 5.38E−06 37B2.1 TAGAGGAGGCAAGAAGACCATTGATGA GGTTCCTGCAATAGGTCATTTGA 2036 3144771 9 RBM12B CGGGGCCTGTGGATATTCGTCACTTCTTC 0.001852254 0.007359204 5.57E−06 ACGGGATTGACTATTCCTGATGGAGGAG TGCATATAATTGGAGGGGAAATTGGGGA GGCTTTTATTATTTTTGCAACAGATGAAG ATGCAAGACGTGCCATAAGTCGTTCAGG AGGGTTTATCAAGGATTCATCTGTAGAG CTCTTTCTTAGTAGCAAGGCAGAAATGC AGAAGACTATAGAAATGAAAAGAACTG ATCGTGTAGGAAGAGGGCGTCCAGGATC TGGGACATCAGGGGTTGACAGCCTGTCT AATTTTATTGAGTCTGTTAAGGAAGAAG CAAGTAATTCTGGATATGGCTCTTCAATT AATCAAGATGCTGGGTTTCATACTAATG GTACAGGACATGGTAATTTAAGGCCAAG AAAGACAAGGCCATTGAAGGCCGAGAA TCCTTACTTGTTTCTACGAGGTTTGCCTT ACCTAGTAAATGAAGATGATGTACGTGT CTTTTTCTCTGGTTTGTGCGTGGATGGAG TAATTTTCTTAAAACATCATGATGGCCG AAATAATGGTGATGCCATAGTAAAATTT GCTTCATGTGTTGATGCTTCAGGAGGTCT TAAATGTCATAGAAGTTTTATGGGTTCA AGATTTATAGAAGTAATGCAAGGATCAG AACAACAGTGGATTGAGTTTGGTGGTAA TGCAGTTAAGGAGGGTGACGTTCTTAGG AGATCTGAAGAACATTCTCCACCAAGAG GAATTAATGATAGACATTTTCGAAAACG GTCTCATTCAAAATCTCCCAGAAGAACA CGTTCTCGTTCCCCTCTTGGATTTTATGT TCACTTAAAAAATCTGTCCCTCAGTATTG ACGAAAGAGATTTAAGAAATTTCTTTAG AGGTACTGATCTGACTGATGAACAGATT AGGTTTTTATATAAAGATGAAAATAGAA CAAGATATGCCTTTGTGATGTTCAAGAC TCTGAAAGACTATAATACCGCTCTGAGT TTACATAAGACTGTTTTACAATATCGTCC AGTTCATATTGATCCAATTTCTAGAAAA CAAATGCTGAAGTTCATTGCACGTTATG AAAAGAAGAGATCAGGGTCACTAGAGA GAGATAGGCCCGGACATGTTTCACAAAA ATA 1393 3145100 6 AGTACAATGCATACTCCTTAGGTTCTTAA 0.011131791 0.007702451 5.96E−06 ACTCTACCAGTCTAACAGAAAGCACCAA GATACAGATGCCAAAGTCAGAAAAAAT ACAAAGCAGCTCAGAATCAATATCATAT ATCTTATTCAAGGTAAATTTTATGTTAGA TTCTTTGTCTGGCATTTGGGAGGCTAAAT TAACTTAGGAGGCTAGAGATCCCATCTC  777 3145187 5 C8orf38 TTTTGGAACCTATAGAACACAACAAAGA 0.000468776 0.009489743 4.21E−06 GAGAATTTTACTGCATGTACTTTTAAATA AATTCATTCATTCATTCTTTAAGTAATTT TTAAAAAGAAGATTATTAGATTGTCTCC CTCACTCACTACTAAGAATGG  204 3145592 9 MTERFD1 ACTAGAGATCTGGTAGTTCGTCTCCCAA 2.95E−06 0.023094718 1.57E−05 GGCTGCTAACTGGAAGTCTGGAACCCGT GAAAGAA  454 3145807 2 TSPYL5 TGAGGACTGGGCCTATATAGAATCCAGA 0.001925692 0.011918826 6.99E−06 TACCATTGTCAACTTCCCTTATTCCCGTC TAAGATGTGAGCAGAGTGCCATAGTAGG GGTTCT  102 3145886 5 MTDH TTGGTTCCTGGGACTTTAGAAGTGAAGC 3.41E−05 0.03013173 3.38E−05 TCTTTCTTCGTCTACCCAATTGCCCCACT CTTCTGCTGGTGCATTCCAATCAGAGTTG GGATCAGCAGAAGACAGACCATCTAAA ATTTAA  130 3145888 7 MTDH TTTTATGGTGGTGTCCGCAGTTTTGTTTT 2.84E−05 0.027153197 2.73E−05 AAAAATTGGTTTAAATTTATATAAAACT CTGTACATGTTCACAAATTATTGCATAA ACAGCATAATCTTCAAGACAAGTGTTTG CAAACACATGTCCAATTCAGGAA  149 3145890 7 MTDH GTTTGCTCAATTGTCGGTACAGATAGGT 0.000101783 0.020297858 2.08E−05 AGGATTCCAGTCTGGAGAAACCCCTAAA CCACTACACCCTGCCTCAGAGTAGGGAA GAATTTTCAGTATGTATGTGGAGACAGG CTGGATTAGGGAGCCTTTTGAGTGGCTT C 1811 3145981 2 HRSP12 TGCTGTGTAGTCTGGAATTGTTAACATTT 4.53E−05 0.009789405 6.30E−06 TAATTTTTACAATTGATGTAACATCTTAA TTAACCTTTTAATTTTCACAATTGATGAC AGTGTGAGTTTGATGAAAATATCTGAAG CTATTATGGAAATACCATGTAATAGGGA GAGTTGAACATGAATATTAGAGAAGGAA TCCAGTTACTTTTTTAAATTACACCTGTG TGCACCTGTATTACTGAATATAGGAAAG AGATACCCATTACATAGTTACTCAGTAA ACAAAAGAGAAATACCAGGTAGGAAAG AAGAGTTACTATTCCTGAGAAATAATCA AGAACATATTTAATTTAAACTAATGATG TGAACTATTTAGTTTTGATGTCCGTTATG TGATTCTGC 1722 3146344 4 RP11- GACCTATTCCATACCTATCAGACTGACA 2.08E−05 0.008830151 5.09E−06 410L14.2 ATATTTTTAATGTATAATGTTAATGAGTG GCATGATAGGAACCTAGTGCACTGTTGC TGAGAACAACACAGTGGAGAGGAATTA AGCAATATCTAGCAGAGTTGAAGACGCA TATACCCTA 1738 3146442 9 COX6C TTTCGTGTGGCTGATCAAAGAAAGAAGG 0.000110135 0.010882068 6.38E−06 CATACGCAGATTTCTACAGAAACTACGA TGTCATGAAAGATTTTGA 1244 3146529 9 FBXO43 ACTGATCGGCAAGAAAATGGGTATAGAA 0.003390971 0.011341658 9.24E−06 AAACTGGACATCTTAACAGAATTAAAAT ATAGAAATTTAAAGCATATTCTTGCTAT GGTTTTAGAGTCCTTGACCGCAGAGAGC CTATGCA 1215 3146566 2 RNF19A CATTATGGTGCTACTGAGCGTTTTCTTTT 0.000148906 0.010441166 1.00E−05 GGTAAAAAGAAAAATGCCATGGGCTGC AGTCTTCTTCCATCACTTTTCCCTACCAG GTCCATTAATATGCTTATAACACTAGTGC CAGTTATTTTATTTGATAATGCTTATGGT ATTTGTATATTTGTTTGCATTCCAATTTT GTTTAATAATGAGTGTGTAAACTGCATA CGTTA  362 3146569 9 RNF19A CACCCGAAGTCATGCTGGCGGTTCATCC 0.00010545 0.021503954 1.92E−05 AGTGGCTTGCCTGAAGGTAAATCTAGTG CCACCAAGTGGTCCAAAGAAGCAACAGC AGGGAAAAAATCAAAAAGTGGTAAACT GAGGAAAAAGGGTAACATGAAGATAAA TGAGACGAGAGAGGACATGGATGCACA GTTGTTAGAACAACAAAGCACGAACTCA AGTGAATTTGAGGCTCCATCCCTCAGTG ACAGTATGCCTTCTGTAGCAGATTCTCAC TCTAGTCATTTTTCTGAATTTAGTTGTTC TGACCTAGAAAGCATGAAAACTTCTTGT AGTCATGGTTCCAGTGATTATCACACCC GCTTTGCTACTGTTAACATTCTTCCTGAG GTAGAAAATGACCGTC 2019 3146577 9 RNF19A TCGGTGTTCCTATTATGTTAGCTTATGTC 0.000885779 0.006579631 3.15E−06 TATGGCGTAGTTCCAATTTCTCTTTGTCG AAGCGGAGGTTGTGGAGTCTCAGCAGGC AATGGAAAAGGAGTTAGGATTGAATTTG ATGATGAAAATGATATAAATGTTGGTGG AACTAACACAGCTGTA  478 3146675 2 ANKRD46 TTTCTTAGCGCAAAGCAGTGAGGGCAGT 3.35E−05 0.019301227 1.64E−05 ACATGTTCTTTTTGCATTTTTAATTATTGT AATCCTTTTAGATAATGATGTGTTCATTT GAACTAACTACATACTATGATCAAGTAT ATTGCATCCTAACGCTACCTCTGACTCAA CCTGACTTTGTA 1945 3146698 3 ANKRD46 AGTATGGAGTACTGAAGGCCAAGTAAAG 0.006376399 0.006617936 4.09E−06 AGTTTTTCAGGGAGAAAGTGACCAACTG TGTCTCCTCCTGCTGATTGACAAGTCAAG TAAGATGAAGACTAGGAGATGACCATTG GATTTAGTAATAGGAAGGTCCTTGGTGA CCTTGCAAGAGCACTTTCAGGAGAATAG TGAGGAAGAAAACCTGATTGGTGTGGTT TCAAGAGACAACAGGAGGAAGAGCATT GGAGACTGCAGTATGGACAGCTCTTTGG  639 3146904 6 TTTTCATGTAAATTAGTCTTGGTTCTGAA 1.45E−05 0.020079582 2.10E−05 ACTTCTCTAAAGGAAATTGTACATTTTTT GAAATTTATTCCTTATTCCCTCTTGGCAG CTAATGGGCTCTTACCAAGTTTAAACAC AAAATTTATCATAACAAAAATACTACTA ATATAACTACTGTTTCCATGTC 1126 3147061 2 ZNF706 TCCCTCCAGTTTGTCGCATTTAATCAAGG 0.002671169 0.009051504 4.43E−06 AGCGGTTGTAGCTGCCTACGATTTTGTA GAAAATTGTGTTGGCTTGAGAGCAAGTC CTAAGTTGAGCTGTCCAAAAGCAGGTGG TTGGTTCGTTTGAATTTCTGCTTTCAGAA AGGAAATCGATGGGGCGTGTTGTCAGAA GTTAGGGGCCTACCTCATGCATTTAGCTT ATTTTATTCCATTTCCTTTACCTGGTGTT AAGTTTTCTGTCTTCAGAATAAGAACAA GTGACTACTGTCTTTATTAAGTCTCTTCG GTCTTTTTGGTTGCTGTTTGGTGACAATG GAAAATGGGTTGAATCTATTGTGTAATG TTATATTTTAGGGAAAGTCCTAAGTGCA AAAGTTAAAAATAATTTTGTGTGTCTAA TGACATTGCTTTGTACGAGTCACAACAT GGAAATATCAAAATAGCTAGTAACTTCT AGAAAGCAAAGGAACTTCTGAAATTAGT GGCTTACCATTTTTGAAGATTTTTTTTAA CATAAAACAAGATTTCCCACAAAATCAG TGTATTAAGATACATAAAATACATTGTG TCGAAGAGTTAAGATGTGTGAGAAGACT GGCTATTTTGTTACAAGGTCCTGATAGTA AGACATTGAGACAAAAAACCTTGCAAAA CATTGGTATACATAAAGGCTGATCACGT GACTACTGTCGTCCAAATAATACATAAG TATCCAAACCTGTTTCCATGGGAATAGG TTTGTAAGCTTGCGGTAACATCGGACTT AAATACACTTTTAAAAAAAATGTGCCAT TTGGCTTAGAATTAATAATTTTTTTTAAA GCAAAAATGGAAGCTTAGTCTTCAAGGA CTGATAACAGCTGGTAATATTTACCATT GTTTGGTGGGAATGGGGTTCTCATATTA GGCTAGCACGCTAAACATTTTCAATTAC GAAAATGTATTAGGCTCGTGTGCTACCC TAATATAAAAACCCCATATTTCCTCAGTT GAAATAGTCAGCTGACTATCCTGAAAAG CATTGACCCTCTTTTATATTTTATCTGAC TTTCAGTTCATTTTTTTAATGCTAGTGGG AACTTCTCCAATCAGTGTATTTTTTTAGT TTCCTTTTTTGGGGAACAGGAGGAGCTC AGTAATTTTTATGAAATGCTTTGACCTCA TATCCATTAACTAATTATGGTCCTAGTCA GAAGAAGCTAGCACCCTTCCCTGGTGAA GTTGATACAAATCCATTGTATGTTCCTGT CCTGCAATGATTTACATTCAGTTACAGTA CTAGTCAAAACTATATATATATGAATTCT ACTTAGGATCCAATTTTGATATATTTAAA AAGCAATTGAGACTCATGATAGACTTTA TGAGCAGGTTTAACTTGTGTGGTCGAAT AAAAGCCTTTAATTTAAATGGAAAAGTA AAAGTAACTTTTTTCAGTGACTTGATTTT TTTTTTTGTTTTAATCCATTTGGGTTCAC GTCAGATCATCGGTA 1323 3147137 5 GRHL2 TTTAGGAAAAGGCTGCTATACTGTGGAC 5.83E−05 0.007715533 3.80E−06 GAAGTCTCAGATCAGAA 1821 3147154 5 GRHL2 AGACAGATTATGTTGGATTGAGAAATGG 0.000250234 0.006855299 2.16E−06 GTGACAGTTTAAGATGTCGGGCAGGAAG TGTAGGCTCCTCTTTTAAGAAACATGAG GTGCCTG 1778 3147288 2 RRM2B TTTTTTGGCTTAGTATGTTGAAATAAACT 0.000691504 0.00650489 5.26E−06 ATGG 1312 3147309 4 RRM2B GAAAGAGGACTGTGGCGGCTCTGCTGGA 0.002509145 0.006651229 1.26E−06 GAGGTGCATACCATTTGGGATGGTGACA AGGAGTTGGAGAACGCGTGTGGAAATTG AC  133 3147316 8 KB- TCGGTTGTTTACGCACGAAACCAGCCAG 1.68E−05 0.02024896 1.20E−05 431C1.4 CCC   95 3147353 9 UBR5 CAGAGATTAAGGAACCGAGGAGAGAGA 1.40E−05 0.029777153 2.71E−05 GACCGGGAAAGGGAGAGAGAAAGGGAA ATGAGGAGGAGTAGTGGTTTGCGAGCAG GTTCTCGGAGGGACCGGGATAG 1951 3147355 9 UBR5 CGGGATCGAGATCTTCTCATTCAGCAGA 4.38E−05 0.008446581 2.80E−06 CTATGAGGCAGCTTAACAATCACTTTGG TCGAAGATGTGCTACTACACCAATGGCT GTACACAGAGTAAAAGTCACATTTAAGG ATGAGCCAGGAGAGGGCAGTGGTGTAG CACGAAGTTTTTA   57 3147362 9 UBR5 ATGATAAGGATGATGACTCTCTTCCTGC 3.58E−05 0.042037758 5.21E−05 AGAAACTGGCCAAAACCATCCATTTTTC CGACGTTCAGACTCCATGACATTCCTTG GGTGTATACCCCCAAATCCATTTGA  693 3147378 4 UBR5 GCCAGTATATGTGTCCCAATTTTTCCTTT 1.55E−05 0.014008764 7.94E−06 AATGTCAGGTGTCCCTTTAATCTAAATCC AGTTTTGTCTGACAGAGCTCTCCCATAGT ATCCTTGATACTGATATACATCCAGGAC TTGTTGAAAACTGTTACAAATCAAGCTG TGTATCTTCAGACTTGTCAAATCTATCCC ATGATTAAATAATTCTGCTTGTGAGATCT GCTTGGACTCTGTATGATTTTCCTGATCT TGATACCCTGTGAGGAAC 1937 3147416 4 UBR5 CTACACAGTAGCACAGGAGGCATTGGGA 1.05E−05 0.007966735 3.42E−06 AATCACAGGAGGCTGCACAGAATGATTA CAAAGAGTGTGGACTCTGAAGTCAAACT GCTGGATTTCCTATCCTAATCCTACCACT GTCTAGTTGTGTGATCTTGATCAAGTTCT TTAACTTCTCTCTGCCTTGGTTTTCTCAT ATAGATAGATATAGTAATACTTTTTACAT TATGGGTTTGTTATGAGAATTAAATAAG TTAGTTTATGTAAAGTGCAAAGAGCAAG GAGAAGCATGGTCCTGTCCCAGGAAGGG AGAACGGGCAGTTCCTGCAGGTCATGGG AGGGTGAGAGAGCCCAGTTGGGTATTTC GAAGTACGTTTATGTGGCACTTGTGTGTT ATGTGCCAGGTTCTCTGTTAGTAGTGAAT TGGACACAGACCAAAAAGATACAGATC ATGCATGCCCCCTTTATCTGACTGGACTA GAATGAATTCAAGTTATGAAAACATTTT ATTATAGTAATAATTTAGTGTAATAGGA AATTAAGGGCAGCCTATATGTACCAAAG TGAGAAGGGGAGGGAGTGCCTAAGTCTG TGCTCTAAGTTC  571 3147425 9 UBR5 GTCAAAGTTGAACAGCAACTCGGGGGCA 0.000504026 0.016922667 1.60E−05 GGGAGGACGTCAAGGCCTGGTAGGACA AGCGACTCTCCATGGTTTCTCTCAGGTTC TGAGACTCTAGGCAGGC   90 3147426 9 UBR5 TGGTTTTTCAGTACAGCCAGACAGATTG 3.18E−06 0.031095942 3.24E−05 GAATTGGGTAAACCTGATAATAA  175 3147427 9 UBR5 TTGAATGTATTGGAACAGGCTACTATTA 5.48E−06 0.025869674 1.89E−05 AACAGTGTGTGGTGGGACCAAATCATGC TGCCTTTCTTCTT 1992 3147613 9 AZIN1 TTGATGATGCAAACTACTCCGTTGGCCT 0.000264928 0.007282996 6.61E−06 GTTGGATGAAGGAACAAACCTTGGAAAT GTTATTGATAACTA 1750 3147677 7 ATP6V1C1 TGTGGGTGTTGACAGTGCTCATTGATTG 0.02057934 0.007555028 6.58E−06 AAATTTGAAACGTTCAGAAATCCCATAC CTGAAGATGGTCACATATTCTTTACATCA TGATTCAGTAACTATTCAACAGTTATGTC TACTAAATACAGTGAACAAAACAGTATA AATGTTTACACCATTCCCCTGTGAACAG GGCTTTTGTGCACAATAGTAAC  793 3148720 9 TMEM74 ATGGAGCTCCACTACCTTGCTAAGAAGA 0.007582294 0.010273983 6.22E−06 GCAACCAGGCAGACCTCTGTGATGCCAG GGACTGGAGTTCAAGAGGGCTGCCTGGT GACCAGGCAGATACAGCAGCCACAAGA GCTGCTCTCTGCTGTCAGAAACAGTGTG CATCCACCCCAAGAGCAACCGAGATGGA AGGGTCTAAACTTAGTTCTTCTCCAGCAT CCCCCTCCTCCTCTCTGCAAAACAGTACT CTTCAGCCAGATGCCTTTCCACCAGGAC TTCTC 1693 3148899 4 SYBU GCAACAGCCACCAAGAAGGGTTCTCATC 4.91E−05 0.006815011 2.32E−06 ACCCTGTTATTCAGGGCCAGAGTTTCTTC AGGAGTTCAGGAAGAACGCAACGTATTT AAAAGAGCCCGAAGACTGCAGGCATGA GCAGCACCCTAAAAACCA 1953 3149782 3 EIF3H AGCAGTCTGGCAGGCCTTCTCAAGTAAA 4.99E−05 0.006519112 2.50E−06 TACCAACCCTGTTTCTGCAGCAGCCTCA GCAGCAGCTCAGTCTAGACAGGGTTTCC TTCTTTCTGTTTATTTTTCTTGCTATCAGA GCCCTGATGTGTACATTTTGGAATGCTG GAGTAGCTGCTTCATTTCTATTCCTCCAT CTCCCCTCCCTCATTGAAGGGGCTGGTG GAACTAGACCAGATGTCTAACAAACCCC GATTGCTAGAGTGTCTGGCTCTGTACGT GACTGACCAATCATAATACGGTGTGCCA AGTTTTTTTTATACCTCTGACAACAGCGT ACAAAACCTGGACTGTTTC 1978 3149863 9 RAD21 GATTCAGTGGATCCCGTTGAACCAATGC 3.09E−05 0.010598225 6.84E−06 CAACCATGACTGATCAA 2069 3149864 9 RAD21 GCAGCCTGCACATGACGATATGGATGAG 0.000142286 0.006938925 5.44E−06 GAT   96 3149866 9 RAD21 AGCAGTTCAGCTTGAATCAGAGTAGAGT 5.86E−05 0.032413212 3.97E−05 GG  566 3150181 4 EXT1 TGGATTCCAAATAATGGGGCTTCTCATA 0.007337714 0.011167989 7.79E−06 AAAGATTTGGACCCTGCCCCGAGGCTTT TGGTAATAAATGTGGCCGCTTTGTTTTTT TCCCTAATTATTTCATTCGTAAAAGTCTT ATCTTCCCAATAAAGATGGTAACTCCTCT GGACTGGGTCTGCTTTTCGCATTTTCCTT C  200 3150260 1 AGCAGTTCAGCATGGGACTAGTACCAAG 0.005450518 0.009774559 1.03E−05 ACTCACACTAAGGAAGAAGGAGTTGGA ATAAATTGAAAGAACACTCTGGGGTTGT GCATTCCCCATTGCAGAATTGGGGACAC TGCTGTAAATGGGGAGTACTCACTGGA 1535 3150537 4 RP11- TTGTCATTCAACTCACAAGTCTAGAATGT 1.59E−05 0.012061709 7.83E−06 4K16.2 GATTAAGCTACAAATCTAAGTATTCACA GATGTGTCTTAGGCTTGGTTTGTAACAAT CTAGAAGCAATCTGTTTACAAAAGTGCC ACCAAAGCATTTTAAAGAAACCAATTTA ATGCCACCAAACATAAGCCTGCTATA 1956 3150666 9 TAF2 ACCTTTGGAGATGAGTATGCATCCAGCG 2.80E−05 0.007484629 3.54E−06 GCAAGCGCTCCACTCTCAGTCTTTACTAA GGAATCTACAGCCTCCAAACACA  221 3151057 1 TGGGAAGTTTAGACCAGGAAATTGCAGC 1.19E−06 0.016560632 1.54E−05 TGTATTCACATGCTATCATGCTTCGGGTA CAGAGAGGCCCTCTATGCCCCATGAGTT CAGAAACCTA 1758 3151568 4 ATAD2 CGTTTTTTAACCAGGGATGATGCCATCCC 0.000958852 0.006912877 2.11E−06 CCTCCCCGAAGGGACAGATATCTAGAGA CAGTTATGGTTGTCACAACTGGTGGGGG CAGCTACTTAGCATTTGGTAGATGAAGG CTGTTAAACATCTTACACGTACAGGACA GCTCTCCACAACAAATAATTATCTGGCC CAAAATGTCAGTAGTGCTAATTTGGGAA ACCTTTATCTAAACAATAATTATCAATG GCCACTCAAGCAGTAAGATAAAAAAGA AGTTTGATGGGGATATTTATGATGGGTG GAACAAGCTGTTAACACCTGACCGAAAC TCAACCCACTGATTGACCTTAAATGGGA AACTGATATTAGGTGCCTCCTGTGGGGA TATAATAG 1148 3151571 9 ATAD2 ATCAGATGCGCCCATCAATTATTTTTT 2.14E−06 0.01249276 1.03E−05 GACGAAATTGATGGTCTGGCTCCAGTAC GGTCAAGCAGGCAAGATCAGATTCACA 1530 3151576 9 ATAD2 CATGCAATCCACAGTAGTGACTCGACTT 0.021434136 0.007350183 7.31E−06 CATCTTCCTCCTCTGAAGATGAACAGCA CTTTGAGAGGCGGAGGAAAAGGAGTCGT AATAGGGCTATCAATA 1931 3151874 1 CACATATTGGAGTTCACTGGCAAGAACT 0.00010865 0.008065512 2.97E−06 CTAAGATAACTATGACTAATGTGTTTGA GACAATTATGGATAAGATAATAGGCAAA GACTTTGATCAGAAAAGTAATCTATAAA AATCAAATGGATATTCTAGAACTGAATA CAGTGTCTGGAGTTGAGAACACAGTAGG TGGATGTAATAGTGGATTTGTGTAACAA AAGACAAGATTAGTGAACTACAAGACA GGTCAGTAGAAAAAAATACATACTGAAG CATGTATTGGAGGCATGTAAACACAATG AAAAGCCTTTAGAAAGATAATTGGAGTC TTGGAATAGAATGGGGCCAAAGTA 1544 3151880 1 CTTTCTGCCTTAAACCCTGGTGCTCACTT 0.000986793 0.007880354 4.89E−06 CTCTTCTTTACTAATAAATGTTCTTTGTG GCATATTATTATTTTTCCATAATAGGGCA CTTCTGTCTGCCTTAAGAACCTGTTTTGG TAGATATGCTTTCTCCTCAATGATTTTCT TAATGGCATCTGGGAACTCATTTGCTGC CTCTTGGTCATCAGGAGCTGCCTCTTCTG TTATCTTAACATTTTTAAAGCCAAACTTC TTTCTAATATTATCAAGCCATCCTTTGCT GGCATTAAATTCTCTAGATTTAGATCCTT CACCTTCCTTTTGCTTTAAATTGTCATAT AATGACCGCCTTTTCTCCAATCATATTAG AGCCTATAGGTACGTCTTTCTTGTAGCAA TACTGCACCCACATAAAAGTTGCATTTTT AATACGAGATAAAAAGGTATATCACAAA AAGTGTAAGGTTTGCTGGTATAGATGCA GTAATGGCTTCATAAATTTTCTTAATTTT TTTTAACAGTGGTCCTTATGCTGGATTCA TTTATCTTGAAGGATGGGCAACTACAGC TGCAGACCAGTACACATCAAGCAATTTA ACTTTTTCTTGTAATGTCATGACTTTGCT CCTTGGGAGCACTTCCAGCGTCACTAGC GGGACTTCATATGGGTCCCTTGGTATTAT TGCAAGGTTTATGGTTGTACTAAACATG ATGAAAAATAACTGAGAACCATGAGAG ATCACTTTTTACTACGATACACAATTTAC TGGAGAGATGAACTGCCCATGTGGAGAT GATAAACATCACATGGCATTTTAAGTGA ATACAGCACTTGAGCTCACAGCAACAGC AACAGGAGGTAGCTCTGAAATTATGGTA GTAGTGCAGTATGTACTATAGTTAATCTT ATCCAGTTGTAATTTAGTACTGCATCTTT ATGTTTGTCTCAACTGCAAATGGCTCCA ATGTATAGTCTGTGTA 1541 3151942 5 RNF139 TGCGCCTGTGTGCTGAATCACTCCATTTC 0.000302186 0.01206077 9.57E−06 TTTCTCTTTGAACATCATCATCACAATCT GTACTGTCATCTTCGTTCAATTCCCTGTC AGATTCAGCAGCAGCTTCTCTTACAGCTT CCTCTGGAGTTTCATTGGGTGGAATAAA TCCATTGTTGTTAGATACATTTGAATTAT CCTTGATATCATCTTCGATGTATACTTTC TGATGGCACATTGGACAAGTATCTTGAA TGTACAGCCATTTCCGAAGGCAAAGTGC ATGGAAATAATGATTACACGGTGTAATA CGAGCAGATGTTGTAAACTCATGATAGC AGATTGCACATACATCATTTATTTCTTGT AAGCGGCTCCCTTTTATTTCAGGAAGTG AATTAATTTTCTTCACAGCAGTCCTACGA TTCATAAATGTCTTCCAGCCATTTTTGGC TTGTAAGTAGATGTTAAAATATGCATGT AGGCACATCATAAAAGCCCGAATTTTAC TTCCCGACTCAAACATCATAGTGTAAGC CCCATTTCCAAACATTACAACTCCAAAT ATAAATTCAATAATACTGCCTGTTGAAC GAACGTAGTAGACATAATCGTCAAGCTT TTCCCAGAGGACATTATAGTAGCC  725 3151996 9 MTSS1 AATCTCAATGCTAGGGGAAATAACCCAC 2.75E−05 0.013085414 6.46E−06 CTTCAGACCATCTCGGAAGATCTAAAAA GCCTGACCATGGACCCTCACAAACTGCC CTC 2011 3152016 9 MTSS1 CGCTTTAATTGATTGTCTGATAAACCCAC 0.001921299 0.006534607 2.49E−06 TTCAAGAACAGATGGAAGAATGGAAGA AAGTGGCCAACCAGCTGGATAAAGACCA CGCAAAA 1564 3152038 4 MTSS1 AAGGTTTCTGGCTCTAATCAGCCCATCA 0.002514771 0.006782061 3.70E−06 CAAAAATGAGATGAGTATTTCCCTGTTG TCATAACCCCTTAGGGTGAGGAGTGTAT CCTTGGTGACAGACCAAAATCAAATCAT TTTTACAAATATTTATGGAGTATGGTTTG AGAGGATGAAGAAGAAAAGCATGTGGA AACATGGGGCAAATTGGGACTTTTTAT 1573 3152088 9 MTSS1 TGATTGAGAAGGAATGCAGCGCGCTCGG 0.038614454 0.007217448 6.83E−06 AGGCCTC 1877 3152261 9 KIAA0196 GAGATGGTTCTGGACAATATCCCAAAGC 0.000153344 0.008032919 2.64E−06 TTCTGAACTGCCTGAGAGACTGCAATGT TGCCATCCGATGGCTGATGCTTCATA 1042 3152298 5 NSMCE2 ACTGGTGGAATGGTGATGTCTCTGACAG 0.031432454 0.00702341 4.58E−06 AAACCAACCTAGATCTGTGATTACAATA TATTTGGGAGTTATGACAATCTTATCACG AGTTTCATCTCCTCCATCTCTGTTTTCCCT GCCCCAACTCATAAACTTCCTTGTATTAA TACAAAGATGTCTTGGA  496 3152302 5 NSMCE2 ATGGCACAAAACGATGCAGATGGGCATC 0.000199853 0.012091556 8.22E−06 ACCT 1029 3152910 8 PVT1 TGGGGCTAATTATAGCACCATCCTCCTA 0.025177619 0.00679582 3.81E−06 GGATTATTACAGGAATTAAATTATTTAA CAGATGAGACCAAATTCGCACTGCCCAG AAGTTAATAAGCACTAGATAAATGTCAG CTATGATTATTAGTTACTAATCTAATTAT TATCATTAGGAAGTCATTTAATTTAACTG ATTTGACTGGTAGGTTCTTCATGAGTTAT CAATCACACAGAGATTTACCAAGGAAAG GCCATAAAGAAAAGAAGGAAGAAAATT AGCATTCTTTGTCAGCTTCCTACACATGT GATCATTTCAGGTCAGGATTTCACATTC  874 3152978 8 PVT1 TTCAGCTGGTCCAGACGCAGTGGCTCTG 0.018228464 0.007100921 6.91E−06 ACGTTCTCTGGCAG  157 3153331 2 FAM49B ACGGGCCATCTAAGGCAGCTAATTATGC 8.86E−07 0.031562714 3.42E−05 ATTGCATTGGGGTCTCTACTGAGAAAAA TTCTGTGACTTGAACTAAATATTTTTAAA TGTGGATTTTTTTTGAAACTAATATTTAA TATTGCTTCTCCTGCATGGCAAAACTGCC TATTCTGCTATTTAAAAACCCTCAATGAC TTTATTTTCTACTGCCGCCTTTTTCATGTG CAACCAAA  481 3153338 4 FAM49B GGCTTCTACTACGTATTTGGCAATATAA 0.000449203 0.008890397 4.61E−06 ATAGATAATTAGATATAAGGAATTTTGA GTCATATCCTTTAATTCCTTTGGCCAAAG GCCATTTCAAATAAAATGTTTATTTCAGA ATGCATATAAAAAGTCAGTAGTGCTGCT GGGCGTGCTGGCTCATGCCTGTAGCCCA AGCACTTTGGCAGGCTGAAGCAGGAGGA TCACTTGAGCCCAGGAGTAGAAGACCAG CCTGGGCAGCATAGTGAGACCCCCATTT CTACAAAAAAAAAAAAAAAATTAGCCA GGTGTGGTGGCACACATCGGTAGTCACA GCTACGTTGAGAGGCTGAAGTGGGAGGA TCCCTTGAGCCCAGGAGTTCCAGCCTGC AGTGAGCCACGATCACACCACTGCATTC AGTCTGGGTGAGAGAGAGACCCTGTCTT GAAATTAAAAAGACAGCCAGTAGGATG CTCCAGTGGAAAAAGATGAAGACTTTAT GTATTTTCCCTCCCCTACCTAGTCATAAT AATTTGTGACTATAGTTGGCTCTCGACTT TTCTTCTCTCTGTAAAAGTTTGTATTAGA AATAGTTTTCTAATTTCTCTACTTCGTAG TTTCTTTCCCCAACCTCTCACATCTAGTT CATTAGTGTTTGGTGAGAATTGTCTTCCC GTTTCCCTTTCATAGCTAGTTTAGGCTCT TAGCATTTCGGATCTCGATTACTGATTAC TAGCCAAGCTTGTTGCCTTCATGTACACC TGTCA 1474 3153369 2 FAM49B CTGGAACAAGTGAACTAGGAAAGAGGG 0.016492423 0.010486458 6.26E−06 AACGCCAATCCAAG  542 3153531 9 ASAP1 GAGAAAAGAGAGCACGCAAAACAACAT 0.000611594 0.015079374 1.42E−05 GGG  791 3153572 4 ASAP1 TTATTGTGATGGGAGATAGTCGTCCTGC 0.000563692 0.013482063 1.03E−05 ACTTCTGTAGATTACAGGCCAGCAGGTG GAAGCCTGGGCTGTGGAATCAGATTGGG TTTGAGTCCCAGGTCTGCTTCTTGGCCAC TGGGCATGCAAGGCCTTCATTTTC 1713 3153586 4 ASAP1 GTGAGTCGTAGACCCTGTTCCTACAGTTT 0.003557945 0.007447963 1.39E−06 CAACAAACCCTGATGGTGGCATTTCAGT TTATCGTAGAGGTTTCTTTTCCCCTACAA GGGTCATTCTCTCTTGCCCAATTTTGGCT GAGAAGGGAGGAATATCATGGCCGTTTT GGCTGTATGGTGTTACTGTATAATGATAT GGGGATTGGTGAGTGAAAAATAAAATG AACCCTCACTTGCTTAGGTACCAGTTT  517 3155043 5 KHDRBS3 GCACACGGCGACCAACTCAAACATAAAA 0.000319739 0.010247178 7.03E−06 TTTAAGTTCAGAATCTGGATTCATGCAAT CTTCAGCAAGTCTTTAGTCCTCTTCAAAT ATTTATATAATAAAGGAGCCCTAAAAAT AGCTAGACATGCACAAATGAATTGACAG GAAGCTGCTGTTTCAGAGTCCAAATGTC CTTATTCTCTTCCCATTAATATCTTTAAG GTCTTTCTACGGCCATCTCTCCTCCCTCT CTTCACATGCTCTGGCCAGTCACTCACCG TAGGAATCATAAGTCTCCTCACTGAGTC CATGTCCGTAATC 1984 3155047 5 KHDRBS3 GGCTATTTCACAACATCAGACAGTACAA 0.000192114 0.006667798 4.43E−06 TCAGTATCTGCCATATGGCTGGTCTCTGT AGACGCCCTTTGCTGTCCTCGCTGAAGG TGCCTTGTGTCTTGAGTTAGTCCACTC 1262 3155524 4 FAM135B TGCAGTCACTGCAACAATGACAATACCA 0.00247563 0.006678738 3.02E−06 ACATACCTGGCCTAGGGAATGCTGGCTC CCT  490 3156104 4 TRAPPC9 CTTGGGGCTCGGATTCTTGAATCTTTATC 0.000636171 0.01047113 6.63E−06 AGTGGGAGTCAGAAATTGCCTTTGAGTT CATTGGCATG 1914 3156387 9 PTK2 TTGGCCAACAGCGAAAAGCAAGGCATGC 0.036159066 0.008448362 6.92E−06 GGACACACGCCGTCTCTGTGTCAG  958 3156443 4 PTK2 TTTAAGAAGCTGCTCCGTGTTTGGCCAA 0.000130223 0.010054359 6.30E−06 ATTGGAGAGA  388 3158057 5 SPATC1 CAGGCCTTTCCTATGCAGCACTCGGGAC 5.48E−05 0.018175287 1.55E−05 ACTGCCACGGACGGGCTCCACGGCAAGT GAGTGGCAGCAGGTGTCACAGAATCTCT GTCTGAACACAGGGTGGGCGCATTACAA ATCAATC  745 3158586 9 SLC39A4 CTCCCGGCGATGTTGAAAGTACGGGACC 0.000385118 0.010205084 4.89E−06 CGCGGCCCTGGCTCCTCTTCCTGCTGCAC AACGTGGGCCTGCTGGGCGGCTGGACCG TCCTGCTGCT 1461 3158698 2 CYHR1 CTCTGTCATGGGGTCTTGAGACTGAGGC 0.004759574 0.010659625 7.27E−06 TTGGGCAGGAAGATCCAGGTAGGGTCGG GGCTGCCCTGGCCAACCGGCCGCTCCCA GGGAGACAGGACTCAGCCACCAGGGCTC AGCAGGCATTTTCCGAAAGCAGGGTGAA ATTGTCTCTTCCCAGGAAAAAGATTAAA CTCCTTGCAGGCTCTTGGATA  239 3158768 2 AC084125.3; GTAGAGCTGGGGTTGTCAGAGGCTAGGG 0.000189098 0.02025759 2.25E−05 RECQL4 CAGTGACTGAGGACCTGGGCAAAACCTG CCACAGGGTGTGGGAACGAGGAGGCTCC AAAATGCA  332 3160259 8 KIAA0020 ATGCCTGGCCGCTTTCCTTACTTCTTATA 0.009010521 0.018759046 1.78E−05 CAAACATTAACTCAAAATGGACTAAAGA ATTAAATGTAAAATCTGAAACCATAAAA ACTCTAGAAGTAAATCGGGGCAACACCA TTTAGGACAT  205 3162826 5 NFIB AAACAGCCTTCTTCACGCTTCGGCTCCCC 0.000288505 0.016847222 1.49E−05 TATCGATTCAAACGTAAA 1420 3163197 7 PSIP1 CGTCTCAACGGCTCGGAATCGCAACCGC 7.08E−06 0.009902923 2.89E−06 GCCGCCGCTGCCGCCGCCGTAGCTGCGC TGCTCCCGCGCGGCTCCCGCTCGGCGCC CGCTAGCACTGGGGCGCGACCAACTGTT TACCGAGAGAGGGGGGATGTTGCAGCAC CCGGCGAAGCTGTGTGGCTCCGAAGCGG ATTTTCTGGAAACCCTACGTCCCCAAGTT CGCTTTCATGTAACAGGTGCATGCAGAT GGAGAGGAAGACGCAAGCGAAGAAGAA AGGACTGGGCGAAAATAGCTCGGCCTGC CGCA 2041 3164984 4 MTAP; TTCTCAGGAGTTAGTGGTAAACCCATGA 0.01575619 0.006644381 4.63E−06 CDKN2B- ACATGTATTTTTAAACCAAATTACCCACC AS1 TCTTGGAGTTCAATCTCTGTTAATTCTTT ATTAAAGTAGTGAAGTATCAGITGTTCC AATGATATAATGATCAAGCAACCCTGGA AATTAAATCCCAAAGCAGTGCACCTTTA GTTTGTTCAGTGATAGTAGGACATCCCA CGAGCCATCATATATTTTCAAGTTTTTAT ACTCAATCTACTTTTTCAGCAATCTTTTG GGAACTATCCCAAGATAATTTACTGCAT AAGTGCATCTATCTTCTAAAAGACATTT GGAATATTTCTTAGTCTGACCTCTGCACC CTGAGACACTCTATAAAGGAAACAATCA GAAAAATTTAACAAAGAAATAAATAGGT TAAGAAGAAAGCAATCTAGGCGTTTGCA CTGAGTTTGCA  644 3165859 9 TEK GGCAACCAATATTTCCAAGCTCGGAAGA 0.001040005 0.011526316 8.47E−06 TGACTTTTATGTTGAAGTGGAGAGAAGG TCTGTGCAAAAAAGTGATCAGCAGAATA TTAAAGTTCCAGGCAACTTGACTTCGGT GCTACTTAACAACTTACATCCCAGGGAG CAGTACGTGGTCCGAGCTAGAGTCAACA 1214 3168684 4 RP11- TAGCTCACTGTCAACTTTGAACACTTGG 0.008902214 0.008733067 7.44E−06 220I1.1 G  876 3173552 6 CTCGAGTGGGTCCTGTTGGATTGAAGTC 0.001890803 0.008001967 7.79E−06 TGACAGTGGTGATTCCCTTCAACAAA  886 3173564 4 PGM5 GCTGACTTTACTATCAAAAGCACTTGAA 0.001187787 0.007799223 4.99E−06 ATTTAAAAATTATGTCCATGATTAAAAA CTTGCAGAAGTTGCCCAGCAACTATTTTC ATTCCCCAGAGGCAGAGAGTATAATGGA AAGGAGGAATTTGGGGTGAGATGTCTTT CTTGTGTTTAAATTTTCTACTCTGAACTT GGACAAGTCACTTATCTTCCTAAATCCC AATTCCTCAT 1281 3173991 4 FAM189A2 TCTCGACAGTATTCTGATGCTTGCAAAA 0.022116149 0.007416716 3.04E−06 AGAAATACTATCATACCACGTTGTTCTGT GACAGAAAGCTTCTAAGATAAGTTTTTG GAATTAAGAAGTACACATTATTGCATGA GGGTCATAATAATAGCCAGCATTTATTT GGGCACTTTCCACGAGCCAAACACCATC TAAGTCCTTTACATGCATCCTCTCCTGAG AATTGTCTTATGGAGGCAGCGTTATTA 1349 3174918 3 RP11- AACGGCGTGCTGACCTACCATCCAAATT 0.007322669 0.00657993 4.06E−06 549A6.1 TACATGATTACATGAAGAATATTCATGG TAAAGAGATTGACCTTGGGAGA  524 3175377 9 PCSK5 GCAGTGCCACTCCTGCCGACCGGGCTGG 0.015107347 0.00744564 4.09E−06 TTCCAGCTAGGAAAAGAGTGCCTGC 1864 3179420 4 CENPP GCATTTATATAGAGCTTTCGGTTTCTGTC 8.56E−06 0.008122664 4.87E−06 TGTTTAATTTGATGCTCTGCTTATTCAGT TATACTAGATGTGTTTCTCAGAGTTATCC AGTCCATACGTATTTGAAGAGACAATTT GGTGTAGAATTGTTAGTGTCCAGGCTCTT CCAAGCAAGGTCTTCCAAAGGGATATCT CAAAAATATTCCTTAGAGTTGAAGTGGC AATGTTATATAGCCTAACAATTTTCATGC TATTAAAAGCTTATAATAGCGGATCATT AAAATGCGAGTTACA 1878 3180308 6 GATCAGTTTCGAATCTGCCTCCTCGACCA 7.16E−05 0.006665582 1.89E−06 ACTAAAACTGGGGAGTTTATGTACCGAA AAAAGGAATGTAACTATGTGTGAGGAAA ACAGCAATTAGGAAAAGGATAAGGAAG CAGTCCTGACCTATGAGGGGAAAGAGGT GTCTGGGGTCTCATTGTCAAATGGTGATT TGGTGAGTTTCAGTCCGTTGCCTGAGGA AAGA  878 3180982 2 HABP4 GGGGAGACTTTTCCAGCTGGGCCAAGGG 0.000525832 0.014120969 1.08E−05 AGTCAGACTCTAAGAACAATAGATGTTG CTTTTCCCGTGTCATGTAAATTTGTTGCA CTTTTTTGGGCTGAGCTGTTAGAGGGGCT TCTCCAGAGGCTCGAGAGCAGGCCATTT CCCAAGAAGATGAAGAATGGTGACTGTG TTTTTATTGAAGGAATTTCAAATGAAGA ATAATGTTTAAAATGTGTATATAGAGAT AGTATAGACTCCTCCGCGGAAGCATGGA GGGAAAGGAGGTTGTAAAATAGACTCCA TGGAGACTCTTAGGAAGCAGTAGATTCC CGGGGGCTGTGCCTTTAGCGTTAGAGGA AACACATAGAGCTGGAACTGTTAATGGA AAGCAGTCACAGCTGAGTTTTCGGAGAC CAA 1598 3183013 4 NIPSNAP3B TGGCTTCAAATGCTATCTGTGTGTGGATA 0.027405312 0.006936068 3.26E−06 GCTCCTCCAGTCCACACCTCTTTTCTGAA TCTTTTTTCAAATTCACACATGTGAATTT GAATTCCAGGCTCATCACATCCAGGTGT GTTCCCCACACCTCCACCTGAATGTCTAT TAGAAATCTCACACCCCTCTTGTCCAAA ACTGAGCTCTTGATCTTTAACCAGAAAC TTTATCTCAGCTATTGGCAACTCCAGGTT TCTGTTTTGCTCAGGCCACAGACTTCAGA GTCATTCTCACACTGCCTTTTCTCTCATA CACCATTATGTACCTGTCAGCAGGTCCC AAATATCTAGAATTTGATTGCTTCACATC CCTATAGCAACTCTCCTGGTTCAAGCCC ATCATCATCTGGATTTTTGGGAAGTGGTC TTAACTGGTGTGCTGCCCTTC  953 3184500 2 PALM2; AACACAGTTTCCTTGAGCCTTCTGAGCA 0.001852254 0.008987807 5.92E−06 PALM2- ATCTTAGAATTATTCAGAAGCTTTCAGG AKAP2; AAACTCAAATTCTATTAATTTGATTTGGT AKAP2 TCCTTTCCAAAATGTTAATAGACATGTAT TTGCTTAAAACGTCTACCTATTCCATTTA ATTTCCTGCTGATAAATGTATTTTATCTA CAAGCAAGTAGAATATTTTGTTTTGGTTA AAGTCAAGTTTTTATAAAAGGAGGGGAA GTATAAGAGAGAGTTTCCTAGAGATACA ATATCATCTCTGGAGCAAAATGTTGAGG CCAAGTGTAAAAACAGACTATTTCTCTTT ACTTCCTGCAGAATTTCATTTCAAGGGA CCACAGCACACCCTTGAAAATTACCATT TATTTAATGCCAGTTGAACCAATGGGTA GCAAAAGAGGAGGGAGGGAACATGGTC ATAGAGACAAAATCTAACTACTATACCA GGTCTTCCTTTGTAAGAAATATTAGCCCT GCCAATATAAAACGCAGATGGACATAGA CAGAATAAGCATCGAGGACTTTTTCTTA TTTACTTGAAATCTAGAAGCTCAGTCATC TCTGCTCATCCCTGGACCCACTGGAGAG TTTTACTCACTAACAGGTCCTTTCCTGGA AGAAATAACCTCATCTCCTGCCATATTA GTTTACAATAAAAATCATTCCAAAGTGA GCCATTTCACATTGCATTTTTGCCACATG CACATTTGCTATTGAAACCACAGATTCTC AGCATAAGTAAGACATAGGTGTTTCAGA AACTTCATAAATACACGATCTTTCAGGT GCTCCTCAATTTCTTAATCAAGGTATATT GAACTCCAGTGATTAGGATAGAACCTGA AAACATCCTTTGTTCTATTGGATAGTACA ACACAGCAAGAGCACACAGTTATTTGTA TAATAAAACAACTTAATTAATGAGGAAG ATGGGATGTTTGATTCCTGCTACCACCA GTTCACTTCACAAAGGCCTTCTTCTGGTA TTACCAGGAAAACTTTCCTGCATTTTCTA GGGAAAAAGAAAAGTCGTTTATTAGGAG CACAATGCAGATATGTATCTGTGTTTTCA TAGCTTCAGCAAACTTCTTAGTAAAATTC CCATTTCAACAAAAACCAAAATACTGAT TGTTTGAATGTAGAAAGGTATAGAATAA AGACTACAAAGGGGAATTTTACCAGGGC TCCTTAGACCAGCTTCCCCAGCATAATTT TTATATAACTCAAGTAAGCCTCTGCTTCC CCTCTCCTTTCCAGTATAATATAAGAAG GTCGGAACTGTCGCACAAAAGAACTTGA TTTCAATATGAAAATATAATATGTAATTT TGGGGACTGCAGACTTTCTGCATCAAAG ATCTGGACAGCCTTAACTTTTATAAAAA TAATTTTTCAATGTTCTCTTTTACTAACC AGGAAAACAAGATGTTTTCTGAAATTAA TGACTTTTTCTATTTTGGGTCTGTTTTCTA AGTTTTTACAGGTTGAGGTATAAAGGGT CGTCTTCTCCTCATATTGCCTCTTCATAA TCACCTGGGG 1871 3184589 2 PALM2- CCTGAGGATTTCTAGCCAGAGGTCCCAG 0.000408197 0.009970306 8.46E−06 AKAP2; ATGCCTGGGCTGAGAACCCAGCGATAAG AKAP2 GGGGCGTTCCCAAAGCAGACACAGGGAT AAGAACAGAGGAGGCAGCAGCATTGCA CAGCCCCAGGCACAGTGGCAGTTAGGAT GGCTGGAGAGTAGGATAGTTCTATGGGT TGCCCAAAAAATGTGATGCGCTTCATGT TTTCTCTGACTCATGGATCTGGTAGAGAC CATAGACATGATATAGACTAACTTCCCC ATTTTTCACAAGAGGAAACCATCCTTAT GACTTACCTTAAAGTTTTTTGTTCTGTTT TGAAGGAAACCATGTGCTTCATGAAACC TACAGTTGACAAGAGAATGTACAGCTAA GAGAAAAGCTTAAGAGGCCACACTATTC GCGGAATGGCTTTAGAGGCAGATGAAGT GGTCTTTGACCACAGTTGATTGAACCAG AGCACTTATTGCTTAAAGAATAACAGAG TTCTAGAGCTGGGGGTTCTTGGGCCATG CTCCGTGTGTGGATAAGGAAAGAAATAC TGTTTCTGGGACTCTCCCACAGTCACAA AGCTGTTTTCACTGTGGCCCCTACATCTC TTAACTTTTGCTATTACTCCTATGCTGCC TTCCGGATTACTGCTGTCTATCTTCTTGC TCCACTCACTGAAGATCCTATTATAATCC CATGAAAATGTAAATTACAGTTTACTTG GGAGAGCCAGATTTTCTCTGTGCTCTTGA GTTTTTTATTCATTCAAGAAACCTTGGGC CACCGCTTTGTACATAGCA  413 3184813 5 LPAR1 TAGTCTCCAGTACCCTTCTACCTCCACAA 0.002868156 0.010363738 7.70E−06 GCTTCGAGATTGGTCCCACCACTTCCTGC CACAAACCGTCAATTTCAGGCACTCCTC 1922 3184980 2 DNAJC25; CTTCACAAGTGTTTTACTTCGACGATGTG 1.35E−05 0.009724691 6.25E−06 DNAJC25- CCTTTGATTTAATTTGGGACACTTTTTTA GNG10; GAAGGATACATTATTCGTGTTTGCAACG GNG10 GTCTTTGAAGAGCT  969 3187623 9 CEP110 TGCCAAATCTCAGGAGCAAGTTTTTGGT 0.041709394 0.008605407 4.58E−06 TTAGATAAAGAACTGAAGAAACTAAAG AAAGCCGTGGCCACCTCTGATAAGCTAG CCACAGCTGAGCTCACCATTGCCAAAGA CCAG 1741 3187835 1 TCCCGGCGTCTTCCTATTTTAGACATCTC 2.54E−05 0.007378865 4.73E−06 GCTGCCTCAGTCCCTTCTAATGTTTCCAG CCAGGCTGCGGGGGGAGGAAAAAGAGG TTACTGCTACTTTAAATGTACTGTATGAA GGCGAGGGCTGGAAAGGGGCCTGCTTGC AGGAATACCCAGTCATCTAGTTGGAAAA GCCGCCAGATGGAATACAAAAGGAGGA ACCCAGACGCTCATGGAGACAGCCTCGG TTCATAAATCAGG 1429 3188396 3 RABGAP1 GGAGACTCATTACAACTCCTGCTGAAGC 0.000570716 0.006841685 6.73E−06 TCCTAATCTTCTTCCCTTCTCTTCTACCCT TTCCCCCTACCCTCACTTGGCCTGAAGAC GTTCTCCCCAGAGTTTACCTTGCTCCCCT GGTGCTATGTGTATGGTGAACCTGGCAC TATGGCCGCGTCTGGGACTGGCCAGACA ACTGCTGCTGGCTCTCCTTATTCCAGGAA  315 3188421 5 STRBP GAAGAAATCTTGAGGGCCCAAGTGAATA 0.000850201 0.01607902 1.45E−05 ATAAATGGTGCGACGCTCAGAGGCTGGC AATAGGGGCTGTCAATGAAAAAACCACC TACAGTGGAGAAAAGAGCAGAGAAGCA AAACTTCATGTTAATCTCAGGCAATTTG GTGAAGCCAAGA  712 3188741 4 NEK6 AGCCAGCCTTTGCCACGCTGGGACTCCA 0.000100405 0.010689095 8.10E−06 GCT  534 3189377 9 PBX3 TGGCAGGACGCAACAACTCCATCTTCTG 0.006232171 0.00879012 7.47E−06 TGACTTCTCCTACAGAAGGCCCAGGAAG TGTGCACTCGGATACCTCTAACTA  989 3190108 3 RP11- CCAGGTGGCAGCTGTCTAACTGGAGCAG 0.005040635 0.006714995 6.12E−06 228B15.4 GAACTCGGAGACGGATGGGGAC  405 3191266 5 FNBP1 GTCAGGCATTGTTCCCAGTACAGTTGGT 0.023538302 0.014455398 1.63E−05 AGACAATCCTCAAACGGCTGCCTCTTGA AAGTGCACACCACGATCAGGGTC 1151 3193448 1 ACCAGCAAACAAGCCCTAAGGTGGACA 0.011131791 0.009354179 9.05E−06 AGTGCCACAGCGACTCAAGGGCACCTCC ATCGTGGTCCA  399 3196844 2 RFX3 TACACTGGAGGCATGCCCATTTGGCAGC 0.002978182 0.009216545 4.49E−06 AGATGCATCAAATTTGCTTTTGAAAGGT GCTTTTCATTGGACAGAACCATAAGACA CTATTTTGATAACATTTTGAGTATGGAGA GAGAATACAGAGCATTTTTATTATAGTG CTAGAGGGTTTGGAAGGTCATCTATTTTT CTCTGAGGAAAAAATGAGCTGTACATTT ATCAGTTCAGAGTAAATGACAGAATTGC AAGAGATTATGCTAATATGTACATAATT TGTGTACATAATTATTAAACCATGTTAAC AATGCAAGCTTCCGTTAAACATTGAATT TTAACTATTATTTGCATACCAATTCCTCT GTTTAAAGACTACTGATTCTGTATTTGGG ACCACTGCACAGATGCATTCTGCTGTTA AGTGGGGGCTGTTATAGTTAGATACTGA AGCAGAAAAAAAAGACTTGACTTTTTTT TTTTAAGTGTACATGCTACTTATGCTGAG CTGGACATACAGGAAACCATTCCATTTG GATGACTTTCTTTTATTCCAGGTCTTTTT CCTAATAGTAGTTCAATATGCTGCTATTA TAAACGAGAATTTATAGAATGCAAGGAA TGTAGCAACCTACATAACGTTATTTCCTT CAAAACTATTTCCTGGTTTCTAAAGTATG TGGATTTAAATTGTAAACAGAACCTGAA GGCAGTGTAACTGGCACACCTCACTGTT ACTTATCCCCAATTCTGTAGGATTTGGAT AGGTGGCTGGATGGACCATTGCCATTGA AGAATGTACATCAGGGATCATCGTACCT CGGCTATTA 2047 3203380 6 GTGCAAGCCTTCAAGAAGCAGCATATTA 6.62E−06 0.006812633 5.06E−06 TGATAAACCCCTCCTACAGAAAGGTATC ATTTTTATCACTGATACCACAGGATAAA TTATATATTACGCCATCTTCAAGTAACAG CTGAGGCAACAGAATAAATGCAGAGGC ATTACAATGAATCCCACTTAATATAAAG AACTATACAGACCAACACTTCTCTACAA AATTTTTTTTTCCTCATTGCCAGTTAAAT ACAGAGTTTTACTTTCATAGCTTAACAAT GAAGGGTCATACACTGAAGCCAATACAT ATACCTAGCATTTCAGTCTAAGCTTGTCC ACGTACATA  698 3203820 3 UBAP2 TCCATGTAAGAGAACACTGGTACACAAG 0.002817689 0.016552722 1.81E−05 ACAAACCATCAAATTTGTGATTTTTTTTT TTTGGGAAAACCATATTATATGATAAAT TAAAATTTTGAATAGTTTTTGTTTACTGA CCTGGGACTAAGTATCCTGGGTTTTGCA AAATATGGAGGATCTGTTTACCTTATCG CTAATGGGTACAGCAGAGAGTGGCT 1386 3204770 9 TLN1 TGTGAAACGGCCATTGCAGCTCTGAACA 0.035351019 0.008277517 1.13E−05 GTTGTCTACGGGACCTAGACCAGGCTTC CCTCGCTGCAGTCAGCCAGCAGCTTGCT CCCCGTGAGG  167 3204782 9 TLN1 CCTCCTAGCACTGGGACATTTCAAGAAG 0.023971749 0.016308237 1.76E−05 CTCAGAGCCGGTTGAATGAAGCTGCTGC TGGGCTGAATCAGGCAGCCACAGAACTG GTGCAGGCCTCTCGGGGAACCCCTCAGG ACCTGGCTCGAGCCTCAGGCCGATTTGG ACAGGACTTCAGCA  429 3205204 4 RNF38 TCCCTTTTTGCCGAGACGCAGGTGAAAT 4.84E−05 0.013951133 8.09E−06 GATGTCACCCAGGAGAACGCGGAACCCG GTCGAAAGGGTCCTCTCTGGCGTCCTTCT GCTTCCGTGGGTTTCTGGATAGGCTGCGT TTTGTTCTCAGGGGATGCAAGTTCTTCCT TTCAGGGTTGAAGCGTGAGA  245 3205740 2 SHB AGGACGCCGAGAAGTTCCCGCGGCAGCC 0.002743526 0.0122041 1.11E−05 GCGGATCCCGGCCAAGGCGGAGGCTGCG GCTCCGACGGGGCAGGAGCGCGATCCAC GGCGAGGGGCGTACGGCCAAAGGGTCC GCGGCGTGGAGCGCTCGGACCTTCCGCT CTCCCCCGGGCGTGGGCCGGGACCCCAT GAGACGCGCCCACGAGGGGCGCGAGAT TCCTAGCTTGGGCGGCGCTAGGCGGAGG GAGGTGTTGCAGCCGCCGGAGCCAGAGA GCTGCCGGCAGGAGGCGGCGGCGGCAA GAACTTGAACTTG 1054 3208576 8 PIP5K1B AGAAACTCCAGGTATTCGAGGCCTTGCA 0.003024609 0.006720951 4.71E−06 AAGTGTGATGCTCACCCTCATCTCTG 1241 3210613 4 PRUNE2 ATCTTGGATACAGGTGGCCAGACTAAAT 0.007218138 0.007096218 4.96E−06 GGTCTCTCAACTTGTCTTCAAGTTTAGGA TTTTAATTTTTGATATTTTTCACTTCTCTC TGGAAATTTGTTCAATTCTCAATTGTTGG GGGAGTG  259 3212839 7 PHBP7 CAGTGAGTTGGTGATCAGCTCGGCCACC 4.89E−05 0.017439809 1.18E−05 TTGGA 2048 3214846 2 ASPN TCATGTCTTAGAGCCCGTCTTTATGTTTA 0.00021566 0.007049369 3.82E−06 AAACTAATTTCTTAAAATAAAGCCTTCA GTAAATGTTCATTACCAACTTGATAAAT GCTACTCATAAGAGCTGGTTTGGGGCTA TAGCATATGCTTTTTTTTTTTTAATTATTA CCTGATTTAAAAATCTCTGTAAAAACGT GTAGTGTTTCATAAAATCTGTAACTCGC ATTTTAATGATCCGCTATTATAAGCTTTT AATAGCATGAAAATTGTTAGGCTATATA ACATTGCCACTTCAACTCTAAGGAATAT TTTTGAGATATCCCTTTGGAAGACCTTGC TTGGAAGAGCCTGGACACTAACAATTCT ACACCAAATTGTCTCTTCAAATACGTAT GGACTGGATAACTCTGAGAA 1938 3214862 9 ASPN TTTGATCTGTTTCCAATGTGTCCATTTGG 6.07E−06 0.006832329 4.54E−06 ATGTCAGTGCTATTCACGAGTTGTACATT GC 1023 3215437 5 PTPDC1 GGCTGGACACTGGACTAAGACACTGAAT 0.027851225 0.007438226 1.37E−06 TCTGTAAGCCCCAGTTTCTCTCTATGAAA CTCATCCCCTGCTTCACAAGCTGTTGGGC TGATTGACTGAGATAAGGTCGGTTAAAG CTTATAGCACAGGGAAAGGGCTTAGTTA ATCCAAGTTCTCTACTTTATTCAGAAACC ACAGAAACAGTTCACAAGAGTCTTCCTT TTCAGCCTTCTGGTGAACAAAACAGAAC TATTTTTTTGCAATAAAGTAGATGGTAG ATGAGAAAGTAGAAATAAGGGAACATTT ATACATTAACCTGGGGTCTA 1504 3219170 5 RAD23B CTCACCCTAAGAGGCCAGTATTACCCAG 0.001095886 0.007364521 2.15E−06 ACACCAAATTCAGACAAAAACATCACAA AAAAACTACAGACCAATATGACTTATGA ACAGATGCAAAAATCCTCAACAAAATAC AAGCAGGCTAAATCCAGCAACATATAAA AAAGATCATATGCTGTAACCAGTAAAAT TTATCTCAGAAATGCAAGGTTGGTTCAA CATACAAAATCAATCAATGTAATAAAGC ATACTAAAGGACAAAAATCACATGATCA TCTTAATAAAGAAAGAAAAAAAATTTGA CAAAATCCAACACCTTTTCGTGATGAAC AAACTAGTAACAGAAGAGAATTTCTTCA ATCTGATAAAGGGCATCCACAAAAAACC CATAGATAATATCATACTTAGTGATGAA AGACTGAATGCTTTCCCTTAAGATCAAG AACCAGACAAGGATGTTGTTGGTTCTTG CTAGTCTA  250 3220872 2 SUSD1 AGAGGCTCCGTGTGACTTCCGTCCAGGG 0.009531934 0.011306015 8.69E−06 AGCATGTGGGCCTGCAACTTTCTCCATTC CCAGCTGGGCCCCATTCCTGGATTTAAG ATGGTGGCTATCCCTGAGGAG 1917 3221558 2 CDC26 AAGTCGTAGTAGGAAATGGCGTCGTGGC 0.00011347 0.006784429 2.24E−06 ATTGAGGGGCATCCCTCCTAGAACCTCC AGGAAAAGCTCGCGGAAGACGAGGTTCT GCGGAGAGAGAGGCTCCAAGCAGTCTG GGAAGTGTAGTCCAGTTGGCTTAGCAGT AGTTTC 1172 3222049 5 ATP6V1G1 GGAGACACAGGTATTTTGGTTTCTAGAA 0.00160961 0.011736719 9.61E−06 GTGAGTGGCTTAACATACAGCTGGAAAA AATCTCTAGGTTTGGTCAGAGTCTACAT GAAAACAGACCACAAGGACAGCCAACA TATA 1561 3223277 1 ACACCACCTGTCATGCTGCGTCCTCCTCC 0.0264846 0.006904205 5.16E−06 TACTCGGGTATCTGACAGTTTCCACGAC ACGTGA  656 3223629 9 FBXW2 GTGATAAGTGCCTGTACAGAGGTGTGGC 4.32E−05 0.012411705 9.21E−06 AGACTGCATGTAAAAATTTGGGCTGGCA GATAGATGATTCTGTTCAGGACGCTTTG CACTGGAAGAAG 1833 3224597 9 STRBP CAAAGGCGAGTGCAGCTTTAGCTGCCTT 0.000148906 0.008661385 4.92E−06 GGAGAAACTGTTTTCTGGACCCAATGCG GCAAATAATAAGAA 1784 3224614 2 STRBP AGAACAAGCCTTCAGACATTTGCTATAT 6.13E−05 0.007866017 4.57E−06 T  195 3224665 4 DENND1A CATCTGCATGGGAACTCCACGCGGAGAC 0.00877735 0.010604445 9.39E−06 AAGGTGGGCAGAGGCGGGAGCAGCCGT GGGGGATGATGGGGTCTGATCCATGACG GACGGCCAGCCTTTCTTCTGCACCAAGA CTCTGGCAGCCCTCGCTGGGCAGCCAAG TTTGCCGCAACCTGCCTTTTCACAGACAG CTCTTTGTGTGTAATAAAATCCAGGCAA GTGGTGGGTGGCAGACCGCAGGGGAGT AGCTGAATT  595 3224695 4 DENND1A CCAGCTTTGCCCTTATGGTAGGTTGTCCT 8.71E−06 0.010346806 7.49E−06 TGAGTCTTTTCCCGGGTCCCTGGTTTGAT GGGCTGTTGACCGTAAGAAGTACGGTTT CTAGAGCACCTACTACCGGCAGGCATGA GTTTTAAGGACTTGATATTCTTCCCAAAG AACAGTCTCTTGAGTTTCATTTCAGAAGT TTTTACCACACTCTCTTACCATCTATACT ATTTTCTTTACTTGATAGTTTTCTTTAAAT AAGACTCAGACCTGACATCTATAGCATC TTAGCCTCATCTTCAGAGATGCCATTGGT AAAATTATAGGCTTGATATACTAGTCCC AGTTTTTTCTAACATATAAAACAATTTTA AGTGTTCATCTATGAATCACCTAATGCA CTCACGTAGCCCTAATGG   64 3224721 4 DENND1A GTGTACCAGCGCATCAATAACGGTGTCC 0.000204101 0.030370222 2.60E−05 CAATAGCAGCTTCTAATTAAATTTTATCA CAGTCCTGAATGCACCGCTGACCCACAC ACTCTTCCAAGTGGGTCCGATTCACAGG ATATTTGCGCAGTTCCGCAGATCTGCAG ATTTGAAGAGGTATTTATTCTCATTTCTG CCTTCCCAGTCCAGCAGAAGTTCTAATTT GTGGACGGCAGCTTTGGTAATTAACAAA GTGTGTTCTGTGAAGTGAAGCAGGAAAA CTCAGGACTGGGGAGTCTCGCTTTGGGT ATTTATA 2055 3225482 9 MAPKAP1 GATTCGCAAATTGACATAGCCACAGTAC 0.000357766 0.007505626 3.36E−06 AGGATATGCTTAGCAGCCACCATTACAA GTCATTCAAAGTCAGCATGATCCACAGA CTGCGATTCACAACCGACGTACAGCT  683 3225668 1 CCACCATGCTATGACTGGACATCTGATT 0.015967819 0.007726744 4.05E−06 GAATCTCAAACTCACCCTCAGCGCCCAG CACCGCCAGATTCCCGCAGGCACCTCCA GAGGGGCCTGTGTCCACCTCCGTCGGCA CCAGGTGGCTGCTTTAGAG  662 3226162 9 ST6GALNAC6 TACCACTACTACGAGCCCAAGGGGCCGG 0.008619147 0.010328204 3.83E−06 ACGAATGTGTCACCTACATCCAGAATGA GCACAGTCGCAAGGGCAACCACCACCGC TTCATCACCGAGAAAAGGGTC  235 3226361 2 PTGES2 AATTTTATGGTTCGGGTCACAGTAGGAA 0.000332253 0.01043034 6.55E−06 GCGGACAATGAGGCGGGAGGGCAGAGA GAACCGCAACACCTGGTGCCGGGTCGGG TCGTTTCCGGGGCTTTCAGTGGCCGGAA GTCGCGGCGCCTGTACTGACTCTAGGAA GGGCTGGAGTTGTTTTGAATGGGCGCCC 1724 3227198 9 FNBP1 CTCCCATCGCTTCAACGAGTTCATGACCT 0.019499011 0.006759972 5.10E−06 CCAAACCCAAAATCCACTGCTTCAGGAG CCTAAAGCGTGG  972 3227514 1 TGACTGCACGGCTCAGAAAAGAATTGCA 0.029020011 0.007096129 5.16E−06 GCTCCCTTGGCGGATCCCCCAGAACCCC CTGTGATGAGCTTTGGGAACATTTTC 1145 3227768 4 RAPGEF1 TGGCCAGCTCGCCTTGGGAAACCACCCA 0.003105755 0.009440612 3.72E−06 TGCCATCATCGTGCATATGATCTAATGG CTTTAGAGAACTAGGAACAGAGTTATTC CCCAACAAACTGACTGGGAACCTGTTCT GATGAGTATTTTAATTTGTGTGATAAAC AATCATTTTGAGAGGCTGGGGTTTGCCA TTTCCCCTTCCAAGAGGAAGTGCCTTTAC GCATTTGAAACTTGACATGCCATGAAGG TATTTTTGGAGGGCAGGGGACATTTGGG AAGTCATGCAGATTACCTAAGGCAAGTG ATACTTGCGTTTATGGTGCGTGGGGAAT CTGTAGGCACAGAAATGAGACTCAGCAG CAGAGGACAGACAGCACCTGCCTGCCTT CTGGTGGAAACTCAGTGGTGACGGGAGC TTTGCTCATTGCCTTTTTC  663 3228519 4 RALGDS AGTGGCGTGGTCAGTCACCATTGCACGC 0.012305161 0.00667609 3.78E−06 TAGCCACAGGACTATTCTCCACAGAGTC CTTCCCTCTGTCCCCTGCTGCAGAGGTGC CTGGTGATGACAGCCAGCCTGTAGGCCT TGTGCTAAAGTGTCCCTTGTATCTGCTCA GCACTCTGCAAGATAAGTGCCACTGCCA TCCTCACTTCCAGGTGGGGAAACTGAGG CACTGGAAGGGGAAGGAACTCCCACAG CTAGGTAGTGGCAGCTTGGCAATGGCGC CTCCCCGTGTGCACACAAGCCTGGGAAG GGCCAGGCACCAGGACCACATTCCTTCC AATTACAGTGGCCTTCCAACGGTCAGG 1401 3228844 4 SARDH GAGGGTCTGGGACGTCCTCAGGGCAGCG 0.001647248 0.007061409 3.19E−06 GAGTGACAGAAATGCAAGGTGTACCCCA ACCGCAG 1195 3229079 9 BRD3 ACCCAATGGATATGGGGACTATTAAGAA 0.004454644 0.010177232 9.25E−06 GAGACTAGAAAATAATTATTATTGGAGT GCAAGCGAATGTATGCAGGACTTCAA 1325 3232245 1 TCGTCTAAGGTTTCCAAAAGAAGCATCA 0.000288505 0.006672542 4.35E−06 GCCCCAGTCAGAGAAACCCCAATGTCCC AGTCCCTCGTAGGAAGGCAGTGT  383 3233209 4 NET1 TGTAGTGAGTTGTTGACCCCAGATACAG 0.000490372 0.014676043 1.08E−05 TTTCTTACAGATGTGCCATGTTGCAGTTT CTGATGAATATGAGACAGATTTGATCCC ACAACTCTGTTCTACAAACACATAAGGC GTTA 1600 3233220 6 CCATGAAATGGCTTGATGTATTCTAGAC 0.005404779 0.011800116 1.59E−05 TACTGAAAGAAAACCACTTCAAAGATTT TGTTGAAAGTTTTAGTGTTGTCTGAAATG CAAGAGGGAAGGTGATTGGTAGTGAGTT AAAAGAAAAAGAGAGGAAAAGAGAGTA GTTTTGTCTTCAAGTAAAATGTCTGGTTG TGCCAGACATTTCACAAGTGTGAAAGGA GATAGGAGAAGCTCAACTTGAGGGCGTG TAGTAAGTTGTAGAAGGCTCGAGGGGAC GTGGACTTATTTGCCTTG 1768 3233333 4 C10orf18 GCCAATCATGAAGGACCGCGTGCTGTAT 0.002531721 0.006884206 4.90E−06 GACTCTGTTTATAGGAAATGGTCTGGAA TAGGCAAATCTGTAGAGACCGAAAGTAA ATTATGGTTTCCTAGGCCTAGGAACCAG TGAGGGGTGAGGAGGATAGCTAAGGGG TAGAAGGTTTCTTTGGGGATAATGAAAA TACTCTAAAATTGATTGTGGTGAAGGTT GCACAATTCTGTGGATATACTAAGCACA ATTCTGTGGATATACTAAAAGCAATTGA ATTGTACACTTTATGTGGGTGAATTGTAT GCCGTATGAATTATATCTCAACATTGTAT TAGAAAATAAAATTAATGAAGCATAGAA GTTACGGAGAACTACTG 1219 3233453 9 FBXO18 TGAGACGGTTTAAGCGGAAGCATCTTAC 0.003781407 0.008479823 5.51E−06 TGCCATTGACTGCCAGCATTTGGCTCGG AGTCACTTGGCTGTGACCCAGCCCTTCG GTCAAAGATGGACAAACAGAGATCCGA ACCATGGTCTCTATCCTAAACCGAGAAC A 1791 3233454 4 FBXO18 TGTCCAATCTGTCACTAGGTCCATGTGTC 0.006245159 0.006903255 5.00E−06 ATTGTTTTTCCTCCAAAATATTCCTTCAT CCTGAGCTCTTTGTCACCTAGGACCTGG ACTACTACAGTAACCTTGCTCCTTGACTT CAGA  678 3237409 9 CACNB2 AAGGATCTGATGGAAGCACGTCATCTGA 0.006442959 0.009187946 6.21E−06 TACTACCTCAAATA 1367 3238738 9 ARMC3 CAGAGCCAGCTTCTGGACGAAATACTGT 0.001558259 0.006682987 5.03E−06 TCTCAGCAAAAGCGCCACCAAAGAAAA AG  219 3238928 1 CCTGCTAGTGGCACATCCATCAGTACAT 0.048552369 0.014256799 5.10E−06 GAACTGAATATGTCACAGAGTGTATCAA AGCTAAGGTAGGTGCCTGTCCCACCATC AGTTGAATGAGAAGGTTTCTGATATCAG AAATTGGGCTACCCTGCTTTGCCAAGAC TCTCTTTTCCAATCTCTCAAAGGCAGATA ATAACACTAATGGACAATGTGGCCATGA GCATTAAAACAAATCATTAGGCTGGAGG CTTCTCATCAGTGCTTGAGGGCAATTTCA CCACCTGGGGCTTTC 1264 3242177 5 PARD3 AGTCTGTCTGGGTCAAGTCAATGGAAAG 0.044114238 0.007389697 4.64E−06 AG  609 3243790 1 GCCTCATGGGCGCAAACACTCGGGAGCA 0.004987466 0.009165899 5.63E−06 CACGTGGA  706 3245925 4 WDFY4 GGGCCCACTGGCGACAGCCCAGAGTCCA 0.000481864 0.010700417 3.49E−06 CTGGAGCACCCCATCTGCCGCAGGACAG CTCGCAGCCCTGTGGCAGCTTTGCTGAC CGCCTATCACCTGGGA  983 3245926 4 WDFY4 ATGAAGCAAGGAAACGGCTGGTACTCTG 0.001628328 0.007000229 3.48E−06 GGAAG 1301 3246011 3 RP11- AGGTCTCAATCAACCACCATATGTGTGA 0.003133247 0.007051697 5.62E−06 507P23.3 GTGAAGGAACCTTCAGATAATTTTGCTT CCCAGACTTCAAGTCTTTCAGCTGGGGT CCAAGACATCACAAGGCAGAGACAAGC CCTCCTGGAATTCCCCACCCACCGTGAG CATAAGAAAACT  906 3247960 1 GGCAGAGAGCAAGCCGGGAAGTTGGTG 0.008412239 0.007147019 6.25E−06 AACTTGGAATTTGATGAGCTCCTTGT  846 3248990 1 TTTGTATTCGTTGCTCCCTCAGAGGTGGA 0.001314314 0.007676396 8.78E−06 GGTGAGGGGAAAGTGAAGTGTAGTGGTT CCACTCTGATCACAAAATAAACTCCTGG GTTGACGCCTCACCCGCGGTTTGATGTTC AGAGCACACAGCGCCCGCCGCCTGAGTT AGCCTGAATTAGCAGTCCCGCAGTAACA GCAGC 1981 3250089 9 DDX21 AGAAATGGCATGATTCACGACGCTGGCA 0.007597824 0.007720875 6.45E−06 GCTCTCT 1728 3251407 2 DDIT4 CAGAGACGACTGAACTTTTGGGGTGGAG 0.002001825 0.00976791 1.12E−05 ACTAGAGGCAGGAGCTGAGGGACTGATT CCTGTGGTTGGAAAACTGAGGCAGCCAC CTAAGGTGGAGGTGGGGGAATAGTGTTT CCCAGGAAGCTCATTGAGTTGTGTGCGG GTGGCTGTGCATTGGGGACACATACCCC TCAGTACTGTAGCATGAAACAAAGGCTT AGGGGCCAACAAGGCTTCCAGCTGGATG TGTGTGTAGCATGTACCTTATTATTTTTG TTACTGACAGTTAACAGTGGTGTGACAT CCAGAGAGCAGCTGGGCTGCTCCCGCCC CAGCCCGGCCCAGGGTGAAGGAAGAGG CACGTGCTCCTCAGAGCAGCCGGAGGGA GGGGGGAGGTCGGAGGTCGTGGAGGTG GTTTGTGTATCTTACTGGTCTGAAGGGAC CAAGTGTGTTTGTTGTTTGTTTTGTATCT TGTTTTTCTGATCGGAGCATCACTACTGA CCTGTTGTAGGCAGCTATCTTACAGACG CATG 1895 3251899 2 SEC24C AGCTGGAGCGCCGTTCTCTCCTGCTGGG 0.009861702 0.006512534 6.03E−06 ACACCGCTTGGGCTTTGGTATTGACTGA G 1279 3253147 5 KCNMA1 ATGCATAAAGTAGTGAACAGGCCCGGTG 3.45E−05 0.008675527 4.82E−06 CTGATGACAGGACGGACTCTGT 1817 3256044 9 LDB3 TGCCTGCATCTACCTACAGCCCGTCCCCA 0.002743526 0.00667878 5.31E−06 GGGGCCAATTACAGTCCCACTCCCTACA CCCCCTCCCCTGCCCCTGCCTACACCCCC TCCCCTGCCCCTGCCTACACCCCCTCACC TGTCCCCACCTACACTCCATCCCCAGCAC CAGCCTATACCCCCTCACCTGCCCCCAA CTATAACCCTGCACCCTCGG 2065 3257391 9 KIF20B TTGAAGACATGCGAATGACACTAGAAGA 0.00010865 0.006823504 5.42E−06 ACAGGAACAAACTCAGGTAGAACAGGA TCAAGTGCTTGAGGCTA 1211 3258781 9 TMEM20 ATGTCCCTCGCTGATGCCACAGTTATCAC 0.006523669 0.007770014 6.38E−06 GTTTAGCAGTCCAGTGTTTACGTCCATAT TTGCTTGGATATGTCTCAAGGAAAAATA TAGCCCTTGGGATGCTCTTTTCACCGTGT TCACAATCACTGGAGTGATCCTTATCGT GAGACCACCATTTTTGTTTGGTTCCGACA CTTCGGGGATGGAAGAAAGCTATTCAGG CCACCTTAAGGGAACATTCGCAGCAATT GGAAGTGCCGTATTTGCTGCATCGACTC TAGTTATCCTAAGAAAAATGGGAAAATC TGTGGACTACTTTCTGAGCATTTGGTATT ATGTAGTACTTGGCCTCGTTGAAAGTGT CATCATCCTCTCTGTATTAGGAGAGTGG AGTCTGCCTTACTGTGGGTTGGACAGGC TATTTCTCATATTCATTGGGCTCTTTGGT TTGGGGGGTCAGATATTTATCACAAAAG CACTTCAAATAGAAAAAGCAGGGCCAGT AGCAATAATGAAGACAATGGATGTGGTC TTTGCTTTTATCTTTCAGATTATTTTCTTT AATAATGTGCCAACGTGGTGGACAGTGG GTGGTGCTCTCTGCGTAGTAGCCAGTA  949 3258921 4 HELLS GGTGTTAATATCAGAACCAGTATCTACT 0.003504013 0.009449736 7.75E−06 GTGTCATCTAAAACAATTTAGGAGGTTA TCTGAATTTCCTTATATATCTAGATTTTT ATCGATTTCTGTGAGTCATTTCATTTGCT GCTACTCTGGTGTTTATGCCCTTACTGTG CCCTATTTATAG  272 3258959 2 HELLS; TTCTGGCTGTACTGAAGGGACTTTCATG 9.61E−05 0.020646723 1.09E−05 RP11- ATTTCTTCGTTTTTGTACTCTTAGTTTTAT 119K6.6 AATATTGCATAGTAGCTAAGGCCTGGCT GTAGCAGTTATAAACTGTTCTGCAAGTG CGGGAAGTAATAGTTATTCCTATCTCAA GGATGTGGGGTTTAAATGGGTTAGTGCA CAAAAGGACATTTATTAAATTTAGTCAT AATCATCTCAAGGACATGGTAAGTGAAA GAGTGTACATAAAGTACTTAATGTAATG TTTGCTACTTAATGTTCAATAACTCAAAG AGACCACCACCACTACTACATTTTACTTT TATTAGTAATTAATAATAATTAATAATTA GTAATTCAGTGGTAATTAGTATACTACC AAAGAAAGTACTTGAGCAGAAGAGCCA AAATTCAAACCATAGAATCATTTTACTG TGCTTTTATTCTACCTCAAACACTAATCT CCAGGCCTTGGATAAAGGGATTATTTCT CTGAAGGGGAAAGTTATCCTCTTTTTGCC CAAGTCACACTTGTGTCATTTCTTATACT GTAAACATGTGGTTCCAATTCTGAGGTA TTTTCCCGGTTTGTAGGACCCAAAAAGA AGTTAGGCTTGAGAAATTTTAAGTGAAG AGAACAATTCTAGTTCAGAGTGATTGGC TCTTCCTAAAAGCTGACATTTGACTGAA AATTTTGAGGGGAGGGAAAGAAACAAT ACCTTTTACGGCATGTAATAGGAAGAAG ACCTGGATTTTAGTTGCTGCTCTGATGTC CCAACTTGGGTAAGGCAACATAACATAA ATGTCAGTTTCTTCAGATTTGTGATGAAG CTGATAATCCATGCTCAGCTTCCTTTATG GGTCTCTTGCCTATCAAATAAGGTACAG TATGTGAAGATACATTGCAGATTATCTT ATGCATTGCTTCAGGGGATGATTAAACC ATCCTTTATTATAGCCAGAGTCTAGTCTA AGGGAAGAAGGTCATTCTCTATACCAGT GAAGGCTCCATCCAAACCAGTGTT 1666 3260203 1 TTTTGTTGTGCCTAATAAACTGCTCTCCA 0.014792007 0.007368352 7.25E−06 CTCAATGAATATTGTTACTTGACTCCCAT TACAACTC 1616 3260608 6 CTTGAGAAGGTTACTGAGTGAGTTATTG 0.000117217 0.009690655 4.08E−06 GGAGTC  790 3260609 2 SCD; GCCTAAAGTATACAACTGCCTGGGGGGC 0.000153753 0.01256466 6.16E−06 AL139819.1 AGGGTTAGGAATCTCTTCACTACCCTGA TTCTTGATTCCTGGCTCTACCCTGTCTGT CCCTTTTCTTTGACCAGATCTTTCTCTTCC CTGAACGTTTTCTTCTTTCCCTGGACAGG CAGCCTCCTTTGTGTGTATTCAGAGGCA GTGATGACTTGCTGTCCAGGCAGCTCCC TCCTGCACACAGAATGCTCAGGGTCACT GAACCACTGCTTCTCTTTTGAAAGTAGA GCTAGCTGCCACTTTCACGTGGCCTCCGC AGTGTCTCCACCTACACCCCTGTGCTCCC CTGCCACACTGATGGCTCAAGACAAGGC TGGCAAACCCTCCCAGAAACATCTCTGG CCCAGAAAGCCTCTCTCTCCCTCCCTCTC TCATGAGGCACAGCCAAGCCAAGCGCTC ATGTTGAGCCAGTGGGCCAGCCACAGAG CAAAAGAGGGTTTATTTTCAGTCCCCTCT CTCTGGGTCAGAACCAGAGGGCATGCTG AATGCCCCCTGCTTACTTGGTGAGGGTG CCCCGCCTGAGTCAGTGCTCTCAGCTGG CAGTGCAATGCTTGTAGAAGTAGGAGGA AACAGTTCTCACTGGGAAGAAGCAAGGG CAAGAACCCAAGTGCCTCACCTCGAAAG GAGGCCCTGTTCCCTGGAGTCAGGGTGA ACTGCAAAGCTTTGGCTGAGACCTGGGA TTTGAGATACCACAAACCCTGCTGAACA CAGTGTCTGTTCAGCAAACTAACCAGCA TTCCCTACAGCCTAGGGCAGACAATAGT ATAGA 1827 3261067 9 TLX1 CCTGGCCACCGGCTTGCCCACCGTGCCC 0.000620704 0.007366558 7.93E−06 TCTGTGCCTGCCATGCCGGGCGTCAACA ACCTCACTGGCCTCACCTTCCCCTGGATG GAGAGTAACCGCAGATAC 1319 3261680 9 NFKB2 AGGTGAAGGAAGACAGTGCGTACGGGA 0.00620627 0.007045917 5.59E−06 GCCAGTCAGTGGAGCAGGAGGCAGAGA AGCTGGGCCCACCCCCTGAGCCACCAGG AGGGCTCTGCCACGGGCACCCCCAGCC 1087 3262195 7 USMG5 TCACCCACCTGCCAAAGCCGCAAATTCC 1.18E−05 0.011314813 4.65E−06 GCAGCTGGTGTCCTT 1308 3262201 9 PDCD11 GGAGGTACAAGAAAGATCCACAAACCA 0.003266926 0.008070873 4.26E−06 GAGAAAGCTTTCCAGCAGTCAGTTGAAC AAGACAACTTATTT  714 3263441 1 CCCCTCGTCCCTTGCTGCTGAGTGAAATT 0.000273283 0.011872655 6.77E−06 CTGCTCCCTGCTCCCAGCTCATTTTCATC CCGTCCCACAAGCTCCCAGGTATAT 1994 3263816 9 SMC3 GTGACCAAGTCAGCCATCGGGGTGCTCT 2.66E−05 0.00676427 4.02E−06 AACTGGGGGTTATTATGACACAAGGAAG TCTCGACTTGAATTGCAAAAAGATGTTA GAAAAGCAGAAGAAGAACTAGGTGAAC TTGAAGCAAAGCTCAATGAAAACCTGCG CAGAAAT 2066 3263824 9 SMC3 CTTCAGAAGAGTATGGAGCGCTGGAAAA 0.000146929 0.007441363 6.30E−06 ATATGGAAAAAGAACATATGGATGCTAT AAATCATGATACTAAAGAACTGGAAAAG ATGACAAATCGGCAAGGCATGCTATTGA AGAAGAAAGAAGAGTGTATGAAGAAAA TTCGAGAACTTGGATCACTTCCC  297 3265208 9 TDRD1 ATGTGTGTTGCTGGGATAAAATTGCAAG 0.011264381 0.012192501 1.62E−05 CCAGAGTGGTTGAAGTCACTGAAAATGG GATAGGAGTTGAACTCACCGATCTCTCC ACTTGTTATCCCAGAATAATT 2080 3266824 7 C10orf46 ACATCCTCTTCCATGAACAGCTTTGTGAC 1.60E−05 0.006900786 2.85E−06 AGAGCTCCTGAGTGTGTGCAGCCCCCAC TGTGCTCTGAATACAGTCTCTGCAGC 1340 3268609 9 ACADSB CCTTCTTAGTAGATCGTGATACTCCGGGC 0.00453157 0.007532844 4.87E−06 CTTCATATAGGGAAACCTGAAAACAAAT TGGGGCTCAGAGCTTCTTCCACCTGCCC GTTAACATTCGAAAATGTC 2072 3268687 6 CTCTATGGAAAGCTTTGTTTGCTTCCTAC 0.000408197 0.006896832 5.98E−06 AAATACATGCTTATTCCTTAAGGGATGT GTTAGAGTTACTGTGGATTTCTCTGTTTT CTGTCTTACAAGAAACTTGTCTATGTACC TTAATACTTTGTTTAGGATGAGGAGTCTT TGTGTCCCTGTACAGTAGTCTGACGTATT TCCCCTTCTGTCCCCTAGTAAGCCCAGTT GCTGTATC  549 3270603 1 ATGGCGTCGGGAAGAGCCAGGGACCCG 0.001587412 0.010264099 7.78E−06 GCTGTGCGCTTGGATCCATCACTGCTCTG GGC 1608 3270778 1 AAGGCCAGCACAGCGTGGTAAAGCATCA 3.33E−05 0.00732201 4.59E−06 GATCTCTGGCTCTGCATGCCCCGCCGCTG AGCCTCAGCCCAAGCACACT 2033 3271719 9 PPP2R2D CGGACATCATTTCCACCGTTGAGTTTAAT 1.57E−05 0.006604433 4.28E−06 TACTCTGGAGATCTTCTTGCAACAGGAG ACAAGGGCGGCAGAGTTGTTATTTTTCA GCGTGAACA  752 3271859 9 JAKMIP3 GACAAGCTGTTAAGATTCCGGAAGCAAA 0.007566793 0.009133827 1.66E−06 GA 1317 3273492 2 LARP4B GTCGCAGAGCGCTGTGTTAACCACAAAC 0.000163031 0.008013788 4.84E−06 GAGACACTCTCCCACTCAGTGCGAGGGC GAGCCGCTGGTTAGGAGCTTGCAGTGTC TGAGGCCTGTGGGATCCTCAAGTTGGTT TTCTTCTGTGAGTTGGATTCTCCCCCTCT TGAAAAAAAATCGATTTTTCAGGATTTA ATTAATACAAACCTTATTTTAGGTTGGTG CTAACTGGAGGTGATGCATAAGTCTGA TTTTTTTTTCCAAGATAGAAAAAGCATTT ATCCTAACAAATTGGTATTTTTTATTAAG CCTCCATGTGGCTCTGAATGCAAGCTAT ATATAGTGAGTTTTTCTAAATTAAGGGA ACTCTGCTTTTTTTTTTTTTTTTTAAGTAA CTGGTCTGTAAGTGCATATCTCTAGAAC GTCCCCGCAGATGAATGAGGGCCAGTGG CCTTGGCAGAGGCAGGTGTGGCCTCGTA GAGGCAGTGCTGGCCGCGCCAGGGCATC AGTGCTGATGTGGGAGCTGTGCTTCCAC CTAAGCCGTTGGTAGGGGACTGTGGCAT TTAAGAATGTAGAGAGCGCATCCTTTTT GATCTCCTGGGCGGAGTGAACCTGCAGG GGCCACCCCAGAAACCTTGGTTCTGATG CACTGCAAGCAAGTAACCAGCTTCTCAC TCCAGTTTCAAGTGGCTATTATGTAATAT AAATTCAAAGCACATTGTGAATAGAACC TACATGAAAACATACACTTTGTTGCCCA CTGACATGTTA 1831 3273589 7 IDI2-AS1 ATCCAGAGCTCGCTGGGCATCCACCCGG 0.045476068 0.007550062 5.19E−06 TGGGAGACAGGCCAGCACGACCAAGTG GCCAGCACACCA 1134 3273785 9 ADARB2 TAAAGTAAGCATATTGTCAACCTTCCTC 0.041003559 0.007815956 5.26E−06 GCTCCTTTCAAGCACCTGAGTCCTGGCAT CACAAACACGGAGGATGACGACACCCT 1465 3274485 1 AAGTTGGCCACAAGCACCGTGAGTATGG 0.015428709 0.009244812 1.10E−05 CGTGGGTCGCCCTCTTCCCTGTCTCCCTG CTGGACACCCACCCACCCCTTAGCGCCT GCAGAGAAGTCCCCCCAGGAGTCCAGGC CTGGGTCCCTGTGGCCCTGGGGGGTTTG TGGCGACCCCAACACGAGCTCTCTGCGA CTGCACG 1682 3276980 1 TGATCCATTAAGTGAGCTGGGGTTTGAA 0.024015481 0.007284984 4.12E−06 GTTCAGAGGCGTTTGGTGGAACACGTGG ACGGGCTAATAAGACGCTGTGGATCCAT GGGAAAAGGATGGGCACGA 1116 3277460 1 GGCCTTCGATGCTGGCACTGTCTTGGCG 8.36E−05 0.007347087 4.76E−06 CCTGGCTCTACATCATGACAGTGTGACA AGGAAGACAGGCTGCCTGCTGACCATCT TTGGGACAGAGAAGCTTAATATC  468 3280630 2 NEBL TGGTAGACCTCTGGGATCCTTTTCTGTTC 0.00349637 0.007402615 5.15E−06 ACTCACACACCACTGAGATAAGGAGTGA AGTGTGGGCTAAATAGGGCTGAGGCTTG GGCAAGGGCATTTCTGCCAGAGCACCAG AGACGTCAGCATCTCAAGGGCACTGTGG TATGGAAAAGGACGCCACATGAGTAAAT TTTA 1232 3281132 4 PIP4K2A TGTGACCAGCAGTACAGAGAGAACTATA 0.000412342 0.008458062 6.54E−07 CTGTGTTTGCCAAAGGGGATT 1093 3281422 7 KIAA1217 CGTTTCTGCCCGACTTGCAGTTTCAGGGC 0.000272577 0.00776324 3.40E−06 ATGCCAGGACTGCAGCACCCTCTCCGTC CTCCCCCGGAAACGACTTTCAATTCACCT GGAGGCTCTCGAGGCTCCCCCGCGGGCG GGTAGCGTGACAGTGGGTGCAGAGGAG AGGGAGGAGCGCGGGAACGGCGGCGGC CCCAGTGCGCCTCCCGCTTGCTTGGCGA GAA  926 3281437 1 TGCCTTTAAAAAGCTGCGCTAGAGGTTT 0.00877735 0.010032762 6.39E−06 AGGGGGGAAGAGTGGGATAGACGGTGT GGGAGAGTTGGTTTCCACGCTCCTGTAG 2017 3282231 9 YME1L1 TTTAAACCCAATGAAGGAGTTATCATAA 4.43E−06 0.006735584 3.51E−06 TAGGAGCCACAAACTTCCCAGAGGC 1970 3283993 2 KIF5B TACTGTGCGTAACTCTCAGTTTGTGCTTA 0.000784922 0.007852174 3.97E−06 ACTCCATTTGACATGAGGTGACAGAAGA GAGTCTGAGTCTACCTGTGGAATATGTT GGTTTATTTTCAGTGCTTGAAGATACATT CACAAATACTTGGTTTGGGAAGACACCG TTTAATTTTAAGTTAACTTGCATGTTGTA AATGCGT 1820 3283995 2 KIF5B AGGACATGGTATCAAGCAGTCATTCAAT 5.94E−05 0.008521667 5.86E−06 GACTATAACCTCTACTCCCTTGGGATTGT AGAATTATAACTTTTAAAAAAAATGTAT AAATTATACCTGGCCTGTACAGCTGTTTC CTACCTACTCTTCTTGTAAACTCTGCTGC TTCCCAACACAACTAGAGTGCAATTTTG GCATCTTAGGAGGGAAAAAGGACAGTTT ACAACTGTGGCCCTATTTATTACACAGTT TGTCTATCGTGTCTTAAATTTAGTCTTTA CTGTGCCAAGCTAACTGTACCTTATAGG ACTGTACTTTTTGTATTTTTTGTGTATGTT TATTTTTTAATCTCAGTTTAAATTACCTA GCTGCTACTGCTTCTTGTTTTTCTTTTCCT ATTAAAACGTCTTCCTTTTTTTTTCTTAA GAGAAAATGGAACATTTAGGTTAAATGT CTTTAAATTTTACCACTTAACAACACTAC ATGCCCATAAAATATATCCAGTCAGTAC TGTATTTTAAAATCCCTTGAAATGATGAT ATCAGGGTTAAAATTACTTGTATTGTTTC TGAAGTTTGCTCCTGAAAACTACTGTTTG AGCACTGAAACGTTACAAATGCCTAATA GGCATTTGAGACTGAGCAAGGCTACTTG TTATCTCATGAAATGCCTGTTGCCGAGTT ATTTTGAATA 1621 3284211 9 ITGB1 AGGAATGTTACACGGCTGCTGGTGTTTT 1.31E−05 0.01042158 1.05E−05 CCA 1648 3284305 9 NRP1 GAGCACGCCAGGATACGAAGGTGAAGG 0.006429597 0.011846842 1.13E−05 AGAAGGTGACAAGAACATCTCCAGGAA GCCAGGCAATGTGTTGAAGACCTTAGAC CCCATCCTCATCACCATCATAGCCATGA GTGCCCTGGGGGTCCTCCTGGGGGCTGT CTGTGGGGTCGTGCTGTACTGTGCCTGTT GGCATAATGGGATGTCAGA 1762 3284324 9 NRP1 AAAGCCCACGGTCATAGACAGCACCATA 6.28E−06 0.008755286 5.38E−06 CAATCAG  110 3289058 9 TIMM23 TCTGACAGGACTAACACTTACCAGCCTC 2.58E−05 0.018804344 1.65E−05 TATGCACTATATAATAACTGGGAGCACA TGAAAGGCTCCTTGCTCCAACAGTCA  673 3289482 2 A1CF AACAGTGCTGTGCCAAAAACCTGTGGAT 0.04509417 0.00800955 7.31E−06 T 1757 3290799 9 CCDC6 TGTCTGCACAAGGATTAAGACCTCGCAC 1.95E−05 0.009372214 7.09E−06 TGTGTCCAGCCCGATCCCTTACACACCTT CTCCGAGTTCAAGCAGGCCTATATCACC TG 1999 3290817 9 CCDC6 AAGCCGAACTAGAACAGCATCTTGAACA 6.16E−06 0.007807125 6.97E−06 AGAGCAGGAATTTCAGGTCAACAAACTG ATGAAGAAAATTAAAAAACTGGAGAAT GACACCATTTCTAAGCAACTTACATTAG AACAG  920 3292591 2 PBLD CTTGATATATGGCTTGAGAATGATAATG 0.000264928 0.00979269 6.69E−06 TAAAAGGAATTCTTCTCTTACTTCAATAA AATGGGTTTTAACATAACTTTAAATTCA GTTAAATATACAATATTGAATACCTATA GTTGACTTTGGGATGGGGACTTTTTCAA GTCATTAAGAGTGTTTGTTTAAGGTGATC TCATTGATGGTAGTTCTCAGCCGTCTCAA AAACTGCAAGCTAATCAGTCAGACATTC 1732 3292766 4 SLC25A16 GCCGCACAATTATAGCTCTCCGTGACCT 0.000164774 0.006568018 1.05E−06 CCAACTGTTGGCTCACGTCATCCTCCAGC CTTAGTCTCTGAGTACTGAGGCACACCA CCATGCCTTGCTAATTTTTTTTTTTCTTTG AGATGGAGTCTCGCTTTGTCGCCCAGGC TAGAGTGCAATGGTGTGATCTCGGCTCA CTGCAACCTCGGCCTCCTGGGTTCAAGG GATTCTCCTGCCTTAACCTCCCAAATAGC TGGGACTACAGGCGCCTGCCACCATGCC TTGCTAATTTTTTTGTATATTTGATAGAG ACGGGGTTTCACCATGTTGGCCAGGCTG GTGTCGAGCTCCTGACCTCAGGAGATCT GCCCGCCCCGAGCTGCCAAAGTGCTGGG ATTGCAGGCATGAAGCACTGCGCCCAGC CGATTTTAAAAAATTTTTTGTAGAGATG AGGTCTCACTGTGTTTCCCAGGCTGGTCT CAAACTCCTAGTCTCAAGTAATTTTTCTA CCTCAGCCTCCGAAAGTGCTGGGATTAC AGGTGCGAGCTACTGTGCCTGGCCTGTT ATTCACCTTTTTATAAAAGGAGCAACCC ATTTTTTCAAGTCATTACTAGATGTACAG TATTGTAGAGAAGTCTATATTATTGCTTT AGAAGCATGCCAAGCTCGAAGGGCTGGC CTGGACTCTGACCTATGCTAAAGCCCAT GTATGCACTTTATTCTACTTTCATCTATA CTTTTCCCCAGTGGCACATGGTAGGGTC GAAATACA  193 3293219 9 TYSND1 GCATAATCACCAGCAACACCCGGGACAA 0.037563396 0.014951746 2.22E−05 TAA 1413 3293539 2 PCBD1 GAATTTAGACCTTTTCCCTGCACCACTCT 0.00020953 0.012455715 5.62E−06 CTTCATCCTGGGGGCTCTGTTACACTAAT TTGAATAAACTCTCCCCTTTCTTTGCAAC TTCCCAGCAACAATAATGATTTTCTTGCC AGGCCGTCTCTTGCTCCCTAATTCATTTC CCAGGAAGCTGTGATACAGGGTGAAATA AAGTC  905 3293767 2 PSAP CTGCTGGTGGCTTGGGACATCAGTGGGG 6.74E−06 0.014379385 1.31E−05 CCAAGGGTTCTCTGTCCCTGGTTCAACTG TGATTTGGCTTTCCCGTGT 1194 3294169 2 P4HA1 TTTGAGCATCCAGTTTTAGTATTTCACTA 3.50E−05 0.008388232 5.05E−06 CATCTCAGTTGGTGGGTGTTAAGCTAGA ATGGGCTGTGTGATAGGAAACAAATGCC TTACAGATGTGCCTAGGTGTTCTGTTTAC CTAGTGTCTTACTCTGTTTTCTGGATCTG AAGACTAGTAATAAACTAGGACACTAAC TGGGTTCCATGTGATTGCCCTTTCATATG ATCTTCTAAGTTGATTTTTTTCCTCCCAA GTCTTTTTTAAGAAAGTATACTGTATTT TACCAACCCCCTCTCTTTTCTTTTAGCTC CTCTGTGGTG  884 3294190 9 P4HA1 CCTGAACATCAGAGAGCTAATGGTAACT 0.000151311 0.012053017 9.96E−06 TAAAATATTTTGAGTATATAATGGCTAA AGAAAAAGATGTCAATAAGTCTGCTTCA GATGACCAATCTGATCAGAAAACTACAC CAAAGAAAAAAGGGGTTGCTGTGGATTA CCTGCCAGAGAGACAGAAGTACGAAAT GCTGTGCCGTG 1767 3294612 9 USP54 AAGCATGTTTGGTGAGCTGCTGCAGAAT 0.002152759 0.006663838 5.69E−06 GCCAGCACCATGGGGGATCTGCGGAACT GTCCA 1582 3295307 7 SAMD8 TAGTCCGCATTATTTAACTGACTGGTTCT 7.16E−05 0.008856807 3.98E−06 AAGGATAAGTTCTGATTTCAAAGGATAC AAATAAATAGAGCTAGAAGTTCTATTTT TGCCCTTGCAATTCTGGTCAGAAAACTA TGGAGAGGATAGCCACATAAAGAATTCT TGCAGCACAGCCACGAAAGGTTTC 1502 3295752 5 C10orf11 AAGCGGCAGAGTCACCCAGAGCCTTTGC 0.003914828 0.008579333 3.46E−06 TCAGCGGAGCTCAGGCTGACTCTCCTTCT GAACTCAGTTCAAACCCTCACTCCTCTG AACACCCTCAGCCGCCGCACAGGGAGCT CCAGGGCTCTTGGGTCTTTCACAGTCCTC  177 3296861 8 ZMIZ1 GCCCTGTGTAACCAGCCTGTCCTCACAC 0.000850201 0.017485614 1.56E−05 CCACCAGGGAGGAGGAGTCGGCACTGGT TAACCCTCTGGTCTACCAGGCCCGGTTCC CAGGTTGCAGCAGGGA 1341 3297947 5 NRG3 ACCCTTGGTTGGCTCTCCGGCATTCCAGC 0.014905986 0.006924227 7.73E−06 TGCAGCTGCTGGGGCTGGCTGCAGGCAC GTCTGACTGTTCTCCCCTTTGGAGTAGAC AGGGTTGTTCTGGCTGTCCCATGCATTGC CTTTCAATA  392 3298214 1 TCTGCCTCAGGCATATTCGGAGTCTCATG 0.000954268 0.009857566 6.07E−06 GGGGTATCTGTGAAGAAGACGAGCACA AGAAAGCCTAAGTT  839 3298765 9 WAPAL CTGCACCACCATCCAAAGTGATAAAAAC 0.023239041 0.007619348 8.04E−06 TGTGACAATACCTACTCAGCCCTACCAA GATATAGTTACTGCACTGAAATGCAGAC GAGAAGACAAAGA 1856 3301491 4 SORBS1 GGATTTTGGACAAGGGCTGGGCCAGGCA 0.020694087 0.006725547 5.24E−06 CAGCACTGTGTTCTGACCCGTTACGAAG AGGTA 2018 3301871 9 TM9SF3 TATTATGTCTATGGCTTCATGATGCTGGT 0.000358678 0.010592662 6.42E−06 GCTGGTTATCCTGTGCATTGTGACTGTCT GTGTGACTATTGTGTGCACATATT  602 3301947 9 PIK3AP1 GTGAGTGGACTGGTGCCAAGCATGTCCC 0.040239182 0.009496091 6.27E−06 A  407 3302849 2 HPS1 GACATCTGTCTTAGGCTCCAGTGGACCC 0.000475873 0.011980131 1.06E−05 CCGTGCCTCCTAAGGCTTGAGTGCAGGT ACCCGTGTTCCTAGAGCACAGGACGCTG TCTGCGGCTCCCCATCTTCCCTGCCAGCT CCAGCCTGAACTCAAGGATTGTTAAGAC CACTCCACTGATCCCTAAAGCTGTT 1940 3303460 6 CAGACTTCTGCTTTGATGACTGAGCTAC 0.000933891 0.006757907 5.65E−06 AGGGACAGGAGTGGTCCAAGGTTCTCAA ATTCTGTTTTTGTTTTTTTCCAGACTTCTA TACTATTGTCTGCCCTAGGCTGTAGGGA ATGCTGGTTAGTTTGCTGAACAGACACT GTGTTCAGCAGGGTTTGTGGTATCTCAA A  108 3303461 6 CATTTCCAAGGGGTAGGTGCACAGGTCA 6.24E−07 0.02895629 2.30E−05 ACAGAACTAAACTACAGTGATCTTCCCT TAGATCCTTTTCTACTGAGGTGAATAGCT CAAAAGACAAGGATGCCTTTAGTCCAGG CTAACCCCTGTAGCCTCTACGCAATTAA CACAGA  597 3304424 4 ACTR1A TGGATCAACATTCCTGTCAAACTTAAAA 0.004749446 0.008965086 8.27E−06 CTGTCTTTGTGACTATATGGACCTAAATG CAGGCTCTTCAGAAGTTCAACAATAAGC TAAGCATTTGTTTGTTTTGCTTTGGATGT TGTGCTGCTTCAGCCCCCTTTAAAAAAA AAAAAAGAGAGAGAGAGATACTTTAAA CACACAGAAAAATTCGGTGTGGTATATA ACAAGCACCCAGGTAGCATGTGTCTA  125 3305521 5 SORCS3 AGGAACAAGTCCTATTTGATGAAGATAC 0.002324635 0.016042517 9.05E−06 CTCAGGGAGCCTGGGAGCCTATGGAACC AACAGTGCCCTCGACTCTGTCCTTTCCAG GATGGCCACTGCACACTGC 1575 3306389 8 ADD3 GGAGGAGGTGGTAGCGGACTGACTGAGT 0.04624829 0.00697595 7.55E−06 GGG 2038 3306415 8 ADD3 GTAATCAGAAAGGTGATAAGGTTTACTG 0.000862602 0.00712363 4.55E−06 ATTTACTGCAGAACTGGAATCTCCAATG GGAATTAGTGCCCTCTGG  667 3306762 4 BBIP1 AGTGTCACATAGCAGGCTTAATAGCTAA 0.001080374 0.007248372 4.19E−06 ACATCTGCAGCTATTGTGTTCCGTATTAT CTCATTTACTGTCTTTTACTATATGCTTTT TCATGACATCCAGTAAAAGGATAACAAA TGAAACATTGTTTCTTATACCTAAAATTG CCTATTAATTAGCTAATTCCTAAAATTCC TAATTACAATATGAATTTTTTTTAAGAGA CAGGTTGTCACTCTGCCACCCAGGCTTG GGTACAGCTGGCACAACCGTAGCTCACC GCAGCCTTGAACTACTGGGCTCCTGCCC TAGCCTACTGAT  759 3307486 1 CAGTCGGGCTGGGAGAAACATATGGTGC 0.005416181 0.008128483 3.67E−06 CACAAATATCCCTTTTCCAA   69 3308170 1 ATGGAGTGGACGCTAGCAGCCAACAGA 1.05E−05 0.037128898 3.04E−05 AGGAAAGCAGGCTCCCGCTGCTCCAGCC ATTTCTGCTATGCTTACCTGCTGACTCCC GGGACAGATATCTTGCTGCCTTTGAGGT TAATTCACCAAACTCTGAACTGTCTGAA TTCTGTGGAAGCAGAATATATTGAGGTC CTGACCACGGTGTCCAGCCCTGCTGTAG AACTATGTGGATCA  131 3309791 9 MCMBP GTACCATCACTGAACGAAGTTCCCCTTC 1.23E−05 0.026269881 2.80E−05 ATTATTTGAAACCTAATAGTTTTGTGAAA TTTCGTTGCATGATTCAGGATATGTTTGA CCCTGAGTTTTACATGGGAGTTTATGAA ACGGTTA  843 3309876 1 AGCCATCCTAGAAGGGCTCATGCCAGTC 0.024015481 0.008960388 5.20E−06 TCTTGGTTGCAGAGCCCCGGCTT 1350 3310831 1 CCCAGGACAAGTTCTGTGGGCATCCTTC 0.000802243 0.006806731 3.45E−06 GAAAATGAAAGCACCGTTACAACACACC ACTGATCAAGGGGAAAGTGCCTTTGTAC TCAATGGCGCAATTGGTA   53 3312502 9 MKI67 CAGAAGAGTGCGAAGGTTCTCATGCAGA 4.20E−06 0.060126952 7.13E−05 ATCAGAAAGGGAAAGGAGAAGCAGGAA ATTCAGACTCCATGTGCCTGAGATCAAG AAAGACAAAAAGCCAGCCTGCAGCAAG CACTTTGGAGAGCAAATCTGTGCAGAGA GTAACGCGGAGTGTCAA 1716 3312508 9 MKI67 GGAGAACTCTTAGCGTGCAGGAATCTAA 0.004061321 0.007855735 5.63E−06 TGCCATCAGCAGGCAAAGCCATGCACAC GCCTAAACCATCAGTAGGTGAAGAGAAA GACATCATCATATTTGTGGGAACTCCAG TGCAGAAACTGGACCTGACAGAGAACTT AACCGGCAGCAAGAGACGGCCACAAAC TCCTAAGGAAGAGGCCCAGGCTCTGGAA GACCTGACTGGCTTTAAAGAGCTCTTCC AGACCCCTGGTCATACTGAAGAAGCAGT GGCTGCTGGCAAAACTACTAAAATGCCC TGCGAATCTTCTCCACCAGAATCAGCAG ACACCCCAACAAGCACAAGAAGGCAGC CCAAGACACCTTTGGAGAAAAGGGACGT ACAGAAGGAGCTCTCAGCCCTGAAGAAG CTCACACAGACATCAGGGGAAACCACAC ACACAGATAAAGTACCAGGAGGTGAGG ATAAAAGCATCAACGCGTTTAGGGAAAC TGCAAAACAGAAACTGGACCCAGCAGC AAGTGTAACTGGTAGCAAGAGGCACCCA AAAACTAAGGAAAAGGCCCAACCCCTA GAAGACCTGGCTGGCTTGAAAGAGCTCT TCCAGACACCAGTATGCACTGACAAGCC CACGACTCACGAGAAAACTACCAAAATA GCCTGCAGATCACAACCAGACCCAGTGG ACACACCAACAAGCTCCAAGCCACAGTC CAAGAGAAGTCTCAGGAAAGTGGACGT AGAAGAAGAATTCTTCGCACTCAGGAAA CGAACACCATCAGCAGGCAAAGCCATGC ACACACCCAAACCAGCAGTAAGTGGTGA GAAAAACATCTACGCATTTATGGGAACT CCAGTGCAGAAACTGGACCTGACAGAGA ACTTAACTGGCAGCAAGAGACGGCTACA AACTCCTAAGGAAAAGGCCCAGGCTCTA GAAGACCTGGCTGGCTTTAAAGAGCTCT TCCAGACACGAGGTCACACTGAGGAATC AATGACTAACGATAAAACTGCCAAAGTA GCCTGCAAATCTTCACAACCAGACCCAG ACAAAAACCCAGCAAGCTCCAAGCGAC GGCTCAAGACATCCCTGGGGAAAGTGGG CGTGAAAGAAGAGCTCCTAGCAGTTGGC AAGCTCACACAGACATCAGGAGAGACTA CACACACACACACAGAGCCAACAGGAG ATGGTAAGAGCATGAAAGCATTTATGGA GTCTCCAAAGCAGATCTTAGACTCAGCA GCAAGTCTAACTGGCAGCAAGAGGCAGC TGAGAACTCCTAAGGGAAAGTCTGAAGT CCCTGAAGACCTGGCCGGCTTCATCGAG CTCTTCCAGACACCAAGTCACACTAAGG AATCAATGACTAACGAAAAAACTACCAA AGTATCCTACAGAGCTTCACAGCCAGAC CTAGTGGACACCCCAACAAGCTCCAAGC CACAGCCCAAGAGAAGTCTCAGGAAAG CAGACACTGAAGAAGAATTTTTAGCATT TAGGAAACAAACGCCATCAGCAGGCAA AGCCATGCACACACCCAAACCAGCAGTA GGTGAAGAGAAAGACATCAACACGTTTT TGGGAACTCCAGTGCAGAAACTGGACCA GCCAGGAAATTTACCTGGCAGCAATAGA CGGCTACAAACTCGTAAGGAAAAGGCCC AGGCTCTAGAAGAACTGACTGGCTTCAG AGAGCTTTTCCAGACACCATGCACTGAT AACCCCACGACTGATGAGAAAACTACCA AAAAAATACTCTGCAAATCTCCGCAATC AGACCCAGCGGACACCCCAACAAACAC AAAGCAACGGCCCAAGAGAAGCCTCAA GAAAGCAGACGTAGAGGAAGAATTTTTA GCATTCAGGAAACTAACACCATCAGCAG GCAAAGCCATGCACACGCCTAAAGCAGC AGTAGGTGAAGAGAAAGACATCAACAC ATTTGTGGGGACTCCAGTGGAGAAACTG GACCTGCTAGGAAATTTACCTGGCAGCA AGAGACGGCCACAAACTCCTAAAGAAA AGGCCAAGGCTCTAGAAGATCTGGCTGG CTTCAAAGAGCTCTTCCAGACACCAGGT CACACTGAGGAATCAATGACCGATGACA AAATCACAGAAGTATCCTGCAAATCTCC ACAACCAGACCCAGTCAAAACCCCAACA AGCTCCAAGCAACGACTCAAGATATCCT TGGGGAAAGTAGGTGTGAAAGAAGAGG TCCTACCAGTCGGCAAGCTCACACAGAC GTCAGGGAAGACCACACAGACACACAG AGAGACAGCAGGAGATGGAAAGAGCAT CAAAGCGTTTAAGGAATCTGCAAAGCAG ATGCTGGACCCAGCAAACTATGGAACTG GGATGGAGAGGTGGCCAAGAACACCTA AGGAAGAGGCCCAATCACTAGAAGACCT GGCCGGCTTCAAAGAGCTCTTCCAGACA CCAGACCACACTGAGGAATCAACAACTG ATGACAAAACTACCAAAATAGCCTGCAA ATCTCCACCACCAGAATCAATGGACACT CCAACAAGCACAAGGAGGCGGCCCAAA ACACCTTTGGGGAAAAGGGATATAGTGG AAGAGCTCTCAGCCCTGAAGCAGCTCAC ACAGACCACACACACAGACAAAGTACC AGGAGATGAGGATAAAGGCATCAACGT GTTCAGGGAAACTGCAAAACAGAAACTG GACCCAGCAGCAAGTGTAACTGGTAGCA AGAGGCAGCCAAGAACTCCTAAGGGAA AAGCCCAACCCCTAGAAGACTTGGCTGG CTTGAAAGAGCTCTTCCAGACACCAATA TGCACTGACAAGCCCACGACTCATGAGA AAACTACCAAAATAGCCTGCAGATCTCC ACAACCAGACCCAGTGGGTACCCCAACA ATCTTCAAGCCACAGTCCAAGAGAAGTC TCAGGAAAGCAGACGTAGAGGAAGAAT CCTTAGCACTCAGGAAACGAACACCATC AGTAGGGAAAGCTATGGACACACCCAA ACCAGCAGGAGGTGATGAGAAAGACAT GAAAGCATTTATGGGAACTCCAGTGCAG AAATTGGACCTGCCAGGAAATTTACCTG GCAGCAAAAGATGGCCACAAACTCCTAA GGAAAAGGCCCAGGCTCTAGAAGACCTG GCTGGCTTCAAAGAGCTCTTCCAGACAC CAGGCACTGACAAGCCCACGACTGATGA GAAAACTACCAAAATAGCCTGCAAATCT CCACAACCAGACCCAGTGGACACCCCAG CAAGCACAAAGCAACGGCCCAAGAGAA ACCTCAGGAAAGCAGACGTAGAGGAAG AATTTTTAGCACTCAGGAAACGAACACC ATCAGCAGGCAAAGCCATGGACACACCA AAACCAGCAGTAAGTGATGAGAAAAAT ATCAACACATTTGTGGAAACTCCAGTGC AGAAACTGGACCTGCTAGGAAATTTACC TGGCAGCAAGAGACAGCCACAGACTCCT AAGGAAAAGGCTGAGGCTCTAGAGGAC CTGGTTGGCTTCAAAGAA   48 3312516 9 MKI67 CATGGGCAGATGTAGTAAAACTTGGTGC 1.16E−08 0.076247204 0.00010532 AAAACAAACACAAACTAAAGTCATAAA ACATGGTCCTCAAAGGTC  307 3312517 9 MKI67 AAGAGAGTGTCTATCAGCCGAAGTCAAC 3.35E−06 0.022040564 1.75E−05 ATGATATTTTACAGATGATATGTTCCAA AAGAAGAAGTGGTGCTTCGGAAGCAAAT  322 3312528 9 MKI67 TGTGACATCCGTATCCAGCTTCCTGTTGT 0.000276123 0.011794395 7.23E−06 GTCAAAACAACATT 1192 3316579 3 RP13- TGTGTGTGGACACTGCAACCCTCCCGAA 4.46E−05 0.007081656 4.90E−06 870H17.3 GCTGGGCCTGGAAGAAATGACTTCCCCA GAACCTTATCTGGGCCGGAGAGGGGCGT TGGCAGCGGGGGTCTTGCCGCCTTCCGG TCCTCTGCATGCCAGGCACCACCTGGGG CCGGGCCAGGGCAGGCTGCCTGGACACC ATGGACCTGCCCAGCTGTAGGGGAGGTG TGTCCTGCAGCCCTACCCGAGGCCCAGG CCTGCGTGGCTGAGAGGACTGAGGACGG CTGACCCCCTTGGTGACTGCCTGGGCCC AGAGGGGAGTTGGGGGAGTGGTCAGCT GGGTGTGGCCAGCCCTGGGGGAAGGATC CAGGGACTGTGTCCACTTAGGGATAGGA GGCAGCTAGCAGAGCCCTCCCAGCTGAC CAGGGGAGGCCCTGTGGGCACAGGAGG GGCCCCAGGTGTAGGTACAGGTGCAGGG CTGTGCGGCTCTGTGTCACCCAGGTGGA GCGTCTTGCCCCGTTTGATGGCTGACAA AGTGCCCTTGAATGCGTCAGACCCAGCG TGGTCCCAGGGTCCTGACCCTAACATAC CACCCCAAATTACCCTCACCCCAGCCTA CCCCTGCCCTAAATTCACCCCAAGCCTCC ACCCAAACCCCTTAGTCCCAACACCTTA ACCCTAGACCCAACCCTACACCCCAAGC CCTAATCCCTAACCGCTAGCCTCACCCTA ACCTTCCTACCGGATGCCACCTGGCAAA CATCCTCCTGGCCCCTATCTGCCCCTCCC CCGGGGATCCGGGAGGCAGTGGGGTCCC TGGGAGGCTGCTCCCTGCAGAACGCGAT GGACA  456 3317399 4 KCNQ1 GCTCTGGTTGGAAAGTGGCTAGGGTGAC 0.006154763 0.010928167 7.03E−06 CTCTGGGCCTACTGGCAGGGACGCCA 2082 3318045 2 RRM1 TTTGCTTGAGGTGGTAAGGCTTTGCTGG 0.0001169 0.00747355 4.30E−06 ACCCTGTTGCAGGCAAAAGGAGTAATTG ATTTAAAGTACTGTTAATGATGATAATG ATTTTTTTTTTAAACTCATATATTGGGAT TTTCACCAAAATAATGCTTTTGAAAAAA AGAAAAAAAAAACGGATATATTGAGAA TCAAAGTAGAAGTTTTAGGAATGCAAAA TAAGTCATCTTGCATACAGGGAGTGGTT AAGTAAGGTTTCATCACCCCTTTAGCACT GCTTTTCTGAAGACTTCAGTTTTGTTAAG GAGATTTAGTTTTACTGCTTTGACTGGTG GGTCTCTAGAAGCAAAACTGAGTGATAA CTCATGAGAAGTACTGATAGGACCTTTA TCTGGATATGGTCCTATAGGTTATTC   77 3319231 5 CYB5R2 TCTACAGCTGGAGGCGAAATCTCTCATG 0.007337714 0.028273098 4.44E−05 TTGTCCCTTAGAGGATCAAATGACTCCC AAGTCAGAATGGGTCTCGGGGCTCACTC TCTGGATGGAGCCCCTAGAAGCCTCTTA CCTGTGCCCCCAGCAATCATTCCCAGGT GATCGGCCAGTGTTTTTTTAGGCTCACTC GTCTGGTCTGGTCTGATTCCAAGATTCCC TGGAAACACAGAGAATGCTTATGACCTC TGCAGTTCTTGCCTAAAGAGACTGCAAA AGATCACTGACATTCCTTAGGACTCCCA GGAGGCACGTCCAGCTAAGGGACTGTCT GCACCATTTTAAGC  731 3320141 2 ADM AGAATCCGAGTGTTTGCCAGGCTTAAGG 0.000194662 0.007431738 2.85E−06 AGAGGAGAAACTGAGAAATGAATGCTG AGACCCCCGGAGCAGGGGTCTGAGCCAC AGCCGTGCTCGCCCACAAACTGATTTCT CACGGCGTGTCACCCCACCAGGGCGCAA GCCTCACTATTACTTGAACTTTCCAAAAC CTAAAGAGGAAAAGTGCAATGCGTGTTG TACATACAGAGGTAACTATCAATATTTA AGTTTGTTGCTGTCAAGATTTTTTTTGTA ACTTCAAATATAGAGATATTTTTGTACGT TATATATTGTATTAAGGGCATTTTAAAA GCAATTATATTGTCCTCCCCTATTTTAAG ACGTGAATGTCTCAGCGAGGTGTAAAGT TGTTC 1849 3321317 2 FAR1 CTCATAAAACTTAGTGAACACACTGTGT 0.00094743 0.00693472 6.58E−06 TATGCCAGCTCAAATCTACAGTAGCCAC CAAAACCATGACTTAATATTTTGAGCCC TAGAAGAAAGGGGTGTGCTGAGGACAA GAGTGGGGAAATAGGAACACTGACCAG TA 1231 3322467 4 OTOG TTCAGAAGACGGGTTGTGCCAGCAGTGA 0.00877735 0.007993957 8.02E−06 GAGGTCCAGGGTACCCAGGGGATTCCTA CCTGGACATCCCTGATGAAGTGGGGCCT G  343 3326990 4 LDLRAD3 GATAAATCATGTGCAAGTGTCATCGATA 0.008566991 0.009998305 9.60E−06 GACTAACAAGAG  346 3329359 9 MDK CAGGCCCGAGATGTGACCCACCAGTGCC 0.000111942 0.019795601 2.22E−05 TTCTGTCTGCTCGTTAGCTTTAATCAATC ATGCCCTGCCTTGTCCCTCTCACTCCCCA GCCCCACCCCTAAGTGCCCAAAGTGGGG AGGGACAAGGGATTCTGGGAAGCTTGAG CCTCCCCCAAAGCAATGTGAGTCCCAGA GCCCGCTTTTGTTCTTCCCCACAATTCCA TTACTAAGAAACA 1760 3329848 7 CELF1 TGGCTTGCTTGGCACCCAGGGACAGTAG 0.005225318 0.007191149 5.91E−06 CTGTTTGGCTCTCCACCCAAT 1309 3329913 2 NDUFS3 TGAAGTTAGCTGTTCCCTCAGTAGCTCTT 0.02450122 0.006617557 5.96E−06 TGTTCCC  236 3331846 3 GLYATL1 CCTCATCTCTGGGGATCTCAACCTCTC 0.002099724 NA NA  279 3331847 9 GLYATL1 TGTATCACATCAATCACGGGAACCCCTT 0.003636318 0.013971736 1.16E−05  488 3331877 6 GATTGGGCATTTATGATATGGCAGGAAC 0.040446406 0.011268756 7.13E−06 TCCTTCTCACATGGAGACCTGATGTTAA AGGACACAGCCATGCTCTTGAGGAGCTT ACAATCCAAGCTGGAGGCAGGGGAGGG TATAGTCTTTAAATATGCTTAAGTGTTGT AGGGAAGGACAGAGTTACCAATAAACA TGTAACTAGAAAGCCAGGCTCAGTTCTT ACCTCTGGGAATCAGAACTCTTTATGAA ACTTGATTGATAGAATCTACTA 1593 3331913 2 FAM111B ATATGCCAATAATTCCTGGCAAAGATTT 1.74E−05 0.009308618 5.06E−06 CATGACAAAGACACTTAAAGCAATTGCA ACAAAAGTGAAAATTGGCAAATGAGAC CTAATTAAATCTTCTGCACAGCAAAAGA AACTATCAACAGGGTAAACACACAACCT ACGGAATGGGAGAAAATATTTGCAAACT ATGCATACAGCAAAGATCTAATATTCAG AATCCATTAGGAACTTAAACAGATTAAC AAGCAAAAAAAACAAGCAACCCCATTA AAAAGTGGGCAAAGGACATGAACAAAC ACTTTTCAAAAGAAGATATACACATGGC CAACAAGGATATGAAAAAATACCTGATA TCACTAATCATTAGAGAAATGCAAATCA AAAAAATGCCATCACACTAATCAGAATG GCTGTTATTAAAATGCCAAAAAATTACA GATGCTGGCGAGGTTGCAGAGAAAGGG GAATGCTTATACACTGCTAGTGGGAAAA TAAATTAGTTCAGCCATTGTGGAAAGCA GTTGGGTGATTTCTAAAAGAACTTAAAA CAGCTACCATTCAAGCCAGCAATCTCAT GACTGGGTATATGTCCAAAGGAATATAA ATTGTTCTACCATAAAGACATGCACATA TATGTTCACTGCAGCACTATTCACAATA GCAAAACATGAAATCAACCTAAATGCCC ATCAATGGTAGACTGGATAAAGAAAATG TGACACATATACACCATAGCATACTACA CAGCCATAAAAAAGTACAAGATCATGTG CTTTGCAGCAACATGGATGGAACTGAAG GTCATTATCCTAAGCGAACTAATGCAGG AACAGAAAGCCAAGTACCACATGTTCTC TCATAAGTGGAAGCTAAATATTGAGTAC ACATGGACACAAAGAAGAAAACAACAG ATATGGGGCCTACTTGAGGGTGGAGGGT GGGAGGAGGGTGAAGACTGAAAAACTG CCTATGGGGTACTATGCTTATTACCTGGG TGATGAAATAATCTGAACACAAAACCCT GGTGACATGCAGTTTACCTATATAACAA AACTGCACATGGACTCTTAAAC 1489 3332111 3 AP000442.1 CAGGGTCTGAACTCTGTAGGTCTTCACC 0.011353565 0.006946152 3.91E−06 ACGGCTCAGGAGGATGAGGAGCAGTGA CAGGCCAAACTACGAGAAAAGACAGAG GGAATCAAACTCAACACTGTGTCTAAAC CTCCTCCACCACTGTTGAAGGGATCCTG GCATCAGATGGGGAACAGCTCTAAATCA AAATAACCTCACTACTGTGCTTTTCTGTA AAACCAGGTAAAGATCAGACAAGCATG AGTTGAAAGGCTATGTCTCTCTCCAGGC TTTATTCTGCCATAGCAGTGACCAGGCG CAGCCAACAGAAACGGAAAGTCATGGT GTCCAACACGCCTCTCTGTT  168 3332705 2 CD6 GAGCCCTCTGTCTCGGGGATGAACAAGC 6.62E−06 0.024221205 2.00E−05 AGAGTCTGGGCTACCTCTTGACAGCTGG TGGAGGGGAGTTGGGGAGCTGGACTGG ATGACTCTGGAGGCCCCTTCCAAACCTC AAGTGTCCGGCGCTTTGATTGCCTGAGTT TCTGACACTTCAGGGCCCAGAGGTCCTG CGAGGGGCAGAACTGGACCCCCATGCCA GTGCTGCTGCAGGAGGGCCCATATACTA GGGTCTGCTGAGCTGTTGTCACTGATCG GTGGGCGCTGGGGGGGTAGGGTAGCAC ACCAGCTGTCCCAGGCTTTGCTCCGGGC GGTAACTGCACTTGGGCAGGGAATATAG CCTTCCTGGGCACAACTAGCTGACAATG ACAGGTTGACTGTGTACCCCCAACCAAG GAGCTGGGGCCCAAGGCCAGTCCTGCCC CAGAGACACTCCAAGTCCGCCAGGGGCA CAGACCAGTTCTGCAGTGACTGTCCCTG GACAATGGGTCTTTATTCTGAGTTTCCTA TGGTTTACAAAGAGGGCCCCAGCCCAGC CCCACCACAGATCCCAGAGATAGGGGCC CAGTCTCCATGGGGGCAAGGAGCATAGA GATGTTTTCCAGGAAGGGGCTCAGAAGC TGCACTAGGCCCCGAGTCCCCATGTGTC TCCTTGAATTGATGAGGATGCTCCTGGG AGGGATGCGTGACTATGTGGTGTTGCAC CCGGGGCTGCAAACGTCTCCGTGCAGCC CCCAGAGAGAGGCCCATGGGCTCAGACC AGGCTTTGTTGTCCTGCTCTGAGTATCCT GAGATTA  654 3332877 4 DAK; GACGGTCAATATTAGCCCTTCTGCCAAC 4.74E−05 0.008544328 3.23E−06 RP11- ATCTGGCAATGTGAGGCTGGGGTGGACG 286N22.3 TTGGCCTGATGTTGCCAGGAGTAGGATG CTGATGCTGCCAGAGAGTAGGTGGGCTC CAAACCCCAGGCTTCTCACTTGCTTACTA AGCACAGCAGTCTGAAGCTTGGGACCTG GCAGTGCGTCTTTGGAGAAGGCAAAAAA GCCACAGCAGCAACACTTAGGAGCAAG ACCCTTCCCGCTCTCCACCCTATTTCCTC CCCTGAAGAAGAGCAACAGCTCAAGCTC TAGCATGGCACAGAACGCTAGGTTGGGC CAGGCAAGCAGCCATGGTGGGGCCAGGT GAAGCAATGTGGGTCTCAGCAAGGAACC CCTCTGAAGGTGGCAGTGGCTCCCAGGG CTGCTGCACACTGGACACCACAACTTTG GCATCAGCTGCATGGTGAGCTGCAGAGT GGTCAGAGGGGCTGGGGCCCTGCCAAGA GAGCAAGGCCAGACCTGCCCAGCGGGA GGCAGGAAGGCCCTGATCCAGCAAGGA GAAGTAGAGGAAGTCCACAGCCACCTCT GTTACTCATCGCTACTGGGA 2009 3333236 6 TGTTTGTGACTGATTACTGGCTGTGTCTT 0.000457168 0.009182253 5.87E−06 GGGTGGGCAGAAACTCGAACTTGCTATG TAATTTGTGTCTA  632 3333240 7 FADS1 CATGGGTGGTGCATCTGACCCTATCCCA 9.43E−05 0.014572418 1.23E−05 ACATGCCTTAGGACGCTCATCTCCTTGAC TGTCTGCCATCCCCTCCCAAAACTAAGT GGAGGCTCTGTCTTTTCCTCCTAGTTTGA GGTTCTCTTCTCCCAGTGTCTAAAATGAT CAATATGCCTAGAGTAGATGCTGCTGAA GAGGCAAAGTAGTAATCCTGCCACCTGG AAGCAAAGGCTGTGGGTTGGAGGGGGA AGCGGGTGTGAGGGCTGATGATAAGCCC TAGGAGGCTCCTGAGTCATATTCC 1972 3333487 2 ASRGL1 GGACCCTCTGGGAATCCATAGCTTCCTA 0.001265835 0.006689375 4.50E−06 ATCTGGAGATGGGAGGTCATAAGGGAG ACGCTGTGGGGTTCCTTGAAGTTTCTTGG GTTCACAGAGGAGCCCCCTCACTTGGTG TTCTCCCGTGAGCCAGCCTCCACCTGCCA AAGACACTCTGGTCCTCGTATAGTGAGT AATGGGGCTCAGGGCCTCTCCAACAACA GAGAGGAGCTGATGCTGTAGGGCTGACC CCGTGACTTCCTGAGTCCTCACCCTGTCC AGTGCTTTGAGATTCTTCCCACCTCCCCA TCCTCACCAGCCGGATCGGGCGCTGTGC AGTGTGGTCAGCATGGTGAAGAAAGTCA TTTCCTCGGTGGGCAGTATTCCTCTTTAT CTCTCATTACACTGGAAATGTTATTTCTG CTGTATCATCCGTGCTCAACGTTTTAGTC TGTCAGGCTCA  187 3333728 2 SLC3A2 ACATGTTGACCGGTCTGGTTTTGAACTCG 3.46E−05 0.02137965 1.84E−05 CCTGGCCTGCCTTCCCATATCTTAAGGCC CTTCCTTGCTCACATCTGTTTCAATGGAA TGA 1679 3334217 5 MACROD1 GAGCCAGGAACCTCATAAGGACCTAGAA 0.000438052 0.007910565 3.13E−06 ATGCCCACCACCATCCTAATCTGTAAAA TGGATCAGCCCCTTCAGGCCTAGAGGGG TGGGGTAGGGGGCTGGGCTAGGCAGGA AGAGGGGACTTAGAGGGTGTCACTGATT CGTGCAGCCCCTCCCACCATCTGACCAA CTCTCAAGGGCATGGAGTCACTTATTCA TTCAACAAACATCAGGTCAGACATGG 1889 3334931 2 MRPL49 GGGGTCAGGCCTTGCTTGCATAAAGGAG 9.46E−05 0.00816066 3.93E−06 AAAACAACTCTATGTACATGCTGGGG 1744 3335187 3 MALAT1 ATTCTTACATGCAGGAACACTCAGCAGA 2.12E−05 0.006711132 4.85E−06 CACACGTATGCGAAGGGCCAGAGAAGC CAGACCCAGTAAGAAAAAATAGCCTATT TACTTTAAATAAACCAAACATTCCATTTT AAATGTGGGGATTGGGAACCACTAGTTC TTTCAGATGGTATTCTTCAGACTATAGAA GGAGCTTCCAGTTGAATTCACCAGTGGA 2032 3335239 3 NEAT1 CCGATCTGCCATATCCTGTGTAATGACA 0.000296032 0.007557915 4.73E−06 AGTGAGTTGCATTCTCACCGTCACTCCTG GGGTCTCTCCGCTTCCCCTGAGCTGGCTC AGCAGTCTGCTCCATGTGTTTTGATGCAG GGTGACCCATTGGTATTCCCGACACTA 1640 3335344 4 SSSCA1; CAAATGTTTTGCTGACGTTACTTCATTTC 4.05E−05 0.007034036 6.22E−06 FAM89B ATCCGGCTAAATGGATAACCCCATTTTTT GGGTGAGGGTCATGACTAAAGTTGCATA GCTTGCAGGTGG  283 3335444 9 PCNXL3 TGGGACTTGCTGTACAAGCTGCGTTTCGT 0.009647164 0.012006177 6.85E−06 GCTGACCTACATCGCGCCCTGGCAGATC ACCTGGGGCTCGGCTTTCCACGCTTTTGC C 2035 3335570 1 CTGTCTGCTCCCCTATTGGCGGGTGGTGC 7.50E−05 0.006753736 2.46E−06 TGGCTCTGTCCCTGGCAAGGCCAGGCAT GGAGCTGAGCTCAGACTGTCACCGGACT CACCCGGGACAGCAACATCCCAGTCGAG GGCCCAG 2078 3335635 6 AGGTCCCTTACTGGTCCTGCTTCCATGAG 5.37E−05 0.007183286 6.76E−06 TAGCCGTGACCAGGGGAAAAGGGAGAG GAACCAGCCGGCACAGGGAGGGGTCAT CTCCACAACATTCCATTTATACACAGAA CTAAACAGACAAGCACAGAGTCACTATT GCGGTTAGAAGTTGGCAGCATGGGAAGG GGGAGGACCAGGTGGGGAATGGGGATG TTGTTAAAAAAAATACAGGCTCCCCCAC AACTGGGGTGCCTGGGGGGAACTTGGTC TGCTTCAGCCCAAGAGGAATCAAAAGAT CAAAAGCAGTTTGGGAAGGCCAGAACC GTCAAGGGATGGAGGGAGAAGGAAAAT CCAGGGGGTGGGGGGTCTGTTTGGCAAC TGGGGTGAAGGGATTGCCCTCCCCCTGC TGGGATCCCCCCAGCCCCTCCGGTCTGG CAGGAAGGGGGCAGCCTGCAACCCCCA AGGGCAGGTGTGGGGCTGCCAGATGCTC CAGGCAGGGGGCCAGAAGGGGCTCACA AAGGCTTGC 1624 3335777 9 SART1 CGCGTGAAGCGGGAGAAGCGCGATGAC 0.000133772 0.007144549 4.34E−06 GGCTACGAGGCC 1764 3336464 5 RBM4B AGCTGCATGGTGGTCTCAAGAGATCTCA 0.00271316 0.009071279 8.82E−06 AGTCTTGCTGACATGCATATAGGGTACA ACTTATTACAGGTTCATAACATTTGCTTC TCAATTCACATAAAAGAGCAAATTGCTG TGGCTTTGCTTTTTAATTTTTTTTTTTTTT TTTAAGAGAGAGAGGAGCCACTCTTGCC CAGGCTGGAGTGCAGTGGCTAACTGCAG TCTCTCACTCCTGGGCTCAAGGGATCCTC CAGCCTCAGCTTCCTGAATAGTTGGGAC TACAGGCACAAGCCACTGTACACAGCTG CTTTGTTATCTTCTACATATATACCAAAG GGATAAGTTAGGAACACCAGAAACTCAG TAGTAACTCACTTTAACCTTGCTTCTGGG GCTCCAATTCAAGTGATGCTCAATTTCA AGGTACAAGGAAAACCATGAGAATATA AAGTCATAATGCCATTTCCACTCAGATG AAAAGATTTATCTATCTTTAGATACTCAA AATTATTCTTGGCATTTTAGCACTTTTGG TACACATTTCCTGATGTAGGAAATAGTA AAATTTCAGAGCCTATGGCATTGGCTTTC ACCACCTATGCAATTTTCTACACATCTGA AAATTACCAGTTTATCTAACTCCTTAAAT GTTCCTCTCTTCAACAACAAAAAACACA AACAAAAATTGCTGGAAGAAACAGGAA GCATCCAGGTCCAAATGACAGCATAACA GACTATGAAGAAACAGGGCTTAAGTGCC CATCTAGAACAAGATGGTCTAGATTACA ATAAGGACCCCATGGGACAGAACATCAA AACATTCAACTTTCAAGTAAATGTCTTG GAAGTAAACATTTAAAATTTATAGGACT TCCTCTGGCATGTAGGTA  669 3336491 4 C11orf80 TTCTGGGTTCGAAGCAGCTGGACGTGGA 0.000122396 0.008642129 3.62E−06 AGGGCGAGGTTCAGAGGCCACACCTGTG CTCGGGGAGCTGCTCTGGAAGACGGCAC TGAGCGCCTGGCGCCGGCCACGCCCCGT GTGCTCATTTCATTACCCACTTTCACGGC CGGTGCCCAATGGGACGTTGAGCTGCTG TTT  183 3336510 4 C11orf80 GATTTCATCATGGATGCCTCAATTGAGG 2.67E−05 0.021906893 2.50E−05 AGAAA  248 3336517 4 C11orf80 TGATTTCTGATAATTTGTGACAACCTGGA 0.000611594 0.017681213 2.55E−05 GCTGTGATATAGGGCTCAATATATTTAA GATTTAGAATTTAAACACAGGCAAGCAT TAAGTATGTTTA  473 3336722 4 KDM2A CCTTGGCAAACTGACAAGGATGTCATAT 6.62E−06 0.015914087 1.54E−05 ATGTATTGTAGTGGTCAAAATTAATGTTT TGTTTACTTTTTTTTTTGGAGACGGAGTC TTGCTGTGTCACCCAGGGTGGAGTGCAG TGGTGCGATCTCGGCTCACTGCAACCTC CGTCTCCTAGGTTGAAGCAATTCTCCTAC CTCAGCCTCCTGAGTAGCTGGGATTACA GGCACGTGCCACCACACCCGGCTAATTT TTTTTTTTTTTATACTTTTAGTAGAGACG GGGTTTCGCCATGTTGGCCAGGCTGGTC TCGAACTCCTGACCTGAGGTGATCTGCC CACCTTGGCCTCCCAAAGTGCTGGGATT ACAGGTATGAGCCACCACACCTGGCCCT TTTTTTTTTTTTTTTAACTCTTCAGAGACA GGGTGATGATAATTTCTGTTTAGCATTTA TAAGATGACTCACTATTAGTAGTCCTATC CCCATATTATTTAAGCTCTAAATTTCCTG TGGAAATTTAGACTTGGAATATAGACTT GGAAAACCCCTCAAGCGTTGCTTCTCAA TGTGCTC 1202 3336851 2 ADRBK1 GCAGGTTGGGCCATACTGGCCTCGCCTG 0.005203274 0.007814406 2.76E−06 GCCTGAGGTCTCGCTGATGCTG 1009 3337064 9 CARNS1 TGCTCGATGGAGTCTTCAACGTGGAGCT 0.005348101 0.00726324 2.93E−06 CAAGCTGACCGGGGCTGGGCCTCGGCTT ATCGAGATCAACCCCCGCATGGGTGGCT TCTACCTGCGTGATTGGATCCTGGAGCTC TATGGTGTTGACCTGCTGCTGGCTGCTGT TATGGTGGCCTGTGGCTTGCGTCCTGCCC TGCCCACCCGCCCACGTGCTCGTGGCCA TCTGGTGGGCGTCATGTGCCTTGTGTCCC AGCACCTGCAGGCCCTGAGTTCCACCGC CAGCCGTGAGACCCTGCAGGCCCTGCAC GACCGTGGACTGCTACGCCTCAATCTGC TGGA 1226 3338508 9 PPFIA1 CTGGTGTTTCCGAGACGGATAACTCATC 0.043299568 0.006560039 7.24E−06 TCAGGATGCCTTGGGACTTAGCAAATTG GGGGGACAGGCT  873 3339046 6 GAGGCAATTTTACACCCATCCGACGCCT 0.003098917 0.007737485 4.79E−06 CACATTTGAAAACCCAATGGCGGTACTG ACAGGCCTGGGGCAGCGGACGCTCTCAG GCATTGCTGAGGAGAAGGGAAAGCAGC TTGAGCGTTTGGAAAGCTGTCTGTTTCTT AGAAAGTTAAGCATACACTACTCTATGG TCTAGCAAGGCCAGTCCTCAATATTTAA CCAAAAAATTAAAACCAAAAACATGAAT ACGGAAGGACTGGAAGGCATGATTATGT GTTATTTATCATCGCCCCAAACTGCGAA CAATTCAAATATCTATGAACAGGAGAAT GGAGGAACGCCGTGGAGAGTATTTTTAC A  815 3339248 9 RNF121 CAAACCAGAAGATGCCATGGACTTTGGC 0.000337386 0.006535423 3.33E−06 ATCTCCCTTCTCTTCTATGGCCTCTACTA TGGAGTTCTGGAACGGGACTTTGCAGAA ATGTGTGCAGACTACATGGCATCTACCA TA 1599 3339697 5 FCHSD2 AAGGCAATGGAGAGTTTGGCTCCTGCAA 0.000228432 0.006761278 4.54E−06 AGTAAAGGAAACTAAAAGGGCTCACAG TGGGACAGGGATCAGGAGCCAGGTTCAT AGCTTGAAACCAGGCACTATAGTGAGAT TCCCGTGTTCATGAAGGA  794 3339872 2 ARHGEF17 CACACATGTGCCTGCGTGGGCTCTGCCTT 0.034740252 0.006686228 3.12E−06 GTCTTCGCGGAAGCATTCCTGATGGAAC ACCCACTGGCCAGCCAGGCCATGGCTTC TCCCGACCCTCT   92 3340087 4 PAAF1 GGAGTCATTTATGCAGCTCCATCTTCTCT 2.10E−06 0.030966825 3.44E−05 GCCCTTGTAGTTCCTTTACTCCATCCTCC ATCTTAGGGAGTTTTT 1268 3340183 9 PPME1 GTAGAGTTCAGTGTAGGATTGTAGCTTT 0.002514771 0.007854617 3.58E−06 GGATCTGCGAAGTCATG  111 3340387 4 SPCS2 TCAGCTTCTGAGTTTGCCATCAGTTTTTA 6.42E−05 0.027924152 2.54E−05 TTATCTCCTTATTTTAGTTTAGAACTCCA CATATACAAATGGGTATTTATCCTTTTTC CTCCTGTATTCTTCTTCTTGGAAAATGAC ATGATGGCTCCAACAAGTCATCCAAGCC CTAATTCTAGTAGGTGGTCATCTCTGTCT CTTCTCTTTCATGTTCCTTATAACTAGTC TGTTACTAAGTCCTGCCAATTCTACCTCA GAATACTCCCTTTCAGTCCCCCTACTGCT GCTCTGTTGAGCATTGAGGCTCTGCACTT ACATCAGGCCCCATCTGCATCTCTATGTC CAGTGTTACTC  758 3340768 4 UVRAG TCAAAGAAGACGACATTCCCAGATAGAA 0.006855816 0.012411782 9.19E−06 AAGGAAGCAAACGTTTTTTGAGAATGGA GACAAAAACTATTTTGCACATCATAATT TTTCCATTAGCAAGCACAATGCCAGAA 1787 3340811 4 UVRAG CATTTATTTATGATCAACCAGAGAGACT 7.63E−05 0.008875995 5.36E−06 AAACAGTGGACTCATGGGTTTGGACTCT ATTGCAATTCAA 1574 3341181 9 CAPN5 TGCCGGTACTTCACGGACATCATCAAGT 0.000496534 0.009800362 6.74E−06 GCCGCGTGATCAACACATCCCACCTGAG CATCCACAAGACGTGGGA 1294 3341189 2 CAPN5 GTCACCACTGCTAAGGGACTCTATCCAT 0.009436864 0.015307962 1.31E−05 TGAGCACATTTTCCTAAGGCCCTGCTGTC TGCCGAGGAGCGCCAAGAAGATGTCACT TGTTTACACACGAACTGCCACATCCCCA AGCTCCGTTCTTGCCCCTCGTGTCCTAGG CCCAACCCAGCCTCCCAGACCTCACTTTC CCCATCAGCAATACCTGGTGTTCTCCCAC CTTGAAAGGACTCTTGGCTCCTGCCGGG TTCCTGCTCAGGCTGGAATTGGGAAAAT ATGCAGGTGACATTTGTTCATTCTCTAAT CCCATCCTCTCACCCATCCATTTCCTCAC TCAGTGGAGATTTGCCAAATGAATAAAC GACACCTTTGAGGCCCCAGGTGAAGCGG GGCCCTACTCCGGCCTCTGCCTTGGGCCT CGCCTCTGTCCTCAGGTCCTCTCAGAGGC AGATACCTAGGGGAGCTGCTGCTGCCTG CTCATTCTAGCTTCCGA 1857 3341212 4 CAPN5 CCCACTTGGGTCCTTGGCGTTGGTGGCA 2.80E−05 0.006838246 3.07E−06 GCA  617 3345158 4 PIWIL4 TGCAGCTCACACAGAAGGGACTACTGCA 0.006687861 0.010150886 6.44E−06 AAGGACCCAGGTCTACCCTGGCCATTGA CATTAGAGGGCCAGGGATCCTCCCTCAC CCCACCTTCTGCACGCTTCTGTAGGG 2013 3345244 9 AMOTL1 CCCAACCGAGAACATGAACTTGCTGGCC 0.001689593 0.006558789 5.28E−06 ATTCAGCACCAGGCCACAGGGAGTGCAG GACCAGCCCATCCTACAAACAACTTTTC TTCCACGGAAAACCTCACTCAAGAAGAC CCACAAATGGTCTACCAGTCAGCACGCC AAG 1534 3345406 3 SRSF8 TGGGTCCTCCACTAGCTCTCGCTCTGCAT 0.010080553 0.006911306 3.45E−06 CAACCTCCAAATCGAGCTCTGCGCGACG ATCCAAGTCCTCCTCGGTCTCCAGGTCTC GCTCGCGGTCCAGGTCTTCA   82 3345480 4 RP11- GATCCATTTAGGTCAGCTTTAGTCAGAA 1.81E−08 0.037576248 4.27E−05 712B9.2 CTGTAAAATCAGCAAACATAAGAAAAAC AAAACCTAGTAATACATACAAAAGCTTT CATGGGTTCTAGAACCTTCTTAACTGCTG ATTCATGTGGAGGGCATTAAGAGTTGAA AAGGCTTATATGGTTAACTACCTTAGAC TATATCTACAGCAGGGTCTGGTTTGCCA GAACAAGTTTAAAGTGGCTGTTTATTAA GTTTGCTATTTTCAGAATTGAAACTATAA GACCGCCATTTGACACTGAAACTTGCGT GAATCCTAAATTGCATCAATTATCTATTT GATAAAAGCTTATTCTAATTTAAAACCTT ATAGAGTAAGAGACTGATATATATAGCA GTCTTAAAGATCACGTCATCTGCCTTACA TTAGTCCAGTCACGTGCTTCGTA 1964 3345483 4 RP11- TCAGTCTTGTGTGGGTACAGGTTTATATG 1.05E−05 0.010257851 4.80E−06 712B9.2 TGCCAACTAAATGAACTGTAAGCAGCAC TGTGAGCACTGATTATTTAAGGTGACTG AGGATTACTGTCAGTGATAGGATTGTGT TATAATTCCACTTATATACATCTGATATG GAAAACTGAAACTTCCATTTTAGAAGAG AAAGAAAATAGCTGAATTTGGCATTTCA GTAGCATGCTATAGAATTCATCATGATT AATTTCACATTAAATTATGGGCAATAGC TGTATCACATTTCA  959 3345752 5 MAML2 GCTGACTCATGTACCTCACCATGCAGAT 0.001302035 0.007036077 1.13E−06 GAGGGTGTGTTATAACCCACAGTGTGTC TGTGTCCCTGGATGAACTGAGCACTTTAT A 1290 3346491 4 YAP1 CTGCCTACTGTGTCGTCTTTTCTTATGTT 0.000368854 0.008650836 4.28E−06 GAAGTTGACAGACCTGCTCTATTCTCAT ACTAATAGACTATTTTTAGATTTTTTTAA AGTAATCACAATAAATTCAGTATATCTT AAGTCTTTTGGCTTCCTGTGAACTTCTTC CCTTGACAGTTTATCTTAGCACTGAAAC ATCAAATATATTGTATCTGCTTTATCTAA TACTCAGAAACAAAGAACCTACGTGACC AATATCAAATTTTATTTTTTAGTTCTGAC TCCTAAAGTCTTGCTGTCCTATCCTCAAT GCTGTTAAAAACTTCTGAGGTTCCAGTTT TGTTATGTGGTGACTCCATTGGCTCCTGT CTTCGTCAGTCTGCTTCTTCTTGGGTA  401 3348854 2 DLAT TTTGCAACCAGTACAGCCTGCGCGGGGC 0.025452776 0.011991906 1.01E−05 GCGGCCCAGTCCATCCCCCTTCGGATGC GCAGAAGCAGAGGTCACCACGCCGGAC CCCTCGATTCCCTCGCGGGCGATTCCTGG CTCCTTCACCACCCCAGCACTCCAAGAC CCCCGCCCTTTGGCCTGAGGCTCCCACTG CCCTAGCCAGTTCCCGGGCTCACTTCCA GCTTTTCCAGAAAGCTTGGCCACGCCC  349 3349774 4 ZBTB16 CCTTTTGGGGATCTGGCATTGAAGCATCT 0.017855277 0.010864318 6.21E−06 GTTGATCCACTGTCTCTTCGCCACTCCTT GTCGTAACACGAGAAGTGATTCCTA 1915 3350647 6 CAACCTTAGAGGATAGAGCATTATGTGG 0.00028925 0.007811622 4.02E−06 AAGGAGGGTGAGGACTTGATATGAAAA AAGTGATGACATACCCCTGGTTCATTTCT GGGTTTCCTCCTAGGCCAATTCAAAACTT CCAAAATAAGGTCAAGTAACACAATAGG CTCACACTTGCATCACAAGCTG 1210 3350849 6 ATGGGCACACTCTTGGCATCAACTCTCTT 0.038283273 0.007497037 3.10E−06 GGTCCAATGGCAACCCTATATATTGCAC ACGGGACACTTTCTGTGGGGACTCTGAG ATGCAGAGGGACCAGATAACAAGCAGG AAAGGTAGGGCCTGGTGTGAGGGCACG AGACTCACCGACATCCCTGATGACAAGC CTGTAGGTCCCTCGGGCTCTCTCCCCCCA GCATCGCACAGTGGAGAAGGTCCAGTCA TTGAAGCCGTTGGGATCCCTGAGGAAAG AACACAGCAGAAACAGGTGGAAGGCGT GGGCCAGAGAGCTGACCTTCCCCCAGCA ACACTTTCTTACTGTAGTAGCCGTGGAA ACAACCTGGGAGGGTGCCACGAGGGCTT CTCAGGTGCCCCTTTCCCCTGGGGTCTCA TGGAAGGAGGAAATTGTGTTAACGTGGT GTGGTGGAAAAAGCAAGCATGGAGCGC GCACAGGCTTGGAGTCCCACGGATCTAG GTTTATTCTTGTTCTCTTGGGCACTTACT AGCTCCATGACTTGTTTTCTTTTTCTTTCT TTTTTTTTTTGGAGACAGGGTCTCACTCT GTTATCCAAGCTGGAGTGCAGTGGCATG ATCACAGCTCACTGCAGCCTTGACTTCCT GGGTTCAAGTGATCCTCCCACCTCAGTCT CCTGAGTAGCTGGGACTACAGGCATGTA CCACCATGCTCAGCTAATCTTTAAATTTT TTGTAGAGACAGGGTCTCACTTTGTTGCC CAGGCTGGTCTTGAACTCCTGAGTTCAA GTGATTCTCCTGCCTTGACCTCCCAAAGT GCTGGGATTACAGGTGTGAGCCACCACA CCCAGCCAGTTTCCTCATTTGTAAAAGG AGGTTACAAAGTCTAATCTAGGGGGTTC TTAGAAGGATTAGAGAACATGTATGTGA GGTGCAGGGCCTAGCGCTTGAAGAAGGT ATGTGACGAAAGGCTTCCAGCCGCCAGG GATAGCCAGTGCCACAGTAGTTTAGGAC AGTGCCAGGATCCACTTCTTCCATTTCTT TTCCCTGGAAAGGCCCTTGCTGAAAAGG TTGCTCAGGCCTCGGGCGGGTGTACATA CGAGTCCATGCTGCGGGGGGCGCCGATG AGGGACATCATGCCACTGGGGCAGAACA GCTTCAGCTCCAAGCTGCCGCGCCGTGG GTGAGTGATGGAGACTGTCACTGCCACA TGCTCCAGGGTCTTCAGCCCTGACATCTC CAGGTCCATCCTGCTGACTGTAGAAAGT CAGGCTGGGCAGCTGGGAAACCAGCCCA CAAACACGCCTTCACTTCACCCCCACGT ACACAAAGACACACGCTCACTGAAGCCA CATACAAACATCTACGGCAACCCTAACT GGGACCTCGCCTATACTAGTAAATGGAA TGGAGCTGCTGCTCTCAAGTTTACAACG TAGCTTCGAGTGCAGTTGGGAAGACGAC ACATACCCAAGACACAATATAAGAATCC AGCAGAGCAACTTCAATCATTCATTCAT CCAAAACATTATTTACTGGGTACCTCCTC CATTTCAGGCACTGTACTAGATGCTGGG AATATAAAGATAAGATGGGCGTGGTCCC TGCCTCCTACCTGCAAGTGGAAAATGAT ATGGTATGGGAAATATACATAATTGATA AGGGAAGAGAAATAAGTCAGATGGGTTT AGGCACACAGCAGTGAGACACACTGAA GGAAATGAATACAGATCGGTAGACAGG GTTGGTAGAGGGCATTCTAGGCAGTGGA AAAGGCATGAACAAAGACGAAATGCAC ACATCTCACTGAAGATGATGCACAGTTA ATTTTTAAAAAATGCTGGTGGATAAATT TCAAGCAAATTATGTGAGTGAAAAAAGC AATCTCAAAAGAAGCATATAGCCAGGTG TGGTGGTGTGCACCTGTGGTCCCACTAC CGGGGAGGGTGAGGTGGGAGGATCGCTT GAGCCTGGGAGGTGGAGATTGCAGTGAG CCATGCTCATGCTACCACACTCCAGCCT GGGCAACAGAACAAGACCCTGTCTCAAA GAAAAAAAAAAAAAGAAAAAGGATGCG TAGCACACAATTCCATTTAGGTGATGTT AATTGAAGTACCTGCAGTGATACATAAC AGATAAATGGGTGCCAGGGGCCAGGGA CAGGGGAGGGGATGGGTGTGGCCAGAA AGGGGTAACACAAAGGAGTCTTGTGATA ATGGAATTGTTCTGGATCTTGGTTGTGGT GGTAGTTATGCAAGGCTACATGTGATAC AATTGCATACAGCTACACACGCGCATAC ACAAATATTGACAGCATGTGTATCTGGT GAACTCCAAATAAGCTCTATGGATTGTA CCAATGTCAATTTCTTGGTTTTGATATTA TACTTTAATTGTGTGAAACATTAAGATTG GGAGAAGGGTGCACGGGACTTCTCTTGT ACATTTC 1024 3351637 4 UBE4A CACGAGAGTCAGCTGTTGGAGAATTTTG 0.0001886 0.013100313 9.63E−06 AAATCATTGACAAGCTTGTGTGTTCATTA AGATTCTTCTCTTTTTAGGGTTTCTCCCC TTCTCTTCTTTCTTTTCCTTCCTTGTCCCC TTTCCCCAGAAAACATTTTTTAAAAACC AGCAGTTAGTGCAACTAATGTTCAGTCA GCACACAGTG 1511 3351903 3 C2CD2L GCAGGGGCGGTTCCATTGGCTCAGCTTC 0.000138152 0.006533071 1.21E−06 TTCCATTTGTTTCCTCTCTGGGATGGAAT TCAGGAAGGGAGAGTCCTCGAATTAGGA GTCCTTGGGTAAATGGGGCAAGTCAGCC CAGTCACTTT   83 3352135 7 MFRP; GGGGACTTACACTTGCCAGCACAGCACA 1.97E−07 0.031497369 3.10E−05 AP003396.1; CTCCTCTGGTCTTGGGCAGAAATCCAGC C1QTNF5 CACTGCCCCATGCTGCCAGACCTGATCG CAGACAGCCACTGTTCCCATTCCTTG  992 3352315 1 GCCTCGGGCTGCAGACTCTGCTGGTGGA 0.000142286 0.008881946 2.42E−06 TTCAGCGATGAGGCCCTCAGA 1718 3354757 6 AACATCACCGTGAGTCTGAAAGGACCAC 0.00050277 0.011369051 1.04E−05 AGGTTTTTCTGCAGCTATTTTCTAGCATT TGCCAGTCCCTGTGCCTGGACTGATTGG AACACTTTGTTTTTCTCCCTGTGCCATTT ACCCTTCCACCTTTCCATCCTGCCTTCTA CCACCCTTGGATGAATGGATTTTGTAATT CTAGCTGTTGTATTTTGTGAATTTGTTAA TTTTGTTGTTTTTCTGTGAAACACATACA TTGGATATGGGAGGTAAAGGAGTGTCCC AGTTGCTCCTGGTCACTCCCTTTATAGCC ATTACTGTCTTGTTTCTTGTAACTCAGGT TAGGTTTTGGTCTCTCTTGC  482 3355746 4 FLI1 CATGCTCCTCCTATCTGGGCTGCAATCAG 0.018924879 0.010554527 5.80E−06 CAGTGAGGAGAGGAGCGACAGAGCA CATGATTATGACCGGGGCTTGCTGCTGA GCTGCAGGGGTTCAGAGTACTGCTACCT GTGCAATGGCAGCTTCCCCAGAGCGCCC AGGGGCTCCGAGGCCACAGACAGAAAA TATCTTTGCTACCACGTGCTGAAAAATA  554 3355776 9 FLI1 AGAAGAGGAGCTTGGGGCAATAACATG 0.010763744 0.009348037 6.32E−06 AATTCTG 1467 3355783 9 FLI1 CGGGCCCTCCGTTATTACTATGATAAAA 0.000731459 0.00654568 4.54E−06 ACATTATGACCAAAGTGCACGGCAAAAG ATATGCTTACAAATTTGACTTCCACGGC ATTGCCCAGGCTCTGCAGCCACATCCGA CCGAGTCGTCCATGTACAAGTA  971 3357277 4 RP11- CATGAAACTTATATGTAGACGTTCCTAA 0.000111639 0.013337881 8.58E−06 700F16.3 TTAGTGGCGTGTCTGATACCAAACTAGG TATCTTTTAAATTTTTATTATTCTACTATC AGTTATATTCATTTTTCCCCTCATAAAAT ATTCCTTAAAGTAAAGAATAAAATTTCA CAATTCATTTCAGACTCTTCTTATCCTCC TCCCCTCCAAAATTTCTACATAACTGCAT GGGGTCAGTTACAGATACATCCAGA  516 3357313 3 ACAD8 CTAGAAGATAGAATTGTGCTGGGCTCCC 2.85E−06 0.014817037 1.29E−05 TCGACCTCACTGACTTTCTCACCTTCTCT CTGCTGCCTTTTGATCCCTCCTC 1814 3357388 2 GLB1L3 CCACTCCCGGCCGTGAACATATTTTTTGG 0.00180613 0.008448428 5.79E−06 GTTGCTGGAGTTCATCTATAAGTCATTTT TGAGGAATAAGATTTATGTTAAGACTAT CAAACACAGTGTTGCCTACAATAGCAAA AATGTGAAAATAACAACAACAACAAAA CAGCAGAGGAATTGTTATGTATTTTGTA GTCTATCTATATGATGCCTATTTTTAGGC TTTAAAAAGTCTTCAAAATCTTTAATGAC TGATTTATCTAGTTAAATGCTTAATCCTT AGCAGGCTCTTATTCTTTAATTAAACGTG CCTTTGAGTAGATGTG 1086 3359084 3 H19 AACCACTGCACTACCTGACTCAGGAATC 2.99E−05 0.013078059 7.77E−06 GGCTCTGGAAG  528 3359501 3 NAP1L4 GATATTTCCCGCCAGTCCATCGTTGGTTT 9.46E−05 0.014646313 1.11E−05 TTTTAACCTCACGCTAGTCTTTTTTGCGG TGGAGAAGTTTTTCTTGTTCATGGCCCTA TCTGTTGAGCTTTCCCAAAATAGCTTCTA GTAAGTGTTGTGTACTCCAAGCAATCTG TC  842 3360089 3 OR55B1P TGACAGTGCCCTTGGTAGTACTAACTGC 0.006167603 0.010590966 7.17E−06 AAAAGCCCGATTCTGCCGGACAGCAGTG ATTCGACACTTCACCTGTGAGTGCATTGC ACTGCTGAGCATAGCTTGTGGAGACCTG ACCTTCAACAACTGGCTGGGGCTGGCTA TGTGTTTGGTCACTGTAATCTCTGATATG GCCCTGCTGGGGACCTCCTACACCCACA TCATCTATGCTGCCTTCCGGATCTCTTCT TGG 1780 3360163 1 CTGGTGGCTCCCAACATGATAGGACACA 0.002951948 0.006890013 7.80E−06 GAAACTCATGCTCAATGGTACCCGTACT TCGATAAGGAGCAACAGCAAAGTCAGAT GGTGGAAGATCTGTCAGGTGTTTACTTA TGTTGTAGATATGGTTACAAAGCTCAGG GAGCCCCTGTCTAATGGGAAATATGGCT ACCAAACTGATGATGGCCTCCCAGGGAA TCCAATTCTGC  430 3360381 9 OR52A1 CTACATGCCCTCTGTGTTGACACTAGTAG 0.000412342 0.009965671 3.84E−06 GGATCCCAGGCCTAGAATCTGTGCAGTG CTGGATTGGGATTCCATTCTGTGCCATTT ATCTCATTGCTATGATTGGAAATTCCTTG CTTCTGAGCATCATCAAATCTGAGCGCA GTCTCCATGAGCCCTTGTACATTTTCTTA GGCATGCTAGGAGCCACAGACATTGCAC TTGCTA  611 3360900 1 CCTGTTAGGCCAGAAGGAGACTGCACCC 0.000148906 0.009149581 4.11E−06 TTGGACTGGCAAGTCAGTGCAAGGCCCT GCTAATAGGACTATTGAAGACTCTCACT ATGGGTTTTCTGTGGGGTGTTTGTTTCTT GGGGTGAAAGCTTCCCTCTCCCCAGGCA GGCCCAGCAAAATCTGTAGGA  230 3361622 5 TUB AGTGAGTCGGCCTCTTGAACTGCTCAGG 0.000457168 0.017258817 1.23E−05 AAACATCCCCAGATGGAGAGAGAGAAA CAGGCAGTGGGTGAGACCAGAGCTCCCA CCTGAACACAGTCCCCAGCACAGCATTT TTGACTGCACCCCGAGTCCCACCAGGGC CCCTGTACCACTTCTACAGCCCACAGGA TCAGGCCCACTCATCTCTACTAGGCAAA GATTCCAGGGCAGGCCCAGCTGGAAGGA GGCGGCACCCCCAGCCCAGTGTAATCAA GTCAACAGCCAGACCAAAACCTGTGATC AGCCAACAAAGTGCGCACTCAAAAGTTC TGGGCCACCAAACCATACTGAGCCTGAA CAGGGGCAGGGAGAATGTCTGAGAGGA TATGGCCATTGAAGACGGGGAAGAAAG AACAAAGGCTGCATCTTCTGGAAGAGAC CACAACCAGGGCAAGCACTCCAGGGAG CCTACGAGGGGGCTCTGCGGGGATGAGC CCATGGGAGGCTGGGGTGTAGGAGTGCT CAGAACAACAACTCTGGGACACAAGAA GCTACAGGCACCAACAGTGAGGTCTCAG AAGGGTCCCAGCTGGTGGCCTCCAAATT CTCCATACTGCAGAACCCCAATCTGCTC AAAATCCTTGAATGGTTTCTGATTGCTCT TAAGCTGAAGACCAACATTCTCTCCCTTC CCCTAGGTCTAAAATAAACACATACTCC CCACCTCTGGGGCACCAAGAGTTGCAGC CACACCAGGCTGGTCTGTTGCCTCACAT GCACTGCACTCCCTCTTGCCACAGGGCC CTTGCTCCTGCTGCCTGCACTGCCCTCCC CCTCGCCCCCCTCAGTGATCAACTCCCAC TCATCCTGCAGATTTCAGCTTGGATGTCA CCTCCCGAGGGACGCTGTGCCTGCCTCC CTCGTCAGAGCAGGTGTTGTCATCTACTC ACAGAATTTGGCTTCCTTCCACAAAGCA ACCCCGTGACCATCTGTTTAACATTGTCT CTCCACCTAGACTGTAAGGTCCGTGAAA GCAGGGACCACACCCATTTGTGCTCACT TGGGACCTACAGCCTCTA 1111 3361630 2 RIC3 GTAGGAAATGCTCTTGGTCACATCAGAA 0.010262873 0.007017678 4.08E−06 CTCTAGATCTGGGGGAATA   91 3361748 1 AAGCATTGAATGGAGCACCTACCTGCCC 0.001151831 0.018169375 1.73E−05 CCAGTCAGAACATCCCCATCTCGACTGG TGATGAGTCAAATGCAGGGATCACAGTG CATGGGGAGA  122 3362161 2 NRIP3 AGTCAGTTGTCATGGGGTCATTCCCTAG 0.007173756 0.01771743 1.45E−05 GCCCCCTTCCTATCAGCCTCTACCTAAAG AAGCTAGATAGGAAGCTAAGCACAGCC ATGGTTGGGAGGCTATATCTAAAGCTCA TGAGGGGTGATCCCGGGGTTACCAGCCT TCAGCACTCCCTCTAGCAACACCCCATTC TCTTACCTAGCGGGGATTTGTACCTTTCC ACTGAGGCCTCTCCATGCTCMCCCTAC CTTTCATGGCAATACTTTGGCCTGCCTCT TATCCTGGTACTAAGTTGAAGTAAAGCT CACCCTTTACTTCCCTACTTGAAAGTTCT ACTCTGAGCCTTGACTCTTAGCCACAGT G  649 3364941 9 ABCC8 CTTCCTGACAGCGAGATAGGAGAGGACC 0.001173835 0.011380468 9.19E−06 CCAG  242 3365534 2 SPTY2D1 CAGATGCCAGCCTTGATCCTGATGAGCT 0.000208981 0.010413807 5.07E−06 ATGCACTCTAATGTGGGGCCACTCACCA GTCAGCCAATCTTTTATTGTTCCTTTGCT ACTTTGAAAGGAAAAAAAAGGTTGTCTC TTGATTTCTGTAATTCTTCTGCTGATCTG TGAGTAGGGCACTGCCCTGCTCCCAATC AAACTTAGT 1417 3366734 5 LUZP2 TGCTCCTTTCCCTTATGTCAACTCTCCCA 1.89E−05 0.00914798 8.89E−06 CAGGCTCTAGGGAATCCCTTCTCCTCTCT TAATGGCAAGCA  457 3369637 5 LDLRAD3 GCTTCTTGTGTTCCCACAAAACAGCTTCT 0.00020038 0.010462696 7.14E−06 GTTCAAACTTCTGCCCAGAGCAACTCCA TCTCCAGACACCTCTCCAACCCCAGTAA AAATCCCAAACTTGTGTAAACACGCAAA G  425 3370248 6 TTTAATGGCAGTGTGTTTTAATGGCAATG 0.008126841 0.0128565 1.47E−05 TGTTTTATTTCTCTGGTGGAAAAAAGGGT TATGCTCCAGCGACCTAA  887 3370702 3 RP11- CGCAGCCTGTGGCCTCCGAGATTGGCTT 0.0007279 0.006946076 3.70E−06 384E5.2 CTCTG  735 3370815 6 TGTGCAAAGTACGTTCCCGAGAATTCAG 1.54E−06 0.013058631 1.33E−05 TGAGTTCTTCTGGACAAAATAAAC  505 3371611 9 AMBRA1 AGGATCCAGAGAGCACCCAATTTACCCA 0.004360173 0.007627791 2.57E−06 GACCCAGCGAG  434 3372262 2 CELF1 CTGTACAGCTACCTTCTGGGAAATAGTTT 1.18E−05 0.011210977 4.51E−06 TTGACACCTATTTTTCAGATTCTTGTCCG GAATTTCTGCTGCTCTTTTCAAAAAAGG GCATTAACAATTCTCTGGAAATAAAGCA CCTGTTAGCCTGACATATGCAAAAAGCA GGGCGGCATCACCCATTACGAGCTCCCC CAGCCAGCAGTCAGTATTGGATTGGCCT TGCC  427 3374540 4 RP11- CAAGTTGTCTTTGTTATCGGCATCATCTG 0.000148906 0.011207134 8.37E−06 142C4.6 TTGCTTTCTGAGGGAAGTATTTTGAGTTC TCCTACTGAGACTGTGGATTTGCCTATTT CTTTTTGTATGTCAGCTTTTGCCATATGT ATTTTGTAGTTGTGTTGTGAGGAAGATTC ATGACTTATCTTGTGGGAGAATTCTGTAT TTAGCAGATTTTCGTCTTAAGTTCTGTTT TGCTTAGTATTGATGTTATTACTTTGCTT TTTCAGTTTCAAAATCATTTAGTATATCT TTTTCCTTTCTTTTAGCCTTTGTGTTTTTA TTTCAGATGTGCTTTCTTATGTACTGACT GTGATCCCCAAATTCATATGTTGAAGTC CCAACTCCAAATGTATTTGGAGGTGGGC CTTTCAGACGTAATTGAGTTTAGATGAC GTCATGAGGGTGGAGCCCCCATGATGAC ACTAAGTCCTTCTAAGAAAAGGAAGAGA GTCTGAGCCCTCCTCTACACCATGTGAG GGCACAGAGAGAGAGCAGCCATCAACA AGCTGAGAGAGGAGGACTGAGAATGAA ACCTACCTCGCCAGAACCTTG  634 3374581 4 RP11- GTTAGGCTCAGCTTATTATTATGTGGGG 0.013588933 0.010869048 7.19E−06 142C4.6 GCTCAGCGTCTATACCCACCTGAAGCTG GGCTGTCCATGAGGCTTCAGTTCACTAA CCAGATGTGCATGAAACAGATACAAAAA GGGGAAGCCTTTAGGGCCAAAAAATAG ACCTAGGTTTGTATTACTATTTCAGCTTA ATCGTGTATACCTTGTGTTTCCTCGGCCA ACAATGGCTAATTATGGTAAATACTATT TAGAATTATGTGCTATGTACTAAGTGTTT GACATATGGTATCTCATTT 1090 3375092 2 SLC15A3 TTGCTTCACTCTACCGGACAGACGGCAG 0.000358678 0.009310369 7.70E−06 CAGTCCCAGCTCTGGTTTCCTTCTCGGTT TATTCTGTTAGAATGAAATGGTTCCCATA AATAAGGGGCATGAGCCC  160 3375544 2 FADS1 ATGAGCGTCCTAAGGCATGTTGGGATAG 2.85E−06 0.023685263 2.93E−05 GGTCAGATGCACCACCCATGGAGAGGTT TGTCAACACAAAGACATGGAAGGTTAGA GGTTTGTCAACAAAAAGACATGGAAGGT TAGGTTTGTCAACACAAAGACATGGAAG ATTAGAGGTTTGTCAACACAAAGACACA GGAAGAATGGGCTGCAGAAGATTTAGAT GTTTTCCATTTGGGCACATTTTACTTAGC TGGAGAA 1749 3375547 2 FADS1 GGAGGGACCTACTGAACCCAGAGTCAGG 0.002152759 0.00685867 2.62E−06 AAGAGATTTAACACTAAAATTCCACTCA TGCCGGGCGTGGTGGCACGCGCCTGTAA TCCCAGCTACCCAGGAGGCTGAGGCAGG AGAATCGCTTGAACCGGGGAGGTGGAG GTTGCAGTGAGCTGAGATCACGCCATTG TACTCCAGCCTGGGCGACAGAGCAAGAC TCCATTTCAAAAAAAAAAAAAAAATCCA CTCATATAAAAGGTGAGCTCAGCTCACT GGTCCATTTCTCAGTGGCTTCTCCATCCT CATTTGCAAACCTCAGAGGGATAAGGCA GTTGAACCTGATGAGCAAGAATTATAAC AGCAAGGAAACATTAATGCTTAGAATTC TGAGATCCAGCACAACTCAGTCTGTGGG AGCTCAGCTCGCTGCCCAGGGATAGGTA TGACCTATGTCTGCCTTAGGCTGCTGGG AGATGCCATTCTCCAGTTTCAGAAGCAG GCAGGGCAAAGGTCAAGACTGTGGTATT GGGGTCTTTTGGCTCTGAAGGATCCTGG AACCACTGATTTTGGTTTATTCCCTCCAG GGTCTAAAGAGAACA 2074 3375864 2 MTA2 CGGACTTTCCTAATTGGAGTTTGAGGCC 0.000461778 0.007768584 5.69E−06 CCTAAGCTGGCATCAACCCCAGGCCACG CTCGCTCTTTCCTTCCCTCCCCTCCCCCTC TGCCTTTTGTACGCCAGTTCTCAGAAA 1462 3376302 3 SNHG1 CTGTACTGTACGCAACAAATGTCAGGGC 0.000579253 0.008432056 3.82E−06 CCTATTGATTTGTCTGAGGTGTTAGTGAA GGGTG  495 3376751 9 MACROD1 CTGAGCACCTCCACCGACTGGAAGGAGG 0.001974641 0.014172182 1.21E−05 CGAAAT  126 3377027 9 PYGM AGAGAGGGAATACAAAGTCCACATCAA 0.00035324 0.01933795 1.59E−05 CCCCAACTCACTCTTCGACATCCAGGTG AAGCGGATTCACGAATATAAACGACAGC TCCTCAACTGCCTCCATGTCATCACCCTG TA 1872 3377621 7 NEAT1 GCTACAACATAGACGCATCTCGAGGACA 2.62E−05 0.008003529 4.98E−06 CTGTGCTCAGAGAAATAAGCCAGTCACA GACAGACAAATACTTCATGATTTAACTG ATATGAAGTGCTTGGAATAGTCAAACTC ACAGAAACAGAAAGTAGAATGGGGTTG CTGAGGCTGGAGGGAATGGAATGTTTAA TGTTATTTAATGGGTACAGAGTTTGTTTT GCAAGATGAAAAAGTTCTGGAGATTGGT TGTACAACAATGGCGACATACTTAACAC TACTGAATGTATACTTAAAAATGATTCA GATAGTCAACTTCTATTATATGTATTTCA CCACAAAAATTTCTTAAAGTAGCAAGAA ATAAATAAAATTGTAAAAACCTGATGTT AGTGGCTATGTAGGGAAATGGATATCAT ATACTCACAACAGGAAGTGTAGCTTTCT GGAGTCATTTGAGTCTGTGAAGAGAGTT ATAAAACCATAAGTGCTCACTGCCGAGG CAATGCCACTCCAGGGGATACATGTGTA CACTAAATTTACAGAGATGCTCACAGCT GCACGATTTAAAGTAGTCAAAACAGTTT AACAGCTCAAGAGATGGGCTACATATCC TTTAGTATAAGCACAATGGCATAAAATC ATGCAATCATTCATTCATGATCTTTTTTG AGCACGAACAAGCAGATGAAAGTTATGC TTTCCACAGAAAAATACAATTTCAGAGC ATTTATAGACTTCTAGAAACCCATCCAT GGGACTTCCTTTGGGAAGGTTAAGAATC CTGAGAAAAAGCCTCTTCAAATGTGTTT GTGAACTCTGCCGGTACAGGGAAATA  442 3377625 7 NEAT1 ACCATAGGAGTTACTGTCTGTATTGTCCT 1.99E−06 0.018865238 1.97E−05 AGTTTTTGTATTGGATAGGAGATTCAGA AATGCTTACCACATTATTAAAAAACAAT TAAAGAAAGCAAGTAAAAGAGAGCCAT GTTGTGTCCTGAATCAAAGATTAAGATT GAGATTTACCCAGTTCTGTGTATTTGAGT TCCAACAGAGAGAATATTCTTGCCTTAC AGGAGTGTTCTAGCCTCCATTTACCAGA TTTTAAAGCATAATGAAAAGTGATGATC ATTACATTCCATTGCATTTTATTAACAAC AACAACAAAAACTGGAGCCTAAAATTTC CAGAAATAGATCCAGAGAGAAAATGTTA AGAACCATTTGATCTAGCAATCCCACTC CTGGGTATCTACCCAAAGGAAAAGAAGT CATTATACCAGAAAGACACTTGATGGCA GTACAAGTCACAATTGCAAAGATGTGGA ACCAACCCATCAACCAGTGAGTGGATAA ATAAAATGTGGTATCTCTACACCATGGA ATATGACTTAGCAATAAAAAAGAACAAA ATAATGTTTGTGGTTTTTTTTTTTTTTGCA GCAATTTTGGATGGAGCTGGAGGATATT ATTCTAAGTGAAGCAACTCAGGAATGGA AAACCAAATACTGTGTGTTCTCACTTATA AGTGAGAGCTAACTTATGGGTACAAA   85 3377627 7 NEAT1 CAGCTGCAGCCACTACGCAGTTTTACCC 0.002805201 0.030343821 4.67E−05 CAGTTCCACGGCACATGAGGAGAGGACC AACATTATTCTATTTTGGCAGCACGTGCT TTCAACCCATCTCACAAAACAGTGTCAC CAACCAGATGTGCCAAGAGCCAGAGCA GGTGAAGACACCTACAGATGCTGCCTCC TCTGGACACTGCCTCTGGGTGCCTCAGCT CTGCACCCAGAGGGATGCAAAAGAGATC CCCGCAGCACACTTTGAGATGGCTA 1514 3377629 7 NEAT1 CACACATCTATTCATAGGTGAAATTAAC 8.09E−05 0.009289123 3.99E−06 TGGAAGGAAACTAGCAAAGCATTTGCCT TTGGGGTCAGCACAGGAGCAGAGGCCCA GGCAGGGCCTTGCTTTGACACACAGATG ATGGGTCACACAGTTGTCACCTTGACAG AAGAGTAACAGGGACAGCACACCAGTC ACTCTAGGAGCTGAGGCCAGAGGAACTC AGGTATTTCCTTCTAGAGGTAGTAAGTC CA  826 3377633 7 NEAT1 CAAATTAAATAGACGTGAGTGGATGGAA 3.71E−06 0.014719313 1.56E−05 AGACGTACCTTATTCTTGCATAAGAAGA CAACGGCATGAAGACATCACAGGGAAG GTTAAGGTAAACATGCAGCCTGGAATAG C 1790 3377635 7 NEAT1 TCCAGGGAACATACACATATGGCCAACA 0.000417578 0.006683799 4.19E−06 GCACCAGCAAAGGTGCTTGATAGCATCA CTCATCAGAGAAATGCAAATCCAAATGA CACCAGAGGCTACTTCACACTCATTAGA ATGATTATAACCAGAAAGTCAGATAATA ACTAGTGTTGGCAAGAATGCGCAGAAAT TGGAACCCTCTTACTTACTGGTG 1329 3377637 7 NEAT1 CAGCGTCTTAGTCTGTCGCCAAGGCTGG 9.78E−06 0.011817785 1.08E−05 AGTGCAGTGGCGCAATCAAAGCTTGCTG CAGCCTTGAACTCCTGGGCTCAAGCAAT CCTCTTACCTCAGCAACTAGGACTACAG GCACATGCCACCACGCTTGGCCTTCTAA TTTATTTCTGTGTCAACAAAATAAAACTC AGGCCTAGGAATAGCTTGGTTCAGAAAT CACAGAGGGACTTAGTATTCCATTAATA CAAATGGAAACATTAAGTTCATCATCAG ATGATAAAAGGAAAAAAAAAAACCTGA TACTCATCTCAAAAGACGCAGAAAAGAC ATTTGCATAAATCCAGTACCTATTATTAT TTCAAATTTAAAAACTTCTTCTTTTTTAA GAGATAGGGTATCACTATGTTGCCCAGG CTGATCTTGAACTCTTGGCCTCAGATGAT CCTCCTGCCTCAGCCTCCCACAGTGCTGG GACTACAGGCATGAGCCACCACACCCAT CATAAATTAAAACTTCTGAACAATCTAG TAACAAATGGAAATGCTTTCCCATGATC CAGCACATCTAGCAGGGGGTGTCTGCTG ACATTCTACACAAAGAGACACACTGGAG TTGTGCTTCTCATCATTTCACATTAAGAA CCCAACTGCACCTTTTTCTGTGCCTCTAA ACACCTGTAGTCTGATAGGGGACACCC 1646 3377641 7 NEAT1 CTGCCTTCGCAGACAGGAATGCTGTCCT 0.000129873 0.010091592 9.01E−06 TCCAGCTTCTCCTACCCTTCGGGTCAGAG CCCAAAGGTCCCCACCCCTGGTTAGGGC TGTTTTCACTGGGCGGGGGGCGGGGGAC TACACTCCTTGGTAACTGTCACAACTGCC CTTAACTAATGATTTGTGCATTGCCACCT GAGGC 1590 3377659 7 MALAT1 CCTCATTTTGTCCACTGGTGAATTCAACT 3.52E−06 0.009063684 6.47E−06 GGAAGCTCCTTCTATAGTCTGAAGAATA CCATCTGAAAGAACTAGTGGTTCCCAAT CCCCACATTTAAAATGGAATGTTTGGTTT ATTTAAAGTAAATAGGCTATTTTTTCTTA CTGGGTCTGGCTTCTCTGGCCCTTCGCAT ACGTGTGTCTGCTGAGTGTTCCTGCATGT AAGAATTAAGACCAAGGGAGGGGAGAG AGAAACCCACACATAAACAATGCACTAA AGATCACTGAACTGTTTAAACATTTCCA CTTGCCAGTTTAATTTCTTGAAGACTGTT GCTTGTTTGGAATGTTTCTTGTCACTGAT TTTAAGGTTGCATCTGGAAAAGACTAAA GGCTTCAGTCCCCTCCCACCACCAGAAA TGAACAAAAAGCATTTTACCTAAAAATA CACCAGCAAAATGTACTCAGCTTCAATC ACAAATACGACTGCTTAAAACTGCAGAA ATTTCCTCAACACTCAGCCTTTATCACTC AGCTGGATTTTTTCCTTCAACAATCACTA CTCCAAGCATTGGGGAACACAACTTTTA ATCATACTCCAGTCGTTTCACAATGCATT CTAATAGCAGCGGGATCAGAACAGTACT GCATTTA  760 3378515 3 RP11- GGAAGTTAGCTTTTGGTCCACCAGCGAG 1.71E−05 0.011361311 9.90E−06 658F2.3 TTTGAATGGA  894 3379539 8 PPP6R3 CCATAATCAGGCAACAACCAACTTCCAT 3.93E−05 0.011032576 9.23E−06 GACTG  580 3379566 5 PPP6R3 AGTGCTTTGGAGTGTATTTATTTTCAAAA 0.006456347 0.011482378 1.43E−05 TGATCCATGATTGGTTTAAACATGCAAA GAAAAATGTACTGGAAGCTTGTCAATCA GAAAAGAGTAATTATTCTTCCACTTTGA AAAGTTCATATGAAGTGGGTAAATTCTG CAAGCTAAGAGCTTGGCAAGGGCTGTTG TAAGTTAGTTTTG  395 3379697 1 CCCCTTGGCCCTCCTGTTACGCTTGGGGC 0.001001048 0.01468751 1.53E−05 CCCTCTCCCTCCCCCTCAACCCCCTGGGT CCCCTGCAGCTGCGCTCGCCCTAGACTC C  290 3379916 1 GTTAAGGGCAGCCTCGGATCACAGAGGT 0.002099724 0.00944787 5.89E−06 TCCATTTCCGATTTTCCAGAAGTTGCCGA TTATTAATGATCATTGTTCTTTCCTTCTG GGGCATAACAAAGCAG 1596 3380081 2 ORAOV1 GGGTCGCCATGAATCCACTTTGGTTTTAA 0.000102061 0.006925599 2.34E−06 AACCATTCCCGAATGTCCTAGTGGATTG TGTTGTGCTGCCTAAGCTGCCGGCTGCA GGAGCCAGAGAAGTGACCCCCGCGGGA GCAGCGGCAGGTGGATCTCCACGGTGGC TCGCTTTGTTTTTGTTTTGTTTTTTCTTTT AAGACGGAGTCTCACTCTGTCGCCGAGT TTGGAGTGTATTGGCGCGATCTCGGCTC ACTGTAACCTCCGCCTCCTGAATTCAAGT GATTCTCCTGCCTCAGCCTCCCTAGTAGC TGGGATTATAGGCGCCCCCCACCACGCC CAAGTAACTTTTGTATTTTTAGTAGAGAT GGGGTTTTGCCTTGTTGGCCAGGCTGGTC TTGAACTCCCAGCCTGAAATGATCCACC CACGTCCACCTACCAAAGTGCTGGAATT GCAGGCATGAGCCACCACTCCCGGCCTG CTTTTTGTTTTTGAAGACAGGACTTAGGT CTCCTCCTCCCGAACTCTAAACCTGCGTG TGTGGCTGTGCACCGCTCGTTTGTAGCGT CACCTCAGGTCTGGGGAAGTCTGTGCTG GCATCTCCTCATTGTGCCTTCATCAGAGC TGGTGCCTTCGGGCCAGAAAGACTCTCG TTC   68 3380323 4 AP000487.6 TTCAAGAAATAGTGCATATCTCGTCTAT 0.000119134 0.03317763 4.24E−05 GCTGGCCGCTGCAGCAACACAGAAACAG GGCCTGTCCACTCCTCAGGATGCTTTAA AGAACAGACAGACGAGCTGGCAGGAAC CT 1302 3380437 4 SHANK2; TCTCCATCAATCATAGCCCGGTGTGTTTA 0.000378341 0.006723456 4.70E−06 A001271.5 ACTTAGAGTAGATGGTGGCACCACCCGA TAACAATGGTGGTGGCATTCAGCAGCAG CTCAGAGGGTTCCAGAAGCATTCCTCCA GCCTCGAGGGGAAATGGTGCCTCTGGCT AACGGAGGGAACCATCAAAGCCGGGTA TGGTTTCTTTGATCGTGTTTAGCCGCTTT GTGGCTGAGTAGAGATTCTTCCTTCTTCC TGTCCAGGTAATTAATGAGGGACTTCAA AGGCATGAGGCTTTTCTGCTCCAATCAA TTATTCAGATTGGCATATCCAAAGGTCTC TGAACAGGAAATAGAGAGGAAATGGAT TGCTAAGTGGTTATGATGGAGACTAAAT GAATTACTTGTTAATCACCCTTGTCTGCT CTGGTAGTATCTG  217 3381818 2 UCP2 TGGCTTTGTCTCTAGCCGGGCCATGCTTT 5.30E−06 0.022035487 2.14E−05 CCTTTTCTTCCTTCTTTCTCTTCCCTCCTT CCCTTCTCTCCTTCCCTCTTTCCCCACCTC TTCCTTCCGCTCCTTTACCTACCACCTTC CCTCTTTCTACATTCTCATCTACTCATTG TCTCAGTGCTGGTGGAGTTGACATTTGA CAGTGTGGGAGGCCTCGTACCAGCCAGG ATCCCAAGCGTCCCGTCCCTTGGAAAGT TCAGCCAGAATCTTCGTCCTGCCCCCGA CAGCCCAGCCTAGCCCACTTGTCATCCA TAAAGCAAGCTCAACCTTGGCG  997 3383041 2 RSF1 CGCTGGGATCCGCAGAGGAGCCCACTTG 0.039284329 0.007912749 2.11E−06 AGAGCGCCTCCTGTCGTCTGTAAGGTTG CCTTGCCATCCCTCGGC 2007 3386740 6 ATCGATAAGTAGCTCCACCTGAAGAGGG 8.24E−05 0.00957179 7.94E−06 ATGGAACCTCTGGGTCAGGAAACAGCTG GAATCCACACTCACCTCATTCCCATTGTT TGGATCATGCTTCTTTCCAACACGTGTTC ACAATCTCCAAAGGGACTGTATTTCTTCT CTGTGCTTAATGTGATTTGA  864 3387255 2 SESN3 TCTTCTCTCCAGCTAGGTGCACTTGAGGT 1.75E−06 0.014386509 9.69E−06 TGTTCATAAATGTAAAATTATGTCAGGTT TCTAACATGGGACACTGCACACAGTTGT CTGACCTGATGAACCATCCCATTTGAAA GTATAGATTATTATTATTTCTTGTAGTAT TTGGTTGTTTTCCATCTCATTCATGAACA ACTCAACCTGATAGTAGTATCCAATAAA TGCCTTTCAGGGCTCAGGAATGAATTGA CATCCTAGTTAAGAAATGAGACTTAATA ATGGAGACTGAATGAGGCGGTTTGTATT AAATTATATGCCATGAAGTGTTCATTTTA GCTTTAACCTAATTATGACTGTACCACCA TGAAGTACAGAATGAAAAATTATATATA TGGGGGGGAAACAGAATGAATATCTGAT TCTTTTGAATGCTTGTGGAAATCTTTGAG ATCGTGCAGGGCATACCACAAAATAGCC TTTAGAACAGATACCCAATTTTACAGTTC ATAGGACAACATCAAACATTAGTAAGTC TAAATAAGATGAATAGAATTTTTTGTTAT GTAAATTTTGCTAGAACAGTCTATTTTCT TGCACCCCTCAAGTTAACCTCTTAAAAA AATGAATGTATAATTTCTACCGAAAGAA TATCAGAGAGAATCTCTCTGGCCTATAG TGTTAAAATATTGTTCACAAATCCTGATT AGTTAAGTGCATACATTATGAAACTTAC AGAATAAAACTTATTATACATCTCTTTCT TAAATTAATATCTTTACACATTTTCAACT GGCTCCCCAAGTCTGATAAGGAAGGATT AAAAGAAAAAAGAAATGTATTAGTTGG GTGGCCAAGGAGTTTCCTTTGTAATGTTG AGAGACTTCCGCTTTCTGAATTTCGCTGG TTCTCTAAGGTAAAAGAGTTAAATAGTA CCCTTGTTCACCAAGGAAAGTGATCCAA ACTATATATCTAGTGCAGATATTTCCTTT GCATTATTTAGTCTTCTCTGGAGAGAAA ATACAGTTTCCCCTTCCTCTTTCTCTTCA CATTTACTCTTTTCAACCCAAAATAAGA GACATAGAAAGCAAACCACAGCCAGTTT GGCATCTTCTCAGTGCTACTAGTA 1050 3389367 9 CASP1 AGTCAAGCCGCACACGTCTTGCTCTCATT 0.005684569 0.008445273 5.16E−06 ATCTGCAATGAAGAATTTGACAGTATTC CTAGAAGAACTGGAGCTGAGGTTGACAT CACAGGCATGACAATGCTGCTACAAAAT CTGGGGTACAGCGTAGATGTGAAAA  150 3391911 8 ZBTB16 CCCGAACGCATCAGGTGCAGAGACCGGC 0.005359393 0.01781851 1.50E−05 ACCCACCGAGAGCGGCCGGGAGCGCAC GGCGAGCTCCGGTGTCACCGCCGGTCCC GCCGAGAGCCGAGGAGGGCCCGCAGCG CTGCAGACCCTCTGGAGCTTCCCTCCCTC CCCTGCAAAAGGGGGGTGGGGATCAAGT CCAATCAAGAAAAAGCCCACCACGTTTT CTCAAAGAGAAACAAAACGTAAGCAGT CCCAGTCCTGCTCCCCTCCGCCCCCAGAT CTACTCGTCAGCTCCTCCGATT 1501 3392582 8 AP000797.3 CTCTACCCTTTCCAAAATCAAGGTGAAG 0.00060261 0.007086086 3.38E−06 GCAAGACGGCCTCTTCCAGCT  880 3393305 8 CEP164 TGCCTACACTGAGAACTGAATGATGAGT 2.01E−05 0.008257925 3.45E−06 AGGTATTCACTAGACAAAGAAAAAAAG GAAAGCGTGTTCTAACAGATGCATGCAA AAGTCCTTCAGCAGAAGGCAACACGAGG CAAGAAGCAGCACAGTTGGATAGGATGC TGGGGAGGCCAGTGGGAGCCAGGCCAT GCAGACTTGCCCTTTATCATAACAGAAC TAGGGCTGGGCACAGTGGCTCACACCTG CAATCTCAGCACTTTGGGAGGCCAAAGC AGGAGGATCGCTTGAGCCCAGGAGTTCA AGACCACCGTGAGCAACATAAGACGACC CTG 1627 3394419 9 THY1 GAAGCCTCAAGTTCCAGTGCAGAGATCC 0.00080419 0.007549673 4.89E−06 TACTTCTCTGAGTCAGCTGACCCCCTCCC CCCAATCCCTCAAACCTTGAGGAGAAGT GGGGACCCCACCCCTCATCAGGAGTTCC AGTGCTGCATGCGATTATCTACCCACGT CCACGCGGCCACCTCACCCTCTCCGCAC ACCTCTGGCTGTCTTTTTGTACTTTTTGTT CCAGAGCTGCTTCTGTCTGGTTTATTTAG GTTTTATCCTTCCTTTTCTTTGAGAGTTC GTGAAGAGGGAAGCCAGGATTGGGGAC CTGATGGAGAGTGAGAGCATGTGAGGG GTAGTGGGATGGTGGGGTACCAGCCACT GGAGGGGTCATCCTTGCCCATCGGGACC AGAAACCTGGGAGAGACTTGGATGAGG AGTGGTTGGGCTGTGCCTGGGCCTAGCA CGGACATGGTCTGTCCTGACAGCACTCC TCGGCAGGCATG 1415 3397595 2 ETS1 ATCAGTGGATTCTCGGGGITTGGACTTA 0.042209752 0.009491646 1.11E−05 ATGTTGAGCTAAGAAGCATTAAGTCTTT GAACTGAATGTATTTTGCATCCCTGGTTT TGGACGACAGTAAACGTAGGAGCACTGT TGAAGTCCTGGAAGGGAGATCGAAGGA GGAAGATTGACTTGGTTCTTTCTTAGTCC TATATCTGTAGCATAGATGACTTGGAAT AAAAGCTGTATGCATGGGCATTACCCCT CAGGTCCTAAGAAATAAGTCCTGAATGC ATGTCGTTCCAAACTAACACTCTGTAATT TTTCTTTTATGTCTTATTTTCCAAGAGTC CTCCATTTTTTGCACCCCCTCACCGCCAA CTCTGTTATTCAGTAGA  387 3398942 5 NTM CCTCTCTAAGGCAGTACTAGCGAAGACC 0.005672651 0.012339334 1.02E−05 GACTCAGATGCTGCCACA  319 3399568 4 NCAPD3 TCACCAGCAGGAATACGAAGTGTCCCTC 0.005792861 0.010903697 8.85E−06 TGGGTAGCCAGAACGAGCTGACTTCTGT TCCAAGGGGAGGGTGTTGAATTGAGGAC TGAAGGTGGAGCAAGAGCCAAGGTCCCT CAGGGTCTTCTGTGGAGATTTGGGGCTTT TGTCAAAAGCTACTCAACATGTTTCTAAT TCTTTTTCCCCATTTAGAATATATGAGTA GTATTTGTCCCCACCCTATCTTACAAAGC CTTCAGAGTGTTTTTGAGGTAATGCTTACA AAGTCTCCCAGAGAAAAGCAGAGGTCCT CTACATCCAGTATCATAATGAAAAGCAA AAATAAACTTACATAGTGTGGTAGGGTG GCTCTACTCAAAGAACTAGA  921 3399590 9 NCAPD3 GAGGATCAGGGATGAGAAGACCAACGT 0.001666372 0.010212699 6.68E−06 TAGGAAGTCTGCACT 1171 3399602 9 NCAPD3 GCAGTGTAGCCAATCAAGTATTCCACCC 0.001095886 0.008878141 5.06E−06 AGTGATGTTTGACAAATGCATTCAGACT CTAAAGAAGAGCTGGCCCCAGGAATCTA ACTTGAATCGGAAAAGAAAGAAAGAAC AGCCTAAGAGCTCTCAGGCTAACCCCGG GAGGCA 1498 3401999 4 KCNA1; ATGCTTCTGATTTTCTACCCCCGTATCAC 0.030501101 0.00691775 4.16E−06 RP3- TTTCTATTTCTCTGCAGCGTGCATCGATC 377H17.1 GCCCTGGTGGGAGCTTAGAAGGCGGCAG GCGAA  431 3402336 3 CD9 ACTAGCTTGAGTGGATTCATCTTGCTGG 0.000194662 0.013880303 7.94E−06 AAAGAGCTGACAGACTGGACCAGTTTGC ATTCCGAATGTAGGGATTCCCGTGGATA TTCTCTGTCCTGGATTGAGGGCTAATGG GCACCTTCCA  172 3402965 2 RPL13P5; GTTAACCCTTCTCTTGCTGCGGCAGAGTC 0.000284076 0.015901702 1.90E−05 LRRC23 CGCACCCGGGCAGGCCCATCTCAGAATT AACGCTTTGATGGCATCACCGCGTCGGG AATCCCTGGGGATGGTGTTCTCCACCGT CAAGACCTTTGAGCCGCCTGAGCGA  596 3404455 4 CLEC2D CACTAGACAGCAATTCAGAGCCTCCAAA 0.004749446 0.013360002 1.34E−05 ATAAAGAATATTCATAAAAGTAACAATA GAGGTAAATATAAAACCCAGAATTACTA CATGTGTCATATAGTTTATAACTTCTCCT ATTTATAGCTTTCTATATTTATATTTATCT ATAACTTCATAGGCAAATGAATAAAAAT TATAAATATGATAGTGGTCATATAATGT ATAAAGATGCAATCTGTGACAGTCTTAT GAAGCAGGGATGAAGACATATAGGATC AAAATGTTTGCATAGTTATTGAAGCTAT GTTGATATTATGAAATTATATTGTTACAA GTTTAAGATGCTAATTATAATTCTCAAG GTAACCACTAATAAAATTACCAAAATTA TGCAGAAAAGGAAAAAAGAAAAACAAT ACACTATAAAAAACCAATTAAATACAAA AAAAGTCAGTAACAGACAACTTGAGAA ACAAAGACATATAAGATATAGAGAAAA CAAATGATTAAATGGCAAAAGTAAATCT TGTTTTAGTAATCACATTAAATAGAAAA GGATGAAGCCATCCTATTAAAGGGCTGA GACTGACAAGTTGGCTAAAAACTAAAAT AAATTAAAAAGAAAAACAAGACTCATCT ACATGCTGTCTATAAGAGACTTGCCTTA GATATAAGGACACAAAGAAGTTGAAAG TAAAAGGACTGAAAAAGATATTCCATAC AAACAGTAGTAACCAAGATAGTGCCGAG TGGCTATATTTTTGTCAAACAAAATAAA CTAAAGTAAAATTTACAAGAGAAAAAG AAGGGCATTATGCATTGACAAAAATTTT GACATAGCCAAATAATTATGTTATAAAA TATATGTACTTAATAATACAGCCTCAAA ATATATGAAGCAATAATTGCTATAATTT AAGGGAGAAAAGAACAGTTCTATGAAA AGTTAGAGAATGAAATATTCCACTTTCA ACATGAGATTAAACAACTAGACATAAGA TCAATAAGGAAATAGAAAATTTGAACAA CACTATAAACCAATTATCCCTAACAGGC ATATACAGAAGAATCTACCCAACAAGAG CAGAATATTAATTCTTCTCAAATGCACAT GGAACATTCTTAAACCATATGTTAGGCC ACAAAACAAGTGTTAGTAAGTGTGAAAA TTTGAAGTCATAAAAAGTATCTTTTGCA ATTACAATGGAATGAAGCTAGAAATCAA TAACTAGAAAAACCAGAAAAGTCACGC ATATGTAGAAATTTAAAAACCCGCTCTT CAACAGCCATTGGTCAAAGAAGAAATCA CAAGGGACATTAGAAAATACCTTGAGAC AAATGAAGTAAAAATACAAATAGCACGT TTATGGTATACACTGAACA  501 3405316 4 LOH12CR1 AGCTGAGGTGCTGTTAAGAAAATTCTGA 0.008884278 0.011806462 6.56E−06 TGTCTGGGTCTCACTCCGAACCGATTAG ATCAAAATCTTTGAAGGGTGATAGGGTT AGGGCGGTGGGATGTTGGGTATTGGTAT TTATGAAGGTGCTCTAGGTGATTCTAGT ATGTAACCAGGGGAGAACCAGTGTTTTG GAGCATTCATTTAAAAATAAACTGACTT TGGCGGGCGACATG  237 3405606 2 GPRC5A GACTCCAGTTCTTAGAGGCGCTGTAGTA 2.19E−05 0.020038313 1.78E−05 TTTTTTTTTTTTTGTCTCATCCTTTGGATA CTTCTTTTAAGTGGGAGTCTCAGGCAACT CAAGTTTAGACCCTTACTCTTTTTGTTTG TTTTTTGAAACAGGATCTTGCTCTGTCAC CCAGGCTTGAGTGCAGTGGTGCGATCAC AGCCCAGTGCAGCCTCGACCACCTGTGC TCAAGCAATCCTCCCATCTCCATCTCCCA AAGTGCTGGGATGACAGGCGTGAGCCAC AGCTCCCAGCCTAGGCCCTTAATCTTGCT GTTATTTTCCATGGACTAAAGGTCTGGTC ATCTGAGCTCACGCTGGCTCACACAGCT CTAGGGGCCTGCTCCTCTAACTCACAGT GGGTTTTGTGAGGCTCTGTGGCCCAGAG CAGACCTGCATATCTGAGCAAAAATAGC AAAAGCCTCTCTCAGCCCACTGGCCTGA ATCTACACTGGAAGCCAACTTGCTGGCA CCCCCGCTCCCCAACCCTTCTTGCCTGGG TAGGAGAGGCTAAAGATCACCCTAAATT TACTCATCTCTCTAGTGCTGCCTCACATT GGGCCTCAGCAGCTCCCCAGCACCAATT CACAGGTCACCCCTCTCTTCTTGCACTGT CCCCAAACTTGCTGTCAATTCCGAGATCT AATCTCCCCCTACGCTCTGCCAGGAATTC TTTCAGACCTCACTAGCACAAGCCCGGT TGCTCCTTGTCAGGAGAATTTGTAGATC ATTCTCACTTCAAATTCCTGGGGCTGATA CTTCTCTCATCTTGCACCCCAACCTCTGT AAATAGATTTACCGCATTTACGGCTGCA TTCTG  802 3406085 9 ATF7IP CTAAATCACACTCCTGTATCAACCATGA 6.62E−06 0.012402676 9.80E−06 GTTCTTCTCAGCCTGTGTCACGACCATTG CAACCCATACAACCAGCACCGCCTCTTC AACCATCTGGGGTGCCAACAAGTGGACC ATCTCA 1245 3406450 8 EPS8 GAGAGCATGGCCTGCCAACTTAAACCCA 0.043006584 0.007576256 5.93E−06 AATCAATT  590 3408793 7 BHLHE41 CCTCACTCATAGTCAGACTGTTGTGTCTC 0.000617654 0.008783782 3.44E−06 ACCCCTTACATAACATCCAAGTGAGATT TCTCACAGTGCTACCTTGGCAACAAACT AAAAATATCTAGACAAGGTCTTGGTTTA AGCCTTATTAAAAAAGCTTTCTTTGTGAT TATCTGGTATCTGGTTTGGTCTCCAGAAA ATACATAGACTTGGAGATAGGAAGGCCT CACAGGACTTC  855 3409273 4 PPFIBP1 AAAAAGCAGGGGTGCTACAGCAAAGAC 0.030178237 0.007142121 5.18E−06 ACTATCAGATGACAGATGTAGGAGAGTG GTCATGTCAAGAAGCAAAAGGA  727 3411330 9 LRRK2 TATCCATGTGCCTCTGTTGATCGTCTTGG 0.008812862 0.008052347 5.33E−06 ACTCCTATATGAGAGTCGCGAGTGTGCA 1021 3412547 6 AAATCTGGGAGTGTTCTTTGTGAGGGTG 0.001543869 0.010561963 5.59E−06 GAACAGACTCCCTGTGACAGGGAACTAG ATGAAGGAGTCTTGAGAAGCTGATGATC AGGAGTGGTCACA  988 3413308 2 TMEM106C CAAACCATGGAGTGATGTGGAGCTAGGA 3.81E−05 0.017324674 1.55E−05 TTGTGAGTGACCTGCAGGCCATTATCAG TGCCTCATCTGTGCAGAAGTGGCAGCAG AGAGGGACCATCCAAATACCTAAGAGA AAACAGACCTAGTCAGGATATGAATTTG TTTCAGCTGTTCCCAAAGGCCTGGGAGC TTTTTGAAAAGAAAGAAAAAAGTGTGTT GGCTTTTTTTTTTTTTAGAAAGTTAGAAT TGTTTTTACCAAGAGTCTATGTGGGGCTT GATTCACCCTTCATCCATT 2027 3413826 9 TUBA1C CTGTACTTTTACACTCCTTTGTCTTGGAA 1.38E−05 0.009416863 6.80E−06 CTGTCTTATTT  607 3414084 4 RP11- TCAGACACTCTGCATGCTTGCCAGAGAG 0.01309721 0.011337491 8.76E−06 133N21.2 CTCGCTAGAGGACGTGCAGAAGGTCAAA GTCCTCCATCACCAGAGCAAGTTCAGCC ACCAGGC  116 3415017 9 SCN8A GCTGGTGTGTCTCATCTTCTGGCTGATTT 0.005756556 0.027631416 3.31E−05 TCAGCATCATGGGAGTTAACTTGTTTGC GGGAAAGTACCACTACTGCTTTAATGAG ACTTCTGAAATCCGATTTGAAATTGAAG ATGTCAACAATAAAACTGAATGTGAAAA GCTTATGGAGGGGAACAATACAGAGATC AGATGGAAGAACGTGAAGATCAACTTTG ACAATGTTGGGGCAGGATACCTGGC  922 3415243 4 NR4A1 TTCCCTTCGGGGAACGTGCATCTGTTTTT 0.004790078 0.00857609 7.18E−06 AGGAGCGGTGCATGAAGGAGATGGGTG TACGCGCGGGCAGAGAGGATGTTGTAGG GCCGGCATGC  919 3415245 2 NR4A1 TGAGGCTTGTTCAGCAGAACAGGTGCAA 0.036791598 0.008209899 4.22E−06 GCCACATTGTTGCCAAGACCTGCCTGAA GCCGGATTCTCC  511 3415254 9 NR4A1 AGAGAGCTATTCCATGCCTACGGCCTTC 0.000146537 0.010832039 6.60E−06 CCAGGTTTGGCACCCACTTCTCCACACCT TGAGGGCTCGGGGATACTGGATACACCC GTGACCTCAACCAAGGCCCGGAGCGGGG CCCCAGGTGGAAGTGAAGGCCGCTGTGC TGTGTGTGGGGACAACGCTTCATGCCAG CATTATGGTGTCCGCACATG 1131 3415256 4 NR4A1 GAAGCTTTCATTTGCCGGGACACTCGGG 0.00421284 0.007543327 3.79E−06 CCCATGGGATTGCACAGAGCTGGAGGGA GGGGTGAGATAGGGGCAGATAGGAGCT GCAGGGGTGCCTGGCGAGCCTCTGGTTT TCCTCTGCTCCTCTGCCTGTCCTCTCCCA ACTCAAGGTTCTAGTGGGAAGGGGTGCC CCCAGGCTCTCATGTTCCTGGCGTGAGA TGAAAGGATCCCTGCGGAGGGTTTGGTT CTTGAGGGCTGGGGGTGGACTTGGGAAC AGGCTGTGTGTTTGTCCCAGCGATGGTG CCTGCTTAGCTTCCCGTCCCCACCCCCCA GCCCCTTGGCCCTCTCCTGTCTGCCCTAG GGAGAAGGCAGGTGGACAAGGGCCCAT GAAAAAATACAGGTGTCTAGACTGCCAG GGAGACCCTGGCCCCCAGTAGTGTGTCC TGGGGACTTCCTCAGAGCGAGAAACCTC CCCCAATGTCTTCAAGACTTTTCTCTCCC CCCGCCCAACCCCGTCTCTCCCTCCCTTG CCACCCAAATGTTAGAAAAATAGCTGTG AACAGAGAGCGCTTTTGTCTGCAATGGC AGCAGGATCTGGACGGTCCCCTCCCCTA AGTTCCCCCCTCCCCACCCCACACTCTGA CAGCTTGTTCCGTGTTGCCC  486 3415264 4 NR4A1 CTTTCCCTGATACACCTGCCTGTGAACCA 4.81E−05 0.013327502 1.58E−05 CCCTGATCGCTCTTCGTGCC 1619 3416307 4 AC012531.1; CGCATTCCCGGTTGTTTGCAGAAAATTTA 1.54E−05 0.007942225 4.10E−06 HOXC6 CAGCTGAGTAATAAAAGTTTACGATCGA CTCACAAGTTGGATTGGCCACAAGAAGT CATGTGGATTCCATCCATGAACGTGAAC TTTTTATTGTGGTTTGTCCGTTCCGAGCG CTCCGCAGAACAGTC 1692 3418367 9 ARHGEF25 TGAGGGGAGTATATCGGCTTCTGCTGCC 0.000310049 0.007360913 4.16E−06 TCC 1520 3419870 9 TBK1 ACTTATCTACGAAGGGCGACGCTTAGTC 0.000261519 0.008358427 3.52E−06 TTAGAACCTGGAAGGCTGGCACAACATT TCCCTAAAACTACTGAGGAAAACCCTAT ATTTGTAGTAAGCCGGGAACCTCTGAAT A  888 3419989 2 TBC1D30 TGGCACAGGTTTGACACTGCAGGTCGGA 0.000436951 0.0081496 9.21E−06 GGAGGAAGACAGTGGCTGCAAAGGCAA AATCGGGTGTTATTTTCCCAAGAGTCCCT TCAGCGTGAGTGCCGGGGTCAGCTCGAA CTGGAGCCTGTA 1662 3420374 4 HMGA2 TGCATGGATCTATTAGTGGATGGGCGCC 0.00051035 0.007578034 4.27E−06 AGAACGACACAGTCAATGCA  985 3421317 3 MDM2 ATTGTAAAAAGCCATCTGGGCTAACATT 0.000444711 0.013007873 1.22E−05 TC  710 3421365 7 CPM CAGATACAGGGGACACAAACAGCTCTGT 0.002052564 0.011613351 1.08E−05 GTTTATGAACTACAACCAGTTGTTGACTT TTGTTTCAAGTGGCTCCCCTTCCCCAGTG CTGTGTGGACGATGGACTGAAGAGGAGA AGGCTGGGAGCAAGGGACCAGTAAGCT GTTGCAGCAGTGCAGGTGAGATATGAGG CCTCAACTC  613 3421368 7 CPM ACGCGAGTCTGAAGCTCAGGCAAGAGGC 0.017687915 0.008834732 8.09E−06 TAGAGTTACATCTTTGGAGTCATCAGCCT AATGGAGGACTGTGGCA 1331 3422466 9 TRHDE GTTACTCAGTTTTCGCCTACACATGCCAG 0.003428273 0.007617866 7.06E−06 AAAGGCATTTCCTTGTTTTGATGAGCCA ATCTACAAGGCTACTTTCAAAATCAGCA TCAAGCATCAAGCAACCTATTTATCTTTA TCTAATATGCCAGTGGAAACTTCCGTGTT TGAGGAAGATGGATGGGTTACGGATCAC TTTTCACA  112 3426457 1 GCACTTGACAGAGCCAACTTTAACACAG 0.015458225 0.015811581 9.94E−06 ACTTTGAGAAGTGGCCCTGATGAAACCC TGGCCAACAGCCAGCCAGCCACTACCCA AAAATGTCTGCCTGAAAGCAGCTCCAGG AGGCAGGCCATGGGGAGTGGAAGTCGG GGAGAAACTGGAAGAGGCGCCAAGCAG CTGTCA  923 3426889 1 CCTGGTACAGTCGTGGAGGTCCATATGG 0.000389041 0.006909422 6.41E−07 GTGAAAAGCCCAGAAGTCTACCTGAGCT GAAAGCACTCCCAAGGAGTTTGGTTTTG TTTGGGTTTGTTCTAGGTATGGTCCCAGG GATCCC 1072 3426905 1 GAAAAGGCTTTGAAGTGTCTGAAGAGGA 0.002836517 0.006581456 3.08E−06 GAGACAGGGAAGTGACTCACAGCTCAAC AGCTTCACCCTCTGGCTTTGATGGTCCTT GGCTCCGTGATGCTCAG  783 3427524 4 RMST ATGATATTGATCTCTGGCTTACCTAAGCA 0.001689593 0.009272144 3.88E−06 TACTGCGTGATAGTAATTATATTGAAAG ACATTTTTCAATTAAGTTAGGAAAAGAG TAAATCATGATCAATGAAAACTAAATTT GAACTATTAAGAAGCCTATGGGGAGCAG TTTATGTTTCTGATATGATTTATGCTCTA AAATTTCACTAGTTTCCTTTACACTCTTA ACTTTTCATAGTTAGGCCTAAACTAAAC CAAATATTCATGTGCTTTATTATTCTTCC TTGCTTCTCAGTATCACTTTCCTTATCAC CTAAAAGGCATTATTAAAAATCAAAAAA CAAAAAATCTGCACATCTATTATAGTCT GAATGTATGTTTTTAGAGAATAGAAATA AGAAAAAAGGGAGGTATTTAAAATGTTG AAGTAAGTTGTGGCAGACCTGGAAGACA ATGCATGGCTAAAGTACAGAATTACTTT CTCTGAAAAATCTTTAAAACAAGGAAAC CAGTTCATGTCTGTTCAGGGACCTTGCCA ATTTCTTCATC  273 3428610 9 MYBPC1 AGAGAAGGAGGCCGGAACTACACCAGC 0.000102061 0.019860486 1.97E−05 AAAAG  121 3428624 9 MYBPC1 CATTTGAGATGCAGATCATCAAGGCCAA 0.000138152 0.025277716 2.87E−05 AGATAACTTTGCAGGAAATTACAGATGC GAGGTCACCTATAAGGATAAGTTTGACA GCTG   50 3428626 9 MYBPC1 AGGATGCAGGAGAACTTGACTTTAGTGG 2.14E−07 0.070836699 9.91E−05 TCT  421 3428630 9 MYBPC1 CAGTGAGTACGAGAAGATCGCCTTCCAG 5.22E−05 0.012819523 8.90E−06 TATGGAATCACCGACCTGCGCGGCATGC TCAAGCGACTCAAGCGCATGCGCAGA  509 3428631 9 MYBPC1 CTTGATCCTGCATATCAGGTTGACAAAG 0.001171064 0.014030378 9.24E−06 GAGGCAGAGTGAGGTTTGTTGTGGAGCT GGCAGATCCAAAGTTGGAGGTGAAATGG TATAAAAATGGTCAAGAAATTCGACCCA GTACCAA 1901 3428639 9 MYBPC1 AGGAAACAAGCTTCGTCTTGAGATCCCC 4.76E−05 0.007216313 4.05E−06 ATCAGCGGAGAACCACCTCCTAAAGCCA TGTGGAGCCGGGGA 1440 3428640 9 MYBPC1 GGCAGTGGCCGGATAAGAACAGAATCTT 0.011488537 0.007374662 2.66E−06 ACCCTGATAGCAGCACTCTGGTCATTGA TATAGCTGAAAGAGATGACTCTGGTGTT TACCACATCAATCTGAAAAACGAAGCTG GAGAGGCACATGCAAGCATCAAGGTTA  100 3428641 9 MYBPC1 CTGATCCTCCAGTGGCACCGACTGTGAC 7.61E−05 0.029360211 3.68E−05 AGAGGTGGGAGATGACTGGTGTATCATG AACTGGGAGCCTCCTGCCTACGACGGAG GCTCTCCAATCCTAG  498 3428643 9 MYBPC1 CCTCCTACTCTTCTGACTGTGGACTCTGT 0.000547163 0.014490122 1.22E−05 CACTGACACGACTGTCACGATGAGGTGG CGCCCCCCAGACCACATTGGTGCAGCAG GTTTAGATGGCTATGTGCTAGAGTATTG CTTTGA 1495 3428647 9 MYBPC1 TGCGTGTGAAGGCTGTTAATGCAGCTGG 0.005280805 0.008215244 3.64E−06 TGCCAGCGAGCCCAAGTACTATTCTCAG CCCATTCTCGTGAAGGAAATCATAG  459 3428651 9 MYBPC1 CCAAATTGTGAAGATTGAGGATGTCTGG 0.000664925 0.015153353 1.32E−05 GGAGAAAATGTCGCTCTCACATGGACTC CACCAAAGGATGATGGAAATGCTGCTAT CACAGGCTATACCATTCA  355 3428655 9 MYBPC1 TCAGAGGCACCCATGTTTACTCAGCCTTT 0.000579253 0.015754106 1.72E−05 GGTTAACACCTATGCCATAGCTGGTTAC AATGCCACCCTAAACTGCAGTGTG  202 3428665 9 MYBPC1 AGACTCCTCTTGCAAGGCGTACCTCCAA 0.003339377 0.020953424 2.12E−05 ACATAATTGATTCGTATCTGCGAGACTT ACACTCAAGCAATC  970 3429167 9 STAB2 CTTCTTACAATTAGGACCGAGTGCCGAT 0.045322973 0.007449469 6.24E−06 CCTGCGCTCTCAACCTTGGAGTCAAGTG CCCGGATGGTTACACCATGA 1104 3430743 2 FICD TCAGCCGCCTGTGGACATGCGCAAAGGG 0.00551979 0.008200033 5.38E−06 CCCTCTCCTGAGT 1313 3431048 9 ACACB CCAGCGAGTGATCCAGGTGGAGAATTCC 0.001298982 0.006971522 3.36E−06 CACATCATCCTCACAGGAGCAAGTGCTC TCAA 1840 3431135 6 TGCCCAATACACGATTTTGACATTCAGTC 0.00023941 0.010844051 5.73E−06 ATGATTGTTTTAAAGTTTTATTGTAGACT TTGCTGTTGGATACAAAATGAAGGCATA CAACTGTCACAGGCAGGGCAGTAAGTAC AAAGTCTAAGCTGTAAAAACCGTTTGAA AATATAAACTCGTTTTTGGAATACATGT GTCAAAGGCTGCCCATGTTAATACCTTT GGTATAAAACGGTAACGATTCCCTTGAC AAACCCATCCATCACCTGACGCACATTC ACATCTCCTGGTAACTACTCTACCTAGTC TAGTCTCAACCACCCCTGTCAGTCACGA CTCACTCCTGTTC  224 3432191 5 TMEM116 TGTCTGGGTATCTGCATCACGCCGAGCC 0.003302969 0.016329795 1.27E−05 TCCTGCTTTAGTTGGTGGAATTTGTGCTG CGTCCAGCCATATACTCCACAGTTGAGT AGACCCTGAGATGTTGCCGTTAGAGCC  899 3433246 1 AGGCAGCAGATACTCGGGTGCTAAAAAT 0.01286993 0.008994596 7.50E−06 CCCTCCAAACATCTCAACATTTTTTCCCC CTCGGGATCAGTATGGTGTCACG  627 3433531 1 TGGCTAAGTCACGAATAGGCATTTCACC 0.000170561 0.015569748 1.05E−05 ATATGTACATGATAAATGGCCAATCAAA ATAAGGAATGGGGCTCATTCTGCTGGAA ATTAAATACATTCAAACAAGAACAGAGA TCCATTAGCAAAATGTTTAAAAATAATA TCACAGGGTTACCAGGGGTATGACAAAA ATGGACACTTCCATACACACTAGGTGAA TATATTGGTGAAAATAGTTCAGATAAAC ATACAACCATGTATGTAAAAGTATTTAT CATCAATGCATTATTTGTAGTAGCAAAA ACAACAAGCAGCCTTGGAAACCAGTTAA TGTCCTCAGCAGGGAATTAATAATATTA TTGTATATTCATGAAATTGACACCATGTG GCCACACAAATGCATTACACAGGCCTCT ATGTAACATAGGATATTCATTAGAGAAT TGTTTTTCAAGAGGACAAAGTACTTTCAT TTTTGCCTAGAAAATGGGGGAAGACAAA AATGCGCTTCTCTCTAGGTTGTGTGATTT TAGGTTATCCTAAGTTTCATCCTTACGTG CTCCTGA 1825 3435731 8 PITPNM2 AGGAGAAGGAAAGATCTCGTTCTTAGCG 0.001877871 0.007175536 7.03E−06 AACCCCAGGGAGTGTGGCCTCCCTCCAC CCCATGACTCTCGCTACCAGGGCCCGGT GGTCACTATGCCACAAA 1654 3436139 9 DNAH10 CTTGGGCTGACGACAAAGTTGTACATCC 0.009627872 0.006840034 6.70E−06 TGAACCCCAAAGCCGTGAGTGTCATAGA ACTCTACGGCATCCTGGACCCAACCACC CGAGACTGGACAGATG  271 3439162 2 P2RX2 CTGCTCCCGGTCTTGGGCCCTGGGAACC 0.000425014 0.015078838 9.02E−06 CCACCCCACCCCACCCCACAGGCGTTGT AACCTTGAATCTGCCCAGACTCTT  334 3439330 1 CTGCTGATGATCAGTGTCAATGCCCCAG 0.001332936 0.008574024 3.79E−06 CAAAGAGTGGCTTTTCTGGCATGCTGGT CCTTGGACACAAGGGTACAAAGTTCCAT GCTGTATCTGTAGTTTATAATTTAGAACA CTCTGTCCTC 1199 3440108 4 CACNA2D4 CACAACGACAGCACAAGGCTCTTGGCTG 0.000318921 0.007172134 3.04E−06 1555 3440184 3 RP5- ACGTGTCATCCGTCAGTGCTCCATGCAG 0.012305161 0.008586488 8.01E−06 1096D14.2 TGCTCCACCACGGCATCCGCCACTCTGC CACCAGCTCCGCGGGGATGGACGCACAG GCCCCAGTCATGGCCCTGCCCTGAGGAG ATGCTGGTCGTCTTCCTGCTCATTCACTC CCCTGTGCTGCACTGCTGGGGTCAGACA AGGCTCCATCCAAGAACCCATGACTTCA AAAGAAAGAAACCTTTGTCCTCAAATTT GGTAACAGGCAAACGGTCTGCGTGGAAG CCCTGTCTGCAGCCTCTGCTCACTCCAGG ACGTGCTGCCCTCACTGCTCCTCTGATGT GCCCCCGGCTCAAGGCTGAGCATTCCCG TATCCACGCAGGAAGGCCGGGGGACTGG CTCCCAAACAGCGGCCAGGACCTTGGGG GCACCCAGGGAGACTGGGGCCCTGCACC TCAGGGCTTTGGATCCAGGTCTGGGACG AGCCCTGGGAATCAGCATGGGAGCAGTG GCAGCCATCCTGTGGCCCTGAGGGGAGC TGGCTGGAGGACAACCTGAAATGCTGAG GGCAGCAGGAGGAAACACAGAAGGAAC CTGCGTCCTGGGTGACATCCCGGACCTG CTGCACTCGCCGGCCCTGGAGCCACCTG CCTCTGGCTTCATGTGAGCTGTCACACTG TTATTATTATTTCGTTCCTCAAGTAGGGG TTTCCTGCTCCTTGCAGCCGGAAGCAGT AAGTGGTAGCCACCCCACCCCTGCAGGG CAGTCTTCTGATGGCTCTGAGCTCCCTGA GGTGGGGGCGAGGCAGGGTCTGTGCTCC ACTCTGAGGGCCCAGTGGAGCAGCAGGT GTTCGAACACATAGGGTTTACCCCAGGC AGAAACCACCCTCATAAGGGCATGAGAC CCAGGCAGAGTGAGCTCTCTGGCCTCTT GGTATTTTCTTTTGTGTCTGTCTTCTCAG CAGCCTATGAGCTCCTCCAGGGCAAAAA ACTGCCATCATGCTAAGGGGTTCTGGAC CCTGGGGCCAGGCACAGGGCCAGGGAC AGAGTGGGCAGGTAACGAAGGCTTGCTG GGCACCGTGGGAGAGAAGGGAACGGAG GCATTGAGGGGCAAGAGAAAAGGAGAA GTGGAAGGCCAGACAGGCAGAGAAGGA AAGGTTCGTGGAGAGCAGTCTCTTCATG GGGACCCAAGGAGGCCCCACCAGAGAG GAACTGAGGCTGTGAAATGGAAGGATG GAGGCCTGAGGGATCCAGGCCAGTGGAC AAGTGAGCCCGAGCAGACGGAACCATCC CCATGCCTATCTGGTTGTCTCCTCCTCCT CCTGCTCCTCACCCCCTTCCTCCTCCTCC ACCTCCTCCTTCTCCCCCTCCTCCTCCTTC TCCCCCTCTTCCTCCTCGCCCTCTCCCTC CCCCTCTTCTTCCTCCTCCTCCCTCTCTTC CTCCTCCTCCCCCTCTTCCTCCCCCTCTTC ATCCCACTCTTCCTCCTCCCCTCTTCCTC CCCCTCTTCCTCCTCCTCCCCCTCTTACTC CTCCCCTTCTTCTTCCCCCTCTTCCTCCTC CCCTCTTCCTCCTCCTCCTCCTCCCCCTTC CTTCTCCTCCTCTTCTTCCTCCTCCTTCCC CTTCCTCCTCCTCCTCCCCCTCTTCTTCCT CCTTCTCCTATCCTCTTTTTCTTCCTCAAC CTTTTCCTCCTCCTCCTCCTCCTCCTTCCC CGCCTTACCCCTCCTTCCCCACACTCTGA AATGAGCACATGGCTCAGACTGAGAGGA CAAACCTCCAGCTGAATTTAGTTGTAGC TGTGGTTCCCCAAAATGCTTTGAGGATTC ATCAGAACCAGTAGCTGCCTCTCTGCTTC CTCATCTACACACCTAATTTTGTAGCTTC AGAACAGGTGTGACTCAGGCAGAGGAA GGGCTACACAGGTGTCACTGTGCCCACC CCTAGGGAGACTGCTACAGACAGACTTC CCGGTGGGACCCGGCCCCCACCCATGCA TGGTGGCCACGGGCATGAGGAGGGTGAT AATGACAAGGGGAGCCACGATGACCAC AGGGTTTATAGAGATCTCGCCATTTGCT GAGCAATGTGGAGGAACGTTACACACAC CATGTCGCCTCCCCCGATGCCTGCAGGG CAGGTATCATTGCCCTGCATTCTATTGAG GAGGAAATTGAGTTGGAAGTGCCCAAGA TCACGTCGTTA   81 3440944 6 GCGTGCCTGGGCATTTAACAAAGGCAAG 0.00180613 0.026417303 3.09E−05 AAGGAAAAAAAGGAGAAAATTGGGGAT TGAGAAAATTGAATTAAAGAAGAAAAG ATTGATCAGATTATTTGAAGAGAAACCT CATCACATCCCACCGTTGTTTGCCCCCTT CCCGACCCTGTGCTCTCTCTTCCGATTCA GATTCAAAAGCATTAACTGGGCACCTAC TTAAGCTAGACTGTATGCCAAGCTCCTC GCATACAATTTCCTACACTTTTAAAGTTG CAGGCTTTGTAACTGCTCTTAGCAGAGG CAGGTTCTGCTTTAGAAAGTTTGCATACC ATCATTTTTCTCTTGGTTCTTAATCAGCG AATC 1169 3442059 9 CHD4 CAAGCTCTGGTGATTGAGGAACAGCTGC 0.000570716 0.009351255 8.12E−06 GCCGGGCTGCTTACTTGAACATGTCAGA AGACCCTTCTCACCCTTCCATGGCCCTCA ACACCCGCTTTGCTGAGGTGGAGTGTTT GGCGGAAAGTCATCAGCACCTGTCCAAG GAGTCAATGGCAGGAAACAAGCCAGCC AATGCAGTCCTGCACAAA 1114 3448127 8 SSPN ACCAACCCACGGTCTCTGGAGCACCTGT 0.011131791 0.007354431 5.34E−06 GGAATTCGACTGGACTGGCTCCAGCTTT TACAGTCTCTCTGA  379 3448205 4 ITPR2 CCCTTCTCATTAGGACCTGGCTGTGGATA 0.003147077 0.013261635 1.12E−05 AAAATTTCTCCCCAGGTCCATCCCATCTT ATGCAGTGACAATGACCTGTAATGCTAT CCTGACACCAACTGGTAACATACTGCAG TATAATTCCCGGGCTAACCACCCAGAGT CAGCACAGACCACACAAGTTCCAGGGCA TAGTCCTCAAA  107 3449806 9 DENND5B GTTTGCAGATTACGAAGCATTTGTCATTC 0.001925692 0.017715275 1.68E−05 AGACTGCCCAGGACATGGAATCCTGGCT GACCAACCGGGAACAGA  626 3452385 1 GTCACATGTGCTAGATAGTTCTCCACAG 9.00E−05 0.009592315 3.89E−06 AGAAGACCTTGGTCTTCAGGATGTCAGG CAAACCTCCTGACTCAAGCACTGAAATA AACACAAATCACCATTATGAAGTCAAAT CTATAAACAAGCTTGGAAACCAATCCAA AATCCCTCAGATCCACACCTATACACTC AGTGACTCATGTCTATGAGCCATGGTGA CCATGCCCAGGGTTGGGGTCAGAAGAAT CAGGGGAAGTGCAATAGCAAGGGGACT CTTCCACAGCCTTTTTTGAGGGTTCTTCA GTCCTGGCTAACTCTGCATTCCATTTATG ATGCCTATGAGGAATACAAGAGGAGCTT CAAATAAGCACTGGGTATATGAGCCTGG AGCTCACCGAAGTCAGA 1819 3452862 7 TMEM106C CTGGGCACAGGCTAGGCACTGATTCTGC 0.000319739 0.008530675 3.81E−06 TGGTTCTGAGAAACATAAATGGTACCAT AGGGAGGTGTTTCCTCCTAAGTGGCAGG AGGATGTTTGCTGGGAGTTAAGTGAACC AATTCCTCCTCTGCTTACACCACGTGGGG GTAGGTCCAGAACTCAGGCCTTGGGAAC ATATGCTGTGCTCTCTTCTACAGGCGCTG TG  993 3453875 6 CAATTTACGGCAATAGACATTTACAGAA 1.50E−05 0.017942905 1.38E−05 CAAAAATAAGACAGTTCCAAGACAAAG GAGTGTAAAAGTACAGCACACAGGTTAA TACTCTTCACCCTCATCCTCTCCGTCAGC ACTATCTGCTCCAACCTCCTCATAATCCT TCTCAAGGGCAGCCATGTCCTCACGGGC CTCTGAAAACTCGCCTTCCTCCATCCCCT CACCCACGTACCAGTGAACAAAGGCACG CTTGGCATACATCAGGTCAAACTTGTGG TCCAGGCGAGCCCAGGCCTCGGCAACAG CTGTGGTATTGCTC 2014 3454060 4 FMNL3 TCTCTCTGGGGTACAATGGAGTAGAAAA 0.000984436 0.006743349 4.61E−06 CTTAGGGACAGAAGGAATATACGAATGG AGAAATTCGATTTGCCCAATCTTTATTGC TCACCTATTAAAGTGCTAAACAAGCTGA TGGTGATTCCTGTTCTCAGAAGCCTGTGT TCTAGCAGGTTATAAGAAGATGAGTCTG GTTAAAGAGAAGAGCAGGGAAGTGGCT TAGATTATGGCATAAACTGAAGTTGAAA CTCAGAATGAAAAGTAGGAGTTTGCTGA GGGGAAAGCAATATATAAAGTGATTTGT GCTATAGGACATAAGACAGATTATAGAT AAGAGAACTCAGAAATAGTAAGGACAG TGGTAAAAAGTTAAAGGATCCTCCCTTT CCCCAGTTAACCAGGAGACCAAATAAGG GACTTGGTGGTAGGAGTGGTAGGAGCAG GATCAATCACTTATTTATTAAGCACCTGC ACATGATTCAAAGA 1908 3454236 9 RACGAP1 ATCTCTGGCTGTGACCGCACAGTAAAAG 0.000165652 0.008552193 5.05E−06 AGCTG 1892 3454247 9 RACGAP1 TTGAGGATTTCCGTAAAAAGTGGCAGAG 0.007337714 0.008243299 4.88E−06 GACTGACCATGAGCTGGGGAAATACAAG GATCTTTTGATGAAAGCAGAGACTGAGC GAAGTGCTCTGGATGTTAAGCTGAAGCA TGCACGTAATCAGGTGGATGTAGAGATC AAACGGAGACAGAGA 1591 3454249 9 RACGAP1 TTGTGCGCCGGGTGGAGATTCTCAGTGA 0.004304377 0.011117041 8.17E−06 AGGAAAT 1689 3454251 4 RACGAP1 GGTGACAACCTGCAAGTGATAAGGGGGT 0.00076237 0.010799497 7.64E−06 GGGTATGGTAGATACATGAGAGAAGAGT ACACAAGGTTTAGTGATTATGCTGTGGG AAGGGGAGGAACCAGAGGTGATTCTGA AGTTTGGAACTGAGCGACTGAGAGAATG ATAAAAATAGGGAAATCAAAATTGGAA GTCAGTAGGGTATGGGATAGGGTAGGTC AGTGAGTAGCGTAGTTGATGGACA 1797 3454663 2 CSRNP2 CCATCACGTATGTCGCAGCAGCATTTCA 0.026058101 0.006874234 7.89E−06 CCCCTGAAGTCTCTAAACTCTGAGCCTG AAAAGATTTGTATTTAATACACATAACA TTTTTTAGTTCATTCTGCCTTTCCTATTTG TTCCAGTTTTTGCTTGGTTTTAGTTTGGA GGGGAACTTAAGTACACAGATCCTTATC TCTCCCCATCCCCTAGCCTCACAAAACA CAGTTGAGAGTCTTTTAAGTACCTGAGC TCTCGAAGCTACCCAGAACTGAACTAGA CTCCCCTACCTTAGACTGGTACCCTCAAA CACAGGACTGAAGCTTAATTGGGAATTT GGCTTTATGGAGAAAAGAATCTTTTTCA AAGTTTGTGTCGGAAGGGGAGGGTGAGG TTTGCCCACTGTCTCTGCAGGAAGGCTCC GGCTTAATCTAGGAAGTAGATTCCAGCT GCACGATGAGGAACACATTAGCTTTTGG GATCAAACCAGGAATATGAATCTGTAAT TATTAAGCTCATTGCCAACCCACAAGAT ATGTTTCTGAAAACCTGTAGTTTCTTAAT TTAAGTCCATCCCCTTCATTAACGCTACA GTTGTGACTCACACTGATCCCAAACTTTT AAGTGCTAAATATTAACATTTAGCATTA ACTGTCTTGTCAAGCGAAAGGCCTTCTCT ACAACCTAGTCCATCTCACTTCTGGTGCT ACCTGAGTTGGACAGAATTCTAGCTCAT GGTTGCTAGGAAAGCTAGGCCTCTGATC ATAGAAGCAGATAGCTTCAGTCCCAGTC TAGGCCTAGA  377 3455102 5 NR4A1 GCTCTGCTGGCACTTCACAAAAGCGCAT 0.000708617 0.013562634 1.16E−05 TCACATGTTGGCCATTAGTAAGCATCGT CACAAGTCTGAGAAGCAGTAACCCTCAT TATCCTCATACTCCAAGTG  994 3455119 1 AAATTCTGGGGCTACATTTCCATCCTGTA 0.034019558 0.007187542 3.36E−06 TGAAACTATTGAACATCCTTGGTCAACA CTCTCTGTAGAGATTTGTTTTA 1468 3455129 1 TATTGATGAAGGTGTCACAACGGCAAGA 0.024191116 0.006911722 5.22E−06 T  389 3455389 1 TAGCATCATCATTGAAGTCAAGGCCCAG 0.014179003 0.010346618 6.20E−06 CATGAAGACATCGCCAACAACAGCAGG 1436 3456343 1 CTGCCGCCCGCCTGCAAGATGGATTGGC 0.013379902 0.008092246 3.37E−06 CGCATTGAAATTCCTCCGCGAG 1977 3457204 2 SARNP GTCACATATATGCCTAAATGCACAGTCA 0.00011347 0.007559171 2.29E−06 TGTGCCTACGTCCTGCCTCGCAATGAGG GAGCATGTA  924 3457859 9 TIMELESS TCGATTTGGGGGCTCCTATATTGTCCAGG 7.10E−06 0.011459793 8.55E−06 GGTTGAAATCCATTGGGGAGAGGGACCT CATCTTTCACAAAGGCCTTCAC 1048 3461394 4 CPM TTCAGTATCTTTGGCCTTACAGAAGTTTT 0.000172838 0.008653889 5.97E−06 TAATTTTTATGAGATCGTATTCGTCAGTC CTTTTCTTTATGCTTTTATGTTCCATGCCT CACTTAAAAAGGCCCTCTTTCCCCCAAG GTCATAAATATATTCTATACCCTTTTCAA TATTTTTATGGTTTTAGTTTTTATGTTTAG CACCTAACTCCATCTGGAATCTATTTTTG GGAATCGAGTGGTATGTAGATAGATTTC ATGTCTGACAATATATATTTTTGAGCACT CAAATTTTTAAAAAGTATGTATGACTTTG GTAAGCAGAAAGAGCCAAGAGGAGTTT GAAGAGACACTCAGAAAGTGGATGTCCA TTCTGGGTGGGCCCAGGAGTTTGCAATT TTAGC 1453 3462104 2 ZFC3H1 CCTCAAAGTGACTGACATTTATTTTAATT 0.002887295 0.008108262 5.31E−06 TTGCTTTGTTTTTTTTTATTTTCTCCCCCA TTCCTTTATTTTGTGTTATTCCTGACTCAC TTGACACTCTCTGATGCCTGAGAGATTCC TGTTTGGGATTTAATATCCAGGGCTGTGT TTAC 2025 3462988 9 OSBPL8 CTGAATCTAAACTTTATAATGGCTCAGA 0.000563692 0.006950222 6.46E−06 GAAGGACAGTTCAACTTCAAGCAAACTC AC 2040 3462998 9 OSBPL8 AAGAAGCTTATCCAACGCCAACCAAAGA 0.015311147 0.007361228 4.24E−06 TTTGCATCAGCCATCTCTTAGTCCAGCAA GTCCT  749 3465245 1 CAATAATGTTGGGAGATGGGACCTAATA 0.000552621 0.006681797 3.72E−06 AGAGGTGATTTGGTCATGGTCATGAGGG CTCTGCCCAAATAAATGAATTAATTTCAT TATTGGAAGAAATAGTTTTGTTATAAAA ATGAATTTGGCTTATTTTGCACATGTGCA TGTGTTCTCCTACCCTTCCAACATGAGAT GACACAGCAAGAAGGCCCTCACCAGATG TGAGCGCCTTGACTTT  589 3468064 5 MYBPC1 ATGGTGTGTCAAACCATTTGGAACAATT 0.000873066 0.012604826 6.35E−06 TTTTCATTGCTTAGTGATTTATAAAGTGC TGGTGTATCTTAATAGCAGTGGTGTCTTA GACTTGCAGAAATACAGTACATCATAAA TAATACATTAAAGTAGGTCTGCCTCTTAC AATGTGTATACCTTCAGACTTCTACCAA ATCATATGTGCAGTCTTAGAGGTTTCTAG GTA  192 3468071 5 MYBPC1 TCTGTTCTTATCCGGCCACTGCCTTCCAT 4.98E−05 0.018785189 1.97E−05 AATAGCCTAAGAAGTGG  419 3468104 2 GNPTAB TCACGTGCAGGTCTAATTTCAAAGGGCT 0.000655208 0.015552323 1.51E−05 AGAGTTAGTACTACTTACCAGATGTAAT TATGTTTTGGAAATGTACATATTCAAAC AGAAGTGCCTCATTTTAGAAATGAGTAG TGCTGATGGCACTGGCACATTACAGTGG TGTCTTGTTTAATACTCATTGGTATATTC CAGTAGCTATCTCTCTCAGTTGGTTTTTG ATAGAACAGAGGCCAGCAAACTTTCTTT GTAAAAGGCTGGTTAGTAAATTATTGCA GGCCACCTGTGTCTTTGTCATACATTCTT CTTGCTGTTGTTTAGTTTGTTTTTTTTCAA ACAACCCTCTAAAAATGTAAAAACCATG TTTAGCTTGCAGCTGTACAAAAACTGCC CACCAGCCAGATGTGACCCTCAGGCCAT CATTTGCCAATCACTGAGAATTAGTTTTT GTTGTTGTTGTTGTTGTTGTTTTTGAGAC AGAGTCTCTCTCTGTTGCCCAGGCTGGA GTGCAGTGGCGCAATCTCAGCTCACTGC AACCTCCGCCTCCCGGGTTCAAGCAGTT CTGTCTCAGCCTTCTGAGTAGCTGGGACT ACAGGTGCATGCCACCACACCCTGCTAA TTTTTGTATTTTTAGTAGAGACGGGGGTT CCACCATATTGGTCAGGCTTATCTTGAAC TCCTGACCTCAGGTGATCCACCTGCCTCT GCCTCCCAAAGTGCTGAGATTACAGGCA TAAGCCAGTGCACCCAGCCGAGAATTAG TATT 1936 3468105 9 GNPTAB TGCACTTAAGCGGAAGATATTTCCCAGA 1.12E−05 0.007894032 6.49E−06 AGGAGGATACACAAAGAAGCTAGTCCC AATCGAATCAGAGTATAG 1843 3468121 9 GNPTAB CACAAAGTGCGCCATTCTGAGGATATGC 9.90E−05 0.010165009 7.09E−06 AGTTTGCCTTCTCTTATTTTTATTATCTCA TGAGTGCAGTGCAGCCACTGAATATATC TCAAGTCTTTGATGAAGTTGATACAGAT CAATCTGGTGTCTTGTCTGACAGAGAAA TCCGAACACTGGCTACCAGAATTCACGA ACTGC  618 3468122 9 GNPTAB TTTGGATTCACATCGCGGAAAGTCCCTG 6.95E−06 0.011918652 7.85E−06 CTCACATGCCTCACATGATTGACCGGAT TGTTATGCAAGA 1921 3468125 9 GNPTAB CAAATGACAGTTTGGTGGCTCCACAGGA 0.00020953 0.007617622 6.03E−06 AAAACAGGTTCATAAAAGCATCTTGCCA AACAGCTTAGGAGTGTCTGAAAGATTGC AGAGGTTGACTTTTCCTGCAGTGAGTGT AAAAGTGAATGGTCATGACCAGGGTCAG AATCCACCCCTGGACTTGGAGACCACAG CAAGATTTAGAGTGGAAACTCACACCCA AAAAACCATAGGCGGAAATGTGACAAA AGAAAAGCCCCCATCTCTGATTGTTCCA CTGGAAAGCCAGATGACAAAAGAAAAG AAAATCACAGGGAAAGAAAAAGAGAAC AGTAGAATGGAGGAAAATGCTGAAAAT CACATAGGCGTTACTG  579 3468126 9 GNPTAB TGAAGGTGCCTATAGTGACAATCCAATA 3.85E−06 0.014435127 1.06E−05 ATTCGACATGCTTCTATTGCCAACAAGT GGAAAACCATCCACCTCATAATGCACAG TGGAATGAATGCCACCACAATACATTTT AATCTCACGTTTCAAAATACAAACGATG AAGAGTTCAAAATGCAGATAACAGTGGA GGTGGACACAAGGGAGGGACCAAAACT GAATTCTACAGCCCAGAAGGGTTACGAA AATTTAGTTAGTCCCATAACACTTCTTCC AGAGGCGGAAATCCTTTTTGAGGATATT CCCAAAGAAAAACGCTTCCCGAAGTTTA AGAGACATGATGTTAACTCAACAAGGAG AGCCCAGGAAGAGGTGAAAATTCCCCTG GTAAATATTTCACTCCTTCCAAAAGACG CCCAGTTGAG 1015 3469401 1 GCCATCCACATGGCCAATTCAACCTGCT 0.003557945 0.008173686 6.81E−06 1076 3469805 5 RIC8B TGCATTCTTGTTTCCCACTTGCAGATCTC 0.025498894 0.009095378 6.52E−06 CCAAGAGTCCCTTCGAATTTACCTATAC GAGTTTCAGCTTCCCGCTTGCCACTTAGC TTGATAACGACTCAAAAATCATTCCCTT GTTTTCAAGGGCTCTTCTTTCTTGTCTGC TCTGTGTACTACAGGGC   73 3470260 4 SART3 CCTGTGACCAGCAGCATACGGGCTTTGG 0.01575619 0.021496487 3.64E−05 GGT  189 3470958 4 TRPV4 CCCGGCAAGACTGATTTGGAATGGCAGG 3.23E−05 0.013118108 8.19E−06 CACTCACAGTTGTGTTTATTTGAGGGTAC CACAGGAAGTGGGGGCCCCCAAATTGGC TAAGGAGCCCCAGGGTGGAGGGAGGTA GAAGCACACTGGGTCTGTCTGGGAGCCT GAGCACCTTCTCTGTGGGCTCCTTCCTAC CCATGGATTCCAACCCCCACCCACCTCC CCACTGCCCACCCACTCACCCATCTCTTC TGCTTTCCTTCTCCCTGTGCCCCAGGCCA CACCATTCCTCTGTGCACCCTGCACTTTC CCCTCTACACCTTTGTCCTTGACACCTCC TCTGCCCTTTATCTTCCTCCTCCTCCTCCT CACAGCCTTTCCCCCTCCCCATCAGGATT CTGGCTGCCCTTGCTCTGCAACCCTGCCT GGAACTTCAGGTCCCTGATCTTACAGCC TA  543 3471602 4 ATXN2 GTGAACACATCCTACTCTGCTTCTGATTC 0.001339198 0.012656175 7.58E−06 TCAACTTACTGTTTTTGAAGCACATGAAC AGGCCAGGCACGGTGGCTCACGTCTGTA ATCCCAGCACTTTGGGAGGCTGAAGTGG GCGGATCATTTGAGGTCAGGAGTTTGAG ATCAGCCTGGCCAGCATGGCGAAACCCC ATCTCTACTAAAAATACAAAAATTAGCT GGGCGTGGTGGCACATGCCTGTAATCTC AGCTACTCGGGAGGCTGAGGCAGGAGA ATTGCTTGAACCTGGGAGGCAGAGGTTG CAGTGAGCCTGGGCAACAGAGTGAGTGA GACTTATATCTCAAAAAAAAACAAAAAA CAAAAAACTGAAAGACATGAAGAAATG GTTTTTGTACCAAGGTTTGGCCCACGCTG AGATTCACAAAGAACTGGCTTTCAGTTC TTATCTTTATTTTGATTTAAACTGGCCCA TCATGTTGTCCTTTG 1136 3471633 9 ATXN2 AGATTCCAGGCTTCAAGATCAGAGGCAG 0.004061321 0.008273273 6.75E−06 AACTCTCCTGCAGGGAATAAAGAAAATA TTAAACCCAATGAAACATCACCTAGCTT CTCAAAAGCTG 1028 3471764 5 MAPKAPK5 GAGTCAGCTGGACGTGGTAGATCATGCC 0.001705241 0.007376753 3.38E−06  687 3472790 4 TBX3 GAACATGAATCCAACCAAGGGTCCCCCT 0.002880903 0.008033958 6.27E−06 TTCCACCTCTGAGTAACTCTGTGTATATA ACTTCTTCTTCCCACCAAGGGGAAGGGA TTTGAAAGATTACACACTATAGCATTTTT CTCAAAGTGCAAAATGCATGTGCCCTCT AGACCCAGAATCCTGTGAAATGAAGTTG TTAATGTAATAATAAAATGTAGCATTTTT GATCAGACAAAAAGGCCATGGGCCTTCT CCACCTAATGGCCATGGCAGAGCATATA AATGAAAACAGATGTTTCCAGTGGTCAT TCAGTACTGTAACTGTCAATATTG  556 3473370 5 RNFT2 TGTTGACAGTGGACGATACACCCTCCCT 2.29E−06 0.012094303 1.14E−05 TCTCTCTCCGACAGGGTCGCCATCAAAC CCAGTTGAAGAGGGTCCAGTGAGAGCCT ATTAGAGGCTTCACAACTCACTTGCCAG CAGCAGATTTCTCCCATCGCTTAGAGAC TGCTCACTCACACCACTCCTCAGAAGAC CTCCAGCAACATACACAGCCAGGAACGA CAGGAAGGAAGGGACATGACATTTACTG AACGGCAGTGCTGAACCAGGCACTGAGC CAGGGCCTGTTACTAAGGGCAAAGC 1518 3473458 9 TESC TCTCATCGGATCAGATCGAGCAGCTCCA 4.91E−05 0.007870352 2.49E−06 TCGGAGATTTAAGCAGCTGAGTGGAGAT CAGCCTACCATTC   47 3473622 9 KSR2 GACAGAGTCCGTTCCGTGTGACATCAAC 4.80E−07 0.065638753 8.65E−05 AACCCTCTACGGAAGCCACCTCGCTATT CAGACCTGCACATCAGTCAGACGCTC  311 3473690 9 KSR2 CAAAAAGCCTTACAGCAGTGCGAACTGG 0.000664925 0.013784107 1.32E−05 TCCAAAACATGATAGACTTGAGCATCTC CAACCTGGAAGGGCTTAGGACCAAATGT GCTACC  557 3473708 1 AGGGGCTCCCCCCAGACAGTGTCAGGAG 0.046404092 0.008792034 8.42E−06 ACCTGATGGGTGAAGGAGGGATCAGTCG GCACAGTTGA  452 3474192 9 CIT GAAGAGCGGAACATATTATCTCGAAGCA 0.001852254 0.018785154 1.33E−05 CAAGCCCGTGGATCCCCCAATTACAGTA TGCCTTTCAGGACAAAAATC 1441 3474713 3 AC069214.1 CCAACTCCCTCTGTTAAAGGCATCTCTCC 0.002217036 0.008112305 5.71E−06 AACTCGGC  364 3474739 4 AC069214.1 TGACTCCAGAGACGTTCCCATTAAATGC 0.01809196 0.007620008 2.94E−06 ATCACCAACCCTAGAGTTTAGGTCCTGC ACATTGTTAGCTCTGCTGTGCGAAAACA   72 3475900 2 ABCB9; AGAATGAAGCATCCTGCAGGAGCCCTGG 0.000368854 0.025422078 2.24E−05 RP11- CTCGATGCCTGGTAGCCACTATAAATAA 197N18.4 AGAAGAACCAGCAGGCTGTGTGGATGCA AGGCCCAGTGCTCCCCTGTTCTCTGAGG AGG  931 3475981 2 PITPNM2 TTCCCCATCGACGGGAAGGCTTGGACTC 0.00592778 0.007346276 5.13E−06 CAA  267 3476305 5 ATP6V0A2 CCTGAGCCACCAGTTATCACCAGTAACA 0.040585072 0.011750362 7.01E−06 GGGGATGACACACCTACCTCCTGGGGCT GTTGTGAGAATTAAGAAACACTAAGTAA GGAAAGCACACTCTCAGGTATGCGGCA  347 3476911 8 TMEM132B ACCTGCCTGACATTGCCAGTAATTACCA 0.001093286 0.011585565 1.01E−05 TCTTGGTATGAATTTCAGTGATGCAGAA CCCCTGTCAGAGACAGCTGCGTTTGTAA AAGCAAGTCTGGATGACACAGTGATGAT TACATCATCTCCATCTTCATCGCCATCTC ATAGTAAAGTTAACCCACTGTGGCATCT GGCTGATGGTTTTGTGGGAGAGGATTCT ATGTCCCACCGCA  366 3481437 4 TNFRSF19 GTACCTGCCTGCTAAGGAACAGACCCAC 0.001095886 0.012314567 6.70E−06 CTGCCTGCTGTGGTTGTATTGCCAGAAGT GTTGGATTCACATCTTGGCTGCGCTTTGT ACTGATGGTGTAACCTTGGGCAAATAGT CTCCCCTCTTTGAACCTCTGTTTACTCTG GAAAATGCCCAAGTCTGCAGATTTTGGA TAGAACTAAATGAACTAGTAGTCCAGCA ACATGATA  798 3481446 4 TNFRSF19 TCCAACTCCTACCTTGGGAGAGAATGAC 4.12E−05 0.011301562 3.72E−06 AGTGAACCAAACAAGTAAAGTAT  945 3481456 9 TNFRSF19 TGCGCTTGCTCCCATCCATGTGCTGTGAG 2.53E−05 0.009087909 6.89E−06 GAGGCCTGCAGCCCCAACCCGGCGACTC TTGGTTGTGGGGTGCATTCTGCAGCCAG TCTTCAGGCAA 1490 3482106 6 GCCCCAACATTGAAGTGCCAGGATCAAA 0.009647164 0.006783836 4.16E−06 GCCATTCACTAGCATCTCCTCAAACACCT GCCTGCCATCACCACCACAAGTGCCAGG ATCAAAGCCATTCACTAGCATCTCCTCA AACACCTGCCTGCCATCACCACCACAAG CACCAGTAGGAAATCCTCCCTTGGTGC  879 3484182 1 ACCGAGACCCTGATGGGCCAGTGTCTCG 0.00587839 0.006816243 3.47E−06 GGTGGGGTCTGTGCAGCATACTGAACAC AGCGGCGATCCTGAGGGACCCGTGATGC TTCTAGCCCA 1905 3485957 7 POSTN CATAACATACATACAAGGCTCGGTCTTT 0.000905174 0.006832111 4.62E−06 TCAATGGGATAACAGTTCACAACTCTTC GATTTGAATTGTAATGAATCTGGTGACA AGGATTTTTCTCTAATGGATTCCAAAGTT AGCCAGAACTTTTAATGTCAAGATGAAA AAGGGTGTAAGGTGTTATATTTTCTTCAA TTCCTTTACCACAGGAGGCTAACTCCAC AATTTCCCTCATGTTTCTCATTCAGAAAA AAAAATATTAAATTTGTGTTCAGAATTA TTTGATGATTGCTTCTTTGTGCTGATGTT TCAGTTCCTGAAGTCAACTTGGCTCTCA 1492 3487850 4 SERP2 CATTTGGGATTGTGTAGAGGCTCTCTCTC 1.77E−05 0.009359098 3.89E−06 AGAAGCATCTTTCTGTTATTTTAATGCGG ATAGAAAGCTTTACATTCTTTGCTAATAA CATCTGGGTTTTAATAGCGCCTCCTTGCC CTGCCTGTCTCCGGCATCTCTCTTTTTTC CCTCTTCTCCATCTCTAGAGAAGCCACCA GAAAATGGCATCTTGCTTTTGACTTTCTT TGTGCTGATTCTTTTAGAGAACTTAGTGA TCCACTTTGCAATGTCTCGTCTCCTAACA TTTCAGCTTGTTTCTCAGAGGGCCTGTAC TTTGCTTTCTACCAGCTCTTTCATCATTTT CATTTTCTTTAATGAAAAATAAGCAAAA CTGTATGATTTCTAGGITGTCTTCTTCTC CTAAAGGATATTCTTCTTCCGGCCTCTCT TAATCTCTCTTCTCAGCAACTCCCTTGAT CTCTTTTATCATCAATTTATTGTCAATAA AAGTGGCTTTAGGAAGCCTCCTGTTACC TGGCAGGGTTCCAGCTTTCTGACACTTTC CTATGGGACCCACTTGTTATGTCA 1469 3492720 5 PCDH9 CCAGGTGATGGTCTTTAATTAGAGACTT 4.68E−05 0.008721471 8.18E−06 GAATATTGAATCAAAACCACAGAAGATT ATGTTATTACAGCACAACCCTCACCTTG AAACGTGAAAAATGTGTTAAATTATTTT GCTACTTTTCCTTTTAGCCAGGAACTATT CAATACTTTCACAAGTACCTGTTTAACTC AGCCCACTACACTGGCCATCATAAATAA CCAAAACGTGATTTCTTTACTTTCTTTAA GGAAACAGTATCTCGCACTTCCAGTG  551 3494195 4 LMO7 GATTATTGAGTTTCGTATGCTTTTCGAAT 0.000367918 0.009638476 5.96E−06 ATGGTAGGATGTTAAATGTGGTAAAAAG AATGGCTCTTAAATGTGTTTCATAGATCA TATATTAAGCTTGACTAGTGAGAATATTT TTCATCCCTCTATTTTTAGTTATACATAT CTTGAAGCCATTTCTTCTGTTTTAGAATG TCAGCATATGATTTGCTAGGTC 1976 3494747 1 TTGGCTCCACTAACACACTGCACTAACT 0.001265835 0.006763304 1.25E−06 GTGGTCCGGGGATCAGGAAGCAGCATCG TGGCTGCATCATCATGCCTGCCACATTTG CACCAACAG 1887 3497274 3 DNAJC3; TATTCATTTATTGATCTCCCCACACCATC 3.19E−05 0.009677701 3.97E−06 RP11- CAACATCTCTACATGATG 10E18.2   87 3497377 4 HS6ST3 AAGGCAGGCAGTCATCGCCGGAGTCCTA 7.38E−05 0.027178585 2.76E−05 AGCGGCAAAAA 1082 3497692 2 RAP2A TTCCTTCTCGCCTTTAAGGGCTATGGTTG 0.008795089 0.007805083 5.00E−06 TAGTGTGACCCGTGGCTAACCTGCTTTCA AAATCAAGTATTTGCTGTAGCAGAGCTT TATTGCAGGCATTTTAAAAATTGAATAA CCATGTGAAATAATTTGGGCTTAAAAGT GAACATAAATTATAGAGTGGAAGGTAAG GGACAAAAGCCTTTTACCTTTAATTTTCC TGGAGAATTATATAAAGGTTTTCTTAGA ACAATTTTGCCCTGATTACTGAAGCGTC AAATAAAGCTGG 1882 3499158 9 ITGBL1 GCAGGTGTAAGTGTGATAATTCAGATGG 9.32E−06 0.009461541 7.12E−06 AAGTGGACTTGTGTATGGTAAATTTTGT GAGTGTGACGATAGAGAATGCATAGACG ATGAAACAGAAGAA 1993 3499164 9 ITGBL1 GTGGTGAATGTACCTGTCACGATGTTGA 1.12E−05 0.007754542 4.29E−06 TCCGACTGGGGACTGGGGAGATATTCAT GGGGACACCTGTGAATGTGATGAGAGGG ACTGTAGAGCTGTCTATGACCGATATTCT GATGACTTC  521 3499195 9 ITGBL1 TTCTTGTCATTGTGGGAAGTGCATTTGTT 0.002350957 0.016058117 1.81E−05 CTGCTGAAGAGTGGTATATTTCTGGGGA GTTCTGTGACTGTGATGACAGAGACTGC GACAAACATGATGGTCTCATTTGTACA 1459 3499197 2 ITGBL1 TGGTTCCTAACGAGAGCAATTTTTCCACC 0.000475873 0.009854259 3.60E−06 CAAAAGTCATTTGGCAACATCTACAGAC AATTTTGATTGTCACACTGGGTCGGGTA GGAAGGTATGCTGCAGACATTTGGTGGG TAGAGGCCAGGGATGCTGCTGAGCATCC CGCAGTGTACAGGACAGCCCCCAAACAA GGAATTATCCAGCCCCAAATGCCAATAG GGCTCAAACTGAGAAACATTGAGTTATA TGGCTATTAGAAATCCACATTCTTACAC AAGAAAGACCATATTAGAATCTAAGGAA AACATGCATATTCACATTAATTAATCGA TCAGATTTTTCCAGAATTCCGTATCAGTC ACCA 1261 3499203 4 RP11- AGCCCAGTCGCTTTCCCTTGATATAGCCT 0.013881148 0.006923667 2.88E−06 397O8.4 TGTTCTGAATTAAAATGGAAAAAATATT TCAATTATTTTCATCTTGTTCTCAACTGG ATGTTAGTCAATGTGGTCTCTTTTTGAAT ATGTATCAAATATTAATGATCCATAATA TTAGGGAGATAATTTTAAATGAAGTGAT ACGTGTCTAACTTACTTAAAGAATAAGT TTTTGGTTTTTGCTTTTAAAGACAACCAA ATCTGATATTGTTCATCCTGATAAAAATA ACAACTTTTAGTGCTTAAAGCATTAATTA AGCAAGTGGCTAGGTATGATAAAGAACT TCTGCTTGCTCCCCAAGAGGCAAACTAT TAGAAGAACTGGAGCGGGAGTCCTTTGG ACCCATCGTGGATCTCTTTAAGCCACTGC TACCCAAAAACATTCAGGACAAGCAAAC ATTTAGAGCAAGAATCTCCAAATTCTTC AGGATTTGTAATGAAATGATGTTCAGTT CCATTTTGCTCTTTACATAGGGTGGAGA ATTGTCATGTCTTCTCTAATTTTTCCAAG TAAAGTGGTAGCAAAATGTTTTAAAAAG CAATCTTATATTAGAAAACAAAAATGTT GTCACTTGAAATACCAAAACAACATTTC TGAGCGTTGTTGAGGGACTGGCAAAGCA ATCAGCTACTATAACAAATCAGTAGAAA TAACCCTCCCACACCAGATATGCATGCA GAAGGAATGGAGTATTATAGAGACTTGA TACAATGGACATATGCACATGGAGGTAC AAAACACACAGTCTAAATACAAATGAAT TCCATCAGATTTACTATACGGAACATCA GTAGTGACAGATTGCACTTCTTACTTAAT AACAGCAAACTTAATTTCTGAGGGGAAA AAAATGGCGAAGTCTTATCCCAAACAAA TAGCAAGAGAGGTATCATCAAAGAGCTA AAATTTTCTTTGGCATGGTAAAGGGGGA AATTGAGTTTACCAACTTATTTACATGAC ATTTCTCTATATTGGTGAGTAATGCAATG CCATTTTGTTACATAAAGTTGTTTGATGT TTTTTAATATGCCTTCATATAAATATTTT ATTCAATATGTTGTATTTGTGAATTTAAC AAATGATATTAAACACAAACTACAATGC AGACAGACAAACTCTTTGTATGCAAATT AGCAATACATACCAACAGTTCTTGATAC ACAGGTACCTACTACATGCAGCTCATCA TTGCTGTCCTCTTCCCATGCTACAGGTGA GACCAGA  163 3499919 1 TGGAAACAAGCTGTGGACAAACTCTTCT 3.23E−06 0.02130792 1.70E−05 CTT 1020 3499954 1 TCCATGGTCCCGTGCCTGACTTCATGGAT 0.046404092 0.008798959 6.33E−06 GGTTCAATGCTGCAGTTCGTCCAGTTCAT GGACAC  158 3501363 9 COL4A2 TGGCCAATCACTGGTGTCACCGGGCAGC 0.011533849 0.018104363 2.52E−05 TGTCTAGAGGACTTCCGCGCCACACCAT TCATCGAATGCAATGGAGGCCGCGGCAC CTGCCACTACTACGCCAACAAGTACAGC TTCTGGCTGACCACCATTCCCGAGCAGA 1408 3502223 9 ATP11A ATTGGACACACACTACTGGACTTGGATC 0.002212029 0.006829333 5.34E−06 AACCATTTTGTCATCTGGGGGTCGCTGCT GTTCTACGTTGTCTTTTCGCTTCTCTGGG GAG  913 3506074 6 TTTGCTGCGACCACCTTCCATCATAACCT 3.18E−06 0.016317744 1.38E−05 TTGCACTAGTGATTGTACCAAATGGAGA AAACGCTTTCCGGAGACG 1569 3507963 2 KATNAL1 TGGCGAGAGTTTGCTAGTCTCCCTCCCCG 0.015967819 0.010333182 8.40E−06 GCTTTGTGCTGGTATTCCACGTATTCCTG CATTAATATTGCACACCCAAACCAGTCT ATCAGGGAGGCTGAAGCAAGGGCGCAG TGTGATATTTTAGGAATACAGAAGATTT AGAAATACCCCTATTTCTCATTTGCAGTT TTTTTTTCCAATTCTGTGCTCTGTCAACA TGAGGGACCTATC 1929 3510072 9 POSTN ACACACCCGTGAGGAAGTTGCAAGCCAA 0.002951948 0.010200983 8.04E−06 CAAAAAAG 1568 3510096 9 POSTN AGGGAGAAACGGTGCGATTCACATATTC 6.49E−06 0.008737308 7.60E−06 CGCGAGATCATCAAGCCAGCAGAGAAAT CCCTCCATGAAAAGTT 1777 3510099 9 POSTN GTCTATTATGGGAGGAGCAGTCTTTGAG 0.000751323 0.008159496 4.59E−06 ACGCTGGAAGGAAATACAATTGAGATAG GATGTGACGGTGACAGTATAACAGTAAA TGGAATCAAAATGGTGAACAAAAAGGA TATTGTGACAAATAATGGTGTGATCCAT TTGATTGATCAGGTCCTA 1332 3510150 4 TRPC4 TGACTATTGTAGCTCCAAGAACCTCACC 1.22E−05 0.008844699 3.51E−06 CCCAAAGCCAAACAACTATTTTACAAGC TGCGGTGGACCCGCTTACAAAATCAGCT TAAGAAACGTAACCTTAAATTTTAGAAT TACAGATTTTAATGACTTCATATTCCACG ACTGACCCTCTGAGTTTTTT  519 3511633 5 TNFSF11 CCCAGAAAATGAGAACACGGACACAGA 0.000595218 0.012364946 6.51E−06 ATCTCCATCTCACATTGTTTCCTGCTCTG CCTACTTCACCACAGATGACAGCAAAGG ACCAAGAGTTACAACTGCTICTCATCAG AGCCCTGGATCAA  463 3512032 4 ENOX1 TCAAAAGAGTGTGGGACTGGTGTCCCAA 0.033960096 0.007007489 5.15E−06 CAGAAAAATAGATCCTTGGAACAGAAG AAAGAGGCAGAAGTAGATCCACATGTGT ATAGACCGTGGATTTTAGACCAAGGCAT GGGGGCAATTCAGTGGAGAAAGGATTA ATTTTTCAACAAATAGTGTCAAAACAAG ATATCCATAAGCAAAAAATGAACATCAA ACCATATTTTATAATATATACAAAAATG AACACCACATGGACATATATGTAACACC TAAAACTATAAATCTTGTGGAAGAAAAC CTAAGAAATAATCTTTGTGAGATTGGGT TAGACAAAGATTTCTTAGATATGACACT GAAAGTGCAATTC 1613 3513641 1 GCCCACACCAGGGACCATGTTTCATCCT 7.74E−06 0.009463004 4.74E−06 CCTAAA 1123 3517038 1 GCCATGTTGGGAAGCCGCATGACTCGTG 0.012450296 0.006662742 3.90E−06 GACAGGCGGGGAAAAAGAATTGTCACA TCTATGTGGATAACTTACCTTCAGGTATC CCAACCAAGGACACTGAGG  786 3517930 4 KLF12 AGCAGCTGTTTCCAGGTCATATTCAGCT 0.00059375 0.008249929 2.90E−06 GTTTTATTCCTAAAGATATAACAGAAAT CTTTAAGCTACATTTTGGTGTGTCTGTGT AGGCTGGCATAGGACAGGGTGGTGTTTA GTGGGAAATATCTGTGAACCAATTATTG CAGTTGACTTAAGGCTCCAGAAATTTCC AGAATCCATGTTCATATTCTAAAGACGT GCACATTTATGTATGCTCCATCTTTAGAT TTTCACTTTCTTTTTTCCTCTCCACTTCTT GCTCTATCCTGCTCCATTTTTAAGGTTTT AAAGGACTTGGGCATGTGTCGTTGCTTG ATAATGGTGGCGGTAGTGATTGTGCTGT GTACCTAAAACCAGTATCAAGGGCTGTT GTGTAACA  191 3521655 5 HS6ST3 TCTGCACCAGGAATGAGACACACTACAC 0.031823166 0.016338133 2.03E−05 TAGTTTGCTAATTTGTTTCCTAGGGCTGG CATGACAAAGTACCATCATCATGGTGGC TTCATCAACAGAAATATUTTATTACCTCA CAGTTCTGGAGGTAAGAAGTCCAAAATC AAGCAATCTACAGAGITGGTGCTTCTAA GGGGTATGAGAGAACAATTTATTTCAGG CCCATCTCCCTCTATGTGAGTCTGTCTTC AA  428 3523505 7 ITGBL1; GGTACCTGTGTATCAAGAACTGTTGGTA 0.006310467 0.014771455 1.26E−05 RP11- TGTATTGCTAATTTGCATACAAAGAGTTT 397O8.4 GTCTGTCTGCATTGTAGTTTGTGTTTAAT ATCATTTGTTAAATTCACAAATACAACA TATTGAATAAAATATTTATATGAAGGCA TATTAAAAAACATCAAACAACTTTATGT AACAAAATGGCATTGCATTACTCACCAA TATAGAGAAATGTCATGTAAATAAGTTG GTAAACTCAATTTCCCCCTTTACCATGCC AAAGAAAATTTTAGCTCTTTGATGATAC CTCTCTTGCTATTTGTTTGGGATAAGACT TCGCCATTTTTTTCCCCTCAGAAATTAAG TTTGCTGTTATTAAGTAAGAAGTGCAAT CTGTCACTACTGATGTTCCGTATAGTAAA TCTGATGGAATTCATTTGTATTTAGACTG TGTGTTTTGTACCTCCATGTGCATATGTC CATTGTATCAAGTCTCTATAATACTCCAT TCCTTCTGCATGCATATCTGGTGTGGGAG GGTTATTTCTACTGATTTGTTATAGTAGC TGATTGCTTTGCCAGTCCCTCAACAACGC TCAGAAATGTTGTTTTGGTATTTCAAGTG ACAACATTTTTGTTTTCTAATATAAGATT GCTTTTTAAAACATTTTGCTACCACTTTA CTTGGAAAAATTAGAGAAGACATGACAA TTCTCCACCCTATGTAAAGAGCAAAATG GAACTGAACATCATTTCATTACAAATCC TGAAGAATTTGGAGATTCTTGCTCTAAA TGTTTGCTTGTCCTGAATGTTTTTGGGTA GCAGTGGCTTAAAGAGATCCACGATGGG TCCAAAGGACTCCCGCTCCAGTTCTTCTA ATAGTTTGCCTCTTGGGGAGCAAGCAGA AGTTCTTTATCATACCTAGCCACTTGCTT AATTAATGCTTTAAGCACTAAAAGTTGT TATTTTTATCAGGATGAACAATATCAGA TTTGGTTGTCTTTAAAAGCAAAAACCAA AAACTTATTCTTTAAGTAAGTTAGACAC GTATCACTTCATTTAAAATTATCTCCCTA ATATTATGGATCATTAATATTTGATACAT ATTCAAAAAGAGACCACATTGACTAACA TCCAGTTGAGAACAAGATGAAAATAATT GAAATATTTTTTCCATTTTAATTCAGAAC AAGGCTATATCAAGGGAAAGCGACTGG GCTAAATCCTCAATTTTTTTTTCCAAAAT GCAGGCATATCAAAATCCAGGATGTACA TGGTCTTACTTTGAGTGAAATAGTAGTC ATAGCTGAGGTTTCTTAGCCTACAATGT GACATAGGGCCTGTTGACTCTCTTGAAT ATGGAGTAGGGTTTCAAAGTGTTGACAG TTGAGTCTGCAAACTAAGGCTGAGTTAT ATTTTAGTTTTTTTTTTTTTTCCTGGTTTT CACTAAGTCTAATTCCAATGTCTACTGGC AGAGATTGTGTTTGCATTTGAGGTAGTG GAGGGCGGTACTTTCCAAGTGCTGTTGG AATCCAGATAAACTCAAGGAGCCCAGAA AGACAACGGGTATAATGGCTCTCCTCTT ATGACTTAGCACTTTAGTTGACTTTTTTG AAAAAGTCTCTGGGTGGAATACCTCAGT GATGATGATTTGCCAAACAAGCAGCGTT AGTGCCAACACCTTCTCTAAACTTGCTGC ATCCCTTCCAATTGACATTA 1471 3524517 1 AGGCACAGGCGGGAAGGCTGCATACTCT 0.006129156 0.007067951 6.11E−06 CC 1570 3525217 1 TGAAAGGGATAGTCACCTTGGGTTGGGT 0.000794501 0.008468936 4.75E−06 TGGAGGGGATGGTCACGTTGGGTTGGAA GGGACGGTCATCTTTGGATGGAAGGGAT GGACACCTTGGGATGGAGTAAGTGGTCA CCTTGGGATGGAAGAGATGGTCATCTTG GGATGGAAGAGATGGTCATCTAGGGATG GAAGGGATGGTCATCTTTGGATGGAAGG GATGGTCACTTTTGGATGGAAGGGATGG TCATTTTTGGATGGAAGGGATGGTCATC TTGGGATGGAAGGGACGGTCACCTTGGG ATGGAAGAGATGGTCATCTTGGGATGGA ATGGCTGGTCACCTT  799 3525316 2 COL4A1 CCCAGGTTCATGAATATGGTGTCTATTAT 0.00034347 0.014745656 1.67E−05 AGTGAAACATGTACTTTGAGCTTATTGTT TTTATTCTGTATTAAATATTTTCAGGGTT TTAAACACTAATCACAAACTGAATGACT TGACTTCAAAAGCAACAACCTTAAAGGC CGTCATTTCATTAGTATTCCTCATTCTGC ATCCTGGCTTGAAAAACAGCTCTGTTGA ATCACAGTATCAGTATTTTCACACGTAA GCACATTCGGGCCATTTCCGTGGTTTCTC ATGA  282 3525317 2 COL4A1 AGATGTCAGCAATTAGGCAGATCAAGGT 6.70E−07 0.02435786 2.92E−05 TTAGTTTAACTTC  120 3525318 2 COL4A1 GGTGTGGGTGCCTTCCATACTGTTTGCCC 9.07E−07 0.029855107 3.15E−05 ATTTTCATTCTTGTATTATAATTAATTTTC TACCCCCAGAGATAAATGTTTGTTTATAT CACTGTCTAGCTGTTTCAAAATTTAGGTC CCTTGGTCTGTACAAATAATAGCAATGT AAAAATGGTTTTTTGAACCTCCAAATGG AATTACAGACTCAGTAGCCATATCTTCC AACCCCCCAGTATAAATTTCTGTCTTTCT GCTATGTGTGGTACTTTGCAGC 1702 3525346 9 COL4A1 GAGATCAAGGGATAGCGGGTTTCCCAGG 0.017555038 0.007078593 7.84E−06 AAGCCCTGGAGAGAAGGGAGAAAAAGG AAGCATTGGGATCCCAGGAATGCCAGGG TCCCCAGGCCTTAAAGGGTCTCCCGGGA GTGTTGGCTATCCAG 1572 3525347 9 COL4A1 CTGGCCCACAAGGTTCACCTGGCTTACC 0.002951948 0.008002999 5.89E−06 TGGAGACAAAGGTGCAAAAGGAGAGAA AGGGCAGGCAGGCCCACCTGGCATAGGC ATCCCAGGG 2002 3525376 9 COL4A1 TGTGGAATGTCAGCCCGGACCTCCAGGT 0.00140662 0.008255721 7.04E−06 GACCAGGGTCCTCCTGGAATTCCAGGGC AGCCAGGATTTATAGGCGAAATTGGAG 1138 3527440 9 PARP2 GCTTTGGGAGACATTGAAATTGCTATTA 0.000417578 0.009113313 4.95E−06 AGCTGGTGAAAACAGAGCTACAAAGCCC AGAACACCCATTGGACCAACACTATAGA AACCTACATTGTGCCTTGCGCCCCCTTGA CCATGAAAGTTA 1135 3527672 2 RNASE6 TTCGAGTGCCTAGGATGCCAGACCAGAG 0.000909538 0.012047043 1.21E−05 TTGAGACAAAAAGAAATAAGATTATTTT CTGCTTTGTAGTTCTGTACTTTTCGAGAG AAGGGAATAGGGAAGACAGCAAAGAAA GATTCAGATTTCTAACCCTGCAACTTTTG CCAAGCTTTATTGCCCTG 1084 3527990 6 CCAAACATCAGGCTGTTCACAAAAATAA 3.69E−05 0.017132822 1.65E−05 CCCACAGTATCAACTTTAGAAAACAAAT CTTAAGACTATAACACTAATTATTTTTCT AGAGGATGCATTTGACATGCCAACTCTC ATTCA  999 3528533 4 AE000661.28 ATGGTGGCTACTGCAAGGGGTTTTTTGTT 0.005348101 0.006614602 5.62E−06 TAGGGAGAACGCACTGTGGAACTCA 1208 3529692 4 RNF31 TAATCTTGTTCGTCCAGGTGTCTCAGAGT 0.035044469 0.007877746 3.05E−06 CCAGCTATGTTAGACACACTCAGTTAAT ATTAGCCAACACAACAAATATTCTGCTC CCTTTTC  980 3529894 4 LTB4R CAGGGGACATCCACAAGTACACATCTGT 0.045706551 0.007831994 3.62E−06 GGTCACTAAGGTGACCAGCTCATCCCAG TTGGCCTGGAACTTTCCCAGTTTAAGCAC TGAAAACTCCTTGTCCCAGCCCTGCCGG TTTCCCAACAAACTGAGATGGTTGGCCG CTCAAGTGGCTACCCTGACCATCACCCC AGGCTCTACTTTAGCGACTGCTCACACCT CCCTGCTTCCCAGACAGAAGTCAAAACA GCAAAAGAAACCCAGTCCCCAGGGTCAT GCTAGGGCTACCAAAACTGGGATGAACT AGCACCTGTGAACTAGAACAGCAGGGA GTATGCTTAGAGTGCCTGGTCCTGGGTG TGGGGAAGAAAGGCCATCAAGGTAGAT GCGGGTGGGGAACAGCTTGAGAGAGGA GGCAAGGACAACCCAGTTTCTGTCTGAA GGGGCCTCTGGTTGACCCTGGAGTTTCT GTCCCCAAACACAGGCCTCACGGGATTC TTTC 1869 3531193 4 COCH GCCATTAGCAAGATGGATAATCCTTGAT 0.030285522 0.006501799 5.60E−06 AAATAAACTTGTAAATACAGTAAGATGT ACAAAATATCACATAGTGATAGGATGCC AAGATTAGTTTTTTTCTTTAAGAGTTCAT TTGGAGTACTAAACCCCACTGTTTCATTT TAATACACTTAATAGTCCTTGGTTTATGA AGACATTTATGTGATGATGAAAGTTATT TAGCATCTTTATGGAAGGACTTAGCTGA GCTGTATTAGGCAAAAGAAGGAAAGAA AGTGGTTACAGGGCAACGGGTCAGTGAG ATCT  642 3532227 7 SNX6 TTCTGAGTATGACGAGTGCACGATGATG 4.38E−05 0.010058046 7.03E−06 GACCACTGTCATGGGGAACACAGTGCGG CATCACGGCACACAGACTGGCATCGCCT GGGCGTGCGCTGCTCCATGTTTCTCAGA AAA 1850 3533039 1 GGCATGGGTATTTTCCAGCCCCAGATTG 0.002187152 0.007213692 5.97E−06 CTTGGTAAAATGATGGTGGAGAACAAAA AGGTGAGGGCTGCAGTCCTAGCTGGCCA AAGTTCAAAGAACCATGCTGGGCTGGGG CTAAAAGAAAAACCAATGGAATTATTAT GCCCCCAAACTTAGCTATTTGGAAGAAA AAACACAAGATTTAAGGTAATCTGTTGT TAAATGTTATTTGGATACACTAACATCGT GCATGAAA  327 3535010 1 CTAGTGAGCTGAACAGGCAAGGAACAC 0.002182207 0.013765072 9.95E−06 AGAGGTGAGATCAAGGAAGGCAGAACA AGAATGGAGCGGGATTTAGGAATTAAAG CAAATCTGCAATTAAATATAACTGAAGT AATGGTAAATTTCAAGAGAACTAGACTG TAAGAACTAACCTCACATTGTGGGAAAA TAAAAATTTTAACCTTTTCCCCCTTTATT TGAAATGTTCTATGACTACTTGAAAGAA TTTAAAAATGAAAGTATTTGTCAGTTTTG TCCTTGAATATCTTTCATTTGTTATAGAA TACATATTTTGTCCATAGTATTTTGTTTT ATAAGTGTGAGGGTAGATTTTTTTATTGA GAGCCTACTAATATGCCTGG 1102 3536724 4 LGALS3; GGTCATTGTCTTTCCTGTCTCAGTAGTAA 0.011264381 0.007864671 3.99E−06 AL139316.1 TCAATCACTGCTTATCTTCAAAAACCCA GAGTAGGGGATGGGGCAGTTAGTGGGG ACAGAGGGCAGATGGGTAAGATTCAGA GCACAGGCTAGTGTGACGGAAGTTTAAA CTTGTGAGTTAAATAGGGTTTGGCAATC TAGCTGGATAGCATCCCTGCCCCTTGAA GAGATGTTTTTGTGGCGCCACACTACTG ACTTAGG 1162 3537877 7 C14orf37 CTTTATCCCGTGAGGAGCACGCGGAAAC 0.039082309 0.007619176 4.86E−06 CTCTACCCATGCAGGATGTTTCTAAGAA CCACTTCTTCCCTGTCTTAACTAAGAAGG CTCCCACAGCTGGTGCCAATCAGGTGGA GAACATGGCAAGTCCCCGAAATGCACTT CCAAAGACAGGAAAGATTGCAGTGGGA CAGAACCCAGAAAATCTCTCACATTCTC GAAAACCCGAAAGAGAACCTCCAAGAA AGACGTTTGCCTCTCCTCCACCTCTTTAT CTCGGCGGGAGAGGAAGCCTCGCCCCCA TTCATCCCGCCCCTTCTCCCCACCCCGCC GCAGGGAGAAGTTTACCATGGCTGCCTG CGGCCCCTTCACTTCCGGTGCCGGTGCC GCTAGGGCTGCGCCATCCCCCCAGTCAA TCGGACAACCATAGCCTCCAACTGACCT TTCTGACAGCTCTGAGACTCCTCCGGCC ACGACTAGGTGCTGTCCTGGAGGAAACG GTGGAGGACGGCCGCACAAAAACCAAT CTA  766 3540148 2 HSPA2 TTGCACTCAAGTCAGCGTAAACCTCTTTG 0.014622507 0.007412038 3.46E−06 CCTTTCTCTCTCTCTCTTTTTTTTTGTTTG TTTCTTTGAAATGTCCTTGTGCCAAGTAC GAGATCTATTGTTGGAAGTCTTTGGTATA TGCAAATGAAAGGAGAGGTGCAACAAC TTAGTTTAATTATAAAAGTTCCAAAGTTT GTTTTTTAAAAACATTATTCGAGGTTTCT CTTTAATGCATTTTGCGTGTTTGCTGACT TGAGCATTTTTGATTAGTTCGTGCATGGA GATTTGTTTGA  927 3540771 1 CGGGGATATTCAGGCCAACACTAGGAAA 3.85E−06 0.010896849 6.72E−06 CCACAGCCAAGTCAGGCAGGGCTTGGGG CGGAACTGCTGACACCTCCACCCTAGCC AATCCAAGGTGCACGCCTGCCTCATGCA GCCCAGCGTGACTCCCGCCATTGGCACA CTGTGCCCATCACAGGCTGGAGCTCCTTT CCTCCACCGTCTTCCCAACTCCTGCCAAC CAGAACTTAACTACTCCTTTGGATTCTGC TTTTCACTTGTTCTTCATCAGACTATGGA AGCTTAGACTTCATAATTTGGCTGAGAC TTCAAAAATAGTTTTAAAGAAAGCTATT CCCACCCTGCTAAAGTAATTACATGATT CTGCCCCCTTAAACACCCAAAGCCCTAA TCTGTGTTCTCA 1630 3542092 2 SLC39A9 TTGGCTACCAAAGAGACGCAATTGATGA 8.12E−06 0.010138736 5.76E−06 TGAGAAGCATGATTCTTGCTTCCATATA ACCAAAGTTAATCTTAATTGCAATTTGA CTCCGTTTCCTTGGTAGGGATAGACTTTC TTCAGATTCCAAGTGCTCTCTTAAATGGC AAATTAAGTTAAAGAATACTACTGCTCC ATTCCCCTCACTTATTCTCCAGTTAATTG CTTGTCAGTTCCATTTCAAGAAAGCAGT GATGTTCCAGGTTTGATTCAGTTTTCCTG TGCACACTATTGCCAAATTTTTTTTTAGC AAAGATTCTGCACTGGAACGTAGACAGT TGGAAACAGTACTACCTACCTAGAGGTT ATGTGTTTTCTCTTTCTCCCCGCTTTCACC TCTTTCTTTCCCAATTCAAAACAGCCAAG TGAGCCCTGTTCTGGTATTTTGAATCATT AGAGAAAAGAAAGGGAGTGGCTGTTTTG AGTTGTCCTTTCTTTGCAGAAAGGAGAA AATGTGATTGTGTTTTTTTTTTACCAGCC TACTTCTAAGTGTCACTGCCTGGTTTTTC 2031 3542093 2 SLC39A9 ACCAGCATCGGAGTGTATTAAGCCCCTG 1.71E−05 0.008672443 6.82E−06 AAACACATGGTAGCTAGGGACTGAACAC AGGAACCGTATGACAGCAGCACAAACCC CCAAAGGATGTTCCTGCCTTGTGGGCCC CTGAGCCCCTTGGGAGACTGAGAATCAT GACCAGATTCATCCAGAACTGCTGCAGT GTTAAGTGAAAATCCTCTGTAGTTGTTCT GCAGAGGAACCTTCCTTCCATTAGAAAA TTTCTGCTCAATACAGAATGGTCCACATC ACCCAAAGTGCACTGTTGGAGATGCTGT GAAATTAAAACCTCTTTGTACCTGAGAC ATCTAGATTCACCTCAGGAGGCCTGAAG GAAATGTGTAACTTGTGGGAAAGAACTA GACAACCATTTAGGAATTCTCTAGATAT ACTCAGCCTAACCCAGTGGCTTAACACA AGGAGATTGGCTTTGATCTTTTTTTCTTG TGGCATCTTCCAGCAAGTTAGAAGTCTC ATGGGATAAGACTGCAGTTCCCCTGGTT CAATAGCTGGAACAGTG 1583 3543814 8 C14orf43 CCCACAGGGTGTCCATGGGAAGCTGGGA 0.047987301 0.006772589 5.92E−06 TA 1412 3544272 9 YLPM1 GGACCTCTTCGAAGGGCTGGGAGTAGAG 0.003965967 0.006997005 4.50E−06 AGAGAATACCACCCCGAAGAGCT  750 3544533 4 FOS GAACTCTAGCGTACTCTTCCTGGGAATG 0.004800285 0.008329058 7.28E−06 TGGGGGCTGGGTGGGAAGCAGCCCCGG AGATGCAGGAGCCCAGTACAGAGGATG AAGCCACTGATGGGGCTGGCTGCACATC CGTAACTGGGAGCCCTGGCTCCAAGCCC ATTCCATCCCAACTCAGACTCTGAGTCTC ACCCTAAGAAGTACTCTCATAGTTTCTTC CCTAAGTTTCTTACCGCATGCTTTCAGAC TGGGCTCTTCTTTGTTCTCTTGCTGAGGA TCTTATTTTAAATGCAAGTCACACCTAGT CTGCAACTGCAGG  181 3544721 4 TTLL5 GGATCAGTGATGGACAGGGCCCATTTGG 0.008619147 0.018014742 1.83E−05 CTGCCTTCTTGGAGTACCCAGGGTAGTC ACGTTTGTGCCAGGCCTCTTGAAGTCCA GCAACCACAGTGATAGCCTTTTGGCCAC AGCTCTTTTCTGTGTTACTGATGTCTCTC ATC 2075 3545532 6 CTTCAGAAGAAGGACTTCGGAATGCACT 0.003188906 0.007127484 3.35E−06 ACAACAGGAAAATCATATTATAGATGGA GTA 1376 3546925 4 FLRT2 AGGCTTTGTCTTTCACCTGGAGAGAAAA 0.013721065 0.007711219 4.82E−06 TAGGCAGCTTAGCTCTCTCTCGACTTTGG GGACATCTGTCTGCTGGTCGAATCCACC TC 1105 3549156 5 ITPK1 CTGGATTCTGCAGTATGAACAGGGCAAC 0.00247563 0.007281351 2.35E−06 CTCACCAA  298 3549159 5 ITPK1 GACGCTTCCTGGTCTTTGGAACTGACCTG 0.000122396 0.011814315 4.49E−06 AGGCAATGCATCTCCATTCCTGGCTTTGA CTACGATGGTTCTGCGCCCAGCTGGACA AGGAGCACAGTCCAGGGCCCTCAGGTCA AGATGCCTCCTCCTCAGAGTCTCAGCCCT GCACCAGGCCAAACGGGAACCGA  410 3550007 7 CLMN TGGAAGTTTCCTACAAGGGGTGACAGCT 0.024191116 0.007528968 1.46E−06 CTGGACAGGGCATCAGGTGCCTGTGTGC TCACTGCAAGTCTGCCCCTGGTCGGCTAT ATGATCTTGGTCAAGCTGCTCTGTCTCTC TGGGTCCAGCTAGACAAGATGCTCACTG AGTCCCCTCCTGACTCATTTGTGATTTTA TAAGGGTTGCCTGGTACATGCTTTCTGA AGGGGAGAGCAAGGGGAGGAGGAACCA ATGCAGAGACTCACCACGGACCTGAGTC TTGGCAGGGAGGAGAGAGCAGAGGGAG CCTGGGGCTGAGGAAGACTGGGGGCAG GGGTGCTAGAGATGCCTCTCTTCTTTCAC AAACCTCCTGTGCTGGCCTGCTCCCGGA GTGCTGTCCAGAAAGCCTCTTCAAGAAA CCCATTACAAGTGACCACAAAGAATGCC CGTTCCAAGACATGCATTCTGAGGGAGG TGTGCACCAAAGCTTTAGTGGGCAGGAA GCTACCCCACCACCCAGCTCCAGCACTG CTGGGAGCTGATTCCAGCCCAGCCACTC CTCATGGCTTTTATATGGCCCTGCTGGGC CCTGGCGATCTGGTTTGAAAATC 1182 3550126 1 ACGGGTTGAAGATCCGAGAGGCTGAGTC 0.019902689 0.006509539 3.04E−06 ACTTCCACAAAGTAACACAGCTG 1307 3550432 9 PAPOLA GTTTGAGGTGGATATGAAAATTGCTGCA 0.002543079 0.008731933 6.43E−06 ATGCATGTAAAAAGAAAGCAACTCCATC AACTACTACCTAATCA 1152 3550451 2 PAPOLA GGGTACAAGACTAGACATGACTGAAATG 1.66E−05 0.015015134 8.97E−06 GATTTGGGTTTTTTGGTGACCTCCCTTAC TGGGCTAATCAGCACTTGATCGGAAGTC CAGGTTAGTATGTGAAGCCAGG  620 3551602 4 EVL TTGCCACTTGTGAGATATAGATTTGTACA 0.001526056 0.010602987 6.67E−06 GATGTGTCCCTGAAGCCACATATCCAGA TCTGTTTTAAACTTGCCATCCTGTTTCCA TATTCCAGAGCAAACATTTGAGAGAGAT GGGAGAAAACAGTCAAGAATTTATTTTT GAATTTAATTATTCATTCATATGTTTAAC AAAAGTTTATTAAATGCTTACTGAGGGC AAGAAACCGTGTAGGCAAAATAGATAA GAAATGAACAGCGGCCTTCCCCTCAAGG CATTTAGTTTTTCATGGTAGACAGGTTCA TAAACAGCTAACTGGAATGTATTGCAGT AAGTGTTTAAATAAAGGTACGTGCAAGG TACTTAGGGACCACA 1243 3552386 1 AGGAAGGCAGACTCTGGTGAAGACGTG 0.000731459 0.00793614 3.48E−06 GGCCGTCACCGTCAGCCTT  515 3553052 4 WDR20 CACTGACAGCACATTCCACTTGAGACCA 8.57E−07 0.018753834 1.95E−05 GTGCTGCGGGACTGGGGAGTGCAAGCGT CAGGGTCCCAGCCGAAGCCCTTTAGCTT GGGACTTCACAGCCACAGCCTGAGTCCC AGCTCACAACTCCAGACCAAATTCCCCT CCCAGCTCATGTGCTGCGATCAAGACAG ATGC 1912 3553727 9 MARK3 ACAGGTGGATCAATGCAGGGCATGAAG 0.00041969 0.007515649 5.85E−06 AAGATGAACTCAAACCATTTGTTGAACC AGAGCTAGACATCTCAGACCAAAA  134 3553758 2 MARK3 CCGTTACCCTGAGAGTCGGTGTGTGGCC 0.000265615 0.022135548 2.26E−05 CCATCTCCATGTGCCTCCCGTCTGGGTGG GTGTGAGAGTGGACGGTATGTGTGTGAA GTGGTGTATATGGAAGCATCTCCCTACA CTGGCAGCCAGTCATTACTAGTACCTCT GCGGGAGATCATCCGGTGCTAAAACATT ACAGTTGCCAAGGAGGAAAATACTGAAT GACTGCTAAGAATTAACCTTAAGACCAG TTCATAGTTAATACAGGTTTACAGTTCAT GCC  166 3553838 9 C14orf153; GATAAATATTCAAACCTTCGACCTGTTC 9.17E−05 0.018661694 2.19E−05 RP11- ACTTTTACATACCTGAAAATGAATCTCC 73M18.2; ATTGGAACAAAAGCTTAGAAAATTAAGA AL139300.1 CAAGAAACACAAGAATGGAATCAACAG TTCTGGGCAAACCAG 1681 3554544 7 CDCA4 CTCTTAGGTCTAGGAAGATGTGGCTGTG 0.001054975 0.010173309 7.36E−06 TGCGGCTCCTGATTTTCACCCAGGTCTCA CTGCAGCGCAGGACATAATGAAGAAGTA TCACACACACATTTAAAGTAAAACATGA TACATTCACACT 1287 3554623 2 PACS2 CGCCGCCCGCGGGCCTGTCCGACGCCGG 0.009193693 0.006617289 5.66E−06 1932 3554841 2 CRIP2 CTGGCATCCTCTGGGCGTCCCATGATCCC 9.17E−05 0.007654287 3.52E−06 TTCTGTGTCTGCGTGTCCGAATCCCCGTG TGACCCTGTCCCAGCATTTTCCCGCCGAC CCTGCGTGTCCCCGTGGCGCTGTCCGCTC TCCCTCTCCTGCTGCCCACCCACCTGCCA GTGTTATTTATGCTCCCTTCGTGGGTGAT GGCCACGCCCTCACCATGTCCCTGGCAG AGGGCTTCCCTCCGGGATCCCCTGCCTG GTGCCCACACTGCCTCGCAAGCGCTC  351 3556347 9 SUPT16H AATTGAATTCCGTGAAGGCTCCCTAGTA 1.29E−06 0.02158001 2.25E−05 ATCAATAGCAAAA  568 3557916 9 TM9SF1; TGCCAATGTTTCAGTGCGGGACGTCAAG 6.72E−05 0.01010437 7.35E−06 RP11- CCCCACAGCTTGGATGGGTTACGACCTG 468E2.1 ACGAGTTCCTAGGCCTTACCCACACTTAT AGCGTGCGCTGGTCTGAGACTTCAGTGG AGCGTCGGAGTGACAGGCGCCGTGGTGA CGATGGTGGTTTCTTTCCTCGAACACTGG AAATCCATTGGTTGTCCATCATCAACTCC ATGGTGCTTGTGTTTTTACTGGTGGGTTT TGTGGCTGTCATTCTAATGCGTGTGCTTC GGAATGACC  243 3557960 4 TM9SF1; TTAGAACTCATACTGCCACATCTTGATTC 0.000191608 0.016704805 1.10E−05 RP11- CTGCACAATCTCTTATTAGTTGTGATTTT 468E2.1; TAACATCTTTGTGGTTGTTTTCACATTTT AL096870.1; TAAAGTGAAGAGATAGCACGTTCATTGT CHMP4A AGAGATTTGGGGATTAGCAATAACACAG TCAGGTCTCTAGCACATACTATGTATTCA ATGATTGGTGGCTAATATTTTTCCTTCAC AAAATTTGGGCCTACTCCACTGGACTC  960 3560007 8 AKAP6 AGCTTAAAGGACTGAGAGTAGCAAGCAT 0.009417954 0.009483293 6.50E−06  637 3560223 5 NPAS3 ATGTTGCAGCGGGACCCAAGTCGCAGAG 0.006389661 0.009451309 7.54E−06 CAGACAGCAAT  937 3560438 2 EGLN3 GCGCCTCGGCTTCGCGCTCGTGTAGATC 0.001877871 0.009109859 6.72E−06 GTTCCCTCTCTGGTTGCACGCTGGGGATC CCGGACCTCGATTCTGCGGGCGAG 1960 3561338 9 MBIP GTGGTCCAGTGCCAAGAGACATTTATCA 0.001877871 0.00715965 1.92E−06 GAGAATTAAAAAACTTGAGGATAAAATC CTTGAATTGGAAGGCATCTCTCCTG  220 3561724 1 TTGCAAAAAACTGCCGAGATCAATACAA 5.66E−05 0.02169482 2.54E−05 ATTCCTTCCAATGCTGGCCAAAGTAGAA GACCTGTCACCCAAATTAATTAACCTTTC CTCAAGATCAATTGGTTTTCTGTTGATTT AGCAGTAATATTGTAGAACATTTAGCTA TAATGTATTTTAATGTGATCCCTCAATGT CAACA  124 3561767 8 CTD- ATGGGCAGTTTGACAAAAGAGCCACCCT 0.000146145 0.013827712 1.59E−05 2058B24.1 CTGAGAGAAGCAAGAAATCTCCTCGGTG GCCTAACCAGGCACTCTACCTGCATCGC TCCAGGAAACTGCTATG 2008 3562015 9 TRAPPC6B GGCATCTATGTACTTCAGGACAACAAAT 9.90E−05 0.007586042 5.75E−06 TTCGCCTGCTTACTCAGATGTCTGCAGGA AAACAGTATTTAGAACATGCATCTAAG 1774 3562032 6 TGCTAAGGCCATCCATTGTCTTTTGTTAG 1.42E−05 0.009799503 2.98E−06 GAGTCAAACAAAATTTTAGTAACCAAAA CATATTTTCAATAAAATTTTATATGTATA TAAGTAAATAACAAAACAACAAAAAAC AAAAAAAGAACAAAACAGCACCAAGAA CCTATGTAAAATTTCATCATACAATTTCT ATGCAAGCTGCTTGATTACAGAAAACTG TTCAAACTGTTCATCAAAAACTGAGTGG GATTTTCCATTGATATTTCAGATATTCAA ATCAACCCATATTCTGAGTATCAATCTG AATTGCACAGGTTAAGATGTGAACCCTT CACATAGTGTTGAAGATGTGTTGAAATC TGTACTTGAATTGGCATTGTTTTCCTCAG AGTTAGGCTGCCTTCATGAGAAATATCT TCTATCCCTGAGAGATCAGCTACATC 1589 3562055 5 CTAGE5 CATCCCGACCCTCTTGTTATACTTTACAT 0.03244577 0.007294252 6.93E−06 CCCGAGGCAGCGCAGGTCCGAGCCCGAC CCGCACAAGCCTGCGACGTACCCTGTCC TCGCCACCCCACCCCTCGGTTTGGTTTCG GCCGGGCAGCCGCGAGAAGGCGGGGAG GCGCGGACAGCCGCAAACTTCCCCTTCT TCGCGCAAGCTTCGCAGACGTGTCCGGG TCGTTTGCTCTTAAAGGGGCCGGCGCTCT ACCTGGCGAAGCCACCCAGCCCTGGTAG TGGAGAGGCTTGGGACTAGAGGATGAG ATTCGGCCTCATACTCCGCGCTGT 1543 3562729 9 FKBP3 GGTCCACCAAAATATACTAAATCTGTTC 0.000158328 0.012294869 8.50E−06 TGAAAAAGGGAGATAAAACCAACTTTCC CAAAAAGGGAGATGTTGTTCACTGCTGG TATACAGGAACACTACAAGATGGGACTG TTTTTGATACTA 1394 3565024 9 DDHD1 CATCAAGTAGTGGTACCAGACTTCATAG 0.014650635 0.00854315 5.67E−06 AGGTTATGTAGAAGAAGCCACATTAGAA GACAAGCCATCACAGACTACCCATATTG TATTTGTTGTGCATGGCATTGGGCA  144 3565594 9 WDHD1 TACAGGATTTGATGGGGATCAGTGCCTT 3.92E−06 0.029618511 3.19E−05 GGAGTTCAACTGCTAGAGCTGGG 1320 3565810 1 GTACATAGGCTATGCAAAAGGAACGAG 0.039419514 0.006735638 4.08E−06 ATATGCAGAGGCAGAGCCCAGAGTAGAT GCCAGAAAGGCAGTGGAAGCAGAGACT CGTGGCA 1803 3565943 1 ATAGCGCTCTCTCGACGTCACTGTGTCCC 0.009323916 0.006563171 4.38E−06 GGCTTACAACTAGAGGTGTCGCACACAC CCACTTGGGTGCCTCCCCTTCCAAAACC AAGCAGAAAGGCGTCTAGAAAATTAGA AGGTTTTGCCAGTTGGTGCTGGCGTAGA GGACGTTTCGAAGGCGCTTGGAGCACCC CACCGTTGCACTGGATGTAGCTACCCCG GCTTGTGGTCAATAGAGCTCC  898 3566362 1 CTGCTACTGTGGAATAGGTGGAACATGT 2.38E−06 0.01176147 1.04E−05 ATAGTGGGAACCACAAGCTGTCACTGCC ACATTCTTGCATGTCTCAAGAAGCTACT GGCAGGCTTCCCCTTTTTGCCTTATTGGC CAGAAAAGTATTGCATGCCCGCGCCTAA GCCAACCATGACAAGGGAATGGTAGGTA CCATCATGATTAGCTTA  733 3570152 7 SLC39A9 GCCTCCTGAGGTGAATCTAGATGTCTCA 8.43E−06 0.017920236 1.69E−05 GGTACAAAGAGGTTTTAATTTCACAGCA TCTCCAACAGTGCACTTTGGGTGATGTG GACCATTCTGTATTGAGCAGAAATTTTCT AATGGAAGGAAGGTTCCTCTGCAGAACA ACTACAGAGGATTTTCACTTAACACTGC AGCAGTTCTGGATGAATCTGGTCATGAT TCTCAGTCTCCCAAGGGGCTCAGGGGCC CACAAGGCAGGAACATCCTTTGGGGGTT TGTGCTGCTGTCATACGGTTCCTGTGTTC AGTCCCTAGCTACCATGTG  676 3570164 1 ACAACCATTGCTGACCCAGGCTTGAGGA 0.000742232 0.007613108 4.51E−06 AGCGGCAGCTGGATCCCAGAAAGGATGT GGTCCTGCTACTGCCGCTGTTCCTCAACA TGACTCACCCTGTGATGCAACAGTTCGT CCTGGCAG  729 3571068 4 DPF3 CTGGTTTTTAGCCTGTCGTGGAAGTGCTG 0.003217076 0.00842338 9.64E−06 GGACAGAAGCAGCCCCTTCTTCTCTCAC TCCCCGGCTGCCCCTCCTAGCCCCTCTTC AGGGGGTCCCCATGTCTCAGCCCGAGGG AGAAGTTGGCTCTGGCCAGAGCCACGCT CACACTCCCACAGGATGCCGCAAGTCCC AGGCCT 1293 3571928 2 NPC2 AACAACATTAACTTGTGGCCTCTTTCTAC 1.42E−05 0.014150671 1.02E−05 ACCTGGAAATTTA 1756 3572106 5 YLPM1 GCCCATGAATCTCATCGGCTTTATCATGA 0.001143679 0.008301208 6.42E−06 AAGTTTATTGTTTTTAATCCTAGTACAAT CAGCTACCAGTTACATACAGTAAAAAAC AGAAACAGCCACAAAGCAATGATGATA GAGATAGTCTGTGACATTGTACAGTGGA GGAAATACTCTCTGTTGGAATCCTCCAG CAGACCCCCGCCTGGCTTCAGCAGTTAA GCTATCACTCCCTCCCTCCCCAAAACAGT TAAAAGAAAAATTAACGTCTTGCTTGGG TACAGCA 1167 3572167 2 RPS6KL1 CCCTATCTTGTGATTTCAGACTTGGGAGA 0.011762838 0.006906632 3.92E−06 GCAAAAGGGAGGGGAAGAAAATAAGAG TAATGGGGGGAGGAAGGAATGCATGGG TCTGCCCCTTAGAGCAAGTCTGAAACCA GAATCAAGAGTCCTCCTCCCCAGTGGGC CTGTGTGGGGGAAGAGGGGCAGCCTGCC CCAGGGGTGCAAGAGGACAGCAATTCA GCTTCCAGGCCAAAGCAGTTTAGA  978 3575711 1 CACTCCCTACCCTGATGTTGACAAGTGC 0.046404092 0.008276865 7.07E−06 AGCTTGTTTTAAAACTGGGCGCTGCATTT TACATGGAAAAGATTTTATTTTGAAATCT AGGGTGGAGTAAAACTCCAGCCAGTGAA GACTTGCCATGTGCTGTG  755 3576107 1 CGGGGTCTGCGAGGAGGACGTTCATGGG 0.000579253 0.007787951 3.24E−06 CGAGTGTGTGGTGGTGGGTGAACTGCGG CAGAACCCGAGATTAACAGCTGGAAC 1275 3576442 2 CCDC88C CTGTCTCGTGGTTGAGCTCGCAAACCTG 0.000894351 0.006736738 4.90E−06 AAAACTACTGACGCGCCTTCCGACTCTC ACGGCCTTTTCTCTTGCTTGCCTGCGGTG CCAGGAGAGGGTTTGGAATGAGGAAAG GGGTTCCCACGCATTTCTGCTGTTTGTTC TGTGAATGGAAACACTGTGCCAAGCCCC AAGAGGATTACGCTTCCAGGTGTGTAAC GTGTTTTCTGTGTCTGCCGCTTCCAGCAG CTGATATCTTTGGAACAAATAATCCACG TCAGCATGGGGACCAATTAGGATGCAAT GACAAACTGACTTCCCCCAAAGCAGACA CTACTCCAGTATGTCCCAGTAGAACACT CATTTGCAATGTGTTGAGCTCCGTTAAGC ACACACACACTCACACAACAGGCTTACG AGGCTCAGGCCTGGCGGGTCAGAAAGCC CACTCCCTCTCCCAAGGCCACTGGATCC CAGGAGAAGCCCAGACTGGCGATACTAC AAAGGTCTCCAGGGCCTGGCAGACCCCA GAGTCAGGCCTGCTGTTAAAAAGTGAGA GTGCTGCTGTTCCATTCCTGGGGTCCCAA GCACTTCCCTTTACCCCAGGACCCAGGG CAGCCTGCAGGGCAGCTGGCGGTGGCCT TGGCCATTTGCCCCCAGCCTCCAGCTGG CTCCTGAGCTCTGCACCAGGGGGTTTGG GGACCACACAGGCACCTGCCTTCCTAGA TTTCCCTGGCTCACTTTTCTGCAAACACT GGATCTGCCAGGCCTGGGGATTGGGGGG CAGGAAAGAGGCCCCCATCCAGCCCCCT CCAGGCCAGTGTGCACAGTGCACCGAGG GGTCATCCGCACAGAGCGAGGTGCAAGC TCGATGTGTAACCTGGCTGCGGCACCCG ACATCCCCGGTCTCGGGGTGTTGATTTAT TTCTGAATAACTTTTTGGGTATAGAAACC AATTTTTTTTAATATATGACATGTATATG TACACACTCATGTGAAATATGTATACTTT GGGGGGATCTATTTATGTTCCAGTGGGA GTCACTCTCTTCTGTCGGGAA 1580 3576864 4 TRIP11 TGGGGAGCTACCGAAATCCATTTTACCG 0.002951948 0.006832084 5.69E−06 CTTTACGTTCCCCATGCCATAAAGGTGC ATCAGTGAGACAGCTTTGGGGATAGAAA TGAAAGGGCTTCTTTATGTGTGGGGGAA AGCATGGGACCTTGAGGGCAGTCAGAAG CACAGAAGGGCTGGATAACTATGGGAA ATGACTGGTCGCTCCTTGTATCCTAGATA GGGGAAAACGGTTGGCTGTTCCITAGAC CCTAAGC 1828 3577079 2 LGMN AGAAGTCTCCGCTGCTCGGGCCCTCCTG 2.67E−05 0.009777743 6.33E−06 GGGAGCCCCCGCTCCAGGGCTCGCTCCA GGACCTTCTTCACAAGATGACTTGCTCG CTGTTACCTGCTTCCCCAGTCTTTTCTGA AAAACTACAAATTAGGGTGGGAAAAGCT CTGTATTGAGAAGGGTCATATTTGCTTTC TAGGAGGTTTGTTGTTTTGCCTGTTAGTT TTGAGGAGCAGGAAGCTCATGGGGGCTT CTGTAGCCCCTCTCAAAAGGAGTCTTTAT TCTGAGAATTTGAAGCTGAAACCTCTTT AAATCTTCAGAATGATTTTATTGAAGAG GGCCGCAAGCCCCAAATGGAAAACTGTT TTTAGAAAATATGATGATTTTTGATTGCT TTTGTATTTAATTCTGCAGGTGTTCAAGT CTTAAAAAATA  941 3577685 2 SERPINA9 TTCCAAGGCTCAATCACCAAACCATCAA 0.047746878 0.009206783 9.30E−06 CAGGGACCCCAGTCACAAGCCAACACCC ATTAACCCCAGTCAGTGCCCTTTTCCACA AATTCTCCCAG 1818 3579555 9 WARS GATCGGCTATCCTAAACCAGCCCTGCTG 0.004639335 0.006620066 5.48E−06 CACTCCACCTTCTTCCCAGCCCTGCAGGG CGCCCAGACCAAAATGAGTGCCAGCGAC CCCAACTCCTCCATCTTCCTCACCGACAC G 1710 3580123 6 CTGGGGATTGGCTTTGGCTAGATTTTCTA 0.000674778 0.008482164 4.73E−06 TTTTAACCCATGCTTCTTCCCGTTCTTTC ATTT  514 3580457 8 TRAF3 AGGGCTGACATTCCAAGACTGTAACTCT 0.002404431 0.00816779 3.06E−06 AAGGAACACAAGTCCTTCATAACCAGCA AGGATCCCACTCCCTCTATAAAAAGCCT GCCAGGAGGCCAAGCCAGGAGCGTAAG CCACTGATAGGGCTGTGTCTC  208 3581157 9 AKT1 TGAACGAGTTTGAGTACCTGAAGCTGCT 9.72E−07 0.017106987 1.81E−05 GGGCAAGGGCACTTTCGGCAAGGTGATC CTGGTGA 1846 3584519 4 SNRPN; GATCCAGGCAGTTAGCGATATGTTGGAT 0.005336831 0.006734131 8.20E−06 SNORD108 GAATTGAGAAAAATGAGTTTTTCCTTTCC TACTAACTGAATTAGATTAGAAATAAGC AGTTAAGTGAGAAAAATAGGGAATTAGT GCCAGATATGTTGAGGTGTAGTGTTGAC AGGGGGTCTTTTACCTTCAGATGTTTGGT GCAACTTAGAGAATGCAGTGGTAGTTGC TGGCCCAGCCCATCCAAACAACCTCATT TGTGGGGTGATACTTCACAGATGACTTA AAATAAATCCCCTGAAAATAAGAATCTC TGGAAGAGATGACACGTGTATGTGCGTG TGTGCACGTGTGTGCGTGTGTGCACGTG TGTGTGTGTGTGTGTTTTGGTGGAGTGGT AGGAGGAGGGTTGGCTTAATGATGAGAA TCATTATTTCTTGAATTGGATGACACTTT CCATTCCTGCAAAGGGAGCGTG 1894 3587051 6 CCATTGGTGGAGCTTCTCTGGAATCATTT 0.000483071 0.006821996 2.71E−06 GCCAAAAGCCCAAGGCAGAATCCAAGG GTCCAAGACCATTTCCATGGAGCTCATG TTTTTCTTTTCTGTAGGAACTTTTTTTTAA CCAGCACCCACCATAATTCCGAAGGCCA CGTTTCATCTTTCCTGGATCACTACAGTG AAGTATTACAGTTGTACAGTTCCCAGTCT GGC 1853 3588099 2 TMEM85 CTCCATGGTGGGGTGACAGGTCCTAGAA 0.000587911 0.00910916 9.28E−06 GGACAATGTGCATATTACGACAAACACA AAGAAACTATACCATAACCCAAGGCTGA AAATAATGTAGAAAACTTTATTTTTGTTT CCAGTACAGAGCAAAACAACAACAAAA AAACATAACTATGTAAACAAGAGAATAA CTGCTGCTAAATCAAGAACTGTTGCAGC ATC  493 3590406 9 NUSAP1 AGCAACGGAAGAAACGCGAGCAAGAAC 5.35E−07 0.018890824 2.23E−05 GAAAGGAGAAGAAAGCAAAGGTTTTGG GAATGCGAAGGGGCCTCATTTTGGCTGA AGAT 1073 3590434 9 RTF1 CATCCCACAACAAGGAACGGCGTTCCAA 0.002874523 0.01035944 1.38E−05 GCGGGATGAGAAACTAGACAAGAAATC TCAAGCCATGGAGGAGCTAAAAGCAGA GCGAGAAAAACGAAAGA 1272 3591735 4 WDR76 GGAAGCCAAGAGATGAGTTTCAAGGATG 6.02E−05 0.010372129 5.14E−06 GGAGGTTGACAGAGCCTTTTGCAGAGAA GTTAAAAGAATGGAGAAAAGGCCATTG ATTTTGAAAATAGGGTACCATGTAGTGA GTTGAGAGAATAGCTTTGACA  141 3594180 1 GAGCAGGCGGCTCAGACTCTTCCAACAT 0.020503158 0.019553702 2.88E−05 CAACTCCTGTTGCTTTGCCTCCTCTCCCT CATTCTACAACTATGGCTTCTTGGGATGC TGCCTATGTCCAGTTGACTGAGGGAGAA AAACCTCCAGCCTGGATTATAGATGGGT CTGTATGATGTGCTGGTACCACATGAAA GAGAACAGCTGCAGTATTCACTCACACT CACTCAGGGGTGACTGTGAAGGGCAGTG GTGAAGGAGAATCCTTCCAGTGAGCAGA AACTCAAGGCTGTCCACTATGTCTGGAG TGAGAGATGGCCAGAATACAGACCTAAA TTGATTCATGGACAGTCGCTGATGGTTTA GCTGGATGGTCAGGGCCTTAAAAAGAAC AGGACTGGAAGATTGGTGACAAGAAAA TCTTGGAAAGAGATATGTGGCTGAATCC CTCCGAATGGGCAGACTGAAGATATCTG CATCTCACCTGAATGCCCACCAAAGGGC ATCCACTGCAGAGAAGACCCTGAATCAG ATGGACAGAATTACATGCTCTGTGGCTG TCAGCCAGCCTCTCTATGCAGCTGCTGTG GTGTCTGCTCAACGGGCCGATGAACAAA GAGCTCTTGGCAGCAGGGACAGAGGATA TGTATGGGTCCAACAACATGGAATTCTC CCTCCAAAGGCTGA  471 3595274 3 AC016525.1 TGGGGCCCACGAACATCCCAGTGTGGCC 0.006090929 0.010571349 1.04E−05 CTGGACGGGACATCATGCTGGGCAACAC AGCTAAAATGCGGGTGAAGACCAGATTT CTTGCACATGGCGGTGACGGGATGCTCC CTAGAGAGCTT 1106 3595459 9 GCOM1; AAGCCAATGCTGAGGTGATGCGAGAGAT 0.000540412 0.00953604 8.67E−06 AC090651.1; GACCAAGAAGCTGTACAGCCAGTATGAG GRINL1A GA 2083 3596392 6 GCCAGGCAATGCTTAGGCAACTAAAATG 0.00360478 0.006859042 4.20E−06 AGGTTGGGGGTAATGCTAACGTCACCCT CACAGGGATGGCCACGGGGACTGTTATT CGCAAGCTGGTTTTCTAGACCTGTTAGCT GG 1128 3597927 4 SNX22 AAGTCAAAGCCCTAGCCCGCGCTTGGCC 0.005236373 0.009698804 7.02E−06 CCTGCTGCCCCCTAGTGGCCATATGCTA GGAGGCAGGCCTGCTGCCTGGGCCTGTC TGGCCTGGGCCCTGAAGTCTGTTTTCCCT TTGGTGCCTCCTGAGCCCATTTCCCACTC ACCTTTTCCTTCATGGGTCCCTGGTGATG GCAACCCCGTCTCCACCCCTCTGTGGGA TTCTGCCCTGCCTCCCGCACCCATGGTTC ATGACCCTGTTT  771 3598798 9 SMAD6 CTGTCCGATTCCACATTGTCTTACACTGA 0.0079631 0.013209737 1.11E−05 AACGGAGGCTACCAACTCCCTCATCACT GCTCCGGGTGAATTC  950 3598809 4 SMAD6 GGGCCACTGCCGTGTTGAAGAATCACCA 7.32E−06 0.013268823 5.23E−06 CCAGTTTGAGGATCCAGCAGAAATTTCT GTTTGTTCACAGGACGGTGCCAGGCAGG TTCTCATGGACTCAC  658 3600663 5 PKM2 AGGGAAAGAGCCTCCACGACTCCTCCAG 6.11E−05 0.006935628 3.53E−06 ACGCTCAGTCCAGGGCCGCCAGGGTCAG CCACCCTCCCCGCTGTCTCTATCTGTGGC CCTGCCACCAGTCACTCAACCCGACTTTT TGGTCTAGAGTAAGAGCAGCAGCTGTAC CCCAATGGCACAGCAAAGCAAATCCCCC TACAGGCACCATGCAAGGCCAGCACAGG CAGCTCAGTGAAGGCAACAGACTCCAGT GCAGGTCCACAAGGGCCCCCTGCGGGAG CGCCTGTCTGCAGGATGCGGGGCAGAGG GAACTGAATTGGAAGCCAAAGGAAGAG GGCAGCTGGGAGCAGGAGCCCCTAGCCC TTTTCAGAATAGGGCAAAGGTACTCAGA ACTTCTGACTCTGAGGAAGAGGTACAAG ACCTCCTTTCACTGCAGAAGTATCCCAG GACTTAAGCCATGGGAAGAATTCACAAC CTTGAAGTCAGAAGTGAAATAAACTGTG TGGTGTCCAATGAAGG  691 3600707 7 CELF6 GCACCACCATTGATCAGCTTTATATGGC 0.005817181 0.008292249 4.96E−06 ACCCACTGTATACAACAGACAGACAAAG ACAGACAGACAGAGCACACACCACTTCT AAGCTCAACACTGCTCACCAACTAGAAG CACCTCGGTTAAGCACATGTGAGACACT CTTGCATAGGAAAG 1265 3602135 9 C15orf39 ATGCCATGCCAAGGACCAACTTCCACAG 0.000348767 0.008774654 6.01E−06 CTCTGTGGCCTTCATGTTCCGAAAGTTCA AGATCCT  300 3602538 9 FBXO22 AAGAACTAGTATGGAAACAGCACTTGCC 0.000271873 0.010327297 4.23E−06 CTTGAGAAGCTATTCCCCAAACAATGCC AAGTCCTTGGGATT 2024 3605298 6 TGGTTAAGGGCAACTTCATGCAACCAAA 0.000516748 0.007297057 4.19E−06 TAACATGAAATTAAATCAGTAACTTTTA AAAAAGGCTAAAATGTCTTTTCCCCCCG AAACACAACAGAGAGGAATATGAATAA TGTACATACAAACTGGGGTTCTGTCAAT GACAACAAGGACTATGTGTTGGTTCATA TCAAATCCAAGAATATTAGACAACCAAA CATATAACCTTCTTGTGGTTTCTCTTAAT ATGCAGC  531 3606365 9 AKAP13 CGTTCTAGGTTTGCCAGTGGCTCTACAG 0.011925564 0.014048446 1.47E−05 GACAAAGCTGTGACTGACCCACAGGGAG TTGGAACCCCAGAGATGATACCTCTTGA TTGGGAGAAAGGGAAGCTGGAGGGAGC AGACCACAGCTGTACCATGGGTGACGCT GAGGAAGCCCAAATAGACGATGAAGCA CATCCTGTCCTACTGCAGCCTGTTGCCAA GGAGCTCCCCACAGACATGGAGCTCTCA GCCCATGATGATGGGGCCCCAGCTGGTG TGAGGGAAGTCATGCGAGCCCCGCCTTC AGGCAGGGAAAGGAGCACTCCCTCTCTA CCTTGCATGGTCTCTGCCCAGGACGCAC CTCTGCCTAAGGGGGCAGACTTGATAGA GGAGGCTGCCAGCCGTATAGTGGATGCT GTCATCGAACAAGTCAAGGCCGCTGGAG CACTGCTTACTGAGGGGGAGGCCTGTCA CATGTCACTGTCCAGCCCTGAGTTGGGT CCTCTCACTAA  789 3606371 4 AKAP13 TCTGACTACTTAACTCTTCTCCGTGGTGC 0.000562297 0.008998609 4.54E−06 TCTGACAAACTTGCCT  689 3606507 8 KLHL25 CCCACGTGCTCAAGTTGTTTCCAGATAC 0.001268815 0.008091689 3.62E−06 AGAGGCTGGGTTCGGCGACTGAGAAGGC CC 1567 3607176 1 ACTCCACGTACCCTTATCCTTCATCCTCC 0.03244577 0.006957836 8.45E−06 AACAGAACCAAGCAATGCGTGGTGCCCT GTACTCCCAGCTTGGTGCATAGCTCCATC CCT 1962 3607875 4 ZNF710 ACCTGAAGGGCCTACAGATGGATTCATT 0.002887295 0.00824511 3.71E−06 TCTCTATAATTCTTAGCTTGCAGTTTTGA CAACCAGAACCTAAACCCACATAAGAGC CTGCCAATGACCACAGATTCTCAGAGGA ACCTTTTTTTTAAAACTCCACCCACAGCT AACACTAAGATTACTTCCTTCCTGAATAC ATATCACCAGACGCTCTCCTTTGTCCCAT TGTCGCTATATTGCCAAATGCCTTCTCTC GATTTTTGGTCAAAGTCCTAATCATTTCA GGTCCAATTAAAAACTCAGTATCTCTTG AGCCTTCCCCACACCATATGTTGCAAAA TTATCTGGTCTTTCCACATTCACAGCGTT CACAGGCCACTGTTGCATTACCTATTAGT CTGTGAGTGTACACGTTCGGACCC 1122 3608291 9 CRTC3 AGCACCAGCCTGTTCAAAGACCTCAACA 7.71E−05 0.006560753 1.92E−06 GTGCGCTGGCAGGCCTGCCTGAGGTCAG CCTGAACGTGGACACTCCATTTCCACTG GAAGAGGAGCTGCAGATTGAACCCCTGA GCCTGGACGGACTCAACATGTTAAGTGA CTCCAGCATGGGCCTGCTGGACCCCTCT GTTGAAGAGACGTTTCGAGCTGACAGAC TG 1051 3608380 1 ATGCTTGTCCCAGTCCTGATCCTAAGCCC 1.52E−05 0.014679978 1.04E−05 CTGCCTCGTTGG  171 3608542 9 AC068831.1; AGATCTTCCGGAGTAATGGGGTTCAGCT 0.024147101 0.014062914 1.15E−05 UNC45A CTTGCAACGTTTACTGGACATGGGAGAG ACTGACCTCATGCTGGCGGCTCTGCGTA CGCTGGTTGGCATTTG  308 3609034 1 TTGTCCTGCCTCCTAAATATCAAGAAGG 0.00809385 0.008166242 6.40E−06 CAAGGAGGAGGCCACACAAAGAAGCCC AGCTCCATGTCCTGATGATCGCATCAAA ATTGTGGTCACGTTTGCCAGAATAGAGG CTACGCGATGGCGC 1409 3610580 1 AGAAGTCCACTTGGCTCTATCCTGGGTC 0.018126 0.008073478 3.34E−06 CTGAAGGAGAAGCAAGAAGAAGGTCTT CGCAGGGAAGTCTCTGCTCAAAGCAAAA TCTCTTTATGGAATGGCATGAGCTATCTC ATTATTAAATTCACCAGCAGCCA  461 3610850 4 IGF1R ACAGCCGTGAAGAGGCAATTTTCTCCTC 0.000115329 0.011783696 6.89E−06 GAAGGAAGGAACTGGAATGATTGGTTGT ATAATTGCAGAATTGTTTTCAGTATGTCA GCAAGCACTGAAAATGGGGAAACTGTCC CTTCCTACCTCTGTAGGCTGGAGACCTCG GGTTCAGCTCCATTTATCAGGGCACAGG ACCTTCCTGTTCTGAGACTTTGTTCCAGG GGACTTTCACACTTCAGAGAATAGCACA TGTCATCCTGCACTTTTGTGGGGTGATTA AAAGCTCACGGTATCCTTTTATGTTTAGC CCATCCAATTCTTCCAACTGGCCTCAGCC AGAAAAGCAGGGAAGGCACCCCCAGTTT GCAGCTGAGAGACTCCAGCCTGGGAGAG CTGAATAAATCTTTTGCCCAGAGGGGTT CCTCAGTAAATGCTGGAGATGAGGCTCA GACCTGACCTTTGGATTCCCAGATG 1480  3613297 5 CYFIP1 GGCTCTTGACGACCTTCAGCAGCTCCTCC 0.000338249 0.007322941 3.43E−06 ATGACCACGGCGATACCCTGGTAGCCGA GAAGCCGGCAGATGACTTGAAAGTGTGG AGGTCCCACGAAGTTCCGGTAGCTGCCG TAAATGCTGGAGTAGGCCAAGTTCAAAG CCTGGAAAACAGGGCACAGAGCTCTCAG CATGGTCCCCGCACACATGTGCAGATGA AGAACTGTGTGAGAAGATCACTCAACAC ACACAGGCTCAGGTGAGCGGGTCTGAGT CTACTGACTTGTA  433 3615994 9 MTMR10 ACGGTGTTATTCTGCCACGTGTCTCTGGA 0.032789863 0.012174049 9.65E−06 ACACACATAAAACTGTGGAAACTGTGCT ACTTCCGCTGGGTTCCCGAGGCCCAGAT CAGCCTGGGTGGCTCCATCACAGCCTTT CACAAGCTCTCCCTCCTGGCTGATGAAG TCGACGTACTGAGCAGGATGCTGCGGCA ACAGCGCAGTGGCCCCCTGGAGGCCTGC TATGGGGAGCTGGGCCAGAGCAGGATGT ACTTCAACGCCAGCGGC  472 3619652 9 DNAJC17 CGGCAACAGCTGATCGCACGGATGCAGC 0.020051318 0.007567661 2.83E−06 AGGAAGACC 1335 3619970 5 TYRO3 CTGATATGGCAAGGAATGCTGTCTCAAG 0.024995647 0.007527987 5.58E−06 AGAAGATGCCAGCGGGTGGCCGCTGTCC TGGCCTGTGGCTCTTCCCTGCTCCCTTCA CCCTCTCAGGACCAGTCACAGGATGGGG GCCAGCCTCCCGCTCCCTATATGCCCATC AGTCCCCGAGGTGCGGGGTGGGAACTTG GAGAGCACCGTGCTGCATGGAACGCTCT TGTCACCAGCAAATGCCTCAGTGGCTAT GTGGGAACACAA  408 3622256 9 DUOXA1 TTCTGGCTGCTTCGGGTGGTGACCAGCTT 0.001111606 0.013225165 8.44E−06 ATTCATCGGGGCTGCAATC 1685 3623298 6 AGGTGTGTTCCTTATGTCCGGTCTATTCT 0.001201893 0.008487235 4.64E−06 GTAATCTCATTTTGGTTGCTGTTACTGTG GAAAATCCTGCCTCACAAAGATAGGATG TTGAAAATGGAAGGAGGCTTTTCAGTAC TTTTGTGGCAATCTCAGGATGTTCCGCCT TGACTTTAATCGAGAACGTATGGAGATT TGAAGTTGTCTCAAACATACTTTTAAGG CCACCGTCATTTGCAATATCAAGCAGTT GATCCTCTTCTAGCGTGGACAAAGTGGA TTCACCTGGCTTATTCACAAATGGGTCAC AGATCCATTCCGTCTTTT 1201 3624150 9 DMXL2 GTTTCACGTGCCACGATCATGGTGCCAC 0.000113163 0.008737126 3.53E−06 GGTACTGCAGTATGCACCCAAACAGCAA CTCCTAATCTCGGGGGGTAGGAAAGGAC ACGTCTGCATTTTTGA  603 3625209 1 ACCAGCTACAGGTGGAATGCCCAAGTGT 0.000909538 0.009521061 6.84E−06 GCGAGAGAGCAGCTTGGATGGCATAATG GATATGGTGGTTGGCTCCTCGATGGCAT CTCTACCATTCCTAATGCGGTTTGAAAAT TGTGCTCAGC 1355 3626324 9 ALDH1A2 GAGAATTTGGCTTGCGGGAGTACTCAGA 0.006363163 0.006967527 5.37E−06 AGTTA  329 3626947 4 MYO1E TGGGTGTCCTTCCATCATGTCCAAGTCTT 0.000165213 0.012396011 8.86E−06 AGATCAGTTTCTAGATCTAGGCTCAACA AAATTCCCTCCCCTGGACCCCCAAGCCTT CCCAGATAGTCACCTTCCTCTTCCATATG TCCATGGCACCTAGTTTGAAATGTTCTTA CCTCATGCATCATGTTCTGCCTTGTGTTA GACCCTTTAAGCTTTTGTGTCTCATTAAG ATATTGAACTCGGCTGCGTGC 1297 3629800 5 SLC24A1 GGATCCTTAGACTCACCAATAACTGAAG 0.00241526 0.007108487 5.22E−06 CTACAGTGATTACAAACCTGATAGAACC TCACAATTTGAACAGAAAAGGAGGAGA CAAAATTGCAGCGTGTGTTTGGGGCAGA GGTCAGGAAGGCTGAGATGTAGACCACA TCTGCATCTTTTGGGCCAGCAGCCTTTGG AATGATCAGGGAACAGTGAGCGTAGGA GCTTGTCTTATAGCTGCTGCGCCTATCCC AACCTTTGCCCCCAGTTATCTCATTTAGA AAACCCTCTGGCTCCAGGGGTCCTTCTA CTGCCTCCATGTAATAGATGTCTGCATG AGTCAGGGGTAGAAACTCCACCCCTCCA GGGGTGAGGTTCTTAATCCACAATGAGC TGCAGGTGTTTCCAAGGACAAACTTTAG TCTCAGATCACATTCATATCAGAGGTCCT AGGTCACCCAGTTCACTTTCCAGGATCA TATACATTCTTTCATTAGGGTCACAAGA GATACAGTAACTTCTGCATGGTCTTCTGA TCCATGCCCATTGTG 1649 3630807 4 ITGA11 ACTGCCACCGTGATGCCATCAGATGGGA 0.043006584 0.007070619 3.20E−06 GAAAACACAGAACTCGGGATGAAACGT CACACGGTCTGGGCTAAAGATCTTGCTC TTTAATTTCCCAGCAGGTAACCITGTGGC AGTCAC  800 3631715 5 THSD4 CAAAGACTCTACCTGCTGTTGTTAAGCA 0.002350957 0.008460984 5.38E−06 TGAGGTTTATCCCCAGACTACA 1881 3631998 9 PKM2 CAAGATTATCAGCAAAATCGAGAATCAT 1.77E−05 0.008339926 7.97E−06 GA 1707 3633108 7 CSK GTCCTCATGGCGTGGTTTATTACAATTCC 0.00010346 0.006803205 1.99E−06 ATCTCACAAGGCGGGTGGGCGGGTGGCA GCGGCACACGAAATCCAAGCCCCTGACA GACGTCTGCCTCGGGCGCATGCAAACAG TGCAAC  281 3633239 2 RPP25 CACCCCCACCGTTGACAGAGGAAGGCAG 0.004749446 0.011305801 9.00E−06 GGGGTGAGAATTAACTGCTTGAGGGTAG GAGAGTCTGAGATGTGGGGGCCCTATTC CGCTCCC  701 3633468 2 PTPN9 TAGAGATCGTCCTGAGTGCCAAGCACGT 8.24E−05 0.01263796 9.39E−06 TTATAAGTAGGGCGTGTATTCCAGTCCTT TCTGTCATTCTGTGTGTGTGTGTGTGTGC ACTTATGTGTATGGGTCCATATGTACGTG TGTATATAATATATATTGTATGTGATAAT ATGATCGTATTCTATAAATACATATACA CACGATACTCCTTTCCAGAAGTTCCTGG GGCTCCGTGTTGCAGTTCAGGACTCCTTG CTTCTTGGACCCTACTATTTATCCTGGAC TAGCTTGGGTTGGTGATCATGTCTCCTCT TGTCAGGCTACAGAGTGGTGGAAGAGGA CACACACACATCTCCTCCATGTTCCTGCC ACAGGGCCCCTTCCTTAAGTAATGACTT ATCTCCTTCCAGTTGCCACCTGTTGGAGC CAAGAATGTATTAGTTTGTGGTGACACT GGGTTAGCTCAGCATGGATTTCCCTTATC CGATGATTTTTCTACATTTACTTGGCCAA TTTGGGGAACAGACCTCCACTGTGATTC CATACTCTCTCTTTGCTTTCACTATCCCA GGGATGGGAGGCGGAGGGTAGAGATGA ACTCACTGAGCAGCCAGAGCCAAATGCA ATCGGTACGAATCTTAGAAGGAAGGAGG GGGAGCCCAGGTATGAGAAAGAAAAAA CCACTAAGAAAATACCTCCCTGGGAGGA TGAGCTGGGGCCCTTTTTCTTTTGCTGGA TGGTTCCTTTATGCAGCTTGGCCCTGTCT ACCGAGATGCCCATCTCTTCCTGCCTGCT AGCCTGCTAGACCCTCAAACTG  342 3633789 1 TGACTCTGGCTTCCGTCAAGAGCTGTCTT 0.031655198 0.010760075 1.29E−05 GGAAGGAGAAAGGAGCTCCTGAGTTGA ATTTCAGGTGGACACCCACCATGCTAAA TAGAATTCCAAGCCACTAGCCTCTAGCC ACACAGGTTCCATCCCAACACTCCTGTCT GTGGGACTTGATCTGAAAAGCCACACTT TGGTTGGGAACCTTGCCCAGGGCTGGCT GGAGAGGGGCCTGTTGTGCCACTCAGGG AAGGCCTTATGGTTCCCTCATCCTGGGTG GGCTTCAGGCTGGGGCTGCAGACTCTGG CCCAGCTCCCTGGTGGGCCAGTCACCAG CACTGCTGGCTCTGAGTCCTGATTTCTTA CTTTGGCTTTCCTGGTGGCACCTGGTTTG ATTCTGGACAGCTCATTTCACATCTAGCA TGGCATATAATCCAGCCAGACCTGGGTT TGAATCCTGCCACTACAGCTCACTAGTT AGCTGTGTGCCCTTGGGCAAGCCCCTGA ATGAGTCATTCCATGGCTGCTGTTTTCTC CTCTGTAAAGCAGGGAAGATAGCGCCCA CTTTCCAGGGCTGTGCTAAGGAGGGAAG CCTGTGAAGAGCACCTGTCACAACAGGA AATGCAGACGTGGGAGTCACTATTGTTA CCACCCTCTTGTTCTAGCAGGAGACA 1785 3635006 1 GGCGAAGAGTGTCCTCGGCTCTCCTCTTC 0.007013144 0.007732766 5.49E−06 CCAGGGAGCACTCGGGGCTTCGGACTCT GCAGTGGTTTGCAAGGCCAGGGCCAAGT GGTCACTTCACTCACTGA  506 3636219 1 TGCCACTTAGGCATCCCTGAGCATGTCT 0.000487927 0.011230631 7.37E−06 GTTCATGGGTAAGATGGGGTG  530 3636467 3 C15orf40 CCAGGAGGCTGTATTCTGCTTTCTCCTCC 3.19E−05 0.012446094 6.72E−06 CTTGCTTTGGCTGATCGCACCCCTTCTGT CAAGAATACAGCACTCCCATTTCCACCA TCTTTGTTTGGCCAACCCCAGTCCGTTTC TCAGACTCAGCTCAAGCACTGCCTCCTG CTGGCAGCATTCTCCAGTGCCCCAATGC TGATTTGCCTGTGGGGTAATGTTCTGTGC CTATCTCATCGGTGCACTTAGCACAGTGT ATTATAATTTTGTATGTTCTTTCTCCCTC GCAGCAGTCCGAGCTCCTTGAGAGCAAG GACCATGTACCTTTTCATCTTTACATATC CATTGCCTACATATTTGTTGAACGAAAG TTCCTAGCACAGCCCCTGTCCCATAACA GGCCTTTAAATATCAAGCACTATTTTTTT TTCCTCCCTTTCCCGCAACATGCAGACAT ACACACTTTCACCAACATTTATTAGCTCC GACTGCATGAGATACAATGATGAATAAT AAATGATCCCTGCCCCCAAGGAATTGGA AATACAAAGCAGAGGGAGGAGCAAGCA TTAAGGTTTAGAAGCCAGAGTTAGGTTT TCTTGCAAGGGGGGAAAAAACACTGTTG GGTTGATGGGAACCCTTCGTGGGAAAAT TGAGTAGAGCCTTGAAGGTTGTGGGAAA AGCTTTCTAGGTGGCCAGAAGTCCCTGG ACACCACTGATGAGCCTAGTTTG  320 3636521 5 TM6SF1 GCTACTCTGAGTATTTGTTACAGCAGCA 7.74E−05 0.013827425 7.45E−06 GAGCACATAGCCTATCCTTAGACAAATA GGTAAGTAAAACTTTTAACGTGGTTTGC CTGGCATGAAGTAAGGTAATGAGA 1927 3636531 6 CATAGTCCTTGTTGTCATTGACAGAACCC 4.46E−05 0.006967514 2.72E−06 CAGTTTGTATGTACATTATTCATATTCCT CTCTGTTGTGTTTCGGGGGGAAAAGACA TTTTAGCCTTTTTTAAAAGTTACTGATTT AATTTCATGTTATTTGGTTGCATGAAGTT GCCCTTAACCACTAAGGATTATCAAGAT TTTTGCGCAGACTTATACATGTCTAGGAT CCTTTTATCAAGGCAGTTATGATCATCGT TTTCCTGCCTTGACCCCACCATCATCAAA CACTCAGTTAAATATAAATTAACATTTTT TAGATGACCACTCAACATAATGCTTAAG AATGGAATTTCCTCTCTGTGACAGAACC CAGGAATTAATTCCTAAATACATAACGT TGGTATATTGAAGACGAAATTAAAATTG TCCTTCAGTTTTGAGGCCATGTGTAAAGT TTAACCA 1955 3636534 9 AC024270.1 TGGAGATGCGGGCAACGACACAAGAAA 6.74E−06 0.008661601 7.98E−06 CACA  522 3639047 9 PRC1 TTCATGGAGTATGTGGCAGAACAATGGG 0.000293755 0.021280706 1.95E−05 AGATGCATCGATTGGAGAAAGAGA  123 3639054 9 PRC1 TGAGGGGCTGCGTACTCAAATCCGAGAG 0.010100664 0.025201383 3.68E−05 CTCTGGGACAGGTTGCAAATACCTGAAG AAGAAAGAGAAGCTGTGGCCACCATTAT GTCTGGGTCAAAGGCCAAGG 1923 3642244 4 PCSK6 TGAGGTACGCTTGGGCATTCCTGTTGCCT 0.00076237 0.006698636 2.18E−06 GCATGGTTCGGCATT 1486 3642303 9 PCSK6 CAGTCGCTGCCGGTCGGAAATGAATGTC 0.011398396 0.006563752 4.97E−06 CAGGCAGCGTGGAAGAGGGGCTACACA GG  935 3644067 4 MAPK8IP3 ACCTAGGTGGCCAGGCAATTGTGGGAAA 0.014482591 0.006785207 4.01E−06 TGGAAAGA 1142 3644647 9 E4F1 GACTTCACCCGTGATTCACCTGGTGACA 0.012043037 0.009620411 8.84E−06 GATGCCAAGGGCACCGTCATCCACGAAG TCCACGTCCAGATGCAGGAGCTGTCCCT GGGCATGAAAGCCCTGGCC   70 3645319 1 CTCAGGATGTCCACCAGAAACCAGGAGT 0.009940781 0.024791572 2.57E−05 CACCATCCTCTTAAGGGTGGTGCCTGTCC TCCAGAGAGCATATCACTGGGTTCAAAC CCCAGCTCCTACCGGCAAAGCCCGGGGC CTCCACCTGGGTGTTCCCATCCATGAAG CGGGGATACACAGTGTGGAGCCCTTGGG AGGTTGGGGAGTGTGCCTGCCCTCACCG CGCATCAGCTCATAAATACAACAACAGT TGCCTTCACGTGCTGATGCTC  306 3645476 2 KREMEN2 GCGAGATGGACACCTGAGATGCTGTGCT 0.025777155 0.009389094 7.22E−06 GCGCCCTGCCTCGGCCTTGCGCCTGTGTA GGGGCAGCTCGGCCTCTGGTCGCCTTGG GGAGACCAAAAGTCGGACAGGAAACAT CTGGTGCTATTATCTGGGACTTGGCCTGA CCGTGGGGGTCCAGATGGTCCAGGCCCT CTCCATGGACCTGTATGTGGGGGTGGTC TCTGGTTTCGGAGGTCTTTGAAC  341 3645652 1 CCAGTCACCGCGCACCCACCCTGACCCC 0.022361426 0.016525847 1.46E−05 TCCCTCAGCTGTCCTGTGCCCCGCCCTCT CCCGCACACTCAGTCCCCCTGCCTGGCA TTCCTGCCGCAGCTCTGACCTGGCGCTGT CGCCCTGGCATCTTAATAA  552 3646448 9 UBN1 TAGAAAAGACCGAATACAGGACTTGATC 0.000120755 0.016425661 1.61E−05 GATATGGGGTATGGTTATGATGAATCCG ACTCCTTCATCGATAACTCTGAGG 1680 3646802 4 RBFOX1 AAATGTCGTTAACATTAACAAGAGCTCT 0.023281585 0.00682901 3.36E−06 CTCTGGCACTGGCAGGGGGTCTGCAAAC AGAACTGGTTTGGAATATGCAATGGGAG GCTTGAATCAAAGAAAAGCTGTGATACA GACTGTGGAGTGTGTAAGACAAACTCGA TAA 1155 3649263 4 BFAR TAGGCAGGCCTGTGCAAACCTATCCCCT 5.94E−05 0.009644722 5.18E−06 AAATCAGAGGAAGCTGAGGGGCTGAAG GAAGAAGCTGGCAAATTCAGTTTCTCAG AAAGAAACACTTAATAAGGCCTTGCCAA CAGAAGCCCTGTCTGTGTCTTGGATGGT AGCGAGACAAGATGGTGGATCCCCAGAC TCAGGGCTTGTATACATAGGGAAGGGGC ATACATGCTTCAGAAGGGATGTGCAGAA CAATTGCTTAGGGTCGGGATCTATGGTA AGTAAGAGAACATCAAGGCTGTTTCACC AAAGGGCAGGATTTACGTGATGTACGTG CTCTTACACAAGA 2068 3650718 7 ARL6IP1 GCTACAATGGGCACCACTGTTCACAGCA 0.000408197 0.008537529 6.97E−06 ATATTAAAGAGGAGAAAACAACACTTAT TTAATAGGGACAGATATACCACAAGGTA CAACATCAGTGCAATAAATTCACAAAAC TATATTACAGCTAGTTAATCAGTTTAAG AATTGTTCCCGTCAGTCACATTTTTTGGC CCTCAGAAGTTCATTCCTAAAGATTTCA ACTACTCTAAATTTCTAGCTACCAAGAA GTTAAGAATGATTATAAGAAGCTTTCCA AGGAGTTATGAAATCTTTGTAGACCAGA GGCCAACTATCATCACCTCAAGTCTGCT CTCACCAACAGCCCTTGTATTTTTCAGGG AGAAATCTCTAGGAAAAAAGTCAGACAC CAGTGTAGTCACTATCTCCCATGTCAA  491 3650720 7 ARL6IP1 TGTCCTTTTGCCAGTCTTAGAGTGAAAGT 0.000397001 0.017872044 1.57E−05 CATAGACATGAGTCTTAACCTACTGTAT ACTATAGCTAATGTCAGCTGAAAATCTG AAATTAAAAGCATGCTAGAAATCCTAAA TGCAATCTTTTGGAAGTCTGCTATTAAAA AGCCTTTAAGGATTTACTAACTTCGAGTC TAAGTGCAAGGGGACGAAAGCTTAAGCC TGTCAGACATTCCTTTTCTTGGACAAAAA GATCAAAGTTTCCTACAAATTGCTAAGC TTTGCACAAGGGAGAAGCCTACATGTAC TAGTGCATGGAATCAGTTTCATCTTATTT CATGGGGACTCTTCTCCCACTGGAAAGA AACAGAATGAGGAATGAATCTTAATTGG TCTCTTCATCAGAAGTGGTAAACTTGGTC TCTATATTCACGAAGTCAGACAGTTTTTT AAGCAGACTGTGGAAGCAGACAGAACC AGCTTCCTGTAGCCACAGACCACTACAT GGTATCTAAGCTAAAGCAAAGATGAACA ATTATCCAGATTCACTTGAACTGTACTAA AGGGCAAGGTTCACCACTACAAAAAGG A 2049 3650850 2 ITPRIPL2 TTTTGTGGCGAGACACCCTTTGGTAACTC 0.000563692 0.006746985 5.10E−06 CCACTGACCAGTCTTGGGAGCCTTCCTG GAATGATCGTGGGCTGAGCGGAGATGTT TTTTGCAAAATGAAACTGAAGCTGAAAG AAAGGAGAATTCGAGTGAACCAAGAGA AATCCAAAGACCTGGGGAAGGAGGACTT AAGATGAAAGTGAAGCAAGAGAGGGAA GGGGAAATGAAGTGAAAATGGCGTGAG GGTGTGAGAGAGGTTTGGGTTAGGAAAC ATGTTTTTAGTGCTATTTCCAACCAGGGG TCGCAAACTCAGCAGCCTGTAGAAACAG GGGTGGGAGGTGGGGGGGAAGCTGTGC CCACCTTTAAAGAGGGGGCCATTGCTCA GCCATGCAGAAAAAAATGGGGCAACAA GCTGGAAATCAGGTTTTTTTTTTTTAAAG TGAAACTTGATGATTTTTAAACAAGTAA TTAAAAAAATGTCCAAAACACCATGTGG GCCAAACATTTGTTTGAGCCTGGGGGCC ACCAGTTTGCGACCACTGCCTTACGTAG TTAACACCCTGAGTATGTATACAGTCAT ATTTTTTGTTTTGGATATGGTAGTGTTAT ATATACTTGGGGGCGTGATATTTGAAGT CATCTTTATCTCTCAGAGTTAAGCTTTAT TGTAGAAGAAAAAAAAAAAAGTTAACA CAGCCATAGATAACACTTAACTCACAGT TCCCAGGAGGACACTTGATCTCGAAGCT GCTCTTTTTGAGTCAGATCCTACATCAAA CCACTTAGGGCCAGTTTTTGGCATTTCCT TCCTGGTGATTTGGGGTAAACTTCTTTGC TCTGTCGGAGTTTGCAGATGAGTAATCA GAAGGATTGCAGAATAACTTGTTTCTTT GTATTTTATTCTTACATTTAAATTAATTT TGGGGGGTTAGTGGTATCCTAGCTCGTG CCTTTA 1336 3656881 1 AGGCCAAGAGCGGATGTTCTTCATTTCA 3.67E−05 0.007684195 2.95E−06 CTT 1276 3658909 5 SHCBP1 CAGCAGTGATTCTTAGGGCAGCATGTGC 0.000483071 0.010824915 7.91E−06 AAAATCCAGTATTTTGCTATCTACTTACA TCACTGTAGTCAGAAAAGAAATGTGCCA AAACTACCTTTCCCATTCCACTTGAACTG GTTCCCCACAATCCCAACAAACATCTCC TGTGACATTAAGTTGTCATCAGCTTGCGT GATCCCCAGTTCACTCAACCTTTTCTTCT TTATCTGGCCTTTCTGTGTGGAGGCAGCA ATTAGTTCATTTACAATTTCACAATTTCC CTCGACTTGCTCAGAAGGGTC 1482 3659265 1 TTTTGAGGCAGTTCAAGTGGAAAAAGAA 0.024995647 0.006856396 6.12E−06 1133 3659928 1 AACAGTCCTTACTTATGCCTCCTTGCACC 0.000457168 0.012434795 1.58E−05 CCAGTGTTAA 1205 3662100 4 MT3 CCCGCTCGCATCCTGCGCACTGCGCGCC 0.000203565 0.007595331 6.87E−07 CTTGTACCTGCAAAGAAACCCACGCCCT GCGCCTTCGCTCAAGGACACTTGGGGGA AGGGCCCCTGATTCCCTATTCTTCACCTC GTGAAGGGCGGGCATG  705 3663746 1 GTGCGTAGATTGATGACATGGTCCCAGG 0.040170313 0.010447485 7.74E−06 TGAC  252 3665867 4 NUTF2 AGTGGGTAGGAGTCACTCCCATCAATGA 0.002293409 0.012252329 1.43E−05 AGAAATATCCTAGAAAGGGCCAGGTCAG GTAATCACCTGGCCTCGGGGAAGTAAAC TGCCCCCATGAGACTAAGGGATCACTTG C 1120 3667448 5 HYDIN TGGCTTTCCCTCTTACAATGGGTACTCAC 0.00051035 0.007418618 2.56E−06 TCTCCACAAAGGGTTATGCCCACAGGAC AAGAATGATACTGAAACACTACTTTGCT ATTTTACTTTCTTTACTTGGATCTCCTTTC CAACTTTCCCTTCAAGCATGTTGGGCCAT TTTGATCGCTGGTGAGCACATGTGAGTC GGGGAACCAGGGCAAAGGAAGCAGTAC TGGATCCTTTTCC 1623 3667557 1 TCTATCTCAGCTGCCGACTACAGGGCCC 0.003781407 0.006522573 2.35E−06 CCTGCTGTTTCCAGTTCCTGGCCCACCCA GAGTTTTTCCTACTCATGTGGGCTACCCC CAGGACACTGGGAGCGAGGCCCTTGTTT AAGGAATCGTCTTCAGCATCACGGCAGA  159 3668335 1 GTAGAACAGACACAACCGCAGATGCTGC 0.006389661 0.018264551 2.24E−05 TGGATGGAGGCTCCAGGCCCCTTTGGAT TCACTCTTCCCCCACCACAGACTGGTTCA GGTTGTCCAGACCAAGGTGCATAGGGGC TGGCCAGAGTGGTAGGTGGACAATGTCA TCTACTGGCTGCTAAGAATGTTATCCCTG TAGTTTGGGGCTGGTGTGGCTCAGTAAT CAAATGTGTGAGCTTCTTTGAAGTAAGA TGGCCCTGGGTTC 1177 3668759 5 FA2H CAAGGGAGGGCTCCGAAAAGGACATGG 0.000165213 0.009488445 5.47E−06 CGAAGTGGCAAAAAGA 1924 3671836 7 COTL1 CTGAGTGCAGAGATGTTCTTTACAATCC 2.19E−05 0.009188463 4.39E−06 CAATACAGTACAGATTTCTTCCCCAAAA CGAAATGAGCAAGGAAAAACAGAAAAA GAGCTATATCAAATGTGCTCATGAAGAA CCAAGCCAATCTCACCTTTCTTTAAAAAC AAAACAAAACGATCCTTTTGAATGTGTG GTGCAGACGCAGGACTGAAGCCACAGG CTTTTGGGGTGCTGTGAGCCCAGGGCTTT GCTCAGCTCACAGCTAGCGCGGCGG   46 3672375 1 GCATCCTGGTCTATCGAGTGGGTCATTGT 9.32E−08 0.068293918 8.00E−05 GGTGGCTGCCGCCTACCTAACCAAACCT GGTCCCACGGGCCAGCTCTCACTGTGGG GCAGCCAGCTGGAGGGACGGGGCCAGC TTGCCCCACCCCGCCCCTCCCCTCCACAG CAGAGAGTGCCCTGGCTCCATGGGGCCC AGCACAAGCTCTGGAGGCCACAGGAGTG CCTCCCCTCCAGGGCCTGGCAAGGCTGG CTCTCTGCAGGGCTGGTCAGGTCAGCTG CCTTGATTTCCCTCTCCCAGGGGCCTGAT GTCATCATTCAGGGGCAGCCTGGGGACT TGAGGGAGGATGCAGTTCCCACTGCCTT CTCCCGTCCTCCCCTCCCCTTCCCTTGCT TCTCCTTCTCCTTCCTGCTTCCACGTCCT GACCCCCTGGCCCTCCCCAGCCCGGCCC CTTAGCCTCCCCTCCCTCCCGGCCCCTCA CTCCCCCCCTACCAGGGCTGCCCTGTGCT AGCGCCTGCCTGTGTGAATGTCTAATCTC CAATTTTATTCGCTGGGCTCCAGCCCATT TGCATAATCCACACAGTCACCCTGGTTTT AATTGCCCACAACTCTGCAGAAAGATCA TGTGGTTAAGTGGTAAATCATAATTAGA TAAATAATTGGTTTGGCCACAGCAAGCT GCTTTTGTTACACCTGCCATCTGCTGGAC CCGTTTTTTCTTCTGGCCAGAACAATGCG GTTCTGATGACAGAGCATGCTGCTTCTCT CTTCTGGGGGGGCCGGAGGGGGCTGAAT GGAGGGGCTCGGAAGCAGTGCCTGGAA AATTGCCCGGTTGCTGGGGTCCGCGCCT GGCCTGCGCTTCTTTCTCTCCAAGCGGGC ACACCACACACTCGCCATTCATTACCCG GCTTGGTTAATGCATCAGAGTGGCAAAT TTGACTTCTTTGCAGAAAAGGGAGGGAG GAAAGGGGCCTGGAGGAGGAGGGGGAC CAGCCAGGGCTGCCCAAGGCCTGGCCTG CCTGCCGGTTGTCGGTGGCCCCGATGGG CCAGGGCAGGAGGCCTGCTGTGGAGGGC CTGGGCCCGATCCCTGGGGGGTTGGGGG GGGGGGGCGGAGGGGACAGGCGGGCAG GGGTTGGAACCGCCAGACCTCCCTGCCC CACCGCGGTCAGCTTCTCCATCTGCTCTC CACCGAAGCCTCCTTTATTTTCCATGCCC CAGGCCCCATCTGTGAGCCCTGAGTCTC CAGGGGAATTGTGGCTCCCTGGCTGGAC GGTCGCCTGGCCAGGGCCTTCCTTGGGG CTGCTGGCCTGCCTTTCATGCTGTCCTTC CAGCAAGCTCTTAGCTCCTAGACTTCAG GAACGGTTTCAAATTGTCCTTCCTTCACT CGCTCCCTCACGCATACACGCACACATT CATTCATTCAGCAAACGCCCGTGGAGCC TCTTCCTACATCAGAGTGCAGGTTCGAA CTTGGTCTCCGTGGGTCAGATGGCCGCT GTGGGATGTGAGCAAGTTTCTCAGCCTC TCAGAGCAGGTTTCTTCCTCTGTAACACA GGAGTCATTATTGTCCCTGCCTTCTGGGC CTATTAGGAGGATCAAAGGACAGAATGT GGATAAAGTCTGTCGAGTGACACCTGCA CGAAACACAGGCCCAGTGTCTGTGGCTG GTGAGTGCGTGACTGCTGGTCATGCCCG CTCCCGGGGAGGGCGCCAGCGCCGCTCA CCTTGGGCATCATTGGAGGCCCACGAGG CTGTGCTGAACATGCTGAAGGAAGAGGT ACCAGTGCCATGGGAAGGGCCCAGGAAT GAGGAGCCTTGGAAAGAAACCAGGGGG CCAGGGGAACAGGCAGAGGGGCGGTAA GGAAGGGCAGGTTCTCTGGGGCCTGCAC AGGCCAGGACGTTCCTGTCTCTGTTGAG TTCGGACTGGCAGGTTCTCTGGAGCCCA CACAGGCCAGGACGTTCCTGTCTCTGTT GAGTACAGACCGGCAGGTTCTCTGGGGC CCGCACAGGCTGGGACATTCCTGTCTCT CTCGAGTACAGACCAGCACATGGTCCTG CTCTCTGGCCCCTGCATCCCCTCCAGACT GCGTTCTGGAAGCCCTGCCCAGGCCTCA CACGCTGCCCCAAGGGTCTTTATTACCTG GGGTCTTCTAGCATTTTCCTCTGGAGAAA CTCAGGAAGCATCCTTTCTCTGCATCCTT TCTCTTTGGGGGCCCAGCTTCTCCTTTTC AGTTTGACAGACACAGCCTGAATGCCCA AGGCCCCTCTGCGGAGACTTAGAGACTT A  153 3672652 9 FOXC2 GGCTACCAGTGCAGCATGCGAGCGATGA 0.010386073 0.014074276 1.46E−05 GCCTGTACACCGGGGCCGAGC 1506 3672970 2 JPH3 TGAGATGTCGCGGTAGCAAAAATAGAGA 0.004521888 0.007853911 3.53E−06 AAGGGTAGAAAAAAGGGACATTAAAAT TAAAAGCAAAACCACAAGAAGGGAAAG ACCGCAACTCGGACAGCCCAGCGACTTC CAAGT   78 3673319 6 CACTAATATGCAGAACGTGGGGTCCACA 0.011533849 0.025675715 3.77E−05 GAGACGCAGATGCATCAACCAGAGAGC GAGAGAAGCGTCTCTGGAGCTGGGATAG GCCACTGTGTAAGATGCAAGGCTGGAGA GTGGGTATCTGCCAACCC  917 3675052 3 AXIN1 TCCGACAAACTTCGCTGCGGGGTCAGGC 0.046795588 0.007478615 2.60E−06 TTATCCAGAAATCGTGCACAGTTCTGTTT GTCCAATCCCTGCCCTTCAGATGTTTTTA AGGTTTGGGGGCCGTAGGTCTTCCTGAG ATAGGAGCCCTGCAGCCTGCCCTGCCAT CCTAGAGGTGGGAGCTGCAGTGCACCTG GCAGCCAGGCCCTGGCCAGTCGAGGGTG GGGCTGTGAGGCAGCAGGGAGACCTTCG TGCTCCCAGTGAGCGGAGCCGACTCCAC TGCTAGCGGACTAGA  406 3676115 2 NME3 AGATGCGCGTCACAGAGGCTCTCACACT 0.000203565 0.011839051 7.55E−06 CCAGCCTCCTCCAGGGCCCAGGTGGGCG GGCTTCTGGCCCCACCCCACAGCGCTTG GAGCATCCCTTTGGACGGGCTGCTGAAC ATCCACCTGTCTGGACGTTGCATGGA 1315 3676601 4 CASKIN1 TGTCAGTGTGTCAGGGCACCTGTGCGGG 0.001168298 0.007803578 3.44E−06 CACGGACAGGGCTCTGCA  299 3677917 2 ADCY9 CCGAGGTGCTCTGTTTGTCGAAACACAG 4.55E−05 0.019273282 1.32E−05 TAATATTTGTATTTGGCTGTTGTGCTTTC CAAGCGCCACAGTTGCCCTCCCCGGACG TGGTGTTATGTGGTCATTTCAGCCCTAAC TTCTGTGTGGATCACAGTTATTCAGGGTT CATTTTCATCCATTCTTCCCTTTCGCTCCC TTCCCTGGAAACCCCGCTGCCTCTGGGTC ATCCGTTCAGCACGTGGTGGAGAACAAG TGCCTTCAGGGCTGGCCTCGGCCTCGAG TCTCGGGACAGAGGCCGCCAGTGGAGAT CATGGCTTTGGGTATTATTTGACTTTTAG AACAAAAGCTGTGGTTAAGATCTCATTT TTATTGCTTTTTCCCACGTCCCACGAGAC ACTATTTTCGGTTCTCTGGCTAATACCCT GTTTTTGAGTTTATTTTGTTTCTGTCTATG TCACAGTGTTCCTCTACGACCCGACCTCT CTATGTAAGCACA  974 3680474 7 SNN ATGTGCACGTGAGAAATGTTCCCTGGGT 0.001283816 0.008241237 7.03E−06 CCTAAGTGCCTTTAGAGCTGGGTCAGGG GACTGGAGACCCGCTGAGGAAAGTGAA GTCAGAACCCCATAGGCGGACGGTCATC AGAGA 2015 3680538 9 ZC3H7A CCAAAGACCGGCGTGCGATGAGAGTGAT 6.62E−06 0.008429013 5.75E−06 GTCTATTGAAC 1898 3681408 4 PARN GTGATAAACCCAGGCAACATTCTTTTCA 0.000110135 0.006617645 5.82E−06 AATGGATAATCAAAAGAGAGAATTGATC AACCAAGATGAAAGTGTCATAAGGAACC AATAAGTGATAATGTTGGAAGTGAAATT CAAATCAAAACAAGTAGAATTATAAAGA AGAATTAGCTGACCACGGGAATGTTGAC ACTGCTGCCATTTGAGTTACTGTAAATCT GCAGCCAGAGGAACTTAACGAAGGCAA CTTATCAGCATAAATGAGGAAAGTGGTT GTGACAAAAAGGATGAAGATGTCCCAG AAGAAGTAACGCCAGCACA 1242 3685365 1 CCAGGCAATCATTCTATTAAGGATGTGC 0.030555206 0.008234817 1.17E−05 TAGATGACCCACAGACTCAGGCCTGACT CCTCAGGAGCTCACAGTTAGTAGGGGTT CAGACAAGAACACAGGTACATAACTAA AACTCTATTGATAAGGGCGCCTCGGTAA GGTGCTATGGGAAC 1091 3685648 9 ARHGAP17 AAATCCTATTTACGGGAATTGCCTGAAC 0.005416181 0.009485484 9.37E−06 CTTTGATGACTTTTAAT 1253 3685774 1 AGTGAGCTCATCAAAAGCACGGACAGG 0.01415169 0.011101576 7.70E−06 AA 1422 3685788 1 GATTCTACCTCTGCTCTTTCCGCAATCCA 0.002080741 0.008376621 5.65E−06 CCAAGCCCCGTAAACTTGCCAGAAGTTA CATTGTGTCTGCAGTTATAATGTTTAAAA CATGCTCTCACTTGACCCCAGGATTCTCA TTAGCTGGGTTACCC  331 3686345 4 XPO6 ACAGGACTGAGCTTCTGTGCCTGGACTG 0.002571681 0.009429634 1.25E−06 AACTAGTAACTTTTACACCCAGGAATTC CAAAGCAGTTTAAAAATACTTTGCTTAG CCCCCAGGCAGAGGCTTAACCTCCAGG 1324 3686981 8 RUNDC2C TTGTGTGGGCGTTATAGGACAGACCGTG 0.000751323 0.010013645 2.70E−06 GGGTGGGGCGGGGGATGGGGGAGGTGG ACAAATGAGGTCTGGATGAGAAGTGTGA CCAGGCGTGTTTGACTCATGC 1100 3687400 1 GTCAAGAGACACAGTTACCATTCTTGTG 2.99E−05 0.009900281 3.48E−06 CAGGCCTCCAGAAACAACATATGAACAA CTAAGCAAACACGGCTAAGCTCTTTCCC T  435 3687775 5 ZNF48 CTGAGTCACAGAGGACGCAAAGGCAGA 0.009627872 0.010281022 1.32E−05 GAGAGACCGAGGGACAGCGGCTGACCA AAAATAAGGGGAGCCAAAGATTAGCCG CTAGAGACAGAGACGTAGAAACGGATA AGAGATAAAGTCATTGACGCAGAGTCCG AG  244 3687981 3 C16orf93 ACAGCTGTTGAGTGAAGTGAATGAATGG 3.74E−05 0.012026254 7.79E−06 ATACCAGAGAGGGCCTCACTGC  207 3688068 3 CTF2P TGAGCCCATCAGTCAAGCCTATAGCCTG 3.07E−06 0.018860953 1.72E−05 GCCCTCTACATGCAGAAGAACACCTCAG CGCTGCT 2044 3689930 2 VPS35 CGCTAGGTTTCCCTTCCATAGATTGTGCC 0.000319739 0.007906231 5.17E−06 TTTCAGAAATGCTGAGGTAGGTTTCCCA TTTCTTACCTGTGATGTGTTTTACCCAGC ACCTCCGGACA 1660 3689951 9 VPS35 TCAGTTGGAAGGTGTAAATGTGGAACGT 6.38E−06 0.00913068 8.04E−06 TACAAACA 1364 3690072 5 GPT2 TGGCTCCCTGTTGTTCTTAGCACAATGAC 0.001561876 0.010540522 6.53E−06 CCAAATCCTCAGCATGGCCTCTAAGGCC CTGTACTGGTGCCAGCTGCCTTGCCAGC CCACGCCTGGTAACTCCGACCCTTGCTGT GCACTCATCCCCCAGCATCTCCAGTTCCC AGCACTCAGACTCCTGCCAGCTCTAGGC CTCTGCACACAGTGACCTTCAGCTCAGA GCACACCCCCTCTCCCAGTTCACTCCTGT GTGTCCCTCAGGTCGGTGTCTACT 1989 3694664 2 CDH11 TCTAACGCTGAACTGACAATGAAGGGAA 0.00207602 0.008120261 7.70E−06 ATTGTTTATGTGTTATGAACATCCAAGTC TTTCTTCTTTTTTAAGTTGTCAAAGAAGC TTCCACAAAATTAGAAAGGACAACAGTT CTGAGCTGTAATTTCGCCTTAAACTCTGG ACACTCTATATGTAGTGCATTTTTAAACT TGAAATATATAATATTCAGCCAGCTTAA ACCCATACAATGTATGTACAATACAATG TACAATTATGTCTCTTGAGCATCAATCTT GTTACTGCTGATTCTTGTAAATCTTTTTG CTTCTACTTTCATCTTAAACTAATACGTG CCAGATATAACTGTCTTGTTTCAGTGAG AGACGCCCTATTTCTATGTC 1250 3694693 9 CDH11 CCCTACCCAACATGGACAGGGAGGCCAA 4.31E−05 0.008270469 7.34E−06 GGAGGAGTACCACGTGGTGATCCAGGCC AAGGACATGGGTGGACATATGGGCGGA CTCTCAGGGACAACCAAAGTGACGATCA CACTGACCGATGTC  928 3695096 9 AC132186.2 GGGACCTCACCACACCCATACACGGGGA 0.008619147 0.011094646 1.11E−05 CCCAATGATGGCTCTTGTGGACTATCAC GATGGCGTCATCGCCAGCACG 1423 3695391 7 CES4A CCCTGTGTATAGACTTTGGAGTGGCCCT 0.0038061 0.006571526 5.20E−06 GGGGGAGATAAGTGTGGGTGGGAGAGA AGATCCCAAACTACCAAAAGTTTGCTCC ATGTCACAACCTGCCCTAGGCCTCCAGG CCAATGTGAACAGACAGGCACAAGGTTG AGCAGGATGGATGGTAAATGCCAAGCTG GGTGCAGTGACAGGGGCAGTGGCAGTCT GGGTCGACCTCCCATAAGAAGGAGTCAC AAGGAGACATTGAAGGGTGGGAGGATTT GAAGAAGGGAAAAAAAGAGGTTGTCCT GAGGCTGGAGAGCTGAGCACAGTGTGGT GTTGACAGGGCCTGGCCTAACTGGATGT CAACAGTGAAGTAGAGGGGCATCATGG GATGTCAGGCTGGAAAGGGCAGTGCAG GTCCCACACAACAGGCA  586 3696274 1 GCCTCCCGCAAATGGCTGGCCAATAGGG 0.001689593 0.009564298 6.29E−06 ACTCGCCGCCATATAC 1247 3699295 5 ZNRF1 CCTGGGGCTTTCCAGAGTCCGGCTGTGA 0.000873066 0.008486615 4.04E−06 GCGCCCAGCTTGCTGCTGGCGTGGCGCT GGGGAAGCGGGGCTATGTGGGGAG 1690 3699734 9 ADAT1 GTGGGGATGCCTCCATCATTCCGATGCTT 0.000712087 0.006749163 2.51E−06 GAGTTTGAAGATCAGCCTTGCTGT  685 3699913 1 GCCTGTCCATTTTTAAGCCTCCAGGAAA 1.41E−06 0.013152305 1.07E−05 CCCAGGCTGCAGCTTCCAACTATGCCAC AGAGCAGAGTTTTTCCTGTGCCAAGAGG GCTCTGATGAGAAGACCTGGTTGCTCCC TTCTGGAGAAACAGAGGATTGCCTGTCA ACAGATGGGCTACAATTGCTTCTCTTTGG AGAACCAAGAGACTCCCAGTCAACAGGT GGGCTCCATGTGCTCTTCTCTGGAGAAA CAAGGGATTTCCCAGTCAACAGGTGGGTT CCCAGTGCTCCTATCTGGTCGCAGGTACT G  295 3703547 1 TCCTGGAAATGCCATTGCCCCCCTGGGG 0.000221959 0.015552834 1.72E−05 CCTGACCCTCGCTGGCAATCCTCCACTTC CC 1715 3704487 4 FAM38A CTGAGGCGGTCCCACACTTTGGAAAAAA 0.022526284 0.006567648 3.55E−06 ATAGTGTGGGTTCCTCCCTGGTCCTCCCT TGCCCTACTGGGCTCAGTTTCGCAGGGG CGGGGGCCGGCCTCTGCCCTGGTCTGGG GGAGGGGACACCCCCGGAGGCTGTGGCC TGGTGTCAGGGCGGGGCAGGGGTCCCCA GTCCTGGCATCTGTGTTCCCTGCTTGCCG GGCAGTGGTGCCCCTTTCGCGAAGCACA CCCGGGTGGCTTGGTGCTGCACGGCCTG GCACCCCTACCCTTCCCCGACCCTGGCCT AGCCGGGACCCAGGGTCCGCGCCCTCCG CCCGGGGGCTCCCCACGTGTGATTGATC TGGGAAGCAGTCGGATGGAATTAACCCA CGGACAAGTGGGACGGTTTGCATTTGGGA GTCCGCCATGGACACGGCAGGTGGGGCC TTTTGATTGTAAAAGCCCTTTCGGAGCCC TTGCCTCGCTCCAGGTGGGAGCTCGCCC AGCGCTAGCTTTGGGGATCTAGAGCCGC CTGCCTGAGGCTCCCAGACAGACTGCGT TTTGATCGGTCGCACAGAAAGGTGGTGA AACTTGGGGAAGATTTTCTAGACAGGAA TCAATGAAAACCATTGAGGCTGGAGAGG AGAGGTTTTGAGCAACTCTCTTCAGTGC GGTCAGCCCTGTGTGGACTGGGCAGCCT GGGACCTGCTCCCAGTGCAGGGTCAGAT GGGCCGTAAACAGGGCCCGGCTGTGTTC CTTCCTGTGCCTTGAAAACAAGCAGGAC AGCCTGGCACAGAGGCAGAGTCTAGAGC TGACAGGCCTTAGAGAGGGAAACAGGA AAGCTTCTGAAACGTCCCGTTCACACTG ATCGTTCCATTTCCTCTTGTGTCTGAGTG GGAGCGGGTGTCCTCCCTGCAGGGAATG CCCCCCCTCTCAGATGGCAGCTGCTCCTT GGGCAGAGTTGGCAATGTTTTTCTTTAA ATGACCAGATGGTAAATATTTTCATGTC ACAAAATCTTCTTCTTCTGGTATTTTTCC AGCCATTAAATGTAAAAGCCCTCCTGAG TTCATGGGCTGTACCTAAACAGGTGTTG AGCCCGATTCTGTGGCACATGTGGTTTG CTGCCCCCTGGGCATTGGTCAGGGGGCC TGGGTTCTGCCTTCTCGATTGCTATCCGC GTGGGGGATCTGGGGGAGGGATCACTGT TCTTCTTGCTTTTGGCCTCCTTGGGGAGG ATGGGGAGGTAGCCCAGGGGTGCTCACC CAGGCCCCGTGTCAGTCTTCTATGAAAC TTTTAAAGAATAGTGATGACTGACTGTC TGTCTGTATGGTACTTTCCTTAAACCTAA AACTGGTCCCAAATAAAGTCTCTTAATTT GAAAGATGCTGAAGCCCGGGCCATACCC CACACTGATTCTGTGTCTGGGGATGGGG CGTGGGGCCTGGGCCTCACTCAGTGTTTT CTCTCAGTCACCTGGGGGAGATGGAAGT GGAGCCGGCCAAGAACCCTGCCTGCCTG CCTGCTGGCCGGGACTCCTGAGTCAGGC TCTCTGGCCCTGGGGTGTGGGCAGCTCC AGATGGACCCGCGATGTGCAGGTTCAGC TGGCCTGGCCGGAGGTGGGACACTGGCT TTGCTGTCTTTGGAGTGCCCCCTCCCTCT CTGGCGAGCTTTGGCTGGAAGCAGTTCT ACCGTGTTTTGGAAATGAATGAGGCCTT CAGAAGGCATTAGTCAGTGTGTGCCTGC GCTGGCTCAGACAGTGCCTGGTGAGGGT TTGAGTCATCCTGGGGTGCCCCTGGCCC CCACGCCCTCCCTCTCCAGTGCAGGATC ATTACCCAAAAATCTGGCAGGGAGCTGC CCCACCCACAGGGAGCAGGGGCCTCCTT CAGCAGTCTCACCTAATGTTGCTGGAGC CTTGGGGGATCAGGGCCCATCTCTTCTA GAGAGATGTCAGGGCAGGGCTGGGCGC GATGGCTCACACCTGTAATCCCAGAGCT TCGGGAGGCCAAGGTGGGAGGATTGCTT GAGCGTAGCCATTCGAGAGCAGC  640 3704496 1 GGATCCCAGGGAAATATCAGCCTTGGGC 0.012720391 0.009555613 5.12E−06 AACTGCAGTGACCAGGGGCACCGGCTGC CCACAGGGAACACATTCCTTTGCTGGGG TTCAGCGCCTCTCCTGGGGCTGGAAGTG CCAAAGCCTGGGGCAAAGCTGTGTTTCA GCCACACTGAACCCAATTACACACAGCG GGAGAACGCAGTAAACAGCTTTCCCACA AGAGCCGTCTCCTGTCCTCCTGTTCCCCA GGGCAGGGAGCCCCAGGACAACACCAG ACTTCAGCTGTACTGTGGG 1995 3707126 2 ARRB2 CCCACTGTCAATGGGGGATTGTCCCAGC 0.001628328 0.006507684 4.21E−06 CCCTCTTCCCTTCCCCTCACCTGGAAGCT TCTTCAACCAATCCCTTCACACTCTCTCC CCCATCCCCCCAAGATACACACTGGACC CTCTCTTGCTGAATGTGGGCATTAATTTT TTGACTGCAGCTCTGCTTCTCCAGCCCCG CCGTGGGTGGCAAGCTGTGTTCATACCT AAATTTTCTGGAAGGGGACAGTGAAAAG AGGAGTGACAGGAGGGAAAGGGGGAGA CAAAACTCCTACTCTCAACCTCACACCA ACACCTCCCATTATCACTCTCTCTGCCCC CATTCCTTCAAGAGGAGACCCTTT 1610 3708862 9 CD68 TACCAAGAGCCACAAAACCACCACTCAC 0.00071035 0.010528404 1.33E−05 AGGACAACCACCACAGGCACCACCAGCC ACGGACCCACGACTGCCACTCACAA  541 3711048 6 CCACGTGTTTGGTGTTGGTTATACATTAA 0.000996275 0.008838354 6.05E−06 GATGGGGCGGGAGTGAGAACAATCTCTT AACATTCATTGAAAAAAATACTGAAACA TATTTTCAGCACAAATATTAAACTGTCTC TTCTCTACCGATTGGTAAAAAAATATATT ATATTTTGATTTTTTTTTTCTTTTTAAATT ATATGGTTATCCATCCCAGCCAAAGTCG TGCCCGGTCATCTGGTAGAACT 1493 3711987 9 PIGL CTCTGGGTTTGGGACTCCTCAGAACGAA 0.013379902 0.008147589 7.37E−06 TGAAGAGTCGGGAGCAGGGAGGACGGC TGGGAGCCGAAAGCCGGACCCTGCTGGT CATAGCGCACCCTGACGATGAAGCCATG TTTTTTGCTCCCACAGTGCTAGGCTTGGC CCGCCTAAGGCACTGGGTGTACCTG 1454 3717119 9 NF1 TGCTTAAAAGGACCTGACACTTACAACA 2.26E−05 0.009405833 4.88E−06 GTCAAGTTCTGATAGAAGCTACAGTAAT AGCACTAACCAAATTACAGCCACTTCTT AATAAG  561 3718005 5 ACCN1 TGGCTGATAAATCTGTGGACATGTGAAA 0.033664154 0.007046032 5.45E−06 ATGAAGTGCAGCTTGCTATATTATAGCA TCCAAACTGCAGGGGAGCCAACAAACAT CTAACTCTGCCCACTCATTTTACCACTGG GGCGAACGAGGTTCAGGGAGGAGCAGG GACTCACCTGAGCCCAGGAATAGGGAGG CTCAACGGAAACTCAGGCCATTG 1112 3718104 5 ACCN1 CCCGGTGAAGTACGCATGTGAGCTCATC 9.72E−05 0.009822418 5.26E−06 CAATCTGCAGCCACTCCAGGAGGAGGGC ATCATTATCCTCAATAAACAGATGAGCA AACAGAGGCTCATGGAGGGTCAGCGAC GTGTCCAAGGTCACTGACTCATCAGAAG GCTACTTTGTTCTCACTCCATCAGGTGGC CCAAGG  665 3718684 4 AP2B1 ACGGAGAGAAGGGTAACACCAGGCTGG 0.000742232 0.008729072 4.07E−06 GTCGGAGACCGGCGGAGGCGAGGAAAT CCTAAGAGCGTGACCGTTGATGATGCAG GGAACCGTC 1314 3719372 9 AATF AAACTACAAAAAGCTCTGTTGACCACCA 0.000461778 0.007820628 6.09E−06  847 3719860 1 TGCGTGCCTAGAGGTCAAGTGTAACTGG 0.019317948 0.007902788 4.29E−06 TGTTCGTGAGCACCTCGTGGTTGCGGGT CTCTAACTCTCGTGGGTCTCTAAGCGCAC CCGCGGGGCTGGAGCGGAGGTTCGTGTC TCTGGGAGGGTCAGTGGTGTGACTGAAG CTGGGAGTTAGCTCGTGTCTGTGGGTGC CTCGGTGTGTGTCTCTGGGGCTCTGAGTC CCTGTGCGTGCGTGTGTGTCTGTGAACCC GACAGGAAGCTCCCCGAGGGCAGGAAT ATGTTTTGCTCTCTACTCGATCCCAGCGA CTGGCAACGAGCGTTTAATA 1387 3719966 4 PSMB3 CTTTTGACAATGAGAGTAACCCAGCCAC 0.000155402 0.008781182 3.21E−06 TGAGTATCCCTCTTTGCCTTGCCTGCTAG GGGGCTCAAAACAAAACTTTGTGTTCAG TCTGAGTTATCTTGTATTATGTTTTAATG GTTTAGTTTTATTTTTCAGTGTTTTTCATA TAAACTGCCTCCAATCTTTTCTCTAAAGG AGTAGAGGTATAAACATACACATAGAGG ACTGAGTGATGGTAGGACCTTGGGTGAG GAGAGGGAGGATTAGAAGAAAACAATT CTGAAAGAAAGAAGGAGCACAAGAGGG TCAGAGGTGAGAAGGATAGAAAGGTAA GTGTTGAAGAAAAGAAAGTGGAAAAGT CTTAGAATATTTCTAGCTGGCAGGAGAA GGGAGAGGGAGCTGGCCTCAGGGAAAG GTGATCTTCCTAAACAGGTCCTCCATTTC CCTTTGGGTCTGGGTCTAGGCCGGGGCC TTGTCTGAATAGGCTTAAACATGAAAGC GAGCGTTCTTGAGTTCTGGTTTC  762 3720001 2 LASP1 GCTGGGCGTCTGTTCTTTACCAAAACCAT 0.000136311 0.015837481 1.21E−05 CCATCCCTAGAAGAGCACAGAGCCCTGA GGGGCTGGGCTGGGCTGGGCTGAGCCCC TGGTCTTCTCTACAGTTCACAGAGGTCTT TCAGCTCATTTAATCCCAGGAAAGAGGC ATCAAAGCTAGAATGTGAATATAACTTT TGTGGACCAATACTAAGAATAACAAGAA GCCCAGTGGTGAGGAAAGTGCGTTCTCC CAGCACTGCCTCCTGTTTTCTCCCTCTCA TGTCCCTCCAGGGAAAATGACTTTATTG CTTAATTTCTGCCTTTCCCCCCTCACACA TGCACTTTTGGGCCTTTTTTTATAGCTGG AAAAAACAAAATACCACCCTACAAACCT GTATTTAAAAAGAAACAGAAATGACCAC GTGAAATTTGCCTCTGTCCAAACATTTCA TCCGTGTGTATGTGTATGTGTGTGAGTGT GTGAAGCCGCCAGTTCATCTTTTTATATG GGGTTGTTGTCTCATTTTGGTCTGTTTTG GTCCCCTCCCTCGTGGGCTTGTGCTCGGG ATCAAACCTTTCTGG   59 3720978 5 TOP2A GATCATCTTCATCTGACTCTTCCAGGTAC 1.72E−06 0.047128916 4.13E−05 TTTATAGGTTTCTTTGCCCGTACAGATTT TGCCCGAGGAGCCACAGCTGAGTCAAAG TCCATATGGAAGTCATCACTCTCC   44 3720986 5 TOP2A TTTTGGTCTTAGGTGGACTAGCATCTGAT 6.24E−07 0.096289981 0.000148557 GGGACAAAATCTTCATCATCAGTTTTTTC ATCAAAATCTGAGAAATCTTCATCTGAA TCCAAATCCATTGTGAATTTTG 1557 3720988 5 TOP2A CGTGGAGGGACATCAAAATTACTTTCGT 0.000229029 0.01011419 8.45E−06 CACTGCTCCTATCTGATTCTGAATCAGAC CAGGGATTTCTCTTCTTTCCTTTTTTGATT GGCTTAAATGCCAATGTAGTTTGTT   51 3720992 5 TOP2A CATTTCTATGGTTATTCGTGGAATGACTC 2.14E−08 0.063588907 7.19E−05 TTTGACCACGCGGAGAAGGCAAAACTTC AGCCATTTGTGTTTTTTTCCCCTTGGCCT TCCCCCCTTTCCCAGGAAGTCCGACTTGT TCA  877 3721456 9 FKBP10 TGGGGGATTTTGTGCGCTACCACTACAA 7.36E−05 0.009162263 6.97E−06 CGGCACTTTTGAAGATGGC 1512 3726146 1 GGCCCCGTGCCTTCTGACTCACAGCAGC 2.49E−05 0.007143351 5.19E−06 TCAACAGGAAAGCATCTGATCATGCCCA CAGCCCTGGCATCTGGCCCACAGGAGTG GCACCCCTCCCCAAGACCTTCCACACAG TTTCTATATTA 1941 3726285 7 COL1A1 AATAGGTACAGAGTCTTTTGCTTCCTCCC 2.08E−05 0.010400379 8.52E−06 ACCCCTAGGGGGAAAAACTGCTTTGTGC TTTGGGAAGTTGTCTCTGAAACCCGGGG ACAGAGGACGCAGGACAGACTAGGAGG GAGCCGGGAGGATGGGCTGCAGCTGTGG AGGAGGGTTTCAGAGGAGAGAGGTCGG AGAGCAGAGGCCTGAGAAGCCAGAGGC AGGTGGAGAGAGGGTGGAAAGTGAGCA GCGGGCTGGGCTGGAGCCGCACACGCTC TCCTCCCATGTTAAATAGCACCTT  397 3726287 5 COL1A1 CGGCACAAGGGATTGACACGCGTTCCCC 5.98E−06 0.021237214 1.83E−05 AAATCCGATGTTTCTGCTTTGTCGTGGCC CTTCCTGACTCTCCTCCGAACCCAGTGAG GGGCTGGTGGCTCCCCCGGCATGACCCC CTCAAAAACGAAGGGGAGATGTTGCAA GAGCCATGGGAGCGCCAGATGGCAAGG CTTCTTTGGCAGTCTGAGAACCCCAGGT CCCCCAGGGCCTGGGGGTGCTGGGCGGG CAGGAGCGGGCTGAGGGTGGGGGCCAC TTGGGTGTTTGAGCATTGCCTTTGATTGC TGGGCAGACAATACATTGTTTCCTGTGTC TTCTGGGGAGACAGATTTGGGAAGGAGT GGAGGGGAGGCCCCAAGGGGGGTGTGG AGAAAGGAGCAGAAAGGGCAGCATTGG GGTTTCATAAGCCCAACGGGCAGAAAGG GACTTACCCCCGCATGGGTCTTCAAGCA AGTGGACCAAGCTTCCTTTTTTAAAAAG TTATTTATTTATTCTTTTTTTTTTTTTTTTT TTGGTAAGGTTGAATGCACTTTTGGTTTT TGGTCATGTTCGGTTGGTCAAAGATAAA AACTAAGTTTGAGAGATGAATGCAAAGG AAAAAAATATTTTCCAAAGTCCATGTGA AATTGTCTCCCATTTTTTGGCTTTTGAGG GGGTTCAGTTTGGGTTGCTTGTCTGTTTC CGGGTTGGGGGGAAAGTTGGTTGGGTGG GAGGGAGCCAGGTTGGGATGGAGGGAG TTTACAGGAAGCAGACAGGGCCAACGTC GAAGCCGAATTC  833 3726289 5 COL1A1 CGTGCAGCCATCGACAGTGACGCTGTAG 2.23E−05 0.016265471 1.43E−05 GTGAAGCGGCTGTTGCCCTCGGCGCG  688 3726379 9 EME1 AGAAAACCAAGCCGAGTCAGAAGGTCC 0.000474683 0.00860949 8.22E−06 AGGGAAGAGGCTCACACGGATGCCGGC AGCAGAGACAAGCAAGGCAGAAGGAAA GCACCCTGAGAAGACAGGAAAGAAAGA ATGCAGCACTGGTTACCAGGATGAAAGC CCAGAGGCCAGAGGAATGCTTAAAACAC ATCATTGTAGTGCTGGATCCA 1144 3728550 1 TGGGGCCATGTCTGATGAAAGCTTGGTG 0.000862602 0.011254423 5.64E−06 ATCCCTTTTGGGTCAAAAACAAGCTCTG ACTGAAGAGATGCAAGATTTTCTCAGAT GATTTGTGTGTCAGTCAGAGTTCCGCCA GAGAAACACAACCAGTAGGATATATTCT ATCTTGTCTGTCTTCATATCCATGTATCT GTCATCTACCTAGATTTAATGCAAGGAA TTGGTTTATGCAGTTGTAGGGGCTGGCT AGGCAAATCCAAAATCCACAGGGCAGG CCGTGTGGAAGGGAGGTCTGGAAACTCT CAGACAAGACCTGACATTGCAGTCCACT GGTGGAATTTCTCCTTCTTCAGGGAAAC CTCAGCTTTCAACGGAGTGGATCAGACC CAACCATATTATCCAGGATAATCTCCTTT ACATAAAGTTAACTGATTGTAGATGTAA ATTACATTTACAAGATACCTTCATAGCA ACACCTAGGTCAGTTTTTGAATAACTGG GTATTATAGCATAGCCAGGTCAACACGT AAAATTGATCACCACAGTCCATGTCTTG TTAACTTGGCACCTGTA  615 3728572 1 ATGAAGGAAACCACCCTAGACCTAGAAC 0.00028925 0.009148564 6.03E−06 ACGGCCAAGACACTGTAAAGCTGAAGA ATAGGGAGAAATTTCTGCATGAGGCTAA GCAAAG 1305 3728970 9 PRR11 TGCCCAAGTTCAAACAACGAAGACGAAA 2.42E−05 0.013089929 7.09E−06 GCTAAAAGCCAAAGCCGAAAGATTATTC AAAAAAAAAGAAGCCTCTCACTTTCAGT CCAAGCTAATTACACCTC   99 3729181 9 CLTC AAAATCGTGTGGTGGGAGCTATGCAGCT 6.11E−08 0.03000392 3.82E−05 ATATTCTGTAGATAGGAAAGTGTCTCAG CCCATTGAAGGACATGCAGCTAGCTTTG CACAGTTTAAGATGGAAGGAAATGCAGA AGAATCAACGTTATTTTGTTTTGCAGTTC GGGGCCAAGCT 1068 3730880 5 STRADA GGACCCAGGCCCAAACCAGTGAGATTAA 3.45E−05 0.008004559 4.75E−06 TCTACCACCCTGTTGGCTGACGTTTCACG TGTATCTGGTTTGTTTGTTGTTTTGTTGCT GTTGTTTTTAAGATATGGGTTATCTCTTT GTCGCTCAGGC 1655 3731133 1 ATACAACATCCACGAGGGTCCCTGCAGC 0.001204733 0.00994669 1.39E−05 TGTGTCACTGAGGCAAACAGGAAAAGTG ATTTTGGCTAGGCGTGGTTCTCATCTGTG AAATTCCACAGCGCAATGACAGCAGCCT CTCTCCCACCCACTCAAGACACTGTCAG GAATGTCTTAAGACCTCAGGAGACCACT TCTTTAGCAAGCAATTTTGTTTTTTGTTTT TTTTGAGATGGATTCTCACTCTGTCACTC AGGCTGGAGTGCAGTGGCGCGATCTCCG CTCACTACAACCTCCGTTTCCTGGGTTCA AGCGATAATCTCACCTCAGCCTCTTGAG TAGCTGATACTACAGGCATGCGCCACCA CGCCCGGCTAATTCTTGTATTTTTAGTAG AGACAGGGTTTCATCAGGCTGGTCTCAA ACTCCTGACCTCAGGTGATCCGCCCACC TCAGCCTCCTGAAGTGCTGGGATTACAG GCGTGAGCCACCTTGCCTGCCCTGGCAA GGAATACATTTTTAAAAATTAGTAAGAA ACATACACATTTCAAGTTTTCAATTAAG AATAATATTTGCTGATGGCACCATCTTCC TGTCTTTCAGCCITCAGCATGGTAGAGG AAAAGAGAAAGAGTGTAGACAAAAACA GTTGAAGAACATCTGTGCTTGTTCCACCT TCATTTTCTGTTTTGTGCGTTGCCTGAAT GAACGGTGTCTTCAGGTTGGTATTTCAC AGGCGGTGCTCCCAAGTAGTCTGGTTTT CCCATTTGTGGAGGGCGAGGTCATAGAG GGGACAGGGGGAGGCTGTCTGGTCAGCA CTGTGTATTTCCAAAGAACAAGGACTAG CCAAAACTACAAGCCTTTGAAGGACCAA AGGAAAAGAGAAAAAACCAGCCTCTAA CCAGGCCATGCGCTAGAAATGATTG 1674 3731143 6 AGTTAGTTCTGCCTTCGGGCCATGACTCG 8.09E−05 0.006870019 2.73E−06 CTCAGCAGAAGGCACTGCCCACAAGTCA CCGTTGAGAAACCCGCCCTGTG 1254 3732739 6 GGACGAGGCTGATTCCGATTATCTGGAG 6.32E−05 0.009173345 7.10E−06 GAGCTGGAAGACGACGACGACGCCAGTT ACTGCACAGAAAGCAGCTTCAGGAGCCA TAGTACCTACAGCAGCACTCCAGGTACC CACCCAGCCCAGTTGCTGCAGACTCCTT CCCCACCTCCTCTGCCCTCCCCCCTTGCT CACTCGTGTGCTGTGCATCCTGCTCCGAT CTCCCCCCAACCCCGCCTCCCCCCCAAA CAGAGGGGAAATGCGAGGGCACATCAA GTGGCAAAAAACTAGATTTACAAGAGGA AAGAGGCGCATTGTTAAAAATGGAGATT GCATTGTTGCAGTTTGCAGGCTACACTC GCTCGCTCTCTCTCTCCCCCCCAACCTCC TCTTTTTCCTCTTCAAAATTTGTGCCAGT GCAGTGTCTCCACCGGGCAGGATTGAAA CTTTGGCAAACACGTATCCATTGCATTCA TTTCTTTCCCCTTGTTTTGGTCTGGTTTTC TGGAATGAAAGAAGCCTCTTGTTTTACA AACCTCTTTGCATTTCTAATGTGGTTTCT TTCAGATTTTTATTAGATATGTTACTTAA AAGGGAATTAAGGGTTTGGACAGATTGT GGCACACAAACACACACAAAAACATGTC TGTTTTCACATCCCTAGCTGTGGTTTTAA AATTGTGTTAAGGAAATGGATCATTTGG GTTAGTAGGGGAATTTTATCTGGTCCTGT ATGTTTGCTTTTATTCTTCGAGTGCTAAT GGGCCTGTGCAACAGTTGCTGGTAAATG GCTGATTAAAAAGCAAAGCAGAAAGCC AAACAAGACCCACCCAACTTTGGTTATT CATTCGATTCAAAATTGTTTTTGGTTAAA TCAAAAATGAAAGTACAAAACCGCAGG AACGCGCATCTTAGCTCATTTGATCGCTT TGCCTTGCTTGGGAAATGCAGTTTCGTGT CACCTGTTGCAGAAGATATGTAGTTGAT CATCTAGACATAATTGCTGAAGATAAAC TTTTGGACCAACTTCTAAGTCACACAGC ATCATTATCAGATTTATTACACAACGACT TTTTTGTTTTCACTCTATTTCTGAGGAAA AAGCCTTCCCGAAATCCGTAATGAATTT CTCCATGGTAACCCCTCTTCTGTTTTCAC ACAGAAAAGTTTCTCTAGACTGTTGCTA AGATGCATTTTGTTAAATACCCCCCCCCC ACAAAGGCTGCTTTGTATTAAATACGTA GTTGGAATTTACTAAATTGTGAAATTAA CGTAACCGAAGCAACAACCGGCAAGACT TT  569 3734860 9 KIAA0195 GGTCCGAGTCCGCTACCAGAAGCGACAG 0.000712087 0.010991321 6.89E−06 AAGCTGCAGTTTGAAACTAAGCTGGGCA TGAACTCTCCCTTC 1110 3735014 2 MYO15B CCTCTTTGACGTGGGACATGTGACAGAG 0.000203031 0.0074482 3.26E−06 CAACTGCACCAGGCAGCCATACTGGAGG CCGT  773 3735349 9 C17orf106 GCTGCCCAAACCTGGGACCTATTACCTC 0.012043037 0.009510322 6.39E−06 CCCTGGGAGGTTAGTGCAGGCCAAGTTC CTGATGGGAGCACGCTGAGAACATTTGG CAG  844 3735745 1 AGCTGTGGCCGGAAGGAAAGCTTCAGTG 0.004194748 0.007501714 3.37E−06 ATTCCCGAAGCAAAGCAGACAGTCGAGT TCGGAGT  938 3737994 4 RP13- CAGAGCTGAGGCTTAACCCAGGGCCTGC 6.62E−06 0.009372956 8.59E−06 766D20.2 GCCCTCCACGGCCTGCACTGCCCCACCT CCAGCTCCTTGCCCTGTTCCTCCCTCTGC ACCGGATCAGCCCCCGGACTCTGGGTCA CCTCCACACCAGTTGACAGGGCCCCCCA GTCCCCACCGCCAACCACCTGGCCGGCT ACTTGTCAGACA  940 3740825 3 MIR132 TCCAGGGCAACCGTGGCTTTCGATTGTT 0.006674036 0.007581392 2.03E−06 ACTGTGGGAACTGGAG  225 3742407 4 PFN1 GTCCGGGGCACTGCTCCGGTTTGGACCC 0.000909538 0.012421274 8.61E−06 TGA  223 3743231 1 CTCTTGCAAAAGAGGCTCCACATTTTCC 4.19E−05 0.015381152 5.64E−06 AGGCTTTGATGAGAACTTCGACATAAAC GTCAAACACAGTTCCTGCATCCGAACCG ATTCTGAGGCCTTGTA  599 3743292 3 MIR497HG CCAGGAGATCCACAGGTCCGGCATGAAC 0.001098492 0.009759828 2.84E−06 AGTGAGAGGTCAGAGGTGGAAGGCTCA GCAGGAGAGGAGAGGAGGATCAGCAGA GGTCATGAGAAGGCCAGAATCCAGGGTC AGGCTGTCTGGAACAGGAAGTAAAATGG GCCGAGATGGAGCGAGCCCCCAGTGTGC TTCCAAGGCCACTCCCACCTCCCTGAAA CACCCTGCTACGTACTGATCCAATGCCCT GCGCTGTGTATGAGAGC 1788 3745080 1 TGAGTGACACCGTGGGATTGCAGAACCA 0.000126422 0.008893994 4.71E−06 CACGCTAACCATGAAGAATT  870 3748225 9 FLII GAGTGGGCCCAAGGACCCTATGGCTCGC 0.025777155 0.009133044 8.23E−06 AAGATGCGACTGCGGAGGCGCAAGGATT CAGCCCAGGATGACCAGGCCAAGCAGGT GCTGAAGGGCATGTCAGATGTTGC  608 3748820 7 RNF112 CCAGAGGCATTGATGCGAACCAGCAGCA 0.001543869 0.008899881 2.96E−06 GCGGCTCCGCCCTCACAGGACACGTCTC CTGGGCCAGGAGAAGAGAGGGGCCCCT GAGCATCCAGGACCAGCTCCTGACCCTG GAATGTGTTCAGCCTGGAGCTCTGTGTC CTGATGTTCTAGAATAGGGCCAAAGCCA CCCCCTCCTCTTGGGTCTGACTGATTAGG  344 3749011 2 ULK2 AGCTTTTCCATTTGGTGCTCCAATGTCTC 1.52E−05 0.014790792 6.57E−06 CTGCTGGACCCATCTGCCTAGTGGAAGG CAGCAAAATTTCAAGAAACAGGTGAGGT TGAGCAGCTTGGTGCAACCCCATGGGGC CTGGAGTTGGAGCTCAACAGCAATGGAT TTCAGAGACCACCCTGAAACTCCCAGTA AAAAAGACTTGGGAGACATGTTAATA 1388 3749061 9 ULK2 AAAACTGATTGGGAGGTAGCTATTAAAA 0.000310049 0.006756375 6.24E−06 GTA 1539 3749447 6 TTGGGTGTTTGCGCACAAGCAGCCAACC 0.003773209 0.006991449 6.66E−06 1391 3750115 1 GGTCTCGGGAAAATGCTGCCCGCGACAA 0.013302264 0.009082288 7.05E−06 CCCACTGCGGGACCCTAAATGTCTCGAC AATAAGGCCTCCTCGGCACGTCTCTG 2004 3750596 7 TMEM97 TGCCAAGCATCAACGTGAAGAGACCCTC 4.69E−05 0.010906008 6.44E−06 TATGCACACAGTGGATATGTTATGCCTG GCTGTAGCCACCTTCTCTTCTGAAAACA AGATGGGAATGACGGAACTGTATTAAAA GATTAAGTTATCCACTAGGGAGCATACT AGCACACTTCCAGATCAGCCTTGAGATG CTAGA 1071 3751077 4 C17orf63 TTACAGGCATGATCCGTGATGGCTGTCC 0.000645623 0.008905467 3.00E−06 AGTTTCTAGTATCTTTATATGTGAAAATG GGGCTGATGATACATACCCAACCTATCT CAAAGGGCATCTTGAGAAGATGGAGAG AGAATCATGTGAAAAAGCACTTTGAAAA TTGTAAAACTCCCTACAAATGTAAGATA TTGTTAATGACCTTACAAAAACCACCTTT TTAAAATGATTTGGAATCATAGACTCTA AAAGTTGATTCTAGTGGTCTAGTCCA 1286 3752264 9 EVI2B TGGGTCAACCAACACAATTCAGCGACAC 2.99E−05 0.012105796 6.65E−06 TTTTTCTGGACAATCAATATCACCTGCCA AAGTCACTGCTGGACAACCAACACCAGC TGTCTATACCTCTTCTGAAAAACCAGAA GCACATACTTCTGCTGGACAACCACTTG CCTACAACACCAAACAACCAACACCAAT AGCCAACACCTCCTCCCAGCAAGCCGTG TTCACCTCTGCCAGACAACTACCATCTGC CCGTACTTCTACCACACAACCACCAAAG TCATTTGTCTATACTTTTACTCAACAATC ATCATCTGTCCAGATCCCTTCTAGAAAA CAAATAACTGTTCATAATCCATCCACAC AACCAACATCAACTGTCAAAAATTCACC TAGGAGTACACCAGGATTTA 1519 3752342 5 RAB11FIP4 CTCATTCGGAGATGCCTGCCTTCTGGGA 0.00401772 0.006569666 5.67E−07 ACTGCTCACCTGCTATTTCATTGGGAGCC TCTCCTACCCCCTTCACCCCCTCCTTACC CATACCTAAAACATATAAAGTGAAATTG CGAAGTCTCCTCAGAACAGAATCAGTTG TGAAAAACCTCAGCATAACGGGCTGCCC AGATCGGGGACTGCCAGATACCTA   66 3755466 5 LASP1 GAATCACAAGCTGTCGCAGGTTTTAAAA 4.43E−06 0.036109365 2.80E−05 AACAGAGACACTGAAGAATGGACGGGT CACGCCCAGGACGGATGCGATGCCGTGG AATGTGCTGAAGACAGATGGGGGCGCTG CGGGTTCAGATGGCCTCCACGTAGTTGG CCGGCAGCATCCCCGTGTCGCCGGTGCG CTCCACCGTCCCGTACATCCAGCCGTCGT CGATCTGCTGCACGTT   65 3755470 6 CCAGGAGAAAGATTCACTTGTGGTTCAA 4.15E−06 0.044191091 5.33E−05 GTCAAATGTTCAGAATCATAACAGGCCA GAAAGGTTTGATCCCGAGCACAAGCCCA CGAGGGAGGGGACCAAAACAGACCAAA ATGAGACAACAACCCCATATAAAAAGAT GAACTGGCGGCTTCACAC 1013 3755539 9 PLXDC1 TGTCTGTCCCGGAAATCAGCTCCTCCCA 0.001501439 0.007489452 3.31E−06 GCATCCTGTCAAAACCGGCCTATCGGAT GCCTTCATGATTCTCAATCCATCC 1863 3755856 2 IKZF3 AACAGAACCAGTGCTCCAGGTGTTTTTT 0.00016045 0.007545863 2.81E−06 AATTTTTTAATTTATTTTTATTTTTTTTGT ATATGTATATATATGTATGTATATTTTAG AGGACCAGGGTC 1375 3756091 1 ACGACTCCTAGCATCTTCGGGAGGCTCC 0.006167603 0.00745408 3.32E−06 TGAAGGACTGAAGCAAAGGAAATCTCTG AAGGGATTTAGTCCTTGAAAGGGAGTAG GGATACTTAGGGTGTTCTGTGTTGAGCG CTTCTTCCTATCTCTCCAGCTTCATGTAT GTGTGTCTTTATGTCCAAGCAATTGAGCC AACAAGTCCTCAGAATTCCTTGTGAAAA AAACGTTTTTTTTTTTTGAGACGGATTCT CACTCTGTCGCCCAGGCTGGAGTGCAAT GGTGAAATTCAGCTCACTGCAACCTCCG CCTCCGGGGTTCAAGCGATTCTCCTGCCT CAGCCTCCCGAGTAGCTGGGATTACAGT CACGCGCCACCACGCCCAGCTAATTTTG TATTTTTAGTAGAGACAGGATTTCTCCTT GGTCAGGCTGGTCTGGAACTCCCGACTT CAGGTGATCCGCCCGCCTCGGCCTCCCA AAGTGGTGGGATTACAGGTGTGAGCCAC CGTGCCCAGCCCTGAAATAGTCTTAATT GCTTGTTTTTCTTTTTTGTCTGAGGTGTG CTTTTTAAAATCTCTATGGAGATGGAGA AGACTGACATTCTCTGGCCTGATGTGAA AACCTCTC  268 3756105 7 MSL1 TCTGCTAAAAGGATGAAGCCCAATGAAG 1.95E−05 0.015854797 1.50E−05 GAATACTTGAGAAGTGATGTGATACAAG GACATTTATACAGGTTTTGGCATGCCATC CCAAATACTAAGTGCTTTTGTTTACAGCT GTAACTTGTTCTGAAACTAACCATCCCC ACTTTCTTTTCCAAAGATTTTGGTTTTTG AGCAGTAAAGAAATTGTTATCCATTAAC TGAAAAAATAATCACAGCCAAACATCCC TTCCCACATGACTGTATCACAGAATAGT TTCAAATGAACAACTATCTTTTCAGACA GTTATCTACCAACTCTCCGATGTCTTTTC TACTCTGTGAAGATGGCTTGCTTCATCGC TTCACTTGTCATTCCTCTTCTGGTCCTAA AGCTCATGGTGAGGTTGTTTGTTTTATTT TAGGGTTAAAAATCACTATACCCACTAT AAGGAGGGTGTACCAGGGTGAGAAGAG TGCCATGCAGGCACAGCTCTAAAGGAAG GGGCTGCTTCATCTTCCACATGTCTAATG AAGAGAGCCCTTTTACCCCTTTAACATA GGCAAATGTATAGAAACAGACCCCTGAA ACTTCTGAATCTGCCATCCTATAGCTTTA GCTTGAGAGCCCATTTCC  151 3756196 9 TOP2A CAAGGGGGAGAGTGATGACTTCCATATG 1.82E−06 0.028647724 1.83E−05 GACTTTGACTCAGCTGTGGCTCCTCGGG CAAAATCTGTACGGGCAAAGAAACCTAT A 1556 3756197 9 TOP2A CTGGTGTCTCTCAAAAGCCTGATCCTGCC 0.008619147 0.0072412 3.45E−06 AAAACCAAGAATCGCCGCAAAAGGAAG CCATCCACTTCTGATGATTCTGACTCTAA TTTTGAGAAAATTGTTTCGAAAGCAGTC ACAAGCAAG   54 3756230 9 TOP2A TAATGCTGCGGACAACAAACAAAGGGA 8.74E−07 0.053313237 6.05E−05 CCCAAAAATGTCTTGTATTAGAGTCACA ATTGATCC 1206 3756234 2 TOP2A GTTCTTGAGCCCCTTCACGACCGTCACC 0.003465953 0.010570624 8.22E−06   63 3756235 2 TOP2A TTCAAGTGGAGCTCTCCTAACCGACGCG 3.94E−06 0.043172399 4.70E−05 CGTCTGTGGAGAAGCGGCTTGGTCGGGG GTGGTCTCGTGGGGTCCTGCCTGTTTAGT CGCTTTCAG 1434 3757088 9 KRT15 AGAGGTGGCCTCCAACACAGAAATGATC 0.008028233 0.00842142 6.04E−06 CAGACCAGCAAGACGGAGATCACAGAC CTGAGACGCACGATGCAGGAGCTG 1203 3757100 9 KRT15 GGTGGAAGCCGAAGTATCTCAGCTTCTT 0.000689814 0.009508723 9.53E−06 CTGC  577 3757573 4 ZNF385C AGGCCTCCAACTCCAACAAGAAGTGTAA 0.00240984 0.008390462 4.38E−06 GCGTTACTTCAACGAGCACTGGAAAGAG GAGTTTACCTGGCTGGACTTTGACTATG AGCGGAAGCTGATGTTCTGCCTCGAGTG CCGCCAGGCCCTGGTACGGAACAAGCAT GGCAAAGCCGAAAACGCCTTCACTGTGG GCACAGACAACTTCCAGCGC  196 3757645 9 KAT2A GCACAAGACTCTGGCCTTGATCAAGGAT 7.65E−07 0.020633913 2.39E−05 GGGCGGGTCATCGGTGGCATCTGCTTCC GCATGTTTCCCACCCAGGGCTTCACGGA GATTGTCTTCTGTGCTGTCACCTCGAATG AGCAGG  214 3757985 9 PSMC3IP GAGCAGCTGGCGCAACAAGGCAAGATC 0.006245159 0.015412602 1.46E−05 AAAGAGAAGATGTACGGCAAGCAGAAG ATCTATTTTGCGGAT  464 3758792 2 TMEM101 AGGGGCAGAAACAGTACCGGCTCTCTGT 0.002047903 0.009826673 1.07E−05 CACTCACCTTGAGAGTAGAGCAGACCCT GTTCTGCTCTGGGCTGTGAAGGGGTGGA GCAGGCAGTGGCCAGCTTTGCCCTTCCT GCTGTCTCTGTTTCTAGCTCCATGGTTGG CCTGGTGGGGGTGGAGTTCCCTCCCAAA CACCAGA 1998 3758943 2 ATXN7L3 CGCCTGGCATTACCGCATGCTGGGGTCA 0.002162534 0.007948762 3.78E−06 TTGGGGGAGGGGGGTGGGGCTCACGCTG TCCTGTGGTCTTGAGATTTTTATTTTTGC ATATGTAATCCATTCTGTACAG 1178 3759233 4 GPATCH8 GGGTGACTTCACTAAGTCCTGAGGAGGG 1.09E−05 0.00904615 6.29E−06 AGGAATAGATATTACCAAAGATAGGAG ATACTGATGTATACAAGGTAATTGCAGT TGACAAAGAGTAGGTGTGGCTAATTGGA GCAGATTATGTCCATGGTGTAGTGGATT TTATGCGTTTTTTAACAGAAGAAACCAC CTCAATTTTTTTTTTTTGAGGTTAAACTT CAGTATATGAAAGAGGGGGCAACCCAG CAGTTGTTTTGATTGAAGCAGAGTTCTA GGTCTCCAGGAATAGTTTAAAAACTGTA ACTAGGCTGGGCACGATGGCTCATGCCT GTAATCCCCAACACTTTGGGAGGCTGAG GTCGAAACATCTCTTGAA  872 3760226 1 CCTGCCATTTCCTCGCATGTAATTTTTTA 0.032732293 0.00868694 6.90E−06 ACACTCATATCTCAGTGGGCTCTTAGAG GTAATCCAAGGTAAGAACCACCTTTTTA GTTAGGTCTGATGGTTAGAAAGCTTGAG TTGAAGCGTGCCCTTCTGGAATTGCCACT TTGGGCCCAATTTTGTCTACACGGGAAC TGCTTA  178 3761459 2 HOXB7; CGGTGGCTGTCGTGAAATTGTGCTTGTGT 0.023754148 0.016255176 1.79E−05 HOXB9 TTCGTGATTTCTTTGGGGGTGATTGTCTC GCTTGTTTTCAGTTGTCGATTATATGGGA GGGTTCTGGGTGGGAGTGGGGAGGGCG AGGGGCCTAGAGCTCTAATTGTT   75 3762200 2 COL1A1 ATTATTTTGATTGCTGGAATAAAGCATGT 0.000102339 0.036754271 4.77E−05 GG  438 3762201 2 COL1A1 TTCTAAAGGTGCTATTTAACATGGGAGG 1.26E−06 0.020791186 1.69E−05 AGAGCGTGTGCGGCTCCAGCCCAGCCCG CTGCTCACTTTCCACCCTCTCTCCACCTG CCTCTGGCTTCTCAGGCCTCTGCTCTCCG ACCTCTCTCCTCTGAAACCCTCCTCCACA GCTGCAGCCCATCCTCCCGGCTCCCTCCT AGTCTGTCCTGCGTCCTCTGT   67 3762203 2 COL1A1 GACAATTTCACATGGACTTTGGAAAATA 0.000124394 0.038573659 5.08E−05 TTTTTTTCCTTTGCATTCATCTCTCAAACT TAGTTTTTATCTTTGACCAACCGAACATG ACCAAAAACCAAAAGTGCATTCAACCT   76 3762204 9 COL1A1 AGTCACACCGGAGCCTGGGGCAAGACA 2.02E−05 0.035560963 4.53E−05 GTGATTGAATACAAAACCACCAAGACCT CCCGCCTGCCCATCATCGATGTGGCCCC CTTGGACGTTGGTGCCCCAGACCAGGAA TTCGGCTTCGACGTTGGC 1456 3762206 9 COL1A1 AGCTGACCTTCCTGCGCCTGATGTCCACC 4.39E−05 0.014078043 9.84E−06 GAGGCCTCCCAGAACATCACCTACCACT GCAAGAACAGCGTGGCCTACATGGACCA GCAGACTGGCAACCTCAAGAAGGCCCTG CTCCTCCAGGGCTCCAACGAGATCGAGA TCCGCGCCGAGGGCAACAGCCGCTTCAC CTACAGCGTCACTGTCGA  324 3762208 9 COL1A1 AGCGCTGGCGACTTCAGCTTCCTGCC 1.53E−05 0.025263426 1.75E−05 CCAGCCACCTCAAGAGAAGGCTCACGAT GGTGGCCGCTACTACCGGGCTGATGATG CCAATGTGGTTCGTGACCGTGACCTCGA GGTGGACACCACCCTCAAGAGCCTGAGC CAGCAGATCGAGAACATCCGGAGCCCA  746 3762212 9 COL1A1 TGAGACAGGCGAACAGGGCGACAGAGG 3.75E−05 0.013541175 1.07E−05 CATAAAGGGTCACCGTGGCTTCTCTGG   80 3762238 9 COL1A1 TGGGATTCCCTGGACCTAAAGGTGCTGC 5.32E−05 0.027867168 2.65E−05 T 1224 3762257 9 COL1A1 GGTGCTCGAGGATTGCCCGGAACAGCTG 0.000120755 0.013331704 1.14E−05 GC  686 3762258 9 COL1A1 AGCTGGAAAACCTGGTCGTCCTGGTGAG 9.74E−05 0.014149484 1.04E−05 CGTGGGCCTCCT  703 3762268 9 COL1A1 CCTGCGTACAGAACGGCCTCAGGTACCA 5.08E−05 0.018236337 1.83E−05 TGACCGAGACGTGTGGAAACCCGAGCCC TGCCGGATCTGCGTCTGCGACAACGGCA AGGTGTTGTGCGATGACGTGATCTGTGA CGAGACC 2076 3764125 2 SRSF1 ACATATCTGAAGAGATGGATTAAGAATG 0.000628393 0.007325163 4.57E−06 CTTTGGATTAAGGATTGTGGAGCACATT TCAATCATTTTAG 1510 3764880 5 CLTC TGCTCCTGAATGGAATGGTCCCACAGAA 0.000142667 0.010897302 5.34E−06 AAAGCACAGGATACAGCACAACATAAG GGCACCTGTTACATATGAAGTGAGCAAA ACATACTAGCATTTTCTATATGCATAATG GGGAAACCTGCATAGGTTAGAGGGCCTT TTACGCTCATTTAAAAATCAGGCAAGTT GTCTGTAACATTTTTCAATAATCTGGGAA GCACTGCAATCCAGTGTACGATGTGCTG ATTAGTGTTGTCTTTGTTGGCACTGACAG TCTTGCATGGTCATATGCCAGTGTTTTTG CTTTAGCTTTTCTTTGAATAAAACAGATT TAAATGCATTTAGACAATACGTATTTGT AAGCTGTTTACATACACTAAATTTAAGA GATTCAATATTAGAGTTTCTTTGTTTCTT TAAACACTACAGAGTGCAAATCAGGTTC TTCACAACAGATTGAATATTGAGCAGTT CTTTAAAGAAAGAGGGGGAAGAAAAAA AGCCCAAGTGAATAAAACATTGAAACTA TTCCCCTTCGAAAATAAATTCTAAAATG ATGTGGAATGTGAAATAAGGTTTTAACA TAGGTGATCCAAGTTTATAGTTAGAAAC AAAAAGAAGTCCTTCATGAAATAAAGGT TACAAGAACACGTTGCCTGTTTTCCCCCA TTATAAACTGAGAAGTGGGTAAAGACGA TGTTTCAGTACGAAAATAGGTGACTACA GGATCAGCGCTTCATCTCACATGCTGTA CCCAAAGCCAGGCTGTGGCTGTCCATAC GGTGGTGCGGTATAACCATAACCAAAAG GTGCCTGGGGAGGGACGGCAACACTGG GTCCTGCTGTCAGCATCAACTGGGGCTG ACCTACAGTAGAAGAAAACAAAAAGGA GCAGGGGGCAGGGGCAAGGAGGCAGGA CAAACTGTTAGCATTTAGAACACTCCAA TCTCCTCCACTCTAGCAACATAATCTCAA CCTCAAATGAGTTGTATGGGGGGCACAT TTGATTGCTACAATTTTAGCATGACAGTC TTACTCTAAGAAGGTTCCTACCTAAAAA GCCAACAAACAGTGCAGGGCCAAAGGC CAGAACTGCTTATGACTGAACACCGTAT GCCTGACACTCTGTATA 1369 3765948 5 TLK2 TTTTAGCTGTAACAATTAGAAGGAGAAA 5.31E−05 0.009267069 3.83E−06 AGTTGACAGTTATTGAGATGTAGAAGGC TGTGGAAGTCAGGCACGGTGG 1240 3766160 1 CCTCCCAAGAGGATGGCCTGTTAGAATG 0.000402054 0.009821347 6.87E−06 GACTCTGAGCACCTTCTCTTCTATGTGGG CCCTCTCTTCATCACAGGGCCTTCCAGAC ATGATACCTGTTATCAGTGCCCCATCTTA TTCCTGAGAATGGAATAACTCAGCTGCC AAGACTCCAAGCTCCTCCAACTTGTTTTT AAAGCTGAAAGAGGGTGACTCCATTCCC CGCTGGTTCGCCTACCCATTCCCAGCCG ACCGCAGGGGAGTTTGGCCACCATGTGC ACGTGCGTACTGTGTCTGCCTGCAGTTA 1283 3766835 6 CAAGCCCGAACTGGAATCTTCCTTCACA 0.015281883 0.006658549 3.35E−06 CATCTGGACCAAGGTGAAAGACTGAACC TGTCCTGCT  860 3767533 1 GTGCTCTCCTCTGGTTACAAGCTCAGGCC 0.000306094 0.006888914 3.37E−06 AACTCCTAAAAGCCAAACT  326 3768673 9 ABCA8 GTTGAGGAAAACATAACATCACTTGTTA 0.00659163 0.009956292 7.56E−06 AACAGCACATCCCTGATGCCAAATTATC AGCCAAAAGCGAAGGAAA  458 3769694 4 AC007639.1 TCAGGCGGGTGGCAAACAAACATCACAT 0.000547163 0.009413625 2.22E−06 AAAGGAGAGTGTCTGGCTTGTGTCTTCT GGGTACGTGATCCCCCTGACTTCAGTGT GAGAATGTGGCCAGAGCGTCTGGGGAA GACAGGGAGAGTTGTCAGAGAGGAGTTT TGAGGAGGCCCTGAAGGCTCGCCGGCTG TTAAGGCCTGAGCTGTAGTGGGCAAGAA GAGATGGCCAGTTCAGGTAGAGGAAGCC TGCTTTGAGCTGAAGACCGGAGGTGAAT CTGGACAGGGCTTCCC 1170 3770533 4 C17orf28 TCAGGCCAAGCAGTCCCAGTTCATGTGT 0.000357766 0.007280479 2.38E−06 CTTGTGATCTTGGTGGGAAGGTGCTTGA ACTCCCAGAGTTCTAACTTCTGCAGCTA AAACACAGGACCCTAGCTGCCTTCTCAC CCCAGCTAGTGGCAGGCCTCAGTAAATG ACAGAACAGTGGAATGCTCCTC  197 3770609 9 HN1 CTCTGACTGTCCTGAACGCTGTCGTTCTG 0.002303775 0.025254776 2.62E−05 TCTGTTTCCTCCATG  142 3770610 9 HN1 CGTGCCTGCTGCGCCTGTGCCCAGCCCG 2.02E−05 0.021529189 1.88E−05 GTGGCCCCGGCCCCAGTGCCATCCAGAA GAAATCCCCCTGGCGGCAAGTCCAGCCT CGTCTTGG  402 3770724 2 SLC25A19 CCAGCTGCCCCAAGCGGGGTAGCAGCCT 0.000228432 0.011282404 7.12E−06 TGAACCCAC 1014 3772175 5 AFMID GGTATACCAGCGACCGCTGTGCCTTTAG 0.007582294 0.006943524 2.20E−06 CCAGCTGGCAGCCTTAAGGGGAGATGAG GTCCCCCAAACGAATTCAGTTAATGCCA TCATGGGCACCACTCCCACAGCAGTTAC GACCAGGGGAGGCC 1763 3772574 4 CYTH1 CACCTATAATGAGCTGGACACTCTATGG 2.15E−05 0.008498103 5.41E−06 GCCTTGCAATTTAGACATGAATAGAGTT CTCAGGTACCTTACATTCTAATTAGAAG GAGAACTTTGACCTCTAACCAAGACCTG TTTAATTCATAGGAGGGTTTCTTTTCTTT TTTTTAAACTGCACTCACGGTCATCCCCC CAAAGGATGAGGGTTTCTTAAGTTATGT TGAAAATTCAAACCTTGAGTCCGGGCAT GGT 1351 3772842 9 RBFOX3 TGCCGACCCGTACCATCACACCATCGGG 0.004426107 0.006930221 4.64E−06 CCCGCGGCGACCTACAGCATTGGAAC 1862 3775861 9 TYMS CTCTGCCAGTTCTATGTGGTGAACAGTG 0.003071703 0.008057605 3.71E−06 AGCTGTCCTGCCAGCTGTACCAGAGATC GGGAGACATGGGCCTCGGTGTGCCTTTC AACATCGCCAGCTACGCCCTGCTCACGT ACATGATTGCGCACATCACGGGCCTGAA 1836 3775862 9 TYMS GGAGATGCACATAACCTGAATCACA 1.38E−05 0.009694831 4.94E−06 TCGAGCCACTGAAAATT 1754 3778001 9 KIAA0802 GGACCGCGCTAATAAAAACTGCCGAATC 2.89E−05 0.0068828 3.01E−06 CTGCAGTACCGTCTTCGGAAAGCCGAGC AGAAAAGCCTGAAAGTGGCTGAGACGG GTCAGGTGGATGGTGAGCTTATTCGAAG CCTGGAGCAGGA 1295 3778069 9 KIAA0802 TCTCCAGGCCCGAGAGACCAGCAAACCG 0.000663296 0.006827917 4.67E−06 TCGCCCTCCGTCCCGTTGGGCCCCACATT CCCCCACTGCCTCACAGCCTCAGTCACC CGGAGACCCGACGTCCTTGGAGGAGCAT G 1540 3779045 5 FAM38B GTTTGTTGAAAAGACGCCTCCCAGACTC 8.85E−06 0.006719053 3.01E−06 TTCACTCACGAAGTGTG1TACAAAAACT CTCCCGGCAACTGTCCTGACCCTCACCA ATCACGCTACAG  661 3782809 1 AGGGTAGAATAACATGGAAAGCAGCTTT 0.020732462 0.009591141 7.34E−06 TATTCACTCCAAGGACAGCTAA 1061 3784854 4 FHOD3 GGGCAGTAGGGTCTTGTGATTCCAAGTC 0.00010346 0.009326947 5.90E−06 ATGTTCTATGGGCCCCACCATCCAGGAA TGCAAGCAGATGAGGGCAGGCAGCAGC CAACTGGCTGCTTCGGGCTCATAGCCCA GAACCCAACAGGAAGTGTTGAGTGGTGG CCTGCCCTAGGACCGACTCCATGGGTGT GTAACGAGTGTAGTTGCACAGGGCCCCA TATGCAGAAGGGGGCTCTGCACTTGGAA TTTAATGCTATGTGGCTATAGTCCTGAAA TTCTTAATTTTATTTTTGAAGTTGTGTCTT TTAAGCAAAGGCCAACGGGACAGTG 1665 3784859 9 FHOD3 AGAAGCACAGCATCATCCTAAGGACGCA 0.024456705 0.007280018 5.36E−06 GCTGTC 1740 3787462 8 ZBTB7C TCTGCCAATGTGAGAAGAGTCAGGAACA 0.002951948 0.006763521 4.40E−07 GGATTTAGAATATGGGCAACCTTGGTTC CT  986 3787934 6 ATAATCATATTATCTAAGGCAGAAGTGG 0.001628328 0.015025107 1.58E−05 TGGTTACTTGGCAAGAATACGATTTCTTT TAATG  314 3788043 1 TGGGAACCAAAGAGACTAGAACCTGCCA 0.001628328 0.011501453 7.55E−06 TTTTGTCTCATGCAAGTAGCCCATCCTGC ACTGTCCCGGGAAGCCCCACAGCCCGGA TGGCCCTCAGGGGAGCCTCGCGGCCCTT CACCGTCGCGGGAAAAGCCAAGTTGGTG GCAGGAGGAGCCCACCACCAAGGCGAT CTCACTGCGGAAAAACTCGACCCTCCGC CTTCACGTCTAGGGCGGCAGGTGGTAGA GCTGGGCCTCTCAGGCCCATGCCCGAGG GCAGGCGAGACAAGGAGCGCCCCCAAG TGGCCATGCGGTGTCCTCACGGAAGGCA GGGAGGGCGTCACGGGCCTTGGGGACCT TGACACAACCTGGAGCACGAGGCTGAGA AACCCACCACGCAGGCCAGCTGGAGGCT GCCGCCCAGCCGGGAGTCAGAAGCTGGA GCCACTGGGTGCTCCCGAAGCCAT 1431 3788695 9 DCC TCCACTCTGGAGAGGTCGCTGGCTGCAC 0.000802243 0.007942304 3.46E−06 GCCGAGCCCCCCGGGCCAAGCTCATGAT TCCCATGGATGCCCAGTCCAACAATCCT  709 3790001 4 NEDD4L CAGAACAAGTGCATCTGCTGGCAGCCAG 0.002951948 0.008086304 6.49E−06 CTTAAGGAGTTAGCAGCCCTCAATTCCA ATAACGAACGTGTAAATCAGAATTC  623 3791665 5 BCL2 GTCAGAGCGAATGGGGCCACATCAACAG 0.007675909 0.012378141 1.24E−05 AAAGAAGACCCTGTGACCATGGAGAAA CCACCAGTCACAGGACCTTCCCCATCAC CCCCGCCCCCGCCGCCCTGGGCACTGTG CAAGGCTGGATCCCAC  260 3794316 5 ZNF516 GGCCAAGCCTAAGTCCGTCCCTCTCCGC 1.63E−06 0.017848595 1.49E−05 CCACGGGCTTCTCCGAGGCCATCTCCGA AACGCCCTGCAGCTGCTGGCAGAGCCCG CATGGGCCCCTATGTGGCCCCTGGACAG ACCGACGGCACTCCTGG 1612 3794399 1 TCTGATGCTAGAGAACGAGAACCGCAGT 5.57E−05 0.007036327 2.08E−06 GCGTGCCCGACACAAAGGGAAGGACAG GGGACACTGGAACAGGGGAGACGACAT GGAAGAAATCTGGGGGAGCCAAAAGCC GCCATGCCGAGAAGGGGGTCGGAGGAG GCGCGGGAGAGAAAAGCCCAGGGCTGT ACACTCGCATCCCTCTG  918 3795871 5 TYMS GGCCCGTGATGTGCGCAATCATGTACGT 0.000413384 0.009451406 6.52E−06 GAGCAGGGCGTAGCTGGCGATGTTGAAA GGCACACCGAGGCCCATGTCTCCCGATC TCTGGTACAGCTGGCAGGACAGCTCACT GTTCACCACATAGAACTGGCAGAGGGCA TGGCATGGAGGCAGCGCCATCAGAGGA AGATCTGAGGAACCAGCAGAGGAAGAT AAGGAGGGATGGTGGTTTGAAAGACCAC AGCTAAAGGCAAAGTAAAACAGGAGAG AAACAGAAGCCAACTCATATGGTGGAGA CCAGGAGAGAGAGCCACTGGGCTGCAGT GATGTCCATAACAGCCTCTGCAGCGATG GCACGGAGCTGAGGGAGACTATCCATCG GTGCAAGGTTTCTG  666 3797622 9 LAMA1 TTTCTAACGGGAAAGCGGCCGTGCAGCG 0.000132342 0.012744611 1.54E−05 CAGCTCCAGATTTCTAAAAGAAGGCAAC AACCTCAGCAGGAAGCTTCC 1521 3798448 7 RAB31 GGGGCACAGCCCTTATTGTTAGCTAAAA 0.017588173 0.01180553 1.14E−05 GTTAGTTTCGGGCCTTCAACCTTTTAGTC TGCAAGGTAACGTCATATTCAACTGCCT AATGTGCCGTTTTTAACCATAAAATGGC AAGTCAATTATGTGGCAATGTAAAATGC TTGCACAACTCCACTGTCATTCTCAGAG ATTTCCATTGGGAAGCCATGCCTACTTTA TATTAACACATGGCTAGGGGCCAAACTC AGCCAGTGAAATGGATTACATATCGGAG TAACACATATACAATCATATTTACACAG ATACACACTCATGCCACACACGAAAGAA AAAAAAAAGGGAGAAGGAACAAATTTT GGAAAACGATGCCAAGGATGCTACACTA CATGAAACTACATGACTTTTTTTAGCAAC AGTAATTTCCAGGCCTTTACATAATATTA CATGGTTATGGTTCAATTATTAGACAGC CAGGAAGTAATCCCGAGCCAAAACAAA GGAAGGTTGTAAAGCCTCATTGTAGACA AGGCCTGAGCATCCACAGAGAAGATACA ATGTTTATGTGAATCCTGGTGTGCCCAA GTGTGATCTACTCTCTTCACTGACTACTC TGAGTGCTGATGAGAATATATATATTAT CCTCTGACTGGCTTGAATAGCTAAGACA ATACAGAAAGGTAACAGAGTGGTTTCAC ACCCTCATGTGCTTCTGAAATAAAACCA TGGGCTCATTAGTGGGTAGCTCACTATCT GTGGCAAAGACTAGACATTTTATGCAAA ACACAACCACTGCAAACCCAGCCCAAAG ATGCAAAACTCTCAGCTAGGATACTTAC CCCTCAGCTAAAAAACCTGAACAGCTAT CTAGAGATAAACCCAGGTTCTCAGGGAA AACTGGATGAGGAAAGGTTACAAAATA AGCCTGCAACTCAGCTGGAAAGAGGTCA CTTCAATTTTCAACTCATTTTTTTTTTTTT TTTTTTACCTTTGGCAAGGGGTATGATCA TTTCTTGGCCTGCAAGCACAATCATGCC AACCATTAATGTGGACAATGTGGAAAAA ACCCTAAAAATCCCTGCAAAGCCCCTGT CAAGACATCCAAATGCCGCTTGCTAACA GTTTTTGAGGTACCTATTTGGGAGAGCC AAGTGGAACTCTTGAAGCAAAATAAGTG TTTCCCAGCCTTCACATCCTAACACTGTC AATGAACTCTCTTAAGTTGAGTGAAGTG GAAGCGTGCTGAGTTACTGAAGTGCCAG GTCTTTAATCCAATCAGCTCACAACCTCT TTCCTGACTTTTGCGATATAGATTGTCAA TAAAGGTTAGCCGTCCCTTGAATGCTCA TGGCAAAGAAGGTACCAGCTGGCCCTGG CTAGCACACAGCATGATTAACCATTTCT GAGCACCAATCCTAATGTCCTTTAAGAA TCACCCCCTAATATAAGCCCTGGCAGGA AATCAGCTGCTTCTTGATCCCAACTTTTT ATGAAAGTTAGAATGGTAATAGAATTTG AATTTTCAGTAGGAATCAGTTCTCTTCCT TTCCATGCTTTTTCTTCCTTGACTTCCTTT GGATTCAAACATCTTTAATTGAGCAGAC AGGGAATCTGAAAAGGAAGGTTTTCATC GGAGCCCATTCTCAGTTCCTTGGCATTCT AGGGTCAGACCTC  274 3799752 8 C18orf1 GATGCCGCTGGACTTCCTGGCAGAAGCA 0.022526284 0.009387286 1.00E−05 TGGAGGGTCGCTGGCACTCTAGGTCCAG CTATGCCCATG 1844 3799904 5 C18orf1 GCACGTGAGGGTACATCCAGTCTTCTAC 1.71E−05 0.007083003 2.77E−06 CAGCTAATACGTCAGAGACCACATAATG TTAGGCTGGAAGAGACCCTAAAGGTTAT ATAAACCAATTCCCTTATTTTAGAGCTGA GAAATTTCAGGTGCAAAGAAGGGAGAG GCTATAACATGGTGGCACTAGAATAAGA CTGCCGGGTTTGAATCCTGGTGCAACTA CTTATTACCTGTGTGATCTTGGGAAAGTG ACTTAACCTTTCTGGGTCACAGTTTGGAT ACCTATA 1664 3800020 5 C18orf1 CTCAAAGTGTGGTTGCTAGAACAGCAGC 0.035784134 0.007025272 3.31E−06 ATCAGCATCACCTGGGAACCTGTTAGAA ATGCAAATTTTCAGGTCCACCCAGATCT ACTGGGAGCTCTGGGCATGAGGCCAGCA GTCTGGGTTTTACAGAGCCATCTAGGAG ATTCTGATGTATGTTAGAGTTTGAGAAC CCTCTGACCCAAGGAAGCGGTGGTGTTT CAAGAGTGGAAACCTCCAAAAAGAAAA TGAATAAACATATAATATTTTCATATTGC CAGCTTCCTAGGCAATCTGATTT 1187 3802335 1 TCCACCACAATTTGGCCGGTCCAGAGAC 0.002298587 0.007497642 2.52E−06 TGCTGGCATCATTAACTCAGAAACTCAG AGATACAAACGCTCTACTTATCTTGCCG GGCCCTCAGCCAGAAGTCTCCTATAACT CTGCGGATGTTTATACATGCCCTCTGCTT C  659 3803102 1 TGGAGGGGACCGTATCCTAACTATATTA 9.78E−06 0.012949041 5.98E−06 ACTTCCAATTTTCATCGAAAGCCCACCTG TCTAAGAAGAGCTCCTAGACATTCCCTTT CCCCTTCAACTTGGAGGAATTGGGAATG ACAAAGAGAAATTAATCAAAAGAAGAA TTAATCTCTCCAATCAGCCTTGGCATTTT CTTTCTATCTTTGATATGTTGTTTTTTACA GTGTCTTGGTTTTCAGAATAAGCTGTTTG TAACTACTTCCTCCACTATATTGTGAGCC TCTGGAGG  657 3803770 5 DTNA TCATCCATTCCACTAGACGCCTTAAAAA 0.000264928 0.011040738 1.09E−05 AGATAACCTCTGGCCGTGGAGAGATTTG CTTAGAAGTT 1159 3809977 5 NEDD4L GTCCGCGCATCTTTACCGATGCATCTCCA 0.004913892 0.007014438 2.16E−06 CTCATATCAGTCCTCACTC  527 3810024 5 NEDD4L TGACTGTACAGATGGCGAGGCCATCACG 0.000151311 0.010952355 3.58E−06 GAGACAGATGATTCCAGAGAAAGAACA GTTTCTGATATTTTGACATTCCAGGCCAA GAAACTATGTAAGGACAAACAAAAGAT CCTGAATTATACGGCCCCACTAGTGGGT GAAGTCTCACTTCAAGAACATGATGGCT TGACTACATATGCAATAATAAGAGAAGA TGAAATCACACTCCAGAGAGCCAGTACA CCACCGTGGAAGAAAGATATTTG  462 3810026 5 NEDD4L ATGACACCCACAAGTGCACGAAAAAGCT 0.002571681 0.008565392 4.49E−06 A  328 3810046 5 NEDD4L CCTCTGCTGATACCGGGGGAATACCAGC 0.001233477 0.010318079 8.37E−06 AAGTTTTAACACAACTGAGAAGGAATGC GCCCAGCTCGCTACTTATACTGATGATTC  249 3810508 1 CCCTGGCTCTAACAGGTTTGGGAGCCAG 0.024859934 0.011192154 5.93E−06 TTACCTTTCCCAGTTCATTAACCGACTGG CCTTCGCATTAACAGCCCCTCCATCGGG GGTTGCCTTGGAGAC  538 3811176 7 KIAA1468 TGCTGTCTTTCCTCAGGTAAGTCCATTAT 6.13E−05 0.012391652 3.65E−06 ATGCATCTAAGTGCTGGGGAGGTTTAAA TAGCACTTAAAGAATATTCATGAGAGTT CTGAAATGAAGGTTTCGTCTTTAGCTATT GACTGTAGGATTTGTAATTCAAATCATC ACAGCATCCTAAAGAAATACTGTGTGAA TGGAATGCACACAATTCCTACAGAACAC ACAAACTGATGTCCAAAAGGCACAGAGT AATGCTGGTGGCTCTTTCTAGTCAGTTAA GAAACAATAAAAAGTCTGCATTATTCTT TCATAATTTAAATACTTAAGTAATCTCCA CTTTATTATTTTATAACAATGACTTCAAA TTTACATTATTTTAAGTACCATTGTAATA GCTTAGTGTA 1296 3816342 9 SF3A2 CACCTGGGCTCCTATGAATGCAAACTCT 0.002514771 0.007861145 2.79E−06 GCCTGACACTTCACAACAATGAG  605 3816537 5 AC092068.1; CTGCTTGCATGCTAGGAGCTCCCTCCCCA 0.001119544 0.006736721 5.36E−06 GNG7 GCAAGGCCCGGGCCAGAGAGAGAAGGA ACAGCCCAGAGCCAGGAGAAAAGGGAG AGTGAGGCTTTTTATTGTGTATGAATTCA CGTGGTATCGACAACTCCACACAATATT AAAACACTGCGAGAAAGTGGGTGCGGC ACACCTGGAATTTTAAAAAAGTCAGAAA TAAAAACAACCAGACATCCCAATGCAGA TGGCATAGAACCTGCTAGAACCACAGGC GGCGGCTGGAAACAGGAGACAGGTCTTT ACGAAGGTTAGATGGGCAGCGGTTCCGT GGACAGAGGAGGAGGCGCGGCTGGCCG GCATATGGCTTCTGTGCAGAGGGCCTGG CCTCAGGCCGTGGACTTTTTAATAAGTG ACCCCTTGAGGAAGGGCGTGGTGGCTCC ACCTCCACCCGGAAGCCCCCCCGGGTCA CTCACGGGCGGACAGGTGTGTGACGGCC CTCTCCTACCTGCCCCAGAACTTGGGCA GGACGGGCTGTTAACTTGGAGATGGATG CGTGGCCTGGAGGCCTAGCGTTGCGCCT CGGACACGGTGGCCGGCCCGTCAAAGGG ACCACGCAGAAGGAGGGAAACAGGAGC ACCTTCCGCCCTGGCCCAGCCGCCCCGTT TATGTCCCCAGAGGCCAGAGGTCGCAGC TGAGCTATCTGTGCTTGGCCTGGGGTTAC CCCTGGGGAGGGTGGGAGAGGGGTGAG GGTTCTGGCTCCTTCCTGGAGAGAGGAG GGCAGGGGAGGCGGAGCTGGTCCGGGA AGGTGCCCAGGTGGGTCACAACAGGGTC GGGGCCTGGCCCGCTGTGGCCCTTCACC TGGCTACTGGTGTCTCGCTCAG 1513 3817492 7 SH3GL1 CAGGAGACCATGTTCTCTGTCCTCAGGC 0.002242228 0.008418791 8.39E−06 AGATCCCAGCTGGCCTCTGTCCCCGGGC TGCAAGCTGACAGCAGGCCCGGGAGGC GGTGAGGCCCTCTGCCCTGGCCTTGAGG AGAAGGAGTGCGTGTGTGAGGCGGGGG TGCATTGGCCCTGGAGTAGGGCCAGGGC CCATCACCAGCACCAGGCTGGGAGGGAT TTAAAACCAGGGTCCTATCTCTGAGCCA CCCCATGGGGACCCTCGATCCCATCCTG TTA 1494 3818943 9 PNPLA6 TGAGCTCTACGAGAAGGTTTTCTCCAGG 4.60E−05 0.008429176 4.84E−06 CGCGCGGACCGGCACAGCGACTTCTCCC GCTTGGCGAGGGTGCTCACGGGGAACAC CATTGCCCTTGTGCTAGGCGGGG 1088 3819244 5 AC010336.1 AGGAGGCGTGGCTATGGAAGAGGGCGT 0.0207709 0.007382382 4.02E−06 CTCCGGAGGGGGCGTGGTCAATGGCGAA GGT 1614 3819416 4 LASS4 CTTCAGGGCAGAGATGTTGCTTGTTTTCC 0.002453518 0.006618225 3.85E−06 CCACCATTTTGTGTCTTCAGCACCCAAAT ACTAAATGAGCATTCTAGGCAGAGGCCA GTATTTGTAAAGGCTAGGATGTGTGAAA CGATATGGTCTGGTGGGAGCAGAGTATC AGTCAGTAAACTGGTGGGCATTGAAGCT GGGCACATCAGCAGAGGCAAGGCTTGA GATTGTGAGAAGCCATTGCTCCTGTGGT TCTCCCTCATCCCCTACACTCATCATGAC TTGAATGTACCAAGGTGTGCAAGGATGC ATCCAAGACCCTTGGGTGAGGGGAAAAC ATGGAGCTGGGGGTCTGGATGCCTGGGC CTTCCTAGGACACCTAGTCCCCTTCCATC TGCACCTTGGGGTCTGTC 1515 3819433 9 LASS4 TACGAGTCCATCAGCAACAGGGGCCCCT 0.000142286 0.007928883 2.25E−06 TCTTCGGCTACTACTTCTTCAACGGGCTT CTGATGTTGCTGCAGCTGCTGCACGTGTT CTGGTCTTGCCTCATTCTGCGCATGCTCT ATAGCTTCATGAAGAAGGGCC  631 3820347 9 PPAN- GTTCGTAAGAAGAACTCGCTGAAGGACT 0.004924341 0.010289222 1.17E−05 P2RY11; GCGTGGCAGTGGCTGGGCCCCTCGGGGT PPAN CACACACTITCTGATCCTGAG 1677 3821267 2 CNN1 ACGCCGTGAAAGTGTGGGAGATCCTGAA 0.00140662 0.006567496 3.81E−06 GACAGAGGGGGACGGTGAAAGGCAGGA AGCGGGCATCAGAAGTGCGGCAGGGGT CTCCTGACTGTGGAGCTAGGAAGATACC TGGACACCACCTTCATGCTATGGTTGGG TAAACTGAGGTTCGGAGAGGAGAGGCA AATAGCTGGGGTCCCA  681 3822704 9 CD97 TGCTGGTTGGACTTTGAGCAGGGCTTCCT 2.74E−06 0.013772023 4.92E−06 CTGGAGCTTCTTGGGACCTGTGACCTTCA TCATTTT 1328 3823462 4 AC020911.1 ATGACCTCCGGCTTCCTGCGGGGCTCCA 0.032789863 0.006785128 6.44E−06 TGTGGTCTGGACAGACACGGAAGCACAG CAGCGTGAGCGCCAGGACCACCTTCATC TCAGCCATTGCAAACGCCTGCCCAATGC AGTTCCTG  998 3824263 7 PLVAP GCGGAGGTGAATGGCTTCCTGTTCTCAC 2.71E−05 0.013076432 1.57E−05 CTCCGGGTCCAGGCACTGGGGGTGAGGA AGTGGCTGGGAGGCCAGGAGGCTGGAG GAGGGGAGGTGCTGGGGCCCAGGGCTGT GCGGGAGGGGATGGGATCCTGTGGGTAC CTTGGCCCGTGTGCCAGGGTCGGGGGAA CGTGACACTAGGTGAGAATTGGGTAGAA AGTGTGTGTGAAAGGGCATGCGTGCATG TGATGTTGGTGCCATATCTATAGGTGTCG TTGTC 1874 3824338 2 FAM125A GAACCTTCGCCCTGCAAGGCGTTTGCTA 0.000385118 0.007035401 1.60E−06 TCTTCAGCCACTGGGCGGAGCTGCAGCC CTGGAGGAGGGGGCGGGTCGAGGCTGC GTGGTGATGGGGTCTCCGCCCCCACGCC CTGCCGGGCAGGGCTGGAGCTGGACAGA AGCCAGTGCCTTTAAGTCATTTGTGTCAA AACCCTCTGGGGT 1292 3824841 2 PIK3R2 GCGTCCTCAGCTGGCCGAGCATGGTGGC 0.005543059 0.007453355 8.22E−06 AGCCTGCACCCTTGGCTCCCTTGTCTGGT GCAGCCAGCAGAGCCGCCAGCCTTGGGC GCCCATGGCCCTCCGTGTGA  652 3824886 2 IFI30 GGCCGGTGAGCTGCGGAGAGCTCATGGA 4.52E−06 0.017855887 1.23E−05 AGGCGAGTGG 1377 3824888 2 IFI30 CAGATACACAAAATTCCACCCCATGATC 0.003684101 0.010168272 1.04E−05 AAGAATCCTGCTCCACTAAGAATGGTGC TAAAGTAAA 1671 3825896 5 PBX4 ATTCGGATTTAGCAACATGAAGGTCATA 4.91E−05 0.007660187 5.03E−06 GGTGACTCAGCGGAGAGGGAACAAGGT TGGGAGAGAATGTGGAGGTGAGGAGGA AGCGGAAGCAGCAATCACAAAGTCTTT 1200 3829042 7 ANKRD27 TTTGGCACATATCCAAGGCACATTAGAA 0.000124059 0.007752649 1.97E−06 AATTAGAAATCATAAATTACTTTGTAGA AAAATAATCCCTCCCTTCCTTCTGTACAT ACACAAGTATTTCCAAGAACATGGACAA AACCATTTCCCTATCACAAGGTCATTTGA AAACGGACTCAGGACAAACCCATATACG TGTAGCTCTAGGCCAATAACATAAAAAT AACAGTATAATCTATAGAAATTTATAAA AAGGAATAAATGGCAATAAATTCTAACC GAAAGTAACTCTGACCTGGTTTGTGCTG TTAAGTTTTGA 1212 3830127 5 AC020907.3 CTGCCACTGCGAGGCTTCCACCCATGCT 0.03121109 0.010360673 8.51E−06  896 3832101 8 ZNF573 AGAGGATGGGAAAGCACTATGGGGAGA 0.009627872 0.008241546 3.50E−06 CCACC  393 3832546 9 RYR1 TGTGGAGGAGATGTGTCCCGACATCCCG 1.49E−05 0.011890674 7.57E−06 GTGCTGGAGCGGCTCATGGCAGACATTG GGGGGCTGGCCGAGTCAGGTGCCCGCTA CACAGAGATGCCGCATGTCATCGAGATC ACGCTGCCCATGCTATGCAGCTACCTGC CCCGATGGTGGGAGCGCGGGCCCGAGGC ACCCCCTTCCGCCCTGCCCGCCGGCGCC CCCCCACCCTGCACAGCTGTCACCTCTG ACCACCTCAACTCCCTGCTGGGGAATAT CCTGAGAATCATCGTCAACAACCTGGG 1876 3832722 2 ACTN4 GCTTTGTCTGGCCTCACGTGTCTCAGATT 3.39E−05 0.008349225 6.66E−06 T  968 3832980 4 ZFP36 CCGCTCAGACCAGCTTGGTGATTTGGAG 0.004114217 0.010049579 4.54E−06 GTGAAAATGGAACCCGCGACACCCGGCT CTTCGCTCAAACATGGGTGGGGCGGCCC ATGCAAGTGGAAAGTCGGAGAACTTTTC TCAGACCGAGGCTGCCTG 1284 3833496 7 BLVRB TGCAAGGCCTCAGAGTCTCGGCACGCGC 0.03685538 0.006962699 6.88E−06 GGGAACCCACTGGCTGC  443 3833552 9 SPTBN4 ACGTGTCATCAGTGGAGGTGCTCATGAA 0.005040635 0.011004892 3.37E−06 CTACCACCAGGGCCTGAAGACTGAGCTG GAGGCGCGGGTGCCTGAGCTGACCACCT GCCAGGAGCTGGGGCGATCTCTGCTGCT CAACAAAAGTGCCATGGCTGATGAG  853 3834543 9 ARHGEF1 GCTTACTGGGCGCTGGTGGGTGGGTGCA 0.018924879 0.0080258 3.50E−06 GGGTCACCGCTGCCATCTGTGCCTGCCT GTCCCAGGCTCTTGCTCCCCATGCTCCTC TGCTGCTCTCTGGGTCTGGCCATTCCTCT CCCT 1943 3835890 2 APOE CGCGCAGCCTGCAGCGGGAGACCCTGTC 0.000524526 0.007074782 5.65E−06 CCCGCCCCAGCCGTCCTCCTGGGGTGGA CCCTAGTTTAATAAAGATTCACCAAGT 1832 3837064 2 GRLF1 CCGGAACATCGTCTAGCTGGTGTTAGGA 0.002080741 0.007511443 5.05E−06 ATGTTTGCTTAATTTCCAGACTTTTTTTT AAAAACACATCGTGGGTTTTTTGAGGCT CCAACCTGATTAGTGCATGGTCAGCCCT CAATGAAGGCTGAGGCATCTCTGACTGA GGTGTTTTTGTTTGGTTTTGTTTTTTAAA ATCATGTATTTGCTACAAAGTATTTGTACT TGTCTCAATGGGAATGGTGTAAAAAACA AAAGGCCTTATGTGATCTGTATC  600 3837159 9 SAE1 GAATTGTTGAGAGGGTTTATGCCCAGAG 0.004749446 0.010789705 3.01E−06 ACATCCCAGAAGCACTGAACGCACTCAT GCCAAGATGTTAATACCTTTCCTCACTAA A  310 3837244 1 GCTTGGAGCAAAGGACAAATGTCTCTGG 5.29E−05 0.013243168 9.18E−06 GGAGAAGCAGAGTGTCTGCCCTCGTT ACAGCACAGGAGACAAGAGGAGGGGTG GGGTGATATAGGACAATAGCTGGGGTTC TGGGAATTGCTGTTGGTGTAATTATCATG TCAGGGACAGAGGCTGAATCACCCAGGG ATCTCAGTTGGCTGCCGAGAGGGAACGA TGCTGGCCCACTTCCTGGGGTCAGAGAG ATGAGAGTGGATGGCGGCGGCGGTGGTG TTGCTTCTCAGCCTGTCTGGAAATCTCAG AGCCAATGACCAAAGCGCTGTGCTGCCT TG  610 3837791 2 GRIN2D CTTTTTAACGTCACCAGATGGGGCGGGA 0.001921299 0.009458325 6.40E−06 GGTGGGGGGTTCACGCCACTCCCGCGTC CCACCTCCACGCCCGGGGCCGTGGCCCC CACATCACTGTGCAGCTCCCCGGCCCCA GCCGCGCCTCCGGGGAAGCCCGTTTTTA ACCTTTCATCCATTGGGACTCAAAACTGT GAGACGCGTTCGCCAAACTGTGACCCCA GACCTTGGCCCCGCCACACAGAAACCCC TGACCCAGACTGTGACATCCGACTCCTA AAATGGTCATCCGACTCCAGACTGTGAC CCCTGACCCCAAACTGTGACCCGAACCC CAGACTGTGCCCCGACCAGACTGTGACC CTTGACATCAAACCGTGACACCCCCTCC TCCTCTTCCACCCTCGGTCGCTTTTCCCT ACTCTGACCTAGGACACGTCCCCAACGG AAGCCCCGCCTTCCCTTGCACCGCGATG AACCCAACCTCCCTGAAGCCAAAACTTC CCACCCTGCCGCACCTCCGGACCACCCC ACTTGCCACCAAGCACATCCTCTCCAAA TCCAACCCTTATTTGCGACCCTTCAGTGA 1271 3837819 1 CTGGCTTAGTGAAAGGGGCCTCATCCCT 0.030881616 0.00909433 3.40E−06 GACCCCCACCAGCTTATGAAGGCTTCAT CTCAGGGAACTCTGGACCCCCCATTTCTC CCTCCGTCCATCTCCCCTTTATCACGTTT CTTTCTTTCTTCTCTGTGTCCCCCTCTTTC AGAGTCTCCCGTCCCCCACTGCCAGTCTC CCTGCCCCCTAGTCGCTGTCTCGCTCCTC CGCCGCTGTCTCCTGTCCAGCCTGCCTGG GCTGTGGCCCAGCCGCTCTGCCTGGCTG GCCTCCCTGGCTCCCCCTCTGCGGCTCTG AGCTAGCCCCACCCCCGGCCCCCCTCCA TCCAGCCTCTGATCCATCTGTGGACTCCG AGGTCGGGTGCCCGTCACACGGCCCCTG GGACCAAGGACAGACTACAGCCCCTCAG CACCCACAGAGGCTTCCCCTCAGCCCTA GCCGAGGAGCCCCCAGCGGAGGGCATG GGGGTGGGCCGCCCCAACAGGTACGTGC CTCCATGCAAGGCACCGCTGAGCCATCC CCTCCTGCTCTGCTGCGTCGCCCCCATCC ACCCCTGCCCCAGCATCCCTGTCCTCAGC TTGTCCCCTTCAAGAAGGCCTTGTCTTCC CATCAGTGACAGGCTCAGCGCCAGGAGA ATCCACCCCCAGGTTCAGTGCCTCCAAC TCTCACCCCATCCCCATTTTATGCATTTT CTCACTGGCTTCCATCCTTTCAGAGAAAC CCTCTCAGTCTGTCTGTCTCTGTCTCTGT CTCTCTCCCCCATCTCTGTCTCTCCCATC TCTCTCTGCCTCTCTCTGTCTTCACAATTT CATCTCCCCATGTCGCCATTTCTTAAAAC ATTTCTTTTCTCCTTTTCGTTTTCCCAATT GCCCTGTCCGCCTCTATCTTCTCTGTCCC CCTCCATCTAGGTCTCTGTCCCCCCCTCT CTCTGGGTCTCTGTCCCCCTCTGTCTCTG AGTCTCTATCCTCTCAAGGTCTCTGTTCC CCTCTCTCTGGGTCTCTGTCCTCTCTCAA GGTCTCTGTCCCTTTCTCTCTGGATCAAT GTCCCTTTCCTGCTGCCCTCTCTGGGTCT CTGTCCCCCTCTCTCTCAGGGTCCCTGTC CTGCTTGGTCCCTGTACTTTTTCTTGGGG CACCCTCTCAACACCCCTCCTCCTGCCTA TCTCTGCATCTCTTTGTCTTTCTGTAGTCT CTGCTTTCCAACCTGCTGTCCAGCCCCCA CCAGTAGGTGGGGAGTGGTGGGGAACA CCCCTGGTTTCGGAAGAGTGAGAGTGTT GATTTGGGAGGGTGAGGGTGGGGCCTGG GGGCGGGGCTTCTTGGCCTCAGATTAGA CAGTGACTTTGACACGAAGTTGAAGCAC CTTAAGCCCTGTATC  995 3840810 2 ZNF765 GGCATAATTCGCACCTGGCACAACATCC 2.12E−05 0.009499038 5.84E−06 TAGAATTCACATTGGAGAGAAAGCTTAC AAGTATAATGAATGTGACAGGTCTTTAG TGGGCAGTCAACACTTGTTTACCATCAG GCAATCCATGGTGTAGGGAAACTTTACT TATGTAATGATTGTCACAAAGTCTTCAGT TACACTACAACCATTGCGAATCATTGGA GAATCCATAATGAAGAGAGATCATACTA GTTTAAT  188 3841985 4 EPS8L1 GGAGACGAAAACAAAGCAGTGAGGCTG 0.007398176 0.018336943 1.47E−05 GAGGAGACAAAGGGGGGTCTGGGTGAG GGCCCGAGCAGAGGGTCTCAGCAGGGA CAGCGTGCTGGGAGCTGCCGGCCCCACA CAGGGGGTGCCGCGGCCCT 1352 3843632 1 TACAAAAGGATCAGCCCATGACAGCAGC 0.012019459 0.006787939 6.05E−06 TGAACAACACTTAACAGGACAAAAGGA AAATAAAAATGCCAGACAAGATATACA GTGGAGGGATGCACATACAAAGAGTTGG GAAAAAGGAAAAATAATTACATGGGGA AGAGGATTTGCTTCTGTCTCTCCAAGTGA CAATCAGGTGCCTCTGTGGGTGCCCACC AAACATCTGAAGGTCTATCATGAGCCAC ACCAGGAAGAGAGGACTCTGGGAAGAG CCAGAACTCCCTATACGAGTGATGGCAT GAATGAAAATCTCAGAGACAAAGGAAA AGACCAAGAATACTCACCAGGCAGACCC TCCAACATGGGGACA 1789 3844578 4 SHC2 CCCGGACTCTTGGAACTGCGTTTCTTCCC 0.002420691 0.006584521 3.73E−06 TCTCACCCATCCTGACCCTAAGAAGCTG AGAGAATCTGTGCCCCTCTTGGTAGACT GGGAAGGCGGGGGAGAAGCCCCTCTGC CCTCGTCACCCAGCAAGGGCTAGTGCAG CCTCACGTTCATGTGGATTCACAGCCAG ACCCTGTTCCAAGGCAGAGGCAGTCTGG TCAGGACCTGGCAGAATACACATGGGGT CCAGGCAGCTCCCGAGGGAGATGCCCCA AGGTTACCTGCGATGCTGTTCCGGTTTGA ACCATGTGGATAGTTTTTTTTTTTTTTTTT TGGAGACTGAGTCTCATTCTGTTGCCCA GGCTGGACTGCAATGGCACAATCTCAGC TCACTGCAATCTGTGCGTCCTGAATTCAA GTGATTCTCATGCCTCAGCCTCCCAAATA GCTGGGATTGCAGGCGCCCACCACCACG CCTAGCTAATTTTTGCATTTTTAGTAGAG ACGGGGITTCACCATGTTGGCCAGGCTG GTCTCGAACTCCTGACCTCAAATGATTC ACCCACCTCGGCCTCCCAAAGTGCTGGG ATTACAGGCGTGAGCCACCACGCCCGGC CCCATGTAAACACTTTACACGTTCAAAA TACAATTAAAAAAAGAAAGGAAGGAAA ATCCTGAAATAGAACTGAGTCAGAATAA GTGACCCTCCGTGCGTCATGTTGATAGC  852 3844980 9 SBNO2 CCCACAAGGGCTCAGTGGGCCCAAACCC 0.009627872 0.008088964 6.05E−06 TTGAAATCCGTGAAACCGGGTGGTCCCA AGAGCTAGAAACTCAGGAAACCCCAGGT GCTCAGGGCCCCGCGTCTCGGGGGCTCC GTGGGGCAGACCCCTGCTAATATATGCA  564 3847993 4 CD70 AAATGTTCTTGGTTAGGGATGTTTGAAG 0.019681587 0.007379819 3.29E−07 AATAGAGGAAGTGGGCTGGGCACAGTG GCTCATGCCTGTAATCCCAGCACTTTGG GAGGCTGAGGAAGGCAGATCGCTTGAGC CTAGGAGTTCAAGACCAGCCTGGGCAAC ATAGTGAGACCCCCATCTCTACAAAAAA TACAAAAATTAACCAGATGTAGTGGTGT GCTAGTCCAAGCTACTCCAAAGGCTGAA GTGGGAGATTGGGTAGAGCCCA 1373 3850013 9 COL5A3 TTGCTGATCACCTTGCGGGGACAGCCAG 0.034258318 0.006866394 6.03E−06 CCAATCAGTCTGTCCTGCTGTCCATTTAT GATGAAAGGGGTGCCCGGCAGTTGGGCC TGGCACTGGGGCCAGCGCTGGGTCTCCT AGGTGACC 1935 3850053 4 EIF3G GAGGCTCTTCTTCCCCAGGGCTAACCTA 3.34E−05 0.006523882 3.13E−06 GAGGAATTGGAAAACCGTGCTCCCGGAC TTTGTGTTTAGAGATG 1641 3850436 9 KRI1 GAGACATCGTCGCAAAGTTATGTGGAGG 6.18E−06 0.009498748 5.51E−06 AACA  523 3850559 4 TMED1 TGAGTTCAGTCTTGATGCCTGCCTGGGTT 0.001219026 0.011207839 1.11E−05 CAGTTACAGCCCTGCCCTTCCCAGGCGG CCTCAGGTTACCGCCCTGACTGCCCCGCT GAGTCGGCTGGC  785 3851376 1 CTGGAAGCCTCTTACAGTGCTGGTACAA 0.008812862 0.010323631 5.63E−06 ACTAGAATACACAAAGGAAGGGATCATT TTATACGTGTTACTGTGCTACTTGCTCTA TCTACTTAGTGTTCCATACATGTAATTAC CTATTCCATCCTATCCCAAAGTACTGAA AATCTCCATTCTACTTTCTCTGTCTGTGA ATTTGACTATTCATAGAGAGAGAGATAT GTGGAAGTATGCATGTGTCCTTCCATGTC TGGCTTATTTCACTTAGAACGTTTTCAAG GTTTATCCATGTGGTAGCATGTATCAGG AACTCATTGTTTTTGTGTCTGAATAAATT TCCACTGTATGGTTAAAGCATACTTTGTT TATCCATTTTTATGTTGATAAACATGGGT TGTTTCCACAGTAATAATTTGACTGCTAT CAATAAGGCTGCTGTGGATGTGGTATGT CTATGTCTGTGTGAGTCCCTGCTTTCAAT TCTTTTGGATATATGTATCCCTAGGAGTG TAATTGCTGGTTCACAGAATAATTGGTG TAAACCTTTTTCAGGAACAGGTATATTG CTTTACAAAGTGGCTACAATGTTTTACAT TCTCTCCAGCAATGCATAAGGGTTTCTA 1416 3851726 9 HOOK2 TGGACTTTGAGAAAAGCCGAAGTCAGCG 4.98E−05 0.008114691 5.42E−06 GGAGCAGGAAGAAAAGCTGCTCATCAGT GCCTG  105 3852452 9 RFX1 AGCCCCAATATGTCACCGAGCTGCAGAG 0.000124394 0.017123737 1.54E−05 CCCCCAGCCCCAGGCACAGCCACCGGGT GGCCAGAAGCAGTACGTGACGGAGCTCC CGGCTGTACC  819 3852796 4 DNAJB1 CCGCCTTTTGACAGACAGGGAAACTGAG 0.002849134 0.00888026 4.00E−06 GCACGCTGGCCCCTCTCGGCGGCCCCCC GGGAAGGACGCCCCGGGCCGTGGGGCC GAGCTGCCCCGCCCTCCGGCCTCGCGGG CCTCCGCCCTCGGATTGGCGGCCGCGCG GTGGGAGGAGGAGCCTTGGCCCAGCCGC TCGGCCAGAAGCTTCTAGCATGTCTGGG GCTGCCCCTCCCCGGGCGCCTCCTCCCGC GGCCCCGAGCAGCCCCGGGGTGCGGTGC ATGGGGGTGGGGGAGCCGGGGGTGACG ACGGGGACGGCGCGGCGGAGCCCGCTG CGGACCCGGGCTCACCTGGGCTCGGCCG CCGGGGTCCGCGGGGCGGCGCCTCCGGC TCAGCTGCGGGGCGAGGGGTTGTGAATG CAGGAGCCGACCCCGTTCGTGGGCTTGG GGGCTGGGTTGGGATAATTCCCGGGAAG TGATGACCTGGC 1933 3852890 9 EMR2 GGCTTCCTTGGACCTGTCTGCGCCATCTT 0.029699585 0.006995595 3.97E−06 CTC  483 3853114 2 NOTCH3 AAGTAGGCACCCTTGGGCGCACCCACTG 0.000126422 0.016671556 1.24E−05 GGGCCAGGGGTCGGGGGAGTGTTGGGA GCCTCCTCCCCACCCCACCTCCCTCACTT CACTGCATTCCAGATGGGACATGTTCCA TAGCCTTGCTGGGGAAGGGCCCACTGCC AACTCCCTCTGCCCCAGCCCCACCCTTGG CCATCTCCCTTTGGGAACTAGGGGGCTG CTGGTGGGAAATGGGAGCCAGGGCAGA TGTATGCATTCCTTTGTGTCCCTGTAAAT GTGGGACTACAAGAAGAGGAGCTGCCTG AGTGGTACTTTCTCTTCCTGGTAATCCTC TGGCCCAGCCTCATGGCAGAATAGAGGT ATTTTTAGGCTATTTTTGTAATATGGCTT CTGGTCAAAATCCCTGTGTA 1729 3853116 2 NOTCH3 ATCCTTGCCTTGCAGCGTGACCGAGATA 0.003872676 0.007830713 5.66E−06 GGTCATCAGCCCAGGGCTTCAGTCTTCCT TTATTTATAATGGGTGGGGGCTACCACC CACCCTCTCAGTCTTGTGAAGAGTCTGG GACCTCCTTCTTCCCCACTTCTCTCTTCC CTCATTCCTTTCTCTCTCCTTCTGGCCTCT CATTTCCTTACACTCTGACATGAATGAAT TATTATTATTTTTATTTTTCTTTTTTTTTTT ACATTTTGTATAGAAACAAATTCATTTA AACAAACTTATTATTATTATTTTTTACAA AATATATATATGGAGATGCTCCCTCCCC CTGTGAACCCCCCAGTGCCCCCGTGGGG CTGAGTCTGTGGGCCCATTCGGCCAAGC TGGA 1282 3854920 2 LSM4 GTTGACCGCCCTTCGAGCCCGGTGCTGA 0.020465161 0.008117307 7.33E−06 1165 3855225 9 COMP GTTACACTGCCTTCAATGGCGTGGACTTC 0.010785085 0.009827647 9.87E−06 GAGGGCACGTTCCATGTGAACACGGTCA CGGATGACGACTATGCGGGCTTCA  562 3855231 9 COMP GGATCCGCAACCAGGCCGACAACTGCCC 0.000103742 0.016123279 1.50E−05 TAGGGTACCCAACTCAGACCAGAAGGAC AGTGATGGCGATGGTATAGGGGATGCCT GT  636 3855232 9 COMP AACTGCCCGCTGGTGCGGAACCCAGACC 0.000674778 0.012020397 1.25E−05 AGCGCAACACGGACGAGGACAAGTGGG GCGATGCGTGCGACAACTGCCGGTCCCA GAAGAACGACGACCAAAAGGACACAGA CCAGGACGGCCGGGGCGATGCGTGCGAC GACGACATCGACGGCGACC 1089 3855522 4 TMEM161A CCACATCCTGATCTGAGATCCAGCACCC 0.027951183 0.008592818 4.08E−06 CAAAACCGAACTCCTCTAGGTCATCCCC AAGGCCTATTTGTGCAGCAGTGCTTGTTC CCTGGAGTTCTGGGGTCCCAGACGGAGT GTGGT  247 3856015 2 AC104523.1 CCCTCTGACTGAACAGGCGTCTGTGACC 8.64E−05 0.01488092 6.53E−06 TGGCCTCACGACCTGGGACATGCCATCC TCAGGCCACAGACACTGGACTTTGGTCA AGTACTAGCCTCCAGGTGGGGTCCTGGT GCAAGCAGACAGCAACCCCCGAGCCGTG ACTGCGGTTCTCAGTTTGGAGTTTGGTCA AACAACCAATGGGGACAGAGTCTTGGGG TCAGGTCCAGCAGGAACTGCCACCCCTC CCAGGGACAGCCTGTCTCTCCCACTCAC CATCGCTGGTGCCCACGGGCTGCTGACC ACCTGCCAAGTCCTCCTGTCCCTGGACC AGCCTCTCAGGCAGCAGGTCITACCTTT GCCTCCAGGGCACTGATCGATGGCAGCT TTGTCTCACTGTAAGGCAACCCAGACAG AGCTGAGGGCCTGTGCTGGGCCGGGAGC TGTCCTCCTCCTTCCCTAGCAGTCCTAGG GAAGGACCAGCCGTGTCTCTCCCCACCC CACCCCTGGTCTTAGCCCAGGAGACACA CAGGGAAGGTAGGAAGAGGGTCTCCCTG TGGGCTGACGCCTGTGAAGGGACAGGAC CTGGGAGAAGAGGGGTGTGTGGGTGGG GCAGGGACCACTAGGGCCCTGTAGAGCA TGGGCTTGGGCTACACAACAGGGCTGCC CCTCCTGGGCTAGAGGCAGTGCCCTCTG CAGGAGCTGAGAAAGTCCAGTCCTGAGA AAGGACGTGTATGGCCCAGGGTGGGTGA CTGGGCCCCAAAAGCAGTCCTCGAGGGA GTGACCACATTACCAGGCCAGGATC  808 3856288 6 CTCCCACGGTGCTGGTATTAGAATCATG 0.002024742 0.010085361 9.23E−06 AGCCACCGTGCCCAGCAAAAGATGATTT TAAACATTTATTTAGGTGGGTAGGCAAC ATTCTAAGATAATACCCTGGATTACCAG TCTGTTGCACACGTGCTGTGTCATACTTT CCTCTTGAGTGTAAAAAAAATGTGTGAC TGTGGTGGGAAATCACTTATGAAATTAG GTTACTCATCCGTAGACTTTGTGTTTATC AAAATGGAGATTATCCTGATTGTGCTAA ACTTAATCAGAGGTGCTTTTAAGAGAAA GAGACACATCACAGAAAAACACCCCTGC TGGCCTGAAAGTAAGTGACTTCTAGGTA GAACATGTTGTAAGCTGCTTATGGTGGC CACATGGCGGGAAAAATGTTTGTATCTT GCCATCATTTCTGCCTCCTCCATGTTGCT TCCAGTAAGGAACATAAGAGGATTCTAT GGCAGAGGGAAAAAAAAGGGAATCTCA TTCATTCAAGAAATAATCACCTCTCATCT GGGATAGCTTAAGAGAAACAGGAGACC ACAACAGGTCCACATTAATGGGAGGAAA AAGGTAACCTGGGTAAAAGTGCTCACTG GCATTATGGAACAGTATTTAGTAAGCTG TAGTGAATGATCAGCCTCTGGGATACCA ATAGTCTACCAACAAGGCTGAACTCATT  782 3857807 1 TTCCACTCAGGTTGCCGGTGATACAGAC 0.002293409 0.007008648 1.30E−06 ACTCCTTTCAGAGCCAGGAACCACTCTTT TTTTCTGTCTCTCCTCTGTTCTGAAATTTA GCATCTGGGCTTGTTTGATATCCTTGTTA GAGGTCAAGAGCAGGTT 1348 3857937 1 GGCAGAGGTTCTATGCCTCTGTCCCTGA 4.98E−05 0.008955614 5.35E−06 GAACTTCTCCAGGATCTTGGAAATTCCT GGCCTTCA 1095 3859962 7 C19orf55 CTAAGGTTTTTGGTCTGAGCGGCAAAGG 2.42E−05 0.00991284 3.70E−06 ACAGAGC 2020 3860139 2 TYROBP GCCCGAATCATGACAGTCAGCAACATGA 0.003716277 0.008084936 7.41E−06 TACCTGGATCCAGCCATTCCTGAAGCCC ACCCTGCACCTCATTCCAACTCCTACCGC GATACAGACCCACAGAGTGCCATCCCTG AGA 1533 3861561 9 LGALS4 CTGTCCATTCGCTGTGGCTTGGATCGCTT 0.012305161 0.008083965 4.75E−06 CAAG 1288 3862193 9 FCGBP ATGGTCTCCGAGTGGATCTCCCAGCTGA 0.020351547 0.00902822 8.96E−06 GAAGTTAGCATCTGTGTCCGTGAGTCGT ACACCTGATGGCTCCCTGCTAGTCCGCC AGAAG 1687 3865345 2 PPP1R13L ATCCCGTCCAAAGTGCCTCCCATGCCTA 0.000579253 0.007965781 2.31E−06 CCACCATCATCACATCCCCCAGCAAGCC AGCCACCTGCCCAGCCGGGCCTGGGATG GGCCACCACACCACTGGATATTCCTGGG AGTCACTGCTGACACCATCTCTCCCAGC AGTCTTGGGGTCTGGGTGGGAAACATTG GTCTCTA  956 3867149 4 LMTK3 CCCGGTATCAGAGCTAAGGTAGAAGACG 4.32E−05 0.008497033 5.08E−06 CCACTGGAGGGTTTCACTCCTACTTCCCC AATCTTGCCTGAGTCCAGATATTGTCCCT GCCATTTCTTAGCTGTGTGACCTGGGGC AAGTCGCTTTCCCTCTCTGTGCTTCAGTT CCCTCATCTGTAGAGTGGGAATGATAAC AGGATCTAACTCATGAGATTGCTGAGGG AATTAAATGGCTTAATCCTCCCGAGTAT GCAGCACAGCGCCTGTGCAGCAGCAGTC TCTAACCATTA 1370 3867534 5 FTL GAGCAGAGGCTTGAGGGGTATGGTTGGG 0.000617654 0.006556618 4.97E−06 TAGCCATGGATGCAGCGGGTACGTAC 1579 3867772 9 SLC6A16 TGTCTTGGTACTGCTCCCCTGTTTCATCA 0.0015655 0.007315823 5.70E−06 TTGTCGGTTTCTTCATCCGGACTCTACTC CTGGAAGGGG  977 3868126 2 PNKP AGCTCCCCTCCACAATAAACGCTGTTTCT 0.001843787 0.007146769 4.84E−06 CCTT 1714 3868195 9 IL4I1 TGCGCGCCGCCATCAAGATCAACAGCCG 0.041003559 0.007474114 2.69E−06 GAAGGGGCCTGCATCGGACACGGCCAGC CCCGAGGGGCACGCATCTGACATGGAGG GGCAGGGGCATGTGCATGGGGTGGCCAG CAGCCCCTCGCATGACCTGGCAAAGGAA GAAGGCAGCCACCCTCCAGTCCAAGGCC AGTTATCTCTCCAAAACACGACCCACAC GAGGACCTCGCATTAA 1067 3868892 3 KLK14 AGCATCCTGATCTTTACTCCGGCTCTGAT 0.018331444 0.008434542 8.81E−06 CTCTCCTTTCCCAGAGCAGTTGCTTCAGG CGTTTTCTCCCCACCAAGCCCCCACCCTT GCTGTGTCACCATCACTACTCAAGACCG GAGGCACAGAGGGCAGGAGCACAGACC CCTTAAACCGGCATTGTATTCCAAAGAC GACAATTTTTAACACGCTTAGTGTCTCTA AAAACCGA 1063 3868997 2 CLDND2 GAAGACAGGTTCCTCACAGCAAAGCCTG 0.000998659 0.006686711 1.02E−06 TGGTGAAGGTCTCAGAGGCCTCTCAGGG GAAGTCTCAAGGTCTCCAGTAAGGGGAA CGAGGTCTGGAGGGAGGAGGTTGTGGAT CCTCAGGCAGGGTTGTTGAGGGAGGGGG GTCTCCAGGTCCCCAGAAGCAGGGACCT CAGGCAGGAGTACCAGGGGAG  648 3869569 6 GCCCATCTGAGCTCTTACCTGTGTTCACA 0.005648885 0.007042573 6.92E−06 CCTTTGATCCATTCCCTCCCATCTGGATT TTTTTGCTATTTTCCCTTCACTCTCCAGA GTCCAGGGCTCTCTCCTTTGCTCCCACAT AGAGATAATACTCAGGTCAGGAAGACA GATTCCTGTTTATAAAAAAAGAGAACCA AGGTGTACTGTGGCACCTTTAAAACTCA AGCCCTGGGCTGGGTGCAGTGGCCCAGG CCTGTAATCCCAGCACTTTGGGATGCCG AGGCAGGCAGATCACTTGAGGTCAGGAG TTCGAGACCAGCCTGGCCAACGTGGCAA TATGCTGTCTCTACTAAAAATATAAAAA TTAGCCAGGTTTGGTGGTGGACGCCTGT AATCCCAGCTCCCTGGGAGTCTGAGGCA GGAGAATCACTTGAACCCGGGAGGTGGC GGTTGCAATGAGCTGAGATAGCACCACT GCACTCTAGCCTGGGTGACAGAGCGAGG CTCCGTCAAAGTGAAAGAAAAGAAAGA GAGAGAGAAAGGGAGGAAGGAAAGAGA GAAAGAGAAAGAAAGTCAGTCCATGGTT TCCAAAACATACTTCTGTTTCCATTAATT TATTAGGAATGCTCTTCCATCTGGCTGTT GATCTGTGTCCTGTGTAACATCCTTTATA ACAAATGGTACACCTCAGTAAATTGTTT CTCCAAGTTGTGTAAATCACTCTAGCAA TAGCAAATTCTGGGGGCAGTTTTGTGCA ACTGAGCCCTCAGCCTCCTGTGAGATCT AATGCTAACTCCCTATAAATGGTGTCAA ATTGAGTTCAATTAGAGAACACCCAGTT TTTATCTGATGAAAAATAGCTTGTTGGTG GGAAGTAATCCCCACACATTTTGATGAC CGGAGATGAGGCATTCTGTGTTGAGCAT TCACTATTGTGTTGATTGTGAGTAGAAA AAACACTTTGGTTTTTCCTCCTATCTTAT ACACTCACACACCCTACCCCATCCCAGA AGTGAAGATAGTGACCCATACCTGAATG AGTCAAGTCACTGCCTGCCGTCTGGCAG AATAAGGACAGCAAATGGAAGCTAACCT CTGATACCAAGAATTAGGAAATGCACAT GCCTTATAGACAGTTTTCCAATTCTCATC TTCATCTGTATATTTTAAACAAATGTGAT GTTTATTATAGAGAAATTAATCATAATA TCCAATCAATTCATCATTCATCTGGATTG AGTGTCCCCCTCTTTCCTCATTACTGTGT GTTTCTCTACCTACCTCTCATTCTCACCT TCTTTTCCTAGCTTTTTTTTTCTCTTTATT TTTCCCCTAGGATTCTCCTCATTTCAAGC CCTTCTTCCTTCTCCTGCTCTTCCCTCTAT TCCTTCTCTTCCACTTGTTCTGCTCCTTTC TCACTTCTTTCACCTCTTATTCTTCTTTCT GCCCAATATTTGTCTCCAATTTTCATATA GTTCTGCCTCTTTCTTCCCCCCGTCTCTG CTGCCCCCTAGCTTCCCCTGTTAAATCCC CTCTTCCCTGCTATATCCACCTGTCCCCT CTCTGGCATCCCCAGATCCCAGTTCTCCC CAGGCTGTGGTTCTCCCTGTGCTCTCCTT ATCACTGGCTGCCCCTCTTGCTCTCCCAG CACCATGCTGCTCTGTCTGCCCTGGCTCC AAATCCCTCCTTCTCTCCCCAACTCTCCA TCTGAGGAGCCTCCCCTTTTCTGCCCCTC TCCCTATCTTGCTGAACTTTATCTCTCTA GAAACCCAGTTTTTCTCTAAATTTCTCTA GTTGCTTTTCTCCCCCTGCTCCTTTCTCA GCATCTTCATGCACTGTCTCTGCAAATCC CTCATCCACCATCTACTTTGCCATCTGTT TTGTTTTGTTTTTTGTTTTTTGAGATGGA GTTTTGCTCGTCGCCCAGGCTGGAGTGC AATGGTGCGATCTTGGCTCACCGCAACC TCCGCCTCCCGGGTAAAAGCGATTCTCC TGCCTCAGTCTCCAGAGTAGCTGGGATT ACAGGCATTCGCCACCATGCCTGGCTAA TTTTGTATTTTTTAGAGACAGGGTTTCTC CATGTTGGTCAGGCTGGTCTCAAAACTC CTGACCTCAGGTGATCTGCCCGCCTCAG CCTCCCAAAGTGCTGGAATTACAGGCGT GAGCCATCGCACCCAGCTGCCGTCTGTT TATGGGTCTCCTTCATTCTTCTTTCCCATT TCACCATTTTTCTATTTCCTCTCCTCCAC ACATTCATAGGGAGGGGACTG  854 3869641 6 AGTTTCGCTACAGGAGGTGTCTGCACGG 0.008706715 0.008642584 1.06E−05 CCCTACTGCAGAAAAGACCGGGACGGG ACCAGCCTCAGGGCGACTTTAAACTCAA AAGGAAAAGACTCACGGACTCCCACCCG GACGTCTCAATTTGCTCTG  981 3870896 2 CDC42EP5 CCCACTTCTGTATACATAAACGGCCAAG 0.001409908 0.012765074 9.25E−06 GTGTGTGCCCGG 1795 3871283 9 PPP6R1 TCTTGCATGCCCAAGTAGAGGGATGCGT 0.000982084 0.006611289 4.50E−06 GAGCACCATGCTGAGCTTGGGGCCACCT CCTGACAGCAGCCCTGAGACGCCCATCC AAAACCCTGTTG 1919 3872856 9 A1BG; CAGGAGCGAGCCTGCAGACCGGGCGTTG 0.000570716 0.007014539 5.81E−06 ZNF497 CGCCCTTCGCCTCTCCC 1967 3873181 2 TRIB3 GTGGGACTCTTCTGGGGACACTTGGGGT 9.59E−05 0.006721722 2.86E−06 CCACAATCCCAGGTCCATACTCTAGGTTT TGG  400 3876447 5 JAG1 GGCAAAAGGCGTTTTCTCCACATGCAGA 5.48E−06 0.017523697 1.48E−05 AAGTCCCTTGCTCTGAGCACATACGTAC ACACATGCTCTTTCTTTGTATACATGCTG ACTACACGGGCAGGATGCAAATCCTGGC TGCAGAAAGGAGGCAGGTCAAATCAGA ACCCCATCCTTAAGCCCTCCATGTGCCCA CACCATATCTACAGAAGCTCAGGGACTG GAAAAGACAGCAAAAGGCATAAAAGTA AGGGCCTGTCAATTACATTCTGTGATTA GCATCGTGGCAATTG 1934 3878250 6 CCATGTCGCTGGCAATATGTCATTGCGT 0.002600581 0.007315515 4.90E−06 AACACCAAATAACCCCCCAGAAGTAGCC AGAGGCCAGTTTGAACATCACAATTCTA AGTGTTTTAGTAACTATTTCTGGCGTGAG TCAACAGATCATGTAGATAGAGTCAATT ATTGTTTGTGGAGTTTTTCAGCTATAGGG GAGGGGAACTATTAAAATCCATTTGTTT CTATTCAATAGGTAATAAAAATTAGTTG TCCCTGGGTTTGGGAAACTTAAATGCCC ATTACAGCCCTGGGGA  394 3879946 7 NCRNA00261 TGGACGCATGGGAAAACCACTACCCCAG 0.001670221 0.009304477 7.16E−06 CATTGTGGTGCCCTTCTGCTGAGCAAAT AGTTCAAACTGTTCATTCCCATCTTCTAT TCTCTCCCTGGTACATTGTTTGTGCCCTT GCATTTCATTCTGCAAGGAAGGTTGCTCT CTGGGCCTATAAGCAAACAGTCCAGAAA AGGGCTAGCCATCCTCTT 1786 3880845 2 GINS1 CCATGCGCCGAGGCACTTCCAGGCTTCA 0.000570716 0.007449206 4.29E−06 C 1322 3881457 9 TPX2 GGAACTGGAGGGCTTTTTCAGGGCAAAA 1.47E−05 0.011597387 5.87E−06 CTCCTTTGAGAAAGGCTAATCTTCAGCA AGCTATTGTCACACCTTTGAAAC 1223 3881458 9 TPX2 GACAACACTTACTACAAAGAGGCAGAA 0.003181899 0.011954527 9.58E−06 AAAGAAAATCTTGTGGAACAATCCATTC CGTCAAATGCTTGTTCTTCCCTGGAAGTT GAGGCAGCCATATCAAGAAAA  165 3882316 1 GTAAGGATGTTCAAACGCTGGAGCATCA 2.10E−06 0.027157072 2.16E−05 CTGTG 1904 3884900 4 FAM83D TGCTTCGATTGCTTTCGAGTCATGAGTTG 0.000483071 0.007216721 4.26E−06 GTG 1546 3886774 2 SEMG1 TATAAATGACAAGGTCGGCTCAGCTCTC 0.005890702 0.009568906 6.81E−06 A 1826 3887717 7 SULF2 CCACAACTGCGAGGGATTTTCTTTTACAC 0.006618995 0.007122866 2.39E−06 TGGCCACAGAGCGTTTATTGACACCACC ACTCCTGAAAATTGGGATTTCTTATTAGG TTCCCCTAAAAGTTCCCATGTTGATTACA TGTAAATAGTCACATATATACAATGAAG GCAGTTTCTTCAGAGGCAACCAGGGTTT ATAGTGCTAGGTAAATGTCATCTCTTTTG TGCTACTGACTCATTGTCAAACGTCTCTG CACTGTTTTCAGCCTCTCCACGTTGCCTC TGTCCTGCTTCTTAGTTCCTTCTTTGTGA CAAACCAAAAGAATAAGAGGATTTAGA ACAGGACTGCTTTTCCCCTATGATTTAAA AATTCCAATGACTTTCGCCCTTGGGAGA AATTTCCAAGGAAATCTCTCTCGCTCGCT CTCTCCGTTTTCCTTTGTGAGCTTCTGGG GGAGGGTTAGTGGTGACTTTTTGATACG AAAAAATGCATTTTGTGCAGCTGGTGAG GTATAATCC 1668 3889268 4 RP4- AATATGTGCGGGGAGCTGACTGTCCTCT 0.004322902 0.006987245 4.02E−06 723E3.1 GGAGTCCTCCATTGATCTCTGTTCCTTCA TCCCGTCCATGGCCTTGAAAGCACTTACT ACAATTG 1070 3890589 2 RAE1 TCTGCCTCATCTCTGTACGAATTTGGGTC 0.002811439 0.009946063 9.48E−06 CCAGCCTTGTTGGGTTGTCAGCCATGGA CATGGATTTCAACCCCTGGAGAAAACGA TGTCATTGTTCAGCAGCTGAGAGCCCAG GCGTCCGCGGCGACTTGCCGTCTCTCCAT TCCACTGCCTGTTGCAGAGTTTTTCTGTA ACTAAGGGGGTTGAGGTTATTGTAGACG TTAGATTGCGGGCACCGCCAGGGATTTT GCAGCGCTTCA 1059 3890610 4 RBM38 TTTCCACCGTTGCTGTAGGGCTGCAGGA 0.033605237 0.007490625 3.98E−06 TCCACTGAGTGCACCTGCCTTTGTGCTGG AAGCCAGGGCTCCTCTCTGACCCTGAGG GTCCCTGGCTCTGGGGAGGGAGCTCGCA GGGCTCCTCTCTGACCCTGAGGGTCCCT GGCTCTGGGGAGGGAGCTCGCAGGGCTC CTCTCTGACACTGAGGGTCCCTGGCTCTG GGGAGGGAGCACTGTGTTTTCAGTGCCC ACATGTTGCCAAACCGCGCTCCAGAAAG CTGCCCAGTTTCTGTCCCTGCCGAACGCA GGAGAATGCAGGGAAGGATGTTGTACTT TTTCTCCAGAGCTGCTTCCCTTGAGGGGG GCCCCTGCCTACAGGTCAGAAGGAAGCT GAGGTTCCAAGTCACCCCCCAGGCGGGC CTGGCCTGTGTAACACGCAGGCGTGCAA GGCAGAGGAGATACTGATGCCCAGGGC ACAGTGCCGTGCCCTGGAAGACCACTCC GTGCCTCGGACTCTGCAGCAGCTTCTGA TGCCGCGGAGGTGGCTGTTCTGTTGCAG ACGGGAAACTGAGGCTTAGCGGCTTGCC CCAGGCCACCGAGCAGCTGGTTGGCAGA GCAGGCACACGCCAGGAGAGCTGCCTCC CTGAGCCTCATTTCCCCCTGTGCTGAGGG CTGGGCATGCTGTTGTATGGCCAGCCCA CAGCAGGCAGGAAGTGTTGGCCTCAATG CGTTTCCACAGTGGCCTGCCCAGGTAGG GTTAAGAGCACAGCTC  338 3891323 5 CTSZ AGGTCCCATCGTTTCCTGTGTCGCAGGTC 1.03E−06 0.019701911 1.99E−05 ACTTCTTCACCAGGTGGCTGACTGCATC ATTGTGAGGCAGAGCCATGCTGTGCAAG TGTCATAAGTCATCCCACTTTCAACTCTC AGGAACACTCGCAGCCAGTGCCACGCTG TCCTCGCCATCCAATATTGATAGCCACCC CAGTTCCTGCCAGCCAGCCTGGCACACA TAACCATAGGATCCCCTCTGGTCATGGG TCACCATGCCTTTTCTTAAACTGCGCTTC TAGTGACATGGCCTTAAACGATGGGGTC CCCAAATGTACAGTGCTCCTCGATGGCA AGGTTGTA 1717 3893625 4 ZGPAT GCCTCCTGAGTAGACGTTTCCCGGCCAA 0.004976894 0.007043225 5.36E−06 GG  865 3894010 9 MYT1 GTCCAGCAAGCAGAAAGGCATCCTGAGT 0.031823166 0.007346013 6.25E−06 CACGAAGAGGAGGACG 1092 3895779 4 RP11- CGCCACCCTCCTGTGGCGAAGGAGGGGA 0.000152935 0.007248562 4.58E−06 119B16.2 AGTGGGAGCCGGGAAGTAGAGTTGGCCT TTTGCAGGAGAGTCTGGAGCCCCTTTCT GGGTGATGCATTGGGGGCCATAGAAGGA TTTGGCTGCCGCTTTGGAGCATGGAT 1277 3896023 2 PRNT AGAGACAGCCTGGAAAGATTGGGTGCCA 0.018126 0.007004643 4.38E−06 GCTGCAGAGAGGAGAGCAAGGCGACCA AACGCAGG 1078 3896401 4 GPCPD1 TTAGAAGGGCTGTCCTGCATGGGCTCAG 0.000192114 0.009048337 5.25E−06 TATGGCTACTAACAGTTATTCTCATTGTT GAGTAAATAGAGTTGCTAGGCCTGTCTA GTGTAAGCATTCA 1963 3899419 4 OVOL2 ATGGTGTCTTTGTTTGGAGCCCAAAGGG 0.003024609 0.006721937 3.45E−06 AAGGATTGACTAGATTGGGAAAAATGCA GATTGGGAGATGTTTGGAGTGGGCCAGA TGGAGAAGAAAGAGTCAAGTCACCTCCA CCCCTAGTGGCCTGAATGCTGTCATGCG GAATTGCCTGGTCCAGTTAACAAACCCT CGCTTCATTGTTTTATT 1563 3899905 5 RIN2 CATCATTCTAAGGTGCGGTCCAGGAAGC 8.88E−05 0.008535517 1.66E−06 TGTTTTTTGTTTGTTTGTTTGTTTGTTTGT TTGTTTTGGAGCCCTTCAGTGATTCATAC AAACAAGCCAAGGAGAGAACACATGGA CGACAGCATTGATTCACTGGAAAGCAAA GTACAGCTTCCACCATAAAACCCTGCAG CTGAAAAAGGACAAACTGAGCAGCTCTC AAATAAAGACAGCCTCAGCCGTCTTGCA CAGCACGGCCCCTCTCCGTGCCCGAGTC CTGTGCCTGTATGAAAGCACTAAATCAC AGACCCCGCAACCTGTTATAAGCCCTGG TAACAATCAGCAGCTG  305 3901183 5 GZF1 TCCTGATTCTGGAGTGCAGACTGCCTAG 0.006537209 0.011649055 8.10E−06 ATGGCACTCCTTCCAAGCCTGAGAACCA AAAGACCAGAGACGAGTCCTAAAGCCTG AAATGGCATCTCACTGAGGTCTCTACTG AGACTGTGGGACCCGG 1588 3901363 2 CST1 GTGCCAGGCCATTCGCACCAGCCACCAC 0.000435853 0.006853365 3.36E−06 CCACTCCCACCCCCTGTAGTGCTCCCACC CCTGGACTGGTGGCCCCCACCCTGCGGG AGGCCTCCCCATGTGCCTGCGCCAAGAG ACAGACAGAGAAGGCTGCAGGAGTCCTT TGTTGCTCAGCAGGGCGCTCTGCCCTCCC TCCTTCCTTCTTGCTTCTAATAGCCCTGG TACATGGTACACAC 2028 3902753 7 ASXL1 AGCCTCATGGACCAGATCAGTGTCAAAC 2.67E−05 0.006638061 3.60E−06 TGTACCCTTGAGTGTCCCCAAAGGTTCC AGCAGAGGGAAGAAGAGGACTGGACAT GTTTGGGCCCCTGTTCCCGGTCTTTGGTA AACAGACGCTTAAGTTGACAACTTGGAC TTGGCCAATA 2030 3903852 3 EDEM2; AAGGAGGCATCATCAGGCTGTGTTCCTG 0.000532413 0.007106081 6.51E−06 MT1P3 GAACCCCAATAACCCTGGGCCCCCAGGG CCAGCCTGTTGTAGAGGGAGGCTATCTG ACCGCCGGTCTGGCAGAGGAGATGGGTG GGCAGCTCCCAGACACCCCAAAGGACCC GGTTCTCTTCCCAGAGCGTCCTAAGGTTA CTCTTGGAACCTGATCTTTGTTCCCTCAT CCCAGGGAAATGACACACTCTGTATTTC TGTTTTATTTAGAAATGATTTAAAAAAC ATTATACAAAGGCTGATCAGTTTAAAAT GTGACTGACACTGAAATGCTGTGATGTC CCCCAGGCTGAGGGGAAGCTAGGCTCTG GGGCCCCCAGTGCTTTGCCCCTCTGTCTG CCCTGTCCTGGGGTGATGGACAAACAGA TGACCACAGGCAGGAGAATCTGAGATTG GAAGCCTCTAGGCTGAGCCCTCTGGGCC TGGCCCCACATCCCTCACCTCTGCAGCCT GGGCTGCCTGCCTCCATCTCCTGTTCATT CTCAGCTGGCCTGCCAGGAGCCAATGGG GAGCCTGGCGGGAGGCGGGGGTGCCTA GAGCTTTCAAGAAGTGAGAGCACCAACC TGAGGAGTGGACAGGGACCAGGAAGTG GGGGAAGGGAGGCCAGGAAGAGGTGGA TACAGGAGACACTTCTCATCTCATCTCA GACCCTAGAGGGGTCCACAGATGGGGAC ACAAGACCCAGCCAGCCCACTGGATGGC CCGGGCAAGTAACAACCTCTCTGTGCTT CATCTGAGGGCACGGTGAGAGTTACCGT CGGCCTCCCAGGGCCTAACACGAGTTTC ATG 1731 3904090 9 FER1L4; CCCGAATGGAACGAGCAGCTGAGCTTCG 5.05E−05 0.007249279 5.01E−06 AL389875.1 TGGAGCTCTTCCCGCCGCTGACGCGCAG CCTCCGCCTGCAGCTGCGGGACGACGCG CCCCTGGTCGACGCGGCACTCGCTACGC ACGTGCCGGACCTGAGGCGGATCTCCCA TCCGGGCCG  871 3904560 2 NDRG3 TCTTGAGATTCCTCTACTCTCGTTATCTG 0.017888918 0.009731465 6.23E−06 ACC  901 3907235 2 SDC4 TCCAGCTCTGATTACCTITGAAGTGTTCA 9.59E−05 0.014513443 9.93E−06 GAAGAGACATTGTCTTCTACTGTTCTGCC AGGTTCTTCTTGAGCTTTGGGCCTCAGTT GCCCTGGCAGAAAAATGGATTCAACTTG GCCTTTCTGAAGGCAAGACTGGGATTGG ATCACTTCTTAAACTTCCAGTTAAGAATC TAGGTCCGCCCTCAAGCCCATACTGACC ATGCCTCATCCAGAGCTCCTCTGAAGCC AGGGGGCTAACGGATGTTGTGTGGAGTC CTGGCTGGAGGTCCTCCCCCAGTGGCCT TCCTCCCTTCCTTTCACAGCCGGTCTCTC TGCCAGGAAATGGGGGAAGGAACTAGA ACCACCTGCACCTTGAGATGTTTCTGTAA ATGGGTACTTGTGATCACACTACGGGAA TCTCTGTGGTATATACCTGGGGCCATTCT AGGCTCTTTCAAGTGACTTTTGGAAATC AACCTTTTTTATTTGGGGGGGAGGATGG GGAAAAGAGCTGAGAGTTTATGCTGAAA TGGATTTATAGAATATTTGTAAATCTATT TTTAGTGTTTGTTCGTTTTTTTAACTGTTC ATTCCTTTGTGCAGAGTGTATATCTCTGC CTGGGCAAGAGTGTGGAGGTGCCGAGGT GTCTTCATTCTCTC  232 3908635 2 PREX1 CATCTTAGCTTCCAGGTTCACCCTAACCC 0.000518037 0.014616305 1.08E−05 TGTACTAACCTGCTTGGTGGACTTGGAA AAGACTTGGCTCTGTCGGGAAAGGAGAG ACGGGGCCTCCATCACGCCTGTTACCAG AGGATCCCCGAGAGCCACACCAGCTCTG GACATCACCGCCCCTGGAACTGGGGCCA CCAGCCCTGGGCACGAGATTTGCTCTGA CTTTATTTATATGGCATGAAATCTCTGGT TTATTTTGGGATTTTTTGTTGTTGGTGTT GTCAAAGTTTGTTTTTTCTAAAGTTGTGT GATTATATATTTGACATTTTACATTTCAA AGAAAGGTATGTTGTCTAACAGGGGACC AACAGAAGGTAGTATT 1083 3910198 5 TSHZ2 GGGTCTTGCAGCCAGGACAATCCTGTTT 0.000637737 0.007642783 4.14E−06 GGAAACCCGTATGAACTCTCTCACATTC ATCATTCACTTCCTGGAGAGACAGATTTT GTAAACTTTACAGAGCAGCTTTTAATCA TTCGGTGGTTCCCAGATTCCTAGGCCAG AGTCTCTATACTGAATAATTTATAATAG AGGTCATATCCATCATGGTGGCTTGAAT TCTGTCCTCCCAAGAACACAGGCTCAAG TCCTGACCCCTCCTACCTGTGAATGGGA CCTTATTTGGAAATGGAGTCTTTGCAGGT GTAATTCAGTTAAGATGAGGTAGGCCCG AAAAGCAATGACTGA 2005 3910788 2 AURKA GCCAGGGCTGCCATATAACCTGACAGGA 0.002303775 0.008034016 6.32E−06 ACATGCTACTGAAGTTTATTTTACCATTG ACTGCTGCCCTCAATCTAGAACGCTACA CAAGA 1776 3911737 5 GNAS CCAGAAACTCATCTCGAATGAAGTACTT 1.65E−05 0.006751443 4.63E−06 GGCCCGGGTCACGCGTGGGTCCTCTCCG GGCT  655 3911768 2 CTSZ GCCATGTCACTAGAAGCGCAGTTTAAGA 0.000126082 0.017035647 1.84E−05 AAAGGCATGGTGACCCATGACCAGAGG GGATCCTATGGTTATGTGTGCCAGGCTG GCTGGCAGGAACTGGGGTGGCTATCAAT ATTGGATGGCGAGGACAGCGTGGCACTG GCTGCGAGTGTTCCTGAGAGTTGAAAGT GGGATGACTTATGACACTTGCACAGCAT GGCTCTGCCTCACAATGATGCAGTCAGC CACCTGGTGAAGAAGTGACCTGCGACAC AGGAAACGATGGGACCTCAGTCTTCTTC AGCAGAGGACTTGATATTTTGTATTTGG CAACTGTGGGCAATAATATGGCATTTAA GAGGTGAAAGAGTTCAGACTTATCACCA TTCTTATGTCACTTTAGAATCAAGGGTGG GGGAGGGAGGGAGGGAGTTGGCAGTTT CAAATCGCCCAAGTGATG  715 3911769 9 CTSZ GCTGAGGATCGTGACCAGCACCTATAAG 8.58E−06 0.016324218 1.44E−05 GATGGGAAGGGCGCCAGATACAACCTTG CCATCGAGGAGCACT  769 3912527 5 CDH4 TGTAAAGTGGGGCACCTGCCGTGCTCTG 0.004061321 0.009439512 1.15E−05 ATCACGTGGCCCACGGAGCTGGGTCCTG CAGTCACTCCCTGCCATGGCGC  892 3913561 4 DIDO1 CTTCTGCCCATAGCGGGGTACTCTGACCT 0.001283816 0.008853705 3.51E−06 CTTCTCCCTCTTCCCTTCTTTGCCACACA TCAGCTCCTCTGGGAAGCTGATTTGCTCC AGGGACAGGAGGTGGGGGAAATTGCCT GTTAACCTTCCCAACACATCACCTCAAG TTAAAATTGGTGGATTTCCAGAATTTGTA TAGGATGGGAATGGGGACGACACACTTT TGAGCTAGTAGCTTCTGCTCGTTTTGTTA TCCCGTAAATGTTGTCTTCCCAAAAGGT GATTGATTG  962 3913575 9 DIDO1 AAGGCGGCTCAGGACATCAAAGATGAG 2.25E−05 0.010752142 1.01E−05 GAGCCTGGAGACTTGGGCCGACCGAAGC CTGAATGTGAGGGTTACGACCCCAACGC CCTGTATTGCATTTGCCGC 1542 3913577 4 DIDO1 CCCTGCTGCGCGTGTTTGGCGGCAATGT 0.002951948 0.00662747 1.65E−06 CACCTTTTGTTCTGTGGTCAGTTGGTCAC TATGTGCTTACACTTTACCGCTAG 1804 3913713 2 YTHDF1 GGACCGTTGAGCTCACTACCACCTGGAG 0.000722593 0.007517051 5.77E−06 TTTGAGTTGAAGCATGAAAATGGTGCCC ATGCCTGACGCTCCAGCGCCTGGATCTG CACGTGCCCTTGTAGAGGATCCTTACCG TCCTAGAGAGCAGACGCTTTCTGAAAAC TACTTGCTCCAAAAGACCCTCTGAGTTA ACGTTTCAGCTGTATCATTAGACTTGTAT TTAGAGCGTGTCACTTCCTCTGAACTGTT A 1875 3917818 8 TIAM1 GACCACTGCCCAATCACCCATGTCACGG 0.000272577 0.006979198 6.08E−06 GCTTGGCAGCCAGGCTCAGGTGGAAGCT TCCTGCATCCGTCCTCTCCAC 1220 3918161 4 C21orf63 TGAAACAGCCCAAGGACCTGCGCTTATT 0.04726916 0.008466627 6.54E−06 GATCAAAATCTA 1638 3918604 2 IFNAR1 CAGGCTGGCTTCTCGTCTAGCAGTATTCA 0.000200907 0.007891488 3.40E−06 GATACCCCTTCTGCTCAGCCTGCTTGGCG TTAAAATACAAATCATTGAACTGAGGGG GAAAAATGTAACTAGGAAGAAAAACCC AATTTAAGAAATTACATAATGCTTTCCA AAGGCACCTACAACTTAGTTTTAAATTA CTTGCTACTGGGGATTACCCATGGATAT CCTTAATAGGCAGGAAGTCTGGGAATTC TGGTGGCCTCTAGGGCAGTGTTCTCACA GCACCGTTCCGACAGG  453 3919218 7 RCAN1 CCACATTGCATTGCTGCTGTTTTCACAAC 0.001643447 0.006886772 3.36E−06 CTCTCTGCACTAGGCGGCTTCCTGTGGTA CCTCTTCCTACCAGTAGAGAGTGGCCC 1437 3920026 9 CHAF1B GTGGCCTCGGAGGATTCCGTGCTTCTGT 0.000197761 0.007853932 4.30E−06 ATGACACCCAG 1044 3921056 1 GAAGCTCGGTCCACCTCTGAAGCTGGAG 0.003428273 0.009262185 5.83E−06 CTGCTGTCAGTCAATGCTCAGAACCTCTT GGCAAA  206 3922319 1 TCTGTCAGCCGACTTCGGGGGAGCTGTG 0.044564191 0.014070978 1.58E−05 TTCAGGAGAGAAGGGCTTGGGAAAGCTG TGCTCTATTCCATGCTGGATAAAAGGAG CAGAGATAACCCG 1659 3923366 4 AGPAT3 CACAGATTCTGACAGGGTCCAGCTAGGA 0.000462937 0.006632473 3.14E−06 AGGTAAGTGAGAATGCAGACATGAGGC CTATGAAGGGGTGGCTGTGGTGAACATG AGTGAGAGACTGAGGCCTCTTTCACAGG GTCTGGCTCACCTGACCACCCGCTACTG ACCCCCAGCTGAGCAGGGCCAGGTGGGT ATAGGACCAGAGTGACTCCATCTTTAGT CTTCCG 1766 3923935 7 SUMO3 AATAATGTACAAATTGGTGAATAAACAC 0.000873066 0.009282175 6.64E−06 AACAGAGCCAACAAACATCCCACCCGAG CCCATACAGCAAACAGGAAATGAGAAC ATTTCAGCAAGATTTCAAGCAAGCAAGA GATGATGGGTCATTGTTCAGGTGACT 1396 3925911 8 C21orf34 GGGTCCTTACATCATTCATCACATTAAAC 0.044263782 0.007994666 5.95E−06 TGTAACATACTGTCAGAATTCACTGGGC ATTAGAGTAGCTGTCTGGCTTTTGTGTAG ACAAAATACTTTCTCAACTCCACCGCTTG GGCAAAGGCAAGGCTGTGCTGACCCAAT TTCCATTCC 1772 3927606 1 TGATCAGAAACATTGGGGACTTGGCACT 0.002641545 0.006502541 3.15E−06 TATCATGAAA 2073 3929666 2 TMEM50B; GCCAGCACCGACAGCAACGAAAATGTTC 0.000525832 0.007247528 2.97E−06 AP000300.3 CCACGGAGATCAGGATGACTTGCTGAAG CTCAGTGGAGGCTAAAAAGAGGACACG AAAGTGAACAGAATGATCTTCCTACGCA CAACACAAACATCAGTTAATGTTCCATC CATGCTGCTTAAAGAGCATTCCTGTCCTA GTAAAATGGGCAAGTCCCTCTACCCCCC ACCCTCACCTGGTATGCTTACATTA 2006 3930023 5 MRPS6; TGCACATCCCACTAGTCAAAAGGAGAGA 0.000153753 0.007677257 6.18E−06 AP000318.2 TGCAGAGTAAAAGAACTAGAAATAAGA CAAAAGACAGAAACAACATCTAAGGCA CAGGCAGAAACACTTAACAGTGCATCCA AACTTCTAAAAATTCTTGGGATTAAAAT ACAAAACCAAATGGATGTTCAACTCCTG AAGCATATGGGGAACAATACAGCAACA AAAAAAAAAAAAAACCTCAACTCTGAA AAGCCATGGAAAGCTGGAAAGAGAGTC AGAAACTCCTATGAAGAGACAACAGGA CTTTACAGGGGGCCTACCTTAGGGTATG CCAGTGAGATCCCAAATTA 1207 3932278 3 HMGN1 GGGAATACGGTCGACGAGACTCCTCCGG 0.00195225 0.009766647 7.74E−06 TATTCAACTTCATGACATTGTCCTGTCAT GTGGAACTGTAGGGAATAGTGGATGATG GCGACAGTGGTGAAATATAGCTCGGGCT TTAGGATTTGTCATATGTCTAATGAGGCT TGACATGCAAGTACTATTAAAATCTCCTT AGCATACATTGTTTTCCTGATTACTGGGG GGGACCTTAAGTTGTCTCATGTAA 1398 3932707 4 DSCAM TCTACAACTTTAGGGGACACAAGGCAGT 0.014179003 0.007108958 2.59E−06 TCATAGCAGTTGCTCTCCTTTGGTTTGTA TCCAACTACACTGCCTGGTTGATCTTCTC TCTGAATATTTCGGTGCTATCTCTTTCCT TCAGTTTGCATCTTCCCCTCTCAGAAATG TATGTCAATCTAAAAGTCCAATCCCATC CACTTTCTGTATTGGTCATTTCATCATCT TCCAGGGCTTCATCCATGACTTGCACCTG TGTGACC 1673 3934672 9 SUMO3 GCCGTCCATCCTCGCATTGCTGTTGAATG 0.007946892 0.009316771 7.21E−06 GTGAGCACGTGACCATGCCGACCACAAA GGTGTCTGCGGAAACTCGAGGACATTCA CCACGATGATTTTCCTCTCTTTGATGTAC TTCAAGTGCAACTCAAAACTATATCTGC AGGGATGAATCTGTAACTTAAATTGGGC CAATCAGAATTGTTATCTTTGTTCAGGTA AAATGAGTTGCAAGATATTGTGGGTACT TTTGTGTGCTCATTTGTGTTTTCCCCCCCT CCTACAACATTTTTTTAACCCCAAAATTA TAGCCTGAATGTTCGCTTTTAGTCTGGCC AGGGATCTGACTCCTGAGTTGGTTGCCT CTCCCCTGCTCACTCCAGTCACATAGAG AATTGGTGTTTCCCGCAGTGGGGATGCA GCTGTTGGACAGGTATTGGGGGCAAGGT TGGTAGGGAGGACAGACTGTCACTTGCT GTTACAGGCACAGGTGATTAAAATGCTA AATATTGCAAATTTAAGCTTTGTCAGTAT ATGGAAAAGTTGAAGGGAAAATACTGG AATGCTTCTTCAAAGGTTAAAAAATAAC CGAGTCTTTTGGTAATTTGACCCCACGTG CTCTCTGGCCCTCAAGCATGTAACCTCG 1298 3936105 7 CECR1 CAGGGCGAGCACAGGAAAACCTCTCTGA 0.002629781 0.007226038 4.30E−06 GACAGTGACATGAACTTGAAACTTGAAG GGTAAACAGGAGTGGGCAAGACAAAAG GGGAAAGAAGGAATCTTCCAGGCAGAG AGAAAGAGAAAAGACCCAGGCACGGTA TAGAGCCGAGGACATTTGAGGAAGAAA GGGCCGCCGGGGTTGGGGCCCTCTGGGT GACTGGGAGAGGAAGGCGCCGGAATGG ATCCAGATTAAATCGGATGCTGTATGCC CTGTGGAGACATGGGGTGTACCTCTAAA CGCACTGC  670 3936779 3 DGCR5 GGCCTCTCACTTGTGGGACTCCCGAGAT 0.006297356 0.007821734 5.43E−06 GCAGTGGCCAACACGAGTGTAGTGCCCA GTTCACTGCTGGATAAGACAGAGGCCTG TTCTGGTCACACATGGGAGGCAGAACCC AGAGACTGGGCCCAGGAGCCCTTCTGCT GACAGTGGGAACTCCCAGCTACGTGTGG GGGTCCCCATACCAGACAAAGGTCCCTG ACCTTAGTCTTGCCCGAGAGGCCGACAC AGCCCAGCTTTGGGGTCTGGCTTTACCC ACAAGAGGCCACACCTTGCCACAGCACT GTTTATCTGGCCTGTTTCA  882 3937768 9 SNAP29 ACACCTTCGAGCCTATCACCAGAAGATC 0.000509079 0.008037211 5.22E−06 GACAGCAACCTAG 1735 3937798 2 CRKL CCCTAGTAACTGCTGTCGGTGTGGACGC 0.000113778 0.011359599 1.07E−05 TGTGCTGGTTCTGTTTTCTAAAGGAGCAG AAGGACAGGTCTCTGAGACAGGATCGTT GTCCCTACAGGAGGAACAGTGGCCTTGC TTCTTAGACGGTC  653 3939344 1 GGCACGCTGGGGATTCCTGCCAGAATTC 0.012377537 0.006710491 7.82E−06 TGGAAGCTTGGGCCCCATCAAGGCGGTC TCTTGCCCCTGA 1725 3939351 1 CAGCAAGGAACGGAAAGTTCACATTGTA 0.002481187 0.007874982 3.76E−06 AATATGTAGCAGAGTCTGTAATGGCTCA GTCAACGCAAAATGTTGACTACAGTCAA TTACAGGAGATAATATACCCTGAATCAT CAAAATTGGGGGAAGGAGGTCCAGAAT CATTGGGGCCATCAGAGCCTAAACCACG ATC 1175 3939354 1 ATGGGCCATAGTGACGATGGTGGTTTTG 0.0264846 0.007324555 6.75E−06 TCAAAAAGAAAAGGGGGGGATATGTAA GGAAAAGAGAGATCAGACTTTCACTGTG TCTATGTAGAAAAGGAAGACATAAGAA ACTCCATTTTGATCTGTACTAAGAAAAA TTGTTTTGCCTTGAGATGCTGTTAATCTG TAACTTTAGCCCCAACCCTGTGCTCACG GAAACATGTGCTGTAAGGTTTAAGGGAT C  707 3939358 1 CCTTTGAGGGAGATCAAGTCTAAATTTG 0.00040614 0.010891317 8.74E−06 AAGGGAGTCCAAATTCATACTGGGGTAA TTTATTCAGATTATAAAGGGGGAATTCA GTTAGTGATCAGCTCCACTGTTCCCCGG AGTGCCAATCCAGGTGATAGAATTGCTC AATTACTGCTTTTGCCTTATGTTAAAATT GGGGAAAACAAAAAGGAAAGAACAGGA GGGTTTGGAAGTACCAACCCTGCAGGAA AAGCTGCTTATTGGGCTAATCAGGTCTC AGAGGATAGACCCGTGTGTACAGTCACT ATTCAGGGAAAGAGTTTGAAGGATTAGT GGATACCCAGGCTGATGTTTCTGTCATC GGCATAGGTACTGCCTCAG  576 3939495 2 MMP11 GCCTTCTGGCTGACAATCCTGGAAATCT 0.001268815 0.014070716 9.94E−06 GTTCTCCAGAATCCAGGCCAAAAAGTTC ACAGTCAAATGGGGAGGGGTATTCTTCA TGCAGGAGACCCCAGGCCCTGGAGGCTG CAACATACCTCAATCCTGTCCCAGGCCG GATCCTCCTGAAGCCCTTTTCGCAGCACT G  726 3940746 4 ADRBK2 GATCCAGATTGAAACCCACCAGCTATAC 0.003965967 0.011477167 1.06E−05 AAAAGACACTTGAGTCATGGAAATGTGG TTAGAGACTGGGCATTGGATCTTCAGGA ATTATCAATTTGAAGGGGGAGTTGGGAA GTGATAATAGACTGTGTTTATATGAGAA AATTATCCATAATTTTTAGAAATGCAAA CTGAAATAGGCTAAAACGACATGTGGTC TG 1069 3942014 9 RFPL1 CACTTGTTTTTTGCTCCTCCAAGTCCACC 4.10E−05 0.006778254 3.28E−06 TAATGGTGATAAGAGTGTCTTGAGTATC TGTCCTG  233 3942071 9 NF2 AAGGACCTCTTTGATTTGGTGTGCCGGA 1.05E−06 0.019752284 1.31E−05 CTCTGGGGCTCCGAGAAACCTGGTTCTTT GGACTGCAGTACACAATCAAGGACA 1946 3942670 3 MTMR3; GCTGATGTACCTGACTGGCTCTGTAAGA 0.000153344 0.009669208 9.02E−06 TUG1 TCAGAAAACTGTATCCAGAATAAGCCCT ATGGATTAACCCCTGAGTACCCAGAGTA AAAACTAATTTACAGAACTTCCTTATTG ATCTGCTGGTTCTTCCAGATCATATTCTG GCTATTGGTATGGCTGGCCTTTCTGAAG GTACCCTGCTTGTCTATTTTCCTGACTCA GCTCTTGCCTGCCTTTTTCACATGTTGCT GCAATTAGACTCACCGTGAGGACTACAG TCAATTTCAGTCTATCTTGTGCCCAATAC AACAAGGATTTTTAATAGTAACAACCCA CACCTCACCCACTAGGACTCAATGTTCA CAACAGGAAGGACCATTGCTGCATACTC CTTGACCAGCAACTTTTTTGAAGATATTT TTAAGTGCAGAGTAGGCCTCTATTCCTGT ATGTAATTGTTCATTTTCAGCACCTGGAA CCTCATCTATCGGGTCTGGAAGGAATAC AGCAGTTCGAAAGCCGCGTCCATTTCTC TCCTTCAGTAGTGCAGAAATGAGTCCGA TTCACCAGTACACACAGAACTGTACCAG TTCAACCTAGCAAAAGAAGAAAAGTTTC CACTGTACTTAAAATTTACAGCTGACTC AAATTGCCTCACAGAATTATTTGATGTA GAAGGCTAGTTGTCTTACTTCAGATCAG CAGGACAGTTGGGCTCTCAGACTCATGA CCACTGAGTTTGCTTGTGTTGAAACTGTG GTTTCATCCAACATATGCTATTGGACATG ATTATTATTCCATTCAAATGGATTACAGA CTTCTTGAGGACAGGACAAACTTATCTC TCATGGTGTTTTTTTAGAATACTTTTATA ACCAAGGAAGAAACCATGCCAGCTGTTA CCATTCAACTTCTTAAGCAGAGATTAAG CTTTTTCATATCTGTTCTTATCCTGGACA TCAGTAGTTTTTAATTGCCCAGCATCCGT TCCATCTTGTAA  930 3943191 1 TAGGAGAGTCCATCACAGGGCAATCTGA 0.000468776 0.010341943 7.19E−06 CCTAGTCATGAAGGTCAGCAAAGGCTCT CCAAGTGACCATAGAACTGAGAACTACA GGGTAAGCAGGATTAAGTAGAAGAATTG GGGAGGAAAAAATGTTCAGGAAGAGAG GGAAGGGCACGCACAGGGCAAGATAAA GTTGGGAAGTAGGCCTGACCATGCAGTG CTCTTGGGCATGCTGAAGATTTTGATTTT GATTCTTAGAGGTTCTAAGCAAGGAGCA GGTGACAGGATCAGATTTGTATTTTTAA GAGATTATTTTGGCTGTGGTTACAGAAG ATGGAAGCGGGGGATGGGATGAGCAAG TGTGAAAGCCGGAGGCCTGTGGGAAGCC AATGTAGATGTCCAGGAAATTCATGATG GAACCTTGGACTGGGGAGGTGATGGGGG GAGGGGAGGAGTGGATGGACTTGAGGG CCATTTAGGAGATAAAATGGACATGATT GGGCCATGGGTTTTGTGGGAAGGATAAG GGTGAGGGAGTTATCTAGGATGACACCC AGGTTTCTGGATAAAACTGTTGCCAGGC AACAGAGAGAAAGCCAGAAGGGAGTGG GGAAGGGGTGGGACACATTTTCCCTTGC AGTTGTTTTTATGCCCATGTTTGCAAAAT AAAGGGTGTTGGAGGTGTGGGCGTGCAC AGCTCCCTGACTGCCCACCCAAGGATAA GAAGACTGGTTTAAGAAGATTGCATGTT GCAGGGTAAAGGGAGCTAGGTCTTCTAC TCTGGGCTCTGCATGCAGGTAACTGTGT GATTTCACTCCCCTGGCCCAGGACTCTG AAACAGACATCCCTCCTTGTCTGGCAAT TTCATGGCAAAAAGCAGCCTGAGTCGTA TTTGTCCACTCATGCTATTTACAGGACTC CTCCTTGGGAAGTTATTTCTTGTAGATCC ACTTTATCCAGAGCCTGAAGGTGAAAAA TCATCAAGTCTAGAATGTGAGATCTGAA AGGAATCACAGAGCCCATTTTCCCAATC TTCTAATTTTACACTGGGGCAGCCCCCGT GTCTGACCCATGTCTCTATGCTACTCTAC TACCTTGCCTACAGGAAGAGAGGTTAAG GAGTTTGTCCAAAGCCACAAAGCTATTG GGCATAAGGAGGTGACCCCACATTCCTT TTCTTACTTTGGGGGTGGGGATTCTTCTG CAGCCTGCAGTTATTTCCTAGGACAGTG GGGCTAGGTAGAGCTGTGGCGATGAGCT AAGATCATAGACACAGGTGATGCTGAGC ATCTGGGGGAATAATTCATCTGAAGCTG TGCCCTGCTGAGTTGGAGTCCTTTCTGAC TCTTTAAAGATGCCTCTTGTCATGCACCC AGTCGTGACTCCTGAATATCCTCCTGGG GTTGC 1451 3943222 2 YWHAH TTTAACGTGAGGTTTCAGTAGCTCCTTGG 0.00021566 0.013533518 1.67E−05 TTTTGCCTCTTTAAATTATGACGTGCACA AACCTTCTTTTCAATGCAATGCATCTGAA AGTTTTGATACTTGTAACTTTTTTTTTTTT TTGGTTGCAATTGTTTAAGAATCATGGAT TTATTTTTTGTAACTCTTTGGCTATTGTCC TTGTGTATCCTGACAGCGCCATGTGTG 1252 3943311 3 RP1- TGGTCACGGCTGAACAATTTCAAGAAGC 8.73E−05 0.007568258 3.79E−06 90G24.10 GAGTCGATGTCTCATCTCCCTATCTTATC TTGAAAAACCCGTGTACCTAAGTCGTGG ATGTGTCTGCTGCATCCGCTGCATCAGTT CACTTCTGAAGGAACCCCATGAGGAAGG TGTAATGTGCTCCTTTCGCTCTGTGGCTA CTCAGAAGAATGACATCAGGCCCGATTT CCAGCTGGGA 1851 3944661 2 KCTD17 CCTCCTGTGTTTGACTTCCCGGGATGGGT 0.023538302 0.007190772 5.18E−06 CCTTGCTTCTCAGCTGTGTCCGACCCCAC CATGTAATAA  359 3944775 1 ACAGTTCTTGCCACAGGAAGACTCGATA 0.000800301 0.009903548 4.44E−06 AAAACAGATTATT  966 3944939 9 NOL12; GTGCATCGGGCACCGGGATGCACCCCGA 0.002849134 0.008944874 4.95E−06 TRIOBP GCCTCCTCCCCACCCCGCCACCCACCCA GTGACCTAGCGTTCCTGGCACCCTCACCT TCACCGGGCAGCTCTGGGGGCTCCCGGG GCTCAGCGCCTCCCGGGGAGACCAGGCA CAACTTGGAGCGGGAGGAGTACACTGTG CTGGCCGACCTGCC  601 3945520 2 APOBEC3A CAGCAGCTTCCAGGTTGCTCTGATGATA 8.40E−07 0.014765996 1.11E−05 TATTAA  356 3947246 9 SEPT3 CAGGAGAGCATGCCTTTTGCTGTGGTGG 0.004699102 0.013660068 1.15E−05 GAAGTGACAAGGAGTACCAAGTGAATG GCAAGAGGGTCCTCGGCCGAAAAACTCC ATGGGGGATCATC 1428 3947350 6 AGGGCTTCTTCCAGACGGCCTCATCCTTC 0.000372622 0.006796499 3.83E−06 AGCACCGATGACAGGTTGGTGATGAGTG TCGTTCCCTGGGCAGGAGATGCAGGGTG AGAGTGGGGACTGGACTCTAGGATGCTG GGACCCCTGCCACCAAACACACGGGGGA CACACACTGCCTGGCACACAGCTGGACT CTGTCAACTAGTCCTGCGCCCGAGAA  380 3948681 9 FBLN1 AAGGGACATCGCTGCGTGAACTCTCCCG 0.006969913 0.009183224 6.72E−06 GCAGTTTCCGCTGCGAATGCAAGACGGG TTACTATTTTGACGGCATCA  101 3949198 9 GRAMD4 ATACAGTGGAGCATCGTGCCCGAAGTGT 3.80E−05 0.021704647 1.73E−05 C 1075 3949566 1 ATGGCACGCACCCAAGTGCTGGGCATTG 0.000248937 0.007112984 2.14E−06 TGAGAGCTTTCTCTGTGCCGGGCTCTGCT TGTGAACAAGAGCCCTCTGAGACAGTGA TGGGAACCATCTGCATCACAGAAGCACA AGCTCTGGTGATGATG 1751 3951205 6 GGGGTGAACATGAGTACCACAGTTAGAC 0.000130223 0.007570276 4.56E−06 TGAGGTTGGGAAAGATTTTCCAGACAAT TGGAAGAGCATGTGAAAGACACAGATTT TGAGAAATGTTAAGTCTAGGGAACTGCA AGGCTTTTGGCACAAGAAAGCCACTGTA GACTATAGAGGCAGGATGCCTAGATTCA AATCCCAACTGCTACACTTCTAAGCTTTG TAATTTTGGCAAGTTTTTACCCTCTATTT TCTTATCTATAAAATATAGATTTTATATA TATAGATATAGATATATAGATAGATAAT AATTGTGCATGCCTAATAAAGTTGTCAA AGATTAAATGTTATATGTGAAGTATTTG TACGGTGATAGGAACCCAGGA 1603 3952519 9 DGCR14 TGATCCCCCAGGAGTCCCCTCGAGTGGG 0.015281883 0.008978517 1.28E−05 TGGATTTGGATTTGTTGCCACTCCTTCCC 1899 3953861 7 CRKL CGTCTAAGAAGCAAGGCCACTGTTCCTC 0.001504933 0.007170792 4.34E−06 CTGTAGGGACAACGATCCTGTCTCAGAG ACCTGTCCTTCTGCTCCTTTAGAAAACAG AACCAGCACAGCGTCCACACCGACAGCA GTTACTAGG 1237 3954368 2 TOP3B CTGCGGAAGAGTGGAGTCTAAACTTTTT 0.037498543 0.007241529 1.28E−06 CATTGCC 2021 3956783 2 AP1B1 TTGGCAATCACGGACACTTTTTTCCCCTC 7.26E−05 0.007011229 3.96E−06 CACCGAATGTCAGGATTGAAAGCTGCCT CCGAGTGGTTGGGGATGGTTTTCTGACC CTACGGTAACTAGATC 1700 3956841 1 GTCTTCATCATGGTGGGACTGGCTCCAG 0.00515944 0.006531317 3.49E−06 GAGGGATGGTGGAGATATGAAGCCAGA TGGGGCACAGGGCTGTGTTCTGAGGGGC CTTGAGGCCTCAGAGAGGGCTTTGCACT TTATCCAGGGATTTCAGCGGGTCGTAAG CAGGAGGGGCATCTGGTTGGGGCTCTAC TGGAAGGCTCATTGCTTTGGCCAGGAAG ATGGGGAGGCTGGTGGCAAAGAAGCCC GTTGGAGGCTGTTAATGCCACCCAGGCC AGGGAGGCAGGGCCCAGGTGAGCCAGT GACAGGAGTGAAGGAGAGAGGGTGCCA GGGTAGAGAGAGCTGAAGGGGCAGTGG CAGCGCTGGGTAGCCCTGGGTAGCTCAG CACATTTT 1235 3957024 9 ASCC2 CCCTGCTGACGTCTCGCCACAACGTCTTC 0.015136312 0.007228397 3.59E−06 CAGAATGACGAGTTTGATGTGTTCAGCA GGGACTCAGTAGACCTGAGCCGGGTGCA CAAGGGCAA 1339 3958074 7 YWHAH CACACATGGCGCTGTCAGGATACACAAG 6.02E−05 0.01323046 7.68E−06 GACAATAGCCAAAGAGTTACAAAAAAT AAATCCATGATTCTTAAACAATTGCAAC CAAAAAAAAAAAAAAGTTACAAGTATC AAAACTTTCAGATGCATTGCATTGAAAA GAAGGTTTGTGCACGTCATAATTTAAAG AGGCAAAACCAAGGAGCTACTGAAACCT CACGTTAAACAGTTTATTATAAAGCTGA TGGAAAGGAGCAAGTTGTCTCTCTGTAT CAGCTTCCCTTAACAGTTTTCCATTAATT GAAGAAAGAGGTGGGAGGGGTGAATTC ATTTTTGCATGCACAAGATGTACTGCTTA ACGAAACACTATCAGCTTGTTTTAAATG GATCTTTTAAATATCAACTGTAGCCTGGT TGGCTAATTCTTTCTAATCTTCCCCATTA CTTTCGCCTAGATTTCCCATAGATCAACA GGCATAGTAAAATGCCTCATCAGAACAC ACTTCTCCACACAATTCAAAAAGGGAGC TCCTGTGGGCTCAAAGCAACCATCAGTC CAG  885 3958175 9 SLC5A4 TCTTGGGTGGATCTTTGTCCCTATCTACA 0.000873066 0.011103233 8.58E−06 TCAAGTCGGGG  422 3960135 9 CARD10 TGCTGCGGCAGTGCCGTGGCTCAGAGCA 0.042066262 0.010130553 1.11E−05 GGTGCTCTGGGGGCTGCCCTGCTCCTGG GTGCAGGTGCCCGCCCATGAGTGGGGAC ACGCAGAGGAGCTGGCCAAGGTGGTGC GCGGCCGCATCCTGCAGGAGCAGGCCCG CCTCGTGTGGGTGGAGTGCGG  289 3962111 7 SREBF2 GACATACACACAACACGCAGGCGGGCA 0.000511623 0.017319589 1.35E−05 GGGTCCATAAATTACAGTGAGAGTAGGG GAGGGGCAGGAGAGAAAGAAAGCAGGT GGGGTCCAAGCACACCCCAGGGATAACA TTCCAGCCTGCATCAAGGTGGCCCTGCT GTGAGCACCCCCCAGTCTGTGCTGGGGC TCCTGCCCACCCTCTGCTCCAACCAGCCT GAGGATGAGGCACAGGGAGGCAGGGCC CATCACTCAGGAGGCCATGGGAGAAACA GTCTCCGGGAGGTGCTGCACCTGGGGAC CCAGAAAAGTAGGACTTTTTCTCCTAGG ACCCGCATCGAGGCAGGGGACCTCATTC CTAGTGC 1113 3962470 6 TGACAGCATGCACGAAAGCCCGCTTCTC 0.003098917 0.007741604 4.41E−06 ACATCTGATTCCAGGAGAAAGAGCGGCG TGTCCAGCAAGATAAGTTTATCCACCAT CTCGGGGAAGGTACAGAAAAACTGTGA GGATGCCAAAAGGGGAGAATGAATAGG GGGAAGAAGGAAAGGACACTCCCGCCTT TCCCTGGGGACCCTGGAGTTCCCCGAAA CATCTTTTAGGCTGGGGGGAGGGTGCTG ACCAAGAGGCCAGAGGAGAATCTTCTAT CTATGGTGTGCCTTCCCCCACCACCCCTA AGTCTGCACCCAGCACTGAGCTCCAGAC CTTGGTGATGGCTGGACTCC  804 3962932 3 SCUBE1 CTTTGCAGGGTATGTTCCCGGCCCACAG 0.000197241 0.010510173 4.00E−06 GGGGCTCTCCATGGATCTGAGGAGACTG GCAGGGCAGGATCGGAATCGGCACCCTG GAGAAGCTGTCGTTGGAGACGGCCTTGG CGAGACAGTGTGTTGCAGCTCCAGCTCT GTCCGCTGGGTTCAGCCCCCTCACCTTAC CTCAGTCACTAACCTCTGTGCGCTCAGC GTTCTCAGCTGTTAAGTGGACGTAACAC AGGTTGAGCATCCTTTATCCAAAATGCTT GGGACCAGAAGTGTTTCCAGTGTTGGAT GTTTTCACATTTGGGAACATTTGCAGATA CATAATGAAGTAGCTTGTGGATGGACCC A  190 3965086 1 CACAGCCGAGCCAGTGGAGCCGTTCTGG 0.001219026 0.012512162 7.10E−06 GCAGGTGTAAGGCCGTGGTGTCTCAGGG GACATCCCGTGTCACAGCCCGGAG  103 3965316 2 BRD1 GCGGGTCTTGTCCATAGTGTTGATAAGC 0.000113778 0.025245222 2.10E−05 TGTACATGTTTGTATATTGTTCAAAACTT AACTTATTCTGATTTTTAGTTATAGCTCT TTAATTCTTTTTCCCCGGGGAGGGGGGA GGTTTTATTTCCAAGTTTTCTAGGAACCC ATCTCCGTCTGGGCGCTGTGAGTGGGGT GGGCACGTCCGGGCAGCCCAGTGCGTCT GTCGCACGTCCCCAGGCCGTGCTGCTGG CGTCACTTTCTTTGATATGTAGCTTTTTC TTAAAGACTTTTGAATGTTTAATAATTTT GTAAATCATGCTCTTTACACAGAGTACC ACTTATTTAATAAGACGGGATGTAAATT TACAATGACAAATGTGTATTTTAAGAAA GAAAATGACATTATTTTGAATGGTACTTT GTGGAAAGAGGGGAGAATAAAGTTATG CTGTGTACATCACTTGCAGATCACCAAA AACACTCCGCTGCCCGTGACCGCCGGTG GGTGTGTCCCCGCTCCCGTCGTCCCGCCC ACCTCAAACCCCGCAGGTGTGCCTCCCA GCGGATTATTTATTGTAGAAAGTGTATTC ATTTGCTTTATAATGAAAAATACATTTGC AAAGGTATATTGATATGCATTTTTATACA GGCACATAAAAATTCAACTTGGCTTGGG AGCAGAATGCATTGCATTGTATAAATGA CTCTGGCCTGTGTGTACTTTGATTTTA  287 3967872 1 TTTTGAAGGTTATCCGAGGTCACCATCTG 0.01020177 0.012116789 1.25E−05 CATCTTGCCAAAGCCAGGACAGGAAGAT GCATTCTTGCCTGGTTCTTTCTTCCCCTTC AGCCTTTCCCAACACACACCCATTAATT ATCCTTCATTGTCCCACAGTAATTTCTCA GGGATCTAGTCCCATCTCTTTATTCCTTT ACTCGTTCCCTGGGATATAATTACAGCCT GATAACCAGGCTATGACTACGGACTTAT C 1473 3968670 8 MID1 ACTTGCCCAGTTACAACACATCTGAAAT 0.006297356 0.007050988 1.23E−06 TCTAAAGGCCCTTCCCCTACCTGTCGTGC AAATCCCCTTCCGTCTAGTCTCTGGCCTA AAACCAGTTGAGATGGACCCTCCTCCTC GGGAAGTCCTGCCTCTTTCTGAAGGCAG GGTGCCTGCTGAATCTGGTCCCTGTGGC CCTGTTTGCTCAAATG  132 3968897 1 TGAGCATGCAAGTCTAACTAAAGGCATT 1.39E−05 0.017841672 1.98E−05 TAAACACACGTTTTTAAGAACACTGGGG AGGCTGAATGAAACACATCCAAGGGCCA CCACTTTGCAACTCCTGAACCAAGCAAA ACCAACTGGTGTCCTGTTGTATGCGTGTG TTGTAGAGCTTTAAAGC  834 3971935 4 ZFX CGAGGTCGTGTCTTTTGCGGAAACATGG 0.040585072 0.007638758 3.94E−06 ATGGAGCTGGAGGCTATTATCCTTAGCA AACTAACGCAGGAACAGAAAACCAAAT ACCGAATATTCTCACATACAGGTGGGAG CTAACTGATGAACACAAAGAAGGAAAC GAGACACTGGGGGTCTACTAGAGGGTGA AGGGAGGGAGGAGAGAGAGGATCAGAA GAGATAACTATTGGGTACTGGGCTTAAA TACCTGGGTGATGAAATAATCTGTACAA TAAACCCCCGTGACAGAAGTTTACCCAT GTG  353 3973877 2 RP5- CTAGCCCATCTTACTCCAGGTTTGATACT 8.88E−05 0.019334343 2.32E−05 972B16.2; CTTTCCACAATACTGAGCTGCCTCAGAA CYBB TCCTCAAAATCAGTTTTTATATTCCCCAA AAGAAGAAGGAAACCAAGGAGTAGCTA TATATTTCTACTTTGTGTCATTTTTGCCAT CATTATTATCATACTGAAGGAAATTTTCC AGATCATTAGGACATAATACATGTTGAG AGTGTCTCAACACTTATTAGTGACAGTA TTGACATCTGAGCATACTCCAGTTTACTA ATACAGCAGGGTAACTGGGCCAGATGTT CTTTCTACAGAAGAATATTGGATTGATT GGAGTTAATGTAATACTCATCATTTACC ACTGTGCTTGGCAGAGAGCGGATACTCA AGTAAGTTTTGTTAAATGAATGAATGAA TTTAGAACCACACAATGCCAAGATAGAA TTAATTTAAAGCCTTAAACAAAATTTATC TAAAGAAATAACTTCTATTACTGTCATA GACCAAAGGAATCTGATTCTCCCTAGGG TCAAGAACAGGCTAAGGATACTAACCAA TAGGATTGCCTGAAGGGTTCTGCACATT CTTATTTGAAGCATGAAAAAAGAGGGTT GGAGGTGGAGAATTAACCTCCTGCCATG ACTCTGGCTCATCTAGTCCTGCTCCTTGT GCTATAAAATAAATGCAGACTAATTTCC TGCCCAAAGTGGTCTTCTCCAGCTAGCC CTTATGAATATTGAACTTAGGAATTGTG ACAAATATGTATCTGATATGGTCATTTGT TTTAAATAACACCCACCCCTTATTTTCCG TAAATACACACACAAAATGGATCGCATC TGTGTGACTAATGGTTTATTTGTATTATA TCATCATCATCATCCTAAAATTAACAAC CCAGAAACAAAAATCTCTATACAGAGAT CAAATTCACACTCAATAGTATGTTCTGA ATATATGTTCAAGAGAGAGTCTCTAAAT CACTGTTAGTGTGGCCAAGAGCAGGGTT TTCTTTTTGTTCTTAGAACTGCTCCCATTT CTGGGAACTAAAACCAGTTTTATTTGCC CCACCCCTTGGAGCCACAAATGTTTAGA ACTCTTCAACTTCGGTAATGAGGAAGAA GGAGAAAGAGCTGGGGGAAGGGCAGAA GACTGGTTTAGGAGGAAAAGGAAATAA GGAGAAAAGAGAATGGGAGAGTGAGAG AAAATAAAAAAGGCAAAAGGGAGAGAG AGGGGAAGGGGGTCTCATATTGGTCATT CCCTGCCCCAGATTTCTTAAAGTTTGATA TGTATAGAATATAATTGAAGGAGGTATA CACATATTGATGTTGTTTTGATTATCTAT GGTATTGAATCTTTTAAAATCTGGTCACA AATTTTGATGCTGAGGGGGATTATTCAA GGGACTAGGATGAACTAAATAAGAACTC AGTTGTTCTTTGTCATACTACTATTCCTT TCGTCTCCCAGAATCCTCAGGGCACTGA GGGTAGGTCTGACAAATAAGGCCTGCTG TGCGAATATAGCCTTTC 1230 3974321 1 CTGCTAACAACGGACCCAGCCAGTGCCC 0.000103742 0.009748928 6.08E−06 ACCAAATGGCTCCTGCAGCCTTCCTTTGC AGCCACACTGAAAAGCGATCAAATGTGA AATCCCAGGGAGGCCAGAGCAATGCGG CCAGCACTCAGCTCCGGG  748 3974602 3 RP11- GGGAAGCTGCGCCTCCGCAAACGCTCAG 7.28E−05 0.01454949 1.06E−05 169L17.2 AAGCAGCTTCGCCAGACAGCCGCAACGT ACATGTTGACTGCCCGAGGCGGAAGTCG AT 1407 3975196 1 GTGGAGGATGGCTCATAACACTTCTCGG 0.013854351 0.006635681 5.98E−06 AATCCTCCATCAAATGTGCACTCCACTCT CCTCTCCTTCTCTCCCCTAAATCCACATC ACCAGCTTGG 1036 3976688 2 EBP ACCAGGCTCGAACACTGGCCGAGGAGG 0.002157641 0.013487046 1.43E−05 AGCTCTCTGCCTGCCAGAAGAGTCTAGT CCTGCTCCCACAGTTTGGAGGGACAAAG CTAATTGATCTGTCACACTCAGGCTCATG GGCAGGCACAAGAAGGGGAATAAAGGG GCTGTGTGAAGGCACTGCTGGGAGCCAT TAGAACACAGATACAAGAGAAGCCAGG AGGTCTATGATGGTGACGATTTTTA 1868 3977052 9 MAGIX CACCGTTGGTTAGAGACATGTAACGCAC 1.55E−05 0.00881525 6.38E−06 CTCCCCAATTGATC 1505 3977310 4 CLCN5 ATGATTAAAGGGGTGTTGTGGTCTTGTTT 0.023452452 0.007299256 7.03E−06 TAAATACATCACTGGAGATGTAGAGGTC TGGTGGGGACAGTTGAAGCACAACCTCC ACAAAG 1303 3978435 2 TSR2 ACCAAACAGATGAACGAACGGAGCACA 0.013747629 0.011233971 1.17E−05 GCAGTGCTATGAAAG 2050 3979989 2 AR AGGTCCATTTCTGCCCACAGGTAGGGTG 0.00041969 0.007110435 2.61E−06 TTTTTCTTTGATTAAGAGATTGACACTTC TGTTGCCTAGGACCTCCCAACTCAACCA TTTCTAGGTGAAGGCAGAAAAATCCACA TTAGTTACTCCTCTTCAGACATTTCAGCT GAGATAACAAATCTTTTGGAATTTTTTCA CCCATAGAAAGAGTGGTAGATATTTGAA TTTAGCAGGTGGAGTTTCATAGTAAAAA CAGCTTTTGACTCAGCTTTGATTTATCCT CATTTGATTTGGCCAGAAAGTAGGTAAT ATGCATTGATTGGCTTCTGATTCCAATTC AGTATAGCAAGGTGCTAGGTTTTTTCCTT TCCCCACCTGTCTCTTAGCCTGGGGAATT AAATGAGAAGCCTTAGAATGGGTGGCCC TTGTGACCTGAAACACTTCCCACATAAG CTACTTAACAAGATTGTCATGGAGCTGC AGATTCCATTGCCCACCAAAGACTAGAA CACACACATATCCATACACCAAAGGAAA GACAATTCTGAAATGCTGTTTCTCTGGTG GTTCCCTCTCTGGCTGCTGCCTCACAGTA TGGGAACCTGTACTCTGCAGAGGTGACA GGCCAGATTTGCATTATCTCACAACCTTA GCCCTTGGTGCTAACTGTCCTACAGTGA AGTGCCTGGGGGGTTGTCCTATCCCATA AGCCACTTGGATGCTGACAGCAGCCACC ATCAGAATGACCCACGCAAAAAAAAGA AAAAAAAAATTAAAAAGTCCCCTCACAA CCCAGTGACACCTTTCTGCTTTCCTCTAG ACTGGAACATTGATTAGGGAGTGCCTCA GACATGACATTCTTGTGCTGTCCTTGGAA TTAATCTGGCAGCAGGAGGGAGCAGACT ATGTAAACAGAGATAAAAATTAATTTTC AATATTGAAGGAAAAAAGAAATAAGAA GAGAGAGAGAAAGAAAGCATCACACAA AGATTTTCTTAAAAGAAACAATTTTGCTT GAAATCTCTTTAGATGGGGCTCATTTCTC ACGGTGGCACT 1347 3981275 4 NHSL2 ACCCCCAGTCGGCCTACTGTGCCTCAGC 0.001484083 0.007898961 8.62E−06 2029 3981889 1 ACAACCAACTGATCGTTAACTAAGCACA 0.001070147 0.007759571 5.95E−06 CAAAAATATAAACTGGGGAAACAACATC CTACTTAATAAATGGTGCTGGGAAAAGT AGATAGCCCACATGTAGA 1389 3982824 4 SH3BGRL ATGGGCAGAATCCAATACCCGTTTGCTG 0.000425014 0.007299911 3.97E−06 TCAGTTATACCTGTTTGCCAGTTAGTCAG ATGCTCAG 1996 3984554 9 CSTF2 GTGGAATGCATGTCAATGGCGCACCTCC 0.01560657 0.006911261 6.59E−06 TCTGATGCAAGCTTCTATGC 1379 3985558 2 NGFRAP1 AGTTTCTGTCAGCAGTAGYTTCACCCATT 1.89E−05 0.013521885 1.10E−05 TGCATGGAAA  863 3985758 9 PLP1 TGCTTTCCCTGGCAAGGTTTGTGGCTCCA 7.71E−05 0.010589385 6.72E−06 ACCTTCTGTCCA  890 3988764 4 RP5- AAGGGGACTTGAGTGCTGGATTTCTGGA 0.000246362 0.009691417 4.17E−06 1139I1.1 GGAGATCAGTGGAAAATTGAGTGTTGGT C  737 3990584 9 UTP14A GTAGCATTCAATAAAACCGCACAAGTCC 0.000438052 0.011094743 5.44E−06 TCTCCAAATGGGACCCTGTCGTCCTGAA GAACCGGCAGGCA  744 3990660 9 BCORL1 CCTCAGGAACAGGAACCTTCTCTTGCCC 0.013881148 0.008292344 8.84E−06 AACAAAGTC  588 3991537 5 GPC3 GTACAACCCAGCCAGCAGGTCAAAGGAT 0.032963108 0.009771426 5.77E−06 TGGAGGACCACCCTGAACAGCATGGGAA CAACTGGATTACAACAGCTG  946 3991667 4 PHF6 GCAATTTTCCAAGGTTCATGTCAGCCAC 7.84E−05 0.009377693 4.41E−06 AAGGATCAAAGGAGG 1987 3991676 9 PHF6 ACTGGAGCCCTCATCACCTAAAAGTAAA 0.00022254 0.007170117 5.77E−06 AAGAAAAGTCGCAAAGGAAGGCCAAGA AAAACTAATTTTAAAGGGCTGTCAGAAG ATACCAGGTCCACATCCTCCCATGGAAC AGATGAAATG 1691 3991722 2 HPRT1 GTAAGAAGCAGTCAATTTTCACATCAAA 0.000125743 0.008299216 5.16E−06 GACAGCATCTAAGAAGTTTTGTTCTGTCC TGGAATTATTTTAGTAGTGTTTCAGTAAT GTTGACTGTATTTTCCAACTTGTTCAAAT TATTACCAGTGAATCTTTGTCAGCAGTTC 1618 4001867 2 SH3KBP1 ACGTAGTCAGAAGCGAGTGTCCTTTTCTT 0.000155817 0.008800731 7.41E−06 TTGCTTCAGGCTAAGAGCTGCCTCGCTCT TTGTCCCCCCATTAGGATTCTATTACATA TGCAATTGTAGGTTCAACCTGTCCCTTTC CCTGCCAGCAAACCCCACCACCCTAAGA GAAATTTTAGCTTATATATGACGGTATAT TTACAAAAAGAGAAAGAGAAAATCTGG TATTTGCAATGATCTGTGCCTTCTTTTTA CCACCCTCTTGATTGGAGCTTTTGTGATG CAGCTACCATGATTCAAAAAAATTAAAA ATTAAAAAAAAAAAATCTGCCACTTATC CAAGTCCACTAGAGGCCACTGTCTTCAA AGCTTCTCTCACCCTAGCCAAAGGTCCT AAGAGGAGACAGCTGTGAAGTTGGGCGT GCTCTGTGGTACCAGCTGTGACTTTTCTA TTTCTCCTAGTTTTAGGTTGTTCATGAAA CTAGAAATGTCATCCTGCTTGATTTTTCA TCAGCCAAGTTAAACCCCTGCTTTCTGTC CTTTGCACCTTTTGCGTGAACAGAATATG  390 4001936 9 SH3KBP1 AGGTGTTCTCAACGGGAAGACTGGAATG 2.85E−05 0.018253605 1.50E−05 TTTCCTTCCAACTTCATCAAGGAGCTGTC AGGGGAGTCGGATG 1800 4004831 9 DYNLT3 ATGGCTCGGAGTCTCGGGGTCCTGGTGG 3.14E−05 0.007135752 4.30E−06 CACTGCCATTCCCGCTCCCG  263 4005034 5 RP5- TGTGGGAACCCCAAGTACACCAGAGGCA 6.09E−05 0.014111468 1.22E−05 972B16.2; CTTCTCCACAAAGAAGCTTCTATCAATG TSPAN7 GGAAGCCTAGTGTGTCACGGACCA 1402 4005967 4 CASK CGAGACTCCCCTCGACTGTTGTTGGGAT 0.001561876 0.007092994 4.08E−06 GGTGGTTAGCGTGGTAGAGCCGTCTGCT TTGAGTCACCGGGCTGGTCTAGAATATA GAACTGACAGTCCAAATGCTCATCCTTT C 1761 4007481 5 EBP AGGCCAGTATGGGTGCAAGGGGCCCGCG 0.000111942 0.009912108 5.20E−06 TTGGTAGTCATGTCTTTGTGGGCTGATGG CTGCGTGTGTATAGGCAGGAAGTTA  837 4007956 9 CACNA1F CTCCAGCGCCATCTCGGTGGTGAAGATT 0.030881616 0.008004059 3.19E−06 CTGCGAGTACTCCGAGTACTGCGG 1736 4009008 6 GGGATGACCTCCTATTGTGCCACGGGAG 6.02E−05 0.008854541 6.11E−06 ACACAGGGCTTGAGCCCACAGCTGGAGG GAAGGTGCCATCCACACTGAAAGTCAGC CAGCCAGCCAGTAGAAATTATTTATGAT AATACAGGAACCATGGCCAGCATGACAT TTCTACTTCCAGTGGGAAGGCAGGACTT TAGGAATGAGAAAGGAACTGGGATGGA AGAGAGAGGCAGAAGGGGAAGGTGGGG GACAGTGAGGAAAAACACACTGATTGA GAAGGGACCCTGGGGACTTCTGGGATGG TGATCGACCTTG  212 4011774 2 SNX12 TCCCTAAGCCCTTGCTACTTTATGGGTTA 3.98E−05 0.017028115 1.23E−05 GCTTTGCAGGTTTGGTGGCTTGAGGGGT GGGGGCAACTCACCACTGCCAGGTAACT CCCTGAAGGGTGGGAGTGGATTATCTTC TAGGCTCTTACCCGCGGTAGGGAAGGGC ATCAACACTGTCTTCCTTCCATTCTCCTT TCCCCCATCCCATTTAGTGCTGCCACAGG  500 4011923 2 ZMYM3 ACACGAGTGGGAAGCTAAGAGAGACAC 0.004052566 0.008667107 6.03E−06 GGGGAGGGGGAGGGGACCGGGAACCAT TTGAATGAGAGGAGGGGATCACGGGTA GAGTGGGCTCCAGGAGGTAGGGCGAGC AGGGTGTGACGGGGGCCAGACTCTTGAG CCA 1399 4015424 1 ATGCTGCGTAAGGCCTCAATCCCACTGA 6.21E−05 0.007349564 1.18E−06 AAGCTGGAAGCAGTGGGACAGAAGGGT TCCAGAGAGAGGTTAAAGAAGAAAGTG AAGGGGGAGAATATGGAAATCATAGGG AGATCA 1103 4019335 9 RP13- CTCTGCCTAAACCTAGGAGTAAGGTTCC 0.000982084 0.007331499 2.59E−06 347D8.6; TGGAGTTGTGTCTGGAGCCATGTCAGGA RP13- GCTGTGCTTCAAAATGTGCCTACAAGTG 347D8.5 CAGTCTGGGTT 1002 4021793 9 IGSF1 AGCCACTTCAATGCAGCTCTGGGGATCC 0.010262873 0.007382385 5.45E−06 ACCAGTAATGACGGGGCATTCCCCATCA CCAATATATCTGGTACTAGCATGGGGCG TTACAGCTGCTGCTACCACCCTGACTGG ACCAGTT 1698 4023960 4 FGF13 CCATTATGAGAGAACGTTTGAACTGAAA 0.000102061 0.006988413 4.80E−06 AAGTCCTCTGAACTTTGTTCACTAATCTT ATCAAAGAAAATAGAAGCAGAGGATGT AGACAGAAACCTGCA 1625 4024213 4 ATP11C TGGTCAGTCGCTTCCACCAACCGTTTCCT 0.000292246 0.00706917 3.99E−06 TTTGCAGATACTGCCTGGGTCTGAACCT GATTAAAGTTCTACATTATAGGCTTCCTA CTCCAAATCCTAATGTTTATTCTAACTAG TATCAGTCTGTTTCAGTCAAAATACAAA CTATAACAATGAACACGCTATTTTAGAA ATGTAGCCAAAATCCTTACTTATGATCTA TGATTATGTTTCTTTTAAATTTTAAATGT ATTCCTAGGAGTGAACGAAAGCGTTTCT TCATAGTGTTTTATGGTCACCATTAGAGC CCAAATCCTGCTTTCCCTATAGCAACTGG GTG   86 4025394 6 AGATGTTTGTTAATTGCTCTTGGCCTCTC 3.32E−07 0.027696162 2.93E−05 ATTAATCCCCTGTGGGTCATCCAGGAAA TATACTCACCACTGTCTGTTCTCTGAGTT TTCATTTCCAGGCATCCGCCCTGCCTGGA TCTCCTCACCTGCCAGGAACTTCCTCTCC ACAAGCCGGCCATCCCAGCAAAAGTT  765 4025854 6 CTCCTTCAGCTTTGCCGCCTTAGTGATGT 0.001587412 0.013914483 1.16E−05 AAGGCTGCTTTTCACTGTCATTTAAATTA TTCCACATCTCACCCAGCTTTTTTG  288 4027060 9 MECP2 TACACGGAGCGGATTGCAAAGCAAACCA 2.41E−05 0.01789865 1.05E−05 ACAAGAATAAAGGCAGCTGTTGTCTCTT CTCCTTATGGGTAGGGCTCTGACAAAGC TTCCCGATTAACTGAAATA 1667 4030249 1 GGCCAAAAGTGTACGTTGTCACTAGTGC 0.002577437 0.007582739 2.71E−06 CTTGCCCTCTTACATAGCCAGTAGACCA CATCTTCTCCAAGAACTTCCTCAAAGAG GGGAATGCAAGCTACCTCAACCC 1675 4030633 1 TGGATGCGGTTAGAGTCACAGCCTCCCT 0.000126422 0.008284604 3.42E−06 TGAAGCCTGGTTTCTTCCTCCTAATTGGA CTCGGCTA  352 4033522 6 AGAGGATCCCACTCGTGAGCCCATGCCA 0.000972729 0.011250995 1.11E−05 CCAGGGCTTGGCTCCCAACCATAGAGGT GTGCAAATTCTCAACAGCCACTTGTTCTA GAATCTGCCTAAGCCTGCCAAGTTCCAG GGGAAGGGGCGGCCATCACCACTGCTGC AGCTGCCTGCTTTCTAAGCCAGCTGAGC TCTTTGGGGGAAGGGTGGCAGCAACACT TCCACTGCAGGGACTCCCTGCAAGAACT CCAACAGCTCCAGCTAGGGGCTCAGGAA CAAAACTCTGATCTCCCTGGGACTGAGC CCCTAAGGGGATGGTTGGTCTTAGTCTC CACAGACCAGGAGACTTAGTCTTTCCTC CTACTAGCTCTGAGGAATCTGGGAAGCC CTGATGAGTGAGTTTCCCTCCA  294 4037889 1 GAGGGCGCTGCAGAACAACCTTGGAGCT 0.004841315 0.00915344 6.80E−06 AT 1056 4040209 6 ATTTGCAGCGGGATCGTTCTGTGACGGG 0.00587839 0.008940693 5.30E−06 CGGTGGGCAGCCCAGGCAGGGCTGCCGT TTCGTGTATCAGCCCAGAGGTCTGAGAA GGGTGTGGCTCCTTCCCTGGGAAACAAC ATGGGACTAGTTCCAGAGCCA  156 4041204 6 TGGACTGCAGTCCTTCTCATCCACGTCTC 0.008812862 0.014698895 1.37E−05 CTTGTCTATGAC 1765 4044236 6 ACCACCCTTCCCAACAATCCACTAGCAA 0.005170366 0.007435892 4.42E−06 TCCAGAGGCCACCACCCCTTCCCAACAA TCTGGCAACGACCCAGAGGCCA  621 4046788 1 ACACGTGTGTCCCACCCATGGATGATGG 0.000460621 0.011139661 8.65E−06 CACCAGCTGGGGGGTGCACACGTGTGTC ACACCCGTGGACGATGGCATCAGCCAGG GGGTGCACACGTGTGCCACCTTCTTCCC GGCCCTGAATTGTGTGTGA  285 4053554 9 AGRN TGGCGGTACTTGAAGGGCAAAGACCTGG 0.005853836 0.006573388 4.59E−06 TGGCCCGGGAGAGCCTGCTGGACGGCGG CAACAAGGTGGTGATCAGCGGCTTTGGA GACCCCCTCATCTGTGACAACCAGGTGT CCACTGGGGACACCAGGATCTTCTTTGT GAACCCTGCACCCCCATACCTGTGGCCA GCCCACAAGAACGAGCTGATGCTCAACT CCAGCCTCATGCGGATCACCCTGCGGA 1487 4053582 9 AGRN CCGAGTGCGGTTCCGGAGGCTCTGGCTC 0.000183201 0.00684421 3.08E−06 TGGGGAGGACGGTGACTGTGAGCAGGA GCTGTGCCGGCAGCGCGGTGGCATCTGG GACGAGGACTCGGAGGACGGGCCGTGT GTCTGTGAC  508 4053813 4 RILPL1 CTACCGAATTGGATACGTTGAGCTCAAC 0.03724011 0.010183757 7.18E−06 GGTGCTCTCAGAAGCGCGGTGGCTCATG CCTGTCATCCCAGCACTTTGGGAGGCTG AGGCGGGTGGATCACTTGGGGCCAGGAG TTTGAGACCAGCCTGGGCAACATGGCAA AGCCCCATCTCTACAAAAAATACAATAA GTAGCCAGGTGTGGTGGCGTGCACCTGT AATCCCAGCTACTCGGGAGGCTGAGGCA CAAGAATTGCTTGAGCCCGGAAAGCGGA GGTAGCAGTGAGCCGAGATTGCCACCGC TGCGCTCCAGCCTGGGCAACACAGCGAG ACTCGCAAAAAAAAAAAAAAAAAACAA TAACAACAAAATTGCTGTGCCCTCTCTCT GGGCCTTTCTCCGTATGTTTGC 

What is claimed is:
 1. A method comprising: (a) obtaining or having obtained an expression level of a plurality of targets in a sample obtained from a subject with prostate cancer, wherein the plurality of targets comprises ten or more target nucleic acid sequences selected from NFIB, NUSAP1, ZWILCH, ANO7, PCAT-32, UBE2C, CAMK2N1, MYBPC1, PBX1, THBS2, EPPK1, IQGAP3, LASP1, PCDH7, RABGAP1, GLYATL1P4, S1PR4, TNFRSF19 and TSBP, and wherein the plurality of targets comprises at least one target nucleic acid sequence selected from NFIB, ZWILCH, PCAT-32, EPPK1, IQGAP3, LASP1, PCDH7, RABGAP1, GLYATL1P4, S1PR4, TNFRSF19 and TSBP; (b) prognosing the subject as later developing metastatic cancer based on at least the expression level of each of the plurality of targets in the sample obtained in step (a), and (c) administering a cancer treatment to the subject prognosed as later developing metastatic cancer in step (b), wherein the cancer treatment is a chemotherapeutic agent or radiation treatment.
 2. The method of claim 1, wherein the plurality of targets comprises a coding target.
 3. The method of claim 2, wherein the coding target is an exonic sequence.
 4. The method of claim 1, wherein the plurality of targets comprises a non-coding target.
 5. The method of claim 4, wherein the non-coding target comprises an intronic sequence or partially overlaps an intronic sequence.
 6. The method of claim 4, wherein the non-coding target comprises a sequence within the UTR or partially overlaps with a UTR sequence.
 7. The method of claim 1, wherein the nucleic acid sequence is a DNA sequence.
 8. The method of claim 1, wherein the nucleic acid sequence is an RNA sequence.
 9. The method of claim 1, wherein the plurality of targets comprises NFIB, NUSAP1, ZWILCH, ANO7, PCAT-32, UBE2C, CAMK2N1, MYBPC1, PBX1, THBS2, EPPK1, IQGAP3, LASP1, PCDH7, RABGAP1, GLYATL1P4, S1PR4, TNFRSF19 and TSBP.
 10. The method of claim 1, wherein the plurality of targets comprises SEQ ID NOs: 1-22.
 11. The method of claim 1, wherein the plurality of targets comprises SEQ ID NOs: 1-43.
 12. The method of claim 1, further comprising sequencing the plurality of targets.
 13. The method of claim 1, further comprising hybridizing the plurality of targets to a solid support.
 14. The method of claim 13, wherein the solid support is a bead or array. 